PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	RP	EM	RI	OI	FU	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	D2	EA	PG	WC	SC	GA	UT	PM	OA	HC	HP	DAJ	Langston, JL; Moffett, MC; Makar, JR; Burgan, BM; Myers, TM				Langston, Jeffrey L.; Moffett, Mark C.; Makar, Jennifer R.; Burgan, Bradley M.; Myers, Todd M.			Carfentanil toxicity in the African green monkey: Therapeutic efficacy of naloxone	TOXICOLOGY LETTERS			English	Article						Opioid intoxication; Opioid therapy; Mu opioid antagonist; Mu opioid agonist; Operant behaviour; Non-human primate; Behavioral safety; Behavioral efficacy	RHESUS-MONKEYS; THERMAL NOCICEPTION; OPIOID AGONISTS; SCHEDULE; MU; PERFORMANCE; ANTAGONISM; MORPHINE	Carfentanil is an ultra-potent opioid with an analgesic potency 10,000 times that of morphine but has received little scientific investigation. Three experiments were conducted to evaluate the toxicity of carfentanil and the efficacy of naloxone in adult male African green monkeys. The first experiment determined the ED50 (found to be 0.71 mu g/kg) of subcutaneous carfentanil for inducing bradypnea and/or loss of posture. Experiment 2 attempted to establish the ED50 of naloxone for rapidly reversing the bradypnea/loss of posture induced by carfentanil (1.15 mu g/kg). Experiment 3 evaluated the effects of carfentanil (0.575 mu g/kg) alone, the safety of naloxone (71-2841 mu g/kg), and the efficacy of naloxone (71-710 mu g/kg) administration at two time points following carfentanil (1.15 mu g/kg) on operant choice reaction time. Collectively, these experiments characterized the temporal progression of carfentanil-induced toxic signs, determined the range of naloxone doses that restored respiratory and gross behavioral function, and determined the time course and range of naloxone doses that partially or completely reversed the effects of carfentanil on operant choice reaction time performance in African green monkeys. These results have practical relevance for the selection of opioid antagonists, initial doses, and expected functional outcomes following treatment of synthetic opioid overdose in a variety of operational/emergency response contexts.	[Langston, Jeffrey L.; Moffett, Mark C.; Makar, Jennifer R.; Burgan, Bradley M.; Myers, Todd M.] US Army, Res Inst Chem Def, 8350 Ricketts Point Rd, Aberdeen Proving Ground, MD 21010 USA	Myers, TM (reprint author), US Army, Res Inst Chem Def, 8350 Ricketts Point Rd, Aberdeen Proving Ground, MD 21010 USA.	Todd.M.Myers14.civ@mail.mil			Defense Threat Reduction Agency, Medical ST DivisionUnited States Department of DefenseDefense Threat Reduction Agency	This work was supported by the Defense Threat Reduction Agency, Medical S&T Division.	Barrett James E, 2002, Mol Interv, V2, P470, DOI 10.1124/mi.2.8.470; DEWS PB, 1956, ANN NY ACAD SCI, V65, P268, DOI 10.1111/j.1749-6632.1956.tb49639.x; Dixon WJ, 1983, INTRO STAT ANAL; DOWNS DA, 1976, J PHARMACOL EXP THER, V196, P298; Eriksson O, 2015, MOL IMAGING, V14, P476, DOI 10.2310/7290.2015.00019; George AV, 2010, AM J EMERG MED, V28, P530, DOI 10.1016/j.ajem.2010.03.003; GOLDBERG SR, 1981, J PHARMACOL EXP THER, V216, P500; Ingman K, 2005, NEUROPSYCHOPHARMACOL, V30, P2245, DOI 10.1038/sj.npp.1300790; Kelleher R T, 1968, Ergeb Physiol, V60, P1; Kest B, 2000, ANESTHESIOLOGY, V93, P539, DOI 10.1097/00000542-200008000-00034; Lian M, 2016, J WILDLIFE DIS, V52, P327, DOI 10.7589/2015-04-101; LUKAS SE, 1986, J PHARMACOL EXP THER, V238, P924; Lust EB, 2011, J EMERG MED, V40, P198, DOI 10.1016/j.jemermed.2009.09.026; McKearney J.W., 1981, ADV BEHAV PHARM, V3; Minkowski CP, 2012, ADDICT BIOL, V17, P149, DOI 10.1111/j.1369-1600.2010.00256.x; Moffett MC, 2018, INT J TOXICOL, V37, P352, DOI 10.1177/1091581818779362; Myers TM, 2011, BEHAV PHARMACOL, V22, P814, DOI 10.1097/FBP.0b013e32834d6292; Negus SS, 2009, EUR J PHARMACOL, V602, P92, DOI 10.1016/j.ejphar.2008.11.004; NEGUS SS, 1993, J PHARMACOL EXP THER, V267, P896; Negus SS, 2003, DRUG ALCOHOL DEPEN, V70, P17, DOI 10.1016/S0376-8716(02)00331-9; O'Donnell J, 2018, MMWR-MORBID MORTAL W, V67, P767, DOI 10.15585/mmwr.mm6727a4; PORT J D, 1984, Anesthesiology (Hagerstown), V61, pA378, DOI 10.1097/00000542-198409001-00378; RICE DC, 1988, TOXICOL LETT, V43, P361, DOI 10.1016/0378-4274(88)90038-0; Sarton E, 2000, ANESTHESIOLOGY, V93, P1245, DOI 10.1097/00000542-200011000-00018; Stevenson GW, 2005, J PHARMACOL EXP THER, V314, P221, DOI 10.1124/jpet.104.082685; Stevenson GW, 2003, J PHARMACOL EXP THER, V307, P1054, DOI 10.1124/jpet.103.056515; WEISS B, 1969, ANNU REV PHARMACOLOG, V9, P297, DOI 10.1146/annurev.pa.09.040169.001501; Weiss B., 2001, PRINCIPLES METHODS T, P1451; Wong B, 2017, INHAL TOXICOL, V29, P65, DOI 10.1080/08958378.2017.1282065; World Health Organization, 2017, CARF CRIT REV REP; Yong Z, 2014, EUR J PHARMACOL, V738, P153, DOI 10.1016/j.ejphar.2014.05.044	31	0	0	5	5	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0378-4274	1879-3169		TOXICOL LETT	Toxicol. Lett.	JUN 1	2020	325						34	42		10.1016/j.toxlet.2020.02.008			9	Toxicology	Toxicology	KV4TH	WOS:000520474300004	32070766				2020-06-30	J	Alexandridis, AA; Doe-Simkins, M; Scott, G				Alexandridis, Apostolos A.; Doe-Simkins, Maya; Scott, Gregory			A Case for Experiential Expertise in Opioid Overdose Surveillance	AMERICAN JOURNAL OF PUBLIC HEALTH			English	Editorial Material							DEATHS		[Alexandridis, Apostolos A.] US FDA, 10903 New Hampshire Ave,WO 22 RM 2477, Silver Spring, MD 20993 USA; [Doe-Simkins, Maya; Scott, Gregory] Chicago Recovery Alliance, Chicago, IL USA; [Scott, Gregory] Depaul Univ, Dept Sociol, Chicago, IL 60604 USA	Alexandridis, AA (reprint author), US FDA, 10903 New Hampshire Ave,WO 22 RM 2477, Silver Spring, MD 20993 USA.	apostol.alexandridis@fda.hhs.gov	Alexandridis, Apostolos/O-5405-2017	Alexandridis, Apostolos/0000-0001-9140-2889			Bechteler Stephanie Schmitz, 2017, WHITE WASHED AFRICAN; Bohnert ASB, 2011, DRUG ALCOHOL DEPEN, V113, P62, DOI 10.1016/j.drugalcdep.2010.07.008; Carroll J. J., 2018, EVIDENCE BASED STRAT; Denton JS, 2008, J FORENSIC SCI, V53, P452, DOI 10.1111/j.1556-4029.2008.00669.x; Nesoff ED, 2020, AM J PUBLIC HEALTH, V110, P98, DOI 10.2105/AJPH.2019.305368; Nikolaides JK, 2018, AM J EMERG MED, V36, P2126, DOI 10.1016/j.ajem.2018.03.066; Scott G, 2007, J URBAN HEALTH, V84, P292, DOI 10.1007/s11524-007-9157-7	7	0	0	0	0	AMER PUBLIC HEALTH ASSOC INC	WASHINGTON	800 I STREET, NW, WASHINGTON, DC 20001-3710 USA	0090-0036	1541-0048		AM J PUBLIC HEALTH	Am. J. Public Health	APR	2020	110	4					505	507		10.2105/AJPH.2019.305502			3	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	KW0MK	WOS:000520867700038	32159987				2020-06-30	J	Nesoff, ED; Branas, CC; Martins, SS				Nesoff, Elizabeth D.; Branas, Charles C.; Martins, Silvia S.			Nesoff et al. Comment	AMERICAN JOURNAL OF PUBLIC HEALTH			English	Editorial Material							DEATHS; DRUG		[Nesoff, Elizabeth D.; Branas, Charles C.; Martins, Silvia S.] Columbia Univ, Dept Epidemiol, Mailman Sch Publ Hlth, 722 W 168th St,5th Floor, New York, NY 10032 USA	Nesoff, ED (reprint author), Columbia Univ, Dept Epidemiol, Mailman Sch Publ Hlth, 722 W 168th St,5th Floor, New York, NY 10032 USA.	en2408@columbia.edu		Martins, Silvia/0000-0003-3059-9993	National Institute on Drug AbuseUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [T32DA031099]	This work was supported by the National Institute on Drug Abuse (grant T32DA031099).	Center for Preparedness and Response, 2018, RIS NUMB DEATHS INV; Degenhardt L, 2016, LANCET PSYCHIAT, V3, P251, DOI 10.1016/S2215-0366(15)00508-8; Denton JS, 2008, J FORENSIC SCI, V53, P452, DOI 10.1111/j.1556-4029.2008.00669.x; Hohl BC, 2017, JAMA INTERN MED, V177, P317, DOI 10.1001/jamainternmed.2016.8180; McCord ES, 2007, AUST NZ J CRIMINOL, V40, P43, DOI 10.1375/acri.40.1.43; Nesoff ED, 2020, AM J PUBLIC HEALTH, V110, P98, DOI 10.2105/AJPH.2019.305368; Scott G, 2007, J URBAN HEALTH, V84, P292, DOI 10.1007/s11524-007-9157-7	7	0	0	0	0	AMER PUBLIC HEALTH ASSOC INC	WASHINGTON	800 I STREET, NW, WASHINGTON, DC 20001-3710 USA	0090-0036	1541-0048		AM J PUBLIC HEALTH	Am. J. Public Health	APR	2020	110	4					507	508		10.2105/AJPH.2020.305574			3	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	KW0MK	WOS:000520867700039	32159982				2020-06-30	J	Yadav, SK; Nagar, DP; Bhattacharya, R				Yadav, Shiv Kumar; Nagar, D. P.; Bhattacharya, Rahul			Effect of fentanyl and its three novel analogues on biochemical, oxidative, histological, and neuroadaptive markers after sub-acute exposure in mice	LIFE SCIENCES			English	Article						Fentanyl and analogues; Opioids; Sub-acute toxicity; Oxidative stress; Organ toxicity; Neuroadaptive changes	VENTRAL TEGMENTAL AREA; 1-SUBSTITUTED ANALOGS; OPIOID-RECEPTORS; STRESS INCREASE; COCAINE-SEEKING; DRUG-ABUSE; RAT-BRAIN; MORPHINE; HEROIN; GLUTATHIONE	Aims: Comparative sub-acute toxicity, including tolerance and dependence potential of fentanyl and its three novel and potent analogues was determined in mice. Main methods: Comparative sub-acute (21 d, intraperitoneal; 1/10 LD50) toxicity of fentanyl and its three novel analogues viz., N-(1-(2-phenoxyethyl)-4-piperidinyl) propionanilide (2), N-isopropyl-3-(4-(N-phenylpropionamido)piperidin-1-yl)propanamide (5), and N-t-butyl-3-(4-(N-phenylpropionamido)piperidin-1-yl)propanamide (6) was determined in mice. Animals were observed for additional seven days to assess the recovery. The brain, liver and kidney toxicity was assessed on the basis of various biochemical, oxidative, histological, and neuroadaptive markers. The expression levels of key neuronal markers associated with drug tolerance and dependence were investigated by western blot and immunohistochemistry. Key findings: Fentanyl and its analogues caused abnormal levels of liver and kidney specific biomarkers in plasma. Brain malondialdehyde (MDA) levels were raised by all the treatments and kidney MDA level by analogue 6 (21 d). Reduced glutathione levels in brain, liver, and kidney were diminished by all the treatments (21 & 28 d) and a significant change in the levels of antioxidant enzymes was also produced mainly after 21 d. The deleterious effects of fentanyl and its analogues were further substantiated by corresponding histopathological changes in brain, liver and kidney (21 & 28 d). These compounds were also found to produce neuroadaptive changes as evidenced by the increased expression levels of c-Fos, glucocorticoid receptor, N-methyl-D-aspartate receptorl and mu-opioid receptor (21 & 28 d). Significance: Three novel analogues of fentanyl were envisaged to have alternative therapeutic potentials. However, their comparative sub-acute toxicity revealed undesirable side effects, thereby masking their therapeutic ability.	[Yadav, Shiv Kumar; Nagar, D. P.; Bhattacharya, Rahul] Def Res & Dev Estab, Div Pharmacol & Toxicol, Jhansi Rd, Gwalior 474002, Madhya Pradesh, India	Bhattacharya, R (reprint author), Def Res & Dev Estab, Div Pharmacol & Toxicol, Jhansi Rd, Gwalior 474002, Madhya Pradesh, India.	rahul@drde.drdo.in					Atici S, 2005, J BIOSCIENCES, V30, P245, DOI 10.1007/BF02703705; Baselt R.C., 2002, DISPOSITION TOXIC DR, P430; Chao PK, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-39555-x; David V, 2008, NEUROPSYCHOPHARMACOL, V33, P1746, DOI 10.1038/sj.npp.1301529; Deroche-Gamonet V, 2003, J NEUROSCI, V23, P4785; Drewes AM, 2013, BRIT J CLIN PHARMACO, V75, P60, DOI 10.1111/j.1365-2125.2012.04317.x; Erb S, 1996, PSYCHOPHARMACOLOGY, V128, P408, DOI 10.1007/s002130050150; Erdtmann-Vourliotis M, 1999, MOL BRAIN RES, V72, P1, DOI 10.1016/S0169-328X(99)00184-9; Fitzgerald LW, 1996, J NEUROSCI, V16, P274; FLOHE L, 1984, METHOD ENZYMOL, V105, P114; Friedman J, 2011, OXID STRESS APPL BAS, P19, DOI 10.1007/978-1-60327-514-9_2; Goudas LC, 1999, ANESTH ANALG, V89, P1209, DOI 10.1213/00000539-199911000-00023; Gupta PK, 2013, MED CHEM RES, V22, P3888, DOI 10.1007/s00044-012-0390-6; Guzman DC, 2006, NEUROCHEM RES, V31, P549, DOI 10.1007/s11064-006-9053-7; He L, 2009, FASEB J, V23, P4327, DOI 10.1096/fj.09-133223; HISSIN PJ, 1976, ANAL BIOCHEM, V74, P214, DOI 10.1016/0003-2697(76)90326-2; LIU JL, 1994, P NATL ACAD SCI USA, V91, P8537, DOI 10.1073/pnas.91.18.8537; Mao JR, 1999, BRAIN RES REV, V30, P289, DOI 10.1016/S0165-0173(99)00020-X; Mohamed HM, 2019, BIOMED PHARMACOTHER, V110, P239, DOI 10.1016/j.biopha.2018.11.141; Nye HE, 1996, MOL PHARMACOL, V49, P636; OHKAWA H, 1979, ANAL BIOCHEM, V95, P351, DOI 10.1016/0003-2697(79)90738-3; Ossipov MH, 2003, LIFE SCI, V73, P783, DOI 10.1016/S0024-3205(03)00410-7; Pasternak GW, 2013, PHARMACOL REV, V65, P1257, DOI 10.1124/pr.112.007138; Peng PWH, 1999, ANESTHESIOLOGY, V90, P576, DOI 10.1097/00000542-199902000-00034; Piazza PV, 1996, ANNU REV PHARMACOL, V36, P359, DOI 10.1146/annurev.pa.36.040196.002043; Radovanovic D, 2002, ARCH ONCOL, V10, P263; Rajan V, 1998, BIOL NEONATE, V74, P39, DOI 10.1159/000014009; REUL JMHM, 1985, ENDOCRINOLOGY, V117, P2505, DOI 10.1210/endo-117-6-2505; RODRIGUEZ EMR, 1994, CLIN CHIM ACTA, V231, P39, DOI 10.1016/0009-8981(94)90252-6; Roy DN, 2016, CHEM-BIOL INTERACT, V255, P92, DOI 10.1016/j.cbi.2015.09.018; SAMBROOK J, 2001, MOL CLONING LAB MANU, P623; Shaham Y, 2000, BRAIN RES REV, V33, P13, DOI 10.1016/S0165-0173(00)00024-2; Sinha R, 2001, PSYCHOPHARMACOLOGY, V158, P343, DOI 10.1007/s002130100917; Skrabalova J, 2013, MINI-REV ORG CHEM, V10, P367, DOI 10.2174/1570193X113106660031; STANLEY TH, 1992, J PAIN SYMPTOM MANAG, V7, pS3, DOI 10.1016/0885-3924(92)90047-L; Strano-Rossi S, 2011, J APPL TOXICOL, V31, P649, DOI 10.1002/jat.1613; Terrie Y. C., 2011, PHARM TIMES, V77, P36; Trescot AM, 2008, PAIN PHYSICIAN, V11, pS133; Trujillo KA, 1999, PAIN FORUM, V8, P29; Vaskova J., 2016, GLOB J ANESTH, V3; Waldhoer M, 2004, ANNU REV BIOCHEM, V73, P953, DOI 10.1146/annurev.biochem.73.011303.073940; Walwyn WM, 2010, DRUG ALCOHOL DEPEN, V108, P156, DOI 10.1016/j.drugalcdep.2010.01.001; Wilde AS, 2019, FOOD CONTROL, V100, P1, DOI 10.1016/j.foodcont.2018.12.039; Xu B, 2006, BASIC CLIN PHARMACOL, V99, P153, DOI 10.1111/j.1742-7843.2006.pto_461.x; Yadav SK, 2014, CELL MOL BIOL, V60, P1; Yadav S.K., 2018, DEF LIFE SCI J, V3, P24; Yadav SK, 2018, INT J TOXICOL, V37, P28, DOI 10.1177/1091581817750560; Yadav Shiv Kumar, 2014, Interdiscip Toxicol, V7, P93, DOI 10.2478/intox-2014-0013; Zheng QS, 2005, PHARMAZIE, V60, P539; Zhou JF, 2000, BIOMED ENVIRON SCI, V13, P131; Zhu HB, 2001, TRENDS PHARMACOL SCI, V22, P404, DOI 10.1016/S0165-6147(00)01792-2	51	0	0	4	4	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0024-3205	1879-0631		LIFE SCI	Life Sci.	APR 1	2020	246								117400	10.1016/j.lfs.2020.117400			14	Medicine, Research & Experimental; Pharmacology & Pharmacy	Research & Experimental Medicine; Pharmacology & Pharmacy	KU2KK	WOS:000519537200010	32032645				2020-06-30	J	Gummin, DD				Gummin, David D.			Potent opioids and implications for national defense	TOXICOLOGY LETTERS			English	Article						Fentanyl; Fentalogs; Chemical defense; Environmental toxicity		Potent opioids are increasingly responsible for morbidity and mortality in the Western world. Fentanyl and fentanyl derivatives are increasingly prevalent as adulterants or substitutes for opioid drugs of abuse in Europe and in North America. Trafficking and distribution of these chemicals evolve continuously and are poorly characterized at this time. Rescue and emergency personnel are increasingly concerned with the possibility of unintentional environmental exposures that might occur in the course of their operational duties. There is evidence that opioid agonists have been broadcast or applied directly in an offensive manner as incapacitating agents. Defending against toxicity from such agents requires a thoughtful plan for protection, decontamination, and treatment.	[Gummin, David D.] Med Coll Wisconsin, Milwaukee, WI 53226 USA	Gummin, DD (reprint author), Med Coll Wisconsin, Milwaukee, WI 53226 USA.	dgummin@chw.org					Crowley Michael, 2014, TIME; Cui X, 2013, EUR J PHARMACOL, V702, P309, DOI 10.1016/j.ejphar.2013.01.060; Ellis CR, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0197734; Krechetnikov A, 2012, BBC NEWS; Mofenson H C, 1985, Compr Ther, V11, P46; MOFENSON HC, 1974, PEDIATRICS, V54, P336; National Institute for Occupational Safety and Health, 2019, FENT PREV OCC EXP EM; O'Connor S.O., 2019, FENTANYL FLOWS CHINA; Pelletier Danielle E, 2017, Acad Forensic Pathol, V7, P91, DOI 10.23907/2017.011; Riches JR, 2012, J ANAL TOXICOL, V36, P647, DOI 10.1093/jat/bks078; Spencer Merianne R, 2019, Natl Vital Stat Rep, V68, P1; United Nations Office on Drugs and Crime, 2019, WORLD DRUG REP	12	0	0	27	27	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0378-4274	1879-3169		TOXICOL LETT	Toxicol. Lett.	MAR 15	2020	321						90	94		10.1016/j.toxlet.2019.12.017			5	Toxicology	Toxicology	KB6US	WOS:000506628300011	31881244				2020-06-30	J	Truong, L; Kim, JH; Katheria, AC; Finer, NN; Marc-Aurele, K				Truong, Linda; Kim, Jae H.; Katheria, Anup C.; Finer, Neil N.; Marc-Aurele, Krishelle			Haemodynamic effects of premedication for neonatal intubation: an observational study	ARCHIVES OF DISEASE IN CHILDHOOD-FETAL AND NEONATAL EDITION			English	Article							NEAR-INFRARED SPECTROSCOPY; LEFT-HEART-SYNDROME; ENDOTRACHEAL INTUBATION; NASOTRACHEAL INTUBATION; CEREBRAL OXYGENATION; CARDIAC-SURGERY; ATROPINE; REMIFENTANIL; PALLIATION; RESPONSES	Objective To examine changes in blood pressure (BP), cardiac output (CO) and cerebral regional oxygen saturation (rScO2) with administration of premedication for neonatal intubation. Design Pilot, prospective, observational study. Oxygen saturation, heart rate, CO, rScO2 and BP data were collected. Monitoring began 5 min prior to premedication and continued until spontaneous movement. Setting Single-centre, level 3 neonatal intensive care unit Patients 35 infants, all gestational ages. 81 eligible infants: 66 consented, 15 refused. Interventions Intravenous atropine, fentanyl or morphine, +/- cisatracurium Main outcome measures BP, CO, rScO2 Results n=37 intubations. Mean gestational age and median birth weight were 31 4/7 weeks and 1511 g. After premedication, 10 episodes resulted in a BP increase from baseline and 27 in a BP decrease. Of those whose BP decreased, 17 had <20% decrease and 10 had >= 20% decrease. Those with <20% BP decrease took an average of 2.5 min to return to baseline while those with a >= 20% BP decline took an average of 15.2 min. Three did not return to baseline by 35 min. Following intubation, further declines in BP (21%-51%) were observed in eight additional cases. One infant required a bolus for persistently low BPs. CO and rScO2 changes were statistically similar between the two groups. Conclusion About 30% of infants dropped their BP by >= 20% after premedication for elective intubation. These BP changes were not associated with any significant change in rScO2 or CO. More data are needed to better characterise the immediate haemodynamic changes and clinical outcomes associated with premedication.	[Truong, Linda] Stanford Univ, Dept Pediat, Div Neonatal Dev Med, Palo Alto, CA 94304 USA; [Kim, Jae H.; Finer, Neil N.; Marc-Aurele, Krishelle] Univ Calif San Diego Hlth Syst, Dept Pediat, Div Neonatol, San Diego, CA USA; [Kim, Jae H.; Marc-Aurele, Krishelle] Rady Childrens Hosp San Diego, Dept Pediat, Div Neonatol, San Diego, CA USA; [Katheria, Anup C.] Sharp Mary Birch, Neonatol, San Diego, CA USA	Truong, L (reprint author), Stanford Univ, Dept Pediat, Div Neonatal & Dev Med, Palo Alto, CA 94304 USA.	ltruong524@gmail.com					Alverson D C, 1984, Am J Perinatol, V1, P148, DOI 10.1055/s-2007-999991; Anand KJS, 2001, ARCH PEDIAT ADOL MED, V155, P173, DOI 10.1001/archpedi.155.2.173; Austin EH, 1997, J THORAC CARDIOV SUR, V114, P707, DOI 10.1016/S0022-5223(97)70074-6; Ballabh P, 2010, PEDIATR RES, V67, P1, DOI 10.1203/PDR.0b013e3181c1b176; BARRINGTON KJ, 1989, CRIT CARE MED, V17, P1293, DOI 10.1097/00003246-198912000-00009; CASTOR G, 1994, BRIT J ANAESTH, V72, P133, DOI 10.1093/bja/72.1.133; Choong K, 2010, ARCH DIS CHILD-FETAL, V95, pF80, DOI 10.1136/adc.2009.167338; Durrmeyer X, 2018, JAMA-J AM MED ASSOC, V319, P1790, DOI 10.1001/jama.2018.3708; Hayashida M, 2004, BRIT J ANAESTH, V92, P662, DOI 10.1093/bja/aeh120; Hoffman GM, 2004, J THORAC CARDIOV SUR, V127, P223, DOI 10.1016/j.jtcvs.2003.08.021; Hyttel-Sorensen S, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.g7635; Johnson BA, 2009, ANN THORAC SURG, V87, P571, DOI 10.1016/j.athoracsur.2008.10.043; Katheria Anup C, 2015, Matern Health Neonatol Perinatol, V1, P15, DOI 10.1186/s40748-015-0016-3; KELLY MA, 1984, J PEDIATR-US, V105, P303, DOI 10.1016/S0022-3476(84)80137-7; Khan FZ, 2009, EUROPACE, V11, P1666, DOI 10.1093/europace/eup358; Kumar P, 2010, PEDIATRICS, V125, P608, DOI 10.1542/peds.2009-2863; Lemyre Brigitte, 2004, BMC Pediatr, V4, P20, DOI 10.1186/1471-2431-4-20; Li J, 2006, HEART, V92, P1678, DOI 10.1136/hrt.2005.087270; MARSHALL TA, 1984, CRIT CARE MED, V12, P501, DOI 10.1097/00003246-198406000-00006; Nafiu OO, 2009, PEDIATR ANESTH, V19, P1048, DOI 10.1111/j.1460-9592.2009.03140.x; Nollert G, 2000, THORAC CARDIOV SURG, V48, P247, DOI 10.1055/s-2000-6895; Oei J, 2002, J PAEDIATR CHILD H, V38, P146, DOI 10.1046/j.1440-1754.2002.00726.x; Phelps HM, 2009, ANN THORAC SURG, V87, P1490, DOI 10.1016/j.athoracsur.2009.01.071; RAJU TNK, 1980, J PEDIATR-US, V96, P860, DOI 10.1016/S0022-3476(80)80558-0; Roberts KD, 2006, PEDIATRICS, V118, P1583, DOI 10.1542/peds.2006-0590; Schmid MB, 2014, E PAS, V3843, P563; Shangle CE, 2012, J PEDIATR-US, V161, P252, DOI 10.1016/j.jpeds.2012.02.014; Silva YPE, 2007, ARCH DIS CHILD-FETAL, V92, P293, DOI 10.1136/adc.2006.105262; STOW PJ, 1988, BRIT J ANAESTH, V60, P167, DOI 10.1093/bja/60.2.167; van den Berg E, 2010, ARCH DIS CHILD-FETAL, V95, pF53, DOI 10.1136/adc.2008.156414; VanLooy JW, 2008, ANN PHARMACOTHER, V42, P947, DOI 10.1345/aph.1K665; Venkatesh V, 2011, EUR J PEDIATR, V170, P223, DOI 10.1007/s00431-010-1290-8; Welzing L, 2010, PEDIATR ANESTH, V20, P605, DOI 10.1111/j.1460-9592.2010.03330.x; 2006, PEDIATRICS, V118, P2231, DOI DOI 10.1542/PEDS.2006-2277	34	1	1	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1359-2998	1468-2052		ARCH DIS CHILD-FETAL	Arch. Dis. Child.-Fetal Neonatal Ed.	MAR	2020	105	2					F123	F127		10.1136/archdischild-2018-316235			5	Pediatrics	Pediatrics	LR4OP	WOS:000535676600004	31036701				2020-06-30	J	Davis, MP; Behm, B				Davis, Mellar P.; Behm, Bertrand			Reasons to avoid fentanyl	ANNALS OF PALLIATIVE MEDICINE			English	Review						Fentanyl; utility; respiratory depression; wooden chest syndrome; substance abuse	INDUCED MUSCULAR RIGIDITY; INDUCED RESPIRATORY DEPRESSION; CHEST-WALL RIGIDITY; OVERDOSE DEATHS; TRANSDERMAL DELIVERY; BREAKTHROUGH PAIN; OPIOID OVERDOSE; DRUG-USERS; MUSCARINIC RECEPTORS; SYNTHETIC OPIOIDS	Fentanyl has been FDA approval as an analgesic since 1968 and multiple different fentanyl preparations have been developed over the years. Little was known about it is clinical utility defined by risks and benefits until recently. Present commercially available preparations are easily tampered and nonpharmacologic fentanyl has become the major cause of opioid deaths in the United States. This state-ofthe-art review will discuss fentanyl pharmacology, utility, safety and abuse.	[Davis, Mellar P.; Behm, Bertrand] Geisinger Med Ctr, 100 N Acad Ave, Danville, PA 17822 USA	Davis, MP (reprint author), Geisinger Med Ctr, 100 N Acad Ave, Danville, PA 17822 USA.	mdavis2@geisinger.edu					Abrams JT, 1996, ANESTH ANALG, V83, P629, DOI 10.1097/00000539-199609000-00034; Ackerman W E, 1990, Anesth Prog, V37, P46; Adams NG, 2017, J CLIN EPIDEMIOL, V92, P111, DOI 10.1016/j.jclinepi.2017.08.016; Anderson DT, 2000, J ANAL TOXICOL, V24, P627, DOI 10.1093/jat/24.7.627; [Anonymous], 2012, OP PALL CAR SAF EFF; Arens AM, 2016, JAMA INTERN MED, V176, P1554, DOI 10.1001/jamainternmed.2016.4306; Armenian P, 2018, NEUROPHARMACOLOGY, V134, P121, DOI 10.1016/j.neuropharm.2017.10.016; Ashburn MA, 2011, ANESTH ANALG, V112, P693, DOI 10.1213/ANE.0b013e318209d320; ATCHESON R, 1993, BRIT J ANAESTH, V71, P540, DOI 10.1093/bja/71.4.540; Backberg M, 2015, CLIN TOXICOL, V53, P609, DOI 10.3109/15563650.2015.1054505; Backberg M, 2015, CLIN TOXICOL, V53, P46, DOI 10.3109/15563650.2014.981823; BAILEY PL, 1990, ANESTH ANALG, V70, P8; BAILEY PL, 1985, ANESTH ANALG, V64, P48; BAILEY PL, 1990, ANESTHESIOLOGY, V73, P826, DOI 10.1097/00000542-199011000-00005; Baumann MH, 2018, TRENDS PHARMACOL SCI, V39, P995, DOI 10.1016/j.tips.2018.09.006; Bennett JA, 1997, ANESTHESIOLOGY, V87, P1070, DOI 10.1097/00000542-199711000-00010; Bianchi RP, 2006, J FORENSIC SCI, V51, P939, DOI 10.1111/j.1556-4029.2006.00190.x; Boom M, 2013, ANESTHESIOLOGY, V119, P663, DOI 10.1097/ALN.0b013e31829ce4cb; Bostrom E, 2008, ANESTHESIOLOGY, V108, P495, DOI 10.1097/ALN.0b013e318164cf9e; Bostrom E, 2006, DRUG METAB DISPOS, V34, P1624, DOI 10.1124/dmd.106.009746; Bozat-Emre S, 2018, HEALTH PROMOT CHRON, V38, P252, DOI 10.24095/hpcdp.38.6.06; Breton-Provencher V, 2019, NAT NEUROSCI, V22, P218, DOI 10.1038/s41593-018-0305-z; Burns G, 2016, CLIN TOXICOL, V54, P420, DOI 10.3109/15563650.2016.1157722; Cameron-Burr KT, 2017, ENEURO, V4; Cameron-Burr KT, FENTANYL INDUCED BRA; Carson HJ, 2010, LEGAL MED, V12, P157, DOI 10.1016/j.legalmed.2010.03.001; Choi L, 2016, CRIT CARE MED, V44, P64, DOI 10.1097/CCM.0000000000001347; Citrome L, 2013, INT J CLIN PRACT, V67, P407, DOI 10.1111/ijcp.12142; Clarke SFJ, 2005, EMERG MED J, V22, P612, DOI 10.1136/emj.2003.009613; Davis MP, 2012, J PAIN SYMPTOM MANAG, V44, pE1, DOI 10.1016/j.jpainsymman.2012.06.002; Dodou K, 2015, PHARM DEV TECHNOL, V20, P694, DOI 10.3109/10837450.2014.915569; Doyon S, 2014, J MED TOXICOL, V10, P431, DOI 10.1007/s13181-014-0432-1; Drummer OH, 2019, FOREN SCI RES, V4, P95, DOI 10.1080/20961790.2018.1460063; Dworkin RH, 2008, J PAIN, V9, P105, DOI 10.1016/j.jpain.2007.09.005; Fain KM, 2017, J AM MED DIR ASSOC, V18, P138, DOI 10.1016/j.jamda.2016.08.015; Fairbairn N, 2017, INT J DRUG POLICY, V46, P172, DOI 10.1016/j.drugpo.2017.06.005; Fallon Marie, 2011, J Support Oncol, V9, P224, DOI 10.1016/j.suponc.2011.07.004; Firestone M, 2009, INT J DRUG POLICY, V20, P90, DOI 10.1016/j.drugpo.2008.02.016; Friesen KJ, 2016, CAN MED ASSOC J, V188, P648, DOI 10.1503/cmaj.150961; Frisoni P, 2018, BRAIN SCI, V8, DOI 10.3390/brainsci8090170; Fu MJ, 1997, ANESTHESIOLOGY, V87, P1450, DOI 10.1097/00000542-199712000-00024; Gensini Gian Franco, 2003, Ital Heart J, V4, P80; George AV, 2010, AM J EMERG MED, V28, P530, DOI 10.1016/j.ajem.2010.03.003; Gerak LR, 2019, HDB EXP PHARM; Gladden RM, 2016, MMWR-MORBID MORTAL W, V65, P837, DOI 10.15585/mmwr.mm6533a2; GRELL FL, 1970, ANESTH ANAL CURR RES, V49, P523; Gryczynski J, 2019, DRUG ALCOHOL DEPEN, V204, DOI 10.1016/j.drugalcdep.2019.06.017; Gupta R, 2016, NEW ENGL J MED, V375, P2213, DOI 10.1056/NEJMp1609578; Han Y, 2019, TRANSL PSYCHIAT, V9, DOI 10.1038/s41398-019-0625-0; Helander A, 2016, CLIN TOXICOL, V54, P324, DOI 10.3109/15563650.2016.1139715; Hendrickson RG, 2019, CLIN TOXICOL, V57, P813, DOI 10.1080/15563650.2018.1558233; Henthorn TK, 2018, ANESTHESIOLOGY, V128, P867, DOI 10.1097/ALN.0000000000002177; Hill R, 2020, BRIT J PHARMACOL, V177, P254, DOI 10.1111/bph.14860; Horng Huei-Chi, 2010, Acta Anaesthesiol Taiwan, V48, P155, DOI 10.1016/S1875-4597(10)60050-1; HUG CC, 1981, ANESTHESIOLOGY, V55, P369, DOI 10.1097/00000542-198110000-00006; HUSTVEIT O, 1994, JPN J PHARMACOL, V64, P57, DOI 10.1254/jjp.64.57; HUSTVEIT O, 1993, ACTA ANAESTH SCAND, V37, P541, DOI 10.1111/j.1399-6576.1993.tb03761.x; JACKSON FW, 1994, GASTROENTEROLOGY, V106, P820, DOI 10.1016/0016-5085(94)90729-3; Jaiswal J, 1999, INT J PHARMACEUT, V179, P129, DOI 10.1016/S0378-5173(98)00383-4; Jandhyala R, 2013, J PAIN SYMPTOM MANAG, V46, P573, DOI 10.1016/j.jpainsymman.2012.09.009; Janik R, 1988, Anasth Intensivther Notfallmed, V23, P260, DOI 10.1055/s-2007-1001629; Janknegt R, 2018, EUR J HOSP PHARM-S P, V25, pE2, DOI 10.1136/ejhpharm-2016-001127; Jones AA, 2018, JAMA PSYCHIAT, V75, P298, DOI 10.1001/jamapsychiatry.2017.4432; Jones CM, 2018, JAMA-J AM MED ASSOC, V319, P1819, DOI 10.1001/jama.2018.2844; Jones T. S., 2008, Morbidity and Mortality Weekly Report, V57, P793; Jumbelic MI, 2010, AM J FOREN MED PATH, V31, P18, DOI 10.1097/PAF.0b013e31818738b8; Khan N.F., 2019, JAMA INT MED; Kharasch ED, 2013, ANESTHESIOLOGY, V119, P504, DOI 10.1097/ALN.0b013e31829ce70b; Kim HK, 2015, EXPERT OPIN DRUG SAF, V14, P1137, DOI 10.1517/14740338.2015.1037274; Kimergard A, 2018, DRUG TEST ANAL, V10, P917, DOI 10.1002/dta.2397; Kiyatkin EA, 2019, NEUROPHARMACOLOGY, V151, P219, DOI 10.1016/j.neuropharm.2019.02.008; KLAUSNER JM, 1988, ARCH SURG-CHICAGO, V123, P66; Koehntop DE, FENTANYL PHARMACOKIN; Konapur R, 2019, J ADDICT NURS, V30, P2, DOI 10.1097/JAN.0000000000000266; Krenzelok EP, 2017, AM J HEALTH-SYST PH, V74, P556, DOI 10.2146/ajhp170050; Kuczynska K, 2018, FORENSIC SCI INT, V289, P207, DOI 10.1016/j.forsciint.2018.05.042; Kuhlman JJ, 2003, J ANAL TOXICOL, V27, P499, DOI 10.1093/jat/27.7.499; Kukanich B, 2012, J VET PHARMACOL THER, V35, P3, DOI 10.1111/j.1365-2885.2012.01416.x; KUMAR K, 1987, J CHROMATOGR-BIOMED, V419, P464, DOI 10.1016/0378-4347(87)80317-1; Lalley PM, 2003, AM J PHYSIOL-REG I, V285, pR1287, DOI 10.1152/ajpregu.00199.2003; Latimer J, INT J DRUG POLICY; Latkin CA, 2019, SUBST USE MISUSE, V54, P998, DOI 10.1080/10826084.2018.1555597; Lautt WW, 1996, CAN J PHYSIOL PHARM, V74, P223, DOI 10.1139/cjpp-74-3-223; Leen JLS, 2019, CAN J ANESTH, V66, P414, DOI 10.1007/s12630-019-01294-y; Lotsch J, 2013, CLIN PHARMACOKINET, V52, P23, DOI 10.1007/s40262-012-0016-7; Lozier MJ, 2015, J MED TOXICOL, V11, P208, DOI 10.1007/s13181-015-0477-9; LUI PW, 1989, ANESTHESIOLOGY, V70, P984, DOI 10.1097/00000542-198906000-00017; Lui PW, 1997, NEUROSCI LETT, V224, P189, DOI 10.1016/S0304-3940(97)00160-2; LUI PW, 1989, NEUROSCI LETT, V96, P114, DOI 10.1016/0304-3940(89)90252-8; Lui PW, 1995, NEUROSCI LETT, V201, P167, DOI 10.1016/0304-3940(95)12162-5; LUI PW, 1993, NEUROSCI LETT, V157, P145, DOI 10.1016/0304-3940(93)90723-X; Lyden J, 2019, SEMIN PERINATOL, V43, P123, DOI 10.1053/j.semperi.2019.01.001; Lynn RR, 2018, THER ADV DRUG SAF, V9, P63, DOI 10.1177/2042098617744161; Magosso E, 2004, IEEE T BIO-MED ENG, V51, P1115, DOI 10.1109/TBME.2004.827344; MARQUARDT KA, 1995, ANN PHARMACOTHER, V29, P969, DOI 10.1177/106002809502901001; Martin TL, 2006, J ANAL TOXICOL, V30, P603, DOI 10.1093/jat/30.8.603; MATHER LE, 1983, CLIN PHARMACOKINET, V8, P422, DOI 10.2165/00003088-198308050-00004; Mayer S, 2018, DRUG ALCOHOL DEPEN, V193, P69, DOI 10.1016/j.drugalcdep.2018.09.006; MCCLAIN DA, 1980, CLIN PHARMACOL THER, V28, P106, DOI 10.1038/clpt.1980.138; McEvoy Theresa, 2014, Hosp Pharm, V49, P942, DOI 10.1310/hpj4910-942; Mercadante S, 2007, J PAIN SYMPTOM MANAG, V34, P532, DOI 10.1016/j.jpainsymman.2007.01.006; Nakamura S, 2002, ANESTH ANALG, V95, P1389, DOI 10.1097/00000539-200211000-00053; NEIDHART P, 1989, ACTA ANAESTH SCAND, V33, P1, DOI 10.1111/j.1399-6576.1989.tb02849.x; Nelson L, 2009, J MED TOXICOL, V5, P230, DOI 10.1007/BF03178274; Netzer D, 2003, HAREFUAH, V142, P65; Netzer Doron, 2003, Harefuah, V142, P541; Novotna S, 2014, CLIN THER, V36, P357, DOI 10.1016/j.clinthera.2014.01.006; O'Donnell J, 2018, MMWR-MORBID MORTAL W, V67, P767, DOI 10.15585/mmwr.mm6727a4; O'Donnell JK, 2017, MMWR-MORBID MORTAL W, V66, P1197, DOI 10.15585/mmwr.mm6643e1; O'Donnell JK, 2017, MMWR-MORBID MORTAL W, V66, P897, DOI 10.15585/mmwr.mm6634a2; Oechsler Stephanie, 2009, Archiv fuer Kriminologie, V224, P26; Paech MJ, 2012, DRUG TODAY, V48, P119, DOI 10.1358/dot.2012.48.2.1745275; Panchagnula R, 2005, INT J PHARMACEUT, V293, P213, DOI 10.1016/j.ijpharm.2005.01.004; Panchagnula R, 2001, INT J PHARM, V219, P95, DOI 10.1016/S0378-5173(01)00634-2; Passik SD, 2014, PAIN MED, V15, P1365, DOI 10.1111/pme.12431; Passik SD, 2011, J PAIN SYMPTOM MANAG, V41, P116, DOI 10.1016/j.jpainsymman.2010.03.012; Pattinson KTS, 2016, ADV EXP MED BIOL, V903, P145, DOI 10.1007/978-1-4899-7678-9_10; Payne R, 1998, SEMIN ONCOL, V25, P47; Peterson AB, 2016, MMWR-MORBID MORTAL W, V65, P844, DOI 10.15585/mmwr.mm6533a3; Pichini S, 2018, THER DRUG MONIT, V40, P38, DOI 10.1097/FTD.0000000000000465; POKLIS A, 1995, J TOXICOL-CLIN TOXIC, V33, P439, DOI 10.3109/15563659509013752; Prekupec MP, 2017, J ADDICT MED, V11, P256, DOI 10.1097/ADM.0000000000000324; Raffa RB, 2018, J CLIN PHARM THER, V43, P154, DOI 10.1111/jcpt.12640; Raffa RB, 2014, EXPERT OPIN DRUG SAF, V13, P181, DOI 10.1517/14740338.2013.841136; RANDICH A, 1992, J NEUROPHYSIOL, V68, P1027; Rao G, 2003, J FAM PRACTICE, V52, P866; REX MAE, 1970, BRIT J ANAESTH, V42, P891, DOI 10.1093/bja/42.10.891; REX MAE, 1970, BRIT J ANAESTH, V42, P1067, DOI 10.1093/bja/42.12.1067; Richardson BE, 1997, ANN OTO RHINOL LARYN, V106, P920, DOI 10.1177/000348949710601107; Rogers JS, 2016, J EMERG MED, V50, P433, DOI 10.1016/j.jemermed.2015.10.014; Rollman JE, 2019, JAMA-J AM MED ASSOC, V321, P676, DOI 10.1001/jama.2019.0235; Roozekrans M, 2018, ANESTHESIOLOGY, V128, P932, DOI 10.1097/ALN.0000000000002138; Rosas R, 2019, ACS MED CHEM LETT, V10, P1353, DOI 10.1021/acsmedchemlett.9b00335; RUNAGYUTTIKARN W, 1990, J ANAL TOXICOL, V14, P160, DOI 10.1093/jat/14.3.160; Sande TA, 2017, SUPPORT CARE CANCER, V25, P661, DOI 10.1007/s00520-016-3447-0; Schauer CKMW, 2015, BASIC CLIN PHARMACOL, V117, P358, DOI 10.1111/bcpt.12412; Schifano F, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00046; Schiller EY, 2019, OPIOID OVERDOSE; Schneider JP, 2010, CNS DRUGS, V24, P805, DOI 10.2165/11584260-000000000-00000; Scholl L, 2019, MMWR-MORBID MORTAL W, V67, P1419; Schumann H, 2008, CLIN TOXICOL, V46, P501, DOI 10.1080/15563650701877374; Sellers Edward M, 2006, J Opioid Manag, V2, P219; Sheiner L B, 1978, Ann N Y Acad Sci, V304, P112, DOI 10.1111/j.1749-6632.1978.tb25582.x; Sinicina I, 2017, DRUG ALCOHOL DEPEN, V180, P286, DOI 10.1016/j.drugalcdep.2017.08.021; Slavova S, 2017, INT J DRUG POLICY, V46, P120, DOI 10.1016/j.drugpo.2017.05.051; Sohn JT, 2005, ANESTHESIOLOGY, V103, P327, DOI 10.1097/00000542-200508000-00016; Somerville NJ, 2017, MMWR-MORBID MORTAL W, V66, P382, DOI 10.15585/mmwr.mm6614a2; STANLEY TH, 1992, J PAIN SYMPTOM MANAG, V7, pS3, DOI 10.1016/0885-3924(92)90047-L; STANLEY TH, 1991, ANESTHESIOLOGY, V74, P388, DOI 10.1097/00000542-199102000-00043; Stanley TH, 2014, J PAIN, V15, P1215, DOI 10.1016/j.jpain.2014.08.010; STOELTING RK, 1975, ANESTHESIOLOGY, V42, P319, DOI 10.1097/00000542-197503000-00015; Stopka TJ, 2019, INT J DRUG POLICY, V68, P37, DOI 10.1016/j.drugpo.2019.03.024; Streisand JB, FENTANYL INDUCED RIG; Sutter ME, 2017, ACAD EMERG MED, V24, P106, DOI 10.1111/acem.13034; Tharp AM, 2004, AM J FOREN MED PATH, V25, P178, DOI 10.1097/01.paf.0000127398.67081.11; Thomas S, 2008, AM J FOREN MED PATH, V29, P162, DOI 10.1097/PAF.0b013e3181651b66; Thorpe LE, 2002, AM J EPIDEMIOL, V155, P645, DOI 10.1093/aje/155.7.645; Torralva R, 2019, J PHARMACOL EXP THER, V371, P453, DOI 10.1124/jpet.119.258566; TSOU MY, 1989, NEUROPHARMACOLOGY, V28, P1163, DOI 10.1016/0028-3908(89)90206-2; Rivera IV, 2014, ADV THER, V31, P107, DOI 10.1007/s12325-013-0086-4; Wilde M, 2020, TOXICOL LETT, V320, P109, DOI 10.1016/j.toxlet.2019.11.025; WILLETTE RN, 1987, J PHARMACOL EXP THER, V240, P352; WILLETTE RN, 1982, EUR J PHARMACOL, V80, P57, DOI 10.1016/0014-2999(82)90177-7; Willman MW, 2017, CLIN TOXICOL, V55, P81, DOI 10.1080/15563650.2016.1253846; Wong J O, 1997, Acta Anaesthesiol Sin, V35, P25; Woodall KL, 2008, J FORENSIC SCI, V53, P222, DOI 10.1111/j.1556-4029.2007.00597.x; Yamamoto R, 2012, INT J PHARMACEUT, V422, P132, DOI 10.1016/j.ijpharm.2011.10.042; YANG PK, 1992, ANESTHESIOLOGY, V77, P153, DOI 10.1097/00000542-199207000-00022; Yassen A, 2008, PHARM RES, V25, P183, DOI 10.1007/s11095-007-9440-z; YASUDA I, 1978, ANESTHESIOLOGY, V49, P117, DOI 10.1097/00000542-197808000-00012; Zawilska JB, 2017, FRONT PSYCHIATRY, V8, DOI 10.3389/fpsyt.2017.00110	171	0	0	8	8	AME PUBL CO	SHATIN	FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG 00000, PEOPLES R CHINA	2224-5820	2224-5839		ANN PALLIAT MED	Ann. Pallliat. Med.	MAR	2020	9	2					611	624		10.21037/apm.2020.01.12			14	Health Care Sciences & Services	Health Care Sciences & Services	KY7VP	WOS:000522781300068	32156127	Other Gold			2020-06-30	J	Krajewski, LC; Swanson, KD; Bragg, WA; Shaner, RL; Seymour, C; Carter, MD; Hamelin, EI; Johnson, RC				Krajewski, Logan C.; Swanson, Kenneth D.; Bragg, William A.; Shaner, Rebecca L.; Seymour, Craig; Carter, Melissa D.; Hamelin, Elizabeth I.; Johnson, Rudolph C.			Application of the fentanyl analog screening kit toward the identification of emerging synthetic opioids in human plasma and urine by LC-QTOF	TOXICOLOGY LETTERS			English	Article						LC-QTOF; Fentanyl analogs; Synthetic opioids; Fentanyl Analog Screening Kit; Opioid	WHOLE-BLOOD; IMMUNOASSAY; METABOLITES; MS	Human exposures to fentanyl analogs, which significantly contribute to the ongoing U.S. opioid overdose epidemic, can be confirmed through the analysis of clinical samples. Our laboratory has developed and evaluated a qualitative approach coupling liquid chromatography and quadrupole time-of-flight mass spectrometry (LC-QTOF) to address novel fentanyl analogs and related compounds using untargeted, data-dependent acquisition. Compound identification was accomplished by searching against a locally-established mass spectral library of 174 fentanyl analogs and metabolites. Currently, our library can identify 150 fentanyl-related compounds from the Fentanyl Analog Screening (FAS) Kit), plus an additional 25 fentanyl-related compounds from individual purchases. Plasma and urine samples fortified with fentanyl-related compounds were assessed to confirm the capabilities and intended use of this LC-QTOF method. For fentanyl, 8 fentanyl-related compounds and naloxone, lower reportable limits (LRL100), defined as the lowest concentration with 100 % true positive rate (n=12) within clinical samples, were evaluated and range from 0.5 ng/mL to 5.0 ng/mL for urine and 0.25 ng/mL to 2.5 ng/mL in plasma. The application of this high resolution mass spectrometry (HRMS) method enables the real-time detection of known and emerging synthetic opioids present in clinical samples.	[Krajewski, Logan C.] Ctr Dis Control & Prevent, Battelle Mem Inst, Atlanta, GA 30341 USA; [Swanson, Kenneth D.; Bragg, William A.; Shaner, Rebecca L.; Seymour, Craig; Carter, Melissa D.; Hamelin, Elizabeth I.; Johnson, Rudolph C.] CDC, Natl Ctr Environm Hlth, Div Sci Lab, Atlanta, GA 30341 USA	Shaner, RL (reprint author), Ctr Dis Control & Prevent, Div Sci Lab, 4770 Buford Hwy NE,MS-F44, Atlanta, GA 30341 USA.	rebecca.shaner@cdc.hhs.gov			CDC's National Center for Injury prevention and Control; National Center for Injury Prevention and ControlUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA; CDCUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA	TRACEABLE OPIOID MATERIAL, TOM KITS, and the TOM KITS logo are marks of the U.S. Department of Health and Human Services. The CDC appreciates the College of American Pathologists' (CAP) assistance in providing essential information of CAP proficiency testing samples used in this program. This work was funded through CDC's National Center for Injury prevention and Control. The authors would like to especially thank the National Center for Injury Prevention and Control and the many CDC offices that provided support in the areas of contracting, policy, communications, ethics, technology transfer, general counsel, and administrative services.	Angelini DJ, 2019, FORENSIC SCI INT, V300, P75, DOI 10.1016/j.forsciint.2019.04.019; [Anonymous], 2013, J ANAL TOXICOL, V37, P452, DOI 10.1093/jat/bkt054; Buchalter S, 2019, J CHROMATOGR A, V1596, P183, DOI 10.1016/j.chroma.2019.03.011; Busardo FP, 2019, FRONT CHEM, V7, DOI 10.3389/fchem.2019.00184; Butler DC, 2018, J ANAL TOXICOL, V42, pE6, DOI 10.1093/jat/bkx083; Caymen, FENT AN SCREEN KITS; Campos-Manas MC, 2019, SCI TOTAL ENVIRON, V664, P874, DOI 10.1016/j.scitotenv.2019.01.389; DEA, 2018, 2018 EM THREAT REP; Fogarty MF, 2018, J ANAL TOXICOL, V42, P592, DOI 10.1093/jat/bky035; GILLESPIE TJ, 1981, J ANAL TOXICOL, V5, P133, DOI 10.1093/jat/5.3.133; Guerrieri D, 2019, J ANAL TOXICOL, V43, P18, DOI 10.1093/jat/bky060; HENDERSON GL, 1991, J FORENSIC SCI, V36, P422; Martucci HFH, 2018, FORENSIC SCI INT, V283, pE13, DOI 10.1016/j.forsciint.2017.12.005; Misailidi N, 2019, FORENSIC TOXICOL, V37, P238, DOI 10.1007/s11419-018-0449-2; Mochizuki A., 2018, FORENSIC TOXICOL, V37, P27; Mojica MA, 2019, TOXICOL LETT, V317, P53, DOI 10.1016/j.toxlet.2019.09.017; Mounteney J, 2015, INT J DRUG POLICY, V26, P626, DOI 10.1016/j.drugpo.2015.04.003; Noble C, 2018, DRUG TEST ANAL, V10, P651, DOI 10.1002/dta.2263; Palamar JJ, 2019, AM J DRUG ALCOHOL AB, V45, P90, DOI 10.1080/00952990.2018.1550652; Palmquist KB, 2019, FORENSIC SCI INT, V297, P189, DOI 10.1016/j.forsciint.2019.02.006; Partridge E, 2018, J ANAL TOXICOL, V42, P655, DOI 10.1093/jat/bky039; RUNAGYUTTIKARN W, 1990, J ANAL TOXICOL, V14, P160, DOI 10.1093/jat/14.3.160; Salomone A, 2019, J ANAL TOXICOL, V43, P259, DOI 10.1093/jat/bky093; Scholl L, 2019, MMWR-MORBID MORTAL W, V67, P1419; SCHUTTLER J, 1984, ANESTHESIOLOGY, V61, P315, DOI 10.1097/00000542-198409000-00010; Seymour C, 2019, J ANAL TOXICOL, V43, P266, DOI 10.1093/jat/bky096; Shanks KG, 2017, J ANAL TOXICOL, V41, P466, DOI 10.1093/jat/bkx042; Sofalvi S, 2017, J ANAL TOXICOL, V41, P473, DOI 10.1093/jat/bkx052; Strayer KE, 2018, ACS OMEGA, V3, P514, DOI 10.1021/acsomega.7b01536; Swanson DM, 2017, J ANAL TOXICOL, V41, P498, DOI 10.1093/jat/bkx037; United Nations Office on Drugs and Crime, 2017, FENT ITS AN 50 YEARS; VANROOY HH, 1981, J CHROMATOGR, V223, P85, DOI 10.1016/S0378-4347(00)80070-5; Vardanyan RS, 2014, FUTURE MED CHEM, V6, P385, DOI 10.4155/fmc.13.215; Wang GH, 2011, FORENSIC SCI INT, V206, P127, DOI 10.1016/j.forsciint.2010.07.022	34	1	1	20	20	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0378-4274	1879-3169		TOXICOL LETT	Toxicol. Lett.	MAR 1	2020	320						87	94		10.1016/j.toxlet.2019.12.007			8	Toxicology	Toxicology	JZ3SU	WOS:000505022400012	31812604				2020-06-30	J	Wilde, M; Sommer, MJ; Auwarter, V; Hermanns-Clausen, M				Wilde, Maurice; Sommer, Michaela J.; Auwaerter, Volker; Hermanns-Clausen, Maren			Acute severe intoxication with cyclopropylfentanyl, a novel synthetic opioid	TOXICOLOGY LETTERS			English	Article						Opioids; Fentanyl analogues; Cyclopropylfentanyl; Crossreactivity; New psychoactive substances	FENTANYL	Background: Since 2016 an increase has been observed in the availability of new synthetic opioids (NSO) in Europe. Cyclopropylfentanyl is a very potent and selective mu-opioid agonist, which was reported for the first time in August 2017 in Europe. Methods: The case was included in a prospective observational study of patients treated in emergency departments after the intake of novel psychoactive substances (NPS). Clinical features were acquired using a structured questionnaire for physicians. Serum and/or urine samples of ED patients were analyzed using liquid chromatography-electrospray ionization-tandem mass spectrometry (LC-ESI-MS/MS) screening methods for NPS. Case report: Within 10 min after intranasal intake of fentanyl, a 25-year-old male developed nausea, profuse sweating and dyspnoe. Because soon afterwards coma and respiratory insufficiency was noticed, the patient was admitted to hospital. After administration of naloxone (0.8 mg) breathing stabilized. However, the patient displayed recurrent decreases of oxygen saturation for 12 h. The intake of cyclopropylfentanyl was analytically confirmed. Conclusion: The constantly growing diversity of NSO still poses a high risk for drug users and can be a challenging task for clinicians and forensic toxicologists. Clinicians treating opioid overdoses should be aware of the potentially long lasting respiratory depression induced by fentanyl analogs.	[Wilde, Maurice; Sommer, Michaela J.; Auwaerter, Volker] Univ Freiburg, Inst Forens Med, Med Ctr, Forens Toxicol, Freiburg, Germany; [Wilde, Maurice; Sommer, Michaela J.] Univ Freiburg, Hermann Staudinger Grad Sch, Freiburg, Germany; [Auwaerter, Volker] Univ Freiburg, Fac Med, Freiburg, Germany; [Hermanns-Clausen, Maren] Univ Freiburg, Dept Gen Pediat Adolescent Med & Neonatol, Poisons Informat Ctr, Ctr Pediat,Med Ctr, Freiburg, Germany	Hermanns-Clausen, M (reprint author), Univ Freiburg, Dept Gen Pediat Adolescent Med & Neonatol, Poisons Informat Ctr, Ctr Pediat,Med Ctr, Freiburg, Germany.	maren.hermanns-clausen@uniklinik-freiburg.de	Auwarter, Volker/D-1075-2012	Auwarter, Volker/0000-0002-1883-2804	German Federal Ministry of Health (BMG)	This publication has been produced with financial support of the German Federal Ministry of Health (BMG) project "EVA-NpSG Evaluation der Auswirkungen des Neue-psychoaktive-Stoffe Gesetzes (NpSG)".	[Anonymous], 2017, LANCET, V390, P2016, DOI DOI 10.1016/S0140-6736(17)32129-3; Backberg M, 2015, CLIN TOXICOL, V53, P609, DOI 10.3109/15563650.2015.1054505; Brockbals L, 2019, FORENSIC SCI INT, V294, P80, DOI 10.1016/j.forsciint.2018.11.007; Chen QS, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2018.7621; Christrup LL, 2008, CLIN THER, V30, P469, DOI 10.1016/j.clinthera.2008.03.001; Ciccarone D, 2019, INT J DRUG POLICY, V71, P183, DOI 10.1016/j.drugpo.2019.01.010; Compton WM, 2016, NEW ENGL J MED, V374, P154, DOI 10.1056/NEJMra1508490; Drug Enforcement Administration (DEA) Drug and Chemical Evaluation Section Diversion Control Division, 2017, DRUG CHEM EV SECT DI; European Monitoring Centre for Drugs and Drug Addiction, 2018, EUR DRUG REP 2018 TR; European Monitoring Centre for Drugs and Drug Addiction, 2017, EUR DRUG REP 2017 TR; European Monitoring Centre for Drugs and Drug Addiction, 2018, REP RISK ASS N PHEN; European Monitoring Centre for Drugs and Drug Addiction, 2018, FENT SYNTH CANN DRIV; Fagiola M, 2019, J ANAL TOXICOL, V43, pE1, DOI 10.1093/jat/bky094; Gagajewski A, 2002, CLIN CHEM, V48, P205; Helander A, 2018, DRUG TEST ANAL, V10, P1297, DOI 10.1002/dta.2382; Helander A, 2017, CLIN TOXICOL, V55, P589, DOI 10.1080/15563650.2017.1303141; Misicka A., 2019, MOLECULES, V24, P740; Muller D, 2019, CLIN TOXICOL, V57, P806, DOI 10.1080/15563650.2018.1554187; Ritter D, 1997, CLIN CHEM, V43, P635; Rogers JS, 2016, J EMERG MED, V50, P433, DOI 10.1016/j.jemermed.2015.10.014; Sutter ME, 2017, ACAD EMERG MED, V24, P106, DOI 10.1111/acem.13034; Takeda Pharmaceutical Company Ltd, 2009, INST 50 MCG NAS SPRA; United Nations Office on Drugs and Crime, 2019, WORLD DRUG REP 2019; Volpe DA, 2011, REGUL TOXICOL PHARM, V59, P385, DOI 10.1016/j.yrtph.2010.12.007	24	2	2	9	9	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0378-4274	1879-3169		TOXICOL LETT	Toxicol. Lett.	MAR 1	2020	320						109	112		10.1016/j.toxlet.2019.11.025			4	Toxicology	Toxicology	JZ3SU	WOS:000505022400015	31778775				2020-06-30	J	Jasne, AS; Alsherbini, KA; Smith, MS; Kuohn, LR; Pandhi, A; Vagal, A; Kanter, DS				Jasne, Adam S.; Alsherbini, Khalid A.; Smith, Matthew S.; Kuohn, Lindsey R.; Pandhi, Abhi; Vagal, Achala; Kanter, Daniel S.			Response to "Malignant cerebella edema in three-year-old girl following accidental opioid ingestion and fentanyl administration"	NEURORADIOLOGY JOURNAL			English	Letter									[Jasne, Adam S.; Kuohn, Lindsey R.] Yale Sch Med, Dept Neurol, New Haven, CT USA; [Alsherbini, Khalid A.] Univ Tennessee, Hlth Sci Ctr, Dept Neurol & Neurosurg, Knoxville, TN 37996 USA; [Smith, Matthew S.; Kanter, Daniel S.] Univ Cincinnati, Dept Neurol & Rehabil Med, Cincinnati, OH 45221 USA; [Pandhi, Abhi] Univ Tennessee Hlth Sci, Dept Neurol, Knoxville, TN USA; [Vagal, Achala] Univ Cincinnati, Dept Radiol, Cincinnati, OH 45221 USA	Jasne, AS (reprint author), Yale Sch Med, 15 York St LLCI,10th Floor,Suite 1004, New Haven, CT 06520 USA.		Alsherbini, Khalid/AAI-6894-2020				Barash JA, 2018, NEUROCASE, V24, P124, DOI 10.1080/13554794.2018.1475572; Barash JA, 2017, MMWR-MORBID MORTAL W, V66, P76, DOI 10.15585/mmwr.mm6603a2; Chen CH, 2019, NEURORADIOL J, V32, P386, DOI 10.1177/1971400919863713; Jasne AS, 2019, NEUROCRIT CARE, V31, P288, DOI 10.1007/s12028-018-00666-4	4	0	0	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1971-4009	2385-1996		NEURORADIOL J	Neuradiology J.	APR	2020	33	2					158	158	UNSP 1971400920903106	10.1177/1971400920903106		FEB 2020	1	Neuroimaging	Neurosciences & Neurology	LA1RS	WOS:000511558300001	32013696				2020-06-30	J	Fernandez, MDR; Wille, SMR; Jankowski, D; Hill, V; Samyn, N				Ramirez Fernandez, Maria del Mar; Wille, Sarah M. R.; Jankowski, Danielle; Hill, Virginia; Samyn, Nele			Development of an UPLC-MS/MS method for the analysis of 16 synthetic opioids in segmented hair, and evaluation of the polydrug history in fentanyl analogue users	FORENSIC SCIENCE INTERNATIONAL			English	Article						Fentanyl analogues; Hair; Poly-drug use; NPS; Validation; UPLC-MS/MS	MASS-SPECTROMETRY METHOD; WHOLE-BLOOD; LC-MS/MS; INTOXICATIONS	yy Seizures of synthetic opioids have increased since 2012, with a 45 % increase in synthetic opioid related deaths between 2016 and 2017 in US. Recently, concerns have arisen around these substances and their illicit use also in several European countries. Our aim was to develop and validate an ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) method for the analysis of 16 synthetic opioids in segmented hair, including fentanyl, norfentanyl, acetylfentanyl, U-47700, AH-7921, acrylfentanyl, crotonylfentanyl, butyrylfentanyl, methoxacetylfentanyl, U-49900, valeryfentanyl, 4-fluoro-iso-butyrylfentanyl, ocfentanyl, furanylfentanyl, tetrahydrofuranylfentanyl, and alfetanyl. Sample preparation involved washing the hair in dichloromethane, water and methanol, and extraction in methanol, followed by solid phase extraction clean-up. This method was validated for linearity, limit of quantification (LLOQ), precision and bias, selectivity, stability, matrix effects, extraction efficiency of the clean up procedure, and carryover. LLOQs ranged from 0.15-1 pg/mg, and the calibration ranged from the LLOQ up to 500 pg/mg. Intra and inter-day precision were evaluated at low and high concentrations, with spiked QCs, during 8 days and the results were satisfactory with RSD < 15 % for all the compounds except for norfentanyl (22 %) and alfentanyl (19 %). Two external certified QCs containing fentanyl at 11 and 105 pg/mg were also analysed within each batch and the RSD and bias were lower than 16 % and 10 %, respectively. Matrix effects compensated by internal standard fentanyl-d5 (MEIS), were between 77-115 % (RSD < 10 %) and extraction efficiency of the clean-up procedure was between 66-93 % (RSD < 21 %). Processed sample stability and carryover were acceptable for all of the compounds. The method was applied to 17 authentic hair samples (body or head hair) from US fentanyl analogue users. When head hair was available, the hair strands were analysed in 1 cm/segment. Concentrations ranges were as follows: fentanyl (n = 16) 2->ULOQ (500) pg/mg, norfentanyl (n = 14) 1-38 pg/mg, acetylfentanyl (n = 7) 0.6->ULOQ ( 250) pg/mg, furanylfentanyl (n = 5) 2-123 pg/mg, tetrahydrofuranylfentanyl (n = 1) 0.5-63 pg/mg and valerylfentanyl (n = 1) 2.1->ULOQ (50) pg/mg, along the hair strands. To our knowledge, this is the first time where concentrations of tetrahydrofuranylfentanyl, and valerylfentanyl in hair are reported. The same samples were also analysed for the determination of other drugs of abuse using our routine method (also in 1 cm/segment for head hair when available). The results demonstrated poly-drug use in these fentanyl-analogue users population (mean drugs: n = 5): amphetamine and/or methamphetamine (n = 10), buprenorphine (n = 5), cocaine (n = 8), methadone (n = 8), 6-MAM (n = 17), meperidine (n = 1), oxycodone (n = 11), tramadol (n = 3). Evaluation of the concentrations of these drugs, together with the fentanyl analogues is discussed in the present paper. Two authentic samples from two Belgian post-mortem cases, were also analysed showing fentanyl use and in one case polydrug use. The results demonstrated multi-analyte quantitative methods, including fentanyl analogues, are becoming useful in forensic laboratories involved in hair analysis, and in particular when polydrug use is suspected. (C) 2020 Elsevier B.V. All rights reserved.	[Ramirez Fernandez, Maria del Mar; Wille, Sarah M. R.; Samyn, Nele] Natl Inst Criminalist & Criminol, Fed Publ Serv Justice, Chaussee Vilvorde 100, Brussels 1120, Belgium; [Jankowski, Danielle] Kings Coll London, Dept Analyt Environm & Forens Sci, London, England; [Hill, Virginia] Psychemed Corp, Culver City, CA USA	Fernandez, MDR (reprint author), Natl Inst Criminalist & Criminol, Fed Publ Serv Justice, Chaussee Vilvorde 100, Brussels 1120, Belgium.	mariadelmar.ramirezfernandez@just.fgov.be					Backberg M, 2015, CLIN TOXICOL, V53, P609, DOI 10.3109/15563650.2015.1054505; Busardo FP, 2019, FRONT CHEM, V7, DOI 10.3389/fchem.2019.00184; EMCDDA, 2018, EUR DRUG REP; Fernandez MDR, 2014, J CHROMATOGR B, V965, P7, DOI 10.1016/j.jchromb.2014.05.055; Higashikawa Y, 2008, FORENSIC TOXICOL, V26, P1, DOI 10.1007/s11419-007-0039-1; Kahl JH, 2018, J ANAL TOXICOL, V42, P570, DOI 10.1093/jat/bky054; Marchei E, 2018, TRAC-TREND ANAL CHEM, V102, P1, DOI 10.1016/j.trac.2018.01.007; Matuszewski BK, 2006, J CHROMATOGR B, V830, P293, DOI 10.1016/j.jchromb.2005.11.009; Mohr ALA, 2016, J ANAL TOXICOL, V40, P709, DOI 10.1093/jat/bkw086; Mrvos R, 2012, J EMERG MED, V42, P549, DOI 10.1016/j.jemermed.2011.05.017; MULLER D, 2019, CLIN TOXICOL, V18, P1, DOI DOI 10.1080/15563650.2018.1554187; Palamar JJ, 2019, AM J DRUG ALCOHOL AB, V45, P90, DOI 10.1080/00952990.2018.1550652; Pichini S, 2018, THER DRUG MONIT, V40, P38, DOI 10.1097/FTD.0000000000000465; Salomone A, 2019, J ANAL TOXICOL, V43, P259, DOI 10.1093/jat/bky093; Schifano F, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00046; Schug SA, 2017, DRUGS, V77, P747, DOI 10.1007/s40265-017-0727-z; Shoff EN, 2017, J ANAL TOXICOL, V41, P484, DOI 10.1093/jat/bkx041; Sofalvi S, 2017, J ANAL TOXICOL, V41, P473, DOI 10.1093/jat/bkx052; Strayer KE, 2018, ACS OMEGA, V3, P514, DOI 10.1021/acsomega.7b01536; VANBEVER WFM, 1976, ARZNEIMITTELFORSCH, V26, P1548; Verplaetse R, 2010, J CHROMATOGR B, V878, P1987, DOI 10.1016/j.jchromb.2010.05.033; Wille SMR, 2017, CURR PHARM DESIGN, V23, P5442, DOI 10.2174/1381612823666170714154444	22	0	0	6	6	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0379-0738	1872-6283		FORENSIC SCI INT	Forensic Sci.Int.	FEB	2020	307								110137	10.1016/j.forsciint.2019.110137			9	Medicine, Legal	Legal Medicine	LK1TG	WOS:000530640800018	31927248				2020-06-30	J	Evans, RG; Iguchi, N; Cochrane, AD; Marino, B; Hood, SG; Bellomo, R; McCall, PR; May, CN; Lankadeva, YR				Evans, Roger G.; Iguchi, Naoya; Cochrane, Andrew D.; Marino, Bruno; Hood, Sally G.; Bellomo, Rinaldo; McCall, Peter R.; May, Clive N.; Lankadeva, Yugeesh R.			Renal hemodynamics and oxygenation during experimental cardiopulmonary bypass in sheep under total intravenous anesthesia	AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY			English	Article						acute kidney injury; cardiac surgery; hypoxia; renal circulation	ACUTE KIDNEY INJURY; MEDULLARY HYPOXIA; PERFUSION; TENSION; LACTATE; FLOW	Renal medullary hypoxia may contribute to the pathophysiology of acute kidney injury, including that associated with cardiac surgery requiring cardiopulmonary bypass (CPB). When performed under volatile (isoflurane) anesthesia in sheep, CPB causes renal medullary hypoxia. There is evidence that total intravenous anesthesia (TIVA) may preserve renal perfusion and renal oxygen delivery better than volatile anesthesia. Therefore, we assessed the effects of CPB on renal perfusion and oxygenation in sheep under propofol/fentanyl-based TIVA. Sheep (n = 5) were chronically instrumented for measurement of whole renal blood flow and cortical and medullary perfusion and oxygenation. Five days later, these variables were monitored under TIVA using propofol and fentanyl and then on CPB at a pump flow of 80 mL.kg(-1).min(-1) and target mean arterial pressure of 70 mmHg. Under anesthesia, before CPB, renal blood flow was preserved under TIVA (mean difference +/- SD from conscious state: -16 +/- 14%). However, during CPB renal blood flow was reduced (-55 +/- 13%) and renal medullary tissue became hypoxic (-20 +/- 13 mmHg versus conscious sheep). We conclude that renal perfusion and medullary oxygenation are well preserved during TIVA before CPB. However, CPB under TIVA leads to renal medullary hypoxia, of a similar magnitude to that we observed previously under volatile (isoflurane) anesthesia. Thus use of propofol/fentanyl-based TIVA may not be a useful strategy to avoid renal medullary hypoxia during CPB.	[Evans, Roger G.] Monash Univ, Biomed Discovery Inst, Cardiovasc Dis Program, Melbourne, Vic, Australia; [Evans, Roger G.] Monash Univ, Dept Physiol, 26 Innovat Walk, Melbourne, Vic 3800, Australia; [Iguchi, Naoya; Hood, Sally G.; May, Clive N.; Lankadeva, Yugeesh R.] Univ Melbourne, Florey Inst Neurosci & Mental Hlth, Preclin Crit Care Unit, Melbourne, Vic, Australia; [Cochrane, Andrew D.] Monash Univ, Monash Hlth, Dept Cardiothorac Surg, Melbourne, Vic, Australia; [Cochrane, Andrew D.] Monash Univ, Dept Surg, Sch Clin Sci, Monash Hlth, Melbourne, Vic, Australia; [Marino, Bruno] Cellsaving & Perfus Resources, Melbourne, Vic, Australia; [Bellomo, Rinaldo] Austin Hlth, Dept Intens Care, Heidelberg, Vic, Australia; [McCall, Peter R.] Austin Hlth, Dept Anesthesia, Heidelberg, Vic, Australia	Evans, RG (reprint author), Monash Univ, Dept Physiol, 26 Innovat Walk, Melbourne, Vic 3800, Australia.	Roger.Evans@monash.edu		Evans, Roger/0000-0002-9241-0757; May, Clive/0000-0001-8548-3846; Lankadeva, Yugeesh/0000-0002-3589-9111	National Health and Medical Research Council of AustraliaNational Health and Medical Research Council of Australia [GNT1122455]; Victorian Government Operational Infrastructure Support Grant; National Heart Foundation of AustraliaNational Heart Foundation of Australia [NHF-101853]	This work was supported by National Health and Medical Research Council of Australia Grant GNT1122455, Victorian Government Operational Infrastructure Support Grant, and National Heart Foundation of Australia Grant NHF-101853.	ANDERSSON LG, 1994, EUR J CARDIO-THORAC, V8, P597, DOI 10.1016/1010-7940(94)90043-4; Calzavacca P, 2015, AM J PHYSIOL-REG I, V308, pR832, DOI 10.1152/ajpregu.00515.2014; Choi DK, 2014, J CARDIOTHOR VASC AN, V28, P564, DOI 10.1053/j.jvca.2013.12.005; Darby PJ, 2013, PERFUSION-UK, V28, P504, DOI 10.1177/0267659113490219; DAUGHERTY RM, 1967, AM J PHYSIOL, V213, P1102; Evans RG, 2018, ACTA PHYSIOL, V222, DOI 10.1111/apha.12995; Evans RG, 2014, AM J PHYSIOL-REG I, V306, pR45, DOI 10.1152/ajpregu.00437.2013; Franchini KG, 1999, AM J PHYSIOL-REG I, V277, pR1662; Hare GMT, 2018, CAN J ANESTH, V65, P901, DOI 10.1007/s12630-018-1140-0; Himpe D, 2003, BRIT J ANAESTH, V90, P440, DOI 10.1093/bja/aeg084; Hu JC, 2016, J CARDIOTHOR VASC AN, V30, P82, DOI 10.1053/j.jvca.2015.06.017; Iguchi N, 2019, BRIT J ANAESTH, V122, P342, DOI 10.1016/j.bja.2018.11.018; JOHNSON KG, 1971, J AGR SCI, V77, P267, DOI 10.1017/S0021859600024412; Kainuma M, 1996, J CARDIOTHOR VASC AN, V10, P603, DOI 10.1016/S1053-0770(96)80137-6; Landoni G, 2019, NEW ENGL J MED, V380, P1214, DOI 10.1056/NEJMoa1816476; Lankadeva YR, 2019, KIDNEY INT, V95, P1338, DOI 10.1016/j.kint.2019.01.032; Lankadeva YR, 2018, METHODS MOL BIOL, V1717, P207, DOI 10.1007/978-1-4939-7526-6_16; Lannemyr L, 2019, ANN THORAC SURG, V107, P505, DOI 10.1016/j.athoracsur.2018.08.085; Lannemyr L, 2017, ANESTHESIOLOGY, V126, P205, DOI 10.1097/ALN.0000000000001461; Lee CJ, 2019, AM J PHYSIOL-RENAL, V317, pF1483, DOI 10.1152/ajprenal.00315.2019; LUDBROOK J, 1994, CARDIOVASC RES, V28, P303, DOI 10.1093/cvr/28.3.303; McKinlay J, 2018, ANAESTHESIA, V73, P85, DOI 10.1111/anae.14144; Motayagheni N, 2017, AM J NEPHROL, V46, P380, DOI 10.1159/000482014; Murphy GS, 2009, ANESTH ANALG, V108, P1394, DOI 10.1213/ane.0b013e3181875e2e; Ngo JP, 2019, ACTA PHYSIOL, V227, DOI 10.1111/apha.13294; Oh YJ, 2006, BRIT J ANAESTH, V97, P792, DOI 10.1093/bja/ael268; Ow CPC, 2018, ACTA PHYSIOL, V222, DOI 10.1111/apha.12999; Ruf B, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0760-9; Sgouralis I, 2017, MATH MED BIOL, V34, P313, DOI 10.1093/imammb/dqw010; Sgouralis I, 2015, PHYSIOL REP, V3, DOI 10.14814/phy2.12260; Shinde Santosh B, 2005, Ann Card Anaesth, V8, P39; Stafford-Smith M, 2005, PERFUSION-UK, V20, P53, DOI 10.1191/0267659105pf780oa; Svenmarker S, 2006, SCAND CARDIOVASC J, V40, P305, DOI 10.1080/14017430600900261; TUKEY JW, 1949, BIOMETRICS, V5, P99, DOI 10.2307/3001913; Yoo YC, 2014, KIDNEY INT, V86, P414, DOI 10.1038/ki.2013.532; Zhu MZL, 2018, NEPHROL DIAL TRANSPL, V33, P2191, DOI 10.1093/ndt/gfy047	36	1	1	1	1	AMER PHYSIOLOGICAL SOC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0363-6119	1522-1490		AM J PHYSIOL-REG I	Am. J. Physiol.-Regul. Integr. Comp. Physiol.	FEB	2020	318	2					R206	R213		10.1152/ajpregu.00290.2019			8	Physiology	Physiology	KN9CG	WOS:000515142900003	31823674				2020-06-30	J	Terakado, T; Nakai, Y; Ikeda, G; Uemura, K; Matsumaru, Y; Ishikawa, E; Matsumura, A				Terakado, Toshitsugu; Nakai, Yasunobu; Ikeda, Go; Uemura, Kazuya; Matsumaru, Yuji; Ishikawa, Eiichi; Matsumura, Akira			Effectiveness of Low-Dose Intravenous Fentanyl for Postoperative Headache Management After Neck Clipping of Ruptured Intracranial Aneurysms	WORLD NEUROSURGERY			English	Article						Aneurysm clipping; Fentanyl; Headache; Subarachnoid hemorrhage	NONSTEROIDAL ANTIINFLAMMATORY DRUGS; SUBARACHNOID HEMORRHAGE; MAGNESIUM; POLYMORPHISM; GABAPENTIN; MODEL; PAIN	BACKGROUND: After subarachnoid hemorrhage (SAH), headache management is often difficult owing to the need to use multiple analgesic drugs. Fentanyl is an opioid we can use after surgery, and it can decrease pain post SAH. The aim of this study was to investigate the effectiveness and safety of fentanyl for management of headache after SAH. METHODS: Twenty-two patients who underwent surgical clipping for ruptured intracranial aneurysms and complained of severe headache after the surgery were enrolled. Among them, 9 patients were given fentanyl combined with other analgesic drugs. The numeric rating scale score and dietary intake were measured in the acute phase after the SAH. RESULTS: The numeric rating scale scores were significantly lower in the fentanyl ( + ) group. The maximum numeric rating scale decreased to <5 points within 16.5 +/- 2.9 days in the fentanyl ( - ) group and within 12.0 +/- 2.6 days in the fentanyl ( + ) group. The median numeric rating scale decreased to <5 points over 14.0 +/- 4.2 days in the fentanyl ( - ) group and >7.7 +/- 3.8 days in the fentanyl ( + ) group. At day 14, the fentanyl ( + ) group showed significantly better dietary intake than that of the fentanyl ( - ) group. CONCLUSIONS: Using fentanyl after surgical clipping for ruptured intracranial aneurysms might decrease headache and produce few adverse effects. Adequate headache control showed improved dietary intake after SAH.	[Terakado, Toshitsugu; Nakai, Yasunobu; Ikeda, Go; Uemura, Kazuya] Univ Tsukuba, Tsukuba Med Ctr Hosp, Dept Neurosurg, Tsukuba, Ibaraki, Japan; [Matsumaru, Yuji; Ishikawa, Eiichi; Matsumura, Akira] Univ Tsukuba, Fac Med, Dept Neurosurg, Tsukuba, Ibaraki, Japan	Terakado, T (reprint author), Univ Tsukuba, Tsukuba Med Ctr Hosp, Dept Neurosurg, Tsukuba, Ibaraki, Japan.	toshi_0211jp@yahoo.co.jp					Bond C, 1998, P NATL ACAD SCI USA, V95, P9608, DOI 10.1073/pnas.95.16.9608; Bonnet U, 2017, EUR NEUROPSYCHOPHARM, V27, P1185, DOI 10.1016/j.euroneuro.2017.08.430; Connolly ES, 2012, STROKE, V43, P1711, DOI 10.1161/STR.0b013e3182587839; Dhakal LP, 2015, NEUROCRIT CARE, V22, P414, DOI 10.1007/s12028-014-0086-5; Dreier JP, 2000, J NEUROSURG, V93, P658, DOI 10.3171/jns.2000.93.4.0658; FACCHINETTI F, 1991, HEADACHE, V31, P298, DOI 10.1111/j.1526-4610.1991.hed3105298.x; Fassbender K, 2000, STROKE, V31, P2971, DOI 10.1161/01.STR.31.12.2971; Frazier JL, 2004, J NEUROSURG, V101, P93, DOI 10.3171/jns.2004.101.1.0093; Fukuda K, 2009, PAIN, V147, P194, DOI 10.1016/j.pain.2009.09.004; Glisic EK, 2016, AM J CRIT CARE, V25, P136, DOI 10.4037/ajcc2016486; Hjermstad MJ, 2011, J PAIN SYMPTOM MANAG, V41, P1073, DOI 10.1016/j.jpainsymman.2010.08.016; INAGAWA T, 1995, STROKE, V26, P761, DOI 10.1161/01.STR.26.5.761; Japanese Society of Clinicalcytology, 2015, JAP GUID MAN STROK 2, P18; Kita Y, 1999, INT J EPIDEMIOL, V28, P1059, DOI 10.1093/ije/28.6.1059; Lotsch J, 2006, BEHAV NEUROSCI, V120, P1218, DOI 10.1037/0735-7044.120.6.1218; Magalhaes JE, 2013, HEADACHE, V53, P1613, DOI 10.1111/head.12165; Mees SMD, 2010, J NEUROL NEUROSUR PS, V81, P490, DOI 10.1136/jnnp.2009.181404; Mees SMD, 2012, LANCET, V380, P44, DOI 10.1016/S0140-6736(12)60724-7; Morad AH, 2016, HEADACHE, V56, P1617, DOI 10.1111/head.12908; Muroi C, 2014, NEUROCRIT CARE, V20, P240, DOI 10.1007/s12028-013-9930-2; Naganuma Masaki, 2008, J Stroke Cerebrovasc Dis, V17, P334, DOI 10.1016/j.jstrokecerebrovasdis.2008.04.009; Niemi T, 1999, J NEUROSURG ANESTH, V11, P188, DOI 10.1097/00008506-199907000-00006; Patel R, 2016, PHARMACOL RES PERSPE, V4, DOI 10.1002/prp2.205; Rasouli J, 2019, J CLIN NEUROSCI, V68, P9, DOI 10.1016/j.jocn.2019.07.057; Rocha PAS, 2015, HEADACHE, V55, P733, DOI 10.1111/head.12563; Shimony N, 2016, J NEUROSURG, V125, P1513, DOI 10.3171/2015.10.JNS151516; Stanley TH, 2014, J PAIN, V15, P1215, DOI 10.1016/j.jpain.2014.08.010; Steiner T, 2013, CEREBROVASC DIS, V35, P93, DOI 10.1159/000346087; Strassman AM, 2006, J NEUROPHYSIOL, V95, P1298, DOI 10.1152/jn.01293.2005; van den Bergh WM, 2006, STROKE, V37, P2326, DOI 10.1161/01.STR.0000236841.16055.0f	30	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1878-8750	1878-8769		WORLD NEUROSURG	World Neurosurg.	FEB	2020	134						E339	E345		10.1016/j.wneu.2019.10.062			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	KK6VS	WOS:000512878200041	31634620				2020-06-30	J	McFarland, A; Mama, KR; Kinney, ME; Thurber, MI; Clancy, MM; Lamberski, N; Oosterhuis, JE; Howard, LL				McFarland, Alexander; Mama, Khursheed R.; Kinney, Matthew E.; Thurber, Mary, I; Clancy, Meredith M.; Lamberski, Nadine; Oosterhuis, James E.; Howard, Lauren L.			REPEATED USE OF A THIAFENTANIL-BASED ANESTHESIA PROTOCOL IN AN OKAPI (OKAPIA JOHNSTONI)	JOURNAL OF ZOO AND WILDLIFE MEDICINE			English	Article						Anesthesia; Okapi; Okapia johnstoni; thiafentanil	CARFENTANIL-XYLAZINE	Seven anesthesia events were performed over 6 wk on a 1.5-yr-old female okapi (Okapia johnstoni) being managed for a fetlock injury. A combination of butorphanol (B) (median; range) (0.045; 0.031-0.046 mg/kg), medetomidine (M) (0.037; 0.031-0.037 mg/kg), ketamine (K) (0.553; 0.536-1.071 mg/kg), and thiafentanil (T) (0.0045; 0.0040-0.0046 mg/kg) was administered in a padded stall. One dart containing all drugs was used for the first two anesthesias. Subsequently, BM was administered 10 min prior to KT using two darts. Time (median; range) from initial injection to first effects (6; 3-7 min) and recumbency (14; 4-20 min) were recorded. Induction quality with the one-dart protocol was poor or fair and was good or excellent with the two-dart protocol. Following recumbency, the okapi was intubated and ventilated, and physiological parameters were recorded. Anesthesia was consistently achieved with BMKT, but induction was smoother with the staged two-dart approach. Neither resedation nor renarcotization was observed post-reversal.	[McFarland, Alexander; Mama, Khursheed R.] Colorado State Univ, Coll Vet Med & Biomed Sci, Dept Clin Sci, Ft Collins, CO 80523 USA; [Kinney, Matthew E.; Clancy, Meredith M.; Lamberski, Nadine; Oosterhuis, James E.; Howard, Lauren L.] San Diego Zoo Safari Pk, Harter Vet Med Ctr, 15500 San Pasqua Valley Rd, Escondido, CA 92027 USA; [Thurber, Mary, I] Oakland Zoo, 9777 Golf Links Rd, Oakland, CA 94605 USA	Mama, KR (reprint author), Colorado State Univ, Coll Vet Med & Biomed Sci, Dept Clin Sci, Ft Collins, CO 80523 USA.	kmama@colostate.edu					Bertelsen MF, 2015, FOWLERS ZOO WILD ANI, P602; Bouts T, 2017, J ZOO WILDLIFE MED, V48, P616, DOI 10.1638/2016-0047.1; Citino S., 2006, P AM ASS ZOO VET, P211; Citino SB, 2010, P AM ASS ZOO VET, P201; Citino SB, 2014, ZOO ANIMAL AND WILDLIFE IMMOBILIZATION AND ANESTHESIA, 2ND EDITION, P809; Cushing A, 2011, J ZOO WILDLIFE MED, V42, P713, DOI 10.1638/2010-0140.1; Kilgallon CP, 2010, J ZOO WILDLIFE MED, V41, P567, DOI 10.1638/2010-0021.1; Lian M, 2016, J WILDLIFE DIS, V52, P327, DOI 10.7589/2015-04-101; Mallon D., 2015, IUCN RED LIST THREAT, V2015, DOI [10.2305/IUCN.UK.2015-4.RLTS.T15188A51140517.en, DOI 10.2305/IUCN.UK.2015-4.RLTS.T15188A51140517.EN]; Murison PJ, 2012, VET ANAESTH ANALG, V39, P449, DOI 10.1111/j.1467-2995.2012.00738.x	10	0	0	0	0	AMER ASSOC ZOO VETERINARIANS	YULEE	581705 WHITE OAK ROAD, YULEE, FL 32097 USA	1042-7260	1937-2825		J ZOO WILDLIFE MED	J. Zoo Wildl. Med.	JAN	2020	50	4					993	996		10.1638/2019-0037			4	Veterinary Sciences	Veterinary Sciences	KC0LX	WOS:000506880100031	31926534				2020-06-30	J	Chuang, CW; Chen, KS; Lee, WM; Wang, HC				Chuang, Che-Wei; Chen, Kuan-Sheng; Lee, Wei-Ming; Wang, Hsien-Chi			Comparison of the effects of morphine-lidocaine-ketamine and fentanyl-lidocaine-ketamine combinations administered as constant rate infusions on postprocedure rectal temperature in dogs	AMERICAN JOURNAL OF VETERINARY RESEARCH			English	Article							BODY-TEMPERATURE; INTRAVENOUS-INFUSION; HYPOTHERMIA; RECEPTOR; PROSTAGLANDINS; ACETYLCHOLINE; HISTAMINE; AGONISTS; SYSTEM	OBJECTIVE To compare the effects of morphine-lidocaine-ketamine (MLK) and fentanyl-lidocaine-ketamine (FLK) combinations administered as constant rate infusions (CRIs) during and after veterinary procedures on postprocedure rectal temperature in dogs. ANIMALS 32 clinically normal client-owned dogs undergoing nonemergent procedures. PROCEDURES Dogs were randomly assigned to receive an MLK or FLK combination (16 dogs/group). During the procedure, each dog received 2% lidocaine hydrochloride (1 mg/kg/h; both groups), ketamine hydrochloride (0.6 mg/kg/h; both groups), and morphine (0.36 mg/kg/h; MLK group) or fentanyl (4 mu g/kg/h; FLK group) via CRI for analgesia; esophageal temperature was maintained at 37 degrees to 39 degrees C. At extubation, each drug dose in each assigned combination was halved and administered (via CRI) for 12 additional hours for postprocedure analgesia. Rectal temperature and other data were recorded at baseline (prior to administration of premedicants), extubation (0 hours), and 0.5, 1.5, 3, 6, and 12 hours thereafter. RESULTS Mean postprocedure rectal temperature was significantly lower at each postextubation time point for the MLK group, compared with corresponding values for the FLK group. Compared with the baseline value, mean postprocedure rectal temperature was significantly lower at 0, 0.5, 1.5, and 3 hours for the FLK group and at all postprocedure time points for the MLK group. Hypothermia (rectal temperature < 37 degrees C) was detected at >= 1 postprocedure time point more often in dogs in the MLK group (9/16) than in the FLK group (1/16). CONCLUSIONS AND CLINICAL RELEVANCE Dogs that received an MLK combination for analgesia during and after a veterinary procedure developed hypothermia more commonly than did dogs that received an FLK combination under similar conditions.	[Chuang, Che-Wei; Chen, Kuan-Sheng; Lee, Wei-Ming; Wang, Hsien-Chi] Natl Chung Hsing Univ, Coll Vet Med, Dept Vet Med, Taichung 40227, Taiwan; [Chen, Kuan-Sheng; Lee, Wei-Ming; Wang, Hsien-Chi] Natl Chung Hsing Univ, Coll Vet Med, Vet Med Teaching Hosp, Taichung 40227, Taiwan; [Chuang, Che-Wei] Loving Kindness Anim Hosp, 539,Sect 2,Guoguang Rd, Taichung 41266, Taiwan	Wang, HC (reprint author), Natl Chung Hsing Univ, Coll Vet Med, Dept Vet Med, Taichung 40227, Taiwan.; Wang, HC (reprint author), Natl Chung Hsing Univ, Coll Vet Med, Vet Med Teaching Hosp, Taichung 40227, Taiwan.	hcwang@dragon.nchu.edu.tw					ADLER MW, 1988, ANNU REV PHARMACOL, V28, P429, DOI 10.1146/annurev.pa.28.040188.002241; Armstrong SR, 2005, J VET EMERG CRIT CAR, V15, P32, DOI 10.1111/j.1476-4431.2005.04033.x; Baker AK, 2002, J PHARMACOL EXP THER, V302, P1253, DOI 10.1124/jpet.102.037655; Boscan P, 2005, AM J VET RES, V66, P2122, DOI 10.2460/ajvr.2005.66.2122; Brodeur A, 2017, J VET EMERG CRIT CAR, V27, P151, DOI 10.1111/vec.12572; CHEN JC, 1993, LIFE SCI, V52, P389, DOI 10.1016/0024-3205(93)90152-S; CLARK WG, 1980, NEUROSCI BIOBEHAV R, V4, P175, DOI 10.1016/0149-7634(80)90015-9; CLARK WG, 1985, NEUROSCI BIOBEHAV R, V9, P479, DOI 10.1016/0149-7634(85)90023-5; Davis H, 2013, J AM ANIM HOSP ASSOC, V49, P149, DOI 10.5326/JAAHA-MS-5868; Gharagozlou Parham, 2006, BMC Pharmacol, V6, P3, DOI 10.1186/1471-2210-6-3; GLOSTEN B, 1991, REGION ANESTH, V16, P218; Guedes AGP, 2007, J VET PHARMACOL THER, V30, P224, DOI 10.1111/j.1365-2885.2007.00849.x; HASKINS SC, 1985, AM J VET RES, V46, P1855; Holden D, 2007, MANUAL CANINE FELINE, P296; Ikeda T, 2001, ANESTH ANALG, V93, P934, DOI 10.1097/00000539-200110000-00027; Kinoshita Takao, 2004, Journal of Nippon Medical School, V71, P92, DOI 10.1272/jnms.71.92; Kongsayreepong S, 2003, ANESTH ANALG, V96, P826, DOI 10.1213/01.ANE.0000048822.27698.28; Laflamme D, 1997, CANINE PRACT, V22, P10; LEFEBVRE RA, 1981, EUR J PHARMACOL, V69, P139, DOI 10.1016/0014-2999(81)90408-8; Lester PA, 2006, BRAIN RES, V1073, P290, DOI 10.1016/j.brainres.2005.12.066; Lucas AN, 2001, J AM VET MED ASSOC, V218, P884, DOI 10.2460/javma.2001.218.884; MATSUKAWA T, 1995, ANESTHESIOLOGY, V83, P961, DOI 10.1097/00000542-199511000-00008; Pekcan Z, 2010, VET ANAESTH ANALG, V37, P557, DOI 10.1111/j.1467-2995.2010.00571.x; Redondo JI, 2012, VET REC, V171, P374, DOI 10.1136/vr.100476; Reid J, 2007, ANIM WELFARE, V16, P97; SCHULTEAMESCH J, 1978, ACTA NEUROCHIR, V45, P15, DOI 10.1007/BF01774380; YOSHIHARA H, 1985, THROMB RES, V37, P503, DOI 10.1016/0049-3848(85)90096-9	27	0	0	2	2	AMER VETERINARY MEDICAL ASSOC	SCHAUMBURG	1931 N MEACHAM RD SUITE 100, SCHAUMBURG, IL 60173-4360 USA	0002-9645	1943-5681		AM J VET RES	Am. J. Vet. Res.	JAN	2020	81	1					58	64		10.2460/ajvr.81.1.58			7	Veterinary Sciences	Veterinary Sciences	JZ1NW	WOS:000504872500016	31887085	Bronze			2020-06-30	J	Uppal, V; Retter, S; Casey, M; Sancheti, S; Matheson, K; McKeen, DM				Uppal, Vishal; Retter, Susanne; Casey, Margaret; Sancheti, Sushil; Matheson, Kara; McKeen, Dolores M.			Efficacy of Intrathecal Fentanyl for Cesarean Delivery: A Systematic Review and Meta-analysis of Randomized Controlled Trials With Trial Sequential Analysis	ANESTHESIA AND ANALGESIA			English	Review							ANALGESIC EFFICACY; SPINAL-ANESTHESIA; BUPIVACAINE; SUFENTANIL; MORPHINE; SECTION; OPIOIDS	BACKGROUND: Fentanyl and morphine are the 2 most commonly added opioids to bupivacaine for spinal anesthesia during cesarean delivery. Numerous clinical trials have assessed efficacy and safety of different doses of fentanyl added to intrathecal bupivacaine for spinal anesthesia, yet its benefit, harm, and optimal dose remain unclear. This study aimed to systematically review the evidence of the efficacy of fentanyl when added to intrathecal bupivacaine alone and when added to bupivacaine with morphine for spinal anesthesia during cesarean delivery. METHODS: Key electronic databases (PubMed, Embase, and Cochrane Library) were searched for randomized controlled trials in the cesarean delivery population. The primary outcome was the failure rate of spinal anesthesia, as assessed by the need for either conversion to general anesthesia or intraoperative analgesic supplementation. Two reviewers independently extracted the data using a standardized electronic form. Results are expressed as relative risks or mean differences with 95% CIs. RESULTS: Seventeen randomized controlled clinical trials (most judged as low or unclear risk of bias) with 1064 participants provided data for the meta-analysis. Fentanyl added to intrathecal bupivacaine alone reduced the need for intraoperative supplemental analgesia (relative risk, 0.18; 95% CI, 0.11-0.27; number needed to treat, 4) and the incidence of nausea/vomiting (relative risk, 0.41; 95% CI, 0.24-0.70; number needed to treat, 6.5), with longer time to first postoperative analgesia request (mean difference, 91 minutes; 95% CI, 69-113). No difference was observed regarding the need for conversion to general anesthesia (relative risk, 0.67; 95% CI, 0.12-3.57), the incidence of hypotension, the onset of sensory block, or the duration of motor block. However, the addition of intrathecal fentanyl was associated with higher incidence of intraoperative pruritus (relative risk, 5.89; 95% CI, 2.07-16.79; number needed to harm, 13.5). The inclusion of fentanyl to intrathecal bupivacaine-morphine compared to intrathecal bupivacaine-morphine alone conferred a similar benefit, with a significantly reduced need for intraoperative supplemental analgesia (relative risk, 0.16; 95% CI, 0.03-0.95; number needed to treat, 9). Analysis using a funnel plot indicated a possibility of publication bias in included studies. CONCLUSIONS: Current evidence suggests a benefit of using fentanyl as both an additive to intrathecal bupivacaine alone and to intrathecal bupivacaine combined with morphine for cesarean delivery under spinal anesthesia. The possibility of publication bias, small sample size, and high risk of bias in some of the included studies warrant treating the results with caution.	[Uppal, Vishal; Retter, Susanne; Casey, Margaret; Sancheti, Sushil; McKeen, Dolores M.] Dalhousie Univ, Dept Anesthesia Perioperat Med & Pain Management, Nova Scotia Hlth Author, 5th Floor,Halifax Infirm Site,Rm 5452, Halifax, NS B3H 2Y9, Canada; [Uppal, Vishal; Retter, Susanne; Casey, Margaret; Sancheti, Sushil; McKeen, Dolores M.] Izaak Walton Killam Hlth Ctr, 5th Floor,Halifax Infirm Site,Rm 5452, Halifax, NS B3H 2Y9, Canada; [Matheson, Kara] Nova Scotia Hlth Author, Res Methods Unit, Halifax, NS, Canada	Uppal, V (reprint author), Dalhousie Univ, Dept Anesthesia Perioperat Med & Pain Management, Nova Scotia Hlth Author, 5th Floor,Halifax Infirm Site,Rm 5452, Halifax, NS B3H 2Y9, Canada.; Uppal, V (reprint author), Izaak Walton Killam Hlth Ctr, 5th Floor,Halifax Infirm Site,Rm 5452, Halifax, NS B3H 2Y9, Canada.	v.uppal@dal.ca	Uppal, Vishal/AAN-7925-2020; Uppal, Vishal/AAL-8513-2020	Uppal, Vishal/0000-0001-7263-2072			Agrawal Amit, 2016, Anesth Essays Res, V10, P420; Armstrong S, 2016, DRUG SAFETY, V39, P381, DOI 10.1007/s40264-015-0386-5; Bano Fauzia, 2006, J Coll Physicians Surg Pak, V16, P87; BELZARENA SD, 1992, ANESTH ANALG, V74, P653; Betran AP, 2016, PLOS ONE, V11, DOI DOI 10.1371/JOURNAL.PONE.0148343; Biswas BN, 2002, INDIAN J ANAESTH, V46, P469; Carvalho B, 2012, INT J OBSTET ANESTH, V21, P29, DOI 10.1016/j.ijoa.2011.09.002; CHANDRA BJ, 2008, J ANAESTHESIOL CLIN, V24, P420; Cowan CM, 2002, BRIT J ANAESTH, V89, P452; Dahl JB, 1999, ANESTHESIOLOGY, V91, P1919, DOI 10.1097/00000542-199912000-00045; Dahlgren G, 1997, ANESTH ANALG, V85, P1288, DOI 10.1097/00000539-199712000-00020; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Ginosar Y, 2013, BRIT J ANAESTH, V111, P433, DOI 10.1093/bja/aet075; Girgin NK, 2008, J CLIN ANESTH, V20, P180, DOI 10.1016/j.jclinane.2007.07.010; Hamber EA, 1999, REGION ANESTH PAIN M, V24, P255; Higgins JPT, 2009, COCHRANE HDB SYSTEMA, Vxxi, P649; Higgins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928; Idowu O A, 2011, Afr J Med Med Sci, V40, P213; Jain K, 2004, INT J OBSTET ANESTH, V13, P215, DOI 10.1016/j.ijoa.2004.04.006; JAYARAM A, 1993, ANESTH ANALG, V76, P745; Khezri MB, 2014, PAIN RES TREAT, V2014, DOI 10.1155/2014/513628; Khezri Marzieh Beigom, 2016, Middle East J Anaesthesiol, V23, P427; MAHAJAN R, 2005, [No title captured], V21, P51; Moore A, 2014, CAN J ANESTH, V61, P916, DOI 10.1007/s12630-014-0208-8; Ngiam S. K. K., 1998, SMJ, V39, P290; Olofsson C, 1997, ACTA ANAESTH SCAND, V41, P332, DOI 10.1111/j.1399-6576.1997.tb04694.x; PALMER CM, 1991, ANESTHESIOLOGY, V74, P1153, DOI 10.1097/00000542-199106000-00029; Sadegh Ali, 2012, Med J Islam Repub Iran, V26, P85; Shamseer L, 2015, BMJ-BRIT MED J, V349, DOI [10.1136/bmj.i4086, 10.1136/bmj.g7647]; Sharawi N, 2018, ANESTH ANALG, V127, P1385, DOI 10.1213/ANE.0000000000003636; Shende D, 1998, ANAESTHESIA, V53, P706, DOI 10.1046/j.1365-2044.1998.329-az0482.x; Sng BL, 2018, ANAESTHESIA, V73, P499, DOI 10.1111/anae.14084; Tagaloa LAL, 2009, ANESTHESIOL RES PRAC, V2009, DOI 10.1155/2009/510642; Techanivate Anchalee, 2005, Journal of the Medical Association of Thailand, V88, P1214; Tyagi P, 2013, INDIAN J PUBLIC HLTH, V4, P19; Uppal V, 2017, ANESTH ANALG, V125, P1627, DOI 10.1213/ANE.0000000000002254; Uppal V, 2017, CAN J ANESTH, V64, P991, DOI 10.1007/s12630-017-0930-0; Viscomi CM, 1996, REGION ANESTH, V21, P424; Wetterslev J, 2017, BMC MED RES METHODOL, V17, DOI 10.1186/s12874-017-0315-7; WHITEHEAD A, 1991, STAT MED, V10, P1665, DOI 10.1002/sim.4780101105	40	4	4	1	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	JAN	2020	130	1					111	125		10.1213/ANE.0000000000003975			15	Anesthesiology	Anesthesiology	JW3YU	WOS:000502991500028	30633056				2020-06-30	J	Lee, AYS; Smith, AJF; Krummenacher, M; Hughes, TL				Lee, Adrian Y. S.; Smith, Anthony J. F.; Krummenacher, Matthew; Hughes, Tiffany L.			An unusual case of loperamide anaphylaxis	ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY			English	Letter									[Lee, Adrian Y. S.; Smith, Anthony J. F.; Hughes, Tiffany L.] Flinders Med Ctr, Dept Allergy Clin Immunol, Bedford Pk, SA, Australia; [Lee, Adrian Y. S.] SA Pathol FMC, Dept Immunol, Bedford Pk, SA, Australia; [Lee, Adrian Y. S.; Smith, Anthony J. F.; Hughes, Tiffany L.] Flinders Univ S Australia, Coll Med & Publ Hlth, Bedford Pk, SA, Australia; [Lee, Adrian Y. S.] Univ Tasmania, Menzies Inst Med Res, Hobart, Tas, Australia; [Krummenacher, Matthew] Royal Adelaide Hosp, Dept Immunol, Adelaide, SA, Australia	Lee, AYS (reprint author), Flinders Med Ctr, Dept Allergy Clin Immunol, Bedford Pk, SA, Australia.; Lee, AYS (reprint author), SA Pathol FMC, Dept Immunol, Bedford Pk, SA, Australia.; Lee, AYS (reprint author), Flinders Univ S Australia, Coll Med & Publ Hlth, Bedford Pk, SA, Australia.; Lee, AYS (reprint author), Univ Tasmania, Menzies Inst Med Res, Hobart, Tas, Australia.	adrian.lee2@sa.gov.au					Australian and New Zealand Anaesthetic Allergy Group, ANZAAG PER AN INV GU; Blunk JA, 2004, ANESTH ANALG, V98, P364, DOI 10.1213/01.ANE.0000097168.32472.0D; di Bosco AM, 2008, CHEM BIOL DRUG DES, V71, P328, DOI 10.1111/j.1747-0285.2008.00637.x; Li PH, 2017, J ALLER CL IMM-PRACT, V5, P1601, DOI 10.1016/j.jaip.2017.03.035; Nahas O, 2017, ALLERGOL INT, V66, P139, DOI 10.1016/j.alit.2016.05.011; Nasser SMS, 2001, CLIN EXP ALLERGY, V31, P1014, DOI 10.1046/j.1365-2222.2001.01090.x; PARSONS RL, 1977, CLIN PHARMACOKINET, V2, P45, DOI 10.2165/00003088-197702010-00004; Perez-Calderon R, 2004, ALLERGY, V59, P369, DOI 10.1046/j.1398-9995.2003.00393.x; Regnard Claud, 2011, J Pain Symptom Manage, V42, P319, DOI 10.1016/j.jpainsymman.2011.06.001; Srinivasa MR, 2007, ALLERGY, V62, P965, DOI 10.1111/j.1398-9995.2007.01423.x	10	0	0	3	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1081-1206	1534-4436		ANN ALLERG ASTHMA IM	Ann. Allergy Asthma Immunol.	JAN	2020	124	1					93	94		10.1016/j.anai.2019.10.017			3	Allergy; Immunology	Allergy; Immunology	JU9NM	WOS:000501994400015	31669917	Bronze			2020-06-30	J	Nesoff, ED; Branas, CC; Martins, SS				Nesoff, Elizabeth D.; Branas, Charles C.; Martins, Silvia S.			The Geographic Distribution of Fentanyl-Involved Overdose Deaths in Cook County, Illinois	AMERICAN JOURNAL OF PUBLIC HEALTH			English	Article							UNITED-STATES; HEROIN; DISORDER; OPIOIDS; COCAINE; CRIME; USERS	Objectives. To contrast the geographic distribution of fentanyl-involved and nonfentanyl-involved fatal overdoses between 2014 and 2018 in Cook County, Illinois. Methods. We conducted a spatial analysis using locations of fentanyl-involved fatal overdoses (n = 1433) compared with nonfentanyl opioid and polydrug fatal overdoses (n = 1838) collected through the Cook County Medical Examiner's Office from 2014 to 2018. We also used logistic regression to test significant individual- and neighborhood-level covariates. Results. Fentanyl overdoses geographically clustered more than nonfentanyl overdoses, and this difference was statistically significant. One area in particular showed significantly elevated risk for fentanyl overdoses (P<.05) located in 2 specific neighborhoods of Chicago. The odds of a fentanyl-involved overdose were significantly increased for men, Blacks, Latinos/as, and younger individuals. Neighborhood deprivation score was the only significant neighborhood-level predictor (odds ratio = 1.11; 95% confidence interval = 1.07, 1.17). Conclusions. Fentanyl-involved fatal overdoses follow a distinct geographic distribution associated with resource deprivation in neighborhoods where they occur. This suggests an evolving bifurcated drug market, with drug markets in resource-deprived neighborhoods disproportionately likely to include fentanyl.	[Nesoff, Elizabeth D.; Branas, Charles C.; Martins, Silvia S.] Columbia Univ, Dept Epidemiol, Mailman Sch Publ Hlth, 722 W 168th St,5th floor, New York, NY 10032 USA	Nesoff, ED (reprint author), Columbia Univ, Dept Epidemiol, Mailman Sch Publ Hlth, 722 W 168th St,5th floor, New York, NY 10032 USA.	en2408@columbia.edu		Martins, Silvia/0000-0003-3059-9993; Nesoff, Elizabeth/0000-0001-8562-8646	National Institute on Drug AbuseUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [T32DA031099]	This work was supported by the National Institute on Drug Abuse (grant T32DA031099).	Bebinger M., 2018, FENTANYL LACED COCAI; Branas CC, 2018, P NATL ACAD SCI USA, V115, P2946, DOI 10.1073/pnas.1718503115; Centers for Disease Control and Prevention, 2018, RIS NUMB DEATHS INV; Cerda M, 2013, AM J PUBLIC HEALTH, V103, P2252, DOI 10.2105/AJPH.2013.301347; Charlton M., 2002, GEOGRAPHICALLY WEIGH; Ciccarone D, 2017, INT J DRUG POLICY, V46, P146, DOI 10.1016/j.drugpo.2017.06.004; Fairbairn N, 2017, INT J DRUG POLICY, V46, P172, DOI 10.1016/j.drugpo.2017.06.005; Frank RG, 2017, NEW ENGL J MED, V376, P605, DOI 10.1056/NEJMp1615145; Furr-Holden CDM, 2016, J STUD ALCOHOL DRUGS, V77, P17; Jalal H, 2018, SCIENCE, V361, P1218, DOI 10.1126/science.aau1184; Kondo MC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136595; Krieger N, 2016, AM J PUBLIC HEALTH, V106, P256, DOI 10.2105/AJPH.2015.302955; Latkin CA, 2005, HEALTH PSYCHOL, V24, P96, DOI 10.1037/0278-6133.24.1.96; Latkin CA, 2018, SUBST ABUS, V39, P384, DOI 10.1080/08897077.2018.1439801; Leung Y, 2000, ENVIRON PLANN A, V32, P9, DOI 10.1068/a3162; Mars SG, 2018, J PSYCHOACTIVE DRUGS, V50, P167, DOI 10.1080/02791072.2017.1394508; Martinez AN, 2014, INT J DRUG POLICY, V25, P516, DOI 10.1016/j.drugpo.2013.11.008; McGowan CR, 2018, INT J DRUG POLICY, V58, P31, DOI 10.1016/j.drugpo.2018.04.017; O'Donnell JK, 2017, MMWR-MORBID MORTAL W, V66, P1197, DOI 10.15585/mmwr.mm6643e1; O'Donnell JK, 2017, MMWR-MORBID MORTAL W, V66, P897, DOI 10.15585/mmwr.mm6634a2; Palamar JJ, 2015, DRUG ALCOHOL DEPEN, V149, P108, DOI 10.1016/j.drugalcdep.2015.01.029; Ross CE, 2001, J HEALTH SOC BEHAV, V42, P258, DOI 10.2307/3090214; Roux AVD, 2010, ANN NY ACAD SCI, V1186, P125, DOI 10.1111/j.1749-6632.2009.05333.x; Rushovich T, 2017, EPIDEMIOLOGY REPORT; Schueler Harold E, 2017, Acad Forensic Pathol, V7, P36, DOI 10.23907/2017.004; Seth P, 2018, MMWR-MORBID MORTAL W, V67, P349, DOI 10.15585/mmwr.mm6712a1; South EC, 2018, JAMA NETW OPEN, V1, DOI 10.1001/jamanetworkopen.2018.0298; Trinidad JP, 2016, NATL VITAL STAT REP, V65, P258; US Drug Enforcement Administration, 2017, NAT DRUG THREAT ASS; US Drug Enforcement Administration Diversion Control Division, 2017, NAT FOR LAB INF SYST; US Drug Enforcement Administration Diversion Control Division, 2018, NAT FOR LAB INF SYST; Waller LA, 2004, APPL SPATIAL STAT PU; Wheeler DC, 2007, J GEOGR SYST, V9, P145, DOI 10.1007/s10109-006-0040-y	33	2	2	4	4	AMER PUBLIC HEALTH ASSOC INC	WASHINGTON	800 I STREET, NW, WASHINGTON, DC 20001-3710 USA	0090-0036	1541-0048		AM J PUBLIC HEALTH	Am. J. Public Health	JAN	2020	110	1					98	105		10.2105/AJPH.2019.305368			8	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	JT1FA	WOS:000500742700041	31725315				2020-06-30	J	Mojica, MA; Carter, MD; Isenberg, SL; Pirkle, JL; Hamelin, EI; Shaner, RL; Seymour, C; Sheppard, CI; Baldwin, GT; Johnson, RC				Mojica, Mike A.; Carter, Melissa D.; Isenberg, Samantha L.; Pirkle, James L.; Hamelin, Elizabeth, I; Shaner, Rebecca L.; Seymour, Craig; Sheppard, Cody, I; Baldwin, Grant T.; Johnson, Rudolph C.			Designing traceable opioid material kits to improve laboratory testing during the US opioid overdose crisis	TOXICOLOGY LETTERS			English	Article; Proceedings Paper	17th Medical Chemical Defense Conference (MCDC)	MAR 27-28, 2019	Munich, GERMANY			Opioid; Fentanyl; Traceable Opioid Material Kits; TOM Kits; Opioid CRM Kit; FAS Kit; Fentanyl Analog Screening Kit; Opioid Certified Reference Material Kit; Fentanyl analogs; Opioid overdose crisis	FENTANYL ANALOGS; DEATHS; ANALGESICS; STATES; DRUG	In 2017, the U.S. Department of Health and Human Services and the White House declared a public health emergency to address the opioid crisis (Hargan, 2017). On average, 192 Americans died from drug overdoses each day in 2017; 130 (67%) of those died specifically because of opioids (Scholl et al., 2019). Since 2013, there have been significant increases in overdose deaths involving synthetic opioids - particularly those involving illicitly-manufactured fentanyl. The U.S. Drug Enforcement Administration (DEA) estimates that 75% of all opioid identifications are illicit fentanyls (DEA, 2018b). Laboratories are routinely asked to confirm which fentanyl or other opioids are involved in an overdose or encountered by first responders. It is critical to identify and classify the types of drugs involved in an overdose, how often they are involved, and how that involvement may change over time. Health care providers, public health professionals, and law enforcement officers need to know which opioids are in use to treat, monitor, and investigate fatal and non-fatal overdoses. By knowing which drugs are present, appropriate prevention and response activities can be implemented. Laboratory testing is available for clinically used and widely recognized opioids. However, there has been a rapid expansion in new illicit opioids, particularly fentanyl analogs that may not be addressed by current laboratory capabilities. In order to test for these new opioids, laboratories require reference standards for the large number of possible fentanyls. To address this need, the Centers for Disease Control and Prevention (CDC) developed the Traceable Opioid Material Kits product line, which provides over 150 opioid reference standards, including over 100 fentanyl analogs. These kits were designed to dramatically increase laboratory capability to confirm which opioids are on the streets and causing deaths. The kits are free to U.S based laboratories in the public, private, clinical, law enforcement, research, and public health domains.	[Mojica, Mike A.; Carter, Melissa D.; Isenberg, Samantha L.; Pirkle, James L.; Hamelin, Elizabeth, I; Shaner, Rebecca L.; Seymour, Craig; Sheppard, Cody, I; Johnson, Rudolph C.] Natl Ctr Environm Hlth, Div Lab Sci, CDC, Atlanta, GA USA; [Baldwin, Grant T.] Natl Ctr Injury Prevent & Control, Div Unintent Injury Prevent, CDC, Atlanta, GA USA	Carter, MD (reprint author), Ctr Dis Control & Prevent, Div Lab Sci, 4770 Buford Hwy NE,MS-F44, Atlanta, GA 30341 USA.	melissa.carter@cdc.hhs.gov			Centers for Disease Control and PreventionUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA	This work was supported by the Centers for Disease Control and Prevention. The authors would like to especially thank the National Center for Injury Prevention and Control and the many CDC offices that provided support in the areas of contracting, policy, communications, ethics, technology transfer, general counsel, and administrative services.	BILSBACK P, 1985, BRIT J ANAESTH, V57, P943, DOI 10.1093/bja/57.10.943; Brine GA, 1997, CURR MED CHEM, V4, P247; CASY AF, 1988, J PHARM PHARMACOL, V40, P605, DOI 10.1111/j.2042-7158.1988.tb05318.x; Cayman, 2019, FENTANYL ANALOG SCRE; CDC, 2019, TRAC OP MAT KITS IMP; Cerilliant, 2019, OPIOID CERTIFIED REF; Ciccarone D, 2017, INT J DRUG POLICY, V46, P146, DOI 10.1016/j.drugpo.2017.06.004; DEA, 2016, 2016 ANN EM THREAT R; DEA, 2018, 2018 ANN EM THREAT R; DEA, 2018, 2018 NAT DRUG THREAT; DEA, 2018, 2018 EM THREAT REP M; DOJ, 2018, MAN PLEADS GUILT DIS; Elliott Simon P, 2016, Drug Test Anal, V8, P875, DOI 10.1002/dta.1984; [EMCDDA European Monitoring Centre for Drugs and Drug Addicition], 2018, EUR JOINT REP NEW PS; [EMCDDA European Monitoring Centre for Drugs and Drug Addiction], 2015, FENT DRUG PROF; Hargan E., 2017, DETERMINATION PUBLIC; Hedegaard Holly, 2018, Natl Vital Stat Rep, V67, P1; Hedegaard Holly, 2018, NCHS Data Brief, P1; Higashikawa Y, 2008, FORENSIC TOXICOL, V26, P1, DOI 10.1007/s11419-007-0039-1; JANSSEN PAJ, 1982, ACTA ANAESTH SCAND, V26, P262, DOI 10.1111/j.1399-6576.1982.tb01765.x; KUDZMA LV, 1989, J MED CHEM, V32, P2534, DOI 10.1021/jm00132a007; MAGUIRE P, 1992, EUR J PHARMACOL, V213, P219, DOI 10.1016/0014-2999(92)90685-W; Malaquin S, 2010, TETRAHEDRON LETT, V51, P2983, DOI 10.1016/j.tetlet.2010.03.120; Mayer BP, 2016, ANAL CHEM, V88, P4303, DOI 10.1021/acs.analchem.5b04434; NFLIS, 2010, NFLIS 2010 ANN REP; NFLIS, 2012, NFLIS 2012 ANN REP; NFLIS, 2018, NAT FOR LAB INF SYST; NFLIS, 2014, NFLIS 2014 ANN REP; NFLIS, 2016, NFLIS 2016 ANN REP; NFLIS, 2011, NFLIS 2011 ANN REP; NFLIS, 2017, NFLIS 2017 ANN REP; NFLIS, 2015, NFLIS 2015 ANN REP; NFLIS, 2013, NFLIS 2013 ANN REP; O'Donnell JK, 2017, MMWR-MORBID MORTAL W, V66, P1197, DOI 10.15585/mmwr.mm6643e1; Schmitz R, 1985, Pharm Hist, V27, P61; Scholl L, 2019, MMWR-MORBID MORTAL W, V67, P1419; Sigma-Aldrich, 2019, COST PROP CHLOR SIGM; Sigma-Aldrich, 2019, COST PIV CHLOR TRIM; Slavova S, 2015, PUBLIC HEALTH REP, V130, P339, DOI 10.1177/003335491513000411; Valdez CA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108250; Van Norman Gail A, 2016, JACC Basic Transl Sci, V1, P170, DOI 10.1016/j.jacbts.2016.03.002; VANDAELE PGH, 1976, ARZNEIMITTELFORSCH, V26, P1521; Warner Margaret, 2016, Natl Vital Stat Rep, V65, P1	43	1	1	3	17	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0378-4274	1879-3169		TOXICOL LETT	Toxicol. Lett.	DEC 15	2019	317						53	58		10.1016/j.toxlet.2019.09.017			6	Toxicology	Toxicology	JG1ZZ	WOS:000491877400005	31560942				2020-06-30	J	Lam, D; Kay, S; Pickard, J; Harrison, S				Lam, Deborah; Kay, Samantha; Pickard, Jennie; Harrison, Sophie			Unusual case of transdermal fentanyl in cachexia	BMJ SUPPORTIVE & PALLIATIVE CARE			English	Article						drug administration; pain; pharmacology; cachexia; transdermal fentanyl		Fentanyl has a low molecular weight and is lipophilic making it suitable for transdermal administration. However, multiple factors appear to lead to interindividual variation in absorption via this route. Here we describe an unusual case where a patient was found to have twelve 100 mu g/hour fentanyl patches in situ which she was using as background analgesia.	[Lam, Deborah] Manchester Univ NHS Fdn Trust, Wythenshawe Hosp, Manchester M23 9LT, Lancs, England; [Kay, Samantha; Pickard, Jennie; Harrison, Sophie] Manchester Univ NHS Fdn Trust, Palliat Med, Manchester, Lancs, England	Lam, D (reprint author), Manchester Univ NHS Fdn Trust, Wythenshawe Hosp, Manchester M23 9LT, Lancs, England.	deborah.lam@nhs.net					Heiskanen T, 2009, PAIN, V144, P218, DOI 10.1016/j.pain.2009.04.012	1	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	2045-435X	2045-4368		BMJ SUPPORT PALLIAT	BMJ Support. Palliat. Care	DEC	2019	9	4					363	364		10.1136/bmjspcare-2018-001652			2	Health Care Sciences & Services	Health Care Sciences & Services	KA2IZ	WOS:000505622500014	30612090				2020-06-30	J	Thomas, I				Thomas, Ian			A Brief Overview of Identification and Management of Opiate Use Disorder in the Primary Care Setting	NURSING CLINICS OF NORTH AMERICA			English	Article						Opioid epidemic; Overdose; Opioid use disorder; Fentanyl; MAT; Medication-assisted treatment	FENTANYL; OVERDOSE; ANALOGS	This article offers a brief review geared toward primary care providers of the most critical aspects of the management of opiate use disorder, including screening, brief intervention, and referral to treatment as well as medication-assisted treatment and the alarming trends and dangers of illicitly produced fentanyl.	[Thomas, Ian] Carondelet Hlth Network, 2656 North Sahuara Pl, Tucson, AZ 85712 USA	Thomas, I (reprint author), 1601 W St Marys Rd, Tucson, AZ 85745 USA.	IanThomas83@gmail.com					Adams JM, 2018, JAMA-J AM MED ASSOC, V319, P2073, DOI 10.1001/jama.2018.4867; Bigelow GE, 2012, DRUG ALCOHOL DEPEN, V123, P57, DOI 10.1016/j.drugalcdep.2011.10.018; Bose J, 2018, KEY SUBSTANCE USE ME; Fairbairn N, 2017, INT J DRUG POLICY, V46, P172, DOI 10.1016/j.drugpo.2017.06.005; Gomes T, 2018, JAMA NETW OPEN, V1, DOI 10.1001/jamanetworkopen.2018.0217; Green TC, 2016, JAMA INTERN MED, V176, P1555, DOI 10.1001/jamainternmed.2016.4310; Hickman M, 2018, ADDICTION, V113, P1461, DOI 10.1111/add.14188; Jones CM, 2015, MMWR-MORBID MORTAL W, V64, P719; Kuczynska K, 2018, FORENSIC SCI INT, V289, P207, DOI 10.1016/j.forsciint.2018.05.042; National Institute on Drug Abuse, OV DEATH RAT 2018; National Safety Council, 1 TIM WER MOR DIE AC; Ndegwa S, 2016, CADTH ISSUES EMERGIN, P1; O'Donnell J, 2017, TRENDS DEATHS INVOLV; O'Donnell J, 2018, MMWR-MORBID MORTAL W, V67, P767, DOI 10.15585/mmwr.mm6727a4; Pichini S, 2018, THER DRUG MONIT, V40, P38, DOI 10.1097/FTD.0000000000000465; Sansone Randy A, 2015, Innov Clin Neurosci, V12, P32; Saucier R, 2018, DRUG SAFETY, V41, P981, DOI 10.1007/s40264-018-0653-3; Smith PC, 2010, ARCH INTERN MED, V170, P1155, DOI 10.1001/archinternmed.2010.140; Somerville NJ, 2017, MMWR-MORBID MORTAL W, V66, P382, DOI 10.15585/mmwr.mm6614a2; U.S. Food and Drug Administration, 2018, INF MED ASS TREATM M; World Health Organization (WHO), 2017, WHO MOD LISTS ESS ME	21	0	0	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0029-6465	1558-1357		NURS CLIN N AM	Nurs. Clin. North Am.	DEC	2019	54	4					495	+		10.1016/j.cnur.2019.08.006			8	Nursing	Nursing	JW8VO	WOS:000503324800005	31703775				2020-06-30	J	Tang, CX; Poloyac, SM				Tang, Chenxiao; Poloyac, Samuel M.			A Modeling-Based Approach to Estimate Fentanyl Pharmacokinetics in Obese Critically Ill Children	PEDIATRIC CRITICAL CARE MEDICINE			English	Editorial Material						fentanyl; modeling; obesity; pediatric; pharmacokinetics	MANAGEMENT; ANALGESIA; PAIN		[Tang, Chenxiao] Univ Pittsburgh, Sch Pharm, Dept Pharmaceut Sci, Ctr Clin Pharmaceut Sci, Pittsburgh, PA 15261 USA; [Poloyac, Samuel M.] Univ Pittsburgh, Dept Pharmaceut Sci, Ctr Clin Pharmaceut Sci, Pittsburgh, PA USA; [Poloyac, Samuel M.] Univ Pittsburgh, Sch Pharm, Safar Ctr Resuscitat Res, Pittsburgh, PA USA	Tang, CX (reprint author), Univ Pittsburgh, Sch Pharm, Dept Pharmaceut Sci, Ctr Clin Pharmaceut Sci, Pittsburgh, PA 15261 USA.				National Institute of Neurological Disorders and Stroke at the National Institutes of Health (NINDS/NIH); American Association of Colleges of Pharmacy, Society of Critical Care Medicine; NIH study sectionUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA	Dr. Poloyac's institution received funding from the National Institute of Neurological Disorders and Stroke at the National Institutes of Health (NINDS/NIH) and NIH study section (travel coverage and support), and he has received travel awards from the American Association of Colleges of Pharmacy, Society of Critical Care Medicine, and the National Neurotrauma Society for travel support and presentation at national meetings. Ms. Tang disclosed that she does not have any potential conflicts of interest.	Anand KJS, 2001, ARCH PEDIAT ADOL MED, V155, P173, DOI 10.1001/archpedi.155.2.173; Blouin RA, 1999, J PHARM SCI, V88, P1, DOI 10.1021/js980173a; Encinas E, 2013, PEDIATR DRUGS, V15, P247, DOI 10.1007/s40272-013-0029-1; Ezzati M, 2017, LANCET, V390, P2627, DOI 10.1016/S0140-6736(17)32129-3; Hagos FT, 2019, CLIN PHARMACOKINET; Hales Craig M, 2017, NCHS Data Brief, P1; Horvat CM, 2017, PEDIATR RES, V82, P29, DOI 10.1038/pr.2017.103; KATZ R, 1993, CRIT CARE MED, V21, P995, DOI 10.1097/00003246-199307000-00012; Kendrick JG, 2015, CLIN THER, V37, P1897, DOI 10.1016/j.clinthera.2015.05.495; Lim SY, 2019, PEDIATR CRIT CARE ME, V20, pE556, DOI 10.1097/PCC.0000000000002125; O'Hara K, 2015, BRIT J CLIN PHARMACO, V80, P1281, DOI 10.1111/bcp.12741; Peng PWH, 1999, ANESTHESIOLOGY, V90, P576, DOI 10.1097/00000542-199902000-00034; Shibutani K, 2004, ANESTHESIOLOGY, V101, P603, DOI 10.1097/00000542-200409000-00008; Smit C, 2018, EXPERT OPIN DRUG MET, V14, P275, DOI 10.1080/17425255.2018.1440287; Tateishi T, 1996, ANESTH ANALG, V82, P167; Tobias JD, 2005, PEDIATR ANN, V34, P636, DOI 10.3928/0090-4481-20050801-12; Upreti VV, 2016, J CLIN PHARMACOL, V56, P266, DOI 10.1002/jcph.585; Vaughns JD, 2017, PEDIATR DRUGS, V19, P251, DOI 10.1007/s40272-017-0216-6	18	0	0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1529-7535	1947-3893		PEDIATR CRIT CARE ME	Pediatr. Crit. Care Med.	DEC	2019	20	12					1208	1209		10.1097/PCC.0000000000002163			2	Critical Care Medicine; Pediatrics	General & Internal Medicine; Pediatrics	JT7GC	WOS:000501153000029	31804447				2020-06-30	J	Schonfeld, T; Heinemann, A; Schulz, M; Gradl, G; Andresen-Streichert, H; Muller, A; Iwersen-Bergmann, S				Schoenfeld, T.; Heinemann, A.; Schulz, M.; Gradl, G.; Andresen-Streichert, H.; Mueller, A.; Iwersen-Bergmann, S.			Post-mortem analysis of prescription opioids-A follow-up examination by LC-MS/MS with focus on fentanyl	FORENSIC SCIENCE INTERNATIONAL			English	Article						Drug abuse; Opioid; Fatal poisoning; Fentanyl; Prevalence; Post-mortem concentration	TRANSDERMAL PATCH; ABUSE; FATALITIES; DURAGESIC(R); GERMANY	Our aim was to investigate the reason for relatively low detection rates for opioids and fentanyl in particular in post-mortem cases in the State of Hamburg. We re-analysed 822 blood samples from two different time periods, 2011/12 and 2016. These samples had been previously analysed in accordance with post-mortem routine by a case selected strategy. All samples were re-analysed with an LC-MS/MS method specific for prescription opioids. The main point in the evaluation was to determine whether the previous analysis strategy had led to underreporting of drug-related deaths (DRD), especially with regard to fentanyl. Another aim was to evaluate changes in prescribing prevalence of opiates and opioids. We compared pharmacy claims data in Hamburg with Germany. The analyses showed that the number of DRD remained unaffected by the new analytical strategy. Detection rates in DRD, however, increased for fentanyl 3.4-fold from 1.2% to 4.1%, buprenorphine from 5.9% to 7.6%, oxycodone from 0% to 1.8%, tilidine from 1.8% to 2.4%. The most frequently detected opioids in DRD cases were methadone (39.4%) and heroin (20%). Prescription rates between 2011-2017 decreased in Hamburg for nearly all opioids, morphine by - 43.5%, buprenorphine - 43%, codeine - 57%, fentanyl - 25%, tilidine -17%, tramadol - 31%, and hydromorphone -6%. Oxycodone, tapentadol, and piritramide prescription rates increased. For Germany, a decrease in the prescription rates for fentanyl was also found during this period (-12.9 %), although not as pronounced as in Hamburg. Prescription rates for methadone were three to greater than five times higher in Hamburg as compared to the German average due to the higher number of substituted persons per inhabitant. Conclusion: Despite the global problem of opioid abuse, there are significant regional differences in the nature and extent of opioid abuse. It is necessary to collect data at the national level to develop appropriate prevention strategies. (C) 2019 Elsevier B.V. All rights reserved.	[Schoenfeld, T.; Heinemann, A.; Mueller, A.; Iwersen-Bergmann, S.] Univ Med Ctr Hamburg Eppendorf, Dept Legal Med, Hamburg, Germany; [Schulz, M.; Gradl, G.] German Inst Drug Use Evaluat DAPI, Berlin, Germany; [Schulz, M.] Free Univ Berlin, Inst Pharm, Dept Clin Pharm & Biochem, Berlin, Germany; [Andresen-Streichert, H.] Univ Hosp Cologne, Inst Legal Med, Cologne, Germany	Iwersen-Bergmann, S (reprint author), Univ Med Ctr Hamburg Eppendorf, Dept Legal Med, Hamburg, Germany.	s.iwersen-bergmann@uke.de					Anderson DT, 2000, J ANAL TOXICOL, V24, P627, DOI 10.1093/jat/24.7.627; [Anonymous], 2018, DROG SUCHTB, P82; [Anonymous], 2017, BER ZUM SUBST STAND; Boddiger D, 2006, LANCET, V368, P569, DOI 10.1016/S0140-6736(06)69181-2; Concheiro M, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01210; Coopman V, 2007, FORENSIC SCI INT, V169, P223, DOI 10.1016/j.forsciint.2006.03.018; Dart RC, 2015, NEW ENGL J MED, V372, P241, DOI [10.1056/NEJMc1501822, 10.1056/NEJMsa1406143]; EFSA, 2016, EFSA SUPP PUBL, P50; Erbas Beate, 2016, MMW Fortschr Med, V158, P54, DOI 10.1007/s15006-016-7821-0; Gagajewski A, 2002, CLIN CHEM, V48, P205; Gradl G, 2018, PHARMACOEPIDEM DR S, V27, P1344, DOI 10.1002/pds.4643; Hakkinen M, 2014, FORENSIC SCI INT, V245, P121, DOI 10.1016/j.forsciint.2014.10.028; Heinemann A., 2018, CT16IBS017810 EMCDDA; Hull MJ, 2007, J FORENSIC SCI, V52, P1383, DOI 10.1111/j.1556-4029.2007.00564.x; Iwersen-Bergmann S, 2014, INT J LEGAL MED, V128, P751, DOI 10.1007/s00414-014-1017-x; Juebner M, 2014, INT J LEGAL MED, V128, P949, DOI 10.1007/s00414-014-0982-4; Kimergard A, 2018, DRUG TEST ANAL, V10, P917, DOI 10.1002/dta.2397; Kuczynska K, 2018, FORENSIC SCI INT, V289, P207, DOI 10.1016/j.forsciint.2018.05.042; Leifman H., 2016, DRUG RELATED DEATHS, P33; Madea B., 2003, HDB GERICHTLICHE MED, V2, P689, DOI [10.1007/978-3-642-55866-5, DOI 10.1007/978-3-642-55866-5]; MARQUARDT KA, 1995, ANN PHARMACOTHER, V29, P969, DOI 10.1177/106002809502901001; Mounteney J, 2015, INT J DRUG POLICY, V26, P626, DOI 10.1016/j.drugpo.2015.04.003; Oechsler Stephanie, 2009, Archiv fuer Kriminologie, V224, P26; Peters F. T., 2009, TOXICHEM KRIMTECH, V76, P185; Schubert I, 2013, DTSCH ARZTEBL INT, V110, P45, DOI 10.3238/arztebl.2013.0045; Sinicina I, 2017, DRUG ALCOHOL DEPEN, V180, P286, DOI 10.1016/j.drugalcdep.2017.08.021; Tharp AM, 2004, AM J FOREN MED PATH, V25, P178, DOI 10.1097/01.paf.0000127398.67081.11; Thermo Scientific, 2016, DRUGS ABUSE ASSAYS C, P23; Trist Adam Joseph, 2017, BMJ Case Rep, V2017, DOI 10.1136/bcr-2016-217231; van Amsterdam Jan, 2015, Curr Drug Abuse Rev, V8, P3; Weisberg D, 2013, ANAESTHESIA, V68, P1215, DOI 10.1111/anae.12503; Winklhofer S, 2014, EUR RADIOL, V24, P1276, DOI 10.1007/s00330-014-3128-7; Witzel C., 2018, ARCH KRIMINOL, V242, P125; Woodall KL, 2008, J FORENSIC SCI, V53, P222, DOI 10.1111/j.1556-4029.2007.00597.x	34	0	0	7	7	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0379-0738	1872-6283		FORENSIC SCI INT	Forensic Sci.Int.	DEC	2019	305								109970	10.1016/j.forsciint.2019.109970			11	Medicine, Legal	Legal Medicine	JT1NS	WOS:000500765300005	31629200				2020-06-30	J	Haidari, M; Mansani, S; Ponds, D; Romero, L; Cobb, C; Alsaab, S				Haidari, Mehran; Mansani, Sravan; Ponds, Dezaray; Romero, Lissett; Cobb, Christine; Alsaab, Saad			Storage of urine specimens in point of care (POC) urine drug testing cups reduces concentrations of many drugs	CLINICA CHIMICA ACTA			English	Article						Point of care urine drug testing cups; Liquid chromatography mass spectrometry; Clinical toxicology laboratories; Confirmatory urine drug testing; Urine drug testing strips; Urine chemistry dipsticks	BLOOD COLLECTION TUBES; TANDEM MASS-SPECTROMETRY; THERAPEUTIC DRUGS; TIME; IMMUNOASSAY; ABSORPTION; MANAGEMENT; ACCURACY	Background: Many clinical toxicology laboratories receive urine specimens in urine cups that contain point of care (POC) drug testing strips. We conducted this study to evaluate the effect on the stability of commonly measured drugs in the clinical toxicology laboratory when urine is exposed to POC urine drug testing cups. Methods: Drug free urine was spiked with 85 drugs that were measured by a validated liquid chromatography mass spectrometry (LCMS) method after exposure to POC urine drug testing cups at ambient and 2-6 degrees C temperatures. Alterations >= 20% were defined as significant changes in the drugs concentration. Results: Concentrations of amitriptyline, cyclobenzaprine, fentanyl, fluoxetine, flunitrazepam, nortriptyline, paroxetine, and sertraline were significantly reduced when urine specimens were stored inside POC urine drug testing cups for 24 h at ambient temperature. Storage of urine in urine chemistry dipsticks reduced the concentration of several drugs. When spiked urine was exposed to an increasing number of POC urine drug testing strips, the concentrations of some drugs were reduced in a dose-dependent manner. The drugs that were absorbed by POC urine drug testing strips were partially back extracted from the strips. Conclusion: Exposure of urine specimens to POC urine drug testing strips reduces the concentration of several drugs measured by LCMS method.	[Haidari, Mehran; Mansani, Sravan; Ponds, Dezaray; Romero, Lissett; Cobb, Christine; Alsaab, Saad] Elite Med Lab Solut, 1101 Alma St,Suite 100, Tomball, TX 77375 USA	Haidari, M (reprint author), Elite Med Lab Solut, 1101 Alma St,Suite 100, Tomball, TX 77375 USA.	Mehran.haidari@elitemedicallab.com					[Anonymous], 2018, BIOAN METH VAL GUID; Chang YZ, 2012, J IMMUNOASS IMMUNOCH, V33, P180, DOI 10.1080/15321819.2011.618862; Christo PJ, 2011, PAIN PHYSICIAN, V14, P123; Das R, 2013, J CHROMATOGR SCI, V51, P146, DOI 10.1093/chromsci/bms119; Dasgupta A, 2000, THER DRUG MONIT, V22, P427, DOI 10.1097/00007691-200008000-00011; DASGUPTA A, 1994, AM J CLIN PATHOL, V101, P456; Deyo RA, 2009, J AM BOARD FAM MED, V22, P62, DOI 10.3122/jabfm.2009.01.080102; Dowell D., 2016, JAMA-J AM MED ASSOC, V315, P1164; Gencheva R, 2018, PAIN PHYSICIAN, V21, pE583; Gonzales E, 2013, CLIN CHIM ACTA, V416, P80, DOI 10.1016/j.cca.2012.11.020; Haidari M., 2019, ESSENTIAL KNOWLEDGE; Katz N, 2002, CLIN J PAIN, V18, pS76, DOI 10.1097/00002508-200207001-00009; Manchikanti L, 2012, PAIN PHYSICIAN, V15, pS67; Manchikanti L, 2011, PAIN PHYSICIAN, V14, P175; Moeller KE, 2017, MAYO CLIN PROC, V92, P774, DOI 10.1016/j.mayocp.2016.12.007; ORSULAK PJ, 1984, THER DRUG MONIT, V6, P444, DOI 10.1097/00007691-198412000-00011; Pellegrini M, 2017, CURR PHARM BIOTECHNO, V18, P815, DOI 10.2174/1389201019666171211155043; Pesce A, 2010, PAIN PHYSICIAN, V13, P273; Poklis JL, 2012, J CLIN LAB ANAL, V26, P286, DOI 10.1002/jcla.21519; QUATTROCCHI F, 1983, THER DRUG MONIT, V5, P359, DOI 10.1097/00007691-198309000-00020; Saitman A, 2014, J ANAL TOXICOL, V38, P387, DOI 10.1093/jat/bku075; Starrels JL, 2010, ANN INTERN MED, V152, P712, DOI 10.7326/0003-4819-152-11-201006010-00004; Van Acker JT, 1999, CLIN CHEM, V45, P1315	23	1	1	2	2	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0009-8981	1873-3492		CLIN CHIM ACTA	Clin. Chim. Acta	DEC	2019	499						81	86		10.1016/j.cca.2019.09.001			6	Medical Laboratory Technology	Medical Laboratory Technology	JS5YZ	WOS:000500383600012	31491368				2020-06-30	J	Sapci, I; Aiello, A; Hassab, TH; Gorgun, E; Hull, TL; Champagne, BJ; Steele, SR; Valente, MA				Sapci, Ipek; Aiello, Alexandra; Hassab, Tarek H.; Gorgun, Emre; Hull, Tracy L.; Champagne, Bradley J.; Steele, Scott R.; Valente, Michael A.			Colorectal Surgery Resident Participation in Screening Colonoscopies: How Does It Impact Quality?	DISEASES OF THE COLON & RECTUM			English	Article						Adenoma detection rate; Colonoscopy quality; Colorectal surgery resident; Screening colonoscopy	ADENOMA DETECTION RATE; TRAINEE PARTICIPATION; COMPETENCE; POLYP	BACKGROUND: Performing colonoscopies is an integral component of colorectal surgery residency training. There exists a paucity of literature regarding colonoscopy quality metrics with colorectal trainee involvement. OBJECTIVE: This study aimed to investigate the effect of colorectal surgery resident participation on quality metrics in screening colonoscopy. DESIGN: Screening colonoscopies performed between August 1, 2016, and July 31, 2018, were queried from a prospectively maintained institutional database. Data were cross-checked with resident case logs to verify colonoscopies with resident participation. SETTING: This study was conducted by the colorectal surgery department at a tertiary level hospital in the United States. PATIENTS Consecutive, asymptomatic patients aged >= 45 years, undergoing screening colonoscopy, were selected. MAIN OUTCOME MEASURES: The quality parameters measured included overall, male, and female adenoma detection rates; total examination time; withdrawal time; cecal intubation rate; quality of bowel preparation; complications; and medication dosage. RESULTS: A total of 4594 patients were included in the study with a mean age of 60.5 +/- 8.4 years (range, 45-91); 51.7% were women. Overall, 4186 of the colonoscopies were performed without resident participation, and 408 were performed with resident participation. Scope insertion, withdrawal, and total examination times were longer in the resident group. Cecal intubation rate, polypectomy rate, sex-specific and overall adenoma detection rates, and complication rates were similar between the groups. In the multivariate model, trainee involvement had no significant impact on adenoma detection rate. In addition, the trainee group utilized a higher mean dose of fentanyl. LIMITATIONS: The retrospective nature of the data with possible coding errors of the database and the inability to quantify the amount of resident participation and to clarify the degree of attending surgeon assistance and oversight were limitations of the study. CONCLUSIONS: Colorectal surgery resident participation in screening colonoscopy takes longer and appears safe, while achieving all national quality metrics without compromising adenoma detection rates. Changes in colonoscopy scheduling in regard to length of time may prove beneficial when there is resident participation. See Video Abstract at http://links.lww.com/DCR/B43.	[Sapci, Ipek; Aiello, Alexandra; Hassab, Tarek H.; Gorgun, Emre; Hull, Tracy L.; Champagne, Bradley J.; Steele, Scott R.; Valente, Michael A.] Cleveland Clin, Dept Colorectal Surg, Digest Dis & Surg Inst, 9500 Euclid Ave,Desk A-30, Cleveland, OH 44195 USA	Valente, MA (reprint author), Cleveland Clin, Dept Colorectal Surg, Digest Dis & Surg Inst, 9500 Euclid Ave,Desk A-30, Cleveland, OH 44195 USA.	valentm2@ccf.org					Bitar H, 2018, GASTROINTEST ENDOSC, V88, P378, DOI 10.1016/j.gie.2018.04.2338; Chalifoux SL, 2014, J CLIN GASTROENTEROL, V48, P524, DOI 10.1097/MCG.0000000000000022; Chan BPH, 2017, ENDOSC INT OPEN, V5, pE1259, DOI 10.1055/s-0043-120828; Corley DA, 2014, NEW ENGL J MED, V370, P1298, DOI 10.1056/NEJMoa1309086; Eckardt AJ, 2009, DIS COLON RECTUM, V52, P1337, DOI 10.1007/DCR.0b013e3181a80d8f; Gianotti RJ, 2016, DIGEST DIS SCI, V61, P2831, DOI 10.1007/s10620-016-4228-9; Kann BR, 2006, DIS COLON RECTUM, V49, P1763, DOI 10.1007/s10350-006-0654-7; Klare P, 2015, BMC MED EDUC, V15, DOI 10.1186/s12909-015-0312-7; Nishizawa T, 2011, DIGESTION, V84, P245, DOI 10.1159/000330736; Ortolani JB, 2016, AM SURGEON, V82, P835; Ortolani JB, 2015, AM SURGEON, V81, P710; Pace D, 2016, SURG ENDOSC, V30, P1352, DOI 10.1007/s00464-015-4397-1; Qayed E, 2017, WORLD J GASTRO ENDOS, V9, P204, DOI 10.4253/wjge.v9.i5.204; Rex DK, 2015, AM J GASTROENTEROL, V110, P72, DOI 10.1038/ajg.2014.385; Selvasekar CR, 2012, J SURG RES, V174, pE17, DOI 10.1016/j.jss.2011.09.048; Spier BJ, 2010, SURG ENDOSC, V24, P2556, DOI 10.1007/s00464-010-1002-5; Turner JS, 2018, AM SURGEON, V84, P1064	17	0	0	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0012-3706	1530-0358		DIS COLON RECTUM	Dis. Colon Rectum	DEC	2019	62	12					1528	1532		10.1097/DCR.0000000000001503			5	Gastroenterology & Hepatology; Surgery	Gastroenterology & Hepatology; Surgery	JO2SN	WOS:000497432800020	31725583				2020-06-30	J	Shin, HJ; Do, SH; Lee, JS; Kim, TK; Na, HS				Shin, Hyun-Jung; Do, Sang-Hwan; Lee, Jae-Sung; Kim, Tae-Kyun; Na, Hyo-Seok			Comparison of Intraoperative Sedation With Dexmedetomidine Versus Propofol on Acute Postoperative Pain in Total Knee Arthroplasty Under Spinal Anesthesia: A Randomized Trial	ANESTHESIA AND ANALGESIA			English	Article							ANALGESIA; RECOVERY; MECHANISMS; RECEPTOR; CARE	BACKGROUND: In patients undergoing total knee arthroplasty under spinal anesthesia, we compared the postoperative analgesic effect of intraoperative sedation with dexmedetomidine versus propofol. We hypothesized that sedation with dexmedetomidine would result in lower postoperative opioid analgesic consumption than with propofol. METHODS: Forty-eight patients were enrolled and randomly assigned to either a dexmedetomidine group (n = 24), which received a loading dose of 1 mu g/kg dexmedetomidine over 10 minutes, followed by a continuous infusion of 0.1-0.5 mu g center dot kg(-1)center dot hour(-1), or a propofol group (n = 24), which received a continuous infusion of propofol via a target-controlled infusion to maintain the effect-site concentration within a range of 0.5-2.0 mu g/mL. The drug infusion rate was determined according to the sedation level, targeting a modified observer's assessment of alertness/sedation score of 3 or 4. The cumulative amounts of fentanyl administered via intravenous patient-controlled analgesia were recorded at 24 and 48 hours postoperatively (primary outcome). The postoperative numerical rating scale for pain was assessed at 6, 12, 24, and 48 hours (secondary outcome). The postoperative use of additional rescue analgesic (ketoprofen) and antiemetic drugs was also compared between the 2 groups at 24 and 48 hours. RESULTS: Dexmedetomidine significantly reduced postoperative fentanyl consumption (median [interquartile range]) during 0-24 hours (45 [30-71] vs 150 [49-248] mu g, P = .004; median difference = -105 mu g [99.98% CI, 210-7.5]), 24-48 hours (90 [45-143] vs 188 [75-266] mu g, P = .005; median difference = -98 mu g [99.98% CI, 195-45]), and 0-48 hours (135 [68-195] vs 360 [146-480] mu g, P = .003; median difference = -225 mu g [99.98% CI, 405-7.5]). The numerical rating scale (median [interquartile range]) was lower at 6 hours (1 [0-2] vs 2 [1-3], P = .003), 12 hours (1 [1-2] vs 3 [2-3], P < .001), 24 hours (1 [1-2] vs 3 [2-3], P < .001), and 48 hours (2 [2-3] vs 3 [3-4], P < .001) after surgery in the dexmedetomidine group compared to the propofol group. No significant intergroup differences were observed in the amount of rescue analgesics and antiemetics at 24 hours (P = .155 and P = .482) and 48 hours (P = .082 and P = .153) after surgery. CONCLUSIONS: Intraoperative dexmedetomidine sedation was associated with a small but clinically important reduction in postoperative opioid use after total knee arthroplasty.	[Shin, Hyun-Jung; Do, Sang-Hwan; Lee, Jae-Sung; Na, Hyo-Seok] Seoul Natl Univ, Bundang Hosp, Dept Anesthesiol & Pain Med, 82,Gumi Ro 173 Beon Gil, Seongnam Si 13620, Gyeonggi Do, South Korea; [Kim, Tae-Kyun] Seoul Natl Univ, Bundang Hosp, Dept Orthoped Surg, Joint Reconstruct Ctr, Seongnam Si, Gyeonggi Do, South Korea	Na, HS (reprint author), Seoul Natl Univ, Bundang Hosp, Dept Anesthesiol & Pain Med, 82,Gumi Ro 173 Beon Gil, Seongnam Si 13620, Gyeonggi Do, South Korea.	hsknana@gmail.com					Abdallah FW, 2013, ANESTH ANALG, V117, P271, DOI 10.1213/ANE.0b013e318290c566; Alhashemi JA, 2006, BRIT J ANAESTH, V96, P722, DOI 10.1093/bja/ael080; Arain SR, 2002, ANESTH ANALG, V95, P461, DOI 10.1097/00000539-200208000-00042; Athanassoglou V, 2015, J CLIN ANESTH, V27, P606, DOI 10.1016/j.jclinane.2015.06.006; Carollo DS, 2008, CURR OPIN ANESTHESIO, V21, P457, DOI 10.1097/ACO.0b013e328305e3ef; Chan IA, 2016, CAN J ANESTH, V63, P569, DOI 10.1007/s12630-016-0597-y; Ge DJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep21514; Ge DJ, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000001727; Gertler R, 2001, Proc (Bayl Univ Med Cent), V14, P13; Gross JB, 2002, ANESTHESIOLOGY, V96, P1004; Hohener D, 2008, BRIT J ANAESTH, V100, P8, DOI 10.1093/bja/aem342; Hoy SM, 2011, DRUGS, V71, P1481, DOI 10.2165/11207190-000000000-00000; JIE K, 1984, CIRC RES, V54, P447, DOI 10.1161/01.RES.54.4.447; Kassam SI, 2011, ANESTH ANALG, V112, P1339, DOI 10.1213/ANE.0b013e318215e094; Kaygusuz K, 2008, ANESTH ANALG, V106, P114, DOI 10.1213/01.ane.0000296453.75494.64; Kim MH, 2014, PAIN, V155, P22, DOI 10.1016/j.pain.2013.08.027; Link RE, 1996, SCIENCE, V273, P803, DOI 10.1126/science.273.5276.803; Olutoye OA, 2010, ANESTH ANALG, V111, P490, DOI 10.1213/ANE.0b013e3181e33429; Philipp M, 2002, AM J PHYSIOL-REG I, V283, pR287, DOI 10.1152/ajpregu.00123.2002; Robinson BJ, 1997, ANESTHESIOLOGY, V86, P64, DOI 10.1097/00000542-199701000-00010; Rosero EB, 2014, PLAST RECONSTR SURG, V134, p85S, DOI 10.1097/PRS.0000000000000671; Vadivelu N, 2014, LOCAL REG ANESTH, V7, P17, DOI 10.2147/LRA.S62160; Zhang HD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054510	23	7	7	5	13	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	DEC	2019	129	6					1512	1518		10.1213/ANE.0000000000003315			7	Anesthesiology	Anesthesiology	JN5FT	WOS:000496924900030	31743170				2020-06-30	J	Ueshima, H; Hara, E; Otake, H				Ueshima, Hironobu; Hara, Eiko; Otake, Hiroshi			Thoracolumbar interfascial plane block provides effective perioperative pain relief for patients undergoing lumbar spinal surgery; a prospective, randomized and double blinded trial	JOURNAL OF CLINICAL ANESTHESIA			English	Article						Peripheral nerve block; Lumbar spine; Postoperative analgesia	POSTOPERATIVE ANALGESIA; PARAVERTEBRAL BLOCK; EFFICACY; LEVOBUPIVACAINE	Study objective: Background: Although bilateral ultrasound-guided thoracolumbar interfascial plane (TLIP) block provides effective analgesia to the lumbar spinal region, a few previous studies for the TLIP block have only been reported up to the present. We aimed to study whether the TLIP block in combination with general anesthesia would provide more effective pain relief compared to general anesthesia alone. Design: Prospective randomized controlled trial. Setting: Operation and recovery room, hospital ward. Patients: Seventy-two patients undergoing primary lumbar laminoplasty of less than three levels between May 2016 and April 2017. Interventions: Seventy-two patients undergoing primary lumbar laminoplasty of less than three levels were randomly allocated to receive either the TLIP block combined with general anesthesia (T group, n = 35) or general anesthesia alone (C group, n = 34). Measurement: The primary outcome measured the cumulative amount of fentanyl delivered to the patients through PCA within 48 h after the end of surgery. Secondary outcomes measured the number of delivered and requested PCA doses and VAS pain scores at the surgical site obtained at rest as well as with movement at specific time points within 48 h after the surgery. Main results: During the first 48 h after surgery, the cumulative amount of delivered fentanyl (mean [standard deviation]) (mu g) was lower in the T group (198.3 [103.1]) (mu g) than in the C group (452.9 [175.4]) (mu g) (P < 0.001). The number of delivered and requested PCA doses and the VAS pain scores was also lower in the T group than in the C group at all time points (all data were less than P < 0.05). Conclusions: Bilateral TLIP block combined with general anesthesia provides more effective perioperative pain relief than that provided by general anesthesia alone in patients who undergo lumbar spinal surgery.	[Ueshima, Hironobu; Hara, Eiko; Otake, Hiroshi] Showa Univ Hosp, Dept Anesthesiol, Tokyo, Japan	Ueshima, H (reprint author), Showa Univ Hosp, Dept Anesthesiol, Shinagawa Ku, 1-5-8 Hatanodai, Tokyo 1428666, Japan.	ueshimhi@med.showa-u.ac.jp	Otake, Hiroshi/AAB-1327-2020	Otake, Hiroshi/0000-0002-4776-3211			Ahiskalioglu A, 2018, CAN J ANESTH, V65, P603, DOI 10.1007/s12630-018-1051-0; Altiparmak B, 2018, CLIN J PAIN, V34, P1114, DOI 10.1097/AJP.0000000000000640; Ammar MA, 2018, SAUDI J ANAESTH, V12, P559, DOI 10.4103/sja.SJA_177_18; Bardsley H, 1998, BRIT J CLIN PHARMACO, V46, P245, DOI 10.1046/j.1365-2125.1998.00775.x; Buvanendran A, 2019, REG ANESTH PAIN MED; El-Boghdadly K, 2016, BRIT J ANAESTH, V117, P297, DOI 10.1093/bja/aew269; Hand WR, 2015, CAN J ANESTH, V62, P1196, DOI 10.1007/s12630-015-0431-y; Kairaluoma PM, 2006, ANESTH ANALG, V103, P703, DOI 10.1213/01.ane.0000230603.92574.4e; Kulhari S, 2016, BRIT J ANAESTH, V117, P382, DOI 10.1093/bja/aew223; Melvin JP, 2018, CAN J ANESTH, V65, P1057, DOI 10.1007/s12630-018-1145-8; Morselli FSMA, 2017, SPINE, V42, P281, DOI 10.1097/BRS.0000000000001733; Rajaee SS, 2012, SPINE, V37, P67, DOI 10.1097/BRS.0b013e31820cccfb; Rosenberg PH, 2004, REGION ANESTH PAIN M, V29, P564, DOI 10.1016/j.rapm.2004.08.003; Singh K, 2017, SPINE, V42, P1145, DOI 10.1097/BRS.0000000000001992; Ueshima H, 2017, BRIT J ANAESTH, V118, P439, DOI 10.1093/bja/aew449; Ueshima H, 2018, J CLIN, V54, P2; Ueshima H, 2019, ASIAN SPINE J, V13, P254, DOI 10.31616/asj.2018.0114; Ueshima H, 2018, J CLIN ANESTH, V44, P59, DOI 10.1016/j.jclinane.2017.11.009; Ueshima H, 2017, ASIAN SPINE J, V11, P722, DOI 10.4184/asj.2017.11.5.722; Ueshima H, 2016, J CLIN ANESTH, V34, P259, DOI 10.1016/j.jclinane.2016.04.060; Ueshima H, 2016, J CLIN ANESTH, V33, P499, DOI 10.1016/j.jclinane.2015.09.005; Ueshima H, 2016, J CLIN ANESTH, V30, P74, DOI 10.1016/j.jclinane.2015.11.019; Voscopoulos C, 2013, CAN J ANESTH, V60, P888, DOI 10.1007/s12630-013-9983-x; Weinstein JN, 2006, SPINE, V31, P2707, DOI 10.1097/01.brs.0000248132.15231.fe; Xu JL, 2019, J CLIN ANESTH, V52, P21, DOI 10.1016/j.jclinane.2018.08.025; Yasumura R, 2016, ANAESTHESIA, V71, P544, DOI 10.1111/anae.13414; Zeballos JL, 2013, ANAESTHESIA, V68, P649, DOI 10.1111/anae.12296	27	3	3	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0952-8180	1873-4529		J CLIN ANESTH	J. Clin. Anesth.	DEC	2019	58						12	17		10.1016/j.jclinane.2019.04.026			6	Anesthesiology	Anesthesiology	JN4WI	WOS:000496899300006	31029989				2020-06-30	J	Zhang, J; Chen, L; Sun, YY; He, WS				Zhang, Jun; Chen, Liang; Sun, Yunyun; He, Wensheng			Comparative effects of fentanyl versus sufentanil on cerebral oxygen saturation and postoperative cognitive function in elderly patients undergoing open surgery	AGING CLINICAL AND EXPERIMENTAL RESEARCH			English	Article						Anesthesia; Fentanyl; Sufentanil; Cerebral oxygen saturation; Postoperative cognitive dysfunction	QUALITY-OF-LIFE; REMIFENTANIL-PROPOFOL; DYSFUNCTION; ANESTHESIA; PREDICTS; RECOVERY; MOCA	This study was aimed to systematically evaluate the effects of fentanyl and sufentanil on intraoperative cerebral oxygen saturation changes and postoperative cognitive function in elderly patients undergoing open surgery. Ninety-six elderly patients who had undergone open surgery under general anesthesia were randomly divided into fentanyl group (F group, anesthesia by fentanyl, 4 g/kg) and sufentanil group (S group, anesthesia by sufentanil, 0.4 mu g/kg). There were no significant differences between the F group and S group in the general characteristics of patients. Compared to the F group, the S group had a better effect on suppressing the stress response, maintaining a stable hemodynamic status and achieving better anesthesia effects. The anesthesia recovery time of the S group was significantly shorter than that of the F group. There was no significant difference between the two groups in the intraoperative and postoperative agitation. Patient's waking time and extubation time were significantly shorter in the S group than the F group. The VAS scores in the S group were significantly lower than those in the F group at each time point. The Ramsay scores in the S group were significantly higher than those in the F group at each time point. The cerebral oxygen saturation (SctO(2)) levels in both groups were significantly increased following anesthesia induction and intubation compared to that of the awake state (P < 0.05), and SctO(2) was significantly decreased during the surgery in both groups. The changes in SctO(2) levels were not significantly different between the two groups (P > 0.05). The SctO(2) level was significantly higher during surgery than that after intubation. Compared with the F group, the relative value of SctO(2) decline in the S group was smaller. Compared to the day before surgery, the Montreal Cognitive Assessment (MoCA) scores of both groups were significantly reduced after surgery. At 1 day post-surgery, the MoCA scores of the S group were significantly higher and the incidence of postoperative cognitive dysfunction (POCD) was significantly lower compared to the F group. POCD occurred in three patients (6.2%) in the S group, and the ratio was significantly lower than that in the F group (11.9%) (P < 0.05). It showed a consistent trend with the SctO(2) status during the surgery. The relative value of SctO(2) decline in the S group was significantly smaller than that in the F group. The reduction of cognitive function in the S group was significantly lower than that in the F group. These results indicate that the changes in SctO(2) are a good prediction of the incidence of POCD.	[Zhang, Jun; Chen, Liang; Sun, Yunyun; He, Wensheng] Anhui Med Univ, Peoples Hosp Hefei 2, Dept Anesthesia, Affiliated Hefei Hosp, 246 Heping Rd, Hefei 230011, Anhui, Peoples R China	He, WS (reprint author), Anhui Med Univ, Peoples Hosp Hefei 2, Dept Anesthesia, Affiliated Hefei Hosp, 246 Heping Rd, Hefei 230011, Anhui, Peoples R China.	hewensheng617105@163.com					Akan Mert, 2012, Anesth Pain Med, V1, P267, DOI 10.5812/aapm.3805; Ayrian Eugenia, 2015, J Clin Med Res, V7, P731, DOI 10.14740/jocmr2256w; Bilotta F, 2007, EUR J ANAESTH, V24, P122, DOI 10.1017/S0265021506001244; Brodt J, 2016, J CLIN MONIT COMPUT, V30, P649, DOI 10.1007/s10877-015-9758-8; Brown Randall T, 2006, J Opioid Manag, V2, P137; Chan MJ, 2017, J CARDIOTHOR VASC AN, V31, P1155, DOI 10.1053/j.jvca.2017.02.187; CLOTZ MA, 1991, CLIN PHARMACY, V10, P581; d'Alessandro ED, 2011, CLIN TER, V162, pE13; Dalrymple-Alford JC, 2010, NEUROLOGY, V75, P1717, DOI 10.1212/WNL.0b013e3181fc29c9; Davis MP, 2016, CURR ONCOL REP, V18, DOI 10.1007/s11912-016-0558-1; De Cosmo G, 2016, J CLIN ANESTH, V35, P40, DOI 10.1016/j.jclinane.2016.07.016; Egawa J, 2016, CAN J ANESTH, V63, P1161, DOI 10.1007/s12630-016-0700-4; Farzi Farnoush, 2017, Anesth Pain Med, V7, pe12738, DOI 10.5812/aapm.12738; Hemmerling TM, 2008, BRIT J ANAESTH, V101, P870, DOI 10.1093/bja/aen275; Kehlet H, 2003, LANCET, V362, P1921, DOI 10.1016/S0140-6736(03)14966-5; Kim J, 2016, ANESTH ANALG, V123, P436, DOI 10.1213/ANE.0000000000001352; Kofke WA, 1996, ANESTH ANALG, V83, P141, DOI 10.1097/00000539-199607000-00025; Leslie K, 2003, ANESTHESIOLOGY, V99, P1158, DOI 10.1097/00000542-200311000-00024; Lin R, 2013, J ARTHROPLASTY, V28, P494, DOI 10.1016/j.arth.2012.06.041; Martorano PP, 2008, MINERVA ANESTESIOL, V74, P233; Modak SD, 2017, ANN CARD ANAESTH, V20, P163, DOI 10.4103/0971-9784.203930; Moller JT, 1998, LANCET, V351, P857, DOI 10.1016/S0140-6736(97)07382-0; Nasreddine ZS, 2005, J AM GERIATR SOC, V53, P695, DOI 10.1111/j.1532-5415.2005.53221.x; NEWMAN SP, 1995, ANN THORAC SURG, V59, P1351, DOI 10.1016/0003-4975(95)00215-7; Ni C, 2015, BMC ANESTHESIOL, V15, DOI 10.1186/s12871-015-0117-6; Pouraghaei Mahboob, 2014, Anesth Pain Med, V4, pe14618, DOI 10.5812/aapm.14618; Rasmussen LA, 2016, J CLIN ANESTH, V33, P127, DOI 10.1016/j.jclinane.2016.03.023; Royse CF, 2010, ANESTHESIOLOGY, V113, P892, DOI 10.1097/ALN.0b013e3181d960a9; Rundshagen I, 2014, DTSCH ARZTEBL INT, V111, DOI 10.3238/arztebl.2014.0119; Salazar F, 2011, ACTA ANAESTH SCAND, V55, P216, DOI 10.1111/j.1399-6576.2010.02362.x; SCOTT JC, 1991, ANESTHESIOLOGY, V74, P34, DOI 10.1097/00000542-199101000-00007; Shi HJ, 2015, INT J CLIN EXP MED, V8, P3883; Silbert BS, 2006, ANESTHESIOLOGY, V104, P1137, DOI 10.1097/00000542-200606000-00007; Steinmetz J, 2009, ANESTHESIOLOGY, V110, P548, DOI 10.1097/ALN.0b013e318195b569; Sun W, 2015, ARCH GERONTOL GERIAT, V60, P311, DOI 10.1016/j.archger.2014.12.002; Tang L, 2012, BRIT J ANAESTH, V108, P623, DOI 10.1093/bja/aer501; Terrando N, 2011, MAYO CLIN PROC, V86, P885, DOI 10.4065/mcp.2011.0332	37	1	1	0	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1594-0667	1720-8319		AGING CLIN EXP RES	Aging Clin. Exp. Res.	DEC	2019	31	12					1791	1800		10.1007/s40520-019-01123-8			10	Geriatrics & Gerontology	Geriatrics & Gerontology	JI7YX	WOS:000493681600010	30847845				2020-06-30	J	Vereecke, HEM				Vereecke, Hugo E. M.			Administration of anesthetic drugs according to pharmacological principles: are we heading in the right direction?	JOURNAL OF CLINICAL MONITORING AND COMPUTING			English	Editorial Material							PHARMACODYNAMIC INTERACTION; REMIFENTANIL; PROPOFOL		[Vereecke, Hugo E. M.] Univ Med Ctr Groningen, Groningen, Netherlands; [Vereecke, Hugo E. M.] Univ Groningen, Groningen, Netherlands; [Vereecke, Hugo E. M.] AZ Sint Jan Brugge Oostende AV, Dept Anesthesia & Reanimat, Brugge, Belgium	Vereecke, HEM (reprint author), Univ Med Ctr Groningen, Groningen, Netherlands.; Vereecke, HEM (reprint author), Univ Groningen, Groningen, Netherlands.; Vereecke, HEM (reprint author), AZ Sint Jan Brugge Oostende AV, Dept Anesthesia & Reanimat, Brugge, Belgium.	Hugo.Vereecke@azsintjan.be					Absalom AR, 2016, ANESTH ANALG, V122, P70, DOI 10.1213/ANE.0000000000001009; Bouillon TW, 2004, ANESTHESIOLOGY, V100, P1353, DOI 10.1097/00000542-200406000-00006; Egan TD, 2003, ANESTHESIOLOGY, V99, P1039, DOI 10.1097/00000542-200311000-00003; Eleveld DJ, 2018, BRIT J ANAESTH, V120, P942, DOI 10.1016/j.bja.2018.01.018; Kern SE, 2004, ANESTHESIOLOGY, V100, P1373, DOI 10.1097/00000542-200406000-00007; LaPierre CD, 2011, ANESTH ANALG, V113, P490, DOI 10.1213/ANE.0b013e318210fc45; Schnider TW, 2016, ANESTH ANALG, V122, P79, DOI 10.1213/ANE.0000000000001005; Struys MMRF, 2016, ANESTH ANALG, V122, P56, DOI 10.1213/ANE.0000000000001008; Tams C, 2019, J CLIN MONIT COMPUT, V33, P953, DOI 10.1007/s10877-019-00295-y; Tams C, 2019, J CLIN MONIT COMPUT, V33, P959, DOI 10.1007/s10877-019-00298-9	10	1	1	1	1	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	1387-1307	1573-2614		J CLIN MONIT COMPUT	J. Clin. Monitor. Comp.	DEC	2019	33	6					945	947		10.1007/s10877-019-00376-y			3	Anesthesiology	Anesthesiology	JI6WL	WOS:000493607300001	31420759	Bronze			2020-06-30	J	Singh, VM; Browne, T; Montgomery, J				Singh, Vanila M.; Browne, Thom; Montgomery, Joshua			The Emerging Role of Toxic Adulterants in Street Drugs in the US Illicit Opioid Crisis	PUBLIC HEALTH REPORTS			English	Article						adulterants; pharmacological active components; opioid crisis; illicit fentanyl; opioids; cocaine	OVERDOSE DEATHS; COCAINE; RECOMMENDATIONS; INCREASES		[Singh, Vanila M.; Montgomery, Joshua] US Dept HHS, Off Assistant Secretary Hlth, Washington, DC 20201 USA; [Singh, Vanila M.] Stanford Univ, Sch Med, Dept Anesthesiol Perioperat & Pain Med, 300 Pasteur Dr,Room H3580 MC 5640, Stanford, CA 94305 USA; [Browne, Thom] Colombo Plan Secretariat, Colombo, Sri Lanka	Singh, VM (reprint author), Stanford Univ, Sch Med, Dept Anesthesiol Perioperat & Pain Med, 300 Pasteur Dr,Room H3580 MC 5640, Stanford, CA 94305 USA.	vanila@stanford.edu		Montgomery, Joshua/0000-0001-8490-3685	US Department of State; Bureau of International Narcotics & Law Enforcement Affairs; Colombo Plan Secretariat	The authors declared the following financial supports for the research, authorship, and/or publication of this article: Funding for the global toxic adulterant project was provided by the US Department of State, Bureau of International Narcotics & Law Enforcement Affairs and the Colombo Plan Secretariat.	Ahmad FB, 2019, 2018 PROVISIONAL DRU; Akhgari M., 2016, NEUROPATHOLOGY DRUG, V1, P867, DOI [DOI 10.1016/B978-0-12-800213-1.00081-X, 10.1016/B978-0-12-800213-1.00081-X]; Bose J, 2019, HHS PUB, VSMA 18-5068; Bose J, 2019, NSDUH SER H, V53; Centers for Disease Control and Prevention, US OP PRESCR RAT MAP; Centers for Disease Control and Prevention, 2018, MULT CAUS DEATH 1999; Cole C, 2011, DRUG TEST ANAL, V3, P89, DOI 10.1002/dta.220; Davis GG, 2014, J MED TOXICOL, V10, P100, DOI 10.1007/s13181-013-0323-x; Drug Enforcement Administration Intelligence Programs Section, 2016, DEADCWDIR05116 US DE; Drug Enforcement Administration Strategic Intelligence Section, 2017, DEADCIDIB01417; DuPont RL, 2018, J GLOB DRUG POLICY P, V12, P1; DuPont RL, 2018, BRAIN RES BULL, V138, P116, DOI 10.1016/j.brainresbull.2017.06.008; Fiorentin TR, 2019, J FORENSIC SCI, V64, P888, DOI 10.1111/1556-4029.13968; Fiorentin TR, 2019, FORENSIC SCI INT, V295, P199, DOI 10.1016/j.forsciint.2018.12.016; Gold MS, 2017, SOBER WORLD MAGAZINE; Jones CM, 2017, AM J PUBLIC HEALTH, V107, P430, DOI 10.2105/AJPH.2016.303627; Kandel DB, 2017, DRUG ALCOHOL DEPEN, V178, P501, DOI 10.1016/j.drugalcdep.2017.05.047; Phillips KA, 2012, J GEN INTERN MED, V27, P1722, DOI 10.1007/s11606-012-2089-2; Ribeiro M, 2019, TRENDS PSYCHIATR PSY, V41, P186, DOI 10.1590/2237-6089-2017-0143; Scholl L, 2019, MMWR-MORBID MORTAL W, V67, P1419; Slavova S, 2015, PUBLIC HEALTH REP, V130, P339, DOI 10.1177/003335491513000411; U.S. Department of Health and Human Services, 2019, REP PAIN MAN BEST PR; United Nations Office on Drugs and Crime, 2017, 2017 GLOB SYNTH DRUG; United States Drug Enforcement Administration, 2018, 2018 NAT DRUG THREAT; US Department of State Bureau for International Narcotics and Law Enforcement Affairs, 2018, INT NARCOTICS CONTRO, V1; Wang Y, 2020, DRUG DEVELOP RES, V81, P52, DOI 10.1002/ddr.21603; Warner M, 2013, ACAD FORENSIC PATHOL, V3, P231, DOI DOI 10.23907/2013.029; Wu AHB, 2003, CLIN CHEM, V49, P357, DOI 10.1373/49.3.357	28	2	2	0	3	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0033-3549	1468-2877		PUBLIC HEALTH REP	Public Health Rep.	JAN	2020	135	1					6	10	UNSP 0033354919887741	10.1177/0033354919887741		NOV 2019	5	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	JV7MG	WOS:000498324800001	31738861	Bronze			2020-06-30	J	Qiu, J; Zhao, L; Yang, Y; Zhang, JH; Feng, Y; Cheng, R				Qiu, Jie; Zhao, Li; Yang, Yang; Zhang, Jing-han; Feng, Yun; Cheng, Rui			Effects of fentanyl for pain control and neuroprotection in very preterm newborns on mechanical ventilation	JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE			English	Article						Cerebral protection; fentanyl; mechanical ventilation; pain; preterm infant	MANAGEMENT; INFUSION; INFANTS	Objective: This study aimed to evaluate the cerebral protection effect of fentanyl infusion in very preterm infants in the first 72 h of mechanical ventilation. Methods: In this double-blind, randomized, controlled trial, mechanically ventilated newborns (<32 weeks' gestational age) were randomized to fentanyl (continuous infusion of fentanyl) or placebo (continuous infusion of glucose, controls) in the first 72 h of the mechanical ventilation period. The premature infant pain profile (PIPP), cerebral blood flow velocity, neuron-specific enolase (NSE) concentrations in plasma samples, and cerebral function monitoring (CFM) recordings were evaluated. Results: Twenty-seven infants were allocated to the fentanyl group and 26 to the control group. The fentanyl group had significantly lower PIPP scores than did the control group at 12, 24, 48, and 72 h after the start of infusion (all p < .05). No significant changes in hemodynamic parameters were observed during the observation period using transcranial Doppler flow measurements (p > .05). The fentanyl group had lower NSE levels and higher total CFM scores compared with the control group (both p < .05). Conclusion: In very preterm infants on mechanical ventilation, continuous fentanyl infusion might protect the developing brain by relieving pain during the first 72 h of mechanical ventilation.	[Qiu, Jie; Zhao, Li; Yang, Yang; Zhang, Jing-han; Feng, Yun; Cheng, Rui] Nanjing Med Univ, Dept Newborn Infants, Childrens Hosp, Nanjing, Jiangsu, Peoples R China	Feng, Y; Cheng, R (reprint author), Nanjing Med Univ, Dept Newborn Infants, Childrens Hosp, Nanjing, Jiangsu, Peoples R China.	fengyunnj025@163.com; chengrui350@163.com			maternal and Child Health Research Projects in Jiangsu Province [F201644]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81671500]; Jiangsu Provincial Six Talent Peaks; Nanjing Sanitation Engineering of Young Talents; Science and Technology Development Project of Nanjing Medical University [2016NJMUZD056]	Rui Cheng has received the grant from the maternal and Child Health Research Projects in Jiangsu Province [F201644]. Jie Qiu has received the grant from the National Natural Science Foundation of China [No. 81671500], Jiangsu Provincial Six Talent Peaks, and Nanjing Sanitation Engineering of Young Talents during the 13th Five-Year Plan Period. Li Zhao has received the grant from the Science and Technology Development Project of Nanjing Medical University [2016NJMUZD056].	Anand KJS, 2000, BIOL NEONATE, V77, P69, DOI 10.1159/000014197; Anand KJS, 2001, ARCH PEDIAT ADOL MED, V155, P173, DOI 10.1001/archpedi.155.2.173; Ancora G, 2013, J PEDIATR-US, V163, P645, DOI 10.1016/j.jpeds.2013.02.039; Aranda JV, 2005, CLIN THER, V27, P877, DOI 10.1016/j.clinthera.2005.06.019; Burdjalov VF, 2003, PEDIATRICS, V112, P855, DOI 10.1542/peds.112.4.855; Durrmeyer X, 2010, PEDIATR RES, V67, P117, DOI 10.1203/PDR.0b013e3181c8eef3; Fahnenstich H, 2000, CRIT CARE MED, V28, P836, DOI 10.1097/00003246-200003000-00037; Klebermass K, 2001, CHILD NERV SYST, V17, P544; Krzyzaniak N, 2016, J CLIN PHARM THER, V41, P612, DOI 10.1111/jcpt.12440; Lago P, 1998, ARCH DIS CHILD-FETAL, V79, pF194, DOI 10.1136/fn.79.3.F194; Orsini AJ, 1996, J PEDIATR-US, V129, P140, DOI 10.1016/S0022-3476(96)70201-9; Puchalski Mary, 2002, Adv Neonatal Care, V2, P233; Stevens B, 2002, CLIN PERINATOL, V29, P459, DOI 10.1016/S0095-5108(02)00016-7	13	2	2	0	28	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1476-7058	1476-4954		J MATERN-FETAL NEO M	J. Matern.-Fetal Neonatal Med.	NOV 17	2019	32	22					3734	3740		10.1080/14767058.2018.1471593			7	Obstetrics & Gynecology	Obstetrics & Gynecology	IN3UZ	WOS:000478603200006	29712500				2020-06-30	J	Bardsley, R				Bardsley, Russell			Higher naloxone dosing may be required for opioid overdose	AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY			English	Article						carfentanil; fentanyl; heroin; naloxone; overdose	CARFENTANIL	Purpose. Carfentanil is a synthetic opioid with an estimated potency that is 10,000 times more than that of morphine and 100 times more than that of fentanyl. Although there is a paucity of evidence, when considering the potency of carfentanil, it is reasonable to speculate that larger doses of naloxone may be required to resuscitate patients after carfentanil ingestion. This case report discusses the use of high-dose naloxone in 2 patients with suspected carfentanil overdose presenting to a small community hospital. Summary. Two patients with suspected carfentanil overdose presented to a 30-bed emergency department at a community hospital in New Hampshire. Cyanosis and respiratory distress were noted in both instances, and airway intervention was ultimately deemed necessary. Patient 1 required a total of 12 mg of naloxone to be successfully resuscitated, while patient 2 required a total of 10 mg for resuscitation. Both patients were successfully resuscitated with high doses of naloxone. The use of high-dose naloxone prevented the need for intubation in these patients. Conclusion. While more robust studies should be considered, emergency personnel should be comfortable using higher-than-standard doses of naloxone in appropriate cases.	[Bardsley, Russell] Catholic Med Ctr, Emergency Dept, Manchester, NH 03102 USA	Bardsley, R (reprint author), Catholic Med Ctr, Emergency Dept, Manchester, NH 03102 USA.	Russell.Bardsley@outlook.com					Food and Drug Administration, 2016, ADV COMM MOST APPR D; George AV, 2010, AM J EMERG MED, V28, P530, DOI 10.1016/j.ajem.2010.03.003; National Public Radio, DEADL OP OV 1 RESP C; Riches JR, 2012, J ANAL TOXICOL, V36, P647, DOI 10.1093/jat/bks078; Sutter ME, 2017, ACAD EMERG MED, V24, P106, DOI 10.1111/acem.13034; Tomassoni Anthony J, 2017, MMWR Morb Mortal Wkly Rep, V66, P107, DOI 10.15585/mm6604a4	6	1	1	1	1	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	1079-2082	1535-2900		AM J HEALTH-SYST PH	Am. J. Health-Syst. Pharm.	NOV 15	2019	76	22					1835	1837		10.1093/ajhp/zxz208			3	Pharmacology & Pharmacy	Pharmacology & Pharmacy	JX9SK	WOS:000504066700012	31665765				2020-06-30	J	Bossi, P; Ghiani, M; Argenone, A; Depenni, R				Bossi, Paolo; Ghiani, Massimo; Argenone, Angela; Depenni, Roberta			Is pain part of a systemic syndrome in head and neck cancer?	SUPPORTIVE CARE IN CANCER			English	Review						Head and neck cancer; Pain; Pain management; Multidisciplinary approach; Opioids	QUALITY-OF-LIFE; PLACEBO-CONTROLLED TRIAL; PECTIN NASAL SPRAY; ORAL MUCOSITIS; DOUBLE-BLIND; DEPRESSION; FENTANYL; ASSOCIATION; MANAGEMENT; FATIGUE	Head and neck cancers (HNC) represent 5% of all malignancies worldwide with about 180,000 cancer deaths per year. Patients with HNC are characterized by a systemic inflammatory state, generally associated with worse outcomes. Treatment-related toxicity is common among HNC patients and causes systemic consequences such as fatigue or cognitive dysfunction. The therapeutic treatments of HNC involve the release in circulation of inflammatory systemic mediators, whose effects trigger a vicious circle that may lead to functional and behavioral alterations. The areas of the head and neck are highly sensitive to pain. Literature data confirm that in HNC patients, pain is one of the most distressing symptoms across all the phases of treatment. Pain is associated with worse general conditions, depression, fatigue, impaired cognitive functions, and lower survival rate. The treatment of advanced HNC cases is multimodal and requires a multidisciplinary psycho-socio-pharmacological approach mediated by a team of experts. The pharmacological approach in management of HNC patients with pain is fundamental and involves the use of opioids, NSAIDs, steroids, or other drugs. Opioids in pain management therapy in patients with HNC could allow the pain level to be adequately monitored, thus improving quality of life. The integration of opioid and non-opioid therapy as well as non-pharmacological interventions is essential for the rehabilitation of physical, social, and psychological functions and to achieve pain control in patients with HNC. Opioid treatment is the mainstay for pain control, being used both for background and breakthrough cancer pain (BTcP) episodes. Fentanyl, easily absorbed and generally well tolerated, appears to be a possible choice due to its versatility. Non-pharmacological interventions, such as tailored yoga, physical exercise, and acupuncture, may have a role in pain management in patients with HNC.	[Bossi, Paolo] ASST Spedali Civili Brescia, Med Oncol, Brescia, Italy; [Bossi, Paolo] Univ Brescia, Dept Med & Surg Specialties, Radiol Sci & Publ Hlth, Brescia, Italy; [Ghiani, Massimo] A Businco Hosp, Oncol Dept, Cagliari, Italy; [Argenone, Angela] Ist Nazl Tumori IRCCS G Pascale Fdn, Radiat Oncol Dept, Naples, Italy; [Depenni, Roberta] Univ Hosp Modena & Reggio Emilia, Oncol & Haematol Dept, Modena, Italy	Bossi, P (reprint author), ASST Spedali Civili Brescia, Med Oncol, Brescia, Italy.; Bossi, P (reprint author), Univ Brescia, Dept Med & Surg Specialties, Radiol Sci & Publ Hlth, Brescia, Italy.	paolo.bossi@unibs.it					Adair M, 2018, INTEGR CANCER THER, V17, P774, DOI 10.1177/1534735417753540; Al-Dasooqi N, 2009, CANCER CHEMOTH PHARM, V64, P1, DOI 10.1007/s00280-009-0984-y; Allison RR, 2014, CANCER-AM CANCER SOC, V120, P1433, DOI 10.1002/cncr.28553; Apkarian AV, 2004, J NEUROSCI, V24, P10410, DOI 10.1523/JNEUROSCI.2541-04.2004; Bandieri E, 2016, J CLIN ONCOL, V34, P436, DOI 10.1200/JCO.2015.61.0733; Barcellos-Hoff MH, 1998, RADIAT RES, V150, pS109, DOI 10.2307/3579813; Bell BC, 2013, J PAIN RES, V6, P843, DOI 10.2147/JPR.S54788; Bossi P, 2014, ORAL ONCOL, V50, P884, DOI 10.1016/j.oraloncology.2014.06.013; Capuron L, 2003, BRAIN BEHAV IMMUN, V17, pS119; Cavaillon JM, 1992, CIRC SHOCK; Chang Andrew, 2015, J Pain Palliat Care Pharmacother, V29, P247, DOI 10.3109/15360288.2015.1063560; Chapman CR, 1999, LANCET, V353, P2233, DOI 10.1016/S0140-6736(99)01308-2; Chua KSG, 1999, J PAIN SYMPTOM MANAG, V18, P193, DOI 10.1016/S0885-3924(99)00070-6; Ciofi P, 2009, ENDOCRINOLOGY, V150, P5509, DOI 10.1210/en.2009-0584; Clarkson JE, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001973.pub4; Cleeland CS, 2003, CANCER-AM CANCER SOC, V97, P2919, DOI 10.1002/cncr.11382; Cohen E, 2008, CANCER NURS, V31, pE1, DOI 10.1097/01.NCC.0000305693.67131.7d; Criswell T, 2003, ONCOGENE, V22, P5813, DOI 10.1038/sj.onc.1206680; Dantzer R, 2004, EUR J PHARMACOL, V500, P399, DOI 10.1016/j.ejphar.2004.07.040; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Denham JW, 2002, RADIOTHER ONCOL, V63, P129, DOI 10.1016/S0167-8140(02)00060-9; Du MY, 2012, PROG NEURO-PSYCHOPH, V36, P11, DOI 10.1016/j.pnpbp.2011.09.014; DUFTON BD, 1989, INT J PSYCHIAT MED, V19, P291, DOI 10.2190/JDJK-0795-5BFL-5N6K; Enting RH, 2007, J PAIN SYMPTOM MANAG, V34, P523, DOI 10.1016/j.jpainsymman.2007.01.007; Epstein JB, 2001, ORAL ONCOL, V37, P632, DOI 10.1016/S1368-8375(01)00005-7; Giusti R, 2018, BRIT J PAIN, V12, P155, DOI 10.1177/2049463717736787; Green CR, 2011, CANCER-AM CANCER SOC, V117, P1994, DOI 10.1002/cncr.25761; Grond S, 1997, PAIN, V69, P191, DOI 10.1016/S0304-3959(96)03254-X; Gustin SM, 2013, J PAIN, V14, P1642, DOI 10.1016/j.jpain.2013.08.005; Haddad R, 2009, CANCER, V115, P4514, DOI 10.1002/cncr.24525; Hart Robert P, 2003, Curr Pain Headache Rep, V7, P116, DOI 10.1007/s11916-003-0021-5; HESS R, 1972, EUR J CLIN PHARMACOL, V4, P137, DOI 10.1007/BF00561135; Howren MB, 2013, J CONSULT CLIN PSYCH, V81, P299, DOI 10.1037/a0029940; Illi J, 2012, CYTOKINE, V58, P437, DOI 10.1016/j.cyto.2012.02.015; Jain MK, 2005, NAT REV DRUG DISCOV, V4, P977, DOI 10.1038/nrd1901; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI 10.3322/caac.20115; Jiang JR, 2019, J CLIN ONCOL, V37, P135, DOI 10.1200/JCO.18.00896; Johansen-Berg H, 2008, CEREB CORTEX, V18, P1374, DOI 10.1093/cercor/bhm167; Kestenbaum MG, 2014, PAIN MED, V15, P1129, DOI 10.1111/pme.12464; Kim ES, 2015, KOREAN J PAIN, V28, P73, DOI 10.3344/kjp.2015.28.2.73; Krysko DV, 2011, TRENDS IMMUNOL, V32, P157, DOI 10.1016/j.it.2011.01.005; Kvillemo P, 2011, CANCER NURS, V34, P24, DOI 10.1097/NCC.0b013e3181e2d0df; Laird BJA, 2016, J CLIN ONCOL, V34, P2769, DOI 10.1200/JCO.2015.65.7742; Lalla RV, 2014, ORAL ONCOL, V50, P1098, DOI 10.1016/j.oraloncology.2014.08.001; Lalla RV, 2014, CANCER-AM CANCER SOC, V120, P1453, DOI 10.1002/cncr.28592; Li Y, 2008, J NEUROSCI, V28, P2814, DOI 10.1523/JNEUROSCI.5447-07.2008; Logan RM, 2007, ORAL ONCOL, V43, P395, DOI 10.1016/j.oraloncology.2006.04.011; Lopez G, 2018, J CANCER, V9, P3613, DOI 10.7150/jca.26527; May A, 2008, PAIN, V137, P7, DOI 10.1016/j.pain.2008.02.034; Mehanna HM, 2006, ARCH OTOLARYNGOL, V132, P27, DOI 10.1001/archotol.132.1.27; Mejias NH, 2018, J INFLAMM-LOND, V15, DOI 10.1186/s12950-018-0198-3; Mirabile A, 2016, CRIT REV ONCOL HEMAT, V99, P100, DOI 10.1016/j.critrevonc.2015.11.010; MOLE RH, 1953, BRIT J RADIOL, V26, P234, DOI 10.1259/0007-1285-26-305-234; Moore RA, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007076.pub2; Mustian KM, 2013, EUR MED J ONCOL; Paice JA, 2014, J CLIN ONCOL, V32, P1721, DOI 10.1200/JCO.2013.52.5196; Pendergrass JC, 2018, INNOV CLIN NEUROSCI; Pinquart M, 2010, PSYCHOL MED, V40, P1797, DOI 10.1017/S0033291709992285; Rainville P, 1997, SCIENCE, V277, P968, DOI 10.1126/science.277.5328.968; Rodriguez-Raecke R, 2009, J NEUROSCI, V29, P13746, DOI 10.1523/JNEUROSCI.3687-09.2009; Rogers LQ, 2008, HEAD NECK-J SCI SPEC, V30, P1310, DOI 10.1002/hed.20873; Rogers LQ, 2009, HEAD NECK-J SCI SPEC, V31, P994, DOI 10.1002/hed.21053; ROSOW CE, 1987, DRUG ALCOHOL DEPEN, V20, P329, DOI 10.1016/0376-8716(87)90006-8; Roxburgh CSD, 2014, BRIT J CANCER, V110, P1409, DOI 10.1038/bjc.2014.90; Russi EG, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/518261; Sarvizadeh Mostafa, 2015, Adv Biomed Res, V4, P44, DOI 10.4103/2277-9175.151254; Scharpf J, 2009, ARCH OTOLARYNGOL, V135, P789, DOI 10.1001/archoto.2009.107; Schubert C, 2007, BRAIN BEHAV IMMUN, V21, P413, DOI 10.1016/j.bbi.2006.11.004; Schug SA, 2017, DRUGS, V77, P747, DOI 10.1007/s40265-017-0727-z; Sheline YI, 1999, J NEUROSCI, V19, P5034; Shinn EH, 2016, PSYCHOSOM MED, V78, P38, DOI 10.1097/PSY.0000000000000256; Srikrishna G, 2009, NEOPLASIA, V11, P615, DOI 10.1593/neo.09284; Takase H, 2011, AURIS NASUS LARYNX, V38, P495, DOI 10.1016/j.anl.2010.12.012; van Nieuwenhuizen AJ, 2018, SUPPORT CARE CANCER, V26, P1087, DOI 10.1007/s00520-017-3926-y; Weber RJ, 2009, BRAIN BEHAV IMMUN, V23, P993, DOI 10.1016/j.bbi.2009.05.057; Woolf CJ, 2000, SCIENCE, V288, P1765, DOI 10.1126/science.288.5472.1765; Xiao CH, 2013, ORAL ONCOL, V49, P360, DOI 10.1016/j.oraloncology.2012.10.004; Yang CA, 2015, J AUTOIMMUN, V61, P1, DOI 10.1016/j.jaut.2015.05.001; Yennurajalingam S, 2013, J CLIN ONCOL, V31, P3076, DOI 10.1200/JCO.2012.44.4661; Younger JW, 2011, PAIN, V152, P1803, DOI 10.1016/j.pain.2011.03.028; Zeppetella G, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004311.pub4	81	1	1	2	6	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	0941-4355	1433-7339		SUPPORT CARE CANCER	Support. Care Cancer	FEB	2020	28	2					451	459		10.1007/s00520-019-05147-8		NOV 2019	9	Oncology; Health Care Sciences & Services; Rehabilitation	Oncology; Health Care Sciences & Services; Rehabilitation	KW3FF	WOS:000495951700001	31713692				2020-06-30	J	Bardwell, G; Wood, E; Brar, R				Bardwell, Geoff; Wood, Evan; Brar, Rupinder			Fentanyl assisted treatment: a possible role in the opioid overdose epidemic?	SUBSTANCE ABUSE TREATMENT PREVENTION AND POLICY			English	Editorial Material						North America; Opioid overdose epidemic; Opioid agonist treatment; Fentanyl assisted treatment		BackgroundThe current opioid overdose epidemic affecting communities across North America is increasingly driven by illicitly manufactured fentanyl and its related analogues. A variety of public health interventions have been implemented and scaled up, including opioid agonist treatments (OAT). While these treatments are successful for many individuals, they have a variety of limitations. It is critical to trial alternative treatments if conventional opioid agonist treatment options are not successful for a proportion of patients who use illicit fentanyl.Main bodyPrescription fentanyl has been widely used for pain management. The use of transdermal fentanyl, specifically, which provides long acting and stable drug levels post-titration over several days, should be explored as an opioid agonist treatment option. The use of transdermal fentanyl for patients who use illicit fentanyl is currently being piloted in Vancouver, Canada. To address potential diversion, the patch is signed, dated, and a film dressing is applied to mitigate tampering. Evaluation outcomes are still pending, but there have been no adverse outcomes thus far and clinical improvements have been noted for many patients. This exploratory therapeutic approach should be considered across multiple settings and rigorously evaluated.ConclusionsThere are known limitations to existing OAT options and there is a need to urgently evaluate alternative strategies for patients who are using illicit fentanyl not successfully treated with conventional OAT. Many patients may be attracted to, and retained in, fentanyl assisted treatment. This may be another strategy for certain patients to prevent harms caused by illicit fentanyl use, including overdose and death.	[Bardwell, Geoff; Wood, Evan; Brar, Rupinder] British Columbia Ctr Subst Use, 400-1045 Howe St, Vancouver, BC V6Z 2A9, Canada; [Bardwell, Geoff; Wood, Evan] Univ British Columbia, Dept Med, 400-1045 Howe St, Vancouver, BC V6Z 2A9, Canada; [Brar, Rupinder] Univ British Columbia, Dept Family Practice, 5950 Univ Blvd, Vancouver, BC V6T 1Z3, Canada	Bardwell, G (reprint author), British Columbia Ctr Subst Use, 400-1045 Howe St, Vancouver, BC V6Z 2A9, Canada.; Bardwell, G (reprint author), Univ British Columbia, Dept Med, 400-1045 Howe St, Vancouver, BC V6Z 2A9, Canada.	geoff.bardwell@bccsu.ubc.ca		Bardwell, Geoff/0000-0003-3368-7681	United States National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01DA044181]; Canadian Institutes of Health Research Postdoctoral FellowshipCanadian Institutes of Health Research (CIHR); Canada Research Chairs ProgramCanada Research Chairs	This research is supported by a United States National Institutes of Health Grant (R01DA044181). Geoff Bardwell is supported by a Canadian Institutes of Health Research Postdoctoral Fellowship and Evan Wood is supported by the Canada Research Chairs Program.	Ahmad F, 2018, PROVISIONAL DRUG OVE; [Anonymous], 2019, FENT DET ILL DRUG TO; [Anonymous], 2018, OV DEATH RAT; Jones AA, 2018, JAMA PSYCHIAT, V75, P298, DOI 10.1001/jamapsychiatry.2017.4432; Mattick RP, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002207.pub4; Meier A, 2017, HOTSPOT REPORT UNDER; Papamihali KG, 2019, CHANGING LANDSCAPE O; Public Health Agency of Canada, 2018, NAT REP APP OP REL D; Socias ME, 2018, ANN INTERN MED, V168, P141, DOI 10.7326/M17-2373; Somerville N, 2017, CHARACTERISTICS FENT; Stanley TH, 2014, J PAIN, V15, P1215, DOI 10.1016/j.jpain.2014.08.010; Strike C, 2019, INT J DRUG POLICY	12	0	0	1	2	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1747-597X		SUBST ABUSE TREAT PR	Subst/ Abus. Treatment Prev. Pol.	NOV 11	2019	14	1							50	10.1186/s13011-019-0241-2			3	Substance Abuse	Substance Abuse	JM8KM	WOS:000496457000001	31711521	DOAJ Gold, Green Published			2020-06-30	J	Forbes, TP; Lawrence, J; Verkouteren, JR; Verkouteren, RM				Forbes, Thomas P.; Lawrence, Jeffrey; Verkouteren, Jennifer R.; Verkouteren, R. Michael			Discriminative potential of ion mobility spectrometry for the detection of fentanyl and fentanyl analogues relative to confounding environmental interferents	ANALYST			English	Article							DEGRADATION-PRODUCTS; CHEMICAL STANDARDS; AIRBORNE PARTICLES; THERMAL-DESORPTION; EXPLOSIVES; PRESSURE; COMPLEX; AGENTS; DRUGS; ABUSE	The opioid crisis and emergence of fentanyl, fentanyl analogues, and other synthetic opioids has highlighted the need for sensitive and robust detection for interdiction at screening points, notably vehicles at border crossings and packages at postal facilities. This work investigates the discriminative potential, sensitivity and specificity, of ion mobility spectrometry (IMS) for the detection of fentanyl and fifteen (15) fentanyl-related compounds (analogues, other opioids, and metabolites) relative to confounding environmental interferents. The environmental background interferent levels, frequency and intensity, were derived from over 10 000 screening samples collected from delivery vehicles entering a federal site. A receiver operating characteristic (ROC) curve methodology was employed to quantify the relationship between sensitivity and specificity for these target compounds on two instruments/configurations. These instrument configurations differed in desorption and drift tube temperatures, reactant ion dopant chemistry, and analysis time. This work identified reduced mobility areas of high interference that resulted in increased false positive rates (FPR), effectively reducing sensitivity (true positive rate: TPR) in those regions. Except for a few target compounds on either of the instruments that exhibited elevated FPRs, detection of fentanyl and fentanyl-related species was achieved at single to tens of nanograms with >= 90% TPR and >= 2% FPR. This work established the importance of systematic environmental background characterization at each specific screening setting in evaluating a platform's true performance.	[Forbes, Thomas P.; Lawrence, Jeffrey; Verkouteren, Jennifer R.; Verkouteren, R. Michael] NIST, Mat Measurement Sci Div, Gaithersburg, MD 20899 USA	Forbes, TP (reprint author), NIST, Mat Measurement Sci Div, Gaithersburg, MD 20899 USA.	thomas.forbes@nist.gov	; Verkouteren, Robert/C-3240-2014; Forbes, Thomas P/M-3091-2014	Lawrence, Jeffrey/0000-0002-6894-5399; Verkouteren, Robert/0000-0002-5155-9926; Forbes, Thomas P/0000-0002-7594-5514	U.S. Department of Homeland Security Science and Technology DirectorateUnited States Department of Homeland Security (DHS) [IAA HSHQPM-15-T-00050]; National Institute of Standards and TechnologyNational Institute of Standards & Technology (NIST) - USA	The U.S. Department of Homeland Security Science and Technology Directorate sponsored a portion of the production of this material under Interagency Agreement IAA HSHQPM-15-T-00050 with the National Institute of Standards and Technology.	Adams LA, 2005, CLIN CHEM, V51, P1867, DOI 10.1373/clinchem.2005.048389; [Anonymous], WORLD DRUG REP 2018; [Anonymous], DET QUANT CAP; [Anonymous], 2018, OV DEATH RAT; [Anonymous], 2019, BORD CROSS ENTR DAT; Asbury GR, 2000, ANAL CHIM ACTA, V404, P273, DOI 10.1016/S0003-2670(99)00726-6; Asbury GR, 2000, TALANTA, V50, P1291; Carrano J., 2004, CHEM BIOL SENSOR STA; Cecinato A, 2007, J SEP SCI, V30, P1930, DOI 10.1002/jssc.200700039; Cole C, 2011, DRUG TEST ANAL, V3, P89, DOI 10.1002/dta.220; Cotte-Rodriguez I, 2006, ANALYST, V131, P579, DOI 10.1039/b513605a; Demoranville LT, 2013, TALANTA, V106, P375, DOI 10.1016/j.talanta.2013.01.011; Dennis DMK, 2016, FORENSIC SCI INT, V259, P179, DOI 10.1016/j.forsciint.2015.12.034; Eiceman GA, 2004, ANAL CHEM, V76, p390A, DOI 10.1021/ac041665c; Eiceman GA, 2014, ION MOBILITY SPECTROMETRY, 3RD EDITION, P1; Eiceman GA, 2003, ANAL CHIM ACTA, V493, P185, DOI 10.1016/S0003-2670(03)00762-1; EICEMAN GA, 1995, ANAL CHIM ACTA, V306, P21, DOI 10.1016/0003-2670(94)00668-C; Ewing RG, 2001, TALANTA, V54, P515, DOI 10.1016/S0039-9140(00)00565-8; Fawcett T, 2006, PATTERN RECOGN LETT, V27, P861, DOI 10.1016/j.patrec.2005.10.010; Forbes TP, 2016, ANALYST, V141, P4438, DOI 10.1039/c6an00844e; Fraga CG, 2007, ANALYST, V132, P230, DOI 10.1039/b607843e; Heeschen C, 1999, CLIN CHEM, V45, P1789; Howard J, 2018, AM J IND MED, V61, P633, DOI 10.1002/ajim.22874; Jenkins AJ, 2001, FORENSIC SCI INT, V121, P189, DOI 10.1016/S0379-0738(01)00401-7; Kaur-Atwal G, 2009, INT J ION MOBIL SPEC, V12, P1, DOI 10.1007/s12127-009-0021-1; Khayamian T, 2006, TALANTA, V69, P795, DOI 10.1016/j.talanta.2005.11.016; Kozole J, 2012, TALANTA, V99, P799, DOI 10.1016/j.talanta.2012.07.030; LAWRENCE AH, 1987, FORENSIC SCI INT, V34, P73, DOI 10.1016/0379-0738(87)90086-7; Matz LM, 2001, TALANTA, V54, P171, DOI 10.1016/S0039-9140(00)00663-9; Mulligan CC, 2006, ANALYST, V131, P556, DOI 10.1039/b517541k; Najarro M, 2012, ANALYST, V137, P2614, DOI 10.1039/c2an16145a; Pepe MS, STAT EVALUATION MED; Postigo C, 2009, ANAL CHEM, V81, P4382, DOI 10.1021/ac9002485; Rearden P, 2005, ANAL CHIM ACTA, V545, P13, DOI 10.1016/j.aca.2005.04.035; Riches JR, 2012, J ANAL TOXICOL, V36, P647, DOI 10.1093/jat/bks078; Sisco E, 2018, FORENSIC CHEM, V11, P47, DOI 10.1016/j.forc.2018.09.001; Sisco E, 2017, FORENSIC CHEM, V4, P108, DOI 10.1016/j.forc.2017.04.001; U.S. Drug Enforcement Administration Special Testing and Research Laboratory, EM THREAT REP MULT Y; Verkouteren JR, 2014, ANALYST, V139, P5488, DOI 10.1039/c4an01184h; Verkouteren JR, 2008, MEAS SCI TECHNOL, V19, DOI 10.1088/0957-0233/19/11/115101; Verkouteren JR, 2011, FORENSIC SCI INT, V206, P190, DOI 10.1016/j.forsciint.2010.08.005; Verkouteren RM, 2011, LANGMUIR, V27, P9644, DOI 10.1021/la201728f; Verkouteren RM, 2009, ANAL CHEM, V81, P8577, DOI 10.1021/ac901563j; Viana M, 2010, ENVIRON INT, V36, P527, DOI 10.1016/j.envint.2010.04.004; Wysoczanski A, 2014, SPECTROCHIM ACTA B, V100, P70, DOI 10.1016/j.sab.2014.08.005; Zaknoun H, 2019, INT J ION MOBIL SPEC, V22, P1, DOI 10.1007/s12127-019-00244-0; Zimmermann S, 2008, ANAL CHEM, V80, P6671, DOI 10.1021/ac800559h; Zou KH, 2007, CIRCULATION, V115, P654, DOI 10.1161/CIRCULATIONAHA.105.594929; Zou KH, 1997, STAT MED, V16, P2143	49	0	0	8	15	ROYAL SOC CHEMISTRY	CAMBRIDGE	THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND	0003-2654	1364-5528		ANALYST	Analyst	NOV 7	2019	144	21					6391	6403		10.1039/c9an01771b			13	Chemistry, Analytical	Chemistry	KJ9LW	WOS:000512376900027	31579898				2020-06-30	J	Kaplan, S; Bergamasco, A; Sergerie, M; Castilloux, AM; Moride, Y				Kaplan, Sigal; Bergamasco, Aurore; Sergerie, Martin; Castilloux, Anne-Marie; Moride, Yola			Effectiveness of Risk Minimization Measures for Fentanyl Buccal Tablet (FENTORA) in Canada: A Mixed-Methods Evaluation Using Surveys, Medical Chart Records and Web Surveillance	DRUG SAFETY			English	Article							OPIOID-TOLERANT PATIENTS; IMMEDIATE-RELEASE OXYCODONE; BREAKTHROUGH CANCER PAIN; DOUBLE-BLIND; MANAGEMENT; SAFETY; RELIEF; CHALLENGES; PREVALENCE; 12-WEEK	Background Fentanyl buccal tablet (FBT), a potent opioid, was approved in Canada in 2013 for breakthrough pain in opioid-tolerant adult cancer patients. Additional risk minimization measures (aRMMs), consisting of communications to patients and healthcare providers (HCPs), were implemented from November 2014 through September 2015. Objectives The aim of this study was to assess the effectiveness of FBT aRMMs as measured by prescriber knowledge, understanding, and behavior regarding key safety concerns (off-label use, use in non-opioid-tolerant patients, misuse/abuse/diversion, and drug-drug interaction) and to evaluate illicit FBT use. Methods The study included three components: (1) a knowledge and understanding (KAU) survey of FBT prescribers conducted in two waves: November 2016-February 2017 and April-September 2018; (2) a retrospective prescription study of medical records of patients treated with FBT by a subgroup of prescribers from the KAU survey; and (3) Web surveillance of illicit FBT use in Canada using the search term FENTORA (May 2014-September 2018). The aRMMs were considered effective if the lower bound of the 95% confidence interval indicated that at least 65% of respondents met or partly met the knowledge objective for each key safety concern. Results KAU survey: Of 46 eligible HCPs, 97.8% met or partly met the knowledge objective on use in breakthrough pain cancer patients, 97.8% on use in opioid-tolerant patients, 89.1% on dose and titration, 100% on abuse/addiction, and 58.7% on drug-drug interaction. Retrospective prescription study: Of 22 FBT-treated patients identified from 14 HCPs, 45.5% had cancer, 50.0% recorded a breakthrough pain indication, and 36.4% reported opioid tolerance; however, only 13.6% of patients were prescribed FBT according to the approved indication. Web surveillance: Of 932 FBT posts in Canada, only 40 (4.3%) mentioned illicit use. Conclusions The aRMMs as measured by the prescriber KAU were effective for most key safety messages; however, not all key messages of the aRMMs were stringently followed in routine practice.	[Kaplan, Sigal] Teva Pharmaceut Ind Ltd, Netanya, Israel; [Bergamasco, Aurore] YOLARX Consultants, Paris, France; [Sergerie, Martin] Teva Canada Innovat, Montreal, PQ, Canada; [Castilloux, Anne-Marie; Moride, Yola] YOLARX Consultants, Montreal, PQ, Canada; [Moride, Yola] Univ Montreal, Fac Pharm, Montreal, PQ, Canada; [Moride, Yola] Rutgers State Univ, New Brunswick, NJ USA	Kaplan, S (reprint author), Teva Pharmaceut Ind Ltd, Netanya, Israel.	Sigalit.Kaplan@teva.co.il			Teva Canada Innovation	This study was funded by Teva Canada Innovation.	Ashburn MA, 2011, ANESTH ANALG, V112, P693, DOI 10.1213/ANE.0b013e318209d320; Banerjee AK, 2014, DRUG SAFETY, V37, P33, DOI 10.1007/s40264-013-0126-7; Belzak L, 2018, HEALTH PROMOT CHRON, V38, P224, DOI 10.24095/hpcdp.38.6.02; Brant JM, 2017, CLIN J ONCOL NURS, V21, P71, DOI 10.1188/17.CJON.S3.71-80; Busse JW, 2017, CAN MED ASSOC J, V189, pE659, DOI 10.1503/cmaj.170363; Canadian Centre on Substance Use and Addiction (CCSA), 2017, ANN REP 2016 2017; Canadian Institute for Health Information (CIHI), 2017, OP REL HARMS CAN CHA; Caraceni A, 2013, J NATL COMPR CANC NE, V11, pS29; Chang Yaping, 2016, J Opioid Manag, V12, P377, DOI 10.5055/jom.2016.0357; Daeninck P, 2016, CURR ONCOL, V23, P96, DOI 10.3747/co.23.2865; Deandrea S, 2014, J PAIN SYMPTOM MANAG, V47, P57, DOI 10.1016/j.jpainsymman.2013.02.015; Dube PA, 2018, CAN PHARM J, V151, P408, DOI 10.1177/1715163518805509; European Medicines Agency (EMA), 2017, GUID GOOD PHARM PRAC; Farrar JT, 2010, PAIN MED, V11, P1313, DOI 10.1111/j.1526-4637.2010.00939.x; Fine PG, 2010, J PAIN SYMPTOM MANAG, V40, P747, DOI 10.1016/j.jpainsymman.2010.02.009; Fischer B, 2018, PREV MED, V107, P109, DOI 10.1016/j.ypmed.2017.11.001; Food and Drug Administration (FDA), 2019, SURV METH ASS REMS G; Gavrielov-Yusim N, 2018, PHARMACOEPIDEM DR S, V27, P457, DOI 10.1002/pds.4331; Gomes Tara, 2017, CMAJ Open, V5, pE800, DOI 10.9778/cmajo.20170104; Grywacheski Vera, 2018, Healthc Q, V20, P10, DOI 10.12927/hcq.2018.25430; Hauser Winfried, 2017, Pain Rep, V2, pe599, DOI 10.1097/PR9.0000000000000599; Health Canada, 2018, NEW REG PRO BETT INF; Health Canada, 2018, SUBM TARG RISK MAN P; International Narcotics Control Board, 2016, AV INT CONTR DRUGS E; Landsberg W, 2018, DRUG SAFETY, V41, P797, DOI 10.1007/s40264-018-0662-2; Madadi P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060600; Madison T, 2016, EVALUATING EFFECTIVE; Martin TL, 2006, J ANAL TOXICOL, V30, P603, DOI 10.1093/jat/30.8.603; Mercadante S, 2015, CURR OPIN ANESTHESIO, V28, P559, DOI 10.1097/ACO.0000000000000224; National Opioid Use Guideline Group, 2010, CAN GUID SAF EFF US; Nkeng L, 2012, DRUG SAFETY, V35, P535, DOI 10.2165/11599720-000000000-00000; Osborne V, 2014, EUR J PAIN, V18, P506, DOI 10.1002/j.1532-2149.2013.00389.x; Portenoy RK, 2007, CURR MED RES OPIN, V23, P222, DOI 10.1185/030079906X162818; Prieto L, 2012, PHARMACOEPIDEM DR S, V21, P896, DOI 10.1002/pds.3305; Rash JA, 2018, SYST REV-LONDON, V7, DOI 10.1186/s13643-018-0858-7; Simpson DM, 2007, CLIN THER, V29, P588, DOI 10.1016/j.clinthera.2007.04.007; Teva Canada Innovation, 2018, FENT PROF MON; Webster LR, 2013, PAIN MED, V14, P1332, DOI 10.1111/pme.12184; Webster Lynn R, 2011, J Opioid Manag, V7, P297	39	0	0	1	1	ADIS INT LTD	NORTHCOTE	5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND	0114-5916	1179-1942		DRUG SAFETY	Drug Saf.	FEB	2020	43	2					163	177		10.1007/s40264-019-00882-7		NOV 2019	15	Public, Environmental & Occupational Health; Pharmacology & Pharmacy; Toxicology	Public, Environmental & Occupational Health; Pharmacology & Pharmacy; Toxicology	KI8RF	WOS:000494508600002	31691255				2020-06-30	J	Sofalvi, S; Lavins, ES; Brooker, IT; Kaspar, CK; Kucmanic, J; Mazzola, CD; Mitchell-Mata, CL; Clyde, CL; Rico, RN; Apollonio, LG; Goggin, C; Marshall, B; Moore, D; Gilson, TP				Sofalvi, Szabolcs; Lavins, Eric S.; Brooker, Ian T.; Kaspar, Claire K.; Kucmanic, John; Mazzola, Carrie D.; Mitchell-Mata, Christie L.; Clyde, Cassandra L.; Rico, Rindi N.; Apollonio, Luigino G.; Goggin, Charissa; Marshall, Brittany; Moore, Danielle; Gilson, Thomas P.			Unique Structural/Stereo-Isomer and Isobar Analysis of Novel Fentanyl Analogues in Postmortem and DUID Whole Blood by UHPLC-MS-MS	JOURNAL OF ANALYTICAL TOXICOLOGY			English	Article							DESIGNER DRUGS; 3-METHYLFENTANYL; IDENTIFICATION; SPECIMENS; URINE	The presented analytical method enabled the Toxicology Department at the Cuyahoga County Medical Examiner's Office to identify 26 and quantitatively report 24 compounds in 500 mu L of whole blood, including fentanyl analogues (fentalogues) such as methoxyacetyl fentanyl (MeOAF) and cyclopropyl fentanyl (CPF). This second-generation method (FG2) was developed with the objective to improve the existing analysis (FG1) by decreasing sample size, lowering limits of detection (LOD) and lower limit of quantitation, minimizing ion suppression and resolving chromatographic interferences. Interferences may occur in the analysis of fentanyl, MeOAF, CPF, 3-methylfentanyl (3MF), butyryl fentanyl and isobutyryl fentanyl due to isobars and structural or geometric isomerism with another analogue or metabolite. The isomeric and isobaric fentalogues were grouped into three sets. The LOD established for Set 1 [MeOAF, para-methoxyacetyl fentanyl, para-fluoro acryl fentanyl (isobar), fentanyl carbamate], 2-furanyl fentanyl, Set 2 [CPF, (E)-crotonyl fentanyl] and carfentanil was 0.0125 ng/mL. The LOD established for N-methyl norfentanyl, norfentanyl, norcarfentanil, despropionyl fentanyl (4-ANPP), acetyl fentanyl, beta-hydroxy fentanyl, benzyl fentanyl, acryl fentanyl, alfentanil, fentanyl, para-fluoro fentanyl, Set 3 [(+/-)-trans-3MF, (+/-)-cis-3MF, isobutyryl and butyryl fentanyl], para-fluoroisobutyryl fentanyl, sufentanil, phenyl fentanyl and cyclopentenyl fentanyl was 0.0625 ng/mL. Seven-point linear calibration curves were established between 0.025 and 4.0 ng/mL for the 8 analytes with the lower LOD and 0.125 and 20 ng/mL for the 18 analytes with the higher LOD. 4-ANPP and cyclopentenyl fentanyl met qualitative reporting criteria only. The results for five postmortem and two driving under the influence of drugs authentic case samples are presented. To the authors' knowledge, FG2 is the first published method that achieved baseline resolution of the nine structural/stereo isomers and one isobar by ultra-high performance liquid chromatography-MS-MS and provided quantitative validation data for nine compounds. FG2 may be used as the new baseline for future isomers that need to be chromatographically separated.	[Sofalvi, Szabolcs; Lavins, Eric S.; Brooker, Ian T.; Kaspar, Claire K.; Kucmanic, John; Mazzola, Carrie D.; Mitchell-Mata, Christie L.; Clyde, Cassandra L.; Rico, Rindi N.; Apollonio, Luigino G.; Gilson, Thomas P.] CCMEO, Toxicol Dept, 11001 Cedar Ave, Cleveland, OH 44106 USA; [Goggin, Charissa; Marshall, Brittany; Moore, Danielle] Phenomenex, 411 Madrid Ave, Torrance, CA 90501 USA	Sofalvi, S (reprint author), CCMEO, Toxicol Dept, 11001 Cedar Ave, Cleveland, OH 44106 USA.	ssofalvi@cuyahogacounty.us					Almeida AM, 2002, J CHROMATOGR B, V774, P215, DOI 10.1016/S1570-0232(02)00244-1; American Association for Laboratory Accreditation (A2LA), 2014, G104 GUID EST MEAS U; Astrand A, 2019, ARCH TOXICOL, V93, P95, DOI 10.1007/s00204-018-2330-9; Bierly J., 2017, CYCLOPROPYL CROTONYL, V41, P11; Brede WR, 2019, J ANAL TOXICOL, V43, pE7, DOI 10.1093/jat/bky080; BRINE GA, 1995, J MED CHEM, V38, P1547, DOI 10.1021/jm00009a015; Brusius M., 2016, CHROMATOGRAPHY TODAY, P40; Drug Enforcement Administration Special Testing and Research Laboratory, 2017, EM THREAT REP 3 QUAR; Duffy J, 2019, ANAL CHIM ACTA, V1049, P161, DOI 10.1016/j.aca.2018.12.014; European Monitoring Centre for Drugs and Drug Addiction, 2018, JOINT REP; Fagiola M, 2019, J ANAL TOXICOL, V43, pE1, DOI 10.1093/jat/bky094; Fogarty MF, 2018, DRUG TEST ANAL, V10, P1474, DOI 10.1002/dta.2414; Fogarty MF, 2018, J ANAL TOXICOL, V42, P592, DOI 10.1093/jat/bky035; HENDERSON GL, 1988, J FORENSIC SCI, V33, P569; Kahl JH, 2018, J ANAL TOXICOL, V42, P570, DOI 10.1093/jat/bky054; Lavins E.S., 2018, 2018 ANN M AM AC FOR; Maher S, 2018, DRUG TEST ANAL, V10, P1483, DOI 10.1002/dta.2417; Mallette JR, 2019, SCI JUSTICE, V59, P67, DOI 10.1016/j.scijus.2018.07.005; Mardal M, 2018, FORENSIC SCI INT, V290, P310, DOI 10.1016/j.forsciint.2018.07.020; Meyer MR, 2012, ANAL BIOANAL CHEM, V402, P1249, DOI 10.1007/s00216-011-5528-8; Morrow JB, 2019, J ANAL TOXICOL, V43, P1, DOI 10.1093/jat/bky049; Munoz-Munoz AC, 2018, J ANAL TOXICOL, V42, P6, DOI 10.1093/jat/bkx065; Ojanpera I, 2008, INT J LEGAL MED, V122, P395, DOI 10.1007/s00414-008-0230-x; Ojanpera I, 2006, AM J FOREN MED PATH, V27, P328, DOI 10.1097/01.paf.0000188097.78132.e5; Palaty J, 2018, CLIN BIOCHEM, V53, P164, DOI 10.1016/j.clinbiochem.2018.01.013; Pogozheva ID, 1998, BIOPHYS J, V75, P612, DOI 10.1016/S0006-3495(98)77552-6; Poklis J, 2016, J ANAL TOXICOL, V40, P703, DOI 10.1093/jat/bkw048; SCHNEIDER E, 1986, N-S ARCH PHARMACOL, V334, P267, DOI 10.1007/BF00508781; Seymour C, 2019, J ANAL TOXICOL, V43, P266, DOI 10.1093/jat/bky096; Shoff EN, 2017, J ANAL TOXICOL, V41, P484, DOI 10.1093/jat/bkx041; Simons B., 2017, SOC FORENSIC TOX TOX, V41, P9; Sofalvi S., 2016, SOFT ANN M DALL TEX, pS44; Sofalvi S, 2017, J ANAL TOXICOL, V41, P473, DOI 10.1093/jat/bkx052; Strayer KE, 2018, ACS OMEGA, V3, P514, DOI 10.1021/acsomega.7b01536; Tiscione NB, 2018, J ANAL TOXICOL, V42, P476, DOI 10.1093/jat/bky026; Ulrich EL, 2008, NUCLEIC ACIDS RES, V36, pD402, DOI 10.1093/nar/gkm957; VANBEVER WF, 1974, J MED CHEM, V17, P1047, DOI 10.1021/jm00256a003; Wu F, 2017, J ANAL TOXICOL, V41, P289, DOI 10.1093/jat/bkx003	38	1	1	4	5	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0146-4760	1945-2403		J ANAL TOXICOL	J. Anal. Toxicol.	NOV	2019	43	9					673	687		10.1093/jat/bkz056			15	Chemistry, Analytical; Toxicology	Chemistry; Toxicology	KF9BH	WOS:000509530900001	31504606				2020-06-30	J	Voller, S; Flint, RB; Andriessen, P; Allegaert, K; Zimmermann, LJI; Liem, KD; Koch, BCP; Simons, SHP; Knibbe, CAJ				Voller, Swantje; Flint, Robert B.; Andriessen, Peter; Allegaert, Karel; Zimmermann, Luc J. I.; Liem, Kian D.; Koch, Birgit C. P.; Simons, Sinno H. P.; Knibbe, Catherijne A. J.		DINO Study Grp	Rapidly maturing fentanyl clearance in preterm neonates	ARCHIVES OF DISEASE IN CHILDHOOD-FETAL AND NEONATAL EDITION			English	Article							HUMAN LIVER; DRUG-TREATMENT; PHARMACOKINETICS; PAIN; 3A4; METABOLISM; CHILDREN; NEWBORNS; EFFICACY; WEIGHT	Background Fentanyl is frequently used off-label in preterm newborns. Due to very limited pharmacokinetic and pharmacodynamic data, fentanyl dosing is mostly based on bodyweight. This study describes the maturation of the pharmacokinetics in preterm neonates born before 32 weeks of gestation. Methods 442 plasma samples from 98 preterm neonates (median gestational age: 26.9 (range 23.9-31.9) weeks, postnatal age: 3 (range 0-68) days, bodyweight 1.00 (range 0.39-2.37) kg) were collected in an opportunistic trial and fentanyl plasma levels were determined. NONMEM V.7.3 was used to develop a population pharmacokinetic model and to perform simulations. Results Fentanyl pharmacokinetics was best described by a two-compartment model. A pronounced non-linear influence of postnatal and gestational age on clearance was identified. Clearance (L/hour/kg) increased threefold, 1.3-fold and 1.01-fold in the first, second and third weeks of life, respectively. In addition, clearance (L/hour/kg) was 1.4-fold and 1.7-fold higher in case of a gestational age of 28 and 31 weeks, respectively, compared with 25 weeks. Volume of distribution changed linearly with bodyweight and was 8.7 L/kg. To achieve similar exposure across the entire population, a continuous infusion (mu g/kg/hour) dose should be reduced by 50% and 25% in preterm neonates with a postnatal age of 0-4 days and 5-9 days in comparison to 10 days and older. Conclusion Because of low clearance, bodyweight-based dosages may result in fentanyl accumulation in neonates with the lowest postnatal and gestational ages which may require dose reduction. Together with additional information on the pharmacodynamics, the results of this study can be used to guide dosing.	[Voller, Swantje; Knibbe, Catherijne A. J.] Leiden Univ, Leiden Acad Ctr Drug Res, Div Syst Pharmacol & Biomed, Div Pharmacol, NL-2300 RA Leiden, Netherlands; [Flint, Robert B.; Simons, Sinno H. P.] Univ Med Ctr Rotterdam, Erasmus MC Sophia Childrens Hosp, Dept Pediat, Div Neonatol, Rotterdam, Netherlands; [Flint, Robert B.] Radboud Univ Nijmegen, Med Ctr, Radboud Inst Hlth Sci, Dept Pharm, Nijmegen, Netherlands; [Flint, Robert B.; Koch, Birgit C. P.] Univ Med Ctr Rotterdam, Erasmus MC, Dept Pharm, Rotterdam, Netherlands; [Andriessen, Peter] Maxima Med Ctr, Dept Pediat, Div Neonatol, Veldhoven, Netherlands; [Allegaert, Karel] Erasmus MC Sophia Childrens Hosp, Dept Pediat, Div Neonatol, Rotterdam, Netherlands; [Zimmermann, Luc J. I.] Maastricht Univ, Med Ctr, Sch Mental Hlth & Neurosci, Dept Pediat,Sch Oncol & Dev Biol, Maastricht, Netherlands; [Liem, Kian D.] Radboudumc, Dept Pediat, Div Neonatol, Nijmegen, Netherlands; [Knibbe, Catherijne A. J.] St Antonius Hosp, Dept Clin Pharm, Nieuwegein, Netherlands	Voller, S (reprint author), Leiden Univ, Leiden Acad Ctr Drug Res, Div Syst Pharmacol & Biomed, Div Pharmacol, NL-2300 RA Leiden, Netherlands.	s.voller@lacdr.leidenuniv.nl	allegaert, karel/C-3611-2016; Flint, Robert B/A-1862-2016	allegaert, karel/0000-0001-9921-5105; Flint, Robert B/0000-0002-3658-594X; Simons, Sinno/0000-0001-5219-5696; Andriessen, Peter/0000-0002-5159-6874; Knibbe, Catherijne Annette Jantine/0000-0001-9893-4415	Netherlands Organisation for Health Research and Development ZonMwNetherlands Organization for Health Research and Development [836011022]	The DINO study and all accompanying research were funded by the Netherlands Organisation for Health Research and Development ZonMw (grant number: 836011022).	Abduljalil K, 2014, AAPS J, V16, P568, DOI 10.1208/s12248-014-9592-9; Anchieta LM, 2003, BRAZ J MED BIOL RES, V36, P761, DOI 10.1590/S0100-879X2003000600012; Ancora G, 2013, J PEDIATR-US, V163, P645, DOI 10.1016/j.jpeds.2013.02.039; Aranda JV, 2005, CLIN THER, V27, P877, DOI 10.1016/j.clinthera.2005.06.019; Brussee JM, 2016, EXPERT REV CLIN PHAR, V9, P1235, DOI 10.1080/17512433.2016.1198256; Carbajal R, 2008, JAMA-J AM MED ASSOC, V300, P60, DOI 10.1001/jama.300.1.60; Comets E, 2008, COMPUT METH PROG BIO, V90, P154, DOI 10.1016/j.cmpb.2007.12.002; De Cock RFW, 2011, EUR J CLIN PHARMACOL, V67, pS5, DOI 10.1007/s00228-009-0782-9; Encinas E, 2013, PEDIATR DRUGS, V15, P247, DOI 10.1007/s40272-013-0029-1; Feierman DE, 1996, DRUG METAB DISPOS, V24, P932; Flint RB, 2018, BIOMED CHROMATOGR, V32, DOI 10.1002/bmc.4290; GAUNTLETT IS, 1988, ANESTHESIOLOGY, V69, P683, DOI 10.1097/00000542-198811000-00008; Ghersi-Egea JF, 2018, PHARM RES-DORDR, V35, DOI 10.1007/s11095-018-2375-8; Gow PJ, 2001, PHARMACOL TOXICOL, V88, P3, DOI 10.1034/j.1600-0773.2001.088001003.x; Grijalva J, 2013, SEMIN PEDIATR SURG, V22, P185, DOI 10.1053/j.sempedsurg.2013.10.006; Grunau RE, 2006, SEMIN FETAL NEONAT M, V11, P268, DOI 10.1016/j.siny.2006.02.007; Grunau RE, 2013, RAMBAM MAIMONIDES ME, V4, DOI 10.5041/RMMJ.10132; Guinsburg R, 1998, J PEDIATR-US, V132, P954, DOI 10.1016/S0022-3476(98)70390-7; Ibrahim AE, 2003, ANESTHESIOLOGY, V98, P853, DOI 10.1097/00000542-200304000-00011; Ince I, 2009, DRUG DISCOV TODAY, V14, P316, DOI 10.1016/j.drudis.2008.11.004; Johnston C C, 1999, J Obstet Gynecol Neonatal Nurs, V28, P587, DOI 10.1111/j.1552-6909.1999.tb02167.x; Keizer RJ, 2013, CPT-PHARMACOMET SYST, V2, DOI 10.1038/psp.2013.24; KOEHNTOP DE, 1986, ANESTH ANALG, V65, P227; Krekels EHJ, 2017, EUR J PHARM SCI, V109, pS22, DOI 10.1016/j.ejps.2017.05.022; Labroo RB, 1997, DRUG METAB DISPOS, V25, P1072; Lacroix D, 1997, EUR J BIOCHEM, V247, P625, DOI 10.1111/j.1432-1033.1997.00625.x; Lindbom L, 2005, COMPUT METH PROG BIO, V79, P241, DOI 10.1016/j.cmpb.2005.04.005; Meesters NJ, 2016, NEONATOLOGY, V110, P190, DOI 10.1159/000445284; Olhager E, 2014, ACTA PAEDIATR, V103, P337, DOI 10.1111/apa.12520; Pacifici GM, 2015, PEDIATR NEONATOL, V56, P143, DOI 10.1016/j.pedneo.2014.06.002; Palkama VJ, 1998, BRIT J ANAESTH, V81, P598, DOI 10.1093/bja/81.4.598; Ranger M, 2007, SEMIN PERINATOL, V31, P283, DOI 10.1053/j.semperi.2007.07.003; Saarenmaa E, 2000, J PEDIATR-US, V136, P767, DOI 10.1067/mpd.2000.105366; Saunders NR, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00046; Smith GC, 2011, ANN NEUROL, V70, P541, DOI 10.1002/ana.22545; Tateishi T, 1996, ANESTH ANALG, V82, P167; Thewissen L, 2011, ARCH DIS CHILDHOOD-E, V96, P112, DOI 10.1136/adc.2008.145565; Wilson AS, 1997, ANESTH ANALG, V84, P315, DOI 10.1097/00000539-199702000-00013; Ziesenitz VC, 2018, CLIN PHARMACOKINET, V57, P393, DOI 10.1007/s40262-017-0609-2; Ziesenitz VC, 2015, J CLIN PHARMACOL, V55, P708, DOI 10.1002/jcph.469	40	5	5	1	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1359-2998	1468-2052		ARCH DIS CHILD-FETAL	Arch. Dis. Child.-Fetal Neonatal Ed.	NOV	2019	104	6					F598	F603		10.1136/archdischild-2018-315920			6	Pediatrics	Pediatrics	JU5YG	WOS:000501751500006	31498775				2020-06-30	J	Serinelli, S; White, S; Arunkumar, P; Wang, DL; Gitto, L				Serinelli, Serenella; White, Steven; Arunkumar, Ponni; Wang, Dongliang; Gitto, Lorenzo			The Outbreak of Fentanyl-Related Deaths in Cook County, Illinois, Between October 2015 and December 2017: A Retrospective Study and a Comparison with Previous Data	JOURNAL OF FORENSIC SCIENCES			English	Article; Proceedings Paper	71st Annual Scientific Meeting of the American-Academy-of-Forensic-Sciences (AAFS)	FEB 18-23, 2019	Baltimore, MD	Amer Acad Forens Sci		forensic science; fentanyl; fentanyl analogs; drug overdose; toxicology; fatal; autopsy; public health	ILLICIT FENTANYL; OVERDOSE DEATHS; EPIDEMIC; CANADA	The National Institute on Drug Abuse has observed an increase in fentanyl deaths in the United States. One epidemic related to the abuse of fentanyl happened in Cook County in 2005-2007 (350 deaths). Another outbreak of fentanyl deaths occurred in 2015-2017 in the same area. The database of the Cook County Medical Examiner's Office was searched for cases of fentanyl deaths between 2015 and 2017: 1244 deaths were found. A comparison was performed with the previous data: an increase in the number of females was observed in 2015-2017. Also, in 2005-2007, the majority of deaths occurred among African American, while in 2015-2017, Caucasians were more involved. Within our population, some drug combinations were more common in specific demographic subgroups (male/females; Caucasian/African American; and certain age groups). The epidemiology and the most significant drug associations found at the toxicology are discussed, highlighting the usefulness of the knowledge about this outbreak for public health.	[Serinelli, Serenella; Gitto, Lorenzo] SUNY Upstate Med Univ, Dept Pathol, 750 E Adams St, Syracuse, NY 13210 USA; [White, Steven] British Columbia Coroners Serv, 3649 Cambridge St, Vancouver, BC V5K 1M5, Canada; [Arunkumar, Ponni] Cook Cty Off Med Examiner, 2121 W Harrison St, Chicago, IL 60612 USA; [Wang, Dongliang] SUNY Upstate Med Univ, Dept Publ Hlth & Prevent Med, 750 E Adams St, Syracuse, NY 13210 USA	Serinelli, S (reprint author), SUNY Upstate Med Univ, Dept Pathol, 750 E Adams St, Syracuse, NY 13210 USA.	s.serinelli@gmail.com	Serinelli, Serenella/AAH-6010-2020; Gitto, Lorenzo/W-2080-2019	Gitto, Lorenzo/0000-0002-1435-1819			[Anonymous], OV DEATH RAT; Baldwin N, 2018, DRUG ALCOHOL DEPEN, V185, P322, DOI 10.1016/j.drugalcdep.2017.12.032; Colon-Berezin C, 2019, MMWR-MORBID MORTAL W, V68, P37, DOI 10.15585/mmwr.mm6802a3; Denton JS, 2008, J FORENSIC SCI, V53, P452, DOI 10.1111/j.1556-4029.2008.00669.x; Fischer B, 2018, PREV MED, V107, P109, DOI 10.1016/j.ypmed.2017.11.001; HIBBS J, 1991, JAMA-J AM MED ASSOC, V265, P1011, DOI 10.1001/jama.265.8.1011; Kaiser Family Foundation, OP OV DEATHS RAC ETH; MARTIN M, 1991, ANN EMERG MED, V20, P158, DOI 10.1016/S0196-0644(05)81216-8; Mercado-Crespo MC, 2014, MMWR-MORBID MORTAL W, V63, P531; National Institute on Drug Abuse, FENT; Pergolizzi JV, 2018, POSTGRAD MED, V130, P1, DOI 10.1080/00325481.2018.1407618; Schumann H, 2008, CLIN TOXICOL, V46, P501, DOI 10.1080/15563650701877374; SMIALEK JE, 1994, J FORENSIC SCI, V39, P159	13	0	0	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-1198	1556-4029		J FORENSIC SCI	J. Forensic Sci.	NOV	2019	64	6					1735	1742		10.1111/1556-4029.14114			8	Medicine, Legal	Legal Medicine	JU2CI	WOS:000501482700016	31216059				2020-06-30	J	Nara, A; Yamada, C; Saka, K; Kodama, T; Yoshida, M; Iwahara, K; Takagi, T				Nara, Akina; Yamada, Chiho; Saka, Kanju; Kodama, Takanori; Yoshida, Masaki; Iwahara, Kaori; Takagi, Tetsuya			A Fatal Case of Poisoning with Fentanyl Transdermal Patches in Japan	JOURNAL OF FORENSIC SCIENCES			English	Article						forensic science; forensic toxicology; fentanyl; transdermal patch; whole blood; QuEChERS; ultra-high-performance liquid chromatography-tandem mass spectrometry	POSTMORTEM REDISTRIBUTION; BLOOD-CONCENTRATIONS; MISUSE; DEATH; INTOXICATION; MANAGEMENT; MATRIX; ABUSE; PAIN	Fentanyl transdermal patches have been used to treat cancer- and noncancer-related chronic pain. However, its inappropriate or illegal application may cause fatal poisoning. We herein present the case of a Japanese woman in her 40s who was found dead with seven 25-mu g/h fentanyl transdermal patches on her body. We established a detailed toxicological analysis procedure to quantify fentanyl, and its metabolite norfentanyl, and other drugs (acetaminophen, allylisopropylacetylurea, celecoxib, estazolam, promethazine, and sertraline) in human whole blood by ultra-high-performance liquid chromatography-tandem mass spectrometry. The measured fentanyl and norfentanyl concentrations in the femoral and cardiac blood were 0.051 and 0.072 mu g/mL and 0.033 and 0.076 mu g/mL, respectively. The decedent's fentanyl concentrations were consistent with previously reported postmortem blood levels for fatal cases of poisoning by fentanyl transdermal patches. Based on the decedent's case history, autopsy findings, and toxicological analyses, the cause of death was identified as intoxication with transdermal fentanyl.	[Nara, Akina; Yamada, Chiho; Kodama, Takanori; Yoshida, Masaki; Iwahara, Kaori; Takagi, Tetsuya] Tohoku Med & Pharmaceut Univ, Fac Med, Div Legal Med, Miyagino Ku, 1-15-1 Fukumuro, Sendai, Miyagi 9838536, Japan; [Saka, Kanju] Univ Tokyo, Grad Sch Med, Dept Forens Med, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan; [Yoshida, Masaki] Kyorin Univ, Dept Legal Med, 6-20-2 Shinkawa, Mitaka, Tokyo 1818611, Japan; [Iwahara, Kaori; Takagi, Tetsuya] Nippon Dent Univ, Ctr Legal Med Dent, Sch Dent Tokyo, Chiyoda Ku, 1-9-20 Fujimi, Fujimi 1028159, Japan	Nara, A (reprint author), Tohoku Med & Pharmaceut Univ, Fac Med, Div Legal Med, Miyagino Ku, 1-15-1 Fukumuro, Sendai, Miyagi 9838536, Japan.	akina@tohoku-mpu.ac.jp					Akita K, 2018, KANTO J JPN ASS ACUT, V39, P288; Akiyama Yasuko, 2007, Masui, V56, P317; Andresen H, 2012, J ANAL TOXICOL, V36, P182, DOI 10.1093/jat/bks005; [Anonymous], 2018, DUR MT PATCH TRANSD; [Anonymous], 2014, CEL 200 MG JAP PRESC; Bakovic M, 2015, INT J LEGAL MED, V129, P1247, DOI 10.1007/s00414-015-1209-z; Baselt RC, 2017, DISPOSITION TOXIC DR; Carson HJ, 2010, LEGAL MED, V12, P157, DOI 10.1016/j.legalmed.2010.03.001; Edinboro LE, 1997, J FORENSIC SCI, V42, P741; Feierman DE, 1996, DRUG METAB DISPOS, V24, P932; Fitzgerald KT, 2013, TOP COMPANION ANIM M, V28, P13, DOI 10.1053/j.tcam.2013.03.003; Gill JR, 2013, J MED TOXICOL, V9, P34, DOI 10.1007/s13181-012-0253-z; Goeringer KE, 2000, J FORENSIC SCI, V45, P633; Hoy SM, 2008, DRUGS, V68, P1711, DOI 10.2165/00003495-200868120-00008; Juebner M, 2014, INT J LEGAL MED, V128, P949, DOI 10.1007/s00414-014-0982-4; Kramer Christopher, 1998, Journal of the American Osteopathic Association, V98, P385; Krinsky CS, 2014, J FORENSIC SCI, V59, P1275, DOI 10.1111/1556-4029.12381; Kuczynska K, 2018, FORENSIC SCI INT, V289, P207, DOI 10.1016/j.forsciint.2018.05.042; Kuhlman JJ, 2003, J ANAL TOXICOL, V27, P499, DOI 10.1093/jat/27.7.499; Kurita K, 2015, YAKUGAKU ZASSHI, V135, P1307, DOI 10.1248/yakushi.15-00080; Lung DD, 2014, FORENSIC TOXICOL, V32, P118, DOI 10.1007/s11419-013-0216-3; Martin TL, 2006, J ANAL TOXICOL, V30, P603, DOI 10.1093/jat/30.8.603; Moore PW, 2015, J FORENSIC SCI, V60, P243, DOI 10.1111/1556-4029.12559; Olson KN, 2010, AM J CLIN PATHOL, V133, P447, DOI 10.1309/AJCP4X5VHFSOERFT; Palmer RB, 2010, CLIN TOXICOL, V48, P771, DOI 10.3109/15563650.2010.525514; Peng PWH, 1999, ANESTHESIOLOGY, V90, P576, DOI 10.1097/00000542-199902000-00034; Prodduturi S, 2010, J PHARM SCI-US, V99, P2357, DOI 10.1002/jps.22004; Ruan XL, 2016, FORENSIC SCI MED PAT, V12, P363, DOI 10.1007/s12024-016-9789-6; Schug SA, 2017, DRUGS, V77, P747, DOI 10.1007/s40265-017-0727-z; Schulz M, 2012, CRIT CARE, V16, DOI 10.1186/cc11441; Serghini I, 2015, PAN AFR MED J, V20, DOI 10.11604/pamj.2015.20.21.5886; Shimizu Fumitaka, 2007, Rinsho Shinkeigaku, V47, P222; U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Veterinary Medicine (CVM), 2018, GUID IND BIOAN METH; Usui K, 2012, LEGAL MED-TOKYO, V14, P286, DOI 10.1016/j.legalmed.2012.04.008	34	0	0	4	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-1198	1556-4029		J FORENSIC SCI	J. Forensic Sci.	NOV	2019	64	6					1936	1942		10.1111/1556-4029.14127			7	Medicine, Legal	Legal Medicine	JU2CI	WOS:000501482700047	31340064				2020-06-30	J	Davis, CS; Carr, DH; Samuels, EA				Davis, Corey S.; Carr, Derek H.; Samuels, Elizabeth A.			Paraphernalia Laws, Criminalizing Possession and Distribution of Items Used to Consume Illicit Drugs, and Injection-Related Harm	AMERICAN JOURNAL OF PUBLIC HEALTH			English	Article							SYRINGE EXCHANGE; UNITED-STATES; HEPATITIS-C; INCREASES; INTERVENTION; TRANSMISSION; NEEDLE	The United States remains in the grip of an unprecedented epidemic of drug-related harm. Infections of HIV, hepatitis C, and endocarditis related to lack of access to new syringes and subsequent syringe sharing among people who inject drugs have increased alongside a surge in opioid overdose deaths. Overwhelming evidence shows that using a new syringe with every injection prevents injection-related blood-borne disease transmission. Additionally, there is promising research suggesting that the distribution of fentanyl test strips to people who inject drugs changes individuals' injection decisions, which enables safer drug use and reduces the risk of fatal overdose. However, laws prohibiting the possession of syringes and fentanyl test strips persist in nearly every state. The full and immediate repeal of state paraphernalia laws is both warranted and needed to reduce opioid overdose death and related harms. Such repeal would improve the health of people who inject drugs and those with whom they interact, reducing the spread of blood-borne disease and fatal overdose associated with infiltration of illicitly manufactured fentanyl into the illicit drug supply. It would also free up scarce public resources that could be redirected toward evidence-based approaches to reducing drug-related harm.	[Davis, Corey S.; Carr, Derek H.] Network Publ Hlth Law, 3701 Wilshire Blvd 750, Los Angeles, CA 90010 USA; [Davis, Corey S.] East Carolina Univ, Brody Sch Med, Greenville, NC 27858 USA; [Samuels, Elizabeth A.] Brown Univ, Warren Alpert Med Sch, Dept Emergency Med, Providence, RI 02912 USA	Davis, CS (reprint author), Network Publ Hlth Law, 3701 Wilshire Blvd 750, Los Angeles, CA 90010 USA.	cdavis@networkforphl.org	Samuels, Elizabeth/AAC-9987-2020	Samuels, Elizabeth/0000-0003-2414-110X; Carr, Derek/0000-0003-1503-015X			Aspinall EJ, 2014, INT J EPIDEMIOL, V43, P235, DOI 10.1093/ije/dyt243; Bluthenthal RN, 1999, J DRUG ISSUES, V29, P1; Burns RM, 2016, SUBST ABUS, V37, P63, DOI 10.1080/08897077.2015.1080208; Cranston K, 2019, MMWR-MORBID MORTAL W, V68, P253, DOI 10.15585/mmwr.mm6810a6; Davis CS, 2005, AM J PUBLIC HEALTH, V95, P233, DOI [10.2105/AJPH.2003.033563, 10.2105/AJPH.2003.031310]; Goedel WC, 2019, CLIN INFECT DIS; Goldman JE, 2019, HARM REDUCT J, V16, DOI 10.1186/s12954-018-0276-0; Gonsalves GS, 2018, LANCET HIV, V5, pE569, DOI 10.1016/S2352-3018(18)30176-0; HAGAN H, 2005, AIDS S3, V19, pS19; Krieger MS, 2018, INT J DRUG POLICY, V61, P52, DOI 10.1016/j.drugpo.2018.09.009; McClellan C, 2018, ADDICT BEHAV, V86, P90, DOI 10.1016/j.addbeh.2018.03.014; North Kentucky Tribune, 2019, HLTH DEP SHAR CDC RE; Palmateer N, 2010, ADDICTION, V105, P844, DOI 10.1111/j.1360-0443.2009.02888.x; Peiper NC, 2019, INT J DRUG POLICY, V63, P122, DOI 10.1016/j.drugpo.2018.08.007; Platt L, 2018, ADDICTION, V113, P545, DOI 10.1111/add.14012; Razavi H, 2013, HEPATOLOGY, V57, P2164, DOI 10.1002/hep.26218; Rich JD, 2015, JAMA-J AM MED ASSOC, V314, P23, DOI 10.1001/jama.2015.6303; Rudd RA, 2016, MMWR-MORBID MORTAL W, V65, P1445, DOI 10.15585/mmwr.mm655051e1; Ruiz MS, 2016, AIDS BEHAV, V20, P22, DOI 10.1007/s10461-015-1143-6; Satcher D., 2000, EVIDENCE BASED FINDI; Scholl Lawrence, 2018, MMWR Morb Mortal Wkly Rep, V67, P1419, DOI [10.15585/mmwr.mm6751521e1, 10.15585/mmwr.mm675152e1]; Teles SA, 2018, J INFECT PUBLIC HEAL, V11, P526, DOI 10.1016/j.jiph.2017.10.008; Nguyen TQ, 2014, AIDS BEHAV, V18, P2144, DOI 10.1007/s10461-014-0789-9; Wurcel AG, 2016, OPEN FORUM INFECT DI, V3, DOI 10.1093/ofid/ofw157; Zibbell JE, 2018, AM J PUBLIC HEALTH, V108, P175, DOI 10.2105/AJPH.2017.304132	25	0	0	1	1	AMER PUBLIC HEALTH ASSOC INC	WASHINGTON	800 I STREET, NW, WASHINGTON, DC 20001-3710 USA	0090-0036	1541-0048		AM J PUBLIC HEALTH	Am. J. Public Health	NOV	2019	109	11					1564	1567		10.2105/AJPH.2019.305268			4	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	JQ8IE	WOS:000499181400037	31536408				2020-06-30	J	Lord, B; Jennings, PA; Smith, K				Lord, Bill; Jennings, Paul A.; Smith, Karen			Effects of the Introduction of Intranasal Fentanyl on Reduction of Pain Severity Score in Children An Interrupted Time-Series Analysis	PEDIATRIC EMERGENCY CARE			English	Article						paramedic; emergency medical services; pain management; analgesia	PREHOSPITAL ANALGESIA; MANAGEMENT; ATTITUDES; BARRIERS; CARE	Objectives Children are at risk of inadequate analgesia due to paramedics' inexperience in assessing children and challenges in administering analgesics when the patient is distressed and uncooperative. This study reports on the outcome of a change to practice guidelines that added intranasal fentanyl and intramuscular morphine within a large statewide ambulance service. Methods This retrospective study included patients younger than 15 years treated by paramedics between January 2008 and December 2011. The primary outcome of interest was the proportion of patients having a 2/10 or greater reduction in pain severity score using an 11-point Verbal Numeric Rating Scale before and after the intervention. Segmented regression analysis was used to estimate the effect of the intervention over time. A multiple regression model calculated odds ratios with 95% confidence intervals. Results A total of 92,378 children were transported by paramedics during the study period, with 9833 cases included in the analysis. The median age was 11 years; 61.6% were male. Before the intervention, 88.1% (n = 3114) of children receiving analgesia had a reduction of pain severity of 2 or more points, with 94.2% (n = 5933) achieving this benchmark after intervention (P < 0.0001). The odds of a reduction in pain of 2 or more points increased by 1.01 per month immediately before the intervention and 2.33 after intervention (<0.0001). Conclusions This large study of a system-wide clinical practice guideline change has demonstrated a significant improvement in the outcome of interest. However, a proportion of children with moderate to severe pain did not receive analgesia.	[Lord, Bill] Univ Sunshine Coast, Sch Nursing Midwifery & Paramed, Locked Bag 4, Maroochydore, Qld 4558, Australia; [Jennings, Paul A.] Monash Univ, Dept Community Emergency Hlth & Paramed Practice, Clayton, Vic, Australia; [Jennings, Paul A.] Alfred Hosp, Ambulance Victoria, Melbourne, Vic, Australia; [Jennings, Paul A.] Alfred Hosp, Emergency & Trauma Ctr, Melbourne, Vic, Australia; [Jennings, Paul A.] Victoria Univ, Coll Hlth & Biomed, Footscray, Vic, Australia; [Smith, Karen] Ambulance Victoria, Dept Res & Evaluat, Melbourne, Vic, Australia; [Smith, Karen] Monash Univ, Dept Epidemiol & Prevent Med, Clayton, Vic, Australia	Lord, B (reprint author), Univ Sunshine Coast, Sch Nursing Midwifery & Paramed, Locked Bag 4, Maroochydore, Qld 4558, Australia.	wlord@usc.edu.au		Lord, Bill/0000-0001-8821-5353			Alonso-Serra Hector M, 2003, Prehosp Emerg Care, V7, P482; Ambulance Victoria, 2015, AMB VICT 2014 2015 A; Ambulance Victoria, 2012, AMB VICT 2011 2012 A; Bendall JC, 2011, PREHOSP EMERG CARE, V15, P158, DOI 10.3109/10903127.2010.541980; Berben SAA, 2012, INJURY, V43, P1397, DOI 10.1016/j.injury.2011.01.029; Browne LR, 2016, PREHOSP EMERG CARE, V20, P759, DOI 10.1080/10903127.2016.1194931; Browne LR, 2016, PREHOSP EMERG CARE, V20, P59, DOI 10.3109/10903127.2015.1056897; Castren M, 2015, SCAND J PAIN, V8, P17, DOI 10.1016/j.sjpain.2015.02.003; Cox S, 2013, AUST HEALTH REV, V37, P54, DOI 10.1071/AH11161; Doherty S, 2013, EMERG MED AUSTRALAS, V25, P120, DOI 10.1111/1742-6723.12022; French SC, 2006, PREHOSP EMERG CARE, V10, P71, DOI 10.1080/10903120500366086; Gausche-Hill M, 2014, PREHOSP EMERG CARE, V18, P25, DOI 10.3109/10903127.2013.844873; Gordon DB, 2004, PAIN, V107, P1, DOI 10.1016/S0304-3959(03)00267-7; Hennes Halim, 2005, Prehosp Emerg Care, V9, P32, DOI 10.1080/10903120590891705; Iqbal M, 2013, EMERG MED J, V30, DOI 10.1136/emermed-2012-201111; Lzsak E, 2008, PREHOSP EMERG CARE, V12, P182, DOI 10.1080/10903120801907471; MAX MB, 1990, ANN INTERN MED, V113, P885, DOI 10.7326/0003-4819-113-11-885; Merkel S, 2002, AM J NURS, V102, P55; Mudd S, 2011, J PEDIATR HEALTH CAR, V25, P316, DOI 10.1016/j.pedhc.2010.04.011; Murphy A, 2016, PREHOSP EMERG CARE, V20, P52, DOI 10.3109/10903127.2015.1037478; Murphy A, 2014, EMERG MED J, V31, P493, DOI 10.1136/emermed-2012-202166; Penfold RB, 2013, ACAD PEDIATR, V13, pS38, DOI 10.1016/j.acap.2013.08.002; Rahman A, 2015, PREHOSP DISASTER MED, V30, P66, DOI 10.1017/S1049023X14001277; Rutkowska A, 2015, PEDIATR EMERG CARE, V31, P317, DOI 10.1097/PEC.0000000000000313; Samuel N, 2015, AM J EMERG MED, V33, P451, DOI 10.1016/j.ajem.2014.12.012; Schug S. A, 2015, ACUTE PAIN MANAGEMEN; Scott LE, 2013, INT EMERG NURS, V21, P173, DOI 10.1016/j.ienj.2012.08.004; Thomas SH, 2008, J EMERG MED, V35, P47, DOI 10.1016/j.jemermed.2007.05.041; Tomlinson D, 2010, PEDIATRICS, V126, pE1168, DOI 10.1542/peds.2010-1609; Turner J, 2013, PREHOSP DISASTER MED, V28, pS89; Voepel-Lewis T, 2011, ANESTH ANALG, V112, P415, DOI 10.1213/ANE.0b013e318203f495; von Baeyer CL, 2009, PAIN, V143, P223, DOI 10.1016/j.pain.2009.03.002; Wagner AK, 2002, J CLIN PHARM THER, V27, P299, DOI 10.1046/j.1365-2710.2002.00430.x; Walsh B, 2013, PREHOSP EMERG CARE, V17, P78, DOI 10.3109/10903127.2012.717167; Williams DM, 2012, PREHOSP EMERG CARE, V16, P519, DOI 10.3109/10903127.2012.695436	35	0	0	3	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0749-5161	1535-1815		PEDIATR EMERG CARE	Pediatr. Emerg. Care	NOV	2019	35	11					749	754		10.1097/PEC.0000000000001376			6	Emergency Medicine; Pediatrics	Emergency Medicine; Pediatrics	JO3YJ	WOS:000497516400011	29200141				2020-06-30	J	Seiler, M; Landolt, MA; Staubli, G				Seiler, Michelle; Landolt, Markus A.; Staubli, Georg			Nitrous Oxide 70% for Procedural Analgosedation in a Pediatric Emergency Department-With or Without Intranasal Fentanyl?	PEDIATRIC EMERGENCY CARE			English	Article						nitrous oxide 70%; intranasal fentanyl; procedural analgosedation; analgesic efficacy; adverse events	ADVERSE EVENTS; FASTING STATE; SEDATION; ANALGESIA; CHILDREN; PAIN; EFFICACY; SURGERY; SAFETY; DEPTH	Objectives Nitrous oxide 70% (N(2)0 70%) is an excellent medication for procedural analgosedation in a pediatric emergency department. However, its analgesic efficacy remains uncertain for painful procedures; therefore, a combination with intranasal fentanyl (INF), an opioid, was suggested. This study aimed at observing and assessing the analgesic efficacy and rate of adverse events using N(2)0 70% with and without INF. Methods Children who received N(2)0 70% in a tertiary children's hospital emergency department from January 1, 2014 to June 30, 2015 were included in this observational study with prospective data collection. Physicians decided individually whether INF was administered. Medical staff documented the child's behavior during the procedure, adverse events, and satisfaction rate. Results A total of 442 children were included; 206 (46.6%) received INF. Group differences regarding patient behavior were not statistically significant; however, N(2)0 70% application time was longer in the INF group (P = .02). Nausea was the most frequent adverse event with 13.1% in the INF group versus 8.1% without INF. Inadequate procedural analgosedation was documented only in the INF group, affecting 1.8% of all patients (P = .002). In contrast, anxiety was exclusively observed in the group without INF, which was presumably misjudged pain (P = .03); the satisfaction rate in the INF group was 95.6% compared with 98.7% without INF. Conclusions Because of the study design and limitations, no conclusions about adding INF to N(2)0 70% can be made. Additional research is needed to investigate the effect of combining N(2)0 70% with INF.	[Seiler, Michelle; Staubli, Georg] Univ Childrens Hosp Zurich, Pediat Emergency Dept, Zurich, Switzerland; [Landolt, Markus A.] Univ Childrens Hosp Zurich, Dept Psychosomat & Psychiat, Zurich, Switzerland; [Landolt, Markus A.] Univ Zurich, Dept Psychol, Div Child & Adolescent Hlth Psychol, Zurich, Switzerland	Seiler, M (reprint author), Univ Childrens Hosp Zurich, Pediat Emergency Dept, Zurich, Switzerland.	michelle.seiler@kispi.uzh.ch		Landolt, Markus/0000-0003-0760-5558			Babl FE, 2008, EMERG MED J, V25, P717, DOI 10.1136/emj.2007.053751; Babl FE, 2005, PEDIATR EMERG CARE, V21, P736, DOI 10.1097/01.pec.0000186427.07636.fc; Babl FE, 2008, PEDIATRICS, V121, pE528, DOI 10.1542/peds.2007-1044; Babl FE, 2015, ANN EMERG MED, V66, P475, DOI 10.1016/j.annemergmed.2015.04.029; Borland M, 2007, ANN EMERG MED, V49, P335, DOI 10.1016/j.annemergmed.2006.06.016; Borland Meredith L, 2002, Emerg Med (Fremantle), V14, P275, DOI 10.1046/j.1442-2026.2002.00344.x; Brand K, 2010, ANAEST INTENS CARE M, V11, P214, DOI 10.1016/j.mpaic.2010.02.014; Corrigan M, 2015, AM J HEALTH-SYST PH, V72, P1544, DOI 10.2146/ajhp140630; Cravero JP, 2006, PEDIATRICS, V118, P1087, DOI 10.1542/peds.2006-0313; Crellin D, 2010, EMERG MED AUSTRALAS, V22, P62, DOI 10.1111/j.1742-6723.2010.01257.x; Finn M, 2010, EMERG MED J, V27, P300, DOI 10.1136/emj.2008.070474; Frampton A, 2003, EMERG MED J, V20, P410, DOI 10.1136/emj.20.5.410; Heinrich M, 2015, EUR J PEDIATR SURG, V25, P250, DOI 10.1055/s-0034-1371716; HENNRIKUS WL, 1994, J PEDIATR ORTHOPED, V14, P538, DOI 10.1097/01241398-199407000-00023; Krauss B, 2006, LANCET, V367, P766, DOI 10.1016/S0140-6736(06)68230-5; Krauss B, 2000, NEW ENGL J MED, V342, P938, DOI 10.1056/NEJM200003303421306; Kupietzky A, 2008, PEDIATR DENT, V30, P414; Murphy A, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009942.pub2; Pasaron R, 2015, PEDIATR SURG INT, V31, P173, DOI 10.1007/s00383-014-3608-5; Seith RW, 2012, ACAD EMERG MED, V19, P31, DOI 10.1111/j.1553-2712.2011.01241.x; Stinson JN, 2006, PAIN, V125, P143, DOI 10.1016/j.pain.2006.05.006; Tsze DS, 2016, J PEDIATR-US, V169, P260, DOI 10.1016/j.jpeds.2015.10.019; Zier JL, 2011, PEDIATR EMERG CARE, V27, P1107, DOI 10.1097/PEC.0b013e31823aff6d	23	2	2	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0749-5161	1535-1815		PEDIATR EMERG CARE	Pediatr. Emerg. Care	NOV	2019	35	11					755	759		10.1097/PEC.0000000000001213			5	Emergency Medicine; Pediatrics	Emergency Medicine; Pediatrics	JO3YJ	WOS:000497516400012	29112108				2020-06-30	J	Freni, F; Pezzella, S; Vignali, C; Moretti, M; Cisini, S; Rossetti, C; Ravizza, R; Motta, M; Groppi, A; Morini, L				Freni, Francesca; Pezzella, Sara; Vignali, Claudia; Moretti, Matteo; Cisini, Simone; Rossetti, Chiara; Ravizza, Rossana; Motta, Marco; Groppi, Angelo; Morini, Luca			A case report on potential postmortem redistribution of furanyl fentanyl and 4-ANPP	FORENSIC SCIENCE INTERNATIONAL			English	Article						Furanyl fentanyl; 4-ANPP; LC-MS/MS; Tissue distribution; Postmortem	ANALOGS; BLOOD; METABOLITES; DEATH	Fatal intoxications due to accidental or voluntary intake of synthetic opioids represent an actual emerging issue. We report a case where we have analyzed furanyl fentanyl and its metabolite 4-anilino-N-phenetyl-piperidine (4-ANPP) in blood, urine, gastric content, bile and cerebrospinal fluid. In this case, a 53-year-old man was found dead at home with a needle still inserted in a vein; a plastic bag containing a white powder (later identified as a furanyl fentanyl-based product) was discovered in the room. Biological samples were collected during autopsy and extracted/purified onto a SPE cartridge before instrumental analysis. Qualitative and quantitative analyses were performed by LC-MS/MS on peripheral and cardiac blood, urine, cerebrospinal fluid (CSF), bile and gastric content. Furanyl fentanyl was identified and quantified in all the biological fluids collected. Interestingly, gastric content revealed an unexpected high amount of furanyl fentanyl; yet, cardiac blood and femoral blood provided significantly different concentrations (11.8 and 2.7 ng/g respectively). The concentration of furanyl fentanyl in CSF was similar to that measured in femoral blood (2.6 ng/mL), thus confirming that CSF could be a good alternative biological fluid whenever a postmortem redistribution is suspected. Concentrations of 93.5, 50.4, 171.7, 41.9, 10.2 ng/mL(g) were measured for 4-ANPP in cardiac blood, femoral blood, urine, bile and cerebrospinal fluid, respectively. The outcomes from the presented case report suggest that the two substances have been not only injected intravenously, but probably also ingested by the man. Fentanyl derivative and its precursor seemed to undergo an extensive postmortem redistribution. (C) 2019 Published by Elsevier B.V.	[Freni, Francesca; Pezzella, Sara; Vignali, Claudia; Moretti, Matteo; Groppi, Angelo; Morini, Luca] Univ Pavia, Dept Publ Hlth Expt & Forens Med, Via C Forlanini 12, I-27100 Pavia, Italy; [Cisini, Simone; Rossetti, Chiara; Ravizza, Rossana; Motta, Marco] Univ Insubria, Dept Biotechnol & Life Sci, Via J-H Dunant 3, I-21100 Varese, Italy	Morini, L (reprint author), Univ Pavia, Dept Publ Hlth Expt & Forens Med, Via C Forlanini 12, I-27100 Pavia, Italy.	luca.morini@unipv.it		Moretti, Matteo/0000-0001-7420-9366; Morini, Luca/0000-0003-4584-5552			[Anonymous], 2013, J ANAL TOXICOL, V37, P452, DOI 10.1093/jat/bkt054; Armenian P, 2018, NEUROPHARMACOLOGY, V134, P121, DOI 10.1016/j.neuropharm.2017.10.016; Brockbals L, 2019, FORENSIC SCI INT, V294, P80, DOI 10.1016/j.forsciint.2018.11.007; Comer SD, 2019, NEUROSCI BIOBEHAV R, V106, P49, DOI 10.1016/j.neubiorev.2018.12.005; Concheiro M, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01210; Fogarty MF, 2018, J ANAL TOXICOL, V42, P592, DOI 10.1093/jat/bky035; Gerace E, 2018, CURR PHARM BIOTECHNO, V19, P113, DOI 10.2174/1389201019666180405162734; Guerrieri D, 2017, J ANAL TOXICOL, V41, P242, DOI 10.1093/jat/bkw129; Helander A, 2016, CLIN TOXICOL, V54, P324, DOI 10.3109/15563650.2016.1139715; Kahl JH, 2018, J ANAL TOXICOL, V42, P570, DOI 10.1093/jat/bky054; Kiyatkin EA, 2019, NEUROPHARMACOLOGY, V151, P219, DOI 10.1016/j.neuropharm.2019.02.008; Mardal M, 2018, FORENSIC SCI INT, V290, P310, DOI 10.1016/j.forsciint.2018.07.020; Martucci HFH, 2018, FORENSIC SCI INT, V283, pE13, DOI 10.1016/j.forsciint.2017.12.005; Mohr ALA, 2016, J ANAL TOXICOL, V40, P709, DOI 10.1093/jat/bkw086; Morini L, 2017, FORENSIC SCI INT, V279, pE1, DOI 10.1016/j.forsciint.2017.08.028; Palmquist KB, 2019, FORENSIC SCI INT, V297, P189, DOI 10.1016/j.forsciint.2019.02.006; Peters FT, 2017, CURR PHARM DESIGN, V23, P5455, DOI 10.2174/1381612823666170622113331; Poklis J, 2015, FORENSIC SCI INT, V257, P435, DOI 10.1016/j.forsciint.2015.10.021; Schifano F, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00046; Sofalvi S, 2017, J ANAL TOXICOL, V41, P473, DOI 10.1093/jat/bkx052; Staeheli SN, 2016, FORENSIC SCI INT, V266, P170, DOI 10.1016/j.forsciint.2016.05.034; Swanson DM, 2017, J ANAL TOXICOL, V41, P498, DOI 10.1093/jat/bkx037; Tominaga M, 2015, FORENSIC SCI INT, V254, P118, DOI 10.1016/j.forsciint.2015.07.005; Vignali C, 2019, J ANAL TOXICOL, V43, pE1, DOI 10.1093/jat/bky047	24	1	1	3	4	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0379-0738	1872-6283		FORENSIC SCI INT	Forensic Sci.Int.	NOV	2019	304								109915	10.1016/j.forsciint.2019.109915			4	Medicine, Legal	Legal Medicine	JN5XI	WOS:000496970600010	31416646				2020-06-30	J	Manchec, B; Liu, B; Tran, T; Zuchowski, C; Guruvadoo, K; Parente, R; Vicenti, R; Pepe, J; Feranec, N; Ward, TJ				Manchec, Barbara; Liu, Bo; Tran, Tri; Zuchowski, Colin; Guruvadoo, Kharina; Parente, Ryan; Vicenti, Rebecca; Pepe, Julie; Feranec, Nicholas; Ward, Thomas J.			Sedation with Propofol During Catheter-Directed Thrombolysis for Acute Submassive Pulmonary Embolism Is Associated with Increased Mortality	JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY			English	Article							FLEXIBLE BRONCHOSCOPY; EUROPEAN-SOCIETY; 2014 ESC; GUIDELINES; MIDAZOLAM; MANAGEMENT; THERAPY; DIAGNOSIS; SURGERY; DISEASE	Purpose: To evaluate if sedation with propofol during catheter-directed thrombolysis (CDT) in patients with acute submassive pulmonary embolism (PE) affects survival. Materials and Methods: This single-institution, retrospective study identified 136 patients from 2011-2017 who underwent CDT for acute submassive PE. Patients were grouped based on procedural sedation-propofol versus fentanyl and/or midazolam. Groups were compared for differences in baseline characteristics. Primary endpoint was in-hospital mortality. Logistic regression analysis was performed to evaluate for independent variables predictive of mortality. Propensity-matched analysis was also performed. Results: Propofol was given to 18% (n = 25) of patients, and fentanyl and/or midazolam was given to 82% (n = 111) of patients. Mortality was 28% (n = 7) in the propofol group versus 3% (n = 3) in the fentanyl/midazolam group (P = .0003). Patients receiving propofol had 10.4 times the risk of cardiopulmonary arrest or dying during hospitalization compared with patients receiving fentanyl and/or midazolam (95% confidence interval, 2.9-37.3, P = .0003). The number needed to harm was 4 (95% confidence interval, 2.8-6.8). Logistic regression model analysis including Pulmonary Embolism Severity Index score, right-to-left ventricle diameter ratio and age was not predictive of mortality (P = .19). Adding type of sedation made the model predictive of mortality (P < .001). Propensity-matched analysis controlling for baseline differences in age, adjunctive maneuvers, American Society of Anesthesiologists class, and intubation before the procedure revealed that statistical significance between groups remained (P = .01). Conclusions: Sedation with propofol during CDT for acute submassive PE is associated with increased mortality and should be used with caution.	[Manchec, Barbara; Liu, Bo; Tran, Tri; Zuchowski, Colin; Guruvadoo, Kharina; Parente, Ryan; Vicenti, Rebecca; Pepe, Julie; Feranec, Nicholas; Ward, Thomas J.] Advent Hlth Orlando, Dept Radiol, AdventHlth Med Grp, 601 E Rollins St, Orlando, FL 32803 USA	Ward, TJ (reprint author), Advent Hlth Orlando, Dept Radiol, AdventHlth Med Grp, 601 E Rollins St, Orlando, FL 32803 USA.	thomas.ward.md@adventhealth.com					Amer Soc Anesthesiologists Task F, 2018, ANESTHESIOLOGY, V128, P437, DOI 10.1097/ALN.0000000000002043; Barash PG, 2013, CLIN ANESTHESIA; Barash PG, 2017, CLIN ANESTHESIA; Benjamin EJ, 2018, CIRCULATION, V137, pE67, DOI 10.1161/CIR.0000000000000558; Carmi U, 2011, RESPIRATION, V82, P515, DOI 10.1159/000331506; Clark G, 2009, EUR RESPIR J, V34, P1277, DOI 10.1183/09031936.00142108; Devlin JW, 2018, CRIT CARE MED, V46, pE825, DOI 10.1097/CCM.0000000000003299; Fleisher LA, 2007, J AM COLL CARDIOL, V50, P1707, DOI 10.1016/j.jacc.2007.09.001; Flood P, 2015, STOELTINGS PHARM PHY; Gadre A, 2018, SEMIN THROMB HEMOST, V44, P397, DOI 10.1055/s-0038-1642643; Guerra F, 2014, INT J CARDIOL, V176, P930, DOI 10.1016/j.ijcard.2014.08.050; Heit JA, 2005, BLOOD, V106, P910; Hemmings HC, 2019, PHARM PHYSL ANESTHES; Hinkelbein J, 2018, EUR J ANAESTH, V35, P6, DOI 10.1097/EJA.0000000000000683; Horiguchi T, 2002, ANESTH ANALG, V95, P389, DOI 10.1097/00000539-200208000-00027; Jaff MR, 2011, CIRCULATION, V123, P1788, DOI 10.1161/CIR.0b013e318214914f; Kearon C, 2016, CHEST, V149, P315, DOI 10.1016/j.chest.2015.11.026; Keerthy PH, 2015, J MAXILLOFAC ORAL SU, V14, P773, DOI 10.1007/s12663-014-0676-y; Konstantinides SV, 2014, EUR HEART J, V35, P3145, DOI 10.1093/eurheartj/ehu393; Konstantinides SV, 2014, EUR HEART J, V35, P3033, DOI 10.1093/eurheartj/ehu283; Kuo WT, 2018, J VASC INTERV RADIOL, V29, P293, DOI 10.1016/j.jvir.2017.10.024; Kuo WT, 2012, J VASC INTERV RADIOL, V23, P167, DOI 10.1016/j.jvir.2011.10.012; Kuo WT, 2009, J VASC INTERV RADIOL, V20, P1431, DOI 10.1016/j.jvir.2009.08.002; Riphaus A, 2009, SCAND J GASTROENTERO, V44, P1244, DOI 10.1080/00365520903194591; Rosovsky R, 2019, J THROMB THROMBOLYS, V47, P31, DOI 10.1007/s11239-018-1737-8; SALMON JF, 1992, BRIT J OPHTHALMOL, V76, P598, DOI 10.1136/bjo.76.10.598; Stolz D, 2009, EUR RESPIR J, V34, P1024, DOI 10.1183/09031936.00180808; Wagner HJ, 1996, J VASC INTERV RADIOL, V7, P673, DOI 10.1016/S1051-0443(96)70827-8; Wehrmann T, 1999, GASTROINTEST ENDOSC, V49, P677, DOI 10.1016/S0016-5107(99)70281-6; Zuo XL, 2012, WORLD J GASTROENTERO, V18, P1814, DOI 10.3748/wjg.v18.i15.1814	30	3	3	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1051-0443	1535-7732		J VASC INTERV RADIOL	J. Vasc. Interv. Radiol.	NOV	2019	30	11					1719	1724		10.1016/j.jvir.2019.08.009			6	Radiology, Nuclear Medicine & Medical Imaging; Peripheral Vascular Disease	Radiology, Nuclear Medicine & Medical Imaging; Cardiovascular System & Cardiology	JN6UY	WOS:000497032700001	31587943				2020-06-30	J	Olesen, AE; Broens, S; Olesen, SS; Niesters, M; van Velzen, M; Drewes, AM; Dahan, A; Olofsen, E				Olesen, Anne E.; Broens, Suzanne; Olesen, Soren S.; Niesters, Marieke; van Velzen, Monique; Drewes, Asbjorn M.; Dahan, Albert; Olofsen, Erik			A Pragmatic Utility Function to Describe the Risk-Benefit Composite of Opioid and Nonopioid Analgesic Medication	JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS			English	Article							PAIN; FENTANYL; SAFETY	It is not straightforward to simultaneously evaluate the beneficial and harmful effects of pain management, since different drugs may possess different analgesia and adverse effect profiles. Utility functions, derived from the pharmacokinetics and pharmacodynamics of individual outcome parameters, have been constructed to address this problem. Here, we construct "pragmatic" utility functions based on measurements of benefit and harm, but without making assumptions about the underlying pharmacokinetics and pharmacodynamics. Using data from two previous studies, utility functions were designed by estimating the probability of occurrence of benefit and harm and combining these into one function. Study 1 was a clinical trial on the effect of oral pregabalin on pain relief in chronic pancreatitis patients, with endpoint analgesia and dizziness monitored for 21 days. Study 2 was an experimental study on the effect of intravenous fentanyl on antinociception and respiratory depression in healthy volunteers. From study 1, the utility function was negative the first week of treatment, indicative of the greater probability of dizziness than analgesia, but positive thereafter. From study 2, the utility function showed a nadir 30 minutes after dosing, after which the probability function slowly increased toward zero. A pragmatic utility function based on the probability of two binary outcomes, analgesia and adverse effect, was successfully constructed using data from the two previous studies. The results yielded valuable insights into the utility of treatment and may be highly educative for physicians and potentially used in development of potent analgesics without serious side effects.	[Olesen, Anne E.; Olesen, Soren S.; Drewes, Asbjorn M.] Aalborg Univ Hosp, Dept Gastroenterol & Hepatol, Mech Sense, Aalborg, Denmark; [Olesen, Anne E.; Olesen, Soren S.; Drewes, Asbjorn M.] Aalborg Univ, Sch Med & Hlth, Dept Clin Med, Aalborg, Denmark; [Broens, Suzanne; Niesters, Marieke; van Velzen, Monique; Dahan, Albert; Olofsen, Erik] Leiden Univ, Dept Anesthesiol, Med Ctr, POB 9600, NL-2300 RC Leiden, Netherlands	Dahan, A (reprint author), Leiden Univ, Dept Anesthesiol, Med Ctr, POB 9600, NL-2300 RC Leiden, Netherlands.	a.dahan@lumc.nl	van Velzen, Monique/H-7697-2019; Olesen, Anne Estrup/B-3127-2016	van Velzen, Monique/0000-0002-0289-6432; Olesen, Anne Estrup/0000-0001-9365-1918; Drewes, Asbjorn/0000-0001-7465-964X			Boom M, 2013, ANESTHESIOLOGY, V119, P663, DOI 10.1097/ALN.0b013e31829ce4cb; Cullberg M, 2005, CLIN PHARMACOL THER, V77, P279, DOI 10.1016/j.clpt.2004.11.001; Dahan A, 2017, CLIN ANESTH, P505; Dahan A, 2007, PLOS MED, V4, P1195, DOI 10.1371/journal.pmed.0040239; Dahan A, 2017, ANESTHESIOLOGY, V126, P697, DOI 10.1097/ALN.0000000000001529; Dahan A, 2015, PAIN, V156, pS119, DOI [10.1016/j.pain.0000000000000023, 10.1097/01.j.pain.0000460340.62094.3e]; Emery MJ, 2016, ANESTHESIOLOGY, V124, P945, DOI 10.1097/ALN.0000000000000997; Henthorn TK, 2018, ANESTHESIOLOGY, V128, P867, DOI 10.1097/ALN.0000000000002177; Kharasch ED, 2013, ANESTHESIOLOGY, V119, P504, DOI 10.1097/ALN.0b013e31829ce70b; Okie S, 2010, NEW ENGL J MED, V363, P1981, DOI 10.1056/NEJMp1011512; Olesen SS, 2011, GASTROENTEROLOGY, V141, P536, DOI 10.1053/j.gastro.2011.04.003; Roozekrans M, 2018, ANESTHESIOLOGY, V128, P932, DOI 10.1097/ALN.0000000000002138; Sheiner L B, 1978, Ann N Y Acad Sci, V304, P112, DOI 10.1111/j.1749-6632.1978.tb25582.x; van der Schrier R, 2017, BRIT J ANAESTH, V119, P1169, DOI 10.1093/bja/aex295; Yassen A, 2008, PHARM RES, V25, P183, DOI 10.1007/s11095-007-9440-z; Zanderigo E, 2006, ANESTHESIOLOGY, V104, P742, DOI 10.1097/00000542-200604000-00019; 2018, [No title captured], V558, P343	17	3	3	0	2	AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA	0022-3565	1521-0103		J PHARMACOL EXP THER	J. Pharmacol. Exp. Ther.	NOV 1	2019	371	2					416	421		10.1124/jpet.118.253716			6	Pharmacology & Pharmacy	Pharmacology & Pharmacy	JM0OA	WOS:000495922100020	30442653				2020-06-30	J	Torralva, R; Janowsky, A				Torralva, Randy; Janowsky, Aaron			Noradrenergic Mechanisms in Fentanyl-Mediated Rapid Death Explain Failure of Naloxone in the Opioid Crisis	JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS			English	Article							INDUCED MUSCULAR RIGIDITY; CHOLINERGIC RECEPTOR SUBTYPES; INDUCED MUSCLE RIGIDITY; NUCLEUS LOCUS-CERULEUS; VOCAL CORD DYSFUNCTION; HUMAN LIVER-MICROSOMES; CHEST-WALL RIGIDITY; BRAIN-STEM; MUSCARINIC RECEPTORS; NITROUS-OXIDE	In December 2018, the Centers for Disease Control declared fentanyl the deadliest drug in America. Opioid overdose is the single greatest cause of death in the United States adult population (ages 18-50), and fentanyl and its analogs [fentanyl/fentanyl analogs (F/FAs)] are currently involved in >50% of these deaths. Anesthesiologists in the United States were introduced to fentanyl in the early 1970s when it revolutionized surgical anesthesia by combining profound analgesia with hemodynamic stability. However, they quickly had to master its unique side effect. F/FAs can produce profound rigidity in the diaphragm, chest wall and upper airway within an extremely narrow dosing range. This clinical effect was called wooden chest syndrome (WCS) by anesthesiologists and is not commonly known outside of anesthesiology or to clinicians or researchers in addiction research/medicine. WCS is almost routinely fatal without expert airway management. This review provides relevant clinical human pharmacology and animal data demonstrating that the significant increase in the number of F/FA-induced deaths may involve alpha-adrenergic and cholinergic receptor-mediated mechanical failure of the respiratory and cardiovascular systems with rapid development of rigidity and airway closure. Although morphine and its prodrug, heroin, can cause mild rigidity in abdominal muscles at high doses, neither presents with the distinct and rapid respiratory failure seen with F/FA-induced WCS, separating F/FA overdose from the slower onset of respiratory depression caused by morphine-derived alkaloids. This distinction has significant consequences for the design and implementation of new phaimacologic strategies to effectively prevent F/FA-induced death. SIGNIFICANCE STATEMENT Deaths from fentanyl and F/FAs are increasing in spite of availability and awareness of the opioid reversal drug naloxone. This article reviews literature suggesting that naloxone may be ineffective against centrally mediated noradrenergic and cholinergic effects of F/FAs, which clinically manifest as severe muscle rigidity and airway compromise (e.g., wooden chest syndrome) that is rapid and distinct from respiratory depression seen with morphine-derived alkaloids. A physiologic model is proposed and implications for new drug development and treatment are discussed.	[Torralva, Randy] CODA Inc, Res Dept, Portland, OR USA; [Torralva, Randy; Janowsky, Aaron] VA Portland Hlth Care Syst, Res Serv, Portland, OR USA; [Torralva, Randy; Janowsky, Aaron] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97201 USA	Torralva, R (reprint author), Dept Res, 1027 E Burnside St, Portland, OR 97214 USA.	RandyTorralva@codainc.org			Department of Veterans Affairs Merit ReviewUS Department of Veterans Affairs [I01BX002758]; Career Scientist programs; US Food and Drug Administration; US Department of Justice Drug Enforcement Administration [D-15-OD-0002]; National Institutes of Health National Institute on Drug AbuseUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [ADA12013]; CODA, Inc.; Torralva Medical Therapeutics, LLC	This research was funded by The Department of Veterans Affairs Merit Review [Grant I01BX002758] and Career Scientist programs, the US Food and Drug Administration, US Department of Justice Drug Enforcement Administration [Grant D-15-OD-0002], and National Institutes of Health National Institute on Drug Abuse [Grant ADA12013]. Additional funding support was provided by CODA, Inc., and Torralva Medical Therapeutics, LLC.	Abe K, 2003, EUR J PHARMACOL, V465, P237, DOI 10.1016/S0014-2999(03)01494-8; Ackerman W E, 1990, Anesth Prog, V37, P46; AGHAJANIAN GK, 1982, J CLIN PSYCHIAT, V43, P20; Al-Hasani R, 2011, ANESTHESIOLOGY, V115, P1363, DOI 10.1097/ALN.0b013e318238bba6; ALBANESE A, 1980, BRAIN RES BULL, V5, P127, DOI 10.1016/0361-9230(80)90184-7; Allen E, 2018, ANATOMY HEAD NECK LA; Alreja M, 2000, J NEUROSCI, V20, P1179, DOI 10.1523/JNEUROSCI.20-03-01179.2000; Armenian P, 2018, NEUROPHARMACOLOGY, V134, P121, DOI 10.1016/j.neuropharm.2017.10.016; Aston-Jones G, 2004, J NEUROSCI, V24, P2313, DOI 10.1523/JNEUROSCI.5339-03.2004; ATCHESON R, 1993, BRIT J ANAESTH, V71, P540, DOI 10.1093/bja/71.4.540; BAGHDOYAN HA, 1989, NEUROPSYCHOPHARMACOL, V2, P67, DOI 10.1016/0893-133X(89)90009-2; BAILEY P L, 1988, Anesthesiology (Hagerstown), V69, pA813, DOI 10.1097/00000542-198809010-00813; BARON BM, 1989, J NEUROCHEM, V53, P602, DOI 10.1111/j.1471-4159.1989.tb07376.x; Barutell C, 2004, DOLOR, V19, P98; BASTERRA J, 1989, LARYNGOSCOPE, V99, P293; Baumann MH, 2018, TRENDS PHARMACOL SCI, V39, P995, DOI 10.1016/j.tips.2018.09.006; Bennett JA, 1997, ANESTHESIOLOGY, V87, P1070, DOI 10.1097/00000542-199711000-00010; Bentzen BH, 2011, ADV PHARMACOL SCI, V2011, DOI 10.1155/2011/578273; BOROS M, 1984, BRIT J ANAESTH, V56, P195, DOI 10.1093/bja/56.2.195; Bouaziz H, 1996, ANESTHESIOLOGY, V84, P143, DOI 10.1097/00000542-199601000-00017; Breton-Provencher V, 2019, NAT NEUROSCI, V22, P218, DOI 10.1038/s41593-018-0305-z; Brinker T, 2014, FLUIDS BARRIERS CNS, V11, DOI 10.1186/2045-8118-11-10; Bundey RA, 2001, BRIT J PHARMACOL, V134, P257, DOI 10.1038/sj.bjp.0704229; Burns G, 2016, CLIN TOXICOL, V54, P420, DOI 10.3109/15563650.2016.1157722; Chavez JC, 1998, ADV EXP MED BIOL, V454, P461; Chen SW, 1996, EUR J PHARMACOL, V312, P241, DOI 10.1016/0014-2999(96)00571-7; Chieng B, 1996, MOL PHARMACOL, V50, P650; Childers S.R., 1993, OPIOIDS, P189; CHIU TH, 1993, BRIT J PHARMACOL, V110, P903, DOI 10.1111/j.1476-5381.1993.tb13898.x; CHRISTIE MJ, 1991, PROG BRAIN RES, V88, P197; CHUNG DC, 1993, ANAESTHESIA, V48, P229, DOI 10.1111/j.1365-2044.1993.tb06908.x; Ciccarone D, 2017, INT J DRUG POLICY, V46, P107, DOI 10.1016/j.drugpo.2017.06.010; Clark AK, 2014, J ADDICT MED, V8, P153, DOI 10.1097/ADM.0000000000000034; Clarke SFJ, 2005, EMERG MED J, V22, P612, DOI 10.1136/emj.2003.009613; COHEN MR, 1982, LIFE SCI, V30, P2025, DOI 10.1016/0024-3205(82)90443-X; Comer SD, 2019, NEUROSCI BIOBEHAV R, V106, P49, DOI 10.1016/j.neubiorev.2018.12.005; CORTES R, 1984, NEUROSCIENCE, V12, P1003, DOI 10.1016/0306-4522(84)90001-0; CORTES R, 1986, BRAIN RES, V362, P239, DOI 10.1016/0006-8993(86)90449-X; CORTES R, 1986, BRAIN RES, V362, P227, DOI 10.1016/0006-8993(86)90448-8; Coruh B, 2013, CHEST, V143, P1145, DOI 10.1378/chest.12-2131; DASKALOPOULOS NT, 1975, EUR J PHARMACOL, V33, P91, DOI 10.1016/0014-2999(75)90142-9; De Troyer A, 2005, PHYSIOL REV, V85, P717, DOI 10.1152/physrev.00007.2004; Dean Reginald L. III, 2009, P655, DOI 10.1007/978-1-59745-197-0_35; DIAMOND AJ, 1992, LARYNGOSCOPE, V102, P272; Dutschmann M, 2014, RESP PHYSIOL NEUROBI, V195, P44, DOI 10.1016/j.resp.2014.02.009; EGAN TM, 1983, J PHYSIOL-LONDON, V345, P477, DOI 10.1113/jphysiol.1983.sp014990; EGAN TM, 1985, BRIT J PHARMACOL, V85, P733, DOI 10.1111/j.1476-5381.1985.tb11070.x; EGAN TM, 1986, NEUROSCIENCE, V19, P565, DOI 10.1016/0306-4522(86)90281-2; EHLERT FJ, 1990, J PHARMACOL EXP THER, V255, P1148; El Baissari Mabelle C. Tannous, 2014, Middle East Journal of Anesthesiology, V22, P449; Fahnenstich H, 2000, CRIT CARE MED, V28, P836, DOI 10.1097/00003246-200003000-00037; Fairbairn N, 2017, INT J DRUG POLICY, V46, P172, DOI 10.1016/j.drugpo.2017.06.005; Feasel MG, 2016, AAPS J, V18, P1489, DOI 10.1208/s12248-016-9963-5; Feierman DE, 1996, DRUG METAB DISPOS, V24, P932; Fodale V, 2005, ANESTHESIOLOGY, V102, P227, DOI 10.1097/00000542-200501000-00033; Fraigne JJ, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00123; FREUND F, 1964, J APPL PHYSIOL, V19, P693; FREUND FG, 1973, ANESTHESIOLOGY, V38, P358; Fu MJ, 1997, ANESTHESIOLOGY, V87, P1450, DOI 10.1097/00000542-199712000-00024; Fukuhara N, 1998, CAN J ANAESTH, V45, P1123, DOI 10.1007/BF03012404; GAUMANN DM, 1988, NEUROSCI LETT, V91, P30, DOI 10.1016/0304-3940(88)90244-3; Ge DY, 2015, J APPL PHYSIOL, V119, P686, DOI 10.1152/japplphysiol.00045.2015; Gollapudy S, 2012, J CLIN ANESTH, V24, P251, DOI 10.1016/j.jclinane.2011.04.017; GRELL FL, 1970, ANESTH ANAL CURR RES, V49, P523; Griffioen KJS, 2004, BRAIN RES, V1007, P109, DOI 10.1016/j.brainres.2004.02.010; Guitton J, 1997, BIOCHEM PHARMACOL, V53, P1613, DOI 10.1016/S0006-2952(96)00893-3; Halfpenny DM, 1999, BRIT J ANAESTH, V83, P909, DOI 10.1093/bja/83.6.909; HAMILTON WK, 1953, ANESTHESIOLOGY, V14, P550, DOI 10.1097/00000542-195311000-00002; Hedegaard Holly, 2018, Natl Vital Stat Rep, V67, P1; HICKS HC, 1981, ANESTH ANALG, V60, P563; HISA Y, 1982, ARCH OTO-RHINO-LARYN, V234, P33, DOI 10.1007/BF00453535; HISA Y, 1982, ACTA ANAT, V113, P15, DOI 10.1159/000145533; Hoh JFY, 2005, ACTA PHYSIOL SCAND, V183, P133, DOI 10.1111/j.1365-201X.2004.01402.x; Hori Kouichirou, 2002, J Anesth, V16, P187, DOI 10.1007/s005400200022; Horng Huei-Chi, 2010, Acta Anaesthesiol Taiwan, V48, P155, DOI 10.1016/S1875-4597(10)60050-1; HUCHET AM, 1986, J AUTONOM NERV SYST, V17, P175, DOI 10.1016/0165-1838(86)90055-X; HUG CC, 1979, ANESTHESIOLOGY, V50, P342, DOI 10.1097/00000542-197904000-00011; HUSTVEIT O, 1994, JPN J PHARMACOL, V64, P57, DOI 10.1254/jjp.64.57; HUSTVEIT O, 1993, ACTA ANAESTH SCAND, V37, P541, DOI 10.1111/j.1399-6576.1993.tb03761.x; Ikeda K, 2017, J PHYSIOL SCI, V67, P45, DOI 10.1007/s12576-016-0475-y; Jannetto PJ, 2019, CLIN CHEM, V65, P242, DOI 10.1373/clinchem.2017.281626; Janssen Pharmaceutica, 2017, SUBLIMAZE INJECTION; JARROTT B, 1979, BRIT J PHARMACOL, V65, P663, DOI 10.1111/j.1476-5381.1979.tb07879.x; JENKINS AJ, 1994, J ANAL TOXICOL, V18, P317, DOI 10.1093/jat/18.6.317; Jensen BC, 2009, CIRC-HEART FAIL, V2, P654, DOI 10.1161/CIRCHEARTFAILURE.108.846212; JERUSSI TP, 1987, PHARMACOL BIOCHEM BE, V28, P283, DOI 10.1016/0091-3057(87)90226-7; Jette M, 2011, UNDERSTANDING VOICE, P64; Jin X, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146470; Jolas T, 1997, BRAIN RES, V755, P229, DOI 10.1016/S0006-8993(97)00103-0; Kiyatkin EA, 2019, NEUROPHARMACOLOGY, V151, P219, DOI 10.1016/j.neuropharm.2019.02.008; Koenig SJ, 2015, J INTENSIVE CARE MED, V30, P499, DOI 10.1177/0885066614523100; Kouvaras E, 2008, NEUROPHARMACOLOGY, V55, P1172, DOI 10.1016/j.neuropharm.2008.07.025; LABELLA FS, 1982, LIFE SCI, V30, P1565, DOI 10.1016/0024-3205(82)90245-4; Lalley PM, 2003, AM J PHYSIOL-REG I, V285, pR1287, DOI 10.1152/ajpregu.00199.2003; Lautt WW, 1996, CAN J PHYSIOL PHARM, V74, P223, DOI 10.1139/cjpp-74-3-223; Leen JLS, 2019, CAN J ANESTH, V66, P414, DOI 10.1007/s12630-019-01294-y; LEVEY AI, 1994, NEUROSCIENCE, V63, P207, DOI 10.1016/0306-4522(94)90017-5; Lin CS, 2004, CAN J ANAESTH, V51, P654, DOI 10.1007/BF03018421; Lotsch J, 2013, CLIN PHARMACOKINET, V52, P23, DOI 10.1007/s40262-012-0016-7; LOUGHLIN SE, 1986, NEUROSCIENCE, V18, P291, DOI 10.1016/0306-4522(86)90155-7; LUI PW, 1990, NEUROSCI LETT, V108, P183, DOI 10.1016/0304-3940(90)90728-R; LUI PW, 1989, NEUROSCI LETT, V96, P114, DOI 10.1016/0304-3940(89)90252-8; Lui PW, 1995, NEUROSCI LETT, V201, P167, DOI 10.1016/0304-3940(95)12162-5; LUI PW, 1993, NEUROSCI LETT, V157, P145, DOI 10.1016/0304-3940(93)90723-X; LYDIC R, 1989, NEUROSCI LETT, V102, P211, DOI 10.1016/0304-3940(89)90080-3; LYDIC R, 1989, FASEB J, V3, P1625; Lynn RR, 2018, THER ADV DRUG SAF, V9, P63, DOI 10.1177/2042098617744161; MAGUIRE P, 1992, EUR J PHARMACOL, V213, P219, DOI 10.1016/0014-2999(92)90685-W; MATHER LE, 1983, CLIN PHARMACOKINET, V8, P422, DOI 10.2165/00003088-198308050-00004; MCCLAIN DA, 1980, CLIN PHARMACOL THER, V28, P106, DOI 10.1038/clpt.1980.138; MCNAUGHTON N, 1980, PROG NEUROBIOL, V14, P157, DOI 10.1016/0301-0082(80)90021-0; Mikita JA, 2006, ALLERGY ASTHMA PROC, V27, P411, DOI 10.2500/aap.2006.27.2871; MILNE B, 1989, CAN J ANAESTH, V36, P155, DOI 10.1007/BF03011439; MILNE B, 1989, CAN J PHYSIOL PHARM, V67, P532, DOI 10.1139/y89-085; Moller S, 2008, GUT, V57, P268, DOI 10.1136/gut.2006.112177; Morris MJ, 2010, CHEST, V138, P1213, DOI 10.1378/chest.09-2944; Morris MJ, 1999, CHEST, V116, P1676, DOI 10.1378/chest.116.6.1676; MORROW AL, 1986, MOL PHARMACOL, V29, P321; Moss RB, 2019, SUBST ABUSE TREAT PR, V14, DOI 10.1186/s13011-019-0195-4; Moyse E, 1997, EUR J NEUROSCI, V9, P128, DOI 10.1111/j.1460-9568.1997.tb01361.x; Nakamura S, 2002, ANESTH ANALG, V95, P1389, DOI 10.1097/00000539-200211000-00053; NASHAN B, 1984, BRIT J ANAESTH, V56, P1259, DOI 10.1093/bja/56.11.1259; NATTIE EE, 1990, J APPL PHYSIOL, V69, P33; NORTH RA, 1985, J PHYSIOL-LONDON, V364, P265, DOI 10.1113/jphysiol.1985.sp015743; O'Connell TD, 2014, PHARMACOL REV, V66, P308, DOI 10.1124/pr.112.007203; O'Donnell JK, 2017, MMWR-MORBID MORTAL W, V66, P1197, DOI 10.15585/mmwr.mm6643e1; Ochalek TA, 2019, J SUBST ABUSE TREAT, V96, P23, DOI 10.1016/j.jsat.2018.10.007; OHYAMA M, 1972, LARYNGOSCOPE, V82, P237, DOI 10.1288/00005537-197202000-00011; OSBORNE R, 1990, CLIN PHARMACOL THER, V47, P12, DOI 10.1038/clpt.1990.2; OWEN JA, 1983, CLIN PHARMACOL THER, V34, P364, DOI 10.1038/clpt.1983.180; Ozawa Y, 2003, EARLY HUM DEV, V75, pS129, DOI 10.1016/j.carlhumdev.2003.08.016; PARMENTIER P, 1979, BRIT J ANAESTH, V51, P775, DOI 10.1093/bja/51.8.775; PAYNE R, 1986, J PHARMACOL METHOD, V16, P277, DOI 10.1016/0160-5402(86)90032-X; Pilch R, 2003, INT NEGOTIATION, V8, P577, DOI DOI 10.1163/1571806031310798; Pilgrim JL, 2011, FORENSIC SCI MED PAT, V7, P162, DOI 10.1007/s12024-010-9188-3; Planas E, 2000, DOLOR, V15, P7; POKLIS A, 1995, J TOXICOL-CLIN TOXIC, V33, P439, DOI 10.3109/15563659509013752; POSNER J, 1985, PSYCHOPHARMACOLOGY, V87, P468, DOI 10.1007/BF00432515; Ramakrishna D, 2012, Pak J Biol Sci, V15, P871; RANDICH A, 1992, J NEUROPHYSIOL, V68, P1027; RASMUSSEN K, 1985, BRAIN RES, V344, P240, DOI 10.1016/0006-8993(85)90801-7; RAYNOR K, 1994, MOL PHARMACOL, V45, P330; REX MAE, 1970, BRIT J ANAESTH, V42, P891, DOI 10.1093/bja/42.10.891; Richardson BE, 1997, ANN OTO RHINOL LARYN, V106, P920, DOI 10.1177/000348949710601107; Rickli A, 2018, BRIT J PHARMACOL, V175, P532, DOI 10.1111/bph.14105; ROY SD, 1988, PHARMACEUT RES, V5, P580, DOI 10.1023/A:1015994030251; Samuels ER, 2008, CURR NEUROPHARMACOL, V6, P254, DOI 10.2174/157015908785777193; Samuels ER, 2008, CURR NEUROPHARMACOL, V6, P235, DOI 10.2174/157015908785777229; Sato S, 2010, FORENSIC SCI INT, V195, P68, DOI 10.1016/j.forsciint.2009.11.014; SCAMMAN FL, 1983, ANESTH ANALG, V62, P332; Schumann H, 2008, CLIN TOXICOL, V46, P501, DOI 10.1080/15563650701877374; Schuppan D, 2008, LANCET, V371, P838, DOI 10.1016/S0140-6736(08)60383-9; Shanthanna Harsha, 2010, J Anaesthesiol Clin Pharmacol, V26, P547; Skolnick P, 2018, EUR J PHARMACOL, V835, P147, DOI 10.1016/j.ejphar.2018.08.004; Slavova S, 2017, INT J DRUG POLICY, V46, P120, DOI 10.1016/j.drugpo.2017.05.051; Sohn JT, 2005, ANESTHESIOLOGY, V103, P327, DOI 10.1097/00000542-200508000-00016; SOKOLL MD, 1972, ANESTH ANAL CURR RES, V51, P16; Solis E, 2017, ENEURO, V4, DOI 10.1523/ENEURO.0323-17.2017; Somerville NJ, 2017, MMWR-MORBID MORTAL W, V66, P382, DOI 10.15585/mmwr.mm6614a2; Sriraman R, 2007, SOC END BES 2007 BUD, pP482; Stanley TH, 2014, WONDROUSTORY ANEST, P641; STOELTING RK, 1975, ANESTHESIOLOGY, V42, P319, DOI 10.1097/00000542-197503000-00015; STONE DJ, 1988, ANESTH ANALG, V67, P663; STREISAND JB, 1993, ANESTHESIOLOGY, V78, P629, DOI 10.1097/00000542-199304000-00003; TAM SW, 1985, EUR J PHARMACOL, V109, P33, DOI 10.1016/0014-2999(85)90536-9; Tateishi T, 1996, ANESTH ANALG, V82, P167; Thach BT, 2001, AM J MED, V111, P69, DOI 10.1016/S0002-9343(01)00860-9; Tian H, 2015, FRONT PHARMACOL, V6, DOI 10.3389/fphar.2015.00251; Tunon MJ, 1999, SURG ENDOSC-ULTRAS, V13, P668, DOI 10.1007/s004649901070; Uhrig L, 2014, ANN FR ANESTH, V33, P72, DOI 10.1016/j.annfar.2013.11.005; van der Lee R, 2009, ANN PHARMACOTHER, V43, P1724, DOI 10.1345/aph.1M268; Varney VA, 2009, J ASTHMA ALLERGY, V2, P105; Vaughan CW, 1997, J PHYSIOL-LONDON, V498, P463, DOI 10.1113/jphysiol.1997.sp021872; Volpe DA, 2011, REGUL TOXICOL PHARM, V59, P385, DOI 10.1016/j.yrtph.2010.12.007; Wang GY, 2006, AM J PHYSIOL-HEART C, V291, pH2013, DOI 10.1152/ajpheart.00167.2006; Weigel S, 2014, EUR J NEUROSCI, V39, P730, DOI 10.1111/ejn.12438; WEINGER MB, 1989, ANESTHESIOLOGY, V71, P242, DOI 10.1097/00000542-198908000-00013; WEINGER MB, 1988, PHARMACOL BIOCHEM BE, V29, P573, DOI 10.1016/0091-3057(88)90022-6; Wenner MI, 2016, CYTOTECHNOLOGY, V68, P1561, DOI 10.1007/s10616-015-9915-4; WILLETTE RN, 1982, EUR J PHARMACOL, V78, P61, DOI 10.1016/0014-2999(82)90372-7; WILLETTE RN, 1982, EUR J PHARMACOL, V80, P57, DOI 10.1016/0014-2999(82)90177-7; WILLETTE RN, 1987, J PHARMACOL METHOD, V17, P15, DOI 10.1016/0160-5402(87)90033-7; WILLIAMS JT, 1984, NEUROSCIENCE, V13, P137, DOI 10.1016/0306-4522(84)90265-3; Wright BLC, 2012, J NEUROL, V259, P1530, DOI 10.1007/s00415-012-6413-x; YAMANOUE T, 1993, ANESTH ANALG, V76, P382; YANG PK, 1992, ANESTHESIOLOGY, V77, P153, DOI 10.1097/00000542-199207000-00022; Yardley W, 2013, NY TIMES, P1; YASUDA I, 1978, ANESTHESIOLOGY, V49, P117, DOI 10.1097/00000542-197808000-00012; YOKOYAMA T, 1995, J AUTONOM NERV SYST, V56, P50, DOI 10.1016/0165-1838(95)00064-6; YOSHIDA Y, 1992, FOLIA PHONIATR, V44, P194, DOI 10.1159/000266152	190	3	3	2	3	AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA	0022-3565	1521-0103		J PHARMACOL EXP THER	J. Pharmacol. Exp. Ther.	NOV 1	2019	371	2					453	475		10.1124/jpet.119.258566			23	Pharmacology & Pharmacy	Pharmacology & Pharmacy	JM0OA	WOS:000495922100022	31492824	Green Published			2020-06-30	J	Yuan, J; Yang, MC; Wu, MJ; Gou, YS				Yuan, Jing; Yang, Meng-Chang; Wu, Meng-Jun; Gou, Yong-Sheng			Sedative depth on neurological outcomes in a juvenile rat model of cardiopulmonary resuscitation	MEDICAL HYPOTHESES			English	Article							HOSPITAL CARDIAC-ARREST; BISPECTRAL INDEX; HEMODYNAMIC PARAMETERS; ELECTROENCEPHALOGRAPHIC PARAMETERS; EMULSIFIED ISOFLURANE; NARCOTREND((R)) INDEX; CEREBRAL-ISCHEMIA; ANESTHESIA; CHILDREN; SEVOFLURANE	The guidelines for cardiopulmonary resuscitation (CPR) in pediatric advanced life support suggest that midazolam is the preferred agent for sedation in patients with mild hypothermia, whereas children with cardiac arrest (CA) are at a crucial stage regarding their immature nervous system. Studies have shown that midazolam may have a detrimental effect on the developmental of the pediatric nervous system. Our previous study found that midazolam induced neuronal damage after CPR in young rats. It is speculated that: midazolam causes the potential injury of neurons by inhibiting mitochondrial autophagy expression and is an important factor for the poor prognosis in children after successful CPR. This project intends to adopt the modified asphyxiant CPR model in juvenile rats. Survival rate, neurological function and histopathological changes were evaluated to determine the protective effects of appropriate sedation depth on cerebral ischemia-reperfusion injury in juvenile rats after CPR. Combined with cell biology and molecular biology related technologies, the mechanism by which the mitochondrial pinkl-parkin signaling pathway induces autophagy to inhibit neuronal apoptosis may be key factor in the protective effects of sedation depth on the brain. The aim of this study is to provide experimental evidence and elucidate the mechanisms of improvement of cerebral ischemia-reperfusion injury by sedation depth in children after successful CPR and to lay a theoretical and experimental basis for clinical treatment.	[Yuan, Jing] Southwest Jiaotong Univ, Peoples Hosp Chengdu 3, Affiliated Hosp, Chengdu, Sichuan, Peoples R China; [Yang, Meng-Chang] Sichuan Acad Med Sci, Dept Anesthesiol, Chengdu 610072, Sichuan, Peoples R China; [Yang, Meng-Chang] Sichuan Prov Peoples Hosp, Chengdu 610072, Sichuan, Peoples R China; [Wu, Meng-Jun] Chengdu Women & Childrens Cent Hosp, Dept Anesthesiol, Chengdu 610041, Sichuan, Peoples R China; [Gou, Yong-Sheng] Shuangliu First Peoples Hosp, Dept Orthoped, Chengdu 610200, Sichuan, Peoples R China	Wu, MJ (reprint author), Chengdu Women & Childrens Cent Hosp, Dept Anesthesiol, Chengdu 610041, Sichuan, Peoples R China.; Gou, YS (reprint author), Shuangliu First Peoples Hosp, Dept Orthoped, Chengdu 610200, Sichuan, Peoples R China.	mengjunwoo@aliyun.com; 2014982567@qq.com					Agrawal D, 2004, ANN EMERG MED, V43, P247, DOI 10.1016/S0196-0644(03)00721-2; Andersen LW, 2016, JAMA-J AM MED ASSOC, V316, P1786, DOI 10.1001/jama.2016.14486; ARAKI T, 1991, NEUROSCI LETT, V130, P57, DOI 10.1016/0304-3940(91)90226-J; Atkins DL, 2009, CIRCULATION, V119, P1484, DOI 10.1161/CIRCULATIONAHA.108.802678; Bannister CF, 2001, ANESTH ANALG, V92, P877; Chiari PC, 2004, ANESTHESIOLOGY, V101, P1160, DOI 10.1097/00000542-200411000-00016; Davidson AJ, 2001, ANESTH ANALG, V93, P326, DOI 10.1097/00000539-200108000-00017; Degoute CS, 2001, BRIT J ANAESTH, V86, P209, DOI 10.1093/bja/86.2.209; Dunham CM, 2006, CRIT CARE, V10, DOI 10.1186/cc5097; Empey PE, 2012, CRIT CARE MED, V40, P1221, DOI 10.1097/CCM.0b013e31823779f9; Holzer M, 2002, NEW ENGL J MED, V346, P549; Jackson JC, 2010, AM J RESP CRIT CARE, V182, P183, DOI 10.1164/rccm.200903-0442OC; Jevtovic-Todorovic V, 2003, J NEUROSCI, V23, P876, DOI 10.1523/jneurosci.23-03-00876.2003; Kochanek PM, 2012, PEDIATR CRIT CARE ME, V13, pS1, DOI 10.1097/PCC.0b013e31823f435c; Kreuer S, 2004, ANESTHESIOLOGY, V101, P847, DOI 10.1097/00000542-200410000-00008; Larson MJ, 2007, J INT NEUROPSYCH SOC, V13, P595, DOI 10.1017/S1355617707070749; Laver S, 2004, INTENS CARE MED, V30, P2126, DOI 10.1007/s00134-004-2425-z; Madathil RJ, 2016, RESUSCITATION, V105, P85, DOI 10.1016/j.resuscitation.2016.04.009; McCann ME, 2002, PAEDIATR ANAESTH, V12, P519, DOI 10.1046/j.1460-9592.2002.00886.x; Musialowicz T, 2010, EPILEPSIA, V51, P1580, DOI 10.1111/j.1528-1167.2009.02514.x; Niermeyer S, 2000, PEDIATRICS, V106; Nolan JP, 2008, RESUSCITATION, V79, P350, DOI 10.1016/j.resuscitation.2008.09.017; Oddo M, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1294-5; Sadoshima J, 2015, PLOS ONE, V10; Sanders RD, 2009, PEDIATR ANESTH, V19, P1141, DOI 10.1111/j.1460-9592.2009.03141.x; Schmidt GN, 2003, ANESTHESIOLOGY, V99, P1072, DOI 10.1097/00000542-200311000-00012; Schmidt GN, 2002, ANESTH ANALG, V95, P1324, DOI 10.1097/00000539-200211000-00042; WAGNER SR, 1994, ANESTHESIOLOGY, V81, P1516, DOI 10.1097/00000542-199412000-00028; Weber F, 2005, EUR J ANAESTH, V22, P741, DOI 10.1017/S0265021505001237; Weber F, 2005, PEDIATR ANESTH, V15, P727, DOI 10.1111/j.1460-9592.2004.01546.x; Weber F, 2005, PEDIATR ANESTH, V15, P378, DOI 10.1111/j.1460-9592.2005.01465.x; Wu MJ, 2017, EXP THER MED, V13, P891, DOI 10.3892/etm.2017.4044; Young C, 2005, BRIT J PHARMACOL, V146, P189, DOI 10.1038/sj.bjp.0706301; Zhang YJ, 2017, EXP THER MED, V14, P65, DOI 10.3892/etm.2017.4446; Zhang YJ, 2015, MED HYPOTHESES, V84, P20, DOI 10.1016/j.mehy.2014.11.008	35	0	0	1	1	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	0306-9877	1532-2777		MED HYPOTHESES	Med. Hypotheses	NOV	2019	132								109233	10.1016/j.mehy.2019.109233			4	Medicine, Research & Experimental	Research & Experimental Medicine	JM2FX	WOS:000496037800004	31606702				2020-06-30	J	Minutillo, A; Palmi, I; Mastrobattista, L				Minutillo, A.; Palmi, I.; Mastrobattista, L.			The health threat of drugs of abuse adulteration by new psychoactive substances	CLINICA TERAPEUTICA			English	Letter						new psychoactive substances; adulteration; drug of abuse	HEROIN; GHB	The practice of drug of abuse adulteration is changing. Currently, the risk of new adulteration practices involves New Psychoactive Substances (NPS), which can also be used as adulterants. In particular, the phenomenon of adulteration concerns fentanyl and its analogs, substances that can be toxic even if taken in very small quantities. The adulteration that involves NPS is creating a serious threat to the health of drug users, not only because of the pharmacological action but because of the increased toxicity of these new cutting agents.	[Minutillo, A.; Palmi, I.; Mastrobattista, L.] Ist Super Sanita, Ctr Nazl Dipendenze & Doping, Viale Regina Elena 299, I-00161 Rome, Italy	Minutillo, A (reprint author), Ist Super Sanita, Ctr Nazl Dipendenze & Doping, Viale Regina Elena 299, I-00161 Rome, Italy.	adele.minutillo@iss.it					Barcelo B, 2017, FORENSIC SCI INT, V273, pE10, DOI 10.1016/j.forsciint.2017.01.020; Broseus J, 2016, FORENSIC SCI INT, V262, P73, DOI 10.1016/j.forsciint.2016.02.033; Busardo FP, 2019, J ANAL TOXICOL, P1; Busardo FP, 2018, CURR DRUG METAB, V19, P1080, DOI 10.2174/1389200219666180925090834; Ciccarone D, 2017, INT J DRUG POLICY, V46, P146, DOI 10.1016/j.drugpo.2017.06.004; Corkery JM, 2018, CURR DRUG METAB, V19, P1086, DOI 10.2174/1389200218666171108163817; Giorgetti A, 2017, HUM PSYCHOPHARM CLIN, V32, DOI 10.1002/hup.2605; Marchei E, 2018, TRAC-TREND ANAL CHEM, V102, P1, DOI 10.1016/j.trac.2018.01.007; Oliver CF, 2019, PSYCHOPHARMACOLOGY, V236, P869, DOI 10.1007/s00213-018-5066-6; Busardo FP, 2018, CLIN CHEM LAB MED, V56, P198, DOI 10.1515/cclm-2017-0397; Peck Y, 2019, DRUG ALCOHOL DEPEN, V201, P49, DOI 10.1016/j.drugalcdep.2019.03.019; Pichini S, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00785; Pichini S, 2017, DRUG TEST ANAL, V9, P956, DOI 10.1002/dta.2054; Pichini S, 2017, DRUG TEST ANAL, V9, P485, DOI 10.1002/dta.2134; Solimini R, 2017, CURR PHARM BIOTECHNO, V18, P524, DOI 10.2174/1389201018666170710184531	15	2	2	1	2	SOC EDITRICE UNIV	ROME	VIA G B MORGAGNI 1, ROME, 10061, ITALY	0009-9074	1972-6007		CLIN TER	Clin. Ter.	NOV-DEC	2019	170	6					E425	E426		10.7417/CT.2019.2170			2	Medicine, General & Internal; Pharmacology & Pharmacy	General & Internal Medicine; Pharmacology & Pharmacy	JL3MP	WOS:000495435600004	31696904				2020-06-30	J	Machado, ML; Soares, JHN; Pypendop, BH; Henao-Guerrero, N; Pavlisko, ND; Ross, J				Machado, Marcela L.; Soares, Joao H. N.; Pypendop, Bruno H.; Henao-Guerrero, Natalia; Pavlisko, Noah D.; Ross, Juliet			Effect of heart rate on the pharmacokinetics of fentanyl in dogs anesthetized with isoflurane and hydromorphone	VETERINARY ANAESTHESIA AND ANALGESIA			English	Article						cardiac output; dog; fentanyl; heart rate; isoflurane; pharmacokinetics	CARDIAC-OUTPUT; ANESTHESIA; EXCRETION; POTENCY	Objective To compare the pharmacokinetics of fentanyl at lower (LHR) or higher heart rate (HHR) in dogs anesthetized with isoflurane. Study design Prospective, randomized, crossover controlled trial. Animals A group of six healthy 13-month-old male Beagle dogs weighing 9.9 +/- 0.7 kg (mean +/- standard deviation). Methods Dogs were allocated to two treatments: LHR (HR: 45-75 beats minute(-1)) and HHR (HR: 100-130 beats minute(-1)). Anesthesia was maintained with isoflurane and hydromorphone (0.1 mg kg(-1) followed by 0.02-0.10 mg kg(-1) hour(-1)) for both treatments. Glycopyrrolate was administered in HHR to maintain HR within the desired range. Afterwards, fentanyl (20 mu g kg(-1)) was intravenously administered over 5 minutes. Arterial blood samples were collected for plasma fentanyl concentration measurement by liquid chromatography/mass spectrometry. The pharmacokinetics of fentanyl were compared between treatments and the differences were considered significant at p < 0.05. Results A three-compartment model best fitted the changes in plasma fentanyl concentration. Clearance (CL; mL minute(-1) kg(-1)) was 33.2 (24.0-48.0) and 61.3 (44.5-72.7), maximum concentration (ng mL(-1)) 33.6 (23.4-36.6) and 20.0 (16.7-28.0), apparent volume of the rapid peripheral compartment (mL kg(-1)) 436 (352-723) and 925 (499-1887), apparent volume at steady state (mL kg(-1)) 4064 (3453-6546) and 7195 (5077-8601), cardiac index (CI; mL minute(-1) m(-2)) 2.83 (1.98-3.67) and 4.91 (3.22-6.09) and HR (beats minute(-1)) 68 (49-72) and 120 (102-129) for LHR and HHR, respectively, with significant differences between treatments. Significant correlations (0.92 and 0.90) were found between CI and CL, and between HR and CL, respectively. Conclusions and clinical relevance The increase in HR and the resultant improvement in cardiac output increased fentanyl CL and volume of distribution, which resulted in a decrease in plasma fentanyl concentration in isoflurane-anesthetized dogs.	[Machado, Marcela L.; Soares, Joao H. N.; Henao-Guerrero, Natalia; Pavlisko, Noah D.; Ross, Juliet] Virginia Tech, Virginia Maryland Coll Vet Med, Dept Small Anim Clin Sci, Blacksburg, VA USA; [Pypendop, Bruno H.] Univ Calif Davis, Sch Vet Med, Dept Surg & Radiol Sci, 1 Shields Ave, Davis, CA 95616 USA	Soares, JHN (reprint author), Univ Calif Davis, Sch Vet Med, Dept Surg & Radiol Sci, 1 Shields Ave, Davis, CA 95616 USA.	jhsoares@ucdavis.edu			Department of Small Animal Clinical Sciences, Virginia-Maryland College of Veterinary Medicine, Virginia Tech; Department of Surgical and Radiological Sciences, School of Veterinary Medicine, University of California-Davis	The authors thank the staff from the Teaching and Research Animal Care Support Service of Virginia-Maryland College of Veterinary Medicine and Dr John H Rossmeisl for valuable technical assistance. The study was supported by discretionary funds from the Department of Small Animal Clinical Sciences, Virginia-Maryland College of Veterinary Medicine, Virginia Tech (JHNS and NH-G) and from the Department of Surgical and Radiological Sciences, School of Veterinary Medicine, University of California-Davis (BHP).	Chabicovsky M, 2019, TOXICOL APPL PHARM, V370, P154, DOI 10.1016/j.taap.2019.03.016; CONE EJ, 1977, J PHARM SCI, V66, P1709, DOI 10.1002/jps.2600661213; Duke T, 2013, CAN VET J, V54, P276; Dutta S, 2000, J PHARM SCI-US, V89, P519, DOI 10.1002/(SICI)1520-6017(200004)89:4<519::AID-JPS9>3.0.CO;2-U; [EMA European Medicines Agency], 2012, EUR MED AG EMEA H C; FDA, 2015, US FOOD DRUG ADM PRE; Gabrielsson J, 2002, PHARMACOKINETIC PHAR; Gozalo-Marcilla M, 2019, EQUINE VET J, V51, P517, DOI 10.1111/evj.13031; Haskins S, 2005, COMPARATIVE MED, V55, P156; Hayashi K, 1998, Masui, V47, P420; HERZ A, 1970, NEUROPHARMACOLOGY, V9, P539, DOI 10.1016/0028-3908(70)90004-3; ILKIW JE, 1994, CAN J VET RES, V58, P248; Ilkiw JE, 1999, CLIN TECH SMALL AN P, V14, P27, DOI 10.1016/S1096-2867(99)80024-3; MEULDERMANS W, 1987, DRUG METAB DISPOS, V15, P905; MURPHY MR, 1983, ANESTHESIOLOGY, V59, P537, DOI 10.1097/00000542-198312000-00009; MURPHY MR, 1979, ANESTHESIOLOGY, V50, P13, DOI 10.1097/00000542-197901000-00004; MURPHY MR, 1982, ANESTHESIOLOGY, V57, P485, DOI 10.1097/00000542-198212000-00009; Overholser Brian R, 2011, Am J Manag Care, V17 Suppl 11, pS276; REITAN JA, 1978, ANESTH ANALG, V57, P31; Roozekrans M, 2017, CLIN PHARMACOL THER, V102, P115, DOI 10.1002/cpt.601; ROY SD, 1988, PHARMACEUT RES, V5, P580, DOI 10.1023/A:1015994030251; Sano T, 2006, VET ANAESTH ANALG, V33, P266, DOI 10.1111/j.1467-2995.2005.00266.x; Shafer SL, 2010, MILLERS ANESTHESIA, P479; STEFFEY EP, 1977, AM J VET RES, V38, P1833; Thomasy SM, 2007, EQUINE VET J, V39, P54, DOI 10.2746/042516407X153011; Williamson AJ, 2018, VET ANAESTH ANALG, V45, P423, DOI 10.1016/j.vaa.2018.03.001; Williamson AJ, 2017, VET ANAESTH ANALG, V44, P738, DOI 10.1016/j.vaa.2017.02.002	27	0	0	2	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	1467-2987	1467-2995		VET ANAESTH ANALG	Vet. Anaesth. Analg.	NOV	2019	46	6					736	744		10.1016/j.vaa.2019.06.005			9	Veterinary Sciences	Veterinary Sciences	JK7FP	WOS:000495006800004	31353195				2020-06-30	J	Jayaraj, A; Balachander, H; Kuppusamy, SK; Arusamy, S; Rai, Y; Siddiqui, N				Jayaraj, Ashokkumar; Balachander, Hemavathi; Kuppusamy, Suresh K.; Arusamy, Sivakumar; Rai, Yeshith; Siddiqui, Naveed			Comparison of meperidine, tramadol and fentanyl for post-spinal shivering prevention during cesarean delivery: A double-blind randomized controlled trial	JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH			English	Article						cesarean delivery; fentanyl; meperidine; shivering; spinal anesthesia; tramadol	REGIONAL ANESTHESIA; SECTION; SATISFACTION; ONDANSETRON; SEDATION	Aim To assess the effects of intravenously administered meperidine, fentanyl and tramadol in reducing the incidence, onset time and severity of the shivering response in parturients during cesarean delivery under spinal anesthesia. Secondary outcomes included patient satisfaction and sedation scores. Methods After Ethics board approval and informed written consent, 350 parturients (ASA physical status I or II), between 20 and 40 years of age, undergoing emergency or elective cesarean delivery under spinal anesthesia were recruited. Parturients were then randomly allocated to seven study groups: normal saline (control), low-dose meperidine (0.5 mg/kg), high-dose meperidine (0.75 mg/kg), low-dose fentanyl (0.5 mcg/kg), high-dose fentanyl (0.75 mcg/kg), low-dose tramadol (0.5 mg/kg) and high-dose tramadol (0.75 mg/kg). The incidence, onset time and severity of shivering, along with patient satisfaction and sedation scores were measured. Results All study drugs showed significant reduction in incidence, onset time and severity of shivering and greater satisfaction scores compared to the control group (P < 0.01). Within each drug class, no significant differences in shivering were found between the high-dose and low-dose groups. Among study drugs, low-dose tramadol was superior due to shivering prevention and significantly reduced sedation. Conclusion Intravenously administered meperidine, fentanyl and tramadol reduce shivering incidence, onset time and severity in parturients undergoing cesarean delivery following spinal anesthesia. Importantly, low-dose intravenous tramadol (0.5 mg/kg) allowed shivering prevention and low sedation scores, thereby offering greater parturient satisfaction and better maternal-newborn bonding.	[Jayaraj, Ashokkumar; Siddiqui, Naveed] Univ Toronto, Mt Sinai Hosp, Dept Anesthesia & Pain Management, Toronto, ON, Canada; [Rai, Yeshith] Univ Toronto, Fac Med, 1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada; [Jayaraj, Ashokkumar; Siddiqui, Naveed] Univ Toronto, Toronto, ON, Canada; [Balachander, Hemavathi] JIPMER, Dept Anesthesia & Crit Care, Pondicherry, India; [Kuppusamy, Suresh K.] Manakulavinayagar Med Coll & Hosp, Dept Anesthesia & Crit Care, Pondicherry, India; [Arusamy, Sivakumar] Aster Hosp, Dept Anesthesia & Crit Care, Dubai, U Arab Emirates	Rai, Y (reprint author), Univ Toronto, Fac Med, 1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada.; Jayaraj, A (reprint author), Univ Toronto, Mt Sinai Hosp, 600 Univ Ave, Toronto, ON M5G 1X5, Canada.	ashokkumarkarthik1@gmail.com; yesh.rai@mail.utoronto.ca		Rai, Yeshith/0000-0003-3191-9792			Abouleish EI, 1999, ANAESTHESIA, V54, P479, DOI 10.1046/j.1365-2044.1999.00798.x; Bhatnagar S, 2001, ANAESTH INTENS CARE, V29, P149, DOI 10.1177/0310057X0102900209; Butwick AJ, 2007, ANESTH ANALG, V105, P1413, DOI 10.1213/01.ane.0000286167.96410.27; Chan AMH, 1999, CAN J ANAESTH, V46, P253, DOI 10.1007/BF03012605; Chen J C, 1993, Ma Zui Xue Za Zhi, V31, P19; Crowley LJ, 2008, REGION ANESTH PAIN M, V33, P241, DOI 10.1016/j.rapm.2007.11.006; deWitte J, 1997, ACTA ANAESTH SCAND, V41, P506, DOI 10.1111/j.1399-6576.1997.tb04732.x; Goyal P., 2011, J OBSTET ANAESTHESIA, V1, P73; Hohener D, 2008, BRIT J ANAESTH, V100, P8, DOI 10.1093/bja/aem342; KATYAL S, 2002, J ANAESTH CLIN PHARM, V18, P363; Kelsaka E, 2006, REGION ANESTH PAIN M, V31, P40, DOI 10.1016/j.rapm.2005.10.010; Khan ZH, 2011, EUR J ANAESTH, V28, P202, DOI 10.1097/EJA.0b013e3283430802; Kouki P, 2012, PATIENT PREFER ADHER, V6, P569, DOI 10.2147/PPA.S34244; Kranke P, 2002, ANESTH ANALG, V94, P453, DOI 10.1097/00000539-200202000-00043; Kumar VRH, 2014, INDIAN J ANAESTH, V58, P149, DOI 10.4103/0019-5049.130815; KURZ M, 1993, ANESTHESIOLOGY, V79, P1193, DOI 10.1097/00000542-199312000-00009; LIU WHD, 1991, ANAESTHESIA, V46, P344, DOI 10.1111/j.1365-2044.1991.tb09540.x; Mathews S, 2002, ANAESTHESIA, V57, P394; Mitra S, 2012, ACTA ANAESTH SCAND, V56, P706, DOI 10.1111/j.1399-6576.2012.02663.x; Mittal G, 2014, INDIAN J ANAESTH, V58, P257, DOI 10.4103/0019-5049.135031; RAMSAY MAE, 1974, BRIT MED J, V2, P656, DOI 10.1136/bmj.2.5920.656; Roy JD, 2004, ANESTH ANALG, V98, P230, DOI 10.1213/01.ANE.0000093251.42341.74; Sadegh Ali, 2012, Med J Islam Repub Iran, V26, P85; Sessler DI, 2008, ANESTHESIOLOGY, V109, P318, DOI 10.1097/ALN.0b013e31817f6d76; Sharma SK, 2002, ANESTHESIOLOGY, V96, P546, DOI 10.1097/00000542-200203000-00007; Shoorab Nahid Jahani, 2013, Oman Med J, V28, P306, DOI 10.5001/omj.2013.92; Subedi A, 2013, INT J OBSTET ANESTH, V22, P316, DOI 10.1016/j.ijoa.2013.05.009; Tsai YC, 2001, ANESTH ANALG, V93, P1288, DOI 10.1097/00000539-200111000-00052	28	1	1	2	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1341-8076	1447-0756		J OBSTET GYNAECOL RE	J. Obstet. Gynaecol. Res.	NOV	2019	45	11					2202	2208		10.1111/jog.14106			7	Obstetrics & Gynecology	Obstetrics & Gynecology	JJ3GF	WOS:000494049000008	31486253				2020-06-30	J	Pardo, J; Mena, A; Jimenez, E; Aymar, N; Ortiz, I; Roncero, R; Mestre, F; Vidal, M				Pardo, J.; Mena, A.; Jimenez, E.; Aymar, N.; Ortiz, I.; Roncero, R.; Mestre, F.; Vidal, M.			Effectiveness of fentanyl pectin nasal citrate in controlling episodes of breakthrough cancer pain triggered by routine radiotherapy procedures	CLINICAL & TRANSLATIONAL ONCOLOGY			English	Article						Breakthrough cancer pain; Fentanyl pectin nasal spray; Radiotherapy; Procedural	RADIATION-THERAPY; OPIOID ANALGESICS; SPRAY; MANAGEMENT; PREVALENCE; RECOMMENDATIONS; INTENSITY; MUCOSITIS; EFFICACY; HEAD	PurposeThe aim of the study was to evaluate the effectiveness of fentanyl pectin nasal spray (FPNS) in controlling procedural breakthrough cancer pain (BTCP) in advanced cancer patients undergoing radiotherapy.Materials and methodsThis study involved 62 advanced cancer patients, with well-controlled background pain, who presented BTCP associated to routine radiotherapy procedures, treated with FPNS according to our protocol of administration. The BPE intensity was measured using a visual analog scale (VAS).ResultsThe BTCP was triggered during the computed tomography simulation (79.3%) or treatment delivery (20.7%). Patients indicated a mean VAS of 8.8 (range 7-10) when attempting the procedure. After 4.5 min (range 2-10) of the first FPNS dose, the majority of patients (85.5%) indicated a VAS of 4.3 (range 2-6). 15.5% of the patients did not respond after 15 min; requiring a second dose. All these patients responded, reporting a mean VAS of 4.2 (range 4-6) after 3.0 min (range 2-5) of the second dose. None of the patients required a third dose, nor reported an AE after the administration of FPNS.ConclusionsIn our knowledge, our study is the one of highest recruitment, and with the fastest response of BTCP treated with FPNS reported in advanced cancer patients undergoing radiotherapy. FPNS has proven to be highly effective in reducing the intensity of procedural BTCP in a very short period of time.	[Pardo, J.; Mena, A.; Jimenez, E.; Aymar, N.; Ortiz, I.; Roncero, R.; Mestre, F.; Vidal, M.] Hosp Univ Son Espases, Dept Radiat Oncol, Carretera Valldemossa 79, Palma De Mallorca 07010, Spain; [Pardo, J.; Mena, A.; Jimenez, E.] Inst Invest Sanitaria Palma IdISPa, Palma De Mallorca, Spain; [Pardo, J.] Hosp Univ Gen Catalunya, Quironsalud, Barcelona, Spain	Pardo, J (reprint author), Hosp Univ Son Espases, Dept Radiat Oncol, Carretera Valldemossa 79, Palma De Mallorca 07010, Spain.; Pardo, J (reprint author), Inst Invest Sanitaria Palma IdISPa, Palma De Mallorca, Spain.; Pardo, J (reprint author), Hosp Univ Gen Catalunya, Quironsalud, Barcelona, Spain.	jose.pardo@ssib.es		Ortiz Gonzalez, Irene/0000-0003-3009-3626			Bell BC, 2013, J PAIN RES, V6, P843, DOI 10.2147/JPR.S54788; Bossi P, 2014, ORAL ONCOL, V50, P884, DOI 10.1016/j.oraloncology.2014.06.013; Breivik H, 2009, ANN ONCOL, V20, P1420, DOI 10.1093/annonc/mdp001; Bruera E, 2003, JAMA-J AM MED ASSOC, V290, P2476, DOI 10.1001/jama.290.18.2476; Caraceni A, 2004, PALLIATIVE MED, V18, P177, DOI 10.1191/0269216304pm890oa; Caraceni A, 2013, J NATL COMPR CANC NE, V11, pS29; Caraceni A, 2012, LANCET ONCOL, V13, pE58, DOI 10.1016/S1470-2045(12)70040-2; Caravatta L, 2015, TUMORI J, V101, P603, DOI 10.5301/tj.5000308; Davies A, 2006, CANC RELATED BREAKTH, P1; Davies A, 2011, J PAIN SYMPTOM MANAG, V41, P358, DOI 10.1016/j.jpainsymman.2010.11.004; Davies AN, 2009, EUR J PAIN, V13, P331, DOI 10.1016/j.ejpain.2008.06.014; Deandrea S, 2014, J PAIN SYMPTOM MANAG, V47, P57, DOI 10.1016/j.jpainsymman.2013.02.015; Di Franco R, 2017, WORLD CANCER RES J, V4; Escobar Álvarez Y., 2013, Rev. Soc. Esp. Dolor, V20, P61, DOI 10.4321/s1134-80462013000200005; European Medicines Agency, PECFENT FENT; Fallon Marie, 2011, J Support Oncol, V9, P224, DOI 10.1016/j.suponc.2011.07.004; Hjermstad MJ, 2016, BMJ SUPPORT PALLIAT, V6, P344, DOI 10.1136/bmjspcare-2015-000887; Magnani C, 2017, CLIN J PAIN, V33, P707, DOI 10.1097/AJP.0000000000000450; Mazzola R, 2017, CLIN TRANSL ONCOL, V19, P593, DOI 10.1007/s12094-016-1570-5; Mercadante S, 2018, CANCERS, V10, DOI 10.3390/cancers10060175; Mercadante S, 2017, ADV THER, V34, P120, DOI 10.1007/s12325-016-0440-4; Pardo J, 2017, INT J RADIAT ONCOL, V99, pE524, DOI 10.1016/j.ijrobp.2017.06.1859; Portenoy RK, 2011, LANCET, V377, P2236, DOI 10.1016/S0140-6736(11)60236-5; Portenoy Russell K, 2010, J Opioid Manag, V6, P319; Prieto I, 2016, SCAND J PAIN, V11, P52, DOI 10.1016/j.sjpain.2015.12.001; Taylor DR, 2012, FUTURE ONCOL, V8, P121, DOI [10.2217/FON.11.146, 10.2217/fon.11.146]; Watts P, 2009, EXPERT OPIN DRUG DEL, V6, P543, DOI [10.1517/17425240902939135, 10.1517/17425240902939135 ]; Yaromina A, 2012, MOL ONCOL, V6, P211, DOI 10.1016/j.molonc.2012.01.007; Zeppetella G, 2014, J PAIN SYMPTOM MANAG, V47, P772, DOI 10.1016/j.jpainsymman.2013.05.020; Zeppetella G, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004311.pub3	30	0	0	2	2	SPRINGER INTERNATIONAL PUBLISHING AG	CHAM	GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND	1699-048X	1699-3055		CLIN TRANSL ONCOL	Clin. Transl. Oncol.	NOV	2019	21	11					1568	1572		10.1007/s12094-019-02125-8			5	Oncology	Oncology	JJ2NQ	WOS:000493999400016	31093890				2020-06-30	J	Stowell, RD; Sipe, GO; Dawes, RP; Batchelor, HN; Lordy, KA; Whitelaw, BS; Stoessel, MB; Bidlack, JM; Brown, E; Sur, M; Majewska, AK				Stowell, Rianne D.; Sipe, Grayson O.; Dawes, Ryan P.; Batchelor, Hanna N.; Lordy, Katheryn A.; Whitelaw, Brendan S.; Stoessel, Mark B.; Bidlack, Jean M.; Brown, Edward; Sur, Mriganka; Majewska, Ania K.			Noradrenergic signaling in the wakeful state inhibits microglial surveillance and synaptic plasticity in the mouse visual cortex	NATURE NEUROSCIENCE			English	Article							EXPERIENCE-DEPENDENT PLASTICITY; FRACTALKINE RECEPTOR; OCULAR DOMINANCE; SLEEP; BRAIN; MECHANISMS; NEURONS; PHARMACOLOGY; RAMIFICATION; SYNAPSES	Microglia are the brain's resident innate immune cells and also have a role in synaptic plasticity. Microglial processes continuously survey the brain parenchyma, interact with synaptic elements and maintain tissue homeostasis. However, the mechanisms that control surveillance and its role in synaptic plasticity are poorly understood. Microglial dynamics invivo have been primarily studied in anesthetized animals. Here we report that microglial surveillance and injury response are reduced in awake mice as compared to anesthetized mice, suggesting that arousal state modulates microglial function. Pharmacologic stimulation of beta(2)-adrenergic receptors recapitulated these observations and disrupted experience-dependent plasticity, and these effects required the presence of beta(2)-adrenergic receptors in microglia. These results indicate that microglial roles in surveillance and synaptic plasticity in the mouse brain are modulated by noradrenergic tone fluctuations between arousal states and emphasize the need to understand the effect of disruptions of adrenergic signaling in neurodevelopment and neuropathology.	[Stowell, Rianne D.; Dawes, Ryan P.; Batchelor, Hanna N.; Lordy, Katheryn A.; Whitelaw, Brendan S.; Stoessel, Mark B.; Majewska, Ania K.] Univ Rochester, Med Ctr, Dept Neurosci, Rochester, NY 14642 USA; [Stowell, Rianne D.; Dawes, Ryan P.; Whitelaw, Brendan S.; Stoessel, Mark B.] Univ Rochester, Med Ctr, Neurosci Grad Program, Rochester, NY 14642 USA; [Stowell, Rianne D.; Sipe, Grayson O.] MIT, Dept Brain & Cognit Sci, Picower Inst Learning & Memory, E25-618, Cambridge, MA 02139 USA; [Sipe, Grayson O.; Sur, Mriganka] Univ Rochester, Med Ctr, Dept Pharmacol & Physiol, Rochester, NY 14642 USA; [Bidlack, Jean M.] Univ Rochester, Dept Biomed Engn, Rochester, NY USA; [Brown, Edward] Univ Rochester, Med Ctr, Ctr Visual Sci, Rochester, NY 14642 USA	Majewska, AK (reprint author), Univ Rochester, Med Ctr, Dept Neurosci, Rochester, NY 14642 USA.	ania_majewska@urmc.rochester.edu		Stoessel, Mark/0000-0002-7785-2645; /0000-0003-2442-5671; Majewska, Ania/0000-0002-2167-6849; Whitelaw, Brendan/0000-0001-5552-1506	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 EY019277, R21 NS099973, R01 AA027111, R01 EY028219, F31 NS105249, T32 NS007489, F31 NS086241, F32 EY028028]; National Science FoundationNational Science Foundation (NSF) [NSF 1557971]; Schmitt Program on Integrative Brain Research grant; University of Rochester Bilski-Mayer Fellowship; University of Rochester Medical Center Summer Scholars Fellowship	We thank the University of Rochester Medical Center Flow Core for their expert training and services. We thank C. Lamantia for assistance with animal management; J. Olschowka and K. O'Banion for shared PCR resources; F. Rivera-Escalera for providing training on tissue preparation for microglial FACS; A. Ghosh for the Sholl analysis ImageJ plugin; and J. Cang for sharing MATLAB code for OD analysis. This work was supported by National Institutes of Health grants R01 EY019277 (A.K.M.), R21 NS099973 (A.K.M.), R01 AA027111 (A.K.M.), R01 EY028219 (M.S.), F31 NS105249 (R.D.S.), T32 NS007489 (R.D.S., G.O.S.), F31 NS086241 (G.O.S.) and F32 EY028028 (G.O.S.); National Science Foundation grant NSF 1557971 (A.K.M.); a Schmitt Program on Integrative Brain Research grant (G.O.S. and R.P.D.); the University of Rochester Bilski-Mayer Fellowship (H.N.B.); and the University of Rochester Medical Center Summer Scholars Fellowship (K.A.L.).	Aton SJ, 2009, NEURON, V61, P454, DOI 10.1016/j.neuron.2009.01.007; Bellesi M, 2016, SLEEP, V39, P143, DOI 10.5665/sleep.5336; Bernier LP, 2019, CELL REP, V27, P2895, DOI 10.1016/j.celrep.2019.05.010; BILSKI AJ, 1983, J CARDIOVASC PHARM, V5, P430, DOI 10.1097/00005344-198305000-00013; Davalos D, 2005, NAT NEUROSCI, V8, P752, DOI 10.1038/nn1472; Ding FF, 2013, CELL CALCIUM, V54, P387, DOI 10.1016/j.ceca.2013.09.001; Dissing-Olesen L, 2014, J NEUROSCI, V34, P10511, DOI 10.1523/JNEUROSCI.0405-14.2014; Farneback G, 2003, LECT NOTES COMPUT SC, V2749, P363, DOI 10.1007/3-540-45103-x_50; Feng GP, 2000, NEURON, V28, P41, DOI 10.1016/S0896-6273(00)00084-2; Frank MG, 2001, NEURON, V30, P275, DOI 10.1016/S0896-6273(01)00279-3; Frenkel MY, 2004, NEURON, V44, P917, DOI 10.1016/j.neuron.2004.12.003; FRISHMAN W, 1980, AM HEART J, V99, P124, DOI 10.1016/0002-8703(80)90322-1; Gordon JA, 1996, J NEUROSCI, V16, P3274; Guneykaya D, 2018, CELL REP, V24, P2773, DOI 10.1016/j.celrep.2018.08.001; Gyoneva S, 2013, J BIOL CHEM, V288, P15291, DOI 10.1074/jbc.M113.458901; Hinoi E, 2008, J CELL BIOL, V183, P1235, DOI 10.1083/jcb.200809113; Hoshiko M, 2012, J NEUROSCI, V32, P15106, DOI 10.1523/JNEUROSCI.1167-12.2012; JONSSON G, 1981, EUR J PHARMACOL, V72, P173, DOI 10.1016/0014-2999(81)90272-7; Jung S, 2000, MOL CELL BIOL, V20, P4106, DOI 10.1128/MCB.20.11.4106-4114.2000; Kaneko M, 2008, NEURON, V58, P673, DOI 10.1016/j.neuron.2008.04.023; KASAMATSU T, 1976, SCIENCE, V194, P206, DOI 10.1126/science.959850; Kolmus K, 2015, BRAIN BEHAV IMMUN, V45, P297, DOI 10.1016/j.bbi.2014.10.007; Krueger JM, 2001, ANN NY ACAD SCI, V933, P211; Labrousse VF, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006006; Li YY, 2016, EUR J NEUROSCI, V43, P131, DOI 10.1111/ejn.13065; Lowery RL, 2017, GLIA, V65, P1744, DOI 10.1002/glia.23192; Luo F, 2018, J NEUROCHEM, V144, P152, DOI 10.1111/jnc.14248; Madisen L, 2010, NAT NEUROSCI, V13, P133, DOI 10.1038/nn.2467; Madrigal JLM, 2017, NEUROPHARMACOLOGY, V114, P146, DOI 10.1016/j.neuropharm.2016.12.001; Madry C, 2018, P NATL ACAD SCI USA, V115, pE1608, DOI 10.1073/pnas.1715354115; Madry C, 2018, NEURON, V97, P299, DOI 10.1016/j.neuron.2017.12.002; Miyamoto A, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12540; Musiek ES, 2016, SCIENCE, V354, P1004, DOI 10.1126/science.aah4968; Nelson LE, 2003, ANESTHESIOLOGY, V98, P428, DOI 10.1097/00000542-200302000-00024; Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647; O'Donnell J, 2012, NEUROCHEM RES, V37, P2496, DOI 10.1007/s11064-012-0818-x; Paolicelli RC, 2011, SCIENCE, V333, P1456, DOI 10.1126/science.1202529; Parkhurst CN, 2013, CELL, V155, P1596, DOI 10.1016/j.cell.2013.11.030; PETTIGREW JD, 1978, NATURE, V271, P761, DOI 10.1038/271761a0; Polack PO, 2013, NAT NEUROSCI, V16, P1331, DOI 10.1038/nn.3464; Qian L, 2011, J IMMUNOL, V186, P4443, DOI 10.4049/jimmunol.1002449; Root DH, 2015, J NEUROSCI, V35, P3460, DOI 10.1523/JNEUROSCI.4525-13.2015; Ryan KM, 2016, BRAIN BEHAV IMMUN, V56, P114, DOI 10.1016/j.bbi.2016.02.023; Schafer DP, 2013, GLIA, V61, P24, DOI 10.1002/glia.22389; Schafer DP, 2012, NEURON, V74, P691, DOI 10.1016/j.neuron.2012.03.026; Schneble N, 2017, MOL CELL NEUROSCI, V78, P1, DOI 10.1016/j.mcn.2016.11.002; Sipe GO, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10905; Smith AJ, 2017, ELIFE, V6, DOI [10.7554/eLife.27679, 10.7554/elife.27679]; Smith JS, 2016, J BIOL CHEM, V291, P8969, DOI 10.1074/jbc.R115.713313; Stowell RD, 2018, DEV NEUROBIOL, V78, P627, DOI 10.1002/dneu.22572; Toth LA, 2013, COMPARATIVE MED, V63, P91; Tremblay ME, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000527; Wake H, 2009, J NEUROSCI, V29, P3974, DOI 10.1523/JNEUROSCI.4363-08.2009; Wong EL, 2018, BRAIN BEHAV IMMUN, V67, P257, DOI 10.1016/j.bbi.2017.09.003; Wulff K, 2010, NAT REV NEUROSCI, V11, P589, DOI 10.1038/nrn2868; Xie LL, 2013, SCIENCE, V342, P373, DOI 10.1126/science.1241224; Yang G, 2014, SCIENCE, V344, P1173, DOI 10.1126/science.1249098; Zhan Y, 2014, NAT NEUROSCI, V17, P400, DOI 10.1038/nn.3641; Zhang Y, 2014, J NEUROSCI, V34, P11929, DOI [10.1523/JNEUROSCI.1860-14.2014, 10.11772/j.issn.1001-9081.2014.07.1929]	59	11	11	8	14	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1097-6256	1546-1726		NAT NEUROSCI	Nat. Neurosci.	NOV	2019	22	11					1782	+		10.1038/s41593-019-0514-0			14	Neurosciences	Neurosciences & Neurology	JI3VI	WOS:000493396600007	31636451	Green Accepted	N	Y	2020-06-30	J	Warrender, W; Jones, C; Selverian, S; Lutsky, K; Banner, L; Beredjiklian, PK				Warrender, William; Jones, Christopher; Selverian, Stephen; Lutsky, Kevin; Banner, Lauren; Beredjiklian, Pedro K.			Perioperative Risks Are Similar for Normal versus Selected High-Body Mass Index Patients Undergoing Outpatient Hand and Elbow Surgery	PLASTIC AND RECONSTRUCTIVE SURGERY			English	Article							AMBULATORY SURGERY; SLEEVE GASTRECTOMY; OBESE-PATIENTS; COMPLICATIONS; ADMISSIONS; SAFETY	Background: Many ambulatory surgery centers use body mass index as a screening tool to make admissions decisions because of complication risks associated with high-body mass index patients. The objective of this investigation was to evaluate perioperative complications in a cohort of high-body mass index patients undergoing hand and elbow surgery at an ambulatory surgery center. The authors' hypothesis was that anesthesia-related complications for this cohort would be similar to those of a normal-body mass index group. Methods: The authors retrospectively reviewed data from all hand and elbow procedures performed on patients with a high body mass index (>40 kg/m(2)). One hundred eighty-nine high-body mass index patients and 189 normal-body mass index patients were included in the analysis. Results: The average weight-based dosage of propofol was similar in both groups but was lower in the high-body mass index group for midazolam and fentanyl. Two high-body mass index patients had oxygen desaturations in the postanesthesia care unit. No patients developed complications related to anesthesia. In the high-body mass index group, one patient developed hypotension in the postanesthesia care unit, was admitted to the emergency room for monitoring, but was discharged the following morning. Conclusions: Outpatient hand surgical care of high-body mass index patients can be performed safely. Body mass index alone should not be considered as an absolute contraindication for surgery. Careful patient selection, evaluation of comorbidities, and close involvement of the anesthesia and medical teams are critical.	[Warrender, William; Jones, Christopher; Selverian, Stephen; Lutsky, Kevin; Banner, Lauren; Beredjiklian, Pedro K.] Thomas Jefferson Univ Hosp, Rothman Inst, 925 Chestnut St,5th Floor, Philadelphia, PA 19107 USA	Beredjiklian, PK (reprint author), Thomas Jefferson Univ Hosp, Rothman Inst, 925 Chestnut St,5th Floor, Philadelphia, PA 19107 USA.	pedro.beredjiklian@rothmaninstitute.com					American Academy of Orthopedic Surgeons, AMB SURG CTR POS STA; Garcia MA, 2015, REV ESP ANEST REANIM, V62, P125, DOI 10.1016/j.redar.2014.03.016; Billing P, 2017, SURG OBES RELAT DIS, V13, P1117, DOI 10.1016/j.soard.2017.03.012; Billing PS, 2014, SURG OBES RELAT DIS, V10, P101, DOI 10.1016/j.soard.2013.07.005; Cancienne JM, 2017, J BONE JOINT SURG AM, V99, P629, DOI 10.2106/JBJS.16.00287; Goyal KS, 2016, J BONE JOINT SURG AM, V98, P700, DOI 10.2106/JBJS.15.00239; Hofer RE, 2008, MAYO CLIN PROC, V83, P908, DOI 10.4065/83.8.908; Joshi GP, 2013, ANESTH ANALG, V117, P1082, DOI 10.1213/ANE.0b013e3182a823f4; Keyes GR, 2004, PLAST RECONSTR SURG, V113, P1760, DOI 10.1097/01.PRS.0000124743.75839.11; Lopez PP, 2008, AM SURGEON, V74, P834; Martin-Ferrero MA, 2014, J ORTHOP SCI, V19, P332, DOI 10.1007/s00776-013-0501-3; Munnich EL, 2014, HEALTH AFFAIR, V33, P764, DOI 10.1377/hlthaff.2013.1281; Whippey A, 2013, CAN J ANESTH, V60, P675, DOI 10.1007/s12630-013-9935-5	13	0	0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0032-1052	1529-4242		PLAST RECONSTR SURG	Plast. Reconstr. Surg.	NOV	2019	144	5					836E	840E		10.1097/PRS.0000000000006152			5	Surgery	Surgery	JH7ZY	WOS:000492989300014	31688759				2020-06-30	J	Nevo, A; Aptekman, B; Goren, O; Matot, I; Weiniger, CF				Nevo, A.; Aptekman, B.; Goren, O.; Matot, I.; Weiniger, C. F.			Labor epidural analgesia onset time and subsequent analgesic requirements: a prospective observational single-center cohort study	INTERNATIONAL JOURNAL OF OBSTETRIC ANESTHESIA			English	Article						Labor epidural analgesia; Epidural analgesia onset time; Pain in labor	EXTRADURAL ANALGESIA; BUPIVACAINE; ANESTHESIA; FENTANYL; PAIN; PROGRESS; STAGE	Background: We investigated the correlation between lumbar epidural analgesia onset time and pain intensity at 60 and 120 min after initiation. Methods: We conducted a prospective observational study of nulliparous women receiving lumbar epidural analgesia (initial bolus 15 mL bupivacaine 0.1% with fentanyl 3.33 mu g/mL), followed by patient-controlled epidural analgesia (PCEA). The measured variable was lumbar epidural analgesia onset time (time to pain numerical rating score <= 3). Secondary outcomes were pain score at 60 and 120 min and at full dilatation; and analgesic requirements through the labor. Results: One-hundred-and-five women were eligible for analysis. There was a significant correlation between lumbar epidural analgesia onset time and pain intensity at 60 min (Spearman's R-2 =0.286, P=0.003), but not at 120 min (R-2 =0.030, P=0.76). Women who requested more PCEA boluses during the first 120 min had a longer lumbar epidural analgesia onset time (R-2 =0.321, P=0.001) and reported higher pain scores at 60 min (R-2 =0.588, P <0.001) and at 120 min (R-2 =0.539, P <0.001). Women who reported higher pain scores at 60 min had more pain at 120 min (R-2 =0.47, P <0.001) and higher analgesic consumption during labor (R-2 =0.403, P <0.001). Women who were at a greater cervical dilatation at 60 and 120 min had higher pain scores at the same time point (R-2 =0.259, P=0.008 and R-2 =0.243, P=0.013 respectively). Conclusion: There was a correlation between the onset time of lumbar epidural analgesia during labor and the pain score 60 min later but this had disappeared by 120 min. (C) 2019 Elsevier Ltd. All rights reserved.	[Nevo, A.; Aptekman, B.; Goren, O.; Matot, I.; Weiniger, C. F.] Tel Aviv Med Ctr & Sch Med, Div Anesthesia Intens Care & Pain, Weizmann St 6, IL-6423906 Tel Aviv, Israel; [Weiniger, C. F.] Hadassah Hebrew Univ, Dept Anesthesiol & Crit Care Med, Med Ctr, Jerusalem, Israel	Nevo, A (reprint author), Tel Aviv Med Ctr & Sch Med, Div Anesthesia Intens Care & Pain, Weizmann St 6, IL-6423906 Tel Aviv, Israel.	andreynevo@gmail.com					Bang EC, 2012, INT J OBSTET ANESTH, V21, P45, DOI 10.1016/j.ijoa.2011.10.002; Bauer ME, 2016, ANESTH ANALG, V123, P1074, DOI 10.1213/ANE.0000000000001582; Cappiello E, 2008, ANESTH ANALG, V107, P1646, DOI 10.1213/ane.0b013e318184ec14; Conell-Price J, 2008, ANESTH ANALG, V106, P1509, DOI 10.1213/ane.0b013e31816d14f3; Debiec J, 2009, ANESTHESIOLOGY, V111, P1093, DOI 10.1097/ALN.0b013e3181ba3f28; Eichenberger U, 2003, BRIT J ANAESTH, V90, P467, DOI 10.1093/bja/aeg100; Eltzschig HK, 2003, NEW ENGL J MED, V348, P319, DOI 10.1056/NEJMra021276; Ginosar Y, 2010, INT J OBSTET ANESTH, V19, P171, DOI 10.1016/j.ijoa.2009.11.002; Halpern SH, 2009, ANESTH ANALG, V108, P921, DOI 10.1213/ane.0b013e3181951a7f; Harms C, 1999, FETAL DIAGN THER, V14, P368, DOI 10.1159/000020961; Hawkins JL, 2010, NEW ENGL J MED, V362, P1503, DOI 10.1056/NEJMct0909254; Hepner DL, 2000, CAN J ANAESTH, V47, P232, DOI 10.1007/BF03018918; Hess PE, 2001, ANESTH ANALG, V93, P414; HOLLMEN AI, 1982, BRIT J ANAESTH, V54, P837, DOI 10.1093/bja/54.8.837; Liu Henry, 2013, Middle East Journal of Anesthesiology, V22, P257; Mankowitz SKW, 2016, ANESTH ANALG, V123, P1174, DOI 10.1213/ANE.0000000000001437; Mehta PM, 1987, REGIONAL ANESTHESIA, V12, P135; Orbach-Zinger S, 2015, EUR J PAIN, V19, P1382, DOI 10.1002/ejp.737; Sviggum HP, 2015, INT J OBSTET ANESTH, V24, P15, DOI 10.1016/j.ijoa.2014.07.001	19	0	0	1	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0959-289X	1532-3374		INT J OBSTET ANESTH	Int. J. Obstet. Anesth.	NOV	2019	40						39	44		10.1016/j.ijoa.2019.05.008			6	Anesthesiology; Obstetrics & Gynecology	Anesthesiology; Obstetrics & Gynecology	JI1HK	WOS:000493216300006	31230990				2020-06-30	J	Siciliano, CA				Siciliano, Cody A.			Capturing the complexity of sex differences requires multidimensional behavioral models	NEUROPSYCHOPHARMACOLOGY			English	Editorial Material							HEROIN; GENDER		[Siciliano, Cody A.] MIT, Dept Brain & Cognit Sci, Picower Inst Learning & Memory, E25-618, Cambridge, MA 02139 USA; [Siciliano, Cody A.] Vanderbilt Univ, Dept Pharmacol, Sch Med, Nashville, TN 37232 USA	Siciliano, CA (reprint author), MIT, Dept Brain & Cognit Sci, Picower Inst Learning & Memory, E25-618, Cambridge, MA 02139 USA.; Siciliano, CA (reprint author), Vanderbilt Univ, Dept Pharmacol, Sch Med, Nashville, TN 37232 USA.	cody.siciliano@vanderbilt.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [K99 DA04510]; NARSAD Young Investigator Award (Brain and Behavior Research Foundation)NARSAD	C.A.S. is supported NIH grant K99 DA04510 (NIDA), and a NARSAD Young Investigator Award (Brain and Behavior Research Foundation). The authors declares that he has no competing interests.	Becker JB, 2017, J NEUROSCI RES, V95, P136, DOI 10.1002/jnr.23963; Cepeda MS, 2003, CLIN PHARMACOL THER, V74, P102, DOI 10.1016/S0009-9236(03)00152-8; DEWS PB, 1955, J PHARMACOL EXP THER, V113, P393; Lynch WJ, 1999, PSYCHOPHARMACOLOGY, V144, P77, DOI 10.1007/s002130050979; Marsh JC, 2018, J SUBST ABUSE TREAT, V87, P79, DOI 10.1016/j.jsat.2018.01.001; MCKEARNEY JW, 1972, J EXP ANAL BEHAV, V17, P425, DOI 10.1901/jeab.1972.17-425; Rudd RA, 2010, MMWR-MORBID MORTAL W, V2016, P65; Townsend EA, 2019, NEUROPSYCHOPHARMACOL, V44, P2022, DOI 10.1038/s41386-019-0356-1; Venniro M, 2017, NEUROPSYCHOPHARMACOL, V42, P1126, DOI 10.1038/npp.2016.287	9	2	2	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0893-133X	1740-634X		NEUROPSYCHOPHARMACOL	Neuropsychopharmacology	NOV	2019	44	12					1997	1998		10.1038/s41386-019-0424-6			2	Neurosciences; Pharmacology & Pharmacy; Psychiatry	Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry	JD7PZ	WOS:000490174900002	31164710	Other Gold, Green Published			2020-06-30	J	Tuet, WY; Pierce, SA; Racine, MC; Tressler, J; McCranor, BJ; Sciuto, AM; Wong, B				Tuet, Wing Y.; Pierce, Samuel A.; Racine, Michelle C.; Tressler, Justin; McCranor, Bryan J.; Sciuto, Alfred M.; Wong, Benjamin			Changes in murine respiratory dynamics induced by aerosolized carfentanil inhalation: Efficacy of naloxone and naltrexone	TOXICOLOGY LETTERS			English	Article						Carfentanil; Naloxone; Naltrexone; Inhalation exposure; Prophylaxis; Respiratory dynamics; Physiology based pharmacokinetics	OPIATE RECEPTORS; DEPRESSION; PHARMACOKINETICS; PREVENTION; ANALGESIA; REVERSAL; MORPHINE; COMPLEX	Carfentanil (CRF) is an extremely potent opioid capable of inducing fatal respiratory depression. Naloxone (NX) and naltrexone (NTX) are opioid antagonists for which the efficacy against CRF remains largely unexplored. In this study, the effects of aerosolized CRF on respiratory function were investigated using adult male CD-1 mice. Mice were exposed to 0.4 mg/m(3) of CRF for 15 min using custom whole-body plethysmograph units. Minute volume (MV), respiratory frequency (f), duty cycle (DC), and tidal volume (TV) were monitored and compared to control animals exposed to aerosolized H2O. CRF exposure induced respiratory depression, characterized by a marked decrease in MV, which was sustained throughout 24 h post-exposure. Prophylactic and therapeutic treatment with intramuscular (i.m.) NX marginally improved MV, with slight dose-dependent effects. Analogous treatment with i.m. NTX returned MV to baseline levels, with all doses and intervention times performing similarly. Despite improvements in MV, treatment administration did not reverse changes in DC, a measure of respiratory timing. Overall, NX and NTX administration alleviated volumetric aspects of opioid-induced respiratory toxicity, while changes in respiratory timing remained unresolved throughout post-exposure observation. These sustained changes and differences in recovery between two aspects of respiratory dynamics may provide insights for further exploration into the underlying mechanism of action of opioids and opioid antagonists.	[Tuet, Wing Y.; Pierce, Samuel A.; Racine, Michelle C.; Tressler, Justin; McCranor, Bryan J.; Sciuto, Alfred M.; Wong, Benjamin] US Army, Pharmaceut Sci Dept, Med Res Inst Chem Def, 8350 Ricketts Point Rd, Aberdeen Proving Ground, MD 21010 USA	Wong, B (reprint author), US Army, Med Res Inst Chem Def, 8350 Ricketts Point Rd, Aberdeen Proving Ground, MD 21010 USA.	benjamin.j.wong.civ@mail.mil		Wong, Benjamin/0000-0001-6593-278X	Defense Threat Reduction Agency (DTRA-CB)United States Department of DefenseDefense Threat Reduction Agency [CB3950]	The authors would like to thank Dr. Michael Perkins, Ashley Rodriguez, and Jennifer Devorak for their various contributions to this project. The views expressed herein are those of the authors and do not reflect the official policy of the Department of Army, Department of Defense, or the U.S. Government. This work was supported by the Defense Threat Reduction Agency (DTRA-CB, CB3950). W.Y.T., S.A.P., and M.C.R. were supported in part by an appointment to the Postgraduate Research Participation Program at the US Army Medical Research Institute of Chemical Defense administered by the Oak Ridge Institute for Science and Education through an interagency agreement between the US Department of Energy and USAMRDC.	Andersson M, 2015, BMC MED IMAGING, V15, DOI 10.1186/s12880-015-0086-8; Booth N., 1982, VET PHARM THERAPEUTI, P274; Bouillon T, 2003, EUR J ANAESTH, V20, P127, DOI 10.1097/00003643-200302000-00009; Cole A, 2006, J ZOO WILDLIFE MED, V37, P318, DOI 10.1638/05-070.1; Dahan A, 2010, ANESTHESIOLOGY, V112, P226, DOI 10.1097/ALN.0b013e3181c38c25; Dart RC, 2015, NEW ENGL J MED, V372, P241, DOI [10.1056/NEJMc1501822, 10.1056/NEJMsa1406143]; Feng Y, 2012, CURR DRUG TARGETS, V13, P230, DOI 10.2174/138945012799201612; Food and Drug Administration (FDA), 2005, GUID IND EST MAX SAF; FREYE E, 1992, EUR J ANAESTH, V9, P457; FREYE E, 1983, BRIT J ANAESTH, V55, P71, DOI 10.1093/bja/55.1.71; FREYE E, 1991, PHARMACEUT RES, V8, P196, DOI 10.1023/A:1015887919560; FROST JJ, 1989, J CEREBR BLOOD F MET, V9, P398, DOI 10.1038/jcbfm.1989.59; George AV, 2010, AM J EMERG MED, V28, P530, DOI 10.1016/j.ajem.2010.03.003; Heard DJ, 1996, AM J VET RES, V57, P87; Jungquist CR, 2011, PAIN MANAG NURS, V12, P180, DOI 10.1016/j.pmn.2010.02.001; Kolodny A, 2015, ANNU REV PUBL HEALTH, V36, P559, DOI 10.1146/annurev-publhealth-031914-122957; Krechetnikov A., 2012, MOSCOW THEATRE SIEGE; Lalley PM, 2014, J PHYSIOL-LONDON, V592, P1163, DOI 10.1113/jphysiol.2013.258830; Lanthier C, 1999, MAR MAMMAL SCI, V15, P241, DOI 10.1111/j.1748-7692.1999.tb00797.x; Lee LA, 2015, ANESTHESIOLOGY, V122, P659, DOI 10.1097/ALN.0000000000000564; Leen JLS, 2019, CAN J ANESTH, V66, P414, DOI 10.1007/s12630-019-01294-y; Lewanowitsch T, 2002, EUR J PHARMACOL, V445, P61, DOI 10.1016/S0014-2999(02)01715-6; Lumb A.B., 2013, PHARM PHYSL ANESTHES, P445; MANSOUR A, 1988, TRENDS NEUROSCI, V11, P308, DOI 10.1016/0166-2236(88)90093-8; MARTIN WR, 1976, ANN INTERN MED, V85, P765, DOI 10.7326/0003-4819-85-6-765; Miller MW, 1996, J WILDLIFE DIS, V32, P234, DOI 10.7589/0090-3558-32.2.234; Minkowski CP, 2012, ADDICT BIOL, V17, P149, DOI 10.1111/j.1369-1600.2010.00256.x; Montandon G, 2014, J PHYSIOL-LONDON, V592, P1159, DOI 10.1113/jphysiol.2013.261974; Moresco A, 2001, J ZOO WILDLIFE MED, V32, P81, DOI 10.1638/1042-7260(2001)032[0081:UONTRC]2.0.CO;2; Mutlow A, 2004, J ZOO WILDLIFE MED, V35, P489, DOI 10.1638/03-074; Mutolo D, 2007, NEUROSCIENCE, V150, P720, DOI 10.1016/j.neuroscience.2007.09.028; Olofsen E, 2010, ANESTHESIOLOGY, V112, P1417, DOI 10.1097/ALN.0b013e3181d5e29d; Pattinson KTS, 2008, BRIT J ANAESTH, V100, P747, DOI 10.1093/bja/aen094; Raabe O.G., 1988, REGIONAL DEPOSITION, VVI, P53; Riches JR, 2012, J ANAL TOXICOL, V36, P647, DOI 10.1093/jat/bks078; TITELER M, 1989, EUR J PHARMACOL, V167, P221, DOI 10.1016/0014-2999(89)90582-7; Upadhyay J, 2010, BRAIN, V133, P2098, DOI 10.1093/brain/awq138; Warner M, 2014, TRENDS DRUG POISONIN; Wittert G, 1996, BIOCHEM BIOPH RES CO, V218, P877, DOI 10.1006/bbrc.1996.0156; Wong B, 2017, INHAL TOXICOL, V29, P65, DOI 10.1080/08958378.2017.1282065; Yong Z, 2014, EUR J PHARMACOL, V738, P153, DOI 10.1016/j.ejphar.2014.05.044; Zebraski SE, 2000, LIFE SCI, V66, P2221, DOI 10.1016/S0024-3205(00)00434-3	42	0	0	4	9	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0378-4274	1879-3169		TOXICOL LETT	Toxicol. Lett.	NOV	2019	316						127	135		10.1016/j.toxlet.2019.09.012			9	Toxicology	Toxicology	JC2RN	WOS:000489124300013	31539569				2020-06-30	J	Wall, SL; Clarke, DL; Allorto, NL				Wall, S. L.; Clarke, D. L.; Allorto, N. L.			Analgesia protocols for burns dressings: Challenges with implementation	BURNS			English	Article						Burns; Pain; Paediatrics; Analgesia	PAIN; SCALE; RELIABILITY; GUIDELINES; SEDATION; FACES	Background: The aim of this study is to compare doctors' knowledge regarding analgesia in paediatric burns patients in a setting where analgesia protocols are provided but not reinforced to a setting where the same protocols are used but with constant re-enforcement from burns surgeons. Methods: We reviewed questionnaires completed anonymously by doctors managing burns children in the Pietermaritzburg (PMB) Hospital Complex and the referral hospitals. Results: The questionnaire was completed by 43 doctors with 53% of the participants working in the referral hospitals. Procedural sedation was given by 98% of doctors. All PMB doctors giving procedural sedation used ketamine compared to 39% in the referral hospitals, which was statistically significant (x2 = 18.237; p < 0.001). Eighty percent of PMB doctors were aware of the correct doses of ketamine and compared to 8% of referral doctors. This was statistically significant (x2 = 21.778; p < 0.001). When assessing the adequacy of analgesia, all of the doctors from PMB used a scoring system or clinical impression. In the referral doctor group, 54% used a scoring system, 38% used the child screaming as an indicator of inadequate analgesia. Conclusion: We have identified a discrepancy in knowledge between staff in an academic burn centre and those in peripheral referral hospitals. This discrepancy translates into differences in quality of burn analgesia which patients receive. Ongoing efforts must be directed towards changing the culture of district institution and strengthening attempts to standardize care across the region. (C) 2019 Elsevier Ltd and ISBI. All rights reserved.	[Wall, S. L.; Clarke, D. L.; Allorto, N. L.] Univ KwaZulu Natal, Nelson R Mandela Sch Med, Pietermaritzburg Metropolitan Dept Surg, Pietermaritzburg Burn Serv, Durban, South Africa	Wall, SL (reprint author), Univ KwaZulu Natal, Nelson R Mandela Sch Med, Pietermaritzburg Metropolitan Dept Surg, Pietermaritzburg Burn Serv, Durban, South Africa.	shelley_wall@hotmail.com		Clarke, Damian/0000-0002-8467-1455	Fogarty International Center (FIC)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC); NIH Common Fund, Office of Strategic Coordination, Office of the Director (OD/OSC/CF/NIH), Office of AIDS Research, Office of the Director (OAR/NIH); National Institute of Mental Health (NIMH/NIH) of the National Institutes of Health [D43TW010131]	This research is supported by the Fogarty International Center (FIC), NIH Common Fund, Office of Strategic Coordination, Office of the Director (OD/OSC/CF/NIH), Office of AIDS Research, Office of the Director (OAR/NIH), National Institute of Mental Health (NIMH/NIH) of the National Institutes of Health under Award Number D43TW010131. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.	Agency for Health Care Policy and Research, 1995, AHCPR PUBLICATION, V1; Allorto N, 2018, BURNS, V44, P1617, DOI 10.1016/j.burns.2018.09.012; de Jong A, 2010, PAIN, V150, P561, DOI 10.1016/j.pain.2010.06.016; Fagin A, 2017, BURNS TRAUMA, V5, DOI 10.1186/s41038-017-0094-8; Gandhi M, 2010, INT J PEDIAT, DOI 10.1155/2010/825657; Gunduz Murat, 2011, J Anaesthesiol Clin Pharmacol, V27, P220, DOI 10.4103/0970-9185.81823; Hicks CL, 2001, PAIN, V93, P173, DOI 10.1016/S0304-3959(01)00314-1; KANE RL, 1995, J LAW MED ETHICS, V23, P62, DOI 10.1111/j.1748-720X.1995.tb01332.x; Kochman A, 2017, PEDIATR EMERG CARE, V33, P14, DOI 10.1097/PEC.0000000000000995; Merkel S I, 1997, Pediatr Nurs, V23, P293; O'Hara D, 2014, BURNS, V40, P48, DOI 10.1016/j.burns.2013.08.021; Owens VF, 2006, J BURN CARE RES, V27, P211, DOI 10.1097/01.BCR.0000204310.67594.A1; Richardson P, 2009, BURNS, V35, P921, DOI 10.1016/j.burns.2009.03.003; Stoddard FJ, 2002, J BURN CARE REHABIL, V23, P135, DOI 10.1097/00004630-200203000-00012; van Dijk M, 2005, AM J NURS, V105, P33, DOI 10.1097/00000446-200501000-00019; Woolf SH, 1999, BRIT MED J, V318, P527, DOI 10.1136/bmj.318.7182.527	16	0	0	0	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0305-4179	1879-1409		BURNS	Burns	NOV	2019	45	7					1680	1684		10.1016/j.burns.2019.04.012			5	Critical Care Medicine; Dermatology; Surgery	General & Internal Medicine; Dermatology; Surgery	JC1HD	WOS:000489028200021	31230803				2020-06-30	J	Lanzarotta, A; Witkowski, M; Batson, J				Lanzarotta, Adam; Witkowski, Mark; Batson, JaCinta			Identification of Opioids and Related Substances using Handheld Raman Spectrometers	JOURNAL OF FORENSIC SCIENCES			English	Article						forensic science; opioids; handheld Raman; fentanyl; field testing; FDA		This study describes the performance of handheld Raman devices for detecting one hundred opioids and related substances including fentanyl and several analogs. Using a single "parent" device, signatures (spectra) with excellent signal-to-noise ratios were generated using <5 mg of most compounds. The signatures were added to a method (library), which was electronically transferred to three "daughter" devices. The devices were able to discriminate different salt forms and isomers. On average, the daughter devices yielded a true-positive rate of 97.3% for generating an alarm for opioids and were 93.3% effective for correctly identifying the opioid. The devices yielded true-negative, false-positive and false-negative rates of 100%, 0%, and 2.7%, respectively, where false negatives were due to weak signal and fluorescence. These data demonstrate that the parent-daughter electronic transfer method was successful and effective, which permits the ability to develop methods in the laboratory that can be seamlessly pushed out to field devices.	[Lanzarotta, Adam; Witkowski, Mark; Batson, JaCinta] US FDA, Forens Chem Ctr, Off Regulatory Sci, Off Regulatory Affairs, Cincinnati, OH 45237 USA	Lanzarotta, A (reprint author), US FDA, Forens Chem Ctr, Off Regulatory Sci, Off Regulatory Affairs, Cincinnati, OH 45237 USA.	adam.lanzarotta@fda.hhs.gov					Assi S, 2015, ANAL METHODS-UK, V7, P736, DOI 10.1039/c4ay02169j; Dunn JD, 2011, J PHARMACEUT BIOMED, V54, P469, DOI 10.1016/j.jpba.2010.09.017; Frano K, 2017, SPECTROSCOPY, V32, P30; Guirguis A, 2017, FORENSIC SCI INT, V273, P113, DOI 10.1016/j.forsciint.2017.01.027; Lanzarotta A, 2017, J PHARMACEUT BIOMED, V146, P420, DOI 10.1016/j.jpba.2017.09.005; Mainali D, 2016, APPL SPECTROSC, V70, P916, DOI 10.1177/0003702816638305; NPR, TRUMP ADM DECL OP CR; Sisco E, 2017, FORENSIC CHEM, V4, P108, DOI 10.1016/j.forc.2017.04.001; Sorak D, 2012, APPL SPECTROSC REV, V47, P83, DOI 10.1080/05704928.2011.625748; Verkouteren JR, 2011, FORENSIC SCI INT, V206, P190, DOI 10.1016/j.forsciint.2010.08.005; Weyermann C, 2011, FORENSIC SCI INT, V209, P21, DOI 10.1016/j.forsciint.2010.11.027	11	0	0	6	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-1198	1556-4029		J FORENSIC SCI	J. Forensic Sci.	MAR	2020	65	2					421	427		10.1111/1556-4029.14217		OCT 2019	7	Medicine, Legal	Legal Medicine	KQ4IO	WOS:000491565100001	31643087				2020-06-30	J	Swisher, MW; Millar, MB; Gabriel, RA; Said, ET				Swisher, Matthew W.; Millar, Melissa B.; Gabriel, Rodney A.; Said, Engy T.			Analgesic Rescue With Opioid-Only Thoracic Epidural After Surgical Infiltration of Liposomal Bupivacaine: A Case Report	A & A PRACTICE			English	Article							INTERCOSTAL NERVE BLOCK; POSTSURGICAL ANALGESIA; PAIN-CONTROL; DOUBLE-BLIND; INJECTION	We present the case of a 51-year-old man with a history of recurrent lung cancer after left upper lobectomy who presented for an elective completion pneumonectomy via a bilateral anterior thoracotomy incision. At the completion of surgery, bilateral multilevel intercostal infiltration was performed with liposomal bupivacaine. Due to poorly controlled postoperative pain after extubation, a thoracic epidural was placed in the intensive care unit. An opioid-only infusion was started and transitioned to a local anesthetic-based infusion on postoperative day 2. This case report represents a novel stepwise approach of thoracic epidural management after surgical infiltration of liposomal bupivacaine.	[Swisher, Matthew W.; Millar, Melissa B.; Gabriel, Rodney A.; Said, Engy T.] Univ Calif San Diego, Dept Anesthesiol, San Diego, CA 92103 USA; [Gabriel, Rodney A.] Univ Calif San Diego, Div Biomed Informat, San Diego, CA 92103 USA	Swisher, MW (reprint author), Univ Calif San Diego, Dept Anesthesiol, 9500 Gilman Dr MC 0898, La Jolla, CA 92093 USA.	mwswisher@ucsd.edu					Ballantyne JC, 1998, ANESTH ANALG, V86, P598, DOI 10.1097/00000539-199803000-00032; Bramlett K, 2012, KNEE, V19, P530, DOI 10.1016/j.knee.2011.12.004; Buys MJ, 2017, REGION ANESTH PAIN M, V42, P582, DOI 10.1097/AAP.0000000000000636; Gorfine SR, 2011, DIS COLON RECTUM, V54, P1552, DOI 10.1097/DCR.0b013e318232d4c1; Hamilton TW, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011476.pub2; Hu D, 2013, CLIN DRUG INVEST, V33, P109, DOI 10.1007/s40261-012-0043-z; Joshi GP, 2008, ANESTH ANALG, V107, P1026, DOI 10.1213/01.ane.0000333274.63501.ff; Khalil KG, 2015, ANN THORAC SURG, V100, P2013, DOI 10.1016/j.athoracsur.2015.08.017; Lee B, 2018, BEST PRACT RES-CLIN, V32, P101, DOI 10.1016/j.bpa.2018.06.012; Meierhenrich R, 2011, BRIT J ANAESTH, V106, P580, DOI 10.1093/bja/aeq418; Pacira Pharmaceuticals, EXP BUP LIP INJ SUSP; Rice DC, 2015, ANN THORAC SURG, V99, P1953, DOI 10.1016/j.athoracsur.2015.02.074; Romero A, 2013, SEMIN THORAC CARDIOV, V25, P116, DOI 10.1053/j.semtcvs.2013.04.002; Terrien BD, 2017, J PAIN RES, V10, P191, DOI 10.2147/JPR.S111589; Yeung JHY, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009121.pub2	15	0	0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2325-7237			A A PRACT	A A Pract.	OCT 15	2019	13	8					292	294		10.1213/XAA.0000000000001057			3	Anesthesiology	Anesthesiology	JG4MX	WOS:000492049500002	31265441				2020-06-30	J	Ramirez, T; Soto, E; Vega, R				Ramirez, Teresa; Soto, Enrique; Vega, Rosario			Opioid modulation of cochlear auditory responses in the rat inner ear	SYNAPSE			English	Article						auditory loss; drug abuse; fentanyl; morphine; tramadol	SENSORINEURAL HEARING-LOSS; BRAIN-STEM; EVOKED-POTENTIALS; GUINEA-PIG; RECEPTORS; ANESTHESIA; KETAMINE; PHARMACOLOGY; EXPRESSION; MORPHINE	The auditory system has an extensive efferent innervation, which contributes to processes of control and regulation of the afferent input. The expression of receptors to various neurotransmitters and neuropeptides in the inner ear has been described, among which endogenous opioid receptors are found. The role of opioid receptors in the cochlea is not yet fully defined, it has been reported that opioid agonists and antagonists modulate the response to auditory stimuli and in clinical practice, multiple cases have been reported in which the consumption of opioid derivatives induce sensorineural hearing loss. In this work, we evaluated the effects of acute treatment with morphine, fentanyl, tramadol, and naloxone, in the auditory brain stem potentials (ABR), the compound action potential (CAP), and distortion products otacoustic emissions (DPOAE), across a wide range of stimulus frequencies and amplitudes. Adult Long-Evans rats of the strain CII/ZV weighing 180-220 g were used. For the ABR recording drugs were administered intraperitoneally or intravenously. For the CAP and DPOAE drugs were applied by direct perfusion in the middle ear. The opioid agonists produced a consistent increase in the amplitude of the PI component of the ABR and of the N1-P1 amplitude of the CAP. Naloxone produced no significant changes in the ABR and a reduction of the CAP N1-P1 amplitude. Also, opioid agonists induced a decrease in the amplitude of the DPOAE. These results show that the opioid receptor activation modulates both the afferent response at both the afferent response to acoustic stimuli, and also at the cochlear mechanics as revealed by DPOAE changes. These results present a significant step in understanding how opioid modulation of auditory responses may contribute to the auditory processing and to sensorineural hearing loss produced by opioids.	[Ramirez, Teresa; Soto, Enrique; Vega, Rosario] Benemerita Univ Autonoma Puebla, Inst Fisiol, Apartado Postal 405, Puebla 72000, Pue, Mexico	Vega, R (reprint author), Benemerita Univ Autonoma Puebla, Inst Fisiol, Apartado Postal 405, Puebla 72000, Pue, Mexico.	rosario.vega@correo.buap.mx	/C-4073-2013	/0000-0003-2428-7416	Consejo Nacional de Ciencia y Tecnologia (CONACyT)Consejo Nacional de Ciencia y Tecnologia (CONACyT)	Consejo Nacional de Ciencia y Tecnologia (CONACyT), Grant/Award Number: Fronteras de la Ciencia 1544	Arai S, 2008, CAN J VET RES, V72, P287; BROWN MC, 1983, HEARING RES, V10, P345, DOI 10.1016/0378-5955(83)90097-7; BROWNING S, 1982, BRIT J PHARMACOL, V77, P487, DOI 10.1111/j.1476-5381.1982.tb09322.x; Christenson BJ, 2010, ANN PHARMACOTHER, V44, P207, DOI 10.1345/aph.1M250; De la Rosa Jimenez V, 2009, THESIS; DRESCHER MJ, 1983, J NEUROCHEM, V41, P309, DOI 10.1111/j.1471-4159.1983.tb04745.x; EYBALIN M, 1987, BRAIN RES, V421, P336, DOI 10.1016/0006-8993(87)91303-5; EYBALIN M, 1993, PHYSIOL REV, V73, P309; FEX J, 1981, P NATL ACAD SCI-BIOL, V78, P1255, DOI 10.1073/pnas.78.2.1255; Friedman RA, 2000, AM J OTOL, V21, P188, DOI 10.1016/S0196-0709(00)80007-1; GOSSSAMPSON MA, 1991, LAB ANIM, V25, P360, DOI 10.1258/002367791780810074; GREENE SA, 1988, J VET PHARMACOL THER, V11, P295, DOI 10.1111/j.1365-2885.1988.tb00189.x; Guinan J. J., 1996, COCHLEA SPRINGER HDB, P439; Hienz RD, 2001, PHARMACOL BIOCHEM BE, V69, P305, DOI 10.1016/S0091-3057(01)00544-5; Ho Tang, 2007, Pain Physician, V10, P467; HOFFMAN DW, 1993, HEARING RES, V69, P1, DOI 10.1016/0378-5955(93)90087-H; Jongkamonwiwat N, 2003, HEARING RES, V181, P85, DOI 10.1016/S0378-5955(03)00175-8; Jongkamonwiwat N, 2006, EUR J NEUROSCI, V23, P2701, DOI 10.1111/j.1460-9568.2006.04810.x; Lioudyno MI, 2002, MOL CELL NEUROSCI, V20, P695, DOI 10.1006/mcne.2002.1150; Lopez Ivan A., 2012, Seminars in Hearing, V33, P251, DOI 10.1055/s-0032-1315724; Maison S., 2008, JARO-J ASSOC RES OTO, V10, P50; Maison SF, 2003, J COMP NEUROL, V455, P406, DOI 10.1002/cne.10490; Maison SF, 2012, J NEUROSCI, V32, P344, DOI 10.1523/JNEUROSCI.4720-11.2012; Maison SF, 2010, J NEUROSCI, V30, P6751, DOI 10.1523/JNEUROSCI.5080-09.2010; MANSOUR A, 1994, J COMP NEUROL, V350, P412, DOI 10.1002/cne.903500307; Matthews TM, 2005, J COMP PHYSIOL A, V191, P491, DOI 10.1007/s00359-005-0601-4; Mion G, 2013, CNS NEUROSCI THER, V19, P370, DOI 10.1111/cns.12099; Nguyen K. D., 2014, J OTOLOGY RHINOLOGY, V3, P2, DOI [10.4172/2324-8785.1000145, DOI 10.4172/2324-8785.1000145]; Nguyen KD, 2014, BRAIN RES, V1590, P10, DOI 10.1016/j.brainres.2014.09.051; Oroei Mahbobeh, 2018, Addict Health, V10, P64, DOI 10.22122/ahj.v10i1.560; Phansuwan-Pujito P, 2003, HEARING RES, V184, P1, DOI 10.1016/S0378-5955(03)00163-1; POLPATHAPEE S, 1984, J MED ASSOC THAILAND, V67, P57; Prommer E, 2005, J PAIN SYMPTOM MANAG, V30, P305, DOI 10.1016/j.jpainsymman.2005.08.003; Pujol R., 1998, SPRINGER HDB AUDITOR, P175; Raphael Y, 2003, BRAIN RES BULL, V60, P397, DOI 10.1016/S0361-9230(03)00047-9; Rawool V. W, 2016, HEAR J, V69, p[10, 12]; SAHLEY TL, 1991, HEARING RES, V55, P133, DOI 10.1016/0378-5955(91)90099-U; Saifan C, 2013, CASE REP MED, DOI 10.1155/2013/242730; SAMRA SK, 1985, ANESTHESIOLOGY, V62, P437, DOI 10.1097/00000542-198504000-00011; Scholtz AW, 1998, HEARING RES, V118, P123, DOI 10.1016/S0378-5955(98)00023-9; SCHWENDER D, 1993, BRIT J ANAESTH, V71, P622, DOI 10.1093/bja/71.5.622; SCHWENDER D, 1993, BRIT J ANAESTH, V71, P629, DOI 10.1093/bja/71.5.629; Sesena E, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00090; SHAW NA, 1988, PROG NEUROBIOL, V31, P19, DOI 10.1016/0301-0082(88)90021-4; SMITH DI, 1989, ELECTROEN CLIN NEURO, V72, P422, DOI 10.1016/0013-4694(89)90047-3; Taranda J, 2009, PLOS BIOL, V7, P71, DOI 10.1371/journal.pbio.1000018; van Gaalen FA, 2009, EUR ARCH OTO-RHINO-L, V266, P773, DOI 10.1007/s00405-009-0935-6; Vega R, 2003, NEUROSCIENCE, V118, P75, DOI 10.1016/S0306-4522(02)00971-5; Vega R., 2006, 43 INN EAR BIOL WORK; Yorgason JG, 2010, OTOLARYNG HEAD NECK, V142, P814, DOI 10.1016/j.otohns.2010.01.010; Zanos P, 2018, PHARMACOL REV, V70, P621, DOI 10.1124/pr.117.015198	51	0	0	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0887-4476	1098-2396		SYNAPSE	Synapse	JAN	2020	74	1							e22128	10.1002/syn.22128		OCT 2019	11	Neurosciences	Neurosciences & Neurology	JH8BL	WOS:000490132500001	31403743	Bronze			2020-06-30	J	Oderda, GM; Senagore, AJ; Morland, K; Iqbal, SU; Kugel, M; Liu, SZ; Habib, AS				Oderda, Gary M.; Senagore, Anthony J.; Morland, Kellie; Iqbal, Sheikh Usman; Kugel, Marla; Liu, Sizhu; Habib, Ashraf S.			Opioid-related respiratory and gastrointestinal adverse events in patients with acute postoperative pain: prevalence, predictors, and burden	JOURNAL OF PAIN & PALLIATIVE CARE PHARMACOTHERAPY			English	Article							INVESTIGATING OLICERIDINE TRV130; LENGTH-OF-STAY; DRUG EVENTS; CONTROLLED ANALGESIA; AMERICAN-SOCIETY; SLEEP-APNEA; ANESTHESIA; MANAGEMENT; NAUSEA; DEPRESSION	Opioid-induced respiratory depression (OIRD) and postoperative nausea and vomiting (PONV) are challenging, resource-intensive, and costly opioid-related adverse events (ORAEs). Utilizing the Premier Healthcare Database, we identified patients > 18?years old, who underwent at least one surgical procedure of interest (i.e., cardiothoracic/vascular, general/colorectal, obstetric/gynecologic, orthopedic, or urologic), and received at least one dose of intravenous morphine, hydromorphone, or fentanyl for acute postoperative pain. The incidence of OIRD and PONV using ICD-9 codes, factors influencing these AEs, length of stay (LOS) and related costs were analyzed. Among 592,127 inpatient stays, rates of respiratory depression ranged from 3% (obstetric/gynecologic) to 17% (cardiothoracic/vascular) and nausea/vomiting from 44% (obstetric/gynecologic) to 72% (general/colorectal). Increased odds of OIRD were associated with older age (cardiothoracic/vascular, general/colorectal, obstetric/gynecologic); obesity, respiratory conditions, and sleep apnea (all surgery groups); opioid dose (cardiothoracic/vascular, general/colorectal, orthopedic); and sedative use after day 1. Increased odds of PONV were associated with younger age, female sex, and major disease severity. When respiratory depression or nausea/vomiting was present versus absent, LOS was significantly longer, and hospital costs were higher. In this analysis, OIRD and PONV were more prevalent than previously reported, were associated with identifiable risk factors, and had substantial effects on resource utilization and costs.	[Oderda, Gary M.] Univ Utah, Coll Pharm, 30 South 2000 East, Salt Lake City, UT 84112 USA; [Senagore, Anthony J.] Western Michigan Univ, Homer Stryker Sch Med, Borgess Med Ctr, Kalamazoo, MI 49008 USA; [Morland, Kellie; Kugel, Marla; Liu, Sizhu] Xcenda LLC, Palm Harbor, FL USA; [Iqbal, Sheikh Usman] Trevena Inc, Chesterbrook, PA USA; [Habib, Ashraf S.] Duke Univ, Med Ctr, Durham, NC USA	Oderda, GM (reprint author), Univ Utah, Coll Pharm, 30 South 2000 East, Salt Lake City, UT 84112 USA.	goderda@pharm.utah.edu			Trevena, Inc.	This study was sponsored by Trevena, Inc. All authors had full access to all of the data in this study and take complete responsibility for the integrity of the data and accuracy of the data analysis.	Apfel CC, 2012, BRIT J ANAESTH, V109, P742, DOI 10.1093/bja/aes276; Apfel CC, 1999, ANESTHESIOLOGY, V91, P693, DOI 10.1097/00000542-199909000-00022; Ashburn MA, 2012, ANESTHESIOLOGY, V116, P248, DOI 10.1097/ALN.0b013e31823c1030; Averill RF, 2008, 3M TM APR DRG CLASSI; Bloom JD, 2010, 23 ESICM ANN C OCT 9, pA0787; Cashman JN, 2004, BRIT J ANAESTH, V93, P212, DOI 10.1093/bja/aeh180; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Chou R, 2016, J PAIN, V17, P131, DOI 10.1016/j.jpain.2015.12.008; Chung F, 2016, ANESTH ANALG, V123, P452, DOI 10.1213/ANE.0000000000001416; Classen DC, 1997, JAMA-J AM MED ASSOC, V277, P301, DOI 10.1001/jama.277.4.301; Correa D, 2015, ANESTH ANALG, V120, P1273, DOI 10.1213/ANE.0000000000000672; Dahan A, 2010, ANESTHESIOLOGY, V112, P226, DOI 10.1097/ALN.0b013e3181c38c25; de Groot V, 2003, J CLIN EPIDEMIOL, V56, P221, DOI 10.1016/S0895-4356(02)00585-1; Dean M, 2004, J PAIN SYMPTOM MANAG, V28, P497, DOI 10.1016/j.jpainsymman.2004.02.021; Doufas AG, 2014, CURR ANESTHESIOL REP, V4, P1, DOI [DOI 10.1007/S40140-013-0047-0, DOI 10.1007/s40140-013-0047-0]; ETCHES RC, 1994, CAN J ANAESTH, V41, P125, DOI 10.1007/BF03009805; Galhotra S, 2007, QUAL SAF HEALTH CARE, V16, P260, DOI 10.1136/qshc.2007.022210; Gan TJ, 2017, J PAIN RES, V10, P2287, DOI 10.2147/JPR.S144066; Gan TJ, 2014, ANESTH ANALG, V118, P85, DOI 10.1213/ANE.0000000000000002; Gordon Debra B, 2005, Pain Manag Nurs, V6, P30, DOI 10.1016/j.pmn.2004.12.003; Gupta K, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2018-024086; Habib AS, 2006, CURR MED RES OPIN, V22, P1093, DOI 10.1185/030079906X104830; Hagle Mary E, 2004, Orthop Nurs, V23, P18, DOI 10.1097/00006416-200401000-00007; Hanna MH, 2005, ANESTHESIOLOGY, V102, P815, DOI 10.1097/00000542-200504000-00018; Hong D, 2008, ANESTH ANALG, V107, P1384, DOI 10.1213/ane.0b013e3181823efb; Jarzyna D, 2011, PAIN MANAG NURS, V12, P118, DOI 10.1016/j.pmn.2011.06.008; Kessler ER, 2013, PHARMACOTHERAPY, V33, P383, DOI 10.1002/phar.1223; Khanna AK, 2017, ANESTHESIOLOGY OPEN, V2, P9, DOI DOI 10.17140/AOJ-2-109; Khelemsky Y, 2015, PAIN PHYSICIAN, V18, pE827; Koh JC, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000002008; Lee LA, 2015, ANESTHESIOLOGY, V122, P659, DOI 10.1097/ALN.0000000000000564; Liao P, 2017, CHEST, V151, P597, DOI 10.1016/j.chest.2016.12.005; Lu CW, 2010, EUR J ANAESTH, V27, P1052, DOI 10.1097/EJA.0b013e32833f53b8; Macario A, 1999, ANESTH ANALG, V89, P652, DOI 10.1097/00000539-199909000-00022; Macintyre PE, 2011, ANAESTH INTENS CARE, V39, P545, DOI 10.1177/0310057X1103900405; Myles PS, 2000, BRIT J ANAESTH, V84, P6; Niesters M, 2013, BRIT J ANAESTH, V110, P175, DOI 10.1093/bja/aes447; Oderda GM, 2007, ANN PHARMACOTHER, V41, P400, DOI 10.1345/aph.1H386; Oderda Gary M, 2013, J Pain Palliat Care Pharmacother, V27, P62, DOI 10.3109/15360288.2012.751956; Oderda GM, 2003, J PAIN SYMPTOM MANAG, V25, P276, DOI 10.1016/S0885-3924(02)00691-7; Opperer M, 2016, ANESTH ANALG, V122, P1321, DOI 10.1213/ANE.0000000000001178; Overdyk FJ., 2009, POSTOPERATIVE RESP D; Overdyk F, 2014, PAIN MANAG, V4, P317, DOI [10.2217/pmt.14.19, 10.2217/PMT.14.19]; Overdyk FJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150214; Overdyk FJ, 2010, ANESTHESIOLOGY, V113, P259, DOI 10.1097/ALN.0b013e3181e2c1d9; Pizzi LT, 2012, PHARMACOTHERAPY, V32, P502, DOI 10.1002/j.1875-9114.2012.01101.x; Ramachandran SK, 2011, J CLIN ANESTH, V23, P207, DOI 10.1016/j.jclinane.2010.09.003; Senagore A, 2018, ANN SCI M AM SOC COL; Senagore AJ, 2010, CLIN EXP GASTROENTER, V3, P87; Sessler DI, 2015, ANESTHESIOLOGY, V122, P484, DOI 10.1097/ALN.0000000000000565; Shafi S, 2018, JAMA SURG, V153, P757, DOI 10.1001/jamasurg.2018.1039; Shapiro A, 2004, J CLIN ANESTH, V16, P415, DOI 10.1016/j.jclinane.2003.11.002; Singla N, 2017, J PAIN RES, V10, P2413, DOI 10.2147/JPR.S137952; Singla NK, 2019, PAIN PRACT, V19, P715, DOI 10.1111/papr.12801; Smith HS, 2014, EUR J PHARMACOL, V722, P67, DOI 10.1016/j.ejphar.2013.09.074; Sun Z, 2015, ANESTH ANALG, V121, P709, DOI 10.1213/ANE.0000000000000836; Taylor S, 2005, AM J SURG, V190, P752, DOI 10.1016/j.amjsurg.2005.07.015; The Joint Comission, 2012, SAF US OP HOSP; Viscusi ER, 2019, J PAIN RES, V12, P927, DOI 10.2147/JPR.S171013; Weilbach C, 2006, ACTA ANAESTH BELG, V57, P361; Weingarten TN, 2016, J ANESTH, V30, P116, DOI 10.1007/s00540-015-2082-0; Weingarten TN, 2015, ANESTH ANALG, V121, P422, DOI 10.1213/ANE.0000000000000792; Weinger M. B., 2011, ANESTHESIA PATIENT S, V26, P21; Weinger MB., 2007, DANGERS POSTOPERATIV; Wheeler M, 2002, J PAIN, V3, P159, DOI 10.1054/jpai.2002.123652; Yung L, 2017, POSTGRAD MED, V129, P40, DOI 10.1080/00325481.2017.1263139	66	0	0	0	1	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1536-0288	1536-0539		J PAIN PALLIAT CARE	J. Pain Palliat. Care Pharmacother.	OCT 2	2019	33	3-4					82	97		10.1080/15360288.2019.1668902		OCT 2019	16	Anesthesiology; Pharmacology & Pharmacy	Anesthesiology; Pharmacology & Pharmacy	JN6EV	WOS:000490682900001	31609155				2020-06-30	J	Ashok, AH; Myers, J; Marques, TR; Rabiner, EA; Howes, OD				Ashok, Abhishekh H.; Myers, Jim; Marques, Tiago Reis; Rabiner, Eugenii A.; Howes, Oliver D.			Reduced mu opioid receptor availability in schizophrenia revealed with [C-11]-carfentanil positron emission tomographic Imaging	NATURE COMMUNICATIONS			English	Article							IN-VIVO; NUCLEUS-ACCUMBENS; NEGATIVE SYMPTOMS; ANTIPSYCHOTIC-DRUGS; ENDOGENOUS OPIOIDS; ALCOHOL DEPENDENCE; POSTMORTEM BRAIN; C-11 CARFENTANIL; REWARD; DOPAMINE	Negative symptoms, such as amotivation and anhedonia, are a major cause of functional impairment in schizophrenia. There are currently no licensed treatments for negative symptoms, highlighting the need to understand the molecular mechanisms underlying them. Mu-opioid receptors (MOR) in the striatum play a key role in hedonic processing and reward function and are reduced post-mortem in schizophrenia. However, it is unknown if mu-opioid receptor availability is altered in-vivo or related to negative symptoms in schizophrenia. Using [C-11]-carfentanil positron emission tomography (PET) scans in 19 schizophrenia patients and 20 age-matched healthy controls, here we show a significantly lower MOR availability in patients with schizophrenia in the striatum (Cohen's d = 0.7), and the hedonic network. In addition, we report a marked global increase in inter-regional covariance of MOR availability in schizophrenia, largely due to increased cortical-subcortical covariance.	[Ashok, Abhishekh H.; Marques, Tiago Reis; Howes, Oliver D.] Imperial Coll London, MRC London Inst Med Sci, Hammersmith Hosp, Psychiat Imaging Grp, London, England; [Ashok, Abhishekh H.; Marques, Tiago Reis; Howes, Oliver D.] Imperial Coll London, ICS, Psychiat Imaging Grp, Fac Med, London, England; [Ashok, Abhishekh H.; Marques, Tiago Reis; Howes, Oliver D.] Kings Coll London, Inst Psychiat Psychol & Neurosci, London, England; [Ashok, Abhishekh H.] Cambridge Univ Hosp NHS Fdn Trust, Cambridge, England; [Myers, Jim] Imperial Coll London, Fac Med, London, England; [Rabiner, Eugenii A.] Invicro, London, England; [Rabiner, Eugenii A.] Kings Coll London, Inst Psychiat Psychol & Neurosci, Dept Neuroimaging, London, England; [Ashok, Abhishekh H.] Univ Cambridge, Dept Radiol, Cambridge, England	Howes, OD (reprint author), Imperial Coll London, MRC London Inst Med Sci, Hammersmith Hosp, Psychiat Imaging Grp, London, England.; Howes, OD (reprint author), Imperial Coll London, ICS, Psychiat Imaging Grp, Fac Med, London, England.; Howes, OD (reprint author), Kings Coll London, Inst Psychiat Psychol & Neurosci, London, England.	oliver.howes@lms.mrc.ac.uk	Marques, Tiago Reis/F-2489-2010; Howes, Oliver/E-7156-2010; Ashok, Abhishekh Hulegar/X-4485-2018	Marques, Tiago Reis/0000-0003-0602-7661; Howes, Oliver/0000-0002-2928-1972; Ashok, Abhishekh Hulegar/0000-0003-3636-7253	Medical Research Council-UKMedical Research Council UK (MRC) [MC-A656-5QD30]; Maudsley Charity [666]; Brain and Behavior Research Foundation [094849/Z/10/Z]; Wellcome TrustWellcome Trust; King's College London scholarship; Rosetrees TrustRosetrees Trust; Stoneygate Trust; National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London	This study was funded by grants MC-A656-5QD30 from the Medical Research Council-UK, 666 from the Maudsley Charity, 094849/Z/10/Z from the Brain and Behavior Research Foundation, and Wellcome Trust to Dr Howes and King's College London scholarship to Dr Ashok. Dr Myers is supported by the Rosetrees Trust and Stoneygate Trust. Dr Rabiner wishes to acknowledge the support and funding by the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London.	Abbas AI, 2009, PSYCHOPHARMACOLOGY, V205, P119, DOI 10.1007/s00213-009-1521-8; ADDINGTON D, 1990, SCHIZOPHR RES, V3, P247, DOI 10.1016/0920-9964(90)90005-R; ANDREASEN NC, 1982, ARCH GEN PSYCHIAT, V39, P789; Barbano MF, 2006, NEUROPSYCHOPHARMACOL, V31, P1371, DOI 10.1038/sj.npp.1300908; Berridge KC, 2015, NEURON, V86, P646, DOI 10.1016/j.neuron.2015.02.018; Berridge KC, 2009, CURR OPIN PHARMACOL, V9, P65, DOI 10.1016/j.coph.2008.12.014; BRAMBILLA F, 1984, AM J PSYCHIAT, V141, P1183; Bugarski-Kirola D, 2017, BIOL PSYCHIAT, V82, P8, DOI 10.1016/j.biopsych.2016.11.014; CARPENTER WT, 1988, AM J PSYCHIAT, V145, P578; Cervenka S, 2010, SYNAPSE, V64, P478, DOI 10.1002/syn.20765; Chaudhry IB, 2012, J PSYCHOPHARMACOL, V26, P1185, DOI 10.1177/0269881112444941; Chelnokova O, 2014, MOL PSYCHIATR, V19, P746, DOI 10.1038/mp.2014.1; CHEN JF, 1993, NEUROSCIENCE, V54, P669, DOI 10.1016/0306-4522(93)90238-B; Cinque C, 2012, TRANSL PSYCHIAT, V2, DOI 10.1038/tp.2012.83; Colasanti A, 2012, BIOL PSYCHIAT, V72, P371, DOI 10.1016/j.biopsych.2012.01.027; Deakin B, 2018, LANCET PSYCHIAT, V5, P885, DOI 10.1016/S2215-0366(18)30345-6; DiFeliceantonio AG, 2012, CURR BIOL, V22, P1918, DOI 10.1016/j.cub.2012.08.014; Eckblad M., 1982, REVISED SOCIAL UNPUB; Erritzoe D, 2010, J NEUROSCI, V30, P3391, DOI 10.1523/JNEUROSCI.2852-09.2010; FROST JJ, 1985, J COMPUT ASSIST TOMO, V9, P231, DOI 10.1097/00004728-198503000-00001; GABILONDO AM, 1995, BRAIN RES, V682, P245, DOI 10.1016/0006-8993(95)00333-L; Galderisi S, 2018, LANCET PSYCHIAT, V5, P664, DOI 10.1016/S2215-0366(18)30050-6; Galderisi S, 2015, EUR ARCH PSY CLIN N, V265, P543, DOI 10.1007/s00406-015-0590-4; Gard DE, 2007, SCHIZOPHR RES, V93, P253, DOI 10.1016/j.schres.2007.03.008; GROSSISSEROFF R, 1990, BRAIN RES, V530, P312, DOI 10.1016/0006-8993(90)91301-V; GUNNE LM, 1977, J NEURAL TRANSM, V40, P13, DOI 10.1007/BF01250276; HARRINGTON KA, 1995, MOL BRAIN RES, V33, P333, DOI 10.1016/0169-328X(95)00169-S; Henriksen G, 2008, BRAIN, V131, P1171, DOI 10.1093/brain/awm255; Hermann D, 2017, NEUROPSYCHOPHARMACOL, V42, P606, DOI 10.1038/npp.2016.145; Hiller JM, 1996, NEUROCHEM RES, V21, P1333, DOI 10.1007/BF02532374; Hirvonen J, 2009, EUR J NUCL MED MOL I, V36, P275, DOI 10.1007/s00259-008-0935-6; Howes O, 2015, J PSYCHOPHARMACOL, V29, P97, DOI 10.1177/0269881114563634; Howes OD, 2017, BIOL PSYCHIAT, V81, P9, DOI 10.1016/j.biopsych.2016.07.014; Howes OD, 2014, LANCET, V383, P1677, DOI 10.1016/S0140-6736(13)62036-X; Hsu DT, 2015, MOL PSYCHIATR, V20, P193, DOI 10.1038/mp.2014.185; Hsu DT, 2013, MOL PSYCHIATR, V18, P1211, DOI [10.1038/mp.2013.96, 10.1038/mp.2013.139]; IADAROLA MJ, 1988, BRAIN RES, V474, P75, DOI 10.1016/0006-8993(88)90670-1; Jewett DM, 2001, NUCL MED BIOL, V28, P733, DOI 10.1016/S0969-8051(01)00226-8; Kalkman HO, 2001, NEUROPSYCHOPHARMACOL, V25, P904, DOI 10.1016/S0893-133X(01)00285-8; KANE J, 1988, ARCH GEN PSYCHIAT, V45, P789; Karlsson HK, 2015, J NEUROSCI, V35, P3959, DOI 10.1523/JNEUROSCI.4744-14.2015; KAY SR, 1987, SCHIZOPHRENIA BULL, V13, P261, DOI 10.1093/schbul/13.2.261; KIRKPATRICK B, 1989, PSYCHIAT RES, V30, P119, DOI 10.1016/0165-1781(89)90153-4; Kirschner M, 2017, SCHIZOPHR RES, V186, P29, DOI 10.1016/j.schres.2016.05.003; Lammertsma AA, 1996, NEUROIMAGE, V4, P153, DOI 10.1006/nimg.1996.0066; Le Merrer J, 2009, PHYSIOL REV, V89, P1379, DOI 10.1152/physrev.00005.2009; Leucht S, 2017, AM J PSYCHIAT, V174, P927, DOI 10.1176/appi.ajp.2017.16121358; Leucht S, 2016, SCHIZOPHRENIA BULL, V42, pS90, DOI 10.1093/schbul/sbv167; LINDSTROM LH, 1986, PSYCHIAT RES, V19, P93, DOI 10.1016/0165-1781(86)90001-6; LUPICA CR, 1995, J NEUROSCI, V15, P737; Majuri J, 2018, NEUROIMAGE, V183, P1, DOI 10.1016/j.neuroimage.2018.07.069; Mann CL, 2013, J ABNORM PSYCHOL, V122, P745, DOI 10.1037/a0033069; Mechling AE, 2016, P NATL ACAD SCI USA, V113, P11603, DOI 10.1073/pnas.1601640113; Mick I, 2016, NEUROPSYCHOPHARMACOL, V41, P1742, DOI 10.1038/npp.2015.340; Mick I, 2014, INT J NEUROPSYCHOPH, V17, P2069, DOI 10.1017/S1461145714000704; Moles A, 2004, SCIENCE, V304, P1983, DOI 10.1126/science.1095943; MURPHY MR, 1990, J CLIN ENDOCR METAB, V71, P1056, DOI 10.1210/jcem-71-4-1056; Ostlund SB, 2013, PSYCHOPHARMACOLOGY, V229, P105, DOI 10.1007/s00213-013-3077-x; Papaleo F, 2007, EUR J NEUROSCI, V25, P3398, DOI 10.1111/j.1460-9568.2007.05595.x; Quelch DR, 2014, J CEREBR BLOOD F MET, V34, P1604, DOI 10.1038/jcbfm.2014.117; Rabiner EA, 2011, MOL PSYCHIATR, V16, P826, DOI 10.1038/mp.2011.29; Radua J, 2015, JAMA PSYCHIAT, V72, P1243, DOI 10.1001/jamapsychiatry.2015.2196; Ray R, 2011, P NATL ACAD SCI USA, V108, P9268, DOI 10.1073/pnas.1018699108; RAYNOR K, 1994, MOL PHARMACOL, V45, P330; Remington G., 2016, CURR TREAT OPTIONS P, V3, P133, DOI [10.1007/s40501-016-0075-8, DOI 10.1007/S40501-016-0075-8]; Resendez SL, 2013, J NEUROSCI, V33, P9140, DOI 10.1523/JNEUROSCI.4123-12.2013; Scarr E, 2012, BMC PSYCHIATRY, V12, DOI 10.1186/1471-244X-12-126; SCHMAUSS C, 1985, BIOL PSYCHIAT, V20, P1211, DOI 10.1016/0006-3223(85)90179-9; Schotte A, 1996, PSYCHOPHARMACOLOGY, V124, P57, DOI 10.1007/BF02245606; Sery O, 2010, J MOL NEUROSCI, V41, P219, DOI 10.1007/s12031-010-9327-z; Shapiro DA, 2003, NEUROPSYCHOPHARMACOL, V28, P1400, DOI 10.1038/sj.npp.1300203; Skoubis PD, 2003, NEUROSCIENCE, V119, P241, DOI 10.1016/S0306-4522(03)00121-0; Smith CJW, 2018, PSYCHONEUROENDOCRINO, V89, P59, DOI 10.1016/j.psyneuen.2017.12.017; Smith KS, 2007, J NEUROSCI, V27, P1594, DOI 10.1523/JNEUROSCI.4205-06.2007; Spreckelmeyer KN, 2011, BIOL PSYCHIAT, V70, P770, DOI 10.1016/j.biopsych.2011.05.035; Strauss GP, 2011, PSYCHIAT RES, V187, P36, DOI 10.1016/j.psychres.2011.01.012; Tuominen L, 2014, HUM BRAIN MAPP, V35, P1875, DOI 10.1002/hbm.22298; Turton Samuel, 2018, Mol Psychiatry, DOI 10.1038/s41380-018-0107-4; Tziortzi AC, 2011, NEUROIMAGE, V54, P264, DOI 10.1016/j.neuroimage.2010.06.044; Veening JG, 2012, FLUIDS BARRIERS CNS, V9, DOI 10.1186/2045-8118-9-16; Veronese M, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-39005-8; Volk DW, 2012, CEREB CORTEX, V22, P1215, DOI 10.1093/cercor/bhr202; Ward HG, 2006, EUR J NEUROSCI, V23, P1605, DOI 10.1111/j.1460-9568.2006.04674.x; Wassum KM, 2009, P NATL ACAD SCI USA, V106, P12512, DOI 10.1073/pnas.0905874106; Weerts EM, 2008, NEUROPSYCHOPHARMACOL, V33, P653, DOI 10.1038/sj.npp.1301440; Weerts EM, 2013, INT J NEUROPSYCHOPH, V16, P47, DOI 10.1017/S146114571200017X; WIEGANT VM, 1988, LIFE SCI, V42, P1733, DOI 10.1016/0024-3205(88)90039-2; Woods SW, 2003, J CLIN PSYCHIAT, V64, P663, DOI 10.4088/JCP.v64n0607; Zalesky A, 2010, NEUROIMAGE, V53, P1197, DOI 10.1016/j.neuroimage.2010.06.041; Zhang B, 2016, BRAIN IMAGING BEHAV, V10, P920, DOI 10.1007/s11682-015-9457-6	90	1	1	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2041-1723			NAT COMMUN	Nat. Commun.	OCT 3	2019	10								4493	10.1038/s41467-019-12366-4			9	Multidisciplinary Sciences	Science & Technology - Other Topics	JB7VU	WOS:000488774200009	31582737	DOAJ Gold, Green Published			2020-06-30	J	Walley, AY; Bernson, D; Larochelle, MR; Green, TC; Young, L; Land, T				Walley, Alexander Y.; Bernson, Dana; Larochelle, Marc R.; Green, Traci C.; Young, Leonard; Land, Thomas			The Contribution of Prescribed and Illicit Opioids to Fatal Overdoses in Massachusetts, 2013-2015	PUBLIC HEALTH REPORTS			English	Article						overdose; heroin; fentanyl; prescription opioids; prescription drug monitoring programs	FENTANYL-CONTAMINATED HEROIN; UNITED-STATES; PRESCRIPTION HISTORY; DEATHS; DRUG; INCREASES; RISK; MORTALITY; METHADONE; EXPOSURE	Objectives: Opioid-related overdoses are commonly attributed to prescription opioids. We examined data on opioid-related overdose decedents in Massachusetts. For each decedent, we determined which opioid medications had been prescribed and dispensed and which opioids were detected in postmortem medical examiner toxicology specimens. Methods: Among opioid-related overdose decedents in Massachusetts during 2013-2015, we analyzed individually linked postmortem opioid toxicology reports and prescription drug monitoring program records to determine instances of overdose in which a decedent had a prescription active on the date of death for the opioid(s) detected in the toxicology report. We also calculated the proportion of overdoses for which prescribed opioid medications were not detected in decedents' toxicology reports. Results: Of 2916 decedents with complete toxicology reports, 1789 (61.4%) had heroin and 1322 (45.3%) had fentanyl detected in postmortem toxicology reports. Of the 491 (16.8%) decedents with >= 1 opioid prescription active on the date of death, prescribed opioids were commonly not detected in toxicology reports, specifically: buprenorphine (56 of 97; 57.7%), oxycodone (93 of 176; 52.8%), and methadone prescribed for opioid use disorder (36 of 112; 32.1%). Only 39 (1.3%) decedents had an active prescription for each opioid detected in toxicology reports on the date of death. Conclusion: Linking overdose toxicology reports to prescription drug monitoring program records can help attribute overdoses to prescribed opioids, diverted prescription opioids, heroin, and illicitly made fentanyl.	[Walley, Alexander Y.; Larochelle, Marc R.] Boston Univ, Sch Med, Dept Med, Clin Addict Res & Educ Unit,Sect Gen Internal Med, Boston, MA 02118 USA; [Walley, Alexander Y.; Larochelle, Marc R.; Green, Traci C.] Boston Med Ctr, Boston, MA 02118 USA; [Walley, Alexander Y.; Bernson, Dana; Young, Leonard] Massachusetts Dept Publ Hlth, Boston, MA USA; [Green, Traci C.] Boston Univ, Sch Med, Dept Emergency Med, Injury Prevent Ctr, Boston, MA 02118 USA; [Land, Thomas] Univ Massachusetts, Sch Med, Dept Med, Worcester, MA USA	Walley, AY (reprint author), Boston Med Ctr, Clin Addict Res & Educ Unit, 801 Massachusetts Ave,2nd Floor, Boston, MA 02118 USA.	awalley@bu.edu		Walley, Alexander/0000-0002-8158-4882	National Institute on Drug AbuseUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [K23 DA042168]; Boston University School of Medicine Department of Medicine Career Investment Award	The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Dr. Larochelle was supported by award no. K23 DA042168 from the National Institute on Drug Abuse and a Boston University School of Medicine Department of Medicine Career Investment Award.	Abrahamsson T, 2017, DRUG ALCOHOL DEPEN, V174, P58, DOI 10.1016/j.drugalcdep.2017.01.013; [Anonymous], 2019, SAS STUD WIND STAT S; Austin AE, 2017, DRUG ALCOHOL DEPEN, V181, P44, DOI 10.1016/j.drugalcdep.2017.09.014; Baumblatt JAG, 2014, JAMA INTERN MED, V174, P796, DOI 10.1001/jamainternmed.2013.12711; Bharel M, 2017, ASSESSMENT FATAL NON; Buchanich JM, 2018, PUBLIC HEALTH REP, V133, P423, DOI 10.1177/0033354918774330; Carroll JJ, 2017, INT J DRUG POLICY, V46, P136, DOI 10.1016/j.drugpo.2017.05.023; Davis GG, 2014, J MED TOXICOL, V10, P100, DOI 10.1007/s13181-013-0323-x; Ellis AD, 2016, FORENSIC SCI MED PAT, V12, P243, DOI 10.1007/s12024-016-9780-2; Fairbairn N, 2017, INT J DRUG POLICY, V46, P172, DOI 10.1016/j.drugpo.2017.06.005; Gladden RM, 2016, MMWR-MORBID MORTAL W, V65, P837, DOI 10.15585/mmwr.mm6533a2; Guy GP, 2017, MMWR-MORBID MORTAL W, V66, P697, DOI 10.15585/mmwr.mm6626a4; Hall AJ, 2008, JAMA-J AM MED ASSOC, V300, P2613, DOI 10.1001/jama.2008.802; Harruff RC, 2015, ACAD FORENSIC PATHOL, V5, P499, DOI DOI 10.23907/2015.055; Hirsch A, 2014, PAIN MED, V15, P1187, DOI 10.1111/pme.12391; LaBelle CT, 2016, J SUBST ABUSE TREAT, V60, P6, DOI 10.1016/j.jsat.2015.06.010; Lee D, 2016, J ANAL TOXICOL, V40, P588, DOI 10.1093/jat/bkw087; Lev R, 2016, AM J EMERG MED, V34, P510, DOI 10.1016/j.ajem.2015.12.023; Macmadu A, 2017, ADDICT BEHAV, V68, P35, DOI 10.1016/j.addbeh.2017.01.014; Massachusetts Department of Public Health, 2011, UPD PMP MAND ED REQ; Massachusetts Department of Public Health, 2018, DAT BRIEF OP REL OV; Mercado MC, 2018, PAIN MED, V19, P511, DOI 10.1093/pm/pnx015; Milone MC, 2012, J MED TOXICOL, V8, P408, DOI 10.1007/s13181-012-0274-7; Modesto-Lowe V, 2010, J GEN INTERN MED, V25, P305, DOI 10.1007/s11606-009-1225-0; Nechuta SJ, 2018, DRUG ALCOHOL DEPEN, V190, P62, DOI 10.1016/j.drugalcdep.2018.05.004; Paulozzi Leonard J., 2011, Morbidity and Mortality Weekly Report, V60, P1487; Paulozzi LJ, 2009, ADDICTION, V104, P1541, DOI 10.1111/j.1360-0443.2009.02650.x; Peterson AB, 2016, MMWR-MORBID MORTAL W, V65, P844, DOI 10.15585/mmwr.mm6533a3; Rudd RA, 2016, MMWR-MORBID MORTAL W, V65, P1445, DOI 10.15585/mmwr.mm655051e1; Ruhm CJ, 2018, ADDICTION, V113, P1339, DOI 10.1111/add.14144; Seth P, 2018, MMWR-MORBID MORTAL W, V67, P349, DOI 10.15585/mmwr.mm6712a1; Slavova S, 2017, PHARM MED, V31, P155, DOI 10.1007/s40290-017-0185-7; Slavova S, 2015, PUBLIC HEALTH REP, V130, P339, DOI 10.1177/003335491513000411; Somerville NJ, 2017, MMWR-MORBID MORTAL W, V66, P382, DOI 10.15585/mmwr.mm6614a2; Sordo L, 2017, BMJ-BRIT MED J, V357, DOI 10.1136/bmj.j1550; U. S. Department of Health and Human Services, 2015, OP AB US HHS ACT ADD; Walley AY, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f174; Weimer MB, 2011, J ADDICT MED, V5, P188, DOI 10.1097/ADM.0b013e318211c56a; World Health Organization, 2004, INT STAT CLASS DIS R	39	4	4	1	4	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0033-3549	1468-2877		PUBLIC HEALTH REP	Public Health Rep.	NOV	2019	134	6					667	674	UNSP 0033354919878429	10.1177/0033354919878429		OCT 2019	8	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	JJ2XN	WOS:000488718900001	31577519				2020-06-30	J	Vikingsson, S; Rautio, T; Wallgren, J; Astrand, A; Watanabe, S; Dahlen, J; Wohlfarth, A; Konradsson, P; Wu, XY; Kronstrand, R; Green, H				Vikingsson, Svante; Rautio, Tobias; Wallgren, Jakob; Astrand, Anna; Watanabe, Shimpei; Dahlen, Johan; Wohlfarth, Ariane; Konradsson, Peter; Wu, Xiongyu; Kronstrand, Robert; Green, Henrik			LC-QTOF-MS Identification of Major Urinary Cyclopropylfentanyl Metabolites Using Synthesized Standards	JOURNAL OF ANALYTICAL TOXICOLOGY			English	Article; Proceedings Paper	39th Annual Meeting of the Society-of-Forensic-Toxicologists (SOFT)	2019	San Antonio, TX	Soc Forens Toxicol			DETECTION TIMES; ACETYLFENTANYL	Cyclopropylfentanyl is a fentanyl analog implicated in 78 deaths in Europe and over 100 deaths in the United States, but toxicological information including metabolism data about this drug is scarce. The aim of this study was to provide the exact structure of abundant and unique metabolites of cyclopropylfentanyl along with synthesis routes. In this study, metabolites were identified in 13 post-mortem urine samples using liquid chromatography quadrupole time-of-flight mass spectrometry (LC-QTOF-MS). Samples were analyzed with and without enzymatic hydrolysis, and seven potential metabolites were synthesized in-house to provide the identity of major metabolites. Cyclopropylfentanyl was detected in all samples, and the most abundant metabolite was norcyclopropylfentanyl (M1) that was detected in 12 out of 13 samples. Reference materials were synthesized (synthesis routes provided) to identify the exact structure of the major metabolites 4-hydroxyphenethyl cyclopropylfentanyl (M8), 3,4-dihydroxyphenethyl cyclopropylfentanyl (M5) and 4-hydroxy-3-methoxyphenethyl cyclopropylfentanyl (M9). These metabolites are suitable urinary markers of cyclopropylfentanyl intake as they are unique and detected in a majority of hydrolyzed urine samples. Minor metabolites included two quinone metabolites (M6 and M7), not previously reported for fentanyl analogs. Interestingly, with the exception of norcyclopropylfentanyl (M1), the metabolites appeared to be between 40% and 90% conjugated in urine. In total, 11 metabolites of cyclopropylfentanyl were identified, including most metabolites previously reported after hepatocyte incubation.	[Vikingsson, Svante; Astrand, Anna; Wohlfarth, Ariane; Kronstrand, Robert; Green, Henrik] Linkoping Univ, Dept Med & Hlth Sci, Div Drug Res, S-58185 Linkoping, Sweden; [Vikingsson, Svante; Watanabe, Shimpei; Wohlfarth, Ariane; Kronstrand, Robert; Green, Henrik] Natl Board Forens Med, Dept Forens Genet & Forens Toxicol, S-58758 Linkoping, Sweden; [Rautio, Tobias; Wallgren, Jakob; Dahlen, Johan; Konradsson, Peter; Wu, Xiongyu] Linkoping Univ, Dept Phys Chem & Biol, S-58183 Linkoping, Sweden	Vikingsson, S (reprint author), Natl Board Forens Med, Artillerigatan 12, S-58758 Linkoping, Sweden.	Svante.vikingsson@rmv.se		Watanabe, Shimpei/0000-0001-5211-3283; Wu, Xiongyu/0000-0001-6756-2276	Strategiomradet Forensiska Vetenskaper (Strategic Research Area Forensic Sciences) at Linkoping University; Eurostar project Psychomics	This study was supported by Strategiomradet Forensiska Vetenskaper (Strategic Research Area Forensic Sciences) at Linkoping University (S.V. & J.D.) and Eurostar project Psychomics (S.V., J.D., P.K. and H.G.).	Astrand A, 2019, ARCH TOXICOL, V93, P95, DOI 10.1007/s00204-018-2330-9; Bolton JL, 2017, CHEM RES TOXICOL, V30, P13, DOI 10.1021/acs.chemrestox.6b00256; DePriest A, 2010, J ANAL TOXICOL, V34, P444, DOI 10.1093/jat/34.8.444; Drug Enforcement Administration Department of Justice., 2018, Fed Regist, V83, P469; Edison L, 2017, MMWR-MORBID MORTAL W, V66, P1119, DOI 10.15585/mmwr.mm6641a6; EuropeanMonitoring Centre for Drugs and Drug Addiction (EMCDDA), 2018, REP RISK ASS N PHEN; Fogarty MF, 2018, J ANAL TOXICOL, V42, P592, DOI 10.1093/jat/bky035; Forsman M, 2009, J ANAL TOXICOL, V33, P491, DOI 10.1093/jat/33.8.491; Goggin MM, 2017, J ANAL TOXICOL, V41, P367, DOI 10.1093/jat/bkx022; GULDBERG HC, 1975, PHARMACOL REV, V27, P135; Kanamori T, 2019, BIOL PHARM BULL, V42, P623, DOI 10.1248/bpb.b18-00765; Kanamori T, 2018, BIOL PHARM BULL, V41, P106, DOI 10.1248/bpb.b17-00709; Kronstrand R, 2008, J ANAL TOXICOL, V32, P586, DOI 10.1093/jat/32.8.586; Mardal M, 2018, FORENSIC SCI INT, V290, P310, DOI 10.1016/j.forsciint.2018.07.020; Obach RS, 2013, PHARMACOL REV, V65, P578, DOI 10.1124/pr.111.005439; Steuer AE, 2017, DRUG TEST ANAL, V9, P1085, DOI 10.1002/dta.2111; Watanabe S, 2017, AAPS J, V19, P1102, DOI 10.1208/s12248-017-0070-z	17	0	0	2	3	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0146-4760	1945-2403		J ANAL TOXICOL	J. Anal. Toxicol.	OCT	2019	43	8			SI		607	614		10.1093/jat/bkz057			8	Chemistry, Analytical; Toxicology	Chemistry; Toxicology	JZ2KH	WOS:000504932300004	31504610	Green Published, Other Gold			2020-06-30	J	Simpson, KJ; Moran, MT; McCall, KL; Herbert, J; Foster, ML; Simoyan, OM; Shah, DT; Desrosiers, C; Nichols, SD; Piper, BJ				Simpson, Kevin J.; Moran, Matthew T.; McCall, Kenneth L.; Herbert, John; Foster, Michelle L.; Simoyan, Olapeju M.; Shah, Dipam T.; Desrosiers, Clare; Nichols, Stephanie D.; Piper, Brian J.			Increasing heroin, cocaine, and buprenorphine arrests reported to the Maine Diversion Alert Program	FORENSIC SCIENCE INTERNATIONAL			English	Article						Drug; Crime; Prescription; Opiate; Crack; Fentanyl	UNITED-STATES; OPIOID USE; OVERDOSE; NALOXONE; ILLICIT; MISUSE; ABUSE; FILM	Background: The opioid overdose crisis is especially pronounced in Maine. The Diversion Alert Program (DAP) was developed to combat illicit drug use and prescription drug diversion by facilitating communication between law enforcement and health care providers with the goal of limiting drug-related harms and criminal behaviors. Our objectives in this report were to analyze 2014-2017 DAP for: (1) trends in drug arrests and, (2) differences in arrests by offense, demographics (sex and age) and by region. Methods: Drug arrests (N = 8193, 31.3% female, age = 33.1 +/- 9.9) reported to the DAP were examined by year, demographics, and location. Results: The most common substances of the 10,064 unique charges reported were heroin (N = 2203, 21.9%), crack/cocaine (N = 945, 16.8%), buprenorphine (N = 812, 8.1%), and oxycodone (N = 747, 7.4%). While the overall number of arrests reported to the DAP declined in 2017, the proportion of arrests involving opioids (heroin, buprenorphine, or fentanyl) and stimulants (cocaine/crack cocaine, or methamphetamine), increased (p<.05). Women had significantly increased involvement in arrests involving sedatives and miscellaneous pharmaceuticals (e.g. gabapentin) while men had an elevation in stimulant arrests. Heroin accounted for a lower percentage of arrests among individuals age >60 (6.6%) relative to young-adults (18-29, 22.3%, p<.0001). Older-adults had significantly more arrests than younger-adults for oxycodone, hydrocodone, and marijuana. Conclusion: Heroin had the most arrests from 2014 to 2017. Buprenorphine, fentanyl and crack/cocaine arrests increased appreciably suggesting that improved treatment is needed to prevent further nonmedical use and overdoses. The Diversion Alert Program provided a unique data source for research, a harm-reduction tool for health care providers, and an informational resource for law enforcement. (C) 2019 Published by Elsevier B.V.	[Simpson, Kevin J.; Moran, Matthew T.; Simoyan, Olapeju M.; Shah, Dipam T.; Piper, Brian J.] Geisinger Commonwealth Sch Med, Scranton, PA 18509 USA; [McCall, Kenneth L.; Nichols, Stephanie D.] Univ New England, Portland, ME 04103 USA; [Herbert, John; Foster, Michelle L.; Desrosiers, Clare] Divers Alert, Houlton, ME 04730 USA; [Simoyan, Olapeju M.] Geisinger Marworth Treatment Ctr, Waverly, PA 18471 USA; [Nichols, Stephanie D.] Maine Med Ctr, Portland, ME 04102 USA; [Nichols, Stephanie D.] Tufts Univ, Medford, MA 02155 USA; [Piper, Brian J.] Ctr Pharm Innovat & Outcomes, Forty Ft, PA 18704 USA	Piper, BJ (reprint author), Geisinger Commonwealth Sch Med, Dept Med Educ, 525 Pine St, Scranton, PA 18510 USA.	psy391@gmail.com		Piper, Brian/0000-0002-2295-445X	Fahs-Beck Fund for Research and Experimentation; Center of Excellence, Health Resources and Services Administration [D34HP31025]; NIEHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [T32 ES007060-31A1]; State of Maine and Eastern Maine Healthcare Services	This study was supported by the Fahs-Beck Fund for Research and Experimentation. DTS was supported by the Center of Excellence, Health Resources and Services Administration (D34HP31025). Software to complete this project was provided by the Husson University School of Pharmacy, the GCSoM Summer Research Immersion Program, and the NIEHS (T32 ES007060-31A1). The Diversion Alert Program was supported by the State of Maine and Eastern Maine Healthcare Services.	Bohnert ASB, 2019, NEW ENGL J MED, V380, P71, DOI 10.1056/NEJMra1802148; Butler SF, 2018, J SUBST ABUSE TREAT, V84, P42, DOI 10.1016/j.jsat.2017.10.010; Collins LK, 2019, PREV MED, V123, P95, DOI 10.1016/j.ypmed.2019.02.017; Dasgupta N, 2013, J MED INTERNET RES, V15, DOI 10.2196/jmir.2810; Davis C.S., 2019, PAIN MED, DOI [10.1093/pm/pnz159inpres, DOI 10.1093/PM/PNZ159INPRES]; Francis P., 2018, THE DAILY NEWS; Haight SC, 2018, MMWR-MORBID MORTAL W, V67, P845, DOI 10.15585/mmwr.mm6731a1; Hoey D., 2018, PORTLAND PRESS HERAL; Huang E, 2017, J LAW BIOSCI, V4, P159, DOI 10.1093/jlb/lsw064; Larance B, 2016, DRUG ALCOHOL REV, V35, P83, DOI 10.1111/dar.12344; Lavonas EJ, 2014, J SUBST ABUSE TREAT, V47, P27, DOI 10.1016/j.jsat.2014.02.003; Lawlor J., 2018, MEDICATION OPIOID US; Lugoboni F, 2019, EUR ADDICT RES, V25, P10, DOI 10.1159/000496112; Marteau D, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-007629; Martin SL, 2016, PREV CHRONIC DIS, V13, DOI 10.5888/pcd13.160229; Mattick RP, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002207.pub3; McCall K, 2016, PHARMACOTHERAPY, V36, P585, DOI 10.1002/phar.1758; Philp M, 2018, DRUG TEST ANAL, V10, P95, DOI 10.1002/dta.2300; Piper BJ, 2018, AM J PREV MED, V54, P652, DOI 10.1016/j.amepre.2018.01.034; Piper BJ, 2018, FORENSIC SCI INT, V285, P65, DOI 10.1016/j.forsciint.2018.01.025; Piper BJ, 2017, PHARMACOTHERAPY, V37, P791, DOI 10.1002/phar.1952; Piper BJ, 2016, J STUD ALCOHOL DRUGS, V77, P556, DOI 10.15288/jsad.2016.77.556; Ramtekkar UP, 2010, J AM ACAD CHILD PSY, V49, P217, DOI 10.1016/j.jaac.2009.11.011; Remes O, 2016, BRAIN BEHAV, V6, DOI 10.1002/brb3.497; Seth P, 2018, MMWR-MORBID MORTAL W, V67, P349, DOI 10.15585/mmwr.mm6712a1; Simpson KJ, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-027117; Smedslund G., 2012, COCHRANE DB SYST REV, V11, P1552; Soh C., 2018, OPIOID SUPPLY LEVELS; Strickland D.M., 2018, J DRUG METAB TOXICOL, V9, P2, DOI [10.4172/2157-7609.1000240, DOI 10.4172/2157-7609.1000240]; U.S. Department of Justice Drug Enforcement Administration, 2016, NAT DRUG THREAT ASS	30	1	1	0	0	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0379-0738	1872-6283		FORENSIC SCI INT	Forensic Sci.Int.	OCT	2019	303								109924	10.1016/j.forsciint.2019.109924			7	Medicine, Legal	Legal Medicine	JN5WF	WOS:000496967700002	31450173				2020-06-30	J	Kim, DD; Patel, A; Sibai, N				Kim, David Daewhan; Patel, Ankit; Sibai, Nabil			Conversion of Intrathecal Opioids to Fentanyl in Chronic Pain Patients With Implantable Pain Pumps: A Retrospective Study	NEUROMODULATION			English	Article						fentanyl; intrathecal pump; chronic pain; conversion; opioid; equianalgesic	CHRONIC NONMALIGNANT PAIN; MORPHINE; HYDROMORPHONE; INFUSION; MANAGEMENT; ANALGESIA	Objectives Conversion between routes such as intravenous (IV), epidural (EP), and intrathecal (IT) routes for morphine is well established. Conversion ratios for IV:EP:IT fentanyl and conversion from IT morphine/hydromorphone to IT fentanyl have been challenging given the lipophilic nature of fentanyl. Our study reviews the outcomes and conversion ratios reached after converting IT opioids from morphine/hydromorphone to fentanyl in patients with IT pumps. Methods After Institutional Review Board approval at Henry Ford Health System, a chart review was performed on all patients who had Synchromed II IT pumps implanted 2009-2016 and were converted from morphine/hydromorphone to fentanyl. The chart review included the initial fentanyl dose and fentanyl IV:IT conversion ratio, eventual IT fentanyl dose, and IV:IT conversion ratio reached to give superior VAS from previous IT opioid. Wilcoxon non-paired signed rank test was used to examine the change in fentanyl dosage and IV:IT conversion ratio. Results The mean IT morphine equivalent dose at initial conversion was 15.8 mg/day, and the mean fentanyl IT starting dose was 0.73 mg/day (SD = 1.37 mg). The mean fentanyl dose at the end of titration was 0.94 mg/day (SD = 2.05 mg) which represented a significant 25.1% mean dose increase (P = 0.004). The initial mean IV:IT fentanyl conversion ratio was 38.7:1 (SD = 33.01), but the mean IV:IT fentanyl conversion ratio at end of titration with better analgesia was significantly lower at 32.9:1 (SD = 27.1) (P = 0.016). Conclusions Given the pharmacokinetics of lipophilic fentanyl compared to hydrophilic morphine/hydromorphone, the current conversion ratio of IV fentanyl to IT fentanyl and IV morphine to IT fentanyl appears to be conservative.	[Kim, David Daewhan; Patel, Ankit; Sibai, Nabil] Henry Ford Hlth Syst, Dept Anesthesiol, Pain Med Div, Detroit, MI USA	Kim, DD (reprint author), Henry Ford Med Ctr Columbus, Pain Clin, 39450 W 12 Mile Rd, Novi, MI 48377 USA.	dkim1@hfhs.org					Anderson VC, 2001, PAIN MED, V2, P287, DOI 10.1046/j.1526-4637.2001.01052.x; [Anonymous], 2003, DUR MORPH SULF USP; COOMBS DW, 1983, JAMA-J AM MED ASSOC, V250, P2336; D'Angelo R, 1998, ANESTHESIOLOGY, V88, P1519, DOI 10.1097/00000542-199806000-00016; de Castro J, 1991, DRUGS REGIONAL OPIOI, P131; Deer TR, 2017, NEUROMODULATION, V20, P96, DOI 10.1111/ner.12538; Du Pen S, 2006, PAIN MED, V7, P10, DOI 10.1111/j.1526-4637.2006.00083.x; DuPen S, 2000, OPIOID CONVERSION CA; DuPen SL, 2003, SEM PAIN MED, V1, P260; Eisenach JC, 2003, ANESTHESIOLOGY, V99, P166, DOI 10.1097/00000542-200307000-00027; GLASS PSA, 1992, ANESTH ANALG, V74, P345; Gorlin AW, 2016, J PAIN RES, V9, P693, DOI 10.2147/JPR.S113216; Hayek SM, 2016, PAIN MED, V17, P1302, DOI 10.1093/pm/pnv058; Kalso E, 1996, PAIN, V67, P443, DOI 10.1016/0304-3959(96)03161-2; Kedlaya Divakara, 2002, Best Pract Res Clin Anaesthesiol, V16, P651, DOI 10.1053/bean.2002.0253; Krames ES, 1996, J PAIN SYMPTOM MANAG, V11, P333, DOI 10.1016/0885-3924(96)00010-3; Loomba V, 2012, CLIN J PAIN, V28, P172, DOI 10.1097/AJP.0b013e31822364a8; LOPER KA, 1990, ANESTH ANALG, V70, P72; Maino P, 2014, REGION ANESTH PAIN M, V39, P434, DOI 10.1097/AAP.0000000000000132; Palmer CM, 1998, ANESTHESIOLOGY, V88, P355, DOI 10.1097/00000542-199802000-00014; Rathmell JP, 2005, ANESTH ANALG, V101, pS30, DOI 10.1213/01.ANE.0000177101.99398.22; Rocco A G, 1989, Hosp J, V5, P93; Ruan X, 2007, AM J PHYS MED REHAB, V86, P1019, DOI 10.1097/PHM.0b013e31815206c8; Sehgal N, 2011, PAIN PHYSICIAN, V14, P249; Southwell Derek G, 2017, Surg Neurol Int, V8, P159, DOI 10.4103/sni.sni_80_17; Sylvester Robert K, 2004, Am J Hosp Palliat Care, V21, P143, DOI 10.1177/104990910402100214; Ummenhofer WC, 2000, ANESTHESIOLOGY, V92, P739, DOI 10.1097/00000542-200003000-00018; Veizi E, 2016, PAIN PRACT, V16, pE94, DOI 10.1111/papr.12443; von Cube B, 1970, Naunyn Schmiedebergs Arch Pharmakol, V265, P455; Warfield C, 1992, CURRENT CONCEPTS CAN, P147	30	0	0	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1094-7159	1525-1403		NEUROMODULATION	Neuromodulation	OCT	2019	22	7					823	826		10.1111/ner.12936			4	Medicine, Research & Experimental; Clinical Neurology	Research & Experimental Medicine; Neurosciences & Neurology	JF2MS	WOS:000491220100018	30840355				2020-06-30	J	Kwon, Y; Hwang, SM; Jang, JS; Ryu, BY; Kang, BY; Kang, SS; Lee, JJ				Kwon, Youngsuk; Hwang, Sung Mi; Jang, Ji Su; Ryu, Byoung Yoon; Kang, Byung Yong; Kang, Sang Soo; Lee, Jae Jun			Effects of a Preoperative Transdermal Fentanyl Patch on Proinflammatory Cytokine and Pain Levels During the Postoperative Period: A Randomized Controlled Trial	SURGICAL LAPAROSCOPY ENDOSCOPY & PERCUTANEOUS TECHNIQUES			English	Article						interleukin-6; interleukin-8; preemptive; surgery; transdermal fentanyl patch	INTERLEUKIN-6; ANALGESIA; SURGERY; MANAGEMENT; ARTHROPLASTY; ASSOCIATION	Objective: The main objectives of this article were to assess the effect of preoperative transdermal fentanyl patch (TFP) on interleukin (IL)-6 and IL-8 levels and pain after laparoscopic cholecystectomy. Materials and Methods: Patients received a TFP (25 mu g/h) (patch group, n=30) or a placebo patch (control group, n=30) applied 14 hours before operation. After surgery, control group received intravenous continuous fentanyl (25 mu g/h) with loading dose (25 mu g). IL-6 and IL-8 levels were measured at admission and 1, 6, 12, 24, and 48 hours postoperatively. Pain score and consumption of rescue analgesic were evaluated too. Results: At 24 hours postoperatively, IL-6 and IL-8 reached a peak and then decreased. The peak IL-6 levels were 21.92(+/- 6.22) and 24.91(+/- 6.81) pg/mL in the patch and control group. The significant differences of IL-6 between groups were shown at 6 and 12 hours postoperatively (P=0.032, 0.0001). There were no significant differences in IL-8 levels and pain score. Conclusions: Preoperative TFP attenuated the increase in IL-6 levels after surgery and provided similar analgesia to continuous fentanyl infusion. Preemptive TFP may have influence on proinflammatory reactions and pain control after surgery.	[Kwon, Youngsuk; Hwang, Sung Mi; Jang, Ji Su; Lee, Jae Jun] Hallym Univ, Chuncheon Sacred Heart Hosp, Coll Med, Dept Anesthesiol & Pain Med, Chunchon, South Korea; [Ryu, Byoung Yoon] Hallym Univ, Chuncheon Sacred Heart Hosp, Coll Med, Dept Gen Surg, Chunchon, South Korea; [Kang, Byung Yong; Kang, Sang Soo] Hallym Univ, Kangdong Sacred Heart Hosp, Coll Med, Dept Anesthesiol & Pain Med, Seoul, South Korea	Hwang, SM (reprint author), Chuncheon Sacred Heart Hosp, Dept Anesthesiol & Pain Med, 77 Sakju Ro, Chuncheon Si 24253, Gangwon Do, South Korea.	h70sm@hallym.or.kr		Kwon, Young Suk/0000-0001-7753-8464			Al-Mazidi S, 2018, PAIN MED, V19, P1058, DOI 10.1093/pm/pnx145; de Oliveira CMB, 2011, REV BRAS ANESTESIOL, V61, P255, DOI 10.1016/S0034-7094(11)70029-0; Beilin B, 2003, ANESTHESIOLOGY, V98, P151, DOI 10.1097/00000542-200301000-00024; Buvanendran A, 2006, ANESTHESIOLOGY, V104, P403, DOI 10.1097/00000542-200603000-00005; Choileain NN, 2006, SURG-J R COLL SURG E, V4, P23, DOI 10.1016/S1479-666X(06)80018-1; CRUICKSHANK AM, 1990, CLIN SCI, V79, P161, DOI 10.1042/cs0790161; CUNHA FQ, 1991, BRIT J PHARMACOL, V104, P765, DOI 10.1111/j.1476-5381.1991.tb12502.x; Edwards RR, 2008, PAIN, V140, P135, DOI 10.1016/j.pain.2008.07.024; Feng Y, 2008, J PAIN, V9, P45, DOI 10.1016/j.jpain.2007.08.003; GOURLAY GK, 1990, PAIN, V40, P21, DOI 10.1016/0304-3959(90)91046-L; Grond S, 2000, CLIN PHARMACOKINET, V38, P59, DOI 10.2165/00003088-200038010-00004; HARADA A, 1994, J LEUKOCYTE BIOL, V56, P559; Hong JY, 2008, REGION ANESTH PAIN M, V33, P44, DOI 10.1016/j.rapm.2007.07.010; Joshi GP, 2017, BRIT J ANAESTH, V119, P720, DOI 10.1093/bja/aex304; Joshi GP, 2014, BEST PRACT RES-CLIN, V28, P191, DOI 10.1016/j.bpa.2014.03.005; Kato M, 1997, J CLIN ANESTH, V9, P293, DOI 10.1016/S0952-8180(97)00006-8; Kharasch ED, 2016, ANESTHESIOLOGY, V124, P960, DOI 10.1097/ALN.0000000000001012; Kharasch ED, 2016, ANESTHESIOLOGY, V124, P10, DOI 10.1097/ALN.0000000000000914; Kissin I, 2000, ANESTHESIOLOGY, V93, P1138, DOI 10.1097/00000542-200010000-00040; Lehmann LJ, 1997, REGION ANESTH, V22, P24, DOI 10.1016/S1098-7339(06)80052-0; Lin E, 2000, SURGERY, V127, P117, DOI 10.1067/msy.2000.101584; Lu CH, 2004, ANESTH ANALG, V99, P1465, DOI 10.1213/01.ANE.0000132974.32249.C8; Merivirta R, 2015, J PAIN RES, V8, P39, DOI 10.2147/JPR.S69511; Merivirta R, 2013, ARTHROSCOPY, V29, P1129, DOI 10.1016/j.arthro.2013.04.018; Minville V, 2008, J CLIN ANESTH, V20, P280, DOI 10.1016/j.jclinane.2007.12.013; Nelson L, 2009, J MED TOXICOL, V5, P230, DOI 10.1007/BF03178274; Partrick DA, 1996, AM J SURG, V172, P425, DOI 10.1016/S0002-9610(96)00252-8; SAKAMOTO K, 1994, CYTOKINE, V6, P181, DOI 10.1016/1043-4666(94)90040-X; Sathitkarnmanee T, 2014, J PAIN RES, V7, P449, DOI 10.2147/JPR.S66741	29	0	0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1530-4515	1534-4908		SURG LAPARO ENDO PER	Surg. Laparosc. Endosc. Pct. Tech.	OCT	2019	29	5					339	343		10.1097/SLE.0000000000000630			5	Surgery	Surgery	JE5PC	WOS:000490743400011	30676542	Green Published			2020-06-30	J	Morikawa, N; Kasahara, Y; Takahashi, Y; Nishikura, K; Nishihara, M				Morikawa, Norimichi; Kasahara, Yoko; Takahashi, Yuko; Nishikura, Kyoko; Nishihara, Masayuki			Risk Factors, for Poor Pain Control after Opioid Switching from Oxycodone Tablet to Fentanyl Patch	BIOLOGICAL & PHARMACEUTICAL BULLETIN			English	Article						oxycodone tablet; fentanyl patch; opioid switching; risk factor; concomitant drugs with a high protein binding rate; retrospective study	PLASMA-PROTEIN BINDING; METASTASES	Pain control becomes poor in some cases after opioid switching from oxycodone tablet (OXC) to fentanyl patch (FP). However, fewer studies on risk factors have been reported. In this study, we surveyed the states of pain control (PC) and opioid administration, patient background, laboratory test values, and concomitant drugs retrospectively in 86 patients switching from OXC to FP between June 2010 and April 2018 in Mazda Hospital and Hiroshima Prefectural Hospital. The subjects were divided into 2 groups based on the median number of days to the initial dose increase after switching to FP. Between the early (<7.5d) and late (>= 7.5d) increase groups, a significant difference was noted in the presence or absence of liver metastasis (LM), concomitant drugs with a high protein binding rate (CDHPBR), and the state of PC before and after switching to FP (p<0.05). Binary logistic regression analysis showed the presence of CDHPBR, absence of LM, and poor PC after switching were risk factors for early dose increase (presence of CDHPBR: odds ratios (OR), 3.30, 95% confidence interval (CI), 1.09-9.98; presence of LM: OR, 0.31, 95% CI, 0.10-0.93; good PC: OR, 0.23, 95% CI, 0.07-0.79, respectively). The initial dose increase after switching to FP was earlier in patients with CDHPBR and/or without LM than those without CDHPBR and with LM (p<0.05, log-rank test). It was suggested that the analgesic effect of FP after switching from OXC is likely to be insufficient in patients treated with CDHPBR and patients without LM.	[Morikawa, Norimichi; Takahashi, Yuko; Nishikura, Kyoko; Nishihara, Masayuki] Mazda Motor Corp, Mazda Hosp, Dept Pharm, 2-15 Aosakiminami, Fuchu, Hiroshima 7358585, Japan; [Kasahara, Yoko] Hiroshima Prefectural Hosp, Dept Pharm, Minami Ku, 1-5-54 Ujinakanda, Hiroshima 7348530, Japan	Morikawa, N (reprint author), Mazda Motor Corp, Mazda Hosp, Dept Pharm, 2-15 Aosakiminami, Fuchu, Hiroshima 7358585, Japan.	morikawa.no@mazda.co.jp					Benet LZ, 2002, CLIN PHARMACOL THER, V71, P115, DOI 10.1067/mcp.2002.121829; Hattori S, 2010, PAIN CLINIC, V31, P342; Kanda Y, 2013, BONE MARROW TRANSPL, V48, P452, DOI 10.1038/bmt.2012.244; Kodama Y., 2013, MEBIO, V30, P67; Kunishima S, 2003, HEPATO-GASTROENTEROL, V50, P1457; LEEN E, 1991, ANN SURG, V214, P599, DOI 10.1097/00000658-199111000-00010; Palkama VJ, 1998, BRIT J ANAESTH, V81, P598, DOI 10.1093/bja/81.4.598; Sakurai H, 2012, MODERN PHYS, V32, P99; Smith DA, 2010, NAT REV DRUG DISCOV, V9, P929, DOI 10.1038/nrd3287; World Health Organization, 1996, CANC PAIN REL, P15	10	0	0	0	2	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0918-6158			BIOL PHARM BULL	Biol. Pharm. Bull.	OCT	2019	42	10					1674	1678		10.1248/bpb.b19-00271			5	Pharmacology & Pharmacy	Pharmacology & Pharmacy	JB9GA	WOS:000488888300009	31582655	Bronze			2020-06-30	J	Bellini, L; De Benedictis, GM				Bellini, Luca; De Benedictis, Giulia Maria			Effect of three opioid-based analgesic protocols on the perioperative autonomic-mediated cardiovascular response in sheep	LABORATORY ANIMALS			English	Article						sheep; methadone; fentanyl; buprenorphine; analgesia; spinal surgery	CONSTANT RATE INFUSION; ANTINOCICEPTIVE ACTIVITY; ORTHOPEDIC-SURGERY; ISOFLURANE; BUPRENORPHINE; TRAMADOL; FENTANYL; METHADONE; MORPHINE; PHARMACOKINETICS	Few reports evaluate the clinical effects of opioids in sheep during experimental surgical procedures. Catecholamine-mediated haemodynamic changes resulting from surgical noxious stimulation are blunted by opioids. The aim of this study was to evaluate the efficacy of three opioid-based analgesic protocols in avoiding a 20% increase in heart rate (HR) and/or mean arterial blood pressure (MAP) during experimental intervertebral disk nucleotomy in sheep. Eighteen female Brogna sheep were anaesthetized with propofol and maintained with a fixed end-tidal isoflurane concentration of 1.5 +/- 0.1%. Sheep were assigned to one of three groups that intravenously received methadone 0.3 mg/kg (group M), fentanyl 2 mu g/kg followed by 10 mu g/kg/h (group F), or buprenorphine 10 mu g/kg and 30 minutes later ketamine 1 mg/kg followed by 5 mg/kg/h (group BK). Intravenous fentanyl at 2 mu g/kg would have been used for rescue analgesia in case HR and/or MAP had increased. During surgery, HR and MAP values did not increase over 20% in all groups. All animals maintained the percentage change between -4 and 7% for both variables; only one sheep in group BK had an increase in MAP superior to 20% after ketamine administration before surgical stimulation. In group M, HR decreased over time and in group BK, MAP tended to increase during surgery. All the opioid-based protocols tested were able to control the cardiovascular response to noxious stimulation in sheep undergoing spinal surgery, although ketamine may have represented a confounding factor.	[Bellini, Luca] Univ Padua, Vet Teaching Hosp, Viale Univ 16, I-35020 Legnaro, PD, Italy; [De Benedictis, Giulia Maria] Univ Padua, Dept Anim Med Prod & Hlth, Legnaro, PD, Italy	Bellini, L (reprint author), Univ Padua, Vet Teaching Hosp, Viale Univ 16, I-35020 Legnaro, PD, Italy.	luca.bellini@unipd.it	Bellini, Luca/P-6957-2018	Bellini, Luca/0000-0002-7145-6115; De Benedictis, Giulia Maria/0000-0002-8422-6829			Ahern BJ, 2009, AM J VET RES, V70, P418, DOI 10.2460/ajvr.70.3.418; Barletta M, 2016, AM J VET RES, V77, P119, DOI 10.2460/ajvr.77.2.119; Bellini L, 2017, J FELINE MED SURG, V19, P110, DOI 10.1177/1098612X15615655; Borges LPB, 2016, VET ANAESTH ANALG, V43, P549, DOI 10.1111/vaa.12339; Boscan P, 2005, AM J VET RES, V66, P2122, DOI 10.2460/ajvr.2005.66.2122; Christou C, 2015, RES VET SCI, V100, P252, DOI 10.1016/j.rvsc.2015.04.006; Coulter CA, 2009, LAB ANIM-UK, V43, P232, DOI 10.1258/la.2008.008021; De Benedictis GM, 2017, VET ANAESTH ANALG, V44, P1245, DOI 10.1016/j.vaa.2016.11.005; de Carvalho LL, 2016, VET ANAESTH ANALG, V43, P179, DOI 10.1111/vaa.12296; DeRossi R, 2015, AUST VET J, V93, P164, DOI 10.1111/avj.12313; Docquier MA, 2003, ANESTH ANALG, V97, P1033, DOI 10.1213/01.ANE.0000078587.51622.D0; Funes FJ, 2015, VET ANAESTH ANALG, V42, P157, DOI 10.1111/vaa.12216; Gorlin Andrew W, 2016, J Anaesthesiol Clin Pharmacol, V32, P160, DOI 10.4103/0970-9185.182085; Kastner SB, 2006, VET ANAESTH ANALG, V33, P8, DOI 10.1111/j.1467-2995.2005.00230.x; LAUBIE M, 1979, EUR J PHARMACOL, V59, P287, DOI 10.1016/0014-2999(79)90292-9; Nishimura Lilian Toshiko, 2017, Vet Med Int, V2017, P7507616, DOI 10.1155/2017/7507616; NOLAN A, 1987, BRIT J PHARMACOL, V92, P527, DOI 10.1111/j.1476-5381.1987.tb11353.x; Otto KA, 2003, RES VET SCI, V75, P103, DOI 10.1016/S0034-5288(03)00077-8; Raske TG, 2010, LAB ANIMAL, V39, P76, DOI 10.1038/laban0310-76; ROIZEN MF, 1981, ANESTHESIOLOGY, V54, P390, DOI 10.1097/00000542-198105000-00008; Sano T, 2006, VET ANAESTH ANALG, V33, P266, DOI 10.1111/j.1467-2995.2005.00266.x; Schauvliege S, 2006, LAB ANIM-UK, V40, P341, DOI 10.1258/002367706778476406; Schubert A, 1997, J CLIN ANESTH, V9, P52, DOI 10.1016/S0952-8180(96)00208-5; WATERMAN AE, 1991, J VET PHARMACOL THER, V14, P230, DOI 10.1111/j.1365-2885.1991.tb00831.x	24	0	0	2	3	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0023-6772	1758-1117		LAB ANIM-UK	Lab. Anim.	OCT	2019	53	5					491	499		10.1177/0023677218815203			9	Veterinary Sciences; Zoology	Veterinary Sciences; Zoology	JA5VS	WOS:000487911500006	30482087				2020-06-30	J	Hui, D; Bruera, E				Hui, David; Bruera, Eduardo			Authors' Response to: Prophylactic Fentanyl Sublingual Spray for Episodic Exertional Dyspnea in Cancer Patients: A Pilot Double-Blind Randomized Controlled Trial	JOURNAL OF PAIN AND SYMPTOM MANAGEMENT			English	Letter									[Hui, David; Bruera, Eduardo] Univ Texas MD Anderson Canc Ctr, Dept Palliat Care Rehabil & Integrat Med, Houston, TX 77030 USA	Hui, D (reprint author), Univ Texas MD Anderson Canc Ctr, Dept Palliat Care Rehabil & Integrat Med, Houston, TX 77030 USA.	dhui@mdanderson.org					Pinna MAC, 2015, AM J HOSP PALLIAT ME, V32, P298, DOI 10.1177/1049909113513063; Currow DC, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2014-006818; Hui D, 2019, J PAIN SYMPTOM MANAG; Hui D, 2017, J PAIN SYMPTOM MANAG, V54, P798, DOI 10.1016/j.jpainsymman.2017.08.001; Hui D, 2016, J PAIN SYMPTOM MANAG, V52, P459, DOI 10.1016/j.jpainsymman.2016.05.013; Hui D, 2014, J PAIN SYMPTOM MANAG, V47, P209, DOI 10.1016/j.jpainsymman.2013.03.017; Parikh N, 2013, CLIN DRUG INVEST, V33, P391, DOI 10.1007/s40261-013-0079-8; Taylor DR, 2013, CLIN PHARMACOL-ADV A, V5, P131, DOI 10.2147/CPAA.S26649	8	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0885-3924	1873-6513		J PAIN SYMPTOM MANAG	J. Pain Symptom Manage.	OCT	2019	58	4					E17	E18		10.1016/j.jpainsymman.2019.07.019			3	Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology	Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology	IY1ZL	WOS:000486190100009	31356961				2020-06-30	J	Kako, J; Kajiwara, K; Noto, H; Oosono, Y; Kobayashi, M				Kako, Jun; Kajiwara, Kohei; Noto, Hiroko; Oosono, Yasufumi; Kobayashi, Masamitsu			Response to "Prophylactic Fentanyl Sublingual Spray for Episodic Exertional Dyspnea in Cancer Patients: A Pilot Double-Blind Randomized Controlled Trial''	JOURNAL OF PAIN AND SYMPTOM MANAGEMENT			English	Letter									[Kako, Jun; Kajiwara, Kohei] Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Div Nursing Sci, Minami Ku, Hiroshima, Japan; [Noto, Hiroko] Kyushu Univ, Grad Sch Med Sci, Dept Hlth Sci, Fukuoka, Fukuoka, Japan; [Oosono, Yasufumi; Kobayashi, Masamitsu] Natl Def Med Coll, Minist Def, Community Hlth Nursing, Tokorozawa, Saitama, Japan	Kako, J (reprint author), Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Div Nursing Sci, Minami Ku, Hiroshima, Japan.	jkako@hiroshima-u.ac.jp	; Kajiwara, Kohei/D-3711-2019	Kako, Jun/0000-0001-6875-6275; Kajiwara, Kohei/0000-0001-5470-2209; Kobayashi, Masamitsu/0000-0001-8861-1778			Hui D, 2019, J PAIN SYMPTOM MANAG, V58, P605, DOI 10.1016/j.jpainsymman.2019.06.024; Yamaguchi T, 2019, J PAIN SYMPTOM MANAG, V58, P672, DOI 10.1016/j.jpainsymman.2019.06.006	2	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0885-3924	1873-6513		J PAIN SYMPTOM MANAG	J. Pain Symptom Manage.	OCT	2019	58	4					E16	E17		10.1016/j.jpainsymman.2019.07.020			3	Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology	Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology	IY1ZL	WOS:000486190100008	31356962				2020-06-30	J	Triarico, S; Capozza, MA; Mastrangelo, S; Attina, G; Maurizi, P; Ruggiero, A				Triarico, Silvia; Capozza, Michele Antonio; Mastrangelo, Stefano; Attina, Giorgio; Maurizi, Palma; Ruggiero, Antonio			Intranasal therapy with opioids for children and adolescents with cancer: results from clinical studies	SUPPORTIVE CARE IN CANCER			English	Review						Intranasal; Opioids; Cancer pain; Pediatric patients; Fentanyl	DOUBLE-BLIND; MORPHINE-CHITOSAN; BREAKTHROUGH PAIN; NASAL SPRAY; MU-G; PHARMACOKINETICS; FENTANYL; EFFICACY; SUFENTANIL; MANAGEMENT	Opioids are essential for the treatment of pain, which is a serious symptom for children and adolescents affected by cancer. Intranasal opioids may be very useful for the treatment of breakthrough pain in children and adolescents with cancer, for their little invasiveness, ease of administration, rapid onset of action, and high bioavailability. Intranasal drug delivery may be influenced by anatomical and physiological factors (nasal mucosa absorption area, mucociliary clearance, enzymatic activity, anatomical anomalies, chronic or inflammatory alterations of nasal mucosa), drug-related factors (molecular weight, solubility), and delivery device. Fentanyl is a lipophilic opioid commonly proposed for intranasal use among pediatric patients, but no studies have been conducted yet about intranasal use of other available opioids for management of pediatric cancer pain. In this review, we analyze several elements which may influence absorption of intranasal opioids in children and adolescents, with a focus on pharmacokinetics and therapeutic aspects of each opioid currently available for intranasal use.	[Triarico, Silvia; Capozza, Michele Antonio; Mastrangelo, Stefano; Attina, Giorgio; Maurizi, Palma; Ruggiero, Antonio] Catholic Univ Sacred Hearth, Fdn A Gemelli, Pediat Oncol Unit, Largo A Gemelli 8, I-00168 Rome, Italy	Triarico, S (reprint author), Catholic Univ Sacred Hearth, Fdn A Gemelli, Pediat Oncol Unit, Largo A Gemelli 8, I-00168 Rome, Italy.	silviatriarico@libero.it	Ruggiero, Antonio/M-7849-2018; Mastrangelo, Stefano/AAC-1153-2019	Ruggiero, Antonio/0000-0002-6052-3511; Mastrangelo, Stefano/0000-0002-3305-6014	Fondazione per l'Oncologia Pediatrica	This work was supported by Fondazione per l'Oncologia Pediatrica.	Arora P, 2002, DRUG DISCOV TODAY, V7, P967, DOI 10.1016/S1359-6446(02)02452-2; Barton ED, 2005, J EMERG MED, V29, P265, DOI 10.1016/j.jemermed.2005.03.007; Borland ML, 2005, BURNS, V31, P831, DOI 10.1016/j.burns.2005.05.001; Christrup LL, 2008, CLIN THER, V30, P469, DOI 10.1016/j.clinthera.2008.03.001; Coda BA, 2003, ANESTH ANALG, V97, P117, DOI 10.1213/01.ANE.0000066311.40978.4F; Costantino HR, 2007, INT J PHARMACEUT, V337, P1, DOI 10.1016/j.ijpharm.2007.03.025; Del Pizzo J, 2014, PEDIATR EMERG CARE, V30, P496, DOI 10.1097/PEC.0000000000000171; Dowling J, 2008, THER DRUG MONIT, V30, P490, DOI 10.1097/FTD.0b013e3181816214; Fisher A, 2010, INT J CLIN PHARM TH, V48, P860; Fisher A, 2010, INT J CLIN PHARM TH, V48, P138; Hansen MS, 2012, ACTA ANAESTH SCAND, V56, P407, DOI 10.1111/j.1399-6576.2011.02613.x; Illum L, 2002, J PHARMACOL EXP THER, V301, P391, DOI 10.1124/jpet.301.1.391; Jiang LM, 2010, DRUG DEV IND PHARM, V36, P323, DOI [10.3109/03639040903170750, 10.1080/03639040903170750]; Kaasa Stein, 2010, J Opioid Manag, V6, P17; KARL HW, 1992, ANESTHESIOLOGY, V76, P209, DOI 10.1097/00000542-199202000-00009; Kress HG, 2009, CLIN THER, V31, P1177, DOI 10.1016/j.clinthera.2009.05.022; Kurkov SV, 2013, INT J PHARMACEUT, V453, P167, DOI 10.1016/j.ijpharm.2012.06.055; LEOW KP, 1992, THER DRUG MONIT, V14, P479, DOI 10.1097/00007691-199212000-00008; Lofwall MR, 2012, J CLIN PHARMACOL, V52, P600, DOI 10.1177/0091270011401620; Lundeberg S, 2011, PEDIATR ANESTH, V21, P274, DOI 10.1111/j.1460-9592.2010.03411.x; Mercadante S, 2004, PALLIATIVE MED, V18, P654, DOI 10.1191/0269216304pm945rr; Mercadante S, 2016, PAIN, V157, P2657, DOI 10.1097/j.pain.0000000000000721; MORRISON EE, 1990, J COMP NEUROL, V297, P1, DOI 10.1002/cne.902970102; Mudd S, 2011, J PEDIATR HEALTH CAR, V25, P316, DOI 10.1016/j.pedhc.2010.04.011; Murphy A, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009942.pub2; Nave R, 2009, 6 C EUR FED IASP CHA; NEWMAN S P, 1987, Rhinology (Utrecht), V25, P77; Nielsen BN, 2014, PEDIATR ANESTH, V24, P170, DOI 10.1111/pan.12268; Pandey RK, 2011, J CLIN PEDIATR DENT, V36, P79, DOI 10.17796/jcpd.36.1.1774746504g28656; Pavis H, 2002, J PAIN SYMPTOM MANAG, V24, P598, DOI 10.1016/S0885-3924(02)00522-5; Ruggiero A, 2013, PEDIATR BLOOD CANCER, V60, P433, DOI 10.1002/pbc.24332; Salib RJ, 2008, CLIN EXP ALLERGY, V38, P393, DOI 10.1111/j.1365-2222.2007.02926.x; Stoker DG, 2008, PAIN MED, V9, P3, DOI 10.1111/j.1526-4637.2007.00300.x; Takala A, 1997, ACTA ANAESTH SCAND, V41, P309, DOI 10.1111/j.1399-6576.1997.tb04684.x; Tong XW, 2016, COMPUT BIOL MED, V77, P40, DOI 10.1016/j.compbiomed.2016.08.002; Vanky E, 2017, ACTA ANAESTH SCAND, V61, P636, DOI 10.1111/aas.12898; Verghese ST, 2008, ANESTH ANALG, V107, P1176, DOI 10.1213/ane.0b013e3181838e95; Wermeling DP, 2010, J PAIN, V11, P24, DOI 10.1016/j.jpain.2009.05.002; WESTERLING D, 1995, THER DRUG MONIT, V17, P287, DOI 10.1097/00007691-199506000-00013; Wolfe TR, 2010, PEDIATRICS, V126, P532, DOI 10.1542/peds.2010-0616; Zedie N, 1996, CLIN PHARMACOL THER, V59, P341, DOI 10.1016/S0009-9236(96)80012-9; Zhang XL, 2005, DRUG METAB DISPOS, V33, P1423, DOI 10.1124/dmd.105.005769	42	0	0	1	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0941-4355	1433-7339		SUPPORT CARE CANCER	Support. Care Cancer	OCT	2019	27	10					3639	3645		10.1007/s00520-019-04854-6			7	Oncology; Health Care Sciences & Services; Rehabilitation	Oncology; Health Care Sciences & Services; Rehabilitation	IW9OO	WOS:000485323200002	31154533				2020-06-30	J	Abrahao, A; Meng, Y; Llinas, M; Huang, YX; Hamani, C; Mainprize, T; Aubert, I; Heyn, C; Black, SE; Hynynen, K; Lipsman, N; Zinman, L				Abrahao, Agessandro; Meng, Ying; Llinas, Maheleth; Huang, Yuexi; Hamani, Clement; Mainprize, Todd; Aubert, Isabelle; Heyn, Chinthaka; Black, Sandra E.; Hynynen, Kullervo; Lipsman, Nir; Zinman, Lorne			First-in-human trial of blood-brain barrier opening in amyotrophic lateral sclerosis using MR-guided focused ultrasound	NATURE COMMUNICATIONS			English	Article							SPINAL CORD BARRIER; TARGETED DELIVERY; ANTIBODY DELIVERY; PLAQUE REDUCTION; MODEL; DISRUPTION; THERAPY; SOD1; MICE; ACTIVATION	MR-guided focused ultrasound (MRgFUS) is an emerging technology that can accurately and transiently permeabilize the blood-brain barrier (BBB) for targeted drug delivery to the central nervous system. We conducted a single-arm, first-in-human trial to investigate the safety and feasibility of MRgFUS-induced BBB opening in eloquent primary motor cortex in four volunteers with amyotrophic lateral sclerosis (ALS). Here, we show successful BBB opening using MRgFUS as demonstrated by gadolinium leakage at the target site immediately after sonication in all subjects, which normalized 24 hours later. The procedure was well-tolerated with no serious clinical, radiologic or electroencephalographic adverse events. This study demonstrates that non-invasive BBB permeabilization over the motor cortex using MRgFUS is safe, feasible, and reversible in ALS subjects. In future, MRgFUS can be coupled with promising therapeutics providing a targeted delivery platform in ALS.	[Abrahao, Agessandro; Black, Sandra E.; Zinman, Lorne] Univ Toronto, Sunnybrook Hlth Sci Ctr, Dept Med, Div Neurol, Toronto, ON M4N 3M5, Canada; [Abrahao, Agessandro; Meng, Ying; Hamani, Clement; Aubert, Isabelle; Black, Sandra E.; Lipsman, Nir; Zinman, Lorne] Univ Toronto, Sunnybrook Hlth Sci Ctr, Sunnybrook Res Inst, Hurvitz Brain Sci Res Program, Toronto, ON M4N 3M5, Canada; [Abrahao, Agessandro; Meng, Ying; Llinas, Maheleth; Hamani, Clement; Lipsman, Nir] Sunnybrook Res Inst, Harquail Ctr Neuromodulat, Toronto, ON M4N 3M5, Canada; [Meng, Ying; Hamani, Clement; Mainprize, Todd; Lipsman, Nir] Univ Toronto, Sunnybrook Hlth Sci Ctr, Div Neurosurg, Toronto, ON M4N 3M5, Canada; [Llinas, Maheleth; Huang, Yuexi; Black, Sandra E.; Hynynen, Kullervo] Univ Toronto, Sunnybrook Hlth Sci Ctr, Sunnybrook Res Inst, Toronto, ON M4N 3M5, Canada; [Aubert, Isabelle] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5S 3H7, Canada; [Heyn, Chinthaka] Univ Toronto, Sunnybrook Hlth Sci Ctr, Dept Med Imaging, Toronto, ON M4N 3M5, Canada; [Heyn, Chinthaka; Hynynen, Kullervo] Univ Toronto, Sunnybrook Hlth Sci Ctr, Sunnybrook Res Inst, Odette Canc Res, Toronto, ON M4N 3M5, Canada; [Black, Sandra E.; Hynynen, Kullervo] Univ Toronto, Inst Biomat & Biomed Engn, Toronto, ON M5S 3H7, Canada; [Hynynen, Kullervo] Univ Toronto, Dept Med Biophys, Toronto, ON M5S 3H7, Canada	Abrahao, A (reprint author), Univ Toronto, Sunnybrook Hlth Sci Ctr, Dept Med, Div Neurol, Toronto, ON M4N 3M5, Canada.; Abrahao, A (reprint author), Univ Toronto, Sunnybrook Hlth Sci Ctr, Sunnybrook Res Inst, Hurvitz Brain Sci Res Program, Toronto, ON M4N 3M5, Canada.; Abrahao, A (reprint author), Sunnybrook Res Inst, Harquail Ctr Neuromodulat, Toronto, ON M4N 3M5, Canada.	agessandro.abrahao@sunnybrook.ca	Aubert, Isabelle/AAG-4001-2019	Aubert, Isabelle/0000-0001-5163-9961	ALS Society of Canada	This investigator-initiated study was funded by an ALS Society of Canada peer-reviewed grant and generosity of philanthropic gifts to the Sunnybrook Foundation by the Temerty, Stock, Lechem and Harquail families. The authors are grateful to InSightec (R) Ltd (Israel) for the regulatory and technical sponsorship throughout the study. Both InSightec (R) and the ALS Society of Canada had no role in study design, data collection, analysis, interpretation or reporting. The authors also would like to thank Ruby Endre and Garry Detzler for their technical support in the study. N.L. gratefully acknowledge the philanthropic support provided through the Sunnybrook Foundation and the Harquail Centre for Neuromodulation. Finally, we are grateful to the patients and their families for their involvement and contributions.	Albrecht DS, 2016, ACS CHEM NEUROSCI, V7, P470, DOI 10.1021/acschemneuro.6b00056; Alecou T, 2017, J ULTRAS MED, V36, P2257, DOI 10.1002/jum.14256; Alkins R, 2016, NEURO-ONCOLOGY, V18, P974, DOI 10.1093/neuonc/nov318; Alkins R, 2013, CANCER RES, V73, P1892, DOI 10.1158/0008-5472.CAN-12-2609; Alli S, 2018, J CONTROL RELEASE, V281, P29, DOI 10.1016/j.jconrel.2018.05.005; Boado RJ, 2011, MOL PHARMACEUT, V8, P1342, DOI 10.1021/mp200136x; Brooks BR, 2000, AMYOTROPH LATERAL SC, V1, P293, DOI 10.1080/146608200300079536; Burgess A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027877; Carpentier A, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf6086; Coluccia D, 2018, NANOMED-NANOTECHNOL, V14, P1137, DOI 10.1016/j.nano.2018.01.021; Dadon-Nachum M, 2011, J MOL NEUROSCI, V43, P470, DOI 10.1007/s12031-010-9467-1; Eisen A, 2017, J NEUROL NEUROSUR PS, V88, P917, DOI 10.1136/jnnp-2017-315573; Elias WJ, 2016, NEW ENGL J MED, V375, P730, DOI 10.1056/NEJMoa1600159; Fletcher SMP, 2018, IEEE T ULTRASON FERR, V65, P2322, DOI 10.1109/TUFFC.2018.2872171; Garbuzova-Davis S, 2007, BRAIN RES, V1157, P126, DOI 10.1016/j.brainres.2007.04.044; Garbuzova-Davis S, 2016, EXPERT REV NEUROTHER, V16, P1397, DOI 10.1080/14737175.2016.1207530; Garbuzova-Davis S, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00021; Gros-Louis F, 2010, J NEUROCHEM, V113, P1188, DOI 10.1111/j.1471-4159.2010.06683.x; Handley EE, 2017, CEREB CORTEX, V27, P3630, DOI 10.1093/cercor/bhw185; Huang YX, 2017, RADIOLOGY, V282, P123, DOI 10.1148/radiol.2016152154; Hynynen K, 1998, ULTRASOUND MED BIOL, V24, P275, DOI 10.1016/S0301-5629(97)00269-X; Hynynen K, 2001, RADIOLOGY, V220, P640, DOI 10.1148/radiol.2202001804; Idbaih A, 2019, CLIN CANCER RES, V25, P3793, DOI 10.1158/1078-0432.CCR-18-3643; Jablonski MR, 2014, ANN CLIN TRANSL NEUR, V1, P996, DOI 10.1002/acn3.141; Jordao JF, 2013, EXP NEUROL, V248, P16, DOI 10.1016/j.expneurol.2013.05.008; Jordao JF, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010549; Kaufmann P, 2007, AMYOTROPH LATERAL SC, V8, P42, DOI 10.1080/17482960600888156; Kobus T, 2016, J CONTROL RELEASE, V238, P281, DOI 10.1016/j.jconrel.2016.08.001; Konrad C, 2002, EXP BRAIN RES, V143, P51, DOI 10.1007/s00221-001-0981-9; Kovacs ZI, 2017, P NATL ACAD SCI USA, V114, pE75, DOI 10.1073/pnas.1614777114; Lipsman N, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04529-6; Liu HL, 2016, RADIOLOGY, V281, P99, DOI 10.1148/radiol.2016152444; Lule D, 2007, NEUROREHAB NEURAL RE, V21, P518, DOI 10.1177/1545968307300698; Mainprize T, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-36340-0; Martinez HR, 2009, CYTOTHERAPY, V11, P26, DOI 10.1080/14653240802644651; McDannold N, 2005, ULTRASOUND MED BIOL, V31, P1527, DOI 10.1016/j.ultrasmedbio.2005.07.010; McDannold N, 2012, CANCER RES, V72, P3652, DOI 10.1158/0008-5472.CAN-12-0128; Menon P, 2015, CLIN NEUROPHYSIOL, V126, P803, DOI 10.1016/j.clinph.2014.04.023; Ng MC, 2008, J MAGN RESON IMAGING, V27, P8, DOI 10.1002/jmri.21217; Nisbet RM, 2017, BRAIN, V140, P1220, DOI 10.1093/brain/awx052; Noroozian Zeinab, 2019, Methods Mol Biol, V1950, P177, DOI 10.1007/978-1-4939-9139-6_10; O'Reilly MA, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-27335-y; O'Reilly MA, 2017, THERANOSTICS, V7, P3573, DOI 10.7150/thno.20621; Payne AH, 2017, NEURAL REGEN RES, V12, P2045, DOI 10.4103/1673-5374.221162; Reuter M, 2012, NEUROIMAGE, V61, P1402, DOI 10.1016/j.neuroimage.2012.02.084; Silburt J, 2017, P NATL ACAD SCI USA, V114, pE6735, DOI 10.1073/pnas.1710761114; Stanton BR, 2007, J NEUROL, V254, P1260, DOI 10.1007/s00415-006-0513-4; Stoica L, 2016, ANN NEUROL, V79, P687, DOI 10.1002/ana.24618; Thevenot E, 2012, HUM GENE THER, V23, P1144, DOI 10.1089/hum.2012.013; Thomsen GM, 2018, STEM CELLS, V36, P1122, DOI 10.1002/stem.2825; Thomsen GM, 2014, J NEUROSCI, V34, P15587, DOI 10.1523/JNEUROSCI.2037-14.2014; Thonhoff JR, 2018, CURR OPIN NEUROL, V31, P635, DOI 10.1097/WCO.0000000000000599; Urushitani M, 2007, P NATL ACAD SCI USA, V104, P2495, DOI 10.1073/pnas.0606201104; Wang HY, 2014, HUM MOL GENET, V23, P668, DOI 10.1093/hmg/ddt454; Weber-Adrian D, 2015, GENE THER, V22, P568, DOI 10.1038/gt.2015.25	55	10	10	4	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2041-1723			NAT COMMUN	Nat. Commun.	SEP 26	2019	10								4373	10.1038/s41467-019-12426-9			9	Multidisciplinary Sciences	Science & Technology - Other Topics	JB0FR	WOS:000488227700002	31558719	DOAJ Gold, Green Published			2020-06-30	J	Shende, C; Brouillette, C; Farquharson, S				Shende, Chetan; Brouillette, Carl; Farquharson, Stuart			Detection of codeine and fentanyl in saliva, blood plasma and whole blood in 5-minutes using a SERS flow-separation strip	ANALYST			English	Article							RAMAN-SPECTROSCOPY; UNITED-STATES; DRUGS; CARFENTANIL; SCATTERING; CASUALTIES; MOSCOW; ABUSE	A simple-to-use device to measure drugs in saliva, blood plasma, and whole blood for point-of-care analysis and treatment of overdose patients has been investigated. A rudimentary flow strip has been developed to separate opioids from these biofluids for analysis by surface-enhanced Raman spectroscopy (SERS). The strips are based on lateral flow assays, in which the antibodies have been substituted by SERS-active pads for detection. Samples of codeine and fentanyl, artificially added to these biofluids, were measured using the strips by a field-usable Raman spectrometer. We report measurement of these drugs in these biofluids from 0.5 to 5 mu g mL(-1) in 5 minutes. Calculated limits of detection for the spectra suggest that these drugs could be measured at 5 to 20 ng mL(-1) with improvements in the strips' separation capability.	[Shende, Chetan; Brouillette, Carl; Farquharson, Stuart] Real Time Analyzers Inc, 362 Ind Pk Rd,Unit 8, Middletown, CT 06457 USA	Farquharson, S (reprint author), Real Time Analyzers Inc, 362 Ind Pk Rd,Unit 8, Middletown, CT 06457 USA.	stu@rta.biz			Department of Defense, Chemical and Biological Defense [W911QY19C0008]; National Institute of Health, National Institute of Drug AbuseUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [2R44DA032178-02]	The authors are grateful for the support by the Department of Defense, Chemical and Biological Defense (W911QY19C0008) and the National Institute of Health, National Institute of Drug Abuse (2R44DA032178-02).	[Anonymous], 1999, VAL AN PROC METH; [Anonymous], 2019, STAFF REPORTER  0131; Coucke LD, 2016, J ANAL TOXICOL, V40, P148, DOI 10.1093/jat/bkv123; Dana Kathryn, 2015, J Anal Bioanal Tech, V6, P1; de Veij M, 2008, J PHARMACEUT BIOMED, V46, P303, DOI 10.1016/j.jpba.2007.10.021; Dollish F., 1974, CHARACTERISTIC RAMAN, P284; Donahue M., 2011, SPECTROSCOPY; Drummer H., 2006, CLIN BIOCHEM REV, V27, P147; Farquharson S, 2005, J RAMAN SPECTROSC, V36, P208, DOI 10.1002/jrs.1277; Farquharson S, 2008, U.S. Patent, Patent No. [7,393,691, 7393691]; Farquharson S., 2017, J ANAL BIOANAL TECH, V8, P368, DOI 10.4172/2155-9872.100036828944090; Farquharson S., J ANAL BIOANAL TECH; Farquharson S., 2019, FRONTIERCHEM; Farquharson Stuart, 2011, Pharmaceutics, V3, P425, DOI 10.3390/pharmaceutics3030425; Frank RG, 2017, NEW ENGL J MED, V376, P605, DOI 10.1056/NEJMp1615145; Fuguet E, 2008, ELECTROPHORESIS, V29, P2841, DOI 10.1002/elps.200700869; Glennon RA, 2014, ADV PHARMACOL, V69, P581, DOI 10.1016/B978-0-12-420118-7.00015-9; Gorodeizky C., 1965, CLIN PHARMACOL THER, V7, P731; Gossel T., 1994, PRINCIPLES CLIN TOXI, P298; HALL CE, 1959, J BIOPHYS BIOCHEM CY, V5, P11, DOI 10.1083/jcb.5.1.11; Hand S., 2017, XTALKS          0801; Hargreaves MD, 2008, J RAMAN SPECTROSC, V39, P873, DOI 10.1002/jrs.1926; Inscore F, 2011, APPL SPECTROSC, V65, P1004, DOI 10.1366/11-06310; Izake EL, 2010, FORENSIC SCI INT, V202, P1, DOI 10.1016/j.forsciint.2010.03.020; JEANMAIRE DL, 1977, J ELECTROANAL CHEM, V84, P1, DOI 10.1016/S0022-0728(77)80224-6; Jones CM, 2018, JAMA-J AM MED ASSOC, V319, P1819, DOI 10.1001/jama.2018.2844; Klapheke Martin, 2017, MedEdPORTAL, V13, P10621, DOI 10.15766/mep_2374-8265.10621; KORSRUD FR, 1982, J HISTOCHEM CYTOCHEM, V30, P657, DOI 10.1177/30.7.6179983; Leonard J, 2017, J RAMAN SPECTROSC, V48, P1323, DOI 10.1002/jrs.5220; Mildh LH, 2001, ANESTH ANALG, V93, P939, DOI 10.1097/00000539-200110000-00028; Mostowtt T, 2017, TALANTA, V164, P396, DOI 10.1016/j.talanta.2016.11.002; Narcotic Drugs, 2015, NAR DRUGS 2014, P21; Rana V, 2011, J FORENSIC SCI, V56, P200, DOI 10.1111/j.1556-4029.2010.01562.x; Riches JR, 2012, J ANAL TOXICOL, V36, P647, DOI 10.1093/jat/bks078; Santillan JD, 2007, PROC SPIE, V6540, DOI 10.1117/12.723067; Schiller EY, 2019, OPIOID OVERDOSE; Shende C, 2019, MOLECULES, V24, DOI 10.3390/molecules24142578; Subaihi A, 2017, ANALYST, V142, P1099, DOI [10.1039/c7an00193b, 10.1039/C7AN00193B]; Vivolo-Kantor AM, 2018, MMWR-MORBID MORTAL W, V67, P279, DOI 10.15585/mmwr.mm6709e1; Wax PM, 2003, ANN EMERG MED, V41, P700, DOI 10.1067/mem.2003.148; WEAVER MJ, 1985, J CHEM PHYS, V82, P4867, DOI 10.1063/1.448657; West MJ, 2009, SPECTROCHIM ACTA A, V71, P1984, DOI 10.1016/j.saa.2008.07.024; Weyermann C, 2011, FORENSIC SCI INT, V209, P21, DOI 10.1016/j.forsciint.2010.11.027; White ND, 2019, AM J LIFESTYLE MED, V13, P33, DOI 10.1177/1559827618803874; WOODARD HQ, 1986, BRIT J RADIOL, V59, P1209, DOI 10.1259/0007-1285-59-708-1209	45	1	1	26	48	ROYAL SOC CHEMISTRY	CAMBRIDGE	THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND	0003-2654	1364-5528		ANALYST	Analyst	SEP 21	2019	144	18					5449	5454		10.1039/c9an01087d			6	Chemistry, Analytical	Chemistry	IW4UJ	WOS:000484974900011	31424465				2020-06-30	J	Chae, D; Kim, SY; Song, Y; Baek, W; Shin, H; Park, K; Han, DW				Chae, D.; Kim, S. Y.; Song, Y.; Baek, W.; Shin, H.; Park, K.; Han, D. W.			Dynamic predictive model for postoperative nausea and vomiting for intravenous fentanyl patient-controlled analgesia	ANAESTHESIA			English	Article						fentanyl; intravenous patient-controlled analgesia; postoperative nausea and vomiting; predictive model	RANDOMIZED CONTROLLED TRIAL; SIMPLIFIED RISK SCORE; VARIABLE IMPORTANCE; MANAGEMENT; ISOFLURANE; ANESTHESIA; IMPACT; PAIN	Postoperative nausea and vomiting is the most common side-effect of opioid-based intravenous patient-controlled analgesia. Apfel's simplified risk score is popular but it has some limitations. We developed and validated a dynamic predictive model for nausea or vomiting up to 48 postoperative hours, available as an online web application. Fentanyl was used by 22,144 adult patients for analgesia after non-cardiac surgery under general anaesthesia: we randomly divided them into development (80%) and validation (20%) cohorts, repeated 100 times. We used linear discriminant analysis to select variables for multivariate logistic regression. The incidences of postoperative nausea or vomiting were: 0-48 h, 5691/22,144 (26%); 0-6 h, 2749/22,144 (12%); 6-12 h, 2687/22,144 (12%); 12-18 h, 2624/22,144 (12%); 18-24 h, 1884/22,144 (9%); and 24-48 h, 1082/22,144 (5%). The median (95%CI) area under the receiver operating characteristic curve was 0.72 (0.71-0.73) up to 48 postoperative hours compared with 0.65 (0.64-0.66) for the Apfel model, p < 0.001. The equivalent areas for 0-6 h, 6-12 h, 12-18 h, 18-24 h and 24-48 h were: 0.70 (0.69-0.72); 0.71 (0.69-0.73); 0.69 (0.68-0.71); 0.70 (0.67-0.72); and 0.69 (0.66-0.71), respectively. Our web application allows clinicians to calculate incidences of nausea and vomiting in patients receiving intravenous fentanyl for patient-controlled analgesia.	[Chae, D.; Kim, S. Y.; Baek, W.; Shin, H.] Yonsei Univ, Coll Med, Anesthesia & Pain Res Inst, Dept Anesthesiol & Pain Med,Severance Hosp, Seoul, South Korea; [Park, K.] Yonsei Univ, Dept Anesthesiol & Pain Med, Anesthesia & Pain Res Inst, Coll Med,Severance Hosp,Dept Pharmacol, Seoul, South Korea; [Song, Y.; Han, D. W.] Yonsei Univ, Gangnam Severance Hosp, Anesthesia & Pain Res Inst, Dept Anesthesiol & Pain Med,Coll Med, Seoul, South Korea	Han, DW (reprint author), Yonsei Univ, Gangnam Severance Hosp, Anesthesia & Pain Res Inst, Dept Anesthesiol & Pain Med,Coll Med, Seoul, South Korea.	Hanesth@yuhs.ac		Song, Young/0000-0003-4597-387X; Kim, So Yeon/0000-0001-5352-157X; , Dongwoo/0000-0002-7675-3821; Han, Dong Woo/0000-0002-8757-663X	Yonsei University College of Medicine [6-2019-0073]	D. Chae and S. Y. Kim contributed equally and so should be regarded as equal first authors. K. Park and D. W. Han contributed equally and so should be regarded as equal corresponding authors. The authors thank MID (Medical Illustration and Design), a part of the Medical Research Support Services of Yonsei University College of Medicine, for all artistic support related to this work. This study was supported by a faculty research grant from Yonsei University College of Medicine (6-2019-0073). No competing interests declared.	Apfel CC, 2012, BRIT J ANAESTH, V109, P742, DOI 10.1093/bja/aes276; Apfel CC, 1999, ANESTHESIOLOGY, V91, P693, DOI 10.1097/00000542-199909000-00022; Apfel CC, 2002, BRIT J ANAESTH, V88, P659, DOI 10.1093/bja/88.5.659; Apfel CC, 2012, ANESTHESIOLOGY, V117, P475, DOI 10.1097/ALN.0b013e318267ef31; Chandrasekaran S, 2015, SCI PROGRAMMING-NETH, V2015, DOI 10.1155/2015/376317; Choi JB, 2014, YONSEI MED J, V55, P1430, DOI [10.3349/ymj.2014.55.5.1430, 10.3349/YMJ.2014.55.5.1430]; Chou R, 2016, J PAIN, V17, P131, DOI 10.1016/j.jpain.2015.12.008; Eberhart LHJ, 2002, BRIT J ANAESTH, V89, P760, DOI 10.1093/bja/aef261; Gan TJ, 2014, ANESTH ANALG, V118, P85, DOI 10.1213/ANE.0000000000000002; Grass JA, 2005, ANESTH ANALG, V101, pS44, DOI 10.1213/01.ANE.0000177102.11682.20; HUBERTY CJ, 1992, J EDUC STAT, V17, P75, DOI 10.2307/1165080; Kappen TH, 2015, BRIT J ANAESTH, V114, P252, DOI 10.1093/bja/aeu321; Kim SH, 2013, YONSEI MED J, V54, P1273, DOI 10.3349/ymj.2013.54.5.1273; Koh JC, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000002008; Macintyre PE, 2001, BRIT J ANAESTH, V87, P36, DOI 10.1093/bja/87.1.36; Momeni M, 2006, DRUGS, V66, P2321, DOI 10.2165/00003495-200666180-00005; Pusch F, 2002, ANESTH ANALG, V94, P1652; Roberts GW, 2005, ANESTH ANALG, V101, P1343, DOI 10.1213/01.ANE.0000180204.64588.EC; Sajobi TT, 2017, J MOD APPL STAT METH, V16, P99, DOI 10.22237/jmasm/1509494760; Sinclair DR, 1999, ANESTHESIOLOGY, V91, P109, DOI 10.1097/00000542-199907000-00018; Ugochukwu O, 2010, PAN AFR MED J, V7; van den Bosch JE, 2005, ANAESTHESIA, V60, P323, DOI 10.1111/j.1365-2044.2005.04121.x; Visser K, 2001, ANESTHESIOLOGY, V95, P616, DOI 10.1097/00000542-200109000-00012; Wallenborn J, 2007, J CLIN ANESTH, V19, P180, DOI 10.1016/j.jclinane.2006.09.004; White PF, 2008, ANESTH ANALG, V107, P459, DOI 10.1213/ane.0b013e31817aa6e4; Wojciechowski J, 2015, CPT-PHARMACOMET SYST, V4, P146, DOI 10.1002/psp4.21	26	0	1	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0003-2409	1365-2044		ANAESTHESIA	Anaesthesia	FEB	2020	75	2					218	226		10.1111/anae.14849		SEP 2019	9	Anesthesiology	Anesthesiology	KB1AN	WOS:000486841300001	31531854				2020-06-30	J	Gushgari, AJ; Venkatesan, AK; Chen, J; Steele, JC; Halden, RU				Gushgari, Adam J.; Venkatesan, Arjun K.; Chen, Jing; Steele, Joshua C.; Halden, Rolf U.			Long-term tracking of opioid consumption in two United States cities using wastewater-based epidemiology approach	WATER RESEARCH			English	Article						Sewage epidemiology; Heroin; Fentanyl; Opioid overdose estimation; Opioid death estimation	ILLICIT STIMULANT-DRUGS; URINARY-EXCRETION; TREATMENT PLANTS; HEROIN USE; ABUSE; PHARMACOKINETICS; MORPHINE; PHARMACODYNAMICS; VARIABILITY; METABOLISM	Access to near-real time opioid use data is essential to the effective management of the U.S. opioid crisis. Current narcotic data collection methods are limited by time delay and would be complimented by a rapid data acquisition technique. Use of wastewater-based epidemiology (WBE) analysis may offer access to near real-time data on opioid consumption but application in the United States has been limited. From 2015 to 2017, monthly 24-h time-weighted composite samples of municipal raw wastewater from two Midwestern U.S. cities were routinely analyzed using liquid chromatography-tandem mass spectrometry for morphine, codeine, oxycodone, heroin, fentanyl, and select opioid metabolites. Concentrations of opioids (ng/L) in raw wastewater from City 1 and 2, respectively, were: morphine (713 +/- 38; 306 +/- 29; detection frequency (DF): 100%), oxycodone (17.8 +/- 1.1; 78 +/- 6; DF: 100%), codeine (332 +/- 37; 100 +/- 27; DF: 93%), heroin (41 +/- 16; 9 +/- 11; DF: 81%), and fentanyl (1.7 +/- 0.2; 1.0 +/- 0.5; DF: 62%). Average opioid consumption rates estimated using WBE ranged between 9 and 2590 mg/day/1000 persons. Anticipated overdoses and overdose-deaths calculated from analyte concentrations in wastewater forecasted 200 opioid-related overdoses/year and 39 opioid related overdose-deaths/year across the two cities during the year 2016, which aligned well with observed coroner-reported opioid deaths. This long-term U.S. screening study of opioids in wastewater was the first to utilize wastewater epidemiological data to estimate the number of expected overdose and overdose-deaths, and to identify detectable levels of the powerful synthetic opioid fentanyl in community wastewater consistently over the course of one whole year. (C) 2019 Elsevier Ltd. All rights reserved.	[Gushgari, Adam J.; Chen, Jing; Steele, Joshua C.; Halden, Rolf U.] Arizona State Univ, Biodesign Ctr Environm Hlth Engn, Biodesign Inst, 1001 S McAllister Ave, Tempe, AZ 85287 USA; [Gushgari, Adam J.; Chen, Jing; Steele, Joshua C.; Halden, Rolf U.] Arizona State Univ, Sch Sustainable Engn & Built Environm, 1001 S McAllister Ave, Tempe, AZ 85287 USA; [Venkatesan, Arjun K.] SUNY Stony Brook, Dept Civil Engn, Ctr Clean Water Technol, Stony Brook, NY 11794 USA	Halden, RU (reprint author), 1001 S McAllister Ave, Tempe, AZ 85287 USA.	rolf.halden@asu.edu	Halden, Rolf/F-9562-2010; Venkatesan, Arjun Krishna/K-5564-2012	Halden, Rolf/0000-0001-5232-7361; Venkatesan, Arjun Krishna/0000-0001-9760-9004	National Institute of Environmental Health Sciences (NIEHS)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [R01ES020889]; Virginia G. Piper Charitable Trust [LTR 05/01/12]	This project was supported in part by Award Number R01ES020889 from the National Institute of Environmental Health Sciences (NIEHS) and by award LTR 05/01/12 of the Virginia G. Piper Charitable Trust. The content is solely the responsibility of the authors and does not necessarily represent the official views of the sponsors.	Andes D, 2002, INT J ANTIMICROB AG, V19, P261, DOI 10.1016/S0924-8579(02)00022-5; Archer E, 2018, SCI TOTAL ENVIRON, V625, P792, DOI 10.1016/j.scitotenv.2017.12.269; AZDHS, 2017, OP EP REAL TIM OP DA; Baker DR, 2014, SCI TOTAL ENVIRON, V487, P629, DOI 10.1016/j.scitotenv.2013.11.107; Baker DR, 2012, ENVIRON INT, V48, P28, DOI 10.1016/j.envint.2012.06.014; Banta-Green CJ, 2009, ADDICTION, V104, P1874, DOI 10.1111/j.1360-0443.2009.02678.x; Baz-Lomba JA, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-3686-5; Brewer AJ, 2016, DRUG ALCOHOL REV, V35, P133, DOI 10.1111/dar.12185; CCPDAP, 2017, RAT DRUG REL POIS DE; CDC, 2016, REP LAW ENF ENC TEST; CDC and University B, 2017, INCR OV DEATHS INV S; Chiaia AC, 2008, ENVIRON SCI TECHNOL, V42, P8841, DOI 10.1021/es802309v; Compton WM, 2016, NEW ENGL J MED, V374, P154, DOI 10.1056/NEJMra1508490; CONE EJ, 1993, J ANAL TOXICOL, V17, P327, DOI 10.1093/jat/17.6.327; CONE EJ, 1991, J ANAL TOXICOL, V15, P161, DOI 10.1093/jat/15.4.161; Daughton C. G., 2001, ACS PUBLICATIONS; Daughton CG, 2009, ENVIRON TOXICOL CHEM, V28, P2495, DOI 10.1897/08-382.1; Donner B, 1996, PAIN, V64, P527, DOI 10.1016/0304-3959(95)00180-8; Dove A., 2006, NEWS FEATURE DRUGS D; Dowell D, 2016, JAMA-J AM MED ASSOC, V315, P1624, DOI 10.1001/jama.2016.1464; EMCDDA (European Monitoring Centre for Drugs and Drug Addiction), 2016, ASS ILL DRUGS WAST A; Frieden TR, 2016, NEW ENGL J MED, V374, P1501, DOI 10.1056/NEJMp1515917; Gatidou G, 2016, SCI TOTAL ENVIRON, V563, P633, DOI 10.1016/j.scitotenv.2016.04.130; Gerrity D, 2011, WATER RES, V45, P5399, DOI 10.1016/j.watres.2011.07.020; Gushgari AJ, 2018, J HAZARD MATER, V359, P437, DOI 10.1016/j.jhazmat.2018.07.073; Halden R. U., 2016, PLANETARY TALK URBAN; Hancock C., 2017, TREATING RURAL OPIOI; Harocopos A, 2016, INT J DRUG POLICY, V28, P106, DOI 10.1016/j.drugpo.2015.12.021; HASSELSTROM J, 1993, CLIN PHARMACOKINET, V24, P344, DOI 10.2165/00003088-199324040-00007; Heberer T, 2005, J HAZARD MATER, V122, P211, DOI 10.1016/j.jhazmat.2005.03.007; Heuett NV, 2015, SCI TOTAL ENVIRON, V511, P319, DOI 10.1016/j.scitotenv.2014.12.043; JENKINS AJ, 1994, J ANAL TOXICOL, V18, P317, DOI 10.1093/jat/18.6.317; Kankaanpaa A, 2014, SCI TOTAL ENVIRON, V487, P696, DOI 10.1016/j.scitotenv.2013.11.095; Katz J, 2017, NY TIMES; Kim KY, 2015, SCI TOTAL ENVIRON, V524, P440, DOI 10.1016/j.scitotenv.2015.04.065; Kounang N, 2017, CNN; Labroo RB, 1997, DRUG METAB DISPOS, V25, P1072; Lai FY, 2016, SCI TOTAL ENVIRON, V568, P810, DOI 10.1016/j.scitotenv.2016.05.207; Lai FY, 2013, FORENSIC SCI INT, V233, P126, DOI 10.1016/j.forsciint.2013.09.003; Lankenau SE, 2012, INT J DRUG POLICY, V23, P37, DOI 10.1016/j.drugpo.2011.05.014; Lindberg RH, 2005, ENVIRON SCI TECHNOL, V39, P3421, DOI 10.1021/es048143z; Martins SS, 2017, JAMA PSYCHIAT, V74, P445, DOI 10.1001/jamapsychiatry.2017.0113; Mateu-Gelabert P, 2015, J SUBST ABUSE TREAT, V48, P13, DOI 10.1016/j.jsat.2014.07.002; Mayo, 2017, DRUGS SUPPLEMENTS PR; MNDH, 2017, IND DASHB OP DASHB; Moore DR, 2014, ADDICT BEHAV, V39, P987, DOI 10.1016/j.addbeh.2014.01.021; NBC, 2017, NBC; NDIC, 2000, HER CONS US CTR; O'Brien JW, 2017, ENVIRON SCI TECHNOL, V51, P3816, DOI 10.1021/acs.est.6b02755; OHA, 2017, PRESCR OV DAT OR OP; Peavy KM, 2012, J PSYCHOACTIVE DRUGS, V44, P259, DOI 10.1080/02791072.2012.704591; Pineda P., 2019, TEMPE ASU USE SEWAGE; Pollini RA, 2011, SUBST ABUSE REHABIL, V2, P173, DOI 10.2147/SAR.S24800; Postigo C, 2011, ENVIRON INT, V37, P49, DOI 10.1016/j.envint.2010.06.012; RIPO, 2017, PREV OV; Rudd R.A., 2016, MMWR MORBIDITY MORTA; Schuchat A, 2017, JAMA-J AM MED ASSOC, V318, P425, DOI 10.1001/jama.2017.8913; Schwartz JB, 2003, CLIN PHARMACOKINET, V42, P107, DOI 10.2165/00003088-200342020-00001; Siegal HA, 2003, AM FAM PHYSICIAN, V67, P942; Skopp G, 2001, J ANAL TOXICOL, V25, P2, DOI 10.1093/jat/25.1.2; Subedi B, 2014, ENVIRON SCI TECHNOL, V48, P6661, DOI 10.1021/es501709a; Substance Abuse and Mental Health Services Administration (SAMHSA), 2013, RES 2012 NAT SURV DR; Terzic S, 2010, ENVIRON POLLUT, V158, P2686, DOI 10.1016/j.envpol.2010.04.020; Thompson D., 2017, MORE 1 3 AM PRESCRIB; Thorn CF, 2009, PHARMACOGENET GENOM, V19, P556, DOI 10.1097/FPC.0b013e32832e0eac; Tscharke BJ, 2016, SCI TOTAL ENVIRON, V565, P384, DOI 10.1016/j.scitotenv.2016.04.183; U.S. Census Bureau (USCB), 2010, AM FACT FIND; van Nuijs ALN, 2011, SCI TOTAL ENVIRON, V409, P3564, DOI 10.1016/j.scitotenv.2010.05.030; van Nuijs ALN, 2011, ENVIRON INT, V37, P612, DOI 10.1016/j.envint.2010.12.006; VDH, 2017, VIRG OP ADD IND; VREE TB, 1992, BIOPHARM DRUG DISPOS, V13, P445, DOI 10.1002/bdd.2510130607; Vuori E, 2014, SCI TOTAL ENVIRON, V487, P688, DOI 10.1016/j.scitotenv.2013.11.010; Whitaker B., 2017, CBS; YEH SY, 1976, J PHARMACOL EXP THER, V196, P249; Zuccato E, 2008, ENVIRON HEALTH PERSP, V116, P1027, DOI 10.1289/ehp.11022; Zuccato E, 2011, DRUG ALCOHOL DEPEN, V118, P464, DOI 10.1016/j.drugalcdep.2011.05.007; Zuccato Ettore, 2005, Environ Health, V4, P14, DOI 10.1186/1476-069X-4-14	77	2	2	11	37	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0043-1354			WATER RES	Water Res.	SEP 15	2019	161						171	180		10.1016/j.watres.2019.06.003			10	Engineering, Environmental; Environmental Sciences; Water Resources	Engineering; Environmental Sciences & Ecology; Water Resources	IJ6GB	WOS:000475999400019	31195333				2020-06-30	J	Roberts, C; Al Sayegh, R; Ellison, PR; Sedeek, K; Carr, MM				Roberts, Christopher; Al Sayegh, Raihanah; Ellison, Pavithra Ranganathan; Sedeek, Khaled; Carr, Michele M.			How Pediatric Anesthesiologists Manage Children with OSA Undergoing Tonsillectomy	ANNALS OF OTOLOGY RHINOLOGY AND LARYNGOLOGY			English	Article						pediatric obstructive sleep apnea; tonsillectomy; pediatric anesthesia; opioids	OBSTRUCTIVE SLEEP-APNEA; INTRAOPERATIVE INTRAVENOUS ACETAMINOPHEN; PERIOPERATIVE COMPLICATIONS; RESPIRATORY COMPLICATIONS; POSTOPERATIVE ANALGESIA; ANESTHETIC MANAGEMENT; ORAL MIDAZOLAM; ADENOTONSILLECTOMY; PAIN; PREMEDICATION	Objective: The purpose of this study was to describe typical anesthesia practices for children with obstructive sleep apnea (OSA). Study Design: Online survey Method: A sample of pediatric anesthesiologists received the survey by email. Results: 110 respondents were included. 46.4% worked in a free-standing children's hospital and 32.7% worked in a children's facility within a general hospital. 73.6% taught residents. 44.4% saw at least one child with OSA per week, 25.5% saw them daily. On a 100-mm visual analog scale, respondents rated their comfort with managing these children as 84.94 (SD 17.59). For children with severe OSA, 53.6% gave oral midazolam preoperatively, but 24.5% typically withheld premedication and had the parent present for induction. 68.2% would typically use nitrous oxide for inhalational induction. 68.2% used fentanyl intraoperatively, while 20.0% used morphine. 61.5% reduced their intraop narcotic dose for children with OSA. 98.2% used intraoperative dexamethasone, 58.2% used 0.5 mg/kg for the dose. 98.2% used ondansetron, 62.7% used IV acetaminophen, and 8.2% used IV NSAIDs. 83.6% extubated awake. 27.3% of respondents stated that their institution had standardized guidelines for perioperative management of children with OSA undergoing adenotonsillectomy. People who worked in children's hospitals, who had >10 years of experience, or who saw children with OSA frequently were significantly more comfortable dealing with children with OSA (P < 0.05). Conclusion: Apart from using intraoperative dexamethasone and ondansetron, management varied. These children would likely benefit from best practices perioperative management guidelines.	[Roberts, Christopher; Carr, Michele M.] West Virginia Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, POB 9200, Morgantown, WV 26501 USA; [Al Sayegh, Raihanah] Kuwait Univ, Fac Med, Jabriya, Kuwait; [Ellison, Pavithra Ranganathan] West Virginia Univ, Sch Med, Dept Anesthesiol, Morgantown, WV 26501 USA; [Sedeek, Khaled] Penn State Coll Med, Dept Anesthesiol & Perioperat Med, Hershey, PA USA	Carr, MM (reprint author), West Virginia Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, POB 9200, Morgantown, WV 26501 USA.	michele.carr@hsc.wvu.edu	Carr, Michele/AAG-6854-2019	Carr, Michele/0000-0002-7406-4467			Alhashemi JA, 2007, EUR J ANAESTH, V24, P128, DOI 10.1017/S0265021506001232; Alhashemi JA, 2006, BRIT J ANAESTH, V96, P790, DOI 10.1093/bja/ael084; Allford M, 2009, PEDIATR ANESTH, V19, P145, DOI 10.1111/j.1460-9592.2008.02860.x; Alm F, 2017, EUR ARCH OTO-RHINO-L, V274, P3711, DOI 10.1007/s00405-017-4679-4; Baijal RG, 2015, PEDIATR ANESTH, V25, P392, DOI 10.1111/pan.12561; Bolton CM, 2006, BRIT J ANAESTH, V97, P593, DOI 10.1093/bja/ael256; Brown KA, 2011, PEDIATR ANESTH, V21, P771, DOI 10.1111/j.1460-9592.2011.03597.x; Chan DK, 2014, LARYNGOSCOPE, V124, P1789, DOI 10.1002/lary.24555; Cote CJ, 2015, CURR OPIN ANESTHESIO, V28, P327, DOI 10.1097/ACO.0000000000000187; Cote CJ, 2014, ANESTH ANALG, V118, P1276, DOI 10.1213/ANE.0b013e318294fc47; Cox RG, 2006, CAN J ANAESTH, V53, P1213, DOI 10.1007/BF03021583; Diercks GR, 2019, JAMA OTOLARYNGOL, V145, P494, DOI 10.1001/jamaoto.2019.0269; Elshammaa N, 2011, PEDIATR ANESTH, V21, P1009, DOI 10.1111/j.1460-9592.2011.03604.x; Habre W, 2017, LANCET RESP MED, V5, P412, DOI 10.1016/S2213-2600(17)30116-9; Isaiah A, 2015, INT J PEDIATR OTORHI, V79, P638, DOI 10.1016/j.ijporl.2015.01.034; Jaryszak EM, 2011, ARCH OTOLARYNGOL, V137, P15, DOI 10.1001/archoto.2010.226; Keamy DG, 2015, INT J PEDIATR OTORHI, V79, P1838, DOI 10.1016/j.ijporl.2015.08.021; Koo CH, 2018, J CLIN MED, V7, DOI 10.3390/jcm7100353; Liu PP, 2018, BRIT J ANAESTH, V121, P438, DOI 10.1016/j.bja.2018.02.067; Luehmann NC, 2019, J PEDIATR SURG, V54, P189, DOI 10.1016/j.jpedsurg.2018.10.015; Maslin B, 2017, CURR DRUG SAF, V12, P67, DOI 10.2174/1574886311666160719154420; Muffly MK, 2016, ANESTH ANALG, V123, P179, DOI 10.1213/ANE.0000000000001266; Ozdogan HK, 2017, J CLIN ANESTH, V39, P64, DOI 10.1016/j.jclinane.2017.03.001; Patino M, 2013, BRIT J ANAESTH, V111, P83, DOI 10.1093/bja/aet371; Raghavendran S, 2010, ANESTH ANALG, V110, P1093, DOI 10.1213/ANE.0b013e3181cfc435; Roberts CA, 2018, OTOLARYNG HEAD NECK, V158, P368, DOI 10.1177/0194599817728911; Sanders JC, 2006, ANESTH ANALG, V103, P1115, DOI 10.1213/01.ane.0000244318.77377.67; Schwartz CM, 2018, INT J PEDIATR OTORHI, V113, P248, DOI 10.1016/j.ijporl.2018.08.011; Sola C, 2017, PEDIATR ANESTH, V27, P827, DOI 10.1111/pan.13180; Stelter K, 2009, EUR ARCH OTO-RHINO-L, V266, P1615, DOI 10.1007/s00405-008-0909-0; Steward DL, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003997.pub2; Sutters KA, 2014, AM J NURS, V114, P36, DOI 10.1097/01.NAJ.0000443769.04764.65; Swanson RT, 2018, AM J OTOLARYNG, V39, P618, DOI 10.1016/j.amjoto.2018.05.009; Thongyam A, 2014, OTOLARYNG HEAD NECK, V151, P1046, DOI 10.1177/0194599814552059; Titirungruang C, 2019, EUR ARCH OTO-RHINO-L, V276, P585, DOI 10.1007/s00405-018-5202-2; Uysal HY, 2011, J CLIN ANESTH, V23, P53, DOI 10.1016/j.jclinane.2010.07.001; Viitanen H, 1999, ANESTH ANALG, V89, P75, DOI 10.1097/00000539-199907000-00014; von Ungern-Sternberg BS, 2013, EUR J ANAESTH, V30, P529, DOI 10.1097/EJA.0b013e32835df608	38	0	0	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0003-4894	1943-572X		ANN OTO RHINOL LARYN	Ann. Otol. Rhinol. Laryngol.	JAN	2020	129	1					55	62	UNSP 0003489419874371	10.1177/0003489419874371		SEP 2019	8	Otorhinolaryngology	Otorhinolaryngology	JT2NC	WOS:000487422600001	31801377				2020-06-30	J	McGreevy, JL; Piraino, ST; Sandhu, G				McGreevy, Jenna L.; Piraino, Samuel T.; Sandhu, Gagangeet			Fentanyl-Associated Serotonin Syndrome and Chest Wall Rigidity in an Intensive Care Unit Patient	AMERICAN JOURNAL OF THERAPEUTICS			English	Letter									[McGreevy, Jenna L.; Piraino, Samuel T.] St Josephs Hosp, Dept Pharm, Syracuse, NY 13203 USA; [Sandhu, Gagangeet] St Josephs Hosp, Div Crit Care, Dept Med, Syracuse, NY USA	McGreevy, JL (reprint author), St Josephs Hosp, Dept Pharm, Syracuse, NY 13203 USA.						Boyer EW, 2005, NEW ENGL J MED, V352, P1112, DOI 10.1056/NEJMra041867; Coruh B, 2013, CHEST, V143, P1145, DOI 10.1378/chest.12-2131; Fung HB, 2001, CLIN THER, V23, P356, DOI 10.1016/S0149-2918(01)80043-6; Kim MJ, 2013, CRIT CARE MED, V41, DOI 10.1097/01.ccm.0000440472.09030.97; NARANJO CA, 1981, CLIN PHARMACOL THER, V30, P239, DOI 10.1038/clpt.1981.154; Samartzis L, 2013, CASE REP PSYCHIAT, V2013; Sessler CN, 2008, CHEST, V133, P552, DOI 10.1378/chest.07-2026; van Ewijk CE, 2016, ANN INTENSIVE CARE, V6, DOI 10.1186/s13613-016-0186-9	8	0	0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1075-2765	1536-3686		AM J THER	Am. J. Ther.	SEP-OCT	2019	26	5					E612	E614		10.1097/MJT.0000000000000813			4	Pharmacology & Pharmacy	Pharmacology & Pharmacy	KG1JD	WOS:000509696900011	29965805				2020-06-30	J	Hao, JH; Dong, BH; Zhang, J; Luo, ZG				Hao, Jianhong; Dong, Buhuai; Zhang, Jie; Luo, Zhenguo			Pre-emptive analgesia with continuous fascia iliaca compartment block reduces postoperative delirium in elderly patients with hip fracture A randomized controlled trial	SAUDI MEDICAL JOURNAL			English	Article							PREOPERATIVE ANALGESIA; PAIN; SURGERY; NECK	Objectives: To evaluate whether pre-emptive analgesia is an effective technique to reduce postoperative delirium (PD) in geriatric patients with hip fracture. Methods: This is a double-blind randomized clinical trial. Ninety elderly patients scheduled for hipfracture surgery at HongHui Hospital, Xi'an Jiaotong University, Xi'an, China between March 2018 and January 2019 were divided into 2 groups. On arrival at the emergency department, the experimental group (n=44) received ultrasound-guided continuous fascia iliaca compartment block (FICB) for preoperative analgesia, while the control group (n=46) received generic continuous FICB. All patients received spinal anaesthesia and postoperative patient controlled epidural analgesia (PCEA). We compared the change in preoperative and postoperative pain scores, the incidence of PD, and the consumption of opioid between the 2 groups. Results: Five patients did not meet the participation requirements; therefore, 85 patients were included in the study. Patients in the experimental group experienced less preoperative pain (p<0.05). Between the 2 groups, no significant differences were found for postoperative pain scores. The incidence of PD was lower in the experimental group (13.9% versus 35.7%, p=0.018). In addition, before the surgery, a drop in consumption of fentanyl was noted in the experimental group (0.08 +/- 0.21 versus 0.28 +/- 0.13, p=0.037). Conclusion: Pre-emptive analgesia with continuous FICB is an effective technique to reduce PD in geriatric patients with hip fracture.	[Hao, Jianhong; Dong, Buhuai; Zhang, Jie; Luo, Zhenguo] Xi An Jiao Tong Univ, Dept Anaesthesiol, HongHui Hosp, Xian, Shaanxi, Peoples R China	Luo, ZG (reprint author), Xi An Jiao Tong Univ, Dept Anaesthesiol, HongHui Hosp, Xian, Shaanxi, Peoples R China.	luckyhao722@sina.com					Cidral FJ, 2013, EUR J PAIN, V17, P1193, DOI 10.1002/j.1532-2149.2012.00280.x; Colais P, 2015, BMC GERIATR, V15, DOI 10.1186/s12877-015-0140-y; Elkhodair S, 2011, EUR J EMERG MED, V18, P340, DOI 10.1097/MEJ.0b013e32834533dd; Monzon DG, 2010, INT J EMERG MED, V3, P321, DOI 10.1007/s12245-010-0234-4; Hla TK, 2014, PEDIATR ANESTH, V24, P1127, DOI 10.1111/pan.12484; Hogh A, 2008, STRATEG TRAUMA LIMB, V3, P65, DOI 10.1007/s11751-008-0037-9; INOUYE SK, 1990, ANN INTERN MED, V113, P941, DOI 10.7326/0003-4819-113-12-941; Ma YH, 2018, EXP THER MED, V16, P1944, DOI 10.3892/etm.2018.6417; McRae PJ, 2015, J EMERG MED, V48, P581, DOI 10.1016/j.jemermed.2014.12.016; Moja L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046175; Moskowitz EE, 2017, AM J SURG, V214, P1036, DOI 10.1016/j.amjsurg.2017.08.034; Petre BM, 2012, GERIATR ORTHOP SURG, V3, P3, DOI 10.1177/2151458511432758; Plaschke K, 2010, INTENS CARE MED, V36, P2081, DOI 10.1007/s00134-010-2004-4; Radinovic K, 2019, INJURY, VS0020-1383, P30389; Sanchez-Rodriguez E, 2017, J HEALTH PSYCHOL, V22, P1658, DOI 10.1177/1359105316633284; Sieber FE, 2010, MAYO CLIN PROC, V85, P18, DOI 10.4065/mcp.2009.0469; van Munster BC, 2011, REJUV RES, V14, P615, DOI 10.1089/rej.2011.1185; Williams H, 2016, J ORTHOP SURG-HONG K, V24, P31, DOI 10.1177/230949901602400109; Winterhalter M, 2008, EUR J ANAESTH, V25, P326, DOI 10.1017/S0265021507003043; YAMAMOTO N, 2019, [No title captured], P109, DOI DOI 10.1016/B978-0-12-813136-7.00006-5	20	0	0	0	1	SAUDI MED J	RIYADH	ARMED FORCES HOSPITAL, PO BOX 7897,, RIYADH 11159, SAUDI ARABIA	0379-5284			SAUDI MED J	Saudi Med. J.	SEP	2019	40	9					901	906		10.15537/smj.2019.9.24483			6	Medicine, General & Internal	General & Internal Medicine	JU5XI	WOS:000501749100005	31522217	DOAJ Gold			2020-06-30	J	Daniulaityte, R; Carlson, RR; Juhascik, MP; Strayer, KE; Sizemore, IE				Daniulaityte, Raminta; Carlson, Robert R.; Juhascik, Matthew P.; Strayer, Kraig E.; Sizemore, Ioana E.			Street fentanyl use: Experiences, preferences, and concordance between self-reports and urine toxicology	INTERNATIONAL JOURNAL OF DRUG POLICY			English	Article						Fentanyl; Non-pharmaceutical fentanyl; Fentanyl analogues; Novel synthetic opioids; Heroin; Urine toxicology; Carfentanil	DRUG OVERDOSE DEATHS; UNITED-STATES; CONTAMINATED HEROIN; OPIOID OVERDOSE; INCREASES; ANALOGS; EXPOSURE; RISK	Background: Conducted in Dayton, Ohio, the study aims to characterize user knowledge and experiences with non-pharmaceutical fentanyl-type drugs (NPFs) and compare self-reports with urine toxicology for NPFs and heroin. Methods: Between May 2017-January 2018, 60 individuals who self-reported heroin/NPF use were interviewed using structured questionnaire on socio-demographics, NPF and other drug use practices. Unobserved urine samples were collected and analyzed using: 1) liquid-chromatography-tandem mass spectrometry (LC-MS/MS)-based method (Toxicology lab) to identify 34 fentanyl analogues, metabolites, and other synthetic opioids; 2) immunoassay-based method to screen for opiates (heroin). Sensitivity, specificity and Cohen's kappa were calculated to assess agreement between self-reports and urine toxicology. Results: The sample was 52% female, and over 90% white. Almost 60% reported preference for heroin, and 40% for NPF. Participants endorsed a number of ways of distinguishing heroin from NPF, including appearance (88.3%), effects (76.7%), taste (55%), and information provided by dealers (53.3%). Almost 80% felt confident they could distinguish heroin from NPF, but knowledge about fentanyl analogues was limited. LC-MS/MS testing identified 8 types of NPFs. Over 88% tested positive for NPFs, including 86% fentanyl, 48% carfentanil, 42% acetyl fentanyl. About 47% screened positive for opiates/heroin, and all of them were also positive for NPFs. When comparing self-reported use of NPF to urine toxicology, sensitivity and specificity were relatively high (84% and 83.3%, accordingly), while Cohen's Kappa was 0.445, indicating fair agreement. Sensitivity and specificity were lower for heroin (77.8% and 50.0%, accordingly), and Cohen's Kappa was 0.296, indicating low agreement between self-reports of heroin use and urine toxicology. Discussion: Nearly 90% of the study participants tested positive for NPF-type drugs. Participants were more likely to over-report heroin use and underreport NPF use. The majority had little knowledge about fentanyl analogues. Study findings will inform development of novel harm reduction approaches to reduce overdose mortality.	[Daniulaityte, Raminta; Carlson, Robert R.] Wright State Univ, Boonshoft Sch Med, Dept Populat & Publ Hlth Sci, Ctr Intervent Treatment & Addict Res, 3171 Res Blvd, Kettering, OH 45420 USA; [Juhascik, Matthew P.] MCCO, MVRCL, 361 W Third St, Dayton, OH 45402 USA; [Strayer, Kraig E.; Sizemore, Ioana E.] Wright State Univ, Dept Chem, 202 Oelman Hall, Dayton, OH 45420 USA	Daniulaityte, R (reprint author), Wright State Univ, Boonshoft Sch Med, Dept Populat & Publ Hlth Sci, Ctr Intervent Treatment & Addict Res, 3171 Res Blvd, Kettering, OH 45420 USA.	raminta.daniulaityte@wright.edu; robert.carlson@wright.edu; juhascikm@mcohio.org; kraigstrayer10@gmail.com; ioana.pavel@wright.edu		Daniulaityte, Raminta/0000-0001-6507-3866	National Institutes of Health/National Institute on Drug AbuseUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [1R21DA042757, R01 DA040811]	This work was supported by the National Institutes of Health/National Institute on Drug Abuse: 1R21DA042757 (Daniulaityte, PI) and R01 DA040811 (Daniulaityte, PI). The funding source had no further role in the study design, in the collection, analysis and interpretation of the data, in the writing of the report, or in the decision to submit the paper for publication.	Amlani A, 2015, HARM REDUCT J, V12, DOI 10.1186/s12954-015-0088-4; Armenian P, 2018, NEUROPHARMACOLOGY, V134, P121, DOI 10.1016/j.neuropharm.2017.10.016; Bardwell G, 2019, DRUG ALCOHOL DEPEN, V198, P1, DOI 10.1016/j.drugalcdep.2019.01.035; Bisaga A, 2019, ADDICTION, V114, P782, DOI 10.1111/add.14522; Bobashev G, 2018, DRUG ALCOHOL DEPEN, V192, P80, DOI 10.1016/j.drugalcdep.2018.06.039; Carroll JJ, 2017, INT J DRUG POLICY, V46, P136, DOI 10.1016/j.drugpo.2017.05.023; Centers for Disease Control and Prevention, 2015, INCR FENT DRUG CONF; Ciccarone D, 2017, INT J DRUG POLICY, V46, P146, DOI 10.1016/j.drugpo.2017.06.004; Ciccarone D, 2017, INT J DRUG POLICY, V46, P107, DOI 10.1016/j.drugpo.2017.06.010; Cicero TJ, 2017, DRUG ALCOHOL DEPEN, V177, P101, DOI 10.1016/j.drugalcdep.2017.04.004; Cicero TJ, 2014, JAMA PSYCHIAT, V71, P821, DOI 10.1001/jamapsychiatry.2014.366; Daniulaityte R., 2017, FENTANYL DOPE IS WAY; Daniulaityte R, 2019, DRUG ALCOHOL DEPEN, V198, P116, DOI 10.1016/j.drugalcdep.2019.01.045; Daniulaityte R, 2017, MMWR-MORBID MORTAL W, V66, P904, DOI 10.15585/mmwr.mm6634a3; Donovan DM, 2012, ADDICTION, V107, P694, DOI 10.1111/j.1360-0443.2011.03473.x; European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), 2017, RISK ASS REP NEW PSY; Fairbairn N, 2017, INT J DRUG POLICY, V46, P172, DOI 10.1016/j.drugpo.2017.06.005; Gladden RM, 2016, MMWR-MORBID MORTAL W, V65, P837, DOI 10.15585/mmwr.mm6533a2; Hawks R. L., 1986, URINE TESTING DRUGS; Hedegaard H., 2018, NCHS DATA BRIEF, V329; Jones CM, 2018, JAMA-J AM MED ASSOC, V319, P1819, DOI 10.1001/jama.2018.2844; Kenney SR, 2018, J SUBST ABUSE TREAT, V86, P65, DOI 10.1016/j.jsat.2018.01.005; Krieger MS, 2018, INT J DRUG POLICY, V61, P52, DOI 10.1016/j.drugpo.2018.09.009; Lankenau SE, 2012, INT J DRUG POLICY, V23, P37, DOI 10.1016/j.drugpo.2011.05.014; Lozier MJ, 2015, J MED TOXICOL, V11, P208, DOI 10.1007/s13181-015-0477-9; Macmadu A, 2017, ADDICT BEHAV, V68, P35, DOI 10.1016/j.addbeh.2017.01.014; Marinetti LJ, 2014, J ANAL TOXICOL, V38, P592, DOI 10.1093/jat/bku086; Mars SG, 2018, J PSYCHOACTIVE DRUGS, V50, P167, DOI 10.1080/02791072.2017.1394508; Mars SG, 2014, INT J DRUG POLICY, V25, P257, DOI 10.1016/j.drugpo.2013.10.004; McGowan CR, 2018, INT J DRUG POLICY, V58, P31, DOI 10.1016/j.drugpo.2018.04.017; O'Donnell J, 2018, MMWR-MORBID MORTAL W, V67, P767, DOI 10.15585/mmwr.mm6727a4; O'Donnell JK, 2017, MMWR-MORBID MORTAL W, V66, P1197, DOI 10.15585/mmwr.mm6643e1; Ohio Department of Health, 2017, 2016 OH DRUG OV DAT; Ohio Substance Abuse Monitoring Network, 2017, SURV DRUG AB TRENDS; Park JN, 2018, HARM REDUCT J, V15, DOI 10.1186/s12954-018-0240-z; Peiper NC, 2019, INT J DRUG POLICY, V63, P122, DOI 10.1016/j.drugpo.2018.08.007; Public Health Dayton & Montgomery County, 2018, ACC OV DEATH TOT; Rhoades Paul, 2017, Journal of Melittology, V66, P1; Rudd RA, 2016, MMWR-MORBID MORTAL W, V65, P1445, DOI 10.15585/mmwr.mm655051e1; Rudd RA, 2016, MMWR-MORBID MORTAL W, V64, P1378, DOI 10.15585/mmwr.mm6450a3; Shiels MS, 2018, ANN INTERN MED, V168, P453, DOI 10.7326/M17-1812; Siegal HA, 2003, AM FAM PHYSICIAN, V67, P942; Slavova S, 2017, INT J DRUG POLICY, V46, P120, DOI 10.1016/j.drugpo.2017.05.051; Sofalvi S, 2017, J ANAL TOXICOL, V41, P473, DOI 10.1093/jat/bkx052; Somerville NJ, 2017, MMWR-MORBID MORTAL W, V66, P382, DOI 10.15585/mmwr.mm6614a2; Stogner JM, 2014, ANN EMERG MED, V64, P637, DOI 10.1016/j.annemergmed.2014.07.017; Strayer KE, 2018, ACS OMEGA, V3, P514, DOI 10.1021/acsomega.7b01536; Suzuki J, 2017, DRUG ALCOHOL DEPEN, V171, P107, DOI 10.1016/j.drugalcdep.2016.11.033; Tiscione NB, 2018, J ANAL TOXICOL, V42, P476, DOI 10.1093/jat/bky026; Tupper KW, 2018, DRUG ALCOHOL DEPEN, V190, P242, DOI 10.1016/j.drugalcdep.2018.06.020; US Drug Enforcement Administration & Office of Diversion Control, 2019, NETS REP TRACK FENT; Viera AJ, 2005, FAM MED, V37, P360	52	8	8	4	4	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0955-3959	1873-4758		INT J DRUG POLICY	Int. J. Drug Policy	SEP	2019	71						3	9		10.1016/j.drugpo.2019.05.020			7	Substance Abuse	Substance Abuse	JU0YL	WOS:000501405000002	31146200				2020-06-30	J	Bardwell, G; Boyd, J; Tupper, KW; Kerr, T				Bardwell, Geoff; Boyd, Jade; Tupper, Kenneth W.; Kerr, Thomas			"We don't got that kind of time, man. We're trying to get high!": Exploring potential use of drug checking technologies among structurally vulnerable people who use drugs	INTERNATIONAL JOURNAL OF DRUG POLICY			English	Article						Drug checking technologies; Willingness; People who use drugs; Fentanyl; Overdose; Structural vulnerability	INJECTION SETTINGS; HEROIN OVERDOSE; SOCIAL-CONTEXT; VANCOUVER; RISK; HIV; ENVIRONMENT; CANADA; HARM; ROOM	Background: Novel public health interventions are being considered to address the opioid overdose epidemic, including drug checking technologies. We examined the willingness to use various drug checking technologies among structurally-vulnerable people who use drugs (PWUD). Methods: We conducted one-to-one qualitative semi-structured interviews with 20 PWUD in Vancouver, Canada's Downtown Eastside. Participants were purposively recruited from ongoing cohort studies of PWUD. Results: Overall willingness to use drug checking technologies was low among participants. A range of factors undermined potential use of various drug checking technologies including: having to give up a drug sample; time dedication; discrepancies regarding measurements and accuracy; recourse following positive fentanyl results; ambivalence to overdose risk; and availability and accessibility of drug checking technologies. Conclusions: Participants discussed numerous factors that undermined potential willingness to use drug checking technologies. These factors underscore the structural vulnerabilities experienced by PWUD and how they may constrain uptake of drug checking technologies. Future drug checking programming should consider these influencing factors prior to the implementation of drug checking technologies to ensure that drug checking interventions are appropriate and meeting the needs of target populations.	[Bardwell, Geoff; Boyd, Jade; Tupper, Kenneth W.; Kerr, Thomas] British Columbia Ctr Subst Use, 400-1045 Howe St, Vancouver, BC V6Z 2A9, Canada; [Bardwell, Geoff; Boyd, Jade; Kerr, Thomas] Univ British Columbia, Dept Med, 400-1045 Howe St, Vancouver, BC V6Z 2A9, Canada; [Tupper, Kenneth W.] Univ British Columbia, Sch Populat & Publ Hlth, 2206 East Mall, Vancouver, BC V6T 1Z3, Canada	Bardwell, G (reprint author), Univ British Columbia, British Columbia Ctr Subst Use, Dept Med, 400-1045 Howe St, Vancouver, BC V6Z 2A9, Canada.	geoff.bardwell@bccsu.ubc.ca			US National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01DA044181]; Canadian Institutes for Health Research FoundationCanadian Institutes of Health Research (CIHR) [20R74326]; Mitacs Elevate Postdoctoral Fellowship from Mitacs Canada	The authors wish to thank study participants for their contributions to the research. Thank you to research staff at the British Columbia Centre on Substance Use (including Cristy Zonneveld, Cameron Dilworth, and Jennifer Matthews). Special thanks to members of the Vancouver Area Network of Drug Users for their valuable feedback. This study was supported by the US National Institutes of Health (R01DA044181) and a Canadian Institutes for Health Research Foundation Grant (20R74326). Geoff Bardwell is supported by a Mitacs Elevate Postdoctoral Fellowship from Mitacs Canada.	Aitken C, 2002, INT J DRUG POLICY, V13, P193, DOI DOI 10.1016/S0955-3959(02)00075-0; Bardwell G, 2019, DRUG ALCOHOL DEPEN, V198, P1, DOI 10.1016/j.drugalcdep.2019.01.035; Bardwell G, 2018, HEALTH PLACE, V53, P86, DOI 10.1016/j.healthplace.2018.07.011; Bardwell G, 2018, SUBST ABUSE TREAT PR, V13, DOI 10.1186/s13011-018-0156-3; Bardwell G, 2018, INT J DRUG POLICY, V55, P40, DOI 10.1016/j.drugpo.2018.02.004; BC Coroners Service, 2017, FENT DET 81 ILL DRUG; Bluthenthal R. N., 1999, International Journal of Drug Policy, V10, P25, DOI 10.1016/S0955-3959(98)00076-0; Bode AD, 2017, AM J EMERG MED, V35, P1364, DOI 10.1016/j.ajem.2017.02.043; Boyd J, 2016, INT J DRUG POLICY, V34, P72, DOI 10.1016/j.drugpo.2016.05.012; Briggs D, 2009, DRUG-EDUC PREV POLIC, V16, P436, DOI 10.1080/09687630802697685; British Columbia Coroners Service, 2018, ILL DRUG OV DEATHS B; Centers for Disease Control and Prevention, 2017, DEATHS INV FENT FENT; Ciccarone D, 2016, INT J DRUG POLICY, V33, P36, DOI 10.1016/j.drugpo.2016.02.028; Corbin JM, 2015, BASICS QUALITATIVE R; DeBeck K, 2017, LANCET HIV, V4, pE357, DOI 10.1016/S2352-3018(17)30073-5; Duff P, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-643; Fast D, 2010, HEALTH PLACE, V16, P51, DOI 10.1016/j.healthplace.2009.07.004; FISHER RJ, 1993, J CONSUM RES, V20, P303, DOI 10.1086/209351; Galletta A., 2013, MASTERING SEMI STRUC; Goldman JE, 2019, HARM REDUCT J, V16, DOI 10.1186/s12954-018-0276-0; Goodman A, 2017, SOC SCI MED, V178, P87, DOI 10.1016/j.socscimed.2017.01.053; Government of British Columbia Ministry of Mental Health and Addictions, 2017, PROV EXP FENT TEST L; Harper L, 2017, HARM REDUCT J, V14, DOI 10.1186/s12954-017-0179-5; Hedrich D., 2004, EUROPEAN REPORT DRUG; Hembree C, 2005, HEALTH PLACE, V11, P147, DOI 10.1016/j.healthplace.2004.02.005; Hien NT, 2000, AIDS CARE, V12, P483, DOI 10.1080/09540120050123882; Hungerbuehler I, 2011, HARM REDUCT J, V8, DOI 10.1186/1477-7517-8-16; Kemmesies U., 1999, OPEN DRUG SCENE SAFE; Kennedy MC, 2018, DRUG ALCOHOL DEPEN, V185, P248, DOI 10.1016/j.drugalcdep.2017.12.026; Kerr T, 2017, DRUG CHECKING HARM R; Kerr T, 2007, INT J DRUG POLICY, V18, P37, DOI 10.1016/j.drugpo.2006.12.008; Kerr T, 2013, ADDICTION, V108, P1270, DOI 10.1111/add.12151; Knight KR, 2014, INT J DRUG POLICY, V25, P556, DOI 10.1016/j.drugpo.2013.10.011; Krieger MS, 2018, HARM REDUCT J, V15, DOI 10.1186/s12954-018-0213-2; Krumpal I, 2013, QUAL QUANT, V47, P2025, DOI 10.1007/s11135-011-9640-9; Krusi A, 2010, HEALTH SOC CARE COMM, V18, P282, DOI 10.1111/j.1365-2524.2009.00901.x; Lazarus L, 2011, SOC SCI MED, V73, P1600, DOI 10.1016/j.socscimed.2011.09.015; Mateu-Gelabert P, 2017, INT J DRUG POLICY, V46, P17, DOI 10.1016/j.drugpo.2017.05.016; Mateu-Gelabert P, 2010, INT J DRUG POLICY, V21, P179, DOI 10.1016/j.drugpo.2009.08.007; McGowan CR, 2018, INT J DRUG POLICY, V58, P31, DOI 10.1016/j.drugpo.2018.04.017; McNeil R, 2015, HEALTH PLACE, V35, P70, DOI 10.1016/j.healthplace.2015.07.006; McNeil R, 2015, SOC SCI MED, V133, P168, DOI 10.1016/j.socscimed.2015.04.008; McNeil R, 2014, AIDS BEHAV, V18, P473, DOI 10.1007/s10461-013-0540-y; Measham FC, 2019, INT J DRUG POLICY, V67, P102, DOI 10.1016/j.drugpo.2018.11.001; Miron JA, 2003, REV ECON STAT, V85, P522, DOI 10.1162/003465303322369696; Moore D, 2004, SOC SCI MED, V59, P1547, DOI 10.1016/j.socscimed.2004.01.029; Murray Rebecca A., 2012, PHORRNACOTHERAPY J H, V23, P1238, DOI [10.1592/phco.23.12.1238.32704, DOI 10.1592/PHCO.23.12.1238.32704]; National Drug Early Warning System Coordinating Center, 2016, INCR FENT OV; Parkin S., 2016, HABITUS DRUG USING E; Petrar S, 2007, ADDICT BEHAV, V32, P1088, DOI 10.1016/j.addbeh.2006.07.013; Philbin M, 2008, AIDS BEHAV, V12, P552, DOI 10.1007/s10461-008-9372-6; Quesada J, 2011, MED ANTHROPOL, V30, P339, DOI 10.1080/01459740.2011.576725; Ramos R, 2009, HEALTH PLACE, V15, P999, DOI 10.1016/j.healthplace.2009.04.004; Rhodes T, 2006, ADDICTION, V101, P1384, DOI 10.1111/j.1360-0443.2006.01556.x; Rhodes T, 2012, RETHINKING SOCIAL EPIDEMIOLOGY: TOWARDS A SCIENCE OF CHANGE, P205, DOI 10.1007/978-94-007-2138-8_10; Rhodes T, 2009, INT J DRUG POLICY, V20, P193, DOI 10.1016/j.drugpo.2008.10.003; Sagan A., 2015, FENTANYL DEATHS ARE; Sande M, 2018, HARM REDUCT J, V15, DOI 10.1186/s12954-018-0208-z; Schneider J, 2016, INTERN MED J, V46, P1249, DOI 10.1111/imj.13250; Shannon K, 2006, INT J DRUG POLICY, V17, P107, DOI 10.1016/j.drugpo.2005.09.002; Sherman SG, 2019, INT J DRUG POLICY, V68, P46, DOI 10.1016/j.drugpo.2019.03.003; Small W, 2007, INT J DRUG POLICY, V18, P27, DOI 10.1016/j.drugpo.2006.11.019; Small W, 2011, SUBST USE MISUSE, V46, P561, DOI 10.3109/10826084.2010.517714; Strathdee SA, 1997, AIDS, V11, pF59, DOI 10.1097/00002030-199708000-00001; Tempalski B, 2009, INT J DRUG POLICY, V20, P4, DOI 10.1016/j.drugpo.2008.02.002; Tupper KW, 2018, DRUG ALCOHOL DEPEN, V190, P242, DOI 10.1016/j.drugalcdep.2018.06.020; van der Poel A, 2003, EUR ADDICT RES, V9, P94, DOI 10.1159/000068807; Wagner KD, 2012, INT J DRUG POLICY, V23, P54, DOI 10.1016/j.drugpo.2011.05.009; Werb D, 2011, INT J DRUG POLICY, V22, P87, DOI 10.1016/j.drugpo.2011.02.002; Winstock AR, 2001, ADDICTION, V96, P1139, DOI 10.1046/j.1360-0443.2001.96811397.x; Wood E, 2003, CAN MED ASSOC J, V169, P656	71	4	4	2	2	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0955-3959	1873-4758		INT J DRUG POLICY	Int. J. Drug Policy	SEP	2019	71						125	132		10.1016/j.drugpo.2019.06.018			8	Substance Abuse	Substance Abuse	JU0YL	WOS:000501405000017	31336258				2020-06-30	J	Bucerius, SM; Haggerty, KD				Bucerius, Sandra M.; Haggerty, Kevin D.			Fentanyl behind bars: The implications of synthetic opiates for prisoners and correctional officers	INTERNATIONAL JOURNAL OF DRUG POLICY			English	Article						Opioids; Fentanyl; Prison; Prisoners; Correctional officers; Overdose; Qualitative study	DRUG-USE; HIV; PREVALENCE; DISORDERS; CULTURE; INMATES	Background and Aims: Fentanyl and derivatives are lethal components of North America's opioid crisis. Prisons often house a disproportionate number of illicit opiate users. To date, no on-the-ground empirical research exists on how opioids are altering the health and risk profile of prisons. The objectives of this study were to examine (1) how fentanyl and its analogues have shaped the prison experience for prisoners; and (2) how these opioids have altered the occupation of correctional officers (CO's). Methods: We conducted semi-structured interviews with 587 adult prisoners and 131 COs across four provincial prisons in Western Canada. Prisoners were recruited on their housing units and randomly selected. COs were recruited through non-probability, theoretical sampling. We employed a generalized prompt guide and asked a range of questions pertaining to how the presence of fentanyl and its analogues have changed the prison experience for prisoners and have impacted the work routine of COs. Interviews were digitally recorded, transcribed verbatim, thematically coded and analyzed using Nvivo 11. Results: For prisoners, we identified four main results: (1) the presence of fentanyl leads to an increased number of overdoses; (2) prisons are nonetheless perceived as a comparatively safe place to use drugs; (3) fentanyl is often mixed into other drugs, making it hard for drug users to avoid fentanyl; and (4) prisoners fear fentanyl is being weaponized. For officers, we identified: (1) increased fears about inadvertent personal exposure or widespread institutional opioid contamination; (2) fear of targeted poisonings; (3) changing attitudes towards opioid-using prisoners; and (4) a declining commitment to correctional careers. Conclusion: The presence of fentanyl in prisons has significantly influenced how prisoners experience prison and relate to each other and how COs perceive their job. COs now identify fentanyl as the greatest risk to their safety in prisons.	[Bucerius, Sandra M.; Haggerty, Kevin D.] Univ Alberta, Dept Sociol, Edmonton, AB, Canada	Bucerius, SM (reprint author), Univ Alberta, Dept Sociol, Edmonton, AB, Canada.	bucerius@ualberta.ca; Khaggert@ualberta.ca		Bucerius, Sandra/0000-0002-7742-3103	Social Science and Humanities Research Council Canada [SSHRCIG 435-2017-1051]; CRISM (Canadian Research Institute in Substance Misuse)	Social Science and Humanities Research Council Canada SSHRCIG 435-2017-1051 and CRISM (Canadian Research Institute in Substance Misuse).	Alberta Health, 2017, OP SUBST MIS ALB REP; Almani A., 2015, HARM REDUCT J, V12, P1; Australian Institute of Health and Welfare (AIHW), 2013, HLTH AUSTR PRIS 2012; Bell D., 2017, CBC NEWS; Beyrer C, 2003, AIDS BEHAV, V7, P153, DOI 10.1023/A:1023946324822; BIERNACKI P, 1981, SOCIOL METHOD RES, V10, P141, DOI 10.1177/004912418101000205; Bland RC, 1998, INT J LAW PSYCHIAT, V21, P273, DOI 10.1016/S0160-2527(98)00005-3; Bourgois P, 2003, SEARCH RESPECT SELLI, V10; Boys A, 2002, ADDICTION, V97, P1551, DOI 10.1046/j.1360-0443.2002.00229.x; Bucerius S. M., 2014, UNWANTED MUSLIM IMMI; Bucerius SM, 2013, J CONTEMP ETHNOGR, V42, P690, DOI 10.1177/0891241613497747; Chan J, 1996, BRIT J CRIMINOL, V36, P109; Crawley E., 2004, DOING PRISON WORK PU; Crewe B, 2005, PUNISHM SOC, V7, P457, DOI 10.1177/1462474505057122; Damschroder LJ, 2011, PSYCHOL ADDICT BEHAV, V25, P194, DOI 10.1037/a0022284; Dufour A, 1996, AIDS, V10, P1009, DOI 10.1097/00002030-199610090-00012; Fassin Didier, 2017, PRISON WORLDS ETHNOG; Faust J. A., 2017, SLATE; Fazel S, 2006, ADDICTION, V101, P181, DOI 10.1111/j.1360-0443.2006.01316.x; Grant Meghan, 2017, CBC NEWS; Howlett K., 2016, GLOBE MAIL; Kolind T, 2016, DRUG-EDUC PREV POLIC, V23, P89, DOI 10.3109/09687637.2016.1153604; Kouyoumdjian F, 2016, CAN FAM PHYSICIAN, V62, P215; Kruttschnitt C., 2005, MARKING TIME GOLDEN; LIEBLING A, 2010, PRISON OFFICER; Loftus B, 2010, POLIC SOC, V20, P1, DOI 10.1080/10439460903281547; Maxwell J. A., 2013, QUALITATIVE RES DESI; Miller J. Mitchell, 1994, JUSTICE Q, V11, P313, DOI DOI 10.1080/07418829400092271; Mjaland K, 2014, PUNISHM SOC, V16, P336, DOI 10.1177/1462474514527149; Poulin C, 2007, CAN MED ASSOC J, V177, P252, DOI 10.1503/cmaj.060760; Proctor E, 2011, ADM POLICY MENT HLTH, V38, P65, DOI 10.1007/s10488-010-0319-7; Public Health Agency of Canada, 2018, NAT REP APP OP REL D; Reitano J., 2017, ADULT CORRECTIONAL S; Richards L., 2017, SASKATOON STARP 1101; Shi L, 2010, VULNERABLE POPULATIO; Skarbek D., 2014, GOVERNANCE SOC CAPTI, P75; Sloan JA, 2016, MASCULINITIES ADULT; Sykes G. M., 1958, SOC CAPTIVES STUDY M; Transport Canada, 2017, CAN MOT VEH COLL STA; Waddington PAJ, 1999, BRIT J CRIMINOL, V39, P287, DOI 10.1093/bjc/39.2.287; Warren C. A. B., 2001, HDB INTERVIEW RES CO, P83, DOI DOI 10.4135/9781412973588; Watson TM, 2016, SUBST USE MISUSE, V51, P91, DOI 10.3109/10826084.2015.1089907; Wax PM, 2003, ANN EMERG MED, V41, P700, DOI 10.1067/mem.2003.148; Weeks C., 2015, GLOBE MAIL; Weinrath M., 2016, WALLS INMATES CORREC; Wheatley M., 2016, HDB PRISONS, P205; Wikstrom POH, 2006, PATHWAY CRIME, P1; World Health Organization, 2017, WHO REC MOST STRING; WRIGHT R, 1992, J RES CRIME DELINQ, V29, P148, DOI 10.1177/0022427892029002003	49	1	1	0	0	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0955-3959	1873-4758		INT J DRUG POLICY	Int. J. Drug Policy	SEP	2019	71						133	138		10.1016/j.drugpo.2019.05.018			6	Substance Abuse	Substance Abuse	JU0YL	WOS:000501405000018	31349150				2020-06-30	J	Karamouzian, M; Kuo, M; Crabtree, A; Buxton, JA				Karamouzian, Mohammad; Kuo, Margot; Crabtree, Alexis; Buxton, Jane A.			Correlates of seeking emergency medical help in the event of an overdose in British Columbia, Canada: Findings from the Take Home Naloxone program	INTERNATIONAL JOURNAL OF DRUG POLICY			English	Article						Drug overdose; Opioid-related disorders; Emergency treatment; Naloxone; Harm reduction	OPIOID OVERDOSE; DRUG OVERDOSE; PREVENTION; STATES	Background: British Columbia (BC), Canada, is experiencing an unprecedented number of opioid overdoses mainly due to the contamination of illicit drugs with fentanyl and its analogues. Reluctance to seek emergency medical help (i.e., by calling 9-1-1) has been identified as a barrier to optimal care for overdose victims. This study aimed to identify the correlates of seeking help during an overdose event when naloxone was administered via BC's Take Home Naloxone (THN) program. Methods: In this cross-sectional study, we reviewed administrative records (from July 2015 to December 2017) about overdose events submitted by THN participants when they received their replacement naloxone kits (n = 2350). The primary outcome of the study was reported calling 9-1-1 and modified Poisson regression models were built to investigate the factors associated with help-seeking during an overdose event. Results: Most overdose victims were men (69.0%) and > 30 years old (61.5%). Overall, participants reported calling 9-1-1 in 1310 (55.7%) overdose events. In the multivariable model, the likelihood of calling 9-1-1 was significantly and positively associated with the overdose victim being male and receiving rescue breathing. The likelihood of calling 9-1-1 was significantly and negatively associated with the overdoses occurring in private residences and health regions other than Vancouver Coastal which delivers services to mostly urban residents. Conclusion: Overall, medical help was sought for 55.7% of overdoses where naloxone was administered. Overdoses occurring among male victims as well as those receiving higher doses of naloxone and mouth-to-mouth rescue breathing were associated with a higher likelihood of help-seeking by responders. Future interventions need to encourage people who witness an overdose to seek emergency medical help.	[Karamouzian, Mohammad; Buxton, Jane A.] Univ British Columbia, Sch Populat & Publ Hlth, Fac Med, Vancouver, BC, Canada; [Karamouzian, Mohammad] St Pauls Hosp, British Columbia Ctr Subst Use, Vancouver, BC, Canada; [Karamouzian, Mohammad] Kerman Univ Med Sci, HIV STI Surveillance Res Ctr, Kerman, Iran; [Karamouzian, Mohammad] Kerman Univ Med Sci, WHO Collaborating Ctr HIV Surveillance, Inst Futures Studies Hlth, Kerman, Iran; [Kuo, Margot; Crabtree, Alexis; Buxton, Jane A.] British Columbia Ctr Dis Control, Vancouver, BC, Canada	Buxton, JA (reprint author), Univ British Columbia, Sch Populat & Publ Hlth, Fac Med, Vancouver, BC, Canada.; Buxton, JA (reprint author), British Columbia Ctr Dis Control, Vancouver, BC, Canada.	Jane.Buxton@bccdc.ca	Karamouzian, Mohammad/C-9277-2018	Karamouzian, Mohammad/0000-0002-5631-4469	BC Ministry of Health; Vanier Canada Graduate Scholarship; Pierre Elliott Trudeau Foundation Doctoral Scholarships; BC Centre for Disease Control	We would like to thank the BC Centre for Disease Control and the BC Ministry of Health for their support in implementing this program. The authors would like to acknowledge the assistance of program clients and staff, study participants, and the members of the BCTHN Community Advisory Board. No external funding was obtained for this study. Mohammad Karamouzian is supported by the Vanier Canada Graduate Scholarship and the Pierre Elliott Trudeau Foundation Doctoral Scholarships.	Ambrose G, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-011224; Armenian P, 2018, NEUROPHARMACOLOGY, V134, P121, DOI 10.1016/j.neuropharm.2017.10.016; Banjo Oluwajenyo, 2014, CMAJ Open, V2, pE153, DOI 10.9778/cmajo.20140008; Banta-Green CJ, 2013, J URBAN HEALTH, V90, P1102, DOI 10.1007/s11524-013-9814-y; BC Centre for Disease Control, 2018, HIST TAK HOM NAL BRI; BC Centre for Disease Control, 2017, TRAIN OV PREV REC RE; BC Centre for Disease Control, 2018, THN BC INF; BC Coroners Service, 2017, FENT DET ILL DRUG OV; BC Coroners Service, 2018, ILL DRUG OV DEATHS B; BC Coroners Service, 2018, FENTANYL DETECTED IL; Bennett AS, 2011, J URBAN HEALTH, V88, P1020, DOI 10.1007/s11524-011-9600-7; Bird SM, 2016, ADDICTION, V111, P883, DOI 10.1111/add.13265; Buxton JA, 2018, CAN MED ASSOC J, V190, pE539, DOI 10.1503/cmaj.171468; Center for Disease Control and Prevention, 2018, OP OV TREAT EM DEP; Davis CS, 2015, DRUG ALCOHOL DEPEN, V157, P112, DOI 10.1016/j.drugalcdep.2015.10.013; Irvine MA, 2018, LANCET PUBLIC HEALTH, V3, pE218, DOI 10.1016/S2468-2667(18)30044-6; Karamouzian M, 2018, HARM REDUCT J, V15, DOI 10.1186/s12954-018-0252-8; Karamouzian M, 2018, LANCET, V391, P201, DOI 10.1016/S0140-6736(18)30057-6; Klimas J, 2014, AM J EMERG MED, V32, P1168, DOI 10.1016/j.ajem.2014.07.017; Lankenau SE, 2013, J COMMUN HEALTH, V38, P133, DOI 10.1007/s10900-012-9591-7; Latimore AD, 2017, INT J DRUG POLICY, V50, P82, DOI 10.1016/j.drugpo.2017.09.010; MALDONADO G, 1993, AM J EPIDEMIOL, V138, P923, DOI 10.1093/oxfordjournals.aje.a116813; Martins SS, 2015, AM J PUBLIC HEALTH, V105, pE29, DOI 10.2105/AJPH.2015.302843; McDonald R, 2016, ADDICTION, V111, P1177, DOI 10.1111/add.13326; McLean K, 2018, J CRIME JUSTICE, V41, P1, DOI 10.1080/0735648X.2016.1215932; Mueller SR, 2015, SUBST ABUS, V36, P240, DOI 10.1080/08897077.2015.1010032; Olfson M, 2018, JAMA PSYCHIAT, V75, P820, DOI 10.1001/jamapsychiatry.2018.1471; Public Health Agency of Canada, 2018, NAT REP APP OP REL D; Royston P, 2011, J STAT SOFTW, V45, P1, DOI 10.18637/jss.v045.i04; Rudd RA, 2016, AM J TRANSPLANT, V16, P1323, DOI 10.1111/ajt.13776; Scheuermeyer FX, 2018, ANN EMERG MED, V72, P1, DOI 10.1016/j.annemergmed.2018.01.054; Sherman SG, 2008, HARM REDUCT J, V5, DOI 10.1186/1477-7517-5-2; Tobin KE, 2005, ADDICTION, V100, P397, DOI 10.1111/j.1360-0443.2005.00975.x; Tracy M, 2005, DRUG ALCOHOL DEPEN, V79, P181, DOI 10.1016/j.drugalcdep.2005.01.010; Tyndall M, 2018, CAN MED ASSOC J, V190, pE35, DOI 10.1503/cmaj.171060; Vancouver Police Department, 2006, AM REG PROC MAN; Wagner KD, 2015, DRUG ALCOHOL DEPEN, V153, P215, DOI 10.1016/j.drugalcdep.2015.05.026; Walley AY, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f174; Watson WA, 1998, J TOXICOL-CLIN TOXIC, V36, P11, DOI 10.3109/15563659809162577; Zou GY, 2004, AM J EPIDEMIOL, V159, P702, DOI 10.1093/aje/kwh090	40	6	6	0	0	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0955-3959	1873-4758		INT J DRUG POLICY	Int. J. Drug Policy	SEP	2019	71						157	163		10.1016/j.drugpo.2019.01.006			7	Substance Abuse	Substance Abuse	JU0YL	WOS:000501405000022	30691944	Other Gold			2020-06-30	J	Strike, C; Watson, TM				Strike, Carol; Watson, Tara Marie			Losing the uphill battle? Emergent harm reduction interventions and barriers during the opioid overdose crisis in Canada	INTERNATIONAL JOURNAL OF DRUG POLICY			English	Article						Harm reduction; Overdose prevention; Opioids; Canada; Naloxone; Interventions	SUPERVISED INJECTION SERVICES; DRUG CHECKING; UNITED-STATES; NALOXONE; PROGRAMS	Canada continues to experience an escalating opioid overdose crisis that has claimed more than 8000 lives in the country since 2016. The presence of the synthetic opioid fentanyl and its analogues is a central contributor to the increases in preventable opioid-related deaths. However, a number of converging social-structural factors (e.g., the continued criminalisation of drug use, political changes) and political barriers are also complicating and contributing to the current crisis. We briefly outline four harm reduction interventions (i.e., injectable opioid agonist treatment, naloxone distribution programs, overdose prevention sites, and drug checking services) as emerging and rapidly expanding responses to this crisis in Canada. These examples of innovation and expansion are encouraging but also occurring at the same time that the opioid overdose crisis shows few signs of abating. To truly address the crisis, Canada needs political environments at all government levels that are responsive and foster harm reduction innovation and drug policy experimentation.	[Strike, Carol; Watson, Tara Marie] Univ Toronto, Dalla Lana Sch Publ Hlth, 155 College St, Toronto, ON M5T 3M7, Canada	Strike, C (reprint author), Univ Toronto, Dalla Lana Sch Publ Hlth, 155 College St, Toronto, ON M5T 3M7, Canada.	carol.strike@utoronto.ca	Strike, Carol/U-8317-2018	Strike, Carol/0000-0002-2716-3681; Watson, Tara Marie/0000-0003-1268-9899			Aitken C, 2002, INT J DRUG POLICY, V13, P193, DOI DOI 10.1016/S0955-3959(02)00075-0; [Anonymous], 2017, GUIDANCE INJECTABLE; [Anonymous], 2017, WHO MOD LIST ESS MED; Arkell C., 2018, HANN REDUCTION ACTIO; Bardwell G, 2018, HEALTH PLACE, V53, P86, DOI 10.1016/j.healthplace.2018.07.011; Bardwell G, 2017, HARM REDUCT J, V14, DOI 10.1186/s12954-017-0203-9; BC Centre for Disease Control, 2018, TAK HOM NAL MIL 1000; BC Centre for Disease Control, 2017, PUBL HLTH EM BC; Belackova V, 2017, OVERVIEW INT LIT SUP; Benschop A, 2002, PILL TESTING ECSTASY; Boyd S, 2017, HARM REDUCT J, V14, DOI 10.1186/s12954-017-0152-3; Brunt TM, 2017, DRUG TEST ANAL, V9, P188, DOI 10.1002/dta.1954; Brunt TM, 2011, DRUG TEST ANAL, V3, P621, DOI 10.1002/dta.323; Cameron E., 2018, WHY ALBERTA PLANS OF; Centers for Disease Control and Prevention, 2017, UND EP; Centre on Drug Policy Evaluation, 2018, COMP MOD DRUG CHECK; Charlois T., 2009, 5 M EXASS NETW COUNC; Cooper H, 2005, SOC SCI MED, V61, P673, DOI 10.1016/j.socscimed.2004.12.030; Cressman Alex M, 2017, CMAJ Open, V5, pE779, DOI 10.9778/cmajo.20170123; Dasgupta N, 2018, AM J PUBLIC HEALTH, V108, P182, DOI 10.2105/AJPH.2017.304187; Davidson PJ, 2002, ADDICTION, V97, P1511, DOI 10.1046/j.1360-0443.2002.00210.x; Davis CS, 2015, AM J PUBLIC HEALTH, V105, P1530, DOI 10.2105/AJPH.2015.302638; Department of Health and Social Care Medicines and Healthcare products Regulatory Agency & Public Health England, 2017, WID AV NAL; Dubinski K., 2018, CBC NEWS; Ferri M, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003410.pub4; Fischer B, 2002, EUR J PUBLIC HEALTH, V12, P228, DOI 10.1093/eurpub/12.3.228; Gerein K., 2017, EDMONTON J; Government of Canada, 2018, OP REL HARMS CAN; Government of Canada, 2018, FED ACT OP; Hauen J., 2018, GLOBE MAIL; Health Canada, 2018, SUP CONS SIT STAT AP; Health Canada, 2018, NALOXONE; Health Canada, 2016, NOT PRESCR DRUG LIST; Health Canada, 2016, CAN DRUGS SUBST STRA; Kennedy MC, 2018, DRUG ALCOHOL DEPEN, V185, P248, DOI 10.1016/j.drugalcdep.2017.12.026; Kerr T, 2017, DRUG CHECKING HARM R; Kerr T, 2017, HARM REDUCT J, V14, DOI 10.1186/s12954-017-0154-1; Kolla G., 2018, CAN PUBL HLTH ASS C; Lavoie J., 2017, TORONTO HARM REDUCTI; Madah-Amiri D, 2017, DRUG ALCOHOL DEPEN, V173, P17, DOI 10.1016/j.drugalcdep.2016.12.013; Madah-Amiri D, 2016, ADDICTION, V111, P1309, DOI 10.1111/add.13400; McDonald R., 2016, PREVENTING OPIOID OV, P49; McGowan CR, 2018, INT J DRUG POLICY, V58, P31, DOI 10.1016/j.drugpo.2018.04.017; Meshaka Walter E. Jr., 2018, Herpetological Bulletin, P14; Nolen S., 2018, GLOBE MAIL; Nosyk B, 2012, CAN MED ASSOC J, V184, pE317, DOI 10.1503/cmaj.110669; Ontario Ministry of Health and Long-Term Care, 2018, HLTH B APPL NOW OP O; Ontario Ministry of Health and Long-Term Care, 2018, REV SUP CONS SERV OV; Ontario Ministry of Health and Long-Term Care, 2018, NAL FREQ ASK QUEST; Oscapella E., 2012, CANADIAN DRUG POLICY; Overdose prevention groups urge health minister to declare emergency, 2017, CBC NEWS; Oviedo-Joekes E, 2008, J URBAN HEALTH, V85, P812, DOI 10.1007/s11524-008-9312-9; Oviedo-Joekes E, 2016, JAMA PSYCHIAT, V73, P447, DOI 10.1001/jamapsychiatry.2016.0109; Paddon N., 2018, HAMILTON SPECTATOR; Pollini RA, 2006, AM J PREV MED, V31, P261, DOI 10.1016/j.amepre.2006.04.002; Ponciano C., 2018, CBC NEWS; Potier C, 2014, DRUG ALCOHOL DEPEN, V145, P48, DOI 10.1016/j.drugalcdep.2014.10.012; Ramlakhan K., 2018, CBC NEWS; Rhodes T., 2002, INT J DRUG POLICY, V13, P85, DOI DOI 10.1016/S0955-3959(02)00007-5; Rudd RA, 2016, MMWR-MORBID MORTAL W, V64, P1378, DOI 10.15585/mmwr.mm6450a3; Rushowy Kristin, 2018, STAR; Sherman SG, 2008, HARM REDUCT J, V5, DOI 10.1186/1477-7517-5-2; Special Advisory Committee on the Epidemic of Opioid Overdoses, 2018, NAT REP APP OP REL D; Stone K., 2016, GLOBAL STATE HARM RE; Strang J, 2012, NEW HEROIN ASSISTED; Strike C, 2015, BEST PRACTICE RECO 2; Strike C., 2013, BESTPRACTICE RECOM 1; Tait C., 2017, GLOBE MAIL; Tupper KW, 2018, DRUG ALCOHOL DEPEN, V190, P242, DOI 10.1016/j.drugalcdep.2018.06.020; United Nations Office on Drugs and Crime, 2017, FENT ITS AN 50 YEARS; Ventura M., 2013, DRUG CHECKING SERVIC; Wheeler E, 2015, MMWR-MORBID MORTAL W, V64, P631; WHO, 2014, CONS GUID HIV PREV D; WHO UNODC UNAIDS, 2004, WHO UNODC UNAIDS POS; Wodak A, 2005, INT J DRUG POLICY, V16, pS31, DOI 10.1016/j.drugpo.2005.02.004; Wood E, 2004, CAN MED ASSOC J, V170, P1551, DOI 10.1503/cmaj.1031928	76	6	6	3	4	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0955-3959	1873-4758		INT J DRUG POLICY	Int. J. Drug Policy	SEP	2019	71						178	182		10.1016/j.drugpo.2019.02.005			5	Substance Abuse	Substance Abuse	JU0YL	WOS:000501405000025	30975595				2020-06-30	J	Geile, J; Maas, A; Kraemer, M; Doberentz, E; Madea, B				Geile, J.; Maas, A.; Kraemer, M.; Doberentz, E.; Madea, B.			Fatal misuse of transdermal fentanyl patches	FORENSIC SCIENCE INTERNATIONAL			English	Article						Fentanyl; Transdermal patch; Misuse; Intoxication; Post-mortem toxicology	NORMAL ORGAN WEIGHTS; II-THE-BRAIN; BLOOD-CONCENTRATIONS; OVERDOSE DEATHS; POSTMORTEM; METABOLISM; LIVER; CIRCUMSTANCES; TOXICOLOGY; VALSARTAN	Fentanyl is a potent synthetic opioid with a variety of possible applications. Transdermal fentanyl patches are regularly prescribed for patients with severe chronic or cancer-related pain. The potential for abuse is well-known and cases associated with illicit fentanyl intake are common. Fentanyl related fatalities due to unintentional misuse are relatively rare. This study focused on those instances and their identification in forensic examinations and adds new cases and consolidates the existing femoral blood concentrations in the event of fatal fentanyl patch misapplications. A total of 35 cases between 2010 and 2018 in which transdermal fentanyl patches were detected during forensic autopsies were identified and reviewed for the frequency of unspecific macroscopic signs of opioid intoxication. Furthermore, a detailed examination is presented for 11 cases in which toxicological results were available. The cause of death was eventually considered to be related to fentanyl patch misuse in 5 of these 11 cases. Co-administered drugs and signs of opioid intoxication, especially pulmonary edema, were frequently found. Lastly, it is advised to include norfentanyl and hair analysis in the interpretation of post-mortem fentanyl concentrations. (C) 2019 Elsevier B.V. All rights reserved.	[Geile, J.; Maas, A.; Kraemer, M.; Doberentz, E.; Madea, B.] Univ Bonn, Inst Forens Med, Bonn, Germany	Geile, J (reprint author), Univ Bonn, Inst Forens Med, Bonn, Germany.	julian.geile@ukbonn.de					Anderson DT, 2000, J ANAL TOXICOL, V24, P627, DOI 10.1093/jat/24.7.627; Andresen H, 2012, J ANAL TOXICOL, V36, P182, DOI 10.1093/jat/bks005; Bundeskriminalamt, 2017, RAUSCHG BUND, P30; Burns G, 2016, CLIN TOXICOL, V54, P420, DOI 10.3109/15563650.2016.1157722; Coopman V, 2007, FORENSIC SCI INT, V169, P223, DOI 10.1016/j.forsciint.2006.03.018; Daniulaityte R, 2017, MMWR-MORBID MORTAL W, V66, P904, DOI 10.15585/mmwr.mm6634a3; Davis GG, 2013, ACAD FORENSIC PATHOL, V3, P77; Denton JS, 2008, J FORENSIC SCI, V53, P452, DOI 10.1111/j.1556-4029.2008.00669.x; Edinboro LE, 1997, J FORENSIC SCI, V42, P741; Erbas Beate, 2016, MMW Fortschr Med, V158, P54, DOI 10.1007/s15006-016-7821-0; Feierman DE, 1996, DRUG METAB DISPOS, V24, P932; Forrester MB, 2007, J MED TOXICOL, V3, P157, DOI 10.1007/BF03160932; Gill JR, 2013, J MED TOXICOL, V9, P34, DOI 10.1007/s13181-012-0253-z; GUPTA SK, 1992, J PAIN SYMPTOM MANAG, V7, pS17, DOI 10.1016/0885-3924(92)90049-N; Hallberg P, 2006, EUR J CLIN PHARMACOL, V62, P491, DOI 10.1007/s00228-006-0120-4; HARTMANN P, 1994, PATHOLOGE, V15, P165, DOI 10.1007/s002920050040; HENDERSON GL, 1991, J FORENSIC SCI, V36, P422; Jumbelic MI, 2010, AM J FOREN MED PATH, V31, P18, DOI 10.1097/PAF.0b013e31818738b8; Kintz P, 2012, FORENSIC SCI INT, V215, P73, DOI 10.1016/j.forsciint.2011.01.041; Kramer Christopher, 1998, Journal of the American Osteopathic Association, V98, P385; Krinsky CS, 2011, AM J FOREN MED PATH, V32, P347, DOI 10.1097/PAF.0b013e31822ad269; Kuhlman JJ, 2003, J ANAL TOXICOL, V27, P499, DOI 10.1093/jat/27.7.499; Kumbasar B, 2004, INT J CLIN PHARM TH, V42, P328; Labroo RB, 1997, DRUG METAB DISPOS, V25, P1072; Lee D, 2016, J ANAL TOXICOL, V40, P588, DOI 10.1093/jat/bkw087; Lung DD, 2014, FORENSIC TOXICOL, V32, P118, DOI 10.1007/s11419-013-0216-3; Martin TL, 2006, J ANAL TOXICOL, V30, P603, DOI 10.1093/jat/30.8.603; McIntyre I.M., 2012, J FORENSIC RES, V01; Molina DK, 2015, AM J FOREN MED PATH, V36, P182, DOI 10.1097/PAF.0000000000000175; Molina DK, 2012, AM J FOREN MED PATH, V33, P368, DOI 10.1097/PAF.0b013e31823d29ad; Newshan G, 1998, J PAIN SYMPTOM MANAG, V16, P277; Oda Y, 1999, BRIT J ANAESTH, V82, P900; Olkkola KT, 1999, ANESTHESIOLOGY, V91, P681, DOI 10.1097/00000542-199909000-00020; Olson KN, 2010, AM J CLIN PATHOL, V133, P447, DOI 10.1309/AJCP4X5VHFSOERFT; Pelletier Danielle E, 2017, Acad Forensic Pathol, V7, P91, DOI 10.23907/2017.011; Peters FT, 2007, FORENSIC SCI INT, V165, P216, DOI 10.1016/j.forsciint.2006.05.021; Pilgrim JL, 2011, FORENSIC SCI MED PAT, V7, P162, DOI 10.1007/s12024-010-9188-3; Rohner C, 2013, FORENSIC SCI INT, V225, P48, DOI 10.1016/j.forsciint.2012.03.029; Schulz M, 2012, CRIT CARE, V16, DOI 10.1186/cc11441; Shomaker TS, 2000, PAIN MED, V1, P225, DOI 10.1046/j.1526-4637.2000.00030.x; Sinicina I, 2017, DRUG ALCOHOL DEPEN, V180, P286, DOI 10.1016/j.drugalcdep.2017.08.021; Smialek J.E., 1994, J FORENSIC SCI, V39; STANLEY TH, 1992, J PAIN SYMPTOM MANAG, V7, pS3, DOI 10.1016/0885-3924(92)90047-L; Stein C, 2016, ANNU REV MED, V67, P433, DOI 10.1146/annurev-med-062613-093100; STERNBACH H, 1991, AM J PSYCHIAT, V148, P705; Thompson JG, 2007, J FORENSIC SCI, V52, P978, DOI 10.1111/j.1556-4029.2007.00481.x; Tomassoni Anthony J, 2017, MMWR Morb Mortal Wkly Rep, V66, P107, DOI 10.15585/mm6604a4	47	0	0	6	7	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0379-0738	1872-6283		FORENSIC SCI INT	Forensic Sci.Int.	SEP	2019	302								109858	10.1016/j.forsciint.2019.06.016			7	Medicine, Legal	Legal Medicine	JN3LN	WOS:000496801100013	31279508				2020-06-30	J	Reiter, A; Mueller, A; Otto, B; Anders, S; Falckenberg, M; Iwersen-Bergmann, S; Andresen-Streichert, H				Reiter, Alonja; Mueller, Alexander; Otto, Benjamin; Anders, Sven; Falckenberg, Maja; Iwersen-Bergmann, Stefanie; Andresen-Streichert, Hilke			Fast increase of postmortem fentanyl blood concentrations after transdermal application: A call to careful interpretation	FORENSIC SCIENCE INTERNATIONAL			English	Article						Intoxication; Antemortem; Fentanyl patch; Norfentanyl; LC-MS/MS; Opioid; Postmortem redistribution	PHARMACOKINETICS; PATCH; REDISTRIBUTION; MISUSE	Background: Interpretation of postmortem fentanyl concentrations after transdermal application remains a challenge. There are indications that fentanyl shows relevant postmortem redistribution. The aim of this study was to investigate the time course of these changes and to develop recommendations for toxicological case work. Material and method: Blood specimens were collected from palliative care patients who were treated with fentanyl transdermal patches. Antemortem reference samples (ethylenediaminetetraacetic acid (EDTA) and serum specimens) were collected at stable dose rates. Postmortem femoral venous blood specimens were collected at four postmortem time-points: 2 hpm (hours postmortem), 6-8 hpm, 11-16 hpm and approximately 24 hpm. Liquid chromatography tandem mass spectrometry was applied to quantify fentanyl and norfentanyl. Results: Ten patients were included in the study (8 men, 2 women). Fentanyl patches with delivery rates of 12-150 mu g/h were applied. Antemortem fentanyl levels in EDTA samples varied between 0.19 and 4.64 mu g/L. At 6 to 8 hpm, blood concentrations of fentanyl were already significantly (p =0.05) higher in postmortem samples compared to the paired antemortem reference. On average, the antemortem concentration (range: 0.19-4.64 mu g/L) increased 3-fold within 6-8 hpm (range: 0.4-14.9 mu g/L), and 5.5-fold within 24 hpm (range: 0.39-21.88 mu g/L). Norfentanyl concentrations increased significantly (p = 0.01) within 6-8 hpm, too. In half of the patients, norfentanyl concentrations were below fentanyl concentrations, antemortem as well as postmortem. Conclusion: Postmortem fentanyl concentrations increased quickly. As early as 6-8 h after death, postmortem concentrations differ significantly from antemortem ones. Our results strongly indicate that postmortem blood concentrations of fentanyl after transdermal application should be interpreted carefully. (C) 2019 Elsevier B.V. All rights reserved.	[Reiter, Alonja; Mueller, Alexander; Iwersen-Bergmann, Stefanie; Andresen-Streichert, Hilke] Univ Med Ctr Hamburg Eppendorf, Inst Legal Med, Dept Forens Toxicol, Butenfeld 34, D-22529 Hamburg, Germany; [Otto, Benjamin] Univ Med Ctr Hamburg Eppendorf, Dept Internal Med, Martinistr 52, D-20251 Hamburg, Germany; [Anders, Sven] Univ Med Ctr Hamburg Eppendorf, Inst Legal Med, Butenfeld 34, D-22529 Hamburg, Germany; [Falckenberg, Maja] Schmerzambulanz Alten Eichen, Hohe Weide 17b, D-20259 Hamburg, Germany; [Andresen-Streichert, Hilke] Univ Cologne, Fac Med, Inst Legal Med, Dept Forens Toxicol, Melatengurtel 60-62, D-50823 Cologne, Germany	Andresen-Streichert, H (reprint author), Univ Cologne, Fac Med, Inst Legal Med, Dept Forens Toxicol, Melatengurtel 60-62, D-50823 Cologne, Germany.	Hilke.andresen-streichert@uk-koeln.de					Anderson DT, 2000, J ANAL TOXICOL, V24, P627, DOI 10.1093/jat/24.7.627; Andresen H, 2012, J ANAL TOXICOL, V36, P182, DOI 10.1093/jat/bks005; BOWER S, 1982, BRIT J ANAESTH, V54, P871, DOI 10.1093/bja/54.8.871; Ceelen L, 2012, AM J FOREN MED PATH, V33, P119, DOI 10.1097/PAF.0b013e3181fbbb49; Chatterton CN, 2018, FORENSIC SCI INT, V284, P146, DOI 10.1016/j.forsciint.2017.12.031; Drug Enforcement Administration U.S, 2015, DEA ISS NAT AL FENT; Drug Enforcement Administration U.S, 2017, DEA RES GUID; Ferner RE, 2008, BRIT J CLIN PHARMACO, V66, P430, DOI 10.1111/j.1365-2125.2008.03231.x; Janssen-Cilag Limited UK, 2018, SUMM PROD CHAR DUR; Joranson DE, 2000, JAMA-J AM MED ASSOC, V283, P1710, DOI 10.1001/jama.283.13.1710; Lung DD, 2014, FORENSIC TOXICOL, V32, P118, DOI 10.1007/s11419-013-0216-3; MATHER LE, 1983, CLIN PHARMACOKINET, V8, P422, DOI 10.2165/00003088-198308050-00004; Moore PW, 2015, J FORENSIC SCI, V60, P243, DOI 10.1111/1556-4029.12559; Nelson L, 2009, J MED TOXICOL, V5, P230, DOI 10.1007/BF03178274; O'Donnell JK, 2017, MMWR-MORBID MORTAL W, V66, P1197, DOI 10.15585/mmwr.mm6643e1; Olson KN, 2010, AM J CLIN PATHOL, V133, P447, DOI 10.1309/AJCP4X5VHFSOERFT; Palmer RB, 2010, CLIN TOXICOL, V48, P771, DOI 10.3109/15563650.2010.525514; Peters F. T., 2009, TOXICHEM KRIMTECH, V76, P185; POKLIS A, 1995, J TOXICOL-CLIN TOXIC, V33, P439, DOI 10.3109/15563659509013752; Reeves MD, 2002, MED J AUSTRALIA, V177, P552, DOI 10.5694/j.1326-5377.2002.tb04951.x; Ruan XL, 2016, CLIN TOXICOL, V54, P893, DOI 10.1080/15563650.2016.1199030; Schulz M, 2012, CRIT CARE, V16, DOI 10.1186/cc11441; Solassol I, 2005, THER DRUG MONIT, V27, P491, DOI 10.1097/01.ftd.0000160717.50704.42; STANLEY TH, 1992, J PAIN SYMPTOM MANAG, V7, pS3, DOI 10.1016/0885-3924(92)90047-L	24	0	0	6	6	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0379-0738	1872-6283		FORENSIC SCI INT	Forensic Sci.Int.	SEP	2019	302								109896	10.1016/j.forsciint.2019.109896			10	Medicine, Legal	Legal Medicine	JN3LN	WOS:000496801100048	31426021				2020-06-30	J	Vandergrift, GW; Gill, CG				Vandergrift, Gregory W.; Gill, Chris G.			Paper spray mass spectrometry: A new drug checking tool for harm reduction in the opioid overdose crisis	JOURNAL OF MASS SPECTROMETRY			English	Article						direct mass spectrometry; drug checking; harm reduction; opioid overdose crisis; paper spray mass spectrometry (PS-MS)	RAPID ANALYSIS; MINIATURE; IONIZATION; FENTANYL; SUBSTRATE; CARE; COCAINE; BLOOD	Fentanyl and related psychoactive substances are at the forefront of the opioid overdose crisis, for which a complete solution is not immediately obvious. Drug testing for harm reduction may be an effective approach to both reduce overdoses and importantly, engage people who use drugs (PWUD) with the medical system. Paper spray mass spectrometry (PS-MS) is an ambient ionization strategy that is uniquely suited to address this complicated analytical task. This perspectives article presents the merits of PS-MS, with a focus upon the current state of its use as a candidate drug checking strategy for harm reduction. PS-MS is inherently sensitive and selective, with detection limits in the picogram range. It requires small drug samples (~1 mg) for quantitative drug testing, critical to encourage pre-consumption measurements by PWUD in the context of a harm reduction strategy. Calibrations obtained in surrogate drug matrices containing highly concentrated primary drugs demonstrate comparable sensitivities, a wide calibration range, and minimal matrix effects. PS-MS can be interfaced with high-resolution MS for non-targeted analysis, allowing the identification of novel psychoactive substances as they appear in street drugs. Individual quantitative PS-MS measurements for drug testing can be done in 1 minute or less, resulting in high sample throughput. Significant advancement in mass spectrometer miniaturization and mobilization has concomitant benefits for direct, on-site drug checking, such as reduced cost, simplified maintenance and ease of use by less skilled operators. While PS-MS technology continues to rapidly advance, it is our opinion that PS-MS can be utilized as an effective tool for harm reduction in the opioid overdose crisis.	[Vandergrift, Gregory W.; Gill, Chris G.] Vancouver Isl Univ, Chem Dept, AERL, 900 Fifth St, Nanaimo, BC V9R 5S5, Canada; [Vandergrift, Gregory W.; Gill, Chris G.] Univ Victoria, Chem Dept, Victoria, BC, Canada; [Gill, Chris G.] Simon Fraser Univ, Chem Dept, Burnaby, BC, Canada; [Gill, Chris G.] Univ Washington, Environm & Occupat Hlth Sci Dept, Seattle, WA 98195 USA	Gill, CG (reprint author), Vancouver Isl Univ, Chem Dept, AERL, 900 Fifth St, Nanaimo, BC V9R 5S5, Canada.	chris.gill@viu.ca			Natural Sciences and Engineering Research Council of Canada (NSERC)Natural Sciences and Engineering Research Council of Canada [RGPIN-2016-05380]; Vancouver Island University; University of Victoria		de Paula CCA, 2015, ANAL METHODS-UK, V7, P9145, DOI [10.1039/c5ay02263k, 10.1039/C5AY02263K]; Baselt R.C., 2014, DISPOSITION TOXIC DR; BC Coroner's Service, 2017, FENTANYL DETECTED IL, P1; Bills BJ, 2018, FORENSIC CHEM, V11, P15, DOI 10.1016/j.forc.2018.08.002; Carvalho TC, 2016, ANAL METHODS-UK, V8, P614, DOI 10.1039/c5ay01265a; Colletes TC, 2016, ANALYST, V141, P1707, DOI [10.1039/C5AN01954K, 10.1039/c5an01954k]; Costa C, 2017, CLIN CHEM, V63, P1745, DOI 10.1373/clinchem.2017.275578; De Carvalho TC, 2016, FORENSIC SCI INT, V262, P56, DOI 10.1016/j.forsciint.2016.02.039; Drucker E, 2016, J BIOETHIC INQ, V13, P239, DOI 10.1007/s11673-016-9720-6; Espy RD, 2012, INT J MASS SPECTROM, V325, P167, DOI 10.1016/j.ijms.2012.06.017; Espy RD, 2012, ANALYST, V137, P2344, DOI 10.1039/c2an35082c; Fedick PW, 2017, ANAL CHEM, V89, P10973, DOI 10.1021/acs.analchem.7b02798; Florence CS, 2016, MED CARE, V54, P901, DOI 10.1097/MLR.0000000000000625; Gerbig S, 2017, ANAL CHEM, V89, P10717, DOI 10.1021/acs.analchem.7b01689; Government of Canada, 2019, FENT; Hagan H, 2000, J SUBST ABUSE TREAT, V19, P247, DOI 10.1016/S0740-5472(00)00104-5; Hendricks PI, 2014, ANAL CHEM, V86, P2900, DOI 10.1021/ac403765x; Huo DZ, 2005, AIDS EDUC PREV, V17, P170, DOI 10.1521/aeap.17.3.170.62900; Jozaghi E, 2014, SUBST ABUSE TREAT PR, V9, DOI 10.1186/1747-597X-9-31; Kappel N, 2016, HARM REDUCT J, V13, DOI 10.1186/s12954-016-0109-y; Kennedy JH, 2018, RAPID COMMUN MASS SP, V32, P1280, DOI 10.1002/rcm.8164; Krogh ET, 2014, J MASS SPECTROM, V49, P1205, DOI 10.1002/jms.3447; Li LF, 2014, ANAL CHEM, V86, P2909, DOI 10.1021/ac403766c; Liu JJ, 2010, ANAL CHEM, V82, P2463, DOI 10.1021/ac902854g; Ma Q, 2015, TALANTA, V142, P190, DOI 10.1016/j.talanta.2015.04.044; Manicke NE, 2015, J AM SOC MASS SPECTR, V26, P701, DOI 10.1007/s13361-015-1096-z; Manicke NE, 2011, INT J MASS SPECTROM, V300, P123, DOI 10.1016/j.ijms.2010.06.037; McBride EM, 2019, TRAC-TREND ANAL CHEM, V118, P722, DOI 10.1016/j.trac.2019.06.028; McKenna J, 2018, J ANAL TOXICOL, V1, P1; McKenna J, 2017, ANALYST, V142, P1442, DOI 10.1039/c7an00144d; Misailidi N, 2018, FORENSIC TOXICOL, V36, P1, DOI 10.1007/s11419-017-0371-z; Noble C, 2018, DRUG TEST ANAL, V10, P651, DOI 10.1002/dta.2263; O'Leary AE, 2015, ANAL METHODS-UK, V7, P3331, DOI 10.1039/c4ay02778g; Ouyang Z, 2009, ANNU REV ANAL CHEM, V2, P187, DOI 10.1146/annurev-anchem-060908-155229; Pauly B, 2015, ADV NURS SCI, V38, P121, DOI 10.1097/ANS.0000000000000070; Teodoro JAR, 2017, FOOD CHEM, V237, P1058, DOI 10.1016/j.foodchem.2017.06.062; Ren Y, 2013, CHROMATOGRAPHIA, V76, P1339, DOI 10.1007/s10337-013-2458-y; Ren ZY, 2018, VACUUM, V155, P108, DOI 10.1016/j.vacuum.2018.05.048; Richardson LA, 2015, AIDS, V29, P2487, DOI 10.1097/QAD.0000000000000853; Schackman BR, 2006, MED CARE, V44, P990, DOI 10.1097/01.mlr.0000228021.89490.2a; Shen LH, 2013, CLIN CHIM ACTA, V420, P28, DOI 10.1016/j.cca.2012.10.025; Snyder DT, 2016, ANAL CHEM, V88, P2, DOI 10.1021/acs.analchem.5b03070; Su Y, 2013, ANALYST, V138, P4443, DOI 10.1039/c3an00934c; Sutter ME, 2017, ACAD EMERG MED, V24, P106, DOI 10.1111/acem.13034; Tupper KW, 2018, DRUG ALCOHOL DEPEN, V190, P242, DOI 10.1016/j.drugalcdep.2018.06.020; Vandergrift GW, 2018, CLIN BIOCHEM, V54, P106, DOI 10.1016/j.clinbiochem.2018.02.005; Venture M., 2019, DRUG CHECKING SERVIC; Wang H., 2010, ANGEW CHEM, V122, P889, DOI DOI 10.1002/ANGE.200906314; Wang Q, 2015, ANALYST, V140, P8048, DOI [10.1039/c5an01823d, 10.1039/C5AN01823D]; Zhang ZP, 2012, ANALYST, V137, P2556, DOI 10.1039/c2an35196j; Zou R, 2019, ANAL CHEM, V91, P1157, DOI 10.1021/acs.analchem.8b04935	51	2	2	10	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1076-5174	1096-9888		J MASS SPECTROM	J. Mass Spectrom.	SEP	2019	54	9					729	737		10.1002/jms.4431			9	Biochemical Research Methods; Chemistry, Analytical; Spectroscopy	Biochemistry & Molecular Biology; Chemistry; Spectroscopy	JD4IY	WOS:000489941500001	31432563				2020-06-30	J	Hayley, AC; Downey, LA; Green, M; Shiferaw, B; Kenneally, M; Keane, M; Adams, M; Shehabi, Y				Hayley, Amie C.; Downey, Luke A.; Green, Maja; Shiferaw, Brook; Kenneally, Michaela; Keane, Michael; Adams, Mark; Shehabi, Yahya			Driving Simulator Performance After Administration of Analgesic Doses of Ketamine With Dexmedetomidine or Fentanyl	JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY			English	Article						ketamine; fentanyl; dexmedetomidine; SDLP; driving; performance	COGNITIVE FUNCTIONS; HEALTHY-VOLUNTEERS; DOUBLE-BLIND; PAIN; ANESTHESIA; RELEVANT; PROPOFOL; ABILITY	Purpose/Background As a sole agent, ketamine acutely compromises driving ability; however, performance after coadministration with the adjuvant sedating agents dexmedetomidine or fentanyl is unclear. Methods/Procedures Using a randomized within-subject design, 39 participants (mean +/- SD age, 28.4 +/- 5.8 years) received 0.3 mg/kg bolus followed by 0.15 mg kg(-1) h(-1) infusion of ketamine (3-hour duration), in addition to either (i) 0.7 mu g kg(-1) h(-1) infusion of dexmedetomidine for 1.5 hours (n = 19; KET/DEX) or (ii) three 25 mu g fentanyl injections for 1.5 hours (n = 20; KET/FENT). Whole blood drug concentrations were determined during ketamine only, at coadministration (KET/DEX or KET/FENT) and at 2 hours after treatment. Subjective effects were determined using a standardized visual analog scale. Driving performance was assessed at baseline and at posttreatment using a validated computerized driving simulator. Primary outcomes included SD of lateral position (SDLP) and steering variability (SV). Findings/Results Administration of ketamine with dexmedetomidine but not fentanyl significantly increased SDLP (F-1,F-18 = 22.60, P < 0.001) and reduced SV (F-1,F-18 = 164.42, P < 0.001) 2 hours after treatment. These deficits were comparatively greater for the KET/DEX group than for the KET/FENT group (t(37) = -5.21 [P < 0.001] and t(37) = 5.22 [P < 0.001], (respectively). For the KET/DEX group, vehicle control (SV) and self-rated performance (visual analog scale), but not SDLP, was inversely associated with ketamine and norketamine blood concentrations (in nanograms per milliliter). Greater subjective effects were moderately associated with driving deficits.	[Hayley, Amie C.; Downey, Luke A.; Shiferaw, Brook; Keane, Michael] Swinburne Univ Technol, Ctr Human Psychopharmacol, Hawthorn, Vic, Australia; [Downey, Luke A.] Austin Hosp, Inst Breathing & Sleep, Melbourne, Vic, Australia; [Green, Maja] Monash Univ, Monash Hlth Translat Precinct, Dept Oncol, Clayton, Vic, Australia; [Green, Maja; Keane, Michael; Adams, Mark; Shehabi, Yahya] Monash Univ, Sch Clin Sci, Program Crit Care & Perioperat Med, Melbourne, Vic, Australia; [Kenneally, Michaela] Forens Sci South Australia, Adelaide, SA, Australia	Hayley, AC (reprint author), Swinburne Univ Technol, Fac Hlth Arts & Design, Ctr Human Psychopharmacol, Hawthorn, Vic 3122, Australia.	ahayley@swin.edu.au	Downey, Luke/AAG-8854-2020	Downey, Luke/0000-0001-5670-3192; Hayley, Amie/0000-0002-4470-4718	National Health and Medical Council Peter Doherty Biomedical Early Career Research Fellowship [GNT: 1119960 2017-2020]; National Health and Medical Council R.D. Wright Biomedical Career Development Fellowship [GNT: 1122577 2017-2020]	Dr Amie Hayley is supported by a National Health and Medical Council Peter Doherty Biomedical Early Career Research Fellowship (GNT: 1119960 2017-2020). A/ProfDowney is supported by aNational Health and Medical Council R.D. Wright Biomedical Career Development Fellowship (GNT: 1122577 2017-2020).	Australian and New Zealand College of Anaethetists (ANZCA), 2014, GUID SED AN DIAGN IN, P1; BOND A, 1974, BRIT J MED PSYCHOL, V47, P211, DOI 10.1111/j.2044-8341.1974.tb02285.x; Bowdle TA, 1998, ANESTHESIOLOGY, V88, P82, DOI 10.1097/00000542-199801000-00015; Chung F, 1998, ANESTH ANALG, V31, P663; Denolle T, 2002, FUND CLIN PHARMACOL, V16, P527, DOI 10.1046/j.1472-8206.2002.00110.x; Ebert TJ, 2000, ANESTHESIOLOGY, V93, P382, DOI 10.1097/00000542-200008000-00016; Elia N, 2005, PAIN, V113, P61, DOI 10.1016/j.pain.2004.09.036; Giorgetti R, 2015, FORENSIC SCI INT, V252, P127, DOI 10.1016/j.forsciint.2015.04.024; Hayley A, 2018, PSYCHOPHARMACOLOGY, V235, P1273, DOI 10.1007/s00213-018-4842-7; Hayley AC, 2019, PROG NEURO-PSYCHOPH, V94, DOI 10.1016/j.pnpbp.2019.109647; Hayley AC, 2018, PROG NEURO-PSYCHOPH, V86, P83, DOI 10.1016/j.pnpbp.2018.05.015; Honey RAE, 2003, NEUROPSYCHOPHARMACOL, V28, P2037, DOI 10.1038/sj.npp.1300272; Ip HYV, 2009, CURR OPIN ANESTHESIO, V22, P748, DOI 10.1097/ACO.0b013e328331d498; Jagoda AS, 1998, ANN EMERG MED, V31, P663, DOI 10.1016/S0196-0644(98)70216-1; Karthigan R, 2016, INT J SURG, V36, pS70; Kotegawa T., 1998, Pharmacy and Pharmacology Communications, V4, P283; Lin TF, 2009, BRIT J ANAESTH, V102, P117, DOI 10.1093/bja/aen320; Louwerens JW, 1987, ALCOHOL DRUGS TRAFFI, P183, DOI DOI 10.1080/15389588.2014.935356; [马盼盼 Ma Panpan], 2013, [吉林大学学报. 医学版, Journal of Jilin Univeristy. Medicine edition], V39, P128; Menefee LA, 2004, PAIN MED, V5, P42, DOI 10.1111/j.1526-4637.2004.04005.x; Mitchell M, 2015, AMBUL SURG, V21, P4; Peltoniemi MA, 2016, CLIN PHARMACOKINET, V55, P1059, DOI 10.1007/s40262-016-0383-6; Quibell R, 2011, J PAIN SYMPTOM MANAG, V41, P640, DOI 10.1016/j.jpainsymman.2011.01.001; Sabatowski R, 2003, J PAIN SYMPTOM MANAG, V25, P38, DOI 10.1016/S0885-3924(02)00539-0; Schneider U, 1999, NEUROPSYCHOBIOLOGY, V39, P38, DOI 10.1159/000026558; STEVENSON GW, 1986, INVEST RADIOL, V21, P717, DOI 10.1097/00004424-198609000-00008; Subramaniam K, 2004, ANESTH ANALG, V99, P482, DOI 10.1213/01.ANE.0000118109.12855.07; Telles JL, 2016, ANAESTH INTENS CARE, V44, P696, DOI 10.1177/0310057X1604400602; Thabane L, 2013, BMC MED RES METHODOL, V13, DOI 10.1186/1471-2288-13-92; THAPAR P, 1995, ANESTH ANALG, V80, P1092, DOI 10.1097/00000539-199506000-00005; Tobias JD, 2012, PEDIATR CRIT CARE ME, V13, P423, DOI 10.1097/PCC.0b013e318238b81c; Tosun Z, 2006, J CARDIOTHOR VASC AN, V20, P515, DOI 10.1053/j.jvca.2005.07.018; TUCKER AP, 2005, [No title captured], V5, P2; van de Loo AJAE, 2017, PSYCHOPHARMACOLOGY, V234, P3175, DOI 10.1007/s00213-017-4706-6; Verster JC, 2011, INT J GEN MED, V4, P359, DOI 10.2147/IJGM.S19639; Verster JC, 2009, INT J ENV RES PUB HE, V6, P1041, DOI 10.3390/ijerph6031041; Weerink MAS, 2017, CLIN PHARMACOKINET, V56, P893, DOI 10.1007/s40262-017-0507-7; Yatabe T, 2016, J CLIN ANESTH, V33, P92, DOI 10.1016/j.jclinane.2016.03.017	38	0	0	1	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0271-0749	1533-712X		J CLIN PSYCHOPHARM	J. Clin. Psychopharmacol.	SEP-OCT	2019	39	5					446	454		10.1097/JCP.0000000000001101			9	Pharmacology & Pharmacy; Psychiatry	Pharmacology & Pharmacy; Psychiatry	IY1RY	WOS:000486170600006	31433347				2020-06-30	J	Guitart, J; Vargas, MI; De Sanctis, V; Folch, J; Salazar, R; Fuentes, J; Coma, J; Ferreras, J; Moya, J; Tomas, A; Estivill, P; Rodelas, F; Jimenez, AJ; Sanz, A				Guitart, Jordi; Isabel Vargas, Maria; De Sanctis, Vicente; Folch, Jordi; Salazar, Rafael; Fuentes, Jose; Coma, Joan; Ferreras, Julia; Moya, Jordi; Tomas, Albert; Estivill, Pere; Rodelas, Francisco; Javier Jimenez, Antonio; Sanz, Almudena			Effects of Age Among Elderly Cancer Patients on Breakthrough Pain Management with Sublingual Fentanyl Tablets	DRUGS IN R&D			English	Article							OLD-OLD; ASSOCIATION; PREVALENCE; ADULTS	Introduction Sublingual fentanyl tablets (SFTs) have been shown to be a safe and effective option in controlling breakthrough cancer pain (BTcP). However, further examination is required to investigate the use of SFTs among the elderly. The aim of this study was to examine the influence of age in BTcP management with SFTs in the elderly population. Methods We performed subgroup analyses of a recently completed trial in two subsets of individuals: patients aged 65-74 years (low age group) and patients >= 75 years (high age group). Pain intensity (PI), onset of pain relief, frequency and duration of BTcP episodes, and adverse events (AEs) were assessed at 3, 7, 15, and 30 days. Health status instruments used were the Hospital Anxiety and Depression Scale (HADS-A and HADS-D) and the Short Form 12, version 2 (SF-12v2) questionnaire. Results Levels of PI at the end of the study improved significantly as compared with baseline in both the low and the high age groups (30.0% and 27.7% reduction, respectively). The onset of analgesia at the end of the study began in < 10 min in 85.0% of young-old subjects and in 62.5% of patients >= 75 years, but no significant differences were found. BTcP episodes lasted < 15 min in 75.0% of patients in the low age group and 58.3% in the high age group (p = 0.24). Most of patients in both groups experienced one to five BTcP daily episodes, at all assessment points. HADS-D decreased from 10.78 (+/- 4.33) to 8.21 (+/- 3.57) in the low age group, and from 10.96 (+/- 4.26) to 9.36 (+/- 3.35) in the high age group (p = 0.02). Significant differences in HADS-A scores from baseline to the end of the study were also observed in both subgroups (p < 0.05). Patients in the low age group had less favorable mental component summary (MCS) and physical component summary (PCS) scores than patients in the high age group. At the end of the study, 10.0% of young-old patients and 29.2% of patients aged >= 75 years reported AEs related to their treatment. The most commonly reported AEs included nausea, vomiting, constipation, somnolence, and skin disorders and they were generally mild to moderate in severity. Conclusions The results of this study showed that SFTs provided safe and clinically meaningful pain relief in both elderly subgroups. Clinical implications of these findings await validation in large, confirmatory studies to identify age subgroup divergences among elderly cancer patients treated with SFTs.	[Guitart, Jordi; Folch, Jordi] Hosp Plato, Dept Anesthesiol, C Plato 21, Barcelona 08006, Spain; [Isabel Vargas, Maria; Estivill, Pere] Parc Sanitari St Joan Deu, Dept Anesthesiol, Barcelona, Spain; [De Sanctis, Vicente] Hosp Univ Sagrat Cor, Dept Anesthesiol, Pain Unit, Barcelona, Spain; [Salazar, Rafael; Rodelas, Francisco] Hosp Comarcal Inca, Dept Anesthesiol, Palma De Mallorca, Spain; [Fuentes, Jose] Pius Hosp Valls, Dept Anesthesiol, Tarragona, Spain; [Coma, Joan] Hosp Gen Hosp, Dept Anesthesiol, Barcelona, Spain; [Ferreras, Julia] Hosp Residencia St Camil, Dept Anesthesiol, Pain Unit, Barcelona, Spain; [Moya, Jordi] Hosp Mateu Orfila, Dept Anesthesiol, Pain Unit, Minorca, Spain; [Tomas, Albert] Fundacio Hosp St Bernabe, Dept Anesthesiol, Pain Unit, Barcelona, Spain; [Javier Jimenez, Antonio; Sanz, Almudena] Kyowa Kirin Farmaceut SLU, Madrid, Spain	Guitart, J (reprint author), Hosp Plato, Dept Anesthesiol, C Plato 21, Barcelona 08006, Spain.	jordi.guitart@hospitalplato.com			Kyowa Kirin Farmaceutica SLU, Spain	This study was funded by Kyowa Kirin Farmaceutica SLU, Spain.	Alterovitz SSR, 2013, J AGING STUD, V27, P159, DOI 10.1016/j.jaging.2012.12.006; Balducci L, 2006, ONCOLOGY-NY, V20, P135; Bellizzi KM, 2008, CANCER-AM CANCER SOC, V113, P3479, DOI 10.1002/cncr.23937; Berlin CM, 1997, PEDIATRICS, V100, P143; Brant JM, 2018, ASIA-PAC J ONCOL NU, V5, P248, DOI 10.4103/apjon.apjon_11_18; Caraceni A, 2004, PALLIATIVE MED, V18, P177, DOI 10.1191/0269216304pm890oa; Chwieduk CM, 2010, DRUGS, V70, P2281, DOI 10.2165/11200910-000000000-00000; Cohen-Mansfield J, 2013, INT J AGING HUM DEV, V77, P37, DOI 10.2190/AG.77.1.c; Davies AN, 2009, EUR J PAIN, V13, P331, DOI 10.1016/j.ejpain.2008.06.014; Deandrea S, 2014, J PAIN SYMPTOM MANAG, V47, P57, DOI 10.1016/j.jpainsymman.2013.02.015; DICKMAN A, 2009, PHARM J, V283, P213; Green CR, 2010, PAIN MED, V11, P1525, DOI 10.1111/j.1526-4637.2010.00957.x; Guitart J, 2018, DRUGS R&D, V18, P119, DOI 10.1007/s40268-018-0231-2; Guitart J, 2017, DRUGS R&D, V17, P419, DOI 10.1007/s40268-017-0198-4; Guitart J, 2015, CLIN DRUG INVEST, V35, P815, DOI 10.1007/s40261-015-0344-0; Hilmer SN, 2007, FUND CLIN PHARMACOL, V21, P217, DOI 10.1111/j.1472-8206.2007.00473.x; Hutchins LF, 1999, NEW ENGL J MED, V341, P2061, DOI 10.1056/NEJM199912303412706; Lennernas B, 2010, PALLIATIVE MED, V24, P286, DOI 10.1177/0269216309356138; Lewis JH, 2003, J CLIN ONCOL, V21, P1383, DOI 10.1200/JCO.2003.08.010; Margarit Cesar, 2012, J Pain Res, V5, P559, DOI 10.2147/JPR.S36428; McLachlan AJ, 2009, CLIN PHARMACOL THER, V85, P431, DOI 10.1038/clpt.2009.1; Mercadante S, 2000, SUPPORT CARE CANCER, V8, P123, DOI 10.1007/s005200050026; Mercadante S, 2007, DRUG AGING, V24, P761, DOI 10.2165/00002512-200724090-00004; Mercadante S, 2015, DRUG AGING, V32, P315, DOI 10.1007/s40266-015-0253-1; Mercadante S, 2014, CURR MED RES OPIN, V30, P1353, DOI 10.1185/03007995.2014.901942; Pautex S, 2014, DRUG AGING, V31, P405, DOI 10.1007/s40266-014-0181-5; Payne R, 2007, PAIN MED, V8, pS3; Pergolizzi JV, 2015, PAIN PRACT, V15, P778, DOI 10.1111/papr.12253; PORTENOY RK, 1990, PAIN, V41, P273, DOI 10.1016/0304-3959(90)90004-W; Rauck RL, 2009, CURR MED RES OPIN, V25, P2877, DOI 10.1185/03007990903368310; Shenoy Premnath, 2015, Perspect Clin Res, V6, P184, DOI 10.4103/2229-3485.167099; SNAITH RP, 1986, BRIT MED J, V292, P344, DOI 10.1136/bmj.292.6516.344; Swaminathan D, 2015, CANCER BIOL MED, V12, P275, DOI 10.7497/j.issn.2095-3941.2015.0081; Swaminathan V, 2012, ECANCERMEDICALSCIENC, V6, DOI 10.3332/ecancer.2012.243; Uberall MA, 2011, CURR MED RES OPIN, V27, P1385, DOI 10.1185/03007995.2011.583231; VALASEK DL, 1981, [No title captured]; van den Beuken-van Everdingen MHJ, 2016, J PAIN SYMPTOM MANAG, V51, P1070, DOI 10.1016/j.jpainsymman.2015.12.340; Yee KWL, 2003, J CLIN ONCOL, V21, P1618, DOI 10.1200/JCO.2003.12.044; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	39	0	0	2	4	SPRINGER INTERNATIONAL PUBLISHING AG	CHAM	GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND	1174-5886	1179-6901		DRUGS R&D	Drugs R&D	SEP	2019	19	3					247	254		10.1007/s40268-019-0276-x			8	Pharmacology & Pharmacy	Pharmacology & Pharmacy	IW9JQ	WOS:000485310000002	31177479	DOAJ Gold, Green Published			2020-06-30	J	Brighthaupt, SC; Stone, EM; Rutkow, L; McGinty, EE				Brighthaupt, S. C.; Stone, E. M.; Rutkow, L.; McGinty, E. E.			Effect of pill mill laws on opioid overdose deaths in Ohio & Tennessee: A mixed-methods case study	PREVENTIVE MEDICINE			English	Article						Pill mill law; Pain Management Clinic; Opioid Overdose Deaths; Opioid Overprescribing; Heroin; Synthetic control method	STATES; DRUG; PAIN	Pill mill laws impose strict regulations on pain management clinics to prevent them from issuing opioid prescriptions without medical indication. To date, little is known about the implementation or effects of these laws on opioid overdose deaths. A previously untested concern is that by restricting access to prescription opioids, pill mill laws could increase overdose from heroin and synthetic opioids, like illicitly produced fentanyl. We evaluated the effects of pill mill laws on opioid overdose deaths in Ohio and Tennessee. Of the 11 total U.S. states with pill mill laws, Ohio and Tennessee were the only two where: (1) the pill mill law was the only state law designed to curb opioid prescribing implemented in a two-year period, one-year pre/post law; and (2) high-quality drug-specific overdose death data were available from CDC. We conducted synthetic control analyses examining differences in post-pill mill law trends in overdose deaths in Ohio and Tennessee compared to weighted combinations of comparison states. We also conducted qualitative interviews with 11 leaders responsible for pill mill law implementation and enforcement in Ohio and Tennessee. Pill mill law enactment had no effects on overall, prescription opioid, heroin, or synthetic opioid overdose deaths in Ohio or Tennessee. Interview results suggest that both states engaged in robust enforcement and implementation of the law. A multi-pronged policy approach, including but not limited to pill mill laws, may be required to effectively address opioid overdose deaths.	[Brighthaupt, S. C.; McGinty, E. E.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Mental Hlth, 624 N Broadway,8th Floor,Room 886, Baltimore, MD 21205 USA; [Stone, E. M.] Johns Hopkins Sch Med, Div Gen Internal Med, Baltimore, MD USA; [Rutkow, L.; McGinty, E. E.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD 21205 USA	Brighthaupt, SC (reprint author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Mental Hlth, 624 N Broadway,8th Floor,Room 886, Baltimore, MD 21205 USA.	sbright5@jhu.edu			Johns Hopkins Bloomberg School of Public Health, Lipitz Public Health Policy faculty award	This work was supported by a Johns Hopkins Bloomberg School of Public Health, Lipitz Public Health Policy faculty award (PIs: McGinty & Rutkow). The study sponsor had no role in determining study design; data collection, analysis, or interpretation; writing the report; or the decision to submit the report for publication.	Abadie A, 2015, AM J POLIT SCI, V59, P495, DOI 10.1111/ajps.12116; Abadie A, 2010, J AM STAT ASSOC, V105, P493, DOI 10.1198/jasa.2009.ap08746; Centers for Disease Control and Prevention (CDC), 1999, MULT CAUS DEATH DAT; Cicero TJ, 2018, ADDICT BEHAV, V87, P267, DOI 10.1016/j.addbeh.2018.05.030; Finley EP, 2017, BMC HEALTH SERV RES, V17, DOI 10.1186/s12913-017-2354-5; Health Resources and Services Administration, 2014, AR HLTH RES FIL; Kolodny A, 2015, ANNU REV PUBL HEALTH, V36, P559, DOI 10.1146/annurev-publhealth-031914-122957; Lyapustina T, 2016, DRUG ALCOHOL DEPEN, V159, P190, DOI 10.1016/j.drugalcdep.2015.12.025; McGinty EE, 2018, IMPLEMENT SCI, V13, DOI 10.1186/s13012-018-0719-8; Miles M. B, 1994, QUALITATIVE DATA ANA; Ohio State Board of Pharmacy, 2015, PAIN MANG CLIN OH SP; Pitt AL, 2018, AM J PUBLIC HEALTH, V108, P1394, DOI 10.2105/AJPH.2018.304590; Rudd RA, 2016, MMWR-MORBID MORTAL W, V65, P1445, DOI 10.15585/mmwr.mm655051e1; Rutkow L, 2017, AM J PUBLIC HEALTH, V107, P240, DOI 10.2105/AJPH.2016.303568; Rutkow L, 2015, JAMA INTERN MED, V175, P1642, DOI 10.1001/jamainternmed.2015.3931; Smith JR, 2014, PRESCRIPTION DRUG AB; Strauss A., 1990, BASICS QUALITATIVE R; US Census Bureau, H2 URB RUR 2010 CENS; US Census Bureau. American Community Survey, 1 YEAR EST; Volkow ND, 2016, NEW ENGL J MED, V374, P1253, DOI 10.1056/NEJMra1507771	20	0	0	2	2	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0091-7435	1096-0260		PREV MED	Prev. Med.	SEP	2019	126								UNSP 105736	10.1016/j.ypmed.2019.05.024			5	Public, Environmental & Occupational Health; Medicine, General & Internal	Public, Environmental & Occupational Health; General & Internal Medicine	IX6JG	WOS:000485788700040	31152831				2020-06-30	J	Orbach-Zinger, S; Landau, R; Davis, A; Oved, O; Caspi, L; Fireman, S; Fein, S; Ioscovich, A; Bracco, D; Hoshen, M; Eidelman, LA				Orbach-Zinger, Sharon; Landau, Ruth; Davis, Atara; Oved, Oren; Caspi, Liron; Fireman, Shlomo; Fein, Shai; Ioscovich, Alexander; Bracco, Danielle; Hoshen, Moshe; Eidelman, Leonid A.			The Effect of Labor Epidural Analgesia on Breastfeeding Outcomes: A Prospective Observational Cohort Study in a Mixed-Parity Cohort	ANESTHESIA AND ANALGESIA			English	Article							INTRAPARTUM; POSTPARTUM; FENTANYL; PAIN; ASSOCIATION; OXYTOCIN; REDUCE; DRUGS; WOMEN	BACKGROUND: The effect of labor epidural analgesia (LEA) on successful breastfeeding has been evaluated in several studies with divergent results. We hypothesized that LEA would not influence breastfeeding status 6 weeks postpartum in women who intended to breastfeed in an environment that encourages breastfeeding. METHODS: In this prospective observational cohort study, a total of 1204 women intending to breastfeed, delivering vaginally with or without LEA, were included; breastfeeding was recorded at 3 days and 6 weeks postpartum. Primary outcome was breastfeeding at 6 weeks, and the chi(2) test was used for comparisons between women delivering with and without LEA, according to parity status and previous breastfeeding experience. Total epidural fentanyl dose and oxytocin use (yes/no) were recorded. A multivariable logistic regression was performed to assess factors affecting breastfeeding at 6 weeks. RESULTS: The overall breastfeeding rate at 6 weeks was 76.9%; it was significantly lower among women delivering with LEA (74.0%) compared with women delivering without LEA (83.4%; P < .001). Among 398 nulliparous women, 84.9% delivered with LEA, compared with 61.8% of multiparous women (P < .001). Multiparous women (N = 806) were more likely to breastfeed at 6 weeks (80.0% vs 70.6% nullipara; P < .001). Using multivariable logistic regression that accounted for 14 covariates including parity, and an interaction term between parity and LEA use, LEA was significantly associated with reduced breastfeeding at 6 weeks (odds ratio, 0.60; 95% confidence interval, 0.40-0.90; P = .015). In a modified multivariable logistic regression where parity was replaced with previous breastfeeding experience, both as a covariate and in the interaction term, only previous breastfeeding experience was associated with increased breastfeeding at 6 weeks (odds ratio, 3.17; 95% confidence interval, 1.72-5.80; P < .001). CONCLUSIONS: In our mixed-parity cohort, delivering with LEA was associated with reduced likelihood of breastfeeding at 6 weeks. However, integrating women's previous breastfeeding experience, the breastfeeding rate was not different between women delivering with and without LEA among the subset of multiparous women with previous breastfeeding experience. Therefore, our findings suggest that offering lactation support to the subset of women with no previous breastfeeding experience may be a simple approach to improve breastfeeding success. This concept subscribes to the notion that women at risk for an undesired outcome be offered tailored interventions with a personalized approach.	[Orbach-Zinger, Sharon; Davis, Atara; Oved, Oren; Caspi, Liron; Fireman, Shlomo; Fein, Shai; Bracco, Danielle; Eidelman, Leonid A.] Beilinson Med Ctr, Rabin Med Ctr, Dept Anesthesia, 39 Jabotinsky St, Petah Tiqwa, Israel; [Landau, Ruth] Columbia Univ Coll Phys & Surg, Dept Anesthesiol, New York, NY 10032 USA; [Ioscovich, Alexander] Hebrew Univ Jerusalem, Shaare Zedek Med Ctr, Dept Anesthesia, Jerusalem, Israel; [Hoshen, Moshe] Clalit Res Inst, Tel Aviv, Israel	Orbach-Zinger, S (reprint author), Beilinson Med Ctr, Rabin Med Ctr, Dept Anesthesia, 39 Jabotinsky St, Petah Tiqwa, Israel.	sharonorbach@yahoo.com					Bai DL, 2013, J MIDWIFERY WOM HEAL, V58, P25, DOI 10.1111/j.1542-2011.2012.00254.x; Beilin Y, 2005, ANESTHESIOLOGY, V103, P1211, DOI 10.1097/00000542-200512010-00016; Ben Natan M, 2016, MIDWIFERY, V34, P173, DOI 10.1016/j.midw.2015.11.013; Berger-Achituv S, 2005, ISR MED ASSOC J, V7, P515; Brimdyr K, 2015, BIRTH-ISS PERINAT C, V42, P319, DOI 10.1111/birt.12186; Brown A, 2014, BREASTFEED MED, V9, P494, DOI [10.1089/bfm.2014.0048, 10.10]; Ding T, 2014, ANESTH ANALG, V119, P383, DOI 10.1213/ANE.0000000000000107; Fong A, 2015, J MATERN-FETAL NEO M, V28, P793, DOI 10.3109/14767058.2014.932766; Forster DA, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2014-007512; French CA, 2016, J HUM LACT, V32, P507, DOI 10.1177/0890334415623779; Jonas W, 2009, BREASTFEED MED, V4, P71, DOI 10.1089/bfm.2008.0002; Jordan S, 2009, BJOG-INT J OBSTET GY, V116, P1622, DOI 10.1111/j.1471-0528.2009.02256.x; Kramer MS, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003517.pub2; Lee AI, 2017, ANESTHESIOLOGY, V127, P614, DOI 10.1097/ALN.0000000000001793; Odent MR, 2013, MED HYPOTHESES, V81, P889, DOI 10.1016/j.mehy.2013.07.044; Orbach-Zinger S, 2018, ANESTH ANALG, V126, P1590, DOI 10.1213/ANE.0000000000002501; Rassin M, 2009, INT NURS REV, V56, P123, DOI 10.1111/j.1466-7657.2008.00681.x; Shamir Raanan, 2016, Nestle Nutr Inst Workshop Ser, V86, P67, DOI 10.1159/000442724; Volmanen P, 2004, INT J OBSTET ANESTH, V13, P25, DOI 10.1016/S0959-289X(03)00104-3; Wilson MJA, 2010, ANAESTHESIA, V65, P145, DOI 10.1111/j.1365-2044.2009.06136.x; Wisner KL, 2014, ANESTH ANALG, V119, P219, DOI 10.1213/ANE.0000000000000322; Woolhouse H, 2016, WOMEN BIRTH, V29, P381, DOI 10.1016/j.wombi.2016.05.008; World Health Organization, EXCLUSIVE BREASTFEED	23	0	0	1	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	SEP	2019	129	3					784	791		10.1213/ANE.0000000000003442			8	Anesthesiology	Anesthesiology	IV5IN	WOS:000484304500028	31425221				2020-06-30	J	Altan, HA; Bonabi, E; Kesici, S; Sezer, H; Ucar, VB				Altan, Hatice Aysel; Bonabi, Eat; Kesici, Sevgi; Sezer, Hafize; Ucar, Veli Bulent			Growth of Microorganisms in Propofol and Mixture of Propofol, Lidocaine and Fentanyl	JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN			English	Article						Microorganisms; Propofol; Lidocaine; Fentanyl; Anesthetic drugs	ANTIBACTERIAL ACTIVITY; STAPHYLOCOCCUS-AUREUS; BACTERIAL-GROWTH; ESCHERICHIA-COLI; REMIFENTANIL; BUPIVACAINE	Objective: To determine the growth of microorganisms in propofol when combined with fentanyl and lidocaine in different temperatures and times in order to find out whether there is any improvement in antimicrobial effect to lengthen the safe duration of time for application of propofol. Study Design: Cross-sectional study. Place and Duration of Study: Istanbul Aydin University Laboratory, Istanbul, Turkey, from June to September 2018. Methodology: The studied drugs and thier combination was used to determine their effect on bacterial growth of Staphylococcus aureus, Pseudomonas aeruginosa, Candida albicans and Acinetobacter baumanni. Bacterial solutions were prepared at 0.5 MacFarland in sterile 0.9% physiological saline and diluted at 1:100 concentration. Colony numbers were measured as colony forming units mL(-1) at 0, 8, and 24 hours and at 4 degrees C, 22 degrees C and 37 degrees C. Results: In general, propofol supported the growth of microorganisms. Fentanyl with propofol also promoted the growth, especially in room and body temperature at 8th and 24th hours but when combined with lidocaine, the number of CFUs was reduced significantly compared with propofol + fentanyl group. Lidocaine inhibited the growth of microorganisms in all the solutions except for candida albicans. Conclusion: Lidocaine was shown to have antibacterial effect which carries advantage for inhibiting infections due to propofol; but aseptic technique is essential during preparation of propofol infusions. Fentanyl like propofol also promoted the growth at room and body temperatures.	[Altan, Hatice Aysel] Istanbul Aydin Univ, Vocat Sch Hlth Serv, Dept Anesthesiol, Istanbul, Turkey; [Bonabi, Eat] Istanbul Aydin Univ, Fac Med, Dept Med Microbiol, Istanbul, Turkey; [Kesici, Sevgi] Hamidiye Etfal Training & Res Hosp, Dept Anesthesiol, Istanbul, Turkey; [Sezer, Hafize] Istanbul Aydin Univ, Fac Med, Dept Biostat, Istanbul, Turkey; [Ucar, Veli Bulent] Istanbul Aydin Univ, Vocat Sch Hlth Serv, Dept Med Lab Tech, Istanbul, Turkey	Kesici, S (reprint author), Hamidiye Etfal Training & Res Hosp, Dept Anesthesiol, Istanbul, Turkey.	md.kesici@mynet.com					Apan TZ, 2007, J CLIN ANESTH, V19, P346, DOI 10.1016/j.jclinane.2007.02.005; Aydin ON, 2002, EUR J ANAESTH, V19, P455, DOI 10.1017/S026502150200073X; Baker MT, 2005, ANESTHESIOLOGY, V103, P860, DOI 10.1097/00000542-200510000-00026; Crowther J, 1996, ANESTH ANALG, V82, P475, DOI 10.1097/00000539-199603000-00008; Erden IA, 2013, REV BRAS ANESTESIOL, V63, P466, DOI [10.1016/j.bjane.2012.10.003, 10.1016/j.bjan.2012.10.003]; Gajraj RJ, 1998, BRIT J ANAESTH, V81, P444, DOI 10.1093/bja/81.3.444; Graystone S, 1997, ANAESTH INTENS CARE, V25, P640, DOI 10.1177/0310057X9702500608; Guzelant A, 2008, EUR J ANAESTH, V25, P737, DOI 10.1017/S0265021508004377; Isert PR, 1996, J CLIN ANESTH, V8, P329, DOI 10.1016/0952-8180(96)00043-8; Johnson SM, 2008, SURG INFECT, V9, P205, DOI 10.1089/sur.2007.036; Keles GT, 2006, EUR J ANAESTH, V23, P1037, DOI 10.1017/S0265021506000949; King Cecil A, 2012, AORN J, V95, P365, DOI 10.1016/j.aorn.2011.06.009; Langevin PB, 1999, ANESTHESIOLOGY, V91, P1394, DOI 10.1097/00000542-199911000-00032; Ozer Z, 2002, ANAESTH INTENS CARE, V30, P179, DOI 10.1177/0310057X0203000209; Raveendra U. S., 2016, NITTE U J HLTH SCI, V6, P51; ROSENBERG H, 1985, ANESTHESIOLOGY, V62, P178; Sakuragi T, 1999, ACTA ANAESTH SCAND, V43, P476, DOI 10.1034/j.1399-6576.1999.430418.x; SCHABERG DR, 1980, ANN INTERN MED, V93, P420, DOI 10.7326/0003-4819-93-3-420; SOSIS MB, 1993, ANESTH ANALG, V77, P766; Strachan FA, 2008, J SMALL ANIM PRACT, V49, P186, DOI 10.1111/j.1748-5827.2007.00473.x; Tamanai-Shacoori Z, 2004, CAN J ANAESTH, V51, P911, DOI 10.1007/BF03018889; Topal A, 2010, J ANIM VET ADV, V9, P1432; Vidovich MI, 1999, ANESTH ANALG, V88, P936, DOI 10.1097/00000539-199904000-00047	23	0	0	0	1	COLL PHYSICIANS & SURGEONS PAKISTAN	KARACHI	SEVENTH CENTRAL ST, DEFENCE HOUSING AUTHORITY, KARACHI, 75500, PAKISTAN	1022-386X	1681-7168		JCPSP-J COLL PHYSICI	JCPSP-J. Coll. Physicians Surg.	SEP	2019	29	9					828	832		10.29271/jcpsp.2019.09.828			5	Medicine, General & Internal	General & Internal Medicine	IU3EC	WOS:000483463600008	31455476	Bronze			2020-06-30	J	Guteneva, NV; Znoyko, SL; Orlov, AV; Nikitin, MP; Nikitin, PI				Guteneva, Natalia, V; Znoyko, Sergey L.; Orlov, Alexey, V; Nikitin, Maxim P.; Nikitin, Petr, I			Rapid lateral flow assays based on the quantification of magnetic nanoparticle labels for multiplexed immunodetection of small molecules: application to the determination of drugs of abuse	MICROCHIMICA ACTA			English	Article						Magnetic nanolabels; Quantification by non-linear magnetization; Magnetic immunoassay; In vitro diagnostics; Point-of-need; No sample pretreatment; Morphine; Fentanyl; Methamphetamine	SURFACE-PLASMON RESONANCE; BLOOD; METHAMPHETAMINE	A rapid lateral flow immunoassay is presented that uses carboxyl-modified superparamagnetic nanoparticles as labels that can be quantified by highly sensitive multi-channel electronic readers. The approach is generic in that it is likely to be applicable to numerous small molecules. The method permits both single- and multiplex assays at a point-of-need without sample pretreatment. It is user-friendly and offers attractive characteristics demonstrated here for detection of morphine, fentanyl and methamphetamine in urine. The competitive immunoassay uses commercially available reagents that do not require special permissions. After migration of sample, the lateral flow test strips are subjected to an alternating magnetic field at two frequencies. The response from the nanolabels is readout at a combinatorial frequency from the entire volume of a porous immunochromatographic membrane by the magnetic particle quantification technique. Even trace concentrations can be quantified within <= 20 min with the limits of detection (LOD) of 0.20 ng center dot mL(-1), 0.36 ng center dot mL(-1) and 1.30 ng center dot mL(-1) for morphine, fentanyl and methamphetamine, respectively. The second variant presented here features highly sensitive quantification of haptens (LOD for fentanyl - 0.05 ng center dot mL(-1)). This is due to high-affinity trapping of magnetic nanolabels in a universal streptavidin-based test strip, which can be also used for detection of virtually any other small molecule. The third variant is of the multiplexed type and intended for rapid and simultaneous detection of the drugs of abuse in human urine with LODs equal to 0.60 ng center dot mL(-1) and 3.0 ng center dot mL(-1) for morphine and methamphetamine, respectively. In addition to the low LODs, the RSDs did not exceed 7%, 9%, and 11% for methamphetamine, morphine and fentanyl, respectively. Graphical abstract Three variants of small molecule detection in competitive format at a point-of-need. Single-plex variants feature antibody and high-affinity streptavidin test lines, while multiplex variant - several antibody test lines. Magnetic nanolabels are quantified from the whole volume of test strip.	[Guteneva, Natalia, V; Znoyko, Sergey L.; Orlov, Alexey, V; Nikitin, Petr, I] Russian Acad Sci, Prokhorov Gen Phys Inst, 38 Vavilov St, Moscow 119991, Russia; [Guteneva, Natalia, V; Orlov, Alexey, V; Nikitin, Maxim P.] Moscow Inst Phys & Technol, 9 Inst Skii Per, Dolgoprudnyi 141700, Russia	Nikitin, PI (reprint author), Russian Acad Sci, Prokhorov Gen Phys Inst, 38 Vavilov St, Moscow 119991, Russia.	nikitin@kapella.gpi.ru	Guteneva, Nataliya V/O-7514-2017; Znoyko, Sergey/E-1294-2013; Orlov, Alexey/E-4072-2015; Nikitin, Petr/E-3794-2015	Guteneva, Nataliya V/0000-0001-8044-9024; Znoyko, Sergey/0000-0003-1265-328X; Orlov, Alexey/0000-0001-7408-3927; Nikitin, Petr/0000-0003-1573-5512	Russian Foundation for Basic ResearchRussian Foundation for Basic Research (RFBR) [18-33-20252]; Russian Science FoundationRussian Science Foundation (RSF) [16-12-10543]	The authors thank Prof. N.S. Osin (State Research Institute of Biological Engineering, Moscow, Russia) and Dr. A.E. Nosyrev (Department of Analytical and Forensic Toxicology of Sechenov First Moscow State Medical University) for the help with organization of the experiments. Different aspects and parts of this multidisciplinary research were partially supported by the grants of Russian Foundation for Basic Research No. 18-33-20252 (preparation, functionalization and characterization of magnetic particles and rapid immunoassay development) and Russian Science Foundation No. 16-12-10543 (development of 3-channel MPQ-readers and multiplex assays).	Andreou C, 2013, ACS NANO, V7, P7157, DOI 10.1021/nn402563f; [Anonymous], OV DEATH RAT; Cappiello A, 2011, MASS SPECTROM REV, V30, P1242, DOI 10.1002/mas.20329; Dams R, 2002, J CHROMATOGR B, V773, P53, DOI 10.1016/S1570-0232(01)00594-3; Evans AM, 2009, ANAL CHEM, V81, P6656, DOI 10.1021/ac901536h; Farka Z, 2017, CHEM REV, V117, P9973, DOI 10.1021/acs.chemrev.7b00037; Fodey T, 2011, TRAC-TREND ANAL CHEM, V30, P254, DOI 10.1016/j.trac.2010.10.011; Gandhi S, 2009, BIOSENS BIOELECTRON, V25, P502, DOI 10.1016/j.bios.2009.07.018; Goryacheva IY, 2013, TRAC-TREND ANAL CHEM, V46, P30, DOI 10.1016/j.trac.2013.01.013; Hermanson GT, 2013, BIOCONJUGATE TECHNIQUES, 3RD EDITION, P1; Ivanov AE, 2019, SENSOR ACTUAT B-CHEM, V282, P984, DOI 10.1016/j.snb.2018.11.043; Kerrigan S, 2001, CLIN CHEM, V47, P540; Lee JR, 2016, ANAL CHEM, V88, P7457, DOI 10.1021/acs.analchem.6b01688; Mauriz E, 2006, BIOSENS BIOELECTRON, V21, P2129, DOI 10.1016/j.bios.2005.10.013; Navaee A, 2012, BIOSENS BIOELECTRON, V31, P205, DOI 10.1016/j.bios.2011.10.018; Nikitin PI, 2007, J MAGN MAGN MATER, V311, P445, DOI 10.1016/j.jmmm.2006.10.1180; Orlov AV, 2018, SENSOR ACTUAT B-CHEM, V257, P971, DOI 10.1016/j.snb.2017.11.025; Orlov AV, 2017, SENSOR ACTUAT B-CHEM, V246, P1080, DOI 10.1016/j.snb.2016.12.071; Orlov AV, 2016, ANAL CHEM, V88, P10419, DOI 10.1021/acs.analchem.6b02066; Orlov AV, 2015, J MAGN MAGN MATER, V380, P231, DOI 10.1016/j.jmmm.2014.10.019; Sajid M, 2015, J SAUDI CHEM SOC, V19, P689, DOI 10.1016/j.jscs.2014.09.001; Sang SB, 2016, CRIT REV BIOTECHNOL, V36, P465, DOI 10.3109/07388551.2014.991270; Shevchenko KG, 2017, BIOSENS BIOELECTRON, V88, P3, DOI 10.1016/j.bios.2016.09.042; Shipunova VO, 2016, NANOSCALE, V8, P12764, DOI 10.1039/c6nr03507h; Smith DS, 2008, ANAL BIOANAL CHEM, V391, P1499, DOI 10.1007/s00216-008-1897-z; Smith JP, 2009, TOXICOL MECH METHOD, V19, P416, DOI 10.1080/15376510903114959; Taranova NA, 2013, MICROCHIM ACTA, V180, P1165, DOI 10.1007/s00604-013-1043-2; Teerinen T, 2014, ANAL BIOANAL CHEM, V406, P5955, DOI 10.1007/s00216-014-8001-7; Tregubov AA, 2018, CHEM REV, V118, P10294, DOI 10.1021/acs.chemrev.8b00198; Weller MG, 2000, FRESEN J ANAL CHEM, V366, P635, DOI 10.1007/s002160051558; Winek CL, 2001, FORENSIC SCI INT, V122, P107, DOI 10.1016/S0379-0738(01)00483-2; Ye HH, 2018, J MATER CHEM B, V6, P7102, DOI 10.1039/c8tb01603h; Yu SJ, 2013, BIOSENS BIOELECTRON, V48, P224, DOI 10.1016/j.bios.2013.04.025; Znoyko SL, 2018, ANAL CHIM ACTA, V1034, P161, DOI 10.1016/j.aca.2018.07.012	34	5	5	12	42	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0026-3672	1436-5073		MICROCHIM ACTA	Microchim. Acta	SEP	2019	186	9							UNSP 621	10.1007/s00604-019-3726-9			9	Chemistry, Analytical	Chemistry	IQ5CY	WOS:000480770400005	31410571				2020-06-30	J	Tunstall, BJ; Vendruscolo, LF				Tunstall, Brendan J.; Vendruscolo, Leandro F.			Utility of fentanyl vaccines: unique challenges posed by preventing opioid overdose and treating opioid use disorder	NEUROPSYCHOPHARMACOLOGY			English	Editorial Material									[Tunstall, Brendan J.; Vendruscolo, Leandro F.] NIDA, Neurobiol Addict Sect, Integrat Neurosci Res Branch, Intramural Res Program,NIH, Baltimore, MD 21224 USA	Tunstall, BJ; Vendruscolo, LF (reprint author), NIDA, Neurobiol Addict Sect, Integrat Neurosci Res Branch, Intramural Res Program,NIH, Baltimore, MD 21224 USA.	brendan.tunstall@nih.gov; leandro.vendruscolo@nih.gov		Tunstall, Brendan/0000-0001-9430-9612	NIDA-IRPUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)	The authors thank Drs. Joel E. Schlosburg and Yavin Shaham for their comments on an earlier version of the paper and Michael Arends for editing the paper. BJT and LFV are supported by NIDA-IRP.	Bremer PT, 2016, ANGEW CHEM INT EDIT, V55, P3772, DOI 10.1002/anie.201511654; Carmack SA, 2019, J CLIN INVEST, V129, P2480, DOI 10.1172/JCI125534; Jannetto PJ, 2019, CLIN CHEM, V65, P242, DOI 10.1373/clinchem.2017.281626; OBRIEN CP, 1975, PHARMACOL REV, V27, P533; Reiner DJ, 2019, NEUROPSYCHOPHARMACOL, V44, P465, DOI 10.1038/s41386-018-0234-2; Schlosburg JE, 2013, P NATL ACAD SCI USA, V110, P9036, DOI 10.1073/pnas.1219159110; Townsend EA, 2019, NEUROPSYCHOPHARMACOL, V44, P1681, DOI 10.1038/s41386-019-0385-9; Wilde M, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00238	8	2	2	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0893-133X	1740-634X		NEUROPSYCHOPHARMACOL	Neuropsychopharmacology	SEP	2019	44	10					1675	1676		10.1038/s41386-019-0418-4			2	Neurosciences; Pharmacology & Pharmacy; Psychiatry	Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry	IQ3IA	WOS:000480643900001	31127167				2020-06-30	J	Townsend, EA; Blake, S; Faunce, KE; Hwang, CS; Natori, Y; Zhou, B; Bremer, PT; Janda, KD; Banks, ML				Townsend, E. Andrew; Blake, Steven; Faunce, Kaycee E.; Hwang, Candy S.; Natori, Yoshihiro; Zhou, Bin; Bremer, Paul T.; Janda, Kim D.; Banks, Matthew L.			Conjugate vaccine produces long-lasting attenuation of fentanyl vs. food choice and blocks expression of opioid withdrawal-induced increases in fentanyl choice in rats	NEUROPSYCHOPHARMACOLOGY			English	Article							ENVIRONMENTAL MANIPULATIONS; BUPRENORPHINE-NALOXONE; RELEASE NALTREXONE; RHESUS-MONKEYS; HEROIN; CLONIDINE; DRUG; METHAMPHETAMINE; ABSTINENCE; DEPENDENCE	The current opioid crisis remains a significant public health issue and there is a critical need for biomedical research to develop effective and easily deployable candidate treatments. One emerging treatment strategy for opioid use disorder includes immunopharmacotherapies or opioid-targeted vaccines. The present study determined the effectiveness of a fentanyl-tetanus toxoid conjugate vaccine to alter fentanyl self-administration using a fentanyl-vs.-food choice procedure in male and female rats under three experimental conditions. For comparison, continuous 7-day naltrexone (0.01-0.1 mg/kg/h) and 7-day clonidine (3.2-10 mu g/kg/h) treatment effects were also determined on fentanyl-vs.-food choice. Male and female rats responded for concurrently available 18% diluted Ensure (R) (liquid food) and fentanyl (0-10 mu g/kg/infusion) infusions during daily sessions. Under baseline and saline treatment conditions, fentanyl maintained a dose-dependent increase in fentanyl-vs.-food choice. First, fentanyl vaccine administration significantly blunted fentanyl reinforcement and increased food reinforcement for 15 weeks in non-opioid dependent rats. Second, surmountability experiments by increasing the unit fentanyl dose available during the self-administration session 10-fold empirically determined that the fentanyl vaccine produced an approximate 22-fold potency shift in fentanyl-vs.-food choice that was as effective as the clinically approved treatment naltrexone. Clonidine treatment significantly increased fentanyl-vs.-food choice. Lastly, fentanyl vaccine administration prevented the expression of withdrawal-associated increases in fentanyl-vs.-food choice following introduction of extended 12 h fentanyl access sessions. Overall, these results support the potential and further consideration of immunopharmacotherapies as candidate treatments to address the current opioid crisis.	[Townsend, E. Andrew; Faunce, Kaycee E.; Banks, Matthew L.] Virginia Commonwealth Univ, Sch Med, Dept Pharmacol & Toxicol, Richmond, VA 23298 USA; [Blake, Steven; Hwang, Candy S.; Natori, Yoshihiro; Zhou, Bin; Bremer, Paul T.; Janda, Kim D.] Scripps Res Inst, Worm Inst Res & Med, Skaggs Inst Chem Biol, Dept Chem, La Jolla, CA 92037 USA; [Blake, Steven; Hwang, Candy S.; Natori, Yoshihiro; Zhou, Bin; Bremer, Paul T.; Janda, Kim D.] Scripps Res Inst, Worm Inst Res & Med, Skaggs Inst Chem Biol, Dept Immunol & Microbial Sci, La Jolla, CA 92037 USA; [Hwang, Candy S.] Southern Connecticut State Univ, Dept Chem, 501 Crescent St, New Haven, CT 06515 USA; [Natori, Yoshihiro] Tohoku Med & Pharmaceut Univ, Fac Pharmaceut Sci, Aoba Ku, Komatsushima 4-4-1, Sendai, Miyagi 9818558, Japan	Banks, ML (reprint author), Virginia Commonwealth Univ, Sch Med, Dept Pharmacol & Toxicol, Richmond, VA 23298 USA.; Janda, KD (reprint author), Scripps Res Inst, Worm Inst Res & Med, Skaggs Inst Chem Biol, Dept Chem, La Jolla, CA 92037 USA.; Janda, KD (reprint author), Scripps Res Inst, Worm Inst Res & Med, Skaggs Inst Chem Biol, Dept Immunol & Microbial Sci, La Jolla, CA 92037 USA.	kdjanda@scripps.edu; mbanks7@vcu.edu		Faunce, Kaycee/0000-0002-9178-0692; Hwang, Candy/0000-0003-2826-4078	International Study Group Investigating Drugs as Reinforcers (ISGIDAR); National Institute on Drug Abuse of the National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [UH3DA041146, T32DA007027, F32DA047026, F32AI126628]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA	Research was supported by institutional professional development funds, the International Study Group Investigating Drugs as Reinforcers (ISGIDAR) travel award, and the National Institute on Drug Abuse of the National Institutes of Health under Award Numbers UH3DA041146, T32DA007027, F32DA047026, and F32AI126628. The National Institute on Drug Abuse had no role in study design, collection, analysis or interpretation of the data, in the writing or decision to submit the manuscript for publication. The manuscript content is solely the responsibility of the authors and does not necessarily reflect the official views of the National Institutes of Health. All authors declare their research has been funded by the NIH. The authors declare no competing interests. KDJ is an inventor on a Scripps Research patent that covers the conjugate fentanyl-TT vaccine and has been licensed.	Association AP, 2013, DIAGN STAT MAN MENT; Baehr C, 2019, NEUROPSYCHOPHARMACOL, V44, P217, DOI 10.1038/s41386-018-0197-3; Banks ML, 2019, NEUROPSYCHOPHARMACOL, V44, P1011, DOI 10.1038/s41386-019-0336-5; Banks ML, 2018, TRENDS PHARMACOL SCI, V39, P908, DOI 10.1016/j.tips.2018.08.001; Banks ML, 2017, ANN NY ACAD SCI, V1394, P92, DOI 10.1111/nyas.13276; Banks ML, 2017, TRENDS PHARMACOL SCI, V38, P181, DOI 10.1016/j.tips.2016.11.002; Banks Matthew L, 2015, Curr Treat Options Psychiatry, V2, P136; Banks ML, 2015, NEUROPSYCHOPHARMACOL, V40, P2198, DOI 10.1038/npp.2015.63; BONESE KF, 1974, NATURE, V252, P708, DOI 10.1038/252708a0; Bremer PT, 2017, J AM CHEM SOC, V139, P8601, DOI 10.1021/jacs.7b03334; Bremer PT, 2017, PHARMACOL REV, V69, P298, DOI 10.1124/pr.117.013904; Bremer PT, 2016, ANGEW CHEM INT EDIT, V55, P3772, DOI 10.1002/anie.201511654; Comer SD, 2006, ARCH GEN PSYCHIAT, V63, P210, DOI 10.1001/archpsyc.63.2.210; Epstein DH, 2018, TRENDS PHARMACOL SCI, V39, P911, DOI 10.1016/j.tips.2018.06.002; Hedegaard Holly, 2017, NCHS Data Brief, P1; Huskinson SL, 2017, PSYCHOPHARMACOLOGY, V234, P589, DOI 10.1007/s00213-016-4492-6; Hwang CS, 2018, ACS CHEM NEUROSCI, V9, P1269, DOI 10.1021/acschemneuro.8b00079; Hwang CS, 2018, MOL PHARMACEUT, V15, P1062, DOI 10.1021/acs.molpharmaceut.7b00933; Kowalczyk WJ, 2017, J ADDICT MED, V11, P454, DOI 10.1097/ADM.0000000000000345; Kowalczyk WJ, 2015, AM J PSYCHIAT, V172, P760, DOI 10.1176/appi.ajp.2014.14081014; Lenoir M, 2013, NEUROPSYCHOPHARMACOL, V38, P1209, DOI 10.1038/npp.2013.17; Ling W, 2005, ADDICTION, V100, P1090, DOI 10.1111/j.1360-0443.2005.01154.x; Maguire DR, 2019, J PHARMACOL EXP THER, V368, P88, DOI 10.1124/jpet.118.252353; Mantsch JR, 2016, NEUROPSYCHOPHARMACOL, V41, P335, DOI 10.1038/npp.2015.142; Negus S.S., 2013, ADDICTION; Negus SS, 2018, PHARMACOL BIOCHEM BE, V164, P32, DOI 10.1016/j.pbb.2017.04.006; Negus SS, 2009, NEUROPSYCHOPHARMACOL, V34, P899, DOI 10.1038/npp.2008.127; Negus SS, 2006, J PHARMACOL EXP THER, V317, P711, DOI 10.1124/jpet.105.095380; Negus SS, 2003, NEUROPSYCHOPHARMACOL, V28, P919, DOI 10.1038/sj.npp.1300096; Nguyen JD, 2018, NEUROPHARMACOLOGY, V138, P292, DOI 10.1016/j.neuropharm.2018.06.026; OSSIPOV MH, 1990, ANESTHESIOLOGY, V73, P1227, DOI 10.1097/00000542-199012000-00022; Pravetoni M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101807; Raleigh MD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115696; Schlosburg JE, 2013, P NATL ACAD SCI USA, V110, P9036, DOI 10.1073/pnas.1219159110; SPRAGG S. D. S., 1940, COMPAR PSYCHOL MONOGR, V15, P1; Stowe GN, 2011, J MED CHEM, V54, P5195, DOI 10.1021/jm200461m; Sulima A, 2018, J MED CHEM, V61, P329, DOI 10.1021/acs.jmedchem.7b01427; Sullivan MA, 2006, PSYCHOPHARMACOLOGY, V189, P37, DOI 10.1007/s00213-006-0509-x; Tanum L, 2017, JAMA PSYCHIAT, V74, P1197, DOI 10.1001/jamapsychiatry.2017.3206; Thomsen M, 2013, J EXP ANAL BEHAV, V99, P211, DOI 10.1002/jeab.15; Townsend EA, 2017, PSYCHOPHARMACOLOGY, V234, P2597, DOI 10.1007/s00213-017-4652-3; Volkow ND, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aan2595; Volkow ND, 2017, NEW ENGL J MED, V377, P391, DOI 10.1056/NEJMsr1706626; Volkow ND, 2014, NEW ENGL J MED, V370, P2063, DOI 10.1056/NEJMp1402780; Wade CL, 2015, NEUROPSYCHOPHARMACOL, V40, P421, DOI 10.1038/npp.2014.188; WURSTER RM, 1977, PHARMACOL BIOCHEM BE, V7, P519, DOI 10.1016/0091-3057(77)90248-9	46	9	9	2	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0893-133X	1740-634X		NEUROPSYCHOPHARMACOL	Neuropsychopharmacology	SEP	2019	44	10					1681	1689		10.1038/s41386-019-0385-9			9	Neurosciences; Pharmacology & Pharmacy; Psychiatry	Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry	IQ3IA	WOS:000480643900004	31043682				2020-06-30	J	Fragale, JE; Pantazis, CB; James, MH; Aston-Jones, G				Fragale, Jennifer E.; Pantazis, Caroline B.; James, Morgan H.; Aston-Jones, Gary			The role of orexin-1 receptor signaling in demand for the opioid fentanyl	NEUROPSYCHOPHARMACOLOGY			English	Article							BEHAVIORAL ECONOMICS; ALCOHOL-SEEKING; COCAINE; OREXIN/HYPOCRETIN; DEPENDENCE; HYPOCRETIN; MOTIVATION; PREFERENCE; HEROIN; REINSTATEMENT	The orexin system is a potential treatment target for drug addiction. Orexin-1 receptor (OxR1) antagonism reduces demand for cocaine and remifentanil, indicating that orexin-based therapies may reduce demand for many classes of abused drugs. However, pharmacokinetics vary greatly among opioids and it is unclear if OxR1 antagonism would reduce demand for all opioids, particularly ones with high abuse liability. Here, we established a behavioral economics (BE) procedure to assess the effects of OxR1 antagonism on demand for the highly abused opioid fentanyl. We also investigated the utility of our procedure to predict OxR1 antagonism efficacy and relapse propensity. Demand parameters alpha (demand elasticity or price sensitivity of consumption, an inverse measure of drug motivation) and Q(o) (drug consumption at null cost) were assessed. The OxR1 antagonist SB-334867 (SB) decreased motivation (increased alpha) for fentanyl without affecting Q(o). Baseline alpha values predicted SB efficacy, such that SB was most effective at reducing motivation (increasing alpha) in highly motivated rats. Baseline alpha values predicted the amount of cued reinstatement of fentanyl seeking; this reinstatement behavior was attenuated by SB administration. These results highlight the promise of the orexin system as a treatment target for opioid addiction and emphasize the usefulness of BE procedures in the study of opioid abuse.	[Fragale, Jennifer E.; Pantazis, Caroline B.; James, Morgan H.; Aston-Jones, Gary] Rutgers State Univ, Brain Hlth Inst, Piscataway, NJ 08854 USA; [Fragale, Jennifer E.; Pantazis, Caroline B.; James, Morgan H.; Aston-Jones, Gary] Rutgers Biomed & Hlth Sci, Piscataway, NJ 08854 USA; [James, Morgan H.] Univ Melbourne, Florey Inst Neurosci & Mental Hlth, Melbourne, Vic, Australia	Aston-Jones, G (reprint author), Rutgers State Univ, Brain Hlth Inst, Piscataway, NJ 08854 USA.; Aston-Jones, G (reprint author), Rutgers Biomed & Hlth Sci, Piscataway, NJ 08854 USA.	aston.jones@rutgers.edu		James, Morgan/0000-0001-9298-8607; Pantazis, Caroline/0000-0002-2768-4903	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [K12 GM093854, F31DA042588]; National Health and Medical Research Council of Australia C.J. Martin FellowshipNational Health and Medical Research Council of Australia [1072706]; National Institute on Drug Abuse (NIDA)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [K99DA045765]; U.S. Public Health Service award from NIDA [R01 DA006214]	This work was supported by NIH postdoctoral fellowship (K12 GM093854) to JEF, NIH graduate fellowship (F31DA042588) to CBP, National Health and Medical Research Council of Australia C.J. Martin Fellowship (No. 1072706) and National Institute on Drug Abuse (NIDA; K99DA045765) Fellowships to MHJ, and by a U.S. Public Health Service award from NIDA to GA-J (R01 DA006214). The authors declare that the research was conducted without any commercial or financial relationships that could be considered a potential conflict of interest.	Baimel C, 2015, BRIT J PHARMACOL, V172, P334, DOI 10.1111/bph.12639; Bentzley BS, 2015, EUR J NEUROSCI, V41, P1149, DOI 10.1111/ejn.12866; Bentzley BS, 2014, P NATL ACAD SCI USA, V111, P11822, DOI 10.1073/pnas.1406324111; Bickel WK, 2010, CURR TOP BEHAV NEURO, V3, P319, DOI 10.1007/7854_2009_22; BICKEL WK, 1993, DRUG ALCOHOL DEPEN, V33, P173, DOI 10.1016/0376-8716(93)90059-Y; Borgland SL, 2009, J NEUROSCI, V29, P11215, DOI 10.1523/JNEUROSCI.6096-08.2009; Boutrel B, 2005, P NATL ACAD SCI USA, V102, P19168, DOI 10.1073/pnas.0507480102; Brodnik Z.D., 2018, BRAIN RES; Bruner NR, 2014, PSYCHOPHARMACOLOGY, V231, P889, DOI 10.1007/s00213-013-3312-5; Cason AM, 2013, PSYCHOPHARMACOLOGY, V226, P155, DOI 10.1007/s00213-012-2902-y; CHAPLAN SR, 1994, J NEUROSCI METH, V53, P55, DOI 10.1016/0165-0270(94)90144-9; Christensen CJ, 2008, PHARMACOL BIOCHEM BE, V91, P209, DOI 10.1016/j.pbb.2008.07.009; Edwards S, 2012, NEUROPHARMACOLOGY, V62, P1142, DOI 10.1016/j.neuropharm.2011.11.006; Espana RA, 2010, EUR J NEUROSCI, V31, P336, DOI 10.1111/j.1460-9568.2009.07065.x; Fragale JEC, 2017, FRONT NEUROSCI-SWITZ, V11, DOI 10.3389/fnins.2017.00077; Georgescu D, 2003, J NEUROSCI, V23, P3106; Harris GC, 2005, NATURE, V437, P556, DOI 10.1038/nature04071; Harris GC, 2006, TRENDS NEUROSCI, V29, P571, DOI 10.1016/j.tins.2006.08.002; Hollander JA, 2012, FRONT BEHAV NEUROSCI, V6, DOI 10.3389/fnbeh.2012.00047; HUG CC, 1981, ANESTHESIOLOGY, V55, P369, DOI 10.1097/00000542-198110000-00006; HURSH SR, 1991, J EXP ANAL BEHAV, V56, P377, DOI 10.1901/jeab.1991.56-377; Hursh SR, 2008, PSYCHOL REV, V115, P186, DOI 10.1037/0033-295X.115.1.186; Inturrisi CE, 2002, CLIN J PAIN, V18, pS3, DOI 10.1097/00002508-200207001-00002; James MH, 2019, EUR J NEUROSCI, V50, P2602, DOI 10.1111/ejn.14166; James MH, 2019, BIOL PSYCHIAT, V85, P925, DOI 10.1016/j.biopsych.2018.07.022; James MH, 2017, CURR TOP BEHAV NEURO, V33, P247, DOI 10.1007/7854_2016_57; Kenny PJ, 2011, PHARMACOL BIOCHEM BE, V97, P700, DOI 10.1016/j.pbb.2010.08.015; Lawrence AJ, 2006, BRIT J PHARMACOL, V148, P752, DOI 10.1038/sj.bjp.0706789; MacKillop J, 2008, EXP CLIN PSYCHOPHARM, V16, P57, DOI 10.1037/1064-1297.16.1.57; MacKillop J, 2019, ADDICT BIOL, V24, P303, DOI 10.1111/adb.12592; Moorman DE, 2017, BRAIN RES, V1654, P34, DOI 10.1016/j.brainres.2016.10.018; Moorman DE, 2016, EUR J NEUROSCI, V43, P710, DOI 10.1111/ejn.13170; Moorman DE, 2009, ALCOHOL, V43, P379, DOI 10.1016/j.alcohol.2009.07.002; Murphy JG, 2009, EXP CLIN PSYCHOPHARM, V17, P396, DOI 10.1037/a0017684; Narita M, 2006, J NEUROSCI, V26, P398, DOI 10.1523/JNEUROSCI.2761-05.2006; Park PE, 2015, ADDICT BIOL, V20, P275, DOI 10.1111/adb.12120; Pickover AM, 2016, EXP CLIN PSYCHOPHARM, V24, P38, DOI 10.1037/pha0000052; Plaza-Zabala A, 2012, BIOL PSYCHIAT, V71, P214, DOI 10.1016/j.biopsych.2011.06.025; Porter-Stransky KA, 2017, ADDICT BIOL, V22, P303, DOI 10.1111/adb.12323; Prasad AA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110385; Rasmussen K, 2019, NEUROPSYCHOPHARMACOL, V44, P657, DOI 10.1038/s41386-018-0292-5; Reiner DJ, 2019, NEUROPSYCHOPHARMACOL, V44, P465, DOI 10.1038/s41386-018-0234-2; Rudd RA, 2010, MMWR-MORBID MORTAL W, V2016, P65; Sakurai T, 1998, CELL, V92, P573, DOI 10.1016/S0092-8674(00)80949-6; Schmeichel BE, 2015, NEUROPSYCHOPHARMACOL, V40, P1123, DOI 10.1038/npp.2014.293; Sharf R, 2010, BRAIN RES, V1314, P130, DOI 10.1016/j.brainres.2009.08.028; Sharf R, 2010, BRAIN RES, V1317, P24, DOI 10.1016/j.brainres.2009.12.035; Smith RJ, 2012, EUR J NEUROSCI, V35, P798, DOI 10.1111/j.1460-9568.2012.08013.x; Smith RJ, 2009, EUR J NEUROSCI, V30, P493, DOI 10.1111/j.1460-9568.2009.06844.x; Volpe DA, 2011, REGUL TOXICOL PHARM, V59, P385, DOI 10.1016/j.yrtph.2010.12.007; Wade CL, 2015, NEUROPSYCHOPHARMACOL, V40, P421, DOI 10.1038/npp.2014.188	51	10	10	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0893-133X	1740-634X		NEUROPSYCHOPHARMACOL	Neuropsychopharmacology	SEP	2019	44	10					1690	1697		10.1038/s41386-019-0420-x			8	Neurosciences; Pharmacology & Pharmacy; Psychiatry	Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry	IQ3IA	WOS:000480643900005	31112988				2020-06-30	J	Prabhu, SS; Khan, SA; Doudnikoff, AL; Mueller, N; Reebye, UN				Prabhu, Shamit S.; Khan, Saad A.; Doudnikoff, Alexander L.; Mueller, Nicholas; Reebye, Uday N.			Anesthetic management for a patient with medium-chain acyl-CoA dehydrogenase deficiency in an outpatient setting using ketamine and fentanyl	JOURNAL OF CLINICAL ANESTHESIA			English	Letter									[Prabhu, Shamit S.; Khan, Saad A.; Doudnikoff, Alexander L.; Mueller, Nicholas; Reebye, Uday N.] Triangle Implant Ctr, 5318 NC Highway 55 Suite 106, Durham, NC 27713 USA; [Prabhu, Shamit S.] Wake Forest Sch Med, Winston Salem, NC 27101 USA	Khan, SA (reprint author), 761 Meadowood Dr, Burlington, NC 27215 USA.	saad.khan92294@gmail.com		Prabhu, Shamit/0000-0001-5954-4748; Khan, Saad/0000-0002-7082-5230; Doudnikoff, Alexander/0000-0002-3676-7823			Allen C, 2017, PEDIATR ANESTH, V27, P60, DOI 10.1111/pan.13065; DEARLOVE OR, 1995, ANAESTHESIA, V50, P265, DOI 10.1111/j.1365-2044.1995.tb04584.x; Jameson E., 2015, PAEDIAT CHILD HLTH, V25, P145; Justiz AC, 2006, PEDIATR ANESTH, V16, P1293, DOI 10.1111/j.1460-9592.2006.02003.x; Wang SY, 2002, ANESTH ANALG, V94, P1595, DOI 10.1097/00000539-200206000-00043	5	0	0	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0952-8180	1873-4529		J CLIN ANESTH	J. Clin. Anesth.	SEP	2019	56						45	46		10.1016/j.jclinane.2019.01.031			2	Anesthesiology	Anesthesiology	HZ2YA	WOS:000468713500016	30684927				2020-06-30	J	Hayley, AC; Green, M; Downey, LA; Keane, M; Kenneally, M; Adams, M; Shehabi, Y				Hayley, Amie C.; Green, Maja; Downey, Luke A.; Keane, Michael; Kenneally, Michaela; Adams, Mark; Shehabi, Yahya			Neurocognitive performance under combined regimens of ketamine-dexmedetomidine and ketamine-fentanyl in healthy adults: A randomised trial	PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY			English	Article						Ketamine; Dexmedetomidine; Fentanyl; Neurocognitive; Analgesic; Postoperative	BEHAVIORAL PERFORMANCE; INTRAVENOUS FENTANYL; COGNITIVE FUNCTION; VOLUNTEERS; PLASMA; PHARMACOLOGY; PAIN	Analgesic doses of ketamine affects neurocognition; however, deficits under co-administration regimens are unknown. This study evaluated the effects of ketamine, alone and in combination with dexmedetomidine or fentanyl on neurocognition. Using a randomised, within-subjects gender stratified design, 39 participants (mean age = 28.4, SD +/- 5.8) received a ketamine bolus of 0.3 mg/kg followed by 0.15 mg/kg/h infusion of ketamine (3 h duration). At 1.5 h post-ketamine infusion commencement, participants received either: i) 0.7 mu g/kg/h infusion of dexmedetomidine (n = 19) (KET/DEX) or (ii) three 25 mu g fentanyl injections over 1.5 h (n = 20) (KET/FENT). Reaction and Movement time (RTI, Simple and 5Choice), Visuospatial Working Memory (SWM) and Verbal Recognition Memory (VRM) were assessed using the Cambridge Neuropsychological Test Automated Battery (CANTAB). Whole blood drug concentrations were determined during ketamine-only infusion, at co-administration (KET/DEX or KET/FENT) and at 2-h post-treatment. Ketamine-only administration impaired psychomotor response speed (Simple and 5Choice) and impaired memory (all p < .001), however did not alter executive function abilities. Independent of sedation, co-administration of dexmedetomidine produced synergistic performance and memory deficits which persisted at post-treatment (KET/DEX) (all p < .001), and were comparatively greater than for KET/FENT (all p < .05). Ketamine, norketamine and dexmedetomidine concentrations were modestly associated with reduced psychomotor speed and accuracy (all p < .05), and an inverse relationship was found between blood concentrations of ketamine, norketamine and dexmedetomidine and performance on memory tasks. Co-administration of ketamine with dexmedetomidine but not with fentanyl exerts synergistic effects on psychomotor performance and memory without executive dysfunction. Assessment of these effects in clinical groups is warranted.	[Hayley, Amie C.; Downey, Luke A.; Keane, Michael] Swinburne Univ Technol, Ctr Human Psychopharmacol, Hawthorn, Vic, Australia; [Hayley, Amie C.; Downey, Luke A.] Austin Hosp, Inst Breathing & Sleep, Melbourne, Vic, Australia; [Green, Maja; Keane, Michael; Adams, Mark; Shehabi, Yahya] Monash Univ, Sch Clin Sci, Crit Care & Perioperat Med, Melbourne, SA, Australia; [Green, Maja] Monash Univ, Dept Oncol, Monash Hlth Translat Precinct, Clayton, Vic, Australia; [Kenneally, Michaela] FSSA, Adelaide, SA, Australia	Hayley, AC (reprint author), Swinburne Univ Technol, Fac Hlth Arts & Design, Ctr Human Psychopharmacol, Hawthorn, Vic 3122, Australia.	ahayley@swin.edu.au	Downey, Luke/AAG-8854-2020	Downey, Luke/0000-0001-5670-3192; Hayley, Amie/0000-0002-4470-4718; Keane, Michael/0000-0002-9131-7008; Green, Maja/0000-0002-7982-2503	National Health and Medical Council (NHMRC) Peter Doherty Biomedical Early Career Research FellowshipNational Health and Medical Research Council of Australia [APP1119960]; NHMRC R.D. Wright Biomedical Career Development Fellowship (CDF: 2017-2020)National Health and Medical Research Council of Australia	Dr. Amie Hayley is supported by a National Health and Medical Council (NHMRC) Peter Doherty Biomedical Early Career Research Fellowship (APP1119960). A/Prof Downey is supported by an NHMRC R.D. Wright Biomedical Career Development Fellowship (CDF: 2017-2020). Dr. Green, Dr. Keane, Ms. Kenneally, Dr. Adams and Prof Shehabi declare no potential conflicts of interest.	Bowdle TA, 1998, ANESTHESIOLOGY, V88, P82, DOI 10.1097/00000542-199801000-00015; Bustillo MA, 2002, J NEUROSURG ANESTH, V14, P209, DOI 10.1097/00008506-200207000-00006; Cherny NI, 1996, DRUGS, V51, P713, DOI 10.2165/00003495-199651050-00002; CLEMENTS JA, 1981, BRIT J ANAESTH, V53, P27, DOI 10.1093/bja/53.1.27; Ebert TJ, 2000, ANESTHESIOLOGY, V93, P382, DOI 10.1097/00000542-200008000-00016; El Deen HMS, 2012, EGYPT J ANAESTH, V28, P49, DOI 10.1016/j.egja.2011.10.003; El sayed AA, 2015, EGYPT J ANAESTH, V31, P35, DOI 10.1016/j.egja.2014.11.001; Haas D A, 1992, Anesth Prog, V39, P61; Hall JE, 2000, ANESTH ANALG, V90, P699, DOI 10.1097/00000539-200003000-00035; HARTVIG P, 1995, CLIN PHARMACOL THER, V58, P165, DOI 10.1016/0009-9236(95)90194-9; Hayley A, 2018, PSYCHOPHARMACOLOGY, V235, P1273, DOI 10.1007/s00213-018-4842-7; Honey RAE, 2003, NEUROPSYCHOPHARMACOL, V28, P2037, DOI 10.1038/sj.npp.1300272; Khan ZP, 1999, BRIT J ANAESTH, V83, P372; LANNING CF, 1975, ANNU REV MED, V26, P137, DOI 10.1146/annurev.me.26.020175.001033; Lofwall MR, 2006, EXP CLIN PSYCHOPHARM, V14, P439, DOI 10.1037/1064-1297.14.4.439; Magalhaes A, 2017, LAB ANIM-UK, V51, P147, DOI 10.1177/0023677216652380; Mantz J, 2011, EUR J ANAESTH, V28, P3, DOI 10.1097/EJA.0b013e32833e266d; MATTILA MJ, 1991, EUR J CLIN PHARMACOL, V41, P217, DOI 10.1007/BF00315433; MCCLAIN DA, 1980, CLIN PHARMACOL THER, V28, P106, DOI 10.1038/clpt.1980.138; Mion G, 2013, CNS NEUROSCI THER, V19, P370, DOI 10.1111/cns.12099; Monk TG, 2011, CURR OPIN CRIT CARE, V17, P376, DOI 10.1097/MCC.0b013e328348bece; Panzer O, 2009, CRIT CARE CLIN, V25, P451, DOI 10.1016/j.ccc.2009.04.004; PEARCE RE, 1988, ARCH SURG-CHICAGO, V123, P1525; Peng PWH, 1999, ANESTHESIOLOGY, V90, P576, DOI 10.1097/00000542-199902000-00034; Quibell R, 2011, J PAIN SYMPTOM MANAG, V41, P640, DOI 10.1016/j.jpainsymman.2011.01.001; Schneider U, 1999, NEUROPSYCHOBIOLOGY, V39, P38, DOI 10.1159/000026558; SCHWINN DA, 1991, J PHARMACOL EXP THER, V259, P1147; SMITH DJ, 1987, NEUROPHARMACOLOGY, V26, P1253, DOI 10.1016/0028-3908(87)90084-0; SOBELL LC, 1995, ADDICT BEHAV, V20, P233, DOI 10.1016/0306-4603(94)00071-9; Thabane L, 2013, BMC MED RES METHODOL, V13, DOI 10.1186/1471-2288-13-92; Tobias JD, 2012, PEDIATR CRIT CARE ME, V13, P423, DOI 10.1097/PCC.0b013e318238b81c; VESELIS RA, 1994, ANESTH ANALG, V79, P952; Visser E, 2006, BIOMED PHARMACOTHER, V60, P341, DOI 10.1016/j.biopha.2006.06.021; Wong JJ, 2016, PEERJ, V4, DOI 10.7717/peerj.1710; Yatabe T, 2016, J CLIN ANESTH, V33, P92, DOI 10.1016/j.jclinane.2016.03.017; ZACNY JP, 1992, PSYCHOPHARMACOLOGY, V107, P319, DOI 10.1007/BF02245155; [张晓栋 Zhang Xiaodong], 2013, [吉林大学学报. 医学版, Journal of Jilin Univeristy. Medicine edition], V39, P133	37	1	1	1	5	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0278-5846	1878-4216		PROG NEURO-PSYCHOPH	Prog. Neuro-Psychopharmacol. Biol. Psychiatry	AUG 30	2019	94								UNSP 109647	10.1016/j.pnpbp.2019.109647			9	Clinical Neurology; Neurosciences; Pharmacology & Pharmacy; Psychiatry	Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry	II8PF	WOS:000475453200019	31095995	Green Accepted			2020-06-30	J	Rosner, B; Neicun, J; Yang, JC; Roman-Urrestarazu, A				Rosner, Bastian; Neicun, Jessica; Yang, Justin Christopher; Roman-Urrestarazu, Andres			Opioid prescription patterns in Germany and the global opioid epidemic: Systematic review of available evidence	PLOS ONE			English	Review							CHRONIC NONCANCER PAIN; CANCER PAIN; HEROIN USE; THERAPY; HISTORY	Introduction Opioids are one of the most important and effective drug classes in pain medicine with a key role in most medical fields. The increase of opioid prescription over time has led to higher numbers of prescription opioid misuse, abuse and opioid-related deaths in most developed OECD (Organisation for Economic Co-operation and Development) countries around the world. Whilst reliable data on the prevalence of opioid treatment is accessible for many countries, data on Germany specifically is still scarce. Considering Germany being the largest country in the European Union, the lack of evidence-based strategies from long-term studies is crucial. The aim of this work is to review and summarise relevant published literature on the prevalence of opioid prescription in Germany to adequately inform health policy strategies. Methods A systematic review of the epidemiology of opioid prescription in Germany was conducted, searching PubMed and Web of Science. Eligibility criteria were defined prior to conducting the search. Literature concerning Germany, published in English and German was included and the search was replicated by three independent researchers. Two levels of screening were employed. Disagreement was resolved by face-to-face discussion, leading to a consensus judgement. Results Our electronic search yielded 735 articles. Reviewing titles and abstracts yielded 19 relevant articles. Three authors examined each article's full text more closely and determined that twelve papers should be included. Of the twelve identified studies-with publication dates ranging from 1985 to 2016-six were retrospective cross-sectional studies and six were retrospective repeated-measures cross-sectional studies. Sample sizes ranged from 92,842 to approximate to 11,000,000 participants. Data sources of included studies showed vast heterogeneity. The reviewed literature suggested an increase in the number of patients with opioid prescriptions and defined daily doses of opioids per recipient in Germany over time. The majority of opioid prescriptions was used for patients with non-cancer pain. Opioid use was more common in older people, women and in the north of Germany. Fentanyl was shown to be the most prescribed strong opioid in outpatient settings in Germany, despite not being the first-line choice for chronic pain conditions. All data published before 2000-but none of the more recent studies-suggested an insufficient treatment of pain using opioids. There were no signs for a current opioid epidemic in Germany. Conclusions Despite some limitations of the review and the heterogeneity of studies, it can be stated that the number of opioid prescriptions overall as well as the number of people receiving opioid treatment have increased over time. Most prescriptions were found to be for strong opioids and patients with non-cancer pain. Even though patterns of opioid prescription follow trends observed in other developed countries, there are no signs of an opioid epidemic in Germany. Therefore, this review could currently not find a need for urgent health policy interventions regarding opioid prescription practices. However, critical gaps in the literature remain and more research is needed to make more reliable judgements.	[Rosner, Bastian; Yang, Justin Christopher; Roman-Urrestarazu, Andres] Univ Cambridge, Inst Publ Hlth, Forvie Site, Cambridge, England; [Neicun, Jessica; Roman-Urrestarazu, Andres] Maastricht Univ, Dept Int Hlth, Care & Publ Hlth Res Inst CAPHRI, Fac Hlth Med & Life Sci, Maastricht, Netherlands	Roman-Urrestarazu, A (reprint author), Univ Cambridge, Inst Publ Hlth, Forvie Site, Cambridge, England.; Roman-Urrestarazu, A (reprint author), Maastricht Univ, Dept Int Hlth, Care & Publ Hlth Res Inst CAPHRI, Fac Hlth Med & Life Sci, Maastricht, Netherlands.	aer56@cam.ac.uk	Yang, Justin C./H-1780-2018; Roman-Urrestarazu, Andres/U-9224-2018	Yang, Justin C./0000-0003-2881-4906; Roman-Urrestarazu, Andres/0000-0002-2405-9432; Neicun, Jessica/0000-0002-8710-8238; Rosner, Bastian/0000-0002-4338-1582			Agence nationale de securitedu medicament et des produits de sante, 2019, ET LIEUX CONS LEURS; Andersen MH, 2011, INCIDENCE PREVALENCE; [Anonymous], 2018, INF OP REL HARMS CAN; [Anonymous], 2018, WORLD FACTB; [Anonymous], 1998, VERORDNUNG VERSCHREI; Australian Institute of Health and Welfare, 2016, NAT OP PHARM STAT NO; Baker DW, 2017, JAMA-J AM MED ASSOC, V317, P1117, DOI 10.1001/jama.2017.0935; Ballantyne JC, 2003, ONCOLOGIST, V8, P567, DOI 10.1634/theoncologist.8-6-567; BOARD INC, 2017, NARC DRUGS; Buth S, 2017, BUNDESGESUNDHEITSBLA, V60, P865, DOI 10.1007/s00103-017-2571-4; Carlson CL, 2016, J PAIN RES, V9, P515, DOI 10.2147/JPR.S97759; Carlson RG, 2016, DRUG ALCOHOL DEPEN, V160, P127, DOI 10.1016/j.drugalcdep.2015.12.026; Cicero TJ, 2017, DIALOGUES CLIN NEURO, V19, P259; Cicero TJ, 2014, JAMA PSYCHIAT, V71, P821, DOI 10.1001/jamapsychiatry.2014.366; European Monitoring Centre for Drugs and Drug Addiction, 2019, GERM COUNTR DRUG REP; Freye E., 2010, OPIOIDE MED; Gilson Aaron M, 2011, J Pain Palliat Care Pharmacother, V25, P246, DOI 10.3109/15360288.2011.599485; Hauser W, 2016, PAIN MANAG, V6, P249, DOI 10.2217/pmt.16.5; Hauser W, 2014, DTSCH ARZTEBL INT, V111, P732, DOI 10.3238/arztebl.2014.0732; Hauser Winfried, 2017, Pain Rep, V2, pe599, DOI 10.1097/PR9.0000000000000599; Hider-Mlynarz K, 2018, BRIT J CLIN PHARMACO, V84, P1324, DOI 10.1111/bcp.13564; Hoer A, 2008, SCHMERZ, V22, P156, DOI 10.1007/s00482-007-0575-y; Hoffmann F, 2012, SCHMERZ, V26, P707, DOI 10.1007/s00482-012-1240-7; Hyman J, 2015, J AM DENT ASSOC, V146, P283, DOI 10.1016/j.adaj.2015.02.010; Ihle P, 2012, PHARMACOEPIDEM DR S, V21, P172; Jacob L, 2018, POSTGRAD MED, V130, P32, DOI 10.1080/00325481.2018.1391658; Jones MR, 2018, PAIN THER, V7, P13, DOI 10.1007/s40122-018-0097-6; Kaiser T., 2018, DEUTSCHLAND DROHT OP; Kassebaum NJ, 2016, LANCET, V388, P1603, DOI 10.1016/S0140-6736(16)31460-X; Kieble M., 2012, GKV MARKTANTEILE NAC; Kipping K, 2014, PAIN PHYSICIAN, V17, P81; Lindena G, 1996, SCHMERZ, V10, P319, DOI 10.1007/s004820050057; Marschall U, 2016, EUR J PAIN, V20, P767, DOI 10.1002/ejp.802; Nobis H-GR, AKUTE CHRONISCHE SCH; Noble M, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006605.pub2; OECD, 2018, OP; OECD, 2019, ADDRESSING PROBLEMAT; Reinecke H, 2009, SCHMERZ, V23, P440, DOI 10.1007/s00482-009-0839-9; Rivat Cyril, 2016, Pain Rep, V1, pe570, DOI 10.1097/PR9.0000000000000570; Rosenblum A, 2008, EXP CLIN PSYCHOPHARM, V16, P405, DOI 10.1037/a0013628; Schubert I, 2013, DTSCH ARZTEBL INT, V110, P45, DOI 10.3238/arztebl.2013.0045; Sorge J, 1990, Schmerz, V4, P151, DOI 10.1007/BF02527878; Sullivan MD, 2013, PAIN, V154, pS94, DOI 10.1016/j.pain.2013.09.009; Trivedi MS, 2007, PHARM OPIOIDS 1; Vashishtha D, 2017, HARM REDUCT J, V14, DOI 10.1186/s12954-017-0135-4; Vowles KE, 2015, PAIN, V156, P569, DOI 10.1097/01.j.pain.0000460357.01998.f1; Werber A, 2015, PAIN PHYSICIAN, V18, pE323; Willweber-Strumpf A, 1992, Schmerz, V6, P255, DOI 10.1007/BF02527815; Zee AV, 2009, AM J PUBLIC HEALTH, V99, P221, DOI 10.2105/AJPH.2007.131714; Zeitung P., 2018, OPIOID MISSBRAUCH AU; ZENZ M, 1995, J PAIN SYMPTOM MANAG, V10, P187, DOI 10.1016/0885-3924(94)00122-2	51	5	5	2	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 28	2019	14	8							e0221153	10.1371/journal.pone.0221153			20	Multidisciplinary Sciences	Science & Technology - Other Topics	IW5XV	WOS:000485052300023	31461466	DOAJ Gold, Green Published			2020-06-30	J	Shin, DW; Kim, Y; Hong, B; Yoon, SH; Lim, CS; Youn, S				Shin, Dong Wook; Kim, Yeojung; Hong, Boohwi; Yoon, Seok-Hwa; Lim, Chae Seong; Youn, Sookyoung			Effect of fentanyl on nausea and vomiting in cesarean section under spinal anesthesia: a randomized controlled study	JOURNAL OF INTERNATIONAL MEDICAL RESEARCH			English	Article						Cesarean section; nausea; midazolam; opioid; spinal anesthesia; intraoperative nausea and vomiting; sedation	POSTOPERATIVE NAUSEA; DOUBLE-BLIND; MIDAZOLAM; PROPOFOL; SATISFACTION; DELIVERY	Objective Although opioids may induce nausea and vomiting, they possess sedative effects and can reduce intraoperative nausea and vomiting (IONV). This study assessed the effect of adding fentanyl to midazolam on sedation levels and IONV during cesarean section under spinal anesthesia. Methods Eighty parturients scheduled for elective cesarean section were enrolled in the study. Following fetal delivery, patients were administered 0.05 mg/kg of midazolam plus 0.03 mL/kg of normal saline (M group) or 0.05 mg/kg of midazolam plus 1.5 mu g/kg of fentanyl (MF group). The primary outcome was the incidence of IONV. The secondary outcomes were incidence of postoperative nausea and vomiting (PONV), intraoperative sedation level, and five-point patient satisfaction score (PSS). Results The IONV incidence was significantly lower in the MF group compared with the M group (5% [2/40] vs. 25% [10/40]). The PONV incidence did not differ significantly between the groups. The intraoperative sedation level tended to be deeper in the MF group. The five-point PSS was significantly higher in the M group. There was a strong correlation between the sedation level and IONV incidence. Conclusions Adding fentanyl to midazolam is effective for sedation and to prevent IONV in women who are undergoing cesarean section under spinal anesthesia.	[Shin, Dong Wook; Kim, Yeojung] CHA Univ Gumi, CHA Gumi Med Ctr, Dept Anesthesiol & Pain Med, Gumi, South Korea; [Hong, Boohwi; Yoon, Seok-Hwa; Lim, Chae Seong; Youn, Sookyoung] Chungnam Natl Univ, Coll Med, Dept Anesthesiol & Pain Med, 282 Munhwa Ro, Daejeon 35015, South Korea	Hong, B (reprint author), Chungnam Natl Univ, Coll Med, Dept Anesthesiol & Pain Med, 282 Munhwa Ro, Daejeon 35015, South Korea.	koho0127@gmail.com		Hong, Boohwi/0000-0003-2468-9271	Chungnam National University	This work was supported by a research fund from Chungnam National University.	Akoglu H, 2018, TURK J EMERG MED, V18, P91, DOI 10.1016/j.tjem.2018.08.001; Apfel CC, 1999, ANESTHESIOLOGY, V91, P693, DOI 10.1097/00000542-199909000-00022; Apfel Christian C, 2003, Int Anesthesiol Clin, V41, P13, DOI 10.1097/00004311-200341040-00004; Balki M, 2005, INT J OBSTET ANESTH, V14, P230, DOI 10.1016/j.ijoa.2004.12.004; Borgeat A, 2003, ANESTHESIOLOGY, V98, P530, DOI 10.1097/00000542-200302000-00036; Bowring J, 2006, J Obstet Gynaecol, V26, P433, DOI 10.1080/01443610600720345; Dahl JB, 1999, ANESTHESIOLOGY, V91, P1919, DOI 10.1097/00000542-199912000-00045; Danielak-Nowak M, 2016, ANAESTH INTENSIVE TH, V48, P13, DOI 10.5603/AIT.2016.0003; Di Florio T, 1999, ANAESTH INTENS CARE, V27, P38; Frolich MA, 2006, CAN J ANAESTH, V53, P79; Gan TJ, 1999, ANESTHESIOLOGY, V90, P1564, DOI 10.1097/00000542-199906000-00011; Gan TJ, 1996, ANESTHESIOLOGY, V85, P1036, DOI 10.1097/00000542-199611000-00011; Hobson JA, 2006, INT J OBSTET ANESTH, V15, P18, DOI 10.1016/j.ijoa.2005.05.008; Johnson OG, 2017, EMERG MED AUSTRALAS, V29, P303, DOI 10.1111/1742-6723.12762; Lee JH, 2011, KOREAN J ANESTHESIOL, V60, P103, DOI 10.4097/kjae.2011.60.2.103; Macario A, 1999, ANESTH ANALG, V89, P652, DOI 10.1097/00000539-199909000-00022; Marucci M, 2003, Minerva Anestesiol, V69, P809; NAULTY JS, 1985, ANESTHESIOLOGY, V63, P694, DOI 10.1097/00000542-198512000-00025; Numazaki M, 2003, J CLIN ANESTH, V15, P423, DOI 10.1016/S0952-8180(03)00086-2; Patki Abhiruchi, 2011, J Anaesthesiol Clin Pharmacol, V27, P47; Rasooli Sousan, 2014, Anesth Pain Med, V4, pe19384, DOI 10.5812/aapm.19384; Rodola F, 2006, Eur Rev Med Pharmacol Sci, V10, P121; Seyedhejazi Mahin, 2013, Saudi J Anaesth, V7, P266, DOI 10.4103/1658-354X.115339; Shahriari Ali, 2009, JPMA Journal of the Pakistan Medical Association, V59, P756; Tarhan O, 2007, MINERVA ANESTESIOL, V73, P629	25	0	0	1	1	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0300-0605	1473-2300		J INT MED RES	J. Int. Med. Res.	OCT	2019	47	10					4798	4807	UNSP 0300060519869515	10.1177/0300060519869515		AUG 2019	10	Medicine, Research & Experimental; Pharmacology & Pharmacy	Research & Experimental Medicine; Pharmacology & Pharmacy	JG3AA	WOS:000484212300001	31452417	DOAJ Gold, Green Published			2020-06-30	J	Wu, J; Ku, SC; Ko, AL				Wu, Jiang; Ku, Stephen C.; Ko, Andrew L.			Use of Dexmedetomidine for Postoperative Pain Management Following Spine Fusion Surgery in a Highly Opioid-Tolerant Patient	JOURNAL OF PAIN & PALLIATIVE CARE PHARMACOTHERAPY			English	Article						Acute pain; dexmedetomidine; opioid-tolerant; palliative	ANALGESIA; MORPHINE	A 51-year-old man with metastatic renal cell carcinoma whose fentanyl requirement was 3000-4000 mu g/h in inpatient hospice presented for a thoracic (T) vertebral 4-10 posterior spinal fusion for a lytic T7 compression fracture. He underwent total intravenous (IV) anesthesia with propofol, remifentanil, and ketamine; liposome bupivacaine was locally infiltrated at the end of the case. Following extubation on postoperative day (POD) 1, he had severe pain refractory to high-dose IV fentanyl patient control analgesia and ketamine infusion. His pain dramatically improved after a dexmedetomidine infusion was added and titrated to the analgesic effect. He participated in neurological examinations and fulfilled both surgical and pain management goals without side effects. Dexmedetomidine was successfully weaned off on POD 3.	[Wu, Jiang; Ku, Stephen C.] Univ Washington, Dept Anesthesiol & Pain Med, RR442A,1959 NE Pacific St,Box 356640, Seattle, WA 98195 USA; [Ko, Andrew L.] Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA	Wu, J (reprint author), Univ Washington, Dept Anesthesiol & Pain Med, RR442A,1959 NE Pacific St,Box 356640, Seattle, WA 98195 USA.	jiangwu@uw.edu		Ko, Andrew/0000-0002-6253-9891			[Anonymous], 2013, PRECEDEX DEXMEDETOMI; Blaudszun G, 2012, ANESTHESIOLOGY, V116, P1312, DOI 10.1097/ALN.0b013e31825681cb; Chetty S, 2011, SOUTH AFR J ANAESTH, V17, P139, DOI 10.1080/22201173.2011.10872760; Dunn LK, 2016, BEST PRACT RES-CLIN, V30, P79, DOI 10.1016/j.bpa.2015.11.002; Gao YT, 2018, CLIN J PAIN, V34, P155, DOI 10.1097/AJP.0000000000000527; Garg N, 2016, J NEUROSURG ANESTH, V28, P27, DOI 10.1097/ANA.0000000000000193; Gertler R, 2001, Proc (Bayl Univ Med Cent), V14, P13; Kosharskyy B, 2013, PAIN PHYSICIAN, V16, P231; Lin TF, 2009, BRIT J ANAESTH, V102, P117, DOI 10.1093/bja/aen320; Lundorf LJ, 2013, COCHRANE DB SYST REV, V2013, DOI [10.1002/14651858.cd010358, DOI 10.1002/14651858.CD010358]; Weerink MAS, 2017, CLIN PHARMACOKINET, V56, P893, DOI 10.1007/s40262-017-0507-7	11	0	0	0	4	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1536-0288	1536-0539		J PAIN PALLIAT CARE	J. Pain Palliat. Care Pharmacother.	APR 3	2019	33	1-2					49	53		10.1080/15360288.2019.1651439		AUG 2019	5	Anesthesiology; Pharmacology & Pharmacy	Anesthesiology; Pharmacology & Pharmacy	JG2KL	WOS:000484178200001	31465697				2020-06-30	J	Cruickshank, A; Qeadan, F; Kuttesch, JF; Agarwal, HS				Cruickshank, Amy; Qeadan, Fares; Kuttesch, John F.; Agarwal, Hemant S.			Eutectic mixture of lidocaine and prilocaine versus 1% lidocaine injection for lumbar punctures in pediatric oncology patients	PEDIATRIC BLOOD & CANCER			English	Article						EMLA cream; local anesthetic; lumbar puncture; pediatric oncology; procedural sedation	PROCEDURAL SEDATION; TOPICAL APPLICATION; PAINFUL PROCEDURES; PROPOFOL; EMLA; CHILDREN; ANALGESIA; ANESTHESIA; INFILTRATION; REDUCTION	Background The role of local analgesics for lumbar punctures (LPs) in pediatric oncology patients has not been specifically studied. Aim To compare the efficacy of eutectic mixture of local anesthetics (EMLA) cream to 1% lidocaine injection for LPs. Method This was a retrospective observational study of all patients receiving either EMLA cream (EMLA group) or 1% lidocaine subcutaneous injection (lidocaine group) in addition to fentanyl and propofol for LPs over 18 months. Demographics, vital parameters, procedural and recovery times, propofol and fentanyl doses, and adverse events were studied. Results Two hundred ninety LPs in 49 children were studied: 148 in the EMLA group and 142 in the lidocaine group. There was no difference in demographics or preprocedural parameters between the two groups. LPs in the EMLA group were completed in a shorter time (7.5 minutes [CI 7.0-8.1] vs 9.4 minutes [CI 8.9-9.9]) with a faster recovery time (38.7 minutes [CI 36.9-40.9] vs 43.9 minutes. [CI 41.9-45.9]) as compared with the lidocaine group (P < 0.001). The EMLA group required less maintenance doses (0.54 mg/kg [CI 0.47-0.62] vs 1.14 mg/kg [CI 1.06-1.21]) and total doses (2.58 mg/kg [CI 2.42-2.75] vs 3.12 mg/kg [CI 2.95-3.29]) of propofol as compared with the lidocaine group (P < 0.0001). Adverse events in the EMLA group were less (19% vs 41%) as compared with the lidocaine group (P < 0.0001). Conclusion The addition of EMLA cream for procedural sedation for LPs in pediatric oncology patients significantly improves pain management in comparison with 1% lidocaine injection.	[Cruickshank, Amy; Kuttesch, John F.; Agarwal, Hemant S.] Univ New Mexico, Dept Pediat, Hlth Sci Ctr, 2211 Lomas Blvd NE,MSC105590, Albuquerque, NM 87131 USA; [Cruickshank, Amy; Kuttesch, John F.; Agarwal, Hemant S.] Univ New Mexico, Albuquerque, NM 87131 USA; [Qeadan, Fares] Univ New Mexico, Hlth Sci Ctr, Div Epidemiol Biostat & Prevent Med, Dept Internal Med, Albuquerque, NM 87131 USA	Agarwal, HS (reprint author), Univ New Mexico, Dept Pediat, Hlth Sci Ctr, 2211 Lomas Blvd NE,MSC105590, Albuquerque, NM 87131 USA.	hemantagarwal@hotmail.com		Cruickshank, Amy/0000-0002-2206-7519			ARENDTNIELSEN L, 1988, ANESTH ANALG, V67, P115; BJERRING P, 1990, BRIT J ANAESTH, V64, P173, DOI 10.1093/bja/64.2.173; Carraccio C, 1996, ARCH PEDIAT ADOL MED, V150, P1044, DOI 10.1001/archpedi.1996.02170350046007; Cechvala MM, 2008, J PEDIAT HEMATOL ONC, V30, P142, DOI 10.1097/MPH.0b013e31815d8953; Cepeda MS, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006581.pub2; Chayapathi V, 2018, PEDIATR BLOOD CANCER, V65, DOI 10.1002/pbc.27108; CHRISTOPH RA, 1988, ANN EMERG MED, V17, P117, DOI 10.1016/S0196-0644(88)80293-2; Cravero JP, 2009, ANESTH ANALG, V108, P795, DOI 10.1213/ane.0b013e31818fc334; EVERS H, 1985, BRIT J ANAESTH, V57, P997, DOI 10.1093/bja/57.10.997; Fein D, 2010, PEDIATR EMERG CARE, V26, P357, DOI 10.1097/PEC.0b013e3181db2026; Gimenez JCJ, 1996, ANN PHARMACOTHER, V30, P1235; Gorman R, 2002, PEDIATRICS, V110, P836; Gottschling S, 2005, J PEDIAT HEMATOL ONC, V27, P471, DOI 10.1097/01.mph.0000179238.37647.91; Gross JB, 2002, ANESTHESIOLOGY, V96, P1004; HALPERIN DL, 1989, PEDIATRICS, V84, P281; Hoffman GM, 2002, PEDIATRICS, V109, P236, DOI 10.1542/peds.109.2.236; Holdsworth MT, 2003, ANN PHARMACOTHER, V37, P17; Holdsworth MT, 1997, PHARMACOTHERAPY, V17, P1017; Hollman GA, 2008, PEDIATR CRIT CARE ME, V9, P616, DOI 10.1097/PCC.0b013e31818e3ad3; Jayabose S, 2001, J PEDIAT HEMATOL ONC, V23, P290, DOI 10.1097/00043426-200106000-00011; KAPELUSHNIK J, 1990, PAIN, V42, P31, DOI 10.1016/0304-3959(90)91088-Z; KAUFFMAN RE, 1992, PEDIATRICS, V89, P1110; Klein Scott M, 2003, Pediatr Crit Care Med, V4, P78, DOI 10.1097/00130478-200301000-00016; Ljungman G, 2000, PEDIATR HEMAT ONCOL, V17, P211, DOI 10.1080/088800100276389; Ljungman G, 2001, MED PEDIATR ONCOL, V36, P372, DOI 10.1002/mpo.1088; MORRIS R, 1987, ANESTH ANALG, V66, P1180; MORRIS RW, 1984, ANAESTH INTENS CARE, V12, P113, DOI 10.1177/0310057X8401200204; Parham SM, 1996, CAN J SURG, V39, P31; Patel Meral M, 2016, Hosp Pediatr, V6, P95, DOI 10.1542/hpeds.2015-0065; Pinheiro JM, 2007, PEDIATRICS, V119, pe631; STEEN KH, 1993, NEUROSCI LETT, V154, P113, DOI 10.1016/0304-3940(93)90184-M; Von Heijne M, 2004, PEDIATR ANESTH, V14, P670; Wahlgren CF, 2000, J AM ACAD DERMATOL, V42, P584, DOI 10.1016/S0190-9622(00)90169-5; Whitlow PG, 2015, PEDIATR BLOOD CANCER, V62, P85, DOI 10.1002/pbc.25236; ZELTZER L K, 1990, Pediatrics, V86, P826; Zernikow B, 2005, EUR J PAIN, V9, P395, DOI 10.1016/j.ejpain.2004.09.008	36	0	0	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1545-5009	1545-5017		PEDIATR BLOOD CANCER	Pediatr. Blood Cancer	NOV	2019	66	11							e27957	10.1002/pbc.27957		AUG 2019	8	Oncology; Hematology; Pediatrics	Oncology; Hematology; Pediatrics	IZ4ZW	WOS:000481785300001	31423750				2020-06-30	J	Minagar, M; Dehghan-Tezerjani, M; Khan, ZH				Minagar, Milad; Dehghan-Tezerjani, Mohammad; Khan, Zahid Hussain			Anesthetic Considerations in Cobb Syndrome: A Case Report	A & A PRACTICE			English	Article							VENOUS THROMBOEMBOLISM	Cutaneomeningospinal angiomatosis, popularly known as Cobb syndrome, is a rare clinical disorder predominantly presenting with a vascular skin lesion and a spinal angioma at the same dermatomal level. Several case reports and case series have reported on the surgical management of this syndrome, but we failed to find any information about its anesthetic considerations in the Medline database. Our case report describes the perioperative anesthetic management of a 46-year-old man with Cobb syndrome.	[Minagar, Milad; Dehghan-Tezerjani, Mohammad; Khan, Zahid Hussain] Univ Tehran Med Sci, Dept Anesthesiol & Crit Care, Imam Khomeini Med Complex, Tehran, Iran	Khan, ZH (reprint author), Univ Tehran Med Sci, Imam Khomeini Med Complex, Keshavarz Blvd, Tehran 1419733141, Iran.	khanzh51@yahoo.com	Dehghan-Tezerjani, Mohammad/A-3199-2019; Minagar, Milad/AAC-2017-2019	Dehghan-Tezerjani, Mohammad/0000-0002-6966-6818; Minagar, Milad/0000-0001-6162-0156			Abtahi-naeini B, 2016, INT WOUND J, V13, P1009, DOI 10.1111/iwj.12494; Cobb S, 1915, ANN SURG, V62, P641, DOI 10.1097/00000658-191512000-00001; Faraoni D, 2018, EUR J ANAESTH, V35, P90, DOI 10.1097/EJA.0000000000000710; Gao P, 2011, ACTA NEUROCHIR, V153, P1657, DOI 10.1007/s00701-011-1025-2; Garza-Serna U, 2018, INT J SURG CASE REP, V51, P117, DOI 10.1016/j.ijscr.2018.08.023; GREENAWALT JW, 1992, ANESTH ANALG, V75, P294; GUINARD JP, 1993, ANESTH ANALG, V76, P1134; Johans TG, 2007, ANESTH ANALG, V104, P742, DOI 10.1213/01.ane.0000255967.96092.2a; Johnson WD, 2009, J NEUROSURG-SPINE, V10, P430, DOI 10.3171/2009.1.SPINE08334; Lowe LH, 2012, SEMIN ROENTGENOL, V47, P106, DOI 10.1053/j.ro.2011.11.002; Mirski MA, 2007, ANESTHESIOLOGY, V106, P164, DOI 10.1097/00000542-200701000-00026; Pal P, 2015, ANN NEUROSCI, V22, P191, DOI 10.5214/ans.0972.7531.220312; Piper K, 2017, J NEUROSURG-SPINE, V26, P90, DOI 10.3171/2016.6.SPINE1656; Rodesch G, 2003, EUR J RADIOL, V46, P221, DOI 10.1016/S0720-048X(03)00093-7	14	1	1	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2325-7237			A A PRACT	A A Pract.	AUG 15	2019	13	4					137	139		10.1213/XAA.0000000000001016			3	Anesthesiology	Anesthesiology	IV7VF	WOS:000484474200006	30973350				2020-06-30	J	Nan, Q; Ping, X; Shen, BH; Zhuo, XY; Yan, S; Song, FY				Nan, Qin; Ping, Xiang; Shen Baohua; Zhuo Xianyi; Yan, Shi; Song Fenyun			Application of a validated UHPLC-MS/MS method for 28 fentanyl-analogue and novel synthetic opioids in whole blood in authentic forensic cases	JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES			English	Article						Fentanyl; Novel synthetic opioids; UHPLC-MS/MS; Method validation	LC-MS/MS; HUMAN PLASMA; HUMAN URINE; QUANTITATIVE-ANALYSIS; BODY-FLUIDS; HAIR; METABOLITES; DRUGS; SUFENTANIL; QUANTIFICATION	The abuse of fentanyl and its analogues, which are potent, short-acting, synthetic narcotic analgesics, has become a major issue. Many cases containing fentanyl-analogue and novel synthetic opioids have also been reported. Hence, we report the determination of fentanyl, fentanyl-analogue and novel synthetic opioids in whole blood by liquid chromatography-tandem mass spectrometry (LC-MS/MS). The method is characterized by the use of a simple, fast and inexpensive liquid-liquid extraction (LLE) for sample preparation, a rapid run time (8 min) and a low required volume of whole blood (100 mu l). The limits of detection (LODs) ranged from 0.005 to 0.03 ng/ml, and the lower limits of quantitation (LLOQs) ranged from 0.05 to 0.2 ng/ml. The method was shown to be liner over a concentration range of 0.2-40 ng/ml for fentanyl, norfentanyl and norcarfentanil and 0.05-40 ng/ml for all other target analytes. Recoveries were within the range of 72.09%-103.22%, and the matrix effects were in the 67.95%-113.32% range. Moreover, the method was applied to the detection and quantification of fentanyl and its analogues in whole blood from real forensic cases. This methodology has great potential for use in the determination of fentanyl and its analogues in forensic cases.	[Nan, Qin; Song Fenyun] Guangdong Pharmaceut Univ, Sch Pharm, Guangzhou 510006, Guangdong, Peoples R China; [Nan, Qin; Ping, Xiang; Shen Baohua; Zhuo Xianyi; Yan, Shi] Acad Forens Sci, Dept Forens Toxicol, Shanghai Key Lab Forens Med, Shanghai Forens Sci Platform, Shanghai 200063, Peoples R China	Song, FY (reprint author), Guangdong Pharmaceut Univ, Sch Pharm, Guangzhou 510006, Guangdong, Peoples R China.; Yan, S (reprint author), Acad Forens Sci, Dept Forens Toxicol, Shanghai Key Lab Forens Med, Shanghai Forens Sci Platform, Shanghai 200063, Peoples R China.	shiy@ssfjd.cn			National Key Research and Development Program of China [2016YFC0800704]; Research Institute Projects [2019G-4]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81501633]; Shanghai Key Laboratory of Forensic Medicine [17DZ2273200]; Shanghai Forensic Service Platform [19DZ2292700]	This study was supported by grants from National Key Research and Development Program of China (2016YFC0800704), Research Institute Projects (2019G-4), National Natural Science Foundation of China (81501633), Shanghai Key Laboratory of Forensic Medicine (17DZ2273200) and Shanghai Forensic Service Platform (19DZ2292700).	[Anonymous], 2013, J ANAL TOXICOL, V37, P452, DOI 10.1093/jat/bkt054; Armenian P, 2018, NEUROPHARMACOLOGY, V134, P121, DOI 10.1016/j.neuropharm.2017.10.016; Beers R, 2004, CNS DRUGS, V18, P1085, DOI 10.2165/00023210-200418150-00004; Bista SR, 2015, CLIN THER, V37, P2468, DOI 10.1016/j.clinthera.2015.09.002; Bista SR, 2014, J CHROMATOGR B, V960, P27, DOI 10.1016/j.jchromb.2014.04.019; Boumba VA, 2017, FORENSIC SCI INT, V279, P192, DOI 10.1016/j.forsciint.2017.08.031; Chatterton CN, 2018, FORENSIC SCI INT, V284, P146, DOI 10.1016/j.forsciint.2017.12.031; Clavijo CF, 2011, J SEP SCI, V34, P3568, DOI 10.1002/jssc.201100422; Cooreman S, 2010, J SEP SCI, V33, P2654, DOI 10.1002/jssc.201000330; Eckart K, 2015, J CHROMATOGR B, V1001, P1, DOI 10.1016/j.jchromb.2015.06.028; European Medicines Agency, 2011, GUID BIOAN METH VAL; Fleming SW, 2017, J ANAL TOXICOL, V41, P173, DOI 10.1093/jat/bkw131; Fogarty MF, 2018, J ANAL TOXICOL, V42, P592, DOI 10.1093/jat/bky035; Gergov M, 2009, FORENSIC SCI INT, V186, P36, DOI 10.1016/j.forsciint.2009.01.013; GILLESPIE TJ, 1982, J ANAL TOXICOL, V6, P139, DOI 10.1093/jat/6.3.139; Giorgetti A, 2017, HUM PSYCHOPHARM CLIN, V32, DOI 10.1002/hup.2605; HENDERSON GL, 1991, J FORENSIC SCI, V36, P422; Kim J, 2014, J PHARMACEUT BIOMED, V89, P99, DOI 10.1016/j.jpba.2013.10.041; Klima M, 2016, FORENSIC SCI INT, V265, P166, DOI 10.1016/j.forsciint.2016.02.021; Kronstrand R, 1997, FORENSIC SCI INT, V88, P185, DOI 10.1016/S0379-0738(97)00068-6; Kronstrand R, 2018, FORENSIC SCI INT, V283, P9, DOI 10.1016/j.forsciint.2017.12.001; Lung DD, 2014, FORENSIC TOXICOL, V32, P118, DOI 10.1007/s11419-013-0216-3; Lurie IS, 2009, J CHROMATOGR A, V1216, P1515, DOI 10.1016/j.chroma.2008.12.097; MATHER LE, 1983, CLIN PHARMACOKINET, V8, P422, DOI 10.2165/00003088-198308050-00004; Matuszewski BK, 2003, ANAL CHEM, V75, P3019, DOI 10.1021/ac020361s; Misailidi N, 2018, FORENSIC TOXICOL, V36, P12, DOI 10.1007/s11419-017-0379-4; Mohr ALA, 2016, J ANAL TOXICOL, V40, P709, DOI 10.1093/jat/bkw086; Moody MT, 2018, DRUG TEST ANAL, V10, P1358, DOI 10.1002/dta.2393; Moore C, 2008, FORENSIC SCI INT, V176, P47, DOI 10.1016/j.forsciint.2007.06.027; Muijsers RBR, 2001, DRUGS, V61, P2289, DOI 10.2165/00003495-200161150-00014; Noble C, 2018, DRUG TEST ANAL, V10, P651, DOI 10.1002/dta.2263; Nosseir NS, 2014, J CHROMATOGR B, V973, P133, DOI 10.1016/j.jchromb.2014.10.006; Peters FT, 2007, FORENSIC SCI INT, V165, P216, DOI 10.1016/j.forsciint.2006.05.021; Rodda LN, 2017, J ANAL TOXICOL, V41, P318, DOI 10.1093/jat/bkx013; Rosenblum A, 2008, EXP CLIN PSYCHOPHARM, V16, P405, DOI 10.1037/a0013628; RUNAGYUTTIKARN W, 1990, J ANAL TOXICOL, V14, P160, DOI 10.1093/jat/14.3.160; Saari TI, 2012, J PHARMACEUT BIOMED, V66, P306, DOI 10.1016/j.jpba.2012.03.050; Schmidt R, 2006, J CHROMATOGR B, V836, P98, DOI 10.1016/j.jchromb.2006.03.052; Schneider S, 2008, J ANAL TOXICOL, V32, P260, DOI 10.1093/jat/32.3.260; Seither J, 2017, J ANAL TOXICOL, V41, P493, DOI 10.1093/jat/bkx049; Shaner RL, 2017, ANAL METHODS-UK, V9, P3876, DOI [10.1039/c7ay00532f, 10.1039/C7AY00532F]; Shaner RL, 2014, J CHROMATOGR B, V962, P52, DOI 10.1016/j.jchromb.2014.05.025; Shanks KG, 2017, J ANAL TOXICOL, V41, P466, DOI 10.1093/jat/bkx042; Shoff EN, 2017, J ANAL TOXICOL, V41, P484, DOI 10.1093/jat/bkx041; SILVERSTEIN JH, 1993, ANESTH ANALG, V76, P618; Smith ML, 2007, J ANAL TOXICOL, V31, P237, DOI 10.1093/jat/31.5.237; Sofalvi S, 2017, J ANAL TOXICOL, V41, P473, DOI 10.1093/jat/bkx052; STANLEY TH, 1992, J PAIN SYMPTOM MANAG, V7, pS3, DOI 10.1016/0885-3924(92)90047-L; Stanley TH, 2014, J PAIN, V15, P1215, DOI 10.1016/j.jpain.2014.08.010; Strano-Rossi S, 2011, ANAL BIOANAL CHEM, V399, P1623, DOI 10.1007/s00216-010-4471-4; Strayer KE, 2018, ACS OMEGA, V3, P514, DOI 10.1021/acsomega.7b01536; Suzuki J, 2017, DRUG ALCOHOL DEPEN, V171, P107, DOI 10.1016/j.drugalcdep.2016.11.033; Swanson DM, 2017, J ANAL TOXICOL, V41, P498, DOI 10.1093/jat/bkx037; Tiscione NB, 2017, J ANAL TOXICOL, V41, P313, DOI 10.1093/jat/bkx005; Wang BT, 2014, J ANAL TOXICOL, V38, P672, DOI 10.1093/jat/bku103; Wang LQ, 2006, J ANAL TOXICOL, V30, P335, DOI 10.1093/jat/30.5.335; WARD CF, 1983, JAMA-J AM MED ASSOC, V250, P922, DOI 10.1001/jama.250.7.922; Wax PM, 2003, ANN EMERG MED, V41, P700, DOI 10.1067/mem.2003.148; Wong B, 2017, INHAL TOXICOL, V29, P65, DOI 10.1080/08958378.2017.1282065; Yong Z, 2014, EUR J PHARMACOL, V738, P153, DOI 10.1016/j.ejphar.2014.05.044	60	5	5	5	15	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	1570-0232	1873-376X		J CHROMATOGR B	J. Chromatogr. B	AUG 15	2019	1124						82	99		10.1016/j.jchromb.2019.05.025			18	Biochemical Research Methods; Chemistry, Analytical	Biochemistry & Molecular Biology; Chemistry	IM0NN	WOS:000477685600009	31177051	Bronze			2020-06-30	J	Zoorob, M				Zoorob, Michael			Fentanyl shock: The changing geography of overdose in the United States	INTERNATIONAL JOURNAL OF DRUG POLICY			English	Article						Supply shock; Fentanyl; Overdose; Opioid epidemic	HEROIN	Background: Rapid increases in drug overdose deaths in the United States since 2014 have been highly regionally stratified, with the largest increases occurring in the eastern and northeastern states. By contrast, many western states saw overdose deaths plateau. This paper shows how the differential influx of fentanyl and fentanyl analogues in the drug supply has reshaped the geography and demography of the overdose crisis in the United States. Methods: Using all state lab drug seizures obtained by Freedom of Information Act request, I analyze the regionally distinctive presence of fentanyl in the US drug supply with descriptive plots and statistical models. Main analyses explore state-year overdose trends using two-way fixed effects ordinary least squares (OLS) regression and two-stage least squares regression (2SLS) instrumenting for fentanyl exposure with state-longitude times a linear trend. Results: First, fentanyl exposure is highly correlated with geography and only weakly explained by overdose rates prior to 2014. States in the east (higher degrees longitude) are much more heavily affected. Second, fentanyl exposure exhibits a statistically significant and important effect on overdose mortality, with model-predicted deaths broadly consistent with official death statistics. Third, fentanyl exposure explains most of the variation in increased overdose mortality between 2011 and 2017. Consequently, the epicenter of the overdose crisis shifted towards the eastern United States over these years. Conclusion: These findings shed light on the "third-wave" of the overdose epidemic, characterized by rapid and geographically disparate changes in drug supply that heighten the risk of overdose. Above all, they underscore the urgency of adopting evidence-based policies to combat addiction in light of the rapidly changing drug environment.	[Zoorob, Michael] Harvard Univ, Dept Govt, 1737 Cambridge St, Cambridge, MA 02138 USA	Zoorob, M (reprint author), Harvard Univ, Dept Govt, 1737 Cambridge St, Cambridge, MA 02138 USA.	mzoorob@g.harvard.edu					CDC, 2018, DRUG OV DEATH DAT; Ciccarone D, 2005, INT J DRUG POLICY, V16, P289, DOI 10.1016/j.drugpo.2005.06.001; Ciccarone D., 2019, INT J DRUG POLICY; Ciccarone D, 2017, INT J DRUG POLICY, V46, P146, DOI 10.1016/j.drugpo.2017.06.004; Ciccarone D, 2017, INT J DRUG POLICY, V46, P107, DOI 10.1016/j.drugpo.2017.06.010; Ciccarone D, 2016, DRUG ALCOHOL DEPEN, V163, P126, DOI 10.1016/j.drugalcdep.2016.04.009; Ciccarone D, 2009, INT J DRUG POLICY, V20, P277, DOI 10.1016/j.drugpo.2008.08.003; Dasgupta N, 2018, AM J PUBLIC HEALTH, V108, P182, DOI 10.2105/AJPH.2017.304187; Gladden R. M, 2016, FENTANYL LAW ENFORCE; Glasser S, 2017, DUTCH CUT OVERDOSE D; Gunasekara FI, 2014, INT J EPIDEMIOL, V43, P264, DOI 10.1093/ije/dyt221; Hadland S. E, 2018, TIGHTER PRESCRIBING; Hedegaard H., 2017, DRUG OVERDOSE DEATHS; Irvine MA, 2018, LANCET PUBLIC HEALTH, V3, pE218, DOI 10.1016/S2468-2667(18)30044-6; Krieger MS, 2018, HARM REDUCT J, V15, DOI 10.1186/s12954-018-0213-2; Larochelle MR, 2018, ANN INTERN MED, V169, P137, DOI 10.7326/M17-3107; MA DPH, 2018, DAT BRIEF OP REL OV; Mars SG, 2019, ADDICTION, V114, P774, DOI 10.1111/add.14474; McLean K, 2016, INT J DRUG POLICY, V29, P19, DOI 10.1016/j.drugpo.2016.01.009; National Academies of Sciences Engineering and Medicine, 2017, PAIN MAN OP EP BAL S; NIDA, 2018, FENT OTH SYNTH OP DR; O'Donnell JK, 2017, MMWR-MORBID MORTAL W, V66, P1197, DOI 10.15585/mmwr.mm6643e1; Peiper NC, 2019, INT J DRUG POLICY, V63, P122, DOI 10.1016/j.drugpo.2018.08.007; Quinones S., 2015, DREAMLAND TRUE TALE; Rassen JA, 2009, J CLIN EPIDEMIOL, V62, P1226, DOI 10.1016/j.jclinepi.2008.12.005; Ruhm CJ, 2019, J HEALTH ECON, V64, P25, DOI 10.1016/j.jhealeco.2019.01.001; Ruhm CJ, 2018, ADDICTION, V113, P1339, DOI 10.1111/add.14144; Seth P, 2018, AM J TRANSPLANT, V18, P1556, DOI 10.1111/ajt.14905; Springer Y. P., 2019, MMWR MORBIDITY MORTA, V68; Strang J, 2015, BRIT J PSYCHIAT, V207, P5, DOI 10.1192/bjp.bp.114.149195; Szalavitz M, 2016, UNBROKEN BRAIN REVOL; Unick GJ, 2017, INT J DRUG POLICY, V46, P112, DOI 10.1016/j.drugpo.2017.06.003; Volkow ND, 2018, ANN INTERN MED, V169, P190, DOI 10.7326/M18-1397; Wood EF, 2017, INT J DRUG POLICY, V41, P132, DOI 10.1016/j.drugpo.2016.12.010; Zoorob MJ, 2017, DRUG ALCOHOL DEPEN, V173, P1, DOI 10.1016/j.drugalcdep.2016.12.011; Zoorob MJ, 2018, PHARMACOEPIDEM DR S, V27, P541, DOI 10.1002/pds.4417	36	12	12	0	4	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0955-3959	1873-4758		INT J DRUG POLICY	Int. J. Drug Policy	AUG	2019	70						40	46		10.1016/j.drugpo.2019.04.010			7	Substance Abuse	Substance Abuse	IS9XT	WOS:000482501900006	31079029				2020-06-30	J	Peterson, M; Rich, J; Macmadu, A; Truong, AQ; Green, TC; Beletsky, L; Pognon, K; Brinkley-Rubinstein, L				Peterson, Meghan; Rich, Josiah; Macmadu, Alexandria; Truong, Ashley Q.; Green, Traci C.; Beletsky, Leo; Pognon, Kimberly; Brinkley-Rubinstein, Lauren			"One guy goes to jail, two people are ready to take his spot": Perspectives on drug-induced homicide laws among incarcerated individuals	INTERNATIONAL JOURNAL OF DRUG POLICY			English	Article						Qualitative research; Incarceration; Overdose; Fentanyl	FENTANYL-CONTAMINATED HEROIN; OPIOID OVERDOSE; HARM REDUCTION; PUBLIC-HEALTH; RISK; TRENDS; MORTALITY; EXPOSURE; RELEASE; DEATH	Background: As overdose deaths have increased in the United States, some lawmakers have explored punitive, "supply-side" interventions aimed at reducing the supply of fentanyl. While a rationale of seeking to protect people who use drugs is often given to justify harsh sentences for fentanyl distribution, there is no research to our knowledge on perceptions of the effect of drug-induced homicide laws among people who use drugs. Methods: We conducted semi-structured, qualitative interviews with 40 people with opioid use disorder (OUD) who were enrolled in a medication for addiction treatment (MAT) program in a unified jail and prison system in Rhode Island on attitudes surrounding increased sentences for distribution of fentanyl, including recently enacted drug-induced homicide laws. Codes were developed using a generalized, inductive method and interviews analyzed in NVivo 12 after being coded by two coders. Results: Most participants stated that drug-induced homicide laws would not be an effective strategy to stem the overdose crisis. We identified key themes, including discussions surrounding the autonomy of people who use drugs, widespread fentanyl prevalence as a barrier to implementation of drug-induced homicide laws, discussions of mass incarceration as ineffective for addressing substance use disorders, feelings that further criminalization could lead to violence, criminalization as a justification for interpersonal loss, and intention as meaningful to categorizing an act as homicide. Conclusions: Findings highlight the importance of centering the experiences of people with OUD in creating policies surrounding the overdose epidemic, potential unintended health consequences of drug-induced homicides laws such as deterrence from calling 911 and increased violence, and how drug-induced homicide laws may undermine advances made in expanding access to OUD treatment for people who are criminal justice-involved.	[Peterson, Meghan] Brown Univ, Sch Publ Hlth, 121 South Main St,Box G-S121-3, Providence, RI 02901 USA; [Peterson, Meghan; Rich, Josiah; Macmadu, Alexandria; Truong, Ashley Q.; Pognon, Kimberly] Ctr Prisoner Hlth & Human Rights, Providence, RI USA; [Rich, Josiah; Macmadu, Alexandria] Brown Univ, Dept Epidemiol, Sch Publ Hlth, Providence, RI 02912 USA; [Rich, Josiah; Green, Traci C.] Brown Univ, Warren Alpert Med Sch, Dept Emergency Med, Providence, RI 02912 USA; [Green, Traci C.] Rhode Isl Hosp, Providence, RI USA; [Beletsky, Leo] Northeastern Univ, Sch Law, Boston, MA 02115 USA; [Beletsky, Leo] Northeastern Univ, Bouve Coll Hlth Sci, Boston, MA 02115 USA; [Beletsky, Leo] Univ Calif San Diego, Sch Med, La Jolla, CA 92093 USA; [Brinkley-Rubinstein, Lauren] Univ N Carolina, Dept Social Med, Chapel Hill, NC 27515 USA; [Brinkley-Rubinstein, Lauren] Univ N Carolina, Ctr Hlth Equ Res, Chapel Hill, NC 27515 USA	Peterson, M (reprint author), Brown Univ, Sch Publ Hlth, 121 South Main St,Box G-S121-3, Providence, RI 02901 USA.	Meghan_peterson@brown.edu			National Institute on Drug Abuse (NIDA)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [5R21DA044443-02]; National Institute of General Medical SciencesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)	This study was funded by the National Institute on Drug Abuse (NIDA) under grant number 5R21DA044443-02 and by the National Institute of General Medical Sciences under grant number1P20GM125507-01.	[Anonymous], 2019, PROVIDENCE J; Beletsky L, 2019, UTAH LAW REV; Binswanger IA, 2013, ANN INTERN MED, V159, P592, DOI 10.7326/0003-4819-159-9-201311050-00005; Binswanger IA, 2011, DRUG ALCOHOL DEPEN, V117, P1, DOI 10.1016/j.drugalcdep.2010.11.029; Bluthenthal R. N., 1999, International Journal of Drug Policy, V10, P25, DOI 10.1016/S0955-3959(98)00076-0; Brinkley-Rubinstein L, 2013, HLTH JUSTICE, V1, P3; Brinkley-Rubinstein L, 2017, INCREASED RISK UNPUB; Brinkley-Rubinstein L, 2018, DRUG ALCOHOL DEPEN, V184, P57, DOI 10.1016/j.drugalcdep.2017.11.023; Calcaterra S, 2013, DRUG ALCOHOL DEPEN, V131, P263, DOI 10.1016/j.drugalcdep.2012.11.018; Carroll JJ, 2017, INT J DRUG POLICY, V46, P136, DOI 10.1016/j.drugpo.2017.05.023; Cerda M, 2013, DRUG ALCOHOL DEPEN, V132, P53, DOI 10.1016/j.drugalcdep.2012.12.027; Csete J, 2016, LANCET, V387, P1427, DOI 10.1016/S0140-6736(16)00619-X; Dasgupta N, 2018, AM J PUBLIC HEALTH, V108, P182, DOI 10.2105/AJPH.2017.304187; Drug Policy Alliance, 2017, OV DEATH IS NOT MURD; Dumont DM, 2013, J HEALTH CARE POOR U, V24, P78, DOI 10.1353/hpu.2013.0000; Farrell M, 2008, ADDICTION, V103, P251, DOI 10.1111/j.1360-0443.2007.02081.x; Flath N, 2017, SUBST USE MISUSE, V52, P1003, DOI 10.1080/10826084.2016.1268630; Friedman SR, 2011, AM J PUBLIC HEALTH, V101, P344, DOI 10.2105/AJPH.2010.191759; Friedman SR, 2006, AIDS, V20, P93, DOI 10.1097/01.aids.0000196176.65551.a3; Green TC, 2018, JAMA PSYCHIAT, V75, P405, DOI 10.1001/jamapsychiatry.2017.4614; Greenfield VA, 2017, INT J DRUG POLICY, V41, P162, DOI 10.1016/j.drugpo.2017.01.010; Greenfield VA, 2012, INT J DRUG POLICY, V23, P6, DOI 10.1016/j.drugpo.2011.04.007; Gregg Katherine, 2018, PROVIDENCE J; Hoffer LD, 2009, AM J COMMUN PSYCHOL, V44, P273, DOI 10.1007/s10464-009-9268-2; Kenan Kristen, 2012, Open Med, V6, pe41; Kerr T, 2008, J PSYCHOACTIVE DRUGS, V40, P147, DOI 10.1080/02791072.2008.10400624; Latimore AD, 2017, INT J DRUG POLICY, V50, P82, DOI 10.1016/j.drugpo.2017.09.010; Levy N, 2016, J MED PHILOS, V41, P56, DOI 10.1093/jmp/jhv033; Lynch MJ, 2018, PREHOSP EMERG CARE, V22, P157, DOI 10.1080/10903127.2017.1367446; Macmadu A, 2017, ADDICT BEHAV, V68, P35, DOI 10.1016/j.addbeh.2017.01.014; Mars S. G, 2018, ADDICTION, DOI 10. 1111/add. 14474; McCormick Meghan, 2017, R I Med J (2013), V100, P37; McLean K, 2018, J CRIME JUSTICE, V41, P1, DOI 10.1080/0735648X.2016.1215932; Mercado Melissa C, 2018, Pain Med, V19, P511, DOI 10.1093/pm/pnx015; Merrall ELC, 2010, ADDICTION, V105, P1545, DOI 10.1111/j.1360-0443.2010.02990.x; Moore LD, 2008, AM J PUBLIC HEALTH, V98, pS176, DOI 10.2105/AJPH.98.Supplement_1.S176; Parker AM, 2018, J LAW MED ETHICS, V46, P367, DOI 10.1177/1073110518782946; Rudd RA, 2016, MMWR-MORBID MORTAL W, P65; Szott K, 2015, HEALTH-LONDON, V19, P507, DOI 10.1177/1363459314556904; Thomas DR, 2006, AM J EVAL, V27, P237, DOI 10.1177/1098214005283748	40	0	0	0	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0955-3959	1873-4758		INT J DRUG POLICY	Int. J. Drug Policy	AUG	2019	70						47	53		10.1016/j.drugpo.2019.05.001			7	Substance Abuse	Substance Abuse	IS9XT	WOS:000482501900007	31082662				2020-06-30	J	Bergh, MSS; Bogen, IL; Wohlfarth, A; Wilson, SR; Oiestad, AML				Bergh, Marianne Skov-Skov; Bogen, Inger Lise; Wohlfarth, Ariane; Wilson, Steven Ray; Oiestad, Ase Marit Leere			Distinguishing Between Cyclopropylfentanyl and Crotonylfentanyl by Methods Commonly Available in the Forensic Laboratory	THERAPEUTIC DRUG MONITORING			English	Article						cyclopropylfentanyl; crotonylfentanyl; structural isomer separation; metabolism; UHPLC-MS/MS	FENTANYL; IDENTIFICATION; EPIDEMIC; POTENT	Background: The opioid analgesic fentanyl and its analogues pose a major health concern due to its high potency and the increasing number of overdose deaths worldwide. The analogues of fentanyl may differ in potency, toxicity, and legal status, and it is therefore important to develop analytical methods for their correct identification. This can be challenging since many fentanyl analogues are structural isomers. Two fentanyl isomers that have been in the spotlight lately due to difficulties regarding separation and identification are cyclopropylfentanyl and crotonylfentanyl, which have been reported to display nearly identical fragmentation patterns and chromatographic behavior. Methods: Chromatographic separation of cyclopropylfentanyl and crotonylfentanyl by ultra-high-performance liquid chromatography was investigated using 3 different stationary phases (high strength silica T3, ethylsiloxane/silica hybrid C-18, and Kinetex biphenyl) using gradient elution with a mobile phase consisting of 10 mM ammonium formate pH 3.1 and MeOH. Detection was performed by tandem mass spectrometry. In addition, the major metabolites of the 2 compounds formed on incubation with human liver microsomes were identified by ultra-high-performance liquid chromatography-quadrupole time-of-flight mass spectrometry analysis. Results: Baseline separation of cyclopropylfentanyl and crotonylfentanyl was achieved on the ethylsiloxane/silica hybrid C-18 column with retention times of 6.79 and 7.35 minutes, respectively. The major metabolites of the 2 analogues formed by human liver microsomes differed, with the main biotransformation being N-dealkylation and carboxylation for cyclopropylfentanyl and crotonylfentanyl, respectively. We demonstrated the usefulness of the 2 approaches by unambiguously identifying cyclopropylfentanyl, as well as its metabolites, in 2 authentic postmortem blood samples. Conclusions: In this study, we successfully demonstrated that cyclopropylfentanyl and crotonylfentanyl can be distinguished by methods commonly available in forensic laboratories.	[Bergh, Marianne Skov-Skov; Bogen, Inger Lise; Oiestad, Ase Marit Leere] Oslo Univ Hosp, Dept Forens Sci, Div Lab Med, Oslo, Norway; [Bergh, Marianne Skov-Skov; Wilson, Steven Ray] Univ Oslo, Fac Math & Nat Sci, Dept Chem, Oslo, Norway; [Bogen, Inger Lise] Univ Oslo, Fac Med, Inst Basic Med Sci, Oslo, Norway; [Wohlfarth, Ariane] Linkoping Univ, Natl Board Forens Med, Dept Forens Genet & Forens Toxicol, Linkoping, Sweden; [Wohlfarth, Ariane] Linkoping Univ, Dept Med Hlth Sci, Div Drug Res, Linkoping, Sweden	Bergh, MSS (reprint author), Oslo Univ Hosp, Div Lab Med, Dept Forens Sci, Sect Drug Abuse Res, Lovisenberggata 6, N-0456 Oslo, Norway.	Marianne.Skov-Skov.Bergh@ous-hf.no	Bergh, Marianne Skov-Skov/AAB-9563-2019	Oiestad, Ase Marit Leere/0000-0001-7909-5863			[Anonymous], OV DEATH RAT; Backberg M, 2015, CLIN TOXICOL, V53, P609, DOI 10.3109/15563650.2015.1054505; Bergh MSS, 2018, THER DRUG MONIT, V40, P738, DOI 10.1097/FTD.0000000000000564; Breindahl T, 2017, DRUG TEST ANAL, V9, P415, DOI 10.1002/dta.2046; Drug Enforecement Administration Department of Justice, 2018, Fed Regist, V83, P5188; European Monitoring Centre for Drugs and Drug Addiction, 2012, EMCDDA TRENDSP STUD; European Monitoring Centre for Drugs and Drug Addiction, 2016, EUR DRUG REP 2016 TR; European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), 2018, REP RISK ASS N PHENY; European Monitoring Centre for Drugs Drug Addiction [ EMCDDA], 2018, EMCDDA EUR JOINT REP; Fagiola M, 2019, J ANAL TOXICOL, V43, pE1, DOI 10.1093/jat/bky094; George AV, 2010, AM J EMERG MED, V28, P530, DOI 10.1016/j.ajem.2010.03.003; Iula DM, WHAT DO WE KNOW META; Maher S, 2018, DRUG TEST ANAL, V10, P1483, DOI 10.1002/dta.2417; Mallette JR, 2019, SCI JUSTICE, V59, P67, DOI 10.1016/j.scijus.2018.07.005; Mounteney J, 2015, INT J DRUG POLICY, V26, P626, DOI 10.1016/j.drugpo.2015.04.003; Ojanpera I, 2008, INT J LEGAL MED, V122, P395, DOI 10.1007/s00414-008-0230-x; Palaty J, 2018, CLIN BIOCHEM, V53, P164, DOI 10.1016/j.clinbiochem.2018.01.013; Scientific Working Group for the Analysis of Seized Drugs (SWGDRUG), CROT; Shaner RL, 2014, J CHROMATOGR B, V962, P52, DOI 10.1016/j.jchromb.2014.05.025; Simons B., 2017, SOC FORENSIC TOX TOX, V41, P9; Smith DA, 2012, PHARMACOKINETICS MET; Steuer AE, 2017, DRUG TEST ANAL, V9, P1085, DOI 10.1002/dta.2111; The Lovdata Foundation, FORSKR ENDR FORSKR N; The Swedish Police, NAT LAG FENT; United Nations Office on Drugs and Crime, GLOB SMART UPD, V17; United States Drug Enforcement Administration (US DEA), CYCL FENT BACKGR INF; Watanabe S, 2017, AAPS J, V19, P1102, DOI 10.1208/s12248-017-0070-z	27	0	0	2	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0163-4356	1536-3694		THER DRUG MONIT	Ther. Drug Monit.	AUG	2019	41	4					519	527		10.1097/FTD.0000000000000617			9	Medical Laboratory Technology; Pharmacology & Pharmacy; Toxicology	Medical Laboratory Technology; Pharmacology & Pharmacy; Toxicology	IQ4HK	WOS:000480711500013	30807539				2020-06-30	J	Cutler, C; Hudson, S				Cutler, Charlotte; Hudson, Simon			In vitro metabolism of the novel synthetic opioid agonist cyclopropylfentanyl and subsequent confirmation in authentic human samples using liquid chromatography-high resolution mass spectrometry	DRUG TESTING AND ANALYSIS			English	Article						Authentic human samples; Cyclopropylfentanyl; High resolution mass spectrometry; In vitro metabolism; Novel synthetic opioids	URINE SPECIMENS; FENTANYL; IDENTIFICATION; EXPOSURE; ANALOGS; BLOOD	Novel synthetic opioids (NSOs) are a class of novel psychoactive substances (NPS) that are growing in popularity and presenting a significant public health risk. Included in this class are derivatives of the highly potent analgesic, fentanyl. Cyclopropylfentanyl (CycP-F) was first reported to the EU Early Warning System in August 2017, and was subsequently linked to more than 100 deaths in the US alone. Limited pharmacological, pharmacokinetic or toxicological data is available for many emerging NSOs; however we can expect novel fentanyl analogues to present limited detection windows, short onset, narrow therapeutic indices and the potential for very high potency. Knowledge of the metabolism of these drugs is essential for the identification of analytical targets for their detection. Therefore in vitro metabolites of CycP-F were produced using human liver microsomal incubations. Metabolites formed were elucidated using liquid chromatography-high resolution accurate mass analysis (LC-HRAM). Identified metabolites were added to our accurate mass screening database for NPS which was utilised for subsequent screening analysis. CycP-F and metabolites were identified in two human blood case samples. Eleven metabolites were identified in vitro, with the major metabolites produced via N-dealkylation, monohydroxylation and N-oxidation. Analysis of the positive case samples identified four in vivo metabolites, all of which were observed in vitro. The major metabolite identified in vitro and in vivo was the N-dealkylated nor-metabolite; two further mono-hydroxylated and one dihydroxylated metabolite were detected in vivo.	[Cutler, Charlotte; Hudson, Simon] LGC, Fordham, Cambs, England	Hudson, S (reprint author), LGC, Fordham, Cambs, England.	simon.hudson@lgcgroup.com		Cutler, Charlotte/0000-0002-6340-6644			Allibe N, 2018, DRUG TEST ANAL, V10, P995, DOI 10.1002/dta.2326; Astrand A, 2019, ARCH TOXICOL, V93, P95, DOI 10.1007/s00204-018-2330-9; Concheiro M, 2018, FRONT PHARMACOL, V26, P9; Cunningham SM, 2016, J FORENSIC SCI, V61, pS276, DOI 10.1111/1556-4029.12953; DEA, 2018, SCHED CONTR SUBST TE; EMCDDA, 2017, EUR DRUG REP 2017 TR; European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), 2017, RISK ASS REP NEW PSY; Feasel MG, 2016, AAPS J, V18, P1489, DOI 10.1208/s12248-016-9963-5; Helanders A, 2016, CLIN TOXICOL, V54, P4; Hikin L, 2018, FORENSIC SCI INT, V282, P179, DOI 10.1016/j.forsciint.2017.11.036; Krotulski AJ, 2018, DRUG TEST ANAL, V10, P127, DOI 10.1002/dta.2228; Labroo RB, 1997, DRUG METAB DISPOS, V25, P1072; Macmadu A, 2017, ADDICT BEHAV, V68, P35, DOI 10.1016/j.addbeh.2017.01.014; Maher S, 2018, DRUG TEST ANAL, P1; Mallette JR, 2019, SCI JUSTICE, V59, P67, DOI 10.1016/j.scijus.2018.07.005; MCCLAIN DA, 1980, CLIN PHARMACOL THER, V28, P106, DOI 10.1038/clpt.1980.138; Menzies EL, 2014, DRUG TEST ANAL, V6, P506, DOI 10.1002/dta.1541; Meyer MR, 2012, ANAL BIOANAL CHEM, V402, P3; Mohr ALA, 2016, J ANAL TOXICOL, V6, P40; Moody MT, 2018, DRUG TEST ANAL, V10, P1358, DOI 10.1002/dta.2393; Noble C, 2018, DRUG TEST ANAL, V10, P651, DOI 10.1002/dta.2263; Palaty J, 2018, CLIN BIOCHEM, V53, P164, DOI 10.1016/j.clinbiochem.2018.01.013; Poklis J, 2016, J ANAL TOXICOL, V6, P40; Richeval C, 2017, CURR PHARM BIOTECHNO, V18, P806, DOI 10.2174/1389201018666171122124401; Rudd RA, 2016, MMWR-MORBID MORTAL W, V65, P1445, DOI 10.15585/mmwr.mm655051e1; Simons B, 2017, SOC FORENSIC TOXICOL, V41, P3; Steuer AE, 2017, DRUG TEST ANAL, V9, P1085, DOI 10.1002/dta.2111; Suzuki J, 2017, DRUG ALCOHOL DEPEN, V171, P107, DOI 10.1016/j.drugalcdep.2016.11.033; Takase I, 2016, LEGAL MED-TOKYO, V21, P38, DOI 10.1016/j.legalmed.2016.05.006; UNDOC, 2017, WORLD DRUG REP 2017; Watanabe S, 2017, AAPS J, V19, P1102, DOI 10.1208/s12248-017-0070-z; Zawilska JB, 2017, FRONT PSYCHIATRY, V8, DOI 10.3389/fpsyt.2017.00110	32	1	1	3	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1942-7603	1942-7611		DRUG TEST ANAL	Drug Test. Anal.	AUG	2019	11	8					1134	1143		10.1002/dta.2611			10	Biochemical Research Methods; Chemistry, Analytical; Pharmacology & Pharmacy	Biochemistry & Molecular Biology; Chemistry; Pharmacology & Pharmacy	IN7VB	WOS:000478888800002	31081594				2020-06-30	J	Wang, K; Xu, B; Wu, JF; Zhu, YJ; Guo, L; Xie, JW				Wang, Kai; Xu, Bin; Wu, Jianfeng; Zhu, Yingjie; Guo, Lei; Xie, Jianwei			Elucidating fentanyls differentiation from morphines in chemical and biological samples with surface-enhanced Raman spectroscopy	ELECTROPHORESIS			English	Article						Differentiation; Fentanyls; Morphines; SERS; Urine	PRINCIPAL COMPONENT ANALYSIS; ON-SITE; HEROIN; METABOLITES; IDENTIFICATION; OCFENTANIL; NARCOTICS; FATALITY; ANALOGS; CODEINE	Fentanyl and morphine are opioid drugs as well as new psychoactive substances. Even originally introduced as efficient anesthetic drugs to relieve moderate-to-severe pain in clinic, the overdose of new synthetic opioids is currently a serious public health problem in numerous countries worldwide. The entire category of fentanyls has been included in the regulatory list in several countries. There is a great and urgent demand to rapidly recognize fentanyls and morphines in various samples. Here, we report an on-site surface-enhanced Raman spectroscopic method to classify fentanyls from morphines by the Raman spectroscopic signature of the molecular scaffold structure, with an assistance of principle component analysis algorithm. Moreover, by simple but fine-tuning approach of inorganic salt-induced aggregation of gold nanoparticles substrate, we achieved a selective detection of 10 ng/mL fentanyl from 2000-fold of heroin, the most common coexisting substance in chemical samples. Good differentiation of 50 ng/mL fentanyl from 10 000-fold morphine as a main metabolite of heroin in urine samples was also possible after a feasible pretreatment by StageTip procedures. Depending on different structures, the detection sensitivity of five fentanyls ranged from 50 to 2000 ng/mL.	[Guo, Lei] Acad Mil Med Serv, State Key Lab Toxicol & Med Countermeasures, Beijing 100850, Peoples R China; [Guo, Lei] Acad Mil Med Serv, Lab Toxicant Anal, Inst Pharmacol & Toxicol, Beijing 100850, Peoples R China	Guo, L (reprint author), Acad Mil Med Serv, State Key Lab Toxicol & Med Countermeasures, Beijing 100850, Peoples R China.; Guo, L (reprint author), Acad Mil Med Serv, Lab Toxicant Anal, Inst Pharmacol & Toxicol, Beijing 100850, Peoples R China.	guolei@bmi.ac.cn			National Key Research and Development Program of China [2018YFC1602600]; Military Medicine and Healthy Major Project [AWS16J016]		[Anonymous], 2015, INCREASES FENTANYL D; [Anonymous], 2018, CHINA AGREES MAKE FE; [Anonymous], 2011, SCI WORKING GROUP AN; Burns SM, 2018, ACS CHEM NEUROSCI, V9, P2428, DOI 10.1021/acschemneuro.8b00174; Cicero TJ, 2017, ADDICT BEHAV, V74, P63, DOI 10.1016/j.addbeh.2017.05.030; Coopman V, 2007, FORENSIC SCI INT, V169, P223, DOI 10.1016/j.forsciint.2006.03.018; Coopman V, 2016, FORENSIC SCI INT, V266, P469, DOI 10.1016/j.forsciint.2016.07.005; Devereaux AL, 2018, ACS CHEM NEUROSCI, V9, P2395, DOI 10.1021/acschemneuro.8b00150; Drug Enforcement Administration, 2017, 2017 NAT DRUG THREAT; Feng SY, 2015, INT J NANOMED, V10, P537, DOI 10.2147/IJN.S71811; Feng SY, 2009, CHIN OPT LETT, V7, P1055, DOI 10.3788/COL20090711.1055; FRENS G, 1973, NATURE-PHYS SCI, V241, P20, DOI 10.1038/physci241020a0; Ghassabian S, 2012, J CHROMATOGR B, V903, P126, DOI 10.1016/j.jchromb.2012.07.005; Gushgari AJ, 2018, J HAZARD MATER, V359, P437, DOI 10.1016/j.jhazmat.2018.07.073; Haddad A, 2018, ANAL CHEM, V90, P12678, DOI 10.1021/acs.analchem.8b02909; Haiss W, 2007, ANAL CHEM, V79, P4215, DOI 10.1021/ac0702084; Hedegaard Holly, 2017, NCHS Data Brief, P1; Kazarian SG, 2006, BBA-BIOMEMBRANES, V1758, P858, DOI 10.1016/j.bbamem.2006.02.011; Kong L. C., 2010, J LIGHT SCATT, V22, P34, DOI [10.13883/j.issn1004-5929.2010.01.016, DOI 10.13883/J.ISSN1004-5929.2010.01.016]; Leonard J, 2017, J RAMAN SPECTROSC, V48, P1323, DOI 10.1002/jrs.5220; MAKOWSKI GS, 1995, ANN CLIN LAB SCI, V25, P169; MCCLAIN DA, 1980, CLIN PHARMACOL THER, V28, P106, DOI 10.1038/clpt.1980.138; Misailidi N, 2018, FORENSIC TOXICOL, V36, P12, DOI 10.1007/s11419-017-0379-4; Moody MT, 2018, DRUG TEST ANAL, V10, P1358, DOI 10.1002/dta.2393; Mounteney J, 2015, INT J DRUG POLICY, V26, P626, DOI 10.1016/j.drugpo.2015.04.003; Muramoto S, 2011, J PHYS CHEM C, V115, P24247, DOI 10.1021/jp208035x; Ohta H, 1999, J ANAL TOXICOL, V23, P280, DOI 10.1093/jat/23.4.280; Rana V, 2011, J FORENSIC SCI, V56, P200, DOI 10.1111/j.1556-4029.2010.01562.x; Rappsilber J, 2007, NAT PROTOC, V2, P1896, DOI 10.1038/nprot.2007.261; Rook EJ, 2006, CURR CLIN PHARMACOL, V1, P109, DOI 10.2174/157488406775268219; Ryder AG, 2002, J FORENSIC SCI, V47, P275; Silva TG, 2016, ANAL CHEM, V88, P5145, DOI 10.1021/acs.analchem.6b00072; Sisco E, 2017, FORENSIC CHEM, V4, P108, DOI 10.1016/j.forc.2017.04.001; Subaihi A, 2017, ANALYST, V142, P1099, DOI [10.1039/c7an00193b, 10.1039/C7AN00193B]; Tateishi T, 1996, ANESTH ANALG, V82, P167; U. S. Drug Enforcement Administration, 2018, CHIN ANN SCHED CONTR; Van Nimmen NFJ, 2007, J CHROMATOGR B, V846, P264, DOI 10.1016/j.jchromb.2006.09.002; VansBever W. F., 1976, ARZNEIMITTELFORSCH, V26, P1548; VansDaele P. G., 1976, ARZNEIMITTELFORSCH, V26, P1521; Wang K, 2018, J RAMAN SPECTROSC, V49, P1461, DOI 10.1002/jrs.5416; Wen Q, 2011, ACTA PHARMACOL SIN, V32, P1215, DOI 10.1038/aps.2011.83; Xinhua, 2018, XINHUA; YEH SY, 1976, J PHARMACOL EXP THER, V196, P249; Yu BR, 2018, CHEM-EUR J, V24, P4800, DOI 10.1002/chem.201800487	44	3	3	6	24	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0173-0835	1522-2683		ELECTROPHORESIS	Electrophoresis	AUG	2019	40	16-17			SI		2193	2203		10.1002/elps.201900004			11	Biochemical Research Methods; Chemistry, Analytical	Biochemistry & Molecular Biology; Chemistry	IN5XQ	WOS:000478750500023	30815884				2020-06-30	J	Tan, D; Xia, HF; Sun, SJ; Wang, FQ				Tan, Dan; Xia, Haifa; Sun, Shujun; Wang, Fuquan			Effect of ancillary drugs on sevoflurane related emergence agitation in children undergoing ophthalmic surgery: a Bayesian network meta-analysis	BMC ANESTHESIOLOGY			English	Article						Ophthalmic surgery; Emergence agitation; Anesthetic drugs; Network meta-analysis; Randomized control trial	STRABISMUS SURGERY; PEDIATRIC-PATIENTS; CATARACT-SURGERY; DEXMEDETOMIDINE; FENTANYL; PREVENTION; DESFLURANE; ANESTHESIA; PROPOFOL; SUFENTANIL	BackgroundThe comparative efficacy of ancillary drugs on sevoflurane related emergence agitation (EA) in children undergoing ophthalmic surgery remains controversial.MethodsThe databases were retrieved in an orderly manner from the dates of their establishment to October, 2018, including PubMed, The Cochrane Library and Web of Science, to collect randomized controlled trials (RCT) of different anesthetic drugs combined with sevoflurane for ophthalmic surgery. Then a network meta-analysis was conducted using R and Stata 12.0 softwares.ResultsThe meta-analysis showed that, in reducing sevoflurane related EA, dexmedetomidine, ketamine, propofol, fentanyl, midazolam, sufentanil, remifentanil and clonidine were superior to placebo (P<0.05). The network meta-analysis showed that the effects of ancillary drugs combine with sevoflurane in reducing risk of EA in children undergoing ophthalmic surgery was superior to placebo: dexmedetomidine (OR=0.17, 95% CrI 0.12-0.22), ketamine (OR=0.30, 95% CrI 0.11-0.49), propofol (OR=0.24, 95% CrI 0.09-0.63), fentanyl (OR=0.16, 95% CrI 0.08-0.56), midazolam (OR=0.20, 95% CrI 0.09-0.40), sufentanil (OR=0.27, 95% CrI 0.14-0.41), remifentanil (OR=0.18, 95% CrI 0.08-0.54) and clonidine (OR=0.14, 95% CrI 0.07-0.41). The SUCRA of placebo, dexmedetomidine, ketamine, propofol, fentanyl, midazolam, sufentanil, remifentanil, clonidine were respectively 0.26, 77.93, 27.71, 42.8, 69.43, 52.89, 59.83, 57.62 and 61.53%.ConclusionsThe effects of dexmedetomidine combine with sevoflurane in reducing risk of emergence agitation in children undergoing ophthalmic surgery was superior to other drugs.	[Tan, Dan] Wuhan Univ, Zhongnan Hosp, Journal New Med, Editorial Off, 169 Donghu Rd, Wuhan 430071, Hubei, Peoples R China; [Xia, Haifa; Sun, Shujun; Wang, Fuquan] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Inst Anesthesia & Crit Care,Dept Anesthesiol, Wuhan, Hubei, Peoples R China	Tan, D (reprint author), Wuhan Univ, Zhongnan Hosp, Journal New Med, Editorial Off, 169 Donghu Rd, Wuhan 430071, Hubei, Peoples R China.	tadan_dta@163.com	Xia, Haifa/AAP-7056-2020				Adelgais KM, 2017, J EMERG MED, V53, P607, DOI 10.1016/j.jemermed.2017.05.027; Aouad MT, 2007, ANESTHESIOLOGY, V107, P733, DOI 10.1097/01.anes.0000287009.46896.a7; Bae JH, 2010, KOREAN J ANESTHESIOL, V58, P45, DOI 10.4097/kjae.2010.58.1.45; Chen JY, 2013, CAN J ANESTH, V60, P385, DOI 10.1007/s12630-013-9886-x; Chen JY, 2010, PEDIATR ANESTH, V20, P873, DOI 10.1111/j.1460-9592.2010.03375.x; Cho EJ, 2014, ANESTHESIOLOGY, V120, P1354, DOI 10.1097/ALN.0000000000000181; Choi EK, 2018, PEDIATR ANESTH, V28, P739, DOI 10.1111/pan.13446; Choi YH, 2016, BMC ANESTHESIOL, V16, DOI 10.1186/s12871-016-0213-2; Cravero J, 2000, PAEDIATR ANAESTH, V10, P419, DOI 10.1046/j.1460-9592.2000.00560.x; Dahmani S, 2010, BRIT J ANAESTH, V104, P216, DOI 10.1093/bja/aep376; Daoud YJ, 2009, AM J OPHTHALMOL, V147, P573, DOI 10.1016/j.ajo.2008.12.028; DESA L, 1992, INT OPHTHALMOL CLIN, V32, P31, DOI 10.1097/00004397-199223000-00003; Devasya A, 2015, J CLIN PEDIATR DENT, V39, P401, DOI 10.17796/1053-4628-39.5.401; Ducloyer JB, 2018, EUR J OPHTHALMOL; Gayer Steven, 2006, Ophthalmol Clin North Am, V19, P269; Ghai B, 2010, ANAESTH INTENS CARE, V38, P530, DOI 10.1177/0310057X1003800319; Heinmiller LJ, 2013, J PEDIAT OPHTH STRAB, V50, P150, DOI 10.3928/01913913-20130205-02; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Jain S, 2018, SAUDI J ANAESTH, V12, P28, DOI 10.4103/sja.SJA_235_17; Jeong WJ, 2012, KOREAN J ANESTHESIOL, V63, P203, DOI 10.4097/kjae.2012.63.3.203; Jung HJ, 2010, KOREAN J ANESTHESIOL, V58, P148, DOI 10.4097/kjae.2010.58.2.148; Kanaya A, 2016, J ANESTH, V30, P261, DOI 10.1007/s00540-015-2098-5; Keating GM, 2015, DRUGS, V75, P1119, DOI 10.1007/s40265-015-0419-5; Khanna P, 2015, J ANESTH, V29, P857, DOI 10.1007/s00540-015-2042-8; Khokhar SK, 2017, INDIAN J OPHTHALMOL, V65, P1340, DOI 10.4103/ijo.IJO_1023_17; Kim J, 2014, YONSEI MED J, V55, P508, DOI 10.3349/ymj.2014.55.2.508; Kim KM, 2016, J INT MED RES, V44, P258, DOI 10.1177/0300060515621639; Kulka PJ, 2001, ANESTH ANALG, V93, P335, DOI 10.1097/00000539-200108000-00019; Kumari Sarika, 2017, Anesth Essays Res, V11, P185, DOI 10.4103/0259-1162.194586; Liang P, 2014, PAK J MED SCI, V30, P1059, DOI 10.12669/pjms.305.4483; Lin YQ, 2016, J CLIN ANESTH, V33, P289, DOI 10.1016/j.jclinane.2016.04.027; Lodes U, 1999, Anaesthesiol Reanim, V24, P13; Lysakowski C, 2001, BRIT J ANAESTH, V86, P523, DOI 10.1093/bja/86.4.523; Mahmoud M, 2015, BRIT J ANAESTH, V115, P171, DOI 10.1093/bja/aev226; MAZE M, 1991, ANESTHESIOLOGY, V74, P581, DOI 10.1097/00000542-199103000-00029; Mizrak A, 2011, MED PRIN PRACT, V20, P427, DOI 10.1159/000324554; Mizrak A, 2010, CLIN OPHTHALMOL, V4, P673; Park JH, 2014, KOREAN J ANESTHESIOL, V66, P34, DOI 10.4097/kjae.2014.66.1.34; Plambech MZ, 2015, MINERVA ANESTESIOL, V81, P320; Sakai EM, 2005, PHARMACOTHERAPY, V25, P1773, DOI 10.1592/phco.2005.25.12.1773; Schug SA, 2017, DRUGS, V77, P747, DOI 10.1007/s40265-017-0727-z; Song IA, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162785; Suzuki J, 2017, DRUG ALCOHOL DEPEN, V171, P107, DOI 10.1016/j.drugalcdep.2016.11.033; Thomson IR, 2000, J CARDIOTHOR VASC AN, V14, P652, DOI 10.1053/jcan.2000.18307; Weerink MAS, 2017, CLIN PHARMACOKINET, V56, P893, DOI 10.1007/s40262-017-0507-7; Xu LL, 2012, J ANESTH, V26, P556, DOI 10.1007/s00540-012-1354-1	46	1	1	0	3	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1471-2253			BMC ANESTHESIOL	BMC Anesthesiol.	AUG 1	2019	19								138	10.1186/s12871-019-0810-y			11	Anesthesiology	Anesthesiology	IN3JS	WOS:000478573800001	31370793	DOAJ Gold, Green Published			2020-06-30	J	Pan, S; Duffull, SB				Pan, Shan; Duffull, Stephen B.			Automated proper lumping for simplification of linear physiologically based pharmacokinetic systems	JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS			English	Article						Model simplification; Proper lumping; Autolumping; Physiologically based pharmacokinetic models; Systems models	BIOLOGY; SEARCH; MODELS	Physiologically based pharmacokinetic (PBPK) models are an important type of systems model used commonly in drug development before commencement of first-in-human studies. Due to structural complexity, these models are not easily utilised for future data-driven population pharmacokinetic (PK) analyses that require simpler models. In the current study we aimed to explore and automate methods of simplifying PBPK models using a proper lumping technique. A linear 17-state PBPK model for fentanyl was identified from the literature. Four methods were developed to search the optimal lumped model, including full enumeration (the reference method), non-adaptive random search (NARS), scree plot plus NARS, and simulated annealing (SA). For exploratory purposes, it was required that the total area under the fentanyl arterial concentration-time curve (AUC) between the lumped and original models differ by 0.002% at maximum. In full enumeration, a 4-state lumped model satisfying the exploratory criterion was found. In NARS, a lumped model with the same number of lumped states was found, requiring a large number of random samples. The scree plot provided a starting lumped model to NARS and the search completed within a short time. In SA, a 4-state lumped model was consistently delivered. In simplify an existing linear fentanyl PBPK model, SA was found to be robust and the most efficient and may be suitable for general application to other larger-scale linear systems. Ultimately, simplified PBPK systems with fundamental mechanisms may be readily used for data-driven PK analyses.	[Pan, Shan; Duffull, Stephen B.] Univ Otago, Sch Pharm, Dunedin, New Zealand; [Pan, Shan] Guys & St Thomas NHS Fdn Trust, St Johns Inst Dermatol, London SE1 7EH, England	Pan, S (reprint author), Univ Otago, Sch Pharm, Dunedin, New Zealand.; Pan, S (reprint author), Guys & St Thomas NHS Fdn Trust, St Johns Inst Dermatol, London SE1 7EH, England.	shan.pan@kcl.ac.uk			University of Otago	Shan Pan was supported by a University of Otago PhD scholarship during the conduct of research and preparation of the manuscript. The authors would like to thank Thomas J Harper for his assistance with the simulated annealing algorithm in MATLAB (R). The authors would also like to thank the editor and reviewers for valuable comments.	BJORKMAN S, 1994, J PHARMACOKINET BIOP, V22, P381, DOI 10.1007/BF02353862; Cao YG, 2012, J PHARMACOKINET PHAR, V39, P711, DOI 10.1007/s10928-012-9280-2; DARGENIO DZ, 1981, J PHARMACOKINET BIOP, V9, P739, DOI 10.1007/BF01070904; Dokoumetzidis A, 2009, IET SYST BIOL, V3, P40, DOI 10.1049/iet-syb:20070055; Dokoumetzidis A, 2009, J PHARMACOKINET PHAR, V36, P613, DOI 10.1007/s10928-009-9141-9; Duffull SB, 2002, COMPUT METH PROG BIO, V69, P25, DOI 10.1016/S0169-2607(01)00178-X; Foo LK, 2011, OPTIMAL DESIGN PHARM; GOFFE WL, 1994, J ECONOMETRICS, V60, P65, DOI 10.1016/0304-4076(94)90038-8; Gulati A, 2014, CPT-PHARMACOMET SYST, V3, DOI 10.1038/psp.2013.67; Hasegawa C, 2018, CPT-PHARMACOMET SYST, V7, P562, DOI 10.1002/psp4.12324; Lo A, 2011, CLIN TRIAL SIMULATIO; Marieb E.N., 2012, ESSENTIALS HUMAN ANA; METROPOLIS N, 1949, J AM STAT ASSOC, V44, P335, DOI 10.2307/2280232; Nestorov IA, 1998, J PHARMACOKINET BIOP, V26, P21, DOI 10.1023/A:1023272707390; Nestorov I, 2007, EXPERT OPIN DRUG MET, V3, P235, DOI 10.1517/17425255.3.2.235; Okino MS, 1998, CHEM REV, V98, P391, DOI 10.1021/cr950223l; Pilari S, 2010, J PHARMACOKINET PHAR, V37, P365, DOI 10.1007/s10928-010-9165-1; Sale M, 2015, BRIT J CLIN PHARMACO, V79, P28, DOI 10.1111/bcp.12179; Tsamandouras N, 2015, BRIT J CLIN PHARMACO, V79, P48, DOI 10.1111/bcp.12234; van der Graaf PH, 2011, PHARM RES-DORDR, V28, P1460, DOI 10.1007/s11095-011-0467-9; Wendling T, 2016, AAPS J, V18, P196, DOI 10.1208/s12248-015-9840-7; Youssef H, 2001, ENG APPL ARTIF INTEL, V14, P167, DOI 10.1016/S0952-1976(00)00065-8	22	0	0	2	2	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1567-567X	1573-8744		J PHARMACOKINET PHAR	J. Pharmacokinet. Pharmacodyn.	AUG	2019	46	4					361	370		10.1007/s10928-019-09644-5			10	Pharmacology & Pharmacy	Pharmacology & Pharmacy	IL0YX	WOS:000477027200003	31227954	Other Gold, Green Published			2020-06-30	J	Anand, KJS				Anand, Kanwaljeet J. S.			Discovering Pain in Newborn Infants	ANESTHESIOLOGY			English	Editorial Material							HUMAN NEONATE; ANESTHESIA; ANALGESIA; ENDOCRINE; SURGERY; TRIAL	Randomised Trial of Fentanyl Anesthesia in Preterm Babies Undergoing Surgery: Effects on the Stress Response. By Anand KJ, Sippell WG, and Aynsley-Green A. Lancet 1987; 1:243-8. Reprinted with permission. In a randomised controlled trial, preterm babies undergoing ligation of a patent ductus arteriosus were given nitrous oxide and d-tubocurarine, with (n = 8) or without (n = 8) the addition of fentanyl (10 mu g/kg intravenously) to the anesthetic regimen. Major hormonal responses to surgery, as indicated by changes in plasma adrenaline, noradrenaline, glucagon, aldosterone, corticosterone, 11-deoxycorticosterone, and 11-deoxycortisol levels, in the insulin/glucagon molar ratio, and in blood glucose, lactate, and pyruvate concentrations were significantly greater in the nonfentanyl than in the fentanyl group. The urinary 3-methylhistidine/creatinine ratios were significantly greater in the nonfentanyl group on the second and third postoperative days. Compared with the fentanyl group, the nonfentanyl group had circulatory and metabolic complications postoperatively. The findings indicate that preterm babies mount a substantial stress response to surgery under anesthesia with nitrous oxide and curare and that prevention of this response by fentanyl anesthesia may be associated with an improved postoperative outcome.	[Anand, Kanwaljeet J. S.] Stanford Univ, Sch Med, Dept Anesthesiol Perioperat & Pain Med, Stanford, CA 94305 USA	Anand, KJS (reprint author), Stanford Univ, Sch Med, Dept Anesthesiol Perioperat & Pain Med, Stanford, CA 94305 USA.	anandam@stanford.edu					ANAND KJS, 1987, LANCET, V1, P243; ANAND KJS, 1987, NEW ENGL J MED, V317, P1321, DOI 10.1056/NEJM198711193172105; ANAND KJS, 1985, HORM RES, V22, P115, DOI 10.1159/000180083; ANAND KJS, 1988, BRIT MED J, V296, P668, DOI 10.1136/bmj.296.6623.668; ANAND KJS, 1985, J PEDIATR SURG, V20, P41, DOI 10.1016/S0022-3468(85)80390-0; ANAND KJS, 1985, MODERN PROBLEMS PAED, V23, P143; Barash P, 2015, ANESTH ANALG, V120, P663, DOI 10.1213/ANE.0000000000000513; BERRY FA, 1987, ANESTHESIOLOGY, V67, P291; BOOKER PD, 1987, ANAESTHESIA, V42, P343, DOI 10.1111/j.1365-2044.1987.tb03971.x; Forfar J O, 1987, Br Med J (Clin Res Ed), V295, P659; HARRISON H, 1986, BIRTH-ISS PERINAT C, V13, P165, DOI 10.1111/j.1523-536X.1986.tb01038.x; HATCH DJ, 1987, BRIT MED J, V294, P970, DOI 10.1136/bmj.294.6577.920; Lawson JR, 1986, BIRTH-ISS PERINAT C, V13, P125; LOWENSTEIN E, 1981, ANESTHESIOLOGY, V55, P195, DOI 10.1097/00000542-198109000-00001; MCGRAW MB, 1943, NEUROMUSCULAR MATURA; NEUMAN GG, 1980, CAN ANAESTH SOC J, V27, P248, DOI 10.1007/BF03007435; NORMAN EA, 1986, BRIT J ANAESTH, V58, P934, DOI 10.1093/bja/58.8.934-b; OWENS ME, 1984, PAIN, V20, P77, DOI 10.1016/0304-3959(84)90813-3; OWENS ME, 1984, PAIN, V20, P213, DOI 10.1016/0304-3959(84)90012-5; RACKOW H, 1961, PEDIATRICS, V28, P697; REES GJ, 1950, BRIT MED J, V2, P1419, DOI 10.1136/bmj.2.4694.1419; SHEARER MH, 1986, BIRTH-ISS PERINAT C, V13, P79, DOI 10.1111/j.1523-536X.1986.tb01012.x; SILVERMAN WA, 1991, CONTROL CLIN TRIALS, V12, P355, DOI 10.1016/0197-2456(91)90015-E; YASTER M, 1987, J PEDIATR-US, V111, P394, DOI 10.1016/S0022-3476(87)80461-4	24	0	0	2	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-3022	1528-1175		ANESTHESIOLOGY	Anesthesiology	AUG	2019	131	2					392	395		10.1097/ALN.0000000000002810			4	Anesthesiology	Anesthesiology	IJ1ZD	WOS:000475696900023	31233407				2020-06-30	J	Gabriel, L; Young, J; Hoesli, I; Girard, T; Dell-Kuster, S				Gabriel, L.; Young, J.; Hoesli, I; Girard, T.; Dell-Kuster, S.			Generalisability of randomised trials of the programmed intermittent epidural bolus technique for maintenance of labour analgesia: a prospective single centre cohort study	BRITISH JOURNAL OF ANAESTHESIA			English	Article						analgesia; epidural; labour; obstetrics; patient controlled analgesia; randomised controlled trial	EXTERNAL VALIDITY; INFUSION; FENTANYL	Background: Several randomised controlled trials show that maintenance of labour epidural analgesia with programmed intermittent epidural bolus reduces the maternal motor block compared with maintenance with a continuous infusion. However, these trials were usually restricted to healthy nulliparous parturients. To assess the generalisability of these randomised controlled trials to 'real-world' conditions, we compared maternal motor function (modified Bromage score) over time between healthy nulliparous and parous women using routinely collected quality-control data. Methods: After ethical approval, all parturients receiving programmed intermittent epidural bolus labour analgesia between June 2013 and October 2014 were included in this prospective cohort study. Bupivacaine 0.1% with fentanyl 2 mu g ml(-1) was used allowing for patient-controlled bolus every 20 min. The maternal motor function (primary outcome) was regularly assessed from insertion of the epidural catheter until delivery. Results: Of the 839 parturients included, 553 (66%) were nulliparous and 286 (34%) were parous. The parous women had a shorter median duration of epidural analgesia (3 h 59 min vs 5 h 45 min) and a higher incidence of spontaneous delivery (66% vs 37%). The probability of being in a certain Bromage category at birth was similar in nulliparous and parous women in a general additive model adjusting for duration of epidural analgesia, number of rescue top-ups, and number of catheter manipulations (cumulative odds ratio: 1.18; 95% confidence interval: 0.98-1.41). Parous women required a higher time-weighted number and volume of rescue top-ups. Conclusions: The results of the randomised controlled trials on a reduced motor block with programmed intermittent epidural bolus seem generalisable to parturients typically not included in these trials.	[Gabriel, L.; Hoesli, I; Girard, T.; Dell-Kuster, S.] Univ Basel, Basel, Switzerland; [Young, J.; Dell-Kuster, S.] Univ Hosp Basel, Basel Inst Clin Epidemiol & Biostat, Basel, Switzerland; [Hoesli, I] Univ Hosp Basel, Dept Obstet & Antenatal Care, Basel, Switzerland; [Girard, T.; Dell-Kuster, S.] Univ Hosp Basel, Surg Intens Care Prehosp Emergency Med & Pain The, Dept Anaesthesia, Basel, Switzerland	Dell-Kuster, S (reprint author), Univ Basel, Basel, Switzerland.; Dell-Kuster, S (reprint author), Univ Hosp Basel, Basel Inst Clin Epidemiol & Biostat, Basel, Switzerland.; Dell-Kuster, S (reprint author), Univ Hosp Basel, Surg Intens Care Prehosp Emergency Med & Pain The, Dept Anaesthesia, Basel, Switzerland.	salome.dell-kuster@usb.ch			Foundation for Research and Education in Anaesthesia, University Hospital Basel, Switzerland	Foundation for Research and Education in Anaesthesia, University Hospital Basel, Switzerland.	Babyak MA, 2004, PSYCHOSOM MED, V66, P411, DOI 10.1097/01.psy.0000127692.23278.a9; Benchimol EI, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001885; Black N, 1996, BRIT MED J, V312, P1215; Bothwell LE, 2016, NEW ENGL J MED, V374, P2175, DOI 10.1056/NEJMms1604593; BREEN TW, 1993, ANESTH ANALG, V77, P919; Bullingham A, 2018, BRIT J ANAESTH, V121, P432, DOI 10.1016/j.bja.2018.03.038; Calik KY, 2018, SAUDI J BIOL SCI, V25, P1085, DOI 10.1016/j.sjbs.2018.02.014; Capogna G, 2011, ANESTH ANALG, V113, P826, DOI 10.1213/ANE.0b013e31822827b8; Carpenter J., 2013, MULTIPLE IMPUTATION; Chua SMH, 2004, CAN J ANAESTH, V51, P581, DOI 10.1007/BF03018402; Essex HN, 2013, BJOG-INT J OBSTET GY, V120, P732, DOI 10.1111/1471-0528.12177; Fettes PDW, 2006, BRIT J ANAESTH, V97, P359, DOI 10.1093/bja/ael157; George RB, 2013, ANESTH ANALG, V116, P133, DOI 10.1213/ANE.0b013e3182713b26; Halpern SH, 2009, ANESTH ANALG, V108, P921, DOI 10.1213/ane.0b013e3181951a7f; Heslehurst N, 2008, OBES REV, V9, P635, DOI 10.1111/j.1467-789X.2008.00511.x; Kennedy-Martin T, 2015, TRIALS, V16, DOI 10.1186/s13063-015-1023-4; Leo S, 2010, INT J OBSTET ANESTH, V19, P357, DOI 10.1016/j.ijoa.2010.07.006; Lim Y, 2005, INT J OBSTET ANESTH, V14, P305, DOI 10.1016/j.ijoa.2005.05.004; McKenzie CP, 2016, INT J OBSTET ANESTH, V26, P32, DOI 10.1016/j.ijoa.2015.11.005; Papke LE, 1996, J APPL ECONOM, V11, P619, DOI 10.1002/(SICI)1099-1255(199611)11:6<619::AID-JAE418>3.0.CO;2-1; RANTA P, 1995, ACTA ANAESTH SCAND, V39, P60, DOI 10.1111/j.1399-6576.1995.tb05593.x; Rothwell PM, 2005, LANCET, V365, P82, DOI 10.1016/S0140-6736(04)17670-8; Salim R, 2005, OBSTET GYNECOL, V106, P301, DOI 10.1097/01.AOG.0000171109.53832.8d; Sia AT, 2007, ANESTH ANALG, V104, P673, DOI 10.1213/01.ane.0000253236.89376.60; Tien M, 2016, CURR MED RES OPIN, V32, P1435, DOI 10.1080/03007995.2016.1181619; Vandenbroucke JP, 2007, PLOS MED, V4, P1628, DOI 10.1371/journal.pmed.0040297; von Elm E, 2007, LANCET, V370, P1453, DOI 10.1016/S0140-6736(07)61602-X; Wilson MJA, 2009, ANAESTHESIA, V64, P266, DOI 10.1111/j.1365-2044.2008.05756.x; Wong CA, 2006, ANESTH ANALG, V102, P904, DOI 10.1213/01.ane.0000197778.57615.1a; Wong CA, 2009, IN J WOMENS HEALTH, V1, P139; Wong CA, 2011, ANESTH ANALG, V112, P904, DOI 10.1213/ANE.0b013e31820e7c2f; Wood SN, 2016, J AM STAT ASSOC, V111, P1548, DOI 10.1080/01621459.2016.1180986	32	1	1	1	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0007-0912	1471-6771		BRIT J ANAESTH	Br. J. Anaesth.	AUG	2019	123	2					E434	E441		10.1016/j.bja.2019.02.016			8	Anesthesiology	Anesthesiology	IK3GN	WOS:000476477600039	31331592	Green Published			2020-06-30	J	Pourfakhr, P; Khajavi, MR; Jalali, A; Memari, F; Etezadi, F; Roochi, MM; Moharari, RS; Najafi, A				Pourfakhr, Pejman; Khajavi, Mohammad Reza; Jalali, Ali; Memari, Faramarz; Etezadi, Farhad; Roochi, Mehrnoush Momeni; Moharari, Reza Shariat; Najafi, Atabak			Low-dose preoperative pregabalin improves postoperative pain management in septorhinoplasty surgery: a double-blind randomized clinical trial	EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY			English	Article						Pregabalin; Pain; Septorhinoplasty; Opioid sparing; Agitation; Remifentanil	ANALGESIA; EFFICACY; ANESTHESIA; ANXIETY; SCALE	PurposeTo evaluate theefficacy of single lowdose (75mg) preoperative pregabalin in reducing post-operative pain of septorhinoplasty.MethodsA doubleblind singlecenter Randomized controlled trialbased on block randomization. In thepregabalin group (PG) 34 participants received 75mg pregabalin orally one hour before anesthesia induction while in control group (CG) 34 participants receiveda placebo. Pain and sedation were repeatedly measured with Visual Analouge Scale (VAS)and Riker Sedation-Agitation Scale (RSAS) respectively, 0.5, 1, 2, 6, 24hours postextubation. Cumulative doses offentanyl and ibuprofen received in both groups were compared.ResultsThirty-two of theparticipants in PG and 33 of theparticipants in CG completed the study. TheMean VASpain score was less in PG versus CG 30min postoperatively (2.301.30 vs. 4.851.17), one hour (2.28 +/- 0.92 vs. 4.27 +/- 0.78), two hours (2.11 +/- 0.88 vs. 3.60 +/- 0.61) and six hours (1.47 0.62 vs. 2.76 +/- 0.91) but not 24-hours postoperatively (0.84 +/- 0.62 vs. 1.09 +/- 0.92). Participants in thePG were less agitated during early post-extubation period (at 10min: RSAS 3.93 +/- 0.43 vs. 4.42 +/- 0.50) and more alert during the first hour post-extubation (at 60min: RSAS 3.90 +/- 0.29 vs. 3.36 +/- 0.69). The total dose of rescue fentanyl and ibuprofen was lower in thePG compared to theCG.Conclusions Asingle dose of 75mg pregabalin is very effective for pain control after septorhinoplasty procedure when administered one hour before anesthesia induction. Side effects are rare and opioid sparing was noted.Trial registration Clinical trial number: IRCT2017043033706N1	[Pourfakhr, Pejman; Khajavi, Mohammad Reza; Jalali, Ali; Etezadi, Farhad; Moharari, Reza Shariat; Najafi, Atabak] Univ Tehran Med Sci, Sina Hosp, Dept Anesthesiol, Tehran, Iran; [Memari, Faramarz] Erfan Hosp, Dept Otol Neurotol, Tehran, Iran; [Roochi, Mehrnoush Momeni] Univ Tehran Med Sci, Sina Hosp, Dept Oral & Maxillofacial Surg, Tehran, Iran	Jalali, A (reprint author), Univ Tehran Med Sci, Sina Hosp, Dept Anesthesiol, Tehran, Iran.	a.jalali.md@gmail.com	Etezadi, Farhad/A-3141-2019	Etezadi, Farhad/0000-0002-3437-6431			Ahlers SJ, 2008, CRIT CARE, V12, DOI 10.1186/cc6789; Akad K, 2013, RHEUMATOL INT, V33, P2617, DOI 10.1007/s00296-013-2789-x; Ben-Menachem E, 2004, EPILEPSIA, V45, P13, DOI 10.1111/j.0013-9580.2004.455003.x; Bockbrader HN, 2010, J CLIN PHARMACOL, V50, P941, DOI 10.1177/0091270009352087; Brown EN, 2010, NEW ENGL J MED, V363, P2638, DOI 10.1056/NEJMra0808281; de Leon-Casasola O A, 1996, J Fla Med Assoc, V83, P695; Demirhan A, 2014, PAIN RES TREAT, V2014, DOI 10.1155/2014/850794; Demirhan A, 2013, AESTHET PLAST SURG, V37, P1100, DOI 10.1007/s00266-013-0207-0; Generoso MB, 2017, INT CLIN PSYCHOPHARM, V32, P49, DOI 10.1097/YIC.0000000000000147; KEHLET H, 1993, ANESTH ANALG, V77, P1048; Kim JH, 2014, CLIN EXP OTORHINOLAR, V7, P102, DOI 10.3342/ceo.2014.7.2.102; Lam DMH, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000001944; Lauria-Horner BA, 2003, EXPERT OPIN INV DRUG, V12, P663, DOI 10.1517/13543784.12.4.663; Myrvik MP, 2015, J PEDIAT HEMATOL ONC, V37, P190, DOI 10.1097/MPH.0000000000000306; Park IJ, 2016, LARYNGOSCOPE, V126, P2232, DOI 10.1002/lary.25951; Sagit M, 2013, J CRANIOFAC SURG, V24, P373, DOI 10.1097/SCS.0b013e31827fece5; Szychta P, 2010, J LARYNGOL OTOL, V124, P1194, DOI 10.1017/S0022215110001519; Turan A, 2004, ANESTH ANALG, V99, P375; Vanderah TW, 2001, J NEUROSCI, V21, P279, DOI 10.1523/JNEUROSCI.21-01-00279.2001; White PF, 2009, ANESTH ANALG, V108, P1140, DOI 10.1213/ane.0b013e31818d40ce; Wittekindt D, 2012, EUR ARCH OTO-RHINO-L, V269, P1613, DOI 10.1007/s00405-011-1854-x	21	1	1	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0937-4477	1434-4726		EUR ARCH OTO-RHINO-L	Eur. Arch. Oto-Rhino-Laryn.	AUG	2019	276	8					2243	2249		10.1007/s00405-019-05448-y			7	Otorhinolaryngology	Otorhinolaryngology	IJ1PV	WOS:000475671600018	31055640				2020-06-30	J	Johansson, J; Hirvonen, J; Lovro, Z; Ekblad, L; Kaasinen, V; Rajasilta, O; Helin, S; Tuisku, J; Siren, S; Pennanen, M; Agrawal, A; Crystal, R; Vainio, PJ; Alho, H; Scheinin, M				Johansson, Jarkko; Hirvonen, Jussi; Lovro, Zsofia; Ekblad, Laura; Kaasinen, Valtteri; Rajasilta, Olli; Helin, Semi; Tuisku, Jouni; Siren, Saija; Pennanen, Mirka; Agrawal, Arvind; Crystal, Roger; Vainio, Petri J.; Alho, Hannu; Scheinin, Mika			Intranasal naloxone rapidly occupies brain mu-opioid receptors in human subjects	NEUROPSYCHOPHARMACOLOGY			English	Article							POSITRON-EMISSION-TOMOGRAPHY; PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND; IN-VIVO; EARLY ABSTINENCE; TEST-RETEST; NALTREXONE; BINDING; PET; OCCUPANCY	Nasal spray formulations of naloxone, a mu-opioid receptor (MOR) antagonist, are currently used for the treatment of opioid overdose. They may have additional therapeutic utility also in the absence of opioid agonist drugs, but the onset and duration of action at brain MORs have been inadequately characterized to allow such projections. This study provides initial characterization of brain MOR availability at high temporal resolution following intranasal (IN) naloxone administration to healthy volunteers in the absence of a competing opioid agonist. Fourteen participants were scanned twice using positron emission tomography (PET) and [C-11] carfentanil, a selective MOR agonist radioligand. Concentrations of naloxone in plasma and MOR availability (relative to placebo) were monitored from 0 to 60 min and at 300-360 min post naloxone. Naloxone plasma concentrations peaked at similar to 20 min post naloxone, associated with slightly delayed development of brain MOR occupancy (half of peak occupancy reached at similar to 10 min). Estimated peak occupancies were 67 and 85% following 2 and 4 mg IN doses, respectively. The estimated half-life of occupancy disappearance was similar to 100 min. The rapid onset of brain MOR occupancy by IN naloxone, evidenced by the rapid onset of its action in opioid overdose victims, was directly documented in humans for the first time. The employed high temporal-resolution PET method establishes a model that can be used to predict brain MOR occupancy from plasma naloxone concentrations. IN naloxone may have therapeutic utility in various addictions where brain opioid receptors are implicated, such as gambling disorder and alcohol use disorder.	[Johansson, Jarkko; Hirvonen, Jussi; Ekblad, Laura; Helin, Semi; Tuisku, Jouni] Univ Turku, Turku PET Ctr, Turku, Finland; [Johansson, Jarkko] Umea Univ, Dept Radiat Sci, Umea, Sweden; [Hirvonen, Jussi] Univ Turku, Dept Radiol, Turku, Finland; [Lovro, Zsofia; Pennanen, Mirka; Scheinin, Mika] Clin Res Serv Turku CRST Ltd, Turku, Finland; [Lovro, Zsofia; Rajasilta, Olli; Siren, Saija; Vainio, Petri J.; Scheinin, Mika] Univ Turku, Inst Biomed, Turku, Finland; [Lovro, Zsofia; Rajasilta, Olli; Siren, Saija; Vainio, Petri J.; Scheinin, Mika] Turku Univ Hosp, Unit Clin Pharmacol, Turku, Finland; [Kaasinen, Valtteri] Univ Turku, Div Clin Neurosci, Turku, Finland; [Kaasinen, Valtteri] Turku Univ Hosp, Turku, Finland; [Agrawal, Arvind; Crystal, Roger] Opiant Pharmaceut Inc, Santa Monica, CA USA; [Alho, Hannu] Natl Inst Hlth & Welf, Helsinki, Finland; [Alho, Hannu] Univ Hosp Helsinki, Abdominal Ctr, Helsinki, Finland	Johansson, J (reprint author), Univ Turku, Turku PET Ctr, Turku, Finland.; Johansson, J (reprint author), Umea Univ, Dept Radiat Sci, Umea, Sweden.	Jarkko.johansson@umu.se	Johansson, Jarkko/M-1443-2019; Hirvonen, Jussi/AAC-1864-2020; Kaasinen, Valtteri/O-2086-2016	Johansson, Jarkko/0000-0002-4501-4735; Siren, Saija/0000-0003-0109-5155; Kaasinen, Valtteri/0000-0002-3446-7093; Ekblad, Laura/0000-0002-5863-8088; Scheinin, Mika/0000-0001-7579-9126	Ministry of Social Affairs and Health, Helsinki, Finland; Opiant Pharmaceuticals Inc.	The Ministry of Social Affairs and Health, Helsinki, Finland, funded the study ( 52 Appropriation of the Lotteries Act). The Ministry had no role in the study design, analysis, or interpretation of the results presented here or in any phase of the publication process. The study was also supported by an unrestricted grant from Opiant Pharmaceuticals Inc., to the National Institute for Health and Welfare, Helsinki, Finland. HA is principal investigator in a clinical trial evaluating IN naloxone as treatment of PG (ClinicalTrials. gov Identifier: NCT03430180). HA has no conflict of interest in relation to this manuscript. AA was employed by Opiant Pharmaceuticals, Inc. during the course of these studies. RC is a full-time employee and shareholder of Opiant Pharmaceuticals Inc. MS is an employee and shareholder and ZL and MP are employees of CRST Ltd., a clinical research organization that was contracted by the National Institute for Health and Welfare to perform the current study. The other authors declare no competing interests.	Ashburner J, 2005, NEUROIMAGE, V26, P839, DOI 10.1016/j.neuroimage.2005.02.018; Avetian GK, 2018, CURR MED RES OPIN, V34, P573, DOI 10.1080/03007995.2017.1334637; Desikan RS, 2006, NEUROIMAGE, V31, P968, DOI 10.1016/j.neuroimage.2006.01.021; Grant JE, 2006, AM J PSYCHIAT, V163, P303, DOI 10.1176/appi.ajp.163.2.303; Grant JE, 2008, J CLIN PSYCHIAT, V69, P783, DOI 10.4088/JCP.v69n0511; Grant JE, 2010, BRIT J PSYCHIAT, V197, P330, DOI 10.1192/bjp.bp.110.078105; HANDAL KA, 1983, ANN EMERG MED, V12, P438, DOI 10.1016/S0196-0644(83)80343-6; Heinz A, 2005, ARCH GEN PSYCHIAT, V62, P57, DOI 10.1001/archpsyc.62.1.57; Hirvonen J, 2009, EUR J NUCL MED MOL I, V36, P275, DOI 10.1007/s00259-008-0935-6; Hodgins DC, 2011, LANCET, V378, P1874, DOI 10.1016/S0140-6736(10)62185-X; Ichise M, 2003, J CEREBR BLOOD F MET, V23, P1096, DOI 10.1097/01.WCB.0000085441.37552.CA; Ingman K, 2005, NEUROPSYCHOPHARMACOL, V30, P2245, DOI 10.1038/sj.npp.1300790; Innis RB, 2007, J CEREBR BLOOD F MET, V27, P1533, DOI 10.1038/sj.jcbfm.9600493; Johansson J, 2017, J CEREBR BLOOD F MET, V37, P210; Karjalainen T, 2016, SOC COGN AFFECT NEUR, V11, P1310, DOI 10.1093/scan/nsw044; Karlsson HK, 2015, J NEUROSCI, V35, P3959, DOI 10.1523/JNEUROSCI.4744-14.2015; Kim S, 1997, J NUCL MED, V38, P1726; Kim SW, 2001, BIOL PSYCHIAT, V49, P914, DOI 10.1016/S0006-3223(01)01079-4; Kovanen L, 2016, EUR ADDICT RES, V22, P70, DOI 10.1159/000435876; Krieter P, 2016, J CLIN PHARMACOL, V56, P1243, DOI 10.1002/jcph.759; LESIEUR HR, 1987, AM J PSYCHIAT, V144, P1184; Love TM, 2009, ARCH GEN PSYCHIAT, V66, P1124, DOI 10.1001/archgenpsychiatry.2009.134; Majuri J, 2017, NEUROPSYCHOPHARMACOL, V42, P1169, DOI 10.1038/npp.2016.265; MARTIN WR, 1976, ANN INTERN MED, V85, P765, DOI 10.7326/0003-4819-85-6-765; MEYER MC, 1984, J CLIN PSYCHIAT, V45, P15; Mick I, 2016, NEUROPSYCHOPHARMACOL, V41, P1742, DOI 10.1038/npp.2015.340; Normandin MD, 2012, NEUROIMAGE, V59, P2689, DOI 10.1016/j.neuroimage.2011.07.002; Nummenmaa L, 2018, BRIT J PHARMACOL, V175, P2737, DOI 10.1111/bph.13812; Rabiner EA, 2011, MOL PSYCHIATR, V16, P826, DOI 10.1038/mp.2011.29; Saanijoki T, 2018, NEUROPSYCHOPHARMACOL, V43, P246, DOI 10.1038/npp.2017.148; Saccone PA, 2016, J PHARMACOL EXP THER, V359, P366, DOI 10.1124/jpet.116.235192; Sander CY, 2013, P NATL ACAD SCI USA, V110, P11169, DOI 10.1073/pnas.1220512110; Skolnick P, 2018, EUR J PHARMACOL, V835, P147, DOI 10.1016/j.ejphar.2018.08.004; Toneatto T, 2009, AM J ADDICTION, V18, P219, DOI 10.1080/10550490902787007; Tuulari JJ, 2017, J NEUROSCI, V37, P8284, DOI 10.1523/JNEUROSCI.0976-17.2017; Tylleskar I, 2017, EUR J CLIN PHARMACOL, V73, P555, DOI 10.1007/s00228-016-2191-1; Williams TM, 2007, BRIT J PSYCHIAT, V191, P63, DOI 10.1192/bjp.bp.106.031120; Williams TM, 2009, EUR NEUROPSYCHOPHARM, V19, P740, DOI 10.1016/j.euroneuro.2009.06.007; Wu YJ, 2002, J CEREBR BLOOD F MET, V22, P1440, DOI 10.1097/01.WCB.0000033967.83623.34	39	4	4	3	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0893-133X	1740-634X		NEUROPSYCHOPHARMACOL	Neuropsychopharmacology	AUG	2019	44	9					1667	1673		10.1038/s41386-019-0368-x			7	Neurosciences; Pharmacology & Pharmacy; Psychiatry	Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry	II8WU	WOS:000475474900020	30867551				2020-06-30	J	Park, SM; Kim, GU; Kim, HJ; Choi, JH; Chang, BS; Lee, CK; Yeom, JS				Park, Sang-Min; Kim, Gang-Un; Kim, Ho-Joong; Choi, Jae Heouk; Chang, Bong-Soon; Lee, Choon-Ki; Yeom, Jin S.			Is the Use of a Unilateral Biportal Endoscopic Approach Associated with Rapid Recovery After Lumbar Decompressive Laminectomy? A Preliminary Analysis of a Prospective Randomized Controlled Trial	WORLD NEUROSURGERY			English	Article						Biportal endoscopic spine surgery; Degenerative spine; Lumbar spinal stenosis; Unilateral laminectomy and bilateral decompression; Visual analog scale	SERUM CREATINE-PHOSPHOKINASE; SPINAL-CANAL STENOSIS; BILATERAL-DECOMPRESSION; RADIOLOGICAL OUTCOMES; INVASIVE DECOMPRESSION; INTERBODY FUSION; TECHNICAL NOTE; MUSCLE INJURY; SURGERY; LAMINOTOMY	OBJECTIVE: The purpose of this study was to assess the immediate postoperative clinical outcomes and perform a preliminary analysis of the effectiveness of biportal endoscopic approaches to lumbar decompressive laminectomy in the treatment of lumbar spinal stenosis. METHODS: All participants (64 patients) were randomly assigned in a 1:1 ratio to either the biportal endoscopic lumbar decompressive laminectomy (BE-D) group or the mini-open microscopic lumbar decompressive laminectomy (MI-D) group. Early postoperative outcomes were evaluated using clinical and surgical technique-related outcomes. The visual analog scale (VAS) pain score was measured at 6 time points after surgery (at 4, 8, 16, 24, and 48 hours and 2 weeks). Surgical technique-related outcomes were also analyzed. RESULTS: There were no significant differences in the preoperative demographics between the 2 groups. The VAS pain score from 8 to 48 hours (P < 0.05) was significantly lower in the BE-D group than in the MI-D group. Moreover, the total amount of fentanyl usage was higher in the MI-D group than in the BE-D group after surgery (P = 0.026). The length of hospital stay was lower in the BE-D group than in the MI-D group (P = 0.048). The operative time and creatinine phosphokinase level were not significantly different between the groups (P >0.05). Postoperative drainage was significantly higher in the BE-D group than in the MI-D group. CONCLUSIONS: BE-D was associated with rapid pain recovery, low fentanyl usage, and early discharge after surgery, but its other benefits have not yet been shown.	[Park, Sang-Min; Kim, Ho-Joong; Yeom, Jin S.] Seoul Natl Univ, Coll Med, Spine Ctr, Seongnam, South Korea; [Park, Sang-Min; Kim, Ho-Joong; Yeom, Jin S.] Seoul Natl Univ, Coll Med, Dept Orthopaed Surg, Seongnam, South Korea; [Park, Sang-Min; Kim, Ho-Joong; Yeom, Jin S.] Seoul Natl Univ, Bundang Hosp, Seongnam, South Korea; [Choi, Jae Heouk; Chang, Bong-Soon; Lee, Choon-Ki] Seoul Natl Univ, Dept Orthopaed Surg, Coll Med, Seoul, South Korea; [Choi, Jae Heouk; Chang, Bong-Soon; Lee, Choon-Ki] Seoul Natl Univ Hosp, Seoul, South Korea; [Kim, Gang-Un] Inje Univ, Coll Med, Sanggye Paik Hosp, Dept Orthopaed Surg, Seoul, South Korea	Yeom, JS (reprint author), Seoul Natl Univ, Coll Med, Spine Ctr, Seongnam, South Korea.; Yeom, JS (reprint author), Seoul Natl Univ, Coll Med, Dept Orthopaed Surg, Seongnam, South Korea.; Yeom, JS (reprint author), Seoul Natl Univ, Bundang Hosp, Seongnam, South Korea.	highcervical@gmail.com		Yeom, Jin S/0000-0002-8241-5335			Akcakaya MO, 2016, CLIN NEUROL NEUROSUR, V145, P74, DOI 10.1016/j.clineuro.2016.04.004; Arai Y, 2014, SPINE, V39, P332, DOI 10.1097/BRS.0000000000000136; Arts MP, 2007, J NEUROSURG-SPINE, V7, P282, DOI 10.3171/SPI-07/09/282; Birkenmaier C, 2013, PAIN PHYSICIAN, V16, P335; Cavusoglu H, 2007, EUR SPINE J, V16, P2133, DOI 10.1007/s00586-007-0471-2; Choi CM, 2016, ACTA NEUROCHIR, V158, P459, DOI 10.1007/s00701-015-2670-7; Choi DJ, 2019, CLIN ORTHOP SURG, V11, P82, DOI 10.4055/cios.2019.11.1.82; Choi DJ, 2018, ASIAN SPINE J, V12, P569, DOI 10.4184/asj.2018.12.3.569; Choi DJ, 2016, ASIAN SPINE J, V10, P624, DOI 10.4184/asj.2016.10.4.624; Choi KC, 2018, WORLD NEUROSURG, V116, pE750, DOI 10.1016/j.wneu.2018.05.085; Copay AG, 2008, SPINE J, V8, P968, DOI 10.1016/j.spinee.2007.11.006; Costa F, 2007, J NEUROSURG-SPINE, V7, P579, DOI 10.3171/SPI-07/12/579; Demirayak M, 2015, ASIAN SPINE J, V9, P713, DOI 10.4184/asj.2015.9.5.713; Dohzono S, 2017, ASIAN SPINE J, V11, P285, DOI 10.4184/asj.2017.11.2.285; Eum JH, 2016, J NEUROSURG-SPINE, V24, P602, DOI 10.3171/2015.7.SPINE15304; Fairbank JCT, 2000, SPINE, V25, P2940, DOI 10.1097/00007632-200011150-00017; Forsth P, 2016, NEW ENGL J MED, V374, P1413, DOI 10.1056/NEJMoa1513721; Fujimoto T, 2015, CLIN NEUROL NEUROSUR, V131, P21, DOI 10.1016/j.clineuro.2015.01.014; Heo DH, 2018, WORLD NEUROSURG, V120, pE684, DOI 10.1016/j.wneu.2018.08.144; Herdman M, 2011, QUAL LIFE RES, V20, P1727, DOI 10.1007/s11136-011-9903-x; Katz JN, 2008, NEW ENGL J MED, V358, P818, DOI 10.1056/NEJMcp0708097; Kim JE, 2019, ASIAN SPINE J, V13, P334, DOI 10.31616/asj.2018.0210; Kim JE, 2019, WORLD NEUROSURG, V126, pE786, DOI 10.1016/j.wneu.2019.02.150; Kim JE, 2018, CLIN ORTHOP SURG, V10, P508, DOI 10.4055/cios.2018.10.4.508; Kim JE, 2018, CLIN ORTHOP SURG, V10, P439, DOI 10.4055/cios.2018.10.4.439; Kim JE, 2018, CLIN ORTHOP SURG, V10, P328, DOI 10.4055/cios.2018.10.3.328; Kim JE, 2018, J ORTHOP, V15, P366, DOI 10.1016/j.jor.2018.01.039; Kim JE, 2018, CLIN ORTHOP SURG, V10, P248, DOI 10.4055/cios.2018.10.2.248; Kim SK, 2018, J ORTHOP SURG RES, V13, DOI 10.1186/s13018-018-0725-1; Komp M, 2015, PAIN PHYSICIAN, V18, P61; Liu JM, 2017, INT ORTHOP, V41, P2297, DOI 10.1007/s00264-017-3619-7; Mobbs RJ, 2014, J NEUROSURG-SPINE, V21, P179, DOI 10.3171/2014.4.SPINE13420; Park SM, 2019, WORLD NEUROSURG, V122, pE1007, DOI 10.1016/j.wneu.2018.10.197; Polikandriotis JA, 2013, J ORTHOP, V10, P13, DOI 10.1016/j.jor.2013.01.006; Sairyo K, 2010, MINIM INVAS NEUROSUR, V53, P175, DOI 10.1055/s-0030-1262814; Schizas C, 2010, SPINE, V35, P1919, DOI 10.1097/BRS.0b013e3181d359bd; Soliman HM, 2015, SPINE J, V15, P2282, DOI 10.1016/j.spinee.2015.07.009; Thome C, 2005, J NEUROSURG-SPINE, V3, P129, DOI 10.3171/spi.2005.3.2.0129; Torudom Y, 2016, ASIAN SPINE J, V10, P335, DOI 10.4184/asj.2016.10.2.335; Uehara M, 2014, ASIAN SPINE J, V8, P768, DOI 10.4184/asj.2014.8.6.768; Wong AP, 2012, MINIM INVASIVE SURG, V2012, DOI 10.1155/2012/325095	41	3	3	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1878-8750	1878-8769		WORLD NEUROSURG	World Neurosurg.	AUG	2019	128						E709	E718		10.1016/j.wneu.2019.04.240			10	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	IJ4SX	WOS:000475895100084	31077891				2020-06-30	J	Lin, YC; Liu, YT; Wu, ZF; Chan, SM				Lin, Yi-Chin; Liu, Yin-Tzu; Wu, Zhi-Fu; Chan, Shun-Ming			The successful application of high flow nasal cannula for awake craniotomy	JOURNAL OF CLINICAL ANESTHESIA			English	Letter						High flow nasal cannula; Awake craniotomy			[Lin, Yi-Chin; Liu, Yin-Tzu; Wu, Zhi-Fu; Chan, Shun-Ming] Triserv Gen Hosp, Dept Anesthesiol, Natl Def Med Ctr, 325 Chenggung Rd,Sect 2, Taipei 114, Taiwan; [Lin, Yi-Chin] Taichung Armed Forces Gen Hosp, Div Anesthesiol, Taichung, Taiwan	Chan, SM (reprint author), Triserv Gen Hosp, Dept Anesthesiol, Natl Def Med Ctr, 325 Chenggung Rd,Sect 2, Taipei 114, Taiwan.	chansm0620@gmail.com					Cherng CH, 2016, J NEUROSURG ANESTH, V28, P275, DOI 10.1097/ANA.0000000000000202; Kumar P, 2017, J NEUROSURG ANESTH, V29, P368, DOI 10.1097/ANA.0000000000000312; Sivasankar C, 2016, ANESTH ANALG, V122, P509, DOI 10.1213/ANE.0000000000001072	3	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0952-8180	1873-4529		J CLIN ANESTH	J. Clin. Anesth.	AUG	2019	55						140	141		10.1016/j.jclinane.2019.01.012			2	Anesthesiology	Anesthesiology	HQ8RZ	WOS:000462694300046	30658329				2020-06-30	J	Chen, CH; Mullen, AJ; Hofstede, D; Rizvi, T				Chen, Cathy H.; Mullen, Alexander J.; Hofstede, Dustin; Rizvi, Tanvir			Malignant cerebellar edema in three-year-old girl following accidental opioid ingestion and fentanyl administration	NEURORADIOLOGY JOURNAL			English	Article						Fentanyl toxicity; pediatric opioid overdose; toxic leukoencephalopathy; CT scan; MRI; cytotoxic edema	TOXIC LEUKOENCEPHALOPATHY; METHADONE INTOXICATION; CHILDREN	A three-year-old girl was found altered with an unknown timeline. Gas chromatography mass spectrometry was positive for hydromorphone, dihydrocodeine, and hydrocodone. Initial computed tomography and magnetic resonance imaging suggested a malignant cerebellar edema not confined to a vascular distribution. She received fentanyl boluses on hospital days 0 and 1 before receiving a continuous infusion on day 1. On day 3, she had an episode of acute hypertension and bradycardia. Emergent computed tomography showed an evolving hydrocephalus and similar diffuse edema throughout both cerebellar hemispheres. External ventricular drain was placed to relieve the increased intracranial pressure. Following drain placement and fentanyl discontinuation, the patient recovered, though not without fine- and gross-motor deficits at the four-month follow-up. Our case adds to a handful of case reports of opioid toxicity in pediatric patients that present as toxic leukoencephalopathy. Though the mechanism is poorly understood, it has been suggested to be a consequence of the neurotoxic effects of the drug, which has particular affinity for mu opioid receptors-the primary opioid receptor found in the cerebellum. Clinicians would do well to recognize that this syndrome is primarily caused by direct toxicity rather than ischemia. This case adds insight by suggesting that lipophilic opioid analgesics may worsen this neurotoxicity. When intervening with mechanical ventilation, clinicians should consider avoiding lipophilic opioid drugs for analgesia until the pathogenesis of cerebellar edema is better understood.	[Chen, Cathy H.; Mullen, Alexander J.] Univ Mississippi, Sch Med, University, MS 38677 USA; [Hofstede, Dustin] Univ Mississippi, Med Ctr, Dept Radiol, University, MS 38677 USA; [Rizvi, Tanvir] Univ Virginia Hlth Syst, Dept Radiol, Charlottesville, VA USA	Rizvi, T (reprint author), Univ Virginia Hlth Syst, 1215 Lee St, Charlottesville, VA 22903 USA.	rizvi.tanvir@gmail.com	Rizvi, Tanvir/AAF-6641-2019	Rizvi, Tanvir/0000-0002-0335-8310; Mullen, Alexander/0000-0003-3769-3923; Chen, Cathy/0000-0001-8120-1362			ACHAMALLAH N, 2018, J INTENSIVE CARE SOC, V20, P80; ALLEN JD, 2017, PEDIATRICS, V139; Anand KJS, 2013, PEDIATR CRIT CARE ME, V14, P27, DOI 10.1097/PCC.0b013e318253c80e; Anselmo M, 2006, J CHILD NEUROL, V21, P618, DOI 10.1177/08830738060210071101; Bartlett E, 2005, BRIT J RADIOL, V78, P997, DOI 10.1259/bjr/61535842; Bazmamoun Hassan, 2014, Iran J Child Neurol, V8, P34; Beauchamp GA, 2016, J EMERG MED, V51, P382, DOI 10.1016/j.jemermed.2016.05.056; Boyer EW, 2012, NEW ENGL J MED, V367, P146, DOI 10.1056/NEJMra1202561; Buttner A, 2000, FORENSIC SCI INT, V113, P435, DOI 10.1016/S0379-0738(00)00204-8; Cunha-Oliveira T, 2008, BRAIN RES REV, V58, P192, DOI 10.1016/j.brainresrev.2008.03.002; Devlin John W, 2011, Anesthesiol Clin, V29, P567, DOI 10.1016/j.anclin.2011.09.001; Dolansky G, 2008, PAED CHILD HEALT-CAN, V13, P307, DOI 10.1093/pch/13.4.307; DURAN D, 2017, FRONT NEUROL, V8, DOI DOI 10.3389/FNEUR.2017.00362; Foy L, 2011, PEDIATR EMERG CARE, V27, P854, DOI 10.1097/PEC.0b013e31822c281f; Hosseini F, 2017, J PEDIAT REV, V5, DOI 10.17795/jpr-8803; Huang BY, 2008, RADIOGRAPHICS, V28, P417, DOI 10.1148/rg.282075066; Juttler E, 2009, STROKE, V40, P3060, DOI 10.1161/STROKEAHA.109.550913; Kane JM, 2018, PEDIATRICS, V141, DOI 10.1542/peds.2017-3335; KATZ R, 1993, CRIT CARE MED, V21, P995, DOI 10.1097/00003246-199307000-00012; Kremer Michael J, 2018, AANA J, V86, P321; Mendes Dos Santos C, 2012, ACTA MEDICA PORT, V25, P38; Mills F, 2008, PEDIATR RADIOL, V38, P227, DOI 10.1007/s00247-007-0635-6; Murphy A, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009942.pub2; Nanan R, 2000, NEURORADIOLOGY, V42, P845, DOI 10.1007/s002340000442; Reisner A, 2015, J NEUROSURG-PEDIATR, V16, P752, DOI 10.3171/2015.4.PEDS14667; Riascos R, 2008, EMERG RADIOL, V15, P67, DOI 10.1007/s10140-007-0627-8; Ries RK, 2009, PRINCIPLES ADDICTION; Ryan A, 2005, J NEUROL NEUROSUR PS, V76, P1014, DOI 10.1136/jnnp.2004.047134; Schadrack J, 1999, NEUROREPORT, V10, P619, DOI 10.1097/00001756-199902250-00032; STOLBERG VB, 2016, PAINKILLERS HIST SCI, DOI DOI 10.1227/01.NEU.0000245608.07570.D2; Verghese Susan T, 2010, J Pain Res, V3, P105; Vet NJ, 2016, FRONT PEDIATR, V4, DOI 10.3389/fped.2016.00089; WOLTERS EC, 1982, LANCET, V2, P1233; ZAGON IS, 1990, BRAIN RES, V523, P62, DOI 10.1016/0006-8993(90)91635-T; Zanin A, 2010, J CHILD NEUROL, V25, P748, DOI 10.1177/0883073809343318	35	2	2	1	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1971-4009	2385-1996		NEURORADIOL J	Neuradiology J.	OCT	2019	32	5					386	391		10.1177/1971400919863713		JUL 2019	6	Neuroimaging	Neurosciences & Neurology	IV8DR	WOS:000477321500001	31328634				2020-06-30	J	Ugata, K; Imamachi, N; Hashimoto, A; Saito, Y				Ugata, Kei; Imamachi, Noritaka; Hashimoto, Ai; Saito, Yoji			Anesthetic Management in an Adult Patient With Costello Syndrome: A Case Report	A & A PRACTICE			English	Article							CHILD	Costello syndrome is a rare genetic disorder characterized by mental and growth retardation and distinctive coarse facies. A significant proportion of patients with Costello syndrome have hypertrophic cardiomyopathy, papillomata, and malignant tumors. General anesthesia practice, especially airway and cardiac management, in patients with Costello syndrome may be complicated by anatomical features and cardiac abnormalities. There have been several reports on the anesthetic management of children with Costello syndrome, but few have reported on the anesthetic management of adults with Costello syndrome. In adults, careful preoperative evaluation as well as preparation for adult-onset and previously unrecognized medical conditions are key for safe anesthetic management.	[Ugata, Kei; Imamachi, Noritaka; Hashimoto, Ai; Saito, Yoji] Shimane Univ, Fac Med, Dept Anesthesiol, 89-1 Enyacho, Izumo, Shimane 6938501, Japan	Imamachi, N (reprint author), Shimane Univ, Fac Med, Dept Anesthesiol, 89-1 Enyacho, Izumo, Shimane 6938501, Japan.	imamachi@med.shimane-u.ac.jp					Abe Y, 2012, AM J MED GENET A, V158A, P1083, DOI 10.1002/ajmg.a.35292; Aoki Y, 2005, NAT GENET, V37, P1038, DOI 10.1038/ng1641; Benni F, 2002, PAEDIATR ANAESTH, V12, P376, DOI 10.1046/j.1460-9592.2002.t01-3-00845.x; COSTELLO JM, 1971, NEW ZEAL MED J, V74, P397; Dearlove O, 1997, PAEDIATR ANAESTH, V7, P476, DOI 10.1046/j.1460-9592.1997.d01-120.x; Dickson PI, 2004, AM J MED GENET A, V130A, P402, DOI 10.1002/ajmg.a.30288; Katcher K, 2003, PAEDIATR ANAESTH, V13, P257, DOI 10.1046/j.1460-9592.2003.01052.x; Shukry M, 2008, PEDIATR ANESTH, V18, P567, DOI 10.1111/j.1460-9592.2008.02488.x; Tsutsui M, 2009, PEDIATR ANESTH, V19, P714, DOI 10.1111/j.1460-9592.2009.03050.x; White SM, 2005, AM J MED GENET A, V136A, P128, DOI 10.1002/ajmg.a.30747	10	0	0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2325-7237			A A PRACT	A A Pract.	JUL 15	2019	13	2					41	43		10.1213/XAA.0000000000000983			3	Anesthesiology	Anesthesiology	II8XT	WOS:000475477700002	30807300				2020-06-30	J	Buchalter, S; Marginean, L; Yohannan, J; Lurie, IS				Buchalter, Sydney; Marginean, Loan; Yohannan, Joshua; Lurie, Ira S.			Gas chromatography with tandem cold electron ionization mass spectrometric detection and vacuum ultraviolet detection for the comprehensive analysis of fentanyl analogues	JOURNAL OF CHROMATOGRAPHY A			English	Article						Fentanyl analogues; Vacuum ultraviolet detection; Cold electron ionization mass; spectrometric detection; Positional isomers	GC-MS; IDENTIFICATION; DISCRIMINATION; 3-METHYLFENTANYL; SPECTROSCOPY; DERIVATIVES; SEPARATION; HOMOLOGS; ISOMERS	Fentanyl and its derivatives are amongst the ever-growing list of emerging drugs which are impinging on current traditional analytical techniques employed in forensic laboratories. To avoid current regulations, fentanyl analogues are being illicitly synthesized by slight alterations of functional groups to the fentanyl skeleton leading to inaccurate identifications, thus posing the greatest challenge to laboratories. In this study, a novel analytical technique is presented in which gas chromatography (GC) is interfaced with both cold electron ionization mass spectrometric (cold El MS) and vacuum ultraviolet (VUV) detection by the means of a flow splitter for the simultaneous qualitative and quantitative analysis of twenty-four fentanyl analogues, including seven sets of positional isomers. For most of the twenty-four analogues, enhanced molecular ions were obtained with at least 1% intensity relative to base peak. In addition to enhanced molecular ions, the GC-cold El MS maintained fragmentation pathways observed by GC-MS with classical electron ionization. For the most part, VUV detection resulted in unique VUV spectra for fentanyl analogues including positional isomers. The combination of these two complementary detectors in tandem with the high resolving power of the gas chromatograph, allows for higher confidence in analyte identification by the combination of retention times, cold El mass spectra and VUV spectra. The preferred method for quantitation was based on VUV detection and offered excellent determination coefficients (R-2 >= 0.999) for most analytes over two orders of magnitude dynamic range, without the need for deuterated internal standards. For both run-to-run and day-to-day repeatability studies, at moderate solute concentrations, the correct fentanyl related compound was identified in almost every instance from a library containing all the fentanyl analogues plus hundreds of other analytes. (C) 2019 Elsevier B.V. All rights reserved.	[Buchalter, Sydney; Marginean, Loan; Lurie, Ira S.] George Washington Univ, 2100 Foxhall Rd NW, Washington, DC 20007 USA; [Yohannan, Joshua] Allegheny Cty Off Med Examiner, 1520 Penn Ave, Pittsburgh, PA 15222 USA	Lurie, IS (reprint author), George Washington Univ, 2100 Foxhall Rd NW, Washington, DC 20007 USA.	islurie@gwu.edu			National Institute of Justice, Office of Justice Programs [2017-R2-CX-0028]; United States Department of Justice	This project is supported by Award No. 2017-R2-CX-0028 awarded by the National Institute of Justice, Office of Justice Programs, and the United States Department of Justice. The opinions, findings, and conclusions expressed in this presentation are those of the author(s) and may not necessarily reflect those of The Department of Justice. The authors gratefully acknowledge the support from Dale Harrison, Mark Ramsdale, and Tom Steen from VUV Analytics, as well as Tom Mancuso and Paul Ortolan from Perkin Elmer.	Amirav A, 2002, REV SCI INSTRUM, V73, P2872, DOI 10.1063/1.1488683; Amirav A, 2008, J MASS SPECTROM, V43, P141, DOI 10.1002/jms.1380; Amirav A, 2017, CHROMATOGRAPHIA, V80, P295, DOI 10.1007/s10337-017-3249-7; Anthony IGM, 2018, ANAL CHEM, V90, P12307, DOI 10.1021/acs.analchem.8b04028; Anthony IGM, 2018, ANAL CHEM, V90, P4878, DOI 10.1021/acs.analchem.8b00531; Armenian P, 2018, NEUROPHARMACOLOGY, V134, P121, DOI 10.1016/j.neuropharm.2017.10.016; Breindahl T, 2017, DRUG TEST ANAL, V9, P415, DOI 10.1002/dta.2046; Centers for disease control and prevention, 2008, JAMA-J AM MED ASSOC, V300, P1512; COOPER D, 1986, J FORENSIC SCI, V31, P511; DEA, 2018, DEADCTDIB00318; Department of Justice, 2018, DEA476 DEP JUST; ESPOSITO FM, 1991, J FORENSIC SCI, V36, P86; Fialkov AB, 2006, INT J MASS SPECTROM, V251, P47, DOI 10.1016/j.ijms.2005.12.045; Gras R., J CHROMATOGR A, V2018, P171; Kanamori T, 2017, J FORENSIC SCI, V62, P1472, DOI 10.1111/1556-4029.13395; Levitas MP, 2018, FORENSIC SCI INT, V288, P107, DOI 10.1016/j.forsciint.2018.04.026; Lurie IS, 2012, FORENSIC SCI INT, V220, P191, DOI 10.1016/j.forsciint.2012.02.024; Lurie IS, 2009, J CHROMATOGR A, V1216, P1515, DOI 10.1016/j.chroma.2008.12.097; LURIE IS, 1984, J LIQ CHROMATOGR, V7, P463, DOI 10.1080/01483918408073979; LURIE IS, 1984, J CHROMATOGR, V292, P283, DOI 10.1016/S0021-9673(01)83609-8; Maher S, 2018, DRUG TEST ANAL, P1; MOORE JM, 1986, ANAL CHEM, V58, P1656, DOI 10.1021/ac00121a013; Ohta H, 1999, J ANAL TOXICOL, V23, P280, DOI 10.1093/jat/23.4.280; Philp M, 2018, DRUG TEST ANAL, V10, P95, DOI 10.1002/dta.2300; Rittgen J, 2012, ELECTROPHORESIS, V33, P1595, DOI 10.1002/elps.201100655; Rojkiewicz M, 2017, DRUG TEST ANAL, V9, P405, DOI 10.1002/dta.2135; RUNAGYUTTIKARN W, 1990, J ANAL TOXICOL, V14, P160, DOI 10.1093/jat/14.3.160; Santos IC, 2017, J SEP SCI, V40, P138, DOI 10.1002/jssc.201601023; Schueler H. E., 2019, EMERGING SYNTHETIC F; Schug KA, 2017, LC GC N AM, V35, P511; Schug KA, 2014, ANAL CHEM, V86, P8329, DOI 10.1021/ac5018343; Shipman R., 2013, FORENSIC DRUG IDENTI; Sirchie, 2019, NARK 2 FENT REAG; Sisco E, 2017, FORENSIC CHEM, V4, P108, DOI 10.1016/j.forc.2017.04.001; Skultety L, 2017, ANAL CHIM ACTA, V971, P55, DOI 10.1016/j.aca.2017.03.023; Smolianitski-Fabian E, 2018, DRUG TEST ANAL, V10, P474, DOI 10.1002/dta.2247; SUZUKI S, 1989, FORENSIC SCI INT, V43, P15, DOI 10.1016/0379-0738(89)90117-5; United Nations Office on Drugs and Crime, 2017, REC METH ID AN FENT; Vardanyan RS, 2014, FUTURE MED CHEM, V6, P385, DOI 10.4155/fmc.13.215; Wang BT, 2014, J ANAL TOXICOL, V38, P672, DOI 10.1093/jat/bku103	40	10	9	3	26	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0021-9673	1873-3778		J CHROMATOGR A	J. Chromatogr. A	JUL 5	2019	1596						183	193		10.1016/j.chroma.2019.03.011			11	Biochemical Research Methods; Chemistry, Analytical	Biochemistry & Molecular Biology; Chemistry	HZ9BV	WOS:000469151700020	30876740				2020-06-30	J	Naldan, ME; Arslan, Z; Ay, A; Yayik, AM				Naldan, Muhammet Emin; Arslan, Zakir; Ay, Aysenur; Yayik, Ahmet Murat			Comparison of Lidocaine and Atropine on Fentanyl-Induced Cough: A Randomized Controlled Study	JOURNAL OF INVESTIGATIVE SURGERY			English	Article						Fentanyl; cough; atropine; premedication; lidocaine; pediatric	INTRAVENOUS LIDOCAINE; PROPOFOL; KETAMINE	Objective of the Study: Fentanyl and atropine are drugs used for analgesia during induction and for premedication, respectively. The aim of this study was to observe the effect of atropine used for premedication on cough developing in association with fentanyl use during anesthesia induction. Methods: This was a single-blind, prospective, multi-arm, parallel, randomized clinical trial involving 120 patients between ages 3 and 15 years undergoing general anesthesia. Patients were randomized into three groups: a control group (Group C), an atropine group (Group A), and a lidocaine group (Group L). Results: Incidence of cough was 45% (n = 16) in Group C, 16% (n = 6) in Group A, and 16% in Group L (n = 6) (p = 0.009). Cough was moderate in two cases in Group A and in two in Group L, and mild in all others in these groups. In Group C, cough was mild in seven cases, moderate in six, and severe in two. Conclusion: We determined that premedication with atropine suppressed the incidence and severity of fentanyl-induced cough during induction of general anesthesia. We think that, due to its antimuscarinic effect, atropine is as effective as lidocaine as a premedication.	[Naldan, Muhammet Emin; Arslan, Zakir; Ay, Aysenur; Yayik, Ahmet Murat] Erzurum Reg Training & Res Hosp, Dept Anesthesiol & Reanimat, TR-2500 Erzurum, Turkey	Naldan, ME (reprint author), Erzurum Reg Training & Res Hosp, Dept Anesthesiol & Reanimat, TR-2500 Erzurum, Turkey.	muhammetnaldan@gmail.com					AKCABOY ZN, 2012, J TURK ANAESTH INT C, V40, P33; BOHRER H, 1990, ANAESTHESIA, V45, P18, DOI 10.1111/j.1365-2044.1990.tb14496.x; Decaj-Dashi A, 2013, COUGH, V9, P20, DOI [10.1186/1745-9974-9-20, DOI 10.1186/1745-9974-9-20]; El Baissari Mabelle C. Tannous, 2014, Middle East Journal of Anesthesiology, V22, P449; Han JI, 2011, KOREAN J ANESTHESIOL, V60, P391, DOI 10.4097/kjae.2011.60.6.391; Kamei Junzo, 2013, Cough, V9, P3, DOI 10.1186/1745-9974-9-3; Karayazili R, 2010, HASEKI TIP BUL, V48, P146; Lin CS, 2004, CAN J ANAESTH, V51, P654, DOI 10.1007/BF03018421; Lin JA, 2007, J FORMOS MED ASSOC, V106, P649, DOI 10.1016/S0929-6646(08)60022-4; LOU YP, 1993, ACTA PHYSIOL SCAND, V149, P1; Lui PW, 1996, CAN J ANAESTH, V43, P1216; Ozmen O, 2016, PAK J MED SCI, V32, P715, DOI 10.12669/pjms.323.9496; Pandey CK, 2004, ANESTH ANALG, V99, P1696, DOI 10.1213/01.ANE.0000136967.82197.82; REITAN JA, 1978, ANESTH ANALG, V57, P31; Sedighinejad Abbas, 2013, Anesth Pain Med, V2, P170, DOI 10.5812/aapm.8383; STELLATO C, 1992, ANESTHESIOLOGY, V77, P932, DOI 10.1097/00000542-199211000-00016; Tang QF, 2010, UPSALA J MED SCI, V115, P121, DOI 10.3109/03009730903291034; Tweed WA, 2001, ANESTH ANALG, V92, P1442; Uvelin A, 2009, ACTA ANAESTH SCAND, V53, P1228, DOI 10.1111/j.1399-6576.2009.02041.x; Yakc u, 2013, ANESTEZI DERGISI, V21, P17; YASUDA I, 1978, ANESTHESIOLOGY, V49, P117, DOI 10.1097/00000542-197808000-00012; Yeh CC, 2007, J CLIN ANESTH, V19, P53, DOI 10.1016/j.jclinane.2006.05.021; Yu H, 2007, ANAESTHESIA, V62, P919, DOI 10.1111/j.1365-2044.2007.05147.x	23	0	0	0	0	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0894-1939	1521-0553		J INVEST SURG	J. Invest. Surg.	JUL 4	2019	32	5					428	432		10.1080/08941939.2018.1424272			5	Surgery	Surgery	IN7UL	WOS:000478887200006	29388856				2020-06-30	J	Reardon, S				Reardon, Sara			US opioid crisis is driving a spike in infectious diseases	NATURE			English	News Item																Edelman EJ, 2019, JAMA INTERN MED, V179, P297, DOI 10.1001/jamainternmed.2018.6101; Kumar R, 2004, J VIROL, V78, P11425, DOI 10.1128/JVI.78.20.11425-11428.2004; Schranz AJ, 2019, ANN INTERN MED, V170, P31, DOI 10.7326/M18-2124	3	1	1	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 4	2019	571	7763					15	16		10.1038/d41586-019-02019-3			2	Multidisciplinary Sciences	Science & Technology - Other Topics	IG4DV	WOS:000473755200008	31267051	Bronze			2020-06-30	J	Shende, C; Farquharson, A; Brouillette, C; Smith, W; Farquharson, S				Shende, Chetan; Farquharson, Amelia; Brouillette, Carl; Smith, Wayne; Farquharson, Stuart			Quantitative Measurements of Codeine and Fentanyl on a Surface-Enhanced Raman-Active Pad	MOLECULES			English	Article						SERS; Raman; opioid detection; codeine; fentanyl; forensics	SILVER; IDENTIFICATION; SPECTROSCOPY; SCATTERING; AMPHETAMINE; TABLETS; DRUGS; SERS	The USA is in the midst of an opioid crisis that included over 60,000 overdose fatalities in 2017, mostly unintentional. This is due to excessive use of prescription opioids and the use of very strong synthetic opioids, such as fentanyl, mixed with illicit street drugs. The ability to rapidly determine if people or packages entering the country have or contain drugs could reduce their availability, and thereby decrease the use of illicit drugs. In an effort to address this problem, we have been investigating the ability of surface-enhanced Raman spectroscopy to detect trace amounts of opioids on clothing and packages. Here, we report the measurement of codeine and fentanyl at 100 ng/mL for 5 min on a pad impregnated with gold colloids, as well as a preliminary measurement of 500 pg of fentanyl on a glass surface using one of these pads. The calculated limit of detection for this measurement was 40 pg. This data strongly suggests that these pads, used with portable Raman analyzers, would be invaluable to airport security, drug raids, crime scenes, and forensic analysis.	[Shende, Chetan; Farquharson, Amelia; Brouillette, Carl; Smith, Wayne; Farquharson, Stuart] Real Time Analyzers Inc, Middletown, CT 06457 USA	Farquharson, S (reprint author), Real Time Analyzers Inc, Middletown, CT 06457 USA.	stu@rta.biz			USA Department of Defense, Chemical and Biological Defense [W911QY19C0008]; USA National Institute of Health, National Institute of Drug Abuse [2R44DA032178-02]	This research was funded by the USA Department of Defense, Chemical and Biological Defense, contract no. W911QY19C0008, and the USA National Institute of Health, National Institute of Drug Abuse, grant no. 2R44DA032178-02.	Angel SM, 1999, J RAMAN SPECTROSC, V30, P795, DOI 10.1002/(SICI)1097-4555(199909)30:9<795::AID-JRS451>3.0.CO;2-2; Bell SEJ, 2004, J RAMAN SPECTROSC, V35, P409, DOI 10.1002/jrs.1160; Bell SEJ, 2000, ANALYST, V125, P541, DOI 10.1039/a908091k; de Veij M, 2008, J PHARMACEUT BIOMED, V46, P303, DOI 10.1016/j.jpba.2007.10.021; Donahue M., 2011, SPECTROSCOPY, V26, P24; Farquharson S, 2004, J RAMAN SPECTROSC, V35, P82, DOI 10.1002/jrs.1111; Farquharson S, 2000, P SOC PHOTO-OPT INS, V4200, P89, DOI 10.1117/12.411716; Farquharson Stuart, 2011, Pharmaceutics, V3, P425, DOI 10.3390/pharmaceutics3030425; Faulds K, 2002, ANALYST, V127, P282, DOI 10.1039/b107318b; GORODETZKY CW, 1965, CLIN PHARMACOL THER, V6, P731; Haddad A, 2018, ANAL CHEM, V90, P12678, DOI 10.1021/acs.analchem.8b02909; Hargreaves MD, 2008, J RAMAN SPECTROSC, V39, P873, DOI 10.1002/jrs.1926; Int Narc Control Board United Nations, NARC DRUGS STAT 2013; JEANMAIRE DL, 1977, J ELECTROANAL CHEM, V84, P1, DOI 10.1016/S0022-0728(77)80224-6; Jones CM, 2010, JAMA-J AM MED ASSOC, V319, P1819, DOI DOI 10.1001/jama.2018.2844; Langmuir I, 1918, J AM CHEM SOC, V40, P1361, DOI 10.1021/ja02242a004; Lanzarotta A, 2017, J PHARMACEUT BIOMED, V146, P420, DOI 10.1016/j.jpba.2017.09.005; Leonard J, 2017, J RAMAN SPECTROSC, V48, P1323, DOI 10.1002/jrs.5220; Mabbott S, 2013, ANAL CHEM, V85, P923, DOI 10.1021/ac302542r; Moshtaghian A., 2018, CNN; NIH National Institute on Drug Abuse, OV DEATH RAT; Rana V, 2011, J FORENSIC SCI, V56, P200, DOI 10.1111/j.1556-4029.2010.01562.x; Sagmuller B, 2001, ANALYST, V126, P2066, DOI 10.1039/b105321n; Santillan J.D., 2007, P SOC PHOTO-OPT INS, V6540, P1; U. S. Customs and Border Protection, CBP OFF SEIZ LARG AM; WEAVER MJ, 1985, J CHEM PHYS, V82, P4867, DOI 10.1063/1.448657; West MJ, 2009, SPECTROCHIM ACTA A, V71, P1984, DOI 10.1016/j.saa.2008.07.024	27	3	3	2	7	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		1420-3049		MOLECULES	Molecules	JUL 2	2019	24	14							2578	10.3390/molecules24142578			8	Biochemistry & Molecular Biology; Chemistry, Multidisciplinary	Biochemistry & Molecular Biology; Chemistry	IS7AS	WOS:000482303000061	31315188	DOAJ Gold, Green Published			2020-06-30	J	Yamada, LAP; Guimaraes, GMN; Silva, MAS; Sousa, AM; Ashmawi, HA				Pinto Yamada, Leia Alessandra; Nunes Guimaraes, Gabriel Magalhaes; Santos Silva, Magda Aparecida; Sousa, Angela Maria; Ashmawi, Hazem Adel			Development of a multivariable predictive model for postoperative nausea and vomiting after cancer surgery in adults	REVISTA BRASILEIRA DE ANESTESIOLOGIA			Portuguese	Article						Postoperative nausea and vomiting; Muttivariabte model; Cancer; Smoking; Prognostic	SCORE	Background and objectives: Predicting postoperative nausea and vomiting risk is the cornerstone for deciding prophylaxis. Apfel's score does not define how long a person must be abstinent from smoking to be considered a non-smoker, and the use of intraoperative spinal opioids as a risk factor for predicting postoperative nausea and vomiting is also not addressed. The aim of this study was to quantify predicting postoperative nausea and vomiting risk by an ordinal smoking status and the use of intraoperative opioids (systemic or neuraxial), and to develop a new predictive model. Methods: Patients scheduled for cancer surgery were prospectively evaluated for predicting postoperative nausea and vomiting in the first 24 h after surgery. Results: Of 2014 initially included patients, 185 participants were excluded. Smoking status classification was associated with predicting postoperative nausea and vomiting incidence rates of 14.1%, 18.1%, 24.7%, 29.4% and 33.9% for smokers, patients who stopped smoking up to 1 month prior to surgery, one to 6 months prior, more than 6 months prior or patients who never smoked, respectively, which was significant in the multiple comparisons analysis (adjusted p= 0.015). The multiple comparisons-adjusted hypothesis tests for association with predicting postoperative nausea and vomiting for sex, age, previous predicting postoperative nausea and vomiting, chemotherapy-induced nausea, and ordinal smoking status had p-values of <0.001. The type of surgery (p= 0.04), total fentanyl consumption (p= 0.04), both intraoperative and postoperative, were significant predictors. A new model was developed and showed higher discriminative power than Apfel's score (AUC 67.9% vs. 63.7%, p < 0.001). Conclusion: Smoking status showed a significant and linear impact on predicting postoperative nausea and vomiting incidence, and we developed a new model that uses unambiguous smoking and opioid predictors. (C) 2019 Sociedade Brasileira de Anestesiologia. Published by Elsevier Editora Ltda.	[Pinto Yamada, Leia Alessandra] Univ Sao Paulo, Fac Med, Sao Paulo, SP, Brazil; [Nunes Guimaraes, Gabriel Magalhaes] Univ Brasilia, Fac Med, Brasilia, DF, Brazil; [Santos Silva, Magda Aparecida] Univ Paulista, Sao Paulo, SP, Brazil; [Sousa, Angela Maria] Inst Canc Estado Sao Paulo, Ctr Integrad Tratamento Dor, Sao Paulo, SP, Brazil; [Ashmawi, Hazem Adel] Univ Sao Paulo, Fac Med, Disciplina Anestesiol, Sao Paulo, SP, Brazil	Guimaraes, GMN (reprint author), Inst Canc Estado Sao Paulo, Sao Paulo, SP, Brazil.	gabrielmng@gmail.com	sousa, angela maria/J-8157-2015	sousa, angela maria/0000-0003-1732-9083			Apfel CC, 1999, ANESTHESIOLOGY, V91, P693, DOI 10.1097/00000542-199909000-00022; Benjamini Y, 2001, ANN STAT, V29, P1165; da Silva HBG, 2015, ACTA ANAESTH SCAND, V59, P1145, DOI 10.1111/aas.12552; Dahl JB, 1999, ANESTHESIOLOGY, V91, P1919, DOI 10.1097/00000542-199912000-00045; DELONG ER, 1988, BIOMETRICS, V44, P837, DOI 10.2307/2531595; Franck M, 2010, ANAESTHESIST, V59, P524, DOI 10.1007/s00101-010-1712-z; Gan TJ, 2014, ANESTH ANALG, V118, P85, DOI 10.1213/ANE.0000000000000002; Kooij FO, 2012, BRIT J ANAESTH, V108, P961, DOI 10.1093/bja/aes024; Lim H, 2016, KOREAN J ANESTHESIOL, V69, P51, DOI 10.4097/kjae.2016.69.1.51; Nguefack-Tsague G, 2011, EPIDEMIOL HEALTH, V33, DOI 10.4178/epih/e2011006; Sigaut S, 2010, ANN FR ANESTH, V29, P765, DOI 10.1016/j.annfar.2010.08.004	11	0	0	2	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0034-7094	1806-907X		REV BRAS ANESTESIOL	Rev. Bras. Anestesiol.	JUL-AUG	2019	69	4					342	349		10.1016/j.bjan.2019.03.002			8	Anesthesiology	Anesthesiology	IY3ZY	WOS:000486332500003		DOAJ Gold			2020-06-30	J	Taher-Baneh, N; Ghadamie, N; Sarshivi, F; Sahraie, R; Nasseri, K				Taher-Baneh, Naseh; Ghadamie, Negin; Sarshivi, Farzad; Sahraie, Reza; Nasseri, Karim			Comparison of fentanyl and dexmedetomidine as an adjuvant to bupivacaine for unilateral spinal anesthesia in lower limb surgery: a randomized trial	REVISTA BRASILEIRA DE ANESTESIOLOGIA			Portuguese	Article						Bupivacaine; Dexmedetomidine; Fentanyl; Unilateral spinal anesthesia	DOSE HYPERBARIC BUPIVACAINE; CLONIDINE; METAANALYSIS; OPIOIDS	Background and objectives: One of the disadvantages of unilateral spinal anesthesia is the short duration of post-operative analgesia, which can be addressed by adding adjuvants to local anesthetics. The aim of current study was to compare the effects of adding dexmedetomidine, fentanyl, or saline to bupivacaine on the properties of unilateral spinal anesthesia in patients undergoing calf surgery. Methods: In this double-blind clinical trial, 90 patients who underwent elective calf surgery were randomly divided into three groups. The spinal anesthetic rate in each of the three groups was 1 mL bupivacaine 0.5% (5 mg). In groups BD, BF and BS, 5 mu g of dexmedetomidine, 25 mu g of fentanyl and 0.5 mL saline were added, respectively. The duration of the motor and sensory blocks in both limbs and the rate of pain during 24 h after surgery were calculated. Hemodynamic changes were also measured during anesthesia for up to 90 min. Results: The duration of both of motor and sensory block was significantly longer in dependent limb in the BF (96 and 169 min) and BD (92 and 166 min) groups than the BS (84 and 157 min) group. Visual Analog Scale was significantly lower in the two groups of BF (1.4) and BD (1.3), within 24 h after surgery, than the BS (1.6) group. Conclusions: The addition of fentanyl and dexmedetomidine to bupivacaine in unilateral spinal anesthesia can increase the duration of the motor and sensory block in dependent limb and prolong the duration of postoperative pain. However, fentanyl is more effective than dexmedetomidine. (C) 2019 Sociedade Brasileira de Anestesiologia. Published by Elsevier Editora Ltda.	[Taher-Baneh, Naseh] Kurdistan Univ Med Sci, Sch Med, Dept Anesthesiol, Sanandaj, Iran; [Ghadamie, Negin; Sarshivi, Farzad; Nasseri, Karim] Kurdistan Univ Med Sci, Fac Med, Dept Anesthesiol, Sanandaj, Iran; [Sahraie, Reza] Kurdistan Univ Med Sci, Fac Med, Dept Orthoped Surg, Sanandaj, Iran	Nasseri, K (reprint author), Kurdistan Univ Med Sci, Fac Med, Dept Anesthesiol, Sanandaj, Iran.	nasseri_k@muk.ac.ir					Al-Ghanem SM, 2009, AM J APPL SCI, V6, P882, DOI DOI 10.3844/AJASSP.2009.882.887; Bottros MM, 2014, J PAIN RES, V7, P615, DOI 10.2147/JPR.S37591; Bromage PR, 1978, EPIDURAL ANALGESIA, P144; Carollo DS, 2008, CURR OPIN ANESTHESIO, V21, P457, DOI 10.1097/ACO.0b013e328305e3ef; Casati A, 2004, ANESTH ANALG, V99, P1387, DOI 10.1213/01.ANE.0000132972.61498.F1; Gupta Rajni, 2011, J Anaesthesiol Clin Pharmacol, V27, P339, DOI 10.4103/0970-9185.83678; Henke VG, 2013, ANESTH ANALG, V117, P686, DOI 10.1213/ANE.0b013e31829eeef5; Kanazi GE, 2006, ACTA ANAESTH SCAND, V50, P222, DOI 10.1111/j.1399-6576.2006.00919.x; KANJHAN R, 1995, CLIN EXP PHARMACOL P, V22, P397, DOI 10.1111/j.1440-1681.1995.tb02029.x; Kuusniemi KS, 2000, REGION ANESTH PAIN M, V25, P605, DOI 10.1053/rapm.2000.8500; Li Z, 2015, DRUG RES, V65, P581, DOI 10.1055/s-0034-1395614; Marhofer P, 2016, CURR OPIN ANESTHESIO, V29, P632, DOI 10.1097/ACO.0000000000000364; Nayagam HA, 2014, INDIAN J ANAESTH, V58, P430, DOI 10.4103/0019-5049.138979; Popping DM, 2012, PAIN, V153, P784, DOI 10.1016/j.pain.2011.11.028; Saadalla Ayman Eskander T, 2017, Anesth Essays Res, V11, P554, DOI 10.4103/aer.AER_210_16; Safari Farhad, 2016, Anesth Pain Med, V6, pe26714, DOI 10.5812/aapm.26714; Sudheesh K, 2015, INDIAN J ANAESTH, V59, P648, DOI 10.4103/0019-5049.167485; Sun SJ, 2017, DRUG DES DEV THER, V11, P3413, DOI 10.2147/DDDT.S146092; Tekye SMM, 2014, REV BRAS ANESTESIOL, V64, P173, DOI 10.1016/j.bjane.2013.06.014; Van Tuijl I, 2008, ACTA ANAESTH SCAND, V52, P343, DOI 10.1111/j.1399-6576.2007.01574.x	20	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0034-7094	1806-907X		REV BRAS ANESTESIOL	Rev. Bras. Anestesiol.	JUL-AUG	2019	69	4					369	376		10.1016/j.bjan.2019.03.005			8	Anesthesiology	Anesthesiology	IY3ZY	WOS:000486332500006		DOAJ Gold			2020-06-30	J	Abdullayev, R; Uludag, O; Celik, B				Abdullayev, Ruslan; Uludag, Oznur; Celik, Bulent			Analgesia Nociception Index: assessment of acute postoperative pain	REVISTA BRASILEIRA DE ANESTESIOLOGIA			Portuguese	Article						Analgesia/nociception index; Postoperative pain; Pain assessment	SURGICAL STRESS INDEX; SKIN-CONDUCTANCE; ANALGESIA/NOCICEPTION INDEX; PARAMETER	Background and objectives: Patient self-rating based scales such as Numerical Rating Scale, Visual Analog Scale that is used for postoperative pain assessment may be problematic in geriatric or critically ill patients with communication problems. A method capable of the assessment of pain in objective manner has been searched for years. Analgesia nociception index, which is based on electrocardiographic data reflecting parasympathetic activity, has been proposed for this. In this study we aimed to investigate the effectiveness of analgesia nociception index as a tool for acute postoperative pain assessment. Our hypothesis was that analgesia nociception index may have good correlation with Numerical Rating Scale values. Methods: A total of 120 patients of American Society of Anesthesiologists (ASA) physical status I and II undergoing any surgical procedure under halogenated-based anesthesia with fentanyl or remifentanil were enrolled for the study. At the 15th minute of arrival to the Postoperative Care Unit the patients' pain was rated on a 0-10 point Numerical Rating Scale. The patients' heart rate, blood pressure, and analgesia nociception index scores were simultaneously measured at that time. The correlation between analgesia nociception index, heart rate, blood pressure and Numerical Rating Scale was examined. Results: The study was completed with 107 patients, of which 46 were males (43%). Mean (SD) analgesia nociception index values were significantly higher in patients with initial Numerical Rating Scale < 3, compared with Numerical Rating Scale <= 3 (69.1 [13.4] vs. 58.1 [12.9] respectively, p <0.001). A significant negative linear relationship (r2 = -0.312, p= 0.001) was observed between analgesia nociception index and Numerical Rating Scale. Conclusion: Analgesia nociception index measurements at postoperative period after volatile agent and opioid-based anesthesia correlate well with subjective Numerical Rating Scale scores. (C) 2019 Sociedade Brasileira de Anestesiologia. Published by Elsevier Editora Ltda.	[Abdullayev, Ruslan] Marmara Univ, Med Sch, Anesthesiol & Reanimat Dept, Istanbul, Turkey; [Uludag, Oznur] Adiyaman Univ, Med Sch, Anesthesiol & Reanimat Dept, Adiyaman, Turkey; [Celik, Bulent] Gazi Univ, Fac Sci, Dept Biostat, Ancara, Turkey	Uludag, O (reprint author), Adiyaman Univ, Med Sch, Anesthesiol & Reanimat Dept, Adiyaman, Turkey.	uludagoznur@gmail.com					Aissou M, 2012, ANESTHESIOLOGY, V116, P1006, DOI 10.1097/ALN.0b013e318251d1fb; Ashburn MA, 2012, ANESTHESIOLOGY, V116, P248, DOI 10.1097/ALN.0b013e31823c1030; Boselli E, 2014, BRIT J ANAESTH, V112, P715, DOI 10.1093/bja/aet407; Boselli E, 2013, BRIT J ANAESTH, V111, P453, DOI 10.1093/bja/aet110; GALLETLY DC, 1994, BRIT J ANAESTH, V72, P177, DOI 10.1093/bja/72.2.177; Gerbershagen HJ, 2013, ANESTHESIOLOGY, V118, P934, DOI 10.1097/ALN.0b013e31828866b3; Gruenewald M, 2015, MINERVA ANESTESIOL, V81, P480; Ilies C, 2010, BRIT J ANAESTH, V105, P533, DOI 10.1093/bja/aeq203; Jeanne M, 2012, J CLIN MONIT COMPUT, V26, P289, DOI 10.1007/s10877-012-9354-0; LATSON TW, 1992, J CLIN ANESTH, V4, P265, DOI 10.1016/0952-8180(92)90127-M; Le Guen M, 2012, INT J OBSTET ANESTH, V21, P146, DOI 10.1016/j.ijoa.2012.01.001; Ledowski T, 2006, BRIT J ANAESTH, V97, P862, DOI 10.1093/bja/ael280; Ledowski T, 2005, ANESTH ANALG, V101, P1700, DOI 10.1213/01.ane.0000184041.32175.14; Ledowski T, 2013, BRIT J ANAESTH, V111, P627, DOI 10.1093/bja/aet111; Ledowski T, 2010, ANAESTHESIA, V65, P1001, DOI 10.1111/j.1365-2044.2010.06480.x; Ledowski T, 2009, ANAESTHESIA, V64, P727, DOI 10.1111/j.1365-2044.2008.05834.x; Logier R, 2011, IEEE ENG MED BIO, P3776, DOI 10.1109/IEMBS.2011.6090645; Logier R, 2010, IEEE ENG MED BIO, P1194, DOI 10.1109/IEMBS.2010.5625971; Migeon A, 2013, PEDIATR ANESTH, V23, P1160, DOI 10.1111/pan.12243; Sabourdin N, 2013, PEDIATR ANESTH, V23, P149, DOI 10.1111/pan.12071	20	0	0	1	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0034-7094	1806-907X		REV BRAS ANESTESIOL	Rev. Bras. Anestesiol.	JUL-AUG	2019	69	4					396	402		10.1016/j.bjan.2019.01.003			7	Anesthesiology	Anesthesiology	IY3ZY	WOS:000486332500010		DOAJ Gold			2020-06-30	J	An, GH; Fang, B; Wang, ZM				An, Guanghui; Fang, Bin; Wang, Zhaomin			Comparing the insertion and ventilation of laryngeal mask airway according to the patient's head position and muscle relaxation use A prospective clinical trial	SAUDI MEDICAL JOURNAL			English	Article							FIBEROPTIC SCORING SYSTEM; NECK POSITIONS; INTUBATION; SURGERY	Objectives: To assess the insertion and ventilation of the laryngeal mask airway (LMA) classic while using different head positions with or without muscle relaxant. Methods: This is a double-blind randomized clinical trial. Patients scheduled for ureteral calculus surgery at Shanghai General Hospital, Shanghai, China were recruited between November 2017 and November 2018. A total of 132 adults were consecutively selected. Patients were randomly divided into 4 groups according to head positioning and muscle relaxant use. An 8-cm-high pillow was used to achieve the sniffing position. The insertion time, initial peak pressure (Ppeak), mean pressure (Pmean) of the airway during intermittent positive pressure ventilation (primary endpoint) and fiberoptic score of the LMA position (secondary endpoint) were evaluated via electronic bronchoscopy through the mask bar. All adverse events were recorded. Results: Data were analyzed by ANOVA, 2-way ANOVA, Chi-squared, Cochran-Mantel-Haenszel, and Kruskal-Wallis tests. The insertion time required for the first attempt, fiberoptic score, Ppeak and Pmean did not differ among the groups. However, the incidence of adverse events in groups not using muscle relaxant was higher than in those using muscle relaxant. Conclusion: Use of a sniffing position and muscle relaxant slightly eased the insertion of the LMA but did not affect the fiberoptic score or ventilation parameters. Using a muscle relaxant, but not the sniffing position, reduced the incidence of adverse effects.	[An, Guanghui; Fang, Bin; Wang, Zhaomin] Shanghai Jiao Tong Univ, Sch Med, Shanghai Gen Hosp, Dept Anesthesiol, Shanghai, Peoples R China	Wang, ZM (reprint author), Shanghai Gen Hosp, Dept Anesthesiol, Shanghai, Peoples R China.	494230079@qq.com					Akhtar Mehmooda, 2017, Anesth Essays Res, V11, P762, DOI 10.4103/0259-1162.204206; Akihisa Y, 2015, AM J EMERG MED, V33, P1606, DOI 10.1016/j.ajem.2015.06.049; Aleksandrowicz D, 2018, EMERGENCIAS, V30, P186; Banerjee G, 2018, INDIAN J ANAESTH, V62, P103, DOI 10.4103/ija.IJA_594_17; BRIMACOMBE J, 1993, ANESTH ANALG, V76, P457; Fujiwara A, 2015, J ANESTH, V29, P580, DOI 10.1007/s00540-015-1982-3; Grady DM, 2001, ANESTHESIOLOGY, V94, P760, DOI 10.1097/00000542-200105000-00012; Hagberg CA, 2014, WONDROUSTORY ANEST, P723; Jannu Anubhav, 2017, Arch Craniofac Surg, V18, P223, DOI 10.7181/acfs.2017.18.4.223; Jun JH, 2011, KOREAN J ANESTHESIOL, V60, P244, DOI 10.4097/kjae.2011.60.4.244; Keller C, 2000, ANASTH INTENSIV NOTF, V35, P692, DOI 10.1055/s-2000-8164; Kim H, 2016, AM J EMERG MED, V34, P1855, DOI 10.1016/j.ajem.2016.06.011; Kim MS, 2015, J KOREAN MED SCI, V30, P1197, DOI 10.3346/jkms.2015.30.8.1197; Kong M, 2016, EXP THER MED, V11, P65, DOI 10.3892/etm.2015.2844; Kulnig J, 2018, EUR J PEDIATR, V177, P871, DOI 10.1007/s00431-018-3134-x; Kuna ST, 2000, RESP PHYSIOL, V119, P155, DOI 10.1016/S0034-5687(99)00110-3; Mishra SK, 2015, ANESTHESIOL RES PRAC, V2015, DOI 10.1155/2015/705869; Porhomayon Jahan, 2015, Middle East J Anaesthesiol, V23, P9; Singh A, 2018, INDIAN J ANAESTH, V62, P858, DOI 10.4103/ija.IJA_153_18; Somri M, 2016, BMC ANESTHESIOL, V16, DOI 10.1186/s12871-016-0237-7; Tulgar S, 2017, J PEDIATR SURG, V52, P1705, DOI 10.1016/j.jpedsurg.2017.02.010	21	0	0	0	0	SAUDI MED J	RIYADH	ARMED FORCES HOSPITAL, PO BOX 7897,, RIYADH 11159, SAUDI ARABIA	0379-5284			SAUDI MED J	Saudi Med. J.	JUL	2019	40	7					687	693		10.15537/smj.2019.7.24299			7	Medicine, General & Internal	General & Internal Medicine	IT2BO	WOS:000482652600006	31287129	DOAJ Gold			2020-06-30	J	Tseng, WC; Lin, WL; Lai, HC; Huang, TW; Chen, PH; Wu, ZF				Tseng, Wei-Cheng; Lin, Wei-Lin; Lai, Hou-Chuan; Huang, Tsai-Wang; Chen, Pin-Hsuan; Wu, Zhi-Fu			Fentanyl-based intravenous patient-controlled analgesia with low dose of ketamine is not inferior to thoracic epidural analgesia for acute post-thoracotomy pain following video-assisted thoracic surgery A randomized controlled study	MEDICINE			English	Article						acute postoperative pain; ketamine; patient-controlled analgesia; thoracic epidural analgesia; video-assisted thoracic surgery	ACUTE POSTOPERATIVE PAIN; THORACOSCOPIC SURGERY; ADDING KETAMINE; LUNG-CANCER; LOBECTOMY; MORPHINE; MANAGEMENT; INFUSION; CARE	Background: Thoracic epidural analgesia is the preferred method for postoperative analgesia following thoracic surgery. However, intravenous patient-controlled analgesia (IVPCA) may be an effective alternative. This study was conducted because few scientific reports exist comparing fentanyl-based IVPCA including a low dose of ketamine (fk-IVPCA) with thoracic patient-controlled epidural analgesia (t-PCEA) for the treatment of postoperative pain after video-assisted thoracic surgery (VATS). Methods: This prospective, and randomized study included 70 patients randomized into fk-IVPCA and t-PCEA groups. Pain at rest and during movement, successful and unsuccessful triggers after pressing the PCA device button, the need for rescue analgesia, drug-related adverse events, and patient satisfaction were recorded for 48 hours postoperatively. Results: No significant differences in the intensity of pain at rest or during movement were observed between the 2 groups within 48 hours postoperatively. The number of unsuccessful PCA triggers in the t-PCEA group 0 to 4 hours after surgery was significantly higher than that in the fk-IVPCA group. However, the numbers of successful PCA triggers in the fk-IVPCA group at 4 to 12 and 0 to 24 hours after surgery were significantly higher than those in the t-PCEA group. The incidence of analgesic-related side effects and patient satisfaction were similar in both groups. Conclusions: Compared with t-PCEA, the addition of a subanesthetic dose of ketamine to fentanyl-based IVPCA resulted in similar pain control after VATS with no increase in the incidence of drug-related adverse effects. The results confirm that both multimodal intravenous analgesia and epidural analgesia can provide sufficient pain control and are safe strategies for treating acute post-thoracotomy pain.	[Tseng, Wei-Cheng; Lin, Wei-Lin; Lai, Hou-Chuan; Chen, Pin-Hsuan; Wu, Zhi-Fu] Triserv Gen Hosp, Dept Anesthesiol, Tainan, Taiwan; [Huang, Tsai-Wang] Triserv Gen Hosp, Div Chest Surg, Dept Surg, Tainan, Taiwan; [Huang, Tsai-Wang] Natl Def Med Ctr, Tainan, Taiwan; [Chen, Pin-Hsuan] Natl Def Med Ctr, Grad Inst Publ Hlth, Tainan, Taiwan; [Wu, Zhi-Fu] Chi Mei Med Ctr, Dept Anesthesiol, 901 Zhonghua Rd, Tainan 71004, Taiwan	Wu, ZF (reprint author), Chi Mei Med Ctr, Dept Anesthesiol, 901 Zhonghua Rd, Tainan 71004, Taiwan.	aneswu@gmail.com					Bendixen M, 2016, LANCET ONCOL, V17, P836, DOI 10.1016/S1470-2045(16)00173-X; Bialka S, 2018, J THORAC DIS, V10, DOI 10.21037/jtd.2018.07.88; Brinck EC, 2018, COCHRANE DB SYST REV, V12; Carstensen M, 2010, BRIT J ANAESTH, V104, P401, DOI 10.1093/bja/aeq041; El-Tahan MR, 2017, J CARDIOTHOR VASC AN, V31, P1417, DOI 10.1053/j.jvca.2016.09.010; Elmore B, 2015, THORAC SURG CLIN, V25, P393, DOI 10.1016/j.thorsurg.2015.07.005; Falcoz PE, 2016, EUR J CARDIO-THORAC, V49, P602, DOI 10.1093/ejcts/ezv154; Grass JA, 2005, ANESTH ANALG, V101, pS44, DOI 10.1213/01.ANE.0000177102.11682.20; Kamiyoshihara Mitsuhiro, 2010, Asian Cardiovasc Thorac Ann, V18, P464, DOI 10.1177/0218492310381817; Kim JA, 2009, J KOREAN MED SCI, V24, P930, DOI 10.3346/jkms.2009.24.5.930; Kupersztych-Hagege E, 2017, J CARDIOTHOR VASC AN, V31, P446, DOI 10.1053/j.jvca.2016.07.022; Laursen LO, 2016, EUR J CARDIO-THORAC, V49, P870, DOI 10.1093/ejcts/ezv205; Lee CY, 2018, J THORAC DIS, V10, P3814, DOI 10.21037/jtd.2018.05.161; Mathews TJ, 2012, INTERACT CARDIOV TH, V14, P194, DOI 10.1093/icvts/ivr081; McNicol ED, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003348.pub3; Niu ZJ, 2018, THORAC CANCER, V9, P1174, DOI 10.1111/1759-7714.12820; Obuchi T, 2017, J THORAC DIS, V9, P4347, DOI 10.21037/jtd.2017.09.133; Rodriguez-Aldrete D, 2016, J CARDIOTHOR VASC AN, V30, P762, DOI 10.1053/j.jvca.2015.07.029; Steinthorsdottir KJ, 2014, EUR J CARDIO-THORAC, V45, P959, DOI 10.1093/ejcts/ezt525; Tiippana E, 2014, SCAND J PAIN, V5, P240, DOI 10.1016/j.sjpain.2014.07.001; von Hosslin T, 2016, EUR J ANAESTH, V33, P708, DOI 10.1097/EJA.0000000000000446; Wang L, 2016, CAN J ANESTH, V63, P311, DOI 10.1007/s12630-015-0551-4; Wu CL, 2005, ANESTHESIOLOGY, V103, P1079, DOI 10.1097/00000542-200511000-00023; Yie Jr-Chi, 2012, Acta Anaesthesiol Taiwan, V50, P92, DOI 10.1016/j.aat.2012.08.004	24	1	1	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0025-7974	1536-5964		MEDICINE	Medicine (Baltimore)	JUL	2019	98	28							e16403	10.1097/MD.0000000000016403			8	Medicine, General & Internal	General & Internal Medicine	IQ4RU	WOS:000480738900063	31305450	DOAJ Gold, Green Published			2020-06-30	J	Grafinger, KE; Bernhard, W; Weinmann, W				Grafinger, Katharina Elisabeth; Bernhard, Werner; Weinmann, Wolfgang			Scheduling of new psychoactive substance the Swiss way: A review and critical analysis	SCIENCE & JUSTICE			English	Review						New psychoactive substances; Scheduling; Narcotics law; BetmVV-EDI; SR 812.121.11	POLICY; DECRIMINALIZATION	Since the introduction of the European Early Warning System in 2005, > 700 new psychoactive substances (NPS) have been listed. This review article presents for the first time the Swiss narcotic law in perspective of scheduling of NPS, and compares it to the regulations of the German speaking neighbours Austria and Germany. The Swiss way is a fast and effective way for scheduling NPS, with the purpose to restrict drug trafficking and for controlling the NPS drug market: the legal basis for scheduling substances of abuse is the "Law about narcotics and psychotropic substances" (BetmG, SR 812.121), which includes the "narcotic law directory (BetmVV-EDI, SR 812.121.11) suitable for listing all controlled substances. The BetmVV-EDI, SR 812.121.11 contains seven indices, with index e specifically designed for the fast scheduling of NPS. Newly appearing NPS can either be controlled under a structure analogues definition or by listing single substances. The list of single substances is updated at least once per year, and structure analogues definitions can be implemented, in order to keep track with new developments on the NPS market. The latest version from November 30th 2018 contains ten different structure analogue definitions and 207 single substances. Requirements to list NPS are their appearance on the NPS market, suspected psychotropic effects and their suggestions by Forensic professionals. As soon as substances are newly placed, on Schedule I of the 1961 Convention or Schedule II of the 1971 Convention by the Commission on Narcotic Drugs of the World Health Organization they can easily be transferred from index e to index a-d of the BetmVV-EDI, SR 812.121.11. The Austrian law uses a structure analogue and single substances approach (introduced in 2012, one update in 2016), whereas the German NPS law (established in 2016, no update yet) only lists two structure-analogue-definitions. All three legislations have defined which core structures, kinds and sites of substitutions are regulated.	[Grafinger, Katharina Elisabeth; Bernhard, Werner; Weinmann, Wolfgang] Univ Bern, Inst Forens Med Forens Toxicol & Chem, Bern, Switzerland; [Grafinger, Katharina Elisabeth] Univ Bern, Grad Sch Cellular & Biomed Sci, Bern, Switzerland	Grafinger, KE (reprint author), Inst Forens Med, Buhlstr 20, CH-3012 Bern, Switzerland.	katharina.grafinger@insel.ch			Swiss Federal Office of Public Health [15.029013]	This research received financial support by the Swiss Federal Office of Public Health (BAG project No. 15.029013).	Allemann D, 2010, CHIMIA, V64, P668, DOI 10.2533/chimia.2010.668; Angerer V, 2018, DRUG TEST ANAL, V10, P597, DOI 10.1002/dta.2237; Astrand A, 2019, ARCH TOXICOL, V93, P95, DOI 10.1007/s00204-018-2330-9; Auwarter V, 2009, J MASS SPECTROM, V44, P832, DOI 10.1002/jms.1558; Chatwin C, 2017, INT J DRUG POLICY, V40, P111, DOI 10.1016/j.drugpo.2016.11.002; Corazza O, 2017, NOVEL PSYCHOACTIVE S; Coulson C, 2012, ADDICTION, V107, P766, DOI 10.1111/j.1360-0443.2011.03697.x; Csete J, 2012, INT J DRUG POLICY, V23, P82, DOI 10.1016/j.drugpo.2011.07.011; EDI, 2017, BUND BET PSYCH STOFF; EDI, 2017, VER EDI VERZ BET PSY; EMCCDA, 2018, EUR JOINT REP NEW PS; EMCDDA, 2010, RISK ASS NEW PSYCH S, P92; EMCDDA, 2017, EUR DRUG REP 2017 TR; EMCDDA, 2017, GERM COUNTR DRUG REP, P21; EMCDDA, 2017, AUSTR COUNTR DRUG RE; EMCDDA Eurojust, 2016, NEW PSYCH SUBST EUR, P30; European-Commission, 2011, COM689 EUR COMM; Felix S, 2017, INT J DRUG POLICY, V39, P121, DOI 10.1016/j.drugpo.2016.10.014; Hughes CE, 2010, BRIT J CRIMINOL, V50, P999, DOI 10.1093/bjc/azq038; Humair T., 2011, DEPENDANCES, V42, P23; Khan R, 2014, EUR ADDICT RES, V20, P200, DOI 10.1159/000357234; Maier L. J., 2017, 5 INT C NOV PSYCH SU; Reuter P, 2017, INT J DRUG POLICY, V40, P117, DOI 10.1016/j.drugpo.2016.10.020; UNODC, 2013, CHALL NEW PSYCH SUBS; Winstock AR, 2010, ADDICTION, V105, P1685, DOI 10.1111/j.1360-0443.2010.03163.x	25	0	0	3	4	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1355-0306	1876-4452		SCI JUSTICE	Sci. Justice	JUL	2019	59	4					459	466		10.1016/j.scijus.2019.03.005			8	Medicine, Legal; Pathology	Legal Medicine; Pathology	IJ2IN	WOS:000475721600012	31256819				2020-06-30	J	Farzi, F; Mehrafza, M; Mirmansouri, A; Sorouri, ZZ; Roushan, ZA; Raoufi, A; Shalkohi, R; Samadnia, S; Hosseini, A				Farzi, Farnoush; Mehrafza, Marzieh; Mirmansouri, Ali; Sorouri, Ziba Zahiri; Roushan, Zahra Atrkar; Raoufi, Azadeh; Shalkohi, Reyhane; Samadnia, Sajedeh; Hosseini, Ahmad			Hemodynamic parameters and reproductive outcome after intracytoplasmic sperm injection and fresh embryo transfer in patients undergoing oocyte retrieval with general anesthesia using fentanyl, remifentanil or alfentanil - A randomized clinical trial	TAIWANESE JOURNAL OF OBSTETRICS & GYNECOLOGY			English	Article						Alfentanil; Fentanyl; Remifentanil; General anesthesia; Intracytoplasmic sperm injections	FOLLICULAR-FLUID; FERTILIZATION; ANALGESIA; SEDATION; TECHNOLOGIES; IMPACT	Objective: Anesthesia for assisted reproductive technology is very important to provide less stressful and painful environment for patients, with minimal side effects on oocytes. In the present study, we aimed to evaluate hemodynamic parameters, recovery time and intracytoplasmic sperm injection (ICSI) outcome among patients underwent anesthesia with fentanyl, remifentanil or alfentanil. Material and methods: This randomized double-blinded clinical trial was conducted in patients undergoing anesthesia for transvaginal ultrasound guided oocyte retrieval (TUGOR). Patients were randomly allocated to alfentanil (A; 15 mu g/kg), fentanyl (F; 1.5 mu g/kg) or remifentanil (R; 1.5 mu g/kg) groups. Results: Three hundred forty patients were assessed for eligibility and randomized for transvaginal oocyte retrieval following general anesthesia and 105 were lost to follow up. No statistically significant differences were noted among groups regarding basic characteristics. Although, time to respond to verbal command was significantly different among groups (A: 1.99 +/- 1.64, F: 2.56 +/- 1.72, R: 1.78 +/- 1.34, P = 0.014). There were no significant differences among groups with respect to the first and second postoperative pain intensity, patient satisfaction, pre-induction and post-induction systolic and diastolic blood pressure (BP). Terminal systolic (A: 101.61 +/- 9.15, F: 105.29 +/- 12.61, R: 102 +/- 12.91, P = 0.01) and diastolic (A: 59.97 +/- 9, F: 65.63 +/- 9.13, R: 63.69 +/- 11.01, P = 0.003) BP was significantly different among groups. The fertilization rate was significantly different among groups (A: 51.6%, F: 54.4%, R: 62.2%, P = 0.018). Implantation rate, biochemical and clinical pregnancy rate was similar among groups. Conclusions: The results of present study demonstrated that all three opioids have the same efficiency, in regards to patient satisfaction and pregnancy outcome. However, Anesthesia with alfentanil compared with fentanyl and remifentanil, seems to be inferior for TUGOR due to higher effect on fertilization rate and less hemodynamic stability. (C) 2019 Taiwan Association of Obstetrics & Gynecology. Publishing services by Elsevier B.V.	[Farzi, Farnoush; Mirmansouri, Ali; Sorouri, Ziba Zahiri; Roushan, Zahra Atrkar] Guilan Univ Med Sci, Alzahra Hosp, Anesthesia Res Ctr, Dept Anesthesiol, Namjoo St, Rasht, Iran; [Mehrafza, Marzieh; Raoufi, Azadeh; Shalkohi, Reyhane; Samadnia, Sajedeh; Hosseini, Ahmad] Guilan Univ Med Sci, Mehr Fertil Res Ctr, Mehr Med Inst, Ershad St,Shahid Ansari Blvd, Rasht, Iran	Mirmansouri, A (reprint author), Guilan Univ Med Sci, Alzahra Hosp, Anesthesia Res Ctr, Dept Anesthesiol, Namjoo St, Rasht, Iran.	farnoushfarzi1374@gmail.com; marzieh.mehrafza@gmail.com; mirmansoori.ali@gmail.com; drzibazahiri@yahoo.com; atrkarroushan@gmail.com; az.raoufi@gmail.com; reyhane.t.sh@gmail.com; s.samadnia@gmail.com; prof_hosseini@yahoo.com	MIRMANSOURI, Ali/AAF-7293-2019	MIRMANSOURI, Ali/0000-0001-8818-4083			Azmude Azra, 2013, Anesth Pain Med, V3, P239, DOI 10.5812/aapm.11223; Casati A, 1999, EUR J ANAESTH, V16, P773, DOI 10.1046/j.1365-2346.1999.00584.x; Christiaens F, 1999, HUM REPROD, V14, P345, DOI 10.1093/humrep/14.2.345; COETSIER T, 1992, HUM REPROD, V7, P1422, DOI 10.1093/oxfordjournals.humrep.a137586; Gejervall AL, 2010, EUR J OBSTET GYN R B, V150, P66, DOI 10.1016/j.ejogrb.2010.01.007; GONEN O, 1995, J ASSIST REPROD GEN, V12, P678, DOI 10.1007/BF02212892; Hammadeh ME, 1999, ARCH GYNECOL OBSTET, V263, P56, DOI 10.1007/s004040050263; Jarahzadeh MH, 2011, INT J FERTIL STERIL, V5, P86; Kim JY, 2008, ANAESTHESIA, V63, P495, DOI 10.1111/j.1365-2044.2007.05414.x; Komatsu R, 2007, ANAESTHESIA, V62, P1266, DOI 10.1111/j.1365-2044.2007.05221.x; Kwan I, 2006, HUM REPROD, V21, P1672, DOI 10.1093/humrep/del002; Matsota Paraskevi, 2012, Middle East Journal of Anesthesiology, V21, P685; Minto CF, 1997, ANESTHESIOLOGY, V86, P24, DOI 10.1097/00000542-199701000-00005; Piroli A, 2012, GYNECOL ENDOCRINOL, V28, P796, DOI 10.3109/09513590.2012.664193; Rolland L, 2017, J ASSIST REPROD GEN, V34, P1523, DOI 10.1007/s10815-017-1002-7; Saleh SE, 2012, MIDDLE EAST FERTIL S, V17, P256, DOI 10.1016/j.mefs.2012.07.003; SOUSSIS I, 1995, FERTIL STERIL, V64, P1003, DOI 10.1016/S0015-0282(16)57919-9; VANDERVEN HH, 1988, HUM REPROD, V3, P85, DOI 10.1093/oxfordjournals.humrep.a136659; Vardanyan RS, 2014, FUTURE MED CHEM, V6, P385, DOI 10.4155/fmc.13.215; Vlahos NF, 2009, INT J GYNECOL OBSTET, V105, P201, DOI 10.1016/j.ijgo.2009.01.017; Wilhelm W, 2002, J CLIN ANESTH, V14, P1, DOI 10.1016/S0952-8180(01)00331-2	21	0	0	4	4	ELSEVIER TAIWAN	TAIPEI	RM N-412, 4F, CHIA HSIN BUILDING 11, NO 96, ZHONG SHAN N ROAD SEC 2, TAIPEI, 10449, TAIWAN	1028-4559			TAIWAN J OBSTET GYNE	Taiwan. J. Obstet. Gynecol.	JUL	2019	58	4					536	540		10.1016/j.tjog.2019.05.019			5	Obstetrics & Gynecology	Obstetrics & Gynecology	II8FE	WOS:000475427000019	31307747	DOAJ Gold			2020-06-30	J	Bedocs, P; Evers, DL; Buckenmaier, CC				Bedocs, Peter; Evers, David L.; Buckenmaier, Chester C., III			Predosing Chemical Stability of Admixtures of Propofol, Ketamine, Fentanyl, and Remifentanil	ANESTHESIA AND ANALGESIA			English	Article							PROCEDURAL SEDATION; COMBINATION; COMPATIBILITY; KETOFOL; ANALGESIA; LIDOCAINE	Admixtures of propofol-ketamine, propofol-ketamine-fentanyl, and propofol-ketamine-remifentanil were subjected to various clinically relevant conditions to study their chemical stability. A novel high-performance liquid chromatography-mass spectrometry method revealed no degradation of any compound by incubation at 37 degrees C, constant mixing, or table-top storage for 6- and 24-hour time periods, except variable recovery of both propofol and fentanyl in the admixtures of propofol-ketamine-fentanyl suggesting possible degradation.	[Bedocs, Peter; Buckenmaier, Chester C., III] Henry M Jackson Fdn, Def & Vet Ctr Integrat Pain Management, 11300 Rockville Pike,Suite 709, Rockville, MD 20852 USA; [Buckenmaier, Chester C., III] Uniformed Serv Univ Hlth Sci, Bethesda, MD USA; [Evers, David L.] Walter Reed Natl Mil Med Ctr, Bethesda, MD USA	Bedocs, P (reprint author), Henry M Jackson Fdn, Def & Vet Ctr Integrat Pain Management, 11300 Rockville Pike,Suite 709, Rockville, MD 20852 USA.	peter.bedocs.ctr@usuhs.edu			US Army Medical Research and Materiel CommandU.S. Army Medical Research & Materiel Command (USAMRMC)	US Army Medical Research and Materiel Command.	Alves HC, 2007, LAB ANIM-UK, V41, P329, DOI 10.1258/002367707781282767; Andolfatto G, 2011, ACAD EMERG MED, V18, P237, DOI 10.1111/j.1553-2712.2011.01010.x; Baker MT, 2005, ANESTHESIOLOGY, V103, P860, DOI 10.1097/00000542-200510000-00026; Frizelle HP, 1997, ANESTH ANALG, V84, P1318, DOI 10.1097/00000539-199706000-00026; Godwin SA, 2014, ANN EMERG MED, V63, P247, DOI 10.1016/j.annemergmed.2013.10.015; Haytural C, 2015, BIOMED RES INT, DOI 10.1155/2015/465465; Jalili M, 2016, AM J EMERG MED, V34, P558, DOI 10.1016/j.ajem.2015.12.074; Kanji S, 2010, CRIT CARE MED, V38, P1890, DOI 10.1097/CCM.0b013e3181e8adcc; Masaki Y, 2003, ANESTH ANALG, V97, P1646, DOI 10.1213/01.ANE.0000087802.50796.FB; Nalini KB, 2014, J CLIN DIAGN RES, V8, pGC1, DOI 10.7860/JCDR/2014/8144.4393; Nemec K, 2009, PHARMAZIE, V64, P94, DOI 10.1691/ph.2008.8161; Park JW, 2003, ANESTH ANALG, V97, P769, DOI 10.1213/01.ANE.0000074797.70349.CA; Slavik VC, 2007, PHARMACOTHERAPY, V27, P1588, DOI 10.1592/phco.27.11.1588; Smischney NJ, 2012, J TRAUMA ACUTE CARE, V73, P94, DOI 10.1097/TA.0b013e318250cdb8; Smith WD, 2009, AM J HEALTH-SYST PH, V66, P1369, DOI 10.2146/ajhp080373; Stewart JT, 2000, ANESTH ANALG, V90, P1450, DOI 10.1097/00000539-200006000-00037; Sun MY, 2006, DIS COLON RECTUM, V49, P1059, DOI 10.1007/s10350-006-0572-8; United States Pharmacopeial Convention, 2003, US PHARM NAT FORM US; Yalcin S, 2012, J ANESTH, V26, P562, DOI 10.1007/s00540-012-1378-6	19	2	2	1	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	JUL	2019	129	1					E13	E15		10.1213/ANE.0000000000003772			3	Anesthesiology	Anesthesiology	IH0TX	WOS:000474206500004	30286006				2020-06-30	J	Ellis, CR; Racz, R; Kruhlak, NL; Kim, MT; Hawkins, EG; Strauss, DG; Stavitskaya, L				Ellis, Christopher R.; Racz, Rebecca; Kruhlak, Naomi L.; Kim, Marlene T.; Hawkins, Edward G.; Strauss, David G.; Stavitskaya, Lidiya			Assessing the Structural and Pharmacological Similarity of Newly Identified Drugs of Abuse to Controlled Substances Using Public Health Assessment via Structural Evaluation	CLINICAL PHARMACOLOGY & THERAPEUTICS			English	Article							OPIOID RECEPTOR; FENTANYL; SEROTONIN; BINDING	The US Food and Drug Administration's Center for Drug Evaluation and Research (CDER) developed an investigational Public Health Assessment via Structural Evaluation (PHASE) methodology to provide a structure-based evaluation of a newly identified opioid's risk to public safety. PHASE utilizes molecular structure to predict biological function. First, a similarity metric quantifies the structural similarity of a new drug relative to drugs currently controlled in the Controlled Substances Act (CSA). Next, software predictions provide the primary and secondary biological targets of the new drug. Finally, molecular docking estimates the binding affinity at the identified biological targets. The multicomponent computational approach coupled with expert review provides a rapid, systematic evaluation of a new drug in the absence of in vitro or in vivo data. The information provided by PHASE has the potential to inform law enforcement agencies with vital information regarding newly emerging illicit opioids.	[Ellis, Christopher R.; Racz, Rebecca; Kruhlak, Naomi L.; Kim, Marlene T.; Strauss, David G.; Stavitskaya, Lidiya] US FDA, Div Appl Regulatory Sci, Off Clin Pharmacol, Off Translat Sci,Ctr Drug Evaluat & Res, Silver Spring, MD 20993 USA; [Hawkins, Edward G.] US FDA, Controlled Subst Staff, Ctr Drug Evaluat & Res, Silver Spring, MD USA	Stavitskaya, L (reprint author), US FDA, Div Appl Regulatory Sci, Off Clin Pharmacol, Off Translat Sci,Ctr Drug Evaluat & Res, Silver Spring, MD 20993 USA.	Lidiya.Stavitskaya@fda.hhs.gov		Racz, Rebecca/0000-0002-5487-5692	US Food and Drug Administration (FDA)	The work was internally funded by the US Food and Drug Administration (FDA).	[Anonymous], 2017, MOL OP ENV MOE; Ashok AH, 2017, MOL PSYCHIATR, V22, P666, DOI 10.1038/mp.2017.16; Berman BD, 2011, NEUROHOSPITALIST, V1, P41, DOI 10.1177/1941875210386491; Calderon SN, 2014, NEUROPHARMACOLOGY, V87, P97, DOI 10.1016/j.neuropharm.2014.04.001; Carhart-Harris RL, 2017, J PSYCHOPHARMACOL, V31, P1091, DOI 10.1177/0269881117725915; CHEN JC, 1993, LIFE SCI, V52, P389, DOI 10.1016/0024-3205(93)90152-S; Drug Enforcement Administration, 2017, ANN ENF THREAT REP; Drug Enforcement Administration Department of Justice, 2017, Fed Regist, V82, P20544; Ellis CR, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0197734; Eshleman AJ, 2017, J PHARMACOL EXP THER, V360, P33, DOI 10.1124/jpet.116.236349; Eshleman AJ, 2013, BIOCHEM PHARMACOL, V85, P1803, DOI 10.1016/j.bcp.2013.04.004; Frank RG, 2017, NEW ENGL J MED, V376, P605, DOI 10.1056/NEJMp1615145; Garcia-Serna R, 2015, CHEM RES TOXICOL, V28, P1875, DOI 10.1021/acs.chemrestox.5b00260; Gaulton A, 2017, NUCLEIC ACIDS RES, V45, pD945, DOI 10.1093/nar/gkw1074; Huang WJ, 2015, NATURE, V524, P315, DOI 10.1038/nature14886; Jain AN, 2006, CURR PROTEIN PEPT SC, V7, P407, DOI 10.2174/138920306778559395; JANSSEN PAJ, 1982, ACTA ANAESTH SCAND, V26, P262, DOI 10.1111/j.1399-6576.1982.tb01765.x; Keiser MJ, 2007, NAT BIOTECHNOL, V25, P197, DOI 10.1038/nbt1284; Keiser MJ, 2009, NATURE, V462, P175, DOI 10.1038/nature08506; Kieffer BL, 1999, TRENDS PHARMACOL SCI, V20, P19, DOI 10.1016/S0165-6147(98)01279-6; Lalanne L, 2014, FRONT PSYCHIATRY, V5, DOI 10.3389/fpsyt.2014.00170; Li P, 2016, CURR TOP MED CHEM, V16, P3385, DOI 10.2174/1568026616666160608084834; Meng XY, 2011, CURR COMPUT-AID DRUG, V7, P146; Morris Garrett M., 2008, V443, P365, DOI 10.1007/978-1-59745-177-2_19; Price TE, 2017, SECRETARY PRICE ANNO; Rudd RA, 2016, MMWR-MORBID MORTAL W, V65, P1445, DOI 10.15585/mmwr.mm655051e1; Sanguinetti MC, 2006, NATURE, V440, P463, DOI 10.1038/nature04710; Smith SW, 2009, TOXICOL SCI, V110, P4, DOI 10.1093/toxsci/kfp097; Throckmorton DC, 2018, NEW ENGL J MED, V379, P205, DOI 10.1056/NEJMp1806486; TRAYNOR JR, 1995, MOL PHARMACOL, V47, P848; United Nations Office on Drugs and Crime, 2017, US DRUG ENF ADM ISS; United Nations Office on Drugs and Crime, 2017, FENT ITS AN 50 YEARS; Vardanyan RS, 2014, FUTURE MED CHEM, V6, P385, DOI 10.4155/fmc.13.215; Vicente-Sanchez A, 2016, NEUROSCIENCE, V338, P145, DOI 10.1016/j.neuroscience.2016.06.028; Volpe DA, 2011, REGUL TOXICOL PHARM, V59, P385, DOI 10.1016/j.yrtph.2010.12.007; Volpi-Abadie J, 2013, OCHSNER J, V13, P533; Vuckovic S, 2009, CURR MED CHEM, V16, P2468, DOI 10.2174/092986709788682074; Willett P, 1998, J CHEM INF COMP SCI, V38, P983, DOI 10.1021/ci9800211	38	5	5	1	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0009-9236	1532-6535		CLIN PHARMACOL THER	Clin. Pharmacol. Ther.	JUL	2019	106	1					116	122		10.1002/cpt.1418			7	Pharmacology & Pharmacy	Pharmacology & Pharmacy	IG8EN	WOS:000474029300027	30957872	Other Gold, Green Published			2020-06-30	J	Gewandter, JS; McDermott, MP; He, H; Gao, S; Cai, XY; Farrar, JT; Katz, NP; Markman, JD; Senn, S; Turk, DC; Dworkin, RH				Gewandter, Jennifer S.; McDermott, Michael P.; He, Hua; Gao, Shan; Cai, Xueya; Farrar, John T.; Katz, Nathaniel P.; Markman, John D.; Senn, Stephen; Turk, Dennis C.; Dworkin, Robert H.			Demonstrating Heterogeneity of Treatment Effects Among Patients: An Overlooked but Important Step Toward Precision Medicine	CLINICAL PHARMACOLOGY & THERAPEUTICS			English	Article							DOUBLE-BLIND; VARIANCE-COMPONENTS; RANDOMIZED-TRIALS; BREAKTHROUGH PAIN; CLINICAL-TRIAL; N-OF-1 TRIALS; CANCER; EFFICACY; SPRAY	Although heterogeneity in the observed outcomes in clinical trials is often assumed to reflect a true heterogeneous response, it could actually be due to random variability. This retrospective analysis of four randomized, double-blind, placebo-controlled multiperiod (i.e., episode) crossover trials of fentanyl for breakthrough cancer pain illustrates the use of multiperiod crossover trials to examine heterogeneity of treatment response. A mixed-effects model, including fixed effects for treatment and episode and random effects for patient and treatment-by-patient interaction, was used to assess the heterogeneity in patients' responses to treatment during each episode. A significant treatment-by-patient interaction was found for three of four trials (P < 0.05), suggesting heterogeneity of the effect of fentanyl among different patients in each trial. Similar analyses in other therapeutic areas could identify conditions and therapies that should be investigated further for predictors of treatment response in efforts to maximize the efficiency of developing precision medicine strategies.	[Gewandter, Jennifer S.; Dworkin, Robert H.] Univ Rochester, Dept Anesthesiol & Perioperat Med, Rochester, NY 14627 USA; [McDermott, Michael P.; Gao, Shan; Cai, Xueya] Univ Rochester, Dept Biostat & Computat Biol, Rochester, NY USA; [He, Hua] Tulane Univ, Dept Epidemiol, New Orleans, LA 70118 USA; [Farrar, John T.] Univ Penn, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA; [Katz, Nathaniel P.] Analges Solut, Natick, MA USA; [Katz, Nathaniel P.] Tufts Univ, Sch Med, Boston, MA 02111 USA; [Markman, John D.] Univ Rochester, Dept Neurosurg, Rochester, NY USA; [Senn, Stephen] Luxembourg Inst Hlth, Strassen, Luxembourg; [Turk, Dennis C.] Univ Washington, Dept Anesthesiol & Pain Med, Seattle, WA 98195 USA	Gewandter, JS (reprint author), Univ Rochester, Dept Anesthesiol & Perioperat Med, Rochester, NY 14627 USA.	jennifer_gewandter@urmc.rochester.edu			ACTTION public-private partnership from the FDA	Financial support for this project was provided by the ACTTION public-private partnership, which has received unrestricted research contracts, grants, or other revenue from the FDA, multiple pharmaceutical and device companies, philanthropy, and other sources.	Araujo A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167167; Demant DT, 2014, PAIN, V155, P2263, DOI 10.1016/j.pain.2014.08.014; Dworkin RH, 2014, PAIN, V155, P457, DOI 10.1016/j.pain.2013.09.019; European Medicines Agency, 2014, GUID INV SUBGR CONF; GUYATT GH, 1990, ANN INTERN MED, V112, P293, DOI 10.7326/0003-4819-112-4-293; GUYATT GH, 1990, CONTROL CLIN TRIALS, V11, P88, DOI 10.1016/0197-2456(90)90003-K; Herrett E, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-016604; Lillie EO, 2011, PERS MED, V8, P161, DOI 10.2217/PME.11.7; Lonergan M, 2017, DRUG DISCOV TODAY, V22, P173, DOI 10.1016/j.drudis.2016.10.016; Mahon J, 1996, BRIT MED J, V312, P1069; Mallal S, 2008, NEW ENGL J MED, V358, P568, DOI 10.1056/NEJMoa0706135; Moore RA, 2014, EUR J PAIN, V18, P67, DOI 10.1002/j.1532-2149.2013.00341.x; Moore RA, 2010, PAIN, V149, P173, DOI 10.1016/j.pain.2009.08.007; Morrell CH, 1998, BIOMETRICS, V54, P1560, DOI 10.2307/2533680; National Cancer Institute, PREC MED CANC TREATM; Portenoy RK, 2006, CLIN J PAIN, V22, P805, DOI 10.1097/01.ajp.0000210932.27945.4a; Portenoy RK, 2010, PAIN, V151, P617, DOI 10.1016/j.pain.2010.07.028; Punja S, 2016, TRIALS, V17, DOI 10.1186/s13063-016-1499-6; Rauck R, 2010, ANN ONCOL, V21, P1308, DOI 10.1093/annonc/mdp541; Rauck R, 2012, CURR MED RES OPIN, V28, P859, DOI 10.1185/03007995.2012.683111; Senn S, 2004, BMJ-BRIT MED J, V329, P966, DOI 10.1136/bmj.329.7472.966; Senn S, 2016, STAT MED, V35, P966, DOI 10.1002/sim.6739; Senn Stephen, 2011, Stat Methods Med Res, V20, P657, DOI 10.1177/0962280210379174; STRAM DO, 1994, BIOMETRICS, V50, P1171, DOI 10.2307/2533455; Viechtbauer W, 2010, J STAT SOFTW, V36, P1, DOI 10.18637/jss.v036.i03; Yelland MJ, 2007, RHEUMATOLOGY, V46, P135, DOI 10.1093/rheumatology/kel195; Yelland MJ, 2009, PAIN MED, V10, P754, DOI 10.1111/j.1526-4637.2009.00615.x; Zucker DR, 2006, J RHEUMATOL, V33, P2069	28	1	1	1	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0009-9236	1532-6535		CLIN PHARMACOL THER	Clin. Pharmacol. Ther.	JUL	2019	106	1					204	210		10.1002/cpt.1372			7	Pharmacology & Pharmacy	Pharmacology & Pharmacy	IG8EN	WOS:000474029300036	30661240				2020-06-30	J	Olding, M; Werb, D; Guise, A; Small, W; McNeil, R				Olding, Michelle; Werb, Dan; Guise, Andy; Small, Will; McNeil, Ryan			Navigating social norms of injection initiation assistance during an overdose crisis: A qualitative study of the perspectives of people who inject drugs (PWID) in Vancouver, Canada	INTERNATIONAL JOURNAL OF DRUG POLICY			English	Article						Injection initiation; Injection drug use; People who inject drugs; Fentanyl	MIXED METHODS RESEARCH; NEW-YORK-CITY; HIV RISK; HEROIN; USERS; YOUNG; CIRCUMSTANCES; FENTANYL; CONTEXT; ROUTES	Despite the proliferation of fentanyl and fentanyl-adulterated opioids in North America, the impacts of this drug market change on injection initiation processes have not been examined. With the aim of informing structural interventions to address injection initiation and related harms, we explore how people who inject drugs (PWID) in Vancouver, Canada understand and navigate social norms of initiating others into injecting within the context of an overdose crisis. In-depth qualitative interviews were conducted with 19 PWID who reported helping someone inject for the first time. Participants were recruited from two cohort studies of PWID. Participants articulated moral dilemmas about assisting others with injecting. While participants described a 'moral code' prohibiting assisting injection-naive individuals, this code was not the sole consideration shaping social action around injection initiation. Rather, PWID exercised agency about whether and how to assist novice injectors within the context of constraining and enabling social norms around practicing interpersonal responsibility. Changes to the drug market heightened feelings of moral culpability and criminal liability among PWID who assisted others into injection, given that injecting heightened initiates' risk of overdose. These concerns operated in tension with the aim of protecting novice injectors from harms associated with an increasingly potent and unpredictable drug supply by providing them with injection assistance, education and supervision. Our analysis of how PWID practice interpersonal responsibility helps conceptualise how 'moral codes' prohibiting initiation assistance are managed and negotiated amidst structural vulnerability. Structural interventions reducing the vulnerability of novice injectors should be prioritized, including the implementation of supervised injection sites allowing for assisted injection, Good Samaritan laws, and policy changes conducive to a safer drug supply.	[Olding, Michelle; Small, Will; McNeil, Ryan] British Columbia Ctr Subst Use, 400-1045 Howe St, Vancouver, BC, Canada; [Olding, Michelle] Univ British Columbia, Interdisciplinary Studies Grad Program, Vancouver, BC, Canada; [Werb, Dan] Univ Calif San Diego, Div Infect Dis & Global Hlth, San Diego, CA 92103 USA; [Werb, Dan] St Michaels Hosp, Ctr Drug Policy Evaluat, Toronto, ON, Canada; [Guise, Andy] Kings Coll London, Guys Campus, London, England; [Guise, Andy] Univ Calif Los Angeles, Dept Med, Div Global Publ Hlth, Los Angeles, CA 90024 USA; [Small, Will] Simon Fraser Univ, Fac Hlth Sci, Burnaby, BC, Canada; [McNeil, Ryan] Univ British Columbia, Dept Med, Vancouver, BC, Canada	McNeil, R (reprint author), British Columbia Ctr Subst Use, 400-1045 Howe St, Vancouver, BC, Canada.	ryan.mcneil@bccsu.ubc.ca			National Institute on Drug AbuseUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [D2P-DA050256]; US National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01DA04418]; Vanier Canada Graduate Scholarship; Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR); Ontario Ministry of Research, Innovation and Science; Michael Smith Foundation for Health Research (MSFHR)Michael Smith Foundation for Health Research; MSFHRMichael Smith Foundation for Health Research	We would like to thank study participants for their contributions to this research. We would also like to thank Cameron Dilworth and Will Damon for their respective work on this study recruiting participants and conducting interviews. This work was funded as part of the Preventing Injecting Drug Use by Modifying Existing Responses (PRIMER) study funded by the National Institute on Drug Abuse under award number D2P-DA050256, as well as funding from the US National Institutes of Health (R01DA04418). Michelle Olding is supported by a Vanier Canada Graduate Scholarship. Dan Werb is supported by a New Investigator Award from the Canadian Institutes of Health Research and an Early Career Researcher Award from the Ontario Ministry of Research, Innovation and Science. Will Small is supported by a Michael Smith Foundation for Health Research (MSFHR) Scholar Award. Ryan McNeil is supported by a MSFHR Scholar Award and Canadian Institutes of Health Research New Investigator Award.	Andrade X, 1999, J DRUG ISSUES, V29, P271, DOI 10.1177/002204269902900209; ASHTON J, 1988, [No title captured]; Banta-Green CJ., 2011, WASHINGTONS 911 GOOD; Beletsky L., 2018, AM FAVORITE ANTIDOTE, DOI [10.2139/ssrn.3185180, DOI 10.2139/SSRN.3185180]; Ben Hamida A, 2018, J URBAN HEALTH, V95, P83, DOI 10.1007/s11524-017-0188-4; Bourgois P, 1998, SUBST USE MISUSE, V33, P2323, DOI 10.3109/10826089809056260; Bridge J, 2010, INT J DRUG POLICY, V21, P125, DOI 10.1016/j.drugpo.2010.01.011; British Columbia Coroners Service, 2018, ILL DRUG OV DEATHS B; Bryant J, 2008, AIDS BEHAV, V12, P885, DOI 10.1007/s10461-007-9347-z; BUROWAY M, 1991, [No title captured]; Centers for Disease Control and Prevention, 2018, PROVISIONAL DRUG OVE; Centers for Disease Control and Prevention, 2018, 2018 ANN SURV REP DR; Ciccarone D, 2017, INT J DRUG POLICY, V46, P146, DOI 10.1016/j.drugpo.2017.06.004; Ciccarone D, 2017, INT J DRUG POLICY, V46, P107, DOI 10.1016/j.drugpo.2017.06.010; Ciccarone D, 2009, INT J DRUG POLICY, V20, P277, DOI 10.1016/j.drugpo.2008.08.003; Crofts N, 1996, ADDICTION, V91, P1187, DOI 10.1046/j.1360-0443.1996.918118710.x; Davidson PJ, 2002, ADDICTION, V97, P1511, DOI 10.1046/j.1360-0443.2002.00210.x; Day C. A., 2005, HARM REDUCT J, V2, P2, DOI DOI 10.1186/1477-7517-2-2; Degenhardt L, 2017, LANCET GLOB HEALTH, V5, pE1192, DOI 10.1016/S2214-109X(17)30375-3; Dodds C, 2002, HEALTH, V6, P2; Dolan K, 2004, DRUG ALCOHOL REV, V23, P281, DOI 10.1080/09595230412331289437; Drug Enforcement Administration Diversion Control Division, 2016, NAT FOR LAB INF SYST; Drug Policy Alliance, 2017, OV DEATH IS NOT MURD; Fairbairn N, 2006, DRUG ALCOHOL DEPEN, V82, P41, DOI 10.1016/j.drugalcdep.2005.08.007; Fairbairn N, 2010, HARM REDUCT J, V7, DOI 10.1186/1477-7517-7-20; Fennema JSA, 1997, ADDICTION, V92, P1457; Fitzgerald J.L., 1999, CONTEMP DRUG PROBL, V26, P481, DOI DOI 10.1177/009145099902600307; Fraser S, 2004, HEALTH, V8, P199, DOI 10.1177/1363459304041070; Goffman E., 1973, PRESENTATION SELF EV; Goldsamt LA, 2010, J COMMUN HEALTH, V35, P258, DOI 10.1007/s10900-010-9231-z; Government of Canada, 2018, SUP CONS SIT STAT AP; Grady M. P., 1998, QUALITATIVE ACTION R; GRUND JP, 1993, [No title captured]; Guise A, 2018, INT J DRUG POLICY, V55, P51, DOI 10.1016/j.drugpo.2018.02.009; Guise A, 2017, ADDICTION, V112, P2098, DOI 10.1111/add.13957; Harocopos A, 2009, INT J DRUG POLICY, V20, P317, DOI 10.1016/j.drugpo.2008.06.003; Hunt N, 1998, DRUG-EDUC PREV POLIC, V5, P185, DOI 10.3109/09687639809006684; Jimerson JB, 2006, J CONTEMP ETHNOGR, V35, P24, DOI 10.1177/0891241605280417; Karandinos G, 2014, CURR ANTHROPOL, V55, P1, DOI 10.1086/674613; Kerr T, 2005, J URBAN HEALTH, V82, P267, DOI 10.1093/jurban/jti050; Kerr T, 2007, DRUG ALCOHOL DEPEN, V87, P39, DOI 10.1016/j.drugalcdep.2006.07.009; Kolla G, 2015, SUBST USE MISUSE, V50, P1619, DOI 10.3109/10826084.2015.1023456; Lopez AM, 2013, INT J DRUG POLICY, V24, P101, DOI 10.1016/j.drugpo.2012.12.004; Martin FS, 2010, ADDICT RES THEORY, V18, P511, DOI 10.3109/16066351003611653; Martin J., 2018, BMJ, V361; Mayer S, 2018, DRUG ALCOHOL DEPEN, V193, P69, DOI 10.1016/j.drugalcdep.2018.09.006; McNeil R, 2014, AIDS BEHAV, V18, P473, DOI 10.1007/s10461-013-0540-y; Miller CL, 2002, HEPATOLOGY, V36, P737, DOI 10.1053/jhep.2002.35065; Moore D, 2006, SOC SCI MED, V62, P3035, DOI 10.1016/j.socscimed.2005.11.067; O'Connell JM, 2005, JAIDS-J ACQ IMM DEF, V40, P83, DOI 10.1097/01.qai.0000157006.28535.mL; Owczarzak J, 2009, MED ANTHROPOL Q, V23, P417, DOI 10.1111/j.1548-1387.2009.01071.x; Public Health Agency of Canada, 2018, NAT REP APP OP REL D; Quesada J, 2011, MED ANTHROPOL, V30, P339, DOI 10.1080/01459740.2011.576725; Rhodes T., 2002, INT J DRUG POLICY, V13, P85, DOI DOI 10.1016/S0955-3959(02)00007-5; Rhodes T, 2012, RETHINKING SOCIAL EPIDEMIOLOGY: TOWARDS A SCIENCE OF CHANGE, P205, DOI 10.1007/978-94-007-2138-8_10; Rhodes T, 2011, INT J DRUG POLICY, V22, P445, DOI 10.1016/j.drugpo.2011.07.012; Rhodes T, 2009, INT J DRUG POLICY, V20, P193, DOI 10.1016/j.drugpo.2008.10.003; Rose N, 1996, INVENTING OURSELVES; Rotondi NK, 2014, AIDS BEHAV, V18, P486, DOI 10.1007/s10461-013-0693-8; Simmons J, 2012, INT J DRUG POLICY, V23, P303, DOI 10.1016/j.drugpo.2012.01.009; Small W, 2012, SUBST USE MISUSE, V47, P491, DOI 10.3109/10826084.2012.644107; Small W, 2009, SUBST ABUSE TREAT PR, V4, DOI 10.1186/1747-597X-4-8; Strang J, 1997, DRUG ALCOHOL REV, V16, P329, DOI 10.1080/09595239700186711; Strathdee SA, 1998, JAMA-J AM MED ASSOC, V280, P547, DOI 10.1001/jama.280.6.547; Strike C, 2014, DRUG ALCOHOL DEPEN, V137, P48, DOI 10.1016/j.drugalcdep.2014.01.004; Swift W, 1999, ADDICTION, V94, P71, DOI 10.1046/j.1360-0443.1999.941714.x; Tracy M, 2005, DRUG ALCOHOL DEPEN, V79, P181, DOI 10.1016/j.drugalcdep.2005.01.010; Tupper KW, 2018, DRUG ALCOHOL DEPEN, V190, P242, DOI 10.1016/j.drugalcdep.2018.06.020; United Nations Office on Drugs and Crime (UNODC), 2004, HIV PREV YOUNG INJ D; van Ameijden EJC, 2001, J EPIDEMIOL COMMUN H, V55, P356, DOI 10.1136/jech.55.5.356; Vlahov D, 2004, J URBAN HEALTH, V81, P14, DOI 10.1093/jurban/jth083; Wacquant L., 1992, INVITATION REFLEXIVE; Wagner KD, 2012, INT J DRUG POLICY, V23, P54, DOI 10.1016/j.drugpo.2011.05.009; Wakeman S, 2016, CRIT CRIMINOL-NETH, V24, P363, DOI 10.1007/s10612-015-9312-5; Wenger LD, 2016, INT J DRUG POLICY, V37, P42, DOI 10.1016/j.drugpo.2016.07.008; Werb D, 2018, J URBAN HEALTH, V95, P91, DOI 10.1007/s11524-017-0192-8; Werb D, 2013, DRUG ALCOHOL DEPEN, V133, P669, DOI 10.1016/j.drugalcdep.2013.08.017; Werb D, 2016, HARM REDUCT J, V13, DOI 10.1186/s12954-016-0114-1; Witteveen E, 2006, SUBST USE MISUSE, V41, P1001, DOI 10.1080/10826080600669561; Wood E., 2009, BMJ-BRIT MED J, V338, P1191; Wood EF, 2017, INT J DRUG POLICY, V41, P132, DOI 10.1016/j.drugpo.2016.12.010; Zafar T., 2002, INT J DRUG POLICY, V13, P121	82	1	1	2	4	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0955-3959	1873-4758		INT J DRUG POLICY	Int. J. Drug Policy	JUL	2019	69						24	33		10.1016/j.drugpo.2019.04.004			10	Substance Abuse	Substance Abuse	IH2GG	WOS:000474312600004	31029914				2020-06-30	J	Aso, K; Izumi, M; Sugimura, N; Okanoue, Y; Kamimoto, Y; Yokoyama, M; Ikeuchi, M				Aso, Koji; Izumi, Masashi; Sugimura, Natsuki; Okanoue, Yusuke; Kamimoto, Yuko; Yokoyama, Masataka; Ikeuchi, Masahiko			Additional benefit of local infiltration of analgesia to femoral nerve block in total knee arthroplasty: double-blind randomized control study	KNEE SURGERY SPORTS TRAUMATOLOGY ARTHROSCOPY			English	Article						Total knee arthroplasty; Post-operative pain; Local infiltration of analgesia; Femoral nerve block; Randomized controlled trial	EPIDURAL ANALGESIA; POSTOPERATIVE PAIN; MANAGEMENT; EFFICACY; METAANALYSIS; MORPHINE	PurposeMultimodal analgesia has become an important concept in current pain management following total knee arthroplasty (TKA). However, controversy remains over what is the most accepted combination. In this study, the additional benefits of local infiltration of analgesia to femoral nerve block were evaluated.MethodsForty patients were randomly allocated into a combined local infiltration of analgesia and femoral nerve block or femoral nerve block alone group. In the former, analgesic drugs consisting of ropivacaine and dexamethasone were injected into the peri-articular tissues, while the same amount of saline was injected into the femoral nerve block group. The primary outcome measure was the total amount of fentanyl consumption by the patient-controlled analgesia pump during the 48-h post-operative period.ResultsA combination of local infiltration of analgesia and femoral nerve block had less total fentanyl consumption and a larger knee ROM at post-operative day 2 than femoral nerve block alone (p<0.05). C-reactive protein levels in the combined treatment group were significantly lower than the femoral nerve block group at post-operative day 3 (p<0.01). There was no difference between the two groups, post-operatively, on the visual analogue scale for pain at rest or while walking, quadriceps strength, timed up and go test, circumference of thigh, Knee Society Score, and Western Ontario and McMaster Universities Osteoarthritis Index.ConclusionThe addition of local infiltration of analgesia to femoral nerve block promoted post-operative pain relief and the recovery of knee ROM in the early post-operative period. This combination is an effective method for post-operative pain management after TKA.Level of evidenceRandomized controlled trial, Level I.	[Aso, Koji; Izumi, Masashi; Sugimura, Natsuki; Okanoue, Yusuke; Ikeuchi, Masahiko] Kochi Univ, Kochi Med Sch, Dept Orthopaed Surg, 185-1 Oko Cho Kohasu, Nankoku, Kochi 7838505, Japan; [Kamimoto, Yuko; Yokoyama, Masataka] Kochi Univ, Japan Kochi Med Sch, Kochi Med Sch, Dept Anaesthesiol, 185-1 Oko Cho Kohasu, Nankoku, Kochi 7838505, Japan	Aso, K (reprint author), Kochi Univ, Kochi Med Sch, Dept Orthopaed Surg, 185-1 Oko Cho Kohasu, Nankoku, Kochi 7838505, Japan.	koji.aso@gmail.com		aso, koji/0000-0003-3763-9564			Cutolo M, 2008, AUTOIMMUN REV, V8, P153, DOI 10.1016/j.autrev.2008.07.010; Essving P, 2011, ANESTH ANALG, V113, P926, DOI 10.1213/ANE.0b013e3182288deb; Fowler SJ, 2008, BRIT J ANAESTH, V100, P154, DOI 10.1093/bja/aem373; Fu PL, 2010, J INT MED RES, V38, P1404, DOI 10.1177/147323001003800422; Hinarejos P, 2016, KNEE SURG SPORT TR A, V24, P3299, DOI 10.1007/s00167-016-4187-x; Holte K, 2002, J AM COLL SURGEONS, V195, P694, DOI 10.1016/S1072-7515(02)01491-6; Hu B, 2016, PAIN PHYSICIAN, V19, P205; Ikeuchi M, 2014, KNEE SURG SPORT TR A, V22, P1638, DOI 10.1007/s00167-013-2367-5; Keijsers R, 2015, KNEE SURG SPORT TR A, V23, P1956, DOI 10.1007/s00167-013-2788-1; Li C, 2018, J ORTHOP SURG RES, V13, DOI 10.1186/s13018-018-0770-9; Maheshwari AV, 2009, CLIN ORTHOP RELAT R, V467, P1418, DOI 10.1007/s11999-009-0728-7; Narum S, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2013-004587; Osawa A, 2014, OSTEOARTHR CARTILAGE, V22, pS415, DOI 10.1016/j.joca.2014.02.783; Park JH, 2013, J ARTHROPLASTY, V28, P1538, DOI 10.1016/j.arth.2013.02.025; Paul JE, 2010, ANESTHESIOLOGY, V113, P1144, DOI 10.1097/ALN.0b013e3181f4b18; Ranawat AS, 2007, J ARTHROPLASTY, V22, P12, DOI 10.1016/j.arth.2007.05.040; Schinsky MF, 2001, J ARTHROPLASTY, V16, P1048, DOI 10.1054/arth.2001.26591; Seangleulur A, 2016, EUR J ANAESTH, V33, P816, DOI 10.1097/EJA.0000000000000516; Spreng UJ, 2010, BRIT J ANAESTH, V105, P675, DOI 10.1093/bja/aeq232; Tanikawa H, 2017, J ORTHOP SURG RES, V12, DOI 10.1186/s13018-017-0616-x; Tanikawa H, 2014, J ARTHROPLASTY, V29, P2462, DOI 10.1016/j.arth.2014.04.011; Thorsell Martin, 2010, Orthopedics, V33, P75, DOI 10.3928/01477447-20100104-13; Toftdahl K, 2007, ACTA ORTHOP, V78, P172, DOI 10.1080/17453670710013645; Wang AS, 2013, AM J SURG, V206, P410, DOI 10.1016/j.amjsurg.2012.11.018	24	1	2	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0942-2056	1433-7347		KNEE SURG SPORT TR A	Knee Surg. Sports Traumatol. Arthrosc.	JUL	2019	27	7					2368	2374		10.1007/s00167-018-5322-7			7	Orthopedics; Sport Sciences; Surgery	Orthopedics; Sport Sciences; Surgery	IH3FZ	WOS:000474380000041	30536047				2020-06-30	J	Echelmeyer, J; Taylor, PM; Hopster, K; Rohn, K; Delarocque, J; Kastner, SBR				Echelmeyer, J.; Taylor, P. M.; Hopster, K.; Rohn, K.; Delarocque, J.; Kaestner, S. B. R.			Effect of fentanyl on thermal and mechanical nociceptive thresholds in horses and estimation of anti-nociceptive plasma concentration	VETERINARY JOURNAL			English	Article						Fentanyl; Horse; Nociception; Opioids; Pain	INTRAVENOUS FENTANYL; SOMATIC NOCICEPTION; NARCOTIC ANALGESICS; MORPHINE; PAIN; PHARMACOKINETICS	There are few investigations relating anti-nociception to plasma concentrations of fentanyl in horses. The study objective was to evaluate analgesic efficacy and duration in horses and determine the minimum anti-nociceptive plasma concentrations. Eight horses were treated with saline (P) and fentanyl (F-2.5 = 2.5 mu,g/kg; F-5 = 5 mu g/kg; F-10 = 10 mu g/kg) given IV over 5 min, with a wash-out period of 10 days. To evaluate thermal (degrees C) and mechanical (N) nociceptive threshold single stimulations were applied prior to (baseline) and 10, 30, 60, 90, 120, 180, 240, 300, 360, 420, 540 min and 22.5 h after treatment. Plasma fentanyl concentrations were measured at specific time points. Locomotor activity, heart rate, respiratory rate and gastrointestinal sounds were recorded. Two-way repeated measures ANOVA and pairwise comparisons were used for data analysis (P < 0.05). With treatment F-10, there was a significant increase in thermal threshold above baseline (47.2 o 4.1 degrees C) at t(10) (53.7 o 4.2 degrees C) and t(30) (52.1 o 5.6 degrees C), whereas mechanical threshold increased considerably above baseline (3.7 o 1.3 N) only at t(10) (6.6 o 3.6 N). Estimated mean minimum anti-nociceptive plasma concentration determined by thermal stimulation was 6.1-6.8 ng/mL. Dose-dependent increased locomotion occurred, but no significant changes in heart rate, respiratory rate and gastrointestinal sounds were observed. Fentanyl IV at 10 mu g/kg produced anti-nociception for 10-30 min and fentanyl plasma concentrations of >= 6.1-6.8 ng/mL appear necessary to induce thermal anti-nociception. Dose-dependent increased locomotion was the main side effect observed. (C) 2019 Elsevier Ltd. All rights reserved.	[Echelmeyer, J.; Hopster, K.; Delarocque, J.] Univ Vet Med Hannover, Clin Horses, Bunteweg 9, D-30559 Hannover, Germany; [Taylor, P. M.] Taylor Monroe, Little Downham, Ely CB6 2TY, Cambs, England; [Rohn, K.] Univ Vet Med Hannover, Dept Biometry, Bunteweg 2, D-30559 Hannover, Germany; [Kaestner, S. B. R.] Univ Vet Med Hannover, Clin Small Anim, Bunteweg 9, D-30559 Hannover, Germany	Echelmeyer, J (reprint author), Univ Vet Med Hannover, Clin Horses, Bunteweg 9, D-30559 Hannover, Germany.	julia.echelmeyer@tiho-hannover.de		Taylor, Polly/0000-0003-1322-3468; Kastner, Sabine/0000-0001-6430-6154; Delarocque, Julien/0000-0002-4598-3499			Boscan P, 2006, AM J VET RES, V67, P992, DOI 10.2460/ajvr.67.6.992; Brosnan RJ, 2009, AM J VET RES, V70, P1065, DOI 10.2460/ajvr.70.9.1065; Celerier E, 2000, ANESTHESIOLOGY, V92, P465, DOI 10.1097/00000542-200002000-00029; Chambers JP, 1990, VET ANAESTH ANALG, V17, P42; GOURLAY GK, 1988, ANESTH ANALG, V67, P329; HACKL W, 1986, ANAESTHESIST, V35, P665; KAMERLING S, 1989, EQUINE VET J, V21, P4, DOI 10.1111/j.2042-3306.1989.tb02081.x; KAMERLING SG, 1993, VET CLIN N AM-EQUINE, V9, P605, DOI 10.1016/S0749-0739(17)30388-7; KAMERLING SG, 1985, GEN PHARMACOL, V16, P253, DOI 10.1016/0306-3623(85)90078-3; KAMERLING SG, 1985, J PHARMACOL METHOD, V13, P267, DOI 10.1016/0160-5402(85)90027-0; Love EJ, 2011, VET ANAESTH ANALG, V38, P3, DOI 10.1111/j.1467-2995.2010.00580.x; Maxwell LK, 2003, EQUINE VET J, V35, P484, DOI 10.2746/042516403775600415; Peng PWH, 1999, ANESTHESIOLOGY, V90, P576, DOI 10.1097/00000542-199902000-00034; PIPPI NL, 1979, AM J VET RES, V40, P1082; Poller C, 2013, BMC VET RES, V9, DOI 10.1186/1746-6148-9-4; Robertson SA, 2005, J VET PHARMACOL THER, V28, P87, DOI 10.1111/j.1365-2885.2004.00628.x; Robertson SA, 2005, EQUINE VET J, V37, P122, DOI 10.2746/0425164054223723; Robinson TM, 1999, J AM ANIM HOSP ASSOC, V35, P95, DOI 10.5326/15473317-35-2-95; ROGER T, 1994, CAN J VET RES, V58, P163; Sanchez LC, 2007, J VET INTERN MED, V21, P1067; Sande PDI, 2017, TIERAERZTL PRAX G N, V45, P98, DOI 10.15653/TPG-160655; Stanley TH, 2014, J PAIN, V15, P1215, DOI 10.1016/j.jpain.2014.08.010; Thomasy SM, 2007, EQUINE VET J, V39, P54, DOI 10.2746/042516407X153011; TOBIN T, 1979, J EQUINE MED SURG, V3, P284; Trescot AM, 2008, PAIN PHYSICIAN, V11, pS133; YAMAOKA K, 1978, J PHARMACOKINET BIOP, V6, P165, DOI 10.1007/BF01117450	26	1	1	0	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1090-0233	1532-2971		VET J	Vet. J.	JUL	2019	249						82	88		10.1016/j.tvjl.2019.05.012			7	Veterinary Sciences	Veterinary Sciences	IH2FC	WOS:000474309600014	31239171				2020-06-30	J	Li, DN; Zhao, GQ; Su, ZB				Li, Dong-Ni; Zhao, Guo-Qing; Su, Zhen-Bo			Propofol Target-controlled Infusion in Anesthesia Induction during Painless Gastroscopy	JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN			English	Article						Propofol; Target-controlled infusion; Anesthesia induction; Eyelash reflex; Gastroscope	BISPECTRAL INDEX; UPPER ENDOSCOPY; SEDATION; SAFETY; SYSTEM; KETAMINE; COST	Objective: To investigate the feasibility of using the eyelash reflex as an indicator to calculate the individualised optimal target concentration in anesthesia induction during painless gastroscopy. Study Design: Experimental study. Place and Duration of Study: China-Japan Union Hospital of Jilin University, China, from January to December in 2016. Methodology: A total of 180 patients, who were scheduled to receive painless fibergastroscopic examination or treatment in the last three months, were enrolled in this study. All patients were randomly divided into three groups, according to the doctor visiting order (n=60, each). During the induction of anesthesia using propofol target-controlled infusion, the effect-site concentration upon the disappearance of the eyelash reflex (C0) was recorded first. Then, one mu g/kg of fentanyl was injected. At the same time, the target effect-site concentration induced by propofol was determined: the effect-site concentration in group A was 1.5 times of C0, the effect-site concentration in group B was two times of C0, and the effect-site concentration in group C was 2.5 times of C0. Results: During anesthesia induction, the incidence of motor responses was higher in group A than in groups B and C (p<0.05), and the incidence of hypoxemia was significantly higher in group C than in groups A and B (p<0.01). Conclusion: In the anesthesia option of fentanyl combined with propofol target-controlled infusion, the effect-site concentration of propofol can be set to two times of that at the time the eyelash reflex disappears. This study provides a new pre-assessment method for the induction dose of propofol in painless gastroscopy.	[Li, Dong-Ni; Zhao, Guo-Qing; Su, Zhen-Bo] Jilin Univ, China Japan Union Hosp, Dept Anesthesia, Xiantai St 126, Changchun 130033, Jilin, Peoples R China; [Li, Dong-Ni] Jilin Univ, China Japan Union Hosp, Dept Blood Transfus, Changchun, Jilin, Peoples R China	Su, ZB (reprint author), Jilin Univ, China Japan Union Hosp, Dept Anesthesia, Xiantai St 126, Changchun 130033, Jilin, Peoples R China.	suzb@jlu.edu.cn			Education Department of Jilin Province [JJKH20170862KJ]; Health Department of Jilin Province [2015Z028]	This work was supported by Education Department of Jilin Province, grant number JJKH20170862KJ and Health Department of Jilin Province, grant number 2015Z028.	Abraham NS, 2004, AM J GASTROENTEROL, V99, P1692, DOI 10.1111/j.1572-0241.2004.40157.x; [Anonymous], 2010, Digestion, V81, P152; Bruhn J, 2005, ANAESTHESIST, V54, P1021, DOI 10.1007/s00101-005-0864-8; De Smet T, 2008, ANESTH ANALG, V107, P1200, DOI 10.1213/ane.0b013e31817bd1a6; Gotoda T, 2016, GASTROINTEST ENDOSC, V83, P756, DOI 10.1016/j.gie.2015.08.034; Kilic E, 2016, SAUDI MED J, V37, P1191, DOI 10.15537/smj.2016.11.14557; Koh JC, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000009164; Lehmann A, 2002, ANESTH ANALG, V95, P639, DOI 10.1097/00000539-200209000-00027; Lin OS, 2017, INTEST RES, V15, P456, DOI 10.5217/ir.2017.15.4.456; Luginbuhl M, 2009, CURR OPIN ANESTHESIO, V22, P524, DOI 10.1097/ACO.0b013e32832dbb7c; McVay T, 2017, OBES SURG, V27, P1501, DOI 10.1007/s11695-016-2478-4; Nishizawa T, 2018, UNITED EUR GASTROENT, V6, P801, DOI 10.1177/2050640618767594; Nishizawa T, 2014, DIGEST ENDOSC, V26, P701, DOI 10.1111/den.12342; Padmanabhan A, 2017, DIS COLON RECTUM, V60, P1102, DOI 10.1097/DCR.0000000000000909; Pasin L, 2017, ANESTH ANALG, V124, P456, DOI 10.1213/ANE.0000000000001394; Perez-Cuadrado-Robles E, 2016, REV ESP ENFERM DIG, V108, P240, DOI 10.17235/reed.2016.4206/2016; Rajasekaran S, 2014, PEDIATR CRIT CARE ME, V15, pE261, DOI 10.1097/PCC.0000000000000147; Sakai T, 1999, ACTA ANAESTH SCAND, V43, P212, DOI 10.1034/j.1399-6576.1999.430216.x; Seo SI, 2016, DIGEST DIS SCI, V61, P3199, DOI 10.1007/s10620-016-4256-5; von Delius S, 2009, AM J GASTROENTEROL, V104, P318, DOI 10.1038/ajg.2008.73; Wadhwa V, 2017, CLIN GASTROENTEROL H, V15, P194, DOI 10.1016/j.cgh.2016.07.013; Yoon SW, 2018, DIGEST ENDOSC, V30, P580, DOI 10.1111/den.13050	22	0	0	2	3	COLL PHYSICIANS & SURGEONS PAKISTAN	KARACHI	SEVENTH CENTRAL ST, DEFENCE HOUSING AUTHORITY, KARACHI, 75500, PAKISTAN	1022-386X	1681-7168		JCPSP-J COLL PHYSICI	JCPSP-J. Coll. Physicians Surg.	JUL	2019	29	7					604	607		10.29271/jcpsp.2019.07.604			4	Medicine, General & Internal	General & Internal Medicine	IF7RS	WOS:000473282200003	31253207	Bronze			2020-06-30	J	Moallef, S; Nosova, E; Milloy, MJ; DeBeck, K; Fairbairn, N; Wood, E; Kerr, T; Hayashi, K				Moallef, Soroush; Nosova, Ekaterina; Milloy, M. J.; DeBeck, Kora; Fairbairn, Nadia; Wood, Evan; Kerr, Thomas; Hayashi, Kanna			Knowledge of Fentanyl and Perceived Risk of Overdose Among Persons Who Use Drugs in Vancouver, Canada	PUBLIC HEALTH REPORTS			English	Article						fentanyl; cross-sectional study; overdose; risk perception	NONFATAL HEROIN OVERDOSE; UNITED-STATES; RELEASE; MOTIVATION; DEPENDENCE; INCREASE; DEATHS; PEOPLE; PRISON	Objectives: In North America, the illicit drug supply is increasingly contaminated by illicitly manufactured fentanyl. We sought to assess the level and source of fentanyl risk knowledge, defined as knowledge of the overdose risks associated with fentanyl, and characterize the prevalence and correlates of perceived risk of personally having a fentanyl overdose among persons who use illicit drugs (PWUD) in Vancouver, British Columbia. Methods: We derived data from 3 prospective cohorts of PWUD in Vancouver from December 2016 through May 2017. We used multivariable ordinal regression analysis to identify factors associated with a lower perceived risk of having a fentanyl overdose. Results: Of 1166 participants, 1095 (93.9%) had fentanyl risk knowledge. Of 1137 participants who answered questions about their perceived risk of having a fentanyl overdose, 398 (35.0%) perceived having no risk, 426 (37.5%) perceived having low risk, and 313 (27.5%) perceived having moderate or high risk. Never or rarely using opioids (n = 541, 65.7%) was the most common reason for reporting no or low perceived risk (n = 824), whereas 137 (16.6%) participants reported daily heroin use. In multivariable analysis, compared with participants who perceived a moderate or high risk, participants who perceived a lower risk were less likely to report a recent nonfatal overdose (adjusted odds ratio [aOR] = 0.28; P < .001), recent injection drug use (aOR = 0.34; P < .001), and awareness of recent exposure to fentanyl (aOR = 0.34; P < .001). Conclusion: Despite a high level of fentanyl risk knowledge, most study participants did not translate this knowledge into a risk of having an overdose. Although participants who perceived a lower risk were less likely to have had an overdose, a considerable proportion was engaged in daily opioid use, suggesting the need to improve overdose prevention efforts.	[Moallef, Soroush; Nosova, Ekaterina; Milloy, M. J.; DeBeck, Kora; Fairbairn, Nadia; Wood, Evan; Kerr, Thomas; Hayashi, Kanna] St Pauls Hosp, British Columbia Ctr Subst Use, 400-1045 Howe St, Vancouver, BC V6Z 2A9, Canada; [Moallef, Soroush; Hayashi, Kanna] Simon Fraser Univ, Fac Hlth Sci, Burnaby, BC, Canada; [Nosova, Ekaterina; Milloy, M. J.; Fairbairn, Nadia; Wood, Evan; Kerr, Thomas] Univ British Columbia, Dept Med, Vancouver, BC, Canada; [DeBeck, Kora] Simon Fraser Univ, Sch Publ Policy, Burnaby, BC, Canada	Hayashi, K (reprint author), St Pauls Hosp, British Columbia Ctr Subst Use, 400-1045 Howe St, Vancouver, BC V6Z 2A9, Canada.	bccsu-kh@bccsu.ubc.ca		Nosova, Ekaterina/0000-0002-4474-2757	US National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [U01DA038886, U01DA021525, U01DA0251525]; Canada Research Chairs program through a Tier 1 Canada Research Chair in Inner City MedicineCanada Research Chairs; Canadian Institutes of Health Research (CIHR) through the Canadian Research Initiative on Substance MisuseCanadian Institutes of Health Research (CIHR) [SMN-139 148]; CIHR New Investigator AwardCanadian Institutes of Health Research (CIHR) [MSH-141 971]; Michael Smith Foundation for Health Research (MSFHR) Scholar AwardMichael Smith Foundation for Health Research; St. Paul's Foundation; CIHR New Investigator AwardCanadian Institutes of Health Research (CIHR); MSFHR Scholar AwardMichael Smith Foundation for Health Research; US National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; MSFHR/St. Paul's Hospital Foundation-Providence Health Care Career Scholar Award; MSFHR/St. Paul's Hospital Foundation Scholar Award	The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The study was supported by the US National Institutes of Health (U01DA038886, U01DA021525). This research was undertaken, in part, thanks to funding from the Canada Research Chairs program through a Tier 1 Canada Research Chair in Inner City Medicine, which supports Evan Wood (Director of BC Centre on Substance Use), and the Canadian Institutes of Health Research (CIHR) through the Canadian Research Initiative on Substance Misuse (SMN-139 148). Kanna Hayashi is supported by a CIHR New Investigator Award (MSH-141 971), a Michael Smith Foundation for Health Research (MSFHR) Scholar Award, and the St. Paul's Foundation. MJ Milloy is supported by a CIHR New Investigator Award, an MSFHR Scholar Award, and the US National Institutes of Health (U01DA0251525). His institution received an unstructured gift from NG Biomed, Ltd, to support his research. He is the Canopy Growth Professor of Cannabis Science at the University of British Columbia, a position established by arm's-length gifts to the university by Canopy Growth, a licensed producer of cannabis, and the Government of British Columbia's Ministry of Mental Health and Addictions. Kora DeBeck is supported by an MSFHR/St. Paul's Hospital Foundation-Providence Health Care Career Scholar Award. Nadia Fairbairn is supported by an MSFHR/St. Paul's Hospital Foundation Scholar Award.	Agresti A, 2011, EXAMPLES USING R MOD; Amato L, 2005, J SUBST ABUSE TREAT, V28, P321, DOI 10.1016/j.jsat.2005.02.007; Bardwell G, 2018, SUBST ABUSE TREAT PR, V13, DOI 10.1186/s13011-018-0156-3; Barnett NP, 2006, J STUD ALCOHOL, V67, P754, DOI 10.15288/jsa.2006.67.754; Binswanger IA, 2007, NEW ENGL J MED, V356, P157, DOI 10.1056/NEJMsa064115; Binswanger IA, 2012, ADDICT SCI CLIN PRAC, V7, DOI 10.1186/1940-0640-7-3; Binswanger IA, 2011, DRUG ALCOHOL DEPEN, V117, P1, DOI 10.1016/j.drugalcdep.2010.11.029; Bonar EE, 2016, SUBST USE MISUSE, V51, P1379, DOI 10.3109/10826084.2016.1168447; Bonar EE, 2011, ADDICT BEHAV, V36, P1038, DOI 10.1016/j.addbeh.2011.06.010; British Columbia Coroners Service, 2018, FENT DET ILL DRUG OV; Broadhead RS, 1999, PUBLIC HEALTH, V113, P42; Brugal MT, 2002, ADDICTION, V97, P319, DOI 10.1046/j.1360-0443.2002.00058.x; Buchanich JM, 2018, PUBLIC HEALTH REP, V133, P423, DOI 10.1177/0033354918774330; Buster MCA, 2002, ADDICTION, V97, P993, DOI 10.1046/j.1360-0443.2002.00179.x; Carroll JJ, 2017, INT J DRUG POLICY, V46, P136, DOI 10.1016/j.drugpo.2017.05.023; Caudarella A, 2016, DRUG ALCOHOL DEPEN, V162, P51, DOI 10.1016/j.drugalcdep.2016.02.024; Collins J, 2011, J SOC WORK PRACT ADD, V11, P163, DOI 10.1080/1533256X.2011.570219; Darke S, 2003, J URBAN HEALTH, V80, P189, DOI 10.1093/jurban/jtg022; Darke S, 2007, J URBAN HEALTH, V84, P283, DOI 10.1007/s11524-006-9156-0; Donroe JH, 2016, CAN MED ASSOC J, V188, P1232, DOI 10.1503/cmaj.160290; Ferri M, 2006, J SUBST ABUSE TREAT, V30, P63, DOI 10.1016/j.jsat.2005.09.003; Ford C, 2015, FITTING INTERPRETING; Government of BC, 2018, LETH DRUGS AR CIRC; Government of Canada, 2018, NAT REP APP OP REL D; Hadfield JD, 2010, J STAT SOFTW, V33, P1, DOI 10.18637/jss.v033.i02; Hughes CE, 2010, BRIT J CRIMINOL, V50, P999, DOI 10.1093/bjc/azq038; Kinner SA, 2012, ADDICT BEHAV, V37, P691, DOI 10.1016/j.addbeh.2012.01.019; Linden IA, 2013, J URBAN HEALTH, V90, P559, DOI 10.1007/s11524-012-9771-x; Mattick RP, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002209.pub2; McKnight C, 2018, INT J DRUG POLICY, V60, P82, DOI 10.1016/j.drugpo.2018.08.004; Medley A, 2009, AIDS EDUC PREV, V21, P181, DOI 10.1521/aeap.2009.21.3.181; Merrall ELC, 2010, ADDICTION, V105, P1545, DOI 10.1111/j.1360-0443.2010.02990.x; Murthy VH, 2016, FACING ADDICTION AM; Needle RH, 2005, INT J DRUG POLICY, V16, pS45, DOI 10.1016/j.drugpo.2005.02.009; Nosyk B, 2013, HEALTH AFFAIR, V32, P1462, DOI 10.1377/hlthaff.2012.0846; Pollini RA, 2006, DRUG ALCOHOL DEPEN, V83, P104, DOI 10.1016/j.drugalcdep.2005.10.015; Ravndal E, 2010, DRUG ALCOHOL DEPEN, V108, P65, DOI 10.1016/j.drugalcdep.2009.11.008; Rowe C, 2016, DRUG ALCOHOL DEPEN, V159, P234, DOI 10.1016/j.drugalcdep.2015.12.018; RStudio Team, 2017, RSTUDIO INT DEV R; Rudd RA, 2016, MMWR-MORBID MORTAL W, V65, P1445, DOI 10.15585/mmwr.mm655051e1; Sordo L, 2017, BMJ-BRIT MED J, V357, DOI 10.1136/bmj.j1550; Strathdee SA, 1998, JAMA-J AM MED ASSOC, V280, P547, DOI 10.1001/jama.280.6.547; Tupper KW, 2018, DRUG ALCOHOL DEPEN, V190, P242, DOI 10.1016/j.drugalcdep.2018.06.020; United-Nations-Office-on-Drugs-and-Crime, 2016, WORLD DRUG REP 2016; VARNEY SM, 1995, AM J DRUG ALCOHOL AB, V21, P81, DOI 10.3109/00952999509095231; Warner-Smith M, 2001, ADDICTION, V96, P1113, DOI 10.1046/j.1360-0443.2001.96811135.x; Wood Evan, 2006, Harm Reduct J, V3, P18, DOI 10.1186/1477-7517-3-18; Wood E, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b1649	48	2	2	0	3	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0033-3549	1468-2877		PUBLIC HEALTH REP	Public Health Rep.	JUL	2019	134	4					423	431		10.1177/0033354919857084			9	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	IF3AT	WOS:000472953100015	31211644				2020-06-30	J	Abiramalatha, T; Mathew, SK; Mathew, BS; Shabeer, MP; Arulappan, G; Kumar, M; Jayaseelan, V; Kuruvilla, KA				Abiramalatha, Thangaraj; Mathew, Sumith Koshy; Mathew, Binu Susan; Shabeer, Machilakath Panangandi; Arulappan, Geethanjali; Kumar, Manish; Jayaseelan, Visalakshi; Kuruvilla, Kurien Anil			Continuous infusion versus intermittent bolus doses of fentanyl for analgesia and sedation in neonates: an open-label randomised controlled trial	ARCHIVES OF DISEASE IN CHILDHOOD-FETAL AND NEONATAL EDITION			English	Article						fentanyl; pharmacokinetics; pain score; neonate; continuous infusion; intermittent bolus doses	INFANTS; PAIN; SCALE; BLOOD	Objective Adequate data on fentanyl pharmacokinetics in neonates are lacking. The study was performed to compare serum concentrations and clinical outcome between continuous infusion (CI) and intermittent bolus (IB) doses of fentanyl for analgesia and sedation in neonates. Methods In this open-label randomised controlled trial, neonates requiring 24-48 hours of mechanical ventilation and fentanyl administration were recruited. In CI regimen, 1 mcg/kg loading dose was followed by 1 mcg/kg/hour infusion. In IB regimen, 1mcg/kg/dose was administered every 4 hours. Maximum six blood samples were collected in 48 hours from each baby at prespecified time points for estimating serum fentanyl concentration. Secondary outcomes were pain scores (Neonatal Infant Pain Scale and Neonatal Pain, Agitation and Sedation Scale for acute and ongoing pain, respectively) and incidence of adverse effects of fentanyl. Results 100 neonates were recruited, 53 in CI and 47 in IB group. In CI regimen, median (IQR) serum fentanyl concentration was 0.42 (0.35, 0.46) to 0.61 (0.47, 0.89) ng/mL throughout the infusion period. In IB regimen, median (IQR) peak concentration ranged from 2.21 (1.82, 3.55) to 3.61 (2.91, 4.51) ng/mL and trough concentration 0.41 (0.33, 0.48) to 0.97 (0.56, 1.25) ng/mL for various doses. Median (IQR) peak concentration (C-max, 3.06 (1.09, 4.50) vs 0.78 (0.49, 1.73) ng/mL; p<0.001) was significantly higher and area under concentration-time curve (AUC(0-24), 19.6 (10.4, 33.5) vs 13.2 (10.8, 22.6) mu g center dot hour/L; p=0.12) was higher (though not statistically significant) in IB than CI regimen. Pain scores and adverse effects were comparable between the two regimens. Conclusion CI regimen of fentanyl produces steady serum concentrations, whereas IB regimen produces wide fluctuations in serum concentration with high-peak concentrations. A serum fentanyl concentration of 0.4-0.6 ng/mL produces adequate analgesia and sedation in neonates.	[Abiramalatha, Thangaraj; Shabeer, Machilakath Panangandi; Kumar, Manish; Kuruvilla, Kurien Anil] Christian Med Coll Vellore, Dept Neonatol, Vellore, Tamil Nadu, India; [Abiramalatha, Thangaraj] Sri Ramachandra Med Coll & Res Inst, Dept Neonatol, Chennai, Tamil Nadu, India; [Mathew, Sumith Koshy; Mathew, Binu Susan] Christian Med Coll & Hosp, Dept Pharmacol & Clin Pharmacol, Vellore, Tamil Nadu, India; [Arulappan, Geethanjali] Christian Med Coll & Hosp, Dept Clin Biochem, Vellore, Tamil Nadu, India; [Jayaseelan, Visalakshi] Christian Med Coll & Hosp, Dept Biostat, Vellore, Tamil Nadu, India	Kuruvilla, KA (reprint author), Christian Med Coll & Hosp, Dept Neonatol, Vellore 632004, Tamil Nadu, India.	anilkk@cmcvellore.ac.in	Abiramalatha, Thangaraj/AAH-9993-2020	KUMAR, MANISH/0000-0002-3931-3536	Christian Medical College Vellore; Department of Neonatology	The study was supported by the research funds of Christian Medical College Vellore and the Department of Neonatology.	Ancora G, 2013, J PEDIATR-US, V163, P645, DOI 10.1016/j.jpeds.2013.02.039; [Anonymous], 2018, Zhongguo Dang Dai Er Ke Za Zhi, V20, P5; Bellu R, 2010, ARCH DIS CHILD-FETAL, V95, pF241, DOI 10.1136/adc.2008.150318; Bodor Geza S, 2012, EJIFCC, V23, P55; Carbajal R, 2015, LANCET RESP MED, V3, P796, DOI 10.1016/S2213-2600(15)00331-8; Encinas E, 2013, PEDIATR DRUGS, V15, P247, DOI 10.1007/s40272-013-0029-1; Fahnenstich H, 2000, CRIT CARE MED, V28, P836, DOI 10.1097/00003246-200003000-00037; Howie SRC, 2011, B WORLD HEALTH ORGAN, V89, P46, DOI 10.2471/BLT.10.080010; Hummel P, 2008, J PERINATOL, V28, P55, DOI 10.1038/sj.jp.7211861; Kussman BD, 2005, J CARDIOTHOR VASC AN, V19, P316, DOI 10.1053/j.jvca.2005.03.008; Lago P, 1998, ARCH DIS CHILD-FETAL, V79, pF194, DOI 10.1136/fn.79.3.F194; Lago P, 2017, ITAL J PEDIATR, V43, DOI 10.1186/s13052-017-0343-2; Lawrence J, 1993, Neonatal Netw, V12, P59; McIntyre I.M., 2012, J FORENSIC RES, V3, P157, DOI [DOI 10.4172/2157-7145.1000157, 10.4172/2157-7145.1000157]; Neely MN, 2012, THER DRUG MONIT, V34, P467, DOI 10.1097/FTD.0b013e31825c4ba6; Nemergut ME, 2013, CLIN PERINATOL, V40, P539, DOI 10.1016/j.clp.2013.05.005; NEOFAX, 2011, THOM REUT CLIN ED ST; Nomura M, 2013, CLIN J PAIN, V29, P487, DOI 10.1097/AJP.0b013e318266f6a5; Orsini AJ, 1996, J PEDIATR-US, V129, P140, DOI 10.1016/S0022-3476(96)70201-9; Pacifici GM, 2015, PEDIATR NEONATOL, V56, P143, DOI 10.1016/j.pedneo.2014.06.002; da Motta GDP, 2015, J PAIN SYMPTOM MANAG, V50, P394, DOI 10.1016/j.jpainsymman.2015.03.019; Rey-Santano C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090728; Saarenmaa E, 1999, J PEDIATR-US, V134, P144, DOI 10.1016/S0022-3476(99)70407-5; Saarenmaa E, 2000, J PEDIATR-US, V136, P767, DOI 10.1067/mpd.2000.105366; Santeiro M L, 1997, J Perinatol, V17, P135; Siddiqui M. R., 2013, ARABIAN J CHEM; Tran KM, 2012, ANESTH ANALG, V114, P1265, DOI 10.1213/ANE.0b013e3182378d21; Vaughn PR, 1996, J PEDIATR SURG, V31, P1616, DOI 10.1016/S0022-3468(96)90033-0; Ziesenitz VC, 2018, CLIN PHARMACOKINET, V57, P125, DOI 10.1007/s40262-017-0569-6	29	2	2	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1359-2998	1468-2052		ARCH DIS CHILD-FETAL	Arch. Dis. Child.-Fetal Neonatal Ed.	JUL	2019	104	4					F433	F439		10.1136/archdischild-2018-315345			7	Pediatrics	Pediatrics	IF4HC	WOS:000473041400021	30322973				2020-06-30	J	Kaye, AD; Menard, BL; Ehrhardt, KP; Gennuso, SA; Okereke, EC; Tirumala, SR; Fox, CJ; Cornett, EM				Kaye, Alan David; Menard, Bethany L.; Ehrhardt, Ken P.; Gennuso, Sonja A.; Okereke, Eva C.; Tirumala, Sridhar R.; Fox, Charles J.; Cornett, Elyse M.			Consensus Perioperative Management Best Practices for Patients on Transdermal Fentanyl Patches Undergoing Surgery	CURRENT PAIN AND HEADACHE REPORTS			English	Review						Fentanyl patch; Morphine opioid; Surgery; Transdermal	POSTOPERATIVE PAIN MANAGEMENT; DRUG-DELIVERY; CANCER PAIN; EFFICACY; HEAT; RELIEF; SYSTEM	Purpose of ReviewThe administration of a transdermal fentanyl patch can be complicated with different pharmacokinetics than other fentanyl preparations.Recent FindingsThe medical condition and baseline opioid requirements must all be carefully considered when dosing a fentanyl patch. An advantage of the fentanyl patch is its ability to bypass the gastrointestinal tract and in many patients, provide effective analgesia with minimal side effects. Fentanyl patches must be carefully administered since morbidity and/or mortality can result from the following: Giving higher doses than a patient needs, combining the medication with potent sedatives, or heating a fentanyl patch. The use of a transdermal fentanyl patch for the treatment of acute postoperative pain is not recommended and any patient undergoing a surgical procedure should have the fentanyl patch removed preoperatively.SummaryThe current manuscript discusses the history of fentanyl and the fentanyl patch, as well as perioperative considerations, contraindications, current clinical efficacy, and clinical adversities related to the transdermal fentanyl patch. Regarding the heating of a transdermal fentanyl patch, which significantly increases blood levels of fentanyl, it is of the utmost importance that the patch be removed prior to surgery.	[Kaye, Alan David; Menard, Bethany L.; Ehrhardt, Ken P.] LSU Hlth Sci Ctr, Dept Anesthesiol, Room 656,1542 Tulane Ave, New Orleans, LA 70112 USA; [Gennuso, Sonja A.; Okereke, Eva C.; Tirumala, Sridhar R.; Fox, Charles J.; Cornett, Elyse M.] LSU Hlth Shreveport, Dept Anesthesiol, 1501 Kings Highway, Shreveport, LA 71103 USA	Cornett, EM (reprint author), LSU Hlth Shreveport, Dept Anesthesiol, 1501 Kings Highway, Shreveport, LA 71103 USA.	akaye@lsuhsc.edu; bmenar@lsuhsc.edu; ehrhardtken@gmail.com; sgennu@lsuhsc.edu; eokere@lsuhsc.edu; stirum@lsuhsc.edu; cfox1@lsuhsc.edu; ecorne@lsuhsc.edu					Kreitzer JM, 1995, J AM SOC ANESTHESIOL; [Anonymous], 2008, NY TIMES; [Anonymous], 2005, NEW FENT WARN MOR NE; [Anonymous], 2011, J FAMILY PRACTICE; Arshad Z, 2015, J CLIN DIAGN RES, V9, pUC01, DOI 10.7860/JCDR/2015/16327.6917; Bailey PLST, 1994, MILL ANESTH; Bakeer AH, 2017, SAUDI J ANAESTH, V11, P384, DOI 10.4103/sja.SJA_84_17; Carter KA, 2003, AM J HEALTH-SYST PH, V60, P191, DOI 10.1093/ajhp/60.2.191; Consumer Med Safety, 2012, TOP 10 LIST PROT YOU; DUTHIE DJR, 1988, BRIT J ANAESTH, V60, P614, DOI 10.1093/bja/60.6.614; Ellenhorn J, 1997, ELLENHORNS MED TOXIC; Faust AC, 2011, CASE REP MED, DOI 10.1155/2011/495938; Foley PL, 2001, COMPARATIVE MED, V51, P239; Frolich M, 2001, ANESTH ANALG, V93, P647; Giusti R, 2018, BRIT J PAIN, V12, P155, DOI 10.1177/2049463717736787; Hao JS, 2016, EXPERT OPIN DRUG DEL, V13, P755, DOI 10.1517/17425247.2016.1136286; Indian Society for Study of Pain, IND J PAIN; Institute for Safe Medication Practices (ISMP), 2013, FENT PATCH FAT LINK; Kuehn BM, 2009, JAMA-J AM MED ASSOC, V301, P1328, DOI 10.1001/jama.2009.406; Lee YW, 2014, J OCUL PHARMACOL TH, V30, P783, DOI 10.1089/jop.2013.0125; LoVecchio MPHFDO, 2011, AM J EMERG MED, V29; Margetts L, 2007, BJA EDUC, V7, P171, DOI 10.1093/bjaceaccp/mkm033; MARQUARDT KA, 1995, ANN PHARMACOTHER, V29, P969, DOI 10.1177/106002809502901001; Matsumoto S, 2015, ARCH ORTHOP TRAUM SU, V135, P1291, DOI 10.1007/s00402-015-2265-z; McPherson MLM American Society of Health-System Pharmacists., DEMYSTIFYING OPIOID; Merivirta R, 2015, J PAIN RES, V8, P39, DOI 10.2147/JPR.S69511; Merivirta R, 2013, ARTHROSCOPY, V29, P1129, DOI 10.1016/j.arthro.2013.04.018; Moore KT, 2012, J CLIN PHARMACOL, V52, P1174, DOI 10.1177/0091270011411710; Muijsers RBR, 2001, DRUGS, V61, P2289, DOI 10.2165/00003495-200161150-00014; National Alert Network (NAN), 2012, PROP DISP FENT PATCH; Neary B., 2013, INSUR J; Newman JL, 2006, AM J INFECT CONTROL, V34, pS81, DOI 10.1016/j.ajic.2006.11.003; Niyogi S, 2017, INDIAN J ANAESTH, V61, P923, DOI 10.4103/ija.IJA_118_17; PORTENOY RK, 1993, ANESTHESIOLOGY, V78, P36, DOI 10.1097/00000542-199301000-00007; Rebecca Summey-Lowman MBA, HOSP EMPLOYEES IMPLI; Sathitkarnmanee T, 2014, J PAIN RES DOVE PRES, V7, P449; Scott LJ, 2016, CLIN DRUG INVEST, V36, P321, DOI 10.1007/s40261-016-0387-x; SEVARINO FB, 1992, ANESTHESIOLOGY, V77, P463, DOI 10.1097/00000542-199209000-00010; Song CW, 1995, THERMORADIOTHERAPY T, V1, P139; Stanley TH, 2014, WONDROUS STORY ANEST; Stanley TH, 2008, ANESTH ANALG, V106, P451, DOI 10.1213/ane.0b013e3181605add; Stanley TH, 2014, J PAIN, V15, P1215, DOI 10.1016/j.jpain.2014.08.010; Teske J, 2007, INT J LEGAL MED, V121, P147, DOI 10.1007/s00414-006-0137-3; Todorovic VS, 2016, MED ORAL PATOL ORAL, V21, pE621, DOI 10.4317/medoral.21161	44	1	1	1	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1531-3433	1534-3081		CURR PAIN HEADACHE R	Curr. Pain Headache Rep.	JUL	2019	23	7							50	10.1007/s11916-019-0780-2			9	Clinical Neurology	Neurosciences & Neurology	IE6ZA	WOS:000472523000001	31227918				2020-06-30	J	Romano, M; Portela, DA; Verdier, N; Otero, PE				Romano, Marta; Portela, Diego A.; Verdier, Natali; Otero, Pablo E.			Changes in serum cortisol and blood glucose concentrations in anesthetized, pain-free dogs administered fentanyl	VETERINARY ANAESTHESIA AND ANALGESIA			English	Article						cortisol; dog; dysphoria; fentanyl; glucose	SURGERY	Objective To evaluate whether fentanyl administered at analgesic doses in pain-free anesthetized dogs increases the serum cortisol or blood glucose concentrations and is associated with postanesthetic dysphoria. Study design Experimental, blinded, randomized crossover. Animals A group of six adult research dogs. Methods Each dog was anesthetized twice and was administered fentanyl or saline with a 15-day wash-out period. Treatment allocation was randomly assigned via a closed envelope technique. Cortisol and glucose concentrations were measured on arrival in the research room (TPRE), induction of general anesthesia (TIND), extubation (TEXT) and 1 hour after extubation (TPOST). Dogs were premedicated with methadone (0.1 mg kg(-1)) and carprofen (4 mg kg(-1)) intravenously (IV), anesthesia induced with propofol (4-6 mg kg(-1)) IV and maintained with isoflurane in oxygen. Standard anesthesia monitoring was performed throughout the experiment. Fentanyl (5 mg kg(-1) over 90 seconds followed by 7.5 mg kg(-1) hour(-1)) or an equivalent amount in mL of saline solution were administered IV for 60 minutes. TPRE behavior scores and recovery scores were evaluated using descriptive 4-point scales. Data from serum cortisol and blood glucose concentrations were analyzed with a Split Plot on time test, whereas recovery scores were analyzed using a Wilcox match-pairs signed rank test. Statistical significance was set at p < 0.05. Results There were no significant increases in serum cortisol and blood glucose concentrations over time, and there were no differences between treatments. None of the dogs developed postanesthetic dysphoria with either treatment. Conclusions and clinical relevance Fentanyl, administered at analgesic doses to healthy, pain-free, anesthetized dogs, was not associated with significant changes in serum cortisol or glucose concentrations in the studied population.	[Romano, Marta; Portela, Diego A.] Univ Florida, Coll Vet Med, Dept Comparat Diagnost & Populat Med, Gainesville, FL 32610 USA; [Verdier, Natali; Otero, Pablo E.] Univ Buenos Aires, Fac Ciencias Vet, Catedra Anestesiol & Algiol, Buenos Aires, DF, Argentina	Portela, DA (reprint author), Univ Florida, Dept Comparat Diagnost & Populat Med, POB 100123,2015 SW 16th Ave, Gainesville, FL 32610 USA.	dportela@ufl.edu	Portela, Diego A./I-2025-2019	Portela, Diego A./0000-0002-1796-9710			Ambrisko TD, 2005, AM J VET RES, V66, P406, DOI 10.2460/ajvr.2005.66.406; Animal Health Diagnostic Center, 2017, VET MED REF INT CHEM; Becker WM, 2013, VET SURG, V42, P302, DOI 10.1111/j.1532-950X.2012.01080.x; Brito-Casillas Y, 2014, J VET INTERN MED, V28, P1405, DOI 10.1111/jvim.12397; Higgs P, 2014, J SMALL ANIM PRACT, V55, P153, DOI 10.1111/jsap.12181; Ishibashi M, 2013, J VET MED SCI, V75, P809, DOI 10.1292/jvms.12-0478; Kim R, 2018, J TRANSL MED, V16, DOI 10.1186/s12967-018-1389-7; Romano M, 2016, VET ANAESTH ANALG, V43, P44, DOI 10.1111/vaa.12275; Sacerdote P, 2000, ANESTH ANALG, V90, P1411, DOI 10.1097/00000539-200006000-00028; Snyder GL, 2010, BRIT J ANAESTH, V105, P106, DOI 10.1093/bja/aeq164; Vuong C, 2010, ENDOCR REV, V31, P98, DOI 10.1210/er.2009-0009	11	0	0	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1467-2987	1467-2995		VET ANAESTH ANALG	Vet. Anaesth. Analg.	JUL	2019	46	4					488	491		10.1016/j.vaa.2019.04.007			4	Veterinary Sciences	Veterinary Sciences	IF1ZF	WOS:000472875800011	31151873				2020-06-30	J	Company-Quiroga, J; Alique-Garcia, S; Romero-Mate, A				Company-Quiroga, Jaime; Alique-Garcia, Sergio; Romero-Mate, Alberto			Erythema ab igne	INDIAN JOURNAL OF DERMATOLOGY VENEREOLOGY & LEPROLOGY			English	Editorial Material									[Company-Quiroga, Jaime; Alique-Garcia, Sergio; Romero-Mate, Alberto] Fuenlabrada Univ Hosp, Dept Dermatol, Madrid, Spain	Company-Quiroga, J (reprint author), Camino Molino 2, Madrid 28942, Spain.	j.companyquiroga@gmail.com		Romero-Mate, Alberto/0000-0003-2740-8033				0	0	0	0	0	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0378-6323	0973-3922		INDIAN J DERMATOL VE	Indian J. Dermatol. Venereol. Leprol.	JUL-AUG	2019	85	4					405	406	PMID 30073992	10.4103/ijdvl.IJDVL_918_17			2	Dermatology	Dermatology	IC7LX	WOS:000471156900009	30073992	DOAJ Gold			2020-06-30	J	Rab, E; Flanagan, RJ; Hudson, S				Rab, Edmund; Flanagan, Robert J.; Hudson, Simon			Detection of fentanyl and fentanyl analogues in biological samples using liquid chromatography-high resolution mass spectrometry	FORENSIC SCIENCE INTERNATIONAL			English	Article						Heroin-related deaths; Fentanyl; Carfentanil; Fentanyl analogues; Liquid chromatography-high resolution mass spectrometry; Substance misuse	SYNTHETIC OPIOIDS; OVERDOSE DEATHS; U-47700; DRUG; OCFENTANIL; EXPOSURE	Background: Fentanyl and analogues such as butyrylfentanyl, carfentanil, 4-fluorobutyrylfentanyl, and furanylfentanyl may be either added to, or sold as, heroin. Fentanyl and carfentanil have approximately 100 and 10,000 times the potency of morphine, respectively, and there is thus a high risk of death with the use of these drugs. Methods: We looked for fentanyl/fentanyl analogues using liquid chromatography-high resolution mass spectrometry (LC-HRMS) in selected biological samples obtained post-mortem February 2017-end January 2018. Suspicion of fentanyl poisoning arose from the circumstances of death, a history of heroin use, and the geographical area in which the deceased was discovered, supplemented by drugs intelligence data. Results: Of the 84 deaths investigated, fentanyl and/or a fentanyl analogue were detected in 40 (48%). The fentanyls encountered were carfentanil (N = 17), fentanyl (9), carfentanil and fentanyl together (12), and fentanyl, carfentanil, 4-fluorobutyrylfentanyl, and butyrylfentanyl together (2). The median (range) postmortem blood fentanyl concentration was 2.66 (0.21-107) mu g/L and the median (range) carfentanil concentration was 0.24 (0.03-1.66) mu g/L. The most prevalent compounds present together with fentanyls were ethanol [N = 28, median (range) post-mortem blood concentration: 44 (<10-249) mg/dL)], benzoylecgonine [N = 22, 0.64 (<0.05-3.17) mg/L] and free morphine [N = 20, 0.05 (<0.05-0.34) mg/L]. Deaths in hospital excluded, median blood free morphine, and ethanol concentrations were significantly lower in deaths where fentanyl/fentanyl analogues were present, but there was much overlap with the blood concentrations of these analytes in the non-fentanyl related deaths. A routine drugs of abuse assay using LC-HRMS identified fentanyl with 100% sensitivity and carfentanil with 89% sensitivity. Conclusions: Given their potency, misuse of fentanyl and its analogues is likely to cause severe toxicity. A simple LC-HRMS method detected all cases in which fentanyl was identified post-mortem and most of the cases in which carfentanil was detected. (C) 2019 Elsevier B.V. All rights reserved.	[Rab, Edmund; Flanagan, Robert J.] Sheffield Teaching Hosp NHS Fdn Trust, Specialised Clin Chem, Sheffield, S Yorkshire, England; [Hudson, Simon] LGC Sport & Specialised Analyt Serv, Fordham, Cambs, England	Rab, E (reprint author), Sheffield Teaching Hosp NHS Fdn Trust, Specialised Clin Chem, Sheffield, S Yorkshire, England.	edmund.rab@sth.nhs.uk					[Anonymous], 2018, BBC NEWS; Armenian P, 2018, NEUROPHARMACOLOGY, V134, P121, DOI 10.1016/j.neuropharm.2017.10.016; Armenian P, 2017, ANN EMERG MED, V69, P87, DOI 10.1016/j.annemergmed.2016.06.014; Backberg M, 2015, CLIN TOXICOL, V53, P609, DOI 10.3109/15563650.2015.1054505; Beardsley Patrick M, 2018, Handb Exp Pharmacol, V252, P353, DOI 10.1007/164_2018_149; Coopman V, 2016, FORENSIC SCI INT, V266, P469, DOI 10.1016/j.forsciint.2016.07.005; Coopman V, 2016, FORENSIC SCI INT, V266, P68, DOI 10.1016/j.forsciint.2016.05.001; D'Errico S, 2018, J FORENSIC LEG MED, V60, P35, DOI 10.1016/j.jflm.2018.09.007; Daniulaityte R., 2017, MMWR-MORBID MORTAL W, V66, P94; DDN, 2017, NAT CRIM AG ISS FENT; Dwyer JB, 2018, J FORENSIC SCI, V63, P195, DOI 10.1111/1556-4029.13517; European Monitoring Centre for Drugs and Drug Addiction, 2019, EUR INF SYST DAT NEW; Fleming SW, 2017, J ANAL TOXICOL, V41, P173, DOI 10.1093/jat/bkw131; Fogarty MF, 2018, J ANAL TOXICOL, V42, P592, DOI 10.1093/jat/bky035; Handley S. A., 2018, DRUG SCI POLICY LAW, V4, P1; HENDERSON GL, 1988, J FORENSIC SCI, V33, P569; Hikin L, 2018, FORENSIC SCI INT, V282, P179, DOI 10.1016/j.forsciint.2017.11.036; Jalal H, 2018, SCIENCE, V361, P1218, DOI 10.1126/science.aau1184; Lust EB, 2011, J EMERG MED, V40, P198, DOI 10.1016/j.jemermed.2009.09.026; MAURER HH, 2007, MASS SPECTRAL GC DAT; Misailidi N, 2018, FORENSIC TOXICOL, V36, P12, DOI 10.1007/s11419-017-0379-4; Mohr ALA, 2016, J ANAL TOXICOL, V40, P709, DOI 10.1093/jat/bkw086; Mounteney J, 2015, INT J DRUG POLICY, V26, P626, DOI 10.1016/j.drugpo.2015.04.003; National Crime Agency, 2017, REC DEATHS POSS LINK; Prekupec MP, 2017, J ADDICT MED, V11, P256, DOI 10.1097/ADM.0000000000000324; Public Health England, 2019, WID AV NAL; Rudd RA, 2016, MMWR-MORBID MORTAL W, V65, P1445, DOI 10.15585/mmwr.mm655051e1; Shoff EN, 2017, J ANAL TOXICOL, V41, P484, DOI 10.1093/jat/bkx041; Swanson DM, 2017, J ANAL TOXICOL, V41, P498, DOI 10.1093/jat/bkx037; Tamburro L. P., 2016, J FORENSIC SCI MED, V2, P111, DOI [10.4103/2349-5014.184195, DOI 10.4103/2349-5014.184195]; Tiscione NB, 2018, J ANAL TOXICOL, V42, P476, DOI 10.1093/jat/bky026; Uddayasankar U, 2018, PHARMACOTHERAPY, V38, pE41, DOI 10.1002/phar.2117	32	3	3	5	20	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0379-0738	1872-6283		FORENSIC SCI INT	Forensic Sci.Int.	JUL	2019	300						13	18		10.1016/j.forsciint.2019.04.008			6	Medicine, Legal	Legal Medicine	IC3ZY	WOS:000470903500013	31063883				2020-06-30	J	Angelini, DJ; Biggs, TD; Maughan, MN; Feasel, MG; Sisco, E; Sekowski, JW				Angelini, Daniel J.; Biggs, Tracey D.; Maughan, Michele N.; Feasel, Michael G.; Sisco, Edward; Sekowski, Jennifer W.			Evaluation of a lateral flow immunoassay for the detection of the synthetic opioid fentanyl	FORENSIC SCIENCE INTERNATIONAL			English	Article						Detection; Fentanyl; Forensic science; Illicit drug; Lateral flow immunoassay; Opioid	GC-MS; CARFENTANIL; IMMOBILIZATION; IDENTIFICATION; XYLAZINE; ANALOGS; HEROIN; SERIES; ASSAYS	In 2017, 47,600 overdose deaths were reported to be associated with the abuse of opioids, including prescription painkillers (e.g. oxycodone), opiates (e.g. heroin), or synthetic opioids (e.g. fentanyl) within the United States. The recent spike in the presence of synthetic opioids in lots of heroin distributed on the street present specific and significant challenges to law enforcement. Synthetic opioids are extremely toxic substances, which can easily be inhaled. This type of exposure can lead to accidental overdoses by law enforcement and other first responders answering calls involving illicit drugs containing these substances. Due to this extreme toxicity, it is important for these individuals to have tools that can be easily deployed for accurate presumptive field tests. Currently, there are only a limited number of presumptive tests available for fentanyl detection. In this study, we addressed this technology gap by evaluating newly developed lateral flow immunoassays (LFIs) designed for the detection of fentanyl and its derivatives. These LFIs were evaluated for effectiveness in different biofluid matrices, following an in vivo exposure, cross-reactivity with fentanyl analogs, and in case samples. This study demonstrates that LFIs have the potential to be used by law enforcement for the detection of synthetic opioids. Published by Elsevier B.V.	[Angelini, Daniel J.; Biggs, Tracey D.; Feasel, Michael G.; Sekowski, Jennifer W.] US Army, Combat Capabil Dev Command Chem Biol Ctr, 8198 Blackhawk Rd, Aberdeen Proving Ground, MD 21010 USA; [Maughan, Michele N.] Excet Inc, Springfield, VA USA; [Sisco, Edward] NIST, Mat Measurement Sci Div, Gaithersburg, MD 20899 USA	Angelini, DJ (reprint author), US Army, Combat Capabil Dev Command Chem Biol Ctr, 8198 Blackhawk Rd, Aberdeen Proving Ground, MD 21010 USA.	daniel.j.angelini2.civ@mail.mil	Sisco, Edward/AAI-1921-2019	Sisco, Edward/0000-0003-0252-1910; Feasel, Michael/0000-0001-7029-2764	U.S. Department of Homeland Security Science & Technology DirectorateUnited States Department of Homeland Security (DHS) [HSHQPM-15-X-00119, HSHQPM-17-X-00036]	This work was supported by the U.S. Department of Homeland Security Science & Technology Directorate (HSHQPM-15-X-00119; HSHQPM-17-X-00036).	[Anonymous], 2013, AVMA GUIDELINES EUTH; Blachman-Forshay J, 2018, AM J PUBLIC HEALTH, V108, P1666, DOI 10.2105/AJPH.2018.304694; Concheiro M, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01210; Connor Thomas H, 2016, Pharm Technol Hosp Pharm, V1, P107; COOPER D, 1986, J FORENSIC SCI, V31, P511; Cowles Jr C. E., 2017, J SPEC OPER MED, V17, P120; Express Diagnostics Int'l, 2017, L FENT RAP TEST DIPS; Express Diagnostics Int'l, 2017, L FYL RAP TEST CASS; Gabrielson R, 2016, NY TIMES; George AV, 2010, AM J EMERG MED, V28, P530, DOI 10.1016/j.ajem.2010.03.003; HAIGH JC, 1983, J WILDLIFE DIS, V19, P140, DOI 10.7589/0090-3558-19.2.140; JESSUP DA, 1985, J AM VET MED ASSOC, V187, P1253; Lin DL, 2008, J FOOD DRUG ANAL, V16, P1; Marinetti LJ, 2014, J ANAL TOXICOL, V38, P592, DOI 10.1093/jat/bku086; Misailidi N, 2018, FORENSIC TOXICOL, V36, P12, DOI 10.1007/s11419-017-0379-4; Moody MT, 2018, DRUG TEST ANAL, V10, P1358, DOI 10.1002/dta.2393; Mozola M, 2016, J AOAC INT, V99, P1017, DOI 10.5740/jaoacint.16-0125; Mpoza E, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0190652; Namera A, 2011, FORENSIC TOXICOL, V29, P1, DOI 10.1007/s11419-010-0107-9; National Research Council (U.S.). Committee for the Update of the Guide for the Care and Use of Laboratory Animals Institute for Laboratory Animal Research (U.S.) National Academies Press (U.S.), 2011, GUIDE CARE USE LAB A; O'Donnell J, 2018, MMWR-MORBID MORTAL W, V67, P767, DOI 10.15585/mmwr.mm6727a4; Papich MG, 1997, SEMIN VET MED SURG, V12, P80, DOI 10.1016/S1096-2867(97)80005-9; Philp M, 2018, DRUG TEST ANAL, V10, P95, DOI 10.1002/dta.2300; Plouffe BD, 2017, ELECTROPHORESIS, V38, P501, DOI 10.1002/elps.201600075; Prekupec MP, 2017, J ADDICT MED, V11, P256, DOI 10.1097/ADM.0000000000000324; Ramage JG, 2016, HEALTH SECUR, V14, P351, DOI 10.1089/hs.2016.0041; Rivas L, 2014, LAB CHIP, V14, P4406, DOI 10.1039/c4lc00972j; Rondinone N., 2016, 11 HARTFORD SWAT OFF; Salminen T, 2018, VACCINE, V36, P1429, DOI 10.1016/j.vaccine.2018.01.064; Scholz J, 1996, CLIN PHARMACOKINET, V31, P275, DOI 10.2165/00003088-199631040-00004; SEAL US, 1985, J WILDLIFE DIS, V21, P48, DOI 10.7589/0090-3558-21.1.48; Shanks KG, 2017, J ANAL TOXICOL, V41, P466, DOI 10.1093/jat/bkx042; Valles SM, 2016, ANAL BIOANAL CHEM, V408, P4693, DOI 10.1007/s00216-016-9553-5; Van Nimmen NFJ, 2007, J CHROMATOGR B, V846, P264, DOI 10.1016/j.jchromb.2006.09.002; VANBEVER WFM, 1976, ARZNEIMITTELFORSCH, V26, P1548	35	3	3	11	20	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0379-0738	1872-6283		FORENSIC SCI INT	Forensic Sci.Int.	JUL	2019	300						75	81		10.1016/j.forsciint.2019.04.019			7	Medicine, Legal	Legal Medicine	IC3ZY	WOS:000470903500020	31078080				2020-06-30	J	Lee, J; Krotulski, AJ; Fogarty, MF; Papsun, DM; Logan, BK				Lee, Juseon; Krotulski, Alex J.; Fogarty, Melissa F.; Papsun, Donna M.; Logan, Barry K.			Chromatographic separation of the isobaric compounds cyclopropylfentanyl, crotonylfentanyl, methacrylfentanyl, and para-methylacrylfentanyl for specific confirmation by LC-MS/MS	JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES			English	Article							PSYCHOACTIVE SUBSTANCES; OVERDOSE DEATHS; UNITED-STATES; SYNTHETIC OPIOIDS; FENTANYL; DRUG; INCREASES	Cyclopropylfentanyl has been encountered by law enforcement and public health officials beginning in mid-2017 and has been associated with numerous overdoses and fatalities. The detection and identification of cyclopropylfentanyl has become more challenging with the subsequent emergence of multiple structural isomeric fentanyl species, some of which have been detected in seized drug casework. These include crotonylfentanyl, methacrylfentanyl, para-methylacrylfentanyl, and ortho-methylacrylfentanyl; all of which have the same exact mass and similar fragmentation patterns. Since these compounds may be scheduled differently and pharmacologically act differently, it is important to be able to differentiate them analytically. Our method was developed and validated for the analysis and differentiation of cyclopropylfentanyl from its isomers by liquid chromatography tandem mass spectrometry (LC-MS/MS), in order to confirm the identify of cyclopropylfentanyl in biological specimens from death investigation casework; 36 postmortem blood samples were submitted for analysis. Cyclopropylfentanyl, crotonylfentanyl, methacrylfentanyl, and para-methylacrylfentanyl were successfully resolved using a 13-minute run time and a simple gradient elution. Ortho-methacrylfentanyl was resolved only in a 20-minute chromatographic run. The assay met validation performance characteristics, with an analytical range of 1-100 ng/mL and limits of detection of 0.1 ng/mL for all analytes. Analysis of commonly encountered substances showed no interferences. All samples previously reported positive for cyclopropylfentanyl were confirmed positive for cyclopropylfentanyl in the absence of its isomers. To our knowledge to date, no positive toxicological specimens have been encountered for any cyclopropylfentanyl isomers.	[Lee, Juseon; Krotulski, Alex J.; Fogarty, Melissa F.; Logan, Barry K.] Fredric Rieders Family Fdn, Ctr Forens Sci Res & Educ, Willow Grove, PA 19090 USA; [Lee, Juseon] Natl Forens Serv, Wonju, Gangwon Do, South Korea; [Papsun, Donna M.; Logan, Barry K.] NMS Labs, Willow Grove, PA USA	Krotulski, AJ (reprint author), Fredric Rieders Family Fdn, Ctr Forens Sci Res & Educ, Willow Grove, PA 19090 USA.	alex.krotulski@frfoundation.org			NMS Labs; Agilent Technologies	The authors would like to acknowledge NMS Labs and Agilent Technologies for their support during this study.	[Anonymous], 2013, J ANAL TOXICOL, V37, P452, DOI 10.1093/jat/bkt054; Armenian P, 2018, NEUROPHARMACOLOGY, V134, P121, DOI 10.1016/j.neuropharm.2017.10.016; Cabrices O. G., 2018, PIONEERING TOOL CHAR, V6; Drug Enforcement Administration, 2017, CYCL FENT BACKGR INF; Drug Enforcement Administration, 2017, CROT FENT; Drug Enforcement Administration, 2017, EM THREAT REP 3 Q 20; Drug Enforcement Administration, 2018, SCHED CONTR SUBST TE, VI; Elliott S, 2018, DRUG TEST ANAL, V10, P120, DOI 10.1002/dta.2225; Favretto D, 2013, J CHROMATOGR A, V1287, P84, DOI 10.1016/j.chroma.2012.12.049; Fogarty M. F., 2018, J ANAL TOXICOL, DOI [10.1093/jat/bIcy035, DOI 10.1093/JAT/BICY035]; Griswold MK, 2017, J MED TOXICOL, V13, P287, DOI 10.1007/s13181-017-0632-6; Hedegaard Holly, 2017, NCHS Data Brief, P1; Hondebrink L, 2015, DRUG ALCOHOL DEPEN, V147, P109, DOI 10.1016/j.drugalcdep.2014.11.033; Janssen PAJ, 1965, US patent, Patent No. 3164600; Jones CM, 2018, JAMA-J AM MED ASSOC, V319, P1819, DOI 10.1001/jama.2018.2844; Krotulski AJ, 2018, J ANAL TOXICOL, V42, pE27, DOI 10.1093/jat/bkx092; Liechti ME, 2015, SWISS MED WKLY, V145, DOI 10.4414/smw.2015.14043; Logan BK, 2017, J ANAL TOXICOL, V41, P573, DOI 10.1093/jat/bkx031; Lucyk SN, 2017, ANN EMERG MED, V69, P91, DOI 10.1016/j.annemergmed.2016.08.445; Maher S, 2018, DRUG TEST ANAL, V10, P1483, DOI 10.1002/dta.2417; Mallette JR, 2019, SCI JUSTICE, V59, P67, DOI 10.1016/j.scijus.2018.07.005; Mohr ALA, 2016, J ANAL TOXICOL, V40, P709, DOI 10.1093/jat/bkw086; Palaty J, 2018, CLIN BIOCHEM, V53, P164, DOI 10.1016/j.clinbiochem.2018.01.013; Phalen P, 2018, ADDICT BEHAV, V86, P4, DOI 10.1016/j.addbeh.2018.03.010; Reuter P. H., 2017, NOV PSYCHOACT SUBST, P155, DOI [10.1007/978-3-319-60600-2_12, DOI 10.1007/978-3-319-60600-2_12]; Rivera JV, 2017, CRIT CARE NURS Q, V40, P374, DOI 10.1097/CNQ.0000000000000174; Rudd RA, 2016, MMWR-MORBID MORTAL W, V65, P1445, DOI 10.15585/mmwr.mm655051e1; Rudd RA, 2016, MMWR-MORBID MORTAL W, V64, P1378, DOI 10.15585/mmwr.mm6450a3; Suzuki J, 2017, DRUG ALCOHOL DEPEN, V171, P107, DOI 10.1016/j.drugalcdep.2016.11.033; Zawilska JB, 2015, DRUG ALCOHOL DEPEN, V157, P1, DOI 10.1016/j.drugalcdep.2015.09.030	30	0	0	1	4	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1570-0232	1873-376X		J CHROMATOGR B	J. Chromatogr. B	JUN 15	2019	1118						164	170		10.1016/j.jchromb.2019.04.033			7	Biochemical Research Methods; Chemistry, Analytical	Biochemistry & Molecular Biology; Chemistry	HZ9CO	WOS:000469153600020	31054450				2020-06-30	J	Maurya, A; Rangappa, S; Bae, J; Dhawan, T; Ajjarapu, SS; Murthy, SN				Maurya, Abhijeet; Rangappa, Srinath; Bae, Jungeun; Dhawan, Trisha; Ajjarapu, Sankar Srinivas; Murthy, S. Narasimha			Evaluation of soluble fentanyl microneedles for loco-regional anti-nociceptive activity	INTERNATIONAL JOURNAL OF PHARMACEUTICS			English	Article						Fentanyl; Microneedle; Local delivery; Dermal patch; Antinociception; Drug delivery; Skin	TRANSDERMAL DELIVERY; HYALURONIC-ACID; PAIN; RECEPTOR; MECHANISMS; BUPRENORPHINE; PHARMACOLOGY; INFLAMMATION; INVOLVEMENT; ANALGESICS	The use of opioids for treating acute and chronic pain condition is a common clinical practice. When delivered systemically, the analgesic activity is mediated through the central pathway, which although effective, leads to various adverse effects such as dependence, abuse and respiratory depression. Fentanyl is an opioid analgesic that is available as injection and transdermal patch products for the management of acute and chronic pain. These products require stringent regulatory controls and label warnings on disposal due to the abuse potential associated. This research project evaluated the regional antinociceptive efficacy of fentanyl delivered from soluble microneedles. The microneedle patches were formulated with relatively less drug loading as compared to patches intended for systemic delivery and were tested for their antinociceptive activity in rats by measuring the paw withdrawal latency when exposed to a thermal stimulus. The results indicate that regional delivery of fentanyl mediated through soluble microneedles provides an effective antinociceptive activity. The onset of analgesic activity was faster with microneedle patch (0.5 h) when compared to the adhesive dermal patch (6 h). This study thus demonstrates the effectiveness of microneedle mediated pain management for immediate pain relief.	[Maurya, Abhijeet; Rangappa, Srinath; Ajjarapu, Sankar Srinivas; Murthy, S. Narasimha] Univ Mississippi, Dept Pharmaceut & Drug Delivery, University, MS 38677 USA; [Bae, Jungeun] Univ N Carolina, Eshelman Sch Pharm, Div Pharmacoengn & Mol Pharmaceut, Chapel Hill, NC 27599 USA; [Dhawan, Trisha] Univ Mississippi, Dept Biomol Sci, Div Pharmacol, University, MS 38677 USA; [Murthy, S. Narasimha] Inst Drug Delivery & Biomed Res, Bangalore, Karnataka, India	Murthy, SN (reprint author), Univ Mississippi, Dept Pharmaceut & Drug Delivery, University, MS 38677 USA.; Murthy, SN (reprint author), Inst Drug Delivery & Biomed Res, Bangalore, Karnataka, India.	murthy@olemiss.edu					Al-Hasani R, 2011, ANESTHESIOLOGY, V115, P1363, DOI 10.1097/ALN.0b013e318238bba6; Alford DP, 2006, ANN INTERN MED, V144, P127, DOI 10.7326/0003-4819-144-2-200601170-00010; Andre P., 2004, SEMINARS CUTANEOUS M, V2004, P218; [Anonymous], 2019, WHAT IS FENT; Barry BW, 2004, NAT BIOTECHNOL, V22, P165, DOI 10.1038/nbt0204-165; Benyamin R, 2008, PAIN PHYSICIAN, V11, pS105; Boyd D, 2011, IASP PAIN TERMINOL 3; Campbell W., 2007, PRESCRIBER, V18, P61; Cepeda MS, 2003, CLIN PHARMACOL THER, V74, P102, DOI 10.1016/S0009-9236(03)00152-8; EDDY NB, 1953, J PHARMACOL EXP THER, V107, P385; Fan Sook-Ha, 2014, Evid Based Complement Alternat Med, V2014, P976764, DOI 10.1155/2014/976764; Fein A, 2012, NOCICEPTORS PERCEPTI, P61; FERREIRA SH, 1980, BR J CLIN PHARM, V10, pS23; Fukushima K, 2011, PHARM RES-DORDR, V28, P7, DOI 10.1007/s11095-010-0097-7; Guy RH, 1996, PHARMACEUT RES, V13, P1765, DOI 10.1023/A:1016060403438; Henry S, 1998, J PHARM SCI, V87, P922, DOI 10.1021/js980042+; Hwang S., 1991, TRANSDERMAL FENTANYL, P1; KAYSER V, 1990, PAIN, V42, P215, DOI 10.1016/0304-3959(90)91165-F; Koltzenburg M, 2000, CLIN J PAIN, V16, pS131; Lambropoulos J, 1999, J PHARMACEUT BIOMED, V20, P705, DOI 10.1016/S0731-7085(99)00077-1; Lee SG, 2014, INT J NANOMED, V9, P289, DOI 10.2147/IJN.S54529; LEVINE JD, 1989, NEUROSCIENCE, V32, P571, DOI 10.1016/0306-4522(89)90279-0; Likar R, 2005, ANESTH ANALG, V100, P781, DOI 10.1213/01.ANE.0000145066.06538.20; Liu S, 2012, J CONTROL RELEASE, V161, P933, DOI 10.1016/j.jconrel.2012.05.030; Loeser JD, 2008, PAIN, V137, P473, DOI 10.1016/j.pain.2008.04.025; Manda P, 2014, J PHARM SCI-US, V103, P1638, DOI 10.1002/jps.23946; Margetts L, 2007, BJA EDUC, V7, P171, DOI 10.1093/bjaceaccp/mkm033; MARQUARDT KA, 1994, J TOXICOL-CLIN TOXIC, V32, P75, DOI 10.3109/15563659409000433; Martin TJ, 2001, J PHARMACOL EXP THER, V299, P811; Maurya A, 2014, J PHARM SCI-US, V103, P1497, DOI 10.1002/jps.23938; MEYER K, 1947, PHYSIOL REV, V27, P335; Nelson L, 2009, J MED TOXICOL, V5, P230, DOI 10.1007/BF03178274; Nicholson B, 2006, AM J MANAG CARE, V12, pS256; Pasternak Gavril, 2011, Acta Anaesthesiol Taiwan, V49, P21, DOI 10.1016/j.aat.2010.12.008; Paudel KS, 2010, THER DELIV, V1, P109, DOI 10.4155/TDE.10.16; POKLIS A, 1995, J TOXICOL-CLIN TOXIC, V33, P439, DOI 10.3109/15563659509013752; Reeves A. G., 1995, DISORDERS NERVOUS SY; Riedel W, 2001, Z RHEUMATOL, V60, P404, DOI 10.1007/s003930170003; Roy SD, 1996, J PHARM SCI, V85, P491, DOI 10.1021/js950415w; ROY SD, 1989, PHARMACEUT RES, V6, P147, DOI 10.1023/A:1015932610010; Sawynok J, 2003, PHARMACOL REV, V55, P1, DOI 10.1124/pr.55.1.1; STANLEY TH, 1978, ANESTH ANALG, V57, P411; STEIN C, 1989, J PHARMACOL EXP THER, V248, P1269; STEIN C, 1988, EUR J PHARMACOL, V155, P255, DOI 10.1016/0014-2999(88)90511-0; STEIN C, 1995, NEW ENGL J MED, V332, P1685, DOI 10.1056/NEJM199506223322506; Stein C, 2009, CURR OPIN PHARMACOL, V9, P3, DOI 10.1016/j.coph.2008.12.009; Vadivelu Nalini, 2011, J Opioid Manag, V7, P55; Zhu ZZ, 2014, PHARM RES-DORDR, V31, P3348, DOI 10.1007/s11095-014-1424-1; ZIMMERMANN M, 1983, PAIN, V16, P109, DOI 10.1016/0304-3959(83)90201-4; 2001, INT J PHARM, V219, P51	50	0	0	2	19	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0378-5173	1873-3476		INT J PHARMACEUT	Int. J. Pharm.	JUN 10	2019	564						485	491		10.1016/j.ijpharm.2019.04.066			7	Pharmacology & Pharmacy	Pharmacology & Pharmacy	HY1VL	WOS:000467905200044	31026490				2020-06-30	J	Finkelstein, MJ; Chronister, CW; Stanley, C; Ogilvie, LM; Goldberger, BA				Finkelstein, Marissa J.; Chronister, Chris W.; Stanley, Christina; Ogilvie, Laurie M.; Goldberger, Bruce A.			Analysis of Acetyl Fentanyl in Postmortem Specimens by Gas Chromatography-Mass Spectrometry (GC-MS): Method Validation and Case Report	JOURNAL OF ANALYTICAL TOXICOLOGY			English	Article						acetyl fentanyl; GC-MS; method validation; postmortem toxicology	RHODE-ISLAND	In 2013, the Centers for Disease Control and Prevention released a warning regarding a new recreational drug, acetyl fentanyl. Acetyl fentanyl is a mu-opioid receptor agonist, and its pharmacological effects include euphoria, altered mood, miosis and central nervous system depression. The objective of this report was to develop a sensitive and specific method for the quantitation of acetyl fentanyl by gas chromatography-mass spectrometry in postmortem casework. Acetyl fentanyl was isolated from biological matrices using solid-phase extraction and acetyl fentanyl-C-13(6) was employed as an internal standard. The method was validated utilizing the Scientific Working Group for Forensic Toxicology's published method validation parameters, and the biological matrices used for analysis were postmortem blood and urine. In addition to the quantitation of acetyl fentanyl, a demographic study of cases obtained from the Rhode Island Office of State Medical Examiners and the University of Florida Health Pathology Laboratories-Forensic Toxicology Laboratory was performed to examine potential risk factors for acetyl fentanyl use. The results from this study found that the blood concentrations in these individuals ranged from 17 to 945 ng/mL. This suggests acetyl fentanyl is less potent than its prototype drug, fentanyl and requires an increased dose to achieve its desired effects. The demographic analysis indicated white males aged 21-40 years and individuals with a previous history of drug use have the highest risk for acetyl fentanyl abuse.	[Finkelstein, Marissa J.] Miami Dade Cty Med Examiner Dept, Toxicol Lab, 1851 NW 10th Ave, Miami, FL 33136 USA; [Chronister, Chris W.; Goldberger, Bruce A.] Univ Florida, Coll Med, Dept Pathol Immunol & Lab Med, UF Hlth Pathol Labs,Forens Toxicol Lab, 4800 SW 35th Dr, Gainesville, FL 32608 USA; [Stanley, Christina] Off Chief Med Examiner, 720 Albany St, Boston, MA 02118 USA; [Ogilvie, Laurie M.] State Rhode Isl Dept Hlth, State Hlth Labs, 50 Orms St, Providence, RI 02904 USA	Goldberger, BA (reprint author), Univ Florida, Coll Med, Dept Pathol Immunol & Lab Med, UF Hlth Pathol Labs,Forens Toxicol Lab, 4800 SW 35th Dr, Gainesville, FL 32608 USA.	bruce-goldberger@ufl.edu					[Anonymous], 2013, J ANAL TOXICOL, V37, P452, DOI 10.1093/jat/bkt054; [Anonymous], 2018, AC PUBCHEM; [Anonymous], 2013, THE TIMES PICAYUNE; [Anonymous], 2015, AC CRIT REV REP; [Anonymous], 2013, AC DOS INF; [Anonymous], 2013, AC N 1 PHEN 4 PIP AC; [Anonymous], 2015, NEW WORR FENT AC FEN; [Anonymous], 2015, SCH CONTR SUBST TEMP; Baselt R. C, 2017, DISPOSITION TOXIC DR, P883; CBC, 2013, CBC NEWS; Cunningham SM, 2016, J FORENSIC SCI, V61, pS276, DOI 10.1111/1556-4029.12953; Higashikawa Y, 2008, FORENSIC TOXICOL, V26, P1, DOI 10.1007/s11419-007-0039-1; Lozier MJ, 2015, J MED TOXICOL, V11, P208, DOI 10.1007/s13181-015-0477-9; McIntyre IM, 2015, J ANAL TOXICOL, V39, P490, DOI 10.1093/jat/bkv043; Melent'ev A, 2015, J ANAL CHEM+, V70, P240, DOI 10.1134/S1061934815020124; Ogilvie L, 2013, MMWR-MORBID MORTAL W, V62, P703; Patton AL, 2014, ANAL CHEM, V86, P1760, DOI 10.1021/ac4036197; Rogers JS, 2016, J EMERG MED, V50, P433, DOI 10.1016/j.jemermed.2015.10.014; RUNAGYUTTIKARN W, 1990, J ANAL TOXICOL, V14, P160, DOI 10.1093/jat/14.3.160; Stogner JM, 2014, ANN EMERG MED, V64, P637, DOI 10.1016/j.annemergmed.2014.07.017	20	2	2	6	16	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0146-4760	1945-2403		J ANAL TOXICOL	J. Anal. Toxicol.	JUN	2019	43	5					392	398		10.1093/jat/bky108			7	Chemistry, Analytical; Toxicology	Chemistry; Toxicology	IS8PZ	WOS:000482413200011	30767008				2020-06-30	J	Tomaszek, L; Cepuch, G; Fenikowski, D				Tomaszek, Lucyna; Cepuch, Grazyna; Fenikowski, Dariusz			Influence of preoperative information support on anxiety, pain and satisfaction with postoperative analgesia in children and adolescents after thoracic surgery: A randomized double blind study	BIOMEDICAL PAPERS-OLOMOUC			English	Article						anxiety; preoperative education; psychologist; thoracotomy; Ravitch procedure; postoperative pain	PERIOPERATIVE ANXIETY; MANAGEMENT; ORIENTATION; ANESTHESIA; RECOVERY	Aims/Background. The proportion of patients who experience anxiety prior to planned surgery, even a minimally invasive one, is estimated at 50-70%. Thoracic surgery, causes significant preoperative anxiety, especially in children. The aim of this study was to determine the effect of an important component of psychological preparation for a surgery as information support on levels of anxiety, pain and satisfaction with postoperative analgesia. Methods. The randomized double blind study including patients aged 9-18 years qualified for lateral thoracotomy or Ravitch procedure. The subjects were randomized to the control group (n=56) provided with a routine preoperative information by a nurse, and the experimental group (n=56) offered additional psychological consultation. Data were collected via the State Trait Anxiety Inventory. Results. In the experimental group, the level of state anxiety at 48 h post-surgery was significantly lower than prior to the procedure, but only in subjects with preoperative trait anxiety <7/10 sten. In the control group, the level of postoperative anxiety was significantly higher than prior to the surgery; this effect was observed irrespectively of preoperative trait anxiety level. Lack of preoperative psychological consultation (beta=-0.23), trait anxiety >= 7 sten (beta=0.25), and higher level of preoperative state anxiety (beta=0.65) were independent predictors of greater state anxiety at 48 h post-surgery. Patients from the experimental group did not differ significantly from the controls in terms of their median pain scores and satisfaction with postoperative analgesia. Greater state anxiety was associated with 22% lesser likelihood of complete satisfaction with the analgesia. Conclusion. Information support from a psychologist offered prior to a thoracic surgery decrease the level of postoperative state anxiety solely in children with lower levels of trait anxiety. Higher level of postoperative state anxiety negatively affect patients' satisfaction with post-surgical analgesia.	[Tomaszek, Lucyna; Fenikowski, Dariusz] Inst TB & Lung Dis, Dept Thorac Surg, Pediat Div, Rabka Zdroj, Poland; [Cepuch, Grazyna] Jagiellonian Univ, Coll Med, Fac Hlth Sci, Krakow, Poland	Tomaszek, L (reprint author), Inst TB & Lung Dis, Dept Thorac Surg, Pediat Div, Rabka Zdroj, Poland.	ltomaszek@igrabka.edu.pl			National Tuberculosis and Lung Diseases Research Institute, Poland [10.5]	This work was supported in part by Grants No. 10.5 from the National Tuberculosis and Lung Diseases Research Institute, Poland.	Brewer Stephanie, 2006, J Pediatr Nurs, V21, P13, DOI 10.1016/j.pedn.2005.06.004; Caumo W, 2000, ACTA ANAESTH SCAND, V44, P782, DOI 10.1034/j.1399-6576.2000.440703.x; Chieng YJS, 2014, J ADV NURS, V70, P243, DOI 10.1111/jan.12205; Chieng YJS, 2013, J SPEC PEDIATR NURS, V18, P243, DOI 10.1111/jspn.12030; Chou R, 2016, J PAIN, V17, P131, DOI 10.1016/j.jpain.2015.12.008; Crandall M, 2009, J CHILD HEALTH CARE, V13, P308, DOI 10.1177/1367493509344821; Cuzzocrea F, 2013, PEDIATR ANESTH, V23, P139, DOI 10.1111/pan.12100; Ericsson E, 2006, INT J PEDIATR OTORHI, V70, P1749, DOI 10.1016/j.ijporl.2006.05.017; Ferland CE, 2017, J PEDIATR HEALTH CAR, V31, P5, DOI 10.1016/j.pedhc.2015.12.008; Fincher W, 2012, J CLIN NURS, V21, P946, DOI 10.1111/j.1365-2702.2011.03973.x; Fortier MA, 2015, PEDIATR ANESTH, V25, P27, DOI 10.1111/pan.12546; Fortier MA, 2010, PEDIATR ANESTH, V20, P318, DOI 10.1111/j.1460-9592.2010.03263.x; Glowacki D, 2015, CRIT CARE NURSE, V35, P33, DOI 10.4037/ccn2015440; Jaworowska A., 2005, STAI C INWENTARZ STA; Justus Rachel, 2006, Pediatr Nurs, V32, P35; Kain ZN, 2006, PEDIATRICS, V118, P651, DOI 10.1542/peds.2005-2920; Kain ZN, 2001, ANESTH ANALG, V92, P897; Karimi R, 2014, JPN J NURS SCI, V11, P10, DOI 10.1111/j.1742-7924.2012.00223.x; LaMontagne LL, 2001, APPL NURS RES, V14, P119, DOI 10.1053/apnr.2001.24410; Li HCW, 2007, PATIENT EDUC COUNS, V65, P34, DOI 10.1016/j.pec.2006.04.009; Li WHC, 2009, J CLIN NURS, V18, P3013, DOI 10.1111/j.1365-2702.2009.02913.x; Logan DE, 2004, PAIN, V109, P481, DOI 10.1016/j.pain.2004.02.026; Manworren RCB, 2016, SEMIN PEDIATR NEUROL, V23, P189, DOI 10.1016/j.spen.2016.10.001; Misiolek H, 2014, ANAESTH INTENSIVE TH, V46, P221, DOI [10.5603/AIT.2014.0041, 10.5603/AIT.2014.041]; Perry JN, 2012, J PERIANESTH NURS, V27, P69, DOI 10.1016/j.jopan.2012.01.003; Power NM, 2012, ARCH DIS CHILD, V97, P879, DOI 10.1136/archdischild-2011-301378; Rhodes L, 2015, J PEDIATR ORTHOPED, V35, P276, DOI 10.1097/BPO.0000000000000260; Royse CF, 2013, EUR J ANAESTH, V30, P106, DOI 10.1097/EJA.0b013e328357e584; Tomaszek L., 2015, ANAESTHESIOLOGY RESC, V9, P260, DOI DOI 10.3389/FNBEH.2015.00215; Wrzesniewski K, 2011, INWENTARZ STANU CECH	30	1	1	3	4	PALACKY UNIV, MEDICAL FAC	OLOMOUC	CENTRAL LIBRARY, HNEVOTINSKA 3, OLOMOUC, 00000, CZECH REPUBLIC	1213-8118	1804-7521		BIOMED PAP	Biomed. Pap-Olomouc	JUN	2019	163	2					172	178		10.5507/bp.2018.060			7	Engineering, Biomedical; Medicine, Research & Experimental	Engineering; Research & Experimental Medicine	IM4ID	WOS:000477957000011	30305761	DOAJ Gold			2020-06-30	J	Schwienteck, KL; Negus, SS; Banks, ML				Schwienteck, Kathryn L.; Negus, S. Stevens; Banks, Matthew L.			Sex differences in the effectiveness of buprenorphine to decrease rates of responding in rhesus monkeys	BEHAVIOURAL PHARMACOLOGY			English	Article						buprenorphine; fentanyl; mu-opioid receptors; naltrexone; rhesus monkey; sex differences	OPIOID ANTINOCICEPTION; NONHUMAN-PRIMATES; MU; ANTAGONISM; AGONISTS; NALTREXONE; FENTANYL	Sex differences in mu-opioid receptor (MOR) agonist-induced antinociception have been reported in nonhuman primates. The degree to which mu-opioid receptor agonist sex differences in nonhuman primates extend to other behavioral endpoints remains unknown. The present study compared the behavioral effects of three MOR ligands (fentanyl, buprenorphine, and naltrexone) that varied in efficacy to stimulate [S-35]-GTP gamma S binding (from highest to lowest: fentanyl, buprenorphine, and naltrexone) in male and female rhesus monkeys. Male (n=3) and female (n=3) monkeys were trained to respond under a fixed-ratio 10 schedule of food presentation during daily sessions consisting of multiple components. Once rates of responding were stable, cumulative dose-effect functions were determined for intramuscular fentanyl (0.00032-0.032 mg/kg), buprenorphine (0.001-1 mg/kg), and naltrexone (0.01-0.1 mg/kg). Fentanyl dose-dependently decreased rates of responding in both sexes and the corresponding ED50 values were not significantly different. Buprenorphine dose-dependently decreased rates of responding in females, but not males. Naltrexone did not significantly alter behavior in either females or males. Overall, these results suggest that the expression of sex differences in MOR pharmacology depends upon both the efficacy of the MOR ligand and the behavioral endpoint.	[Schwienteck, Kathryn L.; Negus, S. Stevens; Banks, Matthew L.] Virginia Commonwealth Univ, Dept Pharmacol & Toxicol, Richmond, VA USA	Banks, ML (reprint author), Dept Pharmacol & Toxicol, 410 North 12th St,Box 980613, Richmond, VA 23298 USA.	matthew.banks@vcuhealth.org		Schwienteck, Kathryn/0000-0001-7862-1913	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; National Institute on Drug AbuseUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [F31 DA043921, R01DA037287]	This research was supported by grants from the National Institutes of Health and the National Institute on Drug Abuse [F31 DA043921 (K.L.S.) and R01DA037287 (M.L.B.)].	Banks ML, 2017, ILAR J, V58, P202, DOI 10.1093/ilar/ilx014; Banks ML, 2010, PHARMACOL BIOCHEM BE, V97, P205, DOI 10.1016/j.pbb.2010.07.019; GOLDBERG SR, 1981, J PHARMACOL EXP THER, V216, P500; HOTCHKIS.J, 1971, ENDOCRINOLOGY, V89, P177, DOI 10.1210/endo-89-1-177; Kelleher R T, 1968, Ergeb Physiol, V60, P1; Lozano-Torres X, 2016, FASEB J, V30; Mello NK, 2004, J PHARMACOL EXP THER, V308, P156, DOI 10.1124/jpet.103.057216; MELLO NK, 1985, PHARMACOL BIOCHEM BE, V23, P1037, DOI 10.1016/0091-3057(85)90111-X; NEGUS SS, 1993, J PHARMACOL EXP THER, V267, P896; Negus SS, 2002, BEHAV PHARMACOL, V13, P557, DOI 10.1097/00008877-200211000-00005; Negus SS, 1999, J PHARMACOL EXP THER, V290, P1132; Negus SS, 2002, J PAIN, V3, P218, DOI 10.1054/jpai.2002.124734; NIH, 2015, CONS SEX BIOL VAR NI; Paronis CA, 2011, J PHARMACOL EXP THER, V336, P488, DOI 10.1124/jpet.110.173823; Selley DE, 1997, MOL PHARMACOL, V51, P87; Shively CA, 2009, AM J PRIMATOL, V71, P715, DOI 10.1002/ajp.20720; Stevenson GW, 2003, J PHARMACOL EXP THER, V307, P1054, DOI 10.1124/jpet.103.056515; Weerts EM, 2007, EXP CLIN PSYCHOPHARM, V15, P309, DOI 10.1037/1064-1297.15.4.309; Withey SL, 2018, J PAIN, V19, P728, DOI 10.1016/j.jpain.2018.02.003; Yuan YY, 2013, J MED CHEM, V56, P9156, DOI 10.1021/jm4012214	20	3	3	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0955-8810	1473-5849		BEHAV PHARMACOL	Behav. Pharmacol.	JUN	2019	30	4					358	362		10.1097/FBP.0000000000000437			5	Behavioral Sciences; Neurosciences; Pharmacology & Pharmacy	Behavioral Sciences; Neurosciences & Neurology; Pharmacology & Pharmacy	IF4YL	WOS:000473088000008	30212383	Green Accepted			2020-06-30	J	Pallett, SJC; Dickson, N; Moles, F				Pallett, Scott J. C.; Dickson, Nicola; Moles, Fain			Challenges of Remote Medical Care in South Sudan: Centipede Bites	WILDERNESS & ENVIRONMENTAL MEDICINE			English	Article						arthropod; venom; insect; prehospital; Chilopoda	ARTHROPOD STINGS; VENOM; SCOLOPENDROMORPHA	Centipede bites are a constant risk throughout tropical regions and have the rare potential for systemic side effects. We report a case of multiple centipede bites in South Sudan that was complicated by severe pain refractory to opioid analgesia and an unusual association with acute involuntary muscle contractions. Treatment with local anesthetic, antihistamines, and corticosteroids was effective. This report aims to add to the local literature; because of decades of internal conflict and poor infrastructure, reporting of health data from South Sudan is severely lacking. Further investigation into the pharmacological variation and activity of toxic peptides in centipede venom is recommended. As it stands, this case provides additional information on potential effects of centipede envenomation that should be useful to any healthcare providers preparing for the delivery of remote medical care throughout the Great Upper Nile region.	[Pallett, Scott J. C.; Dickson, Nicola; Moles, Fain] Royal Army Med Corps, Camberley, England	Pallett, SJC (reprint author), RAMC, Army Med Serv, Slim Rd, Camberley GU15 4NP, England.	scott.pallett@nhs.net					Balit CR, 2004, J TOXICOL-CLIN TOXIC, V42, P41, DOI 10.1081/CLT-120028743; Bonato L, 2010, ZOOKEYS, P17, DOI 10.3897/zookeys.69.737; Bush SP, 2001, WILD ENVIRON MED, V12, P93, DOI 10.1580/1080-6032(2001)012[0093:CE]2.0.CO;2; Cooper AM, 2014, TOXICON, V82, P30, DOI 10.1016/j.toxicon.2014.02.003; CREANGE A, 1993, NEUROLOGY, V43, P1483, DOI 10.1212/WNL.43.8.1483; Cummins TR, 2007, PAIN, V131, P243, DOI 10.1016/j.pain.2007.07.026; Essler SE, 2017, WILD ENVIRON MED, V28, P51, DOI 10.1016/j.wem.2016.11.003; Fenderson Joshua L, 2014, Hawaii J Med Public Health, V73, P41; Forrester JA, 2012, WILD ENVIRON MED, V23, P146, DOI 10.1016/j.wem.2012.02.012; Jalali A, 2007, TOXICON, V50, P1019, DOI 10.1016/j.toxicon.2007.05.001; James WD, 2006, ANDREWS DIS SKIN CLI; Knysak I, 1998, REV SAUDE PUBL, V32, P514, DOI 10.1590/S0034-89101998000600003; Kularatne SAM, 2018, CLIN TOXICOL, V56, P880, DOI 10.1080/15563650.2018.1447120; Lin TJ, 1995, TROP GEOGR MED, V47, P300; LOGAN JL, 1985, WESTERN J MED, V142, P549; Luo L, 2018, P NATL ACAD SCI USA, V115, P1646, DOI 10.1073/pnas.1714760115; MOHAMED AH, 1983, TOXICON, V21, P371, DOI 10.1016/0041-0101(83)90093-4; Rates B, 2007, TOXICON, V49, P810, DOI 10.1016/j.toxicon.2006.12.001; SenthilKumaran S, 2011, J NEUROSCI RURAL PRA, V2, P210, DOI 10.4103/0976-3147.83606; Simaiakis SM, 2013, ZOOTAXA, V3734, P169, DOI 10.11646/zootaxa.3734.2.5; Umakanth M., 2017, SAUDI J MED PHARM, V3, P1069; Undheim EAB, 2015, TOXINS, V7, P679, DOI 10.3390/toxins7030679; Uzel AP, 2009, CHIR MAIN, V28, P322, DOI 10.1016/j.main.2009.05.001; WELSH JOHN H., 1963, TOXICON, V1, P165, DOI 10.1016/0041-0101(63)90002-3; Yildiz A, 2006, EMERG MED J, V23, DOI 10.1136/emj.2005.030007	25	0	0	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1080-6032	1545-1534		WILD ENVIRON MED	Wildern. Environ. Med.	JUN	2019	30	2					203	207		10.1016/j.wem.2019.01.003			5	Public, Environmental & Occupational Health; Sport Sciences	Public, Environmental & Occupational Health; Sport Sciences	IF3MY	WOS:000472986100015	31006585	Bronze			2020-06-30	J	Sherman, SG; Morales, KB; Park, JN; McKenzie, M; Marshall, BDL; Green, TC				Sherman, Susan G.; Morales, Kenneth B.; Park, Ju Nyeong; McKenzie, Michelle; Marshall, Brandon D. L.; Green, Traci Craig			Acceptability of implementing community-based drug checking services for people who use drugs in three United States cities: Baltimore, Boston and Providence	INTERNATIONAL JOURNAL OF DRUG POLICY			English	Article						Drug checking; Fentanyl; Opioid overdose; Harm reduction; Prevention; People who use drugs	RHODE-ISLAND; FENTANYL; OVERDOSE; HEROIN; MORTALITY; RISK; WILLINGNESS; PROGRAM	Background: North America is experiencing a rising trend of opioid overdose exacerbated primarily in recent years through adulteration of the heroin supply with fentanyl and its analogues. The east coast of the United States has been particularly hard hit by the epidemic. In three east coast states of Maryland, Massachusetts and Rhode Island, fentanyl has been detected in over half of all overdoses with available toxicology screens. To determine the acceptability of drug checking involving fentanyl test strips (FTS) or other technologies among those at high risk for overdose, we assessed correlates of intention to utilize such services and logistical preferences among people who use drugs (PWUD). Methods: Through FORECAST (the Fentanyl Overdose REduction Checking Analysis STudy), street-based PWUD (N = 334) were recruited in Baltimore, Maryland, Boston, Massachusetts, and Providence, Rhode Island. Questionnaires 7were administered from June to October 2017 and ascertained drug use, overdose history, fentanyl knowledge, and drug checking intent and logistical preferences. Pearson's chi(2) and logistic regression determined factors associated with drug checking intent. Results: Overall, 84% were concerned about fentanyl, 63% had ever overdosed, and 42% had ever witnessed a fatal overdose. Ninety percent felt drug checking would help them prevent an overdose, the majority of those interested would utilize drug checking at least daily (54%). Factors independently associated with intent to use drug checking included: older age (aOR: 1.5, 95% CI: 1.3-1.8); homelessness (aOR: 0.6, 95% CI: 0.5-0.7); being non-white (aOR: 2.0, 95% CI: 1.0-4.0); witnessing >= 1 fatal overdose (aOR: 1.6, 95% CI:1.1-2.3); and suspected recent fentanyl exposure (aOR: 1.8, 95% CI: 1.1-3.1). Conclusions: The majority of PWUD endorsed drug checking for overdose prevention, with intent amplified by having witnessed a fatal overdose and recent fentanyl exposure. Drug checking should be part of a comprehensive approach to address the risks associated with the proliferation of fentanyl.	[Sherman, Susan G.; Morales, Kenneth B.; Park, Ju Nyeong] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Behav & Soc, Baltimore, MD 21205 USA; [McKenzie, Michelle] Miriam Hosp, Providence, RI 02906 USA; [McKenzie, Michelle] Brown Univ, Alpert Med Sch, Providence, RI 02912 USA; [Marshall, Brandon D. L.] Brown Univ, Sch Publ Hlth, Dept Epidemiol, Providence, RI 02912 USA; [Green, Traci Craig] Boston Univ, Sch Med, Dept Emergency Med, Boston, MA 02118 USA; [Green, Traci Craig] Brown Univ, Dept Med, Alpert Med Sch, Providence, RI 02912 USA; [Green, Traci Craig] Brown Univ, Dept Epidemiol, Alpert Med Sch, Providence, RI 02912 USA	Sherman, SG (reprint author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Behav & Soc, Baltimore, MD 21205 USA.	ssherman@jhu.edu		Morales, Kenneth/0000-0003-3357-2542; Park, Ju Nyeong/0000-0001-6490-9887	Bloomberg American Health Initiative; Johns Hopkins University Center for AIDS Research [1P30AI094189]	This work was supported by the Bloomberg American Health Initiative and Dr. Sherman is supported by the Johns Hopkins University Center for AIDS Research (1P30AI094189). The study was approved by the Johns Hopkins School of Public Health (00,000,287) and the Rhode Island Hospital Institutional Review Boards (1062206). S.G. Sherman and T.C. Green conceived and supervised the study. J.N. Park directed the study. K.B. Morales curated the data and completed the analyses with support from J.N. Park. S.G. Sherman and K.B. Morales led the writing. M. McKenzie and B.D.L. Marshall assisted with the study and analyses. All authors provided critical revisions and approved the final manuscript, and the authors thank Saba Rouhani for final drafting assistance. A prior version of this research article was presented at the 2018 National Bit Drug Abuse & Heroin Summit in Atlanta and at the Addiction & Overdose Symposium at the Johns Hopkins University Bloomberg School of Public Health in 2018 (Sherman et al., 2018). There are no financial disclosures to be reported.	Adebajo S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0081981; Ahmad F, 2018, PROVISIONAL DRUG OVE; Amlani A, 2015, HARM REDUCT J, V12, DOI 10.1186/s12954-015-0088-4; [Anonymous], 2016, GLOB STAT HARM RED; Arens AM, 2016, JAMA INTERN MED, V176, P1554, DOI 10.1001/jamainternmed.2016.4306; Baggett TP, 2013, JAMA INTERN MED, V173, P189, DOI 10.1001/jamainternmed.2013.1604; Bardwell G, 2018, SUBST ABUSE TREAT PR, V13, DOI 10.1186/s13011-018-0156-3; Barratt MJ, 2018, GLOBAL REV DRUG CHEC; Bohnert ASB, 2012, DRUG ALCOHOL DEPEN, V120, P168, DOI 10.1016/j.drugalcdep.2011.07.018; Brunt TM, 2017, DRUG TEST ANAL, V9, P188, DOI 10.1002/dta.1954; Brunt TM, 2011, DRUG TEST ANAL, V3, P621, DOI 10.1002/dta.323; Carroll JJ, 2017, INT J DRUG POLICY, V46, P136, DOI 10.1016/j.drugpo.2017.05.023; Centers for Disease Control, 2018, MULT CAUS DEATH 1999; Ciccarone D, 2017, INT J DRUG POLICY, V46, P146, DOI 10.1016/j.drugpo.2017.06.004; Ciccarone D, 2017, INT J DRUG POLICY, V46, P107, DOI 10.1016/j.drugpo.2017.06.010; Coffin PO, 2007, ACAD EMERG MED, V14, P616, DOI 10.1111/j.1553-2712.2007.tb01846.x; Darke S, 2007, J URBAN HEALTH, V84, P283, DOI 10.1007/s11524-006-9156-0; Darke S, 2011, DRUG ALCOHOL DEPEN, V115, P190, DOI 10.1016/j.drugalcdep.2010.10.021; DEA Strategic Intelligence Section, 2015, NAT HER THREAT ASS S; DeBeck K, 2012, AM J DRUG ALCOHOL AB, V38, P55, DOI 10.3109/00952990.2011.600389; Drug Enforcement Administration, 2016, DEA FACT SHEET FENT; Drug Enforcement Administration D.C.D, 2015, NAT FOR LAB INF SYST; Drug Enforcement Administration: Strategic Intelligence Section, 2016, COUNT PRESCR PILLS C; Drug Policy Alliance, 2017, DRUG IND HOM LEG OV; Evans JL, 2012, AM J EPIDEMIOL, V175, P302, DOI 10.1093/aje/kwr318; Glick JL, 2019, DRUG ALCOHOL DEPEN, V194, P527, DOI 10.1016/j.drugalcdep.2018.10.017; Harper L, 2017, HARM REDUCT J, V14, DOI 10.1186/s12954-017-0179-5; Karamouzian M, 2018, HARM REDUCT J, V15, DOI 10.1186/s12954-018-0252-8; Kennedy MC, 2018, DRUG ALCOHOL DEPEN, V185, P248, DOI 10.1016/j.drugalcdep.2017.12.026; Krieger MS, 2018, HARM REDUCT J, V15, DOI 10.1186/s12954-018-0213-2; Kuczynska K, 2018, FORENSIC SCI INT, V289, P207, DOI 10.1016/j.forsciint.2018.05.042; Lysyshyn M, 2017, 25 HARM RED INT C; Marinetti LJ, 2014, J ANAL TOXICOL, V38, P592, DOI 10.1093/jat/bku086; Mars SG, 2018, J PSYCHOACTIVE DRUGS, V50, P167, DOI 10.1080/02791072.2017.1394508; Marshall BDL, 2017, INT J DRUG POLICY, V46, P130, DOI 10.1016/j.drugpo.2017.05.029; Maryland Department of Health and Mental Hygiene, 2017, DRUG ALC REL INT DEA; Massachusetts Department of Public Health, 2016, DAT BRIEF OP REL OV; McGowan CR, 2018, INT J DRUG POLICY, V58, P31, DOI 10.1016/j.drugpo.2018.04.017; O'Donnell J. K, 2017, MMWR-MORBID MORTAL W, V3, P1197; Park J. N, 2018, HRJ, V15, P1; Peiper NC, 2019, INT J DRUG POLICY, V63, P122, DOI 10.1016/j.drugpo.2018.08.007; Roxburgh A, 2013, DRUG ALCOHOL REV, V32, P269, DOI 10.1111/dar.12033; Sherman SG, 2018, FENTANYL OVERDOSE RE; StataCorp, 2015, STAT STAT SOFTW REL; Tupper KW, 2018, DRUG ALCOHOL DEPEN, V190, P242, DOI 10.1016/j.drugalcdep.2018.06.020; Xu J, 2015, NCHS DATA BRIEF, V2016, P1	46	12	12	0	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0955-3959	1873-4758		INT J DRUG POLICY	Int. J. Drug Policy	JUN	2019	68						46	53		10.1016/j.drugpo.2019.03.003			8	Substance Abuse	Substance Abuse	ID5RN	WOS:000471733700007	30991301	Other Gold			2020-06-30	J	Sriganesh, K; Syeda, S; Shanthanna, H; Venkataramaiah, S; Palaniswamy, SR				Sriganesh, Kamath; Syeda, Seham; Shanthanna, Harsha; Venkataramaiah, Sudhir; Palaniswamy, Sangeetha R.			Comparison of intraoperative fentanyl with dexmedetomidine for perioperative analgesia and opioid consumption during craniotomies: A randomised controlled pilot study with non-inferiority design	INTERNATIONAL JOURNAL OF CLINICAL PRACTICE			English	Article						craniotomy; dexmedetomidine; fentanyl; pain; pilot study	TOTAL INTRAVENOUS ANESTHESIA; POSTOPERATIVE NAUSEA; SAMPLE-SIZE; PAIN; PROPOFOL	Background Moderate to severe pain is common despite the use of potent opioids during craniotomies. Non-opioid agents such as dexmedetomidine reduce undesirable opioid effects and are successfully used as primary analgesic during bariatric surgeries. This study assessed the feasibility of conducting a large randomised controlled trial comparing fentanyl with dexmedetomidine for perioperative analgesia during craniotomy. Methods This was a prospective single-centre randomised controlled feasibility trial. Twenty-four consenting adult patients undergoing supratentorial craniotomy at NIMHANS, Bangalore, India, were recruited after ethical approval in March and April 2018. They received either fentanyl 1 mu g kg(-1) h(-1) (n = 12) or dexmedetomidine 0.5 mu g kg(-1) h(-1) (n = 12) as primary intraoperative analgesic drug. Patient, anaesthesiologist, outcome assessor and data analyst were blinded to the study intervention. Our feasibility outcomes (primary) were recruitment and adherence rates. We also explored the potential efficacy of intervention and adverse events. Results We recruited 24 out of 30 eligible patients and had 100% protocol adherence, thereby demonstrating the feasibility of a larger randomised controlled trial. All 24 patients completed the study. The demographic and clinical parameters were similar between the groups. Compared between fentanyl and dexmedetomidine, there was no difference in the intraoperative fentanyl (top-up) consumption (mu g), expressed as median and interquartile range: 25 (0-50) and 0 (0-50); P = 0.844; and no difference in postoperative pain at 15 and 60 minutes. Adverse events were few and similar with fentanyl and dexmedetomidine. Conclusions A large-scale randomised controlled trial of perioperative dexmedetomidine versus fentanyl is feasible. Dexmedetomidine has the potential to be non-inferior to fentanyl for perioperative analgesia during craniotomies.	[Sriganesh, Kamath; Syeda, Seham; Venkataramaiah, Sudhir; Palaniswamy, Sangeetha R.] Natl Inst Mental Hlth & Neurosci, Dept Neuroanaesthesia & Neurocrit Care, Bengaluru, India; [Shanthanna, Harsha] McMaster Univ, Dept Anaesthesia, Hamilton, ON, Canada	Sriganesh, K (reprint author), Natl Inst Mental Hlth & Neurosci, Dept Neuroanaesthesia & Neurocrit Care, Bengaluru, India.	drsri23@gmail.com			Academy of Regional Anaesthesia of India	Academy of Regional Anaesthesia of India	Bakan M, 2015, REV BRAS ANESTESIOL, V65, P191, DOI [10.1016/j.bjane.2014.05.001, 10.1016/j.bjan.2014.05.006]; Bielka K, 2018, BMC ANESTHESIOL, V18, DOI 10.1186/s12871-018-0508-6; Flexman AM, 2010, CURR OPIN ANESTHESIO, V23, P551, DOI 10.1097/ACO.0b013e32833e15b9; Gottschalk A, 2007, J NEUROSURG, V106, P210, DOI 10.3171/jns.2007.106.2.210; Gurbet A, 2006, CAN J ANAESTH, V53, P646, DOI 10.1007/BF03021622; Hertzog MA, 2008, RES NURS HEALTH, V31, P180, DOI 10.1002/nur.20247; Julious SA, 2005, PHARM STAT, V4, P287, DOI 10.1002/pst.185; Lai Lawrence T, 2012, Anesthesiol Clin, V30, P347, DOI 10.1016/j.anclin.2012.05.004; Mansour Mohamed Ahmed, 2013, Saudi J Anaesth, V7, P387, DOI 10.4103/1658-354X.121045; Naik BI, 2016, ANESTH ANALG, V122, P1646, DOI 10.1213/ANE.0000000000001226; Pei LJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142249; Peng K, 2015, CLIN THER, V37, P1114, DOI 10.1016/j.clinthera.2015.02.011; Peng K, 2014, J CLIN NEUROSCI, V21, P1951, DOI 10.1016/j.jocn.2014.02.023; Snapinn SM, 2000, CURR CONTR TRIALS C, V1, P19, DOI DOI 10.1186/CVM-1-1-019; Sourour M, 2018, CAN J NEUROL SCI, V45, pS47; Su SY, 2016, FRONT PHARMACOL, V7, DOI 10.3389/fphar.2016.00407; Tobi KU, 2014, NIGER J CLIN PRACT, V17, P449, DOI 10.4103/1119-3077.134036; Turgut Namigar, 2009, Middle East Journal of Anesthesiology, V20, P63; Wrench IJ, 1997, ANAESTHESIA, V52, P32, DOI 10.1111/j.1365-2044.1997.006-az006.x; Ziemann-Gimmel P, 2014, BRIT J ANAESTH, V112, P906, DOI 10.1093/bja/aet551	20	0	0	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1368-5031	1742-1241		INT J CLIN PRACT	Int. J. Clin. Pract.	JUN	2019	73	6							e13338	10.1111/ijcp.13338			7	Medicine, General & Internal; Pharmacology & Pharmacy	General & Internal Medicine; Pharmacology & Pharmacy	ID5EV	WOS:000471700200006	30829429				2020-06-30	J	Chatron, N; Raymond, L; Schluth-Bolard, C; Bardel, C; Huissoud, C; Nouchy, M; Sanlaville, D; Massoud, M				Chatron, Nicolas; Raymond, Laure; Schluth-Bolard, Caroline; Bardel, Claire; Huissoud, Cyril; Nouchy, Marc; Sanlaville, Damien; Massoud, Mona			Comment on "Trisomy 21 noninvasive prenatal testing for twin pregnancies"	PRENATAL DIAGNOSIS			English	Letter									[Chatron, Nicolas; Schluth-Bolard, Caroline; Sanlaville, Damien] Hosp Civils Lyon, Serv Genet, Lyon, France; [Chatron, Nicolas; Schluth-Bolard, Caroline; Sanlaville, Damien] CNRS, INSERM, UMR 5292, U1028,Equipe GENDEV,CRNL,UCBL1, Lyon, France; [Raymond, Laure; Nouchy, Marc] Lab Eurofins Biomnis, Serv Genet, Lyon, France; [Bardel, Claire] CHU Lyon, Cellule Bioinformat Plateforme Sequencage NGS, Bron, France; [Bardel, Claire] Hosp Civils Lyon, Serv Biostat Bioinformat, Lyon, France; [Huissoud, Cyril] Hosp Civils Lyon, Hop Croix Rousse, Serv Gynecol Obstet, Lyon, France; [Massoud, Mona] Hosp Civils Lyon, Hop Femme Mere Enfants, Twin Pregnancy Unit, Lyon, France	Chatron, N (reprint author), Grp Hosp Est, 2e Etage Ctr Biol Pathol Est, Serv Genet, 59 Blvd Pinel, F-69677 Bron, France.	nicolas.chatron@chu-lyon.fr	Schluth-Bolard, Caroline/AAF-3862-2019; Huissoud, Cyril/B-6146-2013; CHATRON, Nicolas/J-2770-2019; sanlaville, damien/M-4716-2014	CHATRON, Nicolas/0000-0003-0538-0981; Schluth-Bolard, Caroline/0000-0002-2279-4273; sanlaville, damien/0000-0001-9939-2849			El Khattabi LA, 2019, ULTRASOUND OBST GYN, V54, P246, DOI 10.1002/uog.20112; Gil MM, 2017, ULTRASOUND OBST GYN, V50, P302, DOI 10.1002/uog.17484; Kahler C, 2013, ULTRASCHALL MED, V34, P435, DOI 10.1055/s-0033-1335685; Tan YQ, 2016, PRENATAL DIAG, V36, P672, DOI 10.1002/pd.4837; Wald NJ, 2018, PRENATAL DIAG, V38, P1079, DOI 10.1002/pd.5381	5	0	0	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0197-3851	1097-0223		PRENATAL DIAG	Prenat. Diagn.	JUN	2019	39	7					571	572		10.1002/pd.5456			2	Genetics & Heredity; Obstetrics & Gynecology	Genetics & Heredity; Obstetrics & Gynecology	IC4HL	WOS:000470926200009	31106873				2020-06-30	J	Simpson, KJ; Moran, MT; Foster, ML; Shah, DT; Chung, DY; Nichols, SD; McCall, KL; Piper, BJ				Simpson, Kevin J.; Moran, Matthew T.; Foster, Michelle L.; Shah, Dipam T.; Chung, Daniel Y.; Nichols, Stephanie D.; McCall, Kenneth L.; Piper, Brian J.			Descriptive, observational study of pharmaceutical and non-pharmaceutical arrests, use, and overdoses in Maine	BMJ OPEN			English	Article							UNITED-STATES; OPIOID OVERDOSE; FENTANYL; ABUSE; DIVERSION; HEROIN; MISUSE; COCAINE; ILLICIT; DEATHS	Objectives The Maine Diversion Alert Program grants healthcare providers access to law enforcement data on drug charges. The objectives of this report were to analyse variations in drug charges by demographics and examine recent trends in arrests, prescriptions of controlled substances and overdoses. Design Observational. Setting Arrests, controlled prescription medication distribution and overdoses in Maine. Participants Drug arrestees (n= 1272) and decedents (n= 2432). Primary outcome measures Arrestees were analysed by sex and age. Substances involved in arrests were reported by schedule (I-V or non-controlled prescription) and into opioids, stimulants or other classes. Controlled substances reported to the Drug Enforcement Administration (2007-2017) were evaluated. Drug-induced deaths (2007-2017) reported to the medical examiner were examined by the substance(s) identified. Results Males were more commonly arrested for stimulants and schedule II substances. More than twothirds of arrests involved individuals under the age of 40. Individuals age > 60 were elevated for oxycodone arrests. Over three-fifths (63.38%) of arrests involved schedule IIIV substances. Opioids accounted for almost half (44.6%) of arrests followed by stimulants (32.5%) and sedatives (9.1%). Arrests involving buprenorphine exceeded those for oxycodone, hydrocodone, methadone, tramadol and morphine, combined. Prescriptions for hydrocodone (-56.0%) and oxycodone (-46.9%) declined while buprenorphine increased (+ 58.1%) between 2012 and 2017. Deaths from 2007 to 2017 tripled. Acetylfentanyl and furanylfentanyl were the most common fentanyl analogues identified. Conclusions Although the overall profile of those arrested for drug crimes in 2017 involve males, age < 40 and heroin, exceptions (oxycodone for older adults) were observed. Most prescription opioids are decreasing while deaths involving opioids continue to increase in Maine.	[Simpson, Kevin J.; Moran, Matthew T.; Shah, Dipam T.; Chung, Daniel Y.; Piper, Brian J.] Geisinger Commonwealth Sch Med, Med Educ, Scranton, PA USA; [Foster, Michelle L.] Divers Alert, Houlton, ME USA; [Nichols, Stephanie D.] Husson Univ, Pharm Practice, Bangor, ME USA; [McCall, Kenneth L.] Univ New England, Coll Pharm, Pharmacy Practice, Portland, ME USA	Piper, BJ (reprint author), Geisinger Commonwealth Sch Med, Med Educ, Scranton, PA USA.	bpiper@som.geisinger.edu			Fahs-Beck Bund for Research and Experimentation	This publication was supported by Fahs-Beck Bund for Research and Experimentation.	Ahmad F, 2018, PROVISIONAL DRUG OVE; Andrilla CHA, 2019, J RURAL HEALTH, V35, P108, DOI 10.1111/jrh.12307; Anthony JC, 1994, EXP CLIN PSYCHOPHARM, V2, P244, DOI 10.1037/1064-1297.2.3.244; Avedschmidt S, 2019, J FORENSIC SCI, V64, P149, DOI 10.1111/1556-4029.13840; Broseus J, 2016, FORENSIC SCI INT, V262, P73, DOI 10.1016/j.forsciint.2016.02.033; Broseus J, 2015, FORENSIC SCI INT, V257, P307, DOI 10.1016/j.forsciint.2015.09.014; Buchanich JM, 2018, PUBLIC HEALTH REP, V133, P423, DOI 10.1177/0033354918774330; Centers for Disease Control and Prevention, 2013, CDC VIT SIGNS PRESCR; Comer SD, 2002, J PHARMACOL EXP THER, V303, P695, DOI 10.1124/jpet.102.038141; Creppage KE, 2018, PUBLIC HEALTH REP, V133, P142, DOI 10.1177/0033354917753119; Culberson JW, 2008, GERIATRICS-US, V63, P22; Delcher Chris, 2017, J Opioid Manag, V13, P283, DOI 10.5055/jom.2017.0397; Dluzen DE, 2008, GENDER MED, V5, P24, DOI 10.1016/S1550-8579(08)80005-8; Drug Enforcement Agency (DEA), 2016, NAT HER THREAT ASS S; Evoy KE, 2017, DRUGS, V77, P403, DOI 10.1007/s40265-017-0700-x; Federal Bureau of Investigations, 2014, UN CRIM REP 2012; Florence CS, 2016, MED CARE, V54, P901, DOI 10.1097/MLR.0000000000000625; Gerdle B, 2008, BMC MUSCULOSKEL DIS, V9, DOI 10.1186/1471-2474-9-102; Greene Marion S, 2015, Curr Addict Rep, V2, P310; Guarino H, 2018, ADDICT BEHAV, V86, P118, DOI 10.1016/j.addbeh.2018.04.017; Gulec N, 2018, PREHOSP EMERG CARE, V22, P163, DOI 10.1080/10903127.2017.1371262; Haegerich TM, 2014, DRUG ALCOHOL DEPEN, V145, P34, DOI 10.1016/j.drugalcdep.2014.10.001; Higashikawa Y, 2008, FORENSIC TOXICOL, V26, P1, DOI 10.1007/s11419-007-0039-1; Koechl B, 2012, GERONTOLOGY, V58, P540, DOI 10.1159/000339095; Kuczynska K, 2018, FORENSIC SCI INT, V289, P207, DOI 10.1016/j.forsciint.2018.05.042; Lookatch SJ, 2014, J AM COLL HEALTH, V62, P255, DOI 10.1080/07448481.2014.891593; Lozier MJ, 2015, J MED TOXICOL, V11, P208, DOI 10.1007/s13181-015-0477-9; Mallick-Searle T, 2016, J MULTIDISCIP HEALTH, V9, DOI 10.2147/JMDH.S106340; Manchikanti L, 2018, PAIN PHYSICIAN, V21, P309; Martin SL, 2016, PREV CHRONIC DIS, V13, DOI 10.5888/pcd13.160229; Mattick RP, 2004, COCHRANE DB SYST REV, V3; McCall KL, 2013, J SUBST USE, V18, P467, DOI 10.3109/14659891.2012.685794; McPherson SM, 2018, SUBST ABUSE REHABIL, V9, P43, DOI 10.2147/SAR.S138439; National Heart Lung and Blood Institute (NHLBI)., 1997, NIH PUBLICATION, V97-4073; National Institute of Mental Health, 2018, ANXIETY DISORDERS; O'Donnell J, 2018, MMWR-MORBID MORTAL W, V67, P767, DOI 10.15585/mmwr.mm6727a4; Ojha SP, 2014, HARM REDUCT J, V11, DOI 10.1186/1477-7517-11-17; Oppek K, 2014, J ADDICT MED, V8, P290, DOI 10.1097/ADM.0000000000000044; Pichini S, 2018, THER DRUG MONIT, V40, P38, DOI 10.1097/FTD.0000000000000465; Piper BJ, 2018, AM J PREV MED, V54, P652, DOI 10.1016/j.amepre.2018.01.034; Piper BJ, 2018, FORENSIC SCI INT, V285, P65, DOI 10.1016/j.forsciint.2018.01.025; Piper BJ, 2017, PHARMACOTHERAPY, V37, P791, DOI 10.1002/phar.1952; Piper BJ, 2016, J STUD ALCOHOL DRUGS, V77, P556, DOI 10.15288/jsad.2016.77.556; Ricker NN, 2018, ONLY WALGREENS SELLI; Rollason V, 2003, DRUG AGING, V20, P817, DOI 10.2165/00002512-200320110-00003; Sacco LN, R42593 C RES SERV; Seth P, 2018, MMWR-MORBID MORTAL W, V67, P349, DOI 10.15585/mmwr.mm6712a1; Smith RV, 2016, ADDICTION, V111, P1160, DOI 10.1111/add.13324; Sorg M. H., 2003, MAINE POLICY REV, V12, P84; Sorg M. H., 2016, MAINE POLICY REV, V25, P34; Sorg MH, 2018, EXPANDED MAINE DRUG; Stanley TH, 2014, J PAIN, V15, P1215, DOI 10.1016/j.jpain.2014.08.010; Stassinos GL, 2016, J ADDICT MED, V10, P357, DOI 10.1097/ADM.0000000000000249; Substance Abuse and Mental Health Services Administration (SAMHSA), 2014, NSDUH SER H, VH-48; Vivolo-Kantor AM, 2018, MMWR-MORBID MORTAL W, V67, P279, DOI 10.15585/mmwr.mm6709e1; Wen HF, 2017, MED CARE, V55, P336, DOI 10.1097/MLR.0000000000000703	56	5	5	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	2044-6055			BMJ OPEN	BMJ Open	JUN	2019	9	4							e027117	10.1136/bmjopen-2018-027117			10	Medicine, General & Internal	General & Internal Medicine	IC7MA	WOS:000471157200227	31036710	DOAJ Gold, Green Published			2020-06-30	J	Ye, WD; Hu, YH; Wu, YT; Zhu, ZR; Jin, XM; Hu, ZY				Ye, Weidi; Hu, Yuhan; Wu, Yuntao; Zhu, Zhirui; Jin, Xiuming; Hu, Zhiyong			Retrobulbar dexmedetomidine in pediatric vitreoretinal surgery eliminates the need for intraoperative fentanyl and postoperative analgesia: A randomized controlled study	INDIAN JOURNAL OF OPHTHALMOLOGY			English	Article						Pediatric; retrobulbar dexmedetomidine; ropivacaine; vitreoretinal surgery	ANESTHESIA; REMIFENTANIL; CHILDREN; STRESS; BLOCK	Purpose: This study evaluated the efficacy of retrobulbar ropivacaine plus dexmedetomidine compared with systemic fentanyl in pediatric vitreoretinal (VR) surgery. Methods: This prospective double-blind, randomized controlled study was performed in 60 children undergoing VR surgery, age from 2 to 7 years. After general anesthesia, the following procedure was administrated: (1) retrobulbar block with 0.5% ropivacaine plus dexmedetomidine 1 mu g/kg (group RD, n = 20), (2) retrobulbar block with 0.5% ropivacaine (group RB, n = 20), and (3) control group with general anesthesia only (group F, n = 20). Hemodynamics, postoperative pain scores, anesthetics consumption (remifentanil, propofol, fentanyl), and emergence agitation were recorded. Results: Respiratory depression was observed in 7 of the 20 patients in group F after the laryngeal mask airway was removed in the operating room, compared with none in groups RD and RB. All patients in group F required intraoperative rescue fentanyl (average intraoperative fentanyl consumption, 26.6 +/- 12.6 mu g per patient). Some rescue fentanyl was required in group RB (three patients required one dose of rescue fentanyl). Patients in group RD required none. Groups RD and RB reported lower pain scores than group F at 4 h postoperatively (RD group: P < 0.001; RB group: P = 0.002); pain scores in group RD were lower than that in group F at 6 h postoperatively (P < 0.001). Conclusion: Retrobulbar dexmedetomidine as an adjuvant to ropivacaine is a safe and effective alternative to systemic fentanyl. This regimen provides better pain management, hemodynamic stability, and stress response suppression in pediatric VR surgery.	[Ye, Weidi; Wu, Yuntao; Jin, Xiuming] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Anesthesiol & Ophthalmol, Hangzhou, Zhejiang, Peoples R China; [Hu, Yuhan] Yale Univ, Dept Cell Biol, New Haven, CT USA; [Zhu, Zhirui; Hu, Zhiyong] Zhejiang Univ, Sch Med, Childrens Hosp, Dept Anesthesiol, Hangzhou, Zhejiang, Peoples R China	Hu, ZY (reprint author), Zhejiang Univ, Sch Med, Childrens Hosp, 3333 Binsheng Rd, Hangzhou 310052, Zhejiang, Peoples R China.	huzhiyong777@zju.edu.cn		Hu, Yuhan/0000-0001-8009-6097			Chen KZ, 2014, BRIT J ANAESTH, V112, P892, DOI 10.1093/bja/aet490; Dumans-Nizard V, 2017, ANESTH ANALG, V125, P635, DOI 10.1213/ANE.0000000000001996; Gertler R, 2001, Proc (Bayl Univ Med Cent), V14, P13; Gupta Rajni, 2011, J Anaesthesiol Clin Pharmacol, V27, P339, DOI 10.4103/0970-9185.83678; Hammer GB, 2005, PEDIATR ANESTH, V15, P616, DOI 10.1111/j.1460-9592.2005.01656.x; Jooste EH, 2010, ANESTH ANALG, V111, P1490, DOI 10.1213/ANE.0b013e3181f7e2ab; Kallio H, 2008, BRIT J ANAESTH, V101, P383, DOI 10.1093/bja/aen204; Kanazi GE, 2006, ACTA ANAESTH SCAND, V50, P222, DOI 10.1111/j.1399-6576.2006.00919.x; Lee LA, 2015, ANESTHESIOLOGY, V122, P659, DOI 10.1097/ALN.0000000000000564; Li Y, 2016, ANESTH ANALG, V122, P1202, DOI 10.1213/ANE.0000000000001165; Mamie C, 2004, PEDIATR ANESTH, V14, P218, DOI 10.1111/j.1460-9592.2004.01169.x; Shah RD, 2013, BRIT J ANAESTH, V111, P114, DOI 10.1093/bja/aet379; Song IA, 2016, PLOS ONE, V12, P11; Subramaniam R, 2003, REGION ANESTH PAIN M, V28, P43, DOI 10.1053/rapm.2003.50032; Tsiotou AG, 2018, PEDIATR ANESTH, V28, P632, DOI 10.1111/pan.13397; Walker BJ, 2018, ANESTHESIOLOGY, V129, P721, DOI 10.1097/ALN.0000000000002372; Xiang Q, 2013, BRIT J ANAESTH, V110, P420, DOI 10.1093/bja/aes385; Xu HP, 2018, NEUROTOXICOLOGY, V69, P77, DOI 10.1016/j.neuro.2018.09.004; Yao L, 2017, REGION ANESTH PAIN M, V42, P521, DOI 10.1097/AAP.0000000000000610	19	1	1	2	2	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0301-4738	1998-3689		INDIAN J OPHTHALMOL	Indian J. Ophthalmol.	JUN	2019	67	6					922	927		10.4103/ijo.IJO_1905_18			6	Ophthalmology	Ophthalmology	IB5PF	WOS:000470323300043	31124516	DOAJ Gold, Green Published			2020-06-30	J	Kars, MS; Mori, BV; Ahn, S; Merwin, S; Wendolowski, S; Gecelter, R; Rothman, A; Poon, S				Kars, Michelle S.; Mori, Benjamin Villacres; Ahn, Seungjun; Merwin, Sara; Wendolowski, Stephen; Gecelter, Rachel; Rothman, Alyssa; Poon, Selina			Fentanyl versus remifentanil-based TIVA for pediatric scoliosis repair: does it matter?	REGIONAL ANESTHESIA AND PAIN MEDICINE			English	Article							OPIOID-INDUCED HYPERALGESIA; LOW-DOSE KETAMINE; DOUBLE-BLIND; SURGERY; ANALGESIA; MORPHINE; ACETAMINOPHEN; REQUIREMENT; ANESTHESIA; TOLERANCE	Introduction Opioid-induced hyperalgesia (OIH) and acute opioid tolerance have been demonstrated extensively in patients undergoing adolescent idiopathic scoliosis (AIS) repair. Remifentanil infusion has been strongly linked to both tolerance and OIH in these patients; however, the impact of using an intraoperative fentanyl infusion has not been well studied. This study aims to determine if patients undergoing operative management of AIS have decreased opioid consumption and pain scores when an intraoperative fentanyl infusion is used as compared with a remifentanil infusion. Methods This is a retrospective chart review of patients with AIS who underwent posterior spinal fusion. During the period January 2012-June 2013, patients received remifentanil infusion as part of total intravenous anesthesia. From July 2013 to June 2015, remifentanil was replaced by fentanyl as standard protocol. The remifentanil cohort included 37 patients and the fentanyl cohort included 25 patients. The primary outcome was the total opioid consumption (morphine equivalents) in the first 24 hours postsurgery. Secondary outcomes included mean postoperative pain score in the first 24 hours postsurgery, postoperative opioid consumption 24-48 hours after surgery, time to extubation, time to assisted ambulation, length of stay, and incidence of postoperative nausea and vomiting. Results Compared with the remifentanil group, the fentanyl group had significantly higher postoperative opioid usage during the first 48 hours and significantly higher postoperative mean pain score during the first 24 hours. There was no difference between the two groups in mean pain score for 24-48 hours, extubation time, time to assisted ambulation, length of stay, or postoperative nausea and vomiting. Discussion Despite concerns for hyperalgesia and acute tolerance, remifentanil is widely used for intraoperative opioid infusions for surgical correction of AIS. This retrospective study examined a practice change from intraoperative remifentanil to intraoperative fentanyl as a potential approach to avoid OIH. Surprisingly, patients receiving fentanyl intraoperatively showed increased postoperative opioid use and pain scores in the first 24 hours postsurgery compared with the prior cohort receiving remifentanil. Substitution of fentanyl for remifentanil during surgical correction of AIS does not appear to solve the problem of OIH or acute tolerance. Prospective studies are needed to confirm this unexpected result.	[Kars, Michelle S.] Steven & Alexandra Cohen Childrens Med Ctr, Anesthesiol, New Hyde Pk, NY 11040 USA; [Mori, Benjamin Villacres] Hofstra Northwell, Donald & Barbara Zucker Sch Med, Hempstead, NY USA; [Ahn, Seungjun] Feinstein Inst Med Res, Manhasset, NY USA; [Merwin, Sara] Montefiore Hosp & Med Ctr, Bronx, NY USA; [Wendolowski, Stephen; Gecelter, Rachel] Steven & Alexandra Cohen Childrens Med Ctr, Orthoped, New Hyde Pk, NY USA; [Rothman, Alyssa] Boston Med Ctr, Orthoped, Boston, MA USA; [Poon, Selina] Shriners Hosp Children Angeles, Orthoped, Los Angeles, CA USA	Kars, MS (reprint author), Steven & Alexandra Cohen Childrens Med Ctr, Anesthesiol, New Hyde Pk, NY 11040 USA.	mkars@northwell.edu		Villacres, Benjamin/0000-0001-6969-7879			Abu-Kishk I, 2012, YONSEI MED J, V53, P1014, DOI 10.3349/ymj.2012.53.5.1014; Chia YT, 1999, CAN J ANAESTH, V46, P872, DOI 10.1007/BF03012978; Crawford MW, 2006, ANESTH ANALG, V102, P1662, DOI 10.1213/01.ane.0000216036.95705.c2; Engelhardt T, 2008, ANESTH ANALG, V107, P1170, DOI 10.1213/ane.0b013e318183919e; Fletcher D, 2014, BRIT J ANAESTH, V112, P991, DOI 10.1093/bja/aeu137; Gibson PRJ, 2004, ANAESTH INTENS CARE, V32, P548, DOI 10.1177/0310057X0403200413; Gornitzky Alex L, 2016, Spine Deform, V4, P288, DOI 10.1016/j.jspd.2016.01.001; Hayhurst CJ, 2016, ANESTHESIOLOGY, V124, P483, DOI 10.1097/ALN.0000000000000963; Hiller A, 2006, ANESTH ANALG, V102, P1365, DOI 10.1213/01.ane.0000204278.71548.bf; Hiller A, 2012, SPINE, V37, pE1225, DOI 10.1097/BRS.0b013e318263165c; Jabbour HJ, 2014, ACTA ANAESTH SCAND, V58, P572, DOI 10.1111/aas.12304; JELLINEK D, 1991, NEUROSURGERY, V29, P558, DOI 10.1227/00006123-199110000-00012; KALKMAN CJ, 1992, ANESTHESIOLOGY, V76, P502, DOI 10.1097/00000542-199204000-00003; Mauermann E, 2016, ANESTHESIOLOGY, V124, P453, DOI 10.1097/ALN.0000000000000976; Mayell A, 2014, PEDIATR ANESTH, V24, P1239, DOI 10.1111/pan.12524; Perello Marina, 2017, Spine (Phila Pa 1976), V42, pE304, DOI 10.1097/BRS.0000000000001772; Pestieau SR, 2014, PEDIATR ANESTH, V24, P582, DOI 10.1111/pan.12417; Rehberg S, 2008, ANESTHESIOLOGY, V109, P629, DOI 10.1097/ALN.0b013e31818629c2; Song IK, 2016, PEDIATR ANESTH, V26, P438, DOI 10.1111/pan.12864; Suzan E, 2013, PAIN PHYSICIAN, V16, P65	20	1	1	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1098-7339	1532-8651		REGION ANESTH PAIN M	Region. Anesth. Pain Med.	JUN	2019	44	6					627	631		10.1136/rapm-2018-100217			5	Anesthesiology	Anesthesiology	IC7MM	WOS:000471158500004	30923248				2020-06-30	J	Ueshima, H; Tanaka, N; Otake, H				Ueshima, Hironobu; Tanaka, Noriko; Otake, Hiroshi			Greater analgesic effect with intermittent compared with continuous mode of lumbar plexus block for total hip arthroplasty: a randomized controlled trial	REGIONAL ANESTHESIA AND PAIN MEDICINE			English	Article							NERVE BLOCK; ROPIVACAINE; BOLUS; INFUSIONS; PAIN; DURATION	Background and objectives Lumbar plexus block (LPB) is an effective perioperative analgesic therapy for patients undergoing total hip arthroplasty (THA). However, the analgesic efficacy of intermittent administration compared with continuous infusion of LPB in patients remains unclear. Methods Forty adult patients who underwent THA were randomly divided into two groups: continuous infusion group (6 mL/hour continuous infusion of levobupivacaine [0.125%] in LPB, n=20) and intermittent infusion group (12 mL of levobupivacaine [0.125%] bolus delivered every 2 hours in LPB, n=20). The primary outcome was the cumulative fentanyl consumption administered for rescue analgesia during the first 48 hours after surgery. Secondary outcomes were the number of demands for rescue analgesia and successfully delivered rescue analgesia; extent of sensory blockade (cold tests); and pain score on the visual analog scale (VAS) at rest and during mobilization during the first 48 hours after surgery. Results Both the cumulative fentanyl consumption administered for rescue analgesia (mean [SD]: 81.5 [58.5] mu g vs 438 [101.2] mu g among the intermittent infusion and the continuous infusion groups, respectively) and the number of demanded and delivered fentanyl boluses for rescue analgesia were lower in intermittent infusion group than in continuous infusion (p< 0.001 for both). The extent of sensory blockade remained constant in intermittent infusion group, but gradually narrowed in continuous infusion. VAS was lower in intermittent infusion group than in continuous infusion, except at 1 and 12 hours postoperatively (p< 0.05). Conclusions Greater analgesic effect was achieved using the intermittent mode than the continuous mode of LPB administration.	[Ueshima, Hironobu; Tanaka, Noriko; Otake, Hiroshi] Showa Univ, Anesthesiol, Tokyo, Japan	Ueshima, H (reprint author), Showa Univ, Anesthesiol, Shinagawa Ku, Tokyo 1428666, Japan.	ueshimhi@gmail.com	Otake, Hiroshi/AAB-1327-2020	Otake, Hiroshi/0000-0002-4776-3211			Behrends M, 2018, ANESTHESIOLOGY, V129, P536, DOI 10.1097/ALN.0000000000002321; Chong MA, 2017, J CLIN ANESTH, V42, P69, DOI 10.1016/j.jclinane.2017.08.018; Fahs AM, 2018, J ARTHROPLASTY, V33, P2192, DOI 10.1016/j.arth.2018.02.052; Fettes PDW, 2006, BRIT J ANAESTH, V97, P359, DOI 10.1093/bja/ael157; George RB, 2013, ANESTH ANALG, V116, P133, DOI 10.1213/ANE.0b013e3182713b26; Giron-Arango L, 2018, REGION ANESTH PAIN M, V43, P859, DOI 10.1097/AAP.0000000000000847; Ilfeld BM, 2010, ANESTHESIOLOGY, V112, P347, DOI 10.1097/ALN.0b013e3181ca4e5d; Ilfeld BM, 2009, ANESTH ANALG, V109, P586, DOI 10.1213/ane.0b013e3181a9db5d; Johnson RL, 2017, J BONE JOINT SURG AM, V99, P1836, DOI 10.2106/JBJS.16.01305; Kadam VR, 2017, J PAIN RES, V10, P1705, DOI 10.2147/JPR.S132891; Macrae WA, 2001, BRIT J ANAESTH, V87, P88, DOI 10.1093/bja/87.1.88; Mezzatesta JP, 1997, REGION ANESTH, V22, P357, DOI 10.1016/S1098-7339(97)80012-0; Nielsen MV, 2018, MINERVA ANESTESIOL, V84, P115, DOI 10.23736/S0375-9393.17.11783-9; Nielsen TD, 2018, REGION ANESTH PAIN M, V43, P357, DOI 10.1097/AAP.0000000000000737; Njathi CW, 2017, REGION ANESTH PAIN M, V42, P446, DOI 10.1097/AAP.0000000000000589; Oxlund J, 2018, ACTA ANAESTH SCAND, V62, P85, DOI 10.1111/aas.13011; Siddiqui ZI, 2007, REGION ANESTH PAIN M, V32, P393, DOI 10.1016/j.rapm.2007.04.008; Singelyn FJ, 2001, ANESTH ANALG, V92, P455, DOI 10.1213/00000539-200102000-00033; Soltesz S, 2016, INT ORTHOP, V40, P1861, DOI 10.1007/s00264-016-3117-3; Treede RD, 2015, PAIN, V156, P1003, DOI 10.1097/j.pain.0000000000000160; Williams BA, 2007, REGION ANESTH PAIN M, V32, P186, DOI 10.1016/j.rapm.2006.10.011; Wilson SH, 2014, PAIN MED, V15, P465, DOI 10.1111/pme.12309; Yu J, 2018, EXP THER MED, V16, P711, DOI 10.3892/etm.2018.6218; Zakus P, 2018, ANAESTHESIA, V73, P459, DOI 10.1111/anae.14159	24	1	1	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1098-7339	1532-8651		REGION ANESTH PAIN M	Region. Anesth. Pain Med.	JUN	2019	44	6					632	636		10.1136/rapm-2018-100091			5	Anesthesiology	Anesthesiology	IC7MM	WOS:000471158500005	30948522				2020-06-30	J	Zhou, W; Zhang, DS; Tian, SP; Yang, Y; Xing, Z; Ma, RR; Zhou, TQ; Bao, TX; Sun, JH; Zhang, Z				Zhou, Wei; Zhang, Dongsheng; Tian, Shunping; Yang, Yang; Xing, Zhi; Ma, Rongrong; Zhou, Tianqi; Bao, Tianxiu; Sun, Jianhong; Zhang, Zhuan			Optimal dose of pretreated-dexmedetomidine in fentanyl-induced cough suppression: a prospective randomized controlled trial	BMC ANESTHESIOLOGY			English	Article						Dexmedetomidine; Fentanyl; Cough	PROLONGED INJECTION TIME; INTRAVENOUS LIDOCAINE; DOUBLE-BLIND; ANESTHESIA; PREMEDICATION; INDUCTION; PROPOFOL	Background: To investigate the optimal dose of pretreated-dexmedetomidine in fentanyl-induced cough (FIC) suppression. Methods: Patients of 180 undergoing elective surgery with general anesthesia, aged 18-65years, BMI 18.5-30kg/m(2), ASA I or II, were equally randomized into four groups (n=45) to receive intravenous pretreatment of dexmedetomidine with 0 (group 1), 0.3 (group 2), 0.6 (group 3) and 0.9 (group 4) mcg/kg over 10 mins, respectively. After the pretreatment, all patients were given a 5-s intravenous injection of fentanyl 4 mcg/kg. The symptoms of irritating cough including the severity and onset time were recorded for 1min after fentanyl injection. General anesthesia induction was completed with midazolam, propofol and cisatracurium, then endotracheal tube or laryngeal mask was inserted and connected to an anesthesia machine. MAP, HR and SpO(2) at the beginning of pretreatment (T0), 3min (T1), 6min (T2), 9min (T3) and 12min (T4) after the beginning of pretreatment were recorded. Side effects of dexmedetomidine, such as bradycardia, hypertension, hypotension, and respiratory depression were also recorded during the course. Results: Totally 168 patients completed the study. The incidences of cough were 52.4, 42.9, 11.9, and 14.3% in groups 1, 2, 3, and 4, respectively, with no significant differences between groups 1 and 2 (P>0.05) and between groups 3 and 4 (P>0.05). The incidence and severity of cough in groups 3 and 4 were significantly lower than those in groups 1 and 2 (P<0.05). Compared to T0, HR at T2 (P<0.05), T3 (P<0.01), and T4 (P<0.01) decreased significantly and MAP at T4 decreased significantly (P<0.05) in group 4. Bradycardia occurred in 1 case and respiratory depression occurred in 1 case in group 4. Compared to group 1, the onset time of cough in the other 3 groups were delayed significantly (P<0.05). Conclusion: Pretreated dexmedetomidine 0.6 mcg/kg blous intravenous infusion over 10 mins could reduce FIC effectively without side effects.	[Zhou, Wei; Tian, Shunping] Yangzhou Univ, Sch Med, Yangzhou 225009, Jiangsu, Peoples R China; [Zhang, Dongsheng; Yang, Yang; Xing, Zhi; Ma, Rongrong; Bao, Tianxiu; Sun, Jianhong; Zhang, Zhuan] Yangzhou Univ, Dept Anesthesiol, Affiliated Hosp, Yangzhou 225012, Jiangsu, Peoples R China; [Zhou, Tianqi] Yangzhou Univ, Prevent Hlth Care Off, Affiliated Hosp, Yangzhou 225012, Jiangsu, Peoples R China	Zhang, Z (reprint author), Yangzhou Univ, Dept Anesthesiol, Affiliated Hosp, Yangzhou 225012, Jiangsu, Peoples R China.	weizhou3126@163.com; zhangzhuancg@163.com					Agarwal A, 2007, ANAESTHESIA, V62, P1230, DOI 10.1111/j.1365-2044.2007.05249.x; Agarwal A, 2003, CAN J ANAESTH, V50, P297, DOI 10.1007/BF03017801; Ambesh SP, 2010, BRIT J ANAESTH, V104, P40, DOI 10.1093/bja/aep333; Ambesh SP, 2009, INT J ANESTHESIOL, V20, P7; BOHRER H, 1990, ANAESTHESIA, V45, P18, DOI 10.1111/j.1365-2044.1990.tb14496.x; He L, 2012, UPSALA J MED SCI, V117, P18, DOI 10.3109/03009734.2011.629749; Horng HC, 2007, ACTA ANAESTH SCAND, V51, P862, DOI 10.1111/j.1399-6576.2007.01335.x; Hung KC, 2009, ACTA ANAESTH SCAND, V53, P1227, DOI 10.1111/j.1399-6576.2009.02027.x; Ko KH, 2015, KOREAN J ANESTHESIOL, V68, P575, DOI 10.4097/kjae.2015.68.6.575; Kusumoto FM, 2018, HEART RHYTHM; Li Y, 2016, ANESTH ANALG, V122, P1202, DOI 10.1213/ANE.0000000000001165; Lim KJ, 2013, KOREAN J ANESTHESIOL, V65, P251, DOI 10.4097/kjae.2013.65.3.251; Lin CS, 2004, CAN J ANAESTH, V51, P654, DOI 10.1007/BF03018421; Lin JA, 2005, ANESTH ANALG, V101, P670, DOI 10.1213/01.ANE.0000159161.31276.DB; Lui PW, 1996, CAN J ANAESTH, V43, P1216; Oshima T, 2006, CAN J ANAESTH, V53, P753, DOI 10.1007/BF03022790; Pandey CK, 2005, CAN J ANAESTH, V52, P172, DOI 10.1007/BF03027724; Pandey CK, 2004, ANESTH ANALG, V99, P1696, DOI 10.1213/01.ANE.0000136967.82197.82; Sedighinejad Abbas, 2013, Anesth Pain Med, V2, P170, DOI 10.5812/aapm.8383; Tan JA, 2010, INTENS CARE MED, V36, P926, DOI 10.1007/s00134-010-1877-6; Tang QF, 2010, UPSALA J MED SCI, V115, P121, DOI 10.3109/03009730903291034; Tweed WA, 2001, ANESTH ANALG, V92, P1442; Yeh CC, 2007, J CLIN ANESTH, V19, P53, DOI 10.1016/j.jclinane.2006.05.021; Yu H, 2007, ANAESTHESIA, V62, P919, DOI 10.1111/j.1365-2044.2007.05147.x; Yu J, 2012, IRISH J MED SCI, V181, P517, DOI 10.1007/s11845-012-0807-8	25	0	0	0	2	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1471-2253			BMC ANESTHESIOL	BMC Anesthesiol.	JUN 1	2019	19								89	10.1186/s12871-019-0765-z			7	Anesthesiology	Anesthesiology	IA9MF	WOS:000469880600001	31153360	DOAJ Gold, Green Published			2020-06-30	J	Gonzalez-Rojano, E; Marcotegui, J; Morales-Alcelay, S; Alvarez, C; Gordon, J; Abad-Santos, F; Garcia-Arieta, A				Gonzalez-Rojano, Esperanza; Marcotegui, Julio; Morales-Alcelay, Susana; Alvarez, Covadonga; Gordon, John; Abad-Santos, Francisco; Garcia-Arieta, Alfredo			Sex-by-formulation interaction in bioequivalence trials with transdermal patches	EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY			English	Article						Sex-by-formulation interaction; Bioequivalence; Transdermal patches; Males; Females	PHYSIOLOGY	PurposeThe existence of a sex-by-formulation interaction in bioequivalence studies implies that the bioequivalence results (i.e., the test/reference ratio of the pharmacokinetic parameters) obtained in one sex are not similar to those obtained in the other sex. Therefore, results obtained in studies including only males may not be representative of the results obtained in females and vice versa. The best evidence of the existence of a sex-by-formulation interaction has been obtained from a study conducted with transdermal patches. This observation might be caused by the different characteristics of the skin of males and females. The purpose of this work is to investigate the existence of a sex-by-formulation interaction in all bioequivalence studies of transdermal patches submitted to the Spanish Agency for Medicines between 2010 and 2016.MethodsOnly five different products (Buprenorphine-1, Fentantyl-1, Fentanyl-2, Rivastigmine-1 and Rivastigmine-2) that were submitted for registration included nine bioequivalence studies conducted in males and females. As single dose and multiple dose studies are required for registration of transdermal patches in the European Union, more than one study may be available to confirm the existence of a sex-by-formulation interaction.ResultsA sex-by-formulation interaction is suggested in six out of 27 datasets (22%), corresponding to two products, and it is statistically significant in three of them (11%).ConclusionsThe sex-by-formulation interaction detected in some pharmacokinetic parameters of some studies is excluded when the study is repeated, which shows that these results are not reproducible. There is no evidence to require bioequivalence demonstration for transdermal patches in males and females separately.	[Gonzalez-Rojano, Esperanza; Abad-Santos, Francisco] UAM, Inst Invest Sanitaria Princesa IIS IP, Hosp Univ La Princesa, Clin Pharmacol Serv,Inst Teofilo Hernando, Madrid, Spain; [Marcotegui, Julio] Hosp Clin San Carlos, Dept Anaesthesiol Reanimat & Pain Treatment, Madrid, Spain; [Morales-Alcelay, Susana; Garcia-Arieta, Alfredo] Spanish Agcy Med & Hlth Care Prod AEMPS, Serv Pharmacokinet & Gener, Div Pharmacol & Clin Evaluat, Dept Human Use Med, C Campezo 1,Edificio 8,Planta 2 A, Madrid 28022, Spain; [Alvarez, Covadonga] Univ Complutense Madrid, Pharmaceut Technol, Fac Farm, Madrid, Spain; [Gordon, John] Hlth Canada, Bur Pharmaceut Sci, Therapeut Prod Directorate, Div Biopharmaceut Evaluat, Ottawa, ON, Canada	Garcia-Arieta, A (reprint author), Spanish Agcy Med & Hlth Care Prod AEMPS, Serv Pharmacokinet & Gener, Div Pharmacol & Clin Evaluat, Dept Human Use Med, C Campezo 1,Edificio 8,Planta 2 A, Madrid 28022, Spain.	agarciaa@aemps.es	Abad-Santos, Francisco/J-7115-2013	Abad-Santos, Francisco/0000-0002-6519-8885			Alkilani AZ, 2015, PHARMACEUTICS, V7, P438, DOI 10.3390/pharmaceutics7040438; Chen ML, 2000, CLIN PHARMACOL THER, V68, P510, DOI 10.1067/mcp.2000.111184; European Medicines Agency, 2014, EMACHMP5391462013; European Medicines Agency, 2010, CPMPEWPQWP140198REV1; Garcia-Arieta A, 2012, INT J PHARMACEUT, V423, P321, DOI 10.1016/j.ijpharm.2011.11.022; Giacomoni PU, 2009, J DERMATOL SCI, V55, P144, DOI 10.1016/j.jdermsci.2009.06.001; Gonzalez-Rojano E, 2018, BRIT J CLIN PHARMACO, V84, P1729, DOI 10.1111/bcp.13601; Ibarra M, 2016, EUR J PHARM SCI, V85, P106, DOI 10.1016/j.ejps.2016.02.001; Jacobi U, 2005, DERMATOLOGY, V211, P312, DOI 10.1159/000088499; Koren G, 2013, CLIN PHARMACOL THER, V93, P260, DOI 10.1038/clpt.2012.233; Luebberding S, 2013, INT J COSMETIC SCI, V35, P477, DOI 10.1111/ics.12068; US Department of Health and Human Services Food and Drug Administration (FaDA), 2003, GUID IND BIOAV BIOEQ	12	0	0	4	13	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0031-6970	1432-1041		EUR J CLIN PHARMACOL	Eur. J. Clin. Pharmacol.	JUN	2019	75	6					801	808		10.1007/s00228-019-02632-1			8	Pharmacology & Pharmacy	Pharmacology & Pharmacy	IA2CB	WOS:000469367900007	30725220				2020-06-30	J	Ozawa, Y; Ades, A; Foglia, EE; DeMeo, S; Barry, J; Sawyer, T; Singh, N; Glass, K; Jung, P; Quek, B; Johnston, L; Kim, J; Napolitano, N; Shults, J; Nadkarni, VM; Nishisakil, A				Ozawa, Yuri; Ades, Anne; Foglia, Elizabeth E.; DeMeo, Stephen; Barry, James; Sawyer, Taylor; Singh, Neetu; Glass, Kristen; Jung, Philipp; Quek, Bin Huey; Johnston, Lindsay; Kim, Jae; Napolitano, Natalie; Shults, Justine; Nadkarni, Vinay M.; Nishisakil, Akira		Natl Emergency Airway Registry Neo	Premedication with neuromuscular blockade and sedation during neonatal intubation is associated with fewer adverse events	JOURNAL OF PERINATOLOGY			English	Article							ENDOTRACHEAL INTUBATION; TRACHEAL INTUBATION; PRETERM INFANTS; MORPHINE; INDUCTION; IMPACT; TERM; PAIN	Objective To determine the impact of premedication for tracheal intubation (TI) on adverse TI associated events, severe oxygen desaturations, and first attempt success Study design Retrospective cohort study in neonatal intensive care units (NICU) participating in the National Emergency Airway Registry for Neonates from 10/2014 to 6/2017. Premedication for TI was categorized as sedation with neuromuscular blockade, sedation only, or no medication. Results 2260 TIs were reported from 11 NICUs. Adverse TI associated events occurred less often in sedation with neuromuscular blockade group (10%) as compared to sedation only (29%), or no medication group (23%), p < 0.001. The adjusted odds ratio (aOR) for adverse TI associated events were: sedation with neuromuscular blockade aOR 0.48 (95% CI 0.34-0.65, p < 0.001) compared to no medication. Conclusion Use of sedation with neuromuscular blockade was associated with favorable TI outcomes. This study	[Ozawa, Yuri; Ades, Anne; Nadkarni, Vinay M.; Nishisakil, Akira] Childrens Hosp Philadelphia, Ctr Simulat Adv Educ & Innovat, Philadelphia, PA 19104 USA; [Ades, Anne; Foglia, Elizabeth E.] Childrens Hosp Philadelphia, Dept Pediat, Div Neonatol, Philadelphia, PA 19104 USA; [DeMeo, Stephen] WakeMed Hlth & Hosp, Dept Pediat, Campus, NC USA; [Barry, James] Univ Colorado, Sch Med, Div Neonatol, Aurora, CO USA; [Barry, James] Childrens Hosp Colorado, Aurora, CO USA; [Sawyer, Taylor] Univ Washington, Sch Med, Dept Pediat, Div Neonatol, Seattle, WA 98195 USA; [Sawyer, Taylor] Seattle Childrens Hosp, Seattle, WA USA; [Singh, Neetu] Dartmouth Hitchcock Med Ctr, Dept Pediat, Div Neonatol, West Lebanon, NH USA; [Glass, Kristen] Penn State Hlth Childrens Hosp, Penn State Coll Med, Div Neonatol, Dept Pediat, Hershey, PA USA; [Jung, Philipp] Univ Hosp Schleswing Holstein, Dept Pediat, Campus Luebeck, Lubeck, Germany; [Quek, Bin Huey] KK Womens & Childrens Hosp, Neonatol Dept, Singapore, Singapore; [Johnston, Lindsay] Yale Univ, Sch Med, Div Neonatol, New Haven, CT USA; [Kim, Jae] Univ Calif San Diego, Dept Pediat, Div Neonatol, San Diego, CA 92103 USA; [Napolitano, Natalie] Childrens Hosp Philadelphia PA, Resp Therapy Dept, Philadelphia, PA USA; [Shults, Justine] Univ Penn, Perelman Sch Med, Dept Biostat & Epidemiol, Pennsylvania, PA USA; [Nadkarni, Vinay M.; Nishisakil, Akira] Childrens Hosp Philadelphia, Dept Anesthesiol & Crit Care Med, Philadelphia, PA 19104 USA	Ozawa, Y (reprint author), Childrens Hosp Philadelphia, Ctr Simulat Adv Educ & Innovat, Philadelphia, PA 19104 USA.	yuri-nishi@hotmail.com		/0000-0002-9925-5219; Sawyer, Taylor/0000-0002-3908-8957	NICHDUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [1R21HD089151]; AHRQUnited States Department of Health & Human ServicesAgency for Healthcare Research & Quality [1R18HS024511]	The current study is supported by NICHD 1R21HD089151. Drs. Ades, Sawyer, and Nishisaki and Ms. Napolitano are supported by NICHD 1R21HD089151. Dr. Nishisaki and Ms. Napolitano is supported by AHRQ 1R18HS024511.	Attarian S, 2014, BRAIN SCI, V4, P321, DOI 10.3390/brainsci4020321; Avino D, 2014, J PEDIATR-US, V164, P1032, DOI 10.1016/j.jpeds.2014.01.030; Barrington KJ, 2011, PAED CHILD HEALT-CAN, V16, P159, DOI 10.1093/pch/16.3.159; Bissuel M, 2013, ARCH PEDIATRIE, V20, P123, DOI 10.1016/j.arcped.2012.11.004; Chaudhary R, 2009, PEDIATR ANESTH, V19, P653, DOI 10.1111/j.1460-9592.2008.02829.x; Durrmeyer X, 2013, PEDIATR CRIT CARE ME, V14, pE169, DOI 10.1097/PCC.0b013e3182720616; Fahnenstich H, 2000, CRIT CARE MED, V28, P836, DOI 10.1097/00003246-200003000-00037; Feltman DM, 2011, J PERINATOL, V31, P38, DOI 10.1038/jp.2010.74; Foglia EE, 2019, PEDIATRICS, V143, DOI 10.1542/peds.2018-0902; Foglia EE, 2015, NEONATOLOGY, V108, P23, DOI 10.1159/000381252; Ghanta S, 2007, PEDIATRICS, V119, pE1248, DOI 10.1542/peds.2006-2708; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Ing CH, 2014, ANESTHESIOLOGY, V120, P1319, DOI 10.1097/ALN.0000000000000248; Krick J, 2018, J PERINATOL, V38, P681, DOI 10.1038/s41372-018-0082-2; Kumar P, 2010, PEDIATRICS, V125, P608, DOI 10.1542/peds.2009-2863; Kurth T, 2006, AM J EPIDEMIOL, V163, P262, DOI 10.1093/aje/kwj047; Le CN, 2014, J PERINATOL, V34, P458, DOI 10.1038/jp.2014.32; Maheshwari R, 2016, J PAEDIATR CHILD H, V52, P480, DOI 10.1111/jpc.13192; Morriss FH, 2014, JAMA PEDIATR, V168, P746, DOI 10.1001/jamapediatrics.2014.307; Norman E, 2011, J PEDIATR-US, V159, P893, DOI 10.1016/j.jpeds.2011.06.003; Pacifici GM, 2016, CLINICS, V71, P474, DOI 10.6061/clinics/2016(08)11; Raban MS, 2014, SAMJ S AFR MED J, V104, P846, DOI 10.7196/SAMJ.8305; Sauer CW, 2016, J PEDIATR-US, V177, P108, DOI 10.1016/j.jpeds.2016.06.051; van Hasselt TJ, 2017, ARCH DIS CHILD, V102, P780, DOI 10.1136/archdischild-2017-313107; Venkatesh V, 2011, EUR J PEDIATR, V170, P223, DOI 10.1007/s00431-010-1290-8; Wallenstein MB, 2016, J PERINATOL, V36, P112, DOI 10.1038/jp.2015.158; Wheeler B, 2012, J PAEDIATR CHILD H, V48, P997, DOI 10.1111/j.1440-1754.2012.02589.x	27	2	2	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0743-8346	1476-5543		J PERINATOL	J. Perinatol.	JUN	2019	39	6					848	856		10.1038/s41372-019-0367-0			9	Obstetrics & Gynecology; Pediatrics	Obstetrics & Gynecology; Pediatrics	HZ5MD	WOS:000468895300012	30940929				2020-06-30	J	Ren, J; Ding, XQ; Greer, JJ				Ren, Jun; Ding, Xiuqing; Greer, John J.			Activating alpha 4 beta 2 Nicotinic Acetylcholine Receptors Alleviates Fentanyl-induced Respiratory Depression in Rats	ANESTHESIOLOGY			English	Article							INDUCED VENTILATORY DEPRESSION; PREBOTZINGER COMPLEX; OPIOID RECEPTORS; CHANNEL BLOCKER; FORMALIN TEST; MORPHINE; BRAIN; MODULATION; AGONIST; ANTAGONISM	Background: Opioid analgesics are widely used for treatment of acute, postoperative, and chronic pain. However, activation of opioid receptors can result in severe respiratory depression. There is an unmet clinical need to develop a pharmacologic therapy to counter opioid-induced respiratory depression without interfering with analgesia. Further, additional advances to confront accidental lethal overdose with the use of fentanyl and other opioids are needed. Here, the authors test the hypothesis that activation of nicotinic receptors expressed within respiratory rhythm-generating networks would counter opioid-induced respiratory depression without compromising analgesia. Methods: Respiratory neural discharge was measured using in vitro brainstem-spinal cord and medullary slice rat preparations. In vivo, plethysmographic recording, nociception testing, and righting reflexes were used to examine respiratory ventilation, analgesia, and sedation, respectively. Results: The administration of nicotine, selective alpha 4 beta 2 nicotinic receptor agonist A85380, but not a7 nicotinic receptor agonist PNU282987, reversed opioid-induced respiratory depression in neonatal pups in vitro and in vivo. In adult rats in vivo, administration of A85380 (0.03 mg/kg), but not PNU282987, provides a rapid and robust reversal of fentanyl-induced decrease in respiratory rate (93.4 +/- 33.7% of control 3 min after A85380 vs. 31 +/- 20.5% of control after vehicle, n = 8 each, P < 0.001), without marked side effects. The coadministration of A85380 (0.06 mg/kg) with fentanyl or remifentanil markedly reduced respiratory depression and apneas, and enhanced the fentanyl-induced analgesia, as evidenced by increased paw withdrawal latency in Hargreaves plantar test (14.4 +/- 2.8 s vs. vehicle: 11.3 +/- 2.4 s, n = 8 each, P = 0.013) and decreased formalin-induced nocifensive duration (2.5 +/- 2.4 min vs. vehicle: 5.4 +/- 2.7 min, n = 8 each, P = 0.029). Conclusions: The novel strategy of targeting alpha 4 beta 2 nicotinic acetylcholine receptors has the potential for advancing pain control and reducing opioid-induced respiratory depression and overdose.	[Ren, Jun; Ding, Xiuqing; Greer, John J.] Univ Alberta, Dept Physiol, 3-020M Katz Bldg, Edmonton, AB T6G 2S2, Canada	Greer, JJ (reprint author), Univ Alberta, Dept Physiol, 3-020M Katz Bldg, Edmonton, AB T6G 2S2, Canada.	john.greer@ualberta.ca			National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP, Edmonton, Alberta, Canada)	Supported by the National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP, Edmonton, Alberta, Canada; to Dr. Greer).	ABBOTT FV, 1995, PAIN, V60, P91, DOI 10.1016/0304-3959(94)00095-V; Bannon AW, 1998, SCIENCE, V279, P77, DOI 10.1126/science.279.5347.77; Benyamin R, 2008, PAIN PHYSICIAN, V11, pS105; Bitner RS, 2000, BRAIN RES, V871, P66, DOI 10.1016/S0006-8993(00)02442-2; Boom M, 2012, CURR PHARM DESIGN, V18, P5994, DOI 10.2174/138161212803582469; BOURKE DL, 1987, ANESTHESIOLOGY, V66, P153, DOI 10.1097/00000542-198702000-00008; Conde SV, 2006, BRIT J PHARMACOL, V147, P783, DOI 10.1038/sj.bjp.0706676; Curzon P, 1998, J PHARMACOL EXP THER, V287, P847; Dahan A, 2010, ANESTHESIOLOGY, V112, P226, DOI 10.1097/ALN.0b013e3181c38c25; DAMAJ MI, 1995, PSYCHOPHARMACOLOGY, V117, P67, DOI 10.1007/BF02245100; Dietis N, 2011, BRIT J ANAESTH, V107, P8, DOI 10.1093/bja/aer115; DUBUISSON D, 1977, PAIN, V4, P161, DOI 10.1016/0304-3959(77)90130-0; ELMALEM E, 1991, NEUROPHARMACOLOGY, V30, P1059, DOI 10.1016/0028-3908(91)90134-W; Funk GD, 2013, RESP PHYSIOL NEUROBI, V186, P236, DOI 10.1016/j.resp.2013.01.011; Golder FJ, 2013, RESP PHYSIOL NEUROBI, V189, P395, DOI 10.1016/j.resp.2013.06.010; Gotti C, 2006, TRENDS PHARMACOL SCI, V27, P482, DOI 10.1016/j.tips.2006.07.004; Gray PA, 1999, SCIENCE, V286, P1566, DOI 10.1126/science.286.5444.1566; GREER JJ, 1995, J PHYSIOL-LONDON, V485, P845, DOI 10.1113/jphysiol.1995.sp020774; Guenther U, 2012, ANESTHESIOLOGY, V116, P56, DOI 10.1097/ALN.0b013e31823d08fa; Haji A, 2003, NEUROPHARMACOLOGY, V45, P368, DOI 10.1016/S0028-3908(03)00154-0; Hajos M, 2005, J PHARMACOL EXP THER, V312, P1213, DOI 10.1124/jpet.104.076968; Hatori E, 2006, BIOL RES, V39, P321, DOI 10.4067/S0716-97602006000200014; HAVEMANN U, 1981, N-S ARCH PHARMACOL, V317, P321, DOI 10.1007/BF00501313; Haw AJ, 2016, VET ANAESTH ANALG, V43, P528, DOI 10.1111/vaa.12358; Jonkman K, 2018, BRIT J ANAESTH, V120, P1117, DOI 10.1016/j.bja.2018.02.021; Jungquist CR, 2017, AM J NURS S1, V117, P27; Kimes AS, 2008, NEUROIMAGE, V39, P717, DOI 10.1016/j.neuroimage.2007.09.015; Krystal A, 2017, SLEEP, V40, pA212, DOI 10.1093/sleepj/zsx050.570; Lorier AR, 2008, J PHYSIOL-LONDON, V586, P1429, DOI 10.1113/jphysiol.2007.143024; Lorier AR, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008766; Lotsch J, 2005, CLIN PHARMACOL THER, V78, P278, DOI 10.1016/j.clpt.2005.05.010; Lynch G, 2006, CURR OPIN PHARMACOL, V6, P82, DOI 10.1016/j.coph.2005.09.005; Manzke T, 2010, J CLIN INVEST, V120, P4118, DOI 10.1172/JCI43029; Marubio LM, 1999, NATURE, V398, P805; Matta SG, 2007, PSYCHOPHARMACOLOGY, V190, P269, DOI 10.1007/s00213-006-0441-0; McLeod JF, 2014, BRIT J ANAESTH, V113, P875, DOI 10.1093/bja/aeu182; Meza RC, 2012, NEUROCHEM INT, V60, P115, DOI 10.1016/j.neuint.2011.11.011; Montandon G, 2011, J NEUROSCI, V31, P1292, DOI 10.1523/JNEUROSCI.4611-10.2011; Oertel BG, 2007, CLIN PHARMACOL THER, V81, P59, DOI 10.1038/sj.clpt.6100018; Oertel BG, 2010, CLIN PHARMACOL THER, V87, P204, DOI 10.1038/clpt.2009.194; Pilarski JQ, 2009, RESP PHYSIOL NEUROBI, V169, P1, DOI 10.1016/j.resp.2009.07.022; Ren J, 2006, J NEUROSCI, V26, P3721, DOI 10.1523/JNEUROSCI.0026-06.2006; Ren J, 2006, AM J RESP CRIT CARE, V174, P1384, DOI 10.1164/rccm.200606-778OC; Ren J, 2015, ANESTHESIOLOGY, V122, P424, DOI 10.1097/ALN.0000000000000490; Ren J, 2009, ANESTHESIOLOGY, V110, P1364, DOI 10.1097/ALN.0b013e31819faa2a; Romberg R, 2003, BRIT J ANAESTH, V91, P862, DOI 10.1093/bja/aeg279; Roozekrans M, 2015, CLIN PHARMACOL THER, V97, P641, DOI 10.1002/cpt.99; Rueter LE, 2006, CNS DRUG REV, V12, P100, DOI 10.1111/j.1527-3458.2006.00100.x; Seth P, 2018, MMWR-MORBID MORTAL W, V67, P349, DOI 10.15585/mmwr.mm6712a1; Shao XSM, 2002, J NEUROPHYSIOL, V88, P1851, DOI 10.1152/jn.2002.88.4.1851; SHOOK JE, 1990, AM REV RESPIR DIS, V142, P895, DOI 10.1164/ajrccm/142.4.895; Takeda S, 2001, ANESTHESIOLOGY, V95, P740, DOI 10.1097/00000542-200109000-00029; Ueda M, 2004, ANN NUCL MED, V18, P337, DOI 10.1007/BF02984473; Umana IC, 2013, BIOCHEM PHARMACOL, V86, P1208, DOI 10.1016/j.bcp.2013.08.001; van Dorp ELA, 2007, EXPERT OPIN DRUG SAF, V6, P125, DOI 10.1517/14740338.6.2.125; WADA E, 1989, J COMP NEUROL, V284, P314, DOI 10.1002/cne.902840212	56	2	2	2	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-3022	1528-1175		ANESTHESIOLOGY	Anesthesiology	JUN	2019	130	6					1017	1031		10.1097/ALN.0000000000002676			15	Anesthesiology	Anesthesiology	HY1DX	WOS:000467856100019	31008764				2020-06-30	J	Friedrich, S; Raub, D; Teja, BJ; Neves, SE; Thevathasan, T; Houle, TT; Eikermann, M				Friedrich, S.; Raub, D.; Teja, B. J.; Neves, S. E.; Thevathasan, T.; Houle, T. T.; Eikermann, M.			Effects of low-dose intraoperative fentanyl on postoperative respiratory complication rate: a pre- specified, retrospective analysis	BRITISH JOURNAL OF ANAESTHESIA			English	Article						analgesics; opioid; fentanyl; pneumonia; postoperative complications; respiratory failure; respiratory tract diseases	ASSOCIATION; PREVENTION; OPIOIDS	Background: Fentanyl is one of the most frequently administered intraoperative drugs and may increase the risk of postoperative respiratory complications (PRCs). Methods: We performed a pre-specified analysis of 145 735 adult non-cardiac surgical cases under general anaesthesia. Using multivariable logistic regression, we evaluated the association of intraoperative fentanyl dose and PRCs within 3 days after surgery (defined as reintubation, respiratory failure, pneumonia, pulmonary oedema, or atelectasis). We examined effect modification by patient characteristics, surgical site, and anaesthetics used. Results: PRCs within 3 days after surgery occurred in 18 839 (12.9%) patients. In comparison with high intraoperative fentanyl doses [median: 3.85; inter-quartile range (IQR): 3.42-4.50 mu g kg(-1), quartile 4 (Q4)], low intraoperative fentanyl dose [median: 0.80, IQR: 0.00-1.14 mu g kg(-1), quartile 1 (Q1)] was significantly associated with lower odds of PRCs [Q1 vs Q4: 10.9% vs 16.2%; adjusted odds ratio (aOR) 0.79; 95% confidence intervals (CI) 0.75-0.84; P<0.001; adjusted absolute risk difference (aARD) -1.7%]. This effect was augmented by thoracic surgery (P for interaction <0.001; aARD -6.2%), high doses of inhalation anaesthetics (P for interaction=0.016; aARD -2.2%) and neuromuscular blocking agents (NMBAs) (P for interaction=0.001; aARD -3.4%). Exploratory analysis demonstrated that compared with no fentanyl, low-dose fentanyl was associated with lower rates of PRCs (decile 2 vs decile 1: aOR 0.82, CI 0.75-0.89, P<0.001). Conclusions: Intraoperative low-dose fentanyl (about 60-120 mu g for a 70 kg patient) was associated with lower risk of postoperative respiratory complications compared with both no fentanyl and high-dose fentanyl. Beneficial effects of low-dose fentanyl were magnified in specific patient subgroups.	[Friedrich, S.; Raub, D.; Teja, B. J.; Neves, S. E.; Eikermann, M.] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02115 USA; [Friedrich, S.; Raub, D.; Thevathasan, T.; Houle, T. T.] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA; [Friedrich, S.; Raub, D.; Thevathasan, T.; Houle, T. T.] Harvard Med Sch, Boston, MA 02115 USA; [Eikermann, M.] Univ Klinikum Essen, Essen, Germany	Eikermann, M (reprint author), Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02115 USA.; Eikermann, M (reprint author), Univ Klinikum Essen, Essen, Germany.	meikerma@bidmc.harvard.edu			Jeff and Judy Buzen	Unrestricted grant by Jeff and Judy Buzen to ME (philanthropic donation).	Bagchi A, 2017, ANAESTHESIA, V72, P1334, DOI 10.1111/anae.14039; BAUER AJ, 1991, GASTROENTEROLOGY, V101, P970, DOI 10.1016/0016-5085(91)90723-X; Brown D L, 1990, J Cardiothorac Anesth, V4, P368, DOI 10.1016/0888-6296(90)90048-K; Brueckmann B, 2013, ANESTHESIOLOGY, V118, P1276, DOI 10.1097/ALN.0b013e318293065c; Cohen MJ, 2005, SURG CLIN N AM, V85, P1243, DOI 10.1016/j.suc.2005.09.009; Devereaux PJ, 2008, LANCET, V371, P1839, DOI 10.1016/S0140-6736(08)60601-7; Grabitz Stephanie D, 2017, Crit Care Med, V45, pe30; Gritsenko K, 2014, BEST PRACT RES-CLIN, V28, P59, DOI 10.1016/j.bpa.2014.03.001; Grosse-Sundrup M, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e6329; Gupta D, 2012, ANN NEUROL, V72, P629, DOI 10.1002/ana.23685; Hah JM, 2017, ANESTH ANALG, V125, P1733, DOI 10.1213/ANE.0000000000002458; Isono S, 2011, ANAESTHESIA, V66, P3, DOI 10.1111/j.1365-2044.2011.06928.x; Ladha K, 2015, BMJ-BRIT MED J, V351, DOI 10.1136/bmj.h3646; LIU SS, 1995, ANESTHESIOLOGY, V83, P757, DOI 10.1097/00000542-199510000-00015; Long DR, 2018, BRIT J ANAESTH, V120, P1090, DOI 10.1016/j.bja.2017.12.044; Mascha EJ, 2015, ANESTHESIOLOGY, V123, P79, DOI 10.1097/ALN.0000000000000686; McLean DJ, 2015, ANESTHESIOLOGY, V122, P1201, DOI 10.1097/ALN.0000000000000674; Memtsoudis SG, 2018, ANESTHESIOLOGY, V128, P891, DOI 10.1097/ALN.0000000000002132; Miller RD, 2010, MILLERS ANESTHESIA; Miskovic A, 2017, BRIT J ANAESTH, V118, P317, DOI 10.1093/bja/aex002; Pattinson KTS, 2008, BRIT J ANAESTH, V100, P747, DOI 10.1093/bja/aen094; Royston P, 1999, INT J EPIDEMIOL, V28, P964, DOI 10.1093/ije/28.5.964; Rudolph MI, 2018, ANAESTHESIA, V73, P394, DOI 10.1111/anae.14233; Ruscic KJ, 2017, CURR OPIN ANESTHESIO, V30, P399, DOI 10.1097/ACO.0000000000000465; Saravanan S, 2006, BRIT J ANAESTH, V96, P95, DOI 10.1093/bja/aei265; Sayal P, 2018, ANESTH ANALG, V127, P767, DOI 10.1213/ANE.0000000000003307; Shin CH, 2017, BMC ANESTHESIOL, V17, DOI 10.1186/s12871-017-0361-z; Stanley TH, 2014, J PAIN, V15, P1215, DOI 10.1016/j.jpain.2014.08.010; Tagaito Y, 1998, ANESTHESIOLOGY, V88, P1459, DOI 10.1097/00000542-199806000-00007; Thevathasan T, 2017, BRIT J ANAESTH, V119, P595, DOI 10.1093/bja/aex240; Ward DS, 2011, ANAESTHESIA, V66, P19, DOI 10.1111/j.1365-2044.2011.06930.x	31	5	5	1	3	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0007-0912	1471-6771		BRIT J ANAESTH	Br. J. Anaesth.	JUN	2019	122	6					E180	E188		10.1016/j.bja.2019.03.017			9	Anesthesiology	Anesthesiology	HY0MP	WOS:000467806400017	30982564	Bronze			2020-06-30	J	Varshneya, NB; Walentiny, DM; Moisa, LT; Walker, TD; Akinfiresoye, LR; Beardsley, PM				Varshneya, Neil B.; Walentiny, D. Matthew; Moisa, Lea T.; Walker, Teneille D.; Akinfiresoye, Luli R.; Beardsley, Patrick M.			Opioid-like antinociceptive and locomotor effects of emerging fentanyl-related substances	NEUROPHARMACOLOGY			English	Article						Analgesia; Analog; Fentanyl; Locomotion; Mice; Opioid	SYNTHETIC OPIOIDS; INTOXICATIONS; ANALOGS	The emergence of several fentanyl-related substances in the recreational drug marketplace has resulted in a surge of opioid overdose deaths in the United States. Many of these substances have never been examined in living organisms under controlled conditions. In the present study, seven fentanyl-related substances were tested in adult male Swiss Webster mice for their effects on locomotion and antinociception and compared to those of fentanyl and morphine. In locomotor activity tests, fentanyl (1, 10 mg/kg), morphine (100, 180 mg/kg), isobutyrylfentanyl (10 mg/kg), crotonylfentanyl (10 mg/kg), para-fluorobutyrylfentanyl (10, 100 mg/kg), para-methoxybutyrylfentanyl (10 mg/kg), thiophenefentanyl (100 mg/kg), and benzodioxolefentanyl (0.1 mg/kg) produced significant (p <= 0.05) dose-dependent increases in locomotion. Valerylfentanyl, however, was without effects on locomotion up to 100 mg/kg. In warm-water tail-withdrawal tests, all substances produced significant (p <= 0.05) dose-dependent increases in antinociception with increasing ED50 values (CI) of isobutyrylfentanyl [0.0768 mg/kg (0.044-0.128)] > fentanyl [0.0800 mg/kg (0.0403-0.164)] > para-methoxybutyrylfentanyl [0.106 mg/kg (0.0516-0.195)] > crotonylfentanyl [0.226 mg/kg (0.176-0.292)] > para-fluorobutyrylfentanyl [0.908 mg/kg (0.459-1.58)] > thiophenefentanyl [4.66 mg/kg (3.65-5.95)] > valerylfentanyl [6.43 mg/kg (3.91-10.5)] > morphine [7.82 mg/kg (5.42-11.0)] > benzodioxolefentanyl [46.3 mg/kg (25.8-83.4)]. Naltrexone (1 mg/kg) increased antinociceptive ED(50 )values several fold in decreasing magnitudes of isobutyrylfentanyl (233x) > para-methoxybutyrylfentanyl (37.7x) > thiophenefentanyl (34.6x) > valerylfentanyl (11.9x) > para-fluorobutyrylfentanyl (10.9x) > benzodioxolefentanyl (8.42x) > crotonylfentanyl (6.27x) > fentanyl (3.95x) > morphine (1.48x). These findings establish that locomotor and antinociceptive effects of several fentanyl-related substances are similar to those of morphine and fentanyl and are mediated by opioid receptors.	[Varshneya, Neil B.; Walentiny, D. Matthew; Moisa, Lea T.; Beardsley, Patrick M.] Virginia Commonwealth Univ, Dept Pharmacol & Toxicol, POB 980613,410 N 12th St, Richmond, VA 23298 USA; [Walker, Teneille D.; Akinfiresoye, Luli R.] US Dept Justice, Divers Control Div, Drug Enforcement Adm, Springfield, VA USA	Beardsley, PM (reprint author), Virginia Commonwealth Univ, Dept Pharmacol & Toxicol, POB 980613,410 N 12th St, Richmond, VA 23298 USA.	patrick.beardsley@vcuhealth.org	Varshneya, Neil/AAK-1032-2020	Varshneya, Neil/0000-0003-3181-9580	United States Drug Enforcement Administration [DJD-17-HQ-P-0641]; National Institute on Drug AbuseUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [T32DA007027]	This work was supported by the United States Drug Enforcement Administration (DJD-17-HQ-P-0641). N. B. Varshneya was supported by the National Institute on Drug Abuse (T32DA007027). The authors wish to thank Molly Creighton for exceptional technical assistance.	Aceto M., 1987, NAT I DRUG ABUSE RES, V1987; Backberg M, 2015, CLIN TOXICOL, V53, P609, DOI 10.3109/15563650.2015.1054505; BAGLEY JR, 1989, J MED CHEM, V32, P663, DOI 10.1021/jm00123a028; Baumann MH, 2018, TRENDS PHARMACOL SCI, V39, P995, DOI 10.1016/j.tips.2018.09.006; Baumann MH, 2018, NEUROPHARMACOLOGY, V134, P101, DOI 10.1016/j.neuropharm.2017.08.016; Baumann MH, 2018, NEUROPSYCHOPHARMACOL, V43, P216, DOI 10.1038/npp.2017.211; Beardsley P. M., 2007, NONCLINICAL DRUG SAF, P441; Brandt S. D, 2018, CRITICAL REV REPORT; Centers for Disease Control and Prevention, 2018, MULT CAUS DEATH 1999; Committee for the Update of the Guide for the Care and Use of Laboratory Animals; National Research Council, 2011, GUIDE CARE USE LAB A; CORSSEN G, 1964, ANESTH ANALG, V43, P748; Drug Enforcement Administration, 2018, FENT REM MOST SIGN S; Drug Enforcement Administration, 2016, COUNT PRESCR PILLS C; Drug Enforcement Administration, 2018, EM THREAT REP; Drug Enforcement Administration, 2017, NFLIS BRIEF FENT FEN; Drug Enforcement Administration, 2017, NFLIS BRIEF FENT 200, P2001; Essawi MYH, 1999, PHARMAZIE, V54, P307; European Monitoring Centre for Drugs and Drug Addiction, 2018, EUR DRUG REP 2018 TR; Gladden R Matthew, 2016, MORBIDITY MORTALITY, V65; Helander A, 2017, CLIN TOXICOL, V55, P589, DOI 10.1080/15563650.2017.1303141; Helander A, 2016, CLIN TOXICOL, V54, P324, DOI 10.3109/15563650.2016.1139715; Higashikawa Y, 2008, FORENSIC TOXICOL, V26, P1, DOI 10.1007/s11419-007-0039-1; Janowsky A, 2018, CRITICAL REV REPORT; Janssen P. A. J, 1964, COMPOSE ACTIVITE PHA; KUZMIN A, J PHARM EXP THER, V295, P1031; Maher S, 2018, DRUG TEST ANAL, V10, P1483, DOI 10.1002/dta.2417; O'Donnell J. K., 2017, MORBIDITY MORTALITY, V66; Palaty J, 2018, CLIN BIOCHEM, V53, P164, DOI 10.1016/j.clinbiochem.2018.01.013; Peterson A. B., 2016, MORBIDITY MORTALITY, V65; Poklis J, 2016, J ANAL TOXICOL, V40, P703, DOI 10.1093/jat/bkw048; Poklis J, 2015, FORENSIC SCI INT, V257, P435, DOI 10.1016/j.forsciint.2015.10.021; Prekupec MP, 2017, J ADDICT MED, V11, P256, DOI 10.1097/ADM.0000000000000324; ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P; Rudd R. A., 2016, MORBIDITY MORTALITY, P65; Stanley TH, 2014, WONDROUSTORY ANEST, P641; Stanley TH, 2014, J PAIN, V15, P1215, DOI 10.1016/j.jpain.2014.08.010; Sutter ME, 2017, ACAD EMERG MED, V24, P106, DOI 10.1111/acem.13034; Suzuki J, 2017, DRUG ALCOHOL DEPEN, V171, P107, DOI 10.1016/j.drugalcdep.2016.11.033; Volpe DA, 2011, REGUL TOXICOL PHARM, V59, P385, DOI 10.1016/j.yrtph.2010.12.007; Walentiny D. M., 2019, NEUROPHARMACOLOGY; WISE RA, 1987, PSYCHOL REV, V94, P469, DOI 10.1037/0033-295X.94.4.469; Woods J. H., 1988, NAT I DRUG ABUSE RES; Woods J. H., 1987, NAT I DRUG ABUSE RES; WYNN RL, 1991, DRUG DEVELOP RES, V22, P189, DOI 10.1002/ddr.430220209; Zawilska JB, 2017, FRONT PSYCHIATRY, V8, DOI 10.3389/fpsyt.2017.00110	45	3	3	1	2	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3908	1873-7064		NEUROPHARMACOLOGY	Neuropharmacology	JUN	2019	151						171	179		10.1016/j.neuropharm.2019.03.023			9	Neurosciences; Pharmacology & Pharmacy	Neurosciences & Neurology; Pharmacology & Pharmacy	HZ2VW	WOS:000468707900016	30904478				2020-06-30	J	Moerke, MJ; Negus, SS				Moerke, Megan J.; Negus, S. Stevens			Role of agonist efficacy in exposure-induced enhancement of mu opioid reward in rats	NEUROPHARMACOLOGY			English	Article						Intracranial self-stimulation; Morphine; Mu opioid receptor; Efficacy; Repeated dosing	INTRACRANIAL SELF-STIMULATION; INTRINSIC EFFICACY; REPEATED MORPHINE; PAIN; AMPHETAMINE; ANTINOCICEPTION; MODULATION; WITHDRAWAL; TOLERANCE; LIABILITY	The abuse potential of opioid analgesics in humans appears to increase rapidly during initial regimens of opioid exposure. Previous work using intracranial self-stimulation (ICSS), a preclinical procedure useful for studying rewarding drug effects in drug-naive animals, has similarly shown that rewarding effects of mu opioid receptor (MOR) agonists increase rapidly in rats during initial regimens of opioid administration. The goal of the present study was to evaluate the role of MOR agonist efficacy as a determinant in eliciting this trajectory of increased rewarding effects during initial opioid exposure in opioid-naive rats. Separate groups of adult, male Sprague-Dawley rats responded for electrical brain stimulation using a frequency-rate ICSS procedure and received repeated daily treatment with vehicle or one of five MOR agonists that ranged from low to high efficacy (NAQ, nalbuphine, buprenorphine, fentanyl, methadone). Two additional groups were used to evaluate effects of repeated treatment with non-opioids (the cannabinoid CP55940 or the monoamine releaser amphetamine). Morphine was tested after each repeated treatment. In opioid-naive rats tested before repeated dosing, MOR agonists produced primarily dose- and efficacy-dependent decreases in ICSS. Following repeated treatment, all MOR agonists except NAQ produced tolerance to opioid-induced rate-decreasing effects and enhanced expression of ICSS facilitation (indicative of opioid reward) by both the repeatedly administered drug and morphine. Repeated treatment with CP55940 and amphetamine produced different effects. Collectively, these results provide evidence to suggest that enhanced expression of opioid reward after initial regimens of opioid exposure has a low requirement for MOR agonist efficacy and is pharmacologically selective.	[Moerke, Megan J.; Negus, S. Stevens] Virginia Commonwealth Univ, Dept Pharmacol & Toxicol, 410 N 12th St, Richmond, VA 23298 USA	Negus, SS (reprint author), Virginia Commonwealth Univ, Dept Pharmacol & Toxicol, 410 N 12th St, Richmond, VA 23298 USA.	sidney.negus@vcuhealth.org			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01NS07015, T32DA007027]	This work was supported by the National Institutes of Health [grant numbers R01NS07015, T32DA007027]. The authors thank Dr. Kenner Rice (Chemical Biology Research Branch, National Institute on Drug Abuse and National Institute on Alcohol Abuse and Alcoholism) for providing nalbuphine and Dr. Yan Zhang (Department of Medicinal Chemistry, Virginia Commonwealth University) for providing NAQ.	Altarifi AA, 2017, J PSYCHOPHARMACOL, V31, P730, DOI 10.1177/0269881116689257; Altarifi AA, 2015, PSYCHOPHARMACOLOGY, V232, P815, DOI 10.1007/s00213-014-3719-7; Altarifi AA, 2013, BEHAV PHARMACOL, V24, P459, DOI 10.1097/FBP.0b013e328364c0bd; Altarifi AA, 2012, BEHAV PHARMACOL, V23, P678, DOI 10.1097/FBP.0b013e328358593c; Bauer CT, 2013, BRIT J PHARMACOL, V168, P850, DOI 10.1111/j.1476-5381.2012.02214.x; Bauer CT, 2014, PSYCHOPHARMACOLOGY, V231, P2461, DOI 10.1007/s00213-013-3405-1; Bohn LM, 2003, J NEUROSCI, V23, P10265; Bonano JS, 2014, PSYCHOPHARMACOLOGY, V231, P199, DOI 10.1007/s00213-013-3223-5; BROCCO MJ, 1983, J PHARMACOL EXP THER, V224, P34; BROEKKAMP CL, 1976, EUR J PHARMACOL, V36, P443, DOI 10.1016/0014-2999(76)90099-6; Butelman ER, 2018, FRONT PSYCHIATRY, V9, DOI 10.3389/fpsyt.2018.00283; Dowell D, 2016, MMWR RECOMM REP, V65, P1, DOI 10.15585/mmwr.rr6501e1; Emmerson PJ, 1996, J PHARMACOL EXP THER, V278, P1121; Grim TW, 2015, DRUG ALCOHOL DEPEN, V150, P31, DOI 10.1016/j.drugalcdep.2015.01.022; Johnson AR, 2018, NEUROPSYCHOPHARMACOL, V43, P1753, DOI 10.1038/s41386-018-0071-3; Kwilasz AJ, 2012, J PHARMACOL EXP THER, V343, P389, DOI 10.1124/jpet.112.197780; Legakis LP, 2018, J PHARMACOL EXP THER, V365, P9, DOI 10.1124/jpet.117.246215; LETT BT, 1989, PSYCHOPHARMACOLOGY, V98, P357, DOI 10.1007/BF00451687; Li G, 2009, J MED CHEM, V52, P1416, DOI 10.1021/jm801272c; Mavrikaki M, 2010, BEHAV BRAIN RES, V209, P114, DOI 10.1016/j.bbr.2010.01.024; Miller LL, 2015, EXP CLIN PSYCHOPHARM, V23, P405, DOI 10.1037/pha0000042; Morgan D, 1996, BEHAV PHARMACOL, V7, P261; Negus SS, 2019, PEPTIDES, V112, P23, DOI 10.1016/j.peptides.2018.10.007; Negus SS, 2014, PHARMACOL REV, V66, P869, DOI 10.1124/pr.112.007419; Negus SS, 1999, J PHARMACOL EXP THER, V290, P1132; Reid L.D., 1987, METHODS ASSESSING RE, P391; Selley DE, 1998, J PHARMACOL EXP THER, V285, P496; Shah A, 2017, MMWR-MORBID MORTAL W, V66, P265, DOI 10.15585/mmwr.mm6610a1; Sim LJ, 1996, J NEUROSCI, V16, P2684; Siuda ER, 2017, CURR OPIN PHARMACOL, V32, P77, DOI 10.1016/j.coph.2016.11.007; TRAYNOR JR, 1995, MOL PHARMACOL, V47, P848; Vanyukov MM, 2012, DRUG ALCOHOL DEPEN, V123, pS3, DOI 10.1016/j.drugalcdep.2011.12.018; Volkow ND, 2017, NEW ENGL J MED, V377, P391, DOI 10.1056/NEJMsr1706626; Walker EA, 1998, PSYCHOPHARMACOLOGY, V136, P15; Wiebelhaus JM, 2016, J PHARMACOL EXP THER, V356, P43, DOI 10.1124/jpet.115.228940; Zachariou V, 2006, NAT NEUROSCI, V9, P205, DOI 10.1038/nn1636; Zacny JP, 1997, J PHARMACOL EXP THER, V280, P1159	37	3	3	0	1	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3908	1873-7064		NEUROPHARMACOLOGY	Neuropharmacology	JUN	2019	151						180	188		10.1016/j.neuropharm.2019.03.020			9	Neurosciences; Pharmacology & Pharmacy	Neurosciences & Neurology; Pharmacology & Pharmacy	HZ2VW	WOS:000468707900017	30880123	Green Accepted			2020-06-30	J	Kiyatkin, EA				Kiyatkin, Eugene A.			Respiratory depression and brain hypoxia induced by opioid drugs: Morphine, oxycodone, heroin, and fentanyl	NEUROPHARMACOLOGY			English	Article						Opiates; Health complications; Brain hypoxia; Metabolic brain activation; Nucleus accumbens; Rats	PHYSIOLOGICAL FLUCTUATIONS; PHARMACOLOGICAL PROFILES; INTRAVENOUS COCAINE; AROUSING STIMULI; GLUCOSE; BLOOD; METABOLITES; RATS; TEMPERATURE; ACTIVATION	Opioid drugs are important tools to alleviate pain of different origins, but they have strong addictive potential and their abuse at higher doses often results in serious health complications. Respiratory depression that leads to brain hypoxia is perhaps the most dangerous symptom of acute intoxication with opioids, and it could result in lethality. The development of substrate-specific sensors coupled with amperometry made it possible to directly evaluate physiological and drug-induced fluctuations in brain oxygen levels in awake, freely-moving rats. The goal of this review paper is to consider changes in brain oxygen levels induced by several opioid drugs (heroin, fentanyl, oxycodone, morphine). While some of these drugs are widely used in clinical practice, they all are abused, often at doses exceeding the clinical range and often resulting in serious health complications. First, we consider some basic knowledge regarding brain oxygen, its physiological fluctuations, and mechanisms involved in regulating its entry into brain tissue. Then, we present and discuss data on brain oxygen changes induced by each opioid drug within a wide range of doses, from low, behaviorally relevant, to high, likely to be self-administered by drug users. These data allowed us to compare the effects of these drugs on brain oxygen in terms of their potency, time-course, and their potential danger when used at high doses via rapid-onset administration routes. While most data discussed in this work were obtained in rats, we believe that these data have clear human relevance in addressing the alarming rise in lethality associated with the opioid abuse.	[Kiyatkin, Eugene A.] NIDA, Behav Neurosci Branch, Intramural Res Program, NIH,DHHS, 333 Cassell Dr, Baltimore, MD 21224 USA	Kiyatkin, EA (reprint author), NIDA, Behav Neurosci Branch, Intramural Res Program, NIH,DHHS, 333 Cassell Dr, Baltimore, MD 21224 USA.	ekiyatki@intra.nida.nih.gov		Kiyatkin, Eugene A./0000-0002-3744-0873	Intramural Research Program of the NIH, NIDAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)	The original research reviewed in this manuscript was supported by the Intramural Research Program of the NIH, NIDA. The Author wants to thank Ernesto Solis Jr, Aaron Bola, Keaton Cameron -Burr, and Anum Afzal for assisting in experiments described in this work, analyses of data, and fruitful discussions on their functional implications. I also want to specially thank Anum Afzal for careful editing of the present text and helpful comments on its matters.	Attwell D, 2010, NATURE, V468, P232, DOI 10.1038/nature09613; Baud F. -J., 2009, Annales Pharmaceutiques Francaises, V67, P353, DOI 10.1016/j.pharma.2009.06.005; Boix F, 2013, ADDICT BIOL, V18, P1, DOI 10.1111/j.1369-1600.2010.00298.x; BOWES WA, 1989, OBSTET GYNECOL, V74, P541; Bucher ES, 2015, ANNU REV ANAL CHEM, V8, P239, DOI 10.1146/annurev-anchem-071114-040426; Chan S, 2008, CLIN EXP PHARMACOL P, V35, P295, DOI 10.1111/j.1440-1681.2007.04821.x; Compton WM, 2016, NEW ENGL J MED, V374, P154, DOI 10.1056/NEJMra1508490; Dahan A, 2005, BRIT J ANAESTH, V94, P825, DOI 10.1093/bja/aei145; Di Chiara G, 2002, BEHAV BRAIN RES, V137, P75, DOI 10.1016/S0166-4328(02)00286-3; Emery MJ, 2016, ANESTHESIOLOGY, V124, P945, DOI 10.1097/ALN.0000000000000997; Gable RS, 2004, ADDICTION, V99, P686, DOI 10.1111/j.1360-0443.2004.00744.x; GERBER GJ, 1989, PHARMACOL BIOCHEM BE, V32, P527, DOI 10.1016/0091-3057(89)90192-5; Gottas A, 2013, BRIT J PHARMACOL, V170, P546, DOI 10.1111/bph.12305; Hossmann KA, 1999, ADV EXP MED BIOL, V474, P155; INTURRISI CE, 1983, LIFE SCI, V33, P773, DOI 10.1016/0024-3205(83)90616-1; Jaffe J. H., 1997, SUBSTANCE ABUSE COMP, P158; Kabir MM, 2010, PHYSIOL BEHAV, V101, P22, DOI 10.1016/j.physbeh.2010.04.004; Kalso E, 2005, J PAIN SYMPTOM MANAG, V29, pS47, DOI 10.1016/j.jpainsymman.2005.01.010; KAYSER V, 1983, BRAIN RES, V267, P131, DOI 10.1016/0006-8993(83)91046-6; KIYATKIN EA, 1989, INT J NEUROSCI, V45, P231, DOI 10.3109/00207458908986236; Kiyatkin EA, 1999, BRAIN RES, V822, P88, DOI 10.1016/S0006-8993(99)01093-8; Kiyatkin EA, 2015, ACS CHEM NEUROSCI, V6, P108, DOI 10.1021/cn5002304; Kiyatkin EA, 2013, ACS CHEM NEUROSCI, V4, P652, DOI 10.1021/cn300232m; Kiyatkin EA, 2012, J NEUROPHYSIOL, V108, P1669, DOI 10.1152/jn.00521.2012; Kiyatkin EA, 2010, FRONT BIOSCI-LANDMRK, V15, P73, DOI 10.2741/3608; Kuo A, 2015, BRIT J PHARMACOL, V172, P532, DOI 10.1111/bph.12696; MAGUIRE P, 1992, EUR J PHARMACOL, V213, P219, DOI 10.1016/0014-2999(92)90685-W; McLaughlin K, 2017, SCIENCE, V355, P1364, DOI 10.1126/science.355.6332.1364; MOGENSON GJ, 1980, PROG NEUROBIOL, V14, P69, DOI 10.1016/0301-0082(80)90018-0; Nielsen CK, 2007, PAIN, V132, P289, DOI 10.1016/j.pain.2007.03.022; OLDENDORF WH, 1972, SCIENCE, V178, P984, DOI 10.1126/science.178.4064.984; Paris P. M, 2006, ROSENS EMERGENCY MED; Pattinson KTS, 2008, BRIT J ANAESTH, V100, P747, DOI 10.1093/bja/aen094; Peng PWH, 1999, ANESTHESIOLOGY, V90, P576, DOI 10.1097/00000542-199902000-00034; Rebec GV, 2006, NEUROPSYCHOPHARMACOL, V31, P2341, DOI 10.1038/sj.npp.1301160; Schmidt-Nielsen K., 1997, ANIMAL PHYSL ADAPTAT; Selley DE, 2001, BIOCHEM PHARMACOL, V62, P447, DOI 10.1016/S0006-2952(01)00689-X; Simon EJ, 1997, SUBST ABUS, P148; Solis E, 2018, J NEUROPHYSIOL, V120, P2513, DOI 10.1152/jn.00445.2018; Solis E, 2018, NEUROPHARMACOLOGY, V133, P481, DOI 10.1016/j.neuropharm.2018.02.017; Solis E, 2018, NEUROPSYCHOPHARMACOL, V43, P810, DOI 10.1038/npp.2017.181; Solis E, 2017, ENEURO, V4, DOI 10.1523/ENEURO.0151-17.2017; Solis E, 2017, FRONT INTEGR NEUROSC, V11, DOI 10.3389/fnint.2017.00009; Solis Jr E, 2017, ENEURO, V4, P1; Strandberg JJ, 2006, TOXICOL LETT, V166, P11, DOI 10.1016/j.toxlet.2006.05.007; Suzuki J, 2017, DRUG ALCOHOL DEPEN, V171, P107, DOI 10.1016/j.drugalcdep.2016.11.033; von Gunten CF, 2010, J PALLIAT MED, V13, P505, DOI 10.1089/jpm.2010.9815; Wade CL, 2015, NEUROPSYCHOPHARMACOL, V40, P421, DOI 10.1038/npp.2014.188; WILLETTE RN, 1987, J PHARMACOL EXP THER, V240, P352; WISE RA, 1987, PSYCHOL REV, V94, P469, DOI 10.1037/0033-295X.94.4.469; YEADON M, 1990, GEN PHARMACOL, V21, P655, DOI 10.1016/0306-3623(90)91013-H; Zimmer G., 2004, EMERGENCY MED COMPRE, P257	52	10	10	2	10	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3908	1873-7064		NEUROPHARMACOLOGY	Neuropharmacology	JUN	2019	151						219	226		10.1016/j.neuropharm.2019.02.008			8	Neurosciences; Pharmacology & Pharmacy	Neurosciences & Neurology; Pharmacology & Pharmacy	HZ2VW	WOS:000468707900021	30735692	Green Accepted			2020-06-30	J	Brzakala, J; Leppert, W				Brzakala, Joanna; Leppert, Wojciech			The role of rapid onset fentanyl products in the management of breakthrough pain in cancer patients	PHARMACOLOGICAL REPORTS			English	Review						Breakthrough pain; Cancer patients; Clinical assessment; Fentanyl; Treatment	BUCCAL TABLET; OPIOID TREATMENT; ASSESSMENT-TOOL; DOUBLE-BLIND; NASAL SPRAY; CITRATE; PREVALENCE; PHARMACOKINETICS; RECOMMENDATIONS; FORMULATIONS	Breakthrough pain is defined as transient aggravation of pain that arises, despite well controlled or stable baseline pain. It may be preceded by known factors or occur spontaneously. Its prevalence is high and it considerably affects patients' quality of life. Therefore, proper clinical evaluation and treatment is required. Fentanyl transmucosal formulations have become the treatment of choice for spontaneous (idiopathic) episodes because of their rapid onset of action, brief period of analgesia, and easy administration via transmucosal routes. All rapid onset fentanyl formulations show better efficacy than placebo or immediate-release opioids administered via the oral route, with an onset of analgesia within 15 min. Furthermore, most patients show considerable tolerance of these fentanyl formulations, and severe side effects that can potentially be induced by opioids are rarely observed. However, the treatment of breakthrough pain should be adjusted to suit specific patient requirements. Nevertheless, particularly in predictable bursts of pain and also in spontaneous episodes of breakthrough pain with slowly intensifying pain, immediate-release formulations of opioids may play an important role. (C) 2019 Published by Elsevier B.V. on behalf of Institute of Pharmacology, Polish Academy of Sciences.	[Brzakala, Joanna] Pallmed Leading Sue Ryder House, Bydgoszcz, Poland; [Leppert, Wojciech] Poznan Univ Med Sci, Chair & Dept Palliat Med, Poznan, Poland	Leppert, W (reprint author), Poznan Univ Med Sci, Chair & Dept Palliat Med, Poznan, Poland.	wojciechleppert@wp.pl					Blin P, 2014, VALUE HEALTH, V17, pA649, DOI 10.1016/j.jval.2014.08.2357; Brant JM, 2017, CLIN J ONCOL NURS, V21, P71, DOI 10.1188/17.CJON.S3.71-80; Bredenberg S, 2003, EUR J PHARM SCI, V20, P327, DOI 10.1016/j.ejps.2003.07.002; Caraceni A, 2012, LANCET ONCOL, V13, pE58, DOI 10.1016/S1470-2045(12)70040-2; Corli O, 2014, MINERVA ANESTESIOL, V80, P1123; Darwish M, 2010, PERSPECT MED CHEM, V4, P11; Davies A, 2016, J PAIN SYMPTOM MANAG, V51, P538, DOI 10.1016/j.jpainsymman.2015.11.018; Davies AN, 2009, EUR J PAIN, V13, P331, DOI 10.1016/j.ejpain.2008.06.014; Deandrea S, 2014, J PAIN SYMPTOM MANAG, V47, P57, DOI 10.1016/j.jpainsymman.2013.02.015; Fallon M, 2018, ANN ONCOL         S4, V29; Farrar JT, 1998, JNCI-J NATL CANCER I, V90, P611, DOI 10.1093/jnci/90.8.611; Fisher A, 2010, INT J CLIN PHARM TH, V48, P138; Garnock-Jones KP, 2016, CLIN DRUG INVEST, V36, P413, DOI 10.1007/s40261-016-0394-y; Leppert W, 2016, MED PALIATYWNA, V8, P9; Leppert Wojciech, 2010, Cancer Manag Res, V2, P225, DOI 10.2147/CMR.S7926; Lohre ET, 2016, J PAIN SYMPTOM MANAG, V51, P1013, DOI 10.1016/j.jpainsymman.2015.12.329; Meda Pharmaceuticals, 2015, BREAK FENT BUCC SOL; Mercadante S, 2016, J PAIN SYMPTOM MANAG, V52, P27, DOI 10.1016/j.jpainsymman.2016.01.010; Mercadante S, 2015, J PAIN SYMPTOM MANAG, V50, P579, DOI 10.1016/j.jpainsymman.2015.05.016; Mercadante S, 2012, DRUGS, V72, P181, DOI 10.2165/11597260-000000000-00000; Parikh N, 2013, CLIN THER, V35, P236, DOI 10.1016/j.clinthera.2013.02.017; PORTENOY RK, 1990, PAIN, V41, P273, DOI 10.1016/0304-3959(90)90004-W; Portenoy RK, 1999, PAIN, V81, P129, DOI 10.1016/S0304-3959(99)00006-8; Portenoy RK, 2006, CLIN J PAIN, V22, P805, DOI 10.1097/01.ajp.0000210932.27945.4a; Prommer E, 2011, PATIENT PREFER ADHER, V5, P157, DOI 10.2147/PPA.S7665; Radbruch L, 2011, PALLIATIVE MED, V25, P578, DOI 10.1177/0269216310383739; Rauck RL, 2009, CURR MED RES OPIN, V25, P2877, DOI 10.1185/03007990903368310; Simpson DM, 2007, CLIN THER, V29, P588, DOI 10.1016/j.clinthera.2007.04.007; Slatkin N, 2007, J SUPPORT ONCOL, V7, P327; Smith H, 2012, CNS DRUGS, V26, P509, DOI 10.2165/11630580-000000000-00000; Smith HS, 2009, MAYO CLIN PROC, V84, P613, DOI 10.1016/S0025-6196(11)60750-7; Sperlinga R, 2015, EUR J PAIN, V19, P881, DOI 10.1002/ejp.612; Twycross R, 2012, J PAIN SYMPTOM MANAG, V44, P131, DOI 10.1016/j.jpainsymman.2012.05.001; Vissers DCJ, 2011, VALUE HEALTH, V14, P274, DOI 10.1016/j.jval.2010.09.007; Vithlani Rohan Hasmukh, 2010, Rev Pain, V4, P8, DOI 10.1177/204946371000400203; Vyas Tushar K., 2005, Current Drug Delivery, V2, P165, DOI 10.2174/1567201053586047; Webber K, 2014, J PAIN SYMPTOM MANAG, V48, P619, DOI 10.1016/j.jpainsymman.2013.10.026; Zecca E, 2017, J CLIN ONCOL, V35, P759, DOI 10.1200/JCO.2016.69.9504; Zeppetella G, 2000, J PAIN SYMPTOM MANAG, V20, P87, DOI 10.1016/S0885-3924(00)00161-5; 2016, DRUGS, V76, P315, DOI DOI 10.1007/S40265-015-0519-2	40	0	0	2	4	POLISH ACAD SCIENCES INST PHARMACOLOGY	KRAKOW	SMETNA 12, 31-343 KRAKOW, POLAND	1734-1140			PHARMACOL REP	Pharmacol. Rep.	JUN	2019	71	3					438	442		10.1016/j.pharep.2019.01.010			5	Pharmacology & Pharmacy	Pharmacology & Pharmacy	HY5TJ	WOS:000468190600008	31003154				2020-06-30	J	Collins, LK; Pande, LJ; Chung, DY; Nichols, SD; McCall, KL; Piper, BJ				Collins, Lacee K.; Pande, Leana J.; Chung, Daniel Y.; Nichols, Stephanie D.; McCall, Kenneth L.; Piper, Brian J.			Trends in the medical supply of fentanyl and fentanyl analogues: United States, 2006 to 2017	PREVENTIVE MEDICINE			English	Article						Alfentanil; Epidemiology; Opioid; Remifentanil; Sufentanil	ABUSE; OPIOIDS; PHYSICIANS	Fentanyl is an important opioid for pain management, but also has exceptional potential for misuse. Seven states have implemented opioid prescribing laws. The objectives of this study were to: 1) characterize the temporal pattern of fentanyl, fentanyl analogue, and other opioid use over the past decade, and 2) determine whether opioid prescribing laws impacted fentanyl use in the US. Drug weights were obtained from the US Automated Reports of Consolidated Orders System (June 2018), a comprehensive publically available resource, from 2006 to 2017 for fentanyl, sufentanil, remifentanil, alfentanil, other prescription opioids, and analyzed by presence of a state opioid prescribing law. Fentanyl, corrected for population, was reduced from 2016 to 2017 ( - 17.9%) and these decreases significantly exceeded the changes in hydrocodone ( - 12.3%), oxycodone ( - 10.1%), morphine ( - 13.3%), or codeine ( - 8.8%). Fentanyl showed a particularly large decline in Maine, a state with a strong opioid prescribing law. There was a 3.5 fold difference in fentanyl (mu g per capita) in Alaska (488.2) relative to Oregon (1718.4). Hospital use of remifentanil and sufentanil tripled from 2006 to 2017. Although all states experienced a 2016 to 2017 decline in fentanyl, and this reduction was larger than many other prescription opioids, the rate of decline varied over three-fold between states. Strong state laws may account for a portion of the variance in fentanyl and other opioid reductions. The population health risks of fentanyl and fentanyl analogues warrants ongoing vigilance.	[Collins, Lacee K.] Robert Morris Univ, Dept Biol, Moon, PA USA; [Pande, Leana J.] Wilkes Univ, Dept Biol, Wilkes Barre, PA 18766 USA; [Chung, Daniel Y.; Piper, Brian J.] Geisinger Commonwealth Sch Med, Dept Med Educ, 525 Pine St, Scranton, PA 18509 USA; [Nichols, Stephanie D.] Husson Univ, Sch Pharm, Dept Pharm Practice, Bangor, ME USA; [Nichols, Stephanie D.] Tufts Univ, Sch Med, Dept Psychiat, Medford, MA 02155 USA; [McCall, Kenneth L.] Univ New England, Dept Pharm Practice, Biddeford, ME USA; [Piper, Brian J.] Geisinger Precis Hlth Ctr, Ctr Pharm Innovat & Outcomes, Lewisburg, PA USA	Piper, BJ (reprint author), Geisinger Commonwealth Sch Med, Dept Med Educ, 525 Pine St, Scranton, PA 18509 USA.	bpiper@som.geisinger.edu			Fahs-Beck Fellowship; NIEHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [T32 ES007060-31A1]	This research was supported by a Fahs-Beck Fellowship. Software was provided by Husson University School of Pharmacy and NIEHS (T32 ES007060-31A1).	Albert E., 2018, PHARM TIMES; Andrilla CHA, 2019, J RURAL HEALTH, V35, P108, DOI 10.1111/jrh.12307; Armenian P, 2018, NEUROPHARMACOLOGY, V134, P121, DOI 10.1016/j.neuropharm.2017.10.016; Associated Press, 2018, ASS PRESS; Bernstein L, 2016, WASHINGTON POST; Booth JV, 2002, ANESTH ANALG, V95, P1024, DOI 10.1213/01.ANE.0000026379.66419.DB; Cabrera FF, 2019, PEERJ, V7, DOI 10.7717/peerj.6272; Conrad C, 2015, MMWR-MORBID MORTAL W, V64, P443; Coscarelli J., 2018, NY TIMES; Department of Justice, 2018, DIV DRUG CONTR; Dowell D, 2016, JAMA-J AM MED ASSOC, V315, P1624, DOI 10.1001/jama.2016.1464; Drug Enforcement Administration, 2016, FENT; DYER O, 2016, BMJ-BRIT MED J, V355, DOI DOI 10.1136/BMJ.I6742; Goodwin W., 2018, REDUCTIONS FENTANYL; Hadland SE, 2017, AM J PUBLIC HEALTH, V107, P1493, DOI 10.2105/AJPH.2017.303982; Haegerich TM, 2014, DRUG ALCOHOL DEPEN, V145, P34, DOI 10.1016/j.drugalcdep.2014.10.001; Haffajee RL, 2018, HEALTH AFFAIR, V37, P964, DOI 10.1377/hlthaff.2017.1321; Jones CM, 2018, JAMA-J AM MED ASSOC, V319, P1819, DOI 10.1001/jama.2018.2844; Joseph A., 2017, CVS TIGHTENS RESTRIC; Kuczynska K, 2018, FORENSIC SCI INT, V289, P207, DOI 10.1016/j.forsciint.2018.05.042; Kukanich B, 2012, J VET PHARMACOL THER, V35, P3, DOI 10.1111/j.1365-2885.2012.01416.x; Manchikanti L, 2018, PAIN PHYSICIAN, V21, P309; Manchikanti L, 2010, PAIN PHYSICIAN, V13, P401; Marder E, 2013, MMWR-MORBID MORTAL W, V62, P1; Mason DS, 2018, AM J PUBLIC HEALTH, V108, P1162, DOI 10.2105/AJPH.2018.304603; McGinty EE, 2018, IMPLEMENT SCI, V13, DOI 10.1186/s13012-018-0719-8; Ornstein C., 2018, OPIOID MAKERS BLAMED; Piper BJ, 2018, AM J PREV MED, V54, P652, DOI 10.1016/j.amepre.2018.01.034; Schumacher MA, 2018, BASIC CLIN PHARM; Shanon J., 2018, US TODAY; Smith Mitch, 2018, NY TIMES; Soh C., 2018, OPIOID SUPPLY LEVELS; Stanley TH, 2014, J PAIN, V15, P1215, DOI 10.1016/j.jpain.2014.08.010; Warner DO, 2013, JAMA-J AM MED ASSOC, V310, P2289, DOI 10.1001/jama.2013.281954; Wiener-Bronner D., 2018, CNN; Wiles R., 2018, AZ CENTRAL; Zajaczkowska R, 2018, PHARMACOL REP, V70, P812, DOI 10.1016/j.pharep.2018.01.005	37	5	5	0	1	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0091-7435	1096-0260		PREV MED	Prev. Med.	JUN	2019	123						95	100		10.1016/j.ypmed.2019.02.017			6	Public, Environmental & Occupational Health; Medicine, General & Internal	Public, Environmental & Occupational Health; General & Internal Medicine	HY7SR	WOS:000468336900014	30763629				2020-06-30	J	Vijay, A; Rhee, TG; Ross, JS				Vijay, Aishwarya; Rhee, Taeho Greg; Ross, Joseph S.			US prescribing trends of fentanyl, opioids, and other pain medications in outpatient and emergency department visits from 2006 to 2015	PREVENTIVE MEDICINE			English	Article						Opioid; Fentanyl; NSAID; Prescribing	PRIMARY-CARE; UNITED-STATES; ANALGESIC ABUSE; DRUG-TREATMENT; OVERDOSE; INCREASES; DEATHS; PRESCRIPTIONS; MANAGEMENT; MORTALITY	The United States is currently facing an epidemic of opioid-related deaths, increasingly associated with fentanyl use. Our objective was to characterize rates of fentanyl, general opioid and non-opioid pain medication prescription at a national level in both outpatient and emergency department settings. We used a retrospective cross-sectional research design using data from the 2006-2015 National Ambulatory Medical Care Surveys and National Hospital Ambulatory Medical Care Surveys. Between 2006-2015, 66,987 (17.4%) of 390,538 office-based outpatient visits (nationally-representative of 961 million visits) and 134,953 (45.0%) of 305,570 ED visits (nationally-representative of 130 million visits) listed a pain medication prescription. The proportion of all outpatient visits in which any pain medication was prescribed increased from 15.0% in 2006-2007 to 20.5% in 2014-2015 (p < 0.001). The proportion of all outpatient visits in which any fentanyl product was prescribed remained stable at 0.3% and 0.4% (p = 0.32), but increased among ED visits from 0.5% to 1.1% (p = 0.006). In contrast, the proportion of all outpatient visits in which any opioid product was prescribed increased from 6.6% to 9.7% (p < 0.001), but remained relatively stable among ED visits from 26.2% to 24.4% (p = 0.07). Nonopioid pain medication prescription increased in both settings, from 9.7% to 13.7% (p < 0.001) in the outpatient setting and from 25.6% to 27.6% (p = 0.02) in the ED setting between 2006-2007 and 2014-2015, respectively. To address current opioid crisis, both clinical and public health interventions are needed, such as targeted education outreach on evidence-based opioid prescribing and non-opioid alternatives.	[Vijay, Aishwarya] Yale Univ, Sch Med, New Haven, CT USA; [Rhee, Taeho Greg] Univ Connecticut, Sch Med, Dept Community Med & Hlth Care, Farmington, CT 06030 USA; [Rhee, Taeho Greg] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA; [Rhee, Taeho Greg; Ross, Joseph S.] Yale New Haven Hlth Syst, CORE, New Haven, CT USA; [Ross, Joseph S.] Yale Univ, Sch Med, Dept Internal Med, Sect Gen Internal Med, New Haven, CT 06510 USA; [Ross, Joseph S.] Yale Univ, Sch Publ Hlth, Dept Hlth Policy & Management, New Haven, CT USA	Rhee, TG (reprint author), Univ Connecticut, Sch Med, 263 Farmington Ave, Farmington, CT 06030 USA.	rhee@uchc.edu			AHRQ HHSUnited States Department of Health & Human ServicesAgency for Healthcare Research & Quality [R01 HS025164, R01 HS022882]; NCATS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1 TR001863]; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [T32 AG019134]; FDA HHS [U01 FD005938, U01 FD004585]		Bruneau J, 2018, CAN MED ASSOC J, V190, pE247, DOI 10.1503/cmaj.170958; Center for Disease Control and Prevention, 2018, OP OV TREAT EM DEP; Centers for Disease Control and Prevention (CDC), 2017, DRUG OV DEATH DAT; Cicero TJ, 2017, DRUG ALCOHOL DEPEN, V177, P101, DOI 10.1016/j.drugalcdep.2017.04.004; Cicero TJ, 2014, JAMA PSYCHIAT, V71, P821, DOI 10.1001/jamapsychiatry.2014.366; Compton WM, 2006, DRUG ALCOHOL DEPEN, V81, P103, DOI 10.1016/j.drugalcdep.2005.05.009; Cushman P. A., 2017, PRIMARY CARE PROVIDE; Dart RC, 2015, NEW ENGL J MED, V372, P241, DOI [10.1056/NEJMc1501822, 10.1056/NEJMsa1406143]; Davoli M, 2007, ADDICTION, V102, P1954, DOI 10.1111/j.1360-0443.2007.02025.x; Dowell D, 2016, JAMA-J AM MED ASSOC, V315, P1624, DOI 10.1001/jama.2016.1464; Esteban J, 2003, DRUG ALCOHOL DEPEN, V70, P193, DOI 10.1016/S0376-8716(03)00002-4; Frank RG, 2017, NEW ENGL J MED, V376, P605, DOI 10.1056/NEJMp1615145; Gladden R. M., 2016, MMWR-MORBID MORTAL W, DOI [10.1146/annurev-publhealth-031914-122957, DOI 10.1146/ANNUREV-PUBLHEALTH-031914-122957]; Harle CA, 2015, BMC FAM PRACT, V16, DOI 10.1186/s12875-015-0264-3; Hedegaard H, 2017, NCHS DATA BRIEF, V273, p1 ; Jamison Robert N, 2014, J Opioid Manag, V10, P375, DOI 10.5055/jom.2014.0234; Jumbelic MI, 2010, AM J FOREN MED PATH, V31, P18, DOI 10.1097/PAF.0b013e31818738b8; Kolodny A, 2015, ANNU REV PUBL HEALTH, V36, P559, DOI 10.1146/annurev-publhealth-031914-122957; Larney S, 2017, LANCET GLOB HEALTH, V5, pE1208, DOI [10.1016/S2214-109X(17)30373-X, 10.1016/s2214-109x(17)30373-x]; Leece P, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-013244; Liebschutz JM, 2017, JAMA INTERN MED, V177, P1265, DOI 10.1001/jamainternmed.2017.2468; Lilly J. L., 2018, J AM PHYS SURG, V23, P20; Mazer-Amirshahi M, 2014, ACAD EMERG MED, V21, P236, DOI 10.1111/acem.12328; McCann KS, 2018, J AM BOARD FAM MED, V31, P57, DOI 10.3122/jabfm.2018.01.170163; National Center for Health Statistics, 2017, AMB HLTH CAR DAT QUE; National Center for Health Statistics Center for Disease Control and Prevention, 2017, AMB HLTH CAR DAT; O'Donnell JK, 2017, MMWR-MORBID MORTAL W, V66, P1197, DOI 10.15585/mmwr.mm6643e1; Olfson M, 2018, DRUG ALCOHOL DEPEN, V190, P112, DOI 10.1016/j.drugalcdep.2018.06.004; Peterson AB, 2016, MMWR-MORBID MORTAL W, V65, P844, DOI 10.15585/mmwr.mm6533a3; Renthal W, 2016, JAMA NEUROL, V73, P513, DOI 10.1001/jamaneurol.2016.0535; Roxburgh A, 2013, DRUG ALCOHOL REV, V32, P269, DOI 10.1111/dar.12033; Schneiderhan J, 2017, JAMA-J AM MED ASSOC, V317, P2367, DOI 10.1001/jama.2017.5787; Seth P, 2018, AM J PUBLIC HEALTH, V108, P500, DOI 10.2105/AJPH.2017.304265; Somerville NJ, 2017, MMWR-MORBID MORTAL W, V66, P382, DOI 10.15585/mmwr.mm6614a2; Substance Abuse and Mental Health Services Administration, 2018, LOC DAT RISK FACT OP; Suzuki J, 2017, DRUG ALCOHOL DEPEN, V171, P107, DOI 10.1016/j.drugalcdep.2016.11.033; U.S. Department of Health & Human Services, 2015, WHAT IS DIFF MED MED; Vargas-Schaffer G, 2014, CAN FAM PHYSICIAN, V60, P235; Whalen J., 2017, WALL STREET J; Xu J, 2018, DRUG ALCOHOL DEPEN, V189, P37, DOI 10.1016/j.drugalcdep.2018.04.020	40	2	2	1	8	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0091-7435	1096-0260		PREV MED	Prev. Med.	JUN	2019	123						123	129		10.1016/j.ypmed.2019.03.022			7	Public, Environmental & Occupational Health; Medicine, General & Internal	Public, Environmental & Occupational Health; General & Internal Medicine	HY7SR	WOS:000468336900018	30894321	Green Accepted			2020-06-30	J	Nozari, A; Akeju, O; Mirzakhani, H; Eskandar, E; Ma, ZJ; Hossain, MDA; Wang, QP; Greenblatt, DJ; Martyn, JAJ				Nozari, Ala; Akeju, Oluwaseun; Mirzakhani, Hooman; Eskandar, Emad; Ma, Zhijun; Hossain, M. D. Amin; Wang, Qingping; Greenblatt, David J.; Martyn, J. A. Jeevendra			Prolonged therapy with the anticonvulsant carbamazepine leads to increased plasma clearance of fentanyl	JOURNAL OF PHARMACY AND PHARMACOLOGY			English	Article						carbamazepine; enzyme induction; fentanyl; pharmacokinetics	INTRAVENOUS FENTANYL; PHARMACOKINETICS; MIDAZOLAM; PHARMACODYNAMICS; DISPOSITION; METABOLISM; ANESTHESIA; TOLERANCE; MORPHINE; DRUGS	Objectives Fentanyl is a potent analgesic that accounts for an increasing number of overdose deaths in the United States. This study tested whether altered pharmacokinetics plays a pivotal role in the increased fentanyl dose requirements in patients receiving the enzyme-inducing anticonvulsant, carbamazepine. Methods Neurosurgical patients receiving carbamazepine for >6 weeks (N = 11) or no carbamazepine (N = 6, controls) received a single bolus dose of fentanyl (200 mu g) intravenously. Plasma was collected before and for up to 9 h after the bolus. Fentanyl concentrations were measured using liquid chromatography-mass spectrometry. Pharmacokinetic variables were derived from plasma concentration-time curves best fitted to a two-compartment model. Key findings Fentanyl clearance was significantly higher in the carbamazepine group compared to controls (mean +/- SD: 20.1 +/- 6.8 vs 13.2 +/- 4.8 ml/min per kg, P < 0.05), and area under the plasma concentration curve (AUC) was significantly lower (150 +/- 65 vs 233 +/- 70 ng/ml x min, P < 0.02). Volume of distribution was larger in the carbamazepine group, but the difference was not statistically significant (5.4 +/- 3.1 vs 3.6 +/- 1.2 l/kg, P > 0.15). The terminal elimination half-life did not differ between the two groups. Conclusions Chronic carbamazepine therapy leads to increased fentanyl clearance and decreased AUC, which may result in decreased duration of therapeutic plasma concentrations of fentanyl and an increased dose requirement. Assuming that carbamazepine does not change fentanyl pharmacodynamics, patients on chronic carbamazepine therapy may require more frequent or higher fentanyl doses to maintain therapeutic plasma concentrations.	[Nozari, Ala; Akeju, Oluwaseun; Mirzakhani, Hooman; Martyn, J. A. Jeevendra] Massachusetts Gen Hosp, Dept Anesthesiol Crit Care & Pain Med, 55 Fruit St, Boston, MA 02114 USA; [Eskandar, Emad] Massachusetts Gen Hosp, Neurosurg, Boston, MA 02114 USA; [Ma, Zhijun; Hossain, M. D. Amin; Greenblatt, David J.] Tufts Univ, Sch Med, Program Pharmacol & Drug Dev, Boston, MA 02111 USA; [Hossain, M. D. Amin; Wang, Qingping] Sanofi Genzyme, Drug Metab & Pharmacokinet, Waltham, MA USA; [Martyn, J. A. Jeevendra] Harvard Med Sch, Shriners Hosp Children, Boston, MA 02115 USA	Nozari, A (reprint author), Massachusetts Gen Hosp, Dept Anesthesiol Crit Care & Pain Med, 55 Fruit St, Boston, MA 02114 USA.	anozari@mgh.harvard.edu	akeju, oluwaseun/R-7846-2019	Nozari, Ala/0000-0002-5755-6347; Akeju, Oluwaseun/0000-0002-6740-1250	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RO1 GM 11847]; Shriners Hospital Research Philanthropy Grant [85124]	This work was partially supported by grants from NIH RO1 GM 11847 and from Shriners Hospital Research Philanthropy Grant # 85124 (to JAJM).	ABERNETHY DR, 1981, J PHARMACOL EXP THER, V217, P681; Feierman DE, 1996, DRUG METAB DISPOS, V24, P932; Flexman AM, 2014, ANESTHESIOLOGY, V120, P1118, DOI 10.1097/ALN.0000000000000141; Greenblatt DJ, 2018, CLIN PHARM DRUG DEV, V7, P6, DOI 10.1002/cpdd.430; Greenblatt DJ, 2016, J CLIN PHARMACOL, V56, P1180, DOI 10.1002/jcph.732; GREENBLATT DJ, 1993, J CLIN PHARMACOL, V33, P650, DOI 10.1002/j.1552-4604.1993.tb04719.x; Han TH, 2007, J CLIN PHARMACOL, V47, P674, DOI 10.1177/0091270007299756; Hanley MJ, 2010, CLIN PHARMACOKINET, V49, P71, DOI 10.2165/11318100-000000000-00000; HILL HF, 1990, PAIN, V43, P69, DOI 10.1016/0304-3959(90)90051-E; HUNT SP, 1978, BRAIN RES, V142, P152, DOI 10.1016/0006-8993(78)90185-3; Kharasch ED, 2004, ANESTHESIOLOGY, V101, P729, DOI 10.1097/00000542-200409000-00022; Labroo RB, 1997, DRUG METAB DISPOS, V25, P1072; LUNN JK, 1979, ANESTH ANALG, V58, P390; Martyn JAJ, 2019, NEW ENGL J MED, V380, P365, DOI 10.1056/NEJMra1800222; MATHER LE, 1983, CLIN PHARMACOKINET, V8, P422, DOI 10.2165/00003088-198308050-00004; MCCLAIN DA, 1980, CLIN PHARMACOL THER, V28, P106, DOI 10.1038/clpt.1980.138; Morii H, 2007, J PAIN SYMPTOM MANAG, V33, P5, DOI 10.1016/j.jpainsymman.2006.08.005; NIMMO WS, 1985, BRIT J ANAESTH, V57, P250, DOI 10.1093/bja/57.3.250; Schaller SJ, 2017, J PHARM PHARMACOL, V69, P82, DOI 10.1111/jphp.12663; Siniscalchi A, 2012, PHARMACOL RES, V65, P171, DOI 10.1016/j.phrs.2011.09.003; Song L, 2014, BRAIN RES, V1564, P52, DOI 10.1016/j.brainres.2014.03.047; Soriano SG, 2001, BRIT J ANAESTH, V86, P223, DOI 10.1093/bja/86.2.223; Spina E, 1996, CLIN PHARMACOKINET, V31, P198, DOI 10.2165/00003088-199631030-00004; Takane H, 2005, ANN PHARMACOTHER, V39, P2139, DOI 10.1345/aph.1G370; TEMPELHOFF R, 1990, CAN J ANAESTH, V37, P327, DOI 10.1007/BF03005584; Tsunoda SM, 1999, CLIN PHARMACOL THER, V66, P461, DOI 10.1016/S0009-9236(99)70009-3; Ziesenitz VC, 2015, J CLIN PHARMACOL, V55, P708, DOI 10.1002/jcph.469	27	3	3	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3573	2042-7158		J PHARM PHARMACOL	J. Pharm. Pharmacol.	JUN	2019	71	6					982	987		10.1111/jphp.13079			6	Pharmacology & Pharmacy	Pharmacology & Pharmacy	HX3FV	WOS:000467278100010	30793320				2020-06-30	J	Yousef, AA; Alzeftawy, AE				Yousef, Ayman Abdalmaksoud; Alzeftawy, Ashraf Elsayed			The efficacy of oral piroxicam fast-dissolving tablets versus sublingual fentanyl in incident breakthrough pain due to bone metastases: a double-blinded randomized study	SUPPORTIVE CARE IN CANCER			English	Article						Oral piroxicam tablets; Sublingual fentanyl; Incident BTP; Bone metastases	DISINTEGRATING TABLET; SAFETY; PHARMACOKINETICS; TOLERABILITY; ASSOCIATION; MANAGEMENT	PurposeBreakthrough pain (BTP) is a transient exacerbation of pain occurring in a patient with chronic, persistent pain. The most common type is incident pain that is mostly related to bone metastases. The oral mucosa is an attractive route for drug delivery. Sublingual fentanyl preparations are a very attractive agent in controlling attacks of BTP due to its rapid absorption through the oral mucosa. Non-steroidal anti-inflammatory drugs (NSAIDs) play a key role as a first step in treatment of cancer pain; piroxicam sublingual formulations could be a useful alternative in controlling incident pain. Our study hypothesis is to evaluate the efficacy of sublingual fentanyl versus oral piroxicam fast-dissolving tablets in patients with incident pain and its impact on functional status.Patients and methodsA cohort of 100 adults of both genders suffering from bone metastases. Patients were assigned to receive either sublingual fentanyl tablet (group 1) or oral piroxicam fast-dissolving tablets (group 2). The pain intensity reduction on a 0-10 visual analog scale (VAS), frequency of BTP attacks, and onset of pain relief. Secondary end points included the functional interference items of the Brief Pain Inventory (BPI).ResultsThere is no significant difference between the two groups regarding the patients' demographics. Significant decline of the VAS in each group in comparison to the pretreatment values (p=0.001). Non-significant changes of the VAS, duration of pain attacks, and number of rescue doses in comparing both groups were measured. There was significant reduction in group 2 BPI regarding the relation with others, sleep pattern and enjoyment of life parameters at 2 and 4weeks (p=0.001).ConclusionOur study demonstrated that oral piroxicam fast-dissolving tablet is an analgesic alternative to sublingual fentanyl in patients with bone metastasis to control incidental BTP attacks with more favorable cost-benefit values.	[Yousef, Ayman Abdalmaksoud; Alzeftawy, Ashraf Elsayed] Tanta Univ, Fac Med, Dept Anesthesia, Pain Unit, 7 Moheb St, Tanta, Egypt	Yousef, AA (reprint author), Tanta Univ, Fac Med, Dept Anesthesia, Pain Unit, 7 Moheb St, Tanta, Egypt.	ayman.yousef@rocketmail.com					Chwieduk CM, 2010, DRUGS, V70, P2281, DOI 10.2165/11200910-000000000-00000; Davies AN, 2008, J PAIN SYMPTOM MANAG, V35, P406, DOI 10.1016/j.jpainsymman.2007.05.010; Davies AN, 2009, EUR J PAIN, V13, P331, DOI 10.1016/j.ejpain.2008.06.014; Gomez-Batiste X, 2002, J PAIN SYMPTOM MANAG, V24, P45, DOI 10.1016/S0885-3924(02)00421-9; Jandhyala R, 2013, J PAIN SYMPTOM MANAG, V12, P1; Janecki M, 2011, PALLIATIVE MED, V10, P29; Keller S, 2004, CLIN J PAIN, V20, P309, DOI 10.1097/00002508-200409000-00005; Kuo Kuan-Ling, 2013, J Pain Palliat Care Pharmacother, V27, P167, DOI 10.3109/15360288.2013.787137; Lennernas B, 2010, PALLIATIVE MED, V24, P286, DOI 10.1177/0269216309356138; Lister N, 2011, J CLIN PHARMACOL, V51, P1195, DOI 10.1177/0091270010379410; Margarit Cesar, 2012, J Pain Res, V5, P559, DOI 10.2147/JPR.S36428; Mercadante S, 2004, J PAIN SYMPTOM MANAG, V28, P505, DOI 10.1016/j.jpainsymman.2004.02.024; Mercadante S, 2002, CANCER, V94, P832, DOI 10.1002/cncr.10249; Mishra S, 2009, INDIAN J PALLIAT CAR, V15, P14, DOI 10.4103/0973-1075.53506; Omoti Afekhide E, 2007, Pharm Pract (Granada), V5, P99; Patel VF, 2011, J CONTROL RELEASE, V153, P106, DOI 10.1016/j.jconrel.2011.01.027; PAYNE R, 2011, CANCER, V80, P1608, DOI DOI 10.1002/(SICI)1097-0142(19971015)80:8+; Rauck RL, 2009, CURR MED RES OPIN, V25, P2877, DOI 10.1185/03007990903368310; Shimoyama N, 2015, JPN J CLIN ONCOL, V45, P189, DOI 10.1093/jjco/hyu182; Smith HS, 2013, J PAIN RES, V6, P189, DOI 10.2147/JPR.S40745; Uberall MA, 2011, CURR MED RES OPIN, V27, P1385, DOI 10.1185/03007995.2011.583231; Yalcin S, 1998, MED ONCOL, V15, P137, DOI 10.1007/BF02989593; Zhang H, 2002, CLIN PHARMACOKINET, V41, P661, DOI 10.2165/00003088-200241090-00003	23	1	1	0	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0941-4355	1433-7339		SUPPORT CARE CANCER	Support. Care Cancer	JUN	2019	27	6					2171	2177		10.1007/s00520-018-4469-6			7	Oncology; Health Care Sciences & Services; Rehabilitation	Oncology; Health Care Sciences & Services; Rehabilitation	HW8QK	WOS:000466954400026	30306325				2020-06-30	J	Kim, HK; Connors, NJ; Mazer-Amirshahi, ME				Kim, Hong K.; Connors, Nicholas J.; Mazer-Amirshahi, Maryann E.			The role of take-home naloxone in the epidemic of opioid overdose involving illicitly manufactured fentanyl and its analogs	EXPERT OPINION ON DRUG SAFETY			English	Review						Illicitly manufactured fentanyl; fentanyl analogs; take-home naloxone; opioid overdose; opioid abuse; occupational exposure	MEDICAL-SERVICE PROVIDERS; HUMAN LIVER-MICROSOMES; INTRANASAL NALOXONE; SYNTHETIC OPIOIDS; NARCOTIC ANALGESICS; UNITED-STATES; DRUG-ABUSE; NEW-MEXICO; DEATHS; CARFENTANIL	Introduction: There has been an exponential increase in overdose fatalities as illicitly manufactured fentanyl and its analogs (IMF) are becoming more prevalent in the illicit drug supply. In response, overdose education and naloxone distribution (OEND) programs have been implemented throughout the United States as a harm reduction strategy. However, there are increasing reports that higher naloxone doses or repeat administration might be required for overdose victims involving IMF. Areas covered: In this article, we provide a comprehensive review of the epidemiology, public health impact, and pharmacologic properties of IMF. The pharmacokinetic properties of currently available take-home naloxone (THN) kits, the role of THN as a harm reduction strategy and available data on its clinical use are discussed. Implications of occupational IMF exposure for first responders are also described. Expert opinion: THN administration by a bystander is an effective harm reduction intervention. However, there is growing evidence that higher dose or multiple administrations of naloxone are required to fully reverse IMF related toxicity. Recently, the US Food and Drug Administration approved THN kits with a concentrated naloxone dose that produce high bioavailability. However, limited presence of OEND programs and cost of these new devices impede their accessibility to the general public.	[Kim, Hong K.] Univ Maryland, Sch Med, Dept Emergency Med, 110 South Paca St,6th Floor,Suite 200, Baltimore, MD 21201 USA; [Connors, Nicholas J.] Med Univ South Carolina, Dept Emergency Med, Charleston, SC 29425 USA; [Mazer-Amirshahi, Maryann E.] MedStar Washington Hosp Ctr, Dept Emergency Med, Washington, DC USA; [Mazer-Amirshahi, Maryann E.] Georgetown Univ, Sch Med, Washington, DC USA	Kim, HK (reprint author), Univ Maryland, Sch Med, Dept Emergency Med, 110 South Paca St,6th Floor,Suite 200, Baltimore, MD 21201 USA.	hong.kim@som.umaryland.edu	Kim, Hong/X-9537-2019; Connors, Nicholas/AAJ-5888-2020	Kim, Hong/0000-0003-0199-5786; Connors, Nicholas/0000-0002-3431-7052			Accessdata. fda. gov, DUR HIGHL PRESCR INF; ALBURGES ME, 1992, J ANAL TOXICOL, V16, P36, DOI 10.1093/jat/16.1.36; [Anonymous], OV DEATH RAT; [Anonymous], 2018, AC FENT N N1 PHEN 4; [Anonymous], 2017, FENT PREV OCC EXP EM; [Anonymous], 2016, DEA WARN POL PUBL FE; Anton B, 2009, HUM VACCINES, V5, P214, DOI 10.4161/hv.5.4.7556; Arens AM, 2016, JAMA INTERN MED, V176, P1554, DOI 10.1001/jamainternmed.2016.4306; Armenian P, 2018, NEUROPHARMACOLOGY, V134, P121, DOI 10.1016/j.neuropharm.2017.10.016; Barton ED, 2005, J EMERG MED, V29, P265, DOI 10.1016/j.jemermed.2005.03.007; Beletsky L, 2007, J URBAN HEALTH, V84, P126, DOI 10.1007/s11524-006-9120-z; BOAS RA, 1985, BRIT J ANAESTH, V57, P192, DOI 10.1093/bja/57.2.192; BRITTAIN RT, 1973, BRIT J PHARMACOL, V49, pP158; Bryson EO, 2008, ANESTHESIOLOGY, V109, P905, DOI 10.1097/ALN.0b013e3181895bc1; CHENEY BV, 1985, J MED CHEM, V28, P1853, DOI 10.1021/jm00150a017; Clark AK, 2014, J ADDICT MED, V8, P153, DOI 10.1097/ADM.0000000000000034; Cole JB, 2017, AM J EMERG MED, V35, P1743, DOI 10.1016/j.ajem.2017.08.045; Cole JB, 2015, PEDIATRICS, V135, pE740, DOI 10.1542/peds.2014-2878; Concheiro M, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01210; Coon TP, 2005, ANN EMERG MED, V46, P473, DOI 10.1016/j.annemergmed.2005.06.450; Dahan A, 2005, BRIT J ANAESTH, V94, P825, DOI 10.1093/bja/aei145; Dahan A, 2010, ANESTHESIOLOGY, V112, P226, DOI 10.1097/ALN.0b013e3181c38c25; Darke S, 2016, ADDICTION, V111, P1607, DOI 10.1111/add.13429; Darwish M, 2007, J CLIN PHARMACOL, V47, P343, DOI 10.1177/0091270006297749; Davis CS, 2014, ACAD EMERG MED, V21, P1173, DOI 10.1111/acem.12485; Davis CS, 2014, AM J PUBLIC HEALTH, V104, pE7, DOI 10.2105/AJPH.2014.302062; Denton JS, 2008, J FORENSIC SCI, V53, P452, DOI 10.1111/j.1556-4029.2008.00669.x; Diversion Control Division (US), 2018, NAT FOR LAB INF SYST; Diversion Control Division (US), 2017, NFLIS BRIEF FENT FEN; Diversion Control Division (US), 2017, NAT FOR LAB INF SYST; Dowling J, 2008, THER DRUG MONIT, V30, P490, DOI 10.1097/FTD.0b013e3181816214; Doyon S, 2014, J MED TOXICOL, V10, P431, DOI 10.1007/s13181-014-0432-1; Drug Enforcement Administration Department of Justice, 2016, Fed Regist, V81, P79389; Drug Enforcement Administration (US), 2017, 2017 NAT DRUG THREAT; Eccles LJ, 2018, DNA REPAIR, V64, P1, DOI 10.1016/j.dnarep.2018.02.003; Edison L, 2017, MMWR-MORBID MORTAL W, V66, P1119, DOI 10.15585/mmwr.mm6641a6; Edwards E., 2015, FRONT PUBLIC HEALTH, V4, P1; Elliott Simon P, 2016, Drug Test Anal, V8, P875, DOI 10.1002/dta.1984; Elzey MJ, 2017, EXPERT OPIN DRUG DEL, V14, P1045, DOI 10.1080/17425247.2017.1230097; Expert Committee on Drug Dependence (CH), 2017, FUR FENT CRIT REV RE; Expert Committee on Drug Dependence (CH), 2016, U 47700 CRIT REV REP; Expert Committee on Drug Dependence (CH), 2017, CARF CRIT REV REP AG; Expert Committee on Drug Dependence (CH), 2016, BUT BUT CRIT REV REP; Expert Committee on Drug Dependence (CH), 2015, AC CRIT REV REP AG I; Expert Committee on Drug Dependence (CH), 2014, AH 7921 CRIT REV REP; Fairbairn N, 2017, INT J DRUG POLICY, V46, P172, DOI 10.1016/j.drugpo.2017.06.005; Faul M, 2017, PREHOSP EMERG CARE, V21, P411, DOI 10.1080/10903127.2017.1315203; Feasel MG, 2016, AAPS J, V18, P1489, DOI 10.1208/s12248-016-9963-5; Flannagan LM, 1996, J FORENSIC SCI, V41, P320; Frank RG, 2017, NEW ENGL J MED, V376, P605, DOI 10.1056/NEJMp1615145; GAL TJ, 1989, CLIN PHARMACOL THER, V45, P66, DOI 10.1038/clpt.1989.10; George AV, 2010, AM J EMERG MED, V28, P530, DOI 10.1016/j.ajem.2010.03.003; Gourlay GK, 2006, BR J CLIN PHARM, V15, P269; Green TC, 2016, JAMA INTERN MED, V176, P1555, DOI 10.1001/jamainternmed.2016.4310; Green TC, 2013, DRUG ALCOHOL DEPEN, V133, P677, DOI 10.1016/j.drugalcdep.2013.08.018; Griswold MK, 2018, CLIN TOXICOL, V56, P37, DOI 10.1080/15563650.2017.1339889; Gupta R, 2016, NEW ENGL J MED, V375, P2213, DOI 10.1056/NEJMp1609578; HARPER NJ, 1974, J MED CHEM, V17, P1188, DOI 10.1021/jm00257a012; HAYES AG, 1983, BRIT J PHARMACOL, V79, P731, DOI 10.1111/j.1476-5381.1983.tb10011.x; Heaton JD, 2019, J EMERG MED, V56, P642, DOI 10.1016/j.jemermed.2019.02.015; HENDERSON GL, 1983, P W PHARMACOL SOC, V26, P287; HENDERSON GL, 1991, J FORENSIC SCI, V36, P422; HIBBS J, 1991, JAMA-J AM MED ASSOC, V265, P1011, DOI 10.1001/jama.265.8.1011; Higashikawa Y, 2008, FORENSIC TOXICOL, V26, P1, DOI 10.1007/s11419-007-0039-1; Huang B-S, 1986, United States patent, Patent No. 4584303; Jannetto PJ, 2019, CLIN CHEM, V65, P242, DOI 10.1373/clinchem.2017.281626; Jones T. S., 2008, Morbidity and Mortality Weekly Report, V57, P793; Kaleo Inc, 2018, AUTH GEN EVZIO NAL H; Kelly AM, 2005, MED J AUSTRALIA, V182, P24, DOI 10.5694/j.1326-5377.2005.tb06550.x; Kenney SR, 2018, J SUBST ABUSE TREAT, V86, P65, DOI 10.1016/j.jsat.2018.01.005; Kim HK, 2015, EXPERT OPIN DRUG SAF, V14, P1137, DOI 10.1517/14740338.2015.1037274; Klebacher R, 2017, PREHOSP EMERG CARE, V166, P1; Knopf Alison, 2014, Behav Healthc, V34, P48; Kramer Christopher, 1998, Journal of the American Osteopathic Association, V98, P385; Krinsky CS, 2011, AM J FOREN MED PATH, V32, P347, DOI 10.1097/PAF.0b013e31822ad269; Krotulski AJ, 2018, J ANAL TOXICOL, V42, pE27, DOI 10.1093/jat/bkx092; Krotulski AJ, 2018, DRUG TEST ANAL, V10, P127, DOI 10.1002/dta.2228; Lambdin BH, 2018, INT J DRUG POLICY, V52, P52, DOI 10.1016/j.drugpo.2017.11.017; Levy B, 2016, DRUG ALCOHOL DEPEN, V167, P29, DOI 10.1016/j.drugalcdep.2016.07.011; Lynn RR, 2018, THER ADV DRUG SAF, V9, P63, DOI 10.1177/2042098617744161; Mahonski S, 2018, CLIN TOXICOL, V56, P924; MARTIN M, 1991, ANN EMERG MED, V20, P158, DOI 10.1016/S0196-0644(05)81216-8; Mattson CL, 2018, MMWR-MORBID MORTAL W, V67, P945, DOI 10.15585/mmwr.mm6734a2; McDonald R, 2018, ADDICTION, V113, P484, DOI 10.1111/add.14033; McDonald R, 2017, DRUG ALCOHOL DEPEN, V178, P176, DOI 10.1016/j.drugalcdep.2017.05.001; Melent'ev A, 2015, J ANAL CHEM+, V70, P240, DOI 10.1134/S1061934815020124; Minkowski CP, 2012, ADDICT BIOL, V17, P149, DOI 10.1111/j.1369-1600.2010.00256.x; Mohr ALA, 2016, J ANAL TOXICOL, V40, P709, DOI 10.1093/jat/bkw086; Moresco A, 2001, J ZOO WILDLIFE MED, V32, P81, DOI 10.1638/1042-7260(2001)032[0081:UONTRC]2.0.CO;2; Moss MJ, 2017, J MED TOXICOL, V13, P347, DOI 10.1007/s13181-017-0628-2; Muller S, 2018, CLIN TOXICOL, V56, P151, DOI 10.1080/15563650.2017.1355464; Nelson L, 2009, J MED TOXICOL, V5, P230, DOI 10.1007/BF03178274; Networkforphl. org, LEG INT RED OV MORT; Neubig RR, 2003, PHARMACOL REV, V55, P597, DOI 10.1124/pr.55.4.4; Van Nimmen NFJ, 2006, ANN OCCUP HYG, V50, P665, DOI [10.1093/annhyg/mel028, 10.1093/annhyg/me1028]; O'Donnell JK, 2017, MMWR-MORBID MORTAL W, V66, P1197, DOI 10.15585/mmwr.mm6643e1; Office of Diversion Control (US), 2015, NAT FOR LAB INF SYST; Office of National Drug Control Policy, 2010, NAT DRUG CONTR STRAT; Olofsen E, 2010, ANESTHESIOLOGY, V112, P1417, DOI 10.1097/ALN.0b013e3181d5e29d; Piper TM, 2008, SUBST USE MISUSE, V43, P858, DOI 10.1080/10826080701801261; Prekupec MP, 2017, J ADDICT MED, V11, P256, DOI 10.1097/ADM.0000000000000324; Publications Office of the European Union (EU), 2015, PREV FAT OV SYST REV; Publications Office of the European Union (EU), 2017, CARF EMCDDA EUR JOIN; Rambaran Kerry Anne, 2018, Proc (Bayl Univ Med Cent), V31, P303, DOI 10.1080/08998280.2018.1465320; Riches JR, 2012, J ANAL TOXICOL, V36, P647, DOI 10.1093/jat/bks078; ROSENBERG M, 1986, J ORAL MAXIL SURG, V44, P458, DOI 10.1016/S0278-2391(86)80011-8; ROY SD, 1990, PHARMACEUT RES, V7, P842, DOI 10.1023/A:1015912932416; RUNAGYUTTIKARN W, 1990, J ANAL TOXICOL, V14, P160, DOI 10.1093/jat/14.3.160; Ryan SA, 2018, PAIN MANAG, V8, P231, DOI 10.2217/pmt-2017-0060; Sarton E, 2008, ADV EXP MED BIOL, V605, P486; Scholl L, 2019, MMWR-MORBID MORTAL W, V67, P1419; Schumann H, 2008, CLIN TOXICOL, V46, P501, DOI 10.1080/15563650701877374; Seither J, 2017, J ANAL TOXICOL, V41, P493, DOI 10.1093/jat/bkx049; Sharma KK, 2019, FORENSIC TOXICOL, V37, P1, DOI 10.1007/s11419-018-0454-5; SMIALEK JE, 1994, J FORENSIC SCI, V39, P159; Somerville NJ, 2017, MMWR-MORBID MORTAL W, V66, P382, DOI 10.15585/mmwr.mm6614a2; Stam NC, 2018, CLIN TOXICOL, V39, P1; STANLEY TH, 1992, J PAIN SYMPTOM MANAG, V7, pS3, DOI 10.1016/0885-3924(92)90047-L; Stanley TH, 2008, ANESTH ANALG, V106, P451, DOI 10.1213/ane.0b013e3181605add; Stanley TH, 2014, J PAIN, V15, P1215, DOI 10.1016/j.jpain.2014.08.010; Steuer AE, 2017, DRUG TEST ANAL, V9, P1085, DOI 10.1002/dta.2111; Strang J, 2016, DRUG ALCOHOL DEPEN, V163, P16, DOI 10.1016/j.drugalcdep.2016.02.042; Substance Abuse and Mental Health Services Administration, 2013, HHS PUBL, V13-4795; Substance Abuse and Mental Health Services Administration (US), 2013, DAWN SERIES D, VD- 39; Sutter ME, 2017, ACAD EMERG MED, V24, P106, DOI 10.1111/acem.13034; Swanson DM, 2017, J ANAL TOXICOL, V41, P498, DOI 10.1093/jat/bkx037; Takahashi Masahiko, 2004, J Anesth, V18, P1, DOI 10.1007/s00540-003-0214-4; Tenore PL, 2010, J ADDICT DIS, V29, P436, DOI 10.1080/10550887.2010.509277; Tobin KE, 2005, J URBAN HEALTH, V82, P296, DOI 10.1093/jurban/jti052; Trescot AM, 2008, PAIN PHYSICIAN, V11, pS133; U.S. Department of Justice D.E.A., 2007, FED REGISTER, V72, P20039; Uddayasankar U, 2018, PHARMACOTHERAPY, V38, pE41, DOI 10.1002/phar.2117; van Dorp E, 2006, ANESTHESIOLOGY, V105, P51, DOI 10.1097/00000542-200607000-00012; Vo KT, 2016, MMWR-MORBID MORTAL W, V65, P420, DOI 10.15585/mmwr.mm6516e1; Volpe DA, 2011, REGUL TOXICOL PHARM, V59, P385, DOI 10.1016/j.yrtph.2010.12.007; Walley AY, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f174; Walley AY, 2013, J SUBST ABUSE TREAT, V44, P241, DOI 10.1016/j.jsat.2012.07.004; WARD CF, 1983, JAMA-J AM MED ASSOC, V250, P922, DOI 10.1001/jama.250.7.922; Watanabe S, 2017, AAPS J, V19, P1102, DOI 10.1208/s12248-017-0070-z; Wermeling DP, 2015, THER ADV DRUG SAF, V6, P20, DOI 10.1177/2042098614564776; Wheeler E, 2015, MMWR-MORBID MORTAL W, V64, P631; Wilkerson Richard Gentry, 2016, Emerg Med Clin North Am, V34, pe1, DOI 10.1016/j.emc.2015.11.002; Willman MW, 2017, CLIN TOXICOL, V55, P81, DOI 10.1080/15563650.2016.1253846; Winstanley EL, 2016, ADDICTION, V111, P583, DOI 10.1111/add.13255; Wohlfarth A, 2016, DRUG TEST ANAL, V8, P779, DOI 10.1002/dta.1856; Yassen A, 2007, CLIN PHARMACOL THER, V81, P50, DOI 10.1038/sj.clpt.6100025; Zuckerman M, 2014, PREHOSP EMERG CARE, V18, P550, DOI 10.3109/10903127.2014.896961	147	1	1	2	5	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1474-0338	1744-764X		EXPERT OPIN DRUG SAF	Expert Opin. Drug Saf.	JUN 3	2019	18	6					465	475		10.1080/14740338.2019.1613372		MAY 2019	11	Pharmacology & Pharmacy	Pharmacology & Pharmacy	IO0JE	WOS:000470557100001	31033357				2020-06-30	J	Schwienteck, KL; Faunce, KE; Rice, KC; Obeng, S; Zhang, Y; Blough, BE; Grim, TW; Negus, SS; Banks, ML				Schwienteck, Kathryn L.; Faunce, Kaycee E.; Rice, Kenner C.; Obeng, Samuel; Zhang, Yan; Blough, Bruce E.; Grim, Travis W.; Negus, S. Stevens; Banks, Matthew L.			Effectiveness comparisons of G-protein biased and unbiased mu opioid receptor ligands in warm water tail-withdrawal and drug discrimination in male and female rats	NEUROPHARMACOLOGY			English	Article						Mu-opioid receptor; Efficacy; Fentanyl; Drug discrimination; G-protein biased ligands; Warm water tail-withdrawal	SEX-DIFFERENCES; RHESUS-MONKEYS; ANTINOCICEPTIVE INTERACTIONS; INTRINSIC EFFICACY; AGONIST EFFICACY; ANIMAL-MODELS; IN-VIVO; MORPHINE; TRV130; PAIN	One emerging strategy to address the opioid crisis is the development of mu opioid receptor (MOR) ligands that preferentially signal the G-protein vs. beta-arrestin pathway. The present study compared the relative potency and effectiveness of two G-protein biased (GPB)-MOR ligands TRV130 and SR-14968 to five unbiased MOR ligands (NAQ, nalbuphine, buprenorphine, morphine, and methadone) on therapeutic-related (e.g. antinociception) and abuse-related (e.g. discriminative stimulus effects) endpoints. Male and female rats were tested in a warm water tail-withdrawal procedure (50 degrees C) or trained to discriminate fentanyl (0.04 mg/kg, SC) from saline in a two-lever food-reinforced discrimination procedure. TRV130 and SR-14968 were approximately two-fold more potent to produce fentanyl stimulus effects vs. antinociception. Morphine, fentanyl, and methadone were significantly more potent in the fentanyl discrimination vs. tail withdrawal procedure. In addition, maximum antinociceptive and discriminative stimulus effects of fixed-proportion fentanyl/naltrexone mixtures (1:0.018, 1:0.054, 1:0.18, 1:0.3, and 1:0.54) were used to quantify 1) the relative in vivo efficacy of the two GPB-MOR agonists and five unbiased MOR ligands, and 2) potential species differences in MOR ligand effects between rats and monkeys. The efficacy-effect function generated from the fentanyl/naltrexone mixtures stratified the five unbiased ligands consistent with agonist-stimulated GTP gamma S binding (NAQ = nalbuphine < buprenorphine < morphine < methadone). However, TRV130 and SR-14968 produced greater antinociception and less fentanyl-like stimulus effects than was predicted. Furthermore, there was a significant positive correlation between rat and monkey antinociceptive effects. Overall, these results demonstrate GPB-MOR agonists produce undesirable abuse-related effects, albeit with slightly better potency and efficacy ratios compared to unbiased agonists. This article is part of the Special Issue entitled 'Opioid Neuropharmacology: Advances in treating pain and opioid addiction'.	[Schwienteck, Kathryn L.; Faunce, Kaycee E.; Negus, S. Stevens; Banks, Matthew L.] Virginia Commonwealth Univ, Dept Pharmacol & Toxicol, Richmond, VA USA; [Obeng, Samuel; Zhang, Yan] Virginia Commonwealth Univ, Dept Med Chem, Richmond, VA 23298 USA; [Rice, Kenner C.] NIDA, Drug Design & Synth Sect, Mol Targets & Medicat Discovery Branch, Bethesda, MD 20892 USA; [Rice, Kenner C.] NIAAA, Bethesda, MD USA; [Blough, Bruce E.] Res Triangle Inst, Ctr Drug Discovery, Res Triangle Pk, NC USA; [Grim, Travis W.] Scripps Res Inst, Dept Mol Med, Jupiter, FL USA; [Grim, Travis W.] Scripps Res Inst, Dept Neurosci, Jupiter, FL USA	Banks, ML (reprint author), Dept Pharmacol & Toxicol, 410 North 12th St,Box 980613, Richmond, VA 23298 USA.	matthew.banks@vcuhealth.org	Banks, Matthew L/K-4429-2014	Banks, Matthew L/0000-0003-4949-5246; Schwienteck, Kathryn/0000-0001-7862-1913; Faunce, Kaycee/0000-0002-9178-0692	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [F31DA043921, R01DA037287, R01DA024022]; National Institute on Alcohol Abuse and Alcoholism (NIAAA)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA); National Institute on Drug Abuse (NIDA) Intramural Research Programs; NIAAAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)	This work was supported by the National Institutes of Health grants [F31DA043921; R01DA037287; R01DA024022]. A portion of this work was also supported by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) and the National Institute on Drug Abuse (NIDA) Intramural Research Programs. NIAAA and NIDA had no role in study design, collection, analysis, and interpretation of the data, in the writing or decision to submit the manuscript for publication. The content is solely the responsibility of the authors and does not necessarily represent the official views of NIAAA or NIDA.	ADAMS JU, 1990, J PHARMACOL EXP THER, V255, P1027; Alt A, 2001, J PHARMACOL EXP THER, V298, P116; Altarifi AA, 2017, J PSYCHOPHARMACOL, V31, P730, DOI 10.1177/0269881116689257; Banks ML, 2010, J PHARMACOL EXP THER, V335, P497, DOI 10.1124/jpet.110.169276; Becker JB, 2016, PHARMACOL REV, V68, P242, DOI 10.1124/pr.115.011163; Bergman J, 2000, PSYCHOPHARMACOLOGY, V153, P67, DOI 10.1007/s002130000567; COLPAERT FC, 1976, PSYCHOPHARMACOLOGIA, V46, P169, DOI 10.1007/BF00421388; Corbett AD, 2006, BRIT J PHARMACOL, V147, pS153, DOI 10.1038/sj.bjp.0706435; Cornelissen JC, 2018, J PHARMACOL EXP THER, V365, P37, DOI 10.1124/jpet.117.246439; Council National Research, 2011, GUIDE CARE USE LAB A; Craft RM, 2008, EXP CLIN PSYCHOPHARM, V16, P376, DOI 10.1037/a0012931; Emmerson PJ, 1996, J PHARMACOL EXP THER, V278, P1121; FINCH JS, 1967, J CLIN PHARMACOL N D, V7, P46, DOI 10.1002/j.1552-4604.1967.tb00029.x; HOLTZMAN SG, 1985, DRUG ALCOHOL DEPEN, V14, P263, DOI 10.1016/0376-8716(85)90061-4; Holtzman SG, 1997, PHARMACOL BIOCHEM BE, V57, P771, DOI 10.1016/S0091-3057(96)00395-4; Kenakin T, 2015, MOL PHARMACOL, V88, P1055, DOI 10.1124/mol.115.099770; Liang DY, 2019, ANESTH ANALG, V129, P1414, DOI 10.1213/ANE.0000000000003662; Maguire DR, 2014, J PHARMACOL EXP THER, V351, P383, DOI 10.1124/jpet.114.216648; Morgan D, 1999, J PHARMACOL EXP THER, V289, P965; Morgan D, 1996, BEHAV PHARMACOL, V7, P261; Negus SS, 2008, EXP CLIN PSYCHOPHARM, V16, P386, DOI 10.1037/a0013088; Negus SS, 2018, TRENDS PHARMACOL SCI, V39, P916, DOI 10.1016/j.tips.2018.08.007; Negus SS, 2009, EUR J PHARMACOL, V602, P92, DOI 10.1016/j.ejphar.2008.11.004; Rankovic Z, 2016, BIOORG MED CHEM LETT, V26, P241, DOI 10.1016/j.bmcl.2015.12.024; Schmid CL, 2017, CELL, V171, P1165, DOI 10.1016/j.cell.2017.10.035; Seth P, 2018, AM J PUBLIC HEALTH, V108, P500, DOI 10.2105/AJPH.2017.304265; Siemian JN, 2016, J PHARMACOL EXP THER, V357, P509, DOI 10.1124/jpet.116.232421; Singla N, 2017, J PAIN RES, V10, P2413, DOI 10.2147/JPR.S137952; Soergel DG, 2014, PAIN, V155, P1829, DOI 10.1016/j.pain.2014.06.011; Stahl EL, 2015, MOL PHARMACOL, V87, P866, DOI 10.1124/mol.114.096503; Terner JM, 2003, PAIN, V106, P381, DOI 10.1016/j.pain.2003.08.008; Thompson CM, 2004, J PHARMACOL EXP THER, V308, P547, DOI 10.1124/jpet.103.058602; Volkow ND, 2017, NEW ENGL J MED, V377, P391, DOI 10.1056/NEJMsr1706626; Whiteside GT, 2008, NEUROPHARMACOLOGY, V54, P767, DOI 10.1016/j.neuropharm.2008.01.001; Whiteside GT, 2013, NEUROSCI LETT, V557, P65, DOI 10.1016/j.neulet.2013.08.033; Yuan YY, 2015, BIOORGAN MED CHEM, V23, P1701, DOI 10.1016/j.bmc.2015.02.055; Zamarripa CA, 2018, DRUG ALCOHOL DEPEN, V192, P158, DOI 10.1016/j.drugalcdep.2018.08.002; ZERNIG G, 1994, J PHARMACOL EXP THER, V269, P57; Zhang Y, 2014, EUR J PHARMACOL, V736, P124, DOI 10.1016/j.ejphar.2014.04.041; 2013, J PHARMACOL EXP THER, V344, P708, DOI DOI 10.1124/JPET.112.201616; 1998, J PHARMACOL EXP THER, V285, P496	41	3	3	3	9	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3908	1873-7064		NEUROPHARMACOLOGY	Neuropharmacology	MAY 15	2019	150						200	209		10.1016/j.neuropharm.2019.01.020			10	Neurosciences; Pharmacology & Pharmacy	Neurosciences & Neurology; Pharmacology & Pharmacy	HW6UU	WOS:000466826900020	30660628	Green Accepted			2020-06-30	J	Walentiny, DM; Moisa, LT; Beardsley, PM				Walentiny, D. Matthew; Moisa, Lea T.; Beardsley, Patrick M.			Oxycodone-like discriminative stimulus effects of fentanyl-related emerging drugs of abuse in mice	NEUROPHARMACOLOGY			English	Article						Oxycodone; Fentanyl; Fentanyl-related substance; Opioid; Drug discrimination; New psychoactive substances	UNITED-STATES; OVERDOSE DEATHS; SEX-DIFFERENCES; HEROIN; OCFENTANIL; OPIOIDS; MORPHINE; FATALITY	Background: Fentanyl and its structurally related compounds have emerged as the most significant contributors to opioid overdose fatalities in recent years. While there is abundant information about the pharmacological effects of fentanyl, far less is known of its more recently abused analogs. The objective of this study was to determine whether fentanyl and several fentanyl-related substances would engender oxycodone-like responding in a mouse model of oxycodone discrimination. Oxycodone was selected as the training drug due to its high selectivity for mu opioid receptors. Compounds that elicited oxycodone-like responding in this procedure would likely evoke overlapping subjective experiences. Methods: Adult male C57BL/6 mice were trained to discriminate 1.3 mg/kg oxycodone from vehicle in a food-reinforced, two-lever choice procedure. Generalization tests were conducted with fentanyl and the following fentanyl-related compounds: ocfentanil, 3-furanyl fentanyl, crotonylfentanyl, and valerylfentanyl. Results: Fentanyl and each of its analogs completely generalized to the 1.3 mg/kg oxycodone discriminative stimulus and naltrexone pretreatment significantly decreased oxycodone-like responding for each compound. Rank order potency for engendering oxycodone-appropriate responding was ocfentanil > fentanyl > 3-furanyl fentanyl approximate to crotonylfentanyl > oxycodone > valerylfentanyl. Drug doses that evoked full substitution also significantly suppressed response rates compared to vehicle. Conclusions: These results indicate that the discriminative stimulus, and by extension, the interoceptive and subjective effects of the tested fentanyl analogs, overlap with those of oxycodone. These observations consequentially support the prediction that they would also engender the likelihood for abuse similar to oxycodone. This article is part of the Special Issue entitled 'Opioid Neuropharmacology: Advances in treating pain and opioid addiction'.	[Walentiny, D. Matthew; Moisa, Lea T.; Beardsley, Patrick M.] Virginia Commonwealth Univ, Dept Pharmacol & Toxicol, 1217 E Marshall St, Richmond, VA 23298 USA; [Beardsley, Patrick M.] Virginia Commonwealth Univ, Inst Drug & Alcohol Studies, 410 N 12th St,POB 980613, Richmond, VA 23298 USA; [Beardsley, Patrick M.] Virginia Commonwealth Univ, Ctr Biomarker Res & Personalized Med, 410 N 12th St,POB 980613, Richmond, VA 23298 USA	Walentiny, DM (reprint author), 1217 E Marshall St,POB 980613, Richmond, VA 23298 USA.	david.walentiny@vcuhealth.org			National Institute on Drug AbuseUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [NO1DA-14-8917]; United States Drug Enforcement Administration award [DJD-17-HQ-P-0641]; Virginia Commonwealth University [PHTX292321]	Support for D.M.W. and P.M.B. during the preparation of this report was provided by National Institute on Drug Abuse award NO1DA-17-8932 and the United States Drug Enforcement Administration award (DJD-17-HQ-P-0641). P.M.B. was also supported by National Institute on Drug Abuse award NO1DA-14-8917. Research support was provided by Virginia Commonwealth University (PHTX292321). These funding sources had no role in study design; in the collection, analysis and interpretation of data; in the writing of the report; or in the decision to submit the article for publication. We thank the United States Drug Enforcement Administration for providing most drugs for this research. The authors additionally wish to thank Molly Creighton for excellent technical assistance.	Aceto M D, 1987, NIDA Res Monogr, V76, P392; BALSTER RL, 1991, BRIT J ADDICT, V86, P1549; Baumann MH, 2018, NEUROPHARMACOLOGY, V134, P101, DOI 10.1016/j.neuropharm.2017.08.016; Beardsley P.M, 2018, HDB EXPT PHARM; Beardsley PM, 2004, EXP CLIN PSYCHOPHARM, V12, P163, DOI 10.1037/1064-1297.12.3.163; Centers for Disease Control and Prevention National Center for Health Statistics, 2019, MULT CAUS DEATH 1999; Cicero TJ, 2017, ADDICT BEHAV, V74, P63, DOI 10.1016/j.addbeh.2017.05.030; Cicero TJ, 2014, JAMA PSYCHIAT, V71, P821, DOI 10.1001/jamapsychiatry.2014.366; COLPAERT FC, 1977, LIFE SCI, V20, P1097, DOI 10.1016/0024-3205(77)90480-5; Comer SD, 2008, NEUROPSYCHOPHARMACOL, V33, P1179, DOI 10.1038/sj.npp.1301479; Coopman V, 2016, FORENSIC SCI INT, V266, P469, DOI 10.1016/j.forsciint.2016.07.005; Craft RM, 2008, EXP CLIN PSYCHOPHARM, V16, P376, DOI 10.1037/a0012931; Craft RM, 1996, BEHAV PHARMACOL, V7, P764; Drug Enforcement Administration, 2016, COUNT PRESCR PILLS C; Drug Enforecement Administration Department of Justice, 2018, Fed Regist, V83, P5188; Dussy FE, 2016, J ANAL TOXICOL, V40, P761, DOI 10.1093/jat/bkw096; Dykstra LA, 1997, PSYCHOPHARMACOLOGY, V130, P14, DOI 10.1007/s002130050208; Faul M, 2017, PREHOSP EMERG CARE, V21, P411, DOI 10.1080/10903127.2017.1315203; FLETCHER JE, 1991, ANESTH ANALG, V73, P622; Gussow L, 2016, EMERG MED NEWS, V38, P29; Misailidi N, 2018, FORENSIC TOXICOL, V36, P12, DOI 10.1007/s11419-017-0379-4; Neelakantan H, 2015, EXP CLIN PSYCHOPHARM, V23, P217, DOI 10.1037/pha0000028; O'Donnell JK, 2017, MMWR-MORBID MORTAL W, V66, P897, DOI 10.15585/mmwr.mm6634a2; Rudd RA, 2016, MMWR-MORBID MORTAL W, V65, P1445, DOI 10.15585/mmwr.mm655051e1; SCHMIDT WK, 1985, DRUG ALCOHOL DEPEN, V14, P339, DOI 10.1016/0376-8716(85)90066-3; Seth P, 2018, MMWR-MORBID MORTAL W, V67, P349, DOI 10.15585/mmwr.mm6712a1; Seth P, 2018, AM J PUBLIC HEALTH, V108, P500, DOI 10.2105/AJPH.2017.304265; Sutter ME, 2017, ACAD EMERG MED, V24, P106, DOI 10.1111/acem.13034; Varshneya N.B, NEUROPHARMACOLOGY; Walentiny DM, 2018, DRUG ALCOHOL DEPEN, V187, P335, DOI 10.1016/j.drugalcdep.2018.02.035; YOBURN BC, 1995, PHARMACOL BIOCHEM BE, V51, P535, DOI 10.1016/0091-3057(94)00375-S	31	2	2	2	5	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3908	1873-7064		NEUROPHARMACOLOGY	Neuropharmacology	MAY 15	2019	150						210	216		10.1016/j.neuropharm.2019.02.007			7	Neurosciences; Pharmacology & Pharmacy	Neurosciences & Neurology; Pharmacology & Pharmacy	HW6UU	WOS:000466826900021	30735691				2020-06-30	J	McLean, K; Monnat, SM; Rigg, K; Sterner, GE; Verdery, A				McLean, Katherine; Monnat, Shannon M.; Rigg, Khary; Sterner, Glenn E., III; Verdery, Ashton			"You Never Know What You're Getting": Opioid Users' Perceptions of Fentanyl in Southwest Pennsylvania	SUBSTANCE USE & MISUSE			English	Article						Fentanyl; heroin; prescription opioids; overdose; harm reduction	CONTAMINATED HEROIN; OVERDOSE; SETTINGS; EXPOSURE; STATES	Background: Urban areas in the United States have experienced a dramatic surge in fentanyl overdose deaths since 2014, a trend affecting both larger and smaller metropolitan areas. Encompassing only 1.2 million residents, Allegheny County, Pennsylvania, nevertheless saw 412 fentanyl-involved deaths in 2016, a number surpassed only by New York City and Cook County (Chicago), Illinois. Objectives: This article seeks to describe opioid users' perceptions of fentanyl in Allegheny and three adjacent counties; it further considers how the drug's emergence shapes some users' market behaviors and consumption practices. Methods: This article reports on qualitative interview data (N=30) collected as part of a larger, multi-phase, mixed methods study (N=125) among individuals reporting past-year prescription opioid misuse or heroin use in four southwest Pennsylvania Counties. Results: Most interviewees reported past-year suspected exposure to fentanyl, and many reported suffering or seeing suspected fentanyl overdoses. Where roughly one-third reported strategies for avoiding fentanyl, a small group of interviewees identified advantages to fentanyl, while still acknowledging its associated risks. Conclusions/Importance: Given users' diverse opinions around fentanyl, the distribution of fentanyl test strips may represent an effective response to the current crisis.	[McLean, Katherine] Penn State Greater Allegheny, Adm Justice, 4000 Univ Blvd, Mckeesport, PA 15131 USA; [Monnat, Shannon M.] Syracuse Univ, Maxwell Sch Citizenship & Publ Affairs, Sociol, Syracuse, NY USA; [Rigg, Khary] Univ S Florida, Dept Mental Hlth Law & Policy, Coll Behav & Community Sci, Tampa, FL USA; [Sterner, Glenn E., III] Penn State Univ, Justice Ctr Res, University Pk, PA 16802 USA; [Verdery, Ashton] Penn State Univ, Dept Sociol & Criminol, University Pk, PA 16802 USA	McLean, K (reprint author), Penn State Greater Allegheny, Adm Justice, 4000 Univ Blvd, Mckeesport, PA 15131 USA.	kjm47@psu.edu			Social Science Research Institute at Penn State University - Eunice Kennedy Shriver National Institute of Child Health and Human Development [P2CHD041025]; Justice Center for Research at Penn State University; USDA National Institute of Food and Agriculture, Agricultural and Food Research Initiative Competitive Program, Agriculture Economics and Rural Communities [2018-68006-27640]; Population Research Institute - Eunice Kennedy Shriver National Institute of Child Health and Human Development [R24-HD041025]; Institute for CyberScience at Penn State University	This study was funded by the Social Science Research Institute at Penn State University, which is supported by an infrastructure grant by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (P2CHD041025) and by the Justice Center for Research at Penn State University. Dr. Monnat acknowledges funding from the USDA National Institute of Food and Agriculture, Agricultural and Food Research Initiative Competitive Program, Agriculture Economics and Rural Communities, grant #2018-68006-27640. Dr. Verdery acknowledges funding from the Population Research Institute, which is supported by an infrastructure grant by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (R24-HD041025), and the Institute for CyberScience at Penn State University.	[Anonymous], RES SEGR; Bancroft A, 2016, INT J DRUG POLICY, V35, P42, DOI 10.1016/j.drugpo.2015.11.008; Bee C. A., 2013, AM COMMUNITY SURVEY; Bell A, 2019, SUBST ABUS, V40, P52, DOI 10.1080/08897077.2018.1449053; Carroll JJ, 2017, INT J DRUG POLICY, V46, P136, DOI 10.1016/j.drugpo.2017.05.023; Ciccarone D, 2017, INT J DRUG POLICY, V46, P146, DOI 10.1016/j.drugpo.2017.06.004; Dombrowski Kirk, 2012, Adv Appl Sociol, V2, P245; Drug Enforcement Administration, 2017, DEADCTDIR04017; Drug Enforcement Administration, 2017, DEAPHLDIR03417; Frank RG, 2017, NEW ENGL J MED, V376, P605, DOI 10.1056/NEJMp1615145; Gladden RM, 2016, MMWR-MORBID MORTAL W, V65, P837, DOI 10.15585/mmwr.mm6533a2; Harris M, 2015, INT J DRUG POLICY, V26, P51, DOI 10.1016/j.drugpo.2014.09.009; Heckathorn DD, 1997, SOC PROBL, V44, P174, DOI 10.1525/sp.1997.44.2.03x0221m; Kalton G, 2009, SURVEY QUALITY; Krieger MS, 2018, HARM REDUCT J, V15, DOI 10.1186/s12954-018-0213-2; Lewis Nicole, 2017, WASHINGTON POST 0815; Macmadu A, 2017, ADDICT BEHAV, V68, P35, DOI 10.1016/j.addbeh.2017.01.014; Malekinejad M, 2008, AIDS BEHAV, V12, pS105, DOI 10.1007/s10461-008-9421-1; Mars SG, 2018, J PSYCHOACTIVE DRUGS, V50, P167, DOI 10.1080/02791072.2017.1394508; Mars SG, 2016, J PSYCHOACTIVE DRUGS, V48, P270, DOI 10.1080/02791072.2016.1207826; McGowan CR, 2018, INT J DRUG POLICY, V58, P31, DOI 10.1016/j.drugpo.2018.04.017; McKnight C, 2018, INT J DRUG POLICY, V60, P82, DOI 10.1016/j.drugpo.2018.08.004; Mema SC, 2018, HARM REDUCT J, V15, DOI 10.1186/s12954-018-0224-z; O'Donnell JK, 2017, MMWR-MORBID MORTAL W, V66, P1197, DOI 10.15585/mmwr.mm6643e1; OverdoseFreePA, OVERDOSE DEATH DATA; Rhodes T, 2009, INT J DRUG POLICY, V20, P193, DOI 10.1016/j.drugpo.2008.10.003; Somerville NJ, 2017, MMWR-MORBID MORTAL W, V66, P382, DOI 10.15585/mmwr.mm6614a2; WHO, 2013, INTR HIV AIDS SEX TR	28	5	5	0	1	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1082-6084	1532-2491		SUBST USE MISUSE	Subst. Use Misuse	MAY 12	2019	54	6					955	966		10.1080/10826084.2018.1552303			12	Substance Abuse; Psychiatry; Psychology	Substance Abuse; Psychiatry; Psychology	HW8AI	WOS:000466910800009	30676198	Green Accepted			2020-06-30	J	Latkin, CA; Dayton, L; Davey-Rothwell, MA; Tobin, KE				Latkin, Carl. A.; Dayton, Lauren; Davey-Rothwell, Melissa A.; Tobin, Karin E.			Fentanyl and Drug Overdose: Perceptions of Fentanyl Risk, Overdose Risk Behaviors, and Opportunities for Intervention among People who use Opioids in Baltimore, USA	SUBSTANCE USE & MISUSE			English	Article						Fentanyl; opioid; overdose; naloxone	PROTECTION MOTIVATION; FEAR APPEALS; HEROIN; DEATHS; TRENDS; STATES; ABUSE; INCREASES; EXPOSURE; STIGMA	Background: Fentanyl-related mortality has skyrocketed among people who use opioids (PWUO) in North America. The current study of PWUO aims to examine the perceived fentanyl risk and training needs; fatal overdose prevention behaviors; and, feasibility of a peer education approach to reducing fentanyl-related fatal overdoses in Baltimore, Maryland, USA. Methods: 316 street-recruited PWUO were interviewed about fentanyl in Baltimore, MD. Results: Most participants (56%) reported that all or almost all heroin in Baltimore was adulterated with fentanyl and were worried (75%) about their drug buddies overdosing on fentanyl. Half (54%) the participants felt that they needed more training to respond to an overdose. Many participants (66%) reported receiving naloxone or a prescription for it, yet only 17% carried naloxone with them often or always. Among people who inject drugs (PWID) only 13% had naloxone available often or always when they injected with others, and 51% often or always injected alone. Almost half of participants (47%) were very willing to talk with people in their neighborhood about fentanyl. Conclusions: The majority of PWUO perceived that most heroin in Baltimore was adulterated with fentanyl, yet most did not carry naloxone and PWID often did so alone. Given the high perceived risk of fentanyl and relatively low uptake of fatal overdose prevention behaviors, there is an urgency for safe injection facilities, access to medically assisted treatment, and programs that work with the drug-using community to deliver overdose prevention training as well as promote behaviors to carry naloxone and not use drugs alone.	[Latkin, Carl. A.; Dayton, Lauren; Davey-Rothwell, Melissa A.; Tobin, Karin E.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Behav & Soc, 737 Hampton House, Baltimore, MD 21205 USA	Latkin, CA (reprint author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Behav & Soc, 737 Hampton House, Baltimore, MD 21205 USA.	carl.latkin@jhu.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [DA022961, DA040488]	The funding was by NIH. Study participants, NIH grants DA022961 & DA040488 supported this research. The funders had no role in the study design, analyses, interpretation, or writing.	Baltimore City Health Department, 2018, SUBSTANCE USE MISUSE; Baltimore City Health Department, 2017, FENT; Bardwell G, 2018, DRUG ALCOHOL DEPEN, V190, P6, DOI 10.1016/j.drugalcdep.2018.05.023; Carroll JJ, 2017, INT J DRUG POLICY, V46, P136, DOI 10.1016/j.drugpo.2017.05.023; Ciccarone D, 2017, INT J DRUG POLICY, V46, P146, DOI 10.1016/j.drugpo.2017.06.004; Ciccarone D, 2009, INT J DRUG POLICY, V20, P277, DOI 10.1016/j.drugpo.2008.08.003; Dart RC, 2015, NEW ENGL J MED, V372, P241, DOI [10.1056/NEJMc1501822, 10.1056/NEJMsa1406143]; Davidson PJ, 2018, INT J DRUG POLICY, V53, P37, DOI 10.1016/j.drugpo.2017.12.005; Fairbairn N, 2017, INT J DRUG POLICY, V46, P172, DOI 10.1016/j.drugpo.2017.06.005; FISHER RJ, 1993, J CONSUM RES, V20, P303, DOI 10.1086/209351; Gladden RM, 2016, MMWR-MORBID MORTAL W, V65, P837, DOI 10.15585/mmwr.mm6533a2; Green TC, 2016, JAMA INTERN MED, V176, P1555, DOI 10.1001/jamainternmed.2016.4310; Kenney SR, 2018, J SUBST ABUSE TREAT, V86, P65, DOI 10.1016/j.jsat.2018.01.005; Kim JW, 2010, J ADDICT MED, V4, P244, DOI 10.1097/ADM.0b013e3181c1df64; Krieger MS, 2018, HARM REDUCT J, V15, DOI 10.1186/s12954-018-0213-2; Kuczynska K, 2018, FORENSIC SCI INT, V289, P207, DOI 10.1016/j.forsciint.2018.05.042; Kuhlman JJ, 2003, J ANAL TOXICOL, V27, P499, DOI 10.1093/jat/27.7.499; Latkin CA, 2003, HEALTH PSYCHOL, V22, P332, DOI 10.1037/0278-6133.22.4.332; Latkin C, 2013, J URBAN HEALTH, V90, P147, DOI 10.1007/s11524-012-9753-z; MADDUX JE, 1983, J EXP SOC PSYCHOL, V19, P469, DOI 10.1016/0022-1031(83)90023-9; Martins SS, 2015, AM J PUBLIC HEALTH, V105, P2373, DOI 10.2105/AJPH.2015.302843a; Mora-Rios J, 2017, SUBST USE MISUSE, V52, P594, DOI 10.1080/10826084.2016.1245744; O'Donnell JK, 2017, MMWR-MORBID MORTAL W, V66, P1197, DOI 10.15585/mmwr.mm6643e1; Prentice-Dunn S, 1986, HLTH ED RES, V1, P153, DOI DOI 10.1093/HER/1.3.153; Richards JR, 2015, DRUG ALCOHOL DEPEN, V150, P1, DOI 10.1016/j.drugalcdep.2015.01.040; Rogers EM, 1995, DIFFUSION INNOVATION; ROGERS RW, 1975, J PSYCHOL, V91, P93, DOI 10.1080/00223980.1975.9915803; Roxburgh A, 2017, DRUG ALCOHOL DEPEN, V179, P291, DOI 10.1016/j.drugalcdep.2017.07.018; Rudd RA, 2016, MMWR-MORBID MORTAL W, V65, P1445, DOI 10.15585/mmwr.mm655051e1; Sherman SG, 2009, INT J DRUG POLICY, V20, P137, DOI 10.1016/j.drugpo.2008.02.004; Somerville NJ, 2017, MMWR-MORBID MORTAL W, V66, P382, DOI 10.15585/mmwr.mm6614a2; Stanley TH, 2014, J PAIN, V15, P1215, DOI 10.1016/j.jpain.2014.08.010; WINETT RA, 1995, APPL PREV PSYCHOL, V4, P233, DOI 10.1016/S0962-1849(05)80025-3; Winhusen T, 2016, HEALTH EDUC RES, V31, P146, DOI 10.1093/her/cyw010	34	6	6	1	3	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1082-6084	1532-2491		SUBST USE MISUSE	Subst. Use Misuse	MAY 12	2019	54	6					998	1006		10.1080/10826084.2018.1555597			9	Substance Abuse; Psychiatry; Psychology	Substance Abuse; Psychiatry; Psychology	HW8AI	WOS:000466910800014	30767590	Green Accepted			2020-06-30	J	Campos-Manas, MC; Ferrer, I; Thurman, EM; Perez, JAS; Aguera, A				Celia Campos-Manas, Marina; Ferrer, Imma; Thurman, E. Michael; Sanchez Perez, Jose Antonio; Aguera, Ana			Identification of opioids in surface and wastewaters by LC/QTOF-MS using retrospective data analysis	SCIENCE OF THE TOTAL ENVIRONMENT			English	Article						Retrospective analysis; Liquid chromatography; Time of flight-mass spectrometry; Opioids; Wastewater; Surface water	RESOLUTION MASS-SPECTROMETRY; WASTE-WATER; ILLICIT DRUGS; QTOF-MS; METABOLITES; PHARMACEUTICALS; ABUSE; FRAGMENTATION; CONTAMINANTS; CONSUMPTION	Opioids, both as prescription drugs and abuse substances, have been a but topic and a focus of discussion in the media for the last few years. Although the literature published shows the occurrence of opioids and some of their metabolites in the aquatic environment, there are scarce data in the application of high resolution mass spectrometry (HRMS) for the analysis of these compounds in the environment. The use of HRMS allows increasing the number of opioids that can be studied as well as the detection of unknown opioids, their metabolites and potential transformation products. In this work, a retrospective analysis for the identification of opioids and their metabolites using a curated database was applied to surface water and wastewater samples taken in the state of Minnesota (U.S.) in 2009, which were previously analyzed by liquid chromatography/time-of-flight mass spectrometry (LC/TOF-MS) for antidepressants. The database comprised >200 opioids including natural opiates (e.g. morphine and codeine), their semi-synthetic derivatives (e.g. heroin, hydromorphone, hydrocodone, oxycoclone, oxymorphone, mepericline and buprenorphine), fully synthetic opioicls (e.g. fentanyl, methadone, tramadol, dextromethorphan and propoxyphene), as well as some of their metabolites (e.g. 6-monoacetylcodeine, dextrorphan, COOP, normorphine and O-desmethyltramadol). Moreover, additional MS-MS experiments were performed to confirm their identification, as well as to recognize fragmentation patterns and diagnostic ions for several opioids. These data provide a better understanding of the historical occurrence of opioids and their metabolites in surface waters impacted by wastewater sources. The concentrations of individual opioids in surface water and wastewater effluent varied from 8.8 (LOOP) to 1640 (tramadol) ng L-1 and from 12 (dihydrocodeine) to 1288 (tramadol) ng L-1, respectively. The opioids with higher overall frequency detections were tramadol, dextromethorphan and its metabolite, dextrorphan. (C) 2019 Elsevier B.V. All rights reserved.	[Celia Campos-Manas, Marina; Sanchez Perez, Jose Antonio; Aguera, Ana] Joint Ctr Univ Almeria CIEMAT, Solar Energy Res Ctr CIESOL, Ctra Sacramento S-N, Almeria 04120, Spain; [Ferrer, Imma; Thurman, E. Michael] Univ Colorado, Ctr Environm Mass Spectrometry, Dept Environm Engn, Boulder, CO 80303 USA	Ferrer, I (reprint author), Univ Colorado, Ctr Environm Mass Spectrometry, Dept Environm Engn, Boulder, CO 80303 USA.	imma.ferrer@colorado.edu	Ferrer, Imma/A-8161-2008; Sanchez Perez, Jose Antonio/B-5328-2015	Ferrer, Imma/0000-0002-8730-7851; Campos-Manas, Marina Celia/0000-0001-7811-9640; Sanchez Perez, Jose Antonio/0000-0001-5635-3137; THURMAN, E. Michael/0000-0002-2191-1407	Ministry of Economy and Competitiveness of Spain; European Regional Development Fund (ERDF)European Union (EU) [CTQ2016-78255-R]; University of Almeria	The authors gratefully acknowledge the financial support by the Ministry of Economy and Competitiveness of Spain and the European Regional Development Fund (ERDF), project CTQ2016-78255-R. M.C. Campos-Manas is grateful for her pre-doctoral grant from University of Almeria.	Acena J, 2015, ANAL BIOANAL CHEM, V407, P6289, DOI 10.1007/s00216-015-8852-6; Alyzakis NA, 2018, ENVIRON SCI TECHNOL, V52, P5135, DOI 10.1021/acs.est.8b00365; Asimakopoulos AG, 2016, ENVIRON CHEM, V13, P541, DOI 10.1071/EN15202; Baker DR, 2014, SCI TOTAL ENVIRON, V487, P629, DOI 10.1016/j.scitotenv.2013.11.107; Baker DR, 2011, J CHROMATOGR A, V1218, P8036, DOI 10.1016/j.chroma.2011.09.012; Baz-Lomba JA, 2016, ANAL CHIM ACTA, V914, P81, DOI 10.1016/j.aca.2016.01.056; Bijlsma L, 2013, ANAL CHIM ACTA, V768, P102, DOI 10.1016/j.aca.2013.01.010; Bijlsma L, 2011, J MASS SPECTROM, V46, P865, DOI 10.1002/jms.1963; Boix C, 2016, J HAZARD MATER, V302, P175, DOI 10.1016/j.jhazmat.2015.09.053; Bosch ME, 2007, J PHARMACEUT BIOMED, V43, P799, DOI 10.1016/j.jpba.2006.12.005; Campos-Manas MC, 2018, TRENDS ENVIRON ANAL, V20, DOI 10.1016/j.teac.2018.e00059; Cervera MI, 2014, ANAL BIOANAL CHEM, V406, P6843, DOI 10.1007/s00216-014-7853-1; Chiaia-Hernandez AC, 2013, ENVIRON SCI TECHNOL, V47, P976, DOI 10.1021/es303888v; Fedorova G, 2014, CHEMOSPHERE, V111, P55, DOI 10.1016/j.chemosphere.2014.02.067; Foppe KS, 2018, SCI TOTAL ENVIRON, V633, P249, DOI 10.1016/j.scitotenv.2018.03.175; Gago-Ferrero P, 2015, ENVIRON SCI TECHNOL, V49, P12333, DOI 10.1021/acs.est.5b03454; Hanigan D, 2017, J HAZARD MATER, V323, P18, DOI 10.1016/j.jhazmat.2016.04.023; Hanigan D, 2015, ENVIRON SCI TECH LET, V2, P151, DOI 10.1021/acs.estlett.5b00096; Hernandez F, 2014, TRAC-TREND ANAL CHEM, V63, P140, DOI 10.1016/j.trac.2014.08.003; Hernandez F, 2011, J SEP SCI, V34, P3517, DOI 10.1002/jssc.201100540; Hernandez F, 2011, ANAL CHIM ACTA, V684, P96, DOI 10.1016/j.aca.2010.10.043; Heuett NV, 2015, SCI TOTAL ENVIRON, V511, P319, DOI 10.1016/j.scitotenv.2014.12.043; Krauss M, 2010, ANAL BIOANAL CHEM, V397, P943, DOI 10.1007/s00216-010-3608-9; Krizman-Matasic I, 2019, SCI TOTAL ENVIRON, V647, P474, DOI 10.1016/j.scitotenv.2018.07.441; Lopez-Garcia E, 2018, J CHROMATOGR A, V1576, P80, DOI 10.1016/j.chroma.2018.09.038; Bueno MJM, 2007, ANAL CHEM, V79, P9372, DOI 10.1021/ac0715672; MATHER LE, 1983, CLIN PHARMACOKINET, V8, P422, DOI 10.2165/00003088-198308050-00004; McCall AK, 2016, WATER RES, V88, P933, DOI 10.1016/j.watres.2015.10.040; Noble C, 2018, DRUG TEST ANAL, V10, P651, DOI 10.1002/dta.2263; Pal R, 2013, SCI TOTAL ENVIRON, V463, P1079, DOI 10.1016/j.scitotenv.2012.05.086; Poeaknapo C, 2004, PHYTOCHEMISTRY, V65, P1413, DOI 10.1016/j.phytochem.2004.05.005; Polgar L, 2012, J CHROMATOGR A, V1249, P83, DOI 10.1016/j.chroma.2012.05.097; Postigo C, 2008, TRAC-TREND ANAL CHEM, V27, P1053, DOI 10.1016/j.trac.2008.10.002; Raith K, 2003, J AM SOC MASS SPECTR, V14, P1262, DOI 10.1016/S1044-0305(03)00539-7; Rudd RA, 2016, MMWR-MORBID MORTAL W, V65, P1445, DOI 10.15585/mmwr.mm655051e1; Skees AJ, 2018, SCI TOTAL ENVIRON, V631-632, P1457, DOI 10.1016/j.scitotenv.2018.03.060; Thai PK, 2016, ENVIRON INT, V94, P307, DOI 10.1016/j.envint.2016.05.033; Thurman EM, 2012, J CHROMATOGR A, V1259, P158, DOI 10.1016/j.chroma.2012.03.008; United Nations Office on Drugs and Crime, 2018, WORLD DRUG REP 2017, DOI DOI 10.18356/BDC264F4-EN; van Nuijs ALN, 2011, SCI TOTAL ENVIRON, V409, P3564, DOI 10.1016/j.scitotenv.2010.05.030; Wick A, 2011, ENVIRON SCI TECHNOL, V45, P3374, DOI 10.1021/es103489x; Writer JH, 2013, SCI TOTAL ENVIRON, V461, P519, DOI 10.1016/j.scitotenv.2013.04.099; Yadav MK, 2017, WATER RES, V124, P713, DOI 10.1016/j.watres.2017.07.068; Yaksh T. L, 2011, GOODMAN GILMANS PHAR, P814, DOI [10.1017/CBO9780511977633.035, DOI 10.1017/CBO9780511977633.035]	44	5	5	4	58	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0048-9697	1879-1026		SCI TOTAL ENVIRON	Sci. Total Environ.	MAY 10	2019	664						874	884		10.1016/j.scitotenv.2019.01.389			11	Environmental Sciences	Environmental Sciences & Ecology	HN5SQ	WOS:000460245600083	30769311				2020-06-30	J	Salemmilani, R; Moskovits, M; Meinhart, CD				Salemmilani, Reza; Moskovits, Martin; Meinhart, Carl D.			Microfluidic analysis of fentanyl-laced heroin samples by surface-enhanced Raman spectroscopy in a hydrophobic medium	ANALYST			English	Article							ASSISTED EMULSIFICATION-MICROEXTRACTION; NANOPARTICLES; DRUGS	Opioid overdose deaths resulting from heroin contaminated with the potent opioid agonist fentanyl, are currently a serious public health issue. A rapid and reliable method for identifying fentanyl-laced heroin could lead to reduced opioid overdose. Herein, we describe a strategy for detecting fentanyl at low concentrations in the presence of heroin, based on the significant hydrophobicity of fentanyl compared to heroin hydrochloride, by preferentially extracting trace concentrations of fentanyl using ultrasound-assisted emulsification microextraction using octanol as the extracting phase. Surface-enhanced Raman spectroscopy (SERS), is enabled by exposing the analyte to silver nanoparticle-coated SiO2 nanoparticles, designed to be stable in mixtures of octanol and ethanol. The sample is then loaded into an SU8/glass microfluidic device that is compatible with non-aqueous solutions. The SERS-active nanoparticles are aggregated by dielectrophoresis using microelectrodes embedded in the microfluidic channels, and the nanoparticle aggregates are interrogated using Raman spectroscopy. Using this method, we were able to reliably detect fentanyl from samples with as low as 1:10000 (mol/mol) fentanyl-to-heroin ratio, improving the limits of detection of fentanyl-laced heroin samples by two orders of magnitude over current techniques. The described system could also be useful in chemical detection where rapid and robust preconcentration of trace hydrophobic analytes, and rapid SERS detection in non-aqueous solvents is indicated.	[Salemmilani, Reza; Meinhart, Carl D.] Univ Calif Santa Barbara, Dept Mech Engn, Santa Barbara, CA 93106 USA; [Moskovits, Martin] Univ Calif Santa Barbara, Dept Chem & Biochem, Santa Barbara, CA 93106 USA	Meinhart, CD (reprint author), Univ Calif Santa Barbara, Dept Mech Engn, Santa Barbara, CA 93106 USA.	meinhart@ucsb.edu			U.S. Army Research Office at the Edgewood Chemical Biological Center [W911NF-09-0001]	The fabrication was undertaken at the UCSB nanofabrication facility, part of the National Science Foundation-funded national nanofabrication infrastructure network. This work was supported in part through grant W911NF-09-0001 from the U.S. Army Research Office at the Edgewood Chemical Biological Center. The content of the information does not necessarily reflect the position or the policy of the Government, and no official endorsement should be inferred.	Agnihotri S, 2014, RSC ADV, V4, P3974, DOI 10.1039/c3ra44507k; Alshareef M, 2013, BIOMICROFLUIDICS, V7, DOI 10.1063/1.4774312; Andreou C, 2013, ACS NANO, V7, P7157, DOI 10.1021/nn402563f; ARTHUR CL, 1990, ANAL CHEM, V62, P2145, DOI 10.1021/ac00218a019; Cetin B, 2011, ELECTROPHORESIS, V32, P2410, DOI 10.1002/elps.201100167; Chan MY, 2018, CHEMPHYSCHEM, V19, P24, DOI 10.1002/cphc.201700798; Cherukulappurath S, 2014, CHEM MATER, V26, P2445, DOI 10.1021/cm500062b; Ciccarone D, 2017, INT J DRUG POLICY, V46, P107, DOI 10.1016/j.drugpo.2017.06.010; Fontana AR, 2010, J AGR FOOD CHEM, V58, P4576, DOI 10.1021/jf904396g; Gulaboski R, 2007, ANAL BIOCHEM, V361, P236, DOI 10.1016/j.ab.2006.11.006; Haddad A, 2018, ANAL CHEM, V90, P12678, DOI 10.1021/acs.analchem.8b02909; Haynes CL, 2005, ANAL CHEM, V77, p338A, DOI 10.1021/ac053456d; Hermanson KD, 2001, SCIENCE, V294, P1082, DOI 10.1126/science.1063821; Khademhosseini A, 2004, ANAL CHEM, V76, P3675, DOI 10.1021/ac035415s; Kneipp K, 1997, PHYS REV LETT, V78, P1667, DOI 10.1103/PhysRevLett.78.1667; Kneipp K., 2002, J PHYS CONDENS MATT, V14, P28; Lee JN, 2003, ANAL CHEM, V75, P6544, DOI 10.1021/ac0346712; Lotsch J, 2013, CLIN PHARMACOKINET, V52, P23, DOI 10.1007/s40262-012-0016-7; McDonald JC, 2000, ELECTROPHORESIS, V21, P27, DOI 10.1002/(SICI)1522-2683(20000101)21:1<27::AID-ELPS27>3.0.CO;2-C; NAPPER DH, 1977, J COLLOID INTERF SCI, V58, P390, DOI 10.1016/0021-9797(77)90150-3; National Institutes of Health National Institute on Drug Abuse, OV DEATH RAT; NIH, FENT; Park JW, 2014, J AM CHEM SOC, V136, P1907, DOI 10.1021/ja4097384; Ramos A, 1998, J PHYS D APPL PHYS, V31, P2338, DOI 10.1088/0022-3727/31/18/021; Regueiro J, 2008, J CHROMATOGR A, V1190, P27, DOI 10.1016/j.chroma.2008.02.091; Ren YF, 2015, MICROMACHINES-BASEL, V6, P1923, DOI 10.3390/mi6121465; Rezaee M, 2006, J CHROMATOGR A, V1116, P1, DOI 10.1016/j.chroma.2006.03.007; ROY SD, 1988, PHARMACEUT RES, V5, P580, DOI 10.1023/A:1015994030251; Salemmilani R, 2018, ANAL CHEM, V90, P7930, DOI 10.1021/acs.analchem.8b00510; SATO T, 1980, [No title captured], V9; Suzuki J, 2017, DRUG ALCOHOL DEPEN, V171, P107, DOI 10.1016/j.drugalcdep.2016.11.033; Swanson DM, 2017, J ANAL TOXICOL, V41, P498, DOI 10.1093/jat/bkx037; Vardanyan RS, 2014, FUTURE MED CHEM, V6, P385, DOI 10.4155/fmc.13.215; Vila M, 2016, MICROCHEM J, V124, P530, DOI 10.1016/j.microc.2015.09.023; Whitesides GM, 2001, ANNU REV BIOMED ENG, V3, P335, DOI 10.1146/annurev.bioeng.3.1.335; Wu JF, 2009, MICROCHIM ACTA, V166, P157, DOI 10.1007/s00604-009-0179-6; Wustholz KL, 2010, J AM CHEM SOC, V132, P10903, DOI 10.1021/ja104174m; Xu LJ, 2014, ANAL CHEM, V86, P2238, DOI 10.1021/ac403974n; Zhang ZY, 2011, BIOMICROFLUIDICS, V5, DOI 10.1063/1.3659016	39	3	3	6	33	ROYAL SOC CHEMISTRY	CAMBRIDGE	THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND	0003-2654	1364-5528		ANALYST	Analyst	MAY 7	2019	144	9					3080	3087		10.1039/c9an00168a			8	Chemistry, Analytical	Chemistry	HV9RO	WOS:000466320100025	30919846				2020-06-30	J	Kloka, J; Kranepuhl, S; Zacharowski, K; Raimann, FJ				Kloka, Jan; Kranepuhl, Stefanie; Zacharowski, Kai; Raimann, Florian Juergen			Total Intravenous Anesthesia in GLUT1 Deficiency Syndrome Patient: A Case Report	AMERICAN JOURNAL OF CASE REPORTS			English	Article						Anesthesia; Intravenous; Glucose Transporter Type 1; Ketogenic Diet; Metabolism; Inborn Errors; Monosaccharide Transport Proteins; Rare Diseases	GLUCOSE; SEIZURES; INSULIN; STRESS	Background: GLUT1-deficiency-syndrome (G1DS) is an autosomal dominant genetic disorder based on a mutation of the SLC2A1 gene. This mutation can lead to an encephalopathy due to abnormal glucose transport in the brain. G1DS is a rare disease, with an estimated incidence of 1: 90 000. Case Report: We report a case of a 10-year-old female who presented with recurrent fever, headaches, and vertigo for more than 3 days within 2 weeks following pneumonia. A bilateral mastoiditis was proven by a cerebral magnetic resonance imaging and a cranial computed tomography scan. The patient had to undergo mastoidectomy and thus, her first general anesthesia. Half a year previously she was diagnosed with G1DS. According to the standard of care, a ketogenic diet had been administered since the patient's diagnosis 6 months earlier. Our patient received a total intravenous anesthesia (TIVA) using propofol, fentanyl, and rocuronium administered without any incidents. Conclusions: We recommend normoglycemia during the perioperative phase and avoidance of glucose-based medication to keep a patient's ketotic state. Our case highlights that TIVA, with the outlined medication used in this case, was safe when the patient's ketotic state and periprocedural blood glucose was monitored continuously. Nevertheless, we would suggest using remifentanil instead of fentanyl for future TIVAs due to a reduced increase in blood glucose level in our patient.	[Kloka, Jan; Kranepuhl, Stefanie; Zacharowski, Kai; Raimann, Florian Juergen] Univ Hosp Frankfurt, Dept Anesthesiol Intens Care Med & Pain Therapy, Frankfurt, Germany	Raimann, FJ (reprint author), Univ Hosp Frankfurt, Dept Anesthesiol Intens Care Med & Pain Therapy, Frankfurt, Germany.	Florian.Raimann@kgu.de					Alter AS, 2015, J CHILD NEUROL, V30, P160, DOI 10.1177/0883073814531822; Cok OY, 2011, MINERVA ANESTESIOL, V77, P1141; Coman DJ, 2006, J PAEDIATR CHILD H, V42, P263, DOI 10.1111/j.1440-1754.2006.00852.x; DEVIVO DC, 1991, NEW ENGL J MED, V325, P703, DOI 10.1056/NEJM199109053251006; Draskovic B, 2014, TURK J MED SCI, V44, P1095, DOI 10.3906/sag-1305-36; Gras D, 2014, REV NEUROL-FRANCE, V170, P91, DOI 10.1016/j.neurol.2013.09.005; Klepper J, 1999, PEDIATR RES, V46, P677, DOI 10.1203/00006450-199912000-00007; Klepper J, 2007, DEV MED CHILD NEUROL, V49, P707, DOI 10.1111/j.1469-8749.2007.00707.x; Overweg-Plandsoen WCG, 2003, J INHERIT METAB DIS, V26, P559, DOI 10.1023/A:1025999914822; Vore SJ, 2001, AM J PHYSIOL-ENDOC M, V281, pE93; Wang D, 2005, ANN NEUROL, V57, P111, DOI 10.1002/ana.20331; Zuurbier CJ, 2008, ANESTH ANALG, V106, P135, DOI 10.1213/01.ane.0000297299.91527.74	12	0	0	0	2	INT SCIENTIFIC INFORMATION, INC	MELVILLE	150 BROADHOLLOW RD, STE 114, MELVILLE, NY 11747 USA	1941-5923			AM J CASE REP	Am. J. Case Rep.	MAY 5	2019	20						647	650		10.12659/AJCR.914865			4	Medicine, General & Internal	General & Internal Medicine	HX1RD	WOS:000467169900001	31055589	Green Published			2020-06-30	J	Franzen, L; Beck, O; Helander, A				Franzen, Lisa; Beck, Olof; Helander, Anders			An analytically confirmed non-fatal intoxication by carfentanil in Sweden	CLINICAL TOXICOLOGY			English	Letter									[Franzen, Lisa] Swedish Poisons Informat Ctr, SE-17176 Stockholm, Sweden; [Beck, Olof; Helander, Anders] Karolinska Inst, Dept Lab Med, Stockholm, Sweden; [Beck, Olof; Helander, Anders] Karolinska Univ Lab, Dept Clin Pharmacol, Stockholm, Sweden	Franzen, L (reprint author), Swedish Poisons Informat Ctr, SE-17176 Stockholm, Sweden.	lisa.franzen@gic.se		Helander, Anders/0000-0001-7480-8078; Beck, Olof/0000-0002-3546-8872			EMCDDA, 2017, EMCDDA EUR JOINT REP; EMCDDA, 2018, FENT SYNTH CANN DRIV; Helander A, 2017, CLIN TOXICOL, V55, P1, DOI 10.1080/15563650.2016.1217003; Lust EB, 2011, J EMERG MED, V40, P198, DOI 10.1016/j.jemermed.2009.09.026; Sofalvi S, 2017, J ANAL TOXICOL, V41, P473, DOI 10.1093/jat/bkx052	5	1	1	0	0	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1556-3650	1556-9519		CLIN TOXICOL	Clin. Toxicol.	MAY 4	2019	57	5					372	374		10.1080/15563650.2018.1520999			3	Toxicology	Toxicology	HU7HD	WOS:000465451000011	30484713				2020-06-30	J	Kim, KS; Yu, SC; Han, JW; Shim, SM; Kwak, S; Kim, YM; Kim, SS				Kim, Kwan-Sub; Yu, Sung Chul; Han, Jung-Woo; Shim, Sung-Min; Kwak, Soohyun; Kim, Yong-Min; Kim, Seong-Su			Effect of fentanyl nasal packing treatment on patients with acute postoperative pain after closed reduction of nasal bone fracture: a randomized double-blind controlled trial	JOURNAL OF PLASTIC SURGERY AND HAND SURGERY			English	Article						Fentanyl; fentanyl-soaked packing; nasal packing; postoperative pain; closed nasal bone fracture reduction	SUPRASCAPULAR NERVE BLOCK; INTRANASAL FENTANYL; MORPHINE-SULFATE; MANAGEMENT; EFFICACY; LEVOBUPIVACAINE; ACCEPTABILITY; INFILTRATION; PRILOCAINE; ANALGESIA	Purpose: Nasal bone fracture reduction surgery is normally followed by nasal packing to control bleeding. Yet, patients suffer from pain and require further analgesic treatments following nasal packing and removal. This study aimed to evaluate the effect of fentanyl-soaked packing as a method of controlling pain after nasal surgeries in a prospective, randomized, double-blind controlled trial. Methods: Sixty-five patients that have undergone closed nasal bone fracture reduction surgery were included in this study. Thirty-two patients were treated postoperatively with 50 mcg fentanyl-soaked MerocelA (R), a biodegradable synthetic polyurethane foams packing, and the other 33 patients were treated with saline-soaked packings. To analyze the relative nasal pain control effect of fentanyl, Numeric Rating Scale, patient satisfaction and Ramsay Sedation Scale were used. Patients were closely monitored to record relevant cardiopulmonary indicators and degree of adverse symptoms such as headache or sore throat. Results: Fentanyl group had a significantly lower Numeric Rating Scale and higher patient satisfaction for most of the time periods after operation (p < .05). Symptoms of headache and sore throat were also significantly reduced. Ramsay Sedation Scale scores improved compared to the control group (p < .05). No significant differences in cardiopulmonary relevant indicators between the two experimental groups were observed (p > .05). Conclusion: Fentanyl-soaked packing significantly decreased postoperative pain with no observable adverse effects. Our results demonstrate that topical fentanyl application to nasal packing is an effective method of postoperative pain control after closed nasal bone fracture reduction surgery.	[Kim, Kwan-Sub] Dongkang Med Ctr, Dept Anesthesiol & Pain Med, Ulsan, South Korea; [Yu, Sung Chul] Univ Ulsan, Coll Med, Gangneung Asan Med Ctr, Dept Plast Surg, Seoul, South Korea; [Han, Jung-Woo; Shim, Sung-Min; Kim, Seong-Su] Univ Ulsan, Coll Med, Gangneung Asan Med Ctr, Dept Anesthesiol & Pain Med, Seoul, South Korea; [Kwak, Soohyun] Semin Hosp, Dept Rehabil Med, Seoul, South Korea; [Kim, Yong-Min] Hong Kong Univ Sci & Technol, Clear Water Bay, Hong Kong, Peoples R China	Kim, SS (reprint author), Univ Ulsan, Coll Med, Gangneung Asan Med Ctr, Dept Anesthesiol & Pain Med, Seoul, South Korea.	anes1318@mail.ulsan.ac.kr					Adelgais KM, 2017, J EMERG MED, V53, P607, DOI 10.1016/j.jemermed.2017.05.027; Apfelbaum JL, 2003, ANESTH ANALG, V97, P534, DOI 10.1213/01.ANE.0000068822.10113.9E; Apuhan T, 2011, OTOLARYNG HEAD NECK, V145, P418, DOI 10.1177/0194599811410660; Bennett D, 2005, PHARMACOL THERAPEUT, V30, P296; Capper SJ, 2010, EUR J ANAESTH, V27, P241, DOI 10.1097/EJA.0b013e328331a361; Capponi R, 2017, ACTA BIOMED, V87, P347; Chandra Rakesh K, 2004, Curr Opin Otolaryngol Head Neck Surg, V12, P21, DOI 10.1097/00020840-200402000-00007; Checcucci G, 2008, ARTHROSCOPY, V24, P689, DOI 10.1016/j.arthro.2008.01.019; Choi DS, 2015, J PLAST SURG HAND SU, V49, P275, DOI 10.3109/2000656X.2015.1034726; Coluzzi PH, 2001, PAIN, V91, P123, DOI 10.1016/S0304-3959(00)00427-9; Dale O, 2002, ACTA ANAESTH SCAND, V46, P759, DOI 10.1034/j.1399-6576.2002.460702.x; Davies A, 2011, J PAIN SYMPTOM MANAG, V41, P358, DOI 10.1016/j.jpainsymman.2010.11.004; Eloy P, 2017, CURR OPIN OTOLARYNGO, V25, P35, DOI 10.1097/MOO.0000000000000332; Garimella V, 2013, CLIN COLON RECT SURG, V26, P191, DOI 10.1055/s-0033-1351138; Grassin-Delyle S, 2012, PHARMACOL THERAPEUT, V134, P366, DOI 10.1016/j.pharmthera.2012.03.003; Hwang K, 2017, J CRANIOFAC SURG, V28, P785, DOI 10.1097/SCS.0000000000003477; Karaaslan K, 2007, RHINOLOGY, V45, P321; Kim JS, 2017, LARYNGOSCOPE, V127, P1026, DOI 10.1002/lary.26436; Lachanas VA, 2006, AM J RHINOL, V20, P483, DOI 10.2500/ajr.2006.20.2925; Lee JJ, 2014, ARTHROSCOPY, V30, P906, DOI 10.1016/j.arthro.2014.03.014; Mo JH, 2013, AM J RHINOL ALLERGY, V27, pE174, DOI 10.2500/ajra.2013.27.3942; Mudd S, 2011, J PEDIATR HEALTH CAR, V25, P316, DOI 10.1016/j.pedhc.2010.04.011; Murphy AP, 2017, EUR J EMERG MED, V24, P450, DOI 10.1097/MEJ.0000000000000389; Peng PWH, 1999, ANESTHESIOLOGY, V90, P576, DOI 10.1097/00000542-199902000-00034; Reschreiter H, 2006, SURGERY OXFORD, V24, P342; Shim SM, 2018, KOREAN J ANESTHESIOL, V71, P213, DOI 10.4097/kja.d.18.27097; Toussaint S, 2000, CAN J ANAESTH, V47, P299, DOI 10.1007/BF03020941; van Dijk JFM, 2015, PAIN PRACT, V15, P604, DOI 10.1111/papr.12217; Yilmaz S, 2010, J OTOLARYNGOL-HEAD N, V39, P454, DOI 10.2310/7070.2010.090138; Zeppetella G, 2000, J PAIN SYMPTOM MANAG, V20, P253, DOI 10.1016/S0885-3924(00)00180-9	30	0	0	0	0	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	2000-656X	2000-6764		J PLAST SURG HAND SU	J. Plast. Surg. Hand Surg.	MAY 4	2019	53	3					167	172		10.1080/2000656X.2019.1566738			6	Orthopedics; Surgery	Orthopedics; Surgery	HX7QL	WOS:000467600400007	30734629				2020-06-30	J	Bijral, P; Hayhurst, KP; Bird, SM; Millar, T				Bijral, Prun; Hayhurst, Karen P.; Bird, Sheila M.; Millar, Tim			Prevalence of recent fentanyl use among treated users of illicit opioids in England: based on piloted urine drug screens	CLINICAL TOXICOLOGY			English	Article						Fentanyl; opioid; substance use disorder; substance use treatment; prevalence		Objective: To use a pilot of national fentanyl screening to establish the current prevalence of recent fentanyl use among treated users of illicit opioids in the English treatment system and inform the design of a full study.Design: Cross-sectional fentanyl metabolite urine screening in randomly-selected study sites, stratified to cover all nine geographical regions of England, supplemented with self-report subsequent to a positive fentanyl test.Patients: 468 adult (18 years of age and above) patients receiving treatment for opioid use disorder, screened December 2017 to May 2018.Results: The fentanyl-positive rate in patients receiving treatment for opioid use disorder in the English treatment system was 3% (15/468, 95% CI 1.8% to 5.2%) with a per-site range (for the 10 sites in 9 regions where fentanyl was detected) of between 2% (1/57) and 15% (4/27). Self-report data indicated that the majority of fentanyl-positives (12/15, 80%) was unaware of having purchased fentanyl.Conclusions: Despite alerts already in place, patients receiving treatment for opioid use disorder, who were fentanyl-positive, were unwittingly purchasing and consuming fentanyl.	[Bijral, Prun] Change Grow Live, London, England; [Hayhurst, Karen P.; Millar, Tim] Univ Manchester, Ctr Mental Hlth & Safety, Manchester, Lancs, England; [Bird, Sheila M.] Univ Edinburgh, Usher Inst Populat Hlth Sci & Informat, Edinburgh, Midlothian, Scotland; [Bird, Sheila M.] Univ Cambridge, MRC Biostat Unit, Sch Clin Med, Inst Publ Hlth, Cambridge, England	Bijral, P (reprint author), Change Grow Live, London, England.	prun.bijral@cgl.org.uk		Millar, Tim/0000-0003-4630-2357; Hayhurst, Karen/0000-0002-8976-2356	Change, Grow, Live (CGL)	This study was funded by Change, Grow, Live (CGL), one of the main UK providers of substance use disorder treatment services.	Amlani A, 2015, HARM REDUCT J, V12, DOI 10.1186/s12954-015-0088-4; Department of Health (DH), 2017, DRUG MIS DEP UK GUID; Griswold MK, 2018, CLIN TOXICOL, V56, P37, DOI 10.1080/15563650.2017.1339889; Hikin L, 2018, FORENSIC SCI INT, V282, P179, DOI 10.1016/j.forsciint.2017.11.036; National Crime Agency (NCA), 2017, REC DEATHS POSS LINK; O'Connor R, FENTANYL WHATS BEING; Public Health England (PHE), 2017, EV HARM FENT CONT HE; Torjesen I, 2018, BMJ-BRIT MED J, V361, DOI 10.1136/bmj.k1564; UK Drug Focal Point on Drugs, 2017, UK DRUG SIT FOC POIN	9	2	2	0	0	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1556-3650	1556-9519		CLIN TOXICOL	Clin. Toxicol.	MAY 4	2019	57	5					368	371		10.1080/15563650.2018.1527927			4	Toxicology	Toxicology	HW6SB	WOS:000466819500001	30554543				2020-06-30	J	Marquart, K; Herbert, J; Amend, N; Thiermann, H; Worek, F; Wille, T				Marquart, Katharina; Herbert, Julia; Amend, Niko; Thiermann, Horst; Worek, Franz; Wille, Timo			Effect of cholinergic crisis on the potency of different emergency anaesthesia protocols in soman-poisoned rats	CLINICAL TOXICOLOGY			English	Article						Anaesthetics; analgesics; cholinergic crisis; opioids; organophosphate	NERVE AGENT; SPINAL NETWORKS; SEVOFLURANE POTENCY; IN-VIVO; PROPOFOL; CARE; MICROCIRCULATION; OVERSTIMULATION; PHARMACOLOGY; PESTICIDES	Background: In a military or terrorist scenario, combination of organophosphorus compounds (OP) poisoning with physical trauma requiring surgical treatment and thus general anaesthesia are possible. Previous in vitro studies showed an altered potency of relevant anaesthetics during cholinergic crisis. Hence, it is not clear, which anaesthetics are suitable to achieve the necessary stage of surgical anaesthesia in OP poisoning. Methods: In the present study, different anaesthetic regimens (ketamine-midazolam, propofol-fentanyl, thiopental-fentanyl), relevant in military emergency medicine, were examined in soman-poisoned rats. Clinical signs and cardiovascular variables were recorded continuously. Blood samples for acetylcholinesterase (AChE) activity were drawn. After euthanasia or death of the animals, brain and diaphragm were collected for cholinesterase assays. Results: Propofol-fentanyl and thiopental-fentanyl resulted in surgical anaesthesia throughout the experiments. With ketamine-midazolam, surgical anaesthesia without respiratory impairment could not be achieved in pilot experiments (no soman challenge) and was therefore not included in the study. Soman-poisoned and control animals required a comparable amount of propofol-fentanyl or thiopental-fentanyl. In combination with atropine, significantly less propofol was needed. Survival rate was higher with thiopental compared to propofol. Atropine improved survival in both groups. Blood and tissue AChE activities were strongly inhibited after soman administration with and without atropine treatment. Discussion: The current in vivo study did not confirm concerns of altered potency of existing anaesthetic protocols for the application of propofol or thiopental with fentanyl due to soman poisoning. Despite severe cholinergic crisis, sufficient anaesthetic depth could be achieved in all animals. Conclusion: Further experiments in in vivo models closer to human pharmaco- and toxicokinetics (e.g., swine) are required for confirmation of the initial findings and for improving extrapolation to humans.	[Marquart, Katharina; Herbert, Julia; Amend, Niko; Thiermann, Horst; Worek, Franz; Wille, Timo] Bundeswehr Inst Pharmacol & Toxicol, Neuherbergstr 11, D-80937 Munich, Germany	Wille, T (reprint author), Bundeswehr Inst Pharmacol & Toxicol, Neuherbergstr 11, D-80937 Munich, Germany.	timowille@bundeswehr.org			German Ministry of Defence	The study was funded by the German Ministry of Defence. However, the design, performance, data interpretation and manuscript writing was under the control of the authors and has not been influenced by the German Ministry of Defence.	Abraham RB, 2002, ANESTHESIOLOGY, V97, P989, DOI 10.1097/00000542-200210000-00035; Abraham RB, 2001, PAEDIATR ANAESTH, V11, P643, DOI 10.1046/j.1460-9592.2001.00671.x; Brookes ZLS, 2006, SHOCK, V25, P492, DOI 10.1097/01.shk.0000209541.76305.8e; Brookes ZLS, 2002, BRIT J ANAESTH, V88, P255, DOI 10.1093/bja/88.2.255; Brookes ZLS, 2002, SHOCK, V18, P542, DOI 10.1097/00024382-200212000-00010; CLEMENT JG, 1989, J PHARMACOL METHOD, V21, P129, DOI 10.1016/0160-5402(89)90031-4; Conley JD, 2001, INTERACTION CHEM AGE; Cosar A, 2006, MIL MED, V171, P7, DOI 10.7205/MILMED.171.1.7; DAWSON RM, 1994, J APPL TOXICOL, V14, P317, DOI 10.1002/jat.2550140502; DENEEF JH, 1982, BRIT J PHARMACOL, V77, P223; Dorandeu F, 2007, TOXICOLOGY, V233, P128, DOI 10.1016/j.tox.2006.09.013; Drexler B, 2011, TOXICOL LETT, V206, P84, DOI 10.1016/j.toxlet.2011.06.002; Drexler B, 2010, TOXICOL LETT, V198, P342, DOI 10.1016/j.toxlet.2010.07.016; Drexler B, 2010, TOXICOLOGY, V268, P98, DOI 10.1016/j.tox.2009.12.005; Eddleston M, 2016, BRIT J CLIN PHARMACO, V81, P462, DOI 10.1111/bcp.12784; Flecknell P., 2016, LAB ANIMAL ANAESTHES; Garcia PS, 2010, CURR NEUROPHARMACOL, V8, P2, DOI 10.2174/157015910790909502; Grasshoff C, 2007, ANESTHESIOLOGY, V106, P1147, DOI 10.1097/01.anes.0000267598.65120.f2; Grasshoff C, 2007, TOXICOLOGY, V229, P206, DOI 10.1016/j.tox.2006.10.017; Haeseler G, 2005, EUR J ANAESTH, V20, P220; Haitsma JJ, 2009, ACTA ANAESTH SCAND, V53, P176, DOI 10.1111/j.1399-6576.2008.01844.x; HASHIMOTO T, 1994, NEUROCHEM INT, V24, P389, DOI 10.1016/0197-0186(94)90117-1; Henke J, 2015, SCHMERZTHERAPIE BEI; HOLMSTEDT B, 1959, PHARMACOL REV, V11, P567; Houze P, 2008, TOXICOL APPL PHARM, V233, P186, DOI 10.1016/j.taap.2008.08.006; Hudetz AG, 2003, ANESTHESIOLOGY, V99, P1125, DOI 10.1097/00000542-200311000-00019; Hulse EJ, 2014, AM J RESP CRIT CARE, V190, P1342, DOI 10.1164/rccm.201406-1150CI; Kotani Y, 2008, CNS NEUROSCI THER, V14, P95, DOI 10.1111/j.1527-3458.2008.00043.x; Kwong TC, 2002, THER DRUG MONIT, V24, P144, DOI 10.1097/00007691-200202000-00022; Loscher W, 2012, EPILEPSIA, V53, P12, DOI 10.1111/epi.12025; Marrs T. C., 2007, CHEM WARFARE AGENTS, P191; MARRS TC, 1993, PHARMACOL THERAPEUT, V58, P51, DOI 10.1016/0163-7258(93)90066-M; McDonough JH, 2007, CHEM WARFARE AGENTS, P287, DOI DOI 10.1002/9780470060032.CH14; Meuret P, 2000, ANESTHESIOLOGY, V93, P708, DOI 10.1097/00000542-200009000-00020; Mew EJ, 2017, J AFFECT DISORDERS, V219, P93, DOI 10.1016/j.jad.2017.05.002; Myhrer T, 2013, TOXICOLOGY, V314, P221, DOI 10.1016/j.tox.2013.08.005; Myhrer T, 2013, EUR J PHARMACOL, V718, P253, DOI 10.1016/j.ejphar.2013.08.024; Namba T, 1971, B WORLD HEALTH ORGAN, V44; Pinheiro PS, 2017, REPORT INDEPENDENT I, P1; Trapani G, 2000, CURR MED CHEM, V7, P249, DOI 10.2174/0929867003375335; Weber M, 2005, BRIT J PHARMACOL, V144, P98, DOI 10.1038/sj.bjp.0705942; Weimer I, 2016, TOXICOL LETT, V244, P129, DOI 10.1016/j.toxlet.2015.08.1106; Weinbroum AA, 2000, RESUSCITATION, V47, P113, DOI 10.1016/S0300-9572(00)00216-1; White SM, 2002, BRIT J ANAESTH, V89, P306, DOI 10.1093/bja/aef168; Wille T, 2016, TOXICOL LETT, V258, P198, DOI 10.1016/j.toxlet.2016.07.004; Wodey E, 1999, BRIT J ANAESTH, V82, P516; Yagmurdur H, 2006, ACTA ANAESTH SCAND, V50, P1238, DOI 10.1111/j.1399-6576.2006.01145.x; Zhang Y, 2007, ANESTH ANALG, V104, P850, DOI 10.1213/01.ane.0000258018.82583.0b	48	1	1	0	7	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1556-3650	1556-9519		CLIN TOXICOL	Clin. Toxicol.	MAY 4	2019	57	5					343	349		10.1080/15563650.2018.1520241			7	Toxicology	Toxicology	HU7HD	WOS:000465451000007	30307341				2020-06-30	J	Salomone, A; Palamar, JJ; Bigiarini, R; Gerace, E; Di Corcia, D; Vincenti, M				Salomone, Alberto; Palamar, Joseph J.; Bigiarini, Rachele; Gerace, Enrico; Di Corcia, Daniele; Vincenti, Marco			Detection of Fentanyl Analogs and Synthetic Opioids in Real Hair Samples	JOURNAL OF ANALYTICAL TOXICOLOGY			English	Article							NATIONALLY REPRESENTATIVE SAMPLE; PSYCHOACTIVE SUBSTANCES; CANNABINOIDS; DRUG; ATTENDEES; METABOLITES; PREVALENCE; DEATHS; URINE; THC	Novel synthetic opioids include various analogs of fentanyl and emerging non-fentanyl compounds with different chemical structures, such as AH-7921, MT-45 and U-47700. In recent years, these drugs have rapidly emerged on the drug market, and their abuse has been increasing worldwide. The motivations for use of these new compounds include their legal status, ready availability, low cost, users' curiosity or preference for their particular pharmacological properties and the intention to avoid detection. Furthermore, more common drugs like heroin are now increasingly being replaced or cut with fentanyl or new designer opioids; thus, many drug users are unintentionally or unknowingly using synthetic fentanyl analogs. In this scenario, the detection of new psychoactive substances in hair can provide insight into their current diffusion among the population and social characteristics of these synthetic drug users. In this manuscript, we describe a simple, fast, specific and sensitive UHPLC-MS-MS method able to detect 13 synthetic opioids (including fentanyl analogs) and metabolites in hair samples. Furthermore, the method includes the detection of 4-anilino-N-phenethyl-piperidine (4-ANPP), which is considered both a precursor and a metabolite of several fentanyl analogs. The method was applied to 34 real hair samples collected in New York City from subjects who had reported past-year non-medical opioid and/or heroin use. In total, 17 samples tested positive for at least one target analyte, with oxycodone (nine samples) and tramadol (eight samples) being the most common. Among these, the method was able to quantify furanyl-fentanyl and fentanyl in the pg/mg range in two samples. Simultaneously, also 4-ANPP was detected, giving evidence for the first time that this compound can be selected as a marker of fentanyl analogs use via hair testing. In conclusion, this study confirmed the increasing diffusion of new synthetic opioids and "fentalogs" with high potency among non-medical opioid users.	[Salomone, Alberto; Gerace, Enrico; Di Corcia, Daniele; Vincenti, Marco] Ctr Reg Antidoping & Tossicol A Bertinaria, Turin, Italy; [Palamar, Joseph J.] NYU, Langone Med Ctr, Dept Populat Hlth, New York, NY USA; [Palamar, Joseph J.] NYU, Coll Nursing, Ctr Drug Use & HIV HCV Res, New York, NY USA; [Bigiarini, Rachele; Vincenti, Marco] Univ Torino, Dipartimento Chim, Turin, Italy	Salomone, A (reprint author), Ctr Reg Antidoping & Tossicol A Bertinaria, Turin, Italy.	alberto.salomone@antidoping.piemonte.it	Gerace, Enrico/AAI-7232-2020; Vincenti, Marco/M-3495-2015	Palamar, Joseph/0000-0002-8565-9415; Gerace, Enrico/0000-0002-4499-4276; Vincenti, Marco/0000-0002-6275-7194	National Institute on Drug Abuse of the National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [K01DA038800]	Research reported in this publication was supported by the National Institute on Drug Abuse of the National Institutes of Health under Award Number K01DA038800. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.	Arens AM, 2016, JAMA INTERN MED, V176, P1554, DOI 10.1001/jamainternmed.2016.4306; Armenian P, 2017, ANN EMERG MED, V69, P87, DOI 10.1016/j.annemergmed.2016.06.014; Di Corcia D, 2012, J CHROMATOGR B, V899, P154, DOI 10.1016/j.jchromb.2012.05.003; Drug Enforcement Administration, 2017, COUNT PRESCR CONT FE; Drummer OH, 2019, FOREN SCI RES, V4, P95, DOI 10.1080/20961790.2018.1460063; EMCDDA, 2017, EUR DRUG REP 2017 TR; European Monitoring Centre for Drugs and Drug Addiction, 2017, EUR DRUG REP; Fogarty MF, 2018, J ANAL TOXICOL, V42, P592, DOI 10.1093/jat/bky035; Gerace E, 2018, CURR PHARM BIOTECHNO, V19, P113, DOI 10.2174/1389201019666180405162734; Goggin MM, 2017, J ANAL TOXICOL, V41, P367, DOI 10.1093/jat/bkx022; Gottardo R, 2014, MED SCI LAW, V54, P22, DOI 10.1177/0025802413477396; HUBAUX A, 1970, ANAL CHEM, V42, P849, DOI 10.1021/ac60290a013; Hutter M, 2012, J CHROMATOGR B, V903, P95, DOI 10.1016/j.jchromb.2012.07.002; Jones CM, 2017, AM J PUBLIC HEALTH, V107, P430, DOI 10.2105/AJPH.2016.303627; Kintz P, 2015, HAIR ANAL CLIN FOREN; Marchei E, 2018, TRAC-TREND ANAL CHEM, V102, P1, DOI 10.1016/j.trac.2018.01.007; Mars SG, 2018, J PSYCHOACTIVE DRUGS, V50, P167, DOI 10.1080/02791072.2017.1394508; Martucci HFH, 2018, FORENSIC SCI INT, V283, pE13, DOI 10.1016/j.forsciint.2017.12.005; Misailidi N, 2018, FORENSIC TOXICOL, V36, P12, DOI 10.1007/s11419-017-0379-4; Moody MT, 2018, DRUG TEST ANAL, V10, P1358, DOI 10.1002/dta.2393; O'Donnell JK, 2017, MMWR-MORBID MORTAL W, V66, P1197, DOI 10.15585/mmwr.mm6643e1; Palamar JJ, 2018, DRUG ALCOHOL DEPEN, V186, P226, DOI 10.1016/j.drugalcdep.2018.03.001; Palamar JJ, 2017, INT J DRUG POLICY, V48, P91, DOI 10.1016/j.drugpo.2017.07.010; Palamar JJ, 2016, AM J DRUG ALCOHOL AB, V42, P530, DOI 10.1080/00952990.2016.1178269; Palamar JJ, 2016, AM J ADDICTION, V25, P400, DOI 10.1111/ajad.12403; Palamar JJ, 2016, DRUG ALCOHOL DEPEN, V161, P200, DOI 10.1016/j.drugalcdep.2016.02.001; Palamar JJ, 2015, DRUG ALCOHOL DEPEN, V152, P24, DOI 10.1016/j.drugalcdep.2015.05.002; Prekupec MP, 2017, J ADDICT MED, V11, P256, DOI 10.1097/ADM.0000000000000324; Rust KY, 2012, DRUG TEST ANAL, V4, P402, DOI 10.1002/dta.1338; Salomone A, 2016, DRUG TEST ANAL, V8, P996, DOI 10.1002/dta.1999; Salomone A, 2014, DRUG TEST ANAL, V6, P126, DOI 10.1002/dta.1556; Salomone A, 2012, J MASS SPECTROM, V47, P604, DOI 10.1002/jms.2988; Salomone A, 2017, TOXICOL ANAL CLIN, V29, P4, DOI 10.1016/j.toxac.2016.12.008; Salomone A, 2016, ANAL BIOANAL CHEM, V408, P2035, DOI 10.1007/s00216-015-9247-4; SILVERSTEIN JH, 1993, ANESTH ANALG, V76, P618; Sutter ME, 2017, ACAD EMERG MED, V24, P106, DOI 10.1111/acem.13034; United Nations Office on Drugs and Crime, 2017, UNODC GLOB SMART UPD, V17; United Nations Office on Drugs and Crime (UNODC) Laboratory and Scientific Section, 2017, REC METH ID AN FENT; Vincenti M., 2012, MASS SPECTROMETRY RE, V32, P1	39	13	13	6	16	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0146-4760	1945-2403		J ANAL TOXICOL	J. Anal. Toxicol.	MAY	2019	43	4					259	265		10.1093/jat/bky093			7	Chemistry, Analytical; Toxicology	Chemistry; Toxicology	IV1VV	WOS:000484067800005	30462247	Green Published			2020-06-30	J	Seymour, C; Shaner, RL; Feyereisen, MC; Wharton, RE; Kaplan, P; Hamelin, EI; Johnson, RC				Seymour, Craig; Shaner, Rebecca L.; Feyereisen, Melanie C.; Wharton, Rebekah E.; Kaplan, Pearl; Hamelin, Elizabeth I.; Johnson, Rudolph C.			Determination of Fentanyl Analog Exposure Using Dried Blood Spots with LC-MS-MS	JOURNAL OF ANALYTICAL TOXICOLOGY			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; SOLID-PHASE EXTRACTION; WHOLE-BLOOD; TOXICOLOGICAL FINDINGS; GAS-CHROMATOGRAPHY; SYNTHETIC OPIOIDS; MS/MS PROCEDURE; HUMAN URINE; POSTMORTEM; CARFENTANIL	Fentanyl, and the numerous drugs derived from it, are contributing to the opioid overdose epidemic currently underway in the USA. To identify human exposure to these growing public health threats, an LC-MS-MS method for 5 mu L dried blood spots (DBS) was developed. This method was developed to detect exposure to 3-methylfentanyl, alfentanil, alpha-methylfentanyl, carfentanil, fentanyl, lofentanil, sufentanil, norcarfentanil, norfentanyl, norlofentanil, norsufentanil, and using a separate LC-MS-MS injection, cyclopropylfentanyl, acrylfentanyl, 2-furanylfentanyl, isobutyrylfentanyl, ocfentanil and methoxyacetylfentanyl. Preparation of materials into groups of compounds was used to accommodate an ever increasing need to incorporate newly identified fentanyls. This protocol was validated within a linear range of 1.00-100 ng/mL, with precision <= 12% CV and accuracy >= 93%, as reported for the pooled blood QC samples, and limits of detection as low as 0.10 ng/mL. The use of DBS to assess fentanyl analog exposures can facilitate rapid sample collection, transport, and preparation for analysis that could enhance surveillance and response efforts in the ongoing opioid overdose epidemic.	[Seymour, Craig] Ctr Dis Control & Prevent, Battelle Mem Inst, Atlanta, GA 30341 USA; [Shaner, Rebecca L.; Feyereisen, Melanie C.; Wharton, Rebekah E.; Hamelin, Elizabeth I.; Johnson, Rudolph C.] Ctr Dis Control & Prevent, Div Lab Sci, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA; [Kaplan, Pearl] Ctr Dis Control & Prevent, Oak Ridge Inst Sci & Educ, Atlanta, GA 30341 USA	Shaner, RL (reprint author), Ctr Dis Control & Prevent, Div Lab Sci, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA.	Rebecca.Shaner@cdc.hhs.gov		Seymour, Craig/0000-0003-2355-8739			Andresen H, 2012, J ANAL TOXICOL, V36, P182, DOI 10.1093/jat/bks005; Arens AM, 2016, JAMA INTERN MED, V176, P1554, DOI 10.1001/jamainternmed.2016.4306; Bista SR, 2016, J CLIN PHARMACOL, V56, P705, DOI 10.1002/jcph.641; Boland Jason W, 2016, J Opioid Manag, V12, P313, DOI 10.5055/jom.2016.0348; Butler DC, 2018, J ANAL TOXICOL, V42, pE6, DOI 10.1093/jat/bkx083; Carson HJ, 2010, LEGAL MED, V12, P157, DOI 10.1016/j.legalmed.2010.03.001; Centers for Disease Control and Prevention, 2016, INFL FENT LAC COUNT; Chatterton CN, 2018, FORENSIC SCI INT, V284, P146, DOI 10.1016/j.forsciint.2017.12.031; Chepyala D, 2017, J CHROMATOGR A, V1491, P57, DOI 10.1016/j.chroma.2017.02.037; Clavijo CF, 2011, J SEP SCI, V34, P3568, DOI 10.1002/jssc.201100422; Coopman V, 2016, FORENSIC SCI INT, V266, P469, DOI 10.1016/j.forsciint.2016.07.005; Denniff P, 2010, BIOANALYSIS, V2, P1385, DOI 10.4155/BIO.10.103; DePriest A, 2010, J ANAL TOXICOL, V34, P444, DOI 10.1093/jat/34.8.444; Dussy FE, 2016, J ANAL TOXICOL, V40, P761, DOI 10.1093/jat/bkw096; Fisichella M, 2015, MICROCHEM J, V123, P33, DOI 10.1016/j.microc.2015.05.009; Gergov M, 2009, FORENSIC SCI INT, V186, P36, DOI 10.1016/j.forsciint.2009.01.013; GILLESPIE TJ, 1981, J ANAL TOXICOL, V5, P133, DOI 10.1093/jat/5.3.133; Gladden RM, 2016, MMWR-MORBID MORTAL W, V65, P837, DOI 10.15585/mmwr.mm6533a2; Guerrieri D, 2017, J ANAL TOXICOL, V41, P242, DOI 10.1093/jat/bkw129; Hempen CM, 2015, BIOANALYSIS, V7, P2018, DOI 10.4155/bio.15.97; HENDERSON GL, 1983, P W PHARMACOL SOC, V26, P287; Hikin L, 2018, FORENSIC SCI INT, V282, P179, DOI 10.1016/j.forsciint.2017.11.036; Kumar K, 1996, J PHARMACEUT BIOMED, V14, P667, DOI 10.1016/0731-7085(95)01685-6; Lindsay CD, 2016, ISSUES TOXICOL, V27, P259; Martin TL, 2006, J ANAL TOXICOL, V30, P603, DOI 10.1093/jat/30.8.603; Massey J, 2017, MMWR-MORBID MORTAL W, V66, P975, DOI 10.15585/mmwr.mm6637a3; MAUTZ DS, 1994, J CHROMATOGR B, V658, P149, DOI 10.1016/0378-4347(94)00201-0; McIntyre IM, 2012, J FORENSIC RES, V3, P1; MEULDERMANS WEG, 1982, ARCH INT PHARMACOD T, V257, P4; Millington DS, 2014, WIL SER PHARM SCI BI, P314; Mohr ALA, 2016, J ANAL TOXICOL, V40, P709, DOI 10.1093/jat/bkw086; Mommers J, 2013, ANAL CHIM ACTA, V774, P26, DOI 10.1016/j.aca.2013.03.001; Moody MT, 2018, DRUG TEST ANAL, V10, P1358, DOI 10.1002/dta.2393; Mounteney J, 2015, INT J DRUG POLICY, V26, P626, DOI 10.1016/j.drugpo.2015.04.003; Muller S, 2018, CLIN TOXICOL, V56, P151, DOI 10.1080/15563650.2017.1355464; Musshoff F, 2006, J MASS SPECTROM, V41, P633, DOI 10.1002/jms.1021; O'Donnell J, 2018, MMWR-MORBID MORTAL W, V67, P767, DOI 10.15585/mmwr.mm6727a4; Odoardi S, 2014, FORENSIC SCI INT, V243, P61, DOI 10.1016/j.forsciint.2014.04.015; Oiestad EL, 2011, J ANAL TOXICOL, V35, P280, DOI 10.1093/anatox/35.5.280; Ojanpera I, 2008, INT J LEGAL MED, V122, P395, DOI 10.1007/s00414-008-0230-x; Palmer RB, 2010, CLIN TOXICOL, V48, P771, DOI 10.3109/15563650.2010.525514; Papsun D, 2017, J ANAL TOXICOL, V41, P777, DOI 10.1093/jat/bkx068; Pedersen AJ, 2013, J SEP SCI, V36, P2081, DOI 10.1002/jssc.201200921; Przybyciel M, 2006, LC GC N AM, V24, P49; Remane D, 2014, ANAL BIOANAL CHEM, V406, P4411, DOI 10.1007/s00216-014-7841-5; Riches JR, 2012, J ANAL TOXICOL, V36, P647, DOI 10.1093/jat/bks078; RUNAGYUTTIKARN W, 1990, J ANAL TOXICOL, V14, P160, DOI 10.1093/jat/14.3.160; SCHUTTLER J, 1984, ANESTHESIOLOGY, V61, P315, DOI 10.1097/00000542-198409000-00010; Shaner RL, 2017, ANAL METHODS-UK, V9, P3876, DOI [10.1039/c7ay00532f, 10.1039/C7AY00532F]; Shaner RL, 2014, J CHROMATOGR B, V962, P52, DOI 10.1016/j.jchromb.2014.05.025; Shanks KG, 2017, J ANAL TOXICOL, V41, P466, DOI 10.1093/jat/bkx042; Shou WZ, 2001, RAPID COMMUN MASS SP, V15, P466, DOI 10.1002/rcm.255; SILVERSTEIN JH, 1993, ANESTH ANALG, V76, P618; Sofalvi S, 2017, J ANAL TOXICOL, V41, P473, DOI 10.1093/jat/bkx052; Strayer KE, 2018, ACS OMEGA, V3, P514, DOI 10.1021/acsomega.7b01536; Teske J, 2007, INT J LEGAL MED, V121, P147, DOI 10.1007/s00414-006-0137-3; Tomassoni Anthony J, 2017, MMWR Morb Mortal Wkly Rep, V66, P107, DOI 10.15585/mm6604a4; US Department of Health and Human Services Food and Drug Administration, 2016, GUID IND BIOAN METH; VANROOY HH, 1981, J CHROMATOGR, V223, P85, DOI 10.1016/S0378-4347(00)80070-5; Vardanyan RS, 2014, FUTURE MED CHEM, V6, P385, DOI 10.4155/fmc.13.215; Verplaetse R, 2016, DRUG TEST ANAL, V8, P30, DOI 10.1002/dta.1927; Vo KT, 2016, MMWR-MORBID MORTAL W, V65, P420, DOI 10.15585/mmwr.mm6516e1; Wagner M, 2016, MASS SPECTROM REV, V35, P361, DOI 10.1002/mas.21441; Wang GH, 2011, FORENSIC SCI INT, V206, P127, DOI 10.1016/j.forsciint.2010.07.022; Wang LQ, 2006, J ANAL TOXICOL, V30, P335, DOI 10.1093/jat/30.5.335	65	4	4	4	11	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0146-4760	1945-2403		J ANAL TOXICOL	J. Anal. Toxicol.	MAY	2019	43	4					266	276		10.1093/jat/bky096			11	Chemistry, Analytical; Toxicology	Chemistry; Toxicology	IV1VV	WOS:000484067800006	30462229	Bronze			2020-06-30	J	Nash, C; Butzbach, D; Stockham, P; Scott, T; Abroe, G; Painter, B; Gilbert, J; Kostakis, C				Nash, Christine; Butzbach, Danielle; Stockham, Peter; Scott, Timothy; Abroe, Greg; Painter, Ben; Gilbert, John; Kostakis, Chris			A Fatality Involving Furanylfentanyl and MMMP, with Presumptive Identification of Three MMMP Metabolites in Urine	JOURNAL OF ANALYTICAL TOXICOLOGY			English	Article							FURANYL-FENTANYL; DRUG; PHOTOINITIATORS; RISPERIDONE; PREVALENCE; POSTMORTEM; CATHINONES; CHEMISTRY; DEVICES; SYSTEMS	The prevalence of new psychoactive substances (NPS) on the illicit drug market continues to grow, with new analogs being routinely synthesized. Routes of administration for these compounds are also diversifying, and recent research has shown an increase in the incorporation of NPS into vaping liquids. Among the most commonly encountered NPS are the cathinone and fentanyl analogs. Fentanyl analogs in particular have been implicated in a significant number of deaths, usually in combination with other prescription and illicit drugs. We report the case of a 44-year-old male with a history of polysubstance abuse found deceased at his home address. Items located within the vicinity of the deceased were found to contain furanylfentanyl and 2-methyl-4'(methylthio)-2-morpholinopropiophenone (MMMP also known as MTMP, MMTMP, Irgacure 907 and Caccure 907). Both of these compounds were detected in the post-mortem peripheral blood of the deceased: furanylfentanyl at 1.6 ng/mL and MMMP at 6.7 ng/mL. MMMP is an unrestricted, commercially available photo-initiator used in the printing and polymer industry, which structurally can be classed as a highly modified cathinone. Although MMMP has been found previously in drug seizures, this is the first fatality in which MMMP has been detected. A number of other prescription and illicit drugs were also detected in the blood. MMMP was not detected in the postmortem urine; however three metabolites, beta-hydroxy-MMMP, beta-hydroxy-MMMP-sulfoxide and beta-hydroxy-MMMP-sulfone, were presumptively identified. The significance of MMMP to the cause of death is uncertain as its pharmacological and toxicological profile is unclear.	[Nash, Christine; Butzbach, Danielle; Stockham, Peter; Scott, Timothy; Abroe, Greg; Painter, Ben; Gilbert, John; Kostakis, Chris] Forens Sci SA, GPO Box 2790, Adelaide, SA 5001, Australia; [Butzbach, Danielle; Stockham, Peter; Scott, Timothy; Painter, Ben] Flinders Univ South Australia, Sturt Rd, Bedford Pk, SA 5042, Australia	Nash, C (reprint author), Forens Sci SA, GPO Box 2790, Adelaide, SA 5001, Australia.	christine.nash@sa.gov.au					Allen NS, 1996, J PHOTOCH PHOTOBIO A, V100, P101, DOI 10.1016/S1010-6030(96)04426-7; [Anonymous], 2016, VAL VER GUID V2 SEPT; [Anonymous], 2017, EUR JOINT REP NEW PS; [Anonymous], 2014, CLH REP SUBST NAM 2; Atherton D, 2019, J FORENSIC SCI, V64, P304, DOI 10.1111/1556-4029.13823; Blundell M, 2018, QJM-INT J MED, V111, P9, DOI 10.1093/qjmed/hcx178; Blundell MS, 2018, QJM-INT J MED, V111, P145, DOI 10.1093/qjmed/hcx049; Bowen RAR, 2010, CLIN BIOCHEM, V43, P4, DOI 10.1016/j.clinbiochem.2009.10.001; Butzbach DM, 2013, J FORENSIC SCI, V58, P90, DOI 10.1111/j.1556-4029.2012.02280.x; Cai HM, 2017, FOOD ADDIT CONTAM A, V34, P1632, DOI 10.1080/19440049.2017.1331470; Carmo H, 2003, TOXICOL APPL PHARM, V190, P262, DOI 10.1016/S0041-008X(03)00190-X; Coulter AA, 2018, DRUGS, V78, P1113, DOI 10.1007/s40265-018-0946-y; Daniulaityte R, 2017, MMWR-MORBID MORTAL W, V66, P904, DOI 10.15585/mmwr.mm6634a3; Elliott SP, 2000, J ANAL TOXICOL, V24, P85, DOI 10.1093/jat/24.2.85; European Monitoring Centre for Drugs and Drug Addiction, 2018, EUR DRUG REP TRENDS; European Monitoring Centre for Drugs and Drug Addiction, 2017, EUR DRUG REP TRENDS; Gerostamoulos D., 2012, TIAFT B, V42, P52; Gittard SD, 2010, ADV ENG MATER, V12, pB77, DOI 10.1002/adem.200980012; Goggin MM, 2017, J ANAL TOXICOL, V41, P367, DOI 10.1093/jat/bkx022; Guerrieri D, 2017, J ANAL TOXICOL, V41, P242, DOI 10.1093/jat/bkw129; Head J. M, SYNTHETIC DRUG THREA; Hendricks EJ, 2014, INT J OBESITY, V38, P292, DOI 10.1038/ijo.2013.74; Kawasaki Y, 2012, BIOL PHARM BULL, V35, P256, DOI 10.1248/bpb.35.256; Kelly JP, 2011, DRUG TEST ANAL, V3, P439, DOI 10.1002/dta.313; Klar SA, 2016, HEALTH PROMOT CHRON, V36, P200, DOI 10.24095/hpcdp.36.9.05; Koch K, 2018, DRUG TEST ANAL, V10, P1336, DOI 10.1002/dta.2391; Kolanos R, 2013, ACS CHEM NEUROSCI, V4, P1524, DOI 10.1021/cn4001236; Krotulski AJ, 2018, J ANAL TOXICOL, V42, pE27, DOI 10.1093/jat/bkx092; Lago MA, 2015, FOOD ADDIT CONTAM A, V32, P779, DOI 10.1080/19440049.2015.1014866; Liechti M. E., 2015, SWISS MED WKLY, V145, P12; Majchrzak M, 2018, FORENSIC TOXICOL, V36, P525, DOI 10.1007/s11419-018-0417-x; Meyer MR, 2012, J MASS SPECTROM, V47, P253, DOI 10.1002/jms.2960; Mirfazaelian A, 2003, BIOPHARM DRUG DISPOS, V24, P199, DOI 10.1002/bdd.355; Mohr ALA, 2016, J ANAL TOXICOL, V40, P709, DOI 10.1093/jat/bkw086; Namera A, 2015, FORENSIC TOXICOL, V33, P175, DOI 10.1007/s11419-015-0270-0; Ovsianikov A., MICR BIOMEMS MED MIC; Partridge E, 2018, J ANAL TOXICOL, V42, P220, DOI 10.1093/jat/bkx108; PETERSEN MC, 1981, J PHARM SCI, V70, P1139, DOI 10.1002/jps.2600701012; Schymanski EL, 2014, ENVIRON SCI TECHNOL, V48, P2097, DOI 10.1021/es5002105; Segurola J, 1999, POLYM DEGRAD STABIL, V64, P39, DOI 10.1016/S0141-3910(98)00169-4; Shen DX, 2009, ANAL BIOANAL CHEM, V395, P2359, DOI 10.1007/s00216-009-3115-z; Shoff EN, 2017, J ANAL TOXICOL, V41, P484, DOI 10.1093/jat/bkx041; Strickland EC, 2016, J ANAL TOXICOL, V40, P687, DOI 10.1093/jat/bkw078; Swanson DM, 2017, J ANAL TOXICOL, V41, P498, DOI 10.1093/jat/bkx037; Taylor K, 2013, DRUG TEST ANAL, V5, P748, DOI 10.1002/dta.1503; Thurtle N, 2017, J MED TOXICOL, V13, P61, DOI 10.1007/s13181-016-0583-3; Tiscione NB, 2018, J ANAL TOXICOL, V42, P476, DOI 10.1093/jat/bky026; U.S. Drug Enforcement Administration Office of Diversion Control, 2016, NAT FOR LAB INF SYST; United Nations Office on Drugs and Crime, 2017, WORLD DRUG REP 2017; Varlet V, 2016, TOXICS, V4, DOI 10.3390/toxics4040029; Wikstrom M, 2010, J ANAL TOXICOL, V34, P594, DOI 10.1093/jat/34.9.594; Willavize S, 2017, J CLIN PHARMACOL, V57, P255, DOI 10.1002/jcph.800; Winstock AR, 2002, DRUG ALCOHOL DEPEN, V67, P111, DOI 10.1016/S0376-8716(02)00018-2; Zaami S, 2018, EUR REV MED PHARMACO, V22, P268, DOI 10.26355/eurrev_201801_14129; Zuba D, 2012, TRAC-TREND ANAL CHEM, V32, P15, DOI 10.1016/j.trac.2011.09.009	55	4	4	1	4	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0146-4760	1945-2403		J ANAL TOXICOL	J. Anal. Toxicol.	MAY	2019	43	4					291	298		10.1093/jat/bky099			8	Chemistry, Analytical; Toxicology	Chemistry; Toxicology	IV1VV	WOS:000484067800009	30566582				2020-06-30	J	Fagiola, M; Hahn, T; Avella, J				Fagiola, Michael; Hahn, Timothy; Avella, Joseph			Five Postmortem Case Reports with Qualitative Analysis of Cyclopropylfentanyl by LC-MS-MS	JOURNAL OF ANALYTICAL TOXICOLOGY			English	Article							SYNTHETIC OPIOIDS; FENTANYL; HEROIN; ANALOGS; USERS; RISK	In January 2018, the Drug Enforcement Agency temporarily designated cyclopropylfentanyl as a Schedule I drug. Over the course of 5 months (December 2017-May 2018), the Nassau County Medical Examiner Toxicology Laboratory qualitatively identified and confirmed cyclopropylfentanyl in specimens obtained from five postmortem cases. We describe the five cases and include pertinent autopsy findings and decedent histories, along with results for cyclopropylfentanyl determined in postmortem cardiac blood. Samples were prepared by an alkaline liquid-liquid extraction, with sample pH adjusted to >9 and utilizing an extraction solvent consisting of 90:10 hexane: ethyl acetate. Instrumental analysis was achieved via liquid chromatography tandem mass spectrometry with a dual jetstream electrospray source operating in positive ion mode. Two ion transitions were monitored for each analyte of interest and the internal standard. The estimated concentration range of cyclopropylfentanyl in the reported cases was 5.6 to 82 ng/mL for five postmortem cardiac blood specimens. All five cases included cyclopropylfentanyl in the established cause of death.	[Fagiola, Michael; Hahn, Timothy; Avella, Joseph] Nassau Cty Med Examiner, Dept Forens Toxicol, 2251 Hempstead Turnpike,Bldg R, E Meadow, NY 11554 USA	Fagiola, M (reprint author), Nassau Cty Med Examiner, Dept Forens Toxicol, 2251 Hempstead Turnpike,Bldg R, E Meadow, NY 11554 USA.	mfagiola@nassaucountyny.gov					[Anonymous], 2013, J ANAL TOXICOL, V37, P452, DOI 10.1093/jat/bkt054; Bell C, 2011, DRUG TEST ANAL, V3, P496, DOI 10.1002/dta.306; BROWN DL, 1985, CHEST, V88, P779, DOI 10.1378/chest.88.5.779; Carroll JJ, 2017, INT J DRUG POLICY, V46, P136, DOI 10.1016/j.drugpo.2017.05.023; Ciccarone D, 2017, INT J DRUG POLICY, V46, P146, DOI 10.1016/j.drugpo.2017.06.004; Ciccarone D, 2017, INT J DRUG POLICY, V46, P107, DOI 10.1016/j.drugpo.2017.06.010; Drug Enforcement Administration Department of Justice., 2018, Fed Regist, V83, P469; Edison L, 2017, MMWR-MORBID MORTAL W, V66, P1119, DOI 10.15585/mmwr.mm6641a6; Fogarty MF, 2018, J ANAL TOXICOL, V42, P592, DOI 10.1093/jat/bky035; Gerostamoulos D, 2016, J ANAL TOXICOL, V40, P318, DOI 10.1093/jat/bkw013; Janssen P. A. J., 1965, 1 ARALKYL 4 N ARYL C; Maher S, 2018, DRUG TEST ANAL, V10, P1483, DOI 10.1002/dta.2417; Mars SG, 2018, J PSYCHOACTIVE DRUGS, V50, P167, DOI 10.1080/02791072.2017.1394508; Moody MT, 2018, DRUG TEST ANAL, V10, P1358, DOI 10.1002/dta.2393; Pathan H, 2012, BRIT J PAIN, V6, P11, DOI 10.1177/2049463712438493; Prekupec MP, 2017, J ADDICT MED, V11, P256, DOI 10.1097/ADM.0000000000000324; Quintana P, 2017, INT J DRUG POLICY, V40, P78, DOI 10.1016/j.drugpo.2016.10.006; RUNAGYUTTIKARN W, 1990, J ANAL TOXICOL, V14, P160, DOI 10.1093/jat/14.3.160; Schueler Harold E, 2017, Acad Forensic Pathol, V7, P36, DOI 10.23907/2017.004; Smydo J, 1979, Anesth Prog, V26, P47; The Public Health Agency of Sweden, 2018, 14 NYA AMN KAN KLASS; Torjesen I, 2018, BMJ-BRIT MED J, V361, DOI 10.1136/bmj.k1564; U.S. Department of Justice: Drug Enforcement Administration, 2018, EM THREAT REP 1 QUAR; U.S. Department of Justice: Drug Enforcement Administration, 2018, INT BRIEF FENT REM M; U.S. Department of Justice: Drug Enforcement Administration, 2017, EM THREAT REP 3 QUAR; U.S. Department of Justice: Drug Enforcement Administration, 2017, EM THREAT REP 4 QUAR; VANLEEUWEN L, 1981, ANAESTHESIST, V30, P397; Wong SC, 2008, J FORENSIC SCI, V53, P495, DOI 10.1111/j.1556-4029.2007.00648.x	28	4	4	1	6	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0146-4760	1945-2403		J ANAL TOXICOL	J. Anal. Toxicol.	MAY	2019	43	4					E1	E6		10.1093/jat/bky094			6	Chemistry, Analytical; Toxicology	Chemistry; Toxicology	IV1VV	WOS:000484067800001	30476101				2020-06-30	J	Maher, DP; Walia, D; Heller, NM				Maher, Dermot P.; Walia, Deepa; Heller, Nicola M.			Suppression of Human Natural Killer Cells by Different Classes of Opioids	ANESTHESIA AND ANALGESIA			English	Article							CANCER RECURRENCE; IMMUNE-RESPONSES; RECEPTOR 4; ANESTHETIC TECHNIQUE; MORPHINE; SURGERY; ACTIVATION; TRAMADOL; PAIN; CYTOTOXICITY	BACKGROUND: The use of regional and other opioid-sparing forms of anesthesia has been associated with a decrease in the recurrence of certain malignancies. Direct suppression of human natural killer cells by opioids has been postulated to explain this observation. However, the effect of different classes of opioids on suppression of natural killer cell cytotoxicity has not been systematically characterized. METHODS: After confirming that freshly isolated natural killer cells from peripheral human blood express opioid receptors, cells were incubated with increasing concentrations of clinically used or receptor-specific opioid agonists. We also evaluated the effect of pretreatment with receptor-specific antagonists or naloxone. Treated natural killer cells were then coincubated with a carboxyfluorescein succinimidyl ester-labeled target tumor cell line, K562. Annexin V staining was used to compare the percent of tumor cell apoptosis in the presence of opioid-pretreated and untreated natural killer cells. Treated samples were compared to untreated samples using Kruskal-Wallis tests with a post hoc Dunn correction. RESULTS: Morphine, methadone, buprenorphine, loperamide, [D-Ala2, N-MePhe4, Gly-ol]-enkephalin, and U-50488 significantly decreased natural killer cell cytotoxicity. When natural killer cells were pretreated with naloxone, cyprodime, and nor-binaltorphimine before exposure to morphine, there was no difference in natural killer cytotoxicity, compared to the amount observed by untreated natural killer cells. Fentanyl, O-desmethyltramadol, and [D-Pen2, D-Pen5] enkephalin did not change natural killer cell cytotoxicity compare to untreated natural killer cells. CONCLUSIONS: Incubation of isolated natural killer cells with certain opioids causes a decrease in activity that is not observed after naloxone pretreatment. Suppression of natural killer cell cytotoxicity was observed with mu- and kappa-receptor agonists but not delta-receptor agonists. These data suggest that the effect is mediated by mu- and kappa-receptor agonism and that suppression is similar with many clinically used opioids.	[Maher, Dermot P.; Walia, Deepa; Heller, Nicola M.] Johns Hopkins Univ Hosp, Dept Anesthesiol & Crit Care Med, Baltimore, MD 21287 USA	Maher, DP (reprint author), Johns Hopkins Univ, Sch Med, Johns Hopkins Blaustein Pain Treatment Ctr, 601 N Caroline St, Baltimore, MD 21205 USA.	dmaher3@jhmi.edu			Blaustein Pain Research Fund Grant; National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [5T32GM075774]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 HL124477]	D.P.M. received funding from the Blaustein Pain Research Fund Grant and National Institutes of Health (NIH) Grant 5T32GM075774. N.M.H. receives funding from NIH Grant R01 HL124477. No copyrighted material from outside sources was used in preparation of this manuscript. This study has not been previously presented.	Aubry JP, 1999, CYTOMETRY, V37, P197, DOI 10.1002/(SICI)1097-0320(19991101)37:3<197::AID-CYTO6>3.0.CO;2-L; Bakr MAEM, 2016, CLIN J PAIN, V32, P889, DOI 10.1097/AJP.0000000000000338; BAYER BM, 1990, NEUROPHARMACOLOGY, V29, P369, DOI 10.1016/0028-3908(90)90096-A; Beilin B, 1996, ANESTH ANALG, V82, P492, DOI 10.1097/00000539-199603000-00011; BEILIN B, 1989, Brain Behavior and Immunity, V3, P129, DOI 10.1016/0889-1591(89)90013-5; Biki B, 2008, ANESTHESIOLOGY, V109, P180, DOI 10.1097/ALN.0b013e31817f5b73; Borner C, 2008, MOL PHARMACOL, V74, P496, DOI 10.1124/mol.108.046029; Borner C, 2009, J IMMUNOL, V183, P882, DOI 10.4049/jimmunol.0802763; Boland Jason W, 2016, J Opioid Manag, V12, P313, DOI 10.5055/jom.2016.0348; Boland JW, 2014, BMJ SUPPORT PALLIAT, V4, P357, DOI 10.1136/bmjspcare-2013-000573; Carrigan KA, 2004, INT IMMUNOPHARMACOL, V4, P419, DOI 10.1016/j.intimp.2004.01.011; CRONE LAL, 1988, ANESTH ANALG, V67, P318; Exadaktylos AK, 2006, ANESTHESIOLOGY, V105, P660, DOI 10.1097/00000542-200610000-00008; Fischer K, 2002, J IMMUNOL METHODS, V259, P159, DOI 10.1016/S0022-1759(01)00507-5; Franchi S, 2012, BRAIN BEHAV IMMUN, V26, P480, DOI 10.1016/j.bbi.2011.12.010; Fuggetta MP, 2005, J EXP CLIN CANC RES, V24, P255; Gaspani L, 2002, J NEUROIMMUNOL, V129, P18, DOI 10.1016/S0165-5728(02)00165-0; Gupta K, 2002, CANCER RES, V62, P4491; Hutchinson MR, 2012, J NEUROSCI, V32, P11187, DOI 10.1523/JNEUROSCI.0684-12.2012; Hutchinson MR, 2010, BRAIN BEHAV IMMUN, V24, P83, DOI 10.1016/j.bbi.2009.08.004; Lai J, 1996, EUR J PHARMACOL, V316, P369, DOI 10.1016/S0014-2999(96)00770-4; Lennon FE, 2012, ANESTHESIOLOGY, V116, P857, DOI 10.1097/ALN.0b013e31824babe2; Lewis SS, 2012, J PAIN, V13, P498, DOI 10.1016/j.jpain.2012.02.005; Liu T, 2012, NEUROSCI BULL, V28, P131, DOI 10.1007/s12264-012-1219-5; Maher DP, 2014, BRIT J ANAESTH, V113, P88, DOI 10.1093/bja/aeu192; Maher DP, 2016, J CLIN ANESTH, V28, P36, DOI 10.1016/j.jclinane.2015.05.010; Martucci C, 2004, PAIN, V110, P385, DOI 10.1016/j.pain.2004.04.020; Menendez ME, 2015, CLIN ORTHOP RELAT R, V473, P2402, DOI 10.1007/s11999-015-4173-5; Phan MT, 2017, HUM IMMUNOL, V78, P103, DOI 10.1016/j.humimm.2016.11.006; Mojadadi S, 2009, CELL MOL IMMUNOL, V6, P111, DOI 10.1038/cmi.2009.15; Nelson CJ, 2000, BRAIN BEHAV IMMUN, V14, P170, DOI 10.1006/brbi.1999.0575; Nguyen J, 2014, BRIT J ANAESTH, V113, P4, DOI 10.1093/bja/aeu090; Oliver L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019820; Page GG, 2001, PAIN, V90, P191, DOI 10.1016/S0304-3959(00)00403-6; Plein LM, 2018, BRIT J PHARMACOL, V175, P2717, DOI 10.1111/bph.13750; Royds J, 2016, INT ANESTHESIOL CLIN, V54, pE76, DOI 10.1097/AIA.0000000000000123; Sacerdote P, 2000, ANESTH ANALG, V90, P1411, DOI 10.1097/00000539-200006000-00028; Tabellini G, 2014, INT IMMUNOPHARMACOL, V18, P169, DOI 10.1016/j.intimp.2013.11.015; VanderLaan JW, 1996, INT J IMMUNOPHARMACO, V18, P401, DOI 10.1016/S0192-0561(96)00011-2; Wang K, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000001333; Wang X, 2005, J LEUKOCYTE BIOL, V78, P772, DOI 10.1189/jlb.0305167; Yardeni Israel Z, 2008, J Opioid Manag, V4, P27; YEAGER MP, 1995, ANESTHESIOLOGY, V83, P500, DOI 10.1097/00000542-199509000-00008; Yoon JJ, 2018, KOREAN J PAIN, V31, P43, DOI 10.3344/kjp.2018.31.1.43	44	2	2	1	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	MAY	2019	128	5					1013	1021		10.1213/ANE.0000000000004058			9	Anesthesiology	Anesthesiology	IQ4LV	WOS:000480723100032	30801358	Green Accepted			2020-06-30	J	Mahapatra, SJ; Jain, S; Bopanna, S; Gupta, S; Singh, P; Trikha, A; Sreenivas, V; Shalimar,; Garg, PK				Mahapatra, Soumya Jagannath; Jain, Saransh; Bopanna, Sawan; Gupta, Swatantra; Singh, Preet; Trikha, Anjan; Sreenivas, Vishnubhatla; Shalimar; Garg, Pramod Kumar			Pentazocine, a Kappa-Opioid Agonist, Is Better Than Diclofenac for Analgesia in Acute Pancreatitis: A Randomized Controlled Trial	AMERICAN JOURNAL OF GASTROENTEROLOGY			English	Article							PAIN RELIEF; CONSERVATIVE TREATMENT; DOUBLE-BLIND; PROSTAGLANDIN; BUPRENORPHINE; INDOMETHACIN; NECROSECTOMY; INFLAMMATION; METAANALYSIS; EFFICACY	OBJECTIVES:The ideal analgesic is not known for patients with acute pancreatitis (AP). Concerns have been raised about serious adverse effects of opioid analgesics increasing the severity of AP. We hypothesized that nonsteroidal anti-inflammatory drugs might be better analgesics because of their anti-inflammatory effect. Our objective was to compare pentazocine, an opioid, and diclofenac, a nonsteroidal anti-inflammatory drug, for adequate analgesia in patients with AP.METHODS:In a double-blind randomized controlled trial, patients with AP were randomized to either intravenous diclofenac 75 mg or pentazocine 30 mg. Fentanyl was given as a rescue analgesic through a patient-controlled analgesia pump. Primary outcome was pain relief measured objectively by the dose of fentanyl required as the rescue analgesic, pain-free period, and numbers of effective and ineffective demands of fentanyl. Secondary outcome was adverse events.RESULTS:Fifty patients were randomized, 24 to the pentazocine group and 26 to the diclofenac group. Baseline characteristics were comparable between the groups. Pentazocine was found to be better than diclofenac in terms of significantly lower dose of the rescue analgesic (fentanyl) required (126 mu g (interquartile range (IQR) 65-218 mu g) vs 225.5 mu g (IQR 133-427 mu g); P = 0.028) and longer pain-free period (31.1 8.2 vs 27.9 +/- 6.6 hours, P = 0.047). The number of effective and ineffective demands was lower in the pentazocine group compared with the diclofenac group (11.5 (IQR 8-15) vs 16 (IQR 13-20), P = 0.098) although not statistically significant. Adverse events were similar between the groups.CONCLUSIONS:Pentazocine, a kappa-opioid receptor agonist, was significantly better than diclofenac for pain relief in AP (Trial registration number: CTRI/2016/09/007326).	[Mahapatra, Soumya Jagannath; Jain, Saransh; Bopanna, Sawan; Gupta, Swatantra; Shalimar; Garg, Pramod Kumar] All India Inst Med Sci, Dept Gastroenterol, New Delhi, India; [Singh, Preet; Trikha, Anjan] All India Inst Med Sci, Dept Anaesthesiol, New Delhi, India; [Sreenivas, Vishnubhatla] All India Inst Med Sci, Dept Biostat, New Delhi, India	Garg, PK (reprint author), All India Inst Med Sci, Dept Gastroenterol, New Delhi, India.	pkgarg@aiims.ac.in	Shalimar, ./J-5686-2016	Shalimar, ./0000-0003-1247-437X			Afshar K, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006027.pub2; Akriviadis EA, 1997, GASTROENTEROLOGY, V113, P225, DOI 10.1016/S0016-5085(97)70099-4; BALTHAZAR EJ, 1985, RADIOLOGY, V156, P767, DOI 10.1148/radiology.156.3.4023241; Banks PA, 2006, AM J GASTROENTEROL, V101, P2379, DOI 10.1111/j.1572-0241.2006.00856.x; Banks PA, 2013, GUT, V62, P102, DOI 10.1136/gutjnl-2012-302779; Banks Peter A, 2010, Gastroenterol Hepatol (N Y), V6, P1; Barlass U, 2018, GUT, V67, P719, DOI 10.1136/gutjnl-2017-313717; Ona XB, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009179.pub2; BLAMEY SL, 1984, BMJ-BRIT MED J, V288, P1494, DOI 10.1136/bmj.288.6429.1494-a; COELLE EF, 1983, GASTROENTEROLOGY, V85, P1307; Dhingra R, 2015, GASTROINTEST ENDOSC, V81, P351, DOI 10.1016/j.gie.2014.07.060; EBBEHOJ N, 1985, SCAND J GASTROENTERO, V20, P798, DOI 10.3109/00365528509088825; Egede JO, 2017, J CLIN DIAGN RES, V11, pQC1, DOI 10.7860/JCDR/2017/25294.9519; Elmunzer BJ, 2008, GUT, V57, P1262, DOI 10.1136/gut.2007.140756; Figini M, 1997, AM J PHYSIOL-GASTR L, V272, pG785; Fraquelli M, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006390.pub2; Garg PK, 2010, CLIN GASTROENTEROL H, V8, P1089, DOI [10.1016/j.cgh.2010.04.011, 10.1016/j.cgh.2010.02.017]; Gulen B, 2016, TURK J GASTROENTEROL, V27, P192, DOI 10.5152/tjg.2015.150398; Jakobs R, 2000, SCAND J GASTROENTERO, V35, P1319; Jaworek J, 2001, J PHYSIOL PHARMACOL, V52, P107; Kahl S, 2004, DIGESTION, V69, P5, DOI 10.1159/000076541; Kotter T, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122918; Lanas Angel, 2012, Gastroenterol Hepatol, V35 Suppl 1, P35, DOI 10.1016/S0210-5705(12)70032-8; Lankisch PG, 2015, LANCET, V386, P85, DOI 10.1016/S0140-6736(14)60649-8; LEVINE JD, 1988, PAIN, V33, P369, DOI 10.1016/0304-3959(88)90298-9; Liddle RA, 2004, PANCREATOLOGY, V4, P551, DOI 10.1159/000082180; Lin JJ, 2013, CYTOKINE, V61, P842, DOI 10.1016/j.cyto.2013.01.002; Magrini M, 1998, INT J CLIN PHARM RES, V18, P87; Meng WB, 2013, PANCREATOLOGY, V13, P201, DOI 10.1016/j.pan.2013.02.003; Mouli VP, 2013, GASTROENTEROLOGY, V144, P333, DOI 10.1053/j.gastro.2012.10.004; Nathan JD, 2002, AM J PHYSIOL-GASTR L, V283, pG938, DOI 10.1152/ajpgi.00105.2002; Peery AF, 2012, GASTROENTEROLOGY, V143, P1179, DOI 10.1053/j.gastro.2012.08.002; Peiro AM, 2008, PANCREATOLOGY, V8, P25, DOI 10.1159/000114852; Pezzilli R, 2010, PHARMACEUTICALS, V3, P558, DOI 10.3390/ph3030558; Schulz F, 2010, BMJ-BRIT MED J, V340, pc332; Sharma M, 2007, AM J GASTROENTEROL, V102, P2688, DOI 10.1111/j.1572-0241.2007.01446.x; STANDFIELD NJ, 1983, BRIT J SURG, V70, P573, DOI 10.1002/bjs.1800701002; Stein C, 2016, ANNU REV MED, V67, P433, DOI 10.1146/annurev-med-062613-093100; Stevens M, 2002, APPL NURS RES, V15, P102, DOI 10.1053/apnr.2002.29532; Ungprasert P, 2015, EUR J INTERN MED, V26, P285, DOI 10.1016/j.ejim.2015.03.008	40	1	1	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0002-9270	1572-0241		AM J GASTROENTEROL	Am. J. Gastroenterol.	MAY	2019	114	5					813	821		10.14309/ajg.0000000000000224			9	Gastroenterology & Hepatology	Gastroenterology & Hepatology	IK5YH	WOS:000476661200022	31008736				2020-06-30	J	Monje, B; Gimenez-Manzorro, A; Ortega-Navarro, C; Herranz-Alonso, A; Sanjurjo-Saez, M				Monje, Beatriz; Gimenez-Manzorro, Alvaro; Ortega-Navarro, Cristina; Herranz-Alonso, Ana; Sanjurjo-Saez, Maria			Trends in hospital consumption of analgesics after the implementation of a pain performance improvement plan	REVISTA BRASILEIRA DE ANESTESIOLOGIA			Portuguese	Article						Analgesic; Consumption; Pain; Opioid	MANAGEMENT; OPIOIDS	Background: Pain management committee established a pain performance improvement plan in 2012. Objective: The aim of the study was to assess the trends in analgesic consumption in a tertiary teaching hospital and the associated economic impact. Methods: A descriptive, retrospective study was conducted between 2011 and 2015. The analysis included: anti-inflammatory and antirheumatic products non-steroids, opioid analgesics and other analgesics and antipyretics. Data are converted into DDD/100 bed-days to analyze consumption trends. Main outcome measure: assessment of the analgesic consumption after the implementation of a pain performance improvement plan. Results: Overall, non-steroidal anti-inflammatory and antirheumatic products consumption decreased in 24.8 DDD/100 bed-days (-28.3%), accounting for most of the total analgesic consumption decrease (-13%) and total cost (-44.3%). Opioid consumption increased markedly from 22.3 DDD/100 bed-days in 2011 to 26.5 DDD/100 bed-days in 2015 (+18.9%). In 2011, the most consumed opioid was morphine (8.6 DDD/100 bed-days). However, there was an increasing trend in fentanyl consumption (from 8.1 to 12.1 DDD/100 bed-days in 2015), which resulted in fentanyl replacing morphine from the most consumed opioid in 2015 (12.1 DDD/100 bed-days). In 2015, the group of other analgesics and antipyretics represented 46.2% of the total analgesic consumption. Acetaminophen was the most commonly consumed analgesic drug (53.2 DDD/100 bed-days in 2015) and had the highest total cost, it represented 55.4% of the overall cost in 2015. Conclusion: Opioid consumption showed an increasing trend during the 5 year period, with fentanyl replacing morphine as the most used opioid. In general, analgesics diminished use was due to the decreasing trend of consumption of non-steroidal anti-inflammatory and antirheumatic products. (C) 2018 Sociedade Brasileira de Anestesiologia. Published by Elsevier Editora Ltda.	[Monje, Beatriz; Gimenez-Manzorro, Alvaro; Ortega-Navarro, Cristina; Herranz-Alonso, Ana; Sanjurjo-Saez, Maria] Univ Gregorio Maranon, Pharm Dept, Hosp Gen, Madrid, Spain; [Monje, Beatriz; Gimenez-Manzorro, Alvaro; Ortega-Navarro, Cristina; Herranz-Alonso, Ana; Sanjurjo-Saez, Maria] IiSGM, Madrid, Spain	Monje, B (reprint author), Univ Gregorio Maranon, Pharm Dept, Hosp Gen, Madrid, Spain.; Monje, B (reprint author), IiSGM, Madrid, Spain.	beatriz.monje@salud.madrid.org					[Anonymous], 1986, Pain Suppl, V3, pS1; [Anonymous], 1992, Clin Pharm, V11, P391; del Pozo JG, 2008, EUR J CLIN PHARMACOL, V64, P411, DOI 10.1007/s00228-007-0419-9; Dowell D, 2016, MMWR RECOMM REP, V65, P1, DOI 10.15585/mmwr.rr6501e1; Genf World Health Organization, 1986, CANC PAIN REL; Gómez Salcedo P., 2009, Rev. Soc. Esp. Dolor, V16, P373; Gordon DB, 2005, ARCH INTERN MED, V165, P1574, DOI 10.1001/archinte.165.14.1574; Loeser JD, 2008, PAIN, V137, P473, DOI 10.1016/j.pain.2008.04.025; McNicol ED, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006332.pub2; Molloy AR, 1997, MED J AUSTRALIA, V167, P9, DOI 10.5694/j.1326-5377.1997.tb138754.x; Ripamonti CI, 2012, ANN ONCOL, V23, P139, DOI 10.1093/annonc/mds233; Rolland B, 2017, REV MED INTERNE, V38, P539, DOI 10.1016/j.revmed.2016.12.024; Simo RM, 1986, EVOLUCION UTILIZACIO; Spanish Agency of Medicinal Products and Medical Devices (AEMPS), 2007, KET CAMB MED US HOSP; Spanish Agency of Medicinal Products and Medical Devices (AEMPS), 2008, UT ANT EST AINE ESP; Spanish Agency of Medicinal Products and Medical Devices (AEMPS), 2012, SEG CARD AINE TRAD C; Spanish Agency of Medicinal Products and Medical Devices (AEMPS), 2013, DICL RIESG CARD REST; Spanish Agency of Medicinal Products and Medical Devices (AEMPS), 2017, UOPIV113022017 AEMPS; Wells N., 2008, PATIENT SAFETY QUALI; Werber A, 2015, PAIN PHYSICIAN, V18, pE323; World Health Organization. Narcotic & Psychotropic Drugs, 2000, NARC PSYCH DRUGS ACH; Zin CS, 2014, EUR J PAIN, V18, P1343, DOI 10.1002/j.1532-2149.2014.496.x	22	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0034-7094	1806-907X		REV BRAS ANESTESIOL	Rev. Bras. Anestesiol.	MAY-JUN	2019	69	3					259	265		10.1016/j.bjan.2018.11.008			7	Anesthesiology	Anesthesiology	II8GK	WOS:000475430300005		DOAJ Gold			2020-06-30	J	Koh, GH; Jung, KT; So, KY; Seo, JS; Kim, SH				Koh, Gi-Ho; Jung, Ki Tae; So, Keum Young; Seo, Jong Sik; Kim, Sang Hun			Effect of different doses of intravenous oxycodone and fentanyl on intubation-related hemodynamic responses A prospective double-blind randomized controlled trial (CONSORT)	MEDICINE			English	Article						fentanyl; hemodynamic responses; intubation; oxycodone	TRACHEAL INTUBATION; ANESTHESIA; INDUCTION; LARYNGOSCOPY; HYPERTENSION	Background: Intubation using direct laryngoscopy is a risky and painful procedure that is associated with undesirable hemodynamic changes such as tachycardia, hypertension, and arrhythmia. Recently, intravenous oxycodone was introduced and used for the control of acute postoperative pain and to attenuate intubation-related hemodynamic responses (IRHRs), but there is insufficient information regarding its proper dosage. We investigated the attenuating effects of different doses of oxycodone and fentanyl on IRHRs. Methods: For calculating oxycodone effective dose (ED95), which attenuated all IRHR changes to less than 20% over baseline values in 95% of male patients at 1minute after intubation, oxycodone 0.1 mg/kg was injected for the first patient 1 hour before intubation, and the next dose for each subsequent patient was determined by the response of the previous patient using Dixon up-and-down method with an interval of 0.01 mg/kg. After obtaining the predictive oxycodone ED95, 148 patients were randomly allocated to roups receiving normal saline (group C), oxycodone ED95 (group O1), oxycodone 2 x ED95 (group O2), or fentanyl 2 mu g/kg (group F). We recorded the incidence of "success" as a less than 20% change from baseline values in all IRHRs 1minute after intubation. Results: The predictive oxycodone ED95 was 0.091 (0.081-0.149) mg/kg. The incidence of "success" was highest in group O2 (75.7%), followed by group O1 (62.2%) and group F (45.9%) with significant differences between the groups (P<.001). The systolic, diastolic, mean arterial pressure, and heart rate were not significantly different among groups after administration of either oxycodone or fentanyl. The percentage hemodynamic changes of the group O2 were significantly lower than those of groups F and O1, but the absolute percentage hemodynamic changes were not significantly different among groups F, O1, and O2. The recalculated oxycodone ED95 with probit analysis (0.269 mg/kg) was needed to prevent any arterial pressure and heart rate changes. Conclusions: Oxycodone 0.182 mg/kg is more effective in attenuating all IRHRs than fentanyl 2 mu g/kg with safe hemodynamic changes. Further research is required to determine if the recalculated oxycodone ED95 (0.269 mg/kg) is also effective and hemodynamically safe for preventing all IRHRs.	[Koh, Gi-Ho] Univ Ulsan, Dept Anesthesiol & Pain Med, Asan Med Ctr, Coll Med, Seoul, South Korea; [Jung, Ki Tae; So, Keum Young; Kim, Sang Hun] Chosun Univ Hosp, Dept Anesthesiol & Pain Med, Gwangju, South Korea; [Jung, Ki Tae; So, Keum Young; Kim, Sang Hun] Chosun Univ, Dept Anesthesiol & Pain Med, Sch Med, 309 Pilmun Daero, Gwangju 61453, South Korea; [Seo, Jong Sik] Chosun Univ, Dept Med, Grad Sch, Gwangju, South Korea	Kim, SH (reprint author), Chosun Univ, Dept Anesthesiol & Pain Med, Sch Med, 309 Pilmun Daero, Gwangju 61453, South Korea.	ksh3223@chosun.ac.kr		Kim, Sang Hun/0000-0003-3869-9470; koh, giho/0000-0003-0221-9420			Andreassen TN, 2011, EUR J CLIN PHARMACOL, V67, P493, DOI 10.1007/s00228-010-0948-5; Bostan H, 2012, INT J ANAESTH, V2, P24; DIXON WJ, 1980, ANNU REV PHARMACOL, V20, P441, DOI 10.1146/annurev.pa.20.040180.002301; EDWARDS ND, 1994, BRIT J ANAESTH, V73, P537, DOI 10.1093/bja/73.4.537; Gallego AO, 2007, CLIN TRANSL ONCOL, V9, P298, DOI 10.1007/s12094-007-0057-9; Hao GT, 2014, PHARMACOL REP, V66, P153, DOI 10.1016/j.pharep.2013.08.012; Hosalli V, 2014, J CLIN DIAGN RES, V8, pGC01, DOI 10.7860/JCDR/2014/8245.4816; Jeon S, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000012187; Jung KW, 2016, CLIN EXP PHARMACOL P, V43, P745, DOI 10.1111/1440-1681.12586; KAUTTO UM, 1982, ACTA ANAESTH SCAND, V26, P217, DOI 10.1111/j.1399-6576.1982.tb01757.x; Khan FA, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004087.pub2; Kim NS, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000006286; KORPINEN R, 1995, CAN J ANAESTH, V42, P298, DOI 10.1007/BF03010706; Lee BW, 2012, KOREAN J ANESTHESIOL, V63, P504, DOI 10.4097/kjae.2012.63.6.504; Lee KH, 2017, PAIN RES MANAG, V2017, DOI 10.1155/2017/9741729; Lee YS, 2016, BMC ANESTHESIOL, V16, DOI 10.1186/s12871-016-0279-x; Liukas A, 2011, DRUG AGING, V28, P41, DOI 10.2165/11586140-000000000-00000; Park KB, 2016, SAUDI MED J, V37, P847, DOI 10.15537/smj.2016.8.14822; Park YH, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000006234; Prys-Roberts C, 1998, BRIT J ANAESTH, V80, P106; Sawano Y, 2013, J ANESTH, V27, P505, DOI 10.1007/s00540-012-1552-x; SHRIBMAN AJ, 1987, BRIT J ANAESTH, V59, P295, DOI 10.1093/bja/59.3.295; Wang JG, 2016, ANAESTH INTENSIVE TH, V48, P300, DOI 10.5603/AIT.a2016.0052; Zare Mohammad Amin, 2014, Eur J Orthop Surg Traumatol, V24, P1305, DOI 10.1007/s00590-013-1392-x	24	0	1	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0025-7974	1536-5964		MEDICINE	Medicine (Baltimore)	MAY	2019	98	18							e15509	10.1097/MD.0000000000015509			9	Medicine, General & Internal	General & Internal Medicine	IF5FO	WOS:000473106900085	31045840	DOAJ Gold, Green Published			2020-06-30	J	Jobski, K; Bantel, C; Hoffmann, F				Jobski, Kathrin; Bantel, Carsten; Hoffmann, Falk			Utilization of transdermal fentanyl in German nursing home residents from 2010 to 2014	PHARMACOEPIDEMIOLOGY AND DRUG SAFETY			English	Article						aged; fentanyl; nursing home; pharmacoepidemiology	PRESCRIPTION; OPIOIDS; PAIN	Purpose: Transdermal fentanyl (TF) is the most commonly used opioid in Germany although it is associated with an increased risk for hypoventilation and potentially life-threatening respiratory depression if used inappropriately. The objective of this study was to characterize nursing home residents newly receiving TF with regards to (1) patients' conditions at patch initiation, (2) previous analgesic treatment, and (3) the initial TF dose. Methods: Using claims data (2010-2014), we studied a cohort of new nursing home residents aged greater than or equal to 65 years initiating TF. Results: TF was the most commonly prescribed opioid in nursing home residents. During their nursing home stay, 8571 persons (median age: 86 years, 79.2% female and 28.6% with a diagnosis of cancer) started TF (6.7% of all residents). Almost half of the new TF users were opioid-naive and 56.2% of those who had been treated with opioids in the 180 days before TF initiation had only received low potency opioids such as tilidine/naloxone or tramadol. Opioid-naive TF users more often were care dependent and had a higher prevalence of dementia than patients previously treated with opioids. Overall, patients often received anxiolytic/hypnotic (29.7%) or antipsychotic (31.4%) comedication. About 61% of opioid-naive users started with the lowest available dose (12.5 mu g/h), followed by 32% treated with 25 mu g/h. Conclusions: TF as a noninvasive treatment option is the first-choice opioid in German nursing homes. Although initial doses seemed more appropriate than those identified in previous studies, the large proportion of opioid-naive patients in this vulnerable population warrants attention, given the limited controllability of the treatment.	[Jobski, Kathrin; Hoffmann, Falk] Carl von Ossietzky Univ Oldenburg, Dept Hlth Serv Res, D-26111 Oldenburg, Germany; [Bantel, Carsten] Klinikum Oldenburg, Univ Dept Anesthesiol Crit Care Emergency & Pain, Oldenburg, Germany	Jobski, K (reprint author), Carl von Ossietzky Univ Oldenburg, Dept Hlth Serv Res, D-26111 Oldenburg, Germany.	kathrin.jobski@uni-oldenburg.de	Hoffmann, Falk/F-5201-2013	Hoffmann, Falk/0000-0003-0182-5373			Arzneimittelkommission der Deutschen Arzteschaft (AKdA), 2012, DTSCH ARZTEBL, V109, pA724; Barber JB, 2009, DRUG SAFETY, V32, P457, DOI 10.2165/00002018-200932060-00003; Boger R, 2017, ARZNEIVERORDNUNGS RE, P237; Bosetti C, 2019, EUR J PAIN, V23, P697, DOI 10.1002/ejp.1337; Dorks M, 2016, DRUG AGING, V33, P45, DOI 10.1007/s40266-015-0333-2; Fain KM, 2017, J AM MED DIR ASSOC, V18, P138, DOI 10.1016/j.jamda.2016.08.015; Gadzhanova S, 2015, MED J AUSTRALIA, V203, DOI 10.5694/mja15.00174; Garbe E, 2012, PHARMACOEPIDEM DR S, V21, P191, DOI 10.1002/pds.2164; Hoffmann F, 2012, SCHMERZ, V26, P707, DOI 10.1007/s00482-012-1240-7; Hoffmann F, 2010, PHARMACOEPIDEM DR S, V19, P1071, DOI 10.1002/pds.2013; Hunnicutt JN, 2019, PHARMACOEPIDEM DR S, V28, P31, DOI 10.1002/pds.4568; JANSSEN-CILAG GmbH, 2017, FACH DUR SMAI TRANSD; Jensen-Dahm C, 2015, ALZHEIMERS DEMENT, V11, P691, DOI 10.1016/j.jalz.2014.06.013; Mojtabai R, 2018, PHARMACOEPIDEM DR S, V27, P526, DOI 10.1002/pds.4278; Mundkur ML, 2018, PHARMACOEPIDEM DR S, V27, P495, DOI 10.1002/pds.4322; Schug SA, 2017, DRUGS, V77, P747, DOI 10.1007/s40265-017-0727-z; The Association of the Scientific Medical Societies in Germany (AWMF), S3 GUID LONTS LONG T; Tumorschmerzen, 2007, TUM EMPF THER TUM	18	0	0	1	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1053-8569	1099-1557		PHARMACOEPIDEM DR S	Pharmacoepidemiol. Drug Saf.	MAY	2019	28	5					754	759		10.1002/pds.4753			6	Public, Environmental & Occupational Health; Pharmacology & Pharmacy	Public, Environmental & Occupational Health; Pharmacology & Pharmacy	ID9KN	WOS:000472006100001	30861622				2020-06-30	J	Angi, C; Lurie, IS; Marginean, I				Angi, Carolyn; Lurie, Ira S.; Marginean, Ioan			Analysis of fentanyl derivatives by ultra high performance liquid chromatography with diode array ultraviolet and single quadrupole mass spectrometric detection	JOURNAL OF SEPARATION SCIENCE			English	Article						fentanyl analogues; homologues; positional isomers; ultra high performance liquid chromatography; ultraviolet detection	QUANTITATIVE-ANALYSIS; GAS-CHROMATOGRAPHY; WHOLE-BLOOD; LC-MS/MS; ANALOGS; URINE; DRUGS; IDENTIFICATION; METABOLITES; OPIOIDS	Fentanyl has become pervasive as a drug of abuse and as adulterant in seized drugs. Positional isomers analyzed by gas chromatography with mass spectrometry can follow the same fragmentation pathway and therefore may not be differentiated. Additionally, electron ionization leads to lack of discernible molecular ion for most fentanyl related compounds. Liquid chromatography may be used as an orthogonal identification technique with diode array ultraviolet and mass spectrometric detection. Here we provide a chromatographic method for the separation of 20 different fentanyl analogues, homologues and positional isomers using ultra high performance liquid chromatography with photodiode array ultraviolet and mass spectrometry detection. Five different columns were investigated utilizing reverse phase chromatography and hydrophilic interaction chromatography. Chromatographic systems were evaluated to determine which could separate the most compounds overall, as well as the most positional isomers. We found that isocratic elution, with a methanol modifier (35%) and formic acid (0.1%) as an additive, on a C18 column at a temperature of 25 degrees C could resolve 10/20 compounds overall and 16/20 positional isomers. Using electrospray ionization, compounds with different masses could easily be distinguished based on their pseudo molecular ions. Ultraviolet detection facilitated differentiation of positional isomers that could not be distinguished by either electron ionization or electrospray ionization mass spectrometry alone.	[Angi, Carolyn; Lurie, Ira S.; Marginean, Ioan] George Washington Univ, Dept Forens Sci, 2100 Fox Hall Rd,NW20007, Washington, DC 20052 USA	Marginean, I (reprint author), George Washington Univ, Dept Forens Sci, 2100 Fox Hall Rd,NW20007, Washington, DC 20052 USA.	mnelu@gwu.edu	Marginean, Ioan/A-4183-2008	Marginean, Ioan/0000-0002-6693-0361; Lurie, Ira/0000-0003-3844-5120			[Anonymous], 2018, FED REGISTER, P83; Armenian P, 2018, NEUROPHARMACOLOGY, V134, P121, DOI 10.1016/j.neuropharm.2017.10.016; BANSAL R, 1995, J LIQ CHROMATOGR, V18, P339, DOI 10.1080/10826079508009243; Boleda MR, 2007, J CHROMATOGR A, V1175, P38, DOI 10.1016/j.chroma.2007.10.029; Carnes S, 2017, J SEP SCI, V40, P3545, DOI 10.1002/jssc.201700349; COOPER D, 1986, J FORENSIC SCI, V31, P511; Cooreman S, 2010, J SEP SCI, V33, P2654, DOI 10.1002/jssc.201000330; de Boer D, 2003, J PHARMACEUT BIOMED, V31, P557, DOI 10.1016/S0731-7085(02)00684-2; Eckart K, 2015, J CHROMATOGR B, V1001, P1, DOI 10.1016/j.jchromb.2015.06.028; Estonian Forensic Service Centre, 2003, FORENSIC SCI INT, P96; Gergov M, 2009, FORENSIC SCI INT, V186, P36, DOI 10.1016/j.forsciint.2009.01.013; Gupta PK, 2007, ANAL BIOANAL CHEM, V388, P579, DOI 10.1007/s00216-007-1279-y; Helland A, 2017, J ANAL TOXICOL, V41, P708, DOI 10.1093/jat/bkx050; Kanamori T, 2017, J FORENSIC SCI, V62, P1472, DOI 10.1111/1556-4029.13395; KINGSBURY DP, 1995, J ANAL TOXICOL, V19, P27, DOI 10.1093/jat/19.1.27; Li L, 2014, FORENSIC SCI INT, V237, P100, DOI 10.1016/j.forsciint.2014.01.018; Lurie IS, 2011, J CHROMATOGR A, V1218, P9336, DOI 10.1016/j.chroma.2011.10.067; Lurie IS, 2009, J CHROMATOGR A, V1216, P1515, DOI 10.1016/j.chroma.2008.12.097; Mao CL, 2006, J PHARMACEUT BIOMED, V41, P1332, DOI 10.1016/j.jpba.2006.03.009; Mohr ALA, 2016, J ANAL TOXICOL, V40, P709, DOI 10.1093/jat/bkw086; Noble C, 2018, DRUG TEST ANAL, V10, P651, DOI 10.1002/dta.2263; Ohta H, 1999, J ANAL TOXICOL, V23, P280, DOI 10.1093/jat/23.4.280; Pihlainen K, 2005, J MASS SPECTROM, V40, P539, DOI 10.1002/jms.831; Poklis J, 2015, FORENSIC SCI INT, V257, P435, DOI 10.1016/j.forsciint.2015.10.021; Riches JR, 2012, J ANAL TOXICOL, V36, P647, DOI 10.1093/jat/bks078; Rittgen J, 2012, ELECTROPHORESIS, V33, P1595, DOI 10.1002/elps.201100655; Rowe WF, 2017, DRUG TEST ANAL, V9, P1512, DOI 10.1002/dta.2163; RUNAGYUTTIKARN W, 1990, J ANAL TOXICOL, V14, P160, DOI 10.1093/jat/14.3.160; Seither J, 2017, J ANAL TOXICOL, V41, P493, DOI 10.1093/jat/bkx049; Seth P, 2018, AM J PUBLIC HEALTH, V108, P500, DOI 10.2105/AJPH.2017.304265; Shaner RL, 2014, J CHROMATOGR B, V962, P52, DOI 10.1016/j.jchromb.2014.05.025; Shoff EN, 2017, J ANAL TOXICOL, V41, P484, DOI 10.1093/jat/bkx041; Sisco E, 2017, FORENSIC CHEM, V4, P108, DOI 10.1016/j.forc.2017.04.001; SNYDER LR, 1972, J CHROMATOGR SCI, V10, P200, DOI 10.1093/chromsci/10.4.200; Strano-Rossi S, 2011, J APPL TOXICOL, V31, P649, DOI 10.1002/jat.1613; Strayer KE, 2018, ACS OMEGA, V3, P514, DOI 10.1021/acsomega.7b01536; SUZUKI S, 1989, FORENSIC SCI INT, V43, P15, DOI 10.1016/0379-0738(89)90117-5; U. S. Department of Justice, 2015, NFLIS BRIEF FENT 200; Verplaetse R, 2010, J CHROMATOGR B, V878, P1987, DOI 10.1016/j.jchromb.2010.05.033	39	0	0	2	9	WILEY-V C H VERLAG GMBH	WEINHEIM	POSTFACH 101161, 69451 WEINHEIM, GERMANY	1615-9306	1615-9314		J SEP SCI	J. Sep. Sci.	MAY	2019	42	9					1686	1694		10.1002/jssc.201801098			9	Chemistry, Analytical	Chemistry	IC9RV	WOS:000471322300015	30829433				2020-06-30	J	Vieira, C; Bras, M; Fragoso, M				Vieira, Claudia; Bras, Marta; Fragoso, Maria			Opioids for Cancer Pain and its Use under Particular Conditions: A Narrative Review	ACTA MEDICA PORTUGUESA			Portuguese	Review						Analgesics; Opioid/therapeutic use; Cancer Pain/drug therapy; Deglutition Disorders; Hepatic Insufficiency; Neoplasms; Renal Insufficiency	POSITION PAPER; MANAGEMENT; QUALITY; ASSOCIATION; MODERATE; LIFE; END	Introduction: All health professionals should be aware of the importance of evaluating pain - fifth vital sign- in cancer patients. Peripheral and central acting analgesics are widely used to treat moderate to severe pain, particularly cancer pain. Many guidelines have addressed this issue. However, real life patients' have other problems and comorbidities that may raise doubts when prescribing. Material and Methods: Authors made a literature search, trying to clarify same specific situations: loss of oral route, renal impairment (hemodialysis), hepatic impairment, frequent opiod interactions and the availability of short-acting formulations. Results: The following medicines were included in this analysis: the natural opiates (morphine and codeine), their synthetic and semisynthetic derivatives (hydromorphone, oxycodone, and fentanyl), the partial agonist buprenorphine and finally tramadol and tapentadol. Transdermal systems are only available for buprenorphine and fentanyl. In hepatic impairment, fentanyl is safe, but with the exception of codeine and tramadol; other opioids should be used with caution. In renal failure: fentanyl, hydromorphone, and tapentadol are safe. Morphine should be avoided; other opioids should be used with caution. In hemodialysis, buprenorphine, fentanyl, hydromorphone and tramadol (at doses up to 200 mg/day) may be used. Discussion: Failure to recognize the impact of various situations described throughout this work, including the bioavailability due to oss of oral route, due to pharmacokinetics and pharmacodynamics of the various drugs, either in the context of the impaired metabolism or excretion, or in due to pharmacological interactions, conditions a serious risk of subtreatment of pain and consequent impact in terms of quality of life. Conclusion: Opioid prescription is safe and effective, even in moderate to severe comorbidities such as renal and hepatic impairment and in patients with no oral route available. In this case, as when considering pharmacological interactions, an individualized therapeutic plan is the best solution and the patient should be assessed regularly. Unadjusted doses may relate to bad pain control and a higher prevalence of adverse events.	[Vieira, Claudia; Fragoso, Maria] Inst Portugues Oncol Porto Francisco Gentil IPO P, Med Oncol Dept, Porto, Portugal; [Vieira, Claudia] Inst Portugues Oncol Porto Francisco Gentil IPO P, Res Ctr, Mol Oncol Grp, Porto, Portugal; [Vieira, Claudia] Univ Porto, Fac Med, Porto, Portugal; [Bras, Marta] Hosp Dist Figueira da Foz, Internal Med Dept, Figueira Da Foz, Portugal; [Fragoso, Maria] Inst Portugues Oncol Porto Francisco Gentil IPO P, Unit Study & Treatment Pain, Porto, Portugal	Vieira, C (reprint author), Inst Portugues Oncol Porto Francisco Gentil IPO P, Med Oncol Dept, Porto, Portugal.; Vieira, C (reprint author), Inst Portugues Oncol Porto Francisco Gentil IPO P, Res Ctr, Mol Oncol Grp, Porto, Portugal.; Vieira, C (reprint author), Univ Porto, Fac Med, Porto, Portugal.	claudiampvieira@gmail.com		Vieira, Claudia Margarida/0000-0001-5396-9753			Alcock MM, 2017, PAIN, V158, P761, DOI 10.1097/j.pain.0000000000000828; [Anonymous], 2016, PRONT TER; Argoff CE, 2009, MAYO CLIN PROC, V84, P602, DOI 10.1016/S0025-6196(11)60749-0; BC Guidelines. ca, 2017, PALLIATIVE CARE PA 2; Cardoso A, 2014, DISSERTACAO CONTROLO; Chandok N, 2010, MAYO CLIN PROC, V85, P451, DOI 10.4065/mcp.2009.0534; Christensen HN, 2016, SCAND J PAIN, V11, P104, DOI 10.1016/j.sjpain.2015.12.007; COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580; Coluzzi F, 2016, REV BRAS ANESTESIOL, V66, P310, DOI [10.1016/j.bjane.2014.09.005, 10.1016/j.bjan.2016.02.008]; Davies PS, 2016, NURSE PRACT, V41, P26, DOI 10.1097/01.NPR.0000482376.29488.79; Davison, 2016, MAN CHRON PAIN CHRON; Davison SN, 2016, CLIN J AM SOC NEPHRO, V11, P1879, DOI 10.2215/CJN.06800616; Direccao-Geral da Saude, 2008, CIRC NORM UT MED OP; Direccao-Geral da Saude, 2003, CIRC NORM DOR COM 5; Faria J, 2018, EUR J PAIN, V22, P827, DOI 10.1002/ejp.1196; Fauci A., 2008, HARRISONS PRINCIPLES; Fernandes JP, 2009, MANUAL TERAPEUTICA M; Garrett J, 1999, TERAPEUTICA MEDICAME, VI; Goncalves F, 2002, CONTROLO SINTOMAS CA; Gourlay DL, 2005, PAIN MED, V6, P107, DOI 10.1111/j.1526-4637.2005.05031.x; Hamilton JP, 2016, MANAGEMENT PAIN PATI; Hanks GW, 2001, BRIT J CANCER, V84, P587, DOI 10.1054/bjoc.2001.1680; HEEL RC, 1979, DRUGS, V17, P81, DOI 10.2165/00003495-197917020-00001; Hennemann-Krause L, 2012, REV HOSP U PEDRO ERN, V11, P1; JADAD AR, 1995, JAMA-J AM MED ASSOC, V274, P1870, DOI 10.1001/jama.274.23.1870; Johnson SJ, OPIOID SAFETY PATIEN; Jost L, 2008, ANN ONCOL, V19, P119, DOI 10.1093/annonc/mdn108; King S, 2011, PALLIATIVE MED, V25, P525, DOI 10.1177/0269216311406313; Koppert W, 2005, J PAIN, V6, P757, DOI 10.1016/j.jpain.2005.07.002; Lamb EJ, 2013, CLIN CHEM, V59, P462, DOI 10.1373/clinchem.2012.184259; Lee WM, 2012, HEPATOLOGY, V55, P965, DOI 10.1002/hep.25551; Marcus NJ, 2005, CANCER INVEST, V23, P84, DOI 10.1081/CNV-200046516; Mercadante S, 2011, CURR MED RES OPIN, V27, P2373, DOI 10.1185/03007995.2011.628982; National Comprehensive Cancer Network, 2018, AD CANC PAIN VERS 1; Nielsen LM, 2015, PAIN PRACT, V15, P580, DOI 10.1111/papr.12232; O'Brien T, 2017, EUR J PAIN, V21, P3, DOI 10.1002/ejp.970; Pentheroudakis G, 2016, ESMO POCKET GUIDELIN; Pereira D, 2015, TRATAMENTO SUPORTE O; Pereira S, 2017, J PAIN SYMPTOM MANAG, V54, P877, DOI 10.1016/j.jpainsymman.2017.04.011; Pergolizzi Joseph, 2008, Pain Pract, V8, P287, DOI 10.1111/j.1533-2500.2008.00204.x; PORTENOY RK, 1994, QUAL LIFE RES, V3, P183, DOI 10.1007/BF00435383; Radbruch L, 2011, PALLIATIVE MED, V25, P578, DOI 10.1177/0269216310383739; Reis Pina P, 2016, MANUAL CUIDADOS PALI, P74; Reis-Pina P, 2017, J PAIN RES, V10, P2097, DOI 10.2147/JPR.S139715; Reis-Pina P, 2015, ACTA MEDICA PORT, V28, P376, DOI 10.20344/amp.5801; Ripamonti CI, 2012, ANN ONCOL, V23, P139, DOI 10.1093/annonc/mds233; Ritto C, 2017, MANUAL DOR CRONICA, p[123, 155, 229, 315]; Sacerdote P, 2006, PALLIATIVE MED, V20, pS9, DOI 10.1191/0269216306pm1124oa; Sutton LM, 2002, PAIN, V99, P5, DOI 10.1016/S0304-3959(02)00236-1; van den Beuken-van Everdingen MHJ, 2016, J PAIN SYMPTOM MANAG, V51, P1070, DOI 10.1016/j.jpainsymman.2015.12.340; von Moos R, 2017, EUR J CANCER, V71, P80, DOI 10.1016/j.ejca.2016.10.021; Walsh D, 2000, SEMIN ONCOL, V27, P45; Weinstein Sharon M, 2009, Ther Clin Risk Manag, V5, P75; Williams ACD, 2016, PAIN, V157, P2420, DOI 10.1097/j.pain.0000000000000613; World Health Organization, 1996, CANC PAIN REL PALL C	55	2	2	0	0	ORDEM MEDICOS	LISBON	AV ALMIRANTE GAGO COUTINHO, 151, LISBON, 1749-084, PORTUGAL	1646-0758			ACTA MEDICA PORT	Acta Medica Port.	MAY	2019	32	5					388	399		10.20344/amp.10500			12	Medicine, General & Internal	General & Internal Medicine	IB0GB	WOS:000469935100011	31166900	DOAJ Gold			2020-06-30	J	Roda, G; Faggiani, F; Bolchi, C; Pallavicini, M; Dei Cas, M				Roda, Gabriella; Faggiani, Francesca; Bolchi, Cristiano; Pallavicini, Marco; Dei Cas, Michele			Ten Years of Fentanyl-like Drugs: a Technical-analytical Review	ANALYTICAL SCIENCES			English	Review						Fentanyl; designer opioids; fentanyl-like compounds; illicit fentanyls; mass spectrometry	TANDEM MASS-SPECTROMETRY; PERFORMANCE LIQUID-CHROMATOGRAPHY; FAST GC/MS-TOF; ACETYL FENTANYL; WHOLE-BLOOD; SYNTHETIC OPIOIDS; HUMAN PLASMA; LC-MS/MS; URINE SPECIMENS; QUANTITATIVE-DETERMINATION	Synthetic opioids, such as fentanyl and its analogues, are a new public health warning. Clandestine laboratories produce drug analogues at a faster rate than these compounds can be controlled or scheduled by drug agencies. Detection requires specific testing and clinicians may be confronted with a sequence of severe issues concerning the diagnosis and management of these contemporary opioid overdoses. This paper deals with methods for biological sample treatment, as well as the methodologies of analysis that have been reported, in the last decade, in the field of fentanyl-like compounds. From this analysis, it emerges that the gold standard for the identification and quantification of 4-anilinopiperidines is LC-MS/MS, coupled with liquid-liquid or solid-phase extraction. In the end, the return to the scene of illicit fentanyls can be considered as a critical problem that can be tackled only with a global multidisciplinary approach.	[Roda, Gabriella; Faggiani, Francesca; Bolchi, Cristiano; Pallavicini, Marco] Univ Milan, Dept Pharmaceut Sci, Milan, Italy; [Dei Cas, Michele] Univ Milan, Dept Hlth Sci, Milan, Italy	Dei Cas, M (reprint author), Univ Milan, Dept Hlth Sci, Milan, Italy.	michele.deicas@unimi.it	Cas, Michele Dei/AAO-2132-2020; bolchi, cristiano/G-5239-2015	Cas, Michele Dei/0000-0001-7359-8558; bolchi, cristiano/0000-0002-6726-9501	PhD program in Molecular and Translational Medicine of the University of Milan, Milan	MDC was supported by the PhD program in Molecular and Translational Medicine of the University of Milan, Milan.	Allibe N, 2018, DRUG TEST ANAL, V10, P995, DOI 10.1002/dta.2326; Ando A, 2018, ANAL SCI, V34, P177, DOI 10.2116/analsci.34.177; Armenian P, 2018, NEUROPHARMACOLOGY, V134, P121, DOI 10.1016/j.neuropharm.2017.10.016; Beardsley Patrick M, 2018, Handb Exp Pharmacol, V252, P353, DOI 10.1007/164_2018_149; Berg T, 2013, J ANAL TOXICOL, V37, P159, DOI 10.1093/jat/bkt005; Bista SR, 2014, J CHROMATOGR B, V960, P27, DOI 10.1016/j.jchromb.2014.04.019; Blanco ME, 2015, DRUG TEST ANAL, V7, P804, DOI 10.1002/dta.1778; Boleda MR, 2007, J CHROMATOGR A, V1175, P38, DOI 10.1016/j.chroma.2007.10.029; Boumba VA, 2017, FORENSIC SCI INT, V279, P192, DOI 10.1016/j.forsciint.2017.08.031; Breindahl T, 2017, DRUG TEST ANAL, V9, P415, DOI 10.1002/dta.2046; Burke MJ, 2017, J VET EMERG CRIT CAR, V27, P539, DOI 10.1111/vec.12644; Butler DC, 2018, J ANAL TOXICOL, V42, pE6, DOI 10.1093/jat/bkx083; Cannaert A., 2018, FRONT PHARMACOL, V9, P1; Casale J., 2017, 253 ACS NAT M EXP, P293; Caspar AT, 2018, TALANTA, V176, P635, DOI 10.1016/j.talanta.2017.08.063; Chambers M., 2017, 253 ACS NAT M EXP, P468; Clavijo CF, 2011, J SEP SCI, V34, P3568, DOI 10.1002/jssc.201100422; Concheiro M, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01210; Coopman V, 2016, FORENSIC SCI INT, V266, P469, DOI 10.1016/j.forsciint.2016.07.005; Cooreman S, 2010, J SEP SCI, V33, P2654, DOI 10.1002/jssc.201000330; Corner S. D., NEUROSCI BIOBEHAV RE; Cunningham SM, 2016, J FORENSIC SCI, V61, pS276, DOI 10.1111/1556-4029.12953; de Bruijn P, 2018, J PHARMACEUT BIOMED, V149, P475, DOI 10.1016/j.jpba.2017.11.035; del M., 2014, J ANAL TOXICOL, V38, P280; Donnarumma F., 2013, ANAL SCI, V396, P2629; Eckart K, 2015, J CHROMATOGR B, V1001, P1, DOI 10.1016/j.jchromb.2015.06.028; El Hamd MA, 2015, BIOMED CHROMATOGR, V29, P325, DOI 10.1002/bmc.3281; Elliott SP, 2018, J ANAL TOXICOL, V42, pE41, DOI 10.1093/jat/bkx109; Fakhari AR, 2013, DRUG TEST ANAL, V5, P589, DOI 10.1002/dta.1387; Fare F, 2018, EUR J LIPID SCI TECH, V120, DOI 10.1002/ejlt.201700525; Fedick PW, 2017, ANAL CHEM, V89, P10973, DOI 10.1021/acs.analchem.7b02798; Fels H, 2017, FORENSIC SCI INT, V277, pE30, DOI 10.1016/j.forsciint.2017.04.003; Fleming SW, 2017, J ANAL TOXICOL, V41, P173, DOI 10.1093/jat/bkw131; Fogarty MF, 2018, J ANAL TOXICOL, V42, P592, DOI 10.1093/jat/bky035; Fort C, 2016, J ANAL TOXICOL, V40, P754, DOI 10.1093/jat/bkw068; Fu JH, 2012, ANAL SCI, V28, P1081, DOI 10.2116/analsci.28.1081; Gambaro V, 2014, J ANAL TOXICOL, V38, P289, DOI 10.1093/jat/bku016; Gardner MA, 2015, J ANAL TOXICOL, V39, P118, DOI 10.1093/jat/bku136; Gergov M, 2009, FORENSIC SCI INT, V186, P36, DOI 10.1016/j.forsciint.2009.01.013; Ghassabian S, 2012, J CHROMATOGR B, V903, P126, DOI 10.1016/j.jchromb.2012.07.005; Griswold MK, 2017, J MED TOXICOL, V13, P287, DOI 10.1007/s13181-017-0632-6; Guerrieri D, 2017, J ANAL TOXICOL, V41, P242, DOI 10.1093/jat/bkw129; Guerrini K, 2013, J PHARMACEUT BIOMED, V73, P125, DOI 10.1016/j.jpba.2012.04.001; Haddad A, 2018, ANAL CHEM, V90, P12678, DOI 10.1021/acs.analchem.8b02909; Helander A, 2018, DRUG TEST ANAL, V10, P1297, DOI 10.1002/dta.2382; Helander A, 2016, CLIN TOXICOL, V54, P324, DOI 10.3109/15563650.2016.1139715; Helland A, 2017, J ANAL TOXICOL, V41, P708, DOI 10.1093/jat/bkx050; Hikin L, 2018, FORENSIC SCI INT, V282, P179, DOI 10.1016/j.forsciint.2017.11.036; Hisada T, 2013, BIOL PHARM BULL, V36, P412, DOI 10.1248/bpb.b12-00825; Inscore F, 2011, APPL SPECTROSC, V65, P1004, DOI 10.1366/11-06310; Jannetto PJ, 2019, CLIN CHEM, V65, P242, DOI 10.1373/clinchem.2017.281626; Jeleazcov C, 2012, BRIT J ANAESTH, V109, P698, DOI 10.1093/bja/aes253; Kanamori T, 2017, J FORENSIC SCI, V62, P1472, DOI 10.1111/1556-4029.13395; Karila L., NEUROSCI BIOBEHAV RE; Kim T, 2011, J PHARMACEUT BIOMED, V55, P487, DOI 10.1016/j.jpba.2011.01.040; Kinshella MLW, 2018, HARM REDUCT J, V15, DOI 10.1186/s12954-018-0271-5; Koster RA, 2015, ANESTH ANALG, V120, P1235, DOI 10.1213/ANE.0000000000000643; Krotulski AJ, 2018, J ANAL TOXICOL, V42, pE27, DOI 10.1093/jat/bkx092; Krotulski AJ, 2018, DRUG TEST ANAL, V10, P127, DOI 10.1002/dta.2228; Kudo T, 2013, J ANESTH, V27, P615, DOI 10.1007/s00540-012-1549-5; Lafreniere NM, 2010, FORENSIC SCI INT, V194, P60, DOI 10.1016/j.forsciint.2009.10.008; Leonard J, 2017, J RAMAN SPECTROSC, V48, P1323, DOI 10.1002/jrs.5220; Liang LL, 2011, J PHARMACEUT BIOMED, V54, P838, DOI 10.1016/j.jpba.2010.11.016; Lozier MJ, 2015, J MED TOXICOL, V11, P208, DOI 10.1007/s13181-015-0477-9; Lu CA, 2010, BIOMED CHROMATOGR, V24, P711, DOI 10.1002/bmc.1351; Lucyk SN, 2017, ANN EMERG MED, V69, P91, DOI 10.1016/j.annemergmed.2016.08.445; Mahlke NS, 2014, INT J LEGAL MED, V128, P771, DOI 10.1007/s00414-014-1040-y; Malkawi AH, 2008, AAPS J, V10, P261, DOI 10.1208/s12248-008-9031-x; Mars S. G., ADDICTION; Martucci HFH, 2018, FORENSIC SCI INT, V283, pE13, DOI 10.1016/j.forsciint.2017.12.005; McIntyre IM, 2016, J ANAL TOXICOL, V40, P162, DOI 10.1093/jat/bkv138; Meyer MR, 2012, ANAL BIOANAL CHEM, V402, P1249, DOI 10.1007/s00216-011-5528-8; Miller JM, 2018, DRUG ALCOHOL REV, V37, P121, DOI 10.1111/dar.12502; Mochizuki A, 2018, FORENSIC TOXICOL, V36, P81, DOI 10.1007/s11419-017-0384-7; Mohr ALA, 2016, J ANAL TOXICOL, V40, P709, DOI 10.1093/jat/bkw086; Moody MT, 2018, DRUG TEST ANAL, V10, P1358, DOI 10.1002/dta.2393; Nakazawa H, 2014, ANAL SCI, V30, P25, DOI 10.2116/analsci.30.25; Noble C, 2018, DRUG TEST ANAL, V10, P651, DOI 10.1002/dta.2263; Nosseir NS, 2014, J CHROMATOGR B, V973, P133, DOI 10.1016/j.jchromb.2014.10.006; Odoardi S, 2014, FORENSIC SCI INT, V243, P61, DOI 10.1016/j.forsciint.2014.04.015; Ohta H, 1999, J ANAL TOXICOL, V23, P280, DOI 10.1093/jat/23.4.280; Palaty J, 2018, CLIN BIOCHEM, V53, P164, DOI 10.1016/j.clinbiochem.2018.01.013; Patton AL, 2014, ANAL CHEM, V86, P1760, DOI 10.1021/ac4036197; Pedersen AJ, 2013, J SEP SCI, V36, P2081, DOI 10.1002/jssc.201200921; Poklis J, 2016, J ANAL TOXICOL, V40, P703, DOI 10.1093/jat/bkw048; Poklis J, 2015, FORENSIC SCI INT, V257, P435, DOI 10.1016/j.forsciint.2015.10.021; Prekupec MP, 2017, J ADDICT MED, V11, P256, DOI 10.1097/ADM.0000000000000324; Procaccianti P, 2017, J ANAL TOXICOL, V41, P771, DOI 10.1093/jat/bkx056; Quintana P, 2017, INT J DRUG POLICY, V40, P78, DOI 10.1016/j.drugpo.2016.10.006; Ramos-Matos C., 2015, U J CLIN MED, V3, P6; Remane D, 2014, ANAL BIOANAL CHEM, V406, P4411, DOI 10.1007/s00216-014-7841-5; Remane D, 2014, THER DRUG MONIT, V36, P257, DOI 10.1097/FTD.0b013e3182a94e91; Ristimaa J, 2010, ANAL BIOANAL CHEM, V398, P925, DOI 10.1007/s00216-010-3942-y; Roda G., 2015, PHARM ANAL ACTA, V6, P1; Roda G, 2018, J ANAL TOXICOL, V42, pE51, DOI 10.1093/jat/bky015; Saari TI, 2012, J PHARMACEUT BIOMED, V66, P306, DOI 10.1016/j.jpba.2012.03.050; Said R, 2011, J CHROMATOGR B, V879, P815, DOI 10.1016/j.jchromb.2011.02.002; Saraji M, 2011, ANAL BIOANAL CHEM, V400, P2149, DOI 10.1007/s00216-011-4874-x; Seither J, 2017, J ANAL TOXICOL, V41, P493, DOI 10.1093/jat/bkx049; Shaner RL, 2014, J CHROMATOGR B, V962, P52, DOI 10.1016/j.jchromb.2014.05.025; Shanks KG, 2017, J ANAL TOXICOL, V41, P466, DOI 10.1093/jat/bkx042; Shoff EN, 2017, J ANAL TOXICOL, V41, P484, DOI 10.1093/jat/bkx041; Sinicina I, 2017, DRUG ALCOHOL DEPEN, V180, P286, DOI 10.1016/j.drugalcdep.2017.08.021; Snyder ML, 2011, CLIN CHIM ACTA, V412, P946, DOI 10.1016/j.cca.2011.01.029; Sofalvi S, 2017, J ANAL TOXICOL, V41, P473, DOI 10.1093/jat/bkx052; Song AY, 2016, ANAL SCI, V32, P645, DOI 10.2116/analsci.32.645; Steuer AE, 2017, DRUG TEST ANAL, V9, P1085, DOI 10.1002/dta.2111; Strano-Rossi S, 2011, J APPL TOXICOL, V31, P649, DOI 10.1002/jat.1613; Strano-Rossi S, 2011, ANAL BIOANAL CHEM, V399, P1623, DOI 10.1007/s00216-010-4471-4; Strayer KE, 2018, ACS OMEGA, V3, P514, DOI 10.1021/acsomega.7b01536; Swanson DM, 2017, J ANAL TOXICOL, V41, P498, DOI 10.1093/jat/bkx037; Takase I, 2016, LEGAL MED-TOKYO, V21, P38, DOI 10.1016/j.legalmed.2016.05.006; Takashina Y, 2009, J CLIN PHARM THER, V34, P523, DOI 10.1111/j.1365-2710.2009.01033.x; Tiscione NB, 2017, J ANAL TOXICOL, V41, P313, DOI 10.1093/jat/bkx005; Verplaetse R, 2016, DRUG TEST ANAL, V8, P30, DOI 10.1002/dta.1927; Verplaetse R, 2010, J CHROMATOGR B, V878, P1987, DOI 10.1016/j.jchromb.2010.05.033; Wang GH, 2011, FORENSIC SCI INT, V206, P127, DOI 10.1016/j.forsciint.2010.07.022; Watanabe S, 2017, AAPS J, V19, P1102, DOI 10.1208/s12248-017-0070-z; Yang P, 2018, DRUG DEV IND PHARM, V44, P953, DOI 10.1080/03639045.2018.1425426; Yonemitsu K, 2016, FORENSIC SCI INT, V267, pE6, DOI 10.1016/j.forsciint.2016.08.025; Zahedi P, 2016, J PHARMACEUT BIOMED, V117, P485, DOI 10.1016/j.jpba.2015.10.002; Zawilska JB, 2017, FRONT PSYCHIATRY, V8, DOI 10.3389/fpsyt.2017.00110; Ziesenitz VC, 2018, CLIN PHARMACOKINET, V57, P125, DOI 10.1007/s40262-017-0569-6	123	3	3	12	28	JAPAN SOC ANALYTICAL CHEMISTRY	TOKYO	26-2 NISHIGOTANDA 1 CHOME SHINAGAWA-KU, TOKYO, 141, JAPAN	0910-6340	1348-2246		ANAL SCI	Anal. Sci.	MAY	2019	35	5					479	491		10.2116/analsci.18R004			13	Chemistry, Analytical	Chemistry	IA9UF	WOS:000469901700002	30686797	Bronze			2020-06-30	J	Daniulaityte, R; Juhascik, MP; Strayer, KE; Sizemore, IE; Zatreh, M; Nahhas, RW; Harshbarger, KE; Antonides, HM; Martins, SS; Carlson, RG				Daniulaityte, Raminta; Juhascik, Matthew P.; Strayer, Kraig E.; Sizemore, Ioana E.; Zatreh, Mussa; Nahhas, Ramzi W.; Harshbarger, Kent E.; Antonides, Heather M.; Martins, Silvia S.; Carlson, Robert G.			Trends in fentanyl and fentanyl analogue-related overdose deaths - Montgomery County, Ohio, 2015-2017	DRUG AND ALCOHOL DEPENDENCE			English	Article						Fentanyl; Illicitly manufactured fentanyl; Fentanyl analogs; Carfentanil; Unintentional overdose deaths; Ohio	UNITED-STATES; INCREASES; HEROIN; DRUG; USERS; RISK	Introduction: There is a lack of information on illicitly manufactured fentanyl and fentanyl analogue-related (IMF) unintentional overdose death trends over time. The study analyzes IMF-related unintentional overdose fatalities that occurred between July 2015 and June 2017 in Montgomery County, Ohio, an area with the highest rates of unintentional overdose mortality in Ohio. Methods: LC-MS/MS-based method was used to identify fentanyl analogs and metabolites in 724 unintentional overdose death cases. The Chi-square statistic was used to assess differences over time in demographic and drug-related characteristics. Results: The number of unintentional overdose death cases testing positive for IMFs increased by 377% between second half of 2015 and first half of 2017. The majority of decedents were white (82.5%) and male (67.8%). The proportion of fentanyl-only (no other analogs) cases declined from 89.2%-24.6% (p < 0.001), while proportion of fentanyl analogue-containing cases increased from 9.8%-70.3% (p < 0.001) between the second half of 2015 and first half of 2017. The most commonly identified fentanyl analogs were carfentanil (29.7%), furanyl fentanyl (14.1%) and acryl fentanyl (10.2%). Proportion of IMF cases also testing positive for heroin declined from 21.6% to 5.4% (p < 0.001), while methamphetamine positive cases increased from 1.4%-17.8% (p < 0.001) over the same time period. Discussion: Emergence of fentanyl analogs contributed to substantial increases in unintentional overdose deaths. The data indicate a growing overlap between the IMF and methamphetamine outbreaks. Continuous monitoring of local IMF trends and rapid information dissemination to active users are needed to reduce the risks associated with IMF use.	[Daniulaityte, Raminta; Zatreh, Mussa; Carlson, Robert G.] Wright State Univ, Boonshoft Sch Med, Ctr Intervent Treatment & Addict Res, Dept Populat & Publ Hlth Sci, 3171 Res Blvd, Kettering, OH 45420 USA; [Juhascik, Matthew P.; Harshbarger, Kent E.; Antonides, Heather M.] MCCO MVRCL, 361 W Third ST, Dayton, OH 45402 USA; [Strayer, Kraig E.; Sizemore, Ioana E.] Wright State Univ, Dept Chem, Coll Sci & Math, 202 Oelman Hall, Dayton, OH 45435 USA; [Nahhas, Ramzi W.] Wright State Univ, Boonshoft Sch Med, Dept Populat & Publ Hlth Sci, 3171 Res Blvd, Kettering, OH 45420 USA; [Nahhas, Ramzi W.] Wright State Univ, Boonshoft Sch Med, Dept Psychiat, 627 S Edwin C Moses Blvd,Suite 1, Dayton, OH 45417 USA; [Martins, Silvia S.] Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, 722 West 168th St, New York, NY 10032 USA	Daniulaityte, R (reprint author), Wright State Univ, Boonshoft Sch Med, Ctr Intervent Treatment & Addict Res, Dept Populat & Publ Hlth Sci, 3171 Res Blvd, Kettering, OH 45420 USA.	raminta.daniulaityte@wright.edu		Martins, Silvia/0000-0003-3059-9993; Daniulaityte, Raminta/0000-0001-6507-3866	National Institute on Drug Abuse (NIDA)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [1R21DA042757, R01 DA040811]	This study was supported by the National Institute on Drug Abuse (NIDA) Grants: 1R21DA042757 (Daniulaityte, PI) and R01 DA040811 (Daniulaityte, PI). The funding source had no further role in the study design, in the collection, analysis and interpretation of the data, in the writing of the report, or in the decision to submit the paper for publication.	Carroll JJ, 2017, INT J DRUG POLICY, V46, P136, DOI 10.1016/j.drugpo.2017.05.023; Ciccarone D, 2017, INT J DRUG POLICY, V46, P146, DOI 10.1016/j.drugpo.2017.06.004; Ciccarone D, 2017, INT J DRUG POLICY, V46, P107, DOI 10.1016/j.drugpo.2017.06.010; Cicero TJ, 2017, DRUG ALCOHOL DEPEN, V177, P101, DOI 10.1016/j.drugalcdep.2017.04.004; Daniulaityte R., 2019, STREET FENTANYL USE; Daniulaityte R., 2017, THAT FENTANYL DOPE I; Daniulaityte R, 2017, MMWR-MORBID MORTAL W, V66, P904, DOI 10.15585/mmwr.mm6634a3; DEA, 2018, NAT FOR LAB INF SYST; Drug Enforcement Administration (DEA), 2018, 2017 NAT DRUG THREA; Ellis MS, 2018, DRUG ALCOHOL DEPEN, V193, P14, DOI 10.1016/j.drugalcdep.2018.08.029; Gladden RM, 2016, MMWR-MORBID MORTAL W, V65, P837, DOI 10.15585/mmwr.mm6533a2; Harper L, 2017, HARM REDUCT J, V14, DOI 10.1186/s12954-017-0179-5; Hedegaard H., 2018, DRUG OVERDOSE DEATHS; HOMMEL G, 1988, BIOMETRIKA, V75, P383, DOI 10.2307/2336190; Jones CM, 2018, JAMA-J AM MED ASSOC, V319, P1819, DOI 10.1001/jama.2018.2844; Klar SA, 2016, MMWR-MORBID MORTAL W, V65, P1015, DOI 10.15585/mmwr.mm6537a6; Kuramoto SJ, 2011, DRUG ALCOHOL DEPEN, V118, P237, DOI 10.1016/j.drugalcdep.2011.03.030; Lokala U, 2019, COMPUT MATH ORGAN TH, V25, P48, DOI 10.1007/s10588-018-09283-0; Mars SG, 2018, J PSYCHOACTIVE DRUGS, V50, P167, DOI 10.1080/02791072.2017.1394508; National Drug Early Warning System (NDEWS), 2015, FENT FENT AN; NDEWS, 2017, HIGHL NDEWS NEW HAMP; O'Donnell JK, 2017, MMWR-MORBID MORTAL W, V66, P1197, DOI 10.15585/mmwr.mm6643e1; Peiper NC, 2019, INT J DRUG POLICY, V63, P122, DOI 10.1016/j.drugpo.2018.08.007; Peterson AB, 2016, MMWR-MORBID MORTAL W, V65, P844, DOI 10.15585/mmwr.mm6533a3; Rudd RA, 2016, MMWR-MORBID MORTAL W, V65, P1445, DOI 10.15585/mmwr.mm655051e1; Slavova S, 2017, INT J DRUG POLICY, V46, P120, DOI 10.1016/j.drugpo.2017.05.051; Somerville NJ, 2017, MMWR-MORBID MORTAL W, V66, P382, DOI 10.15585/mmwr.mm6614a2; Strayer KE, 2018, ACS OMEGA, V3, P514, DOI 10.1021/acsomega.7b01536; Suzuki J, 2017, DRUG ALCOHOL DEPEN, V171, P107, DOI 10.1016/j.drugalcdep.2016.11.033; Tomassoni Anthony J, 2017, MMWR Morb Mortal Wkly Rep, V66, P107, DOI 10.15585/mm6604a4	30	7	7	6	8	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0376-8716	1879-0046		DRUG ALCOHOL DEPEN	Drug Alcohol Depend.	MAY 1	2019	198						116	120		10.1016/j.drugalcdep.2019.01.045			5	Substance Abuse; Psychiatry	Substance Abuse; Psychiatry	IA1GH	WOS:000469306800018	30909018				2020-06-30	J	Floresta, G; Rescifina, A; Abbate, V				Floresta, Giuseppe; Rescifina, Antonio; Abbate, Vincenzo			Structure-Based Approach for the Prediction of Mu-opioid Binding Affinity of Unclassified Designer Fentanyl-Like Molecules	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES			English	Article						QSAR; fentanyl; OR; opioid binding affinity; designer fentanyl-like molecules; novel synthetic opioids; new psychoactive substances	OVERDOSE DEATHS; UNITED-STATES; QSAR; IDENTIFICATION; INHIBITORS; INCREASES; 3D-QSAR; POTENT; DRUG	Three quantitative structure-activity relationship (QSAR) models for predicting the affinity of mu-opioid receptor (OR) ligands have been developed. The resulted models, exploiting the accessibility of the QSAR modeling, generate a useful tool for the investigation and identification of unclassified fentanyl-like structures. The models have been built using a set of 115 molecules using Forge as a software, and the quality was confirmed by statistical analysis, resulting in being effective for their predictive and descriptive capabilities. The three different approaches were then combined to produce a consensus model and were exploited to explore the chemical landscape of 3000 fentanyl-like structures, generated by a theoretical scaffold-hopping approach. The findings of this study should facilitate the identification and classification of new OR ligands with fentanyl-like structures.	[Floresta, Giuseppe; Rescifina, Antonio] Univ Catania, Dept Drug Sci, I-95125 Catania, Italy; [Abbate, Vincenzo] Kings Coll London, Sch Populat Hlth & Environm Sci, Kings Forens, Franklin Wilkins Bldg,150 Stamford St, London SE1 9NH, England	Floresta, G (reprint author), Univ Catania, Dept Drug Sci, I-95125 Catania, Italy.; Abbate, V (reprint author), Kings Coll London, Sch Populat Hlth & Environm Sci, Kings Forens, Franklin Wilkins Bldg,150 Stamford St, London SE1 9NH, England.	giuseppe.floresta@unict.it; arescifina@unict.it; vincenzo.abbate@kcl.ac.uk	Rescifina, Antonio/E-7412-2012; Floresta, Giuseppe/X-6629-2019	Rescifina, Antonio/0000-0001-5039-2151; Floresta, Giuseppe/0000-0002-0668-1260; Abbate, Vincenzo/0000-0002-3300-0520			ALEMAN C, 1993, J COMPUT CHEM, V14, P799, DOI 10.1002/jcc.540140706; [Anonymous], DEADCTDIB00318; Armenian P, 2018, NEUROPHARMACOLOGY, V134, P121, DOI 10.1016/j.neuropharm.2017.10.016; Cheeseright T, 2006, J CHEM INF MODEL, V46, P665, DOI 10.1021/ci050357s; Cherkasov A, 2014, J MED CHEM, V57, P4977, DOI 10.1021/jm4004285; Choudhari Prafulla B, 2012, Sci Pharm, V80, P283, DOI 10.3797/scipharm.1112-09; Clarke DL, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2018.6950; DEJONG S, 1993, CHEMOMETR INTELL LAB, V18, P251, DOI 10.1016/0169-7439(93)85002-X; Ellis CR, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0197734; Floresta G, 2019, DATA BRIEF, V22, P471, DOI 10.1016/j.dib.2018.12.047; Floresta G, 2019, BIOORG CHEM, V84, P276, DOI 10.1016/j.bioorg.2018.11.045; Floresta G, 2018, MOLECULES, V23, DOI 10.3390/molecules23092183; Floresta G, 2018, BIOORG CHEM, V81, P334, DOI 10.1016/j.bioorg.2018.08.023; Floresta G, 2018, CHEMMEDCHEM, V13, P1336, DOI 10.1002/cmdc.201800176; Floresta G, 2017, EUR J MED CHEM, V139, P884, DOI 10.1016/j.ejmech.2017.08.053; Fomin D, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000013449; Frank RG, 2017, NEW ENGL J MED, V376, P605, DOI 10.1056/NEJMp1615145; Gracies JM, 2018, MUSCLE NERVE, V57, P245, DOI 10.1002/mus.25721; Gupta SP, 2010, MED CHEM, V6, P87, DOI 10.2174/157340610791321460; JIANG H, 2011, INT J QUANTUM CHEM, V78, P285, DOI DOI 10.1002/(SICI)1097-461X(2000)78:4; Kubinyi H, 1998, J MED CHEM, V41, P2553, DOI 10.1021/jm970732a; Lake S, 2016, J ADDICT DIS, V35, P73, DOI 10.1080/10550887.2015.1127712; Lopez-Lopez E, 2019, EXPERT OPIN DRUG DIS, V14, P335, DOI 10.1080/17460441.2019.1581170; Mounteney J, 2015, INT J DRUG POLICY, V26, P626, DOI 10.1016/j.drugpo.2015.04.003; Olesen P H, 2001, Curr Opin Drug Discov Devel, V4, P471; Rescifina A, 2017, DATA BRIEF, V13, P514, DOI 10.1016/j.dib.2017.06.022; Rescifina A, 2017, EUR J PHARM SCI, V106, P94, DOI 10.1016/j.ejps.2017.05.061; Roy PP, 2008, CHEMOMETR INTELL LAB, V90, P31, DOI 10.1016/j.chemolab.2007.07.004; Rudd RA, 2016, MMWR-MORBID MORTAL W, V65, P1445, DOI 10.15585/mmwr.mm655051e1; Rudd RA, 2016, MMWR-MORBID MORTAL W, V64, P1378, DOI 10.15585/mmwr.mm6450a3; Stewart JJP, 2004, J MOL MODEL, V10, P155, DOI 10.1007/s00894-004-0183-z; Vecchio M, 2017, J STROKE CEREBROVASC, V26, P2536, DOI 10.1016/j.jstrokecerebrovasdis.2017.05.046; Vecchio M, 2012, LANCET, V379, P2116, DOI 10.1016/S0140-6736(12)60315-8; Wang SC, 2019, CELL TRANSPLANT, V28, P233, DOI 10.1177/0963689718811060; Wold S, 2001, CHEMOMETR INTELL LAB, V58, P109, DOI 10.1016/S0169-7439(01)00155-1	35	1	1	1	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND	1422-0067			INT J MOL SCI	Int. J. Mol. Sci.	MAY 1	2019	20	9							2311	10.3390/ijms20092311			10	Biochemistry & Molecular Biology; Chemistry, Multidisciplinary	Biochemistry & Molecular Biology; Chemistry	IA7RK	WOS:000469753500258	31083294	DOAJ Gold, Green Published			2020-06-30	J	Brimdyr, K; Cadwell, K; Widstrom, AM; Svensson, K; Phillips, R				Brimdyr, Kajsa; Cadwell, Karin; Widstrom, Ann-Marie; Svensson, Kristin; Phillips, Rayle			The effect of labor medications on normal newborn behavior in the first hour after birth: A prospective cohort study	EARLY HUMAN DEVELOPMENT			English	Article						Newborn behavior; Skin-to-skin; Labor medications; Epidural; Synthetic oxytocin; Widstrom's 9 stages	SKIN-TO-SKIN; EPIDURAL ANALGESIA; BREAST; ANESTHESIA; OXYTOCIN; FENTANYL; EXPOSURE; CONTACT; MOTHER	Background: Skin-to-skin contact after birth between mother and baby has immediate and long-term advantages. Widstr8m's 9 Stages of Newborn Behavior offer an opportunity to evaluate a baby in the natural, expected and optimal habitat. Intrapartum drugs, including fentanyl administered via epidural and synthetic oxytocin (synOT), have been studied in relation to neonatal outcomes with conflicting results. Aims: Determine the effects of common intrapartum medications on the instinctive behavior of healthy new-borns during the first hour after birth through a prospective cohort study. Study design: Video record newly-born term infants during the first hour after birth while in skin-to-skin contact with mother. Code and analyze videos using Widstrom's 9 Stages; compare with the labor medications mothers received. Subjects: Convenience sample of sixty-three low-income mothers self-selected to labor with or without intrapartum analgesia. Outcome measures: Duration of time infants spend in each of Widstrom's 9 Stages for four cohorts: 1) exposed to no synOT or epidural fentanyl during labor, 2) exposed to fentanyl (but not synOT), 3) exposed synOT (but not fentanyl), 4) exposed to both fentanyl and synOT. Results: A strong inverse correlation was found between intrapartum exposure to fentanyl and synOT and the normal behavior of an infant, as measured by time in each Stage. Conclusions: Intrapartum exposure to the drugs fentanyl and synOT is associated with altered newborn infant behavior, including suckling, while in skin-to-skin contact with mother during the first hour after birth. Widstrom's 9 Stages offer an opportunity to analyze newborn behavior whilst in the optimal habitat of the infant.	[Brimdyr, Kajsa] Hlth Children Project, 327 Quaker Meeting House Rd, East Sandwich, MA 02537 USA; [Cadwell, Karin; Widstrom, Ann-Marie; Svensson, Kristin] Karolinska Inst, Tomtebodavagen 23a, S-17165 Solna, Sweden; [Phillips, Rayle] Loma Linda Univ, Sch Med, 11234 Anderson St, Loma Linda, CA 92354 USA; [Svensson, Kristin] Karolinska Univ Hosp, Eugeniavagen 3, S-17176 Solna, Sweden	Brimdyr, K (reprint author), Hlth Children Project, 327 Quaker Meeting House Rd, East Sandwich, MA 02537 USA.	kajsa@centerforbreastfeeding.org; karin@centerforbreastfeeding.org; Ann-Marie.Widstrom@ki.se; Kristin.Svensson@ki.se; RPhillips@llu.edu		svensson, kristin/0000-0002-7138-6209; Brimdyr, Kajsa/0000-0003-3789-635X			Almgren M, 2018, GENES DIS, V5, P24, DOI 10.1016/j.gendis.2018.01.004; ANAGNOSTAKIS D, 1992, J PEDIATR-US, V121, P291, DOI 10.1016/S0022-3476(05)81207-7; Baumgarder DJ, 2003, J AM BOARD FAM PRACT, V16, P7, DOI 10.3122/jabfm.16.1.7; Beilin Y, 2005, ANESTHESIOLOGY, V103, P1211, DOI 10.1097/00000542-200512010-00016; Bell AF, 2013, EARLY HUM DEV, V89, P137, DOI 10.1016/j.earlhumdev.2012.09.017; Brimdyr K, 2012, MAGICAL HOUR HOLDING; Brimdyr K, 2011, SKIN SKIN 1 HOUR BIR; Brimdyr K, 2018, MATERN CHILD NUTR, V14, DOI 10.1111/mcn.12571; Brimdyr K, 2015, BIRTH-ISS PERINAT C, V42, P319, DOI 10.1111/birt.12186; Brimdyr K, 2012, J PERINAT EDUC, V21, P149, DOI 10.1891/1058-1243.21.3.149; Bystrova K, 2009, BIRTH-ISS PERINAT C, V36, P97, DOI 10.1111/j.1523-536X.2009.00307.x; Cadwell K, 2017, ANN NURS RES PRACT, V2, P1024; Cadwell K, 2018, BREASTFEED MED, V13, P485, DOI 10.1089/bfm.2018.0048; Collado MC, 2012, GUT MICROBES, V3, P352, DOI 10.4161/gmic.21215; Cooper J, 1999, BRIT J ANAESTH, V82, P929; Crenshaw JT, 2012, BREASTFEED MED, V7, P69, DOI 10.1089/bfm.2011.0040; Dani C, 2015, J HUM LACT, V31, P452, DOI 10.1177/0890334414566238; Dozier AM, 2013, MATERN CHILD HLTH J, V17, P689, DOI 10.1007/s10995-012-1045-4; EMDE RN, 1975, ARCH GEN PSYCHIAT, V32, P780; HAGNEVIK K, 1984, ACTA PAEDIATR SCAND, V73, P602, DOI 10.1111/j.1651-2227.1984.tb09982.x; Halpern SH, 2005, ANESTHESIOLOGY, V103, P1111, DOI 10.1097/00000542-200512000-00002; Jonas W, 2009, BREASTFEED MED, V4, P71, DOI 10.1089/bfm.2008.0002; Kennell JH, 2008, NOVART FDN SYMP, P87, DOI [10.1002/9780470720158.ch6, DOI 10.1002/9780470720158.CH6]; Lieberman E, 2000, PEDIATRICS, V105, P8, DOI 10.1542/peds.105.1.8; Lind JN, 2014, J HUM LACT, V30, P167, DOI 10.1177/0890334413520189; Gabriel MAM, 2015, BREASTFEED MED, V10, P209, DOI 10.1089/bfm.2014.0156; Marwah R, 2012, CAN J ANESTH, V59, P246, DOI 10.1007/s12630-011-9625-0; Moises ECD, 2005, EUR J CLIN PHARMACOL, V61, P517, DOI 10.1007/s00228-005-0967-9; Moore ER, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003519.pub4; NISSEN E, 1995, ACTA PAEDIATR, V84, P140, DOI 10.1111/j.1651-2227.1995.tb13596.x; Noseworthy MD, 1998, FREE RADICAL BIO MED, V24, P942, DOI 10.1016/S0891-5849(97)00383-3; Nystedt A, 2004, J CLIN NURS, V13, P455, DOI 10.1046/j.1365-2702.2003.00849.x; Phaneuf S, 2000, J REPROD FERTIL, V120, P91, DOI 10.1530/reprod/120.1.91; Prince AL, 2014, SEMIN REPROD MED, V32, P14, DOI 10.1055/s-0033-1361818; Radzyminski S, 2005, JOGNN-J OBST GYN NEO, V34, P335, DOI 10.1177/0884217505276283; Ransjo-Arvidson AB, 2001, BIRTH-ISS PERINAT C, V28, P5, DOI 10.1046/j.1523-536x.2001.00005.x; Robinson C, 2003, AM J OBSTET GYNECOL, V188, P497, DOI 10.1067/mob.2003.22; SEPKOSKI CM, 1992, DEV MED CHILD NEUROL, V34, P1072; Spann MN, 2015, MAGN RESON IMAGING, V33, P213, DOI 10.1016/j.mri.2014.08.033; UNICEF, 2016, 1 HOUR LIF MAK CAS 1; Widstrom A. M., 2010, BABYS CHOICE; Widstrom AM, 2011, ACTA PAEDIATR, V100, P79, DOI 10.1111/j.1651-2227.2010.01983.x; WIDSTROM AM, 1988, EARLY HUM DEV, V16, P293, DOI 10.1016/0378-3782(88)90110-7; Wiklund I, 2009, MIDWIFERY, V25, pE31, DOI 10.1016/j.midw.2007.07.005; Winberg J, 2005, DEV PSYCHOBIOL, V47, P217, DOI 10.1002/dev.20094	45	0	0	0	0	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0378-3782	1872-6232		EARLY HUM DEV	Early Hum. Dev.	MAY	2019	132						30	36		10.1016/j.earlhumdev.2019.03.019			7	Obstetrics & Gynecology; Pediatrics	Obstetrics & Gynecology; Pediatrics	HZ3AR	WOS:000468720400006	30953879	Other Gold			2020-06-30	J	Ekstein, M; Bar-Yosef, Y; Ben-Chaim, J; Flaishon, R; Weinbroum, AA				Ekstein, Margaret; Bar-Yosef, Yuval; Ben-Chaim, Jacob; Flaishon, Ron; Weinbroum, Avi A.			Ultrasonographic Assessment of Bladder Volumes in Children Undergoing Penile Surgery: Does the Type of Anesthesia Matter?	AMERICAN JOURNAL OF THERAPEUTICS			English	Article						penile surgery; pediatric; opioids; local; ultrasound; bladder	POSTOPERATIVE URINARY RETENTION; BLOCK	Background: There are scant data reporting postoperative ultrasonographically measured bladder volumes in children undergoing penile surgery. Study Question: We studied the effect of various anesthesia techniques on return of micturition after penile surgery in children, using ultrasonographically measured bladder volumes. Data Sources: Ultrasonographically measured postvoiding residual bladder volumes indexed to ageappropriate capacity, and time elapsed between the end of surgery and spontaneous voiding after pediatric circumcision, distal hypospadias repair, or repair of urethrocutaneous fistula, were studied. Study Design: Children between 4 months and 12 years were randomized to caudal block, intravenous (IV) fentanyl or penile block, in association with inhaled general anesthesia. Bladder volumes were measured before surgery and immediately after voiding for the first time. Time to first postsurgery void was also recorded. Results: Thirty-one children completed all assessments; 12 underwent caudal block, 9 IV fentanyl anesthesia, and 7 were given penile block. The mean first postvoid bladder residual volumes were highest in the caudal and lowest in the penile block children (27.5 vs. 17.3 mL, P = 0.003). The time elapsing between the end of surgery and first voiding was the longest in the fentanyl group compared with caudal and penile blocks (232, 178, 150 minutes, respectively, P = 0.02). Conclusions: None of the anesthetic techniques provoked postoperative urinary retention after minor penile surgery in children. The penile block appears superior to caudal block or to IV fentanyl-based anesthesia with regard to postoperative recovery of normal micturition.	[Ekstein, Margaret; Flaishon, Ron; Weinbroum, Avi A.] Tel Aviv Univ, Tel Aviv Sourasky Med Ctr, Sackler Fac Med, Dept Anesthesiol & Crit Care Med, Tel Aviv, Israel; [Bar-Yosef, Yuval; Ben-Chaim, Jacob] Tel Aviv Univ, Tel Aviv Sourasky Med Ctr, Sackler Fac Med, Dept Urol,Pediat Urol Unit, Tel Aviv, Israel	Bar-Yosef, Y (reprint author), Tel Aviv Sourasky Med Ctr, Dana Dwek Childrens Hosp, Pediat Urol, 6 Weizman St, IL-6423906 Tel Aviv, Israel.	yuvalby@tlvmc.gov.il		Bar-Yosef, Yuval/0000-0003-3769-6606			Baldini G, 2009, ANESTHESIOLOGY, V110, P1139, DOI 10.1097/ALN.0b013e31819f7aea; Choi S, 2012, CAN J ANESTH, V59, P681, DOI 10.1007/s12630-012-9717-5; Dadure C, 2006, ANESTH ANALG, V102, P744, DOI 10.1213/01.ane.0000195439.54650.dc; FISHER QA, 1993, ANESTH ANALG, V76, P173; Flaishon R, 2005, ANESTH ANALG, V101, P1656, DOI 10.1213/01.ANE.0000184205.43759.55; Gatti JM, 2001, J UROLOGY, V165, P918, DOI 10.1016/S0022-5347(05)66574-3; Koomen E, 2002, PAEDIATR ANAESTH, V12, P738, DOI 10.1046/j.1460-9592.2002.00946.x; Metzelder ML, 2010, WORLD J UROL, V28, P87, DOI 10.1007/s00345-009-0420-2; Pappas ALS, 1997, ANESTH ANALG, V85, P706, DOI 10.1097/00000539-199709000-00044; Pawar D, 2012, INDIAN J ANAESTH, V56, P496, DOI 10.4103/0019-5049.103970; Rosseland LA, 2005, ACTA ANAESTH SCAND, V49, P1456, DOI 10.1111/j.1399-6576.2005.00817.x	11	0	0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1075-2765	1536-3686		AM J THER	Am. J. Ther.	MAY-JUN	2019	26	3					E314	E320		10.1097/MJT.0000000000000632			7	Pharmacology & Pharmacy	Pharmacology & Pharmacy	HX9SI	WOS:000467748200003	28767453				2020-06-30	J	Smith, AA; Halliday, LC; Lindeblad, MO; Fortman, JD				Smith, Alexandra A.; Halliday, Lisa C.; Lindeblad, Matthew O.; Fortman, Jeffrey D.			Evaluation of Analgesic Patches in Cynomolgus Macaques (Macaca fascicularis)	JOURNAL OF THE AMERICAN ASSOCIATION FOR LABORATORY ANIMAL SCIENCE			English	Article							TRANSDERMAL FENTANYL PATCHES; POSTOPERATIVE PAIN; SUSTAINED-RELEASE; CLINICAL-PRACTICE; SEX-DIFFERENCES; 2 FORMULATIONS; DOUBLE-BLIND; BUPRENORPHINE; PHARMACOKINETICS; EFFICACY	Opioids are widely used in veterinary and human medicine to manage pain. However, there is a paucity of information in the literature regarding the pharmacokinetics of opioid transdermal patches (TDP) in NHP. Therefore, to determine whether opioid TDP attain therapeutic concentrations in NHP, the pharmacokinetics of fentanyl (25 mu g/h) and buprenorphine (10 and 20 mu g/h) TDP were evaluated in naive, adult, male cynomolgus macaques (n = 4) in a crossover study. Plasma opioid levels were determined by tandem liquid chromatography-mass spectrometry. The AUC(0-mf) for fentanyl and the low and high dose buprenorphine patches were 115 +/- 14, 462 +/- 74, and 778 +/- 344 ngxh/mL, and the plasma half-lifes were 22 +/- 4, 77 +/- 27, and 42 +/- 11 h, respectively. No adverse effects were noted throughout the study. Minimal therapeutic concentrations for fentanyl (0.2 ng/mL) and buprenorphine (0.1 ng/mL) were achieved in all macaques within 8 h of fentanyl and 24 h of buprenorphine TDP application. Therapeutic levels for the fentanyl and low- and high-dose buprenorphine patches were maintained for 96, 120, and 144 h, respectively. These findings suggest that 25-mu g/h fentanyl patches should be replaced every 4 d, and the low-and high-dose buprenorphine patches should be replaced every 5 and 6 d, respectively. The results of this study show that fentanyl and buprenorphine patches achieve minimal therapeutic levels for clinically relevant periods of time and should be considered viable options for pain management in cynomolgus macaques.	[Smith, Alexandra A.; Halliday, Lisa C.; Fortman, Jeffrey D.] Univ Illinois, Biol Resources Lab, Chicago, IL 60607 USA; [Lindeblad, Matthew O.] Univ Illinois, Toxicol Res Lab, Chicago, IL 60607 USA	Smith, AA (reprint author), Univ Illinois, Biol Resources Lab, Chicago, IL 60607 USA.	lasmith84@gmail.com					Allison SO, 2007, J AM ASSOC LAB ANIM, V46, P24; Bajaj S, 2011, BJA EDUC, V11, P39, DOI 10.1093/bjaceaccp/mkq054; Bartok RE, 1997, J PHARMACOL EXP THER, V282, P769; Bellei E, 2011, J VET PHARMACOL THER, V34, P437, DOI 10.1111/j.1365-2885.2010.01263.x; Biddinger B., 2008, USE FENTANYL PATCH C; Carlson AM, 2016, J AM ASSOC LAB ANIM, V55, P436; Chau DL, 2008, CLIN INTERV AGING, V3, P273, DOI 10.2147/CIA.S1847; Ciccone GK, 1999, BRIT J ANAESTH, V82, P255, DOI 10.1093/bja/82.2.255; Criado A, 2010, LAB ANIM, V44, P380; Deschamps JY, 2012, VET ANAESTH ANALG, V39, P653, DOI 10.1111/j.1467-2995.2012.00749.x; Dinis-Oliveira RJ, 2017, FOREN SCI RES, V2, P2, DOI 10.1080/20961790.2017.1285219; Egger CM, 2007, VET ANAESTH ANALG, V34, P200, DOI 10.1111/j.1467-2995.2006.00310.x; Egger CM, 1998, VET SURG, V27, P159, DOI 10.1111/j.1532-950X.1998.tb00114.x; [EMCDDA European Monitoring Centre for Drugs and Drug Addiction], 2015, FENT DRUG PROF; Escher M, 2007, CLIN THER, V29, P1620, DOI 10.1016/j.clinthera.2007.08.007; Evans HC, 2003, DRUGS, V63, P1999, DOI 10.2165/00003495-200363190-00003; Fish R, 2011, ANESTHESIA ANALGESIA; Flecknell P., 2015, ANALGESIA POSTOPERAT, P142, DOI [10.1016/B978-0-12-800036-6.00004-1, DOI 10.1016/B978-0-12-800036-6.00004-1]; Garimella V, 2013, CLIN COLON RECT SURG, V26, P191, DOI 10.1055/s-0033-1351138; Gilberto DB, 2003, CONTEMP TOP LAB ANIM, V42, P21; Grape S, 2010, DRUGS, V70, P57, DOI 10.2165/11531740-000000000-00000; Griessinger N, 2005, CURR MED RES OPIN, V21, P1147, DOI 10.1185/030079905X53315; Hofmeister EH, 2004, J AM ANIM HOSP ASSOC, V40, P468, DOI 10.5326/0400468; Institute for Laboratory Animal Research, 2010, GUIDE CARE USE LAB A; James IGV, 2010, J PAIN SYMPTOM MANAG, V40, P266, DOI 10.1016/j.jpainsymman.2010.01.013; Janseen Pharmaceuticals, 2019, WHAT IS DUR; Johnson RE, 2005, J PAIN SYMPTOM MANAG, V29, P297, DOI 10.1016/j.jpainsymman.2004.07.005; Kapil RP, 2013, J PAIN SYMPTOM MANAG, V46, P65, DOI 10.1016/j.jpainsymman.2012.06.014; Ko JC, 2011, JAVMA-J AM VET MED A, V238, P318, DOI 10.2460/javma.238.3.318; Lankau EW, 2014, J AM ASSOC LAB ANIM, V53, P278; Margetts L, 2007, BJA EDUC, V7, P171, DOI 10.1093/bjaceaccp/mkm033; MATHER LE, 1983, CLIN PHARMACOKINET, V8, P422, DOI 10.2165/00003088-198308050-00004; MedScape, 2018, DUR FENT TRANSD RX; Moll X, 2011, VET J, V187, P124, DOI 10.1016/j.tvjl.2009.11.011; National Institutes of Health, 2002, PHS POL HUM CAR US L; Natl Res Council, 2009, RECOGNITION AND ALLEVIATION OF PAIN IN LABORATORY ANIMALS, P47; Nunamaker EA, 2014, J AM ASSOC LAB ANIM, V53, P494; Nunamaker EA, 2013, J AM ASSOC LAB ANIM, V52, P48; Pasternak GW, 2014, J CLIN ONCOL, V32, P1655, DOI 10.1200/JCO.2013.53.1079; Peng PWH, 1999, ANESTHESIOLOGY, V90, P576, DOI 10.1097/00000542-199902000-00034; Pergolizzi J, 2010, PAIN PRACT, V10, P428, DOI 10.1111/j.1533-2500.2010.00378.x; Pieper K, 2011, VET J, V187, P335, DOI 10.1016/j.tvjl.2010.01.013; Plumb DC, 2011, PLUMBS VET DRUG HDB; Purdue Pharma, 2018, BUTR BUPR TRANSD SYS; Robinson TM, 1999, J AM ANIM HOSP ASSOC, V35, P95, DOI 10.5326/15473317-35-2-95; Roughan JV, 2002, LAB ANIM-UK, V36, P322, DOI 10.1258/002367702320162423; Russell WMS, 1959, PRINCIPLES HUMANE EX; Salyards GW, 2017, J AM ASSOC LAB ANIM, V56, P443; Serpell M, 2016, PATIENT, V9, P35, DOI 10.1007/s40271-015-0151-y; Sittl R, 2003, CLIN THER, V25, P150, DOI 10.1016/S0149-2918(03)90019-1; Smith HS, 2009, MAYO CLIN PROC, V84, P613, DOI 10.1016/S0025-6196(11)60750-7; Thiede AJ, 2014, J AM ASSOC LAB ANIM, V53, P692; Uberall MA, 2012, CURR MED RES OPIN, V28, P1585, DOI 10.1185/03007995.2012.731387	53	0	0	0	4	AMER ASSOC LABORATORY ANIMAL SCIENCE	MEMPHIS	9190 CRESTWYN HILLS DR, MEMPHIS, TN 38125 USA	1559-6109			J AM ASSOC LAB ANIM	J. Amer. Assoc. Lab. Anim. Sci.	MAY	2019	58	3					356	361		10.30802/AALAS-JAALAS-18-000101			6	Veterinary Sciences; Zoology	Veterinary Sciences; Zoology	HY0AP	WOS:000467771700011	31010456	Green Published			2020-06-30	J	Soares, JHN; Henao-Guerrero, N; Pavlisko, ND; Williamson, A; Giannella-Neto, A				Soares, Joao H. N.; Henao-Guerrero, Natalia; Pavlisko, Noah D.; Williamson, Allan; Giannella-Neto, Antonio			The effect of two doses of fentanyl on chest wall rigidity at equipotent doses of isoflurane in dogs	VETERINARY ANAESTHESIA AND ANALGESIA			English	Article						chest wall rigidity; dogs; fentanyl; isoflurane		Objective To evaluate the effect of two doses of fentanyl upon chest wall rigidity of dogs anesthetized at equipotent doses of isoflurane [1.3 minimum alveolar concentration (MACISO) of each dose of fentanyl]. Study design Prospective crossover randomized study. Animals A group of eight male Beagle dogs, approximately 1 year old and weighing 12.1 +/- 1.6 kg (mean +/- standard deviation). Methods The dogs were anesthetized with isoflurane and instrumented for the measurement of esophageal pressure (PESO), flow ((V)over dot and volume (V). Chest wall elastance (E-CW) was estimated by multiple linear regression of the model. PESO(t) = (V)over dot(t) x RCW + V(t) x E-CW + EEPESO where t is time, RCW is chest wall resistance and EEPESO is endexpiratory PESO. Chest wall compliance (CCW) was calculated as 1/E-CW and normalized to the body weight of each dog (mL cmH(2)O(-1) kg(-1)). Anesthesia was maintained at 1.3 MACISO for at least 15 minutes and CCW recorded (CCW-ISO). The dogs were randomly assigned to the lower fentanyl dose [loading dose (33 mu g kg(-1)) and infusion (0.2 mu g kg(-1) minute(-1))] or the higher fentanyl dose [loading dose (102 mu g kg(-1)) and infusion (0.8 mu g kg(-1) minute(-1))]. After 60 minutes of fentanyl infusion, CCW was recorded for each dose (CCW-FENT). During fentanyl infusion, the dogs were maintained at equipotent doses of isoflurane (1.3 MAC(ISO) for each fentanyl dose). A two-way analysis of variance followed by a Bonferroni test was used to compare CCW-ISO and CCW-FENT in both treatments and CCW-FENT between treatments. A p value <0.05 was considered significant. Results Neither of the fentanyl doses decreased CCW and there was no difference in CCW-FENT between doses. Conclusions and clinical relevance Fentanyl at the studied doses did not result in chest wall rigidity in dogs anesthetized with equipotent doses of isoflurane (1.3 MAC(ISO)).	[Soares, Joao H. N.; Henao-Guerrero, Natalia; Pavlisko, Noah D.; Williamson, Allan] Virginia Tech, Virginia Maryland Coll Vet Med, Dept Small Anim Clin Sci, Blacksburg, VA USA; [Giannella-Neto, Antonio] Univ Fed Rio de Janeiro, COPPE, Lab Pulm Engn, Biomed Engn Program, Rio De Janeiro, RJ, Brazil	Soares, JHN (reprint author), Univ Calif Davis, Sch Vet Med, Dept Surg & Radiol Sci, One Shields Ave, Davis, CA 95616 USA.	jhsoares@ucdavis.edu	Soares, Joao/AAD-7928-2019		Veterinary Memorial Fund of the Virginia-Maryland College of Veterinary Medicine, Virginia Tech, Blacksburg, VA, USA [033-4-44167]	The authors thank Betsy Midkiff for valuable technical assistance and Dr John H Rossmeisl Jr. This research was supported by the Veterinary Memorial Fund (no. 033-4-44167) of the Virginia-Maryland College of Veterinary Medicine, Virginia Tech, Blacksburg, VA, USA.	Beda A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103057; Bednarski RM, 2015, VET ANAESTH ANALG, P817, DOI 10.1002/9781119421375; COMSTOCK MK, 1981, ANESTH ANALG, V60, P362; Coruh B, 2013, CHEST, V143, P1145, DOI 10.1378/chest.12-2131; LUI PW, 1990, NEUROSCI LETT, V108, P183, DOI 10.1016/0304-3940(90)90728-R; Ruiz P, 2003, CAN J ANAESTH, V50, P67, DOI 10.1007/BF03020190; SCAMMAN FL, 1983, ANESTH ANALG, V62, P332; Soares JHN, 2014, RESP PHYSIOL NEUROBI, V202, P50, DOI 10.1016/j.resp.2014.07.017; Williamson AJ, 2018, VET ANAESTH ANALG, V45, P423, DOI 10.1016/j.vaa.2018.03.001; Williamson AJ, 2017, VET ANAESTH ANALG, V44, P738, DOI 10.1016/j.vaa.2017.02.002	10	0	0	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1467-2987	1467-2995		VET ANAESTH ANALG	Vet. Anaesth. Analg.	MAY	2019	46	3					360	364		10.1016/j.vaa.2019.01.001			5	Veterinary Sciences	Veterinary Sciences	HW9XL	WOS:000467043900012	30772260				2020-06-30	J	Tayari, H; Otero, P; Rossetti, A; Breghi, G; Briganti, A				Tayari, Hamaseh; Otero, Pablo; Rossetti, Alberto; Breghi, Gloria; Briganti, Angela			Proximal RUMM block in dogs: preliminary results of cadaveric and clinical studies	VETERINARY ANAESTHESIA AND ANALGESIA			English	Article						Axillary sheath; Dog; Loco-regional anaesthesia; Proximal RUMM block; Ultrasound	AXILLARY BRACHIAL-PLEXUS; MID-HUMERAL BLOCK; REGIONAL ANESTHESIA; NERVE BLOCKS; ULNAR; ANALGESIA; ANATOMY; SURGERY; LIMB	Objective To design and assess the perioperative analgesic efficacy of an ultrasound (US)-guided radial (R), ulnar (U), median (M) and musculocutaneous (Mc) nerve blocks, performed together in the axillary space by a single, in-plane approach. Study design Anatomical research and prospective clinical study. Animals A group of three dog cadavers and 15 client-owned dogs undergoing orthopaedic thoracic limb surgery. Methods Phase 1: Anatomical dissection and US study of the axillary space were performed to design the US-guided proximal RUMM block. The technique was considered successful if a total volume of 0.15 mL kg(-1) new methylene blue solution completely stained the four nerves in two cadavers for >= 2 cm. Phase 2: In 15 client-owned dogs undergoing orthopaedic thoracic limb surgery, the RUMM block designed in phase 1 was performed to provide analgesia using a total volume of 0.15 mL kg(-1) of ropivacaine 0.5%. The block was considered effective if the intraoperative fentanyl requirement was <1.2 mcg kg(-1) hour(-1) and until the postoperative pain score was [short-form Glasgow Composite Measure Pain Scale (SF-GCMPS)] <= 5/20. Results Phas(-1): Detection of the four nerves was always feasible in a single US-window. The axillary artery and Mc nerve were used as landmarks. In-plane needling approach was feasible in both cadavers. All the nerves were completely stained for >2 cm. No intrathoracic dye spread was found. Phase 2: In 14/15 anaesthetized dogs, mean intraoperative fentanyl requirement was 0.25 +/- 0.05 mcg kg(-1) hour(-1). Postoperatively, all dogs had SF-GCMPS <= 5/20 up to 8 hours. Conclusions and clinical relevance The US-guided proximal RUMM block performed at the axillary level with a single, in-plane needling approach using 0.15 mL kg(-1) of ropivacaine 0.5% minimized fentanyl requirement during thoracic limb surgery, contributing to postoperative analgesia up to 8 hours after execution of the peripheral nerve block.	[Tayari, Hamaseh; Rossetti, Alberto; Breghi, Gloria; Briganti, Angela] Univ Pisa, Dept Vet Sci, Pisa, Italy; [Otero, Pablo] Univ Buenos Aires, Fac Ciencias Vet, Catedra Anestesiol & Algiol, Buenos Aires, DF, Argentina	Briganti, A (reprint author), Univ Pisa, Dept Vet Sci, Pisa, Italy.	anglela.briganti@unipi.it	briganti, angela/O-7014-2017	briganti, angela/0000-0001-6949-4414; Tayari, Hamaseh/0000-0003-3736-0950			Adami C, 2015, VET ANAESTH ANALG, V42, P230, DOI 10.1111/vaa.12236; Akasaka M, 2017, VET ANAESTH ANALG, V44, P625, DOI 10.1016/j.vaa.2016.08.001; Alemanno F, 2014, ANESTHESIA UPPER LIM, P185; Ay S, 2007, CLIN ANAT, V20, P57, DOI 10.1002/ca.20270; Barrington MJ, 2012, REGION ANESTH PAIN M, V37, P334, DOI 10.1097/AAP.0b013e3182475fba; Bhalla RJ, 2015, VET ANAESTH ANALG, V42, P658, DOI 10.1111/vaa.12288; Bortolami E, 2012, VET ANAESTH ANALG, V39, P446, DOI 10.1111/j.1467-2995.2012.00724.x; Campora C, 2011, J SMALL ANIM PRACT, V52, P301, DOI 10.1111/j.1748-5827.2011.01070.x; Campoy L, 2010, VET ANAESTH ANALG, V37, P144, DOI 10.1111/j.1467-2995.2009.00518.x; DEJONG RH, 1961, ANESTHESIOLOGY, V22, P215; Evans HE, 2012, MILLERS ANATOMY DOG, P253; Guilherme S, 2008, VET RADIOL ULTRASOUN, V49, P577, DOI 10.1111/j.1740-8261.2008.00424.x; Lemke KA, 2008, VET CLIN N AM-SMALL, V38, P1231, DOI 10.1016/j.cvsm.2008.06.003; Marhofer P, 2017, ANAESTHESIA, V71, P461; Mosing M, 2010, VET ANAESTH ANALG, V37, P154, DOI 10.1111/j.1467-2995.2009.00509.x; Navarrete-Calvo R, 2016, RES VET SCI, V105, P36, DOI 10.1016/j.rvsc.2016.01.007; Nowakowski P, 2015, ANAESTH INTENSIVE TH, V47, P409, DOI 10.5603/AIT.2015.0052; Portela DA, 2013, VET ANAESTH ANALG, V40, P552, DOI 10.1111/vaa.12046; Prieto PFC, 2007, CIR GEN, V29, P32; Reid J, 2007, ANIM WELFARE, V16, P97; Romano M, 2016, VET ANAESTH ANALG, V43, P44, DOI 10.1111/vaa.12275; Schafhalter-Zoppoth I, 2005, REGION ANESTH PAIN M, V30, P385, DOI 10.1016/j.rapm.2004.12.008; Sehmbi Herman, 2015, J Anaesthesiol Clin Pharmacol, V31, P296, DOI 10.4103/0970-9185.161654; Spence BC, 2005, REGION ANESTH PAIN M, V30, P198, DOI 10.1016/j.rapm.2004.09.009; Steffey EP, 2015, LUMB JONES VET ANEST, P311; THOMPSON GE, 1983, ANESTHESIOLOGY, V59, P117, DOI 10.1097/00000542-198308000-00009; Tran DQH, 2012, REGION ANESTH PAIN M, V37, P248, DOI 10.1097/AAP.0b013e31824611bf; Trumpatori BJ, 2010, VET SURG, V39, P785, DOI 10.1111/j.1532-950X.2010.00712.x; Vettorato E, 2013, J SMALL ANIM PRACT, V54, P630, DOI 10.1111/jsap.12146; Viscasillas J, 2013, VET ANAESTH ANALG, V40, P104, DOI 10.1111/j.1467-2995.2012.00770.x; Wenger S, 2005, VET REC, V156, P639, DOI 10.1136/vr.156.20.639; Yamamoto K, 1999, REGION ANESTH PAIN M, V24, P36; 2010, ANESTH ANALG, V110, P1222, DOI DOI 10.1213/ANE.0B013E3181CB6791; 2015, VET ANAESTH ANALG, V42, P659, DOI DOI 10.1111/VAA.12292	34	2	2	1	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1467-2987	1467-2995		VET ANAESTH ANALG	Vet. Anaesth. Analg.	MAY	2019	46	3					384	394		10.1016/j.vaa.2018.11.009			11	Veterinary Sciences	Veterinary Sciences	HW9XL	WOS:000467043900016	30962041				2020-06-30	J	Suga, Y; Uchida, M; Suzuki, S; Sugawara, H; Torigoe, K; Futamura, A; Uesawa, Y; Nakagawa, T; Takase, H				Suga, Yukio; Uchida, Mayako; Suzuki, Shinya; Sugawara, Hideki; Torigoe, Kazuhiro; Futamura, Akihiko; Uesawa, Yoshihiro; Nakagawa, Takayuki; Takase, Hisamitsu			Current Status of Adverse Events Related with Opioid Analgesics in Japan: Assessment Based on Japanese Adverse Drug Event Report Database	BIOLOGICAL & PHARMACEUTICAL BULLETIN			English	Article						opioid analgesic; Japanese Adverse Drug Event Report; adverse event; proper use; opioid-related death	ORAL MORPHINE; RISK-FACTORS; RESPIRATORY DEPRESSION; TRANSDERMAL FENTANYL; CANCER PAIN; OVERDOSE; DEATHS; MULTICENTER; MANAGEMENT; MORTALITY	Opioid analgesics have greatly contributed to the advancement of pain management. However, although opioids have been appropriately used in Japan, they rarely induce serious adverse events, such as respiratory depression. The present study aimed to investigate the temporal changes in the occurrence of opioid-related adverse events and deaths between 2004 and 2017 in Japan using the Japanese Adverse Drug Event Report (JADER) database. We analyzed the following points using data extracted from JADER website: 1) temporal changes in the number and proportion of opioid-related adverse event reports; 2) temporal changes in the number of morphine-, oxycodone-, and fentanyl-related adverse event reports per annual consumption; and 3) cases in which the reported outcome following opioid-related adverse events was death. Our results showed no dramatic changes in the overall incidence of opioid-related adverse events, despite the temporal changes in the annual consumption and shared component of each opioid during the survey period. However, the number and rate of fentanyl-related adverse events and their outcome "death" increased since 2010, being the highest among all adverse event including those related to morphine and oxycodone. Outcome "death" by fentanyl-related adverse events was caused mainly due to respiratory depression. These findings suggest that, although opioid-related adverse events can be controlled through proper monitoring and management by medical personnel in Japan, extra caution should be continuously paid for the rare but serious fentanyl-induced adverse events.	[Suga, Yukio] Kanazawa Univ, Inst Med Pharmaceut & Hlth Sci, Fac Pharm, Dept Clin Drug Informat, 13-1 Takaramachi, Kanazawa, Ishikawa 9208641, Japan; [Suga, Yukio; Uchida, Mayako; Suzuki, Shinya; Sugawara, Hideki; Torigoe, Kazuhiro; Futamura, Akihiko; Uesawa, Yoshihiro; Nakagawa, Takayuki; Takase, Hisamitsu] Japanese Soc Pharmaceut Palliat Care & Sci, Res Promot Comm, Osaka 5500001, Japan; [Uchida, Mayako] Osaka Univ Pharmaceut Sci, Educ & Res Ctr Clin Pharm, 4-20-1 Nasahara, Takatsuki, Osaka 5691094, Japan; [Suzuki, Shinya] Natl Canc Ctr Hosp East, Dept Pharm, 6-5-1 Kashiwanoha, Kashiwa, Chiba 2778577, Japan; [Sugawara, Hideki] Kagoshima Univ Hosp, Dept Clin Pharm & Pharmacol, 8-35-1 Sakuragaoka, Kagoshima 8908520, Japan; [Torigoe, Kazuhiro] Hoshi Univ, Div Appl Pharmaceut Educ & Res, Shinagawa Ku, 2-4-41 Ebara, Tokyo 1428501, Japan; [Futamura, Akihiko] Fujita Hlth Univ, Dept Pharm, Nanakuri Mem Hosp, 424-1 Tsu, Tsu, Mie 5141295, Japan; [Uesawa, Yoshihiro] Meiji Pharmaceut Univ, Dept Med Mol Informat, 2-522-1 Noshio, Tokyo 2048588, Japan; [Nakagawa, Takayuki] Kyoto Univ Hosp, Dept Clin Pharmacol & Therapeut, Sakyo Ku, 54 Shogoin Kawahara Cho, Kyoto 6068507, Japan; [Takase, Hisamitsu] Tama Nagayama Hosp, Nippon Med Sch, Tama Ku, Tokyo 2068512, Japan	Suga, Y (reprint author), Kanazawa Univ, Inst Med Pharmaceut & Hlth Sci, Fac Pharm, Dept Clin Drug Informat, 13-1 Takaramachi, Kanazawa, Ishikawa 9208641, Japan.; Suga, Y (reprint author), Japanese Soc Pharmaceut Palliat Care & Sci, Res Promot Comm, Osaka 5500001, Japan.	suga@staff.kanazawa-u.ac.jp	, uesawa/AAA-1691-2020; Suzuki, Shinya/A-1043-2011; Song, Eun Joo/Z-5130-2019	Suzuki, Shinya/0000-0002-2134-887X; 			Barletta JF, 2012, PHARMACOTHERAPY, V32, p12S, DOI 10.1002/j.1875-9114.2012.01178.x; Bohnert ASB, 2011, JAMA-J AM MED ASSOC, V305, P1315, DOI 10.1001/jama.2011.370; Cherny N, 2001, J CLIN ONCOL, V19, P2542, DOI 10.1200/JCO.2001.19.9.2542; Dahan A, 2005, BRIT J ANAESTH, V94, P825, DOI 10.1093/bja/aei145; Dart RC, 2015, NEW ENGL J MED, V372, P241, DOI [10.1056/NEJMc1501822, 10.1056/NEJMsa1406143]; De Conno F, 2008, PALLIATIVE MED, V22, P214, DOI 10.1177/0269216308088692; Dhalla IA, 2009, CAN MED ASSOC J, V181, P891, DOI 10.1503/cmaj.090784; Donner B, 1996, PAIN, V64, P527, DOI 10.1016/0304-3959(95)00180-8; Duthey B, 2014, J PAIN SYMPTOM MANAG, V47, P283, DOI 10.1016/j.jpainsymman.2013.03.015; Fallon M, 2018, ANN ONCOL, V29, P166, DOI 10.1093/annonc/mdy152; Fischer B, 2009, CAN MED ASSOC J, V181, P881, DOI 10.1503/cmaj.091791; Foundation for Promotion of Cancer research, CANC STAT JAP 2017; Fox LM, 2018, ADDICTION, V113, P59, DOI 10.1111/add.13925; Gomes T, 2018, JAMA NETW OPEN, V1, DOI 10.1001/jamanetworkopen.2018.0217; Herzig SJ, 2014, J HOSP MED, V9, P73, DOI 10.1002/jhm.2102; Hirooka T, 2012, DATABASE SAS USER GR, P263; Jumbelic MI, 2010, AM J FOREN MED PATH, V31, P18, DOI 10.1097/PAF.0b013e31818738b8; Kuehn BM, 2010, JAMA-J AM MED ASSOC, V303, P495, DOI 10.1001/jama.2010.71; Madadi P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060600; Mystakidou K, 2003, INT J CANCER, V107, P486, DOI 10.1002/ijc.11416; Nadpara PA, 2018, PAIN MED, V19, P79, DOI 10.1093/pm/pnx038; NAGAI J, 2015, PALLIAT CARE RES, V10, P161; Okie S, 2010, NEW ENGL J MED, V363, P1981, DOI 10.1056/NEJMp1011512; Zedler B, 2014, PAIN MED, V15, P1911, DOI 10.1111/pme.12480	24	1	1	0	1	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0918-6158			BIOL PHARM BULL	Biol. Pharm. Bull.	MAY	2019	42	5					801	806		10.1248/bpb.b18-00997			6	Pharmacology & Pharmacy	Pharmacology & Pharmacy	HW1NW	WOS:000466450600020	31061323	Bronze			2020-06-30	J	Lipinski, PFJ; Jaronczyk, M; Dobrowolski, JC; Sadlej, J				Lipinski, Piotr F. J.; Jaronczyk, Malgorzata; Dobrowolski, Jan Cz.; Sadlej, Joanna			Molecular dynamics of fentanyl bound to -opioid receptor	JOURNAL OF MOLECULAR MODELING			English	Article						mu-opioid receptor; Molecular dynamics; Fentanyl; Morphine; "Fentanyl death"	ALLOSTERIC MODULATION; SOFTWARE NEWS; DOCKING; SWITCHES; EFFICACY; ACTIVATION; RESIDUES; INSIGHTS	The molecular dynamics simulations of fentanyl complexed with the -opioid receptor (OR) were studied using both inactive 4DKL and active 5C1M opioid receptor crystal structures. Analogous simulations in morphine with or without a ligand were done for comparison. Simulations of the inactive states were carried out in the absence and presence of the Na+ ion. The obtained fentanyl's binding mode agrees with some of the mutagenesis data, and it overlaps with that of morphine only to a minor extent. Notably, fentanyl stabilizes different rotameric states of Trp293(6.48) than observed for morphine or unliganded receptor. Another difference is tighter arrangement of the interaction between Asp147(3.32) and Tyr326(7.43) (a link between helices TM3 and TM7) in the presence of fentanyl. Principal component analysis reveals differences in the trajectories dependent on the ligand bound. The differences found could be linked to ligand-dependent efficacy with respect to receptor intracellular signaling events.	[Lipinski, Piotr F. J.] Polish Acad Sci, Mossakowski Med Res Ctr, 5 Pawinskiego St, PL-02106 Warsaw, Poland; [Jaronczyk, Malgorzata; Dobrowolski, Jan Cz.] Natl Med Inst, 30-34 Chelmska Str, PL-00725 Warsaw, Poland; [Sadlej, Joanna] Univ Cardinal Stefan Wyszynski, Fac Math & Nat Sci, 1-3 Woycickiego St, PL-01938 Warsaw, Poland	Lipinski, PFJ (reprint author), Polish Acad Sci, Mossakowski Med Res Ctr, 5 Pawinskiego St, PL-02106 Warsaw, Poland.; Sadlej, J (reprint author), Univ Cardinal Stefan Wyszynski, Fac Math & Nat Sci, 1-3 Woycickiego St, PL-01938 Warsaw, Poland.	plipinski@imdik.pan.pl; m.jaronczyk@nil.gov.pl; j.dobrowolski@nil.gov.pl; j.sadlej@uksw.edu.pl	Jaronczyk, Malgorzata/AAE-3582-2019	Jaronczyk, Malgorzata/0000-0003-4268-102X; Lipinski, Piotr/0000-0002-8364-7955	National Science Centre [2013/11/B/ST4/00785]; Interdisciplinary Centre for Mathematical and Computational Modelling (ICM), Warsaw, Poland [GB65-21]; Swierk Computing Centre, National Centre for Nuclear Research, Warsaw, Poland	This work was supported by the National Science Centre Grant No. 2013/11/B/ST4/00785. Calculations were performed under a computational grant no GB65-21 by Interdisciplinary Centre for Mathematical and Computational Modelling (ICM), Warsaw, Poland, and under a computational grant from Swierk Computing Centre, National Centre for Nuclear Research, Warsaw, Poland. Special thanks are due to Professor Slawomir Filipek from the Faculty of Chemistry of the University of Warsaw for his helpful comments and discussions during the project.	Abdi H, 2010, WIRES COMPUT STAT, V2, P433, DOI 10.1002/wics.101; Abraham Mark James, 2015, SoftwareX, V1-2, P19, DOI 10.1016/j.softx.2015.06.001; Bera I, 2011, J MOL MODEL, V17, P1207, DOI 10.1007/s00894-010-0803-8; Bick MJ, 2017, ELIFE, V6, DOI 10.7554/eLife.28909; Bonner G, 2000, EUR J PHARMACOL, V403, P37, DOI 10.1016/S0014-2999(00)00578-1; Bremer PT, 2016, ANGEW CHEM INT EDIT, V55, P3772, DOI 10.1002/anie.201511654; Carroll FI, 2012, ANN NY ACAD SCI, V1248, P18, DOI 10.1111/j.1749-6632.2011.06199.x; Chaturvedi K, 2000, MOL BRAIN RES, V76, P64, DOI 10.1016/S0169-328X(99)00332-0; Doen-Miovi L, 2006, BIOORGAN MED CHEM, V14, P2887, DOI [10.1016/j.bmc.2005.12.010, DOI 10.1016/J.BMC.2005.12.010]; DosenMicovic L, 1996, ELECTRON J THEOR CH, V1, P199, DOI 10.1002/ejtc.29; Ellis CR, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0197734; Fiser A, 2003, BIOINFORMATICS, V19, P2500, DOI 10.1093/bioinformatics/btg362; Frisch M.J., 2013, GAUSSIAN 09 REVISION; Gladden RM, 2016, MMWR-MORBID MORTAL W, V65, P837, DOI 10.15585/mmwr.mm6533a2; Henthorn TK, 1999, J PHARMACOL EXP THER, V289, P1084; Huang WJ, 2015, NATURE, V524, P315, DOI 10.1038/nature14886; Jo S, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000880; Kaserer T, 2016, SCI REP-UK, V6, DOI 10.1038/srep21548; Kelly E, 2013, BRIT J PHARMACOL, V169, P1430, DOI 10.1111/bph.12222; Koehl A, 2018, NATURE, V558, P547, DOI 10.1038/s41586-018-0219-7; Latorraca NR, 2017, CHEM REV, V117, P139, DOI 10.1021/acs.chemrev.6b00177; Lee J, 2016, J CHEM THEORY COMPUT, V12, P405, DOI 10.1021/acs.jctc.5b00935; Li JG, 1999, LIFE SCI, V65, P175, DOI 10.1016/S0024-3205(99)00234-9; Lipinski PFJ, 2016, COMPUT THEOR CHEM, V1086, P18, DOI 10.1016/j.comptc.2016.04.011; Lomize MA, 2006, BIOINFORMATICS, V22, P623, DOI 10.1093/bioinformatics/btk023; Manglik A, 2017, BIOCHEMISTRY-US, V56, P5628, DOI 10.1021/acs.biochem.7b00747; Manglik A, 2016, NATURE, V537, P185, DOI 10.1038/nature19112; Manglik A, 2012, NATURE, V485, P321, DOI 10.1038/nature10954; Mansour A, 1997, J NEUROCHEM, V68, P344, DOI 10.1046/j.1471-4159.1997.68010344.x; Marino Kristen A, 2018, Br J Pharmacol, V175, P2834, DOI 10.1111/bph.13774; McAllister SD, 2004, J BIOL CHEM, V279, P48024, DOI 10.1074/jbc.M406648200; McCurdy C. R, 2010, BURGERS MED CHEM DRU, V8, P569; McPherson J, 2010, MOL PHARMACOL, V78, P756, DOI 10.1124/mol.110.066613; Michaud-Agrawal N, 2011, J COMPUT CHEM, V32, P2319, DOI 10.1002/jcc.21787; Pasternak GW, 2013, PHARMACOL REV, V65, P1257, DOI 10.1124/pr.112.007138; Perez-Benito L, 2017, STRUCTURE, V25, P1153, DOI 10.1016/j.str.2017.05.021; Pil J, 2003, J PHARMACOL EXP THER, V304, P924, DOI 10.1124/jpet.102.040113; Pogozheva ID, 2005, AAPS J, V7; Sabbadin D, 2014, J CHEM INF MODEL, V54, P169, DOI 10.1021/ci400532b; Shang Y, 2014, BIOCHEMISTRY-US, V53, P5140, DOI 10.1021/bi5006915; Singh R, 2002, J PEPT RES, V60, P357, DOI 10.1034/j.1399-3011.2002.21065.x; Subramanian G, 2000, J MED CHEM, V43, P381, DOI 10.1021/jm9903702; Sutcliffe KJ, 2017, J MOL BIOL, V429, P1840, DOI 10.1016/j.jmb.2017.05.009; Suzuki J, 2017, DRUG ALCOHOL DEPEN, V171, P107, DOI 10.1016/j.drugalcdep.2016.11.033; Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334; Trzaskowski B, 2012, CURR MED CHEM, V19, P1090, DOI 10.2174/092986712799320556; Ulens C, 2000, J PHARMACOL EXP THER, V294, P1024; United Nations Office on Drugs and Crime, 2017, GLOB SMART UPDATE, V17, P3; Vanommeslaeghe K, 2010, J COMPUT CHEM, V31, P671, DOI 10.1002/jcc.21367; Vardanyan RS, 2014, FUTURE MED CHEM, V6, P385, DOI 10.4155/fmc.13.215; Volpe DA, 2011, REGUL TOXICOL PHARM, V59, P385, DOI 10.1016/j.yrtph.2010.12.007; Weltrowska G, 2010, J MED CHEM, V53, P2875, DOI 10.1021/jm9019068; Yuan SG, 2013, ANGEW CHEM INT EDIT, V52, P10112, DOI 10.1002/anie.201302244; Zheng H, 2008, MOL PHARMACOL, V73, P178, DOI 10.1124/mol.107.039842; Zheng H, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.177089; Zuo ZY, 2005, ANESTH ANALG, V101, P728, DOI 10.1213/01.ANE.0000160588.32007.AD	56	4	4	1	6	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1610-2940	0948-5023		J MOL MODEL	J. Mol. Model.	MAY	2019	25	5							UNSP 144	10.1007/s00894-019-3999-2			17	Biochemistry & Molecular Biology; Biophysics; Chemistry, Multidisciplinary; Computer Science, Interdisciplinary Applications	Biochemistry & Molecular Biology; Biophysics; Chemistry; Computer Science	HW8GD	WOS:000466926400002	31053968	Other Gold			2020-06-30	J	Wakeman, SE				Wakeman, Sarah E.			'Policies that Punish the Powerless' in a supply-led illicit fentanyl market	ADDICTION			English	Editorial Material						Fentanyl; illicit drug supply; illicitly manufactured fentanyl; opioids; prescription opioids; prohibition			[Wakeman, Sarah E.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA; [Wakeman, Sarah E.] Harvard Med Sch, Boston, MA 02115 USA	Wakeman, SE (reprint author), Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.; Wakeman, SE (reprint author), Harvard Med Sch, Boston, MA 02115 USA.	swakeman@partners.org					Mars SG, 2019, ADDICTION, V114, P774, DOI 10.1111/add.14474; Peiper NC, 2019, INT J DRUG POLICY, V63, P122, DOI 10.1016/j.drugpo.2018.08.007; Wood EF, 2017, INT J DRUG POLICY, V41, P132, DOI 10.1016/j.drugpo.2016.12.010	3	2	2	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0965-2140	1360-0443		ADDICTION	Addiction	MAY	2019	114	5					781	782		10.1111/add.14484			2	Substance Abuse; Psychiatry	Substance Abuse; Psychiatry	HW0SW	WOS:000466393000003	30513550	Bronze			2020-06-30	J	Bisaga, A				Bisaga, Adam			What should clinicians do as fentanyl replaces heroin?	ADDICTION			English	Editorial Material						Buprenorphine; fentanyl; methadone; naloxone; naltrexone; opioid use disorder treatment; overdose prevention	OPIOIDS; MISUSE		[Bisaga, Adam] Columbia Univ, Vagelos Coll Phys & Surg, New York, NY 10027 USA; [Bisaga, Adam] New York State Psychiat Inst & Hosp, New York, NY 10032 USA	Bisaga, A (reprint author), Columbia Univ, Vagelos Coll Phys & Surg, New York, NY 10027 USA.; Bisaga, A (reprint author), New York State Psychiat Inst & Hosp, New York, NY 10032 USA.	adam.bisaga@nyspi.columbia.edu		Bisaga, Adam/0000-0003-4243-6462	New York State Psychiatric Institute; National Institute of Drug AbuseUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)	A.B. is supported by the New York State Psychiatric Institute and the National Institute of Drug Abuse. The author would like to thank Drs Kenneth Stoller, Robin Williams, Maria Sullivan and Sandra Comer for the discussion of the subject and their helpful feedback on the manuscript.	Comer SD, 2002, PSYCHOPHARMACOLOGY, V159, P351, DOI 10.1007/s002130100909; Frank RG, 2017, NEW ENGL J MED, V376, P605, DOI 10.1056/NEJMp1615145; Geddes L, 2018, DRUG ALCOHOL REV, V37, pS314, DOI 10.1111/dar.12668; Kaplan JL, 1999, ANN EMERG MED, V34, P42, DOI 10.1016/S0196-0644(99)70270-2; Krause D, 2017, SUBST USE MISUSE, V52, P639, DOI 10.1080/10826084.2016.1246571; Mars SG, 2019, ADDICTION, V114, P774, DOI 10.1111/add.14474; National Center for Health Statistics, 2018, VIT STAT RAP REL PRO; Potier C, 2014, DRUG ALCOHOL DEPEN, V145, P48, DOI 10.1016/j.drugalcdep.2014.10.012; Prekupec MP, 2017, J ADDICT MED, V11, P256, DOI 10.1097/ADM.0000000000000324; Skolnick P, 2018, EUR J PHARMACOL, V835, P147, DOI 10.1016/j.ejphar.2018.08.004; Sutter ME, 2017, ACAD EMERG MED, V24, P106, DOI 10.1111/acem.13034; Suzuki J, 2017, DRUG ALCOHOL DEPEN, V171, P107, DOI 10.1016/j.drugalcdep.2016.11.033; Walker EA, 2001, PSYCHOPHARMACOLOGY, V154, P131, DOI 10.1007/s002130000620; Wood E, 2018, NEW ENGL J MED, V378, P1565, DOI 10.1056/NEJMp1800216	14	7	7	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0965-2140	1360-0443		ADDICTION	Addiction	MAY	2019	114	5					782	783		10.1111/add.14522			2	Substance Abuse; Psychiatry	Substance Abuse; Psychiatry	HW0SW	WOS:000466393000004	30661265	Bronze			2020-06-30	J	Mounteney, J; Griffiths, P; Sedefov, R; Evans-Brown, M				Mounteney, Jane; Griffiths, Paul; Sedefov, Roumen; Evans-Brown, Michael			Fentanils: a serious threat to public health	ADDICTION			English	Editorial Material						Early warning; fentanils; fentanyl; opioids; supply; trends			[Mounteney, Jane; Griffiths, Paul; Sedefov, Roumen; Evans-Brown, Michael] European Monitoring Ctr Drugs & Drug Addict, Lisbon, Portugal	Mounteney, J (reprint author), European Monitoring Ctr Drugs & Drug Addict, Lisbon, Portugal.	jane.mounteney@emcdda.europa.eu					Drug Enforcement Administration National Drug Threat Assessment, 2017, FENT, P56; EMCDDA, 2012, EMCDDA TRENDSP STUD; EMCDDA, 2018, FENT SYNTH CANN DRIV; EMCDDA, 2018, EUR DRUG REP; Fischer B, 2018, DRUG ALCOHOL REV, V37, pS199, DOI 10.1111/dar.12539; Griffiths P, 2012, ADDICTION, V107, P1539, DOI 10.1111/j.1360-0443.2012.03829.x; Mars SG, 2019, ADDICTION, V114, P774, DOI 10.1111/add.14474; Mounteney J, 2015, INT J DRUG POLICY, V26, P626, DOI 10.1016/j.drugpo.2015.04.003; Nefau T, 2015, INT J DRUG POLICY, V26, P412, DOI 10.1016/j.drugpo.2014.09.010; Ort C, 2014, ADDICTION, V109, P1338, DOI 10.1111/add.12570; UNODC, 2018, WORLD DRUG REP; Weisberg DF, 2014, INT J DRUG POLICY, V25, P1124, DOI 10.1016/j.drugpo.2014.07.009	12	1	1	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0965-2140	1360-0443		ADDICTION	Addiction	MAY	2019	114	5					783	785		10.1111/add.14542			3	Substance Abuse; Psychiatry	Substance Abuse; Psychiatry	HW0SW	WOS:000466393000005	30659693	Bronze			2020-06-30	J	Mars, SG; Rosenblum, D; Ciccarone, D				Mars, Sarah G.; Rosenblum, Daniel; Ciccarone, Daniel			Fentanyl: the many challenges ahead	ADDICTION			English	Editorial Material						Demand led; fentanyl; illicit opioids; policy; prescription opioids; supply led			[Mars, Sarah G.; Ciccarone, Daniel] Univ Calif San Francisco, Dept Family & Community Med, San Francisco, CA 94143 USA; [Rosenblum, Daniel] Dalhousie Univ, Dept Econ, Halifax, NS B3H 4R2, Canada	Mars, SG (reprint author), Univ Calif San Francisco, Dept Family & Community Med, San Francisco, CA 94143 USA.	sarah.mars@ucsf.edu	Ciccarone, Daniel/I-5404-2013	Ciccarone, Daniel/0000-0002-2355-5477	NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [R01 DA037820, DA037820]		Bisaga A, 2019, ADDICTION, V114, P782, DOI 10.1111/add.14522; Ciccarone D, 2019, INT J DRUG POLICY, V71, P183, DOI 10.1016/j.drugpo.2019.01.010; Hammig R, 2016, SUBST ABUSE REHABIL, V7, P99, DOI 10.2147/SAR.S109919; Hughes CE, 2012, DRUG ALCOHOL REV, V31, P101, DOI 10.1111/j.1465-3362.2011.00383.x; Hughes CE, 2010, BRIT J CRIMINOL, V50, P999, DOI 10.1093/bjc/azq038; Kilmer B., 2018, CONSIDERING HEROIN A; Mars SG, 2019, ADDICTION, V114, P774, DOI 10.1111/add.14474; Mars SG, 2018, J PSYCHOACTIVE DRUGS, V50, P167, DOI 10.1080/02791072.2017.1394508; Mounteney J, 2019, ADDICTION, V114, P783, DOI 10.1111/add.14542; Wakeman SE, 2019, ADDICTION, V114, P781, DOI 10.1111/add.14484	10	1	1	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0965-2140	1360-0443		ADDICTION	Addiction	MAY	2019	114	5					785	786		10.1111/add.14587			2	Substance Abuse; Psychiatry	Substance Abuse; Psychiatry	HW0SW	WOS:000466393000006	30873700	Bronze			2020-06-30	J	Kanamori, T				Kanamori, Tatsuyuki			Study of the Metabolism of New Drugs of Abuse	YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN			Japanese	Review						new drug of abuse; metabolism; hepatocyte; XLR-11; fentanyl	HEPARG CELLS; FENTANYL; PRODUCT	Human hepatocytes possess a wider range of phase I and II drug-metabolizing enzyme activities than other liver tissue -derived products, such as human liver microsomes. Thus, hepatocytes may be useful for predicting the in vivo metabolic fate of new drugs of abuse in humans. Recently, new types of human hepatocytes have been made commercially available for use in drug metabolism studies, such as a liver tumor-derived cell line (HepaRG), and a human induced pluripotent stem cell-derived hepatocyte (h-iPS-HEP). In our laboratory, HepaRG has been used to elucidate the metabolic pathways of XLR-11, a synthetic cannabinoid, and its thermal degradant. In addition, the potential of h-iPS-HEP to metabolize drugs was assessed using fentanyl as a model drug, and indeed, h-iPS-HEP exhibited a pattern for fentanyl metabolite formation similar to that observed in vivo. In addition, the phase I and II drug-metabolizing enzyme activities of HepaRG, h-iPS-HEP, liver-humanized mouse-derived hepatocytes (PXB-cellsTM), and human primary hepatocytes were evaluated and compared. HepaRG showed high phase I and II drug metabolism activities; however, the CYP2D6 activity in these cells was quite low, and therefore h-iPS-HEP lacked O-methylation and conjugation activities. PXB-cells provided optimal results, i.e., these cells are extremely easy to use, and they possess higher phase I and II drug-metabolizing enzyme activities than the other cells tested. Although PXB-cells are contaminated with mouse-derived cells up to a concentration of several percent, this cell system appears to be promising for the prediction of in vivo human metabolism of new drugs of abuse.	[Kanamori, Tatsuyuki] Natl Res Inst Police Sci, Dept Forens Sci 3, Chem Sect 1, 6-3-1 Kashiwanoha, Kashiwa, Chiba 2770882, Japan	Kanamori, T (reprint author), Natl Res Inst Police Sci, Dept Forens Sci 3, Chem Sect 1, 6-3-1 Kashiwanoha, Kashiwa, Chiba 2770882, Japan.	kanamori@nrips.go.jp	Sharma, Ashwani/AAK-3879-2020	Sharma, Ashwani/0000-0001-9835-1973			Adamowicz P, 2013, FORENSIC SCI INT, V233, P320, DOI 10.1016/j.forsciint.2013.10.005; Goromaru T, 1986, Masui, V35, P35; Gripon P, 2002, P NATL ACAD SCI USA, V99, P15655, DOI 10.1073/pnas.232137699; Ishida Y, 2013, SAIBOU, V45, P338; Kanamori T, 2018, FORENSIC TOXICOL, V36, P467, DOI 10.1007/s11419-018-0425-x; Kanamori T, 2018, BIOL PHARM BULL, V41, P106, DOI 10.1248/bpb.b17-00709; Kanamori T, 2015, DRUG TEST ANAL, V7, P341, DOI 10.1002/dta.1765; Kanebratt KP, 2008, DRUG METAB DISPOS, V36, P1444, DOI 10.1124/dmd.107.020016; Takayama K, 2014, P NATL ACAD SCI USA, V111, P16772, DOI 10.1073/pnas.1413481111; Yamasaki C, 2010, DRUG METAB PHARMACOK, V25, P539, DOI 10.2133/dmpk.DMPK-10-RG-047	10	1	1	0	4	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0031-6903			YAKUGAKU ZASSHI	Yakugaku Zasshi-J. Pharm. Soc. Jpn.	MAY	2019	139	5					699	704		10.1248/yakushi.18-00166-3			6	Pharmacology & Pharmacy	Pharmacology & Pharmacy	HW1NU	WOS:000466450400007	31061338	Bronze			2020-06-30	J	Beatty, ME; Bray, K				Beatty, Mark E.; Bray, Kari			A Seat at the Table: Public Health Is Working Differently in Snohomish County, and It's Paying Off	HEALTH SECURITY			English	Editorial Material								From the Field is a semi-regular column that explores what it means to be a local health professional on the front lines of an emergency. Typically, National Association of County and City Health Officials (NACCHO) members share their stories of preparing for and responding to disasters, epidemics, and other major health issues. Through exploring the analysis of the challenges faced and the solutions developed, readers can learn how these public health champions keep their communities safe even in extreme situations. Readers may submit topics of interest to jfox46@jhu.edu.	[Beatty, Mark E.; Bray, Kari] Snohomish Hlth Dist, 3020 Rucker Ave,Suite 304, Everett, WA 98201 USA	Beatty, ME (reprint author), Snohomish Hlth Dist, 3020 Rucker Ave,Suite 304, Everett, WA 98201 USA.	mbeatty@snohd.org			Centers for Disease Control and PreventionUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [U17 CE002734]	Some of the work highlighted in this article was supported by the Grant or Cooperative Agreement Number, U17 CE002734, funded by the Centers for Disease Control and Prevention. The article's contents are solely the responsibility of the authors and do not necessarily represent the official views of the Centers for Disease Control and Prevention or the US Department of Health and Human Services.	Hook EB, 1995, EPIDEMIOL REV, V17, P243, DOI 10.1093/oxfordjournals.epirev.a036192; Snohomish Overdose Prevention, 2018, OP SNOH COUNT POINT; Snohomish Overdose Prevention, 2017, JOINT RES AFF SNOH C; Washington State Department of Health, 2018, PHIMS STD 1992 2017	4	0	0	0	0	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	2326-5094	2326-5108		HEALTH SECUR	Health Secur.	APR 1	2019	17	2					162	165		10.1089/hs.2019.0013		APR 2019	4	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	HU3PX	WOS:000463879800001	30964342				2020-06-30	J	Komen, H; Brunt, LM; Deych, E; Blood, J; Kharasch, ED				Komen, Helga; Brunt, L. Michael; Deych, Elena; Blood, Jane; Kharasch, Evan D.			Intraoperative Methadone in Same-Day Ambulatory Surgery: A Randomized, Double-Blinded, Dose-Finding Pilot Study	ANESTHESIA AND ANALGESIA			English	Article							POSTOPERATIVE PAIN-CONTROL; CHRONIC POSTSURGICAL PAIN; PHARMACOKINETICS; PREDICTORS; PREVENTION; MANAGEMENT; DISCHARGE; RECOVERY; MORPHINE	BACKGROUND: Approximately 50 million US patients undergo ambulatory surgery annually. Postoperative opioid overprescribing is problematic, yet many patients report inadequate pain relief. In major inpatient surgery, intraoperative single-dose methadone produces better analgesia and reduces opioid use compared with conventional repeated dosing of short-duration opioids. This investigation tested the hypothesis that in same-day ambulatory surgery, intraoperative methadone, compared with short-duration opioids, reduces opioid consumption and pain, and determined an effective intraoperative induction dose of methadone for same-day ambulatory surgery. METHODS: A double-blind, dose-escalation protocol randomized 60 patients (2: 1) to intraoperative single-dose intravenous methadone (initially 0.1 then 0.15 mg/kg ideal body weight) or conventional as-needed dosing of short-duration opioids (eg, fentanyl, hydromorphone; controls). Intraoperative and postoperative opioid consumption, pain, and opioid side effects were assessed before discharge. Patient home diaries recorded pain, opioid use, and opioid side effects daily for 30 days postoperatively. Primary outcome was in-hospital (intraoperative and postoperative) opioid use. Secondary outcomes were 30 days opioid consumption, pain intensity, and opioid side effects. RESULTS: Median (interquartile range) methadone doses were 6 (5-6) and 9 (8-9) mg in the 0.1 and 0.15 mg/kg methadone groups, respectively. Total opioid consumption (morphine equivalents) in the postanesthesia care unit was significantly less compared with controls (9.3 mg, 1.3-11.0) in subjects receiving 0.15 mg/kg methadone (0.1 mg, 0.1-3.3; P <. 001) but not 0.1 mg/kg methadone (5.0 mg, 3.3-8.1; P =. 60). Dose-escalation ended at 0.15 mg/kg methadone. Total in-hospital nonmethadone opioid use after short-duration opioid, 0.1 mg/kg methadone, and 0.15 mg/kg methadone was 35.3 (25.0-44.0), 7.1 (3.7-10.0), and 3.3 (0.1-5.8) mg morphine equivalents, respectively (P < .001 for both versus control). In-hospital pain scores and side effects were not different between groups. In the 30 days after discharge, patients who received methadone 0.15 mg/kg had less pain at rest (P = .02) and used fewer opioid pills than controls (P < .0001), whereas patients who received 0.1 mg/kg had no difference in pain at rest (P = .69) and opiod use compared to controls (P = .08). CONCLUSIONS: In same-day discharge surgery, this pilot study identified a single intraoperative dose of methadone (0.15 mg/kg ideal body weight), which decreased intraoperative and postoperative opioid requirements and postoperative pain, compared with conventional intermittent short-duration opioids, with similar side effects.	[Komen, Helga; Blood, Jane; Kharasch, Evan D.] Washington Univ St Louis, Dept Anesthesiol, Campus Box 8054,660 S Euclid Ave, St Louis, MO 63110 USA; [Brunt, L. Michael] Washington Univ St Louis, Dept Surg, St Louis, MO 63110 USA; [Deych, Elena] BioRankings, St Louis, MO USA; [Kharasch, Evan D.] Washington Univ St Louis, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA; [Kharasch, Evan D.] Washington Univ St Louis, Ctr Clin Pharmacol, St Louis Coll Pharm, St Louis, MO 63110 USA	Komen, H (reprint author), Washington Univ St Louis, Dept Anesthesiol, Campus Box 8054,660 S Euclid Ave, St Louis, MO 63110 USA.	komenh@anest.wustl.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 DA042985]; Barnes-Jewish Hospital Foundation [795777]; Washington University in St Louis Department of Anesthesiology, Division of Clinical and Translational Research	Supported by grants from the National Institutes of Health (R01 DA042985 to E.D.K.), Barnes-Jewish Hospital Foundation (795777 to H.K.), and the Washington University in St Louis Department of Anesthesiology, Division of Clinical and Translational Research (to H.K.).	BERDE CB, 1991, J PEDIATR-US, V119, P136, DOI 10.1016/S0022-3476(05)81054-6; Bicket MC, 2017, JAMA SURG, V152, P1066, DOI 10.1001/jamasurg.2017.0831; Callesen T, 1999, J AM COLL SURGEONS, V188, P355, DOI 10.1016/S1072-7515(98)00316-0; Cauley CE, 2017, ANN SURG, V265, P702, DOI 10.1097/SLA.0000000000001945; Chou R, 2016, J PAIN, V17, P131, DOI 10.1016/j.jpain.2015.12.008; CHUI PT, 1992, ANAESTH INTENS CARE, V20, P46, DOI 10.1177/0310057X9202000109; Compton WM, 2016, NEW ENGL J MED, V374, P154, DOI 10.1056/NEJMra1508490; Dart RC, 2015, NEW ENGL J MED, V372, P241, DOI [10.1056/NEJMc1501822, 10.1056/NEJMsa1406143]; Dexter F, 2001, ANESTH ANALG, V92, P1222; Gan TJ, 2014, CURR MED RES OPIN, V30, P149, DOI 10.1185/03007995.2013.860019; Gerbershagen HJ, 2014, ANESTHESIOLOGY, V120, P1237, DOI 10.1097/ALN.0000000000000108; Gerbershagen HJ, 2013, ANESTHESIOLOGY, V118, P934, DOI 10.1097/ALN.0b013e31828866b3; Gottschalk A, 2011, ANESTH ANALG, V112, P218, DOI 10.1213/ANE.0b013e3181d8a095; GOURLAY GK, 1984, ANESTHESIOLOGY, V61, P19, DOI 10.1097/00000542-198461010-00005; GOURLAY GK, 1986, ANESTHESIOLOGY, V64, P322; GOURLAY GK, 1982, ANESTHESIOLOGY, V57, P458, DOI 10.1097/00000542-198212000-00005; Hall Margaret J, 2017, Natl Health Stat Report, P1; Hill MV, 2017, ANN SURG, V265, P709, DOI 10.1097/SLA.0000000000001993; Hoofwijk DMN, 2015, CLIN J PAIN, V31, P1017, DOI 10.1097/AJP.0000000000000207; Ibrahim AE, 2001, ANESTHESIOLOGY, V94, P87, DOI 10.1097/00000542-200101000-00018; Ingrande J, 2010, BRIT J ANAESTH, V105, pI16, DOI 10.1093/bja/aeq312; Jani Samir R, 2016, J Healthc Risk Manag, V35, P38, DOI 10.1002/jhrm.21223; Kehlet H, 2006, LANCET, V367, P1618, DOI 10.1016/S0140-6736(06)68700-X; Kharasch ED, 2017, CLIN PHARM DRUG DEV, V6, P125, DOI 10.1002/cpdd.326; Kharasch ED, 2016, ANESTHESIOLOGY, V124, P960, DOI 10.1097/ALN.0000000000001012; Kharasch ED, 2015, ANESTHESIOLOGY, V123, P1142, DOI 10.1097/ALN.0000000000000867; Kharasch ED, 2015, ANESTHESIOLOGY, V122, P969, DOI 10.1097/ALN.0000000000000634; Kharasch ED, 2011, ANESTH ANALG, V112, P13, DOI 10.1213/ANE.0b013e3181fec9a3; Macintyre PE, 2014, ANAESTH INTENS CARE, V42, P558, DOI 10.1177/0310057X1404200504; Macrae WA, 2008, BRIT J ANAESTH, V101, P77, DOI 10.1093/bja/aen099; Murphy GS, 2017, ANESTHESIOLOGY, V126, P822, DOI 10.1097/ALN.0000000000001609; Murphy GS, 2015, ANESTHESIOLOGY, V122, P1112, DOI 10.1097/ALN.0000000000000633; Pozek JPJ, 2016, MED CLIN N AM, V100, P17, DOI 10.1016/j.mcna.2015.08.005; Richlin D M, 1991, J Clin Anesth, V3, P112, DOI 10.1016/0952-8180(91)90007-A; Rodgers J, 2012, J HAND SURG-AM, V37A, P645, DOI 10.1016/j.jhsa.2012.01.035; Shaheen PE, 2009, J PAIN SYMPTOM MANAG, V38, P409, DOI 10.1016/j.jpainsymman.2009.06.004; Sharma A, 2011, ANESTHESIOLOGY, V115, P1153, DOI 10.1097/ALN.0b013e318238fec5; Weingarten TN, 2015, ANESTH ANALG, V121, P422, DOI 10.1213/ANE.0000000000000792; Weinger M. B., 2011, ANESTHESIA PATIENT S, V26, P21; Weiser TG, 2016, B WORLD HEALTH ORGAN, V94, P201, DOI 10.2471/BLT.15.159293	40	9	9	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	APR	2019	128	4					802	810		10.1213/ANE.0000000000003464			9	Anesthesiology	Anesthesiology	IQ4KN	WOS:000480719700036	29847382	Green Accepted			2020-06-30	J	Taketa, Y; Irisawa, Y; Fujitani, T				Taketa, Yasuko; Irisawa, Yumi; Fujitani, Taro			Programmed intermittent bolus infusion versus continuous infusion of 0.2% levobupivacaine after ultrasound-guided thoracic paravertebral block for video-assisted thoracoscopic surgery A randomised controlled trial	EUROPEAN JOURNAL OF ANAESTHESIOLOGY			English	Article							POSTOPERATIVE ANALGESIA; EPIDURAL BOLUS; AUTOMATED BOLUS; BREAST SURGERY; NERVE BLOCK; EFFICACY; THORACOTOMY; MAINTENANCE; MASTECTOMY; SPREAD	BACKGROUND The analgesic benefits of programmed intermittent bolus infusion for thoracic paravertebral block remain unknown. OBJECTIVE The aim of this study was to compare the analgesia from intermittent bolus infusion with that of a continuous infusion after thoracic paravertebral block. DESIGN A randomised controlled study. SETTING A single centre between December 2016 and November 2017. Seventy patients scheduled for video-assisted thoracoscopic surgery were included in the study. INTERVENTION(S) Patients were randomly assigned to receive 0.2% levobupivacaine via continuous infusion (5 ml h(-1), continuous group) or programmed intermittent bolus infusion (15 ml every 3 h, bolus group) after an initial 15-ml bolus injection of 0.2% levobupivacaine. MAIN OUTCOME MEASURES The main outcome was the amount of rescue fentanyl (per kg of body weight) consumed within 24 h after surgery. Secondary outcomes were postoperative pain scores, plasma levobupivacaine concentrations and the number of dermatomes anaesthetised. RESULTS There was no significant difference between the continuous and bolus groups in the postoperative consumption of fentanyl (median [interquartile range] 5.5 [4 to 9.5] mg kg(-1) versus 6 [3.5 to 9] mg kg(-1) respectively, P = 0.45) and postoperative pain scores within 24 h. At 20 h after initiating the infusions, there was no statistically significant difference between the two groups in terms of the plasma levobupivacaine concentration. The number of dermatomes anaesthetised to pinprick and cold testing was significantly greater in the bolus group. CONCLUSION Our findings suggest that postoperative pain and opioid usage are similar with either programmed intermittent bolus infusion or continuous infusion after thoracic paravertebral block. Programmed intermittent bolus infusion provides a wider sensory blockade and could benefit patients requiring a wider extent of anaesthesia.	[Taketa, Yasuko; Irisawa, Yumi; Fujitani, Taro] Ehime Prefectural Cent Hosp, Dept Anesthesiol & Crit Care, 83 Kasuga Machi, Matsuyama, Ehime 7900024, Japan	Taketa, Y (reprint author), Ehime Prefectural Cent Hosp, Dept Anesthesiol & Crit Care, 83 Kasuga Machi, Matsuyama, Ehime 7900024, Japan.	suko1231@yahoo.co.jp					Bardsley H, 1998, BRIT J CLIN PHARMACO, V46, P245, DOI 10.1046/j.1365-2125.1998.00775.x; Ben-Ari A, 2009, ANESTH ANALG, V109, P1691, DOI 10.1213/ANE.0b013e3181b72d50; Burlacu CL, 2007, REGION ANESTH PAIN M, V32, P136, DOI 10.1016/j.rapm.2006.11.011; Capogna G, 2013, CURR OPIN ANESTHESIO, V26, P261, DOI 10.1097/ACO.0b013e328360b069; Capogna G, 2011, ANESTH ANALG, V113, P826, DOI 10.1213/ANE.0b013e31822827b8; Carvalho B, 2016, ANESTH ANALG, V123, P965, DOI 10.1213/ANE.0000000000001407; Catala E, 1996, J CARDIOTHOR VASC AN, V10, P586, DOI 10.1016/S1053-0770(96)80133-9; Chong MA, 2017, J CLIN ANESTH, V42, P69, DOI 10.1016/j.jclinane.2017.08.018; Fibla JJ, 2015, EUR J CARDIO-THORAC, V47, P631, DOI 10.1093/ejcts/ezu246; Hillegass MG, 2013, J CLIN ANESTH, V25, P281, DOI 10.1016/j.jclinane.2012.11.015; Karmakar MK, 2001, ANESTHESIOLOGY, V95, P771, DOI 10.1097/00000542-200109000-00033; Kasimahanti R, 2016, J CLIN ANESTH, V33, P414, DOI 10.1016/j.jclinane.2016.01.027; Kaynar AM, 1999, ANESTH ANALG, V89, P534, DOI 10.1097/00000539-199908000-00063; Khatibi B, 2017, ANESTH ANALG, V124, P1298, DOI 10.1213/ANE.0000000000001939; Kotze A, 2009, BRIT J ANAESTH, V103, P626, DOI 10.1093/bja/aep272; Kulhari S, 2016, BRIT J ANAESTH, V117, P382, DOI 10.1093/bja/aew223; Kumar K, 2017, ANESTH ANALG, V125, P1749, DOI 10.1213/ANE.0000000000002497; Mesbah A, 2016, BJA EDUC, V16, P1, DOI 10.1093/bjaceaccp/mkv005; Patnaik R, 2018, REGION ANESTH PAIN M, V43, P385, DOI 10.1097/AAP.0000000000000746; Taboada M, 2008, ANESTH ANALG, V107, P1433, DOI 10.1213/ane.0b013e3181824164; Taboada M, 2009, ANESTHESIOLOGY, V110, P150, DOI 10.1097/ALN.0b013e318191693a; Taketa Y, 2017, BRIT J ANAESTH, V119, P339, DOI 10.1093/bja/aex209; Taketa Y, 2018, ACTA ANAESTH SCAND, V62, P1274, DOI 10.1111/aas.13216; Taketa Y, 2017, J ANESTH, V31, P271, DOI 10.1007/s00540-016-2289-8; Terkawi AS, 2015, PAIN PHYSICIAN, V18, pE757; Ueda K, 2005, ANESTHESIOLOGY, V103, P126, DOI 10.1097/00000542-200507000-00019; Vogt A, 2005, BRIT J ANAESTH, V95, P816, DOI 10.1093/bja/aei250; Yanni DS, 2011, NEUROSURGERY, V68, DOI 10.1227/NEU.0b013e318209348c; Yoshida T, 2014, ANAESTHESIA, V69, P231, DOI 10.1111/anae.12531	29	3	3	1	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0265-0215	1365-2346		EUR J ANAESTH	Eur. J. Anaesth.	APR	2019	36	4					272	278		10.1097/EJA.0000000000000945			7	Anesthesiology	Anesthesiology	IQ3XS	WOS:000480685800006	30664012				2020-06-30	J	LaRue, L; Twillman, RK; Dawson, E; Whitley, P; Frasco, MA; Huskey, A; Guevara, MG				LaRue, Leah; Twillman, Robert K.; Dawson, Eric; Whitley, Penn; Frasco, Melissa A.; Huskey, Angela; Guevara, Maria G.			Rate of Fentanyl Positivity Among Urine Drug Test Results Positive for Cocaine or Methamphetamine	JAMA NETWORK OPEN			English	Article								IMPORTANCE Drug overdose deaths continue to increase, despite the leveling off of prescription opioid use and policy changes limiting opioid prescribing. Illicit fentanyl is the leading cause of drug overdose death, and it is important to characterize the emerging combination of other illicit drugs with fentanyl, which increases the risk of overdose. OBJECTIVE To determine whether rates of the combination of nonprescribed fentanyl with cocaine or methamphetamine have changed in urine drug test (UDT) results through time. DESIGN, SETTING, AND PARTICIPANTS This cross-sectional study of UDT results from January 1, 2013, through September 30, 2018, included patient specimens submitted for UDTs by health care professionals as part of routine care. Patients were selected from health care practices across the United States, including substance use disorder treatment centers, pain management practices, primary care practices, behavioral health practices, obstetrics and gynecology practices, and multispecialty groups. The UDT analysis used liquid chromatography-tandem mass spectrometry to detect benzoylecgonine (cocaine metabolite), methamphetamine, fentanyl, and norfentanyl. Specimens from individuals reported to have been prescribed fentanyl were excluded. A convenience sample approach was used to randomly select 1 million unique patient UDT specimens from Millennium Health's UDT database for further analysis. Each specimen had associated cocaine, methamphetamine, and fentanyl UDT results. EXPOSURES Medically necessary UDT to detect benzoylecgonine (cocaine metabolite), methamphetamine, fentanyl, and norfentanyl, ordered by a health care professional as part of routine patient care. MAIN OUTCOMES AND MEASURES Rates of nonprescribed fentanyl positivity among cocaine-or methamphetamine-positive UDT results, quantified through time. RESULTS In a sampling of 1 million unique patients' UDT specimens analyzed for cocaine and fentanyl (median [interquartile range] age, 44 [19-69] years; 55.0% women), positivity rates for nonprescribed fentanyl among the cocaine-positive results increased significantly, from 0.9% (n = 84) (95% CI, 0.7%-1.1%) in 2013 to 17.6% (n = 427) (95% CI, 16.1%-19.1%) in 2018, a 1850% increase (tau = 0.78; z = 9.45; P < .001). In the same sampling of 1 million specimens, positivity rates for nonprescribed fentanyl among the methamphetamine-positive results also increased significantly, from 0.9%(n = 29) (95% CI, 0.6%-1.2%) in 2013 to 7.9%(n = 344) (95% CI, 7.1%-8.7%) in 2018, a 798% increase (tau = 0.72; z = 8.75; P < .001). CONCLUSIONS AND RELEVANCE An increasing number of UDT results positive for cocaine or methamphetamine were also positive for nonprescribed fentanyl. This provides additional insight into recently reported increases in cocaine-and methamphetamine-related overdoses. Stimulant users who may be opioid naive are at a heightened risk of overdose when exposed to fentanyl. Clinicians need to be aware that patients presenting for treatment of suspected drug overdose or substance use disorder may have been exposed, knowingly or unknowingly, to multiple substances, including the combination of stimulants and opioids.	[LaRue, Leah; Dawson, Eric; Whitley, Penn; Frasco, Melissa A.; Huskey, Angela; Guevara, Maria G.] Millennium Hlth, 16981 Via Tazon, San Diego, CA 92127 USA; [Twillman, Robert K.] Univ Kansas, Sch Med, Kansas City, KS USA	LaRue, L (reprint author), Millennium Hlth, 16981 Via Tazon, San Diego, CA 92127 USA.	leah.larue@millenniumhealth.com			Millennium Health	This study was supported by Millennium Health.	Jones CM, 2018, JAMA-J AM MED ASSOC, V319, P1819, DOI 10.1001/jama.2018.2844; Nolan ML, 2019, J URBAN HEALTH, V96, P49, DOI 10.1007/s11524-018-00343-z; Scholl Lawrence, 2018, MMWR Morb Mortal Wkly Rep, V67, P1419, DOI [10.15585/mmwr.mm6751521e1, 10.15585/mmwr.mm675152e1]; Trecki J, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2018.7104; United States Drug Enforcement Administration, 2017 NAT DRUG THREAT; US Drug Enforcement Administration Diversion Control Division, 2018, NAT FOR LAB INF SYST	6	8	8	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2574-3805			JAMA NETW OPEN	JAMA Netw. Open	APR	2019	2	4							e192851	10.1001/jamanetworkopen.2019.2851			6	Medicine, General & Internal	General & Internal Medicine	IK7UT	WOS:000476798700063	31026029	DOAJ Gold, Green Published			2020-06-30	J	Park, SK; Lee, JH; Yoo, S; Kim, WH; Lim, YJ; Bahk, JH; Kim, JT				Park, Sun-Kyung; Lee, Joon Hee; Yoo, Seokha; Kim, Won Ho; Lim, Young-Jin; Bahk, Jae-Hyon; Kim, Jin-Tae			Comparison of bupivacaine plus intrathecal fentanyl and bupivacaine alone for spinal anesthesia with intravenous dexmedetomidine sedation: a randomized, double-blind, noninferiority trial	REGIONAL ANESTHESIA AND PAIN MEDICINE			English	Article; Proceedings Paper	World Congress on Regional Anesthesia and Pain Medicine	APR 19-21, 2018	New York, NY				HYPERBARIC ROPIVACAINE; PATIENT SATISFACTION; REGIONAL ANESTHESIA; METAANALYSIS; ANALGESIA; ADJUVANTS; DELIRIUM; SURGERY	Background and objectives Fentanyl is widely used as an intrathecal adjuvant to local anesthetics to enhance the duration of spinal anesthesia. Recent evidence suggests that intravenous dexmedetomidine prolongs the duration of spinal anesthesia. This noninferiority study evaluated whether bupivacaine alone could provide a noninferior duration of block compared with bupivacaine and fentanyl when intravenous dexmedetomidine was administered intraoperatively. Methods Fifty-six patients scheduled for total knee arthroplasty under spinal anesthesia were randomly allocated to receive either bupivacaine 13 mg with intrathecal fentanyl 20 mu g (Group BF) or bupivacaine 13 mg (Group B). Both groups underwent intravenous dexmedetomidine sedation throughout the surgery (1 mu g kg(-1) for 10 min, followed by 0.5 mu g kg(-1) h(-1)). The primary outcome was the time to two-segment regression of the sensory block. The noninferiority margin for the mean difference was predefined as -10 min. Secondary outcomes included postoperative pain scores, analgesics consumptions, and the incidences of pruritus, nausea, and vomiting. Results There was no significant difference in the two-segment regression time of sensory block (Group B 109.1 +/- 25.0 min vs Group BF 104.3 +/- 25.9 min; p=0.484). The mean difference in the two-segment regression time between the 2 groups was 4.8 min (95 % CI -8.9 to 18.6), demonstrating the noninferiority of bupivacaine alone. Secondary outcomes showed no significant differences between the two groups. Conclusions The duration of spinal anesthesia with bupivacaine alone is noninferior to that of bupivacaine plus fentanyl in patients receiving intravenous dexmedetomidine intraoperatively. Our results suggest that intrathecal fentanyl may not be required when intravenous dexmedetomidine is administered.	[Park, Sun-Kyung; Lee, Joon Hee; Yoo, Seokha; Kim, Won Ho; Lim, Young-Jin; Bahk, Jae-Hyon; Kim, Jin-Tae] Seoul Natl Univ, Coll Med, Seoul Natl Univ Hosp, Dept Anesthesiol & Pain Med, Seoul 03080, South Korea	Kim, JT (reprint author), Seoul Natl Univ, Coll Med, Seoul Natl Univ Hosp, Dept Anesthesiol & Pain Med, Seoul 03080, South Korea.	jintae73@gmail.com	Yoo, Seokha/H-1638-2018; Kim, Jin-Tae/T-7983-2019; KIM, JIN TAE/D-5734-2012; Kim, Won Ho/S-8671-2019	Yoo, Seokha/0000-0003-4679-6027; Kim, Jin-Tae/0000-0002-3738-0081; KIM, JIN TAE/0000-0002-3738-0081; Kim, Won Ho/0000-0003-1748-1296; Bahk, Jae-Hyon/0000-0002-3082-5244			Abdallah FW, 2013, ANESTH ANALG, V117, P271, DOI 10.1213/ANE.0b013e318290c566; Adams R, 2013, BRIT J ANAESTH, V111, P703, DOI 10.1093/bja/aet194; Ben-David B, 2000, REGION ANESTH PAIN M, V25, P235, DOI 10.1016/S1098-7339(00)90004-X; Bhana N, 2000, DRUGS, V59, P263, DOI 10.2165/00003495-200059020-00012; Bidikar Manjunath, 2017, Anesth Essays Res, V11, P495, DOI 10.4103/aer.AER_16_17; Biswas A, 2018, REGION ANESTH PAIN M, V43, P154, DOI 10.1097/AAP.0000000000000724; Cheah JW, 2018, J ARTHROPLASTY, V33, P1693, DOI 10.1016/j.arth.2018.01.016; Chung CJ, 2002, REGION ANESTH PAIN M, V27, P600, DOI 10.1053/rapm.2002.36455; Cowan CM, 2002, BRIT J ANAESTH, V89, P452; DEANDRES J, 1995, REGION ANESTH, V20, P498; Elcicek K, 2010, J ANESTH, V24, P544, DOI 10.1007/s00540-010-0939-9; Gurkan Y, 2004, ACTA ANAESTH SCAND, V48, P513, DOI 10.1111/j.1399-6576.2004.00353.x; Hall JE, 2000, ANESTH ANALG, V90, P699, DOI 10.1097/00000539-200003000-00035; Hohener D, 2008, BRIT J ANAESTH, V100, P8, DOI 10.1093/bja/aem342; Hong JY, 2012, ACTA ANAESTH SCAND, V56, P382, DOI 10.1111/j.1399-6576.2011.02614.x; Jain K, 2004, INT J OBSTET ANESTH, V13, P215, DOI 10.1016/j.ijoa.2004.04.006; Korhonen AM, 2003, ACTA ANAESTH SCAND, V47, P342, DOI 10.1034/j.1399-6576.2003.00092.x; Kubre Jyotsna, 2016, Anesth Essays Res, V10, P273, DOI 10.4103/0259-1162.174465; Kumari Rekha, 2017, J Anaesthesiol Clin Pharmacol, V33, P203, DOI 10.4103/joacp.JOACP_367_15; Lin YY, 2012, J CARDIAC SURG, V27, P481, DOI 10.1111/j.1540-8191.2012.01472.x; Maldonado JR, 2009, PSYCHOSOMATICS, V50, P206, DOI 10.1176/appi.psy.50.3.206; Malinovsky JM, 1999, ANESTHESIOLOGY, V91, P1260, DOI 10.1097/00000542-199911000-00016; Mantz J, 2011, EUR J ANAESTH, V28, P3, DOI 10.1097/EJA.0b013e32833e266d; Mauri L, 2017, NEW ENGL J MED, V377, P1357, DOI 10.1056/NEJMra1510063; Naaz Shagufta, 2014, J Clin Diagn Res, V8, pGE01, DOI 10.7860/JCDR/2014/9624.4946; Nair GS, 2009, BRIT J ANAESTH, V102, P307, DOI 10.1093/bja/aen389; Niu XY, 2013, CNS NEUROSCI THER, V19, P897, DOI 10.1111/cns.12172; Obara S, 2018, J ANESTH, V32, P33, DOI 10.1007/s00540-017-2424-1; Pandharipande PP, 2007, JAMA-J AM MED ASSOC, V298, P2644, DOI 10.1001/jama.298.22.2644; Popping DM, 2012, PAIN, V153, P784, DOI 10.1016/j.pain.2011.11.028; Roussel J R, 1999, AANA J, V67, P337; Seewal R, 2007, REGION ANESTH PAIN M, V32, P20, DOI 10.1016/j.rapm.2006.09.007; Shin H-J, 2018, ANESTHESIA ANALGESIA, V1; Singh Ravanjit, 2015, J Anaesthesiol Clin Pharmacol, V31, P485, DOI 10.4103/0970-9185.169069; Staikou C, 2014, MINERVA ANESTESIOL, V80, P96; Sun SJ, 2017, DRUG DES DEV THER, V11, P3413, DOI 10.2147/DDDT.S146092; Weerink MAS, 2017, CLIN PHARMACOKINET, V56, P893, DOI 10.1007/s40262-017-0507-7; White PF, 1999, ANESTH ANALG, V88, P1069, DOI 10.1097/00000539-199905000-00018; Wu CL, 2001, REGION ANESTH PAIN M, V26, P196, DOI 10.1053/rapm.2001.22257	39	1	1	2	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1098-7339	1532-8651		REGION ANESTH PAIN M	Region. Anesth. Pain Med.	APR	2019	44	4					459	465		10.1136/rapm-2018-100084			7	Anesthesiology	Anesthesiology	IC7LW	WOS:000471156800005	30679336				2020-06-30	J	Abushanab, D; Alsoukhni, O; AbouNahia, F; AI-Badriyeh, D				Abushanab, Dina; Alsoukhni, Omar; AbouNahia, Fouad; AI-Badriyeh, Daoud			Clinical and Economic Analysis of Morphine Versus Fentanyl in Managing Ventilated Neonates With Respiratory Distress Syndrome in the Intensive Care Setting	CLINICAL THERAPEUTICS			English	Article						analgesia; cost-effectiveness; decision analytic model; intensive care unit; neonates; Premature Infant Pain Profile	CRITICALLY-ILL PATIENTS; SAMPLE-SIZE; MECHANICAL VENTILATION; SEDATION; PRETERM; INFANTS; PAIN; ANALGESIA; PROPOFOL; TERM	Purpose: Morphine and fentanyl opioids are common analgesic agents for consideration in the neonatal intensive care unit (NICU) for neonates with respiratory distress syndrome (RDS) and undergoing mechanical ventilation (MV). The aim of this study was to evaluate the clinical and economic impact of morphine versus fentanyl in neonates with RDS undergoing MV. Methods: Retrospective cost-effectiveness analysis of critically ill neonates with RDS receiving standard doses of morphine versus fentanyl at Women's Wellness and Research Center, Qatar. Clinical data of neonates were extracted from medical records of patients from 2014 to 2016. A decision analytic model based on the hospital's perspective was constructed to follow possible consequences of the initial dosing of analgesia, before potential titration. Primary end points were successful pain relief rate based on the Premature Infant Pain Profile scale and overall direct medical cost of therapy. Study population of 126 neonates was used to achieve results with 80% power and 0.05 significance. Sensitivity analysis was conducted to enhance robustness of conclusions against input uncertainties and to increase generalizability of results. Findings: Morphine achieved a success of 68% versus 43% with fentanyl (risk ratio = 1.72; 95% CI, 1.16-2.56; P = 0.0075). Morphine was associated with a minimal incremental costeffectiveness ratio of USD 135 per additional case of successful pain relief over fentanyl. Higher morphine cost was reported in 2% of cases. Sensitivity analysis found model insensitivity to input uncertainties except NICU stay and cost of MV. (C) 2019 Published by Elsevier Inc.	[Abushanab, Dina; Alsoukhni, Omar] Hamad Med Corp, Pharm Dept, Doha, Qatar; [AbouNahia, Fouad] Hamad Med Corp, Neonatal Intens Care Unit Dept, Doha, Qatar; [AI-Badriyeh, Daoud] Qatar Univ, Coll Pharm, Doha, Qatar	AI-Badriyeh, D (reprint author), Qatar Univ, Coll Pharm, Pharmacoecon & Outcomes Res, Doha 2713, Qatar.	daoud.a@qu.edu.qa		Al-Badriyeh, Daoud/0000-0001-7791-954X	Office of Academic Research, Qatar University, Qatar; Qatar University [QUUG-CPHeCPH-15/16-8]	We acknowledge the receipt of study funding by Office of Academic Research, Qatar University, Qatar. This work was supported by Qatar University grant QUUG-CPHeCPH-15/16-8. We also appreciate the support of the neonatal intensive care unit team at the Women's Wellness and Research Center, Hamad Medical Corporataion, Qatar, for the provision of local statistics data via the Vermont Oxford database at the unit.	Al MJ, 2010, CRIT CARE, V14, DOI 10.1186/cc9313; Anadkat JS, 2012, J PERINATOL, V32, P780, DOI 10.1038/jp.2011.191; Anand KJS, 1999, ARCH PEDIAT ADOL MED, V153, P331; Angus DC, 2000, JAMA-J AM MED ASSOC, V284, P2762, DOI 10.1001/jama.284.21.2762; [Anonymous], 2018, LEXICOMP ONLINE PEDI; Aranda JV, 2005, CLIN THER, V27, P877, DOI 10.1016/j.clinthera.2005.06.019; ARNOLD JH, 1990, ANESTHESIOLOGY, V73, P1136, DOI 10.1097/00000542-199012000-00011; Badr Lina Kurdahi, 2010, Pediatr Nurs, V36, P129; Barrientos-Vega R, 2001, CRIT CARE MED, V29, P317, DOI 10.1097/00003246-200102000-00018; BarrientosVega R, 1997, CRIT CARE MED, V25, P33, DOI 10.1097/00003246-199701000-00009; Bellu R, 2010, ARCH DIS CHILD-FETAL, V95, pF241, DOI 10.1136/adc.2008.150318; Bennett S, 2011, RESP CARE, V56, P168, DOI 10.4187/respcare.01095; Biau DJ, 2008, CLIN ORTHOP RELAT R, V466, P2282, DOI 10.1007/s11999-008-0346-9; Brasher PMA, 2007, CAN J ANAESTH, V54, P103, DOI 10.1007/BF03022005; Carpio AL Mora, 2018, POSITIVE END EXPIRAT; CARRASCO G, 1993, CHEST, V103, P557, DOI 10.1378/chest.103.2.557; Condo V, 2017, J MATERN-FETAL NEO M, V30, P1267, DOI 10.1080/14767058.2016.1210597; Cox CE, 2008, CRIT CARE MED, V36, P706, DOI 10.1097/CCM.0B013E3181544248; Melo Gleicia Martins de, 2014, Rev. paul. pediatr., V32, P395, DOI [10.1590/S0103-05822014000400017, 10.1016/j.rpped.2014.04.007]; Glass HC, 2015, ANESTH ANALG, V120, P1337, DOI 10.1213/ANE.0000000000000705; Guinsburg R, 1998, J PEDIATR-US, V132, P954, DOI 10.1016/S0022-3476(98)70390-7; Gupta KK, 2016, SAUDI J ANAESTH, V10, P328, DOI 10.4103/1658-354X.174918; Hall RW, 2007, SEMIN PERINATOL, V31, P289, DOI 10.1053/j.semperi.2007.07.002; Hall RW, 2014, CLIN PERINATOL, V41, P895, DOI 10.1016/j.clp.2014.08.010; Hansen AK, 2008, BMJ-BRIT MED J, V336, P85, DOI 10.1136/bmj.39405.539282.BE; Hummel P, 2008, J PERINATOL, V28, P55, DOI 10.1038/sj.jp.7211861; Institute of Medicine Committee on Understanding Premature Birth and Assuring Healthy Outcomes, 2007, PRETERM BIRTH CAUSES; Kinsella JP, 1997, J PEDIATR-US, V131, P55, DOI 10.1016/S0022-3476(97)70124-0; Kosten Thomas R, 2002, Sci Pract Perspect, V1, P13; McPherson Christopher, 2012, J Pediatr Pharmacol Ther, V17, P351, DOI 10.5863/1551-6776-17.4.351; Menon G, 2008, ARCH DIS CHILD-FETAL, V93, pF362, DOI 10.1136/adc.2007.119297; Morgan MM, 2011, BRIT J PHARMACOL, V164, P1322, DOI 10.1111/j.1476-5381.2011.01335.x; O'Mara Keliana, 2012, J Pediatr Pharmacol Ther, V17, P252, DOI 10.5863/1551-6776-17.3.252; Orsini AJ, 1996, J PEDIATR-US, V129, P140, DOI 10.1016/S0022-3476(96)70201-9; Pandharipande PP, 2007, JAMA-J AM MED ASSOC, V298, P2644, DOI 10.1001/jama.298.22.2644; QUINN MW, 1992, EARLY HUM DEV, V30, P241, DOI 10.1016/0378-3782(92)90073-P; Saarenmaa E, 1999, J PEDIATR-US, V134, P144, DOI 10.1016/S0022-3476(99)70407-5; Saboute M, 2015, OPEN J PEDIAT, V5, P285, DOI [10.4236/ojped.2015.54043, DOI 10.4236/OJPED.2015.54043]; Shah PS, 2011, AM J PERINAT, V28, P360, DOI 10.1055/s-0030-1270112; Shehabi Y, 2009, ANESTHESIOLOGY, V111, P1075, DOI 10.1097/ALN.0b013e3181b6a783; Silbermann M, 2011, J PEDIAT HEMATOL ONC, V33, pS1, DOI 10.1097/MPH.0b013e3182121872; Simons SHP, 2003, JAMA-J AM MED ASSOC, V290, P2419, DOI 10.1001/jama.290.18.2419; Stevens B, 1996, CLIN J PAIN, V12, P13, DOI 10.1097/00002508-199603000-00004; Sun HQ, 2013, LUNG, V191, P425, DOI 10.1007/s00408-013-9475-3; Swart EL, 1999, CRIT CARE MED, V27, P1461, DOI 10.1097/00003246-199908000-00009; YASTER M, 1987, ANESTHESIOLOGY, V66, P433, DOI 10.1097/00000542-198703000-00035; Zhou YF, 2014, CRIT CARE, V18, DOI 10.1186/cc13922; 2006, CRIT CARE MED, V34, P2738, DOI DOI 10.1097/01.CCM.0000241159.18620.AB; CRIT CARE MED, V28, P836, DOI DOI 10.1097/00003246-200003000-00037; 2004, LANCET, V363, P1673, DOI DOI 10.1016/S0140-6736(04)16251-X	50	0	0	1	2	ELSEVIER	BRIDGEWATER	685 ROUTE 202-206, BRIDGEWATER, NJ 08807 USA	0149-2918	1879-114X		CLIN THER	Clin. Ther.	APR	2019	41	4					714	727		10.1016/j.clinthera.2019.02.009			14	Pharmacology & Pharmacy	Pharmacology & Pharmacy	HW9FY	WOS:000466997800011	30846286				2020-06-30	J	Benahmed-Canat, A; Plaisant, F; Riche, B; Rabilloud, M; Canat, G; Paret, N; Claris, O; Kassai, B; Nguyen, KA				Benahmed-Canat, A.; Plaisant, F.; Riche, B.; Rabilloud, M.; Canat, G.; Paret, N.; Claris, O.; Kassai, B.; Nguyen, K. A.			Postsurgery analgesic and sedative drug use in a French neonatal intensive care unit: A single-center retrospective cohort study	ARCHIVES DE PEDIATRIE			English	Article							CONSENSUS STATEMENT; POSTOPERATIVE PAIN; MANAGEMENT; SCALE; PREVENTION; VALIDATION; RESPONSES; CHILDREN; INFANTS	Objective: To describe pain assessment, the pattern of analgesic and sedative drug use, and adverse drug reactions in a neonatal intensive care unit (NICU) during the postsurgery phase. Method: Demographic characteristics, pain scores, and drug use were extracted and analyzed from electronic patient medical files for infants after surgery, admitted consecutively between January 2012 and June 2013. Result: One hundred and sixty-eight infants were included. Acute (DAN score) and prolonged (EDIN score) pain assessment scores were used in 79% and 64% of infants, respectively, on the 1st day. This percentage decreased over the 7 days following surgery. The weekly average scores postsurgery were 2/15 (+/- 2.2) for the EDIN score and 1.6/10 (+/- 2.0) for the DAN score. The rates of pain control were 88% for the EDIN and 72% for the DAN. The most prescribed opiate drug was fentanyl (98 patients; 58%) with an average dose of 1.8 (+/- 0.6) mu g/kg/h. Midazolam was used in 95 patients (56%), with an average dose of 35 (+/- 14) mu g/kg/h. A bolus was administered in 7% (+/- 7.4) of the total dose for fentanyl and 8% (9.3) for midazolam. Similar doses were used in term and preterm neonates. Of 118 patients receiving fentanyl and/or midazolam, 40% presented urinary retention, 28% a weaning syndrome. Paracetamol (155 patients; 92%) and nalbuphine (55 patients: 33%) were the other medications most often prescribed. Conclusion: The off-label use of fentanyl and midazolam was necessary to treat pain after surgery. Pain assessment should be conducted for all neonates in order to optimize their treatment. Research on analgesic and sedative medicine in vulnerable neonates seems necessary to standardize practices and reduce adverse drug reactions. (C) 2019 Elsevier Masson SAS. All rights reserved.	[Benahmed-Canat, A.; Plaisant, F.; Claris, O.; Nguyen, K. A.] Hosp Civils Lyon, Hop Femme Mere Enfant, Dept Neonatol, F-69500 Bron, France; [Riche, B.; Rabilloud, M.] Hosp Civils Lyon, Dept Biostast, F-69500 Bron, France; [Paret, N.; Kassai, B.; Nguyen, K. A.] Univ Lyon 1, Hosp Civils Lyon, Dept Pharmacotoxicol, UMR 5558,LBBE, F-69500 Bron, France; [Claris, O.] Univ Lyon 1, EA 4129, Villeurbanne, France	Nguyen, KA (reprint author), Hosp Civils Lyon, Hop Femme Mere Enfant, Dept Neonatal, Dept Pharmacotoxicol, 59 Blvd Pinel, F-69500 Bron, France.	kim-an.nguyen@chu-lyon.fr		Kassai, Behrouz/0000-0002-1712-120X; Nguyen, Kim An/0000-0001-7594-504X	Hospices Civils de Lyon [D50770]	The authors have no financial relationships relevant to this article to disclose.; This study is part of the REMINEO project (etude EIMHAMMNN) "Relationship between adverse drug reactions and unlicensed or off-label drug use in hospitalized neonates" funded by Hospices Civils de Lyon for the Young Investigator Award, number D50770. The REMINEO project was approved by the local ethics committee on 6 June 2011 (CPP sud est II; no. C.A.L 2011-15). The funder was not involved in any stage of this study.	Allegaert K, 2013, SEMIN FETAL NEONAT M, V18, P42, DOI 10.1016/j.siny.2012.10.001; Anand KJS, 1999, ARCH PEDIAT ADOL MED, V153, P331; Anand KJS, 2001, ARCH PEDIAT ADOL MED, V155, P173, DOI 10.1001/archpedi.155.2.173; Ballantyne M, 1999, CLIN J PAIN, V15, P297, DOI 10.1097/00002508-199912000-00006; Bergqvist LL, 2009, J PERINATOL, V29, P44, DOI 10.1038/jp.2008.129; Bouza H, 2009, J MATERN-FETAL NEO M, V22, P722, DOI [10.1080/14767050902926962, 10.3109/14767050902926962]; Carbajal R, 1997, ARCH PEDIATRIE, V4, P623, DOI 10.1016/S0929-693X(97)83360-X; Carbajal R, 2008, JAMA-J AM MED ASSOC, V300, P60, DOI 10.1001/jama.300.1.60; Debillon T, 2001, ARCH DIS CHILD-FETAL, V85, pF36, DOI 10.1136/fn.85.1.F36; FITZGERALD M, 1991, BRIT MED BULL, V47, P667, DOI 10.1093/oxfordjournals.bmb.a072499; Grunau RE, 1998, PAIN, V76, P277, DOI 10.1016/S0304-3959(98)00046-3; Grunau RE, 2013, RAMBAM MAIMONIDES ME, V4, DOI 10.5041/RMMJ.10132; Knibbe CAJ, 2009, CLIN PHARMACOKINET, V48, P371, DOI 10.2165/00003088-200948060-00003; Krekels EHJ, 2014, CLIN PHARMACOKINET, V53, P553, DOI 10.1007/s40262-014-0135-4; Larsson Bjorn A, 2002, Lakartidningen, V99, P1946; Lawrence J, 1993, Neonatal Netw, V12, P59; Lee TC, 1999, ANESTHESIOLOGY, V90, P451, DOI 10.1097/00000542-199902000-00020; Mackenzie A, 2006, J PAEDIATR CHILD H, V42, P14, DOI 10.1111/j.1440-1754.2006.00780.x; Maitra Souvik, 2014, Acta Anaesthesiol Taiwan, V52, P30, DOI 10.1016/j.aat.2014.02.004; McPherson Christopher, 2012, J Pediatr Pharmacol Ther, V17, P351, DOI 10.5863/1551-6776-17.4.351; Ng E, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002052.pub3; Pacifici GM, 2014, INT J PEDIAT, DOI 10.1155/2014/309342; Pansieri C, 2014, ARCH DIS CHILD-FETAL, V99, pE438, DOI 10.1136/archdischild-2013-305900; Stephenson T, 2005, BRIT J CLIN PHARMACO, V59, P670, DOI 10.1111/j.1365-2125.2005.02445.x; Taylor BJ, 2006, PEDIATRICS, V118, pE992, DOI 10.1542/peds.2005-3203; van Alfen-van der Velden AAEM, 2006, BIOL NEONATE, V90, P197, DOI 10.1159/000093489; van Dijk M, 2000, PAIN, V84, P367, DOI 10.1016/S0304-3959(99)00239-0; 2010, ADDICTION, V105, P524; 2015, J PEDIAT, V166, P1200; 2016, J PEDIAT, V172, P81	30	1	1	0	3	ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER	ISSY-LES-MOULINEAUX	65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE	0929-693X	1769-664X		ARCH PEDIATRIE	Arch. Pediatr.	APR	2019	26	3					145	150		10.1016/j.arcped.2019.02.011			6	Pediatrics	Pediatrics	HW6TI	WOS:000466823100004	30885601				2020-06-30	J	Jain, N; Gera, A; Sharma, B; Sood, J; Chugh, P				Jain, Neetu; Gera, Anjali; Sharma, Bimla; Sood, Jayashree; Chugh, Parul			Comparison of Surgical Pleth Index-guided analgesia using fentanyl versus conventional analgesia technique in laparoscopic cholecystectomy	MINERVA ANESTESIOLOGICA			English	Article						Laparoscopy; Nociception; Fentanyl	STRESS INDEX; POSTOPERATIVE PAIN; REMIFENTANIL; NOCICEPTION; ANESTHESIA; PREDICTION; BALANCE	BACKGROUND. Surgical Pleth Index (SPI) is an objective index and reflects the patient's nociception-antinociception balance during surgery. There are few studies on clinical implication of use of SPI in laparoscopic surgery. The aim of this study was to compare fentanyl requirement using SPI guided administration versus conventional analgesia technique in laparoscopic cholecystectomy. METHODS. One hundred forty patients of ASA physical status I and II, scheduled to undergo laparoscopic cholecystectomy were randomly allocated to SPI group and control group. In SPI group, fentanyl boluses of 0.5 mcg/kg were administered to keep SPI between a range of 20 to 50. In control group, fentanyl boluses 0.5 mcg/kg were given whenever heart rate or mean arterial pressure rose 20% above baseline. Intraoperative heart rate, blood pressure, fentanyl requirement, duration of surgery and recovery time were noted. SPI was monitored only in SPI group. Postoperative Visual Analog Scale (VAS) score, fentanyl requirement, postoperative nausea, vomiting and respiratory depression were recorded. RESULTS. Mean intraoperative fentanyl consumption was significantly higher in SPI group as compared to control group (169 +/- 47.2 vs. 151 +/- 39.34, P=0.017). Hemodynamic changes and recovery time were comparable in both the groups. Post-operative VAS and adjuvant fentanyl consumption were significantly higher in control group as compared to SPI group (P<0.05). PONV and respiratory depression were comparable in both the groups. CONCLUSIONS. Higher doses of fentanyl are required intraoperatively with lesser postoperative rescue analgesic requirements when SPI is used to guide intraoperative analgesia as compared to conventional analgesia technique.	[Jain, Neetu; Gera, Anjali; Sharma, Bimla; Sood, Jayashree] Sir Ganga Ram Hosp, Dept Anesthesiol Pain & Perioperat Med, New Delhi 110060, India; [Chugh, Parul] Sir Ganga Ram Hosp, Dept Res, New Delhi, India	Jain, N (reprint author), Sir Ganga Ram Hosp, Dept Anesthesiol Pain & Perioperat Med, New Delhi 110060, India.	drneetujain@yahoo.com					Ahonen J, 2007, BRIT J ANAESTH, V98, P456, DOI 10.1093/bja/aem035; Bergmann I, 2013, BRIT J ANAESTH, V110, P622, DOI 10.1093/bja/aes426; Bonhomme V, 2011, BRIT J ANAESTH, V106, P101, DOI 10.1093/bja/aeq291; Chen XZ, 2012, SCI WORLD J, DOI 10.1100/2012/879158; Chen XZ, 2010, ANESTHESIOLOGY, V112, P1175, DOI 10.1097/ALN.0b013e3181d3d641; Colombo R, 2015, MINERVA ANESTESIOL, V81, P837; Colombo R, 2014, EUR J ANAESTH, V31, P76, DOI 10.1097/01.EJA.0000436116.06728.b3; Hamunen K, 2012, BRIT J ANAESTH, V108, P838, DOI 10.1093/bja/aes001; Harju J, 2016, BRIT J ANAESTH, V117, P358, DOI 10.1093/bja/aew215; Hocker J, 2010, BRIT J ANAESTH, V105, P150, DOI 10.1093/bja/aeq114; Huiku M, 2007, BRIT J ANAESTH, V98, P447, DOI 10.1093/bja/aem004; Ilies C, 2012, ANAESTHESIA, V67, P508, DOI 10.1111/j.1365-2044.2011.07051.x; Kallio H, 2008, BRIT J ANAESTH, V101, P383, DOI 10.1093/bja/aen204; Kreuer S, 2005, ANESTH ANALG, V101, P427, DOI 10.1213/01.ANE.0000157565.00359.E2; Ledowski T, 2005, ANESTH ANALG, V101, P1700, DOI 10.1213/01.ane.0000184041.32175.14; Ledowski T, 2017, BRIT J ANAESTH, V119, P979, DOI 10.1093/bja/aex300; Ledowski T, 2016, BRIT J ANAESTH, V117, P371, DOI 10.1093/bja/aew226; Mathews DM, 2007, BRIT J ANAESTH, V98, P785, DOI 10.1093/bja/aem084; Park JH, 2015, ANESTHESIOLOGY, V122, P1280, DOI 10.1097/ALN.0000000000000650; Rantanen M, 2006, BRIT J ANAESTH, V96, P367, DOI 10.1093/bja/ael005; Struys MMRF, 2007, BRIT J ANAESTH, V99, P359, DOI 10.1093/bja/aem173; Szental JA, 2015, BRIT J ANAESTH, V114, P640, DOI 10.1093/bja/aeu411; Thee C, 2015, EUR J ANAESTH, V32, P44, DOI 10.1097/EJA.0000000000000095; Wennervirta J, 2008, ACTA ANAESTH SCAND, V52, P1038, DOI 10.1111/j.1399-6576.2008.01687.x; Willms S, 2011, EUR J ANAESTH, V28, P21; Won YJ, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000004743	26	3	3	1	4	EDIZIONI MINERVA MEDICA	TURIN	CORSO BRAMANTE 83-85 INT JOURNALS DEPT., 10126 TURIN, ITALY	0375-9393	1827-1596		MINERVA ANESTESIOL	Minerva Anestesiol.	APR	2019	85	4					358	365		10.23736/S0375-9393.18.12954-3			8	Anesthesiology; Critical Care Medicine	Anesthesiology; General & Internal Medicine	HW5JM	WOS:000466725700007	30605991				2020-06-30	J	Kanamori, T; Iwata, YT; Segawa, H; Yamamuro, T; Kuwayama, K; Tsujikawa, K; Inoue, H				Kanamori, Tatsuyuki; Iwata, Yuko Togawa; Segawa, Hiroki; Yamamuro, Tadashi; Kuwayama, Kenji; Tsujikawa, Kenji; Inoue, Hiroyuki			Metabolism of Butyrylfentanyl in Fresh Human Hepatocytes: Chemical Synthesis of Authentic Metabolite Standards for Definitive Identification	BIOLOGICAL & PHARMACEUTICAL BULLETIN			English	Article						butyrylfentanyl; metabolism; hepatocyte; CYP reaction phenotyping	FENTANYL	The metabolism of butyrylfentanyl, a new designer drug, was investigated using fresh human hepatocytes isolated from a liver-humanized mouse model. In the culture medium of hepatocytes incubated with butyrylfentanyl, the desphenethylated metabolite (nor-butyrylfentanyl), omega-hydroxy-butyrylfentanyl, (omega-1)-hydroxy-butyrylfentanyl, 4'-hydroxy-butyrylfentanyl, beta-hydroxy-butyrylfentanyl, 4'-hydroxy-3'-methoxy-butyrylfentanyl, and omega-carboxy-fentanyl were identified as the metabolites of butyrylfentanyl. Each metabolite was definitively identified by comparing the analytical data with those of authentic standards. The amount of the main metabolite, nor-butyrylfentanyl, reached 37% of the initial amount of butyrylfentanyl at 48h. omega-Hydroxy-butyrylfentanyl and (omega-1)-hydroxy-butyrylfentanyl, formed by hydroxylation at the N-butyryl group of butyrylfentanyl, were the second and third largest metabolites, respectively. The majority of 4'-hydroxy-butyrylfentanyl and 4'-hydroxy-3'-methoxy-butyrylfentanyl was considered to be conjugated. CYP reaction phenotyping for butyrylfentanyl using human liver microsomes and various anti-CYP antibodies revealed that CYP3A4 was involved in the formation of nor-butyrylfentanyl, (omega-1)-hydroxybutyrylfentanyl, and beta-hydroxy-butyrylfentanyl. In contrast, CYP2D6 was involved in the formation of omega-hydroxy-butyrylfentanyl.	[Kanamori, Tatsuyuki; Iwata, Yuko Togawa; Segawa, Hiroki; Yamamuro, Tadashi; Kuwayama, Kenji; Tsujikawa, Kenji; Inoue, Hiroyuki] Natl Res Inst Police Sci, 6-3-1 Kashiwanoha, Kashiwa, Chiba 2770882, Japan	Kanamori, T (reprint author), Natl Res Inst Police Sci, 6-3-1 Kashiwanoha, Kashiwa, Chiba 2770882, Japan.	kanamori@nrips.go.jp			Japan Society for the Promotion of Science (JSPS) KAKENHIMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [15K08895]	This work was supported by Japan Society for the Promotion of Science (JSPS) KAKENHI Grant Number 15K08895.	CROSSLAN.RK, 1970, J ORG CHEM, V35, P3195, DOI 10.1021/jo00834a087; Drug Enforcement Administration Department of Justice, 2016, Fed Regist, V81, P29492; Higashikawa Y, 2008, FORENSIC TOXICOL, V26, P1, DOI 10.1007/s11419-007-0039-1; Kanamori T, 2018, FORENSIC TOXICOL, V36, P467, DOI 10.1007/s11419-018-0425-x; McIntyre IM, 2016, J ANAL TOXICOL, V40, P162, DOI 10.1093/jat/bkv138; Siegfried, SYNTH FENT; Staeheli SN, 2016, FORENSIC SCI INT, V266, P170, DOI 10.1016/j.forsciint.2016.05.034; Steuer AE, 2017, DRUG TEST ANAL, V9, P1085, DOI 10.1002/dta.2111; United Nations Office on Drugs and Crime, 2017, FENT ITS AN 50 YEARS, V17; Yamasaki C, 2010, DRUG METAB PHARMACOK, V25, P539, DOI 10.2133/dmpk.DMPK-10-RG-047	10	4	4	1	3	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0918-6158			BIOL PHARM BULL	Biol. Pharm. Bull.	APR	2019	42	4					623	630		10.1248/bpb.b18-00765			8	Pharmacology & Pharmacy	Pharmacology & Pharmacy	HR9FZ	WOS:000463465900018	30930421	Bronze			2020-06-30	J	Deeks, ED				Deeks, Emma D.			Sufentanil 30 mu g Sublingual Tablet: A Review in Acute Pain	CLINICAL DRUG INVESTIGATION			English	Review							POSTOPERATIVE PAIN; 30 MCG; MANAGEMENT; MODERATE	The sufentanil 30 g sublingual tablet (hereafter referred to as the sufentanil ST) is approved in the EU for acute moderate to severe pain in adults (Dzuveo) and in the USA for acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate (Dsuvia). It is a single-strength tablet housed in a single-dose applicator (which may minimize the likelihood of dosing errors) and is strictly for use in medically supervised/monitored settings. It is administered by a healthcare professional and has a minimum re-dose interval of 1h and no drug delivery setup requirements. In placebo-controlled or noncomparative phase 2 or 3 trials, the sufentanil ST provided effective analgesia for adults with moderate to severe acute pain due to surgery or trauma/injury, reducing the intensity of pain within 15-30min after the first dose and maintaining analgesic benefit over the 2-24h study periods. Such short-term use of the sufentanil ST was also generally well tolerated. Studies directly comparing the sufentanil ST with other opioids in terms of efficacy, tolerability, usability and cost effectiveness would be beneficial, as would analyses of its abuse potential, given sufentanil is considerably more potent than fentanyl or morphine. In the meantime, current data indicate that the sufentanil ST is a noninvasive, fast-acting, opioid formulation for managing moderate to severe acute pain in medically supervised/monitored settings that may be of particular use when oral or intravenous opioid analgesia is not possible/feasible.	[Deeks, Emma D.] Springer, Private Bag 65901, Auckland 0754, New Zealand	Deeks, ED (reprint author), Springer, Private Bag 65901, Auckland 0754, New Zealand.	email@springer.com					Best Practice Advocacy Centre New Zealand, 2018, PRINC MAN AC PAIN PR; Chou R, 2016, J PAIN, V17, P131, DOI 10.1016/j.jpain.2015.12.008; Didonato K, 2017, PAIN MED, V18, P585; European Medicines Agency, 2018, DZUV EU SUMM PROD CH; Faculty of Pain Medicine, 2019, OP AC PAIN MAN; Fisher DM, 2018, ANESTHESIOLOGY, V128, P943, DOI 10.1097/ALN.0000000000002145; Frampton JE, 2016, DRUGS, V76, P719, DOI 10.1007/s40265-016-0571-6; Hutchins JL, 2018, PAIN MED, V19, P2058, DOI 10.1093/pm/pnx248; Keating Liza, 2011, Rev Pain, V5, P13, DOI 10.1177/204946371100500304; Krans B, 2018, SHOULD FDA HAVE APPR; Lotsch JR, 2005, J PAIN SYMPTOM MANAG, V29, pS90, DOI 10.1016/j.jpainsymman.2005.01.012; Malek J., 2017, POSTOPERATIVE PAIN M; MATHER LE, 1995, CLIN EXP PHARMACOL P, V22, P833, DOI 10.1111/j.1440-1681.1995.tb01945.x; Miner JR, 2019, PAIN MANAG, V9, P259, DOI 10.2217/pmt-2018-0090; Miner JR, 2018, AM J EMERG MED, V36, P954, DOI 10.1016/j.ajem.2017.10.058; Minkowitz H, 2017, 42 ANN REG AN AC PAI; Minkowitz HS, 2017, PAIN PRACT, V17, P848, DOI 10.1111/papr.12531; Minkowitz HS, 2015, PAIN MANAG, V5, P237, DOI [10.2217/PMT.15.22, 10.2217/pmt.15.22]; Minkowitz HS, 2015, EXPERT OPIN DRUG DEL, V12, P845, DOI 10.1517/17425247.2015.975202; Pain Free Hospital, GUID PAIN MAN EM TRA; Porela-Tiihonen S, 2017, EXPERT REV NEUROTHER, V17, P101, DOI 10.1080/14737175.2017.1260005; Samcam I, 2016, ACUTE PAIN MANAGEMEN; Singla NK, 2014, J TRAUMA ACUTE CARE, V77, pS198, DOI 10.1097/TA.0000000000000373; The College of Emergency Medicine, 2014, BEST PRACT GUID MAN; US Food and Drug Administration, 2018, DSUV SUF SUBL TABL 3; Volkow ND, 2016, NEW ENGL J MED, V374, P1253, DOI 10.1056/NEJMra1507771; Willsie SK, 2015, CLIN THER, V37, P145, DOI 10.1016/j.clinthera.2014.11.001; World Health Organization, 2015, WHOS CANC PAIN LADD	28	1	1	2	5	ADIS INT LTD	NORTHCOTE	5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND	1173-2563	1179-1918		CLIN DRUG INVEST	Clin. Drug Invest.	APR	2019	39	4					411	418		10.1007/s40261-019-00772-x			8	Pharmacology & Pharmacy	Pharmacology & Pharmacy	HR5BT	WOS:000463162300010	30887417				2020-06-30	J	Argento, E; Tupper, KW; Socias, ME				Argento, Elena; Tupper, Kenneth W.; Socias, M. Eugenia			The tripping point: The potential role of psychedelic-assisted therapy in the response to the opioid crisis	INTERNATIONAL JOURNAL OF DRUG POLICY			English	Editorial Material						Psychedelics; Opioid use disorder; Opioid crisis; Psychedelic-assisted therapy; Addiction treatment	PSILOCYBIN; LSD	The increasing contamination of the drug supply with illicitly manufactured fentanyl and related analogs in North America has resulted in the most severe drug-overdose crisis in history. Available pharmacotherapy options for the treatment of opioid use disorder have had limited success in curbing the current crisis, and a growing body of evidence highlights the need for innovative interventions that target underlying social-structural drivers of opioid use disorder. Re-emerging clinical research suggests that psychedelic-assisted therapy has potential as an alternative treatment for refractory substance use disorders and related comorbidities. Based on the available evidence, our viewpoint supports advancing research on the potential role of psychedelic-assisted therapy within a multifaceted response to the opioid crisis.	[Argento, Elena] Univ British Columbia, Interdisciplinary Studies, 270-2357 Main Mall,HR MacMillan Bldg, Vancouver, BC V6T 1Z4, Canada; [Argento, Elena] Ctr Gender & Sexual Hlth Equ, 1190 Hornby Street, Vancouver, BC V6Z 2K5, Canada; [Tupper, Kenneth W.; Socias, M. Eugenia] British Columbia Ctr Subst Use, 400-1045 Howe St, Vancouver, BC V6Z 2A9, Canada; [Tupper, Kenneth W.] Univ British Columbia, Sch Populat & Publ Hlth, 5804 Fairview Ave, Vancouver, BC V6T 1Z3, Canada; [Socias, M. Eugenia] Univ British Columbia, Dept Med, 2255 Wesbrook Mall, Vancouver, BC V6T 2A1, Canada	Socias, ME (reprint author), Univ British Columbia, Dept Med, BC Ctr Subst Use, 400-1045 Howe St, Vancouver, BC V6Z 2A9, Canada.	bccsu-es@bccsu.ubc.ca		Socias, M. Eugenia/0000-0003-2556-7049	Canadian Institutes of Health Research (CIHR)Canadian Institutes of Health Research (CIHR); Michael Smith Foundation for Health Research (MSFHR)/St Paul's Foundation scholar award	EA is supported by a Canadian Institutes of Health Research (CIHR) doctoral award. MES is supported by a Michael Smith Foundation for Health Research (MSFHR)/St Paul's Foundation scholar award.	Argento E, 2018, J PSYCHOPHARMACOL, V32, P1385, DOI 10.1177/0269881118798610; Brown TK, 2018, AM J DRUG ALCOHOL AB, V44, P24, DOI 10.1080/00952990.2017.1320802; Carhart-Harris R. L., 2017, NEUROPSYCHOPHARMACOL, P1; Dasgupta N, 2018, AM J PUBLIC HEALTH, V108, P182, DOI 10.2105/AJPH.2017.304187; dos Santos RG, 2016, THER ADV PSYCHOPHARM, V6, P193, DOI 10.1177/2045125316638008; Johnson MW, 2017, AM J DRUG ALCOHOL AB, V43, P55, DOI 10.3109/00952990.2016.1170135; Pisano VD, 2017, J PSYCHOPHARMACOL, V31, P606, DOI 10.1177/0269881117691453; SAVAGE C, 1973, ARCH GEN PSYCHIAT, V28, P808; Tupper KW, 2015, CAN MED ASSOC J, V187, P1054, DOI 10.1503/cmaj.141124; Wood E, 2018, NEW ENGL J MED, V378, P1565, DOI 10.1056/NEJMp1800216	10	3	3	5	8	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0955-3959	1873-4758		INT J DRUG POLICY	Int. J. Drug Policy	APR	2019	66						80	81		10.1016/j.drugpo.2018.11.006			2	Substance Abuse	Substance Abuse	HS2JS	WOS:000463687500011	30743091				2020-06-30	J	Tadrous, M; Greaves, S; Martins, D; Nadeem, K; Singh, S; Mamdani, MM; Juurlink, DN; Gomes, T				Tadrous, Mina; Greaves, Simon; Martins, Diana; Nadeem, Komail; Singh, Samantha; Mamdani, Muhammad M.; Juurlink, David N.; Gomes, Tara			Evaluation of the fentanyl patch-for-patch program in Ontario, Canada	INTERNATIONAL JOURNAL OF DRUG POLICY			English	Article						Opioids; Fentanyl; Health policy; Government programs; Drug and narcotic control	PRESCRIPTION MONITORING PROGRAM; IMPACT; MORTALITY	Background: Rising use of prescription opioids is a major public health concern associated with increased risk of mortality worldwide. Fentanyl, a synthetic opioid available in patch form, is particularly concerning given its high potency. To curb the misuse and diversion of fentanyl patches, a Patch-for-Patch (P4P) program was implemented in some counties in Ontario between 2012 and 2015. The program requires that patients prescribed fentanyl must return used patches to the pharmacy before receiving more patches. Objective: To evaluate the impact of the P4P program on fentanyl and non-fentanyl dispensing and opioid-related hospitalizations and deaths. Methods: We conducted a repeated cross-sectional time-series analysis among counties that implemented the P4P program using Ontario administrative claims data. Because intervention dates varied by county due to staggered program initiation, we aligned all intervention months and examined outcome rates in the 5 years preceding and 12 and 24 months following implementation. We explored the monthly rate of prescriptions dispensed for fentanyl and non-fentanyl opioids, opioid toxicity-related hospital and emergency department visits, and opioid-related deaths. We modeled each outcome using an interventional autoregressive integrated moving average (ARIMA) model and tested the impact of the P4P program using a ramp function. Results: We analyzed 16 counties that implemented the P4P program and had at least 12 months of follow-up. The introduction of the P4P program was associated with a 30.5% decline in the volume of fentanyl patches dispensed at 24 months (from 1,277-888 patches per 10,000 population; p = 0.04). In contrast, there was no significant change in the rate of non-fentanyl opioid dispensing (p = 0.32), opioid toxicity related hospitalizations and emergency department visits (p = 0.4) or opioid-related deaths (p = 0.96) in the 12 months following implementation of the program. Conclusions: We found that the implementation of a P4P program in select counties in Ontario was associated with a lower volume of fentanyl patches dispensed by pharmacies, without an increase in use of other opioids. The program had no measurable impact on rates of opioid toxicity-related hospital visits or deaths. Policymakers should consider the use of P4P programs as part of larger opioid strategy.	[Tadrous, Mina; Gomes, Tara] St Michaels Hosp, Li Ka Shing Knowledge Inst, Toronto, ON, Canada; [Tadrous, Mina; Greaves, Simon; Martins, Diana; Singh, Samantha; Mamdani, Muhammad M.; Juurlink, David N.; Gomes, Tara] Inst Clin Evaluat Sci, Toronto, ON, Canada; [Tadrous, Mina; Nadeem, Komail; Mamdani, Muhammad M.; Gomes, Tara] Univ Toronto, Leslie Dan Fac Pharm, Toronto, ON, Canada; [Mamdani, Muhammad M.; Juurlink, David N.; Gomes, Tara] Univ Toronto, Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada; [Mamdani, Muhammad M.] St Michaels Hosp, Li Ka Shing Ctr Healthcare Analyt Res & Training, Toronto, ON, Canada; [Juurlink, David N.] Sunnybrook Res Inst, Toronto, ON, Canada	Tadrous, M (reprint author), 30 Bond St, Toronto, ON, Canada.	tadrousm@smh.ca			Public Safety Canada; Ontario Ministry of Health and Long - Term Care (MOHLTC)Ministry of Health and Long-Term Care, Ontario; Ontario Strategy for Patient -Orientated Research (SPOR) Support Unit - Canadian Institutes of Health Research; Institute for Clinical Evaluative Sciences (ICES) - Ontario MOHLTC; Province of Ontario	This project was funded by Public Safety Canada. The ODPRN is funded by grants from the Ontario Ministry of Health and Long-Term Care (MOHLTC) and Ontario Strategy for Patient-Orientated Research (SPOR) Support Unit, which is supported by the Canadian Institutes of Health Research and the Province of Ontario. The study is also supported by the Institute for Clinical Evaluative Sciences (ICES), which is funded by an annual grant from the Ontario MOHLTC. The opinions, results and conclusions reported in this paper are those of the authors and are independent from the funding sources. No endorsement by ICES, the SPOR Support Unit or the Ontario MOHLTC is intended or should be inferred. Datasets provided by ICES were linked using unique encoded identifiers and analyzed at ICES. Parts of this material are based on data and information compiled and provided by CIHI. However, the analyses, conclusions, opinions and statements expressed herein are those of the author, and not necessarily those of CIHI. We thank Brogan Inc., Ottawa for use of their Drug Product and Therapeutic Class Database. This project would not have been possible without the contributions and support of the Ontario Provincial Police. Lastly, we thank the Office of the Chief Coroner of Ontario which made the opioid-related death data available.	Canadian Pharmaceutical Association, 2008, COMP PHARM SPEC; Chaudhry A, 2018, CAN PHARM J, V151, P12, DOI 10.1177/1715163517743993; Dhalla IA, 2009, CAN MED ASSOC J, V181, P891, DOI 10.1503/cmaj.090784; Fischer B, 2018, PREV MED, V107, P109, DOI 10.1016/j.ypmed.2017.11.001; Gilson AM, 2012, J PAIN, V13, P103, DOI 10.1016/j.jpain.2011.09.006; Gomes T, 2014, CMAJ OPEN, V2, P256; Gomes T, 2017, JAMA INTERN MED, V177, P61, DOI 10.1001/jamainternmed.2016.6851; Gomes T, 2011, ARCH INTERN MED, V171, P686, DOI 10.1001/archinternmed.2011.117; Howlett K., 2016, GLOBE MAIL; Kelly B., 2015, PROGRAM FIGHTS FENTA; Kim S.-M., 2018, HLTH REFORM OBSERVER, V6; Kwok H, 2017, PAIN MED, V18, P1019, DOI 10.1093/pm/pnw351; Ontario Association of Chiefs of Police-Substance Abuse Committee, 2014, FENT AB PREV SHAR RE; Ontario Public Drug Programs Division, 2016, MIN HLTH LONG TERM C; Piszczek J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098003; Pradel V, 2009, PHARMACOEPIDEM DR S, V18, P36, DOI 10.1002/pds.1681; Public Health Ontario, 2017, OP REL MORB MORT ONT; Reifler LM, 2012, PAIN MED, V13, P434, DOI 10.1111/j.1526-4637.2012.01327.x; Statistics C, 2019, ESTIMATES POPULATION; Trescot A. M., 2016, OPIOID PHARM PHARMAC, P45; Young M. M., 2015, CANADIAN J ADDICTION, V13	21	1	1	3	3	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0955-3959	1873-4758		INT J DRUG POLICY	Int. J. Drug Policy	APR	2019	66						82	86		10.1016/j.drugpo.2019.01.025			5	Substance Abuse	Substance Abuse	HS2JS	WOS:000463687500012	30743092				2020-06-30	J	von Plato, H; Mattila, K; Poikola, S; Loyttyniemi, E; Hamunen, K; Kontinen, V				von Plato, Hanna; Mattila, Kristiina; Poikola, Satu; Loyttyniemi, Eliisa; Hamunen, Katri; Kontinen, Vesa			Risk-based targeting of adjuvant pregabalin treatment in laparoscopic cholecystectomy: a randomized, controlled trial	SCANDINAVIAN JOURNAL OF PAIN			English	Article						postoperative pain; day-case cholecystectomy; risk of postoperative pain	ACUTE POSTSURGICAL PAIN; ACUTE POSTOPERATIVE PAIN; PREDICTORS; MANAGEMENT; INTENSITY; METAANALYSES; TRAJECTORIES; CONSUMPTION; PREVENTION	Background and aims: Pain is the most common reason for delayed discharge after day-case laparoscopic cholecystectomy. This study investigates a simple five-item questionnaire in evaluating the risk of postoperative pain in day-case cholecystectomy and the efficacy and safety of single-dose preoperative pregabalin on patients with multiple risk factors for pain. There are no previous studies on targeting adjuvant pain treatment based on the individual risk factors like the preoperative state of anxiety, acute or chronic pain, and the expectation of pain in day-case surgery. Methods: One hundred and thirty patients scheduled for day-case laparoscopic cholecystectomy were evaluated with a five-item questionnaire assessing the risk for postoperative pain. The patients with multiple risk factors (n = 60) were randomized to receive either pregabalin 150 mg or placebo, 1 h before surgery. The primary outcome was abdominal pain intensity on numerical rating scale NRS) 1 h after surgery. Pain, analgesic consumption and adverse effects during first three postoperative days, and the length of hospital stay were also recorded. Results: Pregabalin 150 mg given as an adjuvant analgesic preoperatively did not decrease postoperative abdominal pain or opioid consumption in the first hour after surgery compared to placebo in a preselected group of patients with multiple risk factors for postoperative pain (p = 0.31). Preoperative anxiety assessed with a scale of 0-10 had a positive association with postoperative pain (p = 0.045). Conclusions and implications: This was the first trial on systematically selecting patients with a high-risk factor profile for postoperative pain as a target for a preventive adjuvant analgesic intervention. Although numerous previous studies have identified various risk factors, including those used in the current trial, it seems to be challenging to use these risk factors as predictive tools for targeting adjuvant analgesics in day-case surgery. Preoperative anxiety has a positive association with postoperative pain in day-case laparoscopic cholecystectomy, and this should be taken into account when treating these patients.	[von Plato, Hanna] HUS, Jorvi Hosp, Helsinki Univ Hosp, POB 800, Helsinki 00029, Finland; [von Plato, Hanna; Mattila, Kristiina; Poikola, Satu; Kontinen, Vesa] Univ Helsinki, Jorvi Hosp, Dept Anesthesiol & Intens Care Med, Div Perioperat Care, Helsinki, Finland; [Mattila, Kristiina; Poikola, Satu; Loyttyniemi, Eliisa; Kontinen, Vesa] Helsinki Univ Hosp, Helsinki, Finland; [Loyttyniemi, Eliisa] Univ Turku, Dept Biostat, Turku, Finland; [Hamunen, Katri] Univ Helsinki, Dept Anesthesiol & Intens Care Med, Div Pain Med, Helsinki Pain Clin, Helsinki, Finland	von Plato, H (reprint author), HUS, Jorvi Hosp, Helsinki Univ Hosp, POB 800, Helsinki 00029, Finland.; von Plato, H (reprint author), Univ Helsinki, Jorvi Hosp, Dept Anesthesiol & Intens Care Med, Div Perioperat Care, Helsinki, Finland.	hanna.von.plato@hus.fi			state funding for university-level health research [TYH3052014]	The study has been supported by state funding for university-level health research, project code TYH3052014.	Agarwal A, 2008, BRIT J ANAESTH, V101, P700, DOI 10.1093/bja/aen244; Althaus A, 2014, EUR J PAIN, V18, P513, DOI 10.1002/j.1532-2149.2013.00385.x; Balaban F, 2012, J CLIN ANESTH, V24, P175, DOI 10.1016/j.jclinane.2011.06.027; Bockbrader HN, 2010, CLIN PHARMACOKINET, V49, P661, DOI 10.2165/11536200-000000000-00000; Booth JL, 2016, ANESTH ANALG, V122, P1114, DOI 10.1213/ANE.0000000000000695; Caumo W, 2002, ACTA ANAESTH SCAND, V46, P1265, DOI 10.1034/j.1399-6576.2002.461015.x; Chou R, 2016, J PAIN, V17, P131, DOI 10.1016/j.jpain.2015.12.008; Fabritius ML, 2017, BRIT J ANAESTH, V119, P775, DOI 10.1093/bja/aex227; Fabritius ML, 2016, ACTA ANAESTH SCAND, V60, P1188, DOI 10.1111/aas.12766; Gramke HF, 2009, CLIN J PAIN, V25, P455, DOI 10.1097/AJP.0b013e31819a6e34; Gurusamy KS, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008261.pub2; Hinrichs-Rocker A, 2009, EUR J PAIN, V13, P719, DOI 10.1016/j.ejpain.2008.07.015; Ip HYV, 2009, ANESTHESIOLOGY, V111, P657, DOI 10.1097/ALN.0b013e3181aae87a; Katz J, 2005, PAIN, V119, P16, DOI 10.1016/j.pain.2005.09.008; Kehlet H, 2006, LANCET, V367, P1618, DOI 10.1016/S0140-6736(06)68700-X; Kehlet H, 2007, BEST PRACT RES-CLIN, V21, P149, DOI 10.1016/j.bpa.2006.12.001; Kumar K, 2017, ANESTH ANALG, V125, P1749, DOI 10.1213/ANE.0000000000002497; Li SJ, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000006982; Mattila K, 2010, ACTA ANAESTH SCAND, V54, P268, DOI 10.1111/j.1399-6576.2009.02126.x; Myhre M, 2016, ANESTHESIOLOGY, V124, P141, DOI 10.1097/ALN.0000000000000913; Nielsen S, 2016, PHARMACOEPIDEM DR S, V25, P733, DOI 10.1002/pds.3945; Pan PH, 2013, ANESTHESIOLOGY, V118, P1170, DOI 10.1097/ALN.0b013e31828e156f; Papaioannou M, 2009, PAIN MED, V10, P1452, DOI 10.1111/j.1526-4637.2009.00730.x; Perkins FM, 2000, ANESTHESIOLOGY, V93, P1123, DOI 10.1097/00000542-200010000-00038; Pinto PR, 2017, J PAIN, V18, P947, DOI 10.1016/j.jpain.2017.03.003; Pinto PR, 2017, J PAIN RES, V10, P1087, DOI 10.2147/JPR.S126467; Schulz KF, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c332; Sipila RM, 2017, PAIN, V158, P922, DOI 10.1097/j.pain.0000000000000859; Sommer M, 2010, CLIN J PAIN, V26, P87, DOI 10.1097/AJP.0b013e3181b43d68; Stessel B, 2017, CLIN J PAIN, V33, P405, DOI 10.1097/AJP.0000000000000413; Tiippana EM, 2007, ANESTH ANALG, V104, P1545, DOI 10.1213/01.ane.0000261517.27532.80; Tolska HK, 2017, ANESTH ANALG, V124, P1459, DOI 10.1213/ANE.0000000000002015; Vaughan J, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006798.pub4; Weinrib AZ, 2017, BRIT J PAIN, V11, P169, DOI 10.1177/2049463717720636; Zhang J, 2011, BRIT J ANAESTH, V106, P454, DOI 10.1093/bja/aer027	35	0	0	0	2	WALTER DE GRUYTER GMBH	BERLIN	GENTHINER STRASSE 13, D-10785 BERLIN, GERMANY	1877-8860	1877-8879		SCAND J PAIN	Scand. J. Pain	APR	2019	19	2					309	317		10.1515/sjpain-2018-0330			9	Clinical Neurology	Neurosciences & Neurology	HR7YA	WOS:000463370000010	30703062				2020-06-30	J	Palmquist, KB; Swortwood, MJ				Palmquist, Kaitlyn B.; Swortwood, Madeleine J.			Data-independent screening method for 14 fentanyl analogs in whole blood and oral fluid using LC-QTOF-MS	FORENSIC SCIENCE INTERNATIONAL			English	Article						Fentanyl analogs; Postmortem blood; Oral fluid; Novel synthetic opioids; High resolution mass spectrometry	PERFORMANCE LIQUID-CHROMATOGRAPHY; ACETYL FENTANYL; QUANTITATIVE-ANALYSIS; SYNTHETIC OPIOIDS; FURANYL FENTANYL; POSTMORTEM; URINE; METABOLITES; MS/MS; REDISTRIBUTION	Recently, fentanyl analogs account for significant number of opioid deaths in the United States. Routine forensic analyses are often unable to detect and differentiate these analogs due to low concentrations and presence of structural isomers. A data-independent screening method for 14 fentanyl analogs in whole blood and oral fluid was developed and validated using liquid chromatography-quadrupole-time-offlight mass spectrometry (LC-QTOF-MS). Data were acquired using Time of Flight (TOF) and All Ions Fragmentation (AIF) modes. The limits of detection (LOD) in blood were 0.1-1.0 ng/mL and 0.1-1.0 ng/mL in TOF and AIF modes, respectively. In oral fluid, the LODs were 0.25 ng/mL and 0.25-2.5 ng/mL in TOF and AIF modes, respectively. Matrix effects in blood were acceptable for most analytes (1-14.4%), while the nor-metabolites exhibited ion suppression >25%. Matrix effects in oral fluid were -11.7 to 13.3%. Stability was assessed after 24 h in the autosampler (4 degrees C) and refrigerator (4 degrees C). Processed blood and oral fluid samples were considered stable with -14.6 to 4.6% and -10.1 to 2.3% bias, respectively. For refrigerated stability, bias was -23.3 to 8.2% (blood) and -20.1 to 20.0% (oral fluid). Remifentanil exhibited >20% loss in both matrices. For proof of applicability, postmortem blood (n = 30) and oral fluid samples (n = 20) were analyzed. As a result, six fentanyl analogs were detected in the blood samples with furanyl fentanyl and 4ANN) being the most prevalent. No fentanyl analogs were detected in the oral fluid samples. This study presents a validated screening technique for fentanyl analogs in whole blood and oral fluid using LCQTOF-MS with low limits of detection. (C) 2019 Elsevier B.V. All rights reserved.	[Palmquist, Kaitlyn B.; Swortwood, Madeleine J.] Sam Houston State Univ, Dept Forens Sci, Coll Criminal Justice, Huntsville, TX 77340 USA	Swortwood, MJ (reprint author), Sam Houston State Univ, Dept Forens Sci, 1003 Bowers Blvd,Box 2525, Huntsville, TX 77340 USA.	swortwoodm@shsu.edu			Forensic Science Foundation Lucas Grant Award; National Institute of Justice, Office of Justice Programs, US Department of Justice [2017-R2-CX-0019]	The authors would like to thank and acknowledge the Department of Forensic Science at Sam Houston State University for providing the resources necessary to conduct this research. A portion of this research was funded by the Forensic Science Foundation Lucas Grant Award. A portion of this project was also supported by [Award No. 2017-R2-CX-0019], awarded by the National Institute of Justice, Office of Justice Programs, US Department of Justice. The opinions, findings and conclusions or recommendations expressed in this publication are those of the author(s) and do not necessarily reflect those of the Department of Justice.	[Anonymous], 2013, J ANAL TOXICOL, V37, P452, DOI 10.1093/jat/bkt054; Backberg M, 2015, CLIN TOXICOL, V53, P609, DOI 10.3109/15563650.2015.1054505; Bode AD, 2017, AM J EMERG MED, V35, P1364, DOI 10.1016/j.ajem.2017.02.043; Caspar AT, 2018, TALANTA, V176, P635, DOI 10.1016/j.talanta.2017.08.063; Chatterton CN, 2018, FORENSIC SCI INT, V284, P146, DOI 10.1016/j.forsciint.2017.12.031; Cunningham SM, 2016, J FORENSIC SCI, V61, pS276, DOI 10.1111/1556-4029.12953; Daniulaityte R, 2017, MMWR-MORBID MORTAL W, V66, P904, DOI 10.15585/mmwr.mm6634a3; Drug Enforcement Administration, 2018, DRUG SCHED; Drug Enforcement Administration, 2018, US DRUG ENF ADM EM S; Eckart K, 2015, J CHROMATOGR B, V1001, P1, DOI 10.1016/j.jchromb.2015.06.028; Fogarty MF, 2018, J ANAL TOXICOL, V42, P592, DOI 10.1093/jat/bky035; Fort C, 2016, J ANAL TOXICOL, V40, P754, DOI 10.1093/jat/bkw068; Gergov M, 2009, FORENSIC SCI INT, V186, P36, DOI 10.1016/j.forsciint.2009.01.013; Griswold MK, 2017, J MED TOXICOL, V13, P287, DOI 10.1007/s13181-017-0632-6; Guerrieri D, 2017, J ANAL TOXICOL, V41, P242, DOI 10.1093/jat/bkw129; Helander A, 2017, CLIN TOXICOL, V55, P589, DOI 10.1080/15563650.2017.1303141; Helander A, 2016, CLIN TOXICOL, V54, P324, DOI 10.3109/15563650.2016.1139715; Hikin L, 2018, FORENSIC SCI INT, V282, P179, DOI 10.1016/j.forsciint.2017.11.036; Kahl JH, 2018, J ANAL TOXICOL, V42, P570, DOI 10.1093/jat/bky054; Krotulski AJ, 2018, DRUG TEST ANAL, V10, P127, DOI 10.1002/dta.2228; Lurie IS, 2009, J CHROMATOGR A, V1216, P1515, DOI 10.1016/j.chroma.2008.12.097; Lv JL, 2012, ANAL LETT, V45, P1133, DOI 10.1080/00032719.2012.673096; Manral L, 2008, J CHROMATOGR SCI, V46, P551, DOI 10.1093/chromsci/46.6.551; Martucci HFH, 2018, FORENSIC SCI INT, V283, pE13, DOI 10.1016/j.forsciint.2017.12.005; Matuszewski BK, 2003, ANAL CHEM, V75, P3019, DOI 10.1021/ac020361s; McIntyre IM, 2016, J ANAL TOXICOL, V40, P162, DOI 10.1093/jat/bkv138; McIntyre IM, 2015, J ANAL TOXICOL, V39, P490, DOI 10.1093/jat/bkv043; Mohr ALA, 2016, J ANAL TOXICOL, V40, P709, DOI 10.1093/jat/bkw086; Noble C, 2018, DRUG TEST ANAL, V10, P651, DOI 10.1002/dta.2263; Poklis J, 2016, J ANAL TOXICOL, V40, P703, DOI 10.1093/jat/bkw048; Poklis J, 2015, FORENSIC SCI INT, V257, P435, DOI 10.1016/j.forsciint.2015.10.021; Shaner RL, 2014, J CHROMATOGR B, V962, P52, DOI 10.1016/j.jchromb.2014.05.025; Shanks KG, 2017, J ANAL TOXICOL, V41, P466, DOI 10.1093/jat/bkx042; Shoff EN, 2017, J ANAL TOXICOL, V41, P484, DOI 10.1093/jat/bkx041; Sofalvi S, 2017, J ANAL TOXICOL, V41, P473, DOI 10.1093/jat/bkx052; Staeheli SN, 2016, FORENSIC SCI INT, V266, P170, DOI 10.1016/j.forsciint.2016.05.034; Strano-Rossi S, 2011, J APPL TOXICOL, V31, P649, DOI 10.1002/jat.1613; Strayer KE, 2018, ACS OMEGA, V3, P514, DOI 10.1021/acsomega.7b01536; Suzuki J, 2017, DRUG ALCOHOL DEPEN, V171, P107, DOI 10.1016/j.drugalcdep.2016.11.033; Swanson DM, 2017, J ANAL TOXICOL, V41, P498, DOI 10.1093/jat/bkx037; Truver MT, 2018, J ANAL TOXICOL, V42, P554, DOI 10.1093/jat/bky053; Verplaetse R, 2010, J CHROMATOGR B, V878, P1987, DOI 10.1016/j.jchromb.2010.05.033; Viaene J, 2016, J PHARMACEUT BIOMED, V127, P49, DOI 10.1016/j.jpba.2015.12.055	43	6	6	4	16	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0379-0738	1872-6283		FORENSIC SCI INT	Forensic Sci.Int.	APR	2019	297						189	197		10.1016/j.forsciint.2019.02.006			9	Medicine, Legal	Legal Medicine	HR0LA	WOS:000462818500029	30802648				2020-06-30	J	Hussien, RM; Rabie, AH				Hussien, Rania M.; Rabie, Amal H.			Sequential intrathecal injection of fentanyl and hyperbaric bupivacaine at different rates: does it make a difference? A randomized controlled trial	KOREAN JOURNAL OF ANESTHESIOLOGY			English	Article						Cesarean section; Fentanyl; Hyperbaric bupivacaine; Sequential intrathecal injection; Spinal anesthesia	SPINAL-ANESTHESIA; OPIOIDS	Background: Previous studies have shown that sequential intrathecal injection of fentanyl and hyperbaric bupivacaine for cesarean section (CS) anesthesia provides a superior anesthetic effect than use of bupivacaine alone, and prolongs postoperative analgesia. Herein, we investigated whether rapid intrathecal injection of fentanyl followed by slow injection of hyperbaric bupivacaine affects the duration of postoperative analgesia, the effectiveness of anesthesia, and hemodynamic status. Methods: Fifty-six parturients with American Society of Anesthesiologists physical status I or II, aged 18-40 years, and scheduled to undergo elective CS were randomly assigned to 2 groups of 28 patients each. The normal sequential group received sequential intrathecal injections of fentanyl and hyperbaric bupivacaine at the same rate, each with a 5 ml syringe. The rapid sequential group received a rapid intrathecal injection of fentanyl with an insulin syringe, followed by a slow injection of hyperbaric bupivacaine with a 5 ml syringe. The onset of sensory block, the timing of the first rescue analgesia, the doses of rescue analgesics, the degree of postoperative pain, the onset and duration of motor block, the incidence and duration of hypotension, and spinal anesthesia-related complications were recorded. Results: While both approaches had comparable spinal anesthesia-related complications, incidence and duration of hypotension, and doses of ephedrine, the rapid sequential group exhibited a more rapid onset of sensory block, a higher sensory level, and more prolonged postoperative analgesia. Conclusions: Rapid sequential injection of fentanyl and hyperbaric bupivacaine produced superior anesthesia and more prolonged postoperative analgesia than sequential injections of both at the same rate.	[Hussien, Rania M.; Rabie, Amal H.] Ain Shams Univ, Anesthsia, 4 Eladeeb Mohamed Elsbaei, Cairo 691177, Egypt	Hussien, RM (reprint author), Ain Shams Univ, Anesthsia, 4 Eladeeb Mohamed Elsbaei, Cairo 691177, Egypt.	raniamhm@yahoo.com	Hussien, Rania M/V-6494-2017	Hussien, Rania M/0000-0002-5113-6827			BELZARENA SD, 1992, ANESTH ANALG, V74, P653; Dahl JB, 1999, ANESTHESIOLOGY, V91, P1919, DOI 10.1097/00000542-199912000-00045; Desai S, 2010, ANAESTH INTENS CARE, V38, P280, DOI 10.1177/0310057X1003800209; Goma HM, SPINAL ADDITIVES SUB, DOI [10.5772/58851, DOI 10.5772/58851]; Graham AC, 2001, ANAESTHESIA, V56, P470, DOI 10.1046/j.1365-2044.2001.01524-6.x; Hawker GA, 2011, ARTHRIT CARE RES, V63, pS240, DOI 10.1002/acr.20543; Keera Amr Aly Ismail, 2016, Anesth Essays Res, V10, P312, DOI 10.4103/0259-1162.171447; Khaw KS, 2014, ANESTHESIOLOGY, V120, P1126; Manullang TR, 2000, ANESTH ANALG, V90, P1162, DOI 10.1097/00000539-200005000-00030; Sivevski A, 2006, Prilozi, V27, P225; Thornton Patrick, 2015, Rom J Anaesth Intensive Care, V22, P97; WANG C, 1993, ANESTHESIOLOGY, V79, P766, DOI 10.1097/00000542-199310000-00019	12	0	0	0	1	KOREAN SOC ANESTHESIOLOGISTS	SEOUL	1007 YONG SEONG BIZTEL BLDG, 109 HANGANG-DAERO, YONGSAN-GU, SEOUL, 140-750, SOUTH KOREA	2005-6419	2005-7563		KOREAN J ANESTHESIOL	Korean J. Anesthesiol.	APR	2019	72	2					150	155		10.4097/kja.d.18.00173			6	Anesthesiology	Anesthesiology	HR3NV	WOS:000463046400008	30622224	DOAJ Gold, Green Published			2020-06-30	J	Huang, JW; Liu, X; Ding, SL; Zhu, L; Yan, WJ				Huang, Jinwen; Liu, Xia; Ding, Shaoli; Zhu, Lei; Yan, Wenjun			Small-Dose Ropivacaine Hydrochloride with Fentanyl versus Large-Dose of Ropivacaine Hydrochloride for Cesarean Section	JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN			English	Article						Cesarean section; Parturient; Ropivacaine hydrochloride; Combined spinal-epidural analgesia; Hemodynamics	SPINAL-EPIDURAL ANALGESIA; ANESTHESIA; LABOR; DELIVERY	Objective: To compare the effect of small-dose ropivacaine hydrochloride combined with fentanyl versus large-dose of ropivacaine hydrochloride for cesarean section. Study Design: Experimental study. Place and Duration of Study: Department of Anesthesiology, Gansu People's Hospital, China, from February 2017 to April 2018. Methodology: A total of 134 maternal women, who underwent cesarean section, were randomly divided into control group and observation group, with 67 cases in each group. Control group was anesthetized with a large dose (1.5 mL) of ropivacaine hydrochloride, and observation group was anesthetized with a small dose (1 mL) of ropivacaine hydrochloride in combination with 10 mu g of fentanyl. Then anesthetic effects of the two groups were compared. Results: The onset time of anesthesia and postoperative pain scores of the anesthesia in observation group were better than those in control group (both p<0.001). There was no significant difference in HR, SpO(2), and MAP between the two groups after 15 minutes of anesthesia, and after the operation (p=0.393, 0.275, 0.108, 0.740, 0.068 and 0.230, respectively). After the delivery of the fetuses, the HR, SpO(2), and MAP of the parturients in observation group were better than those in control group (all p<0.001). Frequency of adverse reactions of parturients in observation group was lower than that in control group (p=0.033). Conclusion: In comparison to large-dose of ropivacaine hydrochloride, small-dose of ropivacaine hydrochloride combined with fentanyl, in combined spinal-epidural analgesia on parturients accepting cesarean section, can more effectively maintain their hemodynamic stability, relieve postoperative pain, and have a low incidence of adverse reactions.	[Huang, Jinwen; Ding, Shaoli; Zhu, Lei; Yan, Wenjun] Gansu Peoples Hosp, Dept Anesthesiol, Lanzhou 730000, Gansu, Peoples R China; [Liu, Xia] Lanzhou Univ, Hosp 2, Dept Endocrinol, Lanzhou 730030, Gansu, Peoples R China	Yan, WJ (reprint author), Gansu Peoples Hosp, Dept Anesthesiol, Lanzhou 730000, Gansu, Peoples R China.	qhs400@163.com					Atashkhoie S, 2018, IRAN J MED SCI, V43, P70; Atashkhoyi S, 2013, EUR J OBSTET GYN R B, V170, P247, DOI 10.1016/j.ejogrb.2013.06.026; Bano Fauzia, 2006, J Coll Physicians Surg Pak, V16, P87; Casati A, 1999, ANESTH ANALG, V88, P587, DOI 10.1097/00000539-199903000-00024; Dastkhosh A, 2018, LOCAL REG ANESTH, V11, P45, DOI 10.2147/LRA.S165587; Desai S, 2009, INT J OBSTET ANESTH, V18, P43, DOI 10.1016/j.ijoa.2008.07.012; Djerada Z, 2018, CLIN PHARMACOKINET, V57, P1135, DOI 10.1007/s40262-017-0617-2; Dogan Z, 2014, BASIC CLIN PHARMACOL, V114, P248, DOI 10.1111/bcpt.12146; Everaert N, 2015, J PERINAT MED, V43, P481, DOI 10.1515/jpm-2014-0077; Fu XD, 2017, CHEM PHARM BULL, V65, P229, DOI 10.1248/cpb.c16-00471; Groden J, 2016, INT J OBSTET ANESTH, V26, P4, DOI 10.1016/j.ijoa.2016.01.004; Gunaydin B, 2010, J MATERN-FETAL NEO M, V23, P1481, DOI 10.3109/14767051003678051; Gupta S, 2018, INDIAN J ANAESTH, V62, P658, DOI 10.4103/ija.IJA_445_18; Khemlani KH, 2018, J CLIN ANESTH, V48, P73, DOI 10.1016/j.jclinane.2018.04.010; Kiran S, 2018, J ANAESTH CLIN PHARM, V34, P41, DOI 10.4103/joacp.JOACP_205_16; Li M, 2014, DRUG DES DEV THER, V8, P1269, DOI 10.2147/DDDT.S57258; Poma S, 2019, J MATERN-FETAL NEO M, V32, P3559, DOI 10.1080/14767058.2018.1467892; Sunamak O, 2018, THER CLIN RISK MANAG, V14, DOI 10.2147/TCRM.S175314; Wang F, 2016, INT J GYNECOL OBSTET, V135, P259, DOI 10.1016/j.ijgo.2016.05.017; Xu ZD, 2017, J OBSTET GYNAECOL RE, V43, P669, DOI 10.1111/jog.13253	20	0	0	1	7	COLL PHYSICIANS & SURGEONS PAKISTAN	KARACHI	SEVENTH CENTRAL ST, DEFENCE HOUSING AUTHORITY, KARACHI, 75500, PAKISTAN	1022-386X	1681-7168		JCPSP-J COLL PHYSICI	JCPSP-J. Coll. Physicians Surg.	APR	2019	29	4					301	304		10.29271/jcpsp.2019.04.301			4	Medicine, General & Internal	General & Internal Medicine	HQ9LU	WOS:000462749900002	30925948	Bronze			2020-06-30	J	Pilkey, J; Pedersen, A; Tam, JW; Malik, A; Wong, J				Pilkey, Jana; Pedersen, Allison; Tam, James W.; Malik, Amrit; Wong, Jonathan			The Use of Intranasal Fentanyl for the Palliation of Incident Dyspnea in Advanced Congestive Heart Failure: A Pilot Study	JOURNAL OF PALLIATIVE CARE			English	Article						fentanyl; palliative; heart failure; dyspnea	6-MINUTE WALK TEST; CANCER-PATIENTS; DOUBLE-BLIND; EXERCISE; BREATHLESSNESS; OPIOIDS; PAIN; EFFICACY; SAFETY; SPRAY	Background: Dyspnea is distressing in palliative patients with end-stage heart failure and many are hospitalized to optimize this symptom. We hoped to conduct a pilot study to determine whether the administration of intranasal fentanyl would decrease activity-induced dyspnea in this patient population. Methods: Patients performed two 6-minute walk tests with and without the administration of 50 mu g of intranasal fentanyl. Vital signs were recorded before and after each walk, as were participant reported dyspnea and adverse events scores. Results: Twenty-four patients were screened, 13 were deemed eligible, and 6 completed the study. Dyspnea scores changed from a mean of 6.00 immediately after the walk without fentanyl to a mean of 3.83 after the walk with fentanyl (P = .048). Mean respiratory rate decreased from 21.0 to 18.7 (P = .034) breaths per minute and was considered a favorable outcome by the participants. Distance walked did not significantly increase with the fentanyl pretreatment (136.0-144.2 m; P = .283), although the participants reported feeling better while walking a similar distance. Conclusions: In this pilot study, the preadministration of intranasal fentanyl prior to activity in palliative, end-stage hospitalized heart failure patients, safely reduced tachypnea, and the feeling of shortness of breath. This approach may help palliate advanced heart failure patients by alleviating symptoms brought on by exertional activities.	[Pilkey, Jana; Wong, Jonathan] Univ Manitoba, St Boniface Gen Hosp, Sect Palliat Med, Dept Family Med, A8024-409 Tache Ave, Winnipeg, MB R2H 2A6, Canada; [Pedersen, Allison] Winnipeg Reg Hlth Author, Palliat Care Program, Winnipeg, MB, Canada; [Tam, James W.; Malik, Amrit] Univ Manitoba, Sect Cardiol, Dept Med, Winnipeg, MB, Canada	Pilkey, J (reprint author), Univ Manitoba, St Boniface Gen Hosp, Sect Palliat Med, Dept Family Med, A8024-409 Tache Ave, Winnipeg, MB R2H 2A6, Canada.	jpilkey@wrha.mb.ca			Palliative Care Endowment Fund of St. Boniface Hospital	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by a grant from the Palliative Care Endowment Fund of St. Boniface Hospital.	Ander Douglas S, 2004, Congest Heart Fail, V10, P188, DOI 10.1111/j.1527-5299.2004.03475.x; BITTNER V, 1993, JAMA-J AM MED ASSOC, V270, P1702, DOI 10.1001/jama.270.14.1702; Bittner V, 1997, Cardiologia, V42, P897; Bruera E, 1991, J Palliat Care, V7, P6; Chua TP, 1997, J AM COLL CARDIOL, V29, P147, DOI 10.1016/S0735-1097(96)00446-9; Crapo RO, 2002, AM J RESP CRIT CARE, V166, P111, DOI 10.1164/rccm.166/1/111; Dale O, 2002, ACTA ANAESTH SCAND, V46, P759, DOI 10.1034/j.1399-6576.2002.460702.x; Du Huiyun, 2017, Curr Heart Fail Rep, V14, P158, DOI 10.1007/s11897-017-0330-3; Escalante CP, 1996, CANCER, V78, P1314, DOI 10.1002/(SICI)1097-0142(19960915)78:6<1314::AID-CNCR21>3.0.CO;2-2; Ezekowitz JA, 2017, CAN J CARDIOL, V33, P1342, DOI 10.1016/j.cjca.2017.08.022; Foster D, 2008, ANN PHARMACOTHER, V42, P1380, DOI 10.1345/aph.1L168; Harlos M., 2014, PALLIATIVE CARE INCI; Hui D, 2017, J PAIN SYMPTOM MANAG, V54, P798, DOI 10.1016/j.jpainsymman.2017.08.001; Hui D, 2016, J PAIN SYMPTOM MANAG, V52, P459, DOI 10.1016/j.jpainsymman.2016.05.013; Ingle L., 2014, Annals of Physical and Rehabilitation Medicine, V57, P244, DOI 10.1016/j.rehab.2014.03.004; Janssen DJA, 2008, PALLIATIVE MED, V22, P938, DOI 10.1177/0269216308096906; Johnson MJ, 2016, CANCER-AM CANCER SOC, V122, P158, DOI 10.1002/cncr.29695; Johnson MJ, 2002, EUR J HEART FAIL, V4, P753, DOI 10.1016/S1388-9842(02)00158-7; Kusch L, 2017, NUMBER FENTANYL OVER; Lim Stephen C. B., 2003, Journal of Pharmacy Practice and Research, V33, P59; Mercadante S, 2015, SUPPORT CARE CANCER, V23, P1349, DOI 10.1007/s00520-014-2491-x; Mularski RA, 2010, AM J RESP CRIT CARE, V181, P534, DOI 10.1164/rccm.200903-0462PP; Nave R, 2013, DRUG DELIV, V20, P216, DOI 10.3109/10717544.2012.762435; NELSON K, 1991, Cancer Bulletin (Houston), V43, P423; Oxberry SG, 2013, J PALLIAT MED, V16, P250, DOI 10.1089/jpm.2012.0270; Oxberry SG, 2011, EUR J HEART FAIL, V13, P1006, DOI 10.1093/eurjhf/hfr068; Peeters P, 1996, J GERONTOL A-BIOL, V51, pM147, DOI 10.1093/gerona/51A.4.M147; Pinna GD, 2000, STAT MED, V19, P3087; Rogriguez Dulce, 2015, J Pain Palliat Care Pharmacother, V29, P228, DOI 10.3109/15360288.2015.1047554; Schrover R, 2017, ORPHANET J RARE DIS, V12, DOI 10.1186/s13023-017-0633-1; Shoemaker Michael J, 2013, Cardiopulm Phys Ther J, V24, P21; Sitte Thomas, 2008, J Pain Symptom Manage, V36, pe3, DOI 10.1016/j.jpainsymman.2008.08.002; Smith TJ, 2009, J PALLIAT MED, V12, P771, DOI 10.1089/jpm.2009.0113; Veldhorst-Janssen NML, 2012, J PALLIAT MED, V15, P631, DOI 10.1089/jpm.2012.0013; Watts P, 2013, DRUG DELIV TRANSL RE, V3, P75, DOI 10.1007/s13346-012-0078-y; Williams SG, 2003, HEART, V89, P1085, DOI 10.1136/heart.89.9.1085; Wu G, 2003, AM HEART J, V146, P129, DOI 10.1016/S0002-8703(03)00119-4	37	0	0	0	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0825-8597	2369-5293		J PALLIAT CARE	J. Palliative Care	APR	2019	34	2					96	102		10.1177/0825859718777343			7	Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health	Health Care Sciences & Services; Public, Environmental & Occupational Health	HP5ZQ	WOS:000461762500005	29848173				2020-06-30	J	Shafer, SL				Shafer, Steven L.			Carfentanil: a weapon of mass destruction	CANADIAN JOURNAL OF ANESTHESIA-JOURNAL CANADIEN D ANESTHESIE			English	Editorial Material							OPIATE RECEPTORS; FENTANYL ANALOGS; OVERDOSE DEATHS; BINDING; HUMANS; POTENT; SERIES; STATES		[Shafer, Steven L.] Stanford Univ, Dept Anesthesiol Perioperat & Pain Med, 300 Pasteur Dr, Stanford, CA 94305 USA	Shafer, SL (reprint author), Stanford Univ, Dept Anesthesiol Perioperat & Pain Med, 300 Pasteur Dr, Stanford, CA 94305 USA.	steven.shafer@stanford.edu					Bergstrom S, 1983, POPUL DEV REV, V9, P562, DOI 10.2307/1973343; Daniulaityte R, 2017, MMWR-MORBID MORTAL W, V66, P904, DOI 10.15585/mmwr.mm6634a3; Di Gregorio D, USE CARFENTANIL WMD; Doucet C, TORONTO SUN; Elliott SP, 2018, J ANAL TOXICOL, V42, pE41, DOI 10.1093/jat/bkx109; FROST JJ, 1990, J CEREBR BLOOD F MET, V10, P484, DOI 10.1038/jcbfm.1990.90; FROST JJ, 1985, J COMPUT ASSIST TOMO, V9, P231, DOI 10.1097/00004728-198503000-00001; FROST JJ, 1989, J CEREBR BLOOD F MET, V9, P398, DOI 10.1038/jcbfm.1989.59; Frost JJ, 2001, NUCL MED BIOL, V28, P509, DOI 10.1016/S0969-8051(01)00221-9; Government of Canada, OV NAT DAT OP REL HA; Hikin L, 2018, FORENSIC SCI INT, V282, P179, DOI 10.1016/j.forsciint.2017.11.036; Jane's 360, N KOR BARG NUCL DIPL; JANSSEN PAJ, 1982, ACTA ANAESTH SCAND, V26, P262, DOI 10.1111/j.1399-6576.1982.tb01765.x; JANSSENS F, 1986, J MED CHEM, V29, P2290, DOI 10.1021/jm00161a027; Leen JLS, 2019, CAN J ANESTH, V66, P414, DOI 10.1007/s12630-019-01294-y; Lefebvre LG, 2017, CAN J ANESTH, V64, P211, DOI 10.1007/s12630-016-0775-y; MATHER LE, 1983, CLIN PHARMACOKINET, V8, P422, DOI 10.2165/00003088-198308050-00004; NORSAR, NUCL EXPL N KOR 3 SE; O'Donnell J, 2018, MMWR-MORBID MORTAL W, V67, P767, DOI 10.15585/mmwr.mm6727a4; O'Donnell JK, 2017, MMWR-MORBID MORTAL W, V66, P1197, DOI 10.15585/mmwr.mm6643e1; PubChem, CARF; Samuelson ST, 2017, CAN J ANESTH, V64, P219, DOI 10.1007/s12630-016-0780-1; Shanks KG, 2017, J ANAL TOXICOL, V41, P466, DOI 10.1093/jat/bkx042; The Mackenzie Institute Security Matters, CARF STREET DRUG WEA; Wikipedia, CARF	25	3	3	0	5	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0832-610X	1496-8975		CAN J ANESTH	Can. J. Anesth.	APR	2019	66	4					351	355		10.1007/s12630-019-01295-x			5	Anesthesiology	Anesthesiology	HO3EO	WOS:000460802200001	30644074	Bronze			2020-06-30	J	Bosetti, C; Santucci, C; Radrezza, S; Erthal, J; Berterame, S; Corli, O				Bosetti, Cristina; Santucci, Claudia; Radrezza, Silvia; Erthal, Juliana; Berterame, Stefano; Corli, Oscar			Trends in the consumption of opioids for the treatment of severe pain in Europe, 1990-2016	EUROPEAN JOURNAL OF PAIN			English	Article							CANCER PAIN; REGULATORY BARRIERS; ANALGESICS; PRESCRIPTION; COUNTRIES; ACCESSIBILITY; FENTANYL; ACCESS; LIFE	Background Over the last decades, consumption of opioids for the treatment of pain increased steadily in the United States, Australia, and a few European countries. To date, no study has analysed time trends in opioid consumption across Europe. Methods We analysed data provided by International Narcotics Control Boards on the consumption of fentanyl, oxycodone, morphine, hydromorphone and pethidine in 40 European countries over the last decade. Trends in total opioid consumption from 1990 to 2016 in 22 selected European countries, the European Union (EU) as a whole, and, for comparison purpose, the United States, were analysed using the joinpoint regression analysis. Results In 2014-2016, opioid use was >10,000 defined daily doses for statistical purposes (s-DDD) per 1,000,000 inhabitants die in Western/Northern countries, whereas it was DDD in Southern/Eastern ones. In most European countries, opioid consumption increased to a great extent between 2004-2006 and 2014-2016; it rose from 6,477 to 8,967 s-DDD (+38.4%) in the EU, and from 14,598 to 16,491 s-DDD (+13%) in the United States. The increase in opioid use was steady since the early to mid-1990s in most European countries and it slowed down after the mid- to late 2000s. In Denmark, Finland, France, Ireland, Switzerland, Poland and the EU, opioid use levelled off or declined over most recent years. Conclusions Consumption of opioid analgesics sharply increased in most of European countries since the early to mid-1990s. This notwithstanding, in the mid-2010s there was still a more than 10-fold difference between the highest consumption in Western/Northern countries and the lowest one in Southern/Eastern countries. Significance: This study provides an updated and comprehensive analysis of time trends and geographic variations in opioid consumption use across European countries over the last three decades.	[Bosetti, Cristina; Santucci, Claudia] Ist Ric Farmacol Mario Negri IRCCS, Dept Oncol, Lab Methodol Clin Res, Milan, Italy; [Radrezza, Silvia] Ist Ric Farmacol Mario Negri IRCCS, Dept Publ Hlth, Lab Med Res & Consumer Involvement, Milan, Italy; [Erthal, Juliana; Berterame, Stefano] Vienna Int Ctr, Secretariat Int Narcot Control Board, Vienna, Austria; [Corli, Oscar] Ist Ric Farmacol Mario Negri IRCCS, Dept Oncol, Unit Pain & Palliat Care Res, Milan, Italy	Bosetti, C (reprint author), Ist Ric Farmacol Mario Negri IRCCS, Dept Oncol, Lab Methodol Clin Res, Milan, Italy.	cristina.bosetti@marionegri.it	bosetti, cristina/AAA-6731-2020; radrezza, silvia/K-2608-2018	bosetti, cristina/0000-0003-2090-4608; radrezza, silvia/0000-0002-4447-0448			Barry DT, 2010, J PAIN, V11, P1442, DOI 10.1016/j.jpain.2010.04.002; Berterame S, 2016, LANCET, V387, P1644, DOI 10.1016/S0140-6736(16)00161-6; Breivik H, 2006, EUR J PAIN, V10, P287, DOI 10.1016/j.ejpain.2005.06.009; Caraceni A, 2012, LANCET ONCOL, V13, pE58, DOI 10.1016/S1470-2045(12)70040-2; Chenaf C, 2019, EUR J PAIN, V23, P124, DOI 10.1002/ejp.1291; Cherny NI, 2010, ANN ONCOL, V21, P615, DOI 10.1093/annonc/mdp581; Chinellato A, 2003, LANCET, V362, P78, DOI 10.1016/S0140-6736(03)13819-6; Chinellato A, 2011, EUR J PAIN, V15, P220, DOI 10.1016/j.ejpain.2010.11.005; Clark F, 2015, LANCET, V386, P231, DOI 10.1016/S0140-6736(15)61264-8; Corli O, 2016, ANN ONCOL, V27, P1107, DOI 10.1093/annonc/mdw097; Ctr Dis Control Prevent, 2016, J PAIN PALLIAT CARE, V30, P138, DOI 10.3109/15360288.2016.1173761; De Conno F, 2005, PALLIATIVE MED, V19, P179, DOI 10.1191/0269216305pm1002oa; De Lima L, 2014, J PAIN SYMPTOM MANAG, V48, P649, DOI 10.1016/j.jpainsymman.2013.12.237; del Pozo JG, 2008, EUR J CLIN PHARMACOL, V64, P411, DOI 10.1007/s00228-007-0419-9; Duthey B, 2014, J PAIN SYMPTOM MANAG, V47, P283, DOI 10.1016/j.jpainsymman.2013.03.015; ELS C, 2017, COCHRANE DB SYST REV, V10, DOI DOI 10.1002/14651858.CD012299.PUB2; ESMO, GLOB OP POL IN FORM; Fanelli G, 2014, ORTHOP REV, V6, P51, DOI 10.4081/or.2014.5309; Goldberg DS, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-770; Hamunen K, 2008, EUR J PAIN, V12, P705, DOI 10.1016/j.ejpain.2007.10.012; Hamunen K, 2009, EUR J PAIN, V13, P954, DOI 10.1016/j.ejpain.2008.11.006; Hastie Barbara A, 2014, J Pain Palliat Care Pharmacother, V28, P259, DOI 10.3109/15360288.2014.941132; Hudec R, 2013, BRATISL MED J, V114, P581, DOI 10.4149/BLL_2013_124; International Narcotics Control Board, 2017, REP INT NARC CONTR B; International Narcotics Control Board, 2018, REP INT NARC CONTR B; Jacobsen R, 2010, SCAND J CARING SCI, V24, P781, DOI 10.1111/j.1471-6712.2010.00776.x; Just J, 2016, DTSCH ARZTEBL INT, V113, P213, DOI 10.3238/arztebl.2016.0213; Knaul FM, 2018, LANCET, V391, P1391, DOI 10.1016/S0140-6736(17)32513-8; Krnic D, 2015, THER CLIN RISK MANAG, V11, P1305, DOI 10.2147/TCRM.S86226; National Cancer Institute, 2018, JOINP REGR PROGR VER; Neutel CI, 2014, EUR J PAIN, V18, P438, DOI 10.1002/j.1532-2149.2013.00374.x; O'Brien T, 2017, EUR J PAIN, V21, P3, DOI 10.1002/ejp.970; Paulozzi Leonard J., 2011, Morbidity and Mortality Weekly Report, V60, P1487; Ponizovsky AM, 2012, EUR J CLIN PHARMACOL, V68, P89, DOI 10.1007/s00228-011-1099-z; Schuchat A, 2017, JAMA-J AM MED ASSOC, V318, P425, DOI 10.1001/jama.2017.8913; Seya Marie-Josephine, 2011, J Pain Palliat Care Pharmacother, V25, P6, DOI 10.3109/15360288.2010.536307; Shipton EA, 2018, PAIN THER, V7, P23, DOI 10.1007/s40122-018-0096-7; Vranken MJM, 2018, J PALLIAT MED, V21, P963, DOI 10.1089/jpm.2017.0595; Vranken MJM, 2016, LANCET ONCOL, V17, pE13, DOI 10.1016/S1470-2045(15)00365-4; Werber A, 2015, PAIN PHYSICIAN, V18, pE323; WHO Collaborating Centre for Drug Statistics Methodology, ATC CLASS IND INCL D; World Health Organization, 1996, CARNC PAIN REL; World Health Organization, 2011, ENS BAL NAT POL CONT; World Health Organization, 1986, CARNC PAIN REL; Zin CS, 2014, EUR J PAIN, V18, P1343, DOI 10.1002/j.1532-2149.2014.496.x	45	13	13	0	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1090-3801	1532-2149		EUR J PAIN	Eur. J. Pain	APR	2019	23	4					697	707		10.1002/ejp.1337			11	Anesthesiology; Clinical Neurology; Neurosciences	Anesthesiology; Neurosciences & Neurology	HP1XD	WOS:000461461500007	30407692	Bronze			2020-06-30	J	Mercadante, S; Adile, C; Masedu, F; Marchetti, P; Costanzi, A; Aielli, F				Mercadante, Sebastiano; Adile, Claudio; Masedu, Francesco; Marchetti, Paolo; Costanzi, Andrea; Aielli, Federica			Factors influencing the use of opioids for breakthrough cancer pain: A secondary analysis of the IOPS-MS study	EUROPEAN JOURNAL OF PAIN			English	Article							TRANSMUCOSAL FENTANYL; MANAGEMENT; CLASSIFICATION; ASSOCIATION; MORPHINE	Background Controversies exist about the choice and the doses of opioid medication in breakthrough cancer pain (BTcP). Methods The aim was to assess factors influencing the use and the doses of opioids prescribed for BTcP. There was performed a secondary analysis of a national, multicentre study that involving 32 centres performed in patients having BTcP. Diagnosis of BTcP was based on a definite algorithm. Patients using opioids for background pain and for BTcP were selected. Average pain intensity and opioids used for background pain and BTcP, and adverse effects were assessed, as well as patient's satisfaction and the grade of mucositis. Results The analysis was performed in 2,771 patients. Opioid doses given for BTcP were significantly associated with those given for background pain. No relationship between adverse effects and the use and the doses of opioids used for BTcP was found. Drugs and doses were not correlated to the grade of oral mucositis. Nasal fentanyl preparations provided the fastest meaningful pain relief in comparison with other fentanyl transmucosal preparations or morphine preparations (P = 0.000). The majority of patients were satisfied with opioid medications given for BTcP. Only 2.8% of patients reported adverse effects related to opioid medication used for BTcP. Age and gender were independently associated with dosages of some fentanyl products. Conclusions Opioids for BTcP were effective and safe in a large sample of cancer patients with different stages of disease. Doses of opioids proportional to doses used for background pain seem to guarantee both efficacy and safety. Significance: The use of opioids for breakthough cancer pain was effective and safe in a large sample of advanced cancer patients recruited in different stages of disease and settings. Doses of opioids proportional to opioid doses used for background analgesia, seem to guarantee both effectiveness and safety.	[Mercadante, Sebastiano; Adile, Claudio] La Maddalena Canc Ctr, Main Reg Ctr Pain Relief & Support Palliat Care, Palermo, Italy; [Mercadante, Sebastiano] MD Anderson, Dept Support Palliat Care, Houston, TX USA; [Masedu, Francesco] Univ Aquila, Dept Biotechnol & Appl Clin Sci, Sect Clin Epidemiol & Environm Med, Laquila, Italy; [Marchetti, Paolo; Costanzi, Andrea] Sapienza Univ Rome, Med Oncol, Rome, Italy; [Marchetti, Paolo; Costanzi, Andrea] IRCCS Rome, IDI, Rome, Italy; [Aielli, Federica] Univ Aquila, Dept Appl Clin Sci & Biotechnol, Laquila, Italy	Mercadante, S (reprint author), La Maddalena Canc Ctr, Main Reg Ctr Pain Relief & Support Palliat Care, Palermo, Italy.	terapiadeldolore@lamaddalenanet.it	MASEDU, Francesco/M-2989-2015	MASEDU, Francesco/0000-0003-0290-5324	Molteni, Italy	The study was sponsored by Molteni, Italy. Data were independently analysed by the IOPS MS Scientific Committee. Data were independently managed by authors.	Corli O, 2014, MINERVA ANESTESIOL, V80, P1123; Davies A, 2016, J PAIN SYMPTOM MANAG, V51, P538, DOI 10.1016/j.jpainsymman.2015.11.018; Davies A, 2013, J PAIN SYMPTOM MANAG, V46, P619, DOI 10.1016/j.jpainsymman.2012.12.009; Davies A, 2011, EUR J PAIN, V15, P756, DOI 10.1016/j.ejpain.2010.12.004; Davies AN, 2008, J PAIN SYMPTOM MANAG, V35, P406, DOI 10.1016/j.jpainsymman.2007.05.010; Davies AN, 2009, EUR J PAIN, V13, P331, DOI 10.1016/j.ejpain.2008.06.014; Escobar Y, 2013, CLIN TRANSL ONCOL, V15, P526, DOI 10.1007/s12094-012-0981-1; Hanks GW, 2001, BRIT J CANCER, V84, P587, DOI 10.1054/bjoc.2001.1680; Hans GH, 2013, CURR MED RES OPIN, V29, P1523, DOI 10.1185/03007995.2013.837816; Haugen DF, 2010, PAIN, V149, P476, DOI 10.1016/j.pain.2010.02.035; Jandhyala R, 2013, J PAIN SYMPTOM MANAG, V46, P573, DOI 10.1016/j.jpainsymman.2012.09.009; Lohre ET, 2016, J PAIN SYMPTOM MANAG, V51, P1013, DOI 10.1016/j.jpainsymman.2015.12.329; Mercadante S, 2007, BRIT J CANCER, V96, P1828, DOI 10.1038/sj.bjc.6603811; Mercadante S, 2011, EUR J PAIN, V5, P443; Mercadante S, 2018, CANCERS, V10, DOI 10.3390/cancers10060175; Mercadante S, 2018, CRIT REV ONCOL HEMAT, V122, P60, DOI 10.1016/j.critrevonc.2017.12.016; Mercadante S, 2016, PAIN, V157, P2657, DOI 10.1097/j.pain.0000000000000721; Mercadante S, 2015, CLIN J PAIN, V31, P214, DOI 10.1097/AJP.0000000000000161; Mercadante S, 2014, J PAIN, V15, P602, DOI 10.1016/j.jpain.2014.02.002; Mercadante S, 2012, CURR MED RES OPIN, V28, P963, DOI 10.1185/03007995.2012.683112; Mercadante S, 2012, DRUGS, V72, P181, DOI 10.2165/11597260-000000000-00000; Mercadante S, 2011, CRIT REV ONCOL HEMAT, V80, P460, DOI 10.1016/j.critrevonc.2010.12.002; Mercadante S, 2009, J PAIN SYMPTOM MANAG, V37, P632, DOI 10.1016/j.jpainsymman.2007.12.024; Mercadante S, 2009, EUR J PAIN, V13, P329, DOI 10.1016/j.ejpain.2008.11.021; Narayana A, 2015, PAIN, V156, P252, DOI 10.1097/01.j.pain.0000460305.41078.7d; Portenoy RK, 1999, PAIN, V81, P129, DOI 10.1016/S0304-3959(99)00006-8; WHO, 1979, WHO HDB REP RES CANC, P15	27	4	4	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1090-3801	1532-2149		EUR J PAIN	Eur. J. Pain	APR	2019	23	4					719	726		10.1002/ejp.1339			8	Anesthesiology; Clinical Neurology; Neurosciences	Anesthesiology; Neurosciences & Neurology	HP1XD	WOS:000461461500009	30421474				2020-06-30	J	Tschirhart, JN; Li, WT; Guo, J; Zhang, ST				Tschirhart, Jared N.; Li, Wentao; Guo, Jun; Zhang, Shetuan			Blockade of the Human Ether A-Go-Go-Related Gene (hERG) Potassium Channel by Fentanyl	MOLECULAR PHARMACOLOGY			English	Article							QTC INTERVAL PROLONGATION; HUMAN INWARD RECTIFIER; MOLECULAR DETERMINANTS; I-KR; CARDIAC-ARRHYTHMIA; EXTRACELLULAR K+; XENOPUS-OOCYTES; DE-POINTES; INACTIVATION; REPOLARIZATION	The human ether-a-go-go-related gene (hERG) encodes the pore-forming subunit of the rapidly activating delayed rectifier potassium channel (I-Kr). Drug-mediated or medical condition-mediated disruption of hERG function is the primary cause of acquired long-QT syndrome, which predisposes affected individuals to ventricular arrhythmias and sudden death. Fentanyl abuse poses a serious health concern, with abuse and death rates rising over recent years. As fentanyl has a propensity to cause sudden death, we investigated its effects on the hERG channel. The effects of norfentanyl, the main metabolite, and naloxone, an antidote used in fentanyl overdose, were also examined. Currents of hERG channels stably expressed in HEK293 cells were recorded using the whole-cell voltage-clamp method. When hERG tail currents were analyzed upon -50 mV repolarization after a 50 mV depolarization, fentanyl and naloxone blocked hERG current (I-hERG) with IC50 values of 0.9 and 74.3 mu M, respectively, whereas norfentanyl did not block. However, fentanyl-mediated block of I-hERG was voltage dependent. When a voltage protocol that mimics a human ventricular action potential (AP) was used, fentanyl blocked I(hERG )with an IC50 of 0.3 mu M. Furthermore, fentanyl (0.5 mu M) prolonged AP duration and blocked I-Kr in ventricular myocytes isolated from neonatal rats. The concentrations of fentanyl used in this study were higher than seen with clinical use but overlap with postmortem overdose concentrations. Although mechanisms of fentanyl-related sudden death need further investigation, blockade of hERG channels may contribute to the death of individuals with high-concentration overdose or compromised cardiac repolarization.	[Tschirhart, Jared N.; Li, Wentao; Guo, Jun; Zhang, Shetuan] Queens Univ, Dept Biomed & Mol Sci, 18 Stuart St, Kingston, ON K7L 3N6, Canada	Zhang, ST (reprint author), Queens Univ, Dept Biomed & Mol Sci, 18 Stuart St, Kingston, ON K7L 3N6, Canada.	shetuan.zhang@queensu.ca			Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR) [MOP 72911]; Heart and Stroke Foundation of CanadaHeart & Stroke Foundation of Canada [G-17-0018754]	This work was supported by the Canadian Institutes of Health Research [Grant MOP 72911] and the Heart and Stroke Foundation of Canada [Grant G-17-0018754] to S.Z. No potential conflicts of interest relevant to this article are reported.	BLAIR JR, 1989, ANESTHESIOLOGY, V71, P565, DOI 10.1097/00000542-198910000-00015; Burashnikov A, 2008, CIRC-ARRHYTHMIA ELEC, V1, P202, DOI 10.1161/CIRCEP.107.691931; Cafiero T, 2011, MINERVA ANESTESIOL, V77, P160; Chen J, 2002, P NATL ACAD SCI USA, V99, P12461, DOI 10.1073/pnas.192367299; CURRAN ME, 1995, CELL, V80, P795, DOI 10.1016/0092-8674(95)90358-5; Fenichel RR, 2004, J CARDIOVASC ELECTR, V15, P475, DOI 10.1046/j.1540-8167.2004.03534.x; Ficker E, 1998, CIRC RES, V82, P386, DOI 10.1161/01.RES.82.3.386; Gerlach AC, 2010, MOL PHARMACOL, V77, P58, DOI 10.1124/mol.109.059543; Guo J, 2006, J PHARMACOL EXP THER, V317, P865, DOI 10.1124/jpet.105.098103; Guo J, 2007, J PHARMACOL EXP THER, V321, P911, DOI 10.1124/jpet.107.120931; Guo J, 2009, J CLIN INVEST, V119, P2745, DOI 10.1172/JCI39027; HUG CC, 1981, ANESTHESIOLOGY, V55, P369, DOI 10.1097/00000542-198110000-00006; Katchman AN, 2002, J PHARMACOL EXP THER, V303, P688, DOI 10.1124/jpet.102.038240; Keating MT, 2001, CELL, V104, P569, DOI 10.1016/S0092-8674(01)00243-4; Keller GA, 2016, CURR DRUG SAF, V11, P86, DOI 10.2174/1574886311207040262; Kornick CA, 2003, PAIN, V105, P499, DOI 10.1016/S0304-3959(03)00205-7; Krantz MJ, 2003, PHARMACOTHERAPY, V23, P802, DOI 10.1592/phco.23.6.802.32186; Labroo RB, 1997, DRUG METAB DISPOS, V25, P1072; Lamothe SM, 2017, FASEB J, V31, P5068, DOI 10.1096/fj.201700255R; Lees-Miller JP, 2000, MOL PHARMACOL, V57, P367; Maremmani I, 2005, EUR ADDICT RES, V11, P44, DOI 10.1159/000081416; Martell BA, 2005, AM J CARDIOL, V95, P915, DOI 10.1016/j.amjcard.2004.11.055; Martin TL, 2006, J ANAL TOXICOL, V30, P603, DOI 10.1093/jat/30.8.603; Massaeli H, 2010, CIRC RES, V106, P1072, DOI 10.1161/CIRCRESAHA.109.215970; Mitcheson JS, 2000, J GEN PHYSIOL, V115, P229, DOI 10.1085/jgp.115.3.229; Mitcheson JS, 2000, P NATL ACAD SCI USA, V97, P12329, DOI 10.1073/pnas.210244497; Perry M, 2004, MOL PHARMACOL, V66, P240, DOI 10.1124/mol.104.000117; RAYNOR K, 1994, MOL PHARMACOL, V45, P330; SANGUINETTI MC, 1995, CELL, V81, P299, DOI 10.1016/0092-8674(95)90340-2; SANGUINETTI MC, 1990, J GEN PHYSIOL, V96, P195, DOI 10.1085/jgp.96.1.195; SANTIAGO TV, 1985, J APPL PHYSIOL, V59, P1675; Schonherr R, 1996, J PHYSIOL-LONDON, V493, P635, DOI 10.1113/jphysiol.1996.sp021410; Solis E, 2017, ENEURO, V4, DOI 10.1523/ENEURO.0323-17.2017; Spector PS, 1996, CIRC RES, V78, P499, DOI 10.1161/01.RES.78.3.499; Spector PS, 1996, J GEN PHYSIOL, V107, P611, DOI 10.1085/jgp.107.5.611; Stanley TH, 2014, J PAIN, V15, P1215, DOI 10.1016/j.jpain.2014.08.010; Stork D, 2007, BRIT J PHARMACOL, V151, P1368, DOI 10.1038/sj.bjp.0707356; Surawicz B, 1996, J CARDIOVASC ELECTR, V7, P777, DOI 10.1111/j.1540-8167.1996.tb00583.x; Thompson JG, 2007, J FORENSIC SCI, V52, P978, DOI 10.1111/j.1556-4029.2007.00481.x; Thurlkill RL, 2005, J CARDIOTHOR VASC AN, V19, P759, DOI 10.1053/j.jvca.2004.11.039; TRUDEAU MC, 1995, SCIENCE, V269, P92, DOI 10.1126/science.7604285; Vormberge Thomas, 2006, Journal of Pharmacological and Toxicological Methods, V54, P130, DOI 10.1016/j.vascn.2006.03.011; Wang DX, 2007, J PHARMACOL EXP THER, V321, P544, DOI 10.1124/jpet.106.118810; Wang SM, 1997, FEBS LETT, V417, P43, DOI 10.1016/S0014-5793(97)01245-3; Wang WW, 2017, CELL, V169, P422, DOI 10.1016/j.cell.2017.03.048; Witchel HJ, 2004, MOL PHARMACOL, V66, P1201, DOI 10.1124/mol.104.001743; Wu W, 2015, MOL PHARMACOL, V87, P1042, DOI 10.1124/mol.115.098111; Zhang ST, 1999, CIRC RES, V84, P989, DOI 10.1161/01.RES.84.9.989; Zhou ZF, 1999, J CARDIOVASC ELECTR, V10, P836, DOI 10.1111/j.1540-8167.1999.tb00264.x; Zhou ZF, 1998, BIOPHYS J, V74, P230, DOI 10.1016/S0006-3495(98)77782-3; Zhou ZF, 1998, J BIOL CHEM, V273, P21061, DOI 10.1074/jbc.273.33.21061; Zou AR, 1998, J PHYSIOL-LONDON, V509, P129, DOI 10.1111/j.1469-7793.1998.129bo.x	52	4	4	1	6	AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA	0026-895X	1521-0111		MOL PHARMACOL	Mol. Pharmacol.	APR 1	2019	95	4					386	397		10.1124/mol.118.114751			12	Pharmacology & Pharmacy	Pharmacology & Pharmacy	HN4AV	WOS:000460127500007	30665971	Bronze			2020-06-30	J	Neefjes, ECW; van der Wijngaart, H; van der Vorst, MJDL; ten Oever, D; van der Vliet, HJ; Beeker, A; Rhodius, CA; van den Berg, HP; Berkhof, J; Verheul, HMW				Neefjes, Elisabeth C. W.; van der Wijngaart, Hanneke; van der Vorst, Maurice J. D. L.; ten Oever, Diederik; van der Vliet, Hans J.; Beeker, Aart; Rhodius, Christiaan A.; van den Berg, Hendrik P.; Berkhof, Johannes; Verheul, Henk M. W.			Optimal treatment of opioid induced constipation in daily clinical practice - an observational study	BMC PALLIATIVE CARE			English	Article						Constipation; Opioid; Neoplasms; Methylnaltrexone; Laxatives; Pain management	CANCER PAIN; MANAGEMENT; METHYLNALTREXONE; PRESCRIPTIONS; PREVALENCE	Background: Opioids are prescribed in over 40% of patients with advanced cancer, but side effects occur frequently. In this study we evaluated the development and treatment of opioid induced constipation (OIC), and OIC resolving effect of methylnaltrexone for different opioid subtypes in daily clinical practice. Methods: Patients with cancer using opioids were included in a retrospective chart analysis. Baseline characteristics, data on opioid use, laxative use, and OIC were collected. Patients with OIC who were prescribed methylnaltrexone, were included in a prospective observational trial (NCT01955213). Results: Thirty-nine of 327 patients (pts) with cancer who were treated with opioids suffered from OIC (overall prevalence 12%; 95%-CI: 8-15%). The prevalence of OIC was similar in patients treated with oxycodone or fentanyl (12 of 81 pts. vs. 18 of 110 pts., RR 0.9; 95%CI 0.4-2.0). The morphine equivalent daily dose did not significantly differ between opioid subtypes (fentanyl 89 mg (IQR 60-180) vs. oxycodone 40 mg (40-80), P = 0.231). Twenty-two individual patients (7%) were admitted for OIC. Most effective laxatives in admitted patients were enemas, methylnaltrexone, or 4-l polyethylene-glycol solution. In the prospective observational study, the effect of methylnaltrexone could be evaluated in 23 patients. Eleven patients achieved the primary endpoint of >= 2 laxation responses out of the first four doses methylnaltrexone, independent of opioid subtype. Conclusions: OIC is a burdensome clinical problem independent of opioid subtype. Timely intensification of prophylactic laxative treatment, especially when opioid doses increase, may help to prevent OIC. Clinically overt OIC requires a more intensive laxative regimen with for example methylnaltrexone.	[Neefjes, Elisabeth C. W.; van der Wijngaart, Hanneke; van der Vorst, Maurice J. D. L.; van der Vliet, Hans J.; Verheul, Henk M. W.] Vrije Univ, Amsterdam UMC, Canc Ctr Amsterdam, Dept Med Oncol, Boelelaan 1117, NL-1081 HV Amsterdam, Netherlands; [van der Wijngaart, Hanneke; ten Oever, Diederik] Med Ctr Alkmaar, Dept Internal Med, Alkmaar, Netherlands; [van der Vorst, Maurice J. D. L.] Rijnstate Hosp, Dept Internal Med, Arnhem, Netherlands; [Beeker, Aart; Rhodius, Christiaan A.] Spaarne Gasthuis, Dept Internal Med, Hoofddorp, Netherlands; [Rhodius, Christiaan A.] Hosp Bardo, Hoofddorp, Netherlands; [van den Berg, Hendrik P.] Tergooi, Dept Internal Med, Hilversum, Netherlands; [Berkhof, Johannes] Vrije Univ, Amsterdam UMC, Dept Epidemiol & Biostat, Amsterdam, Netherlands	Verheul, HMW (reprint author), Vrije Univ, Amsterdam UMC, Canc Ctr Amsterdam, Dept Med Oncol, Boelelaan 1117, NL-1081 HV Amsterdam, Netherlands.	h.verheul@vumc.nl	Verheul, Henk/V-6462-2019	Verheul, Henk/0000-0001-5981-922X	non-profit fund Fonds NutsOhra [1201-038]	The prospective observational study was supported by a grant from the non-profit fund Fonds NutsOhra [1201-038]. The funding body had no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.	Bell TJ, 2009, PAIN MED, V10, P35, DOI 10.1111/j.1526-4637.2008.00495.x; Cherny N, 2001, J CLIN ONCOL, V19, P2542, DOI 10.1200/JCO.2001.19.9.2542; de Graeff A, CLIN PRACTICE GUIDEL; DeLuca A, 1996, PHARMACOL THERAPEUT, V69, P103, DOI 10.1016/0163-7258(95)02053-5; Gagnon B, 2015, J PAIN SYMPTOM MANAG, V49, P36, DOI 10.1016/j.jpainsymman.2014.05.015; Higginson IJ, 2012, J CLIN ONCOL, V30, P4373, DOI 10.1200/JCO.2012.42.0919; Larkin PJ, 2008, PALLIATIVE MED, V22, P796, DOI 10.1177/0269216308096908; Mihaylov S, 2008, HEALTH TECHNOL ASSES, V12, P1; Neefjes ECW, 2014, BMC PALLIAT CARE, V13, DOI 10.1186/1472-684X-13-42; Pappagallo M, 2001, AM J SURG, V182, p11S, DOI 10.1016/S0002-9610(01)00782-6; Portenoy RK, 2008, J PAIN SYMPTOM MANAG, V35, P458, DOI 10.1016/j.jpainsymman.2007.12.005; Rentz A M, 2009, J Med Econ, V12, P371, DOI 10.3111/13696990903430481; Ripamonti CI, 2012, ANN ONCOL, V23, P139, DOI 10.1093/annonc/mds233; Singleton PA, 2015, CANCER-AM CANCER SOC, V121, P2681, DOI 10.1002/cncr.29460; Skollerud LM, 2013, SUPPORT CARE CANCER, V21, P67, DOI 10.1007/s00520-012-1494-8; Swarm RA, 2015, NCCN GUIDELINES ADUL; Thomas J, 2008, NEW ENGL J MED, V358, P2332, DOI 10.1056/NEJMoa0707377; Wirz S, 2012, EUR J CANCER CARE, V21, P131, DOI 10.1111/j.1365-2354.2011.01286.x	18	0	0	0	1	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1472-684X			BMC PALLIAT CARE	BMC Palliat. Care	MAR 29	2019	18								31	10.1186/s12904-019-0416-7			9	Health Care Sciences & Services; Health Policy & Services	Health Care Sciences & Services	HS2TO	WOS:000463715500001	30922276	DOAJ Gold, Green Published			2020-06-30	J	Taylor, RG; Budhram, A; Lee, DH; Mirsattari, SM				Taylor, Ryan G.; Budhram, Adrian; Lee, Donald H.; Mirsattari, Seyed M.			Opioid-associated amnestic syndrome observed with fentanyl patch use	CANADIAN MEDICAL ASSOCIATION JOURNAL			English	Editorial Material							TRANSIENT GLOBAL AMNESIA; NEUROTOXICITY; DIFFUSION		[Taylor, Ryan G.; Budhram, Adrian; Lee, Donald H.; Mirsattari, Seyed M.] Western Univ, Dept Clin Neurol Sci, London, ON, Canada; [Lee, Donald H.] Western Univ, Div Radiol, London, ON, Canada	Taylor, RG (reprint author), Western Univ, Dept Clin Neurol Sci, London, ON, Canada.	rtayl@uwo.ca					Ammon-Treiber S, 2007, BRAIN RES, V1183, P60, DOI 10.1016/j.brainres.2007.09.002; Barash JA, 2018, NEW ENGL J MED, V378, P1157, DOI 10.1056/NEJMc1716355; Barash JA, 2017, MMWR-MORBID MORTAL W, V66, P76, DOI 10.15585/mmwr.mm6603a2; Bhattacharyya S, 2017, J NEUROIMAGING, V27, P300, DOI 10.1111/jon.12420; Dutton RP, 2018, NEW ENGL J MED, V378, P2247, DOI 10.1056/NEJMc1805681; Galipienzo J, 2012, REV ESP ANEST REANIM, V59, P335, DOI 10.1016/j.redar.2012.03.015; Kofke WA, 1996, ANESTH ANALG, V83, P1298, DOI 10.1097/00000539-199612000-00029; Kofke WA, 1999, BRAIN RES, V818, P326, DOI 10.1016/S0006-8993(98)01228-1; Lansberg MG, 2001, AM J NEURORADIOL, V22, P637; Rinehart JB, 2012, NEUROLOGIST, V18, P216, DOI 10.1097/NRL.0b013e31825bbef4; WOOD T, 1985, ANESTHESIOLOGY, V62, P807, DOI 10.1097/00000542-198506000-00022	11	4	4	0	1	CMA-CANADIAN MEDICAL ASSOC	OTTAWA	1867 ALTA VISTA DR, OTTAWA, ONTARIO K1G 5W8, CANADA	0820-3946	1488-2329		CAN MED ASSOC J	Can. Med. Assoc. J.	MAR 25	2019	191	12					E337	E339		10.1503/cmaj.181291			3	Medicine, General & Internal	General & Internal Medicine	HQ5LJ	WOS:000462453200003	30910881	Green Published, Bronze			2020-06-30	J	Tsai, HL; Chang, TK; Su, WC; Yeh, YS; Huang, CW; Ma, CJ; Wang, JY				Tsai, Hsiang-Lin; Chang, Tsung-Kun; Su, Wei-Chih; Yeh, Yung-Sung; Huang, Ching-Wen; Ma, Cheng-Jen; Wang, Jaw-Yuan			Comparing efficacy and safety between Naldebain<bold>((R))</bold> and intravenous patient-controlled analgesia with fentanyl for pain management post-laparotomy: study protocol for a randomized controlled, non-inferior trial	TRIALS			English	Article						Efficacy and safety; Naldebain((R)); Fentanyl; Patient-controlled analgesia; Post-laparotomy	POSTOPERATIVE PAIN; DINALBUPHINE SEBACATE; RELEASE; INJECTION	BackgroundA long-acting prodrug of nalbuphine, nalbuphine sebacate, has been developed for meeting the unmet medical need of long-acting analgesics. Naldebain((R)) (nalbuphine sebacate) has been developed as a new premedication for postoperative pain management. The primary objective of this study is to determine the efficacy and safety of a single dose of intramuscular Naldebain((R)) in patients scheduled to undergo elective laparotomy.Methods/designA total of 110 patients will be recruited and randomized into two treatment groups. Group 1 receives a single dose of Naldebain((R)) intramuscularly 2412h prior to surgery. Group 2 receives intravenous patient-controlled analgesia (PCA) with fentanyl through 48h postsurgery. Both groups will have follow-up observations until the final visit (day of discharge, day 6-30). The primary efficacy endpoint is to assess time-specific pain intensity calculated as the area under the curve (AUC) of a visual analog scale at individual time points and by using total AUC. Safety endpointsincluding incidence of treatment, emergent adverse events, and percentage of abnormality from baseline to final visitin vital signs, laboratory tests, and injection site evaluations will also be analyzed. Statistical analyses will be performed on the data to compare the two groups.DiscussionPost-laparotomy pain can have a harmful effect on patient recovery; therefore, a slow-release formulation that can cover at least 7days of analgesic effect is required. This study will demonstrate whether a single use of Naldebain((R)) is not less efficacious than PCA with fentanyl for pain management as a non-inferior trial.	[Tsai, Hsiang-Lin; Chang, Tsung-Kun; Su, Wei-Chih; Yeh, Yung-Sung; Huang, Ching-Wen; Ma, Cheng-Jen; Wang, Jaw-Yuan] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Surg, Div Colorectal Surg, 100 Tzyou 1st Rd, Kaohsiung 807, Taiwan; [Tsai, Hsiang-Lin; Huang, Ching-Wen; Wang, Jaw-Yuan] Kaohsiung Med Univ, Coll Med, Fac Med, Dept Surg, Kaohsiung, Taiwan; [Chang, Tsung-Kun; Yeh, Yung-Sung; Wang, Jaw-Yuan] Kaohsiung Med Univ, Coll Med, Grad Inst Clin Med, Kaohsiung, Taiwan; [Yeh, Yung-Sung] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Surg, Div Trauma & Crit Care, Kaohsiung, Taiwan; [Huang, Ching-Wen; Wang, Jaw-Yuan] Kaohsiung Med Univ, Coll Med, Grad Inst Med, Kaohsiung, Taiwan; [Ma, Cheng-Jen] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Surg, Div Gen & Digest Surg, Kaohsiung, Taiwan; [Wang, Jaw-Yuan] Kaohsiung Med Univ, Ctr Biomarkers & Biotech Drugs, Kaohsiung, Taiwan	Wang, JY (reprint author), Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Surg, Div Colorectal Surg, 100 Tzyou 1st Rd, Kaohsiung 807, Taiwan.; Wang, JY (reprint author), Kaohsiung Med Univ, Coll Med, Fac Med, Dept Surg, Kaohsiung, Taiwan.	cy614112@ms14.hinet.net			Ministry of Science and Techology [MOST107-2321-B-037-003, MOST107-2314-B-037-116, MOST107-2314-B-037-022-MY2, MOST107-2314-B-037-023-MY2]; Ministry of Health and Welfare (Health and Welfare surcharge of tobacco products) [MOHW108-TDU-B-212-13306, MOHW107-TDU-B-212-123006, MOHW107-TDU-B-212-114026B]; Kaohsiung Medical University Hospital [KMUH107-7R28, KMUH107-7R29, KMUH107-7R30, KMUH107-7M22, KMUH107-7M23, KMUH106-6M28, KMUH106-6M29, KMUH106-6M30, KMUH106-6M31, KMUHS10701, KMUHS10706, KMUHS10710]; Grant of Biosignature in Colorectal Cancers, Academia Sinica, Taiwan, R.O.C.	This work was supported by grants through funding from the Ministry of Science and Techology (MOST107-2321-B-037-003, MOST107-2314-B-037-116, MOST107-2314-B-037-022-MY2, MOST107-2314-B-037-023-MY2) and the Ministry of Health and Welfare (MOHW108-TDU-B-212-13306, MOHW107-TDU-B-212-123006, MOHW107-TDU-B-212-114026B funded by Health and Welfare surcharge of tobacco products), and the Kaohsiung Medical University Hospital (KMUH107-7R28, KMUH107-7R29, KMUH107-7R30, KMUH107-7M22, KMUH107-7M23, KMUH106-6M28, KMUH106-6M29, KMUH106-6M30, KMUH106-6M31, KMUHS10701, KMUHS10706, KMUHS10710). In addition, this study was supported by the Grant of Biosignature in Colorectal Cancers, Academia Sinica, Taiwan, R.O.C.	Apfelbaum JL, 2003, ANESTH ANALG, V97, P534, DOI 10.1213/01.ANE.0000068822.10113.9E; Ashburn MA, 2012, ANESTHESIOLOGY, V116, P248, DOI 10.1097/ALN.0b013e31823c1030; Barletta JF, 2011, ANN PHARMACOTHER, V45, P916, DOI 10.1345/aph.1Q041; Beauregard L, 1998, CAN J ANAESTH, V45, P304, DOI 10.1007/BF03012019; Chan AW, 2013, ANN INTERN MED, V158, P200, DOI 10.7326/0003-4819-158-3-201302050-00583; Choi JB, 2014, YONSEI MED J, V55, P1430, DOI [10.3349/ymj.2014.55.5.1430, 10.3349/YMJ.2014.55.5.1430]; Chou R, 2016, J PAIN, V17, P131, DOI 10.1016/j.jpain.2015.12.008; Cullen Karen A, 2009, Natl Health Stat Report, P1; Garimella V, 2013, CLIN COLON RECT SURG, V26, P191, DOI 10.1055/s-0033-1351138; Hall Margaret Jean, 2010, Natl Health Stat Report, P1; Kao CW, 2017, INT J NANOMED, V12, P5893, DOI 10.2147/IJN.S140825; Li CJ, 2017, INT J PHARMACEUT, V531, P306, DOI 10.1016/j.ijpharm.2017.08.083; Macrae WA, 2001, BRIT J ANAESTH, V87, P88, DOI 10.1093/bja/87.1.88; Pazhayattil GS, 2014, INT J NEPHROL RENOV, V7, P457, DOI 10.2147/IJNRD.S39747; Perkins FM, 2000, ANESTHESIOLOGY, V93, P1123, DOI 10.1097/00000542-200010000-00038; Rogers E, 2013, CLIN GERIATR MED, V21; Tien YE, 2017, BIOPHARM DRUG DISPOS, V38, P494, DOI 10.1002/bdd.2088; WARFIELD CA, 1995, ANESTHESIOLOGY, V83, P1090, DOI 10.1097/00000542-199511000-00023; White PF, 2002, ANESTH ANALG, V94, P577, DOI 10.1097/00000539-200203000-00019; Wu YQ, 2013, ANESTH ANALG, V117, P507, DOI 10.1213/ANE.0b013e318297fcee; Yeh CY, 2017, CLIN J PAIN, V33, P429, DOI 10.1097/AJP.0000000000000417	21	0	0	1	1	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1745-6215		TRIALS	Trials	MAR 18	2019	20								173	10.1186/s13063-019-3260-4			10	Medicine, Research & Experimental	Research & Experimental Medicine	HP8SV	WOS:000461964000001	30885242	DOAJ Gold, Green Published			2020-06-30	J	Hessulf, F				Hessulf, Fredrik			Can't take the heat: sauna and Fentanyl patch intoxication	CLINICAL TOXICOLOGY			English	Letter									[Hessulf, Fredrik] Halland Hosp, Dept Anaesthesiol & Intens Care Med, Halmstad, Sweden; [Hessulf, Fredrik] Univ Gothenburg, Sahlgrenska Acad, Inst Med, Dept Mol & Clin Med, Gothenburg, Sweden	Hessulf, F (reprint author), Halland Hosp, Dept Anaesthesiol & Intens Care Med, Halmstad, Sweden.; Hessulf, F (reprint author), Univ Gothenburg, Sahlgrenska Acad, Inst Med, Dept Mol & Clin Med, Gothenburg, Sweden.	fredrik.hessulf@regionhalland.se					GUPTA SK, 1992, J PAIN SYMPTOM MANAG, V7, pS17, DOI 10.1016/0885-3924(92)90049-N; Heinonen I, 2018, AM J PHYSIOL-REG I, V314, pR629, DOI 10.1152/ajpregu.00115.2017; Hull W, 2002, J APPL RES CLIN EXP, V2, P1; Nelson L, 2009, J MED TOXICOL, V5, P230, DOI 10.1007/BF03178274; Sindali Katia, 2012, J Med Case Rep, V6, P220, DOI 10.1186/1752-1947-6-220	5	0	0	1	2	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1556-3650	1556-9519		CLIN TOXICOL	Clin. Toxicol.	MAR 4	2019	57	3					219	219		10.1080/15563650.2018.1499932			1	Toxicology	Toxicology	HQ3OE	WOS:000462319600011	30095280				2020-06-30	J	Altiparmak, B; Toker, MK; Uysal, AI; Demirbilek, SG				Altiparmak, Basak; Toker, Melike Korkmaz; Uysal, Ali Ihsan; Demirbilek, Semra Gumus			Comparison of the efficacy of erector spinae plane block performed with different concentrations of bupivacaine on postoperative analgesia after mastectomy surgery: ramdomized, prospective, double blinded trial	BMC ANESTHESIOLOGY			English	Article						Analgesia; Erector spinae plane block; Mastectomy; Postoperative pain; Ultrasound	ESP BLOCK	Background: Breast cancer surgery is one of the most common surgeries among the female population. Nearly half of the patients suffer chronic pain following breast cancer surgery, and 24% of them categorizing their pain as moderate to high. In this study, effects of ultrasound-guided erector spinae plane (ESP) block performed using two different concentrations of bupivacaine on postoperative tramadol consumption, pain scores, and intraoperative fentanyl requirements among patients who underwent radical mastectomy surgery were compared. Methods: This double-blinded, prospective, and randomized study included patients with age ranged 18-70, American Society of Anesthesiologist physical status I-II, and scheduled for unilateral modified radical mastectomy surgery. The patients were randomly allocated into two groups. In group I, ESP block was performed with 0.375% bupivacaine. In group II, ESP block was performed with 0.25% bupivacaine. General anesthesia was induced in both groups according to the standard procedures. When the pain score was >= 4, patients received intravenous (i.v.) 25 mcg fentanyl in the recovery room or 4 mg of morphine in the surgical ward as a rescue analgesia. The main measurements were postoperative tramadol consumption; Numerical Rating Scale (NRS) scores 15, 30, and 60 min and 12 and 24 h postoperatively; and intraoperative fentanyl requirements. Results: In total, 42 patients (21 patients in each group) were included in the study. The mean tramadol consumption at the postoperative 24th h was 149.52 +/- 25.39 mg in group I, and 199.52 +/- 32.78 mg in group II (p = 0.001). In group I, the NRS scores were significantly lower at every time points compared with those in group II. The mean intraoperative fentanyl requirement was similar in the two groups. Conclusion: Although ESP block performed with both concentrations of bupivacaine provided effective postoperative analgesia, the higher concentration of bupivacaine significantly reduced postoperative tramadol consumption after radical mastectomy surgery.	[Altiparmak, Basak; Demirbilek, Semra Gumus] Mugla Sitki Kocman Univ, Dept Anesthesiol & Reanimat, Mentese Mugla, Turkey; [Toker, Melike Korkmaz; Uysal, Ali Ihsan] Mugla Sitki Kocman Univ, Dept Anesthesiol & Reanimat, Training & Res Hosp, Mentese Mugla, Turkey	Altiparmak, B (reprint author), Mugla Sitki Kocman Univ, Dept Anesthesiol & Reanimat, Mentese Mugla, Turkey.	basak_ugurlu@yahoo.com	Toker, Melike/AAF-5969-2020; toker, melike/AAG-4329-2020	Altiparmak, Basak/0000-0002-8165-3438			Altiparmak B, 2019, J CLIN ANESTH, V54, P61, DOI 10.1016/j.jclinane.2018.10.040; Apfel CC, 1999, ANESTHESIOLOGY, V91, P693, DOI 10.1097/00000542-199909000-00022; Bruce J, 2014, PAIN, V155, P232, DOI 10.1016/j.pain.2013.09.028; Chin KJ, 2017, REGION ANESTH PAIN M, V42, P372, DOI 10.1097/AAP.0000000000000581; Das Adhikary S, 2018, INDIAN J ANAESTH, V62, P75, DOI 10.4103/ija.IJA_693_17; DeSantis C, 2014, CA-CANCER J CLIN, V64, P52, DOI 10.3322/caac.21203; Forero M, 2017, SCAND J PAIN, V17, P325, DOI 10.1016/j.sjpain.2017.08.013; Forero M, 2016, REGION ANESTH PAIN M, V41, P621, DOI 10.1097/AAP.0000000000000451; Gurkan Y, 2018, J CLIN ANESTH, V50, P65, DOI 10.1016/j.jclinane.2018.06.033; Hamilton DL, 2017, BRIT J ANAESTH, V118, P474, DOI 10.1093/bja/aex013; Hannig KE, 2018, CASE REP ANESTH; Ivanusic J, 2018, REGION ANESTH PAIN M, V43, P567, DOI 10.1097/AAP.0000000000000789; Luftig J, 2018, AM J EMERG MED, V36, P1391, DOI 10.1016/j.ajem.2017.12.060; Moloney N, 2016, SUPPORT CARE CANCER, V24, P4533, DOI 10.1007/s00520-016-3292-1; Rosenberg PH, 2004, REGION ANESTH PAIN M, V25, P118; Singh S, 2018, INDIAN J ANAESTH, V62, P148, DOI 10.4103/ija.IJA_726_17; Tulgar S, 2018, J CLIN ANESTH, V49, P101, DOI 10.1016/j.jclinane.2018.06.019; Tulgar Serkan, 2018, Case Rep Anesthesiol, V2018, P3947281, DOI 10.1155/2018/3947281; Ueshima H, 2018, J CLIN ANESTH, V51, P97, DOI 10.1016/j.jclinane.2018.08.013; Veiga M, 2017, REV ESP ANESTESIOL R, V65, P112	20	7	7	3	6	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1471-2253			BMC ANESTHESIOL	BMC Anesthesiol.	MAR 4	2019	19								31	10.1186/s12871-019-0700-3			9	Anesthesiology	Anesthesiology	HP7QO	WOS:000461883900003	30832580	DOAJ Gold, Green Published			2020-06-30	J	Schauer, SG; Naylor, JF; Maddry, JK; Hinojosa-Laborde, C; April, MD				Schauer, Steven G.; Naylor, Jason F.; Maddry, Joseph K.; Hinojosa-Laborde, Carmen; April, Michael D.			Trends in Prehospital Analgesia Administration by US Forces From 2007 Through 2016	PREHOSPITAL EMERGENCY CARE			English	Article						pain; analgesia; military; prehospital; combat	COMBAT CASUALTY CARE; PAIN; KETAMINE; MORPHINE; MULTICENTER; THEATER; INJURY; SAFETY	Background: Tactical Combat Casualty Care (TCCC) guidelines regarding prehospital analgesia agents have evolved. The guidelines stopped recommending intramuscular (IM) morphine in 1996, recommending only intravenous (IV) routes. In 2006, the guidelines recommended oral transmucosal fentanyl citrate (OTFC), and in 2012 it added ketamine via all routes. It remains unclear to what extent prehospital analgesia administered on the battlefield adheres to these guidelines. We seek to describe trends in analgesia administration patterns on the battlefield during 2007-2016. Methods: This is a secondary analysis of a Department of Defense Trauma Registry data set from January 2007 to August 2016. Within that group, we searched for subjects who received IM morphine, IV morphine, OTFC, parenteral fentanyl, or ketamine (all routes). Results: Our predefined ED search codes captured 28,222 subjects during the study period. Of these, 594 (2.1%) received IM morphine; 3,765 (13.3%) received IV morphine; 589 (2.1%) received OTFC; and 1,510 (5.4%) subjects received ketamine. Annual rates of administration of IM morphine were relatively stable during the study period, while those for OTFC and ketamine generally trended upward starting in 2012. In particular, the proportion of subjects receiving ketamine rose from 3.9% (n = 995/25,618) during the study period preceding its addition to the TCCC guidelines (2007 to 2012) to 19.8% thereafter (2013-2016, n = 515/2,604, p < 0.001). Conclusions: During the study period, rates of prehospital administration of IM morphine remained relatively stable while those for OTFC and ketamine both rose. These findings suggest that TCCC guidelines recommending the use of these agents had a material impact on prehospital analgesia patterns.	[Schauer, Steven G.; Hinojosa-Laborde, Carmen] US Army, Inst Surg Res, Jbsa Ft Sam Houston, TX USA; [Schauer, Steven G.; Maddry, Joseph K.] 59th Med Wing, Jbsa Lackland, TX USA; [Schauer, Steven G.; Maddry, Joseph K.; April, Michael D.] Brooke Army Med Ctr, Jbsa Ft Sam Houston, TX USA; [Naylor, Jason F.] Madigan Army Med Ctr, Joint Base Lewis Mcchord, WA USA	Schauer, SG (reprint author), 3698 Chambers Pass, Jbsa Ft Sam Houston, TX 78234 USA.	Steven.g.schauer.mil@mail.mil					Butler FK, 1996, MIL MED, V161, P3; Butler Frank K, 2014, J Spec Oper Med, V14, P13; Butler FK, 2007, MIL MED, V172, P1; Butler FK, 2012, J TRAUMA ACUTE CARE, V73, pS395, DOI 10.1097/TA.0b013e3182754850; Gerhardt RT, 2016, PREHOSP EMERG CARE, V20, P37, DOI 10.3109/10903127.2015.1051683; GLARE PA, 1991, THER DRUG MONIT, V13, P1, DOI 10.1097/00007691-199101000-00001; Glenn Michael Alan, 2008, J Trauma Nurs, V15, P181, DOI 10.1097/01.JTN.0000343323.47463.aa; Green SM, 1999, ANN EMERG MED, V34, P492, DOI 10.1016/S0196-0644(99)80051-1; Green SM, 1998, ANN EMERG MED, V31, P688, DOI 10.1016/S0196-0644(98)70226-4; Holbrook TL, 2010, NEW ENGL J MED, V362, P110, DOI 10.1056/NEJMoa0903326; Kaji AH, 2014, ANN EMERG MED, V64, P292, DOI 10.1016/j.annemergmed.2014.03.025; Kotwal RS, 2004, ANN EMERG MED, V44, P121, DOI 10.1016/j.annemergmed.2004.03.025; Mahinda TB, 2004, ANESTH ANALG, V98, P1698, DOI 10.1213/01.ANE.0000115148.03515.56; McGhee LL, 2008, J TRAUMA, V64, pS195, DOI 10.1097/TA.0b013e318160ba1d; Miller JP, 2015, AM J EMERG MED, V33, P402, DOI 10.1016/j.ajem.2014.12.058; O'Connell KM, 2012, MIL MED, V177, P546, DOI 10.7205/MILMED-D-11-00422; Petz LN, 2015, MIL MED, V180, P14, DOI 10.7205/MILMED-D-14-00383; Robinson John B, 2016, US Army Med Dep J, P87; Schauer SG, 2018, AM J EMERG MED; Schauer Stephen G, 2017, US Army Med Dep J, P92; Schauer SG, 2017, PREHOSP EMERG CARE, V21, P744, DOI 10.1080/10903127.2017.1335814; Schauer Steven G, 2015, J Spec Oper Med, V15, P85; Shackelford SA, 2015, MIL MED, V180, P304, DOI 10.7205/MILMED-D-14-00257; Wedmore IS, 2012, J TRAUMA ACUTE CARE, V73, pS490, DOI 10.1097/TA.0b013e3182754674	24	2	2	2	2	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1090-3127	1545-0066		PREHOSP EMERG CARE	Prehosp. Emerg. Care	MAR 4	2019	23	2					271	276		10.1080/10903127.2018.1489022			6	Emergency Medicine; Public, Environmental & Occupational Health	Emergency Medicine; Public, Environmental & Occupational Health	HN8VL	WOS:000460474800015	30118637				2020-06-30	J	Aljohaney, AA; Albanna, AS; Alhajji, MA; Mobeireek, AF; Batubara, EM; Zalt, MB; Alghamdi, MA				Aljohaney, Ahmed A.; Albanna, Amr S.; Alhajji, Mohammed A.; Mobeireek, Abdullah F.; Batubara, Enas M.; Zalt, Mohammed B.; Alghamdi, Majed A.			Survey of flexible bronchoscopy practice in adults in Saudi Arabia	SAUDI MEDICAL JOURNAL			English	Article							2-PERCENT LIGNOCAINE; TOPICAL ANESTHESIA; ENDOSCOPY; STATEMENT; AUSTRALIA; 1-PERCENT; SEDATION; SOCIETY	Objectives: To assess current adherence to international guidelines for practitioners of bronchoscopy in the Kingdom of Saudi Arabia. Methods: A cross-sectional survey was conducted in Saudi Arabia between December 2016 and March 2017. Pulmonologists, thoracic surgeons, and intensivists were invited to answer an emailed self-administered questionnaire survey seeking information on how they performed flexible bronchoscopy in adults. The data collected were compared between the 3 specialties. Results: Eighty-two (18%) of 456 invited practitioners completed the survey. Fifty-eight (72%) of the 82 respondents were pulmonologists. Forty (53%) of 76 respondents (93%) who had received bronchoscopy training received it abroad. Twenty-seven respondents (33%) had also received training in endobronchial ultrasound, electrocautery, brachytherapy, stent insertion, and laser procedures. Fifty-eight respondents (70%) preferred patients to undergo fasting for at least 4 hours before the procedure. Lidocaine was used for topical anesthesia, mainly by aerosol spray or nebulization. Midazolam was used by 62%, fentanyl by 50%, and propofol by 12% of respondents. Ninety percent of pulmonologists reported requesting a chest radiograph after transbronchial lung biopsy. Safety procedures for bronchoscopists, for example, wearing masks and eye protection, and for patients, for example, availability of anesthetic reversal agents, were not universally applied. Conclusion: Bronchoscopy is not standardized in Saudi Arabia. National guidelines for the indications and practice of bronchoscopy are required.	[Aljohaney, Ahmed A.] King Abdulaziz Univ, Dept Internal Med, Jeddah, Saudi Arabia; [Albanna, Amr S.] King Saud bin Abdulaziz Univ Hlth Sci, King Abdullah Int Med Res Ctr, Jeddah, Saudi Arabia; [Alhajji, Mohammed A.; Mobeireek, Abdullah F.] King Faisal Specialist Hosp & Res Ctr, Dept Med, Riyadh, Saudi Arabia; [Batubara, Enas M.] Prince Sultan Mil Med City, Dept Med, Riyadh, Saudi Arabia; [Zalt, Mohammed B.] King Fahd Med City, Dept Pulm & Crit Care, Riyadh, Saudi Arabia; [Alghamdi, Majed A.] King Abdualziz Med City, Dept Med, Riyadh, Saudi Arabia	Aljohaney, AA (reprint author), King Abdulaziz Univ, Fac Med, Dept Internal Med, Jeddah, Saudi Arabia.	drajohani@yahoo.com		King Saud Bin Abdulaziz University for Health Sciences, Jeddah, College of Medicine,/0000-0001-9073-534X			Alamoudi OS, 2000, SAUDI MED J, V21, P1043; Asano F, 2013, RESPIROLOGY, V18, P284, DOI 10.1111/j.1440-1843.2012.02273.x; Barnett AM, 2016, J BRONCHOL INTERN PU, V23, P22, DOI 10.1097/LBR.0000000000000251; Bolliger CT, 2002, EUR RESPIR J, V19, P356, DOI 10.1183/09031936.02.00204602; Du Rand IA, 2013, THORAX, V68, P1, DOI 10.1136/thoraxjnl-2013-203618; Ernst A, 2015, CHEST, V148, P321, DOI 10.1378/chest.14-0678; Facciolongo N, 2013, Monaldi Arch Chest Dis, V79, P128; Fielding D, 2012, RESPIROLOGY, V17, P1176, DOI 10.1111/j.1440-1843.2012.02253.x; Hautmann H, 2016, PNEUMOLOGIE, V70, P110, DOI 10.1055/s-0041-110288; Heuss LT, 2005, ENDOSCOPY, V37, P161, DOI 10.1055/s-2004-826143; IKEDA S, 1968, Keio Journal of Medicine, V17, P1; Kaur H, 2015, CHEST, V148, P739, DOI 10.1378/chest.15-0022; Lee P, 2008, J BRONCHOL INTERN PU, V15, P215, DOI 10.1097/LBR.0b013e3181893673; Madan K, 2018, J BRONCHOL INTERN PU, V25, P103, DOI 10.1097/LBR.0000000000000458; Madan K, 2018, LUNG INDIA, V35, P98, DOI 10.4103/lungindia.lungindia_417_17; Madan NK, 2016, J CYTOL, V33, P22, DOI 10.4103/0970-9371.175493; Madkour A, 2008, J BRONCHOL INTERN PU, V15, P27, DOI 10.1097/LBR.0b013e3181641b73; Pierce CW, 2011, CHEST, V140, P833, DOI 10.1378/chest.11-0994; PRAKASH UBS, 1991, CHEST, V100, P1668, DOI 10.1378/chest.100.6.1668; Rhee CK, 2010, J BRONCHOL INTERN PU, V17, P317, DOI 10.1097/LBR.0b013e3181f552a5; Smyth CM, 2002, EUR RESPIR J, V19, P458, DOI 10.1183/09031936.02.00103702; Wahidi MM, 2011, CHEST, V140, P1342, DOI 10.1378/chest.10-3361	22	0	0	0	1	SAUDI MED J	RIYADH	ARMED FORCES HOSPITAL, PO BOX 7897,, RIYADH 11159, SAUDI ARABIA	0379-5284			SAUDI MED J	Saudi Med. J.	MAR	2019	40	3					238	245		10.15537/smj.2019.3.23964			8	Medicine, General & Internal	General & Internal Medicine	IE6XP	WOS:000472519300004	30834418	DOAJ Gold, Green Published			2020-06-30	J	Seiler, M; Staubli, G; Landolt, MA				Seiler, Michelle; Staubli, Georg; Landolt, Markus A.			Combined nitrous oxide 70% with intranasal fentanyl for procedural analgosedation in children: a prospective, randomised, double-blind, placebo-controlled trial	EMERGENCY MEDICINE JOURNAL			English	Article							ADVERSE EVENTS; PAIN INTENSITY; SEDATION; EFFICACY; ANALGESIA; VALIDITY; SAFETY; SCALE; DEPTH	Objective Nitrous oxide 70% (N2O 70%) is an excellent medication for procedural analgosedation (PAS), yet the limit of its analgesic power remains uncertain; therefore, a combination with intranasal fentanyl (INF) was suggested. However, this combination seems to result in a higher rate of vomiting and deeper sedation. This study aimed at assessing the analgesic efficacy, sedation depth and rate of adverse events of PAS with N2O 70% with and without INF. Methods Patients aged 2-16 years who qualified for PAS with N2O 70% were randomly assigned to receive either INF or placebo prior to N2O inhalation in this randomised, double-blind study, which was performed in a tertiary children's hospital ED between September 2015 and October 2017. Behaviour during the procedure was evaluated using the Face, Leg, Activity, Cry and Consolability (FLACC) scale and the Modified Behavioural Pain Scale (MBPS); analgesic efficacy was assessed with a self-reported pain scale. Sedation depth using the validated University of Michigan Sedation Scale and adverse events in the ED and during the following 12 hours were documented. Results A total of 402 patients were included; 3 did not tolerate N2O and therefore had to be excluded. Overall, 399 patients were analysed, of whom 201 (50.4%) received INF. No significant group differences with regard to FLACC scale score, self-reported pain, MBPS score and sedation depth were found. In addition, the two groups did not differ with regard to all types of adverse events. Conclusion Combining N2O 70% with INF resulted in no differences with regard to FLACC scale score, self-reported pain, MBPS score, patient and parental satisfaction rate, sedation depth, and adverse events.	[Seiler, Michelle; Staubli, Georg] Univ Childrens Hosp Zurich, Pediat Emergency Dept, CH-8032 Zurich, Switzerland; [Landolt, Markus A.] Univ Childrens Hosp Zurich, Dept Psychosomat & Psychiat, Zurich, Switzerland; [Landolt, Markus A.] Univ Zurich, Div Child & Adolescent Hlth Psychol, Dept Psychol, Zurich, Switzerland	Seiler, M (reprint author), Univ Childrens Hosp Zurich, Pediat Emergency Dept, CH-8032 Zurich, Switzerland.	michelle.seiler@kispi.uzh.ch		Landolt, Markus/0000-0003-0760-5558	Children's Research Center (CRC) of the University Children's Hospital Zurich	This study was supported by a grant from the Children's Research Center (CRC) of the University Children's Hospital Zurich.	Babl FE, 2008, EMERG MED J, V25, P717, DOI 10.1136/emj.2007.053751; Babl FE, 2005, PEDIATR EMERG CARE, V21, P736, DOI 10.1097/01.pec.0000186427.07636.fc; Babl FE, 2008, PEDIATRICS, V121, pE528, DOI 10.1542/peds.2007-1044; Borland M, 2007, ANN EMERG MED, V49, P335, DOI 10.1016/j.annemergmed.2006.06.016; Borland Meredith L, 2002, Emerg Med (Fremantle), V14, P275, DOI 10.1046/j.1442-2026.2002.00344.x; Brand K, 2010, ANAEST INTENS CARE M, V11, P214, DOI 10.1016/j.mpaic.2010.02.014; Corrigan M, 2015, AM J HEALTH-SYST PH, V72, P1544, DOI 10.2146/ajhp140630; Crellin DJ, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-016225; Crellin DJ, 2015, PAIN, V156, P2132, DOI 10.1097/j.pain.0000000000000305; Emmott AS, 2017, J PAIN, V18, P564, DOI 10.1016/j.jpain.2016.12.015; Finn M, 2010, EMERG MED J, V27, P300, DOI 10.1136/emj.2008.070474; Hoeffe J, 2017, AM J EMERG MED, V35, P710, DOI 10.1016/j.ajem.2017.01.004; Keidan I, 2005, J UROLOGY, V174, P1598, DOI 10.1097/01.ju.0000176595.49213.13; Krauss B, 2000, NEW ENGL J MED, V342, P938, DOI 10.1056/NEJM200003303421306; Malviya S, 2002, BRIT J ANAESTH, V88, P241, DOI 10.1093/bja/88.2.241; Manworren Renee C B, 2003, Pediatr Nurs, V29, P140; Merkel S I, 1997, Pediatr Nurs, V23, P293; Miro J, 2009, EUR J PAIN, V13, P1089, DOI 10.1016/j.ejpain.2009.07.002; Pasaron R, 2015, PEDIATR SURG INT, V31, P173, DOI 10.1007/s00383-014-3608-5; Prommer E, 2011, PATIENT PREFER ADHER, V5, P157, DOI 10.2147/PPA.S7665; Seiler M, 2019, PEDIATR EMERG CARE, V35, P755, DOI 10.1097/PEC.0000000000001213; Seith RW, 2012, ACAD EMERG MED, V19, P31, DOI 10.1111/j.1553-2712.2011.01241.x; Stinson JN, 2006, PAIN, V125, P143, DOI 10.1016/j.pain.2006.05.006; von Baeyer CL, 2007, PAIN, V127, P140, DOI 10.1016/j.pain.2006.08.014; Younger J, 2009, CURR PAIN HEADACHE R, V13, P39, DOI 10.1007/s11916-009-0009-x	25	1	1	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1472-0205	1472-0213		EMERG MED J	Emerg. Med. J.	MAR	2019	36	3					142	147		10.1136/emermed-2018-207892			6	Emergency Medicine	Emergency Medicine	ID6UQ	WOS:000471815500003	30630844				2020-06-30	J	Lin, WL; Lee, MS; Wong, CS; Chan, SM; Lai, HC; Wu, ZF; Lu, CH				Lin, Wei-Lin; Lee, Meei-Shyuan; Wong, Chih-Shung; Chan, Shun-Ming; Lai, Hou-Chuan; Wu, Zhi-Fu; Lu, Chueng-He			Effects of intraoperative propofol-based total intravenous anesthesia on postoperative pain in spine surgery Comparison with desflurane anesthesia - a randomised trial	MEDICINE			English	Article						anesthetics i.v.; propofol; postoperative pain; spine surgery	DORSAL-HORN NEURONS; SEVOFLURANE; ANALGESIA; RESPONSES; CORD; ISOFLURANE; HALOTHANE; RATS; MICE; TIME	Background: As reported, patients experience less postoperative pain after propofol-based total intravenous anesthesia (TIVA). In the present study, we investigated the postoperative analgesic effects between propofol-based TIVA and desflurane anesthesia after spine surgery. Methods: Sixty patients were included who received (surgical time > 180 minutes) lumbar spine surgery. Patients were randomly assigned to receive either TIVA (with target-controlled infusion) with propofol/fentanyl-based anesthesia (TIVA group) or desflurane/fentanyl-based anesthesia (DES group), titrated to maintain Bispectral Index values between 45 and 55. All patients received patient-controlled analgesia (PCA) with fentanyl for postoperative pain relief. Numeric pain rating scale (NRS) pain scores, postoperative fentanyl consumption, postoperative rescue tramadol use, and fentanyl-related side effects were recorded. Results: The TIVA group patients reported lower NRS pain scores during coughing on postoperative day 1 but not day 2 and 3 (P=.002, P=.133, P=.161, respectively). Less fentanyl consumption was observed on postoperative days 1 and 2, but not on day 3 (375 mu g vs 485 mu g, P=.032, 414 mu g vs 572 mu g, P=.033, and 421 mu g vs 479 mu g, P=.209, respectively), less cumulative fentanyl consumption at postoperative 48hours (790 mu g vs 1057 mu g, P=.004) and 72hours (1210 mu g vs 1536 mu g, P=.004), and total fentanyl consumption (1393 mu g vs 1704 mu g, P=.007) when compared with the DES group. No difference was found in rescue tramadol use and fentanyl-related side effects. Conclusion: Patients anesthetized with propofol-based TIVA reported less pain during coughing and consumed less daily and total PCA fentanyl after lumbar spine surgery.	[Lin, Wei-Lin; Chan, Shun-Ming; Lai, Hou-Chuan; Wu, Zhi-Fu; Lu, Chueng-He] Triserv Gen Hosp, Dept Anesthesiol, 325,Sect 2,Chenggung Rd, Taipei 114, Taiwan; [Lin, Wei-Lin; Chan, Shun-Ming; Lai, Hou-Chuan; Wu, Zhi-Fu; Lu, Chueng-He] Natl Def Med Ctr, 325,Sect 2,Chenggung Rd, Taipei 114, Taiwan; [Lee, Meei-Shyuan] Natl Def Med Ctr, Sch Publ Hlth, Taipei, Taiwan; [Wong, Chih-Shung] Cathay Gen Hosp, Dept Anesthesiol, Taipei, Taiwan; [Wu, Zhi-Fu] Chi Mei Med Ctr, Dept Anesthesiol, Tainan, Taiwan	Lu, CH (reprint author), Triserv Gen Hosp, Dept Anesthesiol, 325,Sect 2,Chenggung Rd, Taipei 114, Taiwan.; Lu, CH (reprint author), Natl Def Med Ctr, 325,Sect 2,Chenggung Rd, Taipei 114, Taiwan.	box.lu@msa.hinet.net			Tri-Service General Hospital, Taipei, Taiwan, Republic of China [TSGH-C99-05-S02]	This work was supported by grants TSGH-C99-05-S02 from Tri-Service General Hospital, Taipei, Taiwan, Republic of China.	An K, 2008, ANAESTHESIA, V63, P1187, DOI 10.1111/j.1365-2044.2008.05627.x; ANKERMOLLER E, 1991, BRIT J ANAESTH, V66, P185, DOI 10.1093/bja/66.2.185; Antognini JF, 2000, CAN J ANAESTH, V47, P273, DOI 10.1007/BF03018926; Anwar MM, 1998, COMP BIOCHEM PHYS A, V120, P249, DOI 10.1016/S1095-6433(98)00025-7; Bandschapp O, 2010, ANESTHESIOLOGY, V113, P421, DOI 10.1097/ALN.0b013e3181e33ac8; Barter LS, 2008, ANESTH ANALG, V106, P985, DOI 10.1213/ane.0b013e318163f8f3; Chan ACS, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149753; Cheng SS, 2008, ANESTH ANALG, V106, P264, DOI 10.1213/01.ane.0000287653.77372.d9; Cho AR, 2013, ANESTH ANALG, V116, P685, DOI 10.1213/ANE.0b013e31827ee372; Fassoulaki A, 2008, ANESTH ANALG, V107, P1715, DOI 10.1213/ane.0b013e318182d84e; Freye E, 2004, EUR J ANAESTH, V21, P373, DOI 10.1017/S0265021504005046; Gilron I, 1996, ANESTHESIOLOGY, V84, P572, DOI 10.1097/00000542-199603000-00013; Gilron I, 1999, ANESTH ANALG, V88, P414, DOI 10.1097/00000539-199902000-00036; Guindon J, 2007, ANESTH ANALG, V104, P1563, DOI 10.1213/01.ane.0000263278.05423.a3; Hand R Jr, 2001, AANA J, V69, P466; Hotbauer RK, 2004, ANESTHESIOLOGY, V100, P386, DOI 10.1097/00000542-200402000-00031; Kim J, 2007, ANESTH ANALG, V105, P1020, DOI 10.1213/01.ane.0000280483.17854.56; Kingston S, 2006, ANESTHESIOLOGY, V104, P763, DOI 10.1097/00000542-200604000-00021; Kungys G, 2009, ANESTH ANALG, V108, P1531, DOI 10.1213/ane.0b013e31819d9308; Li M, 2012, ACTA ANAESTH SCAND, V56, P368, DOI 10.1111/j.1399-6576.2011.02603.x; Lu CH, 2016, J NEUROSURG-SPINE, V24, P268, DOI 10.3171/2015.4.SPINE141143; Ma X, 2013, ARCH BIOCHEM BIOPHYS, V533, P1, DOI 10.1016/j.abb.2013.03.002; Merrill AW, 2006, ANESTH ANALG, V103, P478, DOI 10.1213/01.ane.0000223847.50233.1b; Nadeson R, 1997, J PHARMACOL EXP THER, V282, P1181; Peng K, 2016, ANESTH ANALG, V123, P846, DOI 10.1213/ANE.0000000000001504; Pokkinen SM, 2014, ACTA ANAESTH SCAND, V58, P980, DOI 10.1111/aas.12366; Rowley TJ, 2005, ANESTH ANALG, V100, P991, DOI 10.1213/01.ANE.0000147708.73945.B3; Samir A, 2015, ANN CARD ANAESTH, V18, P495, DOI 10.4103/0971-9784.166451; Stevens RJN, 2005, ANESTH ANALG, V100, P1696, DOI 10.1213/01.ANE.0000151720.36988.09; Sun YY, 2005, BRAIN RES, V1043, P231, DOI 10.1016/j.brainres.2005.02.048; Tan T, 2010, ANESTH ANALG, V111, P83, DOI 10.1213/ANE.0b013e3181c0ee9e; Tibbs GR, 2013, J PHARMACOL EXP THER, V345, P363, DOI 10.1124/jpet.113.203620; Tsuchiya M, 2001, AM J RESP CRIT CARE, V163, P26, DOI 10.1164/ajrccm.163.1.9911120; UCHIDA H, 1995, ANESTHESIOLOGY, V83, P1312, DOI 10.1097/00000542-199512000-00022; Wu ZF, 2014, ANESTH ANALG, V119, P1393, DOI 10.1213/ANE.0000000000000435; Yeo ST, 2007, BRIT J ANAESTH, V98, P105, DOI 10.1093/bja/ael326; Zacny JP, 1996, J CLIN ANESTH, V8, P469, DOI 10.1016/0952-8180(96)00126-2; Zhang Y, 2000, ANESTH ANALG, V91, P462, DOI 10.1097/00000539-200008000-00044	38	3	3	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0025-7974	1536-5964		MEDICINE	Medicine (Baltimore)	MAR	2019	98	13							e15074	10.1097/MD.0000000000015074			5	Medicine, General & Internal	General & Internal Medicine	HX3UX	WOS:000467319800067	30921241	DOAJ Gold, Green Published			2020-06-30	J	Fleischman, W; Auth, D; Shah, ND; Agrawal, S; Ross, JS				Fleischman, William; Auth, Doris; Shah, Nilay D.; Agrawal, Shantanu; Ross, Joseph S.			Association of a Risk Evaluation and Mitigation Strategy Program With Transmucosal Fentanyl Prescribing	JAMA NETWORK OPEN			English	Article							UNITED-STATES; PRESCRIPTION	IMPORTANCE Transmucosal immediate-release fentanyl (TIRF) drugs are potent, rapid-acting opioids approved to treat breakthrough pain in patients with cancer who are tolerant to other around-the-clock opioid analgesics. In March 2012, a US Food and Drug Administration-approved Risk Evaluation and Mitigation Strategy (REMS) was implemented, mandating prescribers, distributors, pharmacies, and patients to enroll in the REMS to prescribe, dispense, or receive TIRF drugs. OBJECTIVE To evaluate the association of the TIRF-REMS Access Program with TIRF prescribing. DESIGN, SETTING, AND PARTICIPANTS Cohort study using an interrupted time series analysis of TIRF prescriptions to Medicare Part D beneficiaries nationwide from 2010 to 2014. Data were analyzed from August 2017 through July 2018. MAIN OUTCOMES AND MEASURES Prescribing of TIRF per 100 000 Medicare Part D beneficiaries, overall and stratified by cancer status; percentage of TIRF prescriptions for patients without cancer, overall and by brand; and percentage of TIRF prescriptions for patients without known opioid tolerance, defined as patients prescribed at least 60 morphine milligram equivalents per day, overall and by brand. RESULTS There were 99 601 TIRF prescriptions written by 8619 clinicians to 10 472 patients. Most of the patients (79%) were younger than 65 years (mean [SD] age, 56 [13] years), and most (67%) did not have cancer. Implementation of TIRF-REMS was associated with a 26.7% relative level decrease in TIRF prescribing (95% CI, -33.3% to -19.4%; P<.001) but was followed by 2.0% monthly increases in prescribing (95% CI, 1.3% to 2.7%; P<.001). Sensitivity analyses that accounted for overall opioid prescribing trends were consistent with these findings. Furthermore, there were no significant changes associated with REMS implementation in the level (0.47%; 95% CI, -5.36% to 4.69%; P=.85) or trend (0.16%; 95% CI, -0.06% to 0.37%; P=.15) of the percentage of prescriptions for patients without cancer. However, a sensitivity analysis that used a broader cancer definition found implementation was associated with a 7.2%(95% CI, -13.5% to -0.48%; P=.04) level decrease in the percentage of TIRF prescriptions for patients without cancer. Lastly, the TIRF-REMS was associated with a 22.5% level decline in the percentage of TIRF prescriptions for patients without known opioid tolerance (95% CI, -36.1% to -5.95%; P=.01) followed by 1.98% monthly decreases (95% CI, -3.19% to -0.80%; P=.001). CONCLUSIONS AND RELEVANCE Implementation of the TIRF-REMS Access Program, a restrictive drug distribution program, was associated with a temporary reduction in the rate of TIRF prescribing to Medicare Part D beneficiaries, and with a sustained decrease in the percentage of TIRF prescriptions for patients without known opioid tolerance. Implementation may have also been associated with a temporary decrease in the percentage of TIRF prescriptions for patients without cancer.	[Fleischman, William] Hackensack Meridian Hlth, Dept Patient Safety & Qual, Edison, NJ USA; [Fleischman, William; Agrawal, Shantanu] Ctr Medicare & Medicaid Serv, Baltimore, MD USA; [Auth, Doris] US FDA, Silver Spring, MD USA; [Shah, Nilay D.] Mayo Clin, Robert D & Patricia E Kern Ctr Sci Hlth Care Deli, Rochester, MN USA; [Shah, Nilay D.] Mayo Clin, Div Hlth Care Policy & Res, Rochester, MN USA; [Agrawal, Shantanu] Natl Qual Forum, Washington, DC USA; [Ross, Joseph S.] Yale New Haven Med Ctr, Ctr Outcomes Res & Evaluat, 20 York St, New Haven, CT 06504 USA; [Ross, Joseph S.] Yale Sch Publ Hlth, Dept Hlth Policy & Management, New Haven, CT USA; [Ross, Joseph S.] Yale Sch Med, Dept Med, Gen Internal Med Sect, New Haven, CT USA	Fleischman, W (reprint author), Hackensack Meridian Hlth, 343 Thornall St,Seventh Floor, Edison, NJ 08837 USA.	wf3@buffalo.edu	Fleischman, William/Q-8686-2019				Boyd R., BLACK WORLD INSYS TH; Centers for Disease Control and Prevention National Center for Injury Prevention and Control (US), 2017, ANN SURV REP DRUG RE, P83; Centers for Disease Control & Prevention, 2015, OP MORPH EQ CONV FAC; Centers for Medicare & Medicaid Services, 2012, MONTHL CONTR ENR SUM; Guy GP, 2017, MMWR-MORBID MORTAL W, V66, P697, DOI 10.15585/mmwr.mm6626a4; Hoadley J, MEDICARE D; Hughes E., 2018, NY TIMES; Kimmel PL, 2017, J AM SOC NEPHROL, V28, P3658, DOI 10.1681/ASN.2017010098; Kolodny A, 2015, ANNU REV PUBL HEALTH, V36, P559, DOI 10.1146/annurev-publhealth-031914-122957; Linden A, 2017, STATA J, V17, P73, DOI 10.1177/1536867X1701700105; National Center for Health Statistics Centers for Disease Control and Prevention. Health United States, 2013, HLTH US 2013 SPEC FE; Pope GC, 2004, HEALTH CARE FINANC R, V25, P119; Thomas K., 2014, NY TIMES; US Department of Justice, 2017, FOUND OWN PHARM CO I; US Department of Justice, 2016, PHARM EX CHARG RACK; US Food and Drug Administration, 2011, TRANSM IMM REL FENT; Weiner SG, 2017, ANN EMERG MED, V70, P799, DOI 10.1016/j.annemergmed.2017.03.057; Xu J., 2018, NATL VITAL STAT REPO; 2014, MED CARE, V52, P852, DOI DOI 10.1097/MLR.0000000000000183; 2002, J CLIN PHARM THER, V27, P299, DOI DOI 10.1046/J.1365-2710.2002.00430.X; 2015, STATA J, V15, P480, DOI DOI 10.1177/1536867X1501500208; 2017, JAMA INTERN MED, V177, P44, DOI DOI 10.1001/JAMAINTERNMED.2016.6811; 2017, INT J EPIDEMIOL, V46, P348, DOI DOI 10.1093/IJE/DYW098	23	1	1	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2574-3805			JAMA NETW OPEN	JAMA Netw. Open	MAR	2019	2	3							e191340	10.1001/jamanetworkopen.2019.1340			12	Medicine, General & Internal	General & Internal Medicine	HU6XA	WOS:000465424000032	30924899	DOAJ Gold, Green Published			2020-06-30	J	Salmond, S; Allread, V				Salmond, Susan; Allread, Virginia			A Population Health Approach to America's Opioid Epidemic	ORTHOPAEDIC NURSING			English	Article							INJECTING DRUG-USERS; SUBSTANCE MISUSERS; NURSES ATTITUDES; UNITED-STATES; OVERDOSE; PROGRAMS; PAIN	The United States is in the midst of a nationwide public health emergency: an epidemic of opioid misuse and abuse that has been called the deadliest drug crisis in American history. This article reviews the current status of the opioid epidemic, the trends over the last 30-40 years that may have contributed to the epidemic, and a population health approach to addressing the epidemic. The epidemic is conceptualized from a population health perspective-an upstream and midstream perspective focusing on prevention and a downstream perspective targeting access to evidence-based interventions and maximizing health whether using or abstaining. Within the context of acute care, this approach will include patient screening for opioid use and other risk factors for addiction, use of opioid-sparing analgesics, and follow-up care that addresses pain and pain relief without opioids. For individuals who need addiction treatment, a gradualism philosophy is put forward. Gradualism recognizes the incremental nature of behavior change and recommends strategies to maximize health and functioning-through harm reduction-at all points along the journey to overcome addiction. Working within communities to address the broad factors that contribute to opioid-related substance use disorder is also essential.	[Salmond, Susan; Allread, Virginia] Rutgers State Univ, Sch Nursing, Newark, NJ 07102 USA	Salmond, S (reprint author), Rutgers State Univ, Sch Nursing, Newark, NJ 07102 USA.						Alford DP, 2016, PAIN MED, V17, P52, DOI 10.1111/pme.12878; [Anonymous], EMCDDA PAPERS; [Anonymous], 2005, TREATMENT IMPROVEMEN, pA15; Balhara Y. P. S., 2016, WHAT IS DIFFERENCE B; Bartlett Robin, 2013, Medsurg Nurs, V22, P349; Beach House, 2018, HARM RED POL RIS SAF; Bouckoms A. J., 1992, ANN CLIN PSYCHIAT, V4, P185; Brandeis University Heller School for Social Policy and Management, 2013, UPSTR OPP RED HARM A; Brummett CM, 2017, JAMA SURG, V152, DOI 10.1001/jamasurg.2017.0504; Case A., 2017, WASHINGTON POST; Centers for Disease Control and Prevention, 2014, CDC VIT SIGNS; Centers for Disease Control and Prevention, 2018, US DRUG OV DEATHS CO; Centers for Disease Control and Prevention, 2017, OP OV; Chou R, 2016, J PAIN, V17, P131, DOI 10.1016/j.jpain.2015.12.008; Cicero TJ, 2014, JAMA PSYCHIAT, V71, P821, DOI 10.1001/jamapsychiatry.2014.366; Clark H. W., 2014, EVEN NONFATAL OVERDO; Coffin PO, 2016, ANN INTERN MED, V165, P245, DOI 10.7326/M15-2771; Compton WM, 2016, NEW ENGL J MED, V374, P154, DOI 10.1056/NEJMra1508490; Cotten-Oldenburg NU, 2001, J ACQ IMMUN DEF SYND, V27, P183, DOI 10.1097/00126334-200106010-00014; Cullen T., 2017, NEW YORK DAILY NEWS; Darke S, 2003, ADDICTION, V98, P1169, DOI 10.1046/j.1360-0443.2003.00474.x; Dasgupta N, 2018, AM J PUBLIC HEALTH, V108, P182, DOI 10.2105/AJPH.2017.304187; Davis MA, 2017, J AM BOARD FAM MED, V30, P407, DOI 10.3122/jabfm.2017.04.170112; Drug Policy Alliance, 2015, NJ C CHRIST SIGNS BI; Dubois TM, 2017, J ADDICT NURS, V28, P42, DOI 10.1097/JAN.0000000000000158; Duke University Margolis Center for Health Policy, 2018, PUBL WORKSH STRAT PR; Egan KL, 2017, AM J DRUG ALCOHOL AB, V43, P69, DOI 10.1080/00952990.2016.1240801; European Monitoring Centre for Drugs and Drug Addiction, 2015, PREV FAT OV SYST REV; FDA Statement, 2017, COMMUNICATION; Fenton JJ, 2012, ARCH INTERN MED, V172, P405, DOI 10.1001/archinternmed.2011.1662; Florence CS, 2016, MED CARE, V54, P901, DOI 10.1097/MLR.0000000000000625; Gourevitch M., 2018, INFLECTION POINT TAK; Hansen H, 2016, AM J PUBLIC HEALTH, V106, P2127, DOI 10.2105/AJPH.2016.303483; Hayes T. O., 2018, OPIOID EPIDEMIC COST; Henry J., 2018, OP OV RAT RAC ETHN; Hill MV, 2017, ANN SURG, V265, P709, DOI 10.1097/SLA.0000000000001993; Hilton BA, 2001, J ADV NURS, V33, P357, DOI 10.1046/j.1365-2648.2001.01672.x; Hoban B., 2017, BROOKINGS NOW   1025; Hojsted J, 2007, EUR J PAIN, V11, P490, DOI 10.1016/j.ejpain.2006.08.004; Howard MO, 2000, SUBST USE MISUSE, V35, P1227, DOI 10.3109/10826080009147480; Howard MO, 2000, SUBST USE MISUSE, V35, P347, DOI 10.3109/10826080009147701; Howard MO, 2000, SUBST USE MISUSE, V35, P503, DOI 10.3109/10826080009147470; Hsu A., 2017, HLTH NEWS NPR   0822; Humphreys K., 2018, WASHINGTON POST; Inciardi James A, 2007, Law Enforc Exec Forum, V7, P127; Jones CM, 2013, JAMA-J AM MED ASSOC, V309, P657, DOI 10.1001/jama.2013.272; Kastelic A., 2008, OPIOID SUBSTITUTION; Katz J, 2017, NY TIMES; Kounang N., 2017, CNN             1221; Lankenau SE, 2012, INT J DRUG POLICY, V23, P37, DOI 10.1016/j.drugpo.2011.05.014; Larochelle MR, 2018, ANN INTERN MED, V169, P137, DOI 10.7326/M17-3107; Leung PTM, 2017, NEW ENGL J MED, V376, P2194, DOI 10.1056/NEJMc1700150; Lopez G., 2017, CNBC            0629; Mancini GJ, 2017, POSTGRAD MED, V129, P1, DOI 10.1080/00325481.2017.1268901; Mandell BF, 2016, CLEV CLIN J MED, V83, P400, DOI 10.3949/ccjm.83b.06016; Meier B., 2007, NY TIMES; Mercia D., 2017, CNN POLITICS    1026; Mitchell J., 2018, CLARION LEDGER  0126; Moghe S., 2016, CNN             1014; Muhuri PK, 2013, CBHSQ DATA REV; National Institute on Drug Abuse, 2018, OV DEATH RAT; National Institute on Drug Abuse, 2018, OP OV CRIS; Olsen Y, 2014, JAMA-J AM MED ASSOC, V311, P1393, DOI 10.1001/jama.2014.2147; Portman R., 2018, PORTMAN OP ED STOP A; Potier C, 2014, DRUG ALCOHOL DEPEN, V145, P48, DOI 10.1016/j.drugalcdep.2014.10.012; Prescription Drug Monitoring Program Training and Technical Assistance Center, 2018, TECHN ASS GUID HIST; Rao R. B., 2017, EMERGEN MED, P65, DOI [DOI 10.12788/EMED.2017.0010, 10.12788/emed.2017.0010]; SAMHSA, 2018, RISK PROT FACT; U.S. Department of Health and Human Services (HHS), 2016, OFF SURG GEN FAC ADD; United-Nations-Office-on-Drugs-and-Crime, 2016, WORLD DRUG REP 2016; Volkow ND, 2014, AM ADDICTION OPIOIDS; Volkow ND, 2014, NEW ENGL J MED, V370, P2063, DOI 10.1056/NEJMp1402780; Walley AY, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f174; Welham Grace C, 2015, Drugs Real World Outcomes, V2, P129; Wodak A, 2006, SUBST USE MISUSE, V41, P777, DOI 10.1080/10826080600669579	75	2	2	1	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0744-6020	1542-538X		ORTHOP NURS	Orthop. Nurs.	MAR-APR	2019	38	2					95	108		10.1097/NOR.0000000000000521			14	Nursing; Orthopedics	Nursing; Orthopedics	HU9DW	WOS:000465594900004	30768537	Green Published			2020-06-30	J	Zolhavarieh, SM; Mousavi-Bahar, SH; Mohseni, M; Emam, AH; Poorolajal, J; Majzoubid, F				Zolhavarieh, Seyed Mohammad; Mousavi-Bahar, Seyed Habibollah; Mohseni, Maede; Emam, Amir Hossein; Poorolajal, Jalal; Majzoubid, Faeze			Effect of intravenous acetaminophen versus fentanyl on postoperative pain after transurethral lithotripsy	REVISTA BRASILEIRA DE ANESTESIOLOGIA			Portuguese	Article						Acetaminophen; Fentanyl; Morphine; Postoperative pain; Hemodynamic parameters; Transurethral lithotripsy	PARACETAMOL; PROPACETAMOL; EFFICACY; SINGLE; ANALGESIA; INJECTION	Background: Postoperative pain is the most common postoperative complication. This study was conducted to assess the effect of acetaminophen versus fentanyl on postoperative pain relief in patients who underwent urologic surgeries. Methods: This clinical trial was conducted on patients aged 18-65 years. Patients were randomly assigned to receive either 2000 mg acetaminophen (propacetamol) or 2 mcg.kg(-1) fentanyl intravenously, 15 min before the end of surgery. The postoperative pain was evaluated every 6 h for 24 h using the Visual Analog Scale. Total morphine dose taken in 24 h and hemodynamic status were evaluated. Results: Eighty patients were enrolled into the trial. The mean score of pain in 6, 12, 18, and 24 h after surgery was lower in the acetaminophen group than in the fentanyl group but the difference was not statistically significant except in 12 and 18 h after surgery (p < 0.05). The amount of administered morphine was higher in the fentanyl group than in the acetaminophen group, but the difference was not statistically significant. The hemodynamic status including systolic and diastolic blood pressure and heart rates were nearly the same in the two groups but the SpO(2) mean was significantly higher in the acetaminophen group than the fentanyl group. Conclusions: This trial indicated that intravenous acetaminophen is as effective as intravenous fentanyl in pain relief after urologic surgeries (transurethral lithotripsy). (C) 2018 Sociedade Brasileira de Anestesiologia. Published by Elsevier Editora Ltda.	[Zolhavarieh, Seyed Mohammad] Hamadan Univ Med Sci, Dept Urol, Sch Med, Hamada, Iran; [Zolhavarieh, Seyed Mohammad] Hamadan Univ Med Sci, Nephrol Res Ctr, Sch Med, Hamada, Iran; [Zolhavarieh, Seyed Mohammad; Mousavi-Bahar, Seyed Habibollah; Emam, Amir Hossein] Hamadan Univ Med Sci, Sch Med, Dept Anesthesiol, Hamada, Iran; [Mousavi-Bahar, Seyed Habibollah; Mohseni, Maede] Hamadan Univ Med Sci, Sch Publ Med, Dept Urol, Hamada, Iran; [Emam, Amir Hossein; Majzoubid, Faeze] Hamadan Univ Med Sci, Clin Res Dev Unit, Besat Hosp, Hamada, Iran; [Poorolajal, Jalal] Hamadan Univ Med Sci, Sch Publ Hlth, Res Ctr Hlth Sci, Hamada, Iran; [Poorolajal, Jalal] Hamadan Univ Med Sci, Sch Publ Hlth, Dept Epidemiol & Biostat, Hamada, Iran	Zolhavarieh, SM (reprint author), Hamadan Univ Med Sci, Dept Urol, Sch Med, Hamada, Iran.; Zolhavarieh, SM (reprint author), Hamadan Univ Med Sci, Nephrol Res Ctr, Sch Med, Hamada, Iran.; Zolhavarieh, SM (reprint author), Hamadan Univ Med Sci, Sch Med, Dept Anesthesiol, Hamada, Iran.	dsmbszolhavarieh@gmail.com					Bakan M, 2015, REV BRAS ANESTESIOL, V65, P191, DOI [10.1016/j.bjane.2014.05.001, 10.1016/j.bjan.2014.05.006]; BARDEN J, 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD004602; Brunton LL, 2011, GOODMAN GILMANS PHAR; Cakan T, 2008, J NEUROSURG ANESTH, V20, P169, DOI 10.1097/ANA.0b013e3181705cfb; Choudhuri Anirban Hom, 2011, Anesth Essays Res, V5, P196, DOI 10.4103/0259-1162.94777; DELBOS A, 1995, J PAIN SYMPTOM MANAG, V10, P279, DOI 10.1016/0885-3924(95)00004-I; Flouvat B, 2004, INT J CLIN PHARM TH, V42, P50; Grundmann U, 2006, ANESTH ANALG, V103, P217, DOI 10.1213/01.ane.0000221438.08990.06; Haghighi M, 2016, J PIONEER MED SCI, V6, P38; Hernandez-Palazon J, 2001, ANESTH ANALG, V92, P1473, DOI 10.1097/00000539-200106000-00024; Hyllested M, 2002, BRIT J ANAESTH, V88, P199; Hynes D, 2006, ACTA ANAESTH SCAND, V50, P374, DOI 10.1111/j.1399-6576.2006.00971.x; Jarde O, 1997, CLIN DRUG INVEST, V14, P474, DOI 10.2165/00044011-199714060-00005; Karanges EA, 2016, BRIT J CLIN PHARMACO, V82, P255, DOI 10.1111/bcp.12937; Kerr D, 2015, INT J OBSTET ANESTH, V24, P117, DOI 10.1016/j.ijoa.2014.11.006; Kugathas S, 2016, ENVIRON HEALTH PERSP, V124, P452, DOI 10.1289/ehp.1409544; Landwehr S, 2005, CURR MED RES OPIN, V21, P1569, DOI 10.1185/030079905X61857; Lovich-Sapola J, 2015, SURG CLIN N AM, V95, P301, DOI 10.1016/j.suc.2014.10.002; Marshansky S, 2017, PROGR NEUROPSYCHOPHA; Peduto VA, 1998, ACTA ANAESTH SCAND, V42, P293, DOI 10.1111/j.1399-6576.1998.tb04919.x; Pettersson PH, 2004, ACTA ANAESTH SCAND, V48, P867, DOI 10.1111/j.1399-6576.2004.00452.x; Ronald DM, 2010, MILLERS ANESTHESIA; Salihoglu Z, 2009, SURG LAPARO ENDO PER, V19, P321, DOI 10.1097/SLE.0b013e3181b13933; Sinatra RS, 2005, ANESTHESIOLOGY, V102, P822, DOI 10.1097/00000542-200504000-00019; Stoelting RK, 2007, BASIC OF ANESTHESIA; Tzortzopoulou A, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007126.pub2; Wallden J, 2004, ANESTH ANALG, V99, P429; Zhou TJ, 2001, ANESTH ANALG, V92, P1569	28	1	1	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0034-7094	1806-907X		REV BRAS ANESTESIOL	Rev. Bras. Anestesiol.	MAR-APR	2019	69	2					131	136		10.1016/j.bjan.2018.06.009			6	Anesthesiology	Anesthesiology	HQ7UG	WOS:000462627700003		DOAJ Gold			2020-06-30	J	Li, TY; Lu, IC; Cheng, KI; Huang, HF				Li, Tzu-Ying; Lu, I-Cheng; Cheng, Kuang-I; Huang, Hui-Fang			Fentanyl with low concentration ropivacaine induced less motor blockade in epidural analgesia	KAOHSIUNG JOURNAL OF MEDICAL SCIENCES			English	Letter									[Li, Tzu-Ying; Cheng, Kuang-I; Huang, Hui-Fang] Kaohsiung Med Univ Hosp, Dept Anesthesiol, 100 Tz You 1st Rd, Kaohsiung 807, Taiwan; [Lu, I-Cheng] Kaohsiung Municipal Hsiaokang Hosp, Dept Anesthesiol, Kaohsiung, Taiwan	Huang, HF (reprint author), Kaohsiung Med Univ Hosp, Dept Anesthesiol, 100 Tz You 1st Rd, Kaohsiung 807, Taiwan.	wiebittee@gmail.com					Khaw KS, 2014, ANESTHESIOLOGY, V120, P1126; Lee AI, 2017, ANESTHESIOLOGY, V127, P614, DOI 10.1097/ALN.0000000000001793; McClellan KJ, 2000, DRUGS, V60, P1065, DOI 10.2165/00003495-200060050-00007; Zaric D, 1996, REGION ANESTH, V21, P14	4	0	0	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1607-551X	2410-8650		KAOHSIUNG J MED SCI	Kaohsiung J. Med. Sci.	MAR	2019	35	3					183	184		10.1002/kjm2.12030			2	Medicine, Research & Experimental	Research & Experimental Medicine	HP7HM	WOS:000461858700008	30887721	DOAJ Gold			2020-06-30	J	Brede, WR; Krabseth, HM; Michelsen, LS; Aarset, H; Jamt, JP; Slordal, L				Brede, Wenche Rodseth; Krabseth, Hege-Merete; Michelsen, Lisbeth Solem; Aarset, Harald; Jamt, John-Petter; Slordal, Lars			A Wolf in Sheep's Clothing	JOURNAL OF ANALYTICAL TOXICOLOGY			English	Letter							FENTANYL		[Brede, Wenche Rodseth; Krabseth, Hege-Merete; Michelsen, Lisbeth Solem; Slordal, Lars] St Olavs Univ Hosp, Dept Clin Pharmacol, Trondheim, Norway; [Aarset, Harald] St Olavs Univ Hosp, Dept Pathol & Med Genet, Trondheim, Norway; [Jamt, John-Petter] Trondheim Municipal, Overdose Team, Trondheim, Norway; [Slordal, Lars] Norwegian Univ Sci & Technol, Dept Clin & Mol Med, Trondheim, Norway	Slordal, L (reprint author), St Olavs Univ Hosp, Dept Clin Pharmacol, Trondheim, Norway.; Slordal, L (reprint author), Norwegian Univ Sci & Technol, Dept Clin & Mol Med, Trondheim, Norway.	lars.slordal@ntnu.no					Arens AM, 2016, JAMA INTERN MED, V176, P1554, DOI 10.1001/jamainternmed.2016.4306; Fogarty MF, 2018, J ANAL TOXICOL, V42, P592, DOI 10.1093/jat/bky035; Mounteney J, 2015, INT J DRUG POLICY, V26, P626, DOI 10.1016/j.drugpo.2015.04.003; Palaty J, 2018, CLIN BIOCHEM, V53, P164, DOI 10.1016/j.clinbiochem.2018.01.013; Suzuki J, 2017, DRUG ALCOHOL DEPEN, V171, P107, DOI 10.1016/j.drugalcdep.2016.11.033	5	2	2	0	0	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0146-4760	1945-2403		J ANAL TOXICOL	J. Anal. Toxicol.	MAR	2019	43	2					E7	E8		10.1093/jat/bky080			2	Chemistry, Analytical; Toxicology	Chemistry; Toxicology	HO0VR	WOS:000460624200003	30295817				2020-06-30	J	Bennett, KJ; Seddighi, R; Moorhead, KA; Messenger, K; Cox, SK; Sun, XC; Pasloske, K; Pypendop, BH; Doherty, TJ				Bennett, Katherine J.; Seddighi, Reza; Moorhead, Kaitlin A.; Messenger, Kristin; Cox, Sherry K.; Sun, Xiaocun; Pasloske, Kirby; Pypendop, Bruno H.; Doherty, Thomas J.			Effect of fentanyl on the induction dose and minimum infusion rate of alfaxalone preventing movement in dogs	VETERINARY ANAESTHESIA AND ANALGESIA			English	Article						alfaxalone; anesthesia; dogs; fentanyl; minimum infusion rate	TOTAL INTRAVENOUS ANESTHESIA; CONSTANT RATE INFUSION; PROPOFOL; CARDIOPULMONARY; RECOVERY; REQUIREMENTS; ALPHAXALONE; PAIN	Objective To determine the effect of fentanyl on the induction dose and minimum infusion rate of alfaxalone required to prevent movement in response to a noxious stimulus (MIRNM) in dogs. Study design Experimental crossover design. Animals A group of six healthy, adult, intact female mixed-breed dogs, weighing 19.7 +/- 1.3 kg. Methods Dogs were randomly administered one of three treatments at weekly intervals: premedication with 0.9% saline (treatment A), fentanyl 5 mu g kg(-1) (treatment ALF) or fentanyl 10 mu g kg(-1) (treatment AHF), administered intravenously over 5 minutes. Anesthesia was induced 5 minutes later with incremental doses of alfaxalone to achieve intubation and was maintained for 90 minutes in A with alfaxalone (0.12 mg kg(-1) minute(-1)), in ALF with alfaxalone (0.09 mg kg(-1) minute(-1)) and fentanyl (0.1 mu g kg(-1) minute(-1)) and in AHF with alfaxalone (0.06 mg kg(-1) minute(-1)) and fentanyl (0.2 mu g kg(-1) minute(-1)). The alfaxalone infusion was increased or decreased by 0.006 mg kg(-1) minute(-1) based on positive or negative response to antebrachium stimulation (50 V, 50 Hz, 10 ms). Data were analyzed using a mixed-model ANOVA and presented as least squares means +/- standard error. Results Alfaxalone induction doses were 3.50 +/- 0.13 (A), 2.17 +/- 0.10 (ALF) and 1.67 +/- 0.10 mg kg(-1) (AHF) and differed among treatments (p < 0.05). Alfaxalone MIRNM was 0.17 +/- 0.01 (A), 0.10 +/- 0.01 (ALF) and 0.07 +/- 0.01 mg kg(-1) minute(-1) (AHF) and differed among treatments. ALF and AHF decreased the MIRNM by 44 +/- 8% and 62 +/- 5%, respectively (p < 0.05). Plasma alfaxalone concentrations at MIRNM were 5.82 +/- 0.48 (A), 4.40 +/- 0.34 (ALF) and 2.28 +/- 0.09 mu g mL(-1) (AHF). Conclusions and clinical relevance Fentanyl, at the doses studied, significantly decreased the alfaxalone induction dose and MIRNM.	[Bennett, Katherine J.; Seddighi, Reza; Doherty, Thomas J.] Univ Tennessee, Coll Vet Med, Dept Large Anim Clin Sci, Room C222,2407 River Dr, Knoxville, TN 37996 USA; [Moorhead, Kaitlin A.] Univ Tennessee, Coll Vet Med, Knoxville, TN USA; [Messenger, Kristin] North Carolina State Univ, Dept Mol Biomed Sci, Raleigh, NC 27695 USA; [Cox, Sherry K.] Univ Tennessee, Dept Biol & Diagnost Sci, Knoxville, TN USA; [Sun, Xiaocun] Univ Tennessee, Off Informat & Technol, Knoxville, TN USA; [Pasloske, Kirby] Jurox Pty Ltd, Rutherford, NSW, Australia; [Pypendop, Bruno H.] Univ Calif Davis, Sch Vet Med, Dept Surg & Radiol Sci, Davis, CA 95616 USA	Bennett, KJ (reprint author), Univ Tennessee, Coll Vet Med, Dept Large Anim Clin Sci, Room C222,2407 River Dr, Knoxville, TN 37996 USA.	kjbennett8@gmail.com		Pypendop, Bruno/0000-0002-0894-0991; Cox, Sherry/0000-0002-5184-900X	University of Tennessee Companion Animal Fund grant; Jurox Pty Ltd	This study was funded in part by a University of Tennessee Companion Animal Fund grant. Jurox Pty Ltd provided alfaxalone and funded the analysis of plasma alfaxalone concentrations.	Ambros B, 2008, AM J VET RES, V69, P1391, DOI 10.2460/ajvr.69.11.1391; Bennett RC, 2017, AM J VET RES, V78, P956, DOI 10.2460/ajvr.78.8.956; Bigby SE, 2017, VET ANAESTH ANALG, V44, P1267, DOI 10.1016/j.vaa.2017.03.005; Davis CA, 2017, VET ANAESTH ANALG, V44, P727, DOI 10.1016/j.vaa.2016.11.002; Dehuisser V, 2017, VET ANAESTH ANALG, V44, P1276, DOI 10.1016/j.vaa.2017.04.006; Dzikiti BT, 2016, VET ANAESTH ANALG, V43, P316, DOI 10.1111/vaa.12300; Fassoulaki A, 2008, ANESTH ANALG, V107, P1715, DOI 10.1213/ane.0b013e318182d84e; Ferre PJ, 2006, VET ANAESTH ANALG, V33, P229, DOI 10.1111/j.1467-2995.2005.00264.x; Iizuka T, 2013, VET J, V198, P289, DOI 10.1016/j.tvjl.2013.06.021; Laing S, 2009, J SMALL ANIM PRACT, V50, P82, DOI 10.1111/j.1748-5827.2008.00689.x; Liao PT, 2017, VET ANAESTH ANALG, V44, P1016, DOI 10.1016/j.vaa.2017.02.011; Maney JK, 2013, VET ANAESTH ANALG, V40, P237, DOI 10.1111/vaa.12006; Michou JN, 2012, VET ANAESTH ANALG, V39, P275, DOI 10.1111/j.1467-2995.2012.00709.x; Rodriguez JM, 2012, VET ANAESTH ANALG, V39, P357, DOI 10.1111/j.1467-2995.2011.00695.x; Muir W, 2008, VET ANAESTH ANALG, V35, P451, DOI 10.1111/j.1467-2995.2008.00406.x; Okushima S, 2015, VET ANAESTH ANALG, V42, P88, DOI 10.1111/vaa.12166; ROSOW CE, 1982, ANESTHESIOLOGY, V56, P93, DOI 10.1097/00000542-198202000-00003; Ruiz CC, 2016, VET ANAESTH ANALG, V43, P281, DOI 10.1111/vaa.12298; Smith CK, 2017, VET ANAESTH ANALG, V44, P1287, DOI 10.1016/j.vaa.2017.07.004; SMITH JA, 1993, J AM VET MED ASSOC, V202, P1111; Suarez MA, 2012, VET ANAESTH ANALG, V39, P236, DOI 10.1111/j.1467-2995.2011.00700.x; Taboada FM, 2010, VET REC, V167, P85, DOI 10.1136/vr.b4872; Valverde A, 2003, AM J VET RES, V64, P957, DOI 10.2460/ajvr.2003.64.957; Winter L, 2003, ANESTH ANALG, V97, P798, DOI 10.1213/01.ANE.0000075835.73967.F3	24	1	1	0	3	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1467-2987	1467-2995		VET ANAESTH ANALG	Vet. Anaesth. Analg.	MAR	2019	46	2					173	181		10.1016/j.vaa.2018.10.006			9	Veterinary Sciences	Veterinary Sciences	HN3YM	WOS:000460121100005	30554890				2020-06-30	J	Dai, Z; Abate, MA; Smith, GS; Kraner, JC; Mock, AR				Dai, Zheng; Abate, Marie A.; Smith, Gordon S.; Kraner, James C.; Mock, Allen R.			Fentanyl and fentanyl-analog involvement in drug-related deaths	DRUG AND ALCOHOL DEPENDENCE			English	Article						Fentanyl; Fentanyl analog; Death; Illicit drug; Prescription opioid	BRITISH-COLUMBIA; OVERDOSE DEATHS; ILLICIT FENTANYL; UNITED-STATES; RISK-FACTORS; HEROIN; EPIDEMIOLOGY; TOXICOLOGY; INCREASES; COCAINE	Background: To describe and analyze the involvement of fentanyl and fentanyl analogs (FAs) in drug-related deaths in West Virginia (WV), United States. Methods: Retrospective analyses of all WV drug-related deaths from 2005 to 2017 were performed, including comparisons of demographic and toxicological characteristics among total deaths, deaths in which fentanyl/FAs were present, deaths in which they were absent, heroin-related deaths, and prescription opioid-related deaths. Results: Most of the 8813 drug-related deaths were overdoses, with about 11% resulting from transportation/other injuries in which drugs were contributors. Prescription opioid presence (without fentanyl) decreased by 75% from 2005-14 to 2015-17 (3545 deaths to 859 deaths, respectively), while fentanyl involvement in the deaths increased by 122% between these periods (487 to 1082 deaths). Ten FAs were identified (427 instances) after 2015. Alprazolam and ethanol were among the top five most frequently identified substances across years. Fentanyl, heroin and cocaine replaced oxycodone, diazepam and hydrocodone in the top five beginning in 2015. Few decedents had a prescription for fentanyl after 2015, with fewer prescriptions also present for other controlled substances identified. Conclusions: Fentanyl, rapidly emerging FAs, and other illicit drugs in recent years pose a serious health threat even though prescription opioid-related deaths decreased over the same time period.	[Dai, Zheng; Smith, Gordon S.] West Virginia Univ, Sch Publ Hlth, One Med Ctr Dr, Morgantown, WV 26506 USA; [Abate, Marie A.] West Virginia Univ, Sch Pharm, 1124 Hlth Sci North, Morgantown, WV 26506 USA; [Kraner, James C.; Mock, Allen R.] West Virginia Dept Hlth & Human Resources, 619 Virginia St West, Charleston, WV 25302 USA	Dai, Z (reprint author), West Virginia Univ, Sch Publ Hlth, One Med Ctr Dr, Morgantown, WV 26506 USA.	zd0001@hsc.wvu.edu; mabate@hsc.wvu.edu; gordon.smith@hsc.wvu.edu; james.c.kraner@wv.gov; allen.r.mock@wv.gov		Smith, Gordon/0000-0002-2911-3071	National Institute of General Medical SciencesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [2U54GM104942-02]; National Institute of Drug AbuseUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [1R21DA040187, 1UG3DA044825]; Centers for Disease Control and PreventionUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49CE002109]	This work was supported in part by the following awards: National Institute of General Medical Sciences (2U54GM104942-02.), National Institute of Drug Abuse (1R21DA040187 and 1UG3DA044825), and Centers for Disease Control and Prevention (R49CE002109). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or the Centers for Disease Control and Prevention.	Alexander Russell T, 2016, Acad Forensic Pathol, V6, P301, DOI 10.23907/2016.031; Amlani A, 2015, HARM REDUCT J, V12, DOI 10.1186/s12954-015-0088-4; Arens AM, 2016, JAMA INTERN MED, V176, P1554, DOI 10.1001/jamainternmed.2016.4306; Armenian P, 2017, ANN EMERG MED, V69, P87, DOI 10.1016/j.annemergmed.2016.06.014; Baldwin N, 2018, DRUG ALCOHOL DEPEN, V185, P322, DOI 10.1016/j.drugalcdep.2017.12.032; CDC, 2016, INFL FENT LAC COUNT; Centers for Disease Control and Prevention (CDC), 2016, STATS STAT W VIRG; Centers for Disease Control and Prevention (CDC), 2018, HLTH AL NETW HAN 004; Compton WM, 2018, ANN INTERN MED, V168, P826, DOI 10.7326/M18-0883; Dasgupta N, 2018, AM J PUBLIC HEALTH, V108, P182, DOI 10.2105/AJPH.2017.304187; Fink DS, 2018, ANN INTERN MED, V168, P783, DOI 10.7326/M17-3074; Fox LM, 2018, ADDICTION, V113, P59, DOI 10.1111/add.13925; Frank RG, 2017, NEW ENGL J MED, V376, P605, DOI 10.1056/NEJMp1615145; Gomes T, 2018, JAMA NETW OPEN, V1, DOI 10.1001/jamanetworkopen.2018.0217; Harruff RC, 2015, ACAD FORENSIC PATHOL, V5, P499, DOI DOI 10.23907/2015.055; Hayashi K, 2018, DRUG ALCOHOL DEPEN, V183, P1, DOI 10.1016/j.drugalcdep.2017.10.020; Hedegaard Holly, 2017, NCHS Data Brief, P1; Hempstead K, 2014, HEALTH ECON, V23, P688, DOI 10.1002/hec.2937; HIBBS J, 1991, JAMA-J AM MED ASSOC, V265, P1011, DOI 10.1001/jama.265.8.1011; Jones CM, 2017, AM J PUBLIC HEALTH, V107, P430, DOI 10.2105/AJPH.2016.303627; Jozaghi E, 2017, CAN J PUBLIC HEALTH, V108, pE457, DOI [10.17269/cjph.108.6480, 10.17269/CJPH.108.6480]; Klebacher R, 2017, PREHOSP EMERG CARE, V21, P682, DOI 10.1080/10903127.2017.1335818; Marinetti LJ, 2014, J ANAL TOXICOL, V38, P592, DOI 10.1093/jat/bku086; Mars Sarah G, 2018, J Psychoactive Drugs, V50, P167, DOI 10.1080/02791072.2017.1394508; Marshall BDL, 2017, INT J DRUG POLICY, V46, P130, DOI 10.1016/j.drugpo.2017.05.029; Nam YH, 2017, AM J MANAG CARE, V23, P297; O'Donnell JK, 2017, MMWR-MORBID MORTAL W, V66, P897, DOI 10.15585/mmwr.mm6634a2; Pergolizzi JV, 2018, POSTGRAD MED, V130, P1, DOI 10.1080/00325481.2018.1407618; Rockett IRH, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0190200; RUBIN R, 2017, JAMA-J AM MED ASSOC, V318, P2174, DOI DOI 10.1001/JAMA.2017.18602; Rudd RA, 2016, MMWR-MORBID MORTAL W, V65, P1445, DOI 10.15585/mmwr.mm655051e1; Samet JH, 2018, JAMA NETW OPEN, V1, DOI 10.1001/jamanetworkopen.2018.0218; Seth P, 2018, AM J PUBLIC HEALTH, V108, P500, DOI 10.2105/AJPH.2017.304265; Slavova S, 2017, INT J DRUG POLICY, V46, P120, DOI 10.1016/j.drugpo.2017.05.051; Suzuki J, 2017, DRUG ALCOHOL DEPEN, V171, P107, DOI 10.1016/j.drugalcdep.2016.11.033; Thomson E, 2017, ADDICTION, V112, P2068, DOI 10.1111/add.13961; Unick GJ, 2017, INT J DRUG POLICY, V46, P112, DOI 10.1016/j.drugpo.2017.06.003; Webster LR, 2017, ANESTH ANALG, V125, P1741, DOI 10.1213/ANE.0000000000002496	38	7	7	2	12	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0376-8716	1879-0046		DRUG ALCOHOL DEPEN	Drug Alcohol Depend.	MAR 1	2019	196						1	8		10.1016/j.drugalcdep.2018.12.004			8	Substance Abuse; Psychiatry	Substance Abuse; Psychiatry	HM5MN	WOS:000459519900001	30658219	Green Accepted			2020-06-30	J	Gisev, N; Pearson, SA; Larance, B; Larney, S; Blanch, B; Degenhardt, L				Gisev, Natasa; Pearson, Sallie-Anne; Larance, Briony; Larney, Sarah; Blanch, Bianca; Degenhardt, Louisa			A population-based study of transdermal fentanyl initiation in Australian clinical practice	EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY			English	Article						(MeSH): Analgesics; Drug utilization; Fentanyl; Opioids; Pain; Pharmacoepidemiology	CHRONIC NONCANCER PAIN; PRESCRIBING OPIOIDS; SAFETY; EXTENT	y PurposeAlthough guidelines caution against initiation of transdermal (TD) fentanyl among those who are opioid naive, there is concern that not all people receive adequate prior opioid exposure. This study examined the percentage of people who are opioid naive at the time of TD fentanyl initiation in Australia; strengths initiated; and characteristics associated with being opioid naive.MethodsThis is a national retrospective cohort study derived from a 10% sample of Pharmaceutical Benefits Scheme concessional beneficiaries initiating TD fentanyl between 29 September 2009-31 December 2013. Individuals were deemed opioid naive if they had no opioid dispensings in the previous 90days. Logistic regression was used to determine characteristics associated with being opioid naive, including socio-demographics, likely comorbidities and previous analgesic use.ResultsA total of 13,166 people initiated TD fentanyl; 60.4% were female and 76.2% were aged 65years. Three in ten (30.4%) were opioid naive and 63.2% initiated the 12mcg/h patch. Those who were opioid naive were more likely to be female (adjusted odds ratio (aOR) 1.35; 95% CI 1.25-1.46), older (aOR 1.85; 95% CI 1.54-2.28 for those 85years) and previously dispensed medicines for dementia (aOR 1.37; 95% CI 1.04-1.80). People previously dispensed medicines for cancer were less likely to be opioid naive (aOR 0.57; 95% CI 0.48-0.67).ConclusionsThree in ten Australians initiating TD fentanyl are opioid naive. Our findings suggest that specific patient sub-populations already at increased risk of opioid-related adverse events are not receiving prior opioid treatment before initiation, highlighting the need for greater adherence to current treatment guidelines.	[Gisev, Natasa; Larance, Briony; Larney, Sarah; Degenhardt, Louisa] UNSW Sydney, Natl Drug & Alcohol Res Ctr, Sydney, NSW 2052, Australia; [Pearson, Sallie-Anne] UNSW Sydney, Ctr Big Data Res Hlth, Sydney, NSW, Australia; [Blanch, Bianca] Centenary Inst, Sydney, NSW, Australia	Gisev, N (reprint author), UNSW Sydney, Natl Drug & Alcohol Res Ctr, Sydney, NSW 2052, Australia.	n.gisev@unsw.edu.au			National Health and Medical Research Council Health (NHMRC) Centre of Research Excellence in Medicines and Ageing (CREMA)National Health and Medical Research Council of Australia [1060407]; NHMRCNational Health and Medical Research Council of Australia [1005668, 1091878, 1041472, 1073858]; Australian GovernmentAustralian Government	This research is supported, in part, by a National Health and Medical Research Council Health (NHMRC) Centre of Research Excellence in Medicines and Ageing (CREMA) (ID: 1060407), and by funding from an NHMRC grant (#1005668). NG, LD and BL are supported by NHMRC Research Fellowships (#1091878, #1041472, #1073858). The National Drug and Alcohol Research Centre at UNSW Australia is supported by funding from the Australian Government under the SubstanceMisuse Prevention and Service Improvements Grant Fund.	Achterberg WP, 2013, CLIN INTERV AGING, V8, P1471, DOI 10.2147/CIA.S36739; [Anonymous], 2018, ETG COMPL AN; Australian Bureau of Statistics, 2007, REM AR CORR 2006; Australian Government Department of Health, 2017, PHARM BEN SCHEM; Blyth FM, 2001, PAIN, V89, P127, DOI 10.1016/S0304-3959(00)00355-9; Bowie Mark W, 2007, Am J Geriatr Pharmacother, V5, P263, DOI 10.1016/j.amjopharm.2007.10.001; Breekveldt-Postma NS, 2005, PHARMACOEPIDEM DR S, V14, P129, DOI 10.1002/pds.1008; Campbell G, 2015, PAIN, V156, P231, DOI 10.1097/01.j.pain.0000460303.63948.8e; Currow DC, 2016, MED J AUSTRALIA, V204, P305, DOI 10.5694/mja16.00066; Degenhardt L, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2014-007030; Department of Health and Ageing, 2013, TRENDS DRIV PHARM BE; Dosa DM, 2009, J PAIN SYMPTOM MANAG, V38, P515, DOI 10.1016/j.jpainsymman.2008.11.008; Dowell D, 2016, MMWR RECOMM REP, V65, P1, DOI 10.15585/mmwr.rr6501e1; Drug Utilisation Sub-Committee, 2014, OP AN OV; Friesen KJ, 2016, CAN MED ASSOC J, V188, P648, DOI 10.1503/cmaj.150961; Gadzhanova S, 2015, MED J AUSTRALIA, V203, DOI 10.5694/mja15.00174; Garbe E, 2012, PHARMACOEPIDEM DR S, V21, P191, DOI 10.1002/pds.2164; Gisev N, 2018, PHARMACOEPIDEM DR S, V27, P550, DOI 10.1002/pds.4329; Gisev N, 2018, RES SOC ADMIN PHARM, V14, P303, DOI 10.1016/j.sapharm.2017.04.002; Gisev N, 2016, BRIT J CLIN PHARMACO, V82, P1123, DOI 10.1111/bcp.13026; Greenall J, 2008, CAN J HOSP PHARM, V61, P57; International Narcotics Control Board, 2015, NARC DRUGS EST WORLD; Karanges EA, 2016, BRIT J CLIN PHARMACO, V82, P255, DOI 10.1111/bcp.12937; Lu CY, 2011, J CLIN EPIDEMIOL, V64, P223, DOI 10.1016/j.jclinepi.2010.02.015; Mellish Leigh, 2015, BMC Res Notes, V8, P634, DOI 10.1186/s13104-015-1616-8; National Opioid Use Guideline Group, 2010, CAN GUID SAF EFF US; NSW Therapeutic Advisory Group Inc, 2016, OP SKIN PATCH AR HIG; Pergolizzi Joseph, 2008, Pain Pract, V8, P287, DOI 10.1111/j.1533-2500.2008.00204.x; Pimentel CB, 2016, J AM GERIATR SOC, V64, P1772, DOI 10.1111/jgs.14306; Pink B, 2008, INFORM PAPER INTRO S; Roxburgh A, 2017, DRUG ALCOHOL DEPEN, V179, P291, DOI 10.1016/j.drugalcdep.2017.07.018; Schug SA, 2017, DRUGS, V77, P747, DOI 10.1007/s40265-017-0727-z; Tournebize J, 2016, PAIN PRACT, V16, P370, DOI 10.1111/papr.12289; US Food & Drug Administration, 2013, INF HEALTHC PROF FEN	34	2	2	1	4	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0031-6970	1432-1041		EUR J CLIN PHARMACOL	Eur. J. Clin. Pharmacol.	MAR	2019	75	3					401	408		10.1007/s00228-018-2588-0			8	Pharmacology & Pharmacy	Pharmacology & Pharmacy	HM0VN	WOS:000459165800013	30392109	Green Accepted			2020-06-30	J	Saiz-Rodriguez, M; Ochoa, D; Herrador, C; Belmonte, LC; Roman, M; Alday, E; Koller, D; Zubiaur, P; Mejia, G; Hernandez-Martinez, M; Abad-Santos, F				Saiz-Rodriguez, Miriam; Ochoa, Dolores; Herrador, Coral; Belmonte, Carmen L.; Roman, Manuel; Alday, Enrique; Koller, Dora; Zubiaur, Pablo; Mejia, Gina; Hernandez-Martinez, Maria; Abad-Santos, Francisco			Polymorphisms associated with fentanyl pharmacokinetics, pharmacodynamics and adverse effects	BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY			English	Article							TRANSDERMAL FENTANYL; OPIOIDS; ALLELE; PHARMACOGENETICS; MORPHINE; CYP3A4; CYP3A4-ASTERISK-20; IDENTIFICATION; LIGANDS; VARIANT	Fentanyl is an agonist of the mu-opioid receptor commonly used in the treatment of moderate-severe pain. In order to study whether pharmacogenetics explains some of the variability in the response to fentanyl, several genes related to fentanyl receptors, transporters and metabolic enzymes have been analysed. Thirty-five healthy volunteers (19 men and 16 women) receiving a single 300 mu g oral dose of fentanyl were genotyped for 9 polymorphisms in cytochrome P450 (CYP) enzymes (CYP3A4 and CYP3A5), ATP-binding cassette subfamily B member 1 (ABCB1), opioid receptor mu 1 (OPRM1), catechol-O-methyltransferase (COMT) and adrenoceptor beta 2 (ADRB2) by real-time PCR. Fentanyl concentrations were measured by ultra-performance liquid chromatography combined with tandem mass spectrometry (UPLC-MS/MS). Fentanyl pharmacokinetics is affected by sex. Carriers of the CYP3A4*22 allele, which is known to reduce the mRNA expression, showed higher area under the concentration-time curve (AUC) and lower clearance (Cl) values. Although this finding might be of importance, its validity needs to be confirmed in other similar settings. Furthermore, carriers of the ABCB1 C1236T T/T genotype presented a lower AUC and higher Cl, as well as lower half-life (T-1/2). As volunteers were blocked with naltrexone, the effect of fentanyl on pharmacodynamics might be biased; however, we could observe that fentanyl had a hypotensive effect. Moreover, ADRB2 C523A A allele carriers showed a tendency towards reducing systolic blood pressure. Likewise, OPRM1 and COMT minor allele variants were risk factors for the development of somnolence. CYP3A5*3, ABCB1 C3435T and ABCB1 G2677T/A were not associated with fentanyl's pharmacokinetics, pharmacodynamics and safety profile.	[Saiz-Rodriguez, Miriam; Ochoa, Dolores; Herrador, Coral; Belmonte, Carmen L.; Roman, Manuel; Koller, Dora; Zubiaur, Pablo; Mejia, Gina; Hernandez-Martinez, Maria; Abad-Santos, Francisco] Univ Autonoma Madrid, Inst Invest Sanitaria La Princesa IP, Hosp Univ La Princess, Clin Pharmacol Dept,Inst Teofilo Hernando, Madrid, Spain; [Ochoa, Dolores; Belmonte, Carmen L.; Roman, Manuel; Mejia, Gina; Abad-Santos, Francisco] UICEC Hosp Univ La Princesa, Spanish Clin Res Network, Plataforma SCReN, Inst Invest Sanitaria La Princesa IP, Madrid, Spain; [Alday, Enrique] Hosp Univ La Princesa, Inst Invest Sanitaria La Princesa IP, Anesthesiol Dept, Madrid, Spain; [Abad-Santos, Francisco] Inst Salud Carlos III, Ctr Invest Biomed Red Enfermedades Hepat & Digest, Madrid, Spain	Abad-Santos, F (reprint author), Hosp Univ la Princesa, Clin Pharmacol Dept, Madrid, Spain.	francisco.abad@salud.madrid.org	Abad-Santos, Francisco/J-7115-2013	Abad-Santos, Francisco/0000-0002-6519-8885; Mejia Abril, Gina Paola/0000-0002-8689-7941; Saiz Rodriguez, Miriam/0000-0002-1660-3135; Koller, Dora/0000-0002-0415-0466; Zubiaur, Pablo/0000-0002-6150-4320			Agencia Espanola de Medicamentos y Productos Sanitarios (AEMPS), LAB INF FENT; Altshuler DM, 2015, NATURE, V526, P68, DOI 10.1038/nature15393; Anderson D, 2011, J MIDWIFERY WOM HEAL, V56, P222, DOI 10.1111/j.1542-2011.2011.00061.x; Apellaniz-Ruiz M, 2015, PHARMACOGENOMICS J, V15, P288, DOI 10.1038/tpj.2014.67; Barratt DT, 2014, PHARMACOGENET GENOM, V24, P185, DOI 10.1097/FPC.0000000000000032; Bazett HC, 1920, HEART-J STUD CIRC, V7, P353; Cargnin S, 2013, J PAIN, V14, P1097, DOI 10.1016/j.jpain.2013.04.006; Chen LK, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000007009; Donner B, 1996, PAIN, V64, P527, DOI 10.1016/0304-3959(95)00180-8; Elens L, 2013, PHARMACOGENOMICS, V14, P47, DOI [10.2217/PGS.12.187, 10.2217/pgs.12.187]; EMA, EMA GUID INV BIOEQ; Faust AC, 2011, CASE REP MED, DOI 10.1155/2011/495938; FDA (Food and Drug Administration), DRAFT GUID FENT CITR; Greenblatt DJ, 2008, J CLIN PHARMACOL, V48, P1350, DOI 10.1177/0091270008323754; Grond S, 2000, CLIN PHARMACOKINET, V38, P59, DOI 10.2165/00003088-200038010-00004; ICH Harmonized Tripartite Guideline E14, 2005, CLIN EV QT QTC INT P; KARCH FE, 1977, CLIN PHARMACOL THER, V21, P247; Koolen SLW, 2017, PHARMACOGENOMICS, V18, P417, DOI 10.2217/pgs-2017-0022; Kuehl P, 2001, NAT GENET, V27, P383, DOI 10.1038/86882; Kuip EJM, 2017, BRIT J CLIN PHARMACO, V83, P294, DOI 10.1111/bcp.13129; Law V, 2014, NUCLEIC ACIDS RES, V42, pD1091, DOI 10.1093/nar/gkt1068; Brambila-Tapia AJL, 2013, REV INVEST CLIN, V65, P445; Lotsch J, 2013, CLIN PHARMACOKINET, V52, P23, DOI 10.1007/s40262-012-0016-7; Madariaga-Mazon A, 2017, DRUG DISCOV TODAY, V22, P1719, DOI 10.1016/j.drudis.2017.07.002; Marazziti D, 2013, CNS SPECTRUMS, V18, P118, DOI 10.1017/S1092852912001010; Matic M, 2017, CLIN CHEM, V63, P1204, DOI 10.1373/clinchem.2016.264986; Matsuoka H, 2012, ONCOL REP, V27, P1393, DOI 10.3892/or.2012.1660; Nielsen M, 2016, ANESTH ANALG, V122, P1385, DOI 10.1213/ANE.0000000000001167; Rabkin SW, 2015, CAN J PSYCHIAT, V60, P206, DOI 10.1177/070674371506000502; Ramos-Matos CF, 2018, FENTANYL; Rauck R, 2017, CURR MED RES OPIN, V33, P1915, DOI 10.1080/03007995.2017.1352496; Sadhasivam S, 2012, PHARMACOGENOMICS, V13, P1719, DOI [10.2217/PGS.12.152, 10.2217/pgs.12.152]; Saiz-Rodriguez M, 2018, BASIC CLIN PHARMACOL, V123, P474, DOI 10.1111/bcpt.13031; Schwartz JB, 2003, CLIN PHARMACOKINET, V42, P107, DOI 10.2165/00003088-200342020-00001; Senagore AJ, 2017, AM J SURG, V213, P467, DOI 10.1016/j.amjsurg.2016.11.008; Siuda ER, 2017, CURR OPIN PHARMACOL, V32, P77, DOI 10.1016/j.coph.2016.11.007; Stanley TH, 2014, J PAIN, V15, P1215, DOI 10.1016/j.jpain.2014.08.010; Takashina Y, 2012, DRUG METAB PHARMACOK, V27, P414, DOI 10.2133/dmpk.DMPK-11-RG-134; Walter C, 2009, PAIN, V146, P270, DOI 10.1016/j.pain.2009.07.013; Wang H, 2009, J INT MED RES, V37, P1158, DOI 10.1177/147323000903700421; Westlind-Johnsson A, 2006, CLIN PHARMACOL THER, V79, P339, DOI 10.1016/j.clpt.2005.11.015; Xiang K, 2014, J INVEST SURG, V27, P214, DOI 10.3109/08941939.2013.879968	42	3	3	0	16	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1742-7835	1742-7843		BASIC CLIN PHARMACOL	Basic Clin. Pharmacol. Toxicol.	MAR	2019	124	3					321	329		10.1111/bcpt.13141			9	Pharmacology & Pharmacy; Toxicology	Pharmacology & Pharmacy; Toxicology	HL1DW	WOS:000458435400012	30281924	Bronze			2020-06-30	J	Iguchi, N; Kosaka, J; Booth, LC; Iguchi, Y; Evans, RG; Bellomo, R; May, CN; Lankadeva, YR				Iguchi, Naoya; Kosaka, Junko; Booth, Lindsea C.; Iguchi, Yoko; Evans, Roger G.; Bellomo, Rinaldo; May, Clive N.; Lankadeva, Yugeesh R.			Renal perfusion, oxygenation, and sympathetic nerve activity during volatile or intravenous general anaesthesia in sheep	BRITISH JOURNAL OF ANAESTHESIA			English	Article						renal blood flow; fentanyl; i.v. anaesthesia; isoflurane; propofol; renal perfusion; renal sympathetic nerve activity; volatile anaesthesia	MEDULLARY TISSUE OXYGENATION; ACUTE KIDNEY INJURY; CARDIOPULMONARY BYPASS; BLOOD-FLOW; ARTERIAL OXYGENATION; URINARY OXYGENATION; ISOFLURANE; PROPOFOL; HEART; METABOLISM	Background: Global and intra-renal perfusion and oxygenation may be affected by the choice of anaesthetic. We compared the effects of isoflurane with those of propofol and fentanyl on renal blood flow (RBF) and intra-renal perfusion and oxygenation, and assessed how these were associated with renal sympathetic nerve activity (RSNA). Methods: A renal artery flow probe and laser Doppler and oxygen-sensing probes were surgically implanted in the renal medulla and cortex in 20 Merino ewes. RSNA was measured in 12 additional ewes. We compared the effects of volatile or i.v. anaesthesia on global RBF, renal oxygen delivery (RDO2), intra-renal perfusion, and RSNA with the non-anaesthetised state on postoperative day 3 as control reference. Results: Compared with a non-anaesthetised state, volatile an aesthesia reduced global RBF[-76 (82-68)%], RDO2 [-76(83-71)%], and cortical [-68 (74-54)%] and medullary [-76 (84-72)%] perfusion. I.V. anaesthesia reduced RBF [-55 (67-38)%], RDO2 [-55 (65-44)%], and cortical [-27 (45-6)%] andmedullary [-35 (48-30)%] perfusion, but to a lesser extent than volatile anaesthesia. Renal PO2 was not influenced by anaesthesia, whilst RSNA was elevated during volatile, but not during i.v. anaesthesia. Conclusions: Volatile and i.v. general anaesthesia markedly reduced global RBF, RDO2, and regional kidney perfusion. These effects were greater with volatile anaesthesia, and were paralleled by an increase in RSNA. Our findings suggest a neurogenic modulatory effect of anaesthetics on renal perfusion and oxygenation.	[Iguchi, Naoya; Kosaka, Junko; Booth, Lindsea C.; Iguchi, Yoko; May, Clive N.; Lankadeva, Yugeesh R.] Florey Inst Neurosci & Mental Hlth, Preclin Crit Care Unit, Melbourne, Vic, Australia; [Iguchi, Naoya; Iguchi, Yoko] Austin Hosp, Dept Intens Care, Melbourne, Vic, Australia; [Iguchi, Naoya] Osaka Univ, Grad Sch Med, Dept Anaesthesiol & Intens Care Med, Osaka, Japan; [Iguchi, Yoko] Saiseikai Senri Hosp, Dept Anaesthesiol, Osaka, Japan; [Evans, Roger G.] Monash Univ, Biomed Discovery Inst, Cardiovasc Dis Program, Melbourne, Vic, Australia; [Evans, Roger G.] Monash Univ, Dept Physiol, Melbourne, Vic, Australia; [Bellomo, Rinaldo] Univ Melbourne, Sch Med, Melbourne, Vic, Australia	Lankadeva, YR (reprint author), Florey Inst Neurosci & Mental Hlth, Preclin Crit Care Unit, Melbourne, Vic, Australia.	yugeesh.lankadeva@florey.edu.au	Evans, Roger/N-8580-2019; Lankadeva, Yugeesh/R-9253-2019	Evans, Roger/0000-0002-9241-0757; 	National Health and Medical Research Council of AustraliaNational Health and Medical Research Council of Australia [1050672]; Victorian Government Operational Infrastructure Support Grant; National Heart Foundation of Australia Future Leader FellowshipNational Heart Foundation of Australia [101853]; Jack Brockhoff Foundation [4178]	National Health and Medical Research Council of Australia (1050672 to CNM and RGE); Victorian Government Operational Infrastructure Support Grant; National Heart Foundation of Australia Future Leader Fellowship (101853 to YRL); Early Career Medical Research Grant from the Jack Brockhoff Foundation (4178 to YRL).	ANDERSSON LG, 1994, EUR J CARDIO-THORAC, V8, P597, DOI 10.1016/1010-7940(94)90043-4; APERIA AC, 1969, ACTA PHYSIOL SCAND, V75, P353, DOI 10.1111/j.1748-1716.1969.tb04388.x; BEDNARIK JA, 1995, J APPL PHYSIOL, V78, P524; Booke M, 1996, ANESTH ANALG, V82, P738, DOI 10.1097/00000539-199604000-00011; Calzavacca P, 2015, AM J PHYSIOL-REG I, V308, pR832, DOI 10.1152/ajpregu.00515.2014; Darby PJ, 2013, PERFUSION-UK, V28, P504, DOI 10.1177/0267659113490219; Ebert TJ, 2005, ANESTHESIOLOGY, V103, P20, DOI 10.1097/00000542-200507000-00007; Evans RG, 2018, ACTA PHYSIOL, V222, DOI 10.1111/apha.12995; Evans RG, 2013, CLIN EXP PHARMACOL P, V40, P106, DOI 10.1111/1440-1681.12031; Hu JC, 2016, J CARDIOTHOR VASC AN, V30, P82, DOI 10.1053/j.jvca.2015.06.017; Jung SM, 2015, KOREAN J ANESTHESIOL, V68, P224, DOI 10.4097/kjae.2015.68.3.224; Kingery WS, 2002, ANESTHESIOLOGY, V96, P367, DOI 10.1097/00000542-200202000-00023; Lankadeva YR, 2018, CRIT CARE MED, V46, pE41, DOI 10.1097/CCM.0000000000002797; Lankadeva YR, 2016, KIDNEY INT, V90, P100, DOI 10.1016/j.kint.2016.02.017; Lankadeva YR, 2015, CRIT CARE MED, V43, pE221, DOI 10.1097/CCM.0000000000000963; Lannemyr L, 2017, ANESTHESIOLOGY, V126, P205, DOI 10.1097/ALN.0000000000001461; Leong CL, 2007, AM J PHYSIOL-RENAL, V292, pF1726, DOI 10.1152/ajprenal.00436.2006; May CN, 2010, EXP PHYSIOL, V95, P34, DOI 10.1113/expphysiol.2008.046342; MAZZE RI, 1974, ANESTHESIOLOGY, V40, P536, DOI 10.1097/00000542-197406000-00006; MUZI M, 1995, ANESTHESIOLOGY, V82, P919, DOI 10.1097/00000542-199504000-00015; Myles PS, 2018, NEW ENGL J MED, V378, P2263, DOI 10.1056/NEJMoa1801601; Neumann J, 2004, KIDNEY INT, V65, P1568, DOI 10.1111/j.1523-1755.2004.00552.x; O'Connor PM, 2006, AM J PHYSIOL-RENAL, V290, pF688, DOI 10.1152/ajprenal.00275.2005; Okamoto H, 1996, ANESTHESIOLOGY, V84, P1196, DOI 10.1097/00000542-199605000-00022; Rafiq K, 2012, CIRCULATION, V125, P1402, DOI 10.1161/CIRCULATIONAHA.111.064097; Ricksten SE, 2013, CRIT CARE, V17, DOI 10.1186/cc12530; Sanders RD, 2005, BRIT J ANAESTH, V95, P393, DOI 10.1093/bja/aei182; SEAGARD JL, 1984, ANESTHESIOLOGY, V61, P266, DOI 10.1097/00000542-198409000-00006; Segawa H, 1998, ANESTHESIOLOGY, V89, P1407, DOI 10.1097/00000542-199812000-00018; SELLGREN J, 1992, ACTA ANAESTH SCAND, V36, P336, DOI 10.1111/j.1399-6576.1992.tb03478.x; Shiga Y, 2003, PHARMACOLOGY, V68, P17, DOI 10.1159/000068728; SIMONS PJ, 1991, XENOBIOTICA, V21, P1243, DOI 10.3109/00498259109043199; Stafford-Smith M, 2005, PERFUSION-UK, V20, P53, DOI 10.1191/0267659105pf780oa; Upton RN, 2001, ANAESTH INTENS CARE, V29, P117, DOI 10.1177/0310057X0102900205; Wang JYY, 1998, BRIT J ANAESTH, V81, P850; Wang JYY, 2000, ANAESTHESIA, V55, P167, DOI 10.1046/j.1365-2044.2000.055002167.x; Weiser TG, 2008, LANCET, V372, P139, DOI 10.1016/S0140-6736(08)60878-8; Xu H, 2000, EUR J PHARMACOL, V387, P79, DOI 10.1016/S0014-2999(99)00767-0; Yoo YC, 2014, KIDNEY INT, V86, P414, DOI 10.1038/ki.2013.532; Zhu MZL, 2018, NEPHROL DIAL TRANSPL, V33, P2191, DOI 10.1093/ndt/gfy047	40	7	7	0	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0007-0912	1471-6771		BRIT J ANAESTH	Br. J. Anaesth.	MAR	2019	122	3					342	349		10.1016/j.bja.2018.11.018			8	Anesthesiology	Anesthesiology	HL2DN	WOS:000458513600017	30770052	Bronze			2020-06-30	J	Allen, ST; O'Rourke, A; White, RH; Schneider, KE; Kilkenny, M; Sherman, SG				Allen, Sean T.; O'Rourke, Allison; White, Rebecca Hamilton; Schneider, Kristin E.; Kilkenny, Michael; Sherman, Susan G.			Estimating the Number of People Who Inject Drugs in A Rural County in Appalachia	AMERICAN JOURNAL OF PUBLIC HEALTH			English	Article							CAPTURE-RECAPTURE METHODS; SEX WORKER POPULATION; HIV; PREVALENCE; SIZE; SELF; OXYMORPHONE; SETTINGS; INDIANA; CITIES	Objectives. To demonstrate how we applied the capture-recapture method for population estimation directly in a rural Appalachian county (Cabell County, WV) to estimate the number of people who inject drugs (PWID). Methods. We conducted 2 separate 2-week periods of data collection in June ("capture") and July ("recapture") 2018. We recruited PWID from a syringe services program and in community locations where PWID were known to congregate. Participants completed a survey that included measures related to sociodemographics, substance use, and HIV and hepatitis C virus prevention. Results. In total, 797 surveys were completed; of these surveys, 49.6% (n = 395) reflected PWID who reported injection drug use in the past 6 months and Cabell County residence. We estimated that there were 1857 (95% confidence interval = 1147, 2567) PWID in Cabell County. Among these individuals, most reported being White (83.4%), younger than 40 years (70.9%), and male (59.5%). The majority reported injecting heroin (82.0%), methamphetamine (71.0%), and fentanyl (56.3%) in the past 6 months. Conclusions. Capture-recapture methods can be applied in rural settings to estimate the size of PWID populations.	[Allen, Sean T.; White, Rebecca Hamilton; Sherman, Susan G.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Hlth Behav & Soc, 624 N Broadway, Baltimore, MD 21205 USA; [O'Rourke, Allison] George Washington Univ, DC Ctr AIDS Res, Washington, DC USA; [Schneider, Kristin E.] Johns Hopkins Univ, Dept Mental Hlth, Bloomberg Sch Publ Hlth, Baltimore, MD USA; [Kilkenny, Michael] Cabell Huntington Hlth Dept, Huntington, WV USA	Allen, ST (reprint author), Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Hlth Behav & Soc, 624 N Broadway, Baltimore, MD 21205 USA.	Sallen63@jhu.edu		O'Rourke, Allison/0000-0002-0735-9679	Bloomberg American Health Initiative at the Johns Hopkins Bloomberg School of Public Health; National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P30AI094189]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [K01DA046234]; National Institute on Drug AbuseUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [5T32DA007292-25]	This research was supported by the Bloomberg American Health Initiative at the Johns Hopkins Bloomberg School of Public Health. This research has been facilitated by the infrastructure and resources provided by the Johns Hopkins University Center for AIDS Research, a National Institutes of Health (NIH)-funded program (grant P30AI094189). S. T. Allen is also supported by the NIH (grant K01DA046234). K. E. Schneider is supported by the National Institute on Drug Abuse (grant 5T32DA007292-25).	Al-Tayyib A, 2017, SUBST USE MISUSE, V52, P1051, DOI 10.1080/10826084.2016.1271432; Barocas JA, 2018, AM J PUBLIC HEALTH, V108, P1675, DOI 10.2105/AJPH.2018.304673; Conrad C, 2015, MMWR-MORBID MORTAL W, V64, P443; Hay G, 2000, ADDICTION, V95, P1795, DOI 10.1046/j.1360-0443.2000.951217959.x; Hickman M, 1999, ADDICTION, V94, P1653, DOI 10.1046/j.1360-0443.1999.941116534.x; Hickman M, 2006, DRUG ALCOHOL REV, V25, P131, DOI 10.1080/09595230500537274; Holland CE, 2016, PUBLIC HEALTH REP, V131, P773, DOI 10.1177/0033354916677237; Macalino GE, 2002, AIDS EDUC PREV, V14, P367, DOI 10.1521/aeap.14.6.367.24075; Mack Karin A, 2017, MMWR Surveill Summ, V66, P1, DOI 10.15585/mmwr.ss6619a1; Mutagoma M, 2015, INT J STD AIDS, V26, P810, DOI 10.1177/0956462414555931; National Institute on Drug Abuse, 2018, OV DEATH RAT; Perlis TE, 2004, ADDICTION, V99, P885, DOI 10.1111/j.1360-0443.2004.00740.x; Peters PJ, 2016, NEW ENGL J MED, V375, P229, DOI 10.1056/NEJMoa1515195; Roberts B, 2010, INT J EPIDEMIOL, V39, P1584, DOI 10.1093/ije/dyq188; Ruiz MS, 2016, AIDS BEHAV, V20, P363, DOI 10.1007/s10461-015-1085-z; UNAIDS, 2010, GLOB REP UNAIDS REP, P1; United States Census Bureau, 2012, 2010 CENS URB RUR CL; US Census Bureau, 2017, QUICKF CAB COUNT W V; Vaissade L, 2009, EUR J PUBLIC HEALTH, V19, P32, DOI 10.1093/eurpub/ckn126; Van Handel MM, 2016, JAIDS-J ACQ IMM DEF, V73, P323, DOI 10.1097/QAI.0000000000001098; VanDerNagel JEL, 2014, RES DEV DISABIL, V35, P808, DOI 10.1016/j.ridd.2014.01.018; Vuylsteke B, 2010, TROP MED INT HEALTH, V15, P1537, DOI 10.1111/j.1365-3156.2010.02654.x; West Virginia Department of Health & Human Resources, 2017, W VIRG DRUG OV DEATH; White B, 2007, AIDS CARE, V19, P441, DOI 10.1080/09540120701192837	24	11	11	1	4	AMER PUBLIC HEALTH ASSOC INC	WASHINGTON	800 I STREET, NW, WASHINGTON, DC 20001-3710 USA	0090-0036	1541-0048		AM J PUBLIC HEALTH	Am. J. Public Health	MAR	2019	109	3					445	450		10.2105/AJPH.2018.304873			6	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	HK4BH	WOS:000457864000043	30676803	Green Published			2020-06-30	J	Duffy, J; Urbas, A; Niemitz, M; Lippa, K; Marginean, I				Duffy, Jonathan; Urbas, Aaron; Niemitz, Matthias; Lippa, Katrice; Marginean, Ioan			Differentiation of fentanyl analogues by low-field NMR spectroscopy	ANALYTICA CHIMICA ACTA			English	Article						Forensic chemistry; Drug analysis; Fentanyl analogues; NMR; Low-field NMR; Spin system modeling	TANDEM MASS-SPECTROMETRY; QUALITY-CONTROL; SPECTRAL-ANALYSIS; H-1-NMR; IDENTIFICATION; 3-METHYLFENTANYL; CARFENTANIL; ISOMERS; QHNMR; HIFSA	Forensic laboratories commonly receive new psychoactive substances such as fentanyl analogues and other synthetic opioids that are difficult to identify. Slight changes to chemical structures, e.g. shifting the position of functional groups such as methyl groups or halogens on the aromatic ring, may not be distinguished using traditional methods. NMR is a powerful tool used to elucidate distinctive structural information needed to differentiate regioisomers. However, the cost, size, and cryogen maintenance of superconducting NMR spectrometers can be impractical for some forensic laboratories. Recent studies have shown potential applications of low-field NMR as an alternative in forensic drug analysis. These benchtop, semi-portable instruments are less costly, have a smaller footprint, do not use cryogens, and require little maintenance. In this study, we show that 65 fentanyl and related substances, including various types of positional isomers, were readily differentiated using low-field (62 MHz) H-1 NMR spectroscopy. In addition, the use of quantum mechanical spin system analysis was investigated for the purposes of translating experimentally observed high-field 1H spectra to lower field strengths. Spin system analysis of 600 MHz NMR spectra was conducted on a subset (15) of the reference materials analyzed. The results were used to calculate 62 MHz spectra for comparison purposes with the experimental spectra. This was successfully demonstrated, showing that field-strength independent 1H NMR spectral libraries are feasible and can facilitate reference material data dissemination across forensic drug laboratories. (C) 2018 Elsevier B.V. All rights reserved.	[Duffy, Jonathan; Marginean, Ioan] George Washington Univ, Dept Forens Sci, Washington, DC 20052 USA; [Urbas, Aaron; Lippa, Katrice] NIST, Gaithersburg, MD 20899 USA; [Niemitz, Matthias] NMR Solut Oy, Kuopio, Finland	Marginean, I (reprint author), George Washington Univ, Dept Forens Sci, Washington, DC 20052 USA.; Urbas, A (reprint author), NIST, Gaithersburg, MD 20899 USA.	aurbas@nist.gov; mnelu@gwu.edu	Marginean, Ioan/A-4183-2008	Marginean, Ioan/0000-0002-6693-0361; Niemitz, Matthias/0000-0002-5452-5203	National Institute of Standards and Technology Special Programs Office Award [60NANB16D233]	Funding from National Institute of Standards and Technology Special Programs Office Award #60NANB16D233 is greatly appreciated. We would also like to thank Cayman Chemical for supplying the extensive collection of fentanyl-related compounds used in this work.	Assemat G, 2017, FORENSIC SCI INT, V279, P88, DOI 10.1016/j.forsciint.2017.08.006; Bae M, 2017, MAR DRUGS, V15, DOI 10.3390/md15020038; Bogun B, 2017, FORENSIC SCI INT, V278, P68, DOI 10.1016/j.forsciint.2017.06.026; Casale JF, 2017, FORENSIC CHEM, V3, P74, DOI 10.1016/j.forc.2017.02.003; CHENG MT, 1982, ANAL CHEM, V54, P2204, DOI 10.1021/ac00250a016; COOPER D, 1986, J FORENSIC SCI, V31, P511; Coopman V., 2006, LC MS MS ANAL FENTAN, DOI [10.1016/j.forsciint.2006.03.018, DOI 10.1016/J.FORSCIINT.2006.03.018]; Da M, 2013, PLANTA MED, V79, P882; Dashti H, 2017, ANAL CHEM, V89, P12201, DOI 10.1021/acs.analchem.7b02884; Drug Enforcement Administration, 2018, NFLIS BRIEF FENT 201; Drug Enforcement Administration Diversion Control Division, 2017, NFLIS BRIEF FENT 200; Drug Enforecement Administration Department of Justice, 2018, Fed Regist, V83, P5188; ESPOSITO FM, 1991, J FORENSIC SCI, V36, P86; Findeisen M, 2007, MAGN RESON CHEM, V45, P175, DOI 10.1002/mrc.1941; Gao W, 2017, MAGN RESON CHEM, V55, P239, DOI 10.1002/mrc.4425; Henderson G. L., 1988, DESIGNER DRUGS HIST, V33; Isaac-Lam MF, 2016, INT J SPECTROSC, DOI 10.1155/2016/2526946; Jakes W, 2015, FOOD CHEM, V175, P1, DOI 10.1016/j.foodchem.2014.11.110; JANSSEN PAJ, 1982, ACTA ANAESTH SCAND, V26, P262, DOI 10.1111/j.1399-6576.1982.tb01765.x; Kanamori T, 2017, J FORENSIC SCI, V62, P1472, DOI 10.1111/1556-4029.13395; Laatikainen R, 1996, J MAGN RESON SER A, V120, P1, DOI 10.1006/jmra.1996.0094; Leonard J, 2017, J RAMAN SPECTROSC, V48, P1323, DOI 10.1002/jrs.5220; Lurie IS, 2012, FORENSIC SCI INT, V220, P191, DOI 10.1016/j.forsciint.2012.02.024; Mallette JR, 2018, FORENSIC CHEM, V8, P64, DOI 10.1016/j.forc.2018.02.001; Mohr ALA, 2016, J ANAL TOXICOL, V40, P709, DOI 10.1093/jat/bkw086; Napolitano JG, 2015, J NAT PROD, V78, P658, DOI 10.1021/np5008203; Napolitano JG, 2014, J PHARMACEUT BIOMED, V93, P59, DOI 10.1016/j.jpba.2013.06.017; Napolitano JG, 2013, J ORG CHEM, V78, P2827, DOI 10.1021/jo302720h; Napolitano JG, 2012, MAGN RESON CHEM, V50, P569, DOI 10.1002/mrc.3829; Napolitano JG, 2012, J NAT PROD, V75, P238, DOI 10.1021/np200949v; Noble C, 2018, DRUG TEST ANAL, V10, P651, DOI 10.1002/dta.2263; Pages G, 2014, ANAL CHEM, V86, P11897, DOI 10.1021/ac503699u; Parker T, 2014, TRAC-TREND ANAL CHEM, V57, P147, DOI 10.1016/j.trac.2014.02.006; Phansalkar RS, 2017, J NAT PROD, V80, P634, DOI 10.1021/acs.jnatprod.6b00923; Preto MSM, 2013, FOOD CHEM, V136, P1272, DOI 10.1016/j.foodchem.2012.09.045; Riihinen KR, 2013, PHYTOCHEM ANALYSIS, V24, P476, DOI 10.1002/pca.2444; Rittgen J, 2012, ELECTROPHORESIS, V33, P1595, DOI 10.1002/elps.201100655; Shoff EN, 2017, J ANAL TOXICOL, V41, P484, DOI 10.1093/jat/bkx041; Simmler C, 2014, CURR OPIN BIOTECH, V25, P51, DOI 10.1016/j.copbio.2013.08.004; Singh K, 2016, MACROMOL SYMP, V365, P191, DOI 10.1002/masy.201650001; Strano Rossi S., 2014, MASS SPECTROM, V28, P1904, DOI 10.1002/rcm.6969; Suzuki J, 2017, DRUG ALCOHOL DEPEN, V171, P107, DOI 10.1016/j.drugalcdep.2016.11.033; United Nations Office on Drugs and Crime (UNODC), 2017, GLOBAL SMART UPDATE, V17, P1; Vicente JL, 2016, FORENSIC SCI INT, V265, P107, DOI 10.1016/j.forsciint.2016.01.024; Volpe DA, 2011, REGUL TOXICOL PHARM, V59, P385, DOI 10.1016/j.yrtph.2010.12.007	45	6	6	3	35	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0003-2670	1873-4324		ANAL CHIM ACTA	Anal. Chim. Acta	FEB 21	2019	1049						161	169		10.1016/j.aca.2018.12.014			9	Chemistry, Analytical	Chemistry	HG2JK	WOS:000454789100018	30612647				2020-06-30	J	Sarpatwari, A; Curfman, G				Sarpatwari, Ameet; Curfman, Gregory			Mitigating Health Risks of Prescription Drugs Lessons From FDA Oversight of Opioid Products	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							STRATEGIES		[Sarpatwari, Ameet] Harvard Med Sch, Brigham & Womens Hosp, Program Regulat Therapeut & Law, Div Pharmacoepidemiol & Pharmacoecon,Dept Med, Boston, MA 02115 USA	Sarpatwari, A (reprint author), 1620 Tremont St,Ste 3030, Boston, MA 02120 USA.	asarpatwari@bwh.harvard.edu					Blanchette Christopher M, 2015, Drugs Context, V4, DOI 10.7573/dic.212272; Brooks M., MEDSCAPE; Centers for Disease Control and Prevention, DRUG OVERDOSE DEATHS; Hughes E., 2018, NY TIMES; Raymond Nate, 2019, REUTERS; Rollman JE, 2019, JAMA-J AM MED ASSOC, V321, P676, DOI 10.1001/jama.2019.0235; Sarpatwari A, 2015, CLIN PHARMACOL THER, V97, P186, DOI 10.1002/cpt.17; Sarpatwari A, 2017, HARV LAW POLICY REV, V11, P463; Substance Abuse and Mental Health Services Administration, 2018, KEY SUBST US MENT HL; TIRF REMS Access, 2018, TRANSM IMM REL FENT; US Food and Drug Administration, BACKGR MAT REMS STAN; US Food and Drug Administration, 2018, REMS ENWS ED M IMPR; Vokinger KN, 2017, JAMA INTERN MED, V177, P1665, DOI 10.1001/jamainternmed.2017.4650	13	2	2	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 19	2019	321	7					651	653		10.1001/jama.2019.0236			3	Medicine, General & Internal	General & Internal Medicine	HL9MZ	WOS:000459068300013	30778584				2020-06-30	J	Rollman, JE; Heyward, J; Olson, L; Lurie, P; Sharfstein, J; Alexander, GC				Rollman, Jeffrey Eric; Heyward, James; Olson, Lily; Lurie, Peter; Sharfstein, Joshua; Alexander, G. Caleb			Assessment of the FDA Risk Evaluation and Mitigation Strategy for Transmucosal Immediate-Release Fentanyl Products	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								IMPORTANCE Transmucosal immediate-release fentanyls (TIRFs), indicated solely for breakthrough cancer pain in opioid-tolerant patients, are subject to a US Food and Drug Administration (FDA) Risk Evaluation and Mitigation Strategy (REMS) to prevent them from being prescribed inappropriately. OBJECTIVES To evaluate knowledge assessments of pharmacists, prescribers, and patients regarding appropriate TIRF use; to describe sponsor assessments, based on claims data, of whether the REMS program was meeting its goals; and to characterize how the FDA responded to REMS assessments. DESIGN, SETTING, AND PARTICIPANTS Qualitative analysis of 4877 pages of FDA documents obtained through a Freedom of Information Act request, including 6 annual REMS assessment reports (2012-2017), FDA evaluations of these reports, and FDA-sponsor correspondence about safety issues. EXPOSURE A REMS program to reduce the risk of adverse outcomes, including misuse, abuse, addiction, and overdose, arising from use of TIRFs. MAIN OUTCOMES AND MEASURES (1) Knowledge assessments of pharmacists, prescribers, and patients; (2) survey and claims-based prescribing assessments; (3) FDA and TIRF sponsor communications; (4) modifications to the REMS program; and (5) disenrollment of noncompliant prescribers. RESULTS Twelve months after initiation of the program, 24 of 302 pharmacists (7.9%), 35 of 302 prescribers (11.6%), and 5 of 192 patients (2.6%) incorrectly reported that TIRFs can be prescribed to opioid-nontolerant patients, with similar levels of misunderstanding maintained in the subsequent reports. At 60 months, product-specific analyses of claims data indicated that between 34.6% and 55.4% of patients prescribed TIRFs were opioid-nontolerant. In the 48-month survey, 106 of 310 prescribers (34.2%) reported prescribing TIRFs for opioid-tolerant patients with chronic, noncancer pain; at 60 months, 54 of 302 prescribers (18.4%) and 148 of 310 patients (47.7%) erroneously reported that TIRFs were FDA-approved for such use. Over the 60-month period examined, there were few substantive changes made to the REMS to address evidence of high rates of off-label TIRF use, and, although the REMS program had a noncompliance plan, there was no report of prescribers being disenrolled for inappropriate prescribing. CONCLUSIONS AND RELEVANCE In this review of FDA documents pertaining to the TIRF REMS, surveys of pharmacists, prescribers, and patients reflected generally high levels of knowledge regarding proper TIRF prescribing, yet some survey items as well as claims-based analyses indicated substantial rates of inappropriate TIRF use. Despite these findings, the FDA did not require substantive changes to the program. (c) 2019 American Medical Association. All rights reserved.	[Rollman, Jeffrey Eric; Heyward, James; Olson, Lily; Sharfstein, Joshua; Alexander, G. Caleb] Johns Hopkins Bloomberg Sch Publ Hlth, Ctr Drug Safety & Effectiveness, Baltimore, MD 21205 USA; [Lurie, Peter] Ctr Sci Publ Interest, Washington, DC USA; [Sharfstein, Joshua] Johns Hopkins Bloomberg Sch Publ Hlth, Off Publ Hlth Practice & Training, Baltimore, MD 21205 USA; [Alexander, G. Caleb] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, 615 N Wolfe St W6035, Baltimore, MD 21205 USA; [Alexander, G. Caleb] Johns Hopkins Med, Div Gen Internal Med, Baltimore, MD USA	Alexander, GC (reprint author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, 615 N Wolfe St W6035, Baltimore, MD 21205 USA.	galexan9@jhmi.edu					Ahmad F, 2018, PROVISIONAL DRUG OVE; [Anonymous], OV DEATH RAT; [Anonymous], 2015, NON TRADITIONAL REF; Baumgaertner E., 2018, NY TIMES; Office of Inspector General, 2013, FDA LACKS COMPR DAT; Substance Abuse and Mental Health Services Administration, 2017, KEY SUBST US MENT HL; Transmucosal Immediate Release Fentanyl Risk Evaluation and Mitigation Strategy, 2012, TRANSM IMM REL UNPUB; Transmucosal Immediate Release Fentanyl Risk Evaluation and Mitigation Strategy, 2012, TRANSM IMM REL UNPUB; Transmucosal Immediate Release Fentanyl Risk Evaluation and Mitigation Strategy, 2012, TRANSM IMM REL UNPUB, P64; Transmucosal Immediate Release Fentanyl Risk Evaluation and Mitigation Strategy Industry Group, 2013, TRANSM IMM REL UNPUB; US Food and Drug Administration, 2017, NON TRADITIONAL REF, P101; US Food and Drug Administration, 2018, QUEST ANSW MIT STRAT; US Food and Drug Administration, 2017, NON TRADITIONAL REF, P8; US Food and Drug Administration, 2015, NON TRADITIONAL REF, P3; US Food and Drug Administration, 2013, NON TRADITIONAL REF; US Food and Drug Administration, 2016, NON TRADITIONAL REF, P1; US Food and Drug Administration, 2017, NON TRADITIONAL REF, P6; US Food and Drug Administration, 2017, NON TRADITIONAL REF, P7; US Food and Drug Administration Center for Drug Evaluation and Research, 2018, JOINT M DRUG SAF RIS	19	9	9	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 19	2019	321	7					676	685		10.1001/jama.2019.0235			10	Medicine, General & Internal	General & Internal Medicine	HL9MZ	WOS:000459068300016	30778596	Green Published, Bronze			2020-06-30	J	Moss, RB; Carlo, DJ				Moss, Ronald B.; Carlo, Dennis J.			Higher doses of naloxone are needed in the synthetic opiod era	SUBSTANCE ABUSE TREATMENT PREVENTION AND POLICY			English	Article						Naloxone; Fentanyl; High dose; Overdose; Opioids	RESPIRATORY DEPRESSION; FENTANYL; REVERSAL; PHARMACOKINETICS; ANTAGONISM; OVERDOSE	There has been a dramatic increase of deaths due to illicit fentanyl. We examined the pharmacology of fentanyl and reviewed data on the number of repeat doses of naloxone used to treat fentanyl overdoses. Multiple sequential doses of naloxone have been required in a certain percentage of opioid overdoses due to fentanyl. In addition, fentanyl appears to differ from other opioids as having a very rapid onset with high systemic levels found in overdose victims. A rapid competition is required by naloxone to out-compete large numbers of opioid receptors occupied by fentanyl in the CNS. Taken together, we propose that higher doses of naloxone are needed to combat the new era of overdoses due to the more potent synthetic opioids such as fentanyl.	[Moss, Ronald B.; Carlo, Dennis J.] Adamis Pharmaceut, San Diego, CA 92130 USA	Moss, RB (reprint author), Adamis Pharmaceut, San Diego, CA 92130 USA.	rmoss@adamispharma.com			Adamis Pharmaceuticals	This manuscript is supported by funding from Adamis Pharmaceuticals.	Bell A, 2019, SUBST ABUS, V40, P52, DOI 10.1080/08897077.2018.1449053; BROWN JH, 1981, BRIT J ANAESTH, V53, P1033, DOI 10.1093/bja/53.10.1033; Burns SM, 2018, ACS CHEM NEUROSCI, V9, P2428, DOI 10.1021/acschemneuro.8b00174; Dahan A, 2010, ANESTHESIOLOGY, V112, P226, DOI 10.1097/ALN.0b013e3181c38c25; DRUMMOND GB, 1977, BRIT J ANAESTH, V49, P151, DOI 10.1093/bja/49.2.151; Fairbairn N, 2017, INT J DRUG POLICY, V46, P172, DOI 10.1016/j.drugpo.2017.06.005; Faul M, PREHOSPITAL EMERGENC, V21, P411; Fogarty MF, 2018, J ANAL TOXICOL, P1; Freise KJ, 2012, J VET PHARMACOL THER, V35, P45, DOI 10.1111/j.1365-2885.2012.01409.x; GAL TJ, 1989, CLIN PHARMACOL THER, V45, P66, DOI 10.1038/clpt.1989.10; HANDAL KA, 1983, ANN EMERG MED, V12, P438, DOI 10.1016/S0196-0644(83)80343-6; HEISHMAN SJ, 1989, J PHARMACOL EXP THER, V248, P127; Kim HK, 2015, EXPERT OPIN DRUG SAF, V14, P1137, DOI 10.1517/14740338.2015.1037274; Klebacher R, 2017, PREHOSP EMERG CARE, V21, P682, DOI 10.1080/10903127.2017.1335818; Kuczynska K, 2018, FORENSIC SCI INT, V289, P207, DOI 10.1016/j.forsciint.2018.05.042; Lotsch J, 2013, CLIN PHARMACOKINET, V52, P23, DOI 10.1007/s40262-012-0016-7; Lynn RR, 2018, THER ADV DRUG SAF, V9, P63, DOI 10.1177/2042098617744161; MacKenzie M, 2016, ANN PHARMACOTHER, V50, P209, DOI 10.1177/1060028015625659; Marco CA, 2018, J EMERG MED, V55, P64, DOI 10.1016/j.jemermed.2018.04.022; Sarton E, 2008, ADV EXP MED BIOL, V605, P486; Schumann H, 2008, CLIN TOXICOL, V46, P501, DOI 10.1080/15563650701877374; Seth P, 2018, AJPH, V108; Somerville NJ, 2017, MMWR, V66; Stanley TH, 2014, J PAIN, V15, P1215, DOI 10.1016/j.jpain.2014.08.010; Sutter ME, 2017, ACAD EMERG MED, V24, P106, DOI 10.1111/acem.13034; Taylor DR., 2005, MEDSCAPE NEUROLOGY, V7; Tomassoni Anthony J, 2017, MMWR Morb Mortal Wkly Rep, V66, P107, DOI 10.15585/mm6604a4; Tyndale RF, 2018, CLIN PHARMACOL THER, V103, P924, DOI 10.1002/cpt.1074; WAY EL, 1976, ANN NY ACAD SCI, V281, P252, DOI 10.1111/j.1749-6632.1976.tb27936.x; Wong B, 2017, INHAL TOXICOL, V29, P65, DOI 10.1080/08958378.2017.1282065	30	7	7	0	5	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1747-597X			SUBST ABUSE TREAT PR	Subst/ Abus. Treatment Prev. Pol.	FEB 18	2019	14								6	10.1186/s13011-019-0195-4			6	Substance Abuse	Substance Abuse	HM1PR	WOS:000459225000001	30777088	DOAJ Gold, Green Published			2020-06-30	J	Huang, Q; Lin, LY; Lin, XZ				Huang, Qing; Lin, Lan-Ying; Lin, Xian-Zhong			Comparison of Remifentanil-Based Fast-Track and Fentanyl-Based Routine Cardiac Anesthesia for intraoperative Device Closure of Atrial Septal Defect (ASD) in Pediatric Patients	MEDICAL SCIENCE MONITOR			English	Article						Anesthesia; Heart Defects, Congenital; Septal Occluder Device	EARLY-EXTUBATION; SURGICAL-TREATMENT; SURGERY; MANAGEMENT; ANALGESIA; CHILDREN; COHORT	Background: The aim of this study was to evaluate the effectiveness and safety of remifentanil-based fast-track anesthesia for intraoperative device closure of atrial septal defects (ASDs). Material/Methods: The clinical data of 152 pediatric patients who received intraoperative device closure of ASD in our hospital from January 2015 to December 2017 were retrospectively analyzed. Patients were divided into 2 groups: group F (remifentanil-based fast-track anesthesia group, n=72) and group C (fentanyl-based routine anesthesia group, n=80). The relevant data from 2 groups were collected and analyzed. Results: No significant differences were found in the preoperative data or intraoperative hemodynamic index between these 2 groups. Group C was significantly inferior to group F regarding the duration of mechanical ventilation, length of intensive care unit (ICU) stay, length of hospital stay, and hospitalization expenses (P<0.05). In terms of postoperative complications, no death, third-degree atrioventricular block, occluder detachment, or residual leakage was reported in either group. The incidence of lung infections and bronchospasm was significantly higher in group C than in group F. There were no anesthetic-related complications. Conclusions: The application of remifentanil-based fast-track anesthesia for intraoperative device closure of ASD is as effective and safe as fentanyl-based routine anesthesia. Moreover, remifentanil-based fast-track anesthesia has the advantages of shorter duration of mechanical ventilation, shorter length of hospital and ICU stay, fewer postoperative complications, and lower hospitalization expenses, and is therefore worthy of promotion in clinical practice.	[Huang, Qing; Lin, Lan-Ying; Lin, Xian-Zhong] Fujian Med Univ, Affiliated Hosp 1, Dept Anesthesia, Fuzhou, Fujian, Peoples R China	Huang, Q (reprint author), Fujian Med Univ, Affiliated Hosp 1, Dept Anesthesia, Fuzhou, Fujian, Peoples R China.	huangqing2228@163.com					Aytemir K, 2013, CONGENIT HEART DIS, V8, P418, DOI 10.1111/chd.12057; Bainbridge D, 2015, SEMIN CARDIOTHORAC V, V19, P163, DOI 10.1177/1089253215584919; Bergmann I, 2015, BMC ANESTHESIOL, V15, DOI 10.1186/1471-2253-15-3; Chen Q, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000006316; Chen Q, 2012, EUR J CARDIO-THORAC, V41, P121, DOI 10.1016/j.ejcts.2011.04.001; Cheng DCH, 1998, J CARDIOTHOR VASC AN, V12, P72, DOI 10.1016/S1053-0770(98)90061-1; Cregg N, 1999, J CARDIOTHOR VASC AN, V13, P47, DOI 10.1016/S1053-0770(99)90173-8; Fanelli G, 2006, EUR J ANAESTH, V23, P861, DOI 10.1017/S0265021506000718; Fischer JE, 2000, INTENS CARE MED, V26, P942, DOI 10.1007/s001340051285; Groesdonk HV, 2010, J CARDIOTHOR VASC AN, V24, P785, DOI 10.1053/j.jvca.2010.03.018; Gupta P, 2016, J THORAC CARDIOV SUR, V151, P451, DOI 10.1016/j.jtcvs.2015.09.080; Haanschoten MC, 2012, INTERACT CARDIOV TH, V15, P989, DOI 10.1093/icvts/ivs393; Hamilton BCS, 2014, SEMIN CARDIOTHORAC V, V18, P290, DOI 10.1177/1089253213519291; Harris KC, 2014, J THORAC CARDIOV SUR, V148, P2642, DOI 10.1016/j.jtcvs.2014.06.093; Hoashi T, 2015, J CARDIOL, V65, P418, DOI 10.1016/j.jjcc.2014.07.009; Hongxin L, 2005, CHINESE J SURG, V43, P653; Iodice FG, 2011, EUR J CARDIO-THORAC, V40, P610, DOI 10.1016/j.ejcts.2010.12.032; Khanykin B, 2013, HEART SURG FORUM, V16, pE324, DOI 10.1532/HSF98.2013229; Kharouf R, 2008, PEDIATR CARDIOL, V29, P271, DOI 10.1007/s00246-007-9052-8; Lena P, 2008, J CARDIOTHOR VASC AN, V22, P536, DOI 10.1053/j.jvca.2008.04.012; Luo H, 2014, J THORAC CARDIOV SUR, V148, P188, DOI 10.1016/j.jtcvs.2013.08.017; Meyer T, 2010, AM J HEALTH-SYST PH, V67, pS4, DOI 10.2146/ajhp100092; PASTOREK JS, 1994, AM J CARDIOL, V74, P75, DOI 10.1016/0002-9149(94)90498-7; Safdar N, 2005, CRIT CARE MED, V33, P2184, DOI 10.1097/01.CCM.0000181731.53912.D9; Suchon E, 2009, MED SCI MONITOR, V15, pCR612; Svircevic V, 2009, ANESTH ANALG, V108, P727, DOI 10.1213/ane.0b013e318193c423; Tao L, 2006, ANN THORAC SURG, V81, P1417, DOI 10.1016/j.athoracsur.2005.09.081; Zhu F, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003587.pub2	28	2	2	1	2	INT SCIENTIFIC INFORMATION, INC	MELVILLE	150 BROADHOLLOW RD, STE 114, MELVILLE, NY 11747 USA	1643-3750			MED SCI MONITOR	Med. Sci. Monitor	FEB 13	2019	25						1187	1193		10.12659/MSM.913387			7	Medicine, Research & Experimental	Research & Experimental Medicine	HL7IE	WOS:000458912800003	30759074	Green Published			2020-06-30	J	Friesgaard, KD; Kirkegaard, H; Rasmussen, CH; Giebner, M; Christensen, EF; Nikolajsen, L				Friesgaard, Kristian D.; Kirkegaard, Hans; Rasmussen, Claus-Henrik; Giebner, Matthias; Christensen, Erika F.; Nikolajsen, Lone			Prehospital intravenous fentanyl administered by ambulance personnel: a cluster-randomised comparison of two treatment protocols	SCANDINAVIAN JOURNAL OF TRAUMA RESUSCITATION & EMERGENCY MEDICINE			English	Article						Prehospital; Acute pain; Intravenous fentanyl; Ambulance personnel	SEVERE ACUTE PAIN; TRAUMA ANALGESIA; CONTROLLED-TRIAL; DOUBLE-BLIND; EMERGENCY-DEPARTMENT; ADVERSE EVENTS; PATIENT GENDER; MORPHINE; MANAGEMENT; CARE	BackgroundPrehospital acute pain is a frequent symptom that is often inadequately managed. The concerns of opioid induced side effects are well-founded. To ensure patient safety, ambulance personnel are therefore provided with treatment protocols with dosing restrictions, however, with the concomitant risk of insufficient pain treatment of the patients. The aim of this study was to investigate the impact of a liberal intravenous fentanyl treatment protocol on efficacy and safety measures.MethodsA two-armed, cluster-randomised trial was conducted in the Central Denmark Region over a 1-year period. Ambulance stations (stratified according to size) were randomised to follow either a liberal treatment protocol (3g/kg) or a standard treatment protocol (2g/kg). The primary outcome was the proportion of patients with sufficient pan relief (numeric rating scale (NRS, 0-10)<3) at hospital arrival. Secondary outcomes included abnormal vital parameters as proxy measures of safety. A multi-level mixed effect logistic regression model was applied.ResultsIn total, 5278 patients were included. Ambulance personnel following the liberal protocol administered higher doses of fentanyl [117.7g (95% CI 116.7-118.6)] than ambulance personnel following the standard protocol [111.5g (95% CI 110.7-112.4), P=0.0001]. The number of patient with sufficient pain relief at hospital arrival was higher in the liberal treatment group than the standard treatment group [44.0% (95% CI 41.8-46.1) vs. 37.4% (95% CI 35.2-39.6), adjusted odds ratio 1.47 (95% CI 1.17-1.84)]. The relative decrease in NRS scores during transport was less evident [adjusted odds ratio 1.18 (95% CI 0.95-1.48)]. The occurrences of abnormal vital parameters were similar in both groups.ConclusionsLiberalising an intravenous fentanyl treatment protocol applied by ambulance personnel slightly increased the number of patients with sufficient pain relief at hospital arrival without compromising patient safety. Future efforts of training ambulance personnel are needed to further improve protocol adherence and quality of treatment.Trial registrationClinicalTrials.gov (NCT02914678). Date of registration: 26th September, 2016.	[Friesgaard, Kristian D.; Kirkegaard, Hans] Cent Denmark Reg, Prehosp Emergency Med Serv, Res Dept, Olof Palmes Alle 34, DK-8200 Aarhus N, Denmark; [Friesgaard, Kristian D.] Reg Hosp Horsens, Dept Anaesthesiol, Horsens, Denmark; [Rasmussen, Claus-Henrik; Giebner, Matthias] Cent Denmark Reg, Falck Danmark AS, Aarhus, Denmark; [Rasmussen, Claus-Henrik] Cent Denmark Reg, Response AS, Hedensted, Denmark; [Christensen, Erika F.] Aalborg Univ, Dept Clin Med Prehosp & Emergency Res, Aalborg, Denmark; [Christensen, Erika F.] Aalborg Univ Hosp, Dept Anaesthesiol & Intens Care, Emergency Clin, Aalborg, Denmark; [Nikolajsen, Lone] Aarhus Univ Hosp, Dept Anaesthesiol & Intens Care, Aarhus, Denmark	Friesgaard, KD (reprint author), Cent Denmark Reg, Prehosp Emergency Med Serv, Res Dept, Olof Palmes Alle 34, DK-8200 Aarhus N, Denmark.; Friesgaard, KD (reprint author), Reg Hosp Horsens, Dept Anaesthesiol, Horsens, Denmark.	k.friesgaard@me.com		Christensen, Erika F./0000-0003-3673-9694; Nikolajsen, Lone/0000-0002-2705-7088	Health Research Fund of Central Denmark Region	The Health Research Fund of Central Denmark Region funded this project.	Albrecht E, 2013, BRIT J ANAESTH, V110, P96, DOI 10.1093/bja/aes355; Andersen MS, 2013, SCAND J TRAUMA RESUS, V21, DOI 10.1186/1757-7241-21-53; Auffret Y, 2014, AM J EMERG MED, V32, P655, DOI 10.1016/j.ajem.2014.01.048; Bakkelund KE, 2013, EUR J EMERG MED, V20, P428, DOI 10.1097/MEJ.0b013e32835c9fa3; Bendall JC, 2011, PREHOSP DISASTER MED, V26, P422, DOI 10.1017/S1049023X12000180; Bounes V, 2008, AM J EMERG MED, V26, P148, DOI 10.1016/j.ajem.2007.04.020; Bounes V, 2011, AM J EMERG MED, V29, P512, DOI 10.1016/j.ajem.2009.12.005; Bounes V, 2010, ANN EMERG MED, V56, P509, DOI 10.1016/j.annemergmed.2010.03.020; Brown KM, 2014, PREHOSP EMERG CARE, V18, P45, DOI 10.3109/10903127.2013.831510; BRUNS BM, 1992, AM J EMERG MED, V10, P53, DOI 10.1016/0735-6757(92)90127-J; Cashman JN, 2004, BRIT J ANAESTH, V93, P212, DOI 10.1093/bja/aeh180; DeVellis P, 1998, Prehosp Emerg Care, V2, P293, DOI 10.1080/10903129808958883; Eidenbenz D, 2016, ANAESTHESIA, V71, P779, DOI 10.1111/anae.13462; Fleischman RJ, 2010, PREHOSP EMERG CARE, V14, P167, DOI 10.3109/10903120903572301; Frakes MA, 2006, AM J EMERG MED, V24, P286, DOI 10.1016/j.ajem.2005.11.021; Frakes MA, 2009, AM J EMERG MED, V27, P49, DOI 10.1016/j.ajem.2008.01.005; French SC, 2006, PREHOSP EMERG CARE, V10, P71, DOI 10.1080/10903120500366086; French SC, 2013, WEST J EMERG MED, V14, P96, DOI 10.5811/westjem.2012.7.6678; Friesgaard KD, 2016, ACTA ANAESTH SCAND, V60, P537, DOI 10.1111/aas.12662; Fu ES, 2004, CHEST, V126, P1552, DOI 10.1378/chest.126.5.1552; Fullerton-Gleason Lynne, 2002, Prehosp Emerg Care, V6, P411, DOI 10.1080/10903120290938049; Galinski M, 2005, AM J EMERG MED, V23, P114, DOI 10.1016/j.ajem.2004.03.010; Galinski M, 2007, AM J EMERG MED, V25, P385, DOI 10.1016/j.ajem.2006.11.016; Galinski M, 2010, PREHOSP EMERG CARE, V14, P334, DOI 10.3109/10903121003760218; Haley KB, 2016, PREHOSP EMERG CARE, V20, P752, DOI 10.1080/10903127.2016.1182599; Heller GZ, 2016, SCAND J PAIN, V13, P67, DOI 10.1016/j.sjpain.2016.06.012; Hennes Halim, 2005, Prehosp Emerg Care, V9, P32, DOI 10.1080/10903120590891705; Hewes HA, 2018, PREHOSP EMERG CARE, V22, P189, DOI 10.1080/10903127.2017.1367444; Hwang U, 2010, J AM GERIATR SOC, V58, P2122, DOI 10.1111/j.1532-5415.2010.03152.x; Jennings PA, 2012, ANN EMERG MED, V59, P497, DOI 10.1016/j.annemergmed.2011.11.012; Jennings PA, 2012, EMERG MED J, V29, P333, DOI 10.1136/emj.2010.107094; Jennings PA, 2011, EMERG MED J, V28, P530, DOI 10.1136/emj.2010.098954; Johansson P, 2009, SCAND J TRAUMA RESUS, V17, DOI 10.1186/1757-7241-17-61; Kanowitz A, 2006, PREHOSP EMERG CARE, V10, P1, DOI 10.1080/10903120500373264; Tran KP, 2014, PREHOSP EMERG CARE, V18, P257, DOI 10.3109/10903127.2013.851307; Krauss WC, 2011, J EMERG MED, V40, P182, DOI 10.1016/j.jemermed.2009.02.009; Lebon J, 2016, PREHOSP EMERG CARE, V20, P648, DOI 10.3109/10903127.2016.1162887; Lerner EB, 2016, PREHOSP EMERG CARE, V20, P448, DOI 10.3109/10903127.2014.980480; Lord B, 2014, PREHOSP EMERG CARE, V18, P195, DOI 10.3109/10903127.2013.856502; Lord B, 2009, AM J EMERG MED, V27, P525, DOI 10.1016/j.ajem.2008.04.003; McLean Samuel A, 2002, Prehosp Emerg Care, V6, P402, DOI 10.1080/10903120290938021; McManus JG, 2005, EMERG MED CLIN N AM, V23, P415, DOI 10.1016/j.emc.2004.12.009; McRae PJ, 2015, J EMERG MED, V48, P581, DOI 10.1016/j.jemermed.2014.12.016; Middleton PM, 2010, PREHOSP EMERG CARE, V14, P439, DOI 10.3109/10903127.2010.497896; Moore RA, 2013, ANAESTHESIA, V68, P400, DOI 10.1111/anae.12148; Motov Sergey M, 2008, J Pain Res, V2, P5; Oberholzer N, 2017, ANESTH ANALG, V125, P200, DOI 10.1213/ANE.0000000000002016; Platts-Mills TF, 2013, J PAIN, V14, P966, DOI 10.1016/j.jpain.2013.03.014; Pointer James E, 2005, Prehosp Emerg Care, V9, P377, DOI 10.1080/10903120500253805; Ricard-Hibon A, 1999, ANN EMERG MED, V34, P738, DOI 10.1016/S0196-0644(99)70099-5; Ricard-Hibon A, 2008, J EMERG MED, V34, P305, DOI 10.1016/j.jemermed.2007.06.003; Rickard C, 2007, AM J EMERG MED, V25, P911, DOI 10.1016/j.ajem.2007.02.027; Rupp T, 2004, ANN EMERG MED, V43, P494, DOI 10.1016/j.annemergmed.2003.11.019; Schiferer A, 2007, ANESTH ANALG, V105, P1852, DOI 10.1213/01.ane.0000287676.39323.9e; Schmidt M, 2015, CLIN EPIDEMIOL, V7, P449, DOI 10.2147/CLEP.S91125; Schmidt M, 2014, EUR J EPIDEMIOL, V29, P541, DOI 10.1007/s10654-014-9930-3; Shah AA, 2015, MED CARE, V53, P1000, DOI 10.1097/MLR.0000000000000444; Silfvast T, 2001, Eur J Emerg Med, V8, P275, DOI 10.1097/00063110-200112000-00005; Smith MD, 2012, J EMERG MED, V43, P69, DOI 10.1016/j.jemermed.2011.05.018; Soriya GC, 2012, J TRAUMA ACUTE CARE, V72, P755, DOI 10.1097/TA.0b013e31823c4444; Spilman SK, 2016, INJURY, V47, P2018, DOI 10.1016/j.injury.2016.03.012; Studnek JR, 2013, PREHOSP EMERG CARE, V17, P386, DOI 10.3109/10903127.2013.764948; Sundararajan V, 2004, J CLIN EPIDEMIOL, V57, P1288, DOI 10.1016/j.jclinepi.2004.03.012; Thomas SH, 2005, J EMERG MED, V29, P179, DOI 10.1016/j.jemermed.2005.02.007; Thygesen SK, 2011, BMC MED RES METHODOL, V11, DOI 10.1186/1471-2288-11-83; van Breukelen GJP, 2012, J CLIN EPIDEMIOL, V65, P1212, DOI 10.1016/j.jclinepi.2012.06.002; Vergnion M, 2001, ANESTH ANALG, V92, P1543; Walsh B, 2013, PREHOSP EMERG CARE, V17, P78, DOI 10.3109/10903127.2012.717167; Weldon ER, 2016, PREHOSP EMERG CARE, V20, P45, DOI 10.3109/10903127.2015.1056893; Woollard M, 2004, EMERG MED J, V21, P362, DOI 10.1136/emj.2004.014324; Young MF, 2013, J EMERG MED, V45, P46, DOI 10.1016/j.jemermed.2012.07.088; Zedigh C, 2010, CORONARY ARTERY DIS, V21, P113, DOI 10.1097/MCA.0b013e32832fa9e5	72	0	0	0	3	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1757-7241			SCAND J TRAUMA RESUS	Scand. J. Trauma Resusc. Emerg. Med.	FEB 7	2019	27								11	10.1186/s13049-019-0588-4			13	Emergency Medicine	Emergency Medicine	HK7SH	WOS:000458189300001	30732618	DOAJ Gold, Green Published			2020-06-30	J	Hwang, CJ; Lee, JH; Kim, JH; Min, SH; Park, KW; Seo, HY; Song, KS				Hwang, Chang Ju; Lee, Jae Hyup; Kim, Jung-Hoon; Min, Sang Hyuk; Park, Kun-Woo; Seo, Hyoung-Yeon; Song, Kwang-Sup			Gabapentin versus Transdermal Fentanyl Matrix for the Alleviation of Chronic Neuropathic Pain of Radicular Origin: A Randomized Blind Multicentered Parallel-Group Noninferiority Trial	PAIN RESEARCH & MANAGEMENT			English	Article							POSTHERPETIC NEURALGIA; IDIOPATHIC FORMS; CROSSOVER TRIAL; MORPHINE; EFFICACY; SAFETY; PREGABALIN; DIAGNOSIS; OPIOIDS	A number of studies have been published proposing various approaches to the treatment of neuropathic pain; however, to our knowledge, no attempts have been made to compare gabapentin and fentanyl in patients with lumbar radiculopathy. We evaluated the relative efficacy and safety of fentanyl matrix and gabapentin for the treatment of chronic neuropathic pain of radicular origin. The study was designed as a randomized blind multicentered parallel-group noninferiority trial. A total of 108 patients with moderate-to-severe pain (>= 4 intensity on an 11-point numeric rating scale) were randomly prescribed either fentanyl matrix or gabapentin over a period of 56 days. In the primary analysis, the noninferiority of fentanyl matrix treatment was evaluated in relation to the efficacy of gabapentin based on the pain intensity difference (PID) at 56 days after the first dose of the drugs. Secondary endpoints included pain relief, improvement in functional status (the Korean-Oswestry Disability Index (K-ODI)), improvement in depressive symptoms (Korean-Beck Depression Index (K-BDI)) between the 28th and 56th day, and adverse events (AEs). Analysis of the primary efficacy endpoint established the noninferiority of fentanyl matrix compared with gabapentin, with no statistically significant difference observed in the PID after 56 days for the two treatment groups. Similarly, analysis of pain relief revealed no significant differences between the groups on days 28 and 56. There was no difference in the K-ODI and K-BDI between the groups during the study period. The overall incidence of at least one AE was similar for fentanyl matrix (67.3%) and gabapentin (69.6%). The most commonly reported AEs for patients treated with fentanyl matrix and gabapentin included dizziness (30.8% vs. 44.6%, respectively), somnolence (26.9% vs. 35.7%), and constipation (15.4% vs. 17.9%). This study demonstrated that the analgesic effect of fentanyl matrix is noninferior in comparison with gabapentin and supports the use of fentanyl matrix as an effective and safe treatment for moderate-to-severe chronic neuropathic pain.	[Hwang, Chang Ju] Univ Ulsan, Asan Med Ctr, Dept Orthopaed Surg, Coll Med, Seoul, South Korea; [Lee, Jae Hyup] Seoul Natl Univ, Dept Orthopaed Surg, Coll Med, Seoul, South Korea; [Kim, Jung-Hoon] Inje Univ, Ilsan Paik Hosp, Dept Orthopaed Surg, Coll Med, Goyang, South Korea; [Min, Sang Hyuk] Dankook Univ Hosp, Dept Orthopaed Surg, Cheonan, South Korea; [Park, Kun-Woo] Bundang Chuk Hosp, Dept Orthopaed Surg, Seongnam, South Korea; [Seo, Hyoung-Yeon] Chonnam Natl Univ Hosp, Dept Orthopaed Surg, Gwangju, South Korea; [Song, Kwang-Sup] Chung Ang Univ, Dept Orthopaed Surg, Coll Med, Seoul, South Korea	Lee, JH (reprint author), Seoul Natl Univ, Dept Orthopaed Surg, Coll Med, Seoul, South Korea.	spinelee@snu.ac.kr	Song, Kwang-Sup/AAC-3891-2020				Allan L, 2001, BRIT MED J, V322, P1154, DOI 10.1136/bmj.322.7295.1154; Arai T, 2015, CURR MED RES OPIN, V31, P2207, DOI 10.1185/03007995.2015.1092127; ARNER S, 1988, PAIN, V33, P11, DOI 10.1016/0304-3959(88)90198-4; Canneti A, 2013, MINERVA ANESTESIOL, V79, P871; Dellemijn PLI, 1997, LANCET, V349, P753, DOI 10.1016/S0140-6736(96)09024-1; Derry S, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011605.pub2; Eisenberg E, 2005, JAMA-J AM MED ASSOC, V293, P3043, DOI 10.1001/jama.293.24.3043; Farrar JT, 2001, PAIN, V94, P149, DOI 10.1016/S0304-3959(01)00349-9; Finnerup NB, 2015, LANCET NEUROL, V14, P162, DOI 10.1016/S1474-4422(14)70251-0; Fischer D, 1999, JAMA-J AM MED ASSOC, V282, P1157, DOI 10.1001/jama.282.12.1157; Fishbain DA, 2014, PAIN MED, V15, P4, DOI 10.1111/pme.12229; Gehling M, 2011, SCHMERZ, V25, P296, DOI 10.1007/s00482-011-1057-9; Gilron I, 2015, MAYO CLIN PROC, V90, P532, DOI 10.1016/j.mayocp.2015.01.018; Hurley RW, 2013, CURR OPIN ANESTHESIO, V26, P580, DOI 10.1097/ACO.0b013e328363b4bf; JADAD AR, 1992, LANCET, V339, P1367, DOI 10.1016/0140-6736(92)91194-D; Jensen TS, 2011, PAIN, V152, P2204, DOI 10.1016/j.pain.2011.06.017; Kendrick DB, 2005, AM J EMERG MED, V23, P828, DOI 10.1016/j.ajem.2005.07.009; KUPERS RC, 1991, PAIN, V47, P5, DOI 10.1016/0304-3959(91)90004-H; MAX MB, 1988, CLIN PHARMACOL THER, V43, P363, DOI 10.1038/clpt.1988.44; McCarberg B, 2017, CURR MED RES OPIN, V33, P1361, DOI 10.1080/03007995.2017.1321532; MCNICOL ED, 2013, [No title captured], V29, DOI DOI 10.1002/14651858.CD006146.PUB2; Mystakidou K, 2003, J PAIN, V4, P298, DOI 10.1016/S1526-5900(03)00632-1; Park JH, 2011, ACTA NEUROCHIR, V153, P181, DOI 10.1007/s00701-010-0785-4; Portenoy R K, 1990, J Pain Symptom Manage, V5, pS46; Raptis E, 2014, PAIN PRACT, V14, P32, DOI 10.1111/papr.12045; ROWBOTHAM MC, 1991, NEUROLOGY, V41, P1024, DOI 10.1212/WNL.41.7.1024; Sandercock D, 2012, DIABETES RES CLIN PR, V97, P438, DOI 10.1016/j.diabres.2012.03.010; Smith HS, 2012, PAIN PHYSICIAN, V15, pES1; Tai Q., 2016, J SPINAL CORD MED, V25, P100; Tzellos TG, 2010, J CLIN PHARM THER, V35, P639, DOI 10.1111/j.1365-2710.2009.01144.x; Zhang LX, 2013, J PAIN, V14, P590, DOI 10.1016/j.jpain.2013.01.768	31	0	0	0	0	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	1203-6765	1918-1523		PAIN RES MANAG	Pain Res. Manag.	FEB 4	2019	2019								4905013	10.1155/2019/4905013			9	Clinical Neurology	Neurosciences & Neurology	JI2NR	WOS:000493301500002	30863474	DOAJ Gold, Green Published			2020-06-30	J	Lipinski, PFJ; Kosson, P; Matalinska, J; Roszkowski, P; Czarnocki, Z; Jaronczyk, M; Misicka, A; Dobrowolski, JC; Sadlej, J				Lipinski, Piotr F. J.; Kosson, Piotr; Matalinska, Joanna; Roszkowski, Piotr; Czarnocki, Zbigniew; Jaronczyk, Malgorzata; Misicka, Aleksandra; Dobrowolski, Jan Cz.; Sadlej, Joanna			Fentanyl Family at the Mu-Opioid Receptor: Uniform Assessment of Binding and Computational Analysis	MOLECULES			English	Article						fentanyl; opioid receptors; molecular dynamics; designer drugs	PROTEIN-LIGAND INTERACTIONS; SCORING FUNCTION; PHARMACOLOGICAL EVALUATION; MOLECULAR RECOGNITION; ANALGESIC ACTIVITY; DOCKING; DESIGN; ACTIVATION; DYNAMICS; AGONIST	Interactions of 21 fentanyl derivatives with -opioid receptor (OR) were studied using experimental and theoretical methods. Their binding to OR was assessed with radioligand competitive binding assay. A uniform set of binding affinity data contains values for two novel and one previously uncharacterized derivative. The data confirms trends known so far and thanks to their uniformity, they facilitate further comparisons. In order to provide structural hypotheses explaining the experimental affinities, the complexes of the studied derivatives with OR were modeled and subject to molecular dynamics simulations. Five common General Features (GFs) of fentanyls' binding modes stemmed from these simulations. They include: GF1) the ionic interaction between D147 and the ligands' piperidine NH+ moiety; GF2) the N-chain orientation towards the OR interior; GF3) the other pole of ligands is directed towards the receptor outlet; GF4) the aromatic anilide ring penetrates the subpocket formed by TM3, TM4, ECL1 and ECL2; GF5) the 4-axial substituent (if present) is directed towards W318. Except for the ionic interaction with D147, the majority of fentanyl-OR contacts is hydrophobic. Interestingly, it was possible to find nonlinear relationships between the binding affinity and the volume of the N-chain and/or anilide's aromatic ring. This kind of relationships is consistent with the apolar character of interactions involved in ligand-receptor binding. The affinity reaches the optimum for medium size while it decreases for both large and small substituents. Additionally, a linear correlation between the volumes and the average dihedral angles of W293 and W133 was revealed by the molecular dynamics study. This seems particularly important, as the W293 residue is involved in the activation processes. Further, the Y326 (OH) and D147 (C) distance found in the simulations also depends on the ligands' size. In contrast, neither RMSF measures nor D114/Y336 hydrations show significant structure-based correlations. They also do not differentiate studied fentanyl derivatives. Eventually, none of 14 popular scoring functions yielded a significant correlation between the predicted and observed affinity data (R < 0.30, n = 28).	[Lipinski, Piotr F. J.; Matalinska, Joanna; Misicka, Aleksandra] Polish Acad Sci, Dept Neuropeptides, Mossakowski Med Res Ctr, PL-02106 Warsaw, Poland; [Kosson, Piotr] Polish Acad Sci, Toxicol Res Lab, Mossakowski Med Res Ctr, PL-02106 Warsaw, Poland; [Roszkowski, Piotr; Czarnocki, Zbigniew; Misicka, Aleksandra] Univ Warsaw, Fac Chem, PL-02093 Warsaw, Poland; [Jaronczyk, Malgorzata; Dobrowolski, Jan Cz.; Sadlej, Joanna] Natl Med Inst, PL-00725 Warsaw, Poland; [Sadlej, Joanna] Univ Cardinal Stefan Wyszynski, Fac Math & Nat Sci, 1-3 Woycickiego Str, PL-01938 Warsaw, Poland	Lipinski, PFJ (reprint author), Polish Acad Sci, Dept Neuropeptides, Mossakowski Med Res Ctr, PL-02106 Warsaw, Poland.; Sadlej, J (reprint author), Natl Med Inst, PL-00725 Warsaw, Poland.; Sadlej, J (reprint author), Univ Cardinal Stefan Wyszynski, Fac Math & Nat Sci, 1-3 Woycickiego Str, PL-01938 Warsaw, Poland.	plipinski@imdik.pan.pl; pkosson@imdik.pan.pl; jmatalinska@imdik.pan.pl; roszkowski@chem.uw.edu.pl; czarnoz@chem.uw.edu.pl; m.jaronczyk@nil.gov.pl; misicka@imdik.pan.pl; j.dobrowolski@nil.gov.pl; j.sadlej@uksw.edu.pl	Jaronczyk, Malgorzata/AAE-3582-2019	Jaronczyk, Malgorzata/0000-0003-4268-102X; Matalinska, Joanna/0000-0003-0837-7171; Kosson, Piotr/0000-0002-0493-3962; Lipinski, Piotr/0000-0002-8364-7955; Misicka, Aleksandra/0000-0001-7446-2396	National Science Centre, Poland [2013/11/B/ST4/00785]	This research was funded by National Science Centre, Poland, grant number 2013/11/B/ST4/00785.	Abraham Mark James, 2015, SoftwareX, V1-2, P19, DOI 10.1016/j.softx.2015.06.001; Accelrys Software Inc, 2013, DISC STUD MOD ENV 20; Allen WJ, 2015, J COMPUT CHEM, V36, P1132, DOI 10.1002/jcc.23905; BAGLEY JR, 1989, J MED CHEM, V32, P663, DOI 10.1021/jm00123a028; Barbas R, 2019, CHEM COMMUN, V55, P115, DOI 10.1039/c8cc09028a; Bergh MSS, 2018, THER DRUG MONIT, V40, P738, DOI 10.1097/FTD.0000000000000564; Bermudez M, 2016, DRUG DISCOV TODAY, V21, P1799, DOI 10.1016/j.drudis.2016.07.001; Bick MJ, 2017, ELIFE, V6, DOI 10.7554/eLife.28909; Bohm HJ, 1998, J COMPUT AID MOL DES, V12, P309, DOI 10.1023/A:1007999920146; Burns SM, 2018, ACS CHEM NEUROSCI, V9, P2428, DOI 10.1021/acschemneuro.8b00174; CASY AF, 1988, J PHARM PHARMACOL, V40, P605, DOI 10.1111/j.2042-7158.1988.tb05318.x; Chan HCS, 2016, SCI REP-UK, V6, DOI 10.1038/srep34736; Corbeil CR, 2012, J COMPUT AID MOL DES, V26, P775, DOI 10.1007/s10822-012-9570-1; Cortazzo M.H., 2014, PRACTICAL MANAGEMENT; Deekonda S, 2016, BIOORGAN MED CHEM, V24, P85, DOI 10.1016/j.bmc.2015.11.030; Deekonda S, 2015, BIOORG MED CHEM LETT, V25, P4683, DOI 10.1016/j.bmcl.2015.07.064; Dror RO, 2012, ANNU REV BIOPHYS, V41, P429, DOI 10.1146/annurev-biophys-042910-155245; Dyniewicz J, 2017, ACS MED CHEM LETT, V8, P73, DOI 10.1021/acsmedchemlett.6b00381; Ellis CR, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0197734; Enyedy IJ, 2008, J COMPUT AID MOL DES, V22, P161, DOI 10.1007/s10822-007-9165-4; European Monitoring Centre for Drugs and Drug Addiction, 2018, EMCDDA EUR JOINT REP; Fisher DM, 2018, ANESTHESIOLOGY, V128, P943, DOI 10.1097/ALN.0000000000002145; Frisch M.J., 2013, GAUSSIAN 09 REVISION; GANELLIN CR, 1965, J MED CHEM, V8, P619, DOI 10.1021/jm00329a015; GEHLHAAR DK, 1995, CHEM BIOL, V2, P317, DOI 10.1016/1074-5521(95)90050-0; Hikin L, 2018, FORENSIC SCI INT, V282, P179, DOI 10.1016/j.forsciint.2017.11.036; Huang WJ, 2015, NATURE, V524, P315, DOI 10.1038/nature14886; Hulme EC, 2013, TRENDS PHARMACOL SCI, V34, P67, DOI 10.1016/j.tips.2012.11.002; Ivanovic MD, 2004, J SERB CHEM SOC, V69, P955, DOI 10.2298/JSC0411955I; Jain AN, 1996, J COMPUT AID MOL DES, V10, P427, DOI 10.1007/BF00124474; Jevtic II, 2019, J SERB CHEM SOC, V84, P639, DOI 10.2298/JSC181002105J; Jevtic II, 2017, SYNTHESIS-STUTTGART, V49, P3126, DOI 10.1055/s-0036-1588985; Jin WQ, 1996, ACTA PHARM SINIC, V17, P421; Kaiser A, 2018, MOL PHARMACOL, V93, P387, DOI 10.1124/mol.117.110544; Kennedy NM, 2018, J MED CHEM, V61, P8895, DOI 10.1021/acs.jmedchem.8b01136; Koehl A, 2018, NATURE, V558, P547, DOI 10.1038/s41586-018-0219-7; Kolinski M., 2008, OPEN STRUCT BIOL J, V2, P8, DOI DOI 10.2174/1874199100802010008; Kolinski M, 2010, J MOL MODEL, V16, P1567, DOI 10.1007/s00894-010-0678-8; Krammer A, 2005, J MOL GRAPH MODEL, V23, P395, DOI 10.1016/j.jmgm.2004.11.007; KUDZMA LV, 1989, J MED CHEM, V32, P2534, DOI 10.1021/jm00132a007; LALINDE N, 1990, J MED CHEM, V33, P2876, DOI 10.1021/jm00172a032; Latorraca NR, 2017, CHEM REV, V117, P139, DOI 10.1021/acs.chemrev.6b00177; Li JG, 1999, LIFE SCI, V65, P175, DOI 10.1016/S0024-3205(99)00234-9; Li SH, 2017, RSC ADV, V7, P20015, DOI 10.1039/c7ra01346a; Lipiski P.F.J., 2019, J MOL MODEL; Lomize MA, 2006, BIOINFORMATICS, V22, P623, DOI 10.1093/bioinformatics/btk023; Maher S, 2018, DRUG TEST ANAL, V10, P1483, DOI 10.1002/dta.2417; Manglik A, 2012, NATURE, V485, P321, DOI 10.1038/nature10954; Mayer BP, 2016, ANAL CHEM, V88, P4303, DOI 10.1021/acs.analchem.5b04434; Mecozzi S, 1998, CHEM-EUR J, V4, P1016, DOI 10.1002/(SICI)1521-3765(19980615)4:6<1016::AID-CHEM1016>3.0.CO;2-B; Monti L, 2016, J ENZYM INHIB MED CH, V31, P1638, DOI 10.3109/14756366.2016.1160902; Mounteney J, 2015, INT J DRUG POLICY, V26, P626, DOI 10.1016/j.drugpo.2015.04.003; Muegge I, 1999, J MED CHEM, V42, P791, DOI 10.1021/jm980536j; Muegge I, 2006, J MED CHEM, V49, P5895, DOI 10.1021/jm050038s; Nami M, 2018, CHEM BIOL DRUG DES, V91, P902, DOI 10.1111/cbdd.13157; Neudert G, 2011, J CHEM INF MODEL, V51, P2731, DOI 10.1021/ci200274q; Ogawa N, 2016, J PHARM PHARMACOL, V68, P588, DOI 10.1111/jphp.12437; Pearson Julia, 2015, Acad Forensic Pathol, V5, P676, DOI 10.23907/2015.072; Petrov RR, 2013, BIOORG MED CHEM LETT, V23, P3434, DOI 10.1016/j.bmcl.2013.03.065; Plewczynski D, 2011, J COMPUT CHEM, V32, P742, DOI 10.1002/jcc.21643; Poklis J, 2015, FORENSIC SCI INT, V257, P435, DOI 10.1016/j.forsciint.2015.10.021; Rodriguez-Gaztelumendi A, 2018, PAIN, V159, P2277, DOI 10.1097/j.pain.0000000000001328; Sabbadin D, 2014, J CHEM INF MODEL, V54, P169, DOI 10.1021/ci400532b; Schmid CL, 2017, CELL, V171, P1165, DOI 10.1016/j.cell.2017.10.035; Seymour C, 2019, J ANAL TOXICOL, V43, P266, DOI 10.1093/jat/bky096; Shaner RL, 2017, ANAL METHODS-UK, V9, P3876, DOI [10.1039/c7ay00532f, 10.1039/C7AY00532F]; Spahn V, 2017, SCIENCE, V355, P966, DOI 10.1126/science.aai8636; Spahn V, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-27313-4; Stanley TH, 2014, J PAIN, V15, P1215, DOI 10.1016/j.jpain.2014.08.010; Stoddart LA, 2014, BRIT J PHARMACOL, V171, P3827, DOI 10.1111/bph.12739; Sun XQ, 2017, CHEM-EUR J, V23, P4615, DOI 10.1002/chem.201605575; SURRATT CK, 1994, J BIOL CHEM, V269, P20548; Thansandote P, 2007, ORG LETT, V9, P5255, DOI 10.1021/ol702472u; Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334; Trzaskowski B, 2012, CURR MED CHEM, V19, P1090, DOI 10.2174/092986712799320556; US Drug Enforcement Administration, 2017, 3 FACT AN TEMP SCHED; Valdez CA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108250; Vandergrift GW, 2018, CLIN BIOCHEM, V54, P106, DOI 10.1016/j.clinbiochem.2018.02.005; Vanommeslaeghe K, 2010, J COMPUT CHEM, V31, P671, DOI 10.1002/jcc.21367; Varadi A, 2015, ACS CHEM NEUROSCI, V6, P1570, DOI 10.1021/acschemneuro.5b00137; Vardanyan R, 2009, BIOORGAN MED CHEM, V17, P5044, DOI 10.1016/j.bmc.2009.05.065; Vardanyan RS, 2014, FUTURE MED CHEM, V6, P385, DOI 10.4155/fmc.13.215; Volpe DA, 2011, REGUL TOXICOL PHARM, V59, P385, DOI 10.1016/j.yrtph.2010.12.007; WANG ZX, 1995, J MED CHEM, V38, P3652, DOI 10.1021/jm00018a026; Weltrowska G, 2014, BIOORGAN MED CHEM, V22, P4581, DOI 10.1016/j.bmc.2014.07.033; Weltrowska G, 2010, J MED CHEM, V53, P2875, DOI 10.1021/jm9019068; WRIGHT WB, 1961, J ORG CHEM, V26, P485, DOI 10.1021/jo01061a049; Yuan SG, 2015, ANGEW CHEM INT EDIT, V54, P7560, DOI 10.1002/anie.201501742; Yuan SG, 2015, ANGEW CHEM INT EDIT, V54, P556, DOI 10.1002/anie.201409679; Yuan SG, 2013, ANGEW CHEM INT EDIT, V52, P10112, DOI 10.1002/anie.201302244; Zurcher M, 2008, J ORG CHEM, V73, P4345, DOI 10.1021/jo800527n; Zurcher M, 2008, CHEMMEDCHEM, V3, P237, DOI 10.1002/cmdc.200700236	92	3	3	0	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		1420-3049		MOLECULES	Molecules	FEB 2	2019	24	4							740	10.3390/molecules24040740			30	Biochemistry & Molecular Biology; Chemistry, Multidisciplinary	Biochemistry & Molecular Biology; Chemistry	HO3FS	WOS:000460805900086	30791394	DOAJ Gold, Green Published			2020-06-30	J	Ma, J; Li, WY; Chai, Q; Tan, XH; Zhang, KX				Ma, Jin; Li, Wenyao; Chai, Qing; Tan, Xiaohong; Zhang, Kexian			Correlation of P2RX7 gene rs1718125 polymorphism with postoperative fentanyl analgesia in patients with lung cancer	MEDICINE			English	Article						analgesics; fentanyl; P2RX7; polymorphism; postoperative pain	PAIN-CONTROL; RESECTION; SURGERY	The aim of this study was to investigate the association between purinergic receptor P2X7 (P2RX7) gene rs1718125 polymorphism and analgesic effect of fentanyl after surgery among patients with lung cancer in a Chinese Han population. A total of 238 patients with lung cancer who received resection were enrolled in our study. The genotype distributions of P2RX7 rs1718125 polymorphism were detected by polymerase chain reaction and direct sequencing. Postoperative analgesia was performed by patient-controlled intravenous analgesia, and the consumption of fentanyl was recorded. The postoperative pain was measured by visual analog scale (VAS). Differences in postoperative VAS score and postoperative fentanyl consumption for analgesia in different genotype groups were analyzed by analysis of variance assay. The frequencies of GG, GA, and AA genotypes were 46.22%, 44.96%, and 8.82%, respectively. After surgery, the postoperative VAS score of GA group was significantly high in the period of analepsia after general anesthesia and at 6 hours after surgery (P = .041 and P = .030, respectively), while AA group exhibited obviously high in the period of analepsia after general anesthesia (P < .001), at postoperative 6 hours (P = .006) and 24 hours (P = .016). Moreover, the patients carrying GA and AA genotypes needed more fentanyl to control pain within 48 hours after surgery (P < .05 for all). P2RX7 gene rs1718125 polymorphism is significantly associated with postoperative pain and fentanyl consumption in patients with lung cancer.	[Ma, Jin; Li, Wenyao; Chai, Qing; Tan, Xiaohong; Zhang, Kexian] Univ Elect Sci & Technol China, Sichuan Canc Hosp & Inst, Sch Med, Dept Anesthesiol,Sichuan Canc Ctr, Chengdu 610041, Sichuan, Peoples R China	Zhang, KX (reprint author), Univ Elect Sci & Technol China, Sichuan Canc Hosp & Inst, Sch Med, Dept Anesthesiol,Sichuan Canc Ctr, Chengdu 610041, Sichuan, Peoples R China.	zhixiahe2345@163.com					Amaya F, 2013, CURR NEUROPHARMACOL, V11, P592, DOI 10.2174/1570159X11311060003; Andreetti C, 2014, EUR J CARDIO-THORAC, V46, P907, DOI 10.1093/ejcts/ezu092; Bradley HJ, 2011, J BIOL CHEM, V286, P8176, DOI 10.1074/jbc.M110.211284; Burnstock G, 2013, EUR J PHARMACOL, V716, P24, DOI 10.1016/j.ejphar.2013.01.078; Choi EK, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000010156; Hawker GA, 2011, ARTHRIT CARE RES, V63, pS240, DOI 10.1002/acr.20543; Ide S, 2014, MOL PAIN, V10, DOI 10.1186/1744-8069-10-75; Imani Farnad, 2014, Anesth Pain Med, V4, pe12162, DOI 10.5812/aapm.12162; Imani Farnad, 2011, Anesth Pain Med, V1, P6, DOI 10.5812/kowsar.22287523.1810; Jung J, 2016, J THORAC DIS, V8, P1814, DOI 10.21037/jtd.2016.06.16; Kambur O, 2018, PAIN, V159, P1064, DOI 10.1097/j.pain.0000000000001188; Kim MK, 2007, BRIT J ANAESTH, V99, P270, DOI 10.1093/bja/aem146; Losanno T, 2017, EXPERT REV ANTICANC, V17, P787, DOI 10.1080/14737140.2017.1348232; Muraoka W, 2016, MOL PAIN, V12, DOI 10.1177/1744806916683182; Mwaka G, 2013, AFR HEALTH SCI, V13, P768, DOI 10.4314/ahs.v13i3.36; Nada EM, 2018, SAUDI J ANAESTH, V12, P250, DOI 10.4103/sja.SJA_625_17; Nicke A, 2009, J BIOL CHEM, V284, P25813, DOI 10.1074/jbc.M109.033134; Oosten AW, 2016, PHARMACOGENOMICS, V17, P1391, DOI 10.2217/pgs-2016-0082; Raffa RB, 2018, J CLIN PHARM THER, V43, P154, DOI 10.1111/jcpt.12640; Shroyer AL, 2017, ANN THORAC SURG, V104, P1650, DOI 10.1016/j.athoracsur.2017.05.066; Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254; Sluyter Ronald, 2017, Adv Exp Med Biol, V1051, P17, DOI 10.1007/5584_2017_59; Xie W, 2018, ACTA ANAESTH SCAND, V62, P376, DOI 10.1111/aas.13040; Zhang HD, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000006013; Zhang JL, 2018, GENE, V661, P78, DOI 10.1016/j.gene.2018.03.081; Zheng M, 2012, CURR OPIN ANESTHESIO, V25, P428, DOI 10.1097/ACO.0b013e32835561f9	26	2	2	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0025-7974	1536-5964		MEDICINE	Medicine (Baltimore)	FEB	2019	98	7							e14445	10.1097/MD.0000000000014445			5	Medicine, General & Internal	General & Internal Medicine	HQ4NV	WOS:000462389000032	30762755	DOAJ Gold, Green Published			2020-06-30	J	Dhummakupt, ES; Rizzo, GM; Feasel, M; Mach, PM; Tran, BQ; Carmany, DO; Demond, PS; McBride, EM; Maughan, M; Sekowski, JW; Glaros, T				Dhummakupt, Elizabeth S.; Rizzo, Gabrielle M.; Feasel, Michael; Mach, Phillip M.; Tran, Bao Q.; Carmany, Daniel O.; Demond, Paul S.; McBride, Ethan M.; Maughan, Michele; Sekowski, Jennifer W.; Glaros, Trevor			Proteomic and Metabolomic Profiling Identify Plasma Biomarkers for Exposure to Ultra-low Levels of Carfentanil	TOXICOLOGICAL SCIENCES			English	Article						carfentanil; biomarker; opioid; proteomics; metabolomics	ACUTE MYOCARDIAL-INFARCTION; MAJOR METABOLITES; HUMAN URINE; FENTANYL; IDENTIFICATION; SUFENTANIL; CHROMATOGRAPHY; REMIFENTANIL; ALFENTANIL; CASUALTIES	Despite the recent epidemic of fentanyl abuse, there are few validated assays capable of rapidly detecting these compounds. In order to improve the ability to detect carfentanil at physiologically relevant concentrations, we developed a systems biology approach to discover host-based markers which are specifically amplified upon exposure in a rabbit model. For this work, two omics pipelines utilizing mass spectrometry were developed and leveraged. First, a proteomics pipeline was developed to interrogate the blood plasma for protein-based biomarkers. Due to the incredible dynamic range of the plasma protein content, a multi-dimensional fractionation technique was used to partition and more accurately investigate the circulating plasma proteome. Isobaric tandem mass tags were integrated into the workflow to make quantitative assessments across all animals for an extended time course post-exposure. In addition to the proteomics efforts, blood plasma was also processed through an untargeted metabolomics pipeline. This approach allows for the identification of >800 small molecule features. By processing and analyzing data sets in parallel, we were able to identify a unique fingerprint of protein and metabolite perturbations that manifest following exposure to carfentanil.	[Dhummakupt, Elizabeth S.; Feasel, Michael; Mach, Phillip M.; McBride, Ethan M.; Sekowski, Jennifer W.; Glaros, Trevor] US Army, Biosci Div, BioDef Branch, Edgewood Chem Biol Ctr, Bldg E5183,8198 Blackhawk Rd, Aberdeen Proving Ground, MD 21010 USA; [Rizzo, Gabrielle M.; Tran, Bao Q.; Carmany, Daniel O.; Demond, Paul S.; Maughan, Michele] Excet Inc, Springfield, VA 22150 USA	Dhummakupt, ES; Glaros, T (reprint author), US Army, Biosci Div, BioDef Branch, Edgewood Chem Biol Ctr, Bldg E5183,8198 Blackhawk Rd, Aberdeen Proving Ground, MD 21010 USA.	elizabeth.s.dhummakupt.civ@mail.mil; trevor.g.glaros.civ@mail.mil		Feasel, Michael/0000-0001-7029-2764; Dhummakupt, Elizabeth/0000-0003-0116-5598	Chem-Bio Diagnostics program contract from the Department of Defense Chemical and Biological Defense program through the Defense Threat Reduction Agency (DTRA) [CB3810]	This work was supported by the Chem-Bio Diagnostics program contract (CB3810) from the Department of Defense Chemical and Biological Defense program through the Defense Threat Reduction Agency (DTRA) to J.W.S and T.G.	Tran BQ, 2018, J PROTEOME RES, V17, P479, DOI 10.1021/acs.jproteome.7b00642; BORISON HL, 1989, PROG NEUROBIOL, V32, P351, DOI 10.1016/0301-0082(89)90028-2; Bozinovski S, 2008, AM J RESP CRIT CARE, V177, P269, DOI 10.1164/rccm.200705-678OC; Casale JF, 2017, FORENSIC CHEM, V3, P74, DOI 10.1016/j.forc.2017.02.003; Cho KJ, 2011, MOL CELLS, V32, P1, DOI 10.1007/s10059-011-1021-7; Cole JB, 2015, PEDIATRICS, V135, pE740, DOI 10.1542/peds.2014-2878; Cox J, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471-2105-13-S16-S12; Doucette C., 2017, TORONTO SUN; Fisher AB, 2018, J LIPID RES, V59, P1132, DOI 10.1194/jlr.R082578; Fruehauf JP, 2007, CLIN CANCER RES, V13, P789, DOI 10.1158/1078-0432.CCR-06-2082; GALEN RS, 1975, JAMA-J AM MED ASSOC, V232, P145, DOI 10.1001/jama.232.2.145; GRANDY DK, 1990, MOL ENDOCRINOL, V4, P1370, DOI 10.1210/mend-4-9-1370; Haas B, 2011, J PROTEOMICS, V75, P229, DOI 10.1016/j.jprot.2011.06.028; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923; Kall L, 2007, NAT METHODS, V4, P923, DOI 10.1038/NMETH1113; Keshishian H, 2015, MOL CELL PROTEOMIC M, VM114; Kessner D, 2008, BIOINFORMATICS, V24, P2534, DOI 10.1093/bioinformatics/btn323; Krechetnikov A, 2012, BBC NEWS; Kroslak T, 2001, J BIOL CHEM, V276, P39772, DOI 10.1074/jbc.M106991200; Kumar KA, 2009, BIOTECHNOL APPL BIOC, V52, P121, DOI 10.1042/BA20070264; Kutukova N., 2003, ZAMOSKVORETSKIY COUR; Leary S.L., 2013, AVMA GUIDELINES EUTH; LING GSF, 1983, EUR J PHARMACOL, V86, P487; Liu YS, 2015, MOL SYST BIOL, V11, DOI 10.15252/msb.20145728; Mahipal SVK, 2007, BIOCHEM PHARMACOL, V74, P202, DOI 10.1016/j.bcp.2007.04.005; National Research Council, 2010, GUIDE CARE USE LAB A; NOMURA M, 1987, BRIT HEART J, V58, P29; Odum EP, 2018, DIABETES METAB SYND, V12, P141, DOI 10.1016/j.dsx.2017.12.001; Ostuni MA, 2010, FREE RADICAL BIO MED, V49, P900, DOI 10.1016/j.freeradbiomed.2010.06.021; Papsun D, 2017, J ANAL TOXICOL, V41, P777, DOI 10.1093/jat/bkx068; Philp M, 2018, DRUG TEST ANAL, V10, P95, DOI 10.1002/dta.2300; Pilch R, 2003, INT NEGOTIATION, V8, P577, DOI DOI 10.1163/1571806031310798; Pluskal T, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-395; Rhee SG, 2005, FREE RADICAL BIO MED, V38, P1543, DOI 10.1016/j.freeradbiomed.2005.02.026; Riches JR, 2012, J ANAL TOXICOL, V36, P647, DOI 10.1093/jat/bks078; Ruzycki S, 2016, J MED TOXICOL, V12, P185, DOI 10.1007/s13181-015-0509-5; Saunders AB, 2009, VET ANAESTH ANALG, V36, P449, DOI 10.1111/j.1467-2995.2009.00483.x; Schattauer SS, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00791-2; Schmitt A, 2015, BIOCHEM J, V471, P267, DOI 10.1042/BJ20141204; SCHWARTZ MK, 1992, CLIN CHIM ACTA, V206, P77, DOI 10.1016/0009-8981(92)90008-E; Seth P, 2018, AM J TRANSPLANT, V18, P1556, DOI 10.1111/ajt.14905; SHOOK JE, 1990, AM REV RESPIR DIS, V142, P895, DOI 10.1164/ajrccm/142.4.895; Skrabalova J, 2013, MINI-REV ORG CHEM, V10, P367, DOI 10.2174/1570193X113106660031; Tavernise S, 2002, NY TIMES; Thevis M, 2005, EUR J MASS SPECTROM, V11, P419, DOI 10.1255/ejms.761; Van Nimmen NFJ, 2004, J CHROMATOGR B, V804, P375, DOI 10.1016/j.jchromb.2004.01.044; VANBEVER WFM, 1976, ARZNEIMITTELFORSCH, V26, P1548; Wang LQ, 2006, J ANAL TOXICOL, V30, P335, DOI 10.1093/jat/30.5.335; Wang YX, 2011, PROTEOMICS, V11, P2019, DOI 10.1002/pmic.201000722; Wax PM, 2003, ANN EMERG MED, V41, P700, DOI 10.1067/mem.2003.148; WILHELMSEN L, 1984, NEW ENGL J MED, V311, P501, DOI 10.1056/NEJM198408233110804; Zhao HX, 2018, J PROTEOME RES, V17, P656, DOI 10.1021/acs.jproteome.7b00724	53	0	0	3	9	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	1096-6080	1096-0929		TOXICOL SCI	Toxicol. Sci.	FEB	2019	167	2					524	535		10.1093/toxsci/kfy259			12	Toxicology	Toxicology	HQ9KD	WOS:000462745400019	30321427				2020-06-30	J	Moyano, J; Aguirre, L				Moyano, Jairo; Aguirre, Luisa			Opioids in the immune system: from experimental studies to clinical practice	REVISTA DA ASSOCIACAO MEDICA BRASILEIRA			English	Review						Immunosuppression; Immune system; Surgical procedures operative; Analgesics; Analgesics opioid	KILLER-CELL CYTOTOXICITY; STRESS-RESPONSE; REMIFENTANIL; MORPHINE; TRAMADOL; ANESTHESIA; ANALGESIA; FENTANYL; PAIN; MODULATION	INTRODUCTION: Opioids interact with both innate and adaptive immune systems and have direct effects on opioid receptors located on immune cells. Research on this topic has provided evidence of the opioid influence on the immune response associated with surgical stress. The immunological effects of opioids are currently being investigated, particularly whether they influence the outcome of surgery or the underlying disease regarding important aspects like infection or cancer progression. This review addresses background research related to the influence of the opioid receptor on the immune system, the immunosuppressive effect associated with major opioids during the perioperative period, and their clinical relevance. The objective of the study was to review the effects of opioids on the immune system. Methods: A search strategy was conducted in PubMed, Embase, and the Cochrane databases using the terms "immunosuppression," "immune system," "surgical procedures," "analgesics," "opioids" and "perioperative care." Results: The immunosuppressive effect of opioids was identified over 30 years ago. They include signaling and acting directly through immune cells, including B and T lymphocytes, NK cells, monocytes, and macrophages, as well as activating the downstream pathways of the hypothalamic-pituitary-adrenal (HPA) axis leading to the production of immunosuppressive glucocorticoids in the peripheral and sympathetic nervous system.	[Moyano, Jairo; Aguirre, Luisa] Hosp Univ Fdn Santafe Bogota, Pain Serv, Anesthesia Dept, Ave 9 117-20, Bogota, Colombia	Moyano, J (reprint author), Hosp Univ Fdn Santafe Bogota, Pain Serv, Anesthesia Dept, Ave 9 117-20, Bogota, Colombia.	jairo_moyano@hotmail.com; luisafernanda.chirito@gmail.com		Moyano Acevedo, Jairo Ricardo/0000-0002-4534-4136			Alsina E, 2014, CURR PHARM DESIGN, V20, P5449, DOI 10.2174/1381612820666140325105723; Beilin B, 1996, ANESTH ANALG, V82, P492, DOI 10.1097/00000539-199603000-00011; Beilin B, 2005, CAN J ANAESTH, V52, P1035, DOI 10.1007/BF03021601; Boland JW, 2014, BRIT J CANCER, V111, P866, DOI 10.1038/bjc.2014.384; Brack A, 2011, J NEUROIMMUNE PHARM, V6, P490, DOI 10.1007/s11481-011-9290-7; Calvey TN, 2009, PRINCIPLES PRACTICE, DOI [10.1002/9781405194853, DOI 10.1002/9781405194853]; Cata JP, 2013, J CLIN ANESTH, V25, P255, DOI 10.1016/j.jclinane.2012.12.007; Cronin AJ, 2003, BRIT J ANAESTH, V91, P805, DOI 10.1093/bja/aeg273; Desborough JP, 2000, BRIT J ANAESTH, V85, P109, DOI 10.1093/bja/85.1.109; Dwyer JP, 2014, J GASTROEN HEPATOL, V29, P1356, DOI 10.1111/jgh.12560; Eisenstein TK, 1998, J NEUROIMMUNOL, V83, P36, DOI 10.1016/S0165-5728(97)00219-1; Fedesarrollo Fundacion Saldarriaga Concha, 2015, MIS COL ENV CIFR RET; FLORES LR, 1994, J PHARMACOL EXP THER, V268, P1129; Greco A, 2018, CRIT CARE MED, V46, P775, DOI 10.1097/01.ccm.0000529582.89047.1c; Hofbauer R, 2000, ACTA ANAESTH SCAND, V44, P1232, DOI 10.1034/j.1399-6576.2000.441008.x; Hyejin J, 2013, IMMUNOPHARM IMMUNOT, V35, P264, DOI 10.3109/08923973.2013.767346; Imani F, 2014, HEPAT MON, V14, DOI 10.5812/hepatmon.23539; Inagi T, 2015, J HOSP INFECT, V89, P61, DOI 10.1016/j.jhin.2014.10.001; Iwasaki Masae, 2015, Acta Anaesthesiol Taiwan, V53, P99, DOI 10.1016/j.aat.2015.07.002; Jacobs R, 1999, INT J IMMUNOPHARMACO, V21, P445, DOI 10.1016/S0192-0561(99)00025-9; Jamison RN, 2015, MAYO CLIN PROC, V90, P957, DOI 10.1016/j.mayocp.2015.04.010; Labuz D, 2006, J NEUROSCI, V26, P4350, DOI 10.1523/JNEUROSCI.4349-05.2006; Mandel JE, 2014, J CLIN ANESTH, V26, pS1, DOI 10.1016/j.jclinane.2013.11.003; Ninkovic J, 2013, AMINO ACIDS, V45, P9, DOI 10.1007/s00726-011-1163-0; Panerai AE, 1997, IMMUNOL TODAY, V18, P317, DOI 10.1016/S0167-5699(97)01045-1; Pasternak GW, 2013, PHARMACOL REV, V65, P1257, DOI 10.1124/pr.112.007138; Pathan H, 2012, BRIT J PAIN, V6, P11, DOI 10.1177/2049463712438493; Rittner HL, 2008, BRIT J ANAESTH, V101, P40, DOI 10.1093/bja/aen078; Sacerdote P, 2006, PALLIATIVE MED, V20, pS9, DOI 10.1191/0269216306pm1124oa; Sacerdote P, 1997, PAIN, V72, P325, DOI 10.1016/S0304-3959(97)00055-9; Sacerdote P, 2000, ANESTH ANALG, V90, P1411, DOI 10.1097/00000539-200006000-00028; Sacerdote P, 2003, ADV EXP MED BIOL, V521, P106; Sacerdote P, 2001, INT IMMUNOPHARMACOL, V1, P713, DOI 10.1016/S1567-5769(01)00005-4; Sacerdote P, 2012, CURR PHARM DESIGN, V18, P6034, DOI 10.2174/138161212803582496; Garcia JBS, 2012, REV BRAS ANESTESIOL, V62, P709, DOI 10.1016/S0034-7094(12)70169-1; Scott LJ, 2005, DRUGS, V65, P1793, DOI 10.2165/00003495-200565130-00007; Scott LJ, 2005, CNS DRUGS, V19, P1069, DOI 10.2165/00023210-200519120-00010; Vallejo Ricardo, 2004, Am J Ther, V11, P354, DOI 10.1097/01.mjt.0000132250.95650.85; Wang ZY, 2006, CLIN CHIM ACTA, V369, P40, DOI 10.1016/j.cca.2006.01.008; Wilhelm W, 2008, CRIT CARE, V12, DOI 10.1186/cc6152; WYBRAN J, 1979, J IMMUNOL, V123, P1068; Yardeni Israel Z, 2008, J Opioid Manag, V4, P27; YEAGER MP, 1995, ANESTHESIOLOGY, V83, P500, DOI 10.1097/00000542-199509000-00008; Yeager MP, 2002, ANESTH ANALG, V94, P94, DOI 10.1097/00000539-200201000-00018; Yokota T, 2000, CAN J ANAESTH, V47, P303, DOI 10.1007/BF03020942; Yokota Tetsuya, 2004, J Anesth, V18, P190	46	1	1	0	1	ASSOC MEDICA BRASILEIRA	SAO PAULO	RUA SAO CARLOS DO PINHAL 324, CAIXA POSTAL 8904, SAO PAULO, SP, BRAZIL		1806-9282		REV ASSOC MED BRAS	Rev. Assoc. Med. Bras.	FEB	2019	65	2					262	269		10.1590/1806-9282.65.2.262			8	Medicine, General & Internal	General & Internal Medicine	HP2BX	WOS:000461474100027	30892453	DOAJ Gold			2020-06-30	J	Oshikoya, KA; Wharton, GT; Avant, D; Van Driest, SL; Fenn, NE; Lardieri, A; Doe, E; Sood, BG; Taketomo, C; Lieu, P; Yen, L; McMahon, AW				Oshikoya, Kazeem A.; Wharton, Gerold T.; Avant, Debbie; Van Driest, Sara L.; Fenn, Norman E., III; Lardieri, Allison; Doe, Edwin; Sood, Beena G.; Taketomo, Carol; Phuong Lieu; Yen, Lilly; McMahon, Ann W.			Serious Adverse Events Associated with Off-Label Use of Azithromycin or Fentanyl in Children in Intensive Care Units: A Retrospective Chart Review	PEDIATRIC DRUGS			English	Review							DRUG-REACTIONS; MEDICINES	Half of prescription drugs commonly given to children lack product labeling on pediatric safety, efficacy, and dosing. Two drugs most widely used off-label in pediatrics are azithromycin and fentanyl. We sought to determine the risk of serious adverse events (SAEs) when oral azithromycin or intravenous/intramuscular fentanyl are used off-label compared to on-label in pediatric intensive care units (ICUs). Six pediatric hospitals participated in a retrospective chart review of patients administered oral azithromycin (n = 241) or intravenous/intramuscular fentanyl (n = 367) between January 5, 2013 and December 26, 2014. Outcomes were SAEs by drug and labeling status: off-label compared to on-label by Food and Drug Administration (FDA)-approved age and/or indication. Statistical analysis was performed using logistic regression to estimate odds ratios (ORs) and Cox regression to estimate hazard ratios (HRs). Twenty-one (9%) children receiving azithromycin experienced SAEs. Off-label use of azithromycin was not associated with a higher risk of SAE (OR 0.87, 95% CI 0.27-2.71, p = 0.81). Ninety-five (26%) children receiving fentanyl experienced SAEs. Fentanyl off-label use by both age and indication was not associated with a higher risk of overall SAEs compared to on-label use (OR 1.99, 95% CI 0.94-4.19, p = 0.07). However, the risk of the SAE respiratory depression was significantly greater when fentanyl was used off-label by both age and indication (OR 5.05, 95% CI 1.08-23.56, p = 0.044). Results based on HRs were similar. Azithromycin off-label use in pediatric ICUs does not appear to be associated with an increased risk of SAEs. Off-label use of fentanyl appears to be more frequently associated with respiratory depression when used off-label by both age and indication in pediatric ICUs. Prospective studies should be undertaken to assess the safety and efficacy of fentanyl in the pediatric population so that data can be added to the FDA labeling.	[Oshikoya, Kazeem A.; Van Driest, Sara L.] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA; [Wharton, Gerold T.; Avant, Debbie; McMahon, Ann W.] US FDA, Off Pediat Therapeut, Off Commissioner, 10903 New Hampshire Ave,Bldg 32,Room 5158, Silver Spring, MD 20993 USA; [Fenn, Norman E., III] Childrens Natl Hlth Syst, Washington, DC USA; [Lardieri, Allison] Univ Maryland, Childrens Hosp, Baltimore, MD 21201 USA; [Doe, Edwin] INOVA Childrens Hosp, Falls Church, VA USA; [Sood, Beena G.] Childrens Hosp Michigan, Detroit, MI 48201 USA; [Taketomo, Carol; Phuong Lieu; Yen, Lilly] Childrens Hosp Los Angeles, Los Angeles, CA 90027 USA	McMahon, AW (reprint author), US FDA, Off Pediat Therapeut, Off Commissioner, 10903 New Hampshire Ave,Bldg 32,Room 5158, Silver Spring, MD 20993 USA.	Ann.mcmahon@fda.hhs.gov		Fenn, Norm/0000-0002-5272-652X	Burroughs Wellcome FundBurroughs Wellcome Fund [IRSA 1015006];  [UL1 TR000445];  [T32 GM007569]	We thank Drs. Mark Levenson and Elande Baro for their guidance with the statistical analysis on this project. This work was supported by UL1 TR000445 to Vanderbilt University Medical Center, T32 GM007569 (KAO) and Burroughs Wellcome Fund IRSA 1015006 (SLV).	Aagaard L, 2015, BASIC CLIN PHARMACOL, V117, P215, DOI 10.1111/bcpt.12445; Agarwal S, 2010, PEDIATR CRIT CARE ME, V11, P568, DOI 10.1097/PCC.0b013e3181d8e405; Alamu JO, 2009, THESIS; [Anonymous], 2017, I SAFE MEDICATION PR; [Anonymous], 2017, BPCA PRIORITY LIST P; [Anonymous], 2017, ZITHR AZ PACK INS; [Anonymous], 2016, FENT CITR PACK INS; Bellis JR, 2014, BRIT J CLIN PHARMACO, V77, P545, DOI 10.1111/bcp.12222; Bellis JR, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-238; Brunton L.L., 2018, GOODMAN GILMANS PHAR; Corny J, 2016, PAED CHILD HEALT-CAN, V21, P83, DOI 10.1093/pch/21.2.83; Czaja Angela S, 2015, J Pediatr Pharmacol Ther, V20, P186, DOI 10.5863/1551-6776-20.3.186; Gill AM, 1996, ANN PHARMACOTHER, V30, P125, DOI 10.1177/106002809603000202; Horen B, 2002, BRIT J CLIN PHARMACO, V54, P665, DOI 10.1046/j.1365-2125.2002.t01-3-01689.x; Institute for Safe Medication Practices, 2014, QUARTERWATCH SPEC RE; Kabara Shizuko, 2015, Masui, V64, P799; Khan LM, 2013, SAUDI PHARM J, V21, P261, DOI 10.1016/j.jsps.2012.09.004; Prescilla RP, 2015, PEDIAT SEDATION OUTS, P125; Priyadharsini R, 2011, J PHARMACOL PHARMACO, V2, P277, DOI 10.4103/0976-500X.85957; Rashed AN, 2012, DRUG SAFETY, V35, P481, DOI 10.2165/11597920-000000000-00000; Rhoney Denise H., 2002, Pediatr Crit Care Med, V3, P129, DOI 10.1097/00130478-200204000-00007; Sachs AN, 2012, JAMA-J AM MED ASSOC, V307, P1914, DOI 10.1001/jama.2012.3435; Shah SS, 2007, ARCH PEDIAT ADOL MED, V161, P282, DOI 10.1001/archpedi.161.3.282; Silva DCB, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2012-001868; Tiwari Tejpratap, 2005, Morbidity and Mortality Weekly Report, V54, P1; Tobias JD, 2015, PEDIAT SEDATION OUTS, P125; Ufer M, 2004, PHARMACOEPIDEM DR S, V13, P147, DOI 10.1002/pds.858; Vazquez-Alvarez AO, 2017, BMC PHARMACOL TOXICO, V18, DOI 10.1186/s40360-017-0186-x	28	1	1	0	3	ADIS INT LTD	NORTHCOTE	5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND	1174-5878	1179-2019		PEDIATR DRUGS	Pediatr. Drugs	FEB	2019	21	1					47	58		10.1007/s40272-018-0318-9			12	Pediatrics; Pharmacology & Pharmacy	Pediatrics; Pharmacology & Pharmacy	HM1BR	WOS:000459183400006	30484072	Green Accepted			2020-06-30	J	Romeiser, JL; Labriola, J; Meliker, JR				Romeiser, Jamie L.; Labriola, Jake; Meliker, Jaymie R.			Geographic patterns of prescription opioids and opioid overdose deaths in New York State, 2013-2015	DRUG AND ALCOHOL DEPENDENCE			English	Article						Mortality; Prescription opioids; New York State; Spatial patterns	UNITED-STATES; DRUG; INCREASES	Objectives: To examine the relationship between prescription opioid rates and prescription opioid overdose deaths using spatial cluster and regression analyses. Methods: Publicly available county-level data were obtained from the New York State Health Department and the Centers for Disease Control and Prevention, 2013-2015. Kulldorffs spatial scan statistic was used to investigate spatial clustering of New York State opioid prescription overdose death rates, as well as opioid prescription rates. A Poisson regression was used to analyze opioid prescriptions as a predictor of mortality accounting for spatial autocorrelation in the residuals. Results: We report 1440 overdose mortalities and 26.8 million opioid prescriptions throughout New York State in 2013-2015. Multiple significant clusters were found for both opioid prescription mortalities as well as prescriptions, although the locations of the elevated rates did not strongly overlap. Poisson regression showed a significant, small, negative relationship between prescriptions and opioid mortalities, wherein for every 10,000 prescriptions increased, the number of opioid mortalities decreased approximately 0.12%; therefore, essentially a null relationship. Conclusions: Simply reducing the number of prescriptions may not be effective in reducing prescription related mortality; although opioid prescription dosing information should be made available to engender a better evaluation of the epidemic. Geographical differences in opioid mortalities exist above and beyond what can be explained by prescription rate data; identifying these locations may help inform and guide public health interventions. Despite the recent reduction in opioid prescription rates, the overall population is still inundated with prescriptions.	[Romeiser, Jamie L.; Labriola, Jake; Meliker, Jaymie R.] SUNY Stony Brook, Dept Family Populat & Prevent Med, Program Publ Hlth, Stony Brook, NY 11794 USA; [Romeiser, Jamie L.] SUNY Stony Brook, Dept Anesthesiol, Stony Brook, NY 11794 USA	Romeiser, JL (reprint author), SUNY Stony Brook, Dept Family Populat & Prevent Med, Program Publ Hlth, Stony Brook, NY 11794 USA.	Jamie.Romeiser@stonybrookmedicine.edu					Baumblatt JAG, 2014, JAMA INTERN MED, V174, P796, DOI 10.1001/jamainternmed.2013.12711; Center for Disease Control and Prevention, 2017, ANN SURV REP DRUG RE; Center for Disease Control and Prevention, 2017, OP DAT AN RES; Center for Disease Control and Prevention, 2017, PRESCR OP DRUG OV DA; [Centers for Disease Control and Prevention HAN Health Advisory], 2015, HAN HLTH ADV; Centers for Disease Control and Prevention, 2017, US PRESCR RAT MAPS; Cerda M, 2017, ADDICTION, V112, P103, DOI 10.1111/add.13543; Gladden RM, 2016, MMWR-MORBID MORTAL W, V65, P837, DOI 10.15585/mmwr.mm6533a2; Gladstone EJ, 2015, MED CARE, V53, P954, DOI 10.1097/MLR.0000000000000431; Gomes Tara, 2011, Healthc Q, V14, P22; Green TC, 2013, J URBAN HEALTH, V90, P758, DOI 10.1007/s11524-012-9784-5; McDonald DC, 2012, J PAIN, V13, P988, DOI 10.1016/j.jpain.2012.07.007; New York State Department of Health, 2018, OP REL DAT NEW YORK; Rossen LM, 2014, HEALTH PLACE, V26, P14, DOI 10.1016/j.healthplace.2013.11.005; Rudd RA, 2016, MMWR-MORBID MORTAL W, V65, P1445, DOI 10.15585/mmwr.mm655051e1; Rudd RA, 2016, MMWR-MORBID MORTAL W, V64, P1378, DOI 10.15585/mmwr.mm6450a3; Schuchat A, 2017, JAMA-J AM MED ASSOC, V318, P425, DOI 10.1001/jama.2017.8913; Seth P, 2018, AM J PUBLIC HEALTH, V108, P500, DOI 10.2105/AJPH.2017.304265; Sherman RL, 2014, PREV CHRONIC DIS, V11, DOI 10.5888/pcd11.130264; Stewart K, 2017, J URBAN HEALTH, V94, P572, DOI 10.1007/s11524-017-0177-7	20	4	4	0	2	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0376-8716	1879-0046		DRUG ALCOHOL DEPEN	Drug Alcohol Depend.	FEB 1	2019	195						94	100		10.1016/j.drugalcdep.2018.11.027			7	Substance Abuse; Psychiatry	Substance Abuse; Psychiatry	HL4QV	WOS:000458709100015	30605866				2020-06-30	J	Nemeth, M; Jacobsen, N; Bantel, C; Fieler, M; Sumpelmann, R; Eich, C				Nemeth, Marcus; Jacobsen, Nils; Bantel, Carsten; Fieler, Melanie; Suempelmann, Robert; Eich, Christoph			Intranasal Analgesia and Sedation in Pediatric Emergency Care-A Prospective Observational Study on the Implementation of an Institutional Protocol in a Tertiary Children's Hospital	PEDIATRIC EMERGENCY CARE			English	Article						intranasal; analgesia; sedation	RANDOMIZED CONTROLLED-TRIAL; INTRAVENOUS MORPHINE; PROCEDURAL SEDATION; S-KETAMINE; FENTANYL; PAIN; MIDAZOLAM; RELIABILITY; VALIDITY; SCALE	Objectives Children presenting with acute traumatic pain or in need of therapeutic or diagnostic procedures require rapid and effective analgesia and/or sedation. Intranasal administration (INA) promises to be a reliable, minimally invasive delivery route. However, INA is still underused in Germany. We hence developed a protocol for acute pain therapy (APT) and urgent analgesia and/or sedation (UAS). Our aim was to evaluate the effectiveness and safety of our protocol. Methods We performed a prospective observational study in a tertiary children's hospital in Germany. Pediatric patients aged 0 to 17 years requiring APT or UAS were included. Fentanyl, s-ketamine, midazolam, or combinations were delivered according to protocol. Primary outcome variables included quality of analgesia and/or sedation as measured on age-appropriate scales and time to onset of drug action. Secondary outcomes were adverse events and serious adverse events. Results One hundred pediatric patients aged 0.3 to 16 years were enrolled, 34 for APT and 66 for UAS. The median time onset of drug action was 5 minutes (ranging from 2 to 15 minutes). Fentanyl was most frequently used for APT (n = 19). Pain scores decreased by a median of 4 points (range, 0-10; P < 0.0001). For UAS, s-ketamine/midazolam was most frequently used (n = 25). Sedation score indicated minimal sedation in most cases. Overall success rate after the first attempt was 82%. Adverse events consisted of nasal burning (n = 2) and vomiting (n = 2). No serious adverse events were recorded. Conclusions A fentanyl-, s-ketamine-, and midazolam-based INA protocol was effective and safe for APT and UAS. It should then be considered where intravenous access is impossible or inappropriate.	[Nemeth, Marcus; Eich, Christoph] Bult Childrens Hosp, Dept Anesthesia Pediat Intens Care & Emergency Me, Janusz Korczak Allee 12, D-30173 Hannover, Germany; [Nemeth, Marcus] Bult Childrens Hosp, Dept Pediat, Hannover, Germany; [Jacobsen, Nils; Bantel, Carsten] Klinikum Oldenburg, Univ Dept Anesthesiol Crit Care Emergency & Pain, Oldenburg, Germany; [Fieler, Melanie; Suempelmann, Robert] Hannover Med Sch, Clin Anesthesiol & Intens Care Med, Hannover, Germany	Nemeth, M (reprint author), Bult Childrens Hosp, Dept Anesthesia Pediat Intens Care & Emergency Me, Janusz Korczak Allee 12, D-30173 Hannover, Germany.	marcus.nemeth@t-online.de	Nemeth, Marcus/AAJ-1486-2020				Alexander J, 2003, ANN EMERG MED, V41, P617, DOI 10.1067/mem.2003.138; Andolfatto G, 2013, ACAD EMERG MED, V20, P1050, DOI 10.1111/acem.12229; Borland M, 2007, ANN EMERG MED, V49, P335, DOI 10.1016/j.annemergmed.2006.06.016; Borland ML, 2008, EMERG MED AUSTRALAS, V20, P515, DOI 10.1111/j.1742-6723.2008.01138.x; Borland ML, 2005, BURNS, V31, P831, DOI 10.1016/j.burns.2005.05.001; Buttner W, 2000, PAEDIATR ANAESTH, V10, P303, DOI 10.1046/j.1460-9592.2000.00530.x; Chiaretti A, 2011, ARCH DIS CHILD, V96, P160, DOI 10.1136/adc.2010.188433; Del Pizzo J, 2014, PEDIATR EMERG CARE, V30, P496, DOI 10.1097/PEC.0000000000000171; Galinkin JL, 2000, ANESTHESIOLOGY, V93, P1378, DOI 10.1097/00000542-200012000-00006; Graudins A, 2015, ANN EMERG MED, V65, P248, DOI 10.1016/j.annemergmed.2014.09.024; Hansen SL, 2001, J BURN CARE REHABIL, V22, P6, DOI 10.1097/00004630-200101000-00003; Hicks CL, 2001, PAIN, V93, P173, DOI 10.1016/S0304-3959(01)00314-1; Holdgate A, 2010, ACAD EMERG MED, V17, P214, DOI 10.1111/j.1553-2712.2009.00636.x; Kennedy Robert M, 2008, Pediatrics, V122 Suppl 3, pS130, DOI 10.1542/peds.2008-1055e; Lane RD, 2008, PEDIATR EMERG CARE, V24, P300, DOI 10.1097/PEC.0b013e31816ecb6f; Malviya S, 2006, PEDIATR ANESTH, V16, P258, DOI 10.1111/j.1460-9592.2005.01773.x; Malviya S, 2002, BRIT J ANAESTH, V88, P241, DOI 10.1093/bja/88.2.241; Mudd S, 2011, J PEDIATR HEALTH CAR, V25, P316, DOI 10.1016/j.pedhc.2010.04.011; Nielsen BN, 2014, PEDIATR ANESTH, V24, P170, DOI 10.1111/pan.12268; Regan L, 2013, EMERG MED J, V30, P49, DOI 10.1136/emermed-2011-200970; REY E, 1991, EUR J CLIN PHARMACOL, V41, P355, DOI 10.1007/BF00314967; Rickard C, 2007, AM J EMERG MED, V25, P911, DOI 10.1016/j.ajem.2007.02.027; Schmidt AP, 2007, PEDIATR ANESTH, V17, P667, DOI 10.1111/j.1460-9592.2006.02185.x; Smith I, 2011, EUR J ANAESTH, V28, P556, DOI 10.1097/EJA.0b013e3283495ba1; Tsze DS, 2012, PEDIATR EMERG CARE, V28, P767, DOI 10.1097/PEC.0b013e3182624935; Weber F, 2004, PEDIATR ANESTH, V14, P983, DOI 10.1111/j.1460-9592.2004.01358.x; Weber F, 2003, CAN J ANAESTH, V50, P470, DOI 10.1007/BF03021058	27	4	4	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0749-5161	1535-1815		PEDIATR EMERG CARE	Pediatr. Emerg. Care	FEB	2019	35	2					89	95		10.1097/PEC.0000000000001017			7	Emergency Medicine; Pediatrics	Emergency Medicine; Pediatrics	HL2SD	WOS:000458555400011	28121974				2020-06-30	J	Naja, Z; Kanawati, S; El Khatib, Z; Ziade, F; Nasreddine, R; Naja, AS				Naja, Zoher; Kanawati, Saleh; El Khatib, Ziad; Ziade, Fouad; Nasreddine, Rakan; Naja, Ahmad Salah			Three versus five lumbar paravertebral injections for inguinal hernia repair in the elderly: a randomized double-blind clinical trial	JOURNAL OF ANESTHESIA			English	Article						Nerve block; Postoperative pain; Geriatric anesthesia	PERIPHERAL-NERVE BLOCKS; GENERAL-ANESTHESIA; SPINAL-ANESTHESIA; HERNIORRHAPHY; ANALGESIA; RECOVERY; SEDATION; DELIRIUM; ANATOMY; PLEXUS	PurposeThe objective of the study was to compare three nerve stimulator-guided paravertebral injections versus five injections for elderly patients undergoing inguinal hernia repair in terms of the amount of intraoperative fentanyl and propofol consumption and conversion to general anesthesia. The secondary objective was postoperative pain.MethodsA prospective, randomized, double-blind clinical trial was performed. 200 elderly patients undergoing unilateral herniorrhaphy were randomized into two groups. Group III received three PVB injections from T-12 to L-2 and placebo at T-11 and L-3. Group V received five PVB injections from T-11 to L-3.ResultsThe mean intraoperative fentanyl and propofol consumption were significantly lower in group V (4.97.2 mu g versus 20.012.9 mu g and 5.7 +/- 11.6mg versus 34.6 +/- 22.9mg, respectively, p value<0.0001). Five patients (5.0%) in group III had failed block and were converted to general anesthesia (p value=0.024). Group V had significantly lower pain scores compared to group III during the first three postoperative days (p value<0.0001).Conclusion The five PVB injection technique is more suitable as a sole anesthetic technique for elderly patients undergoing herniorrhaphy, since it required less intraoperative supplemental analgesia and provided lower postoperative pain scores compared to the three PVB injection technique.Trial registration Clinicaltrials.gov identifier: NCT02537860.	[Naja, Zoher; Kanawati, Saleh] Makassed Gen Hosp, Anesthesia & Pain Management Dept, POB 11-6301, Beirut 11072210, Lebanon; [El Khatib, Ziad] Makassed Gen Hosp, Surg Dept, Beirut, Lebanon; [Ziade, Fouad] Lebanese Univ, Fac Publ Hlth, Beirut, Lebanon; [Nasreddine, Rakan; Naja, Ahmad Salah] Amer Univ, Beirut Med Ctr, Beirut, Lebanon	Naja, Z (reprint author), Makassed Gen Hosp, Anesthesia & Pain Management Dept, POB 11-6301, Beirut 11072210, Lebanon.	zouhnaja@yahoo.com					Agarwal A, 2009, INDIAN J ANAESTH, V53, P543; Al-Dabbagh AKR, 2002, SURG RADIOL ANAT, V24, P102, DOI 10.1007/s00276-002-0006-9; Allen Douglas J, 2002, Proc (Bayl Univ Med Cent), V15, P369; Awad IT, 2005, REGION ANESTH PAIN M, V30, P143, DOI 10.1016/j.rapm.2004.11.006; Bay-Nielsen M, 2008, ACTA ANAESTH SCAND, V52, P169, DOI 10.1111/j.1399-6576.2007.01514.x; Bhattacharya P, 2010, ACTA ANAESTH SCAND, V54, P246, DOI 10.1111/j.1399-6576.2009.02128.x; Cepeda MS, 2003, CLIN PHARMACOL THER, V74, P102, DOI 10.1016/S0009-9236(03)00152-8; CONZEN P, 1995, ANAESTHESIA, V50, P29, DOI 10.1111/j.1365-2044.1995.tb06187.x; Fredman B, 1998, J CLIN ANESTH, V10, P623, DOI 10.1016/S0952-8180(98)00099-3; Hadzic A, 2006, ANESTH ANALG, V102, P1076, DOI 10.1213/01.ane.0000196532.56221.f2; Jin F, 2001, BRIT J ANAESTH, V87, P608, DOI 10.1093/bja/87.4.608; Karmakar MK, 2001, ANESTHESIOLOGY, V95, P771, DOI 10.1097/00000542-200109000-00033; Kehlet H, 2001, ANESTH ANALG, V93, P1367; Kirchmair L, 2008, REGION ANESTH PAIN M, V33, P109, DOI 10.1016/j.rapm.2007.07.016; Klaassen Z, 2011, CLIN ANAT, V24, P454, DOI 10.1002/ca.21098; Klein SM, 2002, REGION ANESTH PAIN M, V27, P476, DOI 10.1053/rapm.2002.35147; Klein SM, 1998, REGION ANESTH PAIN M, V23, P306, DOI 10.1016/S1098-7339(98)90059-1; Liu JL, 2014, CLIN INTERV AGING, V9, P341, DOI 10.2147/CIA.S56116; Naja M. Z., 2001, Middle East Journal of Anesthesiology, V16, P201; Naja MZ, 2003, EUR J ANAESTH, V20, P897, DOI 10.1097/00003643-200311000-00007; Naja MZ, 2004, ANAESTHESIA, V59, P459, DOI 10.1111/j.1365-2044.2004.03705.x; Naja ZM, 2006, ANAESTHESIA, V61, P1064, DOI 10.1111/j.1365-2044.2006.04833.x; Naja ZM, 2006, REGION ANESTH PAIN M, V31, P196, DOI 10.1016/j.rapm.2005.12.004; Naja ZM, 2005, ANESTHESIOLOGY, V103, P600, DOI 10.1097/00000542-200509000-00024; Neufeld KJ, 2013, ANESTH ANALG, V117, P471, DOI 10.1213/ANE.0b013e3182973650; Nordin P, 2003, LANCET, V362, P853, DOI 10.1016/S0140-6736(03)14339-5; Ozkan D, 2009, REGION ANESTH PAIN M, V34, P312, DOI 10.1097/AAP.0b013e3181ae1169; Pandhare SR, 2013, INT J CURR RES REV, V5, P69; Richardson J, 1998, BRIT J ANAESTH, V81, P230; Saito T, 1996, REGION ANESTH, V21, P304; Sieber FE, 2010, MAYO CLIN PROC, V85, P18, DOI 10.4065/mcp.2009.0469; Steinmetz J, 2010, MINERVA ANESTESIOL, V76, P745; Wassef MR, 1998, REGION ANESTH PAIN M, V23, P451, DOI 10.1016/S1098-7339(98)90026-8; Weltz CR, 2003, WORLD J SURG, V27, P425, DOI 10.1007/s00268-002-6661-5; White PF, 2006, ANESTH ANALG, V102, P1073, DOI 10.1213/01.ANE.0000214179.44007.5F	35	2	2	0	1	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	0913-8668	1438-8359		J ANESTH	J. Anesth.	FEB	2019	33	1					50	57		10.1007/s00540-018-2582-9			8	Anesthesiology	Anesthesiology	HK5EY	WOS:000457989100007	30446826				2020-06-30	J	Kalaydjian, A; Farah, F; Cheng, Y; Acquadro, MA; Gerges, FJ				Kalaydjian, Antranig; Farah, Fadi; Cheng, Yuen; Acquadro, Martin A.; Gerges, Frederic J.			Opioid Induced Hyperalgesia with Intrathecal Infusion of High-Dose Fentanyl	PAIN PRACTICE			English	Article						hyperalgesia; infusion pumps; implantable; intrathecal; low back pain; recurrent; opioid receptors		Introduction Despite being reported since 1943 as well as being the subject of a large body of literature since that time, no consensus has been reached regarding the etiology of opioid induced hyperalgesia (OIH). It is often described as a paradoxical increased pain response to noxious stimuli due to increased sensitization or an acute tolerance to opioids. Case We report the case of a 60 year old patient on chronic Intrathecal combined fentanyl and Bupivacaine who had worsening pain with increasing doses and improved after weaning off intrathecal opioids. Conclusion OIH has been described in various settings including patients on methadone maintenance therapy, perioperative opioid administration, cancer patients on opioids, and healthy volunteers who are acutely exposed to opioids, including high dose intrathecal opioids such as Morphine and Sufentanil. To our knowledge, no cases of opioid induced hyperalgesia was previously reported in the case of intrathecal Fentanyl.	[Kalaydjian, Antranig; Farah, Fadi; Cheng, Yuen] St Elizabeth Hosp, Dept Anesthesiol Crit Care & Pain Med, Boston, MA USA; [Kalaydjian, Antranig; Farah, Fadi; Cheng, Yuen; Gerges, Frederic J.] Tufts Univ, Sch Med, Boston, MA 02111 USA; [Acquadro, Martin A.] Tufts Univ, Sch Med, Anesthesiol, Boston, MA 02111 USA; [Acquadro, Martin A.; Gerges, Frederic J.] St Elizabeths Pain Management Ctr, Dept Anesthesiol Crit Care & Pain Med, Boston, MA USA	Kalaydjian, A (reprint author), St Elizabeths Med Ctr, Dept Anesthesiol Crit Care & Pain Med, 736 Cambridge St, Boston, MA 02135 USA.	akalaydjian@gmail.com					Andrews HL, 1943, J CLIN INVEST, V22, P511, DOI 10.1172/JCI101420; DECONNO F, 1991, PAIN, V47, P337, DOI 10.1016/0304-3959(91)90225-M; Devulder J, 1997, J NEUROSURG ANESTH, V9, P146, DOI 10.1097/00008506-199704000-00007; SOrensen J, 2013, CANC PAIN, P131; Varrassi G, 2018, PAIN THER, V7, P59, DOI 10.1007/s40122-018-0094-9; Wilson George R, 2003, Am J Hosp Palliat Care, V20, P459, DOI 10.1177/104990910302000608	6	1	1	1	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1530-7085	1533-2500		PAIN PRACT	Pain Pract.	FEB	2019	19	2					222	223		10.1111/papr.12726			2	Anesthesiology; Clinical Neurology	Anesthesiology; Neurosciences & Neurology	HK3PZ	WOS:000457830700010	30267637				2020-06-30	J	King, A; Foley, D; Arfken, C; Aaron, C; Sung, L; Hlavaty, L				King, Andrew; Foley, Daniel; Arfken, Cynthia; Aaron, Cynthia; Sung, Lokman; Hlavaty, Leigh			Carfentanil-Associated Mortality in Wayne County, Michigan, 2015-2017	AMERICAN JOURNAL OF PUBLIC HEALTH			English	Article							FENTANYL EPIDEMIC; DEATHS	Objectives. To identify opioids associated with a spike in opioid-related mortality in Wayne County, Michigan, from July 2016 through February 2017. Methods. We reviewed records from the Wayne County Medical Examiner's Office of 645 people who died because of accidental nonmedically prescribed opioid overdoses from July 2015 through July 2017. We analyzed basic demographics, locations of death, and all opioid toxicology results. Decedents who died in hospitals were excluded. Results. Of the 645 people who died because of nonmedically prescribed opioid overdoses, 65% were male and 63% were White, with an average age of 43 years. Carfentanil was detected in 129 (20%) cases. During the 8-month mortality spike, carfentanil was detected in 114 of 419 cases (average = 27.2%; range = 6.4%-45.2%). Substances most frequently detected with carfentanil included morphine (57%), 6-monoacetylmorphine (38%), fentanyl (43%), norfentanyl (33%), tetrahydrocannabinol (34%), and cocaine (29%). Conclusions. The Wayne County spike in mortality temporally corresponded with the detection of carfentanil and a proportional increase in opioid overdose deaths with detectable carfentanil. Public Health Implications. The abrupt decrease in carfentanil-detected mortality coincided with an announcement indicating an impending ban on fentanyl analogs from China, which suggests that source control is an effective countermeasure.	[King, Andrew; Foley, Daniel; Aaron, Cynthia] Wayne State Univ, Sch Med, Dept Emergency Med, Detroit, MI USA; [King, Andrew; Aaron, Cynthia] Michigan Reg Poison Control Ctr, Detroit, MI USA; [Arfken, Cynthia] Wayne State Univ, Sch Med, Dept Psychiat & Behav Neurosci, Detroit, MI USA; [Sung, Lokman; Hlavaty, Leigh] Wayne Cty Med Examiner Off, Detroit, MI USA	King, A (reprint author), 4707 St Antoine St,Suite 302, Detroit, MI 48201 USA.	aking@dmc.org					Algren DA, 2013, J MED TOXICOL, V9, P106, DOI 10.1007/s13181-012-0285-4; Dasgupta N, 2018, AM J PUBLIC HEALTH, V108, P182, DOI 10.2105/AJPH.2017.304187; Drug Enforcement Administration Strategic Intelligence Section, 2016, NAT HER THREAT ASS S; George AV, 2010, AM J EMERG MED, V28, P530, DOI 10.1016/j.ajem.2010.03.003; HIBBS J, 1991, JAMA-J AM MED ASSOC, V265, P1011, DOI 10.1001/jama.265.8.1011; Jones T. S., 2008, Morbidity and Mortality Weekly Report, V57, P793; Kinetz E, 2017, NON TRADITIONAL REF; Schumann H, 2008, CLIN TOXICOL, V46, P501, DOI 10.1080/15563650701877374; SMIALEK JE, 1994, J FORENSIC SCI, V39, P159	9	1	1	0	3	AMER PUBLIC HEALTH ASSOC INC	WASHINGTON	800 I STREET, NW, WASHINGTON, DC 20001-3710 USA	0090-0036	1541-0048		AM J PUBLIC HEALTH	Am. J. Public Health	FEB	2019	109	2					300	302		10.2105/AJPH.2018.304814			3	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	HK4AK	WOS:000457861300045	30571306				2020-06-30	J	Frey, TM; Florin, TA; Caruso, M; Zhang, NH; Zhang, Y; Mittiga, MR				Frey, Theresa M.; Florin, Todd A.; Caruso, Michelle; Zhang, Nanhua; Zhang, Yin; Mittiga, Matthew R.			Effect of Intranasal Ketamine vs Fentanyl on Pain Reduction for Extremity Injuries in Children The PRIME Randomized Clinical Trial	JAMA PEDIATRICS			English	Article							VISUAL ANALOG SCALE; EMERGENCY-DEPARTMENT; DOSE KETAMINE; LIMB INJURY; ANALGESIA; MORPHINE; IBUPROFEN; SEDATION; RELIABILITY; MANAGEMENT	IMPORTANCE Timely analgesia is critical for children with injuries presenting to the emergency department, yet pain control efforts are often inadequate. Intranasal administration of pain medications provides rapid analgesia with minimal discomfort. Opioids are historically used for significant pain from traumatic injuries but have concerning adverse effects. Intranasal ketamine may provide an effective alternative. OBJECTIVE To determine whether intranasal ketamine is noninferior to intranasal fentanyl for pain reduction in children presenting with acute extremity injuries. DESIGN, SETTING, AND PARTICIPANTS The Pain Reduction With Intranasal Medications for Extremity Injuries (PRIME) trial was a double-blind, randomized, active-control, noninferiority trial in a pediatric, tertiary, level 1 trauma center. Participants were children aged 8 to 17 years presenting to the emergency department with moderate to severe pain due to traumatic limb injuries between March 2016 and February 2017. Analyses were intention to treat and began in May 2017. INTERVENTIONS Intranasal ketamine (1.5mg/kg) or intranasal fentanyl (2 mu g/kg). MAIN OUTCOMES AND MEASURES The primary outcome was reduction in visual analog scale pain score 30 minutes after intervention. The noninferiority margin for this outcome was 10. RESULTS Of 90 children enrolled, 45 (50%) were allocated to ketamine (mean [SD] age, 11.8 [2.6] years; 26 boys [59%]) and 45 (50%) to fentanyl (mean [SD] age, 12.2 [2.3] years; 31 boys [74%]). Thirty minutes after medication, the mean visual analog scale reduction was 30.6 mm(95% CI, 25.4-35.8) for ketamine and 31.9 mm (95% CI, 26.6-37.2) for fentanyl. Ketamine was noninferior to fentanyl for pain reduction based on a 1-sided test of group difference less than the noninferiority margin, as the CIs crossed 0 but did not cross the prespecified noninferiority margin (difference in mean pain reduction between groups, 1.3; 90% CI, -6.2 to 8.7). The risk of adverse events was higher in the ketamine group (relative risk, 2.5; 95% CI, 1.5-4.0), but all events were minor and transient. Rescue analgesia was similar between groups (relative risk, 0.89; 95% CI, 0.5-1.6). CONCLUSIONS AND RELEVANCE Ketamine provides effective analgesia that is noninferior to fentanyl, although participants who received ketamine had an increase in adverse events that were minor and transient. Intranasal ketamine may be an appropriate alternative to intranasal fentanyl for pain associated with acute extremity injuries. Ketamine should be considered for pediatric pain management in the emergency setting, especially when opioids are associated with increased risk.	[Frey, Theresa M.; Florin, Todd A.; Zhang, Nanhua; Mittiga, Matthew R.] Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati, OH USA; [Frey, Theresa M.; Florin, Todd A.; Mittiga, Matthew R.] Cincinnati Childrens Hosp Med Ctr, Div Emergency Med, Cincinnati, OH 45229 USA; [Florin, Todd A.] Northwestern Univ, Feinberg Sch Med, Dept Pediat, Chicago, IL 60611 USA; [Florin, Todd A.] Ann & Robert H Lurie Childrens Hosp Chicago, Div Emergency Med, Chicago, IL 60611 USA; [Caruso, Michelle] Cincinnati Childrens Hosp Med Ctr, Div Pharm, Emergency Med, Cincinnati, OH 45229 USA; [Zhang, Nanhua; Zhang, Yin] Cincinnati Childrens Hosp Med Ctr, Div Biostat & Epidemiol, Cincinnati, OH 45229 USA	Frey, TM (reprint author), Univ Cincinnati, Cincinnati Childrens Hosp Med Ctr, Coll Med, Div Emergency Med,Dept Pediat, 3333 Burnet Ave,MLC 2008, Cincinnati, OH 45229 USA.	theresa.frey@cchmc.org		Florin, Todd/0000-0002-4387-2605	Division of Emergency Medicine at Cincinnati Children's Hospital Medical Center; American Academy of Pediatrics Section on Emergency Medicine through the 2016 Ken Graff Young Investigator Award	This work was supported by funding from the Division of Emergency Medicine at Cincinnati Children's Hospital Medical Center, where the trial was completed, and by American Academy of Pediatrics Section on Emergency Medicine through the 2016 Ken Graff Young Investigator Award.	American Heart Association, 2016, PALS PROV MAN EBOOK; Andolfatto G, 2013, ACAD EMERG MED, V20, P1050, DOI 10.1111/acem.12229; Bailey B, 2012, PAIN, V153, P839, DOI 10.1016/j.pain.2012.01.006; Beik N, 2016, PHARM PHARM, V7, P19, DOI [10.4236/pp.2016.71003, DOI 10.4236/PP.2016.71003]; Bhatt M, 2017, JAMA PEDIATR, V171, P957, DOI 10.1001/jamapediatrics.2017.2135; Bijur PE, 2005, ANN EMERG MED, V46, P362, DOI 10.1016/j.annemergmed.2005.03.010; Bijur PE, 2001, ACAD EMERG MED, V8, P1153, DOI 10.1111/j.1553-2712.2001.tb01132.x; Boccio E, 2014, AM J EMERG MED, V32, P1516, DOI 10.1016/j.ajem.2014.09.025; Bowers KJ, 2017, ACAD EMERG MED, V24, P676, DOI 10.1111/acem.13172; Bredmose PP, 2009, ACTA ANAESTH SCAND, V53, P543, DOI 10.1111/j.1399-6576.2008.01852.x; Clark E, 2007, PEDIATRICS, V119, P460, DOI 10.1542/peds.2006-1347; Craven R, 2007, ANAESTHESIA, V62, P48, DOI 10.1111/j.1365-2044.2007.05298.x; Del Pizzo J, 2014, PEDIATR EMERG CARE, V30, P496, DOI 10.1097/PEC.0000000000000171; Dong L, 2012, PEDIATR EMERG CARE, V28, P109, DOI 10.1097/PEC.0b013e3182442c25; Drendel AL, 2009, ANN EMERG MED, V54, P553, DOI 10.1016/j.annemergmed.2009.06.005; Friday JH, 2009, ACAD EMERG MED, V16, P711, DOI 10.1111/j.1553-2712.2009.00471.x; Gallagher EJ, 2001, ANN EMERG MED, V38, P633, DOI 10.1067/mem.2001.118863; Graudins A, 2015, ANN EMERG MED, V65, P248, DOI 10.1016/j.annemergmed.2014.09.024; Green SM, 2011, ANN EMERG MED, V57, P449, DOI 10.1016/j.annemergmed.2010.11.030; Hirota K, 2011, BRIT J ANAESTH, V107, P123, DOI 10.1093/bja/aer221; Hirschfeld G, 2013, PAIN, V154, P2626, DOI 10.1016/j.pain.2013.05.048; Ikeda K, 2005, TRENDS PHARMACOL SCI, V26, P311, DOI 10.1016/j.tips.2005.04.001; Institute of Medicine Committee on Advancing Pain Research Care and Education, 2011, REL PAIN AM BLUEPR T; Tran KP, 2014, PREHOSP EMERG CARE, V18, P257, DOI 10.3109/10903127.2013.851307; Koller DM, 2007, PEDIATR EMERG CARE, V23, P627, DOI 10.1097/PEC.0b013e31814a6a39; Langhan ML, 2011, PEDIATR EMERG CARE, V27, P394, DOI 10.1097/PEC.0b013e318217b538; Le May S, 2013, J EMERG MED, V44, P536, DOI 10.1016/j.jemermed.2012.06.027; Losek JD, 2006, PEDIATR EMERG CARE, V22, P100, DOI 10.1097/01.pec.0000199566.10006.96; Malviya S, 2002, BRIT J ANAESTH, V88, P241, DOI 10.1093/bja/88.2.241; Miller JP, 2015, AM J EMERG MED, V33, P402, DOI 10.1016/j.ajem.2014.12.058; Motov S, 2015, ANN EMERG MED, V66, P222, DOI 10.1016/j.annemergmed.2015.03.004; Nagashima Makoto, 2007, Curr Pain Headache Rep, V11, P115, DOI 10.1007/s11916-007-0008-8; Piaggio G, 2012, JAMA-J AM MED ASSOC, V308, P2594, DOI 10.1001/jama.2012.87802; Poonai N, 2014, CAN MED ASSOC J, V186, P1358, DOI 10.1503/cmaj.140907; Powell CV, 2001, ANN EMERG MED, V37, P28; Reynolds SL, 2017, ACAD EMERG MED, V24, P1430, DOI 10.1111/acem.13313; Rupp T, 2004, ANN EMERG MED, V43, P494, DOI 10.1016/j.annemergmed.2003.11.019; Shimonovich S, 2016, BMC EMERG MED, V16, P1, DOI 10.1186/s12873-016-0107-0; Shrestha R, 2016, WORLD J EMERG MED, V7, P19, DOI 10.5847/wjem.j.1920-8642.2016.01.003; Todd KH, 1996, ANN EMERG MED, V27, P485, DOI 10.1016/S0196-0644(96)70238-X; Visser E, 2006, BIOMED PHARMACOTHER, V60, P341, DOI 10.1016/j.biopha.2006.06.021; von Baeyer Carl L, 2006, Pain Res Manag, V11, P157; Yeaman F, 2014, EMERG MED AUSTRALAS, V26, P237, DOI 10.1111/1742-6723.12173; Yeaman F, 2013, EMERG MED AUSTRALAS, V25, P161, DOI 10.1111/1742-6723.12059	44	6	6	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-6203	2168-6211		JAMA PEDIATR	JAMA Pediatr.	FEB	2019	173	2					140	146		10.1001/jamapediatrics.2018.4582			7	Pediatrics	Pediatrics	HK0EE	WOS:000457570600011	30592476	Bronze, Green Published			2020-06-30	J	Raleigh, MD; Baruffaldi, F; Peterson, SJ; Le Naour, M; Harmon, TM; Vigliaturo, JR; Pentel, PR; Pravetoni, M				Raleigh, Michael D.; Baruffaldi, Federico; Peterson, Samantha J.; Le Naour, Morgan; Harmon, Theresa M.; Vigliaturo, Jennifer R.; Pentel, Paul R.; Pravetoni, Marco			A Fentanyl Vaccine Alters Fentanyl Distribution and Protects against Fentanyl-Induced Effects in Mice and Rats	JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS			English	Article							UNITED-STATES; CONJUGATE VACCINE; OVERDOSE DEATHS; HEROIN; NALOXONE; DRUG; MORPHINE; PHARMACOKINETICS; PREVENTION; ANTIBODIES	Fentanyl is an extremely potent synthetic opioid that has been increasingly used to adulterate heroin, cocaine, and counterfeit prescription pills, leading to an increase in opioid-induced fatal overdoses in the United States, Canada, and Europe. A vaccine targeting fentanyl could offer protection against the toxic effects of fentanyl in both recreational drug users and others in professions at risk of accidental exposure. This study focuses on the development of a vaccine consisting of a fentanyl-based hapten (F) conjugated to keyhole limpet hemocyanin (KLH) carrier protein or to GMP-grade subunit KLH (sKLH). Immunization with F-KLH in mice and rats reduced fentanyl-induced hotplate antinociception, and in rats reduced fentanyl distribution to the brain compared with controls. F-KLH did not reduce the antinociceptive effects of equianalgesic doses of heroin or oxycodone in rats. To assess the vaccine effect on fentanyl toxicity, rats immunized with F-sKLH or unconjugated sKLH were exposed to increasing subcutaneous doses of fentanyl. Vaccination with F-sKLH shifted the dose-response curves to the right for both fentanyl-induced antinociception and respiratory depression. Naloxone reversed fentanyl effects in both groups, showing that its ability to reverse respiratory depression was preserved. These data demonstrate preclinical selectivity and efficacy of a fentanyl vaccine and suggest that vaccines may offer a therapeutic option in reducing fentanyl-induced side effects.	[Raleigh, Michael D.; Baruffaldi, Federico; Peterson, Samantha J.; Harmon, Theresa M.; Vigliaturo, Jennifer R.; Pentel, Paul R.; Pravetoni, Marco] Hennepin Healthcare Res Inst, 701 Pk Ave,Suite S3-340, Minneapolis, MN 55415 USA; [Le Naour, Morgan] Univ Minnesota, Coll Pharm, Dept Med Chem, Minneapolis, MN 55455 USA; [Le Naour, Morgan] MLN BioPharma Consulting LLC, Minneapolis, MN USA; [Pravetoni, Marco] Univ Minnesota, Sch Med, Dept Pharmacol, Minneapolis, MN 55455 USA; [Pentel, Paul R.; Pravetoni, Marco] Univ Minnesota, Sch Med, Dept Med, Minneapolis, MN 55455 USA; [Pravetoni, Marco] Univ Minnesota, Sch Med, Ctr Immunol, Minneapolis, MN 55455 USA	Raleigh, MD (reprint author), Hennepin Healthcare Res Inst, 701 Pk Ave,Suite S3-340, Minneapolis, MN 55415 USA.	rale0011@umn.edu			National Institutes of Health National Institute on Drug AbuseUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [DA026300, DA038876]	This work was supported by the National Institutes of Health National Institute on Drug Abuse [Grants DA026300, DA038876].	Armenian P, 2018, NEUROPHARMACOLOGY, V134, P121, DOI 10.1016/j.neuropharm.2017.10.016; BazinRedureau MI, 1997, J PHARM PHARMACOL, V49, P277, DOI 10.1111/j.2042-7158.1997.tb06795.x; Boyer EW, 2012, NEW ENGL J MED, V367, P146, DOI 10.1056/NEJMra1202561; Bremer PT, 2017, J AM CHEM SOC, V139, P8601, DOI 10.1021/jacs.7b03334; Bremer PT, 2016, ANGEW CHEM INT EDIT, V55, P3772, DOI 10.1002/anie.201511654; Bremer PT, 2014, MOL PHARMACEUT, V11, P1075, DOI 10.1021/mp400631w; Bremer PT, 2012, J MED CHEM, V55, P10776, DOI 10.1021/jm301262z; Clarke SFJ, 2005, EMERG MED J, V22, P612, DOI 10.1136/emj.2003.009613; Dahan A, 2005, BRIT J ANAESTH, V94, P825, DOI 10.1093/bja/aei145; DEA, 2016, COUNT PRESCR PILLS C; DEA (DRUG ENFORCEMENT ADMINISTRATION), 2016, NAT DRUG THREAT ASS; EVANS LEJ, 1973, LANCET, V1, P452; Frank RG, 2017, NEW ENGL J MED, V376, P605, DOI 10.1056/NEJMp1615145; HENDERSON GL, 1975, J PHARMACOL EXP THER, V192, P489; HUG CC, 1981, ANESTHESIOLOGY, V55, P369, DOI 10.1097/00000542-198110000-00006; Huynh NH, 2005, J PHARMACEUT BIOMED, V37, P1095, DOI 10.1016/j.jpba.2004.09.024; Hwang CS, 2018, ACS CHEM NEUROSCI, V9, P1269, DOI 10.1021/acschemneuro.8b00079; Jones CM, 2018, JAMA-J AM MED ASSOC, V319, P1819, DOI 10.1001/jama.2018.2844; Jumbelic MI, 2010, AM J FOREN MED PATH, V31, P18, DOI 10.1097/PAF.0b013e31818738b8; Langham S, 2018, VALUE HEALTH, V21, P407, DOI 10.1016/j.jval.2017.07.014; Le Bars D, 2001, PHARMACOL REV, V53, P597; Lister N, 2011, J CLIN PHARMACOL, V51, P1195, DOI 10.1177/0091270010379410; Lynn RR, 2018, THER ADV DRUG SAF, V9, P63, DOI 10.1177/2042098617744161; Matyas GR, 2013, VACCINE, V31, P2804, DOI 10.1016/j.vaccine.2013.04.027; Mildh LH, 2001, ANESTH ANALG, V93, P939, DOI 10.1097/00000539-200110000-00028; Molina-Martinez LM, 2014, BRAIN BEHAV IMMUN, V42, P60, DOI 10.1016/j.bbi.2014.06.011; Nave R, 2013, DRUG DELIV, V20, P216, DOI 10.3109/10717544.2012.762435; O'Donnell JK, 2017, MMWR-MORBID MORTAL W, V66, P1197, DOI 10.15585/mmwr.mm6643e1; Parikh N, 2013, CLIN THER, V35, P236, DOI 10.1016/j.clinthera.2013.02.017; Peckham EM, 2006, J PHARMACOL EXP THER, V316, P1195, DOI 10.1124/jpet.105.094276; Pravetoni M, 2012, VACCINE, V30, P4617, DOI 10.1016/j.vaccine.2012.04.101; Pravetoni M, 2012, J PHARMACOL EXP THER, V341, P225, DOI 10.1124/jpet.111.189506; Pravetoni M, 2013, J MED CHEM, V56, P915, DOI 10.1021/jm3013745; Raleigh MD, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0184876; Raleigh MD, 2013, J PHARMACOL EXP THER, V344, P397, DOI 10.1124/jpet.112.201194; Raleigh MD, 2018, J PHARMACOL EXP THER, V365, P346, DOI 10.1124/jpet.117.247049; Raleigh MD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115696; Riches JR, 2012, J ANAL TOXICOL, V36, P647, DOI 10.1093/jat/bks078; Rudd RA, 2016, MMWR-MORBID MORTAL W, V65, P1445, DOI 10.15585/mmwr.mm655051e1; Schlosburg JE, 2013, P NATL ACAD SCI USA, V110, P9036, DOI 10.1073/pnas.1219159110; SCHNEIDER E, 1986, N-S ARCH PHARMACOL, V334, P267, DOI 10.1007/BF00508781; Seth P, 2018, MMWR-MORBID MORTAL W, V67, P349, DOI 10.15585/mmwr.mm6712a1; Stowe GN, 2011, J MED CHEM, V54, P5195, DOI 10.1021/jm200461m; Tomassoni Anthony J, 2017, MMWR Morb Mortal Wkly Rep, V66, P107, DOI 10.15585/mm6604a4; TORTEN M, 1975, NATURE, V253, P565, DOI 10.1038/253565a0; Wheeler E, 2015, MMWR-MORBID MORTAL W, V64, P631; Wong J, 2012, POISONING DRUG OVERD, P514	47	8	8	1	9	AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA	0022-3565	1521-0103		J PHARMACOL EXP THER	J. Pharmacol. Exp. Ther.	FEB 1	2019	368	2					282	291		10.1124/jpet.118.253674			10	Pharmacology & Pharmacy	Pharmacology & Pharmacy	HK3XD	WOS:000457851500015	30409833	Bronze, Green Published			2020-06-30	J	Jannetto, PJ; Helander, A; Garg, U; Janis, GC; Goldberger, B; Ketha, H				Jannetto, Paul J.; Helander, Anders; Garg, Uttam; Janis, Gregory C.; Goldberger, Bruce; Ketha, Hemamalini			The Fentanyl Epidemic and Evolution of Fentanyl Analogs in the United States and the European Union	CLINICAL CHEMISTRY			English	Review							HUMAN LIVER-MICROSOMES; PSYCHOACTIVE SUBSTANCE; OVERDOSE DEATHS; DRUG; IDENTIFICATION; HISTORY; U-47700; OPIOIDS; ACETYLFENTANYL; ACRYLFENTANYL	BACKGROUND: Since 2013, an unprecedented surge in fentanyl overdose deaths has been caused by heroin laced with illicitly produced fentanyl and/or fentanyl analogs (FAs) sold as heroin. The US Drug Enforcement Agency's National Forensic Laboratory Information System reported a >300% increase in fentanyl encounters from 4697 in 2014 to 14440 in 2015. In 2015, the CDC reported 9580 deaths caused by synthetic opioids, primarily fentanyl, a 72% increase from 2014. The European Monitoring Centre for Drugs and Drug Addiction has also encountered several new FAs in the heroin supply. Counterfeit pharmaceuticals containing mixtures of fentanyl and FAs continue to be a poorly recognized worldwide problem despite the WHO classifying several FAs as a serious threat to public health. CONTENT: This review covers the epidemiology of fentanyl abuse and discusses the clinical practice implications of widespread fentanyl abuse. It includes a historical perspective on the illicit FAs that have appeared in the US and European Union and reviews the methods available to identify FAs and emerging technologies useful for identifying previously undescribed analogs. A compilation of structural and mass spectral data on FAs reported thus far is provided. SUMMARY: Fentanyl and FAs have evolved into a global public health threat. It is important to understand the analytical, clinical, and regulatory efforts underway to assist communities affected by the current fentanyl epidemic. (C) 2018 American Association for Clinical Chemistry	[Jannetto, Paul J.] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN USA; [Helander, Anders] Karolinska Univ Lab, Karolinska Inst, Dept Lab Med & Pathol, Stockholm, Sweden; [Garg, Uttam] Childrens Mercy Hosp & Clin, Dept Pathol & Lab Med, Kansas City, MO USA; [Janis, Gregory C.] Lab Corp Amer Holdings, MedTox Labs, St Paul, MN USA; [Goldberger, Bruce] Univ Florida, Coll Med, Dept Pathol Immunol & Lab Med, Gainesville, FL USA; [Ketha, Hemamalini] Lab Corp Amer Holdings, Mass Spectrometry & Toxicol, 1447 York Court Ctr Esoter Testing, Burlington, NC 27215 USA	Ketha, H (reprint author), Lab Corp Amer Holdings, Mass Spectrometry & Toxicol, 1447 York Court Ctr Esoter Testing, Burlington, NC 27215 USA.	kethah@labcorp.com					Algren DA, 2013, J MED TOXICOL, V9, P106, DOI 10.1007/s13181-012-0285-4; [Anonymous], CARF CRIT REV REP; [Anonymous], 4 FLUOR CRIT REV REP; [Anonymous], FURN FENT CRIT REV R; [Anonymous], BUT CRIT REV REP; [Anonymous], TETR CRIT REV REP; [Anonymous], AC CRIT REV REP; Armenian P, 2018, NEUROPHARMACOLOGY, V134, P121, DOI 10.1016/j.neuropharm.2017.10.016; AYRES WA, 1981, J PSYCHOACTIVE DRUGS, V13, P91, DOI 10.1080/02791072.1981.10471455; Backberg M, 2015, CLIN TOXICOL, V53, P609, DOI 10.3109/15563650.2015.1054505; BASELT RC, DISPOSITION TOXIC DR; BAUM RM, 1985, CHEM ENG NEWS, V63, P7, DOI 10.1021/cen-v063n036.p007; Beck O, 2018, CLIN TOXICOL, V56, P256, DOI 10.1080/15563650.2017.1370097; Breindahl T, 2017, DRUG TEST ANAL, V9, P415, DOI 10.1002/dta.2046; BROWNSTEIN MJ, 1993, P NATL ACAD SCI USA, V90, P5391, DOI 10.1073/pnas.90.12.5391; Butler DC, 2018, J ANAL TOXICOL, V42, pE6, DOI 10.1093/jat/bkx083; Colby JM, 2017, J ANAL TOXICOL, V41, P1, DOI 10.1093/jat/bkw112; Cole JB, 2015, PEDIATRICS, V135, pE740, DOI 10.1542/peds.2014-2878; Daniulaityte R, 2017, MMWR-MORBID MORTAL W, V66, P904, DOI 10.15585/mmwr.mm6634a3; DiBattista A, 2017, ANAL CHEM, V89, P11853, DOI 10.1021/acs.analchem.7b03590; Feasel MG, 2016, AAPS J, V18, P1489, DOI 10.1208/s12248-016-9963-5; Fels H, 2017, FORENSIC SCI INT, V277, pE30, DOI 10.1016/j.forsciint.2017.04.003; FERRARA SD, 1994, INT J LEGAL MED, V106, P271, DOI 10.1007/BF01225419; Goggin MM, 2017, J ANAL TOXICOL, V41, P367, DOI 10.1093/jat/bkx022; Helander A, 2014, CLIN TOXICOL, V52, P901, DOI 10.3109/15563650.2014.943908; Helander A, 2017, CLIN TOXICOL, V55, P589, DOI 10.1080/15563650.2017.1303141; Helander A, 2017, CLIN TOXICOL, V55, P1, DOI 10.1080/15563650.2016.1217003; Helander A, 2016, CLIN TOXICOL, V54, P324, DOI 10.3109/15563650.2016.1139715; Helander A, 2013, SCAND J CLIN LAB INV, V73, P400, DOI 10.3109/00365513.2013.793817; HENDERSON GL, 1988, J FORENSIC SCI, V33, P569; HIBBS J, 1991, JAMA-J AM MED ASSOC, V265, P1011, DOI 10.1001/jama.265.8.1011; Higashikawa Y, 2008, FORENSIC TOXICOL, V26, P1, DOI 10.1007/s11419-007-0039-1; Jones MJ, 2017, CLIN TOXICOL, V55, P55, DOI 10.1080/15563650.2016.1209767; Katselou M, 2015, FORENSIC TOXICOL, V33, P195, DOI 10.1007/s11419-015-0271-z; Kerensky T, 2017, ADDICT SCI CLIN PRAC, V12, DOI 10.1186/s13722-016-0068-3; KRAM TC, 1981, ANAL CHEM, V53, P1379, DOI 10.1021/ac00235a003; Krotulski AJ, 2018, DRUG TEST ANAL, V10, P127, DOI 10.1002/dta.2228; McIntyre IM, 2016, J ANAL TOXICOL, V40, P162, DOI 10.1093/jat/bkv138; Mohr ALA, 2016, J ANAL TOXICOL, V40, P709, DOI 10.1093/jat/bkw086; Nelson L, 2009, J MED TOXICOL, V5, P230, DOI 10.1007/BF03178274; NFLIS brief, FENT FENT REL SUBST; O'Donnell J. K., 2016, MMWR-MORBID MORTAL W, V66, P1197; Ojanpera I, 2008, INT J LEGAL MED, V122, P395, DOI 10.1007/s00414-008-0230-x; Patton AL, 2014, ANAL CHEM, V86, P1760, DOI 10.1021/ac4036197; Peng PWH, 1999, ANESTHESIOLOGY, V90, P576, DOI 10.1097/00000542-199902000-00034; Peterson AB, 2016, MMWR-MORBID MORTAL W, V65, P844, DOI 10.15585/mmwr.mm6533a3; Quintana P, 2017, INT J DRUG POLICY, V40, P78, DOI 10.1016/j.drugpo.2016.10.006; Reeve JC, 1884, JAMA-J AM MED ASSOC, VII, P233; Rogers JS, 2016, J EMERG MED, V50, P433, DOI 10.1016/j.jemermed.2015.10.014; Ropero-Miller JD, 2013, CLIN TOXICOLOGY LAB, P155; Simons B., 2017, SOC FORENSIC TOX TOX, V41, P9; Sisco E, 2017, FORENSIC CHEM, V4, P108, DOI 10.1016/j.forc.2017.04.001; Sofalvi S, 2017, J ANAL TOXICOL; Sorokin VI SE, 1994, MICROGRAM, V27, P221; STANLEY TH, 1992, J PAIN SYMPTOM MANAG, V7, pS3, DOI 10.1016/0885-3924(92)90047-L; Steentoft A, 2001, FORENSIC SCI INT, V123, P63, DOI 10.1016/S0379-0738(01)00524-2; Stein S. E., 2017, NIST CHEM WEBBOOK; Tuusov J, 2013, J FORENSIC LEG MED, V20, P51, DOI 10.1016/j.jflm.2012.04.023; United Nations Office on Drugs and Crime, GLOB SMART UPD 2017; USDEA National Drug Threat Assessment, DEA DCT DIR 040 17; Wheeler E, 2015, MMWR-MORBID MORTAL W, V64, P631; Wohlfarth A, 2016, DRUG TEST ANAL, V8, P779, DOI 10.1002/dta.1856; World Health Organization, U 47700 CRIT REV REP	63	18	18	7	27	AMER ASSOC CLINICAL CHEMISTRY	WASHINGTON	2101 L STREET NW, SUITE 202, WASHINGTON, DC 20037-1526 USA	0009-9147	1530-8561		CLIN CHEM	Clin. Chem.	FEB	2019	65	2					242	253		10.1373/clinchem.2017.281626			12	Medical Laboratory Technology	Medical Laboratory Technology	HJ0QJ	WOS:000456866500010	30305277	Bronze	Y	N	2020-06-30	J	Romanski, PA; Farland, LV; Tsen, LC; Ginsburg, ES; Lewis, EI				Romanski, Phillip A.; Farland, Leslie, V; Tsen, Lawrence C.; Ginsburg, Elizabeth S.; Lewis, Erin, I			Effect of class III and class IV obesity on oocyte retrieval complications and outcomes	FERTILITY AND STERILITY			English	Article						Body mass index; obesity; in vitro fertilization; oocyte retrieval; complications	BODY-MASS INDEX; IN-VITRO FERTILIZATION; ASSISTED REPRODUCTIVE TECHNOLOGY; 2008-2010 SOCIETY; POOR RESPONDERS; CONCEPTION; IMPACT; CYCLES; WOMEN; RISK	Objective: To assess the effect of class III (body mass index [BMI] 40-49.9 kg/m(2)) and class IV obesity (BMI >= 50 kg/m(2)) on oocyte retrieval complications and outcomes. Design: Cohort study. Setting: Academic center. Patient(s): Women who underwent an oocyte retrieval from January 1, 2012 to May 31, 2017. Women with BMI >= 40 kg/m(2) (n = 144) were age-matched to women with BMI <25, 25-29.9, 30-34.9, and 35-39.9 kg/m(2) (n = 1,016). Intervention(s): None. Main Outcome Measure(s): Anesthetic and procedural outcomes during oocyte retrieval. Result(s): Overall, 1,924 of 1,947 oocyte retrievals (98.8%) were performed under total intravenous anesthesia. No patients with BMI >= 40 kg/m(2) required intraoperative conversion to endotracheal intubation or hospital admission. Two patients (0.8%) with BMI >= 40 kg/m(2) required a laryngeal mask airway intraoperatively owing to oxygen desaturation. An oral/nasal airway was used to resolve oxygen desaturation in 16 patients (6.25%) with BMI >= 40 kg/m(2), compared with in 17 patients (1.0%) with BMI < 40 kg/m(2). As BMI increased, a statistically significant increase in propofol dose, fentanyl dose, and procedure time was observed. Eighteen patients (7.0%) with BMI >= 40 kg/m(2) underwent a transabdominal retrieval, compared with 15 (0.9%) with BMI < 40 kg/m(2). Conclusion(s): Serious intraoperative and postoperative complications were uncommon across all BMI groups, though minor complications were more common with class III and class IV obesity. These patients were also more likely to require higher doses of propofol and fentanyl, have longer oocyte retrievals, and require a transabdominal retrieval. Overall, oocyte retrieval can be safely performed as an outpatient procedure in women with class III and class IV obesity. ((C) 2018 by American Society for Reproductive Medicine.) El resumen esta disponible en Espanol al final del articulo.	[Romanski, Phillip A.; Farland, Leslie, V; Ginsburg, Elizabeth S.; Lewis, Erin, I] Brigham & Womens Hosp, Dept Obstet Gynecol & Reprod Biol, 75 Francis St, Boston, MA 02115 USA; [Romanski, Phillip A.; Farland, Leslie, V; Tsen, Lawrence C.; Ginsburg, Elizabeth S.; Lewis, Erin, I] Harvard Med Sch, Boston, MA USA; [Farland, Leslie, V] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA USA; [Tsen, Lawrence C.] Brigham & Womens Hosp, Dept Anesthesiol Perioperat & Pain Med, Boston, MA 02115 USA	Romanski, PA (reprint author), Brigham & Womens Hosp, Dept Obstet Gynecol & Reprod Biol, 75 Francis St, Boston, MA 02115 USA.	promanski@partners.org		Farland, Leslie/0000-0001-7455-8531			Barton SE, 2011, FERTIL STERIL, V95, P1773, DOI 10.1016/j.fertnstert.2011.01.006; Boots C, 2011, SEMIN REPROD MED, V29, P507, DOI 10.1055/s-0031-1293204; Braat DDM, 2010, HUM REPROD, V25, P1782, DOI 10.1093/humrep/deq080; Cai ZJ, 1999, WHO TECH REP SER, V887, P1; Cheung LP, 2005, HUM REPROD, V20, P616, DOI 10.1093/humrep/deh668; Dechaud H, 2006, EUR J OBSTET GYN R B, V127, P88, DOI 10.1016/j.ejogrb.2005.12.009; Deputy NP, 2018, MMWR-MORBID MORTAL W, V66, P1402, DOI 10.15585/mmwr.mm665152a3; Dragisic KG, 2005, FERTIL STERIL, V84, P1023, DOI 10.1016/j.fertnstert.2005.04.031; Egan B, 2008, J CLIN ANESTH, V20, P356, DOI 10.1016/j.jclinane.2008.03.003; Flegal KM, 2016, JAMA-J AM MED ASSOC, V315, P2284, DOI 10.1001/jama.2016.6458; GREEN BB, 1988, FERTIL STERIL, V50, P721; Langeron O, 2000, ANESTHESIOLOGY, V92, P1229, DOI 10.1097/00000542-200005000-00009; Law DCG, 2007, HUM REPROD, V22, P414, DOI 10.1093/humrep/de1400; Maheshwari A, 2007, HUM REPROD UPDATE, V13, P433, DOI 10.1093/humupd/dmm017; MENDELSON EB, 1988, RADIOLOGY, V166, P321, DOI 10.1148/radiology.166.2.3275976; Metwally M, 2007, REPROD BIOMED ONLINE, V14, P328, DOI 10.1016/S1472-6483(10)60875-9; Metwally M, 2008, FERTIL STERIL, V90, P714, DOI 10.1016/j.fertnstert.2007.07.1290; Pandey S, 2010, HUM REPROD, V25, P815, DOI 10.1093/humrep/deq013; Pasquali R, 2006, REPROD BIOMED ONLINE, V12, P542, DOI 10.1016/S1472-6483(10)61179-0; Provost MP, 2016, FERTIL STERIL, V105, P663, DOI 10.1016/j.fertnstert.2015.11.008; Provost MP, 2016, FERTIL STERIL, V105, P364, DOI 10.1016/j.fertnstert.2015.10.015; Quality Management and Departmental Administration Committee, 2018, CONT DEPTH SED DEF G; Rittenberg V, 2011, REPROD BIOMED ONLINE, V23, P421, DOI 10.1016/j.rbmo.2011.06.018; Robker Rebecca L, 2008, Pathophysiology, V15, P115, DOI 10.1016/j.pathophys.2008.04.004; Scott-Pillai R, 2013, BJOG-INT J OBSTET GY, V120, P932, DOI 10.1111/1471-0528.12193; Serour GI, 1998, FERTIL STERIL, V70, P638, DOI 10.1016/S0015-0282(98)00250-7; Shah DK, 2011, OBSTET GYNECOL, V118, P63, DOI 10.1097/AOG.0b013e31821fd360; Stryne-Gross A, 2005, FERTIL STERIL, V83, P1629, DOI 10.1016/j.fertnstert.2005.01.099; Surrey ES, 1998, FERTIL STERIL, V69, P419, DOI 10.1016/S0015-0282(97)00575-X; TUMMON IS, 1992, FERTIL STERIL, V58, P563; Turner-McGrievy GM, 2015, HUM FERTIL, V18, P215, DOI 10.3109/14647273.2015.1022606	31	1	1	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0015-0282	1556-5653		FERTIL STERIL	Fertil. Steril.	FEB	2019	111	2					294	+		10.1016/j.fertnstert.2018.10.015			9	Obstetrics & Gynecology; Reproductive Biology	Obstetrics & Gynecology; Reproductive Biology	HI9SI	WOS:000456797500023	30691631				2020-06-30	J	Ryan, PM; Kienstra, AJ; Cosgrove, P; Vezzetti, R; Wilkinson, M				Ryan, Patrick M.; Kienstra, Andrew J.; Cosgrove, Peter; Vezzetti, Robert; Wilkinson, Matthew			Safety and effectiveness of intranasal midazolam and fentanyl used in combination in the pediatric emergency department	AMERICAN JOURNAL OF EMERGENCY MEDICINE			English	Article							PAINFUL PROCEDURES; CHILDREN	Objective: To examine the safety and effectiveness of intranasal midazolam and fentanyl used in combination for laceration repair in the pediatric emergency department. Methods: We performed a retrospective chart review of a random sample of 546 children less than 18 years of age who received both intranasal midazolam and fentanyl for laceration repair in the pediatric emergency department at a large, urban children's hospital. Records were reviewed from April 1, 2012 to June 31, 2015. The primary outcome measures were adverse events and failed laceration repair. Results: Of the 546 subjects analyzed, 5.1% had multiple lacerations. Facial lacerations were the most common site representing 70.3%, followed by lacerations to the hand (9.9%) and leg (7.0%). The median length of lacerations was 1.5 cm [1.0-2.5]. The median dose of fentanyl was 2.0 mu g/kg [1.9-2.0] and midazolam was 0.2 mg/kg [0.19-0.20]. There were no serious adverse events reported. The rate of minor side effects was 0.7% (95%Cl 0.2% to 1.9%); 0.5% (95% CI 0.1% to 1.6%) experienced anxiety and 02% (95% CI 0.0% to 1.0%) vomited. No patients developed hypotension or hypoxia. Of the 546 patients, 2.4% (95% CI 1.3% to 4.0%) experienced a treatment failure. 2.0% (95% CI 13% to 4.0%) required IV sedation and 0.4% (95% CI 0.0% to 1.3%) were repaired in the operating room. Conclusions: Our results suggest that the combination of INM and INF may be a safe and effective strategy for procedural sedation in young children undergoing simple laceration repair. (C) 2018 Published by Elsevier Inc.	[Ryan, Patrick M.; Kienstra, Andrew J.; Cosgrove, Peter; Vezzetti, Robert; Wilkinson, Matthew] UT Austin Dell Med Sch, Dept Pediat Emergency Med, 4900 Mueller Blvd, Austin, TX 78723 USA	Ryan, PM (reprint author), UT Austin Dell Med Sch, Dept Pediat Emergency Med, 4900 Mueller Blvd, Austin, TX 78723 USA.	pmryan@seton.org					Bauman BH, 2005, EMERG MED CLIN N AM, V23, P393, DOI 10.1016/j.emc.2004.12.008; Borland M, 2002, EMERGEN MED, V14, P3; Borland M, 2007, ANN EMERG MED, V49, P335, DOI 10.1016/j.annemergmed.2006.06.016; CHIEN YW, 1989, NASAL SYSTEMIC DRUG, P1; Cole J, 2009, EMERG MED AUSTRALAS, V21, P395, DOI 10.1111/j.1742-6723.2009.01216.x; CONNORS K, 1994, ANN EMERG MED, V24, P1074, DOI 10.1016/S0196-0644(94)70236-5; Crocker PJ, 2012, AM J EMERG MED, V30, P861, DOI 10.1016/j.ajem.2011.05.030; Drendel AL, 2011, PEDIATR EMERG CARE, V27, P773, DOI 10.1097/PEC.0b013e31822877f7; Kennedy RM, 1999, PEDIATR CLIN N AM, V46, P1215, DOI 10.1016/S0031-3955(05)70184-X; Lane RD, 2008, PEDIATR EMERG CARE, V24, P300, DOI 10.1097/PEC.0b013e31816ecb6f; Murphy A, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009942.pub2; Primosch RE, 2001, J DENT CHILD, V68, P233; Saunders M, 2010, ACAD EMERG MED, V17, P1155, DOI 10.1111/j.1553-2712.2010.00905.x; Terndrup TE, 1996, ANN EMERG MED, V27, P466, DOI 10.1016/S0196-0644(96)70234-2; Theroux M, 1993, PEDIATRICS, V91, P3; Weisman SJ, 1998, ARCH PEDIAT ADOL MED, V152, P147; Yealy D, 1992, AM J EMERG MED, V10, P6; Young KD, 2005, ANN EMERG MED, V45, P160, DOI 10.1016/j.annemergmed.2004.09.019	18	0	0	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0735-6757	1532-8171		AM J EMERG MED	Am. J. Emerg. Med.	FEB	2019	37	2					237	240		10.1016/j.ajem.2018.05.036			4	Emergency Medicine	Emergency Medicine	HI6DW	WOS:000456544400012	30146398				2020-06-30	J	Wang, SZ; Fernandez, MA; Miras, PM; Merino, NM; Lopez, EH; Alameda, LEM				Wang, S. Zhang; Alvarez Fernandez, M.; Mellado Miras, P.; Martinez Merino, N.; Herrera Lopez, E.; Munoz Alameda, L. E.			Perioperative management of a female diagnosed with heterozygous X-linked adrenoleukodystrophy scheduled for shoulder arthroscopy	REVISTA ESPANOLA DE ANESTESIOLOGIA Y REANIMACION			Spanish	Article						Adrenoleukodystrophy; Anaesthesia; Long chain fatty acids; Carriers	ANESTHETIC MANAGEMENT; ADULT PATIENT; CHILD	X-linked adrenoleukodystrophy (X-ALD) belongs to a family of rare diseases due to inborn errors of metabolism. It has a wide spectrum of clinical manifestations that anaesthesiologists should recognise during the perioperative period (respiratory centre dysfunction, hypotonia, adrenal or hepatic failure, gastroesophageal reflux disease, osteopenia, seizures).The case is presented of a 42-year-old X-linked adrenoteukodystrophy female carrier, who underwent combined general and an ultrasound-guided interscalene brachial plexus block anaesthesia for shoulder arthroscopy. Induction was performed with thiopentone and fentanyl, and sevoflurane was used as inhaled maintenance agent. No events were recorded during the procedure. Her post-operative recovery was satisfactory and she was later discharged home. (C) 2018 Sociedad Espanola de Anestesiologia, Reanimacion y Terapeutica del Dolor. Published by Elsevier Espana, S.L.U. All rights reserved.	[Wang, S. Zhang; Alvarez Fernandez, M.; Mellado Miras, P.; Martinez Merino, N.; Herrera Lopez, E.; Munoz Alameda, L. E.] Hosp Univ Fdn Jimenez Diaz Quiron Salud, Serv Anestesiol & Reanimac, Madrid, Spain	Wang, SZ (reprint author), Hosp Univ Fdn Jimenez Diaz Quiron Salud, Serv Anestesiol & Reanimac, Madrid, Spain.	serena.zhang.wang@gmail.com					Dobson G, 2004, EUR J ANAESTH, V21, P78, DOI 10.1017/S0265021504241126; Engelen M, 2014, BRAIN, V137, P693, DOI 10.1093/brain/awt361; Hamdiye CT, 2006, PEDIATR ANESTH, V16, P221, DOI 10.1111/j.1460-9592.2005.01781.x; Kindopp AS, 1998, CAN J ANAESTH, V45, P990, DOI 10.1007/BF03012307; Kloesel B, 2017, ANESTH ANALG, V125, P822, DOI 10.1213/ANE.0000000000001689; Leykin Y, 2010, EUR J ANAESTH, V27, P214, DOI 10.1097/EJA.0b013e32832c5f3b; Ubeda ML, 2017, ARCH ARGENT PEDIATR, V115, pE279, DOI 10.5546/aap.2017.e279; Tan SH, 2014, INDIAN J ANAESTH, V58, P63, DOI 10.4103/0019-5049.126802	8	0	0	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0034-9356	2340-3284		REV ESP ANEST REANIM	Rev. Esp. Anestesiol. Reanim.	FEB	2019	66	2					113	116		10.1016/j.redar.2018.08.006			4	Anesthesiology	Anesthesiology	HI2FN	WOS:000456260700008	30447897				2020-06-30	J	Benoist, GE; van Oort, IM; Burger, DM; Koch, BCP; Mehra, N; van Erp, NP				Benoist, Guillemette E.; van Oort, Inge M.; Burger, David M.; Koch, Birgit C. P.; Mehra, Niven; van Erp, Nielka P.			The Combination of Enzalutamide and Opioids: A Painful Pitfall?	EUROPEAN UROLOGY			English	Letter												van Oort, Inge/AAD-1197-2020; van Erp, Nielka P./A-1907-2016; van Oort, Inge/L-4554-2015; Mehra, Niven/B-7157-2017	van Oort, Inge/0000-0002-8002-1869; van Oort, Inge/0000-0002-8002-1869; Mehra, Niven/0000-0002-4794-1831			Benoist GE, 2018, BRIT J CLIN PHARMACO, V84, P122, DOI 10.1111/bcp.13425; European Medicines Agency, 2018, EUR PUBL ASS REP XTA; European Medicines Agency, 2018, EUR PUBL ASS REP ZYT; Flint RB, 2018, BIOMED CHROMATOGR, V32, DOI 10.1002/bmc.4290; Oosten AW, 2016, EUR J CLIN PHARMACOL, V72, P459, DOI 10.1007/s00228-015-2005-x	5	2	2	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0302-2838	1873-7560		EUR UROL	Eur. Urol.	FEB	2019	75	2					351	352		10.1016/j.eururo.2018.09.011			2	Urology & Nephrology	Urology & Nephrology	HH6PB	WOS:000455852400044	30245086				2020-06-30	J	Qureshi, AI; Saleem, MA; Naseem, N; Wallery, SS				Qureshi, A., I; Saleem, M. A.; Naseem, N.; Wallery, S. S.			Effectiveness of premedication protocol using intravenous fentanyl to reduce pain associated with femoral artery closure device placement	CLINICAL RADIOLOGY			English	Article							ANALGESIA; INFILTRATION; ANESTHESIA; COMPRESSION; CREAM; EMLA	AIM: To test the effectiveness of a premedication protocol using intravenous bolus of 100 mu g fentanyl to reduce pain associated with femoral artery closure device placement for neuroendovascular procedures. MATERIALS AND METHODS: The severity of pain associated with femoral artery closure device placement was analysed using a numerical rating scale score ranging from 0 (no pain) to 10 (most severe pain) in two cohorts of consecutive adult patients (n=118), those who were (n=64) or were not (n=54) treated with premedication protocol. The primary endpoints were the proportion of patients with excellent (score <= 1) and failed pain control (score >= 8). Stepwise logistic regression analysis was performed to identify the effect of premedication on pain control after adjustment for potential confounders. RESULTS: The median numerical pain rating score at femoral artery closure device placement was significantly lower in patients treated with premedication protocol compared with those who underwent closure without premedication (1 versus 5, p<0.001). There was a significantly higher rate of excellent (56.2% versus 14.8%, p<0.001) and good (68.7% versus 31.2%, p<0.001) pain control at closure device placement among patients treated with premedication protocol. None of the patients treated with premedication protocol reported failed pain control compared with 33.4% of those who underwent closure device placement without premedication. In the multivariate analysis, treatment with the premedication protocol was significantly associated with an increased rate of excellent pain control (odds ratio 2.3; 95% confidence interval 1.9-3.1). CONCLUSION: Premedication with intravenous fentanyl injection prior to femoral artery closure device placement can reduce the intensity of pain associated with closure. (C) 2018 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.	[Qureshi, A., I; Saleem, M. A.; Naseem, N.] Zeenat Qureshi Stroke Inst, St Cloud, MN USA; [Saleem, M. A.] Mercyhlth Janesville, Janesville, WI USA; [Wallery, S. S.] Univ Illinois, Rockford, IL USA; [Wallery, S. S.] Mercyhlth Rockford, Rockford, IL USA	Saleem, MA (reprint author), 849 Kellogg Ave, Janesville, WI 53545 USA.	akmamsaleem@gmail.com		Qureshi, Adnan/0000-0003-4962-540X			Bonfreschi V, 2009, EUR J ANAESTH, V26, P782, DOI 10.1097/EJA.0b013e32832bcc9b; Browne J, 1999, CAN J ANAESTH, V46, P1014, DOI 10.1007/BF03013194; Chistiakov DA, 2015, AUTON NEUROSCI-BASIC, V193, P7, DOI 10.1016/j.autneu.2015.06.005; Choi YJ, 2015, J INT MED RES, V43, P809, DOI 10.1177/0300060515594194; ClinCalc, 2018, POSTH POW CALC; Cox Tiffany, 2015, Surg Technol Int, V27, P32; Fargen KM, 2011, J NEUROINTERV SURG, V3, P219, DOI 10.1136/jnis.2010.003988; Joly LM, 1998, ANESTH ANALG, V87, P403, DOI 10.1097/00000539-199808000-00032; Mankerious N, 2018, J INVASIVE CARDIOL; MILLER DL, 1987, RADIOLOGY, V162, P195, DOI 10.1148/radiology.162.1.3786761; Ogurlu M, 2010, CLIN EXP OBSTET GYN, V37, P209; Pirat A, 2005, J CARDIOTHOR VASC AN, V19, P642, DOI 10.1053/j.jvca.2004.10.007; Qureshi Adnan I, 2018, J Vasc Interv Neurol, V10, P60; RAYBURN W, 1989, AM J OBSTET GYNECOL, V161, P202, DOI 10.1016/0002-9378(89)90266-4; RAYBURN WF, 1989, OBSTET GYNECOL, V74, P604; Rilling William S, 2003, Tech Vasc Interv Radiol, V6, P76, DOI 10.1053/tvir.2003.36448; Rusch D, 2017, J CARDIOTHOR VASC AN, V31, P77, DOI 10.1053/j.jvca.2016.06.008; Schulz-Schupke S, 2014, JAMA-J AM MED ASSOC, V312, P1981, DOI 10.1001/jama.2014.15305; Sheng Yulan, 2018, Int J Physiol Pathophysiol Pharmacol, V10, P17; Sindberg B, 2014, EUR J CARDIOVASC NUR, V13, P221, DOI 10.1177/1474515113482809; Spiliopoulos S, 2011, CLIN RADIOL, V66, P449, DOI 10.1016/j.crad.2011.01.002; U.S. Food and Drug Administration, 2018, FENT CITR INJ USP	22	0	0	0	0	W B SAUNDERS CO LTD	LONDON	32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND	0009-9260	1365-229X		CLIN RADIOL	Clin. Radiol.	FEB	2019	74	2								10.1016/j.crad.2018.10.016			5	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	HH4VK	WOS:000455724000019	30591213				2020-06-30	J	Planelles, B; Margarit, C; Ajo, R; Sastre, Y; Muriel, J; Inda, MD; Esteban, MD; Peiro, AM				Planelles, Beatriz; Margarit, Cesar; Ajo, Raquel; Sastre, Yolanda; Muriel, Javier; Inda, Maria-del-Mar; Esteban, Maria D.; Peiro, Ana M.			Health benefits of an adverse events reporting system for chronic pain patients using long-term opioids	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article						chronic non-cancer pain; opioids; patient's reports of adverse events; pharmacovigilance data recording system; suspected adverse drug reaction	CHRONIC NONCANCER PAIN; VISUAL ANALOG SCALE; CANCER PAIN; ANALGESICS; MANAGEMENT; OXYCODONE; EFFICACY; MORPHINE; MODERATE; THERAPY	Background Safety data from long-term opioid therapy in the real world has been poorly studied in chronic non-cancer pain (CNCP). The aim was to design a pharmacovigilance data recording system and assess whether participation in this recording system improves pain management, enhancing patient ' s health status. Methods A pharmacovigilance data recording system was conducted during 24 months. Data were self-reported by patients (pain, adverse events [AEs] and healthcare resources use) and physicians (morphine equivalent daily dose [MEDD] prescribed and suspected adverse drug reaction [ADRs]). Outcomes from patients with (case) or without (controls) suspected ADRs and cases follow-up were also compared with Spanish Pharmacovigilance System data. Results A total of 753 patients were recruited in 897 visits. Fentanyl and tramadol were the most prescribed opioids, 89% with concomitant drugs, pregabalin being the one with the most potential drug interactions. Cases presented significantly higher pain intensity (VAS 67 +/- 26 vs 59 +/- 30 mm, P < 0.05), number of AEs (8 +/- 6 vs 5 +/- 3 AEs/patient, P < 0.01), polypharmacy related to pain (65% vs 34%, P < 0.01) and MEDD (139 +/- 130 vs 106 +/- 99 mg/d, P < 0.01) than controls. Furthermore, cases presented significant higher changes in pharmacological pain therapy due to pain, unplanned emergency visits and hospital admission than controls. Physicians notified 168 suspected ADRs mostly related to neurological or psychiatric events and 8% of them were previously unknown. Conclusions This data recording system provided important information to achieve a better control of CNCP pharmacological pain therapy, improving patient's health status and reducing costs to the Health System.	[Planelles, Beatriz; Margarit, Cesar; Sastre, Yolanda; Peiro, Ana M.] Alicante Dept Hlth Gen Hosp, Pain Unit, Alicante, Spain; [Planelles, Beatriz; Margarit, Cesar; Ajo, Raquel; Muriel, Javier; Inda, Maria-del-Mar; Peiro, Ana M.] Dept Hlth Alicante Gen Hosp, ISABIAL, Dept Hlth, Neuropharmacol Pain NED,Res Unit, Alicante, Spain; [Esteban, Maria D.] Miguel Hernandez Univ, Operat Res Ctr, Elche, Spain; [Peiro, Ana M.] Alicante Dept Hlth Gen Hosp, Clin Pharmacol Unit, Alicante, Spain	Peiro, AM (reprint author), Alicante Dept Hlth Gen Hosp, Res Grp, Neuropharmacol Pain NED, Pintor Baeza 12, Alicante 03010, Spain.	peiro_ana@gva.es		Peiro, Ana/0000-0002-2385-3749; Muriel, Javier/0000-0003-0048-9451	Spanish Pain Foundation [BF4-15-04]	Spanish Pain Foundation, Grant/Award Number: BF4-15-04	Al Dweik R, 2016, SPRINGERPLUS, V5, DOI 10.1186/s40064-016-1838-9; Anantharaman P, 2007, ADV CHRONIC KIDNEY D, V14, P119, DOI 10.1053/j.ackd.2007.01.002; Annemans L, 2011, CLIN DRUG INVEST, V31, P73, DOI 10.2165/11536290-000000000-00000; [Anonymous], 2006, US OP SPAIN 1992 200, P6; [Anonymous], 2016, ONLINE INFORM CTR ME; Ballantyne Jane C, 2007, Pain Physician, V10, P479; Baxter Karen, 2010, STOCKLEYS DRUG INTER, V495; Bousquet C, 2005, DRUG SAFETY, V28, P19, DOI 10.2165/00002018-200528010-00002; Budnitz DS, 2006, JAMA-J AM MED ASSOC, V296, P1858, DOI 10.1001/jama.296.15.1858; Camacho MC, 2012, OPIOID DRUG USE PROV; Caraceni A, 2012, LANCET ONCOL, V13, pE58, DOI 10.1016/S1470-2045(12)70040-2; Cazacu I, 2015, EUR J CLIN PHARMACOL, V71, P625, DOI 10.1007/s00228-015-1829-8; Clark AJ, 2004, CURR MED RES OPIN, V20, P1419, DOI 10.1185/030079904X2114; Currow DC, 2016, MED J AUSTRALIA, V204, P305, DOI 10.5694/mja16.00066; EINARSON TR, 1993, ANN PHARMACOTHER, V27, P832, DOI 10.1177/106002809302700702; Feinstein JA, 2015, PHARMACOEPIDEM DR S, V24, P1049, DOI 10.1002/pds.3843; Florez J., 2003, FARMACOLOGIA HUMANA; Genco EK, 2016, ANN EMERG MED, V67, P240, DOI 10.1016/j.annemergmed.2015.09.020; Hall WD, 2011, MED J AUSTRALIA, V195, P248, DOI 10.5694/mja11.10832; Harland NJ, 2015, PHYSIOTHERAPY, V101, P50, DOI 10.1016/j.physio.2014.06.004; Hazell L, 2013, DRUG SAFETY, V36, P199, DOI 10.1007/s40264-013-0021-2; Herr K, 2010, J PAIN SYMPTOM MANAG, V39, P803, DOI 10.1016/j.jpainsymman.2009.09.025; Herxheimer A, 2010, DIRECT PATIENT REPOR; Jarernsiripornkul N, 2003, EUR J PAIN, V7, P219, DOI 10.1016/S1090-3801(02)00114-3; KARCH FE, 1977, CLIN PHARMACOL THER, V21, P247; Katz N, 2009, CLIN J PAIN, V25, P170, DOI 10.1097/AJP.0b013e3181850df6; Kelly W, 2009, THERAPIE, V64, P289, DOI 10.2515/therapie/2009041; Lohman D, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-8; Marschall U, 2016, EUR J PAIN, V20, P767, DOI 10.1002/ejp.802; McNicol E, 2003, J PAIN, V4, P231, DOI 10.1016/S1526-5900(03)00556-X; Mora RM, 2015, J THERAP INFORM, V26, P36; Muller-Schwefe GHH, 2011, CURR MED RES OPIN, V27, P2099, DOI 10.1185/03007995.2011.621935; NARANJO CA, 1981, CLIN PHARMACOL THER, V30, P239, DOI 10.1038/clpt.1981.154; Narumol J, 2015, INT J CLIN PHARM-NET, V37, P168, DOI 10.1007/s11096-014-0060-5; Obradovic M, 2013, HEALTH QUAL LIFE OUT, V11, DOI 10.1186/1477-7525-11-110; Perez C, 2013, CURR MED RES OPIN, V29, P643, DOI 10.1185/03007995.2013.787978; Pergolizzi Joseph, 2008, Pain Pract, V8, P287, DOI 10.1111/j.1533-2500.2008.00204.x; Puerro M, 2004, CUSTO REACOES ADVERS; Ram KC, 2008, PAIN, V139, P431, DOI 10.1016/j.pain.2008.05.015; Reed MD, 2014, J CLIN PHARMACOL, V54, P241, DOI 10.1002/jcph.250; Richarz U, 2012, PHARMACOEPIDEM DR S, V21, P453, DOI 10.1002/pds.2250; Starck P L, 2001, Jt Comm J Qual Improv, V27, P191; Tassinari D, 2008, J PALLIAT MED, V11, P492, DOI 10.1089/jpm.2007.0200; van Grootheest Kees, 2004, Expert Opin Drug Saf, V3, P363; Vella-Brincat Jane, 2007, J Pain Palliat Care Pharmacother, V21, P15, DOI 10.1300/J354v21n01_05; Von Korff M, 2004, PAIN, V109, P207, DOI 10.1016/j.pain.2004.02.019; Vondrackova D, 2008, J PAIN, V9, P1144, DOI 10.1016/j.jpain.2008.06.014; Vuong C, 2010, ENDOCR REV, V31, P98, DOI 10.1210/er.2009-0009; World Health Organization, 1966, TECHNICAL REPORT SER, V425, P1; Xu Y, 2013, PAIN RES TREAT, V2013, DOI 10.1155/2013/943014	50	3	3	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-5172	1399-6576		ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	FEB	2019	63	2					248	258		10.1111/aas.13243			11	Anesthesiology	Anesthesiology	HG2SP	WOS:000454814700015	30109708				2020-06-30	J	Karaca, O; Pinar, HU; Arpaci, E; Dogan, R; Cok, OY; Ahiskalioglu, A				Karaca, Omer; Pinar, Huseyin U.; Arpaci, Enver; Dogan, Rafi; Cok, Oya Y.; Ahiskalioglu, Ali			The efficacy of ultrasound-guided type-I and type-II pectoral nerve blocks for postoperative analgesia after breast augmentation: A prospective, randomised study	ANAESTHESIA CRITICAL CARE & PAIN MEDICINE			English	Article						Analgesia technique; Breast augmentation; Pectoral nerves blocks; Postoperative pain	THORACIC PARAVERTEBRAL BLOCK; PECS BLOCK; DOUBLE-BLIND; COMPLICATIONS; MASTECTOMY; TRIAL	Purpose: The present study was planned to evaluate the efficacy and safety of ultrasound-guided Pecs I and II blocks for postoperative analgesia after sub-pectoral breast augmentation. Methods: Fifty-four adult female patients undergoing breast augmentation were randomly divided into two groups: the control group (Group C, n = 27) who were not subjected to block treatment and Pecs group (Group P, n = 27) who received Pecs I (bupivacain 0.25%, 10 mL) and Pecs II (bupivacain 0.25%, 20 mL) block. Patient-controlled fentanyl analgesia was used for postoperative pain relief in both groups, and the patients were observed for the presence of any block-related complications. Results: The 24-h fentanyl consumption was smaller in Group P [mean +/- SD, 378.7 +/- 54.0 mu g and 115.7 +/- 98.1 mu g, respectively; P < 0.001]. VAS scores in Group P were significantly lower at the time of admission to the post-anaesthetic care unit and at 1, 2, 4, 8, 12, and 24 h (P < 0.001). The rates of nausea and vomiting were higher in Group C than in Group P (9 vs 2, P = 0.018). Hospital stay duration was shorter in Group P than in Group C (24.4 +/- 1.2 h vs 27.0 +/- 3.1 h, P < 0.001). No block-related complications were recorded. Conclusions: Combine used of Pecs I and II blocks provide superior postoperative analgesia in patients undergoing breast augmentation and shortens hospital stay. (C) 2018 Societe francaise d'anesthesie et de reanimation (Sfar). Published by Elsevier Masson SAS. All rights reserved.	[Karaca, Omer; Pinar, Huseyin U.; Dogan, Rafi] Baskent Univ, Dept Anaesthesiol, Sch Med, Konya, Turkey; [Arpaci, Enver] Baskent Univ, Dept Plast & Reconstruct Surg, Sch Med, Konya, Turkey; [Cok, Oya Y.] Baskent Univ, Dept Anaesthesiol, Sch Med, Adana, Turkey; [Ahiskalioglu, Ali] Ataturk Univ, Dept Anaesthesiol, Sch Med, Erzurum, Turkey	Karaca, O (reprint author), Baskent Univ, Sch Med, Training & Res Hosp, Saray Ave 1, Konya, Turkey.	dromerkaraca@hotmail.com	Ahiskalioglu, Ali/B-7473-2016; Pinar, Huseyin Ulas/Q-2420-2015	Ahiskalioglu, Ali/0000-0002-8467-8171; Pinar, Huseyin Ulas/0000-0003-0473-6763			Bashandy GMN, 2015, REGION ANESTH PAIN M, V40, P68, DOI 10.1097/AAP.0000000000000163; Blanco R, 2012, REV ESP ANEST REANIM, V59, P470, DOI 10.1016/j.redar.2012.07.003; Blanco R, 2011, ANAESTHESIA, V66, P847, DOI 10.1111/j.1365-2044.2011.06838.x; Butterworth JF, 2013, MORGAN MIKHAILS CLIN, P272; Cooter RD, 2007, AESTHET PLAST SURG, V31, P666, DOI 10.1007/s00266-006-0230-5; Perez MF, 2015, REGION ANESTH PAIN M, V40, P729, DOI 10.1097/AAP.0000000000000243; Gardiner S, 2012, ANESTH ANALG, V115, P1053, DOI 10.1213/ANE.0b013e318264ba33; Giebler RM, 1997, ANESTHESIOLOGY, V86, P55, DOI 10.1097/00000542-199701000-00009; Gutta R, 2013, J ORAL MAXIL SURG, V71, P2029, DOI 10.1016/j.joms.2013.06.220; Haydon NB, 2016, PRS-GLOB OPEN, V4, DOI 10.1097/GOX.0000000000000625; Hinchcliff KM, 2017, ANN PLAS SURG, V78, pS189, DOI 10.1097/SAP.0000000000000954; Jabs Dean, 2008, Aesthet Surg J, V28, P528, DOI 10.1016/j.asj.2008.07.005; Kang CM, 2017, AESTHET PLAST SURG; Kulhari S, 2016, BRIT J ANAESTH, V117, P382, DOI 10.1093/bja/aew223; Leiman D, 2015, PLAST RECONSTR SURG, V2, pe282; Morioka H, 2015, JA CLIN REP, V1, DOI 10.1186/s40981-015-0018-1; Nava MB, 2017, GLAND SURG, V6, P210, DOI 10.21037/gs.2017.04.02; Park SY, 2015, CAN J ANESTH, V62, P252, DOI 10.1007/s12630-014-0284-9; RUNDSHAGEN I, 1995, BRIT J ANAESTH, V75, P598, DOI 10.1093/bja/75.5.598; Tamura T, 2017, J ANESTH, V31, P263, DOI 10.1007/s00540-017-2307-5; Tan P, 2017, ANN PLAS SURG, V78, pS299, DOI 10.1097/SAP.0000000000001132; Ueshima H, 2017, J CLIN ANESTH, V42, P46, DOI 10.1016/j.jclinane.2017.08.006; Versyck B, 2017, J CLIN ANESTH, V40, P46, DOI 10.1016/j.jclinane.2017.03.054; Wahba SS, 2014, EGYPT J ANAESTH, V30, P129, DOI 10.1016/j.egja.2013.10.006; Woodworth GE, 2017, REGION ANESTH PAIN M, V42, P609, DOI 10.1097/AAP.0000000000000641	25	8	9	0	4	ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER	ISSY-LES-MOULINEAUX	65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE	2352-5568			ANAESTH CRIT CARE PA	Anaesth. Crit. Care Pain Med.	FEB	2019	38	1					47	52		10.1016/j.accpm.2018.03.009			6	Anesthesiology; Critical Care Medicine	Anesthesiology; General & Internal Medicine	HG6JH	WOS:000455087000011	29627431	Bronze			2020-06-30	J	Kumar, A; Kumar, N; Sinha, C				Kumar, Amarjeet; Kumar, Neeraj; Sinha, Chandni			Oxygen through suction port: use of a three way stopcock during fiberoptic bronchoscopy	ANAESTHESIA CRITICAL CARE & PAIN MEDICINE			English	Letter							INSUFFLATION		[Kumar, Amarjeet; Kumar, Neeraj] All India Inst Med Sci, Dept Trauma & Emergency, Patna, Bihar, India; [Sinha, Chandni] AIIMS, Dept Anaesthesia, Patna, Bihar, India	Kumar, N (reprint author), All India Inst Med Sci, Dept Trauma & Emergency, Patna, Bihar, India.	neeraj.jlnmc@gmail.com					Chapman N, 2008, ANESTH ANALG, V106, P1592, DOI 10.1213/ane.0b013e31816a3111; Chhajed PN, 2003, CLIN CHEST MED, V24, P511, DOI 10.1016/S0272-5231(03)00050-9; La Combe B, 2016, EUR RESPIR J, V48, P590, DOI 10.1183/13993003.00565-2016; LAWES EG, 1987, BRIT J ANAESTH, V59, P315, DOI 10.1093/bja/59.3.315; Poly Medicure LTD, 2017, 3 WAY STOP COCK; Soong WJ, 2011, J CHIN MED ASSOC, V74, P556, DOI 10.1016/j.jcma.2011.09.016; Willeford KL, 2011, United States Patent Application Publication US, Patent No. [0264004 A1, 0264004]	7	0	0	0	2	ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER	ISSY-LES-MOULINEAUX	65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE	2352-5568			ANAESTH CRIT CARE PA	Anaesth. Crit. Care Pain Med.	FEB	2019	38	1					83	84		10.1016/j.accpm.2018.04.011			2	Anesthesiology; Critical Care Medicine	Anesthesiology; General & Internal Medicine	HG6JH	WOS:000455087000020	29864553	Bronze			2020-06-30	J	Garcia-Quintero, PE; Suthar, R; Suraci, NP; Hasty, FE				Garcia-Quintero, Pedro E.; Suthar, Rekhaben; Suraci, Nicholas P.; Hasty, Frederick E.			Flouride induced muscle weakness: A general anesthesia escape plan!	JOURNAL OF CLINICAL ANESTHESIA			English	Letter									[Garcia-Quintero, Pedro E.; Suthar, Rekhaben; Suraci, Nicholas P.; Hasty, Frederick E.] Mt Sinai Med Ctr, Dept Anesthesia, 4300 Alton Rd, Miami Beach, FL 33140 USA	Garcia-Quintero, PE (reprint author), Mt Sinai Med Ctr, Dept Anesthesia, 4300 Alton Rd, Miami Beach, FL 33140 USA.	pedro.garcia@msmc.com					[Anonymous], MORGAN MIKHAILS CLIN, P199; Golomb Beatrice Alexandra, 2015, BMJ Case Rep, V2015, DOI 10.1136/bcr-2015-209821; Hall MM, 2011, PM&R, V3, P132, DOI 10.1016/j.pmrj.2010.10.003; Lugassy DM, 2009, J MED TOXICOL, V5, P151, DOI 10.1007/BF03161228; Shortt P, 2006, EMERG MED J, V23, DOI 10.1136/emj.2006.035832	5	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0952-8180	1873-4529		J CLIN ANESTH	J. Clin. Anesth.	FEB	2019	52						36	36		10.1016/j.jclinane.2018.08.017			1	Anesthesiology	Anesthesiology	HE7PM	WOS:000453630900014	30172022				2020-06-30	J	Salik, I; Genis, A; Barst, S				Salik, Irim; Genis, Alina; Barst, Samuel			Anesthetic management of an infant with Jeune syndrome and severe pulmonary hypertension for tracheostomy	JOURNAL OF CLINICAL ANESTHESIA			English	Letter									[Salik, Irim; Genis, Alina; Barst, Samuel] New York Med Coll, Westchester Med Ctr, Dept Pediat Anesthesiol, Valhalla, NY 10595 USA	Genis, A (reprint author), New York Med Coll, Westchester Med Ctr, Dept Pediat Anesthesiol, Valhalla, NY 10595 USA.	alina.genis@wmchealth.org		Salik, Irim/0000-0002-8619-9211			Chen H, GENETICS ASPHYXIATIN; FROSTELL C, 1991, CIRCULATION, V83, P2038, DOI 10.1161/01.CIR.83.6.2038; Keogh SJ, 2012, BMC PEDIATR, V12, DOI 10.1186/1471-2431-12-48; Saletti D, 2012, REV BRAS ANESTESIOL, V62, P424, DOI 10.1016/S0034-7094(12)70142-3; Subhedar Nimish V, 2003, Semin Neonatol, V8, P413, DOI 10.1016/S1084-2756(03)00117-9	5	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0952-8180	1873-4529		J CLIN ANESTH	J. Clin. Anesth.	FEB	2019	52						76	77		10.1016/j.jclinane.2018.09.018			2	Anesthesiology	Anesthesiology	HE7PM	WOS:000453630900028	30218885				2020-06-30	J	Piersigilli, F; Di Pede, A; Catena, G; Lozzi, S; Auriti, C; Bersani, I; Capolupo, I; Lipreri, A; Di Ciommo, V; Dotta, A; Sgro, S				Piersigilli, Fiammetta; Di Pede, Alessandra; Catena, Gino; Lozzi, Simona; Auriti, Cinzia; Bersani, Iliana; Capolupo, Irma; Lipreri, Anna; Di Ciommo, Vincenzo; Dotta, Andrea; Sgro, Stefania			Propofol and fentanyl sedation for laser treatment of retinopathy of prematurity to avoid intubation	JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE			English	Article						Intubation; laser photocoagulation; neonates; propofol; retinopathy of prematurity; spontaneous breathing	INTRAVENOUS BOLUS; ANESTHESIA; CHILDREN; KETAMINE; NEWBORN; INFANTS; EFFICACY; INFUSION; MORPHINE; SAFETY	Background: Despite the optimization of neonatal assistance, severe retinopathy of prematurity (ROP, stage III-IV) remains a common condition among preterm infants. Laser photocoagulation usually requires general anesthesia and intubation, but extubation can be difficult and these infants often affected by chronic lung disease. We retrospectively evaluated the clinical charts of 13 neonates that were sedated with propofol in association with fentanyl for the laser treatment of ROP. This protocol was introduced in our unit to avoid intubation and minimize side effects of anesthesia and ventilation. Methods: Propofol 5% followed by a bolus of fentanyl was administered as sedation during laser therapy to 13 preterm infants, affected by ROP stage III-IV. Propofol was initially infused as a slow bolus of 2-4 mg/kg and then continuously during the entire procedure, at 4 mg/kg/hour, increasing the dosage to 6 mg/kg/hour if sedation was not achieved. A laryngeal mask was placed and patients were ventilated with a flow-inflating resuscitation bag. Results: Thirteen neonates were treated allowing to perform surgery without intubation. Only 4/13 (30.8%) of infants required minimal respiratory support during and/or after surgery. Heart rate after the intervention was higher than that at the beginning while remaining in the range of normal values. Blood pressures before, during and after surgery were similar. No episodes of bradycardia nor hypotension were recorded. Laser treatment was always successful. Conclusion: The good level of anesthesia and analgesia achieved sustains the efficacy of sedation with propofol during laser photocoagulation to avoid intubation and mechanical ventilation during and after the procedure.	[Piersigilli, Fiammetta; Di Pede, Alessandra; Lozzi, Simona; Auriti, Cinzia; Bersani, Iliana; Capolupo, Irma; Lipreri, Anna; Dotta, Andrea] Bambino Gesu Pediat Hosp, Dept Med & Surg Neonatol, Rome, Italy; [Catena, Gino] Bambino Gesu Pediat Hosp, Dept Ophthalmol, Rome, Italy; [Di Ciommo, Vincenzo] Bambino Gesu Pediat Hosp, Unit Clin Epidemiol, Rome, Italy; [Sgro, Stefania] Bambino Gesu Pediat Hosp, Dept Anesthesiol, Rome, Italy	Piersigilli, F (reprint author), Bambino Gesu Pediat Hosp, IRCCS, Piazza St Onofrio 4, Rome, Italy.	fiammetta.piersigilli@opbg.net	Dotta, Andrea/AAA-6343-2020; piersigilli, fiammetta/I-6951-2019	piersigilli, fiammetta/0000-0002-6581-2822; Auriti, Cinzia/0000-0001-9820-6557			Allegaert K, 2008, BRIT J ANAESTH, V101, P827, DOI 10.1093/bja/aen276; Allegaert K, 2009, THER DRUG MONIT, V31, P411, DOI 10.1097/FTD.0b013e3181a8cc0a; Anand KJS, 2001, ARCH PEDIAT ADOL MED, V155, P173, DOI 10.1001/archpedi.155.2.173; Bray RJ, 1998, PAEDIATR ANAESTH, V8, P491; Chawla D, 2012, INDIAN J PEDIATR, V79, P501, DOI 10.1007/s12098-010-0279-7; Chen SDM, 2007, EYE, V21, P1033, DOI 10.1038/sj.eye.6702499; Cotsen MR, 1997, AM J ROENTGENOL, V169, P1019, DOI 10.2214/ajr.169.4.9308455; Dong CX, 2013, TOXICOL LETT, V220, P53, DOI 10.1016/j.toxlet.2013.03.030; DUBOIS MC, 1993, ANN FR ANESTH, V12, P566, DOI 10.1016/S0750-7658(05)80623-9; Gole GA, 2005, ARCH OPHTHALMOL-CHIC, V123, P991, DOI 10.1001/archopht.123.7.991; Haigh PM, 1997, BRIT J OPHTHALMOL, V81, P283, DOI 10.1136/bjo.81.4.283; Hartnett ME, 2015, OPHTHALMOLOGY, V122, P200, DOI 10.1016/j.ophtha.2014.07.050; Heard C, 2015, ANESTH ANALG, V120, P157, DOI 10.1213/ANE.0000000000000504; Kirwan C, 2007, ACTA OPHTHALMOL SCAN, V85, P644, DOI 10.1111/j.1600-0420.2007.00900.x; Lyon F, 2008, EYE, V22, P684, DOI 10.1038/sj.eye.6702717; Murat I, 2004, PAEDIATR ANAESTH, V14, P158, DOI 10.1111/j.1460-9592.2004.01167.x; Orge FH, 2013, J AAPOS, V17, P135, DOI 10.1016/j.jaapos.2012.11.020; Papoff P, 2008, PEDIATRICS, V121, P448, DOI 10.1542/peds.2007-3132; Parulekar MV, 2008, EYE, V22, P375, DOI 10.1038/sj.eye.6702642; Sammartino M, 2003, PAEDIATR ANAESTH, V13, P596, DOI 10.1046/j.1460-9592.2003.01101.x; Shah PS, 2011, COCHRANE DB SYST REV, V3; Simons SHP, 2013, ACTA PAEDIATR, V102, pE487, DOI 10.1111/apa.12367; Vanderhaegen J, 2010, NEONATOLOGY, V98, P57, DOI 10.1159/000271224; Veyckemans F, 2001, PAEDIATR ANAESTH, V11, P630, DOI 10.1046/j.1460-9592.2001.0750c.x; Welzing L, 2010, PEDIATR ANESTH, V20, P605, DOI 10.1111/j.1460-9592.2010.03330.x; WESTRIN P, 1991, ANESTHESIOLOGY, V74, P455, DOI 10.1097/00000542-199103000-00011	26	1	1	4	16	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1476-7058	1476-4954		J MATERN-FETAL NEO M	J. Matern.-Fetal Neonatal Med.	FEB 1	2019	32	3					517	521		10.1080/14767058.2017.1383379			5	Obstetrics & Gynecology	Obstetrics & Gynecology	HB0GI	WOS:000450690600024	28974135				2020-06-30	J	Schaller, SJ; Kappler, FP; Hofberger, C; Sattler, J; Wagner, R; Schneider, G; Blobner, M; Kanz, KG				Schaller, Stefan J.; Kappler, Felix P.; Hofberger, Claudia; Sattler, Jens; Wagner, Richard; Schneider, Gerhard; Blobner, Manfred; Kanz, Karl-Georg			Differences in pain treatment between surgeons and anaesthesiologists in a physician staffed prehospital emergency medical service: a retrospective cohort analysis	BMC ANESTHESIOLOGY			English	Article						Prehospital pain management; Prehospital emergency medicine; Emergency physicians	TRAUMA PATIENTS; MYOCARDIAL-INFARCTION; ANALGESIA; MANAGEMENT; OLIGOANALGESIA; UNDERTREATMENT; GUIDELINE; ELEVATION; MORPHINE; FENTANYL	Background: Although pain treatment is an important objective in prehospital emergency medicine the incidence of oligoanalgesia is still high in prehospital patients. Given that prehospital emergency medicine in Germany is open for physicians of any speciality, the prehospital pain treatment may differ depending on the primary medical education. Aim of this study was to explore the difference in pain treatment between surgeons and anaesthesiologists in a physician staffed emergency medical service. Methods: Retrospective single centre cohort analysis in a physician staffed ground based emergency medical service from January 2014 until December 2016. A total of 8882 consecutive emergency missions were screened. Primary outcome measure was the difference in application frequency of prehospital analgesics by anaesthesiologist or surgeon. Univariate and multivariate logistic regression analysis was used for statistical analysis including subgroup analysis for trauma and acute coronary syndrome. Results: A total of 8238 patients were included in the analysis. There was a significant difference in the application frequency of analgesics between surgeons and anaesthesiologists especially for opioids (p < 0.001, OR 0.68 [0.56-0.82]). Fentanyl was the most common administered analgesic in the trauma subgroup, but significantly less common used by surgeons (p = 0.005, OR 0.63 [0.46-0.87]). In acute coronary syndrome cases there was no significant difference in morphine administration between anaesthesiologists and surgeons (p = 0.49, OR 0.88 [0.61-1.27]). Conclusions: Increased training for prehospital pain treatment should be implemented, since opioids were administered notably less frequent by surgeons than by anaesthesiologists.	[Schaller, Stefan J.; Kappler, Felix P.; Hofberger, Claudia; Sattler, Jens; Wagner, Richard; Schneider, Gerhard; Blobner, Manfred] Tech Univ Munich, Klin Anasthesiol & Intens Med, Klinikum Rechts Isar, Sch Med, Munich, Bavaria, Germany; [Kanz, Karl-Georg] Tech Univ Munich, Sch Med, Klin Unfallchirurg, Klinikum Rechts Isar, Munich, Bavaria, Germany	Schaller, SJ (reprint author), Tech Univ Munich, Klin Anasthesiol & Intens Med, Klinikum Rechts Isar, Sch Med, Munich, Bavaria, Germany.	s.schaller@tum.de	Schaller, Stefan J/L-8054-2019; Blobner, Manfred/R-4411-2017	Schaller, Stefan J/0000-0002-6683-9584; Blobner, Manfred/0000-0002-0370-5247; Schneider, Gerhard/0000-0002-4903-0118			Albrecht E, 2013, BRIT J ANAESTH, V110, P96, DOI 10.1093/bja/aes355; Bakkelund KE, 2013, EUR J EMERG MED, V20, P428, DOI 10.1097/MEJ.0b013e32835c9fa3; Butler Frank K, 2014, J Spec Oper Med, V14, P13; Calil AM, 2007, CLINICS, V62, P591, DOI 10.1590/S1807-59322007000500010; Eidenbenz D, 2016, ANAESTHESIA, V71, P779, DOI 10.1111/anae.13462; Fischer M, 2011, RESUSCITATION, V82, P285, DOI 10.1016/j.resuscitation.2010.11.001; Galinski M, 2010, PREHOSP EMERG CARE, V14, P334, DOI 10.3109/10903121003760218; Gausche-Hill M, 2014, PREHOSP EMERG CARE, V18, P25, DOI 10.3109/10903127.2013.844873; Hilbert-Carius P, 2017, ANAESTHESIST, V66, P195, DOI 10.1007/s00101-017-0265-9; Hofmann-Kiefer K, 1998, ANAESTHESIST, V47, P93, DOI 10.1007/s001010050533; Hossfeld B, 2016, ANASTH INTENSIV NOTF, V51, P84, DOI 10.1055/s-0042-101466; Ibanez B, 2018, EUR HEART J, V39, P119, DOI 10.1093/eurheartj/ehx393; Jennings PA, 2011, EMERG MED J, V28, P530, DOI 10.1136/emj.2010.098954; Kanowitz A, 2006, PREHOSP EMERG CARE, V10, P1, DOI 10.1080/10903120500373264; Katzer R, 2012, APPL CLIN INFORM, V3, P301, DOI 10.4338/ACI-2012-03-RA-0008; Kubica J, 2016, EUR HEART J, V37, P245, DOI 10.1093/eurheartj/ehv547; Laudermilch DJ, 2010, J AM COLL SURGEONS, V210, P220, DOI 10.1016/j.jamcollsurg.2009.10.008; Parodi G, 2015, CIRC-CARDIOVASC INTE, V8, DOI 10.1161/CIRCINTERVENTIONS.114.001593; Puymirat E, 2016, EUR HEART J, V37, P1063, DOI 10.1093/eurheartj/ehv567; Roffi M, 2016, EUR HEART J, V37, P267, DOI 10.1093/eurheartj/ehv320; Sattler PW, 2005, THESIS; Smith MD, 2012, J EMERG MED, V43, P69, DOI 10.1016/j.jemermed.2011.05.018; Spilman SK, 2016, INJURY, V47, P2018, DOI 10.1016/j.injury.2016.03.012; Stork B, 2009, ANAESTHESIST, V58, P639, DOI 10.1007/s00101-009-1585-1; TCCC, 2015, J SPECIAL OPERATIONS, V15, P129; Wahlin RR, 2016, BMC EMERG MED, V16, DOI 10.1186/s12873-016-0070-9	26	2	2	0	1	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1471-2253			BMC ANESTHESIOL	BMC Anesthesiol.	JAN 31	2019	19								18	10.1186/s12871-019-0683-0			7	Anesthesiology	Anesthesiology	HP7PU	WOS:000461881600002	30704401	DOAJ Gold, Green Published			2020-06-30	J	Vives, R; Fernandez-Galinski, D; Gordo, F; Izquierdo, A; Oliva, JC; Colilles, C; Pontes, C				Vives, Roser; Fernandez-Galinski, Diana; Gordo, Francisca; Izquierdo, Alberto; Oliva, Joan C.; Colilles, Carmen; Pontes, Caridad			Effects of bupivacaine or levobupivacaine on cerebral oxygenation during spinal anesthesia in elderly patients undergoing orthopedic surgery for hip fracture: a randomized controlled trial	BMC ANESTHESIOLOGY			English	Article						Spinal anesthesia; Regional cerebral oxygen saturation; Bupivacaine; Levobupivacaine	MENTAL STATUS QUESTIONNAIRE; ROPIVACAINE; SATURATION; STAY	Background: Bupivacaine and levobupivacaine have similar pharmacokinetic and pharmacodynamic characteristics, and are used regularly in spinal anesthesia. Whether potential differences in their hemodynamic and anesthetic profiles could determine a differential risk of complications in elderly subjects, is controversial. The main objective was to compare the effects of intrathecally administered levobupivacaine (LB) versus bupivacaine (B), on regional cerebral O-2 saturation during spinal anesthesia, cognitive status and neurological complications in elderly patients undergoing surgery for hip fracture. Methods: This was a randomized, controlled, single blind study. 58 patients aged 70 or older undergoing surgery for hip fracture with spinal anesthesia were allocated with a 1:1 ratio to receive LB or B, combined with fentanyl 15 mu g, by intrathecal route. The primary outcome was the proportion of intraoperative time with regional cerebral desaturation (>= 20% reduction in regional cerebral oxygen saturation from baseline), monitored by near -infrared spectroscopy. Secondary endpoints included hemodynamic parameters, level of sensory and motor block, changes in Short Portable Mental Status Questionnaire (SPMSQ), and neurological complications. Results: The mean percentage of intraoperative time with desaturation in the B group was 6.1% (SD: 17.5) and 4.7% (SD: 11.9) in the left and right hemisphere respectively; in the LB group the mean was 4.8% (SD: 11.4) in the left hemisphere and 2.4% (SD: 8.3) in the right one. No statistically significant differences were found between treatment groups. The level of sensory block at the start of surgery was lower for LB than for B (Th10 vs Th8, p:0.047) and motor block at 15 min was lower for LB (2.5 vs 3, p:0.009). No differences in postoperative SPMSQ were observed. Neurological complications such as confusional state, agitation or disorientation were reported in 50% of patients in the B group and 21.4% of patients in the LB group, p = 0.05. Conclusions: No statistically significant differences in regional cerebral oxygen saturation or hemodynamic parameters were observed between both treatment groups. Bupivacaine and levobupivacaine differed in sensory and motor block achieved. While no differences were observed in cognitive impairment measured by the SPMSQ between treatment groups neurological complications reported by the physician were more frequent with bupivacaine.	[Vives, Roser; Pontes, Caridad] Univ Autonoma Barcelona, Dept Farmacol Terapeut & Toxicol, Clin Pharmacol Unit, Parc Tauli Hosp Univ,I3PT, Parc Tauli 1, Sabadell 08028, Barcelona, Spain; [Fernandez-Galinski, Diana; Gordo, Francisca; Izquierdo, Alberto; Colilles, Carmen] Univ Autonoma Barcelona, Dept Anesthesiol, I3PT, Parc Tauli Hosp Univ, Parc Tauli 1, Sabadell 08028, Barcelona, Spain; [Oliva, Joan C.] Univ Autonoma Barcelona, Stat Unit, I3PT, Parc Tauli Hosp Univ, Parc Tauli 1, Sabadell 08028, Barcelona, Spain	Vives, R (reprint author), Univ Autonoma Barcelona, Dept Farmacol Terapeut & Toxicol, Clin Pharmacol Unit, Parc Tauli Hosp Univ,I3PT, Parc Tauli 1, Sabadell 08028, Barcelona, Spain.	Roser.vives@uab.cat	Pontes, Caridad/L-5131-2013	Pontes, Caridad/0000-0002-3274-6048; Vives, Roser/0000-0002-4369-778X			Ben-David B, 2000, ANESTHESIOLOGY, V92, P6, DOI 10.1097/00000542-200001000-00007; Bjorkelund KB, 2010, ACTA ANAESTH SCAND, V54, P678, DOI 10.1111/j.1399-6576.2010.02232.x; Carlson BW, 2011, J GERONTOL A-BIOL, V66, P150, DOI 10.1093/gerona/glq200; Casati A, 2005, ANESTH ANALG, V101, P740, DOI 10.1213/01.ane.0000166974.96219.cd; de la Iglesia JM, 2001, MED CLIN-BARCELONA, V117, P129; Erdil F, 2009, ANAESTHESIA, V64, P942, DOI 10.1111/j.1365-2044.2009.05995.x; Gautier P, 2003, BRIT J ANAESTH, V91, P684, DOI 10.1093/bja/aeg251; Hoppenstein D, 2005, J CLIN ANESTH, V17, P431, DOI 10.1016/j.jclinane.2004.09.013; McLeod GA, 2004, BRIT J ANAESTH, V92, P547, DOI 10.1093/bja/aeh094; Murkin J M, 2009, Br J Anaesth, V103 Suppl 1, pi3, DOI 10.1093/bja/aep299; Nakasuji M, 2012, J CLIN ANESTH, V24, P201, DOI 10.1016/j.jclinane.2011.07.014; Neuman MD, 2014, JAMA-J AM MED ASSOC, V311, P2508, DOI 10.1001/jama.2014.6499; Nishikawa Koichi, 2007, J Clin Monit Comput, V21, P109; Papadopoulos George, 2012, Open Orthop J, V6, P400, DOI 10.2174/1874325001206010400; PFEIFFER E, 1975, J AM GERIATR SOC, V23, P433, DOI 10.1111/j.1532-5415.1975.tb00927.x; Salazar F, 2014, BMC ANESTHESIOL, V14, DOI 10.1186/1471-2253-14-58; Slater JP, 2009, ANN THORAC SURG, V87, P36, DOI 10.1016/j.athoracsur.2008.08.070; Tosh W, 2016, BJA EDUC, V16, P417, DOI 10.1093/bjaed/mkw024; Zheng F, 2013, ANESTH ANALG, V116, P663, DOI 10.1213/ANE.0b013e318277a255	19	0	0	0	1	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1471-2253			BMC ANESTHESIOL	BMC Anesthesiol.	JAN 31	2019	19								17	10.1186/s12871-019-0682-1			11	Anesthesiology	Anesthesiology	HP7PU	WOS:000461881600001	30704463	DOAJ Gold, Green Published			2020-06-30	J	Lee, B; Park, JD; Choi, YH; Han, YJ; Suh, DI				Lee, Bongjin; Park, June Dong; Choi, Yu Hyeon; Han, Young Joo; Suh, Dong In			Efficacy and Safety of Fentanyl in Combination with Midazolam in Children on Mechanical Ventilation	JOURNAL OF KOREAN MEDICAL SCIENCE			English	Article						Children; Fentanyl; Mechanical Ventilation; Midazolam; Sedation	SEDATION; ANALGESIA; CARE; GUIDELINES	Background: To evaluate the efficacy and safety of fentanyl for sedation therapy in mechanically ventilated children. Methods: This was a double-blind, randomized controlled trial of mechanically ventilated patients between 2 months and 18 years of age. Patients were randomly divided into two groups; the control group with midazolam alone, and the combination group with both fentanyl and midazolam. The sedation level was evaluated using the Comfort Behavior Scale (CBS), and the infusion rates were adjusted according to the difference between the measured and the target CBS score. Results: Forty-four patients were recruited and randomly allocated, with 22 patients in both groups. The time ratio of cumulative hours with a difference in CBS score (measured CBS-target CBS) of >= 4 points (i.e., under-sedation) was lower in the combination group (median, 0.06; interquartile range [IQR], 0-0.2) than in the control group (median, 0.15; IQR, 0.04-0.29) (P < 0.001). The time ratio of cumulative hours with a difference in CBS score of >= 8 points (serious under-sedation) was also lower in the combination group (P < 0.001). The cumulative amount of midazolam used in the control group (0.11 mg/kg/hr; 0.07-0.14 mg/kg/hr) was greater than in the combination group (0.07 mg/kg/hr; 0.06-0.11 mg/kg/hr) (P < 0.001). Two cases of hypotension in each group were detected but coma and ileus, the major known adverse reactions to fentanyl, did not occur. Conclusion: Fentanyl combined with midazolam is safe and more effective than midazolam alone for sedation therapy in mechanically ventilated children.	[Lee, Bongjin; Park, June Dong; Choi, Yu Hyeon; Han, Young Joo; Suh, Dong In] Seoul Natl Univ, Dept Pediat, Coll Med, Seoul, South Korea; [Lee, Bongjin] Chungnam Natl Univ Hosp, Dept Pediat, Daejeon, South Korea	Park, JD (reprint author), Seoul Natl Univ, Coll Med, Dept Pediat, Div Pediat Intens Care, 101 Daehak Ro, Seoul 03080, South Korea.	jdparkmd@snu.ac.kr		Park, June Dong/0000-0001-8113-1384; CHOI, YU HYEON/0000-0002-3057-0886; Suh, Dong In/0000-0002-7817-8728; Lee, Bongjin/0000-0001-7878-9644	Ministry of Food and Drug Safety of KoreaMinistry of Food & Drug Safety (MFDS) [12172MFDS231]	This research was supported by a grant (12172MFDS231) from Ministry of Food and Drug Safety of Korea in 2012.	AMBUEL B, 1992, J PEDIATR PSYCHOL, V17, P95, DOI 10.1093/jpepsy/17.1.95; Anand KJS, 2013, PEDIATR CRIT CARE ME, V14, P27, DOI 10.1097/PCC.0b013e318253c80e; Ancora G, 2013, J PEDIATR-US, V163, P645, DOI 10.1016/j.jpeds.2013.02.039; Aranda JV, 2005, CLIN THER, V27, P877, DOI 10.1016/j.clinthera.2005.06.019; BURTIN P, 1991, LANCET, V337, P1545, DOI 10.1016/0140-6736(91)93235-2; Carbajal R, 2015, LANCET RESP MED, V3, P796, DOI 10.1016/S2213-2600(15)00331-8; Diaper AM, 2014, BRIT J CLIN PHARMACO, V77, P302, DOI 10.1111/bcp.12245; Jenkins IA, 2007, PEDIATR ANESTH, V17, P675, DOI 10.1111/j.1460-9592.2006.02180.x; Kadam Prashant, 2010, Int J Ayurveda Res, V1, P55, DOI 10.4103/0974-7788.59946; Kleinman ME, 2010, CIRCULATION, V122, pS876, DOI 10.1161/CIRCULATIONAHA.110.971101; Kress JP, 2006, CRIT CARE MED, V34, P2541, DOI 10.1097/01.CCM.0000239117.39890.E3; Kudchadkar SR, 2014, CRIT CARE MED, V42, P1592, DOI 10.1097/CCM.0000000000000326; Lopez J, 2015, J PEDIATR-US, V167, P857, DOI 10.1016/j.jpeds.2015.06.046; MARX CM, 1994, CRIT CARE MED, V22, P163, DOI 10.1097/00003246-199401000-00029; Mehta S, 2006, CRIT CARE MED, V34, P374, DOI 10.1097/01.CCM.0000196830.61965.F1; Minardi C, 2012, CURR DRUG TARGETS, V13, P936, DOI 10.2174/138945012800675740; Ostermann ME, 2000, JAMA-J AM MED ASSOC, V283, P1451, DOI 10.1001/jama.283.11.1451; Playfor SD, 2008, ARCH DIS CHILDHOOD-E, V93, P87, DOI 10.1136/adc.2007.119628; Playfor S, 2006, INTENS CARE MED, V32, P1125, DOI 10.1007/s00134-006-0190-x; Richman PS, 2006, CRIT CARE MED, V34, P1395, DOI 10.1097/01.CCM.0000215454.50964.F8; SCHWARTZ GJ, 1976, PEDIATRICS, V58, P259; Takemoto CK, 2014, PEDIAT NEONATAL DOSA; Tripp DA, 2003, J ATHL TRAINING, V38, P154; van Dijk M, 2000, PAIN, V84, P367, DOI 10.1016/S0304-3959(99)00239-0; Wolf AR, 2011, PEDIATR ANESTH, V21, P567, DOI 10.1111/j.1460-9592.2010.03460.x	25	0	0	0	1	KOREAN ACAD MEDICAL SCIENCES	SEOUL	302 75 DONG DU ICHON, DONG YONGSAN KU, SEOUL 140 031, SOUTH KOREA	1011-8934	1598-6357		J KOREAN MED SCI	J. Korean Med. Sci.	JAN 21	2019	34	3							UNSP e21	10.3346/jkms.2019.34.e21			10	Medicine, General & Internal	General & Internal Medicine	HI2IS	WOS:000456269300006	30662387	DOAJ Gold, Green Published			2020-06-30	J	Kliewer, A; Schmiedel, F; Sianati, S; Bailey, A; Bateman, JT; Levitt, ES; Williams, JT; Christie, MJ; Schulz, S				Kliewer, A.; Schmiedel, F.; Sianati, S.; Bailey, A.; Bateman, J. T.; Levitt, E. S.; Williams, J. T.; Christie, M. J.; Schulz, S.			Phosphorylation-deficient G-protein-biased mu-opioid receptors improve analgesia and diminish tolerance but worsen opioid side effects	NATURE COMMUNICATIONS			English	Article							MICE LACKING; FUNCTIONAL SELECTIVITY; TERMINAL TAIL; DESENSITIZATION; MORPHINE; STIMULATION; DEPENDENCE; LIGAND; SITES	Opioid analgesics are powerful pain relievers; however, over time, pain control diminishes as analgesic tolerance develops. The molecular mechanisms initiating tolerance have remained unresolved to date. We have previously shown that desensitization of the mu-opioid receptor and interaction with beta-arrestins is controlled by carboxyl-terminal phosphorylation. Here we created knockin mice with a series of serine- and threonine-to-alanine mutations that render the receptor increasingly unable to recruit beta-arrestins. Desensitization is inhibited in locus coeruleus neurons of mutant mice. Opioid-induced analgesia is strongly enhanced and analgesic tolerance is greatly diminished. Surprisingly, respiratory depression, constipation, and opioid withdrawal signs are unchanged or exacerbated, indicating that beta-arrestin recruitment does not contribute to the severity of opioid side effects and, hence, predicting that G-protein-biased mu-agonists are still likely to elicit severe adverse effects. In conclusion, our findings identify carboxyl-terminal multisite phosphorylation as key step that drives acute mu-opioid receptor desensitization and long-term tolerance.	[Kliewer, A.; Schmiedel, F.; Schulz, S.] Jena Univ Hosp, Friedrich Schiller Univ, Inst Pharmacol & Toxicol, D-07747 Jena, Germany; [Sianati, S.; Christie, M. J.] Univ Sydney, Sch Med Sci, Discipline Pharmacol, Sydney, NSW 2006, Australia; [Bailey, A.] St Georges Univ London, Inst Med & Biomed Educ, London SW17 0RE, England; [Bateman, J. T.; Levitt, E. S.] Univ Florida, Dept Pharmacol & Therapeut, Gainesville, FL 32608 USA; [Williams, J. T.] Oregon Hlth & Sci Univ, Vollum Inst, 3181S W Sam Jackson Pk Rd, Portland, OR 97239 USA	Schulz, S (reprint author), Jena Univ Hosp, Friedrich Schiller Univ, Inst Pharmacol & Toxicol, D-07747 Jena, Germany.	Stefan.Schulz@med.uni-jena.de	Bailey, Alexis/AAI-1489-2020; Christie, MacDonald/AAM-2144-2020; Levitt, Erica/AAJ-6755-2020; Schulz, Stefan/A-6928-2017	Bailey, Alexis/0000-0003-1541-1964; Christie, MacDonald/0000-0002-0622-609X; Sianati, Setareh/0000-0002-5964-6434; Schulz, Stefan/0000-0002-5997-8885	Deutsche ForschungsgemeinschaftGerman Research Foundation (DFG) [SFB/TR166-TPC5, SCHU924/10-3]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [DA08163, DA038069]; National Health and Medical Research Council of AustraliaNational Health and Medical Research Council of Australia [APP1072113, 1045964]; Horizon 2020 EU funding SmokeFreeBrain [681120]	We thank Helga Bechmann, Elke Miess, Pooja Dasgupta, Sebastian Fritzwanker and Heike Stadtler for excellent technical assistance, Ralf Stumm for discussion and Rainer Reinscheid for critical reading of the manuscript. This work was supported by the Deutsche Forschungsgemeinschaft grants SFB/TR166-TPC5 and SCHU924/10-3 to S.S., NIH DA08163 to J.T.W., National Health and Medical Research Council of Australia (APP1072113 and 1045964) to M.J.C., Horizon 2020 EU funding SmokeFreeBrain 681120 to A. B. and NIH DA038069 to E.S.L.	AVIDORREISS T, 1995, J BIOL CHEM, V270, P29732; Bailey CP, 2009, EUR J NEUROSCI, V29, P307, DOI 10.1111/j.1460-9568.2008.06573.x; Birdsong WT, 2015, MOL PHARMACOL, V88, P816, DOI 10.1124/mol.114.097527; Bohn LM, 2000, NATURE, V408, P720, DOI 10.1038/35047086; Bohn LM, 1999, SCIENCE, V286, P2495, DOI 10.1126/science.286.5449.2495; Chen YJ, 2013, J NEUROCHEM, V124, P189, DOI 10.1111/jnc.12071; Chu J, 2010, CELL SIGNAL, V22, P684, DOI 10.1016/j.cellsig.2009.12.003; COLLIER HOJ, 1980, NATURE, V283, P625, DOI 10.1038/283625a0; Dang VC, 2012, MOL PHARMACOL, V82, P473, DOI 10.1124/mol.112.079350; DeWire SM, 2013, J PHARMACOL EXP THER, V344, P708, DOI 10.1124/jpet.112.201616; Doll C, 2012, BRIT J PHARMACOL, V167, P1259, DOI 10.1111/j.1476-5381.2012.02080.x; Doll C, 2011, BRIT J PHARMACOL, V164, P298, DOI 10.1111/j.1476-5381.2011.01382.x; Finn AK, 2001, NEURON, V32, P829, DOI 10.1016/S0896-6273(01)00517-7; Georgiou P, 2016, NEUROPHARMACOLOGY, V105, P520, DOI 10.1016/j.neuropharm.2016.02.012; Gluck L, 2014, BIOL PSYCHIAT, V76, P767, DOI 10.1016/j.biopsych.2014.01.021; Grecksch G, 2011, J NEUROSCI, V31, P13890, DOI 10.1523/JNEUROSCI.2304-11.2011; Illing S, 2014, BRIT J PHARMACOL, V171, P1330, DOI 10.1111/bph.12546; Just S, 2013, MOL PHARMACOL, V83, P633, DOI 10.1124/mol.112.082875; Kenakin T, 2011, J PHARMACOL EXP THER, V336, P296, DOI 10.1124/jpet.110.173948; Kitchen I, 1997, BRAIN RES, V778, P73, DOI 10.1016/S0006-8993(97)00988-8; Koob GF, 1998, NEURON, V21, P467, DOI 10.1016/S0896-6273(00)80557-7; Kuhar JR, 2015, CELL SIGNAL, V27, P1799, DOI 10.1016/j.cellsig.2015.05.019; Lau EK, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001748; Levitt ES, 2015, J PHYSIOL-LONDON, V593, P4453, DOI 10.1113/JP270822; Levitt ES, 2013, J APPL PHYSIOL, V115, P1626, DOI 10.1152/japplphysiol.00889.2013; Lowe JD, 2015, MOL PHARMACOL, V88, P347, DOI 10.1124/mol.115.098293; MALDONADO R, 1992, NEUROPHARMACOLOGY, V31, P1231, DOI 10.1016/0028-3908(92)90051-P; Manglik A, 2016, NATURE, V537, P185, DOI 10.1038/nature19112; McGrath JC, 2010, BRIT J PHARMACOL, V160, P1573, DOI 10.1111/j.1476-5381.2010.00873.x; Melief EJ, 2010, P NATL ACAD SCI USA, V107, P11608, DOI 10.1073/pnas.1000751107; Miess E, 2018, SCI SIGNAL, V11, DOI 10.1126/scisignal.aas9609; MORTOLA JP, 1983, J APPL PHYSIOL, V55, P250; Nestler EJ, 1997, SCIENCE, V278, P58, DOI 10.1126/science.278.5335.58; Prkic I, 2012, J NEUROPHYSIOL, V108, P2430, DOI 10.1152/jn.00185.2012; Raehal KM, 2011, NEUROPHARMACOLOGY, V60, P58, DOI 10.1016/j.neuropharm.2010.08.003; Raehal KM, 2009, DRUG ALCOHOL DEPEN, V104, P187, DOI 10.1016/j.drugalcdep.2009.04.011; Raehal KM, 2005, J PHARMACOL EXP THER, V314, P1195, DOI 10.1124/jpet.105.087254; Rankovic Z, 2016, BIOORG MED CHEM LETT, V26, P241, DOI 10.1016/j.bmcl.2015.12.024; Schmid CL, 2017, CELL, V171, P1165, DOI 10.1016/j.cell.2017.10.035; Schulz S, 2004, EMBO J, V23, P3282, DOI 10.1038/sj.emboj.7600334; Terman GW, 2004, BRIT J PHARMACOL, V141, P55, DOI 10.1038/sj.bjp.0705595; Urban JD, 2007, J PHARMACOL EXP THER, V320, P1, DOI 10.1124/jpet.106.104463; Williams JT, 2013, PHARMACOL REV, V65, P223, DOI 10.1124/pr.112.005942; Yousuf A, 2015, MOL PHARMACOL, V88, P825, DOI 10.1124/mol.115.098244	44	34	34	8	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2041-1723			NAT COMMUN	Nat. Commun.	JAN 21	2019	10								367	10.1038/s41467-018-08162-1			11	Multidisciplinary Sciences	Science & Technology - Other Topics	HI0WL	WOS:000456165100004	30664663	DOAJ Gold, Green Published, Green Accepted	Y	N	2020-06-30	J	Colon-Berezin, C; Nolan, ML; Blachman-Forshay, J; Paone, D				Colon-Berezin, Cody; Nolan, Michelle L.; Blachman-Forshay, Jaclyn; Paone, Denise			Overdose Deaths Involving Fentanyl and Fentanyl Analogs - New York City, 2000-2017	MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT			English	Editorial Material							INCREASES; STATES		[Colon-Berezin, Cody; Nolan, Michelle L.; Blachman-Forshay, Jaclyn; Paone, Denise] Bur Alcohol & Drug Use Prevent Care & Treatment, New York City Dept Hlth & Mental Hyg, Long Isl City, NY 11101 USA	Paone, D (reprint author), Bur Alcohol & Drug Use Prevent Care & Treatment, New York City Dept Hlth & Mental Hyg, Long Isl City, NY 11101 USA.	dpaone@health.nyc.gov		Nolan, Michelle/0000-0003-1951-4151			Centers for Disease Control (CDC), 2015, INCR FENT DRUG CONF; Drug Enforcement Administration, 2007, CONTR CHEM PREC US I; Gladden RM, 2016, MMWR-MORBID MORTAL W, V65, P837, DOI 10.15585/mmwr.mm6533a2; National Center for Health Statistics, 2017, DRUG OV DEATHS US 19; Nolan ML, 2018, UNINTENTIONAL DRUG P; Peterson AB, 2016, MMWR-MORBID MORTAL W, V65, P844, DOI 10.15585/mmwr.mm6533a3; Rudd RA, 2016, MMWR-MORBID MORTAL W, V64, P1378, DOI 10.15585/mmwr.mm6450a3; Sable J, 2016, RECOMMENDATIONS LESS; Scholl L, 2019, MMWR-MORBID MORTAL W, V67, P1419; Somerville NJ, 2017, MMWR-MORBID MORTAL W, V66, P382, DOI 10.15585/mmwr.mm6614a2	10	10	10	0	1	CENTERS  DISEASE CONTROL	ATLANTA	1600 CLIFTON RD, ATLANTA, GA 30333 USA	0149-2195	1545-861X		MMWR-MORBID MORTAL W	MMWR-Morb. Mortal. Wkly. Rep.	JAN 18	2019	68	2					37	40		10.15585/mmwr.mm6802a3			4	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	HI4EY	WOS:000456405100003	30653482	Bronze, Green Published			2020-06-30	J	Springer, YP; Gladden, RM; O'Donnell, J; Seth, P				Springer, Yuri P.; Gladden, R. Matthew; O'Donnell, Julie; Seth, Puja			Fentanyl Drug Submissions - United States, 2010-2017	MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT			English	Article							OVERDOSE DEATHS; ANALOGS		[Springer, Yuri P.; Gladden, R. Matthew; O'Donnell, Julie; Seth, Puja] CDC, Div Unintent Injury Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA	O'Donnell, J (reprint author), CDC, Div Unintent Injury Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA.	irh8@cdc.gov					Gladden RM, 2016, MMWR-MORBID MORTAL W, V65, P837, DOI 10.15585/mmwr.mm6533a2; O'Donnell J, 2018, MMWR-MORBID MORTAL W, V67, P767, DOI 10.15585/mmwr.mm6727a4; O'Donnell JK, 2017, MMWR-MORBID MORTAL W, V66, P1197, DOI 10.15585/mmwr.mm6643e1; Scholl L, 2019, MMWR-MORBID MORTAL W, V67, P1419; Seth P, 2018, MMWR-MORBID MORTAL W, V67, P349, DOI 10.15585/mmwr.mm6712a1	5	5	5	0	0	CENTERS  DISEASE CONTROL	ATLANTA	1600 CLIFTON RD, ATLANTA, GA 30333 USA	0149-2195	1545-861X		MMWR-MORBID MORTAL W	MMWR-Morb. Mortal. Wkly. Rep.	JAN 18	2019	68	2					41	43		10.15585/mmwr.mm6802a4			3	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	HI4EY	WOS:000456405100004	30653486	Bronze			2020-06-30	J	Lee, CH; Choi, SS; Lee, MK; Kim, JE; Chung, DI; Lee, M				Lee, Chung Hun; Choi, Sang Sik; Lee, Mi Kyoung; Kim, Jung Eun; Chung, Dong Ik; Lee, Mido			Electric stimulation-guided epidural analgesia for vaginal delivery: A randomized prospective study	PLOS ONE			English	Article							CONFIRMATION; ANESTHESIA; FAILURE; SPACE	Background The failure rate of epidural anesthesia using the loss of resistance technique is 13-23%. Objectives To investigate the efficacy of epidural electric stimulation-guided epidural analgesia in vaginal delivery. Study design An open label randomized prospective study. Methods Laboring women were randomized to two groups: epidural catheter insertion using only a loss of resistance technique or a loss of resistance technique with confirmation by electric stimulation. Catheters in both groups were initially tested with 3 ml of 1% lidocaine and those with any evidence of motor blockade were considered intrathecal. Sensory blockade and an 11 point numerical rating score for pain were assessed 30 minutes after administration of an epidural bolus of 10 ml of 0.22% ropivacaine with fentanyl. Successful epidural analgesia was defined as a decrease of 2 or more in the pain score and a bilateral L1-T10 sensory blockade. Results Thirty-one patients were randomized to each group. The first 20 patients in each group were enrolled in a pilot study and were also included in the final analysis. One patient in the electric stimulation group was excluded owing to dural puncture by the Tuohy needle. One patient in each group demonstrated motor blockade after test dose and were considered failures. The number (% (95% confidence interval)) of successful cases were 29 out of 30 (97% (85, 100%)) in the electric stimulation group and 24 out of 31 (77% (61, 89%)) in the loss of resistance group (P = 0.053). However, analysis of only patients with absence of motor blockade revealed that 29 out of 29 (100% (92, 100%)) patients in the electric stimulation group and 24 of 29 (80% (63, 91%)) patients in the loss of resistance group had adequate analgesia (P = 0.024). Conclusions Although limited by lack of blinding, small study size and inclusion of pilot study data, this study suggests epidural electric stimulation improves the success rate of subsequent labor analgesia.	[Lee, Chung Hun; Choi, Sang Sik; Lee, Mi Kyoung; Kim, Jung Eun; Chung, Dong Ik; Lee, Mido] Korea Univ, Med Ctr, Guro Hosp, Dept Anesthesiol & Pain Med, Seoul, South Korea	Choi, SS (reprint author), Korea Univ, Med Ctr, Guro Hosp, Dept Anesthesiol & Pain Med, Seoul, South Korea.	clonidine@empal.com			Sewoon Medical Co., Ltd., Seoul, Korea	The authors have no sources of funding to declare, however, the epidural catheter (RegionalStim (TM)) used in this study was provided by Sewoon Medical Co., Ltd., Seoul, Korea. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The funder only provided support in the form of research materials for authors [S. S. C.], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section.	Agaram R, 2009, INT J OBSTET ANESTH, V18, P10, DOI 10.1016/j.ijoa.2007.10.008; Eappen S, 1998, INT J OBSTET ANESTH, V7, P220, DOI 10.1016/S0959-289X(98)80042-3; Gomar C, 2000, EUR J ANAESTH, V17, P542, DOI 10.1046/j.1365-2346.2000.00733.x; Goobie SM, 2003, ANESTH ANALG, V97, P984, DOI 10.1213/01.ANE.0000080609.05942.38; Grau T, 2002, J CLIN ANESTH, V14, P169, DOI 10.1016/S0952-8180(01)00378-6; Grau T, 2001, BRIT J ANAESTH, V86, P798, DOI 10.1093/bja/86.6.798; Hermanides J, 2012, BRIT J ANAESTH, V109, P144, DOI 10.1093/bja/aes214; Hislop H, 2014, PRINCIPLES MANUAL MU, P1; Jeong JS, 2012, KOREAN J ANESTHESIOL, V63, P238, DOI 10.4097/kjae.2012.63.3.238; Kinsella SM, 2008, ANAESTHESIA, V63, P822, DOI 10.1111/j.1365-2044.2008.05499.x; MICHAEL S, 1989, ANAESTHESIA, V44, P578, DOI 10.1111/j.1365-2044.1989.tb11446.x; Pan PH, 2004, INT J OBSTET ANESTH, V13, P227, DOI 10.1016/j.ijoa.2004.04.008; Silva M, 2010, LOCAL REG ANESTH, V3, P143, DOI 10.2147/LRA.S10237; Sutherland MA, 2009, REGION ANESTH PAIN M, V34, P575, DOI 10.1097/AAP.0b013e3181bfbe1e; Thangamuthu A, 2013, INT J OBSTET ANESTH, V22, P310, DOI 10.1016/j.ijoa.2013.04.013; Toledano RD, 2014, ANESTHESIOLOGY, V121, P9, DOI 10.1097/ALN.0000000000000239; Tsui BCH, 1998, CAN J ANAESTH, V45, P640, DOI 10.1007/BF03012093; Wantman A, 2006, ANAESTHESIA, V61, P370, DOI 10.1111/j.1365-2044.2006.04534.x	18	0	0	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 11	2019	14	1							e0209967	10.1371/journal.pone.0209967			10	Multidisciplinary Sciences	Science & Technology - Other Topics	HH1MW	WOS:000455485100010	30633755	DOAJ Gold, Green Published			2020-06-30	J	Bell, A; Bennett, AS; Jones, TS; Doe-Simkins, M; Williams, LD				Bell, Alice; Bennett, Alex S.; Jones, T. Stephen; Doe-Simkins, Maya; Williams, Leslie D.			Amount of naloxone used to reverse opioid overdoses outside of medical practice in a city with increasing illicitly manufactured fentanyl in illicit drug supply	SUBSTANCE ABUSE			English	Article						Community-based overdose prevention; illicitly manufactured fentanyl; naloxone; opioid overdose	DEATHS; STATES	Background: Illicitly manufactured fentanyl (IMF) prevalence has increased. However, there is uncertainty about naloxone dose(s) used by nonmedical bystanders to reverse opioid overdoses in the context of increasing IMF. Methods: We used community naloxone distribution program data about naloxone doses and fatal opioid overdoses from the Allegheny County Medical Examiner. From January 2013 to December 2016, staff interviewed participants who administered naloxone in response to 1072 overdoses. We calculated frequencies, percentages, and conducted a 1-way analysis of variance (ANOVA). Results: Despite increases in fentanyl-contributed deaths, there were no statistically significant differences between any of the 4 years (2013-2016) on average number of naloxone doses used by participants to reverse an overdose (F = 0.88; P = .449). Conclusion: Even though IMF is more potent than heroin and is a rapidly increasing contributor to drug overdose deaths in Allegheny County, the average dose of naloxone administered has not changed. Our findings differ from studies in different areas also experiencing increasing IMF prevalence. Additional investigations are needed to clarify the amount of naloxone needed to reverse opioid overdoses in the community caused by new synthetic opioids.	[Bell, Alice] Prevent Point Pittsburgh, 460 Melwood Ave,Suite 205, Pittsburgh, PA 15213 USA; [Bennett, Alex S.; Williams, Leslie D.] Natl Dev & Res Inst Inc, New York, NY USA; [Jones, T. Stephen] T Stephen Jones Publ Hlth Consulting, Florence, MA USA; [Doe-Simkins, Maya] Harm Reduct Michigan, Maple City, MI USA	Bell, A (reprint author), Prevent Point Pittsburgh, 460 Melwood Ave,Suite 205, Pittsburgh, PA 15213 USA.	abell@pppgh.org					[Anonymous], 2017, FAT OV TIM 2013 2016; [Anonymous], 2017, DRUG ENF ADM AN OV D; Bennett AS, 2011, J URBAN HEALTH, V88, P1020, DOI 10.1007/s11524-011-9600-7; CDC, 2015, CDC HLTH ADV INCR FE; Faul M, 2017, PREHOSP EMERG CARE, V21, P411, DOI 10.1080/10903127.2017.1315203; FDA, 2016, FDA ADV COMM MOST AP; Gladden RM, 2016, MMWR-MORBID MORTAL W, V65, P837, DOI 10.15585/mmwr.mm6533a2; Peterson AB, 2016, MMWR-MORBID MORTAL W, V65, P844, DOI 10.15585/mmwr.mm6533a3; Prekupec MP, 2017, J ADDICT MED, V11, P256, DOI 10.1097/ADM.0000000000000324; Rudd RA, 2016, MMWR-MORBID MORTAL W, V65, P1445, DOI 10.15585/mmwr.mm655051e1; Somerville NJ, 2017, MMWR-MORBID MORTAL W, V66, P382, DOI 10.15585/mmwr.mm6614a2; Wheeler E, 2015, MMWR-MORBID MORTAL W, V64, P631	12	8	8	0	0	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0889-7077	1547-0164		SUBST ABUS	Subst. Abus.	JAN 2	2019	40	1					52	55		10.1080/08897077.2018.1449053			4	Substance Abuse	Substance Abuse	IE0IU	WOS:000472071100008	29558283				2020-06-30	J	Palamar, JJ; Salomone, A; Bigiarini, R; Vincenti, M; Acosta, P; Tofighi, B				Palamar, Joseph J.; Salomone, Alberto; Bigiarini, Rachele; Vincenti, Marco; Acosta, Patricia; Tofighi, Babak			Testing hair for fentanyl exposure: a method to inform harm reduction behavior among individuals who use heroin	AMERICAN JOURNAL OF DRUG AND ALCOHOL ABUSE			English	Article						Heroin; fentanyl; adulterants; hair testing; drug testing; harm reduction	CONTAMINATED HEROIN; RHODE-ISLAND; YOUNG-ADULTS; URINE; DRUGS; OPIOIDS; RISK	Background: Deaths from fentanyl exposure continue to increase in the US. Fentanyl test strips are now available to test urine for presence of fentanyl, but additional testing methods are needed to determine past exposure and to determine exposure to specific analogs. Objectives: To investigate exposure to such analogs through hair testing. Methods: Forty individuals in inpatient detoxification (7.5% female) reporting past-month heroin use were surveyed and provided a hair sample to be tested at a later date. While results could not be provided to patients, they were asked how they would respond if informed that their hair tested positive for fentanyl. UHPLC-MS/MS was used to test for past exposure to fentanyl, six other novel synthetic opioids, and fentanyl biomarkers/metabolites. Results: 27.5% reported known fentanyl use in the past year and 67.5% reported suspected exposure. 97.5% (39 of 40) tested positive for fentanyl, 90.0% tested positive for 4-ANPP (a biomarker) and norfentanyl (a metabolite); 82.5% tested positive for acetyl-fentanyl, 47.5% tested positive for furanyl-fentanyl, and 7.5% tested positive for U-47700. Most participants (82.5%) reported they would warn others about fentanyl if they learned their hair tested positive; 75.0% reported they would try to stop using heroin, and 65.0% reported they would ensure that someone nearby has naloxone to reverse a potential overdose. Conclusions: Hair testing is useful in detecting past exposure to fentanyl, its analogs, and other novel synthetic opioids. Further research is needed to determine whether individuals who use heroin learning about exposure affects drug-taking and treatment-seeking behavior.	[Palamar, Joseph J.; Acosta, Patricia; Tofighi, Babak] NYU, Langone Med Ctr, Dept Populat Hlth, New York, NY 10016 USA; [Salomone, Alberto; Vincenti, Marco] Ctr Reg Antidoping & Tossicol A Bertinaria, Turin, Italy; [Salomone, Alberto; Bigiarini, Rachele; Vincenti, Marco] Univ Torino, Dipartimento Chim, Turin, Italy; [Tofighi, Babak] NYU, Sch Med, Div Gen Internal Med, New York, NY USA	Palamar, JJ (reprint author), Dept Populat Hlth, 180 Madison Ave,Room 1752, New York, NY 10016 USA.	joseph.palamar@nyulangone.org	Vincenti, Marco/M-3495-2015	Vincenti, Marco/0000-0002-6275-7194; Tofighi, Babak/0000-0001-7393-7564; Palamar, Joseph/0000-0002-8565-9415	National Institute on Drug Abuse of the National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [K01DA038800, K23DA042140]	Research reported in this publication was supported by the National Institute on Drug Abuse of the National Institutes of Health under Award Number K01DA038800 (PI: Palamar) and K23DA042140 (PI: Tofighi). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.	Bloomberg American Health Initiative, 2018, FENT OV RED CHECK AN; Carroll JJ, 2017, INT J DRUG POLICY, V46, P136, DOI 10.1016/j.drugpo.2017.05.023; Ciccarone D, 2017, INT J DRUG POLICY, V46, P146, DOI 10.1016/j.drugpo.2017.06.004; Griswold MK, 2018, CLIN TOXICOL, V56, P37, DOI 10.1080/15563650.2017.1339889; Jones AA, 2018, JAMA PSYCHIAT, V75, P298, DOI 10.1001/jamapsychiatry.2017.4432; Jones CM, 2018, JAMA-J AM MED ASSOC, V319, P1819, DOI 10.1001/jama.2018.2844; Kenney SR, 2018, J SUBST ABUSE TREAT, V86, P65, DOI 10.1016/j.jsat.2018.01.005; Kintz P, 2015, HAIR ANAL CLIN FOREN; Krieger MS, 2018, HARM REDUCT J, V15, DOI 10.1186/s12954-018-0213-2; Macmadu A, 2017, ADDICT BEHAV, V68, P35, DOI 10.1016/j.addbeh.2017.01.014; McKnight C, 2018, INT J DRUG POLICY, V60, P82, DOI 10.1016/j.drugpo.2018.08.004; Mema SC, 2018, HARM REDUCT J, V15, DOI 10.1186/s12954-018-0224-z; Moody MT, 2018, DRUG TEST ANAL, V10, P1358, DOI 10.1002/dta.2393; Moore PQ, 2017, AM J EMERG MED, V35, P1706, DOI 10.1016/j.ajem.2017.05.003; Ogilvie L, 2013, MMWR-MORBID MORTAL W, V62, P703; Palamar JJ, 2017, INT J DRUG POLICY, V48, P91, DOI 10.1016/j.drugpo.2017.07.010; Palamar JJ, 2016, DRUG ALCOHOL DEPEN, V161, P200, DOI 10.1016/j.drugalcdep.2016.02.001; Park JN, 2018, HARM REDUCT J, V15, DOI 10.1186/s12954-018-0240-z; POKLIS A, 1995, J TOXICOL-CLIN TOXIC, V33, P439, DOI 10.3109/15563659509013752; Salomone A, 2019, J ANAL TOXICOL, V43, P259, DOI 10.1093/jat/bky093; Salomone A, 2017, J ANAL TOXICOL, V41, P376, DOI 10.1093/jat/bkx020; SILVERSTEIN JH, 1993, ANESTH ANALG, V76, P618; Suzuki J, 2017, DRUG ALCOHOL DEPEN, V171, P107, DOI 10.1016/j.drugalcdep.2016.11.033; Tupper KW, 2018, DRUG ALCOHOL DEPEN, V190, P242, DOI 10.1016/j.drugalcdep.2018.06.020; US Drug Enforcement Administration, 2018, 2017 EM THREAT REP; US Drug Enforcement Administration Diversion Control Division, 2018, NFLIS BRIEF FENT FEN	26	10	10	1	5	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0095-2990	1097-9891		AM J DRUG ALCOHOL AB	Am. J. Drug Alcohol Abuse	JAN 2	2019	45	1					90	96		10.1080/00952990.2018.1550652			7	Psychology, Clinical; Substance Abuse	Psychology; Substance Abuse	HM0KW	WOS:000459137500009	30601034	Green Accepted			2020-06-30	J	Wallace, B; Kennedy, MC; Kerr, T; Pauly, B				Wallace, Bruce; Kennedy, Mary Clare; Kerr, Thomas; Pauly, Bernie			Factors Associated with Nonfatal Overdose During a Public Health Emergency	SUBSTANCE USE & MISUSE			English	Article						Fentanyl; illicit drugs; injection drug users; nonfatal overdose	DRUG-USERS; FENTANYL; HEROIN; RISK; VANCOUVER; PEOPLE; COHORT; REDUCTION	Background: In 2016, in the Canadian province of British Columbia, the Provincial Health Officer declared drug-related overdose deaths a public health emergency. Objectives: In this study, we examine factors associated with recent non-fatal overdose during a time of unprecedented rates of overdose and increasing involvement of fentanyl and fentanyl derivatives in overdose deaths. Methods: Between June and September 2016, a cross-sectional survey was conducted among people who inject drugs (PWID) in Victoria, British Columbia, Canada. Bivariable and multivariable logistic regression analyses were used to examine factors associated with recent non-fatal overdose. Results: A total of 187 PWID were included in the present study, of whom 56 (29.9%) reported having overdosed in the previous 6 months. In multivariable analyses, fentanyl injection (Adjusted Odds Ratio [AOR] = 2.60; 95% confidence interval [CI]: (1.08 - 6.27) and public injection (AOR = 2.20; 95% CI: 1.09 - 4.43) were positively associated with recent non-fatal overdose. Conclusions: Fentanyl injection and public injection were associated with an increased likelihood of non-fatal overdose. These findings underscore the need for drug checking, safer sources of opioids and safer injecting interventions as part of overdose prevention strategies.	[Wallace, Bruce; Pauly, Bernie] Univ Victoria, Ctr Addict Res British Columbia, Victoria, BC V8W 2Y2, Canada; [Wallace, Bruce] Univ Victoria, Sch Social Work, Box 1700 STN SCS, Victoria, BC V8W 2Y2, Canada; [Kennedy, Mary Clare; Kerr, Thomas] St Pauls Hosp, British Columbia Ctr Substance Use, Vancouver, BC, Canada; [Kennedy, Mary Clare] Univ British Columbia, Sch Populat & Publ Hlth, Vancouver, BC, Canada; [Kerr, Thomas] Univ British Columbia, St Pauls Hosp, Dept Med, Vancouver, BC, Canada; [Pauly, Bernie] Univ Victoria, Sch Nursing, Victoria, BC, Canada	Wallace, B (reprint author), Univ Victoria, Sch Social Work, Box 1700 STN SCS, Victoria, BC V8W 2Y2, Canada.	barclay@uvic.ca			University of Victoria; Centre for Addictions Research of BC; YES2SCS; Ontario HIV Treatment Network; Canadian Institute for Health Research (CIHR) Centre for REACH in HIV/AIDS; Bernie Pauly's University of Victoria Community Engaged Scholar Fund; Thomas Kerr's Foundation Grant [FDN-148476]; Social Sciences and Humanities Research Council; Mitacs Canada	The study was supported by funding from the University of Victoria's Internal Research Project Grant, Centre for Addictions Research of BC, YES2SCS, the Ontario HIV Treatment Network, as well as funding from the Canadian Institute for Health Research (CIHR) Centre for REACH in HIV/AIDS, Bernie Pauly's University of Victoria Community Engaged Scholar Fund, and Thomas Kerr's Foundation Grant (FDN-148476). Mary Clare Kennedy is supported by a Social Sciences and Humanities Research Council Doctoral Fellowship and a Mitacs Accelerate Award from Mitacs Canada.	BC Coroners Service, 2018, ILL DRUG OV DEATHS B; BCCDC, 2017, BC PUBL HLTH OP OV E; Bohnert ASB, 2009, ANN EMERG MED, V54, P618, DOI 10.1016/j.annemergmed.2009.05.004; Boyd S, 2017, HARM REDUCT J, V14, DOI 10.1186/s12954-017-0152-3; Carroll JJ, 2017, INT J DRUG POLICY, V46, P136, DOI 10.1016/j.drugpo.2017.05.023; Caudarella A, 2016, DRUG ALCOHOL DEPEN, V162, P51, DOI 10.1016/j.drugalcdep.2016.02.024; Ciccarone D, 2017, INT J DRUG POLICY, V46, P146, DOI 10.1016/j.drugpo.2017.06.004; Ciccarone D, 2017, INT J DRUG POLICY, V46, P107, DOI 10.1016/j.drugpo.2017.06.010; Coffin PO, 2007, ACAD EMERG MED, V14, P616, DOI 10.1111/j.1553-2712.2007.tb01846.x; Darke S, 2014, ADDICTION, V109, P1237, DOI 10.1111/add.12456; DeBeck K, 2009, J EPIDEMIOL COMMUN H, V63, P81, DOI 10.1136/jech.2007.069013; Escudero DJ, 2016, ADDICT BEHAV, V60, P8, DOI 10.1016/j.addbeh.2016.03.029; Fairbairn N, 2017, INT J DRUG POLICY, V46, P172, DOI 10.1016/j.drugpo.2017.06.005; Frank RG, 2017, NEW ENGL J MED, V376, P605, DOI 10.1056/NEJMp1615145; Gladden RM, 2016, MMWR-MORBID MORTAL W, V65, P837, DOI 10.15585/mmwr.mm6533a2; Holloway KR, 2016, J SUBST USE, V21, P471, DOI 10.3109/14659891.2015.1063718; Horyniak D, 2013, DRUG ALCOHOL DEPEN, V132, P541, DOI 10.1016/j.drugalcdep.2013.03.021; Ivsins A, 2012, INT J DRUG POLICY, V23, P338, DOI 10.1016/j.drugpo.2011.11.004; Kerensky T, 2017, ADDICT SCI CLIN PRAC, V12, DOI 10.1186/s13722-016-0068-3; Kerr T, 2007, DRUG ALCOHOL DEPEN, V87, P39, DOI 10.1016/j.drugalcdep.2006.07.009; Lake S, 2015, AM J DRUG ALCOHOL AB, V41, P257, DOI 10.3109/00952990.2014.998366; Lima VD, 2008, AIDS, V22, P2371, DOI 10.1097/QAD.0b013e328315cdd3; Lysyshyn M, 2017, HARM RED INT MONTR Q; MacNeil J, 2010, HARM REDUCT J, V7, DOI 10.1186/1477-7517-7-11; Marshall BDL, 2011, LANCET, V377, P1429, DOI 10.1016/S0140-6736(10)62353-7; Misailidi N., 2017, FORENSIC TOXICOL, V1, P21; Mounteney J, 2015, INT J DRUG POLICY, V26, P626, DOI 10.1016/j.drugpo.2015.04.003; Moyer VA, 2013, ANN INTERN MED, V159, P210, DOI 10.7326/0003-4819-159-3-201308060-00652; Oviedo-Joekes E, 2016, JAMA PSYCHIAT, V73, P447, DOI 10.1001/jamapsychiatry.2016.0109; Pauly B, 2018, DRUG-EDUC PREV POLIC, V25, P21, DOI 10.1080/09687637.2017.1337081; Small W, 2007, INT J DRUG POLICY, V18, P27, DOI 10.1016/j.drugpo.2006.11.019; Stoove MA, 2009, DRUG ALCOHOL REV, V28, P347, DOI 10.1111/j.1465-3362.2009.00057.x; van Dam-Bates P., 2015, J SUBST USE, V21, P1; Wallace B, 2016, EVERY WASHROOM DE FA; Warner-Smith M, 2002, ADDICTION, V97, P963, DOI 10.1046/j.1360-0443.2002.00132.x; Wood E, 2005, AM J PREV MED, V29, P126, DOI 10.1016/j.amepre.2005.04.011	36	2	2	0	1	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1082-6084	1532-2491		SUBST USE MISUSE	Subst. Use Misuse	JAN 2	2019	54	1					39	45		10.1080/10826084.2018.1491051			7	Substance Abuse; Psychiatry; Psychology	Substance Abuse; Psychiatry; Psychology	HL8IP	WOS:000458986400005	30362861				2020-06-30	J	Lovrecic, B; Lovrecic, M; Gabrovec, B; Carli, M; Pacini, M; Maremmani, AGI; Maremmani, I				Lovrecic, Barbara; Lovrecic, Mercedes; Gabrovec, Branko; Carli, Marco; Pacini, Matteo; Maremmani, Angelo G. I.; Maremmani, Icro			Non-Medical Use of Novel Synthetic Opioids: A New Challenge to Public Health	INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH			English	Review						new psychoactive substances; new synthetic opioids; illicit fentanyl; Mitragyna speciosa; o-desmethyltramadol; novel fentanyl derivatives; new generation of novel synthetic opioids; harm reduction strategies; comprehensive treatment	METHADONE-MAINTENANCE TREATMENT; LC-MS-MS; ACETYL FENTANYL; PSYCHOACTIVE SUBSTANCE; MITRAGYNA-SPECIOSA; OVERDOSE DEATHS; LIQUID-CHROMATOGRAPHY; NALOXONE DISTRIBUTION; O-DESMETHYLTRAMADOL; FATAL INTOXICATIONS	Background: In the last decade there has been a progressive increase in the use of new psychoactive substances (NPSs) that are not yet under international control. In particular, novel synthetic opioids (NSOs) have reappeared on the recreational drug market in the last few years. As a result, the use of NSOs has increased rapidly. This poses an emerging and demanding challenge to public health. Aim: To raise awareness among clinicians and other professionals about NPSs, especially NSOs, to summarize current knowledge about pharmacological properties, forms of NSO on the market, pattern of use, effects and consequences of use. Methods: An electronic search was carried out on the Medline/PubMed and Google Scholar databases to find selected search terms. Results: Some NPSs are already controlled, while others can be legally sold directly on the drug market (mainly via internet, less so by drug dealers) or be used as precursors for the synthesis of other designer drugs that mimic the psychoactive effects of controlled substances. Potential side-effects of NSOs include miosis, sedation, respiratory depression, hypothermia, inhibition of gastrointestinal propulsion, death (from opioid overdose). Conclusions: The severity of the opioid crisis has intensified with the introduction of highly potent NSOs on the drug market. As long as addicts are dying from overdose or similar causes, there is something more constructive to do than waiting for addicts to overdose on heroin at a place located near a remedy, as if to say, within reach of naloxone.	[Lovrecic, Barbara; Lovrecic, Mercedes; Gabrovec, Branko] Natl Inst Publ Hlth, Ljubljana 1000, Slovenia; [Lovrecic, Mercedes] Izola Hlth Ctr, Ctr Psychiat & Addict Med, Izola 6310, Slovenia; [Carli, Marco] Univ Pisa, Dept Translat Res & New Technol, I-56100 Pisa, Italy; [Pacini, Matteo; Maremmani, Icro] G De Lisio Inst Behav Sci, I-56100 Pisa, Italy; [Maremmani, Angelo G. I.] North Western Tuscany Reg NHS Local Hlth Unit, Dept Psychiat, I-55049 Viareggio, Italy; [Maremmani, Angelo G. I.; Maremmani, Icro] Assoc Applicat Neurosci Knowledge Social Aim AU C, I-55045 Pietrasanta, Lucca, Italy; [Maremmani, Icro] Univ Pisa, Santa Chiara Univ Hosp, Vincent P Dole Dual Disorder Unit, I-56100 Pisa, Italy	Maremmani, I (reprint author), G De Lisio Inst Behav Sci, I-56100 Pisa, Italy.; Maremmani, I (reprint author), Assoc Applicat Neurosci Knowledge Social Aim AU C, I-55045 Pietrasanta, Lucca, Italy.; Maremmani, I (reprint author), Univ Pisa, Santa Chiara Univ Hosp, Vincent P Dole Dual Disorder Unit, I-56100 Pisa, Italy.	barbara.lovrecic@nijz.si; mercedes.lovrecic@nijz.si; branko.gabrovec@nijz.si; carlimarco@outlook.it; paciland@virgilio.it; angelo.maremmani@uslnordovest.toscana.it; maremman@med.unipi.it	Carli, Marco/AAK-1361-2020; Lovrecic, Mercedes/O-5732-2018	Carli, Marco/0000-0003-1447-4947; Maremmani, Angelo Giovanni Icro/0000-0001-7728-3705; Lovrecic, Mercedes/0000-0001-5935-0599; Gabrovec, Branko/0000-0002-3885-1308			Adkins JE, 2011, CURR TOP MED CHEM, V11, P1165; Alzghari SK, 2017, CUREUS, V9, DOI 10.7759/cureus.1791; Anwar M, 2016, MMWR-MORBID MORTAL W, V65, P748, DOI 10.15585/mmwr.mm6529a4; Armenian P, 2018, NEUROPHARMACOLOGY, V134, P121, DOI 10.1016/j.neuropharm.2017.10.016; Backberg M, 2015, CLIN TOXICOL, V53, P609, DOI 10.3109/15563650.2015.1054505; Bagley SM, 2015, SUBST ABUS, V36, P149, DOI 10.1080/08897077.2014.989352; Barra M, 2014, HEROIN ADDICT REL CL, V16, P101; Baselt R.C., 2014, DISPOSITION TOXIC DR; Bauer SM, 2008, EUR ADDICT RES, V14, P82, DOI 10.1159/000113722; Behar E, 2015, DRUG ALCOHOL DEPEN, V148, P209, DOI 10.1016/j.drugalcdep.2014.12.009; Best D, 2000, DRUG ALCOHOL REV, V19, P213, DOI 10.1080/713659326; Bishop-Freeman SC, 2016, J ANAL TOXICOL, V40, P677, DOI 10.1093/jat/bkw069; Bizzarri JV, 2017, ANN GEN PSYCHIATR, V16, DOI 10.1186/s12991-017-0132-8; Boyer EW, 2008, ADDICTION, V103, P1048, DOI 10.1111/j.1360-0443.2008.02209.x; Boyer EW, 2012, NEW ENGL J MED, V367, P146, DOI 10.1056/NEJMra1202561; BRADBERRY JC, 1981, DRUG INTEL CLIN PHAR, V15, P945, DOI 10.1177/106002808101501205; Bradvik L, 2007, SUICIDE LIFE-THREAT, V37, P475, DOI 10.1521/suli.2007.37.4.475; Breindahl T, 2017, DRUG TEST ANAL, V9, P415, DOI 10.1002/dta.2046; Brugal MT, 2005, ADDICTION, V100, P981, DOI 10.1111/j.1360-0443.2005.01089.x; Buxton J.A., 2009, CONTEMP DRUG PROBL, V36, P447, DOI [10.1177/009145090903600306, DOI 10.1177/009145090903600306]; Caplehorn JRM, 1996, SUBST USE MISUSE, V31, P177, DOI 10.3109/10826089609045806; CCENDUCanadian Community Epidemiology Network on Drug Use, 2016, CCENDU B NOV SYNTH O; Clark AK, 2014, J ADDICT MED, V8, P153, DOI 10.1097/ADM.0000000000000034; Coopman V, 2016, FORENSIC SCI INT, V266, P469, DOI 10.1016/j.forsciint.2016.07.005; Coopman V, 2016, FORENSIC SCI INT, V266, P68, DOI 10.1016/j.forsciint.2016.05.001; Coppola M, 2015, DRUG ALCOHOL REV, V34, P109, DOI 10.1111/dar.12216; Cunningham SM, 2016, J FORENSIC SCI, V61, pS276, DOI 10.1111/1556-4029.12953; Daniulaityte R, 2017, MMWR-MORBID MORTAL W, V66, P904, DOI 10.15585/mmwr.mm6634a3; Dargan P., 2013, NOVEL PSYCHOACTIVE S, V15, P63; Dart RC, 2015, NEW ENGL J MED, V372, P241, DOI [10.1056/NEJMc1501822, 10.1056/NEJMsa1406143]; DEA, 2016, COUNT PRESCR PILLS C; DEADrug Enforcement Administration, 2016, DEA ISS CARF WARN PO; Department of Justice, 2015, FED REGISTER, V80, P29227; Dole V.P., 1995, DRUG ADDICTION RELAT, P45; Dole V. P., 1999, HEROIN ADDICT REL CL, V1, P13; DOLE VP, 1966, NEW YORK STATE J MED, V66, P2011; DOLE VP, 1968, J AMER MED ASSOC, V206, P2708, DOI 10.1001/jama.206.12.2708; DOLE VP, 1976, JAMA-J AM MED ASSOC, V235, P2117, DOI 10.1001/jama.235.19.2117; DOLE VP, 1966, ARCH INTERN MED, V118, P304, DOI 10.1001/archinte.118.4.304; DOLE VP, 1967, ARCH INTERN MED, V120, P19, DOI 10.1001/archinte.120.1.19; DOLE VP, 1972, NEW ENGL J MED, V286, P988, DOI 10.1056/NEJM197205042861808; DOLE VP, 1971, J AMER MED ASSOC, V215, P1131, DOI 10.1001/jama.215.7.1131; Domanski K, 2017, CLIN TOXICOL, V55, P46, DOI 10.1080/15563650.2016.1209763; Dorman C, 2015, HEPATOLOGY, V61, P1086, DOI 10.1002/hep.27612; Dussy FE, 2016, J ANAL TOXICOL, V40, P761, DOI 10.1093/jat/bkw096; Dziadosz M, 2017, INT J LEGAL MED, V131, P1555, DOI 10.1007/s00414-017-1593-7; Elliott Simon P, 2016, Drug Test Anal, V8, P875, DOI 10.1002/dta.1984; EMCDDA, 2017, EUR DRUG REP 2017 TR; EMCDDA, 2017, FENT DRUG PROF; EMCDDA, 2016, AC EMCDDA EUR JOINT; EMCDDA, 2015, REP RISK ASS MT 45 F; EMCDDA, 2014, EMCDDA EUR JOINT REP; Fabregat-Safont D, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-06778-9; FDA, 2016, COUNT MED; Fels H, 2017, FORENSIC SCI INT, V277, pE30, DOI 10.1016/j.forsciint.2017.04.003; Fleming SW, 2017, J ANAL TOXICOL, V41, P173, DOI 10.1093/jat/bkw131; Forliti A., 2018, DANGEROUS DRUG CARFE; Fort C, 2016, J ANAL TOXICOL, V40, P754, DOI 10.1093/jat/bkw068; Gergov M, 2009, FORENSIC SCI INT, V186, P36, DOI 10.1016/j.forsciint.2009.01.013; Gjersing L, 2013, SCAND J PUBLIC HEALT, V41, P119, DOI 10.1177/1403494812472007; Government of Alberta, 2016, ANN TOX OP CARF LINK; Green TC, 2016, JAMA INTERN MED, V176, P1555, DOI 10.1001/jamainternmed.2016.4310; Gregory TB, 2013, CLIN THER, V35, P2007, DOI 10.1016/j.clinthera.2013.09.027; Guerrieri D, 2017, J ANAL TOXICOL, V41, P242, DOI 10.1093/jat/bkw129; Hansen A, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g1686; Helander A, 2017, BRIT J DERMATOL, V176, P1021, DOI 10.1111/bjd.15174; Helander A, 2014, CLIN TOXICOL, V52, P901, DOI 10.3109/15563650.2014.943908; Helander A, 2017, CLIN TOXICOL, V55, P589, DOI 10.1080/15563650.2017.1303141; Helander A, 2016, CLIN TOXICOL, V54, P324, DOI 10.3109/15563650.2016.1139715; Higashikawa Y, 2008, FORENSIC TOXICOL, V26, P1, DOI 10.1007/s11419-007-0039-1; Holler JM, 2011, J ANAL TOXICOL, V35, P54, DOI 10.1093/anatox/35.1.54; Huang XP, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.97222; Ishiyama D, 2013, EMERG MED J, V30, P860, DOI 10.1136/emermed-2013-203100.3; Kapp FG, 2011, J MED TOXICOL, V7, P227, DOI 10.1007/s13181-011-0155-5; Karinen R, 2014, FORENSIC SCI INT, V244, pE21, DOI 10.1016/j.forsciint.2014.08.013; Katselou M, 2016, FORENSIC TOXICOL, V34, P201, DOI 10.1007/s11419-016-0310-4; Katselou M, 2015, FORENSIC TOXICOL, V33, P195, DOI 10.1007/s11419-015-0271-z; Kerr T, 2004, LANCET, V364, P1918, DOI 10.1016/S0140-6736(04)17490-4; Kronstrand R, 2014, J ANAL TOXICOL, V38, P599, DOI 10.1093/jat/bku057; Kronstrand R, 2011, J ANAL TOXICOL, V35, P242, DOI 10.1093/anatox/35.4.242; Liechti ME, 2015, SWISS MED WKLY, V145, DOI 10.4414/smw.2015.14043; Lovrecic M., 2002, HEROIN ADDICT REL CL, V4, P5; Lozier MJ, 2015, J MED TOXICOL, V11, P208, DOI 10.1007/s13181-015-0477-9; Lu J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115648; Lydecker AG, 2016, J MED TOXICOL, V12, P341, DOI 10.1007/s13181-016-0588-y; Madras BK, 2017, CURR TOP BEHAV NEURO, V32, P1, DOI 10.1007/7854_2016_34; Maremmani I, 2009, PRINCIPLES PRACTICE; Maremmani I., 1999, HEROIN ADDICT REL CL, V1, P7; Maremmani I., 2009, PRINCIPLES PRACTICE, P181; Maremmani I, 2011, HEROIN ADDICT REL CL, V13, P5; Maremmani I, 2009, HEROIN ADDICT REL CL, V11, P5; Massey J, 2017, MMWR-MORBID MORTAL W, V66, P975, DOI 10.15585/mmwr.mm6637a3; McIntyre IM, 2017, J ANAL TOXICOL, V41, P158, DOI 10.1093/jat/bkw124; McIntyre IM, 2015, J ANAL TOXICOL, V39, P490, DOI 10.1093/jat/bkv043; McIntyre IM, 2015, J ANAL TOXICOL, V39, P152, DOI 10.1093/jat/bku137; McWhirter L, 2010, EUR ADDICT RES, V16, P229, DOI 10.1159/000320288; Melent'ev A, 2015, J ANAL CHEM+, V70, P240, DOI 10.1134/S1061934815020124; Miller C, 2013, J ANAL TOXICOL, V37, P559, DOI 10.1093/jat/bkt076; Mohr ALA, 2016, J ANAL TOXICOL, V40, P709, DOI 10.1093/jat/bkw086; Mounteney J, 2015, INT J DRUG POLICY, V26, P626, DOI 10.1016/j.drugpo.2015.04.003; National center for biotechnology information, PUBCH COMP DAT; Neerman MF, 2013, J FORENSIC SCI, V58, pS278, DOI 10.1111/1556-4029.12009; Nelsen JL, 2010, J MED TOXICOL, V6, P424, DOI 10.1007/s13181-010-0079-5; Newman R. G., 1995, DRUG ADDICTION RELAT, P109; Nikolaou P, 2017, FORENSIC TOXICOL, V35, P11, DOI 10.1007/s11419-016-0347-4; O'Donnell JK, 2017, MMWR-MORBID MORTAL W, V66, P1197, DOI 10.15585/mmwr.mm6643e1; Ochoa KC, 2001, ADDICT BEHAV, V26, P453, DOI 10.1016/S0306-4603(00)00115-5; Pantano F, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17040580; Papsun D, 2016, J ANAL TOXICOL, V40, P313, DOI 10.1093/jat/bkw012; PATHAK V, 2014, AM J RESP CRIT CARE, V189; Peterson AB, 2016, MMWR-MORBID MORTAL W, V65, P844, DOI 10.15585/mmwr.mm6533a3; Poklis J, 2015, FORENSIC SCI INT, V257, P435, DOI 10.1016/j.forsciint.2015.10.021; Pollack HA, 2008, HEALTH SERV RES, V43, P2143, DOI 10.1111/j.1475-6773.2008.00870.x; Prekupec MP, 2017, J ADDICT MED, V11, P256, DOI 10.1097/ADM.0000000000000324; Prozialeck WC, 2016, J AM OSTEOPATH ASSOC, V116, P802, DOI 10.7556/jaoa.2016.156; Prozialeck WC, 2012, J AM OSTEOPATH ASSOC, V112, P792; Quintana P, 2017, INT J DRUG POLICY, V40, P78, DOI 10.1016/j.drugpo.2016.10.006; Rambaran KA, 2017, J EMERG MED, V53, P509, DOI 10.1016/j.jemermed.2017.05.034; Rech MA, 2015, PHARMACOTHERAPY, V35, P189, DOI 10.1002/phar.1522; Reimer J, 2014, SUBST ABUSE TREAT PR, V9, DOI 10.1186/1747-597X-9-13; Riches JR, 2012, J ANAL TOXICOL, V36, P647, DOI 10.1093/jat/bks078; Roche KM, 2008, CLIN TOXICOL, V46, P598; Ruan XL, 2016, FORENSIC SCI MED PAT, V12, P369, DOI 10.1007/s12024-016-9795-8; SAMHSA Center for the Application of Prevention, 2017, ILL SYNTH OP UND POT; Schifano F, 2015, WORLD PSYCHIATRY, V14, P15, DOI 10.1002/wps.20174; Scott TM, 2014, DRUG TEST ANAL, V6, P959, DOI 10.1002/dta.1673; Seither J, 2017, J ANAL TOXICOL, V41, P493, DOI 10.1093/jat/bkx049; Shanks KG, 2017, J ANAL TOXICOL, V41, P466, DOI 10.1093/jat/bkx042; Sheleg SV, 2011, J ADDICT MED, V5, P300, DOI 10.1097/ADM.0b013e318221fbfa; Shoff EN, 2017, J ANAL TOXICOL, V41, P484, DOI 10.1093/jat/bkx041; Siddiqi S, 2015, CLIN TOXICOL, V53, P54, DOI 10.3109/15563650.2014.983239; Singh D, 2014, DRUG ALCOHOL DEPEN, V139, P132, DOI 10.1016/j.drugalcdep.2014.03.017; Staeheli SN, 2016, FORENSIC SCI INT, V266, P170, DOI 10.1016/j.forsciint.2016.05.034; Stanley TH, 2014, J PAIN, V15, P1215, DOI 10.1016/j.jpain.2014.08.010; Stogner JM, 2014, ANN EMERG MED, V64, P637, DOI 10.1016/j.annemergmed.2014.07.017; Strang J, 2003, BRIT MED J, V326, P959, DOI 10.1136/bmj.326.7396.959; Swanson DM, 2017, J ANAL TOXICOL, V41, P498, DOI 10.1093/jat/bkx037; Swogger MT, 2015, J PSYCHOACTIVE DRUGS, V47, P360, DOI 10.1080/02791072.2015.1096434; Takase I, 2016, LEGAL MED-TOKYO, V21, P38, DOI 10.1016/j.legalmed.2016.05.006; Tungtananuwat W, 2010, J HEALTH RES, V24, P43; Ujvary I, 2017, FORENSIC TOXICOL, V35, P232, DOI 10.1007/s11419-017-0367-8; United Nations Office on Drugs and Crime (UNODC), 2017, FENT ITS AN 50 YEARS; United States Federal Register, 2018, SCHED CONTR SUBST TE; UNODC, 2013, WORLD DRUG REP 2013; UNODC, 2013, CHALL NEW PSYCH SUBS; UNODC, 2017, GLOB SYNTH DRUGS ASS; US Department of Justice, 2018, FED REGISTER, V83, P17486; US Department of Justice, 2017, FED REGISTER, V82, P58557; Vorce SP, 2014, J ANAL TOXICOL, V38, P226, DOI 10.1093/jat/bku011; Walley AY, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f174; Warner ML, 2016, INT J LEGAL MED, V130, P127, DOI 10.1007/s00414-015-1279-y; Warner-Smith M, 2001, ADDICTION, V96, P1113, DOI 10.1046/j.1360-0443.2001.96811135.x; WELLS B, 1994, ADDICTION, V89, P806, DOI 10.1111/j.1360-0443.1994.tb00977.x; Wermeling DP, 2013, DRUG DELIV TRANSL RE, V3, P63, DOI 10.1007/s13346-012-0092-0; WHO, 2016, P EXP COMM DRUG DEP; WHO UNODC UNAIDS, 2004, WHO UNODC UNAIDS POS; World Health Organization, 2014, P EXP COMM DRUG DEP; World Health Organization, 2009, GUID PSYCH ASS PHARM; Yonemitsu K, 2016, FORENSIC SCI INT, V267, pE6, DOI 10.1016/j.forsciint.2016.08.025; Yusoff NHM, 2016, ADDICT BIOL, V21, P98, DOI 10.1111/adb.12185; Zawilska JB, 2017, FRONT PSYCHIATRY, V8, DOI 10.3389/fpsyt.2017.00110	161	2	2	1	7	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		1660-4601		INT J ENV RES PUB HE	Int. J. Environ. Res. Public Health	JAN 2	2019	16	2							177	10.3390/ijerph16020177			21	Environmental Sciences; Public, Environmental & Occupational Health	Environmental Sciences & Ecology; Public, Environmental & Occupational Health	HM0CF	WOS:000459112100012	30634521	DOAJ Gold, Green Published			2020-06-30	J	Masoumi, K; Maleki, SJ; Forouzan, A; Delirrooyfard, A; Hesam, S				Masoumi, Kambiz; Maleki, Seyyed Javad; Forouzan, Arash; Delirrooyfard, Ali; Hesam, Saeed			Dexmedetomidine versus Midazolam-Fentanyl in Procedural Analgesia Sedation for Reduction of Anterior Shoulder Dislocation: A Randomized Clinical Trial	REVIEWS ON RECENT CLINICAL TRIALS			English	Article						Dexmedetomidine; pain management; sedation; shoulder dislocation; randomized clinical trial; analgesia	COMBINATION; RECOVERY; PROPOFOL	Background: Shoulder joint dislocation is the most common dislocation of joints in the body. To reduce the anterior shoulder dislocation, it is necessary to have analgesia and sedation. Methods: In this randomized clinical trial, patients were divided into two equal groups. Group I received midazolam-fentanyl (0.05 mg/kg fentanyl at a dose of 1 mu g/kg) for 10 minutes and group II received dexmedetomidine (1 mu g/kg in the initial dose and then 0.2 mu g/kg/h) for 10 minutes. The levels of analgesia according to VAS criteria and the time to reach desired sedation were compared between the two groups. Results: A total of 60 patients participated in this study. The time to reach the desired sedation was 8.60 +/- 2.3 minutes in the dexmedetomidine group and 11.27 +/- 3.57 minutes in the midazolamfentanyl group (p= 0.001). Also, the VAS score in both midazolam-fentanyl and dexmedetomidine groups was 3.3 +/- 1.24 and 2.57 +/- 0.9, respectively. The differences were statistically significant (p=0.015). There was significant relationship between the time to reach desired sedation and the level of analgesia. Moreover, there was no significant difference between patient age and the time to reach the desired level of analgesia. During this study, no side effect was observed. Conclusion: The findings of this study show that dexmedetomidine provides a higher level of analgesia than midazolam-fentanyl. Moreover, it was also shown that dexmedetomidine causes quicker procedural sedation than midazolam-fentanyl.	[Masoumi, Kambiz; Maleki, Seyyed Javad; Forouzan, Arash; Delirrooyfard, Ali] Ahvaz Jundishapur Univ Med Sci, Dept Emergency Med, Ahwaz, Iran; [Hesam, Saeed] Ahvaz Jundishapur Univ Med Sci, Fac Hlth, Dept Biostat & Epidemiol, Ahwaz, Iran	Delirrooyfard, A (reprint author), Ahvaz Jundishapur Univ Med Sci, Dept Emergency Med, Ahwaz, Iran.	adelir2891@gmail.com	hesam, saeed/AAG-3289-2019; Forouzan, Arash/Q-8158-2017	Masoumi, Kambiz/0000-0001-7234-5671; Forouzan, Arash/0000-0003-0754-9779	Ahvaz Jundishapur University of Medical Sciences [U94116]	This study has been funded by Ahvaz Jundishapur University of Medical Sciences (Number of the project: U94116).	Cho JS, 2014, EUROPACE, V16, P1000, DOI 10.1093/europace/eut365; Chong M, 2006, ANN ROY COLL SURG, V88, P454, DOI 10.1308/003588406X117115; Chung C H, 2004, HONG KONG J EMERG ME, V11, p178 ; Fedor KL, 2017, RESP CARE, V62, P699, DOI 10.4187/respcare.05244; Gerlach AT, 2007, ANN PHARMACOTHER, V41, P245, DOI 10.1345/aph.1H314; Gilotra MN, 2016, J ORTHOP SPORT PHYS, V46, P708, DOI 10.2519/jospt.2016.0413; IANNOTTI JP, 1992, J BONE JOINT SURG AM, V74A, P491, DOI 10.2106/00004623-199274040-00004; Jewett J, 2010, EUR J EMERG MED, V17, P60, DOI 10.1097/MEJ.0b013e3283325ec2; Miller JB, 2014, CLIN NEUROPSYCHOL, V28, P575, DOI 10.1080/13854046.2014.907445; Mwipatayi B. P., 2005, EUROPEAN J TRAUMA, V31, P181, DOI DOI 10.1308/003588406X117115]; Ozturk TC, 2014, HONG KONG J EMERG ME, V21, P346; Pacifici GM, 2014, INT J PEDIAT, DOI 10.1155/2014/309342; Rasheed Mohd Asim, 2015, Anesth Essays Res, V9, P167, DOI 10.4103/0259-1162.156299; Robinson CM, 2011, J BONE JOINT SURG AM, V93A, P1605, DOI 10.2106/JBJS.J.00973; Rouleau DM, 2014, J AM ACAD ORTHOP SUR, V22, P145, DOI 10.5435/JAAOS-22-03-145; Taylor DM, 2005, ACAD EMERG MED, V12, P13, DOI 10.1197/j.aem.2004.08.039; Venn RM, 2000, CRIT CARE, V4, P302, DOI 10.1186/cc712; Visser CPJ, 1999, J BONE JOINT SURG BR, V81B, P679, DOI 10.1302/0301-620X.81B4.9005; Wang XQ, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003639; Yu C, 2014, INT J ORAL MAX SURG, V43, P1148, DOI 10.1016/j.ijom.2014.03.019; Zeyneloglu P, 2008, EUR J ANAESTH, V25, P961, DOI 10.1017/S0265021508004699	21	0	0	2	3	BENTHAM SCIENCE PUBL LTD	SHARJAH	EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES	1574-8871	1876-1038		REV RECENT CLIN TRIA	Rev. Recent Clin. Trials		2019	14	4					269	274		10.2174/1574887114666190809160419			6	Pharmacology & Pharmacy	Pharmacology & Pharmacy	JM1ET	WOS:000495966200007	31400271				2020-06-30	J	Oh, SK; Lee, I; Lim, BG; Jeong, H; Kim, YS; Ji, SG; Park, JS				Oh, Seok Kyeong; Lee, Il Ok; Lim, Byung Gun; Jeong, Hyerim; Kim, Young Sung; Ji, Sul Gi; Park, Jong Sun			Comparison of the Analgesic Effect of Sufentanil versus Fentanyl in Intravenous Patient-Controlled Analgesia after Total Laparoscopic Hysterectomy: A Randomized, Double-blind, Prospective Study	INTERNATIONAL JOURNAL OF MEDICAL SCIENCES			English	Article						Patient-controlled analgesia; Fentanyl; Sufentanil; Postoperative pain; Hysterectomy	POSTOPERATIVE PAIN MANAGEMENT; CONSENSUS GUIDELINES; SAFETY; NAUSEA; INTENSITY	Background: Fentanyl is one of the most widely used opioids for intravenous patient-controlled analgesia (IV-PCA). Sufentanil, a fentanyl analog, is suitable for postoperative pain control because it has no active metabolites and shows a higher therapeutic index and lower frequency of respiratory suppression than fentanyl. This study aimed to compare the two opioids for postoperative pain relief on the basis of analgesic efficacy, adverse effects, and patient satisfaction. Methods: Sixty-four patients undergoing total laparoscopic hysterectomy were randomly allocated into a fentanyl group (n = 31) or a sufentanil group (n = 33). The patients received 50-mu g fentanyl or 10-mu g sufentanil before induction of anesthesia and 5 minutes after uterine incision during surgery in the fentanyl and sufentanil group, respectively. After arriving at the post-anesthesia care unit (PACU), verbal pain score (VPS) and sedation score were assessed. IV-PCA (fentanyl 1250 mu g or sufentanil 250 mu g with ondansetron 8 mg; total volume, 60 ml) was connected and continued for 48 h postoperatively. Postoperative pain was evaluated by using the numeric rating scale (NRS; at rest/during cough) at 6, 12, 24, 36, and 48 hours after surgery. The cumulative PCA consumption, patient satisfaction scores, and adverse effects were measured. Results: In the PACU, VPS was significantly higher and rescue fentanyl consumption was higher in the fentanyl group than in the sufentanil group, while the sedation score and adverse effects were comparable between the groups. No significant differences were observed in the NRS scores for pain (at rest/during cough) in the ward over 48 hours postoperatively, but the cumulative PCA consumption was significantly higher in the fentanyl group (47.4 +/- 9.9 ml vs. 36.2 +/- 14.6 ml, P = 0.01). There were no significant intergroup differences in patient satisfaction score and the incidence of adverse effects in the ward, except for a higher incidence of dry mouth in the fentanyl group. Conclusions: In comparison with fentanyl, sufentanil showed comparable analgesic efficacy and safety with less analgesic consumption (under a potency ratio of 1: 5) in IV-PCA after total laparoscopic hysterectomy. Therefore, we suggest that sufentanil can be a useful alternative to fentanyl for IV-PCA.	[Oh, Seok Kyeong; Lee, Il Ok; Lim, Byung Gun; Jeong, Hyerim; Kim, Young Sung; Ji, Sul Gi; Park, Jong Sun] Korea Univ, Coll Med, Dept Anesthesiol & Pain Med, Guro Hosp, Seoul, South Korea	Lee, I (reprint author), Korea Univ, Dept Anesthesiol & Pain Med, Guro Hosp, Gurodong Ro 148, Seoul 08308, South Korea.	iloklee@korea.ac.kr			BC World Pharm	This work was supported in part by a research grant from the BC World Pharm. The opinions expressed in this paper are those of the authors and do not necessarily represent those of BC World Pharm.	BAILEY PL, 1990, ANESTH ANALG, V70, P8; Bruera E, 1999, SUPPORT CARE CANCER, V7, P280, DOI 10.1007/s005200050261; Dong CS, 2017, BMC ANESTHESIOL, V17, DOI 10.1186/s12871-017-0324-4; Du Manoir B, 2003, BRIT J ANAESTH, V91, P836, DOI 10.1093/bja/aeg264; Gan TJ, 2002, JAMA-J AM MED ASSOC, V287, P1233, DOI 10.1001/jama.287.10.1233; Gan TJ, 2003, ANESTH ANALG, V97, P62, DOI 10.1213/01.ANE.0000068580.00245.95; Gan TJ, 2017, J PAIN RES, V10, P2287, DOI 10.2147/JPR.S144066; Gan TJ, 2014, ANESTH ANALG, V118, P85, DOI 10.1213/ANE.0000000000000002; Gerbershagen HJ, 2013, ANESTHESIOLOGY, V118, P934, DOI 10.1097/ALN.0b013e31828866b3; Gotrick B, 2004, J DENT RES, V83, P393, DOI 10.1177/154405910408300508; Grass JA, 2005, ANESTH ANALG, V101, pS44, DOI 10.1213/01.ANE.0000177102.11682.20; Gupta A, 2010, J ADV PHARM TECHNOL, V1, P97; Hagle Mary E, 2004, Orthop Nurs, V23, P18, DOI 10.1097/00006416-200401000-00007; Hagle ME, 2004, ORTHOP NURS, V23, P8; Han LC, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000011552; HUGHES MA, 1992, ANESTHESIOLOGY, V76, P334, DOI 10.1097/00000542-199203000-00003; Kehlet H, 2006, LANCET, V367, P1618, DOI 10.1016/S0140-6736(06)68700-X; Kim DK, 2017, J KOREAN NEUROSURG S, V60, P54, DOI 10.3340/jkns.2016.0707.007; Kim Kye-Min, 2016, Anesthesia and Pain Medicine, V11, P28, DOI 10.17085/apm.2016.11.1.28; Lin Chun-shui, 2006, Nan Fang Yi Ke Da Xue Xue Bao, V26, P240; Lotsch J, 2001, ANESTHESIOLOGY, V95, P1329; Maciejewski D, 2012, ANAESTH INTENSIVE TH, V44, P35; Macintyre PE, 2001, BRIT J ANAESTH, V87, P36, DOI 10.1093/bja/87.1.36; MANDEL I D, 1976, Oral Sciences Reviews, V8, P25; Momeni M, 2006, DRUGS, V66, P2321, DOI 10.2165/00003495-200666180-00005; Nie YY, 2014, EUR J ANAESTH, V31, P197, DOI 10.1097/EJA.0000000000000011; Nieboer TE, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003677.pub4; OSBORNE RJ, 1986, BRIT MED J, V292, P1548, DOI 10.1136/bmj.292.6535.1548; Palmer Pamela P, 2010, Anesthesiol Clin, V28, P587, DOI 10.1016/j.anclin.2010.08.010; SCHUG SA, 1993, PAIN, V55, P387, DOI 10.1016/0304-3959(93)90016-I; SCOTT JC, 1991, ANESTHESIOLOGY, V74, P34, DOI 10.1097/00000542-199101000-00007; Shea RA, 2002, HEART LUNG, V31, P440, DOI 10.1067/mhl.2002.129449; Sidebotham D, 1997, J PAIN SYMPTOM MANAG, V14, P202, DOI 10.1016/S0885-3924(97)00182-6; Stanley TH, 2014, J PAIN, V15, P1215, DOI 10.1016/j.jpain.2014.08.010; Subrahmanyam M, 2009, INDIAN J ANAESTH, V53, P467; Tsui SL, 1997, ANAESTHESIA, V52, P1042, DOI 10.1111/j.1365-2044.1997.232-az0371.x; Zhang YH, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003915	37	1	1	2	2	IVYSPRING INT PUBL	LAKE HAVEN	PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA	1449-1907			INT J MED SCI	Int. J. Med. Sci.		2019	16	11					1439	1446		10.7150/ijms.34656			8	Medicine, General & Internal	General & Internal Medicine	IZ7KK	WOS:000487271700004	31673234	DOAJ Gold, Green Published			2020-06-30	J	Ilik, MK; Ilik, F				Ilik, Mustafa Kemal; Ilik, Faik			Evaluation of the Retrogasserian Opioid Application in the Treatment of Idiopathic Trigeminal Neuralgia	TURKISH NEUROSURGERY			English	Article						Trigeminal neuralgia; Gasser ganglion; Fentanyl; Bupivacaine	PERCUTANEOUS BALLOON COMPRESSION; TERM-FOLLOW-UP; MICROVASCULAR DECOMPRESSION; GLYCEROL RHIZOTOMY; EXPERIENCE; SAFETY	AIM: To evaluate the clinical outcomes of the retrogasserian opioid application in patients with type 1 trigeminal neuralgia. MATERIAL and METHODS: A total of 37 patients (12 male, 25 female; average age 56.2 +/- 5.4 years) who were administered retrogasserian opioid due to type 1 trigeminal neuralgia between February 2012 and May 2015 were included in the study. A visual analogue scale was used to evaluate pain at the last preoperative and postoperative visits (median follow-up period: 13 months, mean follow-up period: 15.6 months). All parameters were analysed using Wilcoxon signed-rank and Mann-Whitney U tests, with p<0.05 considered statistically significant. RESULTS: Visual analogue scale scores of all 37 patients were significantly improved in the postoperative period. The average visual analogue scale scores were 7.9 +/- 0.62 preoperatively and 2.9 +/- 0.5 postoperatively. All changes were statistically significant. CONCLUSION: Percutaneous retrogasserian opioid injection in type 1 trigeminal neuralgia is an effective and safe method of pain control.	[Ilik, Mustafa Kemal] Farabi Hosp, Dept Neurosurg, Konya, Turkey; [Ilik, Faik] KTO Karatay Univ, Med Hosp, Dept Neurol, Konya, Turkey	Ilik, MK (reprint author), Farabi Hosp, Dept Neurosurg, Konya, Turkey.	mkilik@gmail.com					Andres M, 2009, PATHOPHYSIOLOGY TRIG; Chen JF, 2011, WORLD NEUROSURG, V76, P586, DOI 10.1016/j.wneu.2011.05.021; Cheng JS, 2014, OPER NEUROSURG, V10, P25, DOI 10.1227/NEU.00000000000001687; Civelek Erdinc, 2005, Agri, V17, P19; Coven I, 2016, SPRINGERPLUS, V5, DOI 10.1186/s40064-016-2612-8; Cruccu G, 2008, EUR J NEUROL, V15, P1013, DOI 10.1111/j.1468-1331.2008.02185.x; Harries AM, 2011, BRIT J NEUROSURG, V25, P268, DOI 10.3109/02688697.2011.558946; Hitchon PW, 2016, CLIN NEUROL NEUROSUR, V149, P166, DOI 10.1016/j.clineuro.2016.08.016; Huang QD, 2016, PAIN PHYSICIAN, V19, pE1041; Kanpolat Y, 2001, NEUROSURGERY, V48, P524, DOI 10.1097/00006123-200103000-00013; Kouzounias K, 2010, NEUROSURGERY, V67, P925, DOI 10.1227/NEU.0b013e3181eb5230; Montano N, 2014, ACTA NEUROL BELG, V114, P59, DOI 10.1007/s13760-013-0263-x; MULLAN S, 1983, J NEUROSURG, V59, P1007, DOI 10.3171/jns.1983.59.6.1007; Reddy VK, 2013, NEUROSURGERY, V72, P749, DOI 10.1227/NEU.0b013e318286fad2; Regis J, 2011, J NEUROSURG, V115, P2, DOI 10.3171/2011.12.GKSeditorial; Savage Clare, 2002, Chest Surg Clin N Am, V12, P251, DOI 10.1016/S1052-3359(02)00011-X; Sivakumar W, 2016, CUREUS, V8, DOI 10.7759/cureus.645; Song ZX, 2014, TURK NEUROSURG, V24, P163, DOI 10.5137/1019-5149.JTN.6709-12.1; Tucer B, 2012, J KOREAN NEUROSURG S, V52, P42, DOI 10.3340/jkns.2012.52.1.42; Tun K, 2007, TURK NEUROSURG, V17, P294; Xu-Hui W, 2011, TURK NEUROSURG, V21, P48	21	0	0	0	0	TURKISH NEUROSURGICAL SOC	BAHCELIEVLER	TASKENT CADDESI 13-4, BAHCELIEVLER, ANKARA 06500, TURKEY	1019-5149			TURK NEUROSURG	Turk. Neurosurg.		2019	29	5					631	634		10.5137/1019-5149.JTN.22604-18.2			4	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	IY3XM	WOS:000486326100002	30649785	Bronze			2020-06-30	J	Stiru, O; Stefan, M; Geana, RC; Sorostinean, D; Radu, R; Filipescu, D; Chioncel, O; Iliescu, VA				Stiru, Ovidiu; Stefan, Mihai; Geana, Roxana Carmen; Sorostinean, Diana; Radu, Razvan; Filipescu, Daniela; Chioncel, Ovidiu; Iliescu, Vlad Anton			Mitral Valve Replacement with Thymectomy in a Patient with Ocular Myasthenia Gravis: Case Report	HEART SURGERY FORUM			English	Article							SURGERY	Patients diagnosed with ocular myasthenia gravis (MG) and mitral valve disease represent a significant perioperative management problem, especially for the anaesthesiologist, due to complex inter-actions between the disease, drugs to treat the disease, and anaesthetic agents, such as neuromuscular blocking agents (NMBAs). This paper describes the successful management of a 31-year-old female with mitral valve stenosis and ocular MG who was diagnosed with MG 4 years prior to the indication for cardiac surgery. Preoperatively, the patient was under treatment with Pyridostigmine and Prednisone. Mitral valve replacement and full thymectomy were performed, under general anaesthesia, using Fentanyl, Sevoflurane and low doses of non-depolarising NMBAs. The postoperative course was uneventful, the patient was extubated at 6 hours postoperatively, in-tensive care unit stay was 48 hours, and the patient was discharged after 6 days without any compli-cations. After 3 months, at the follow-up examination, the patient's ocular symptoms (eyelid ptosis) disappeared.	[Stiru, Ovidiu; Stefan, Mihai; Geana, Roxana Carmen; Sorostinean, Diana; Radu, Razvan; Filipescu, Daniela; Chioncel, Ovidiu; Iliescu, Vlad Anton] Emergency Inst Cardiovasc Dis Prof Dr CC Iliescu, Sos Fundeni 258,Sect 2, Bucharest 022328, Romania	Chioncel, O (reprint author), Emergency Inst Cardiovasc Dis Prof Dr CC Iliescu, Sos Fundeni 258,Sect 2, Bucharest 022328, Romania.	ovidiu_stiru@yahoo.com	Filipescu, Daniela/AAP-6967-2020; Stiru, Ovidiu/AAA-5398-2019; Stefan, Mihai/AAP-4564-2020; Iliescu, Vlad Anton/AAA-7692-2019; /R-7556-2017	Stiru, Ovidiu/0000-0002-5482-6794; /0000-0002-3197-3628; Stefan, Mihai/0000-0001-9151-3474			APS C, 1987, BRIT J ANAESTH, V59, P265, DOI 10.1093/bja/59.2.265; Aydin Y, 2017, EURASIAN J MED, V49, P48, DOI 10.5152/eurasianjmed.2017.17009; Blichfeldt-Lauridsen L, 2012, ACTA ANAESTH SCAND, V56, P17, DOI 10.1111/j.1399-6576.2011.02558.x; Conti-Fine BM, 2006, J CLIN INVEST, V116, P2843, DOI 10.1172/JCI29894; Dillon F, 2014, SEMIN NEUROL, V24, P83; DRACHMAN DB, 1994, NEW ENGL J MED, V330, P1797, DOI 10.1056/NEJM199406233302507; Ishimura H, 1998, J CLIN ANESTH, V10, P228, DOI 10.1016/S0952-8180(98)00011-7; Kalb B, 2002, NEUROEPIDEMIOLOGY, V21, P221, DOI 10.1159/000065639; Li KK, 2017, WORLD J SURG ONCOL, V15, DOI 10.1186/s12957-017-1209-1; Narin C, 2009, J CARDIAC SURG, V24, P210, DOI 10.1111/j.1540-8191.2008.00693.x; Vaphiades MS, 2012, CURR OPIN OPHTHALMOL, V23, P537, DOI 10.1097/ICU.0b013e328358b94a; Vincent A, 2001, LANCET, V357, P2122, DOI 10.1016/S0140-6736(00)05186-2; Wang QA, 2011, HEART LUNG CIRC, V20, P130, DOI 10.1016/j.hlc.2010.07.012; Yuan HK, 2007, ACTA NEUROL SCAND, V115, P181, DOI 10.1111/j.1600-0404.2006.00733.x	14	0	0	1	1	FORUM MULTIMEDIA PUBLISHING, LLC	CHARLOTTESVILLE	375 GREENBRIER DR, CHARLOTTESVILLE, VA 22901 USA	1098-3511	1522-6662		HEART SURG FORUM	Heart Surg. Forum		2019	22	5					E340	E342		10.1532/hsf.2627			3	Cardiac & Cardiovascular Systems; Surgery	Cardiovascular System & Cardiology; Surgery	IU1LI	WOS:000483337400006	31596708	Bronze			2020-06-30	J	Rojas-Perez-Ezquerra, P; Micozzi, S; Torrado-Espanol, I; Rodriguez-Fernandez, A; Albendiz-Gutierrez, V; Noguerado-Mellado, B				Rojas-Perez-Ezquerra, Patricia; Micozzi, Sarah; Torrado-Espanol, Ines; Rodriguez-Fernandez, Ana; Albendiz-Gutierrez, Vicente; Noguerado-Mellado, Blanca			Allergic Contact Dermatitis to Fentanyl TTS with Good Tolerance to Systemic Fentanyl	RECENT PATENTS ON INFLAMMATION & ALLERGY DRUG DISCOVERY			English	Article						Allergic contact; buprenorphine; dermatitis; fentanyl; patch test; transdermal therapeutic system	CUTANEOUS REACTIONS	Background: Fentanyl is primarily an opioid agonist. It is frequently used in general anesthesia as a potent analgesic. It can be administered either orally, transdermally or systemically. Adverse effects due to opium alkaloids are usually because of a non-specific histamine release. Only in a few cases, a true allergy mechanism could be involved. Immediate reactions to opioids are most frequent than delayed reactions. In the past years, delayed reactions have increased in frequency because of the wide use of Transdermal Therapeutic System (TTS) with several opioids for its potent analgesic properties. Objective: The objective was to study delayed reaction to fentanyl TTS and cross-reactivity with other opioids. Methods: A 52-year-old man with a diagnosis of pancreatic cancer who began treatment for a bone metastases pain with fentanyl TTS, at a dose of 50 micrograms per hour (mcg/h) is the subject of the study. After 10-15 days of treatment, he developed an itchy papulovesicular rash in the application site of the fentanyl TTS. Afterward, eczema and superficial desquamation just on the application site of the patch were observed. He changed several times the site of application, but always developing the same symptoms in every single application. Later on, he tolerated other opioids such as oral morphine or tramadol. An allergy workout was performed. We performed Patch Tests (PT) with fentanyl at a concentration of 10% in aqua (aq) and with buprenorphine 10% aq., in order to investigate probable cross-reactivity among other topical opioids. Results: Readings were recorded at day 2 (D2) and day 4 (D4), with positive PT only with fentanyl at D2 (+++) and D4 (+++). We decided to perform a single-blind challenge test with buprenorphine 35 mcg/h in TTS, with a negative result. At this moment, fentanyl TTS was replaced by buprenorphine TTS, with good tolerance. Conclusion: We present the case of Allergic Contact Dermatitis (ACD) due to hypersensitivity to fentanyl with good tolerance to buprenorphine. Positive PT in this patient suggests a type IV hypersensitivity mechanism. Allergic reactions to opioids are frequently immediate, but delayed reactions could appear, especially when the drug is administered topically.	[Rojas-Perez-Ezquerra, Patricia; Micozzi, Sarah; Torrado-Espanol, Ines; Rodriguez-Fernandez, Ana; Albendiz-Gutierrez, Vicente; Noguerado-Mellado, Blanca] Hosp Gen Univ Gregorio Maranon, Allergy Dept, Gregorio Maranon Hlth Res Inst IiSGM, Madrid, Spain	Rojas-Perez-Ezquerra, P (reprint author), Hosp Gen Univ Gregorio Maranon, Allergy Dept, 46th Dr Esquerdo St, Madrid 28007, Spain.	patricia.rojas@salud.madrid.org		Rojas-Perez-Ezquerra, Patricia/0000-0002-9635-5476	Spanish National Health System	This study was administratively and financially sponsored by the Spanish National Health System. We confirm that this manuscript has not been published elsewhere and is not under consideration by another journal.	Acino A. G, 2016, Patent No. [EP3067050A1, 3067050]; Bershow A, 2011, DERMATITIS, V22, P193, DOI 10.2310/6620.2011.10135; Chiou TJ, 2010, AM J HOSP PALLIAT ME, V27, P31, DOI 10.1177/1049909109346427; Clifford G, 1997, Patent No. [US5635204A, 5635204]; DAVID I, 2007, Patent No. 20070264319; Dewachter P, 2009, ACTA ANAESTH SCAND, V53, P1092, DOI 10.1111/j.1399-6576.2009.02022.x; Gary A. L, 1993, Patent No. [5213568, US5213568A]; Hulst KV, 2008, CONTACT DERMATITIS, V59, P366, DOI 10.1111/j.1600-0536.2008.01472.x; Hyun-Suk Y, 2017, Patent No. [EP2759294B1, 2759294]; Kenneth C. L, 1967, Patent No. [US3352708A, 3352708]; Li PH, 2017, J ALLER CL IMM-PRACT, V5, P1601, DOI 10.1016/j.jaip.2017.03.035; Mitsuru K, 2006, Patent No. [JP2006169238A, 2006169238]; Musel AL, 2006, DERMATITIS, V17, P109, DOI 10.2310/6620.2006.05051; Perez-Calderon R, 2002, CONTACT DERMATITIS, V46, P303, DOI 10.1034/j.1600-0536.2002.460513.x; Subramanian S. V, 2018, Patent No. [US20180098979A1, 20180098979]	15	0	0	0	2	BENTHAM SCIENCE PUBL LTD	SHARJAH	EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES	1872-213X	2212-2710		RECENT PATENTS INFLA	Recent Patents Inflamm. Allergy Drug Discov.		2019	13	1					66	68		10.2174/1872213X13666190527105718			3	Pharmacology & Pharmacy	Pharmacology & Pharmacy	IN9FI	WOS:000478984100007	31131754	Green Published			2020-06-30	J	Armendariz-Buil, I; Gil-Caballero, S; Guibert-Bayona, MA; Martin-Rubio, AM; de Vera-Floristan, JMV; del Rio-Manterola, J				Armendariz-Buil, I; Gil-Caballero, S.; Guibert-Bayona, M. A.; Martin-Rubio, A. M.; Vicente de Vera-Floristan, J. M.; del Rio-Manterola, J.			Hypobaric spinal anesthesia in a large ventral hernia	ANALES DEL SISTEMA SANITARIO DE NAVARRA			Spanish	Article						Spinal anesthesia; Bupivacaine; Umbilical hernia; Ventral hernia; Airway management	REPAIR	High abdominal wall surgery may require general anesthesia but, in patients with high risk of difficult airway and respiratory complications, local or regional anesthesia is the choice whenever possible. Spinal anesthesia usually used (both isobaric and hyperbaric) could compromise the respiratory function due to blockade of the T6 metamere or higher. Hypobaric spinal anesthesia (HSA) at low doses (3.6 cc of 0.1% hypobaric bupivacaine plus 0.2 cc of 0.005% fentanyl) achieves sufficient analgesia with minimal motor blockade. We present the case of a patient with a large supraumbilical hernia with high risk of difficult airway and respiratory complications, who went through HSA. The patient did not report pain or dyspnea during the surgical procedure thus, HSA at low doses is an option to be taken into account in high abdominal wall surgery despite not having been described for this use.	[Armendariz-Buil, I; Gil-Caballero, S.; Martin-Rubio, A. M.; Vicente de Vera-Floristan, J. M.; del Rio-Manterola, J.] Hosp Reina Sofia, Serv Anestesiol & Reanimac, Navarra, Spain; [Guibert-Bayona, M. A.] Hosp Garcia Orcoyen, Serv Anestesiol & Reanimac, Navarra, Spain	Armendariz-Buil, I (reprint author), Hosp Reina Sofia, Serv Anestesiol & Reanimac, Carretera Tudela Tarazona,Km 3, Tudela 31500, Navarra, Spain.	ignacio.armendariz.buil@navarra.es					Canet J, 2010, ANESTHESIOLOGY, V113, P1338, DOI 10.1097/ALN.0b013e3181fc6e0a; Dhumane P., 2016, IJBR, V7, P201; Donati M, 2010, ACTA CHIR BELG, V110, P45; Krobot R, 2013, PERIOD BIOL, V115, P225; MAROOF M, 1995, CAN J ANAESTH, V42, P691, DOI 10.1007/BF03012666; Meuret P, 2018, TURK J ANAESTHESIOL, V46, P121, DOI 10.5152/TJAR.2018.90699; Saraswat V, 2015, INDIAN J ANAESTH, V59, P557, DOI 10.4103/0019-5049.165850; Smetana GW, 2006, ANN INTERN MED, V144, P581, DOI 10.7326/0003-4819-144-8-200604180-00009; Stierer Tracey L, 2015, Anesthesiol Clin, V33, P305, DOI 10.1016/j.anclin.2015.02.003; Taspinar V, 2011, J ANESTH, V25, P219, DOI 10.1007/s00540-010-1089-9; Tzovaras G, 2008, AM J SURG, V196, P191, DOI 10.1016/j.amjsurg.2007.07.028; Vergari A, 2017, MINERVA ANESTESIOL, V83, P361, DOI 10.23736/S0375-9393.16.11506-8	12	0	0	0	0	GOBIERNO DE NAVARRA	PAMPLONA	NAVAS TOLOSA 21, PAMPLONA, 31002, SPAIN	1137-6627			AN SIST SANIT NAVAR	An. Sist. Sanit. Navar.	JAN-APR	2019	42	1					93	96		10.23938/ASSN.0585			4	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	HU8VE	WOS:000465568300013	30895966	Bronze			2020-06-30	J	Guerrieri, D; Kjellqvist, F; Kronstrand, R; Green, H				Guerrieri, Davide; Kjellqvist, Fanny; Kronstrand, Robert; Green, Henrik			Validation and Cross-Reactivity Data for Fentanyl Analogs With the Immunalysis Fentanyl ELISA	JOURNAL OF ANALYTICAL TOXICOLOGY			English	Article							POSTMORTEM; RECEPTOR	Every year new fentanyl analog compounds, or fentanyls, appear on the drug scene. Development of immunoassays dedicated for screening individual molecules is challenging due to the short-lived presence of these compounds on the recreational drug market. Therefore, we investigated the detecting capabilities of the immunalysis fentanyl direct enzyme-linked immunosorbent assay (ELISA) kit against fentanyl in whole blood, and determined the cross-reactivity of nine fentanyl analogs (2-fluorofentanyl, acetylfentanyl, acrylfentanyl, carfentanil, cyclopropylfentanyl, tetrahydrofuranylfentanyl, furanylfentanyl, ocfentanil, valerylfentanyl) to confirm its validity for the general screening of fentanyls. Immunalysis ELISA assay was used to test whole blood samples fortified with fentanyl on a TECAN Freedom EVOlyzer platform, according to manufacturer specifications. The kit successfully was validated for fentanyl screening with a cutoff set at 0.5 ng/mL, and all tested analogs, with the exclusion of carfentanil, were detected. The lowest cross-reactivity with the kit was obtained with furanylfentanyl (20% +/- 1, 95% confidence intervals (CI)) and 4-fluoroisobutyrfentanyl (25% +/- 1, 95% CI), while the highest was recorded using acetylfentanyl (99% +/- 11, 95% CI) and acrylfentanyl (94% +/- 10, 95% CI). Post-mortem samples containing fentanyl, acrylfentanyl, cyclopropylfentanyl, THF-fentanyl and 4-fluoroisobutyrfentanyl were screened, and sensitivity and specificity of each analog were calculated. Positive screening results were generated by all post-mortem cases containing fentanyl (n = 14), acrylfentanyl (n = 11), cyclopropylfentanyl (n = 14), tetrahydrofuranylfentanyl (n = 13) and 4-fluoroisobutyrfentanyl (n = 10). Concentration of post-mortem fentanyl samples ranged from 0.5 ng/mL (cutoff) to 230 ng/mL, while the range for analogs was 3.4-36 ng/mL (cyclopentylfentanyl), 0.76-370 ng/mL (4-fluoroisobutyrfentanyl), 0.02-12 ng/mL (acrylfentanyl) and 2-26 ng/mL (tetrahydrofuranylfentanyl). The immunalysis fentanyl direct ELISA kit was successfully validated and showed significant cross-reactivity for all tested fentanyls, except carfentanil, making it a suitable technique for fentanyl and fentanyl analogs screening.	[Guerrieri, Davide; Kronstrand, Robert; Green, Henrik] Linkoping Univ, Div Drug Res, Dept Med & Hlth Sci, SE-58185 Linkoping, Sweden; [Kjellqvist, Fanny; Kronstrand, Robert; Green, Henrik] Natl Board Forens Med, Dept Forens Genet & Forens Toxicol, Artillerigatan 12, SE-58758 Linkoping, Sweden	Green, H (reprint author), Natl Board Forens Med, Dept Forens Genet & Forens Toxicol, Artillerigatan 12, SE-58758 Linkoping, Sweden.	henrik.green@rmv.se			Strategic Research Area in Forensic Sciences (Strategiomradet Forensiska Vetenskaper) at Linkoping University; National Board of Forensic Medicine	This research was funded by the Strategic Research Area in Forensic Sciences (Strategiomradet Forensiska Vetenskaper) at Linkoping University and the National Board of Forensic Medicine.	[Anonymous], 2015, EUR DRUG REP TRENDS; [Anonymous], 2012, US PHARM CONV; EMEA, 2015, EMEACHMPEWP192217200; FEINBERG AP, 1976, P NATL ACAD SCI USA, V73, P4215, DOI 10.1073/pnas.73.11.4215; Fort C, 2016, J ANAL TOXICOL, V40, P754, DOI 10.1093/jat/bkw068; Guerrieri D, 2017, FORENSIC SCI INT, V277, pE21, DOI 10.1016/j.forsciint.2017.05.010; Guerrieri D, 2017, J ANAL TOXICOL, V41, P242, DOI 10.1093/jat/bkw129; Levine B., 2009, PRINCIPLES FORENSIC; McIntyre IM, 2015, J ANAL TOXICOL, V39, P490, DOI 10.1093/jat/bkv043; Pereira J, 2001, J PAIN SYMPTOM MANAG, V22, P672, DOI 10.1016/S0885-3924(01)00294-9; Petrov RR, 2006, BIOORG MED CHEM LETT, V16, P4946, DOI 10.1016/j.bmcl.2006.06.040; Schwope DM, 2010, CLIN CHEM, V56, P1007, DOI 10.1373/clinchem.2009.141754; Skulska Agnieszka, 2005, Przegl Lek, V62, P581; SOFT/AAFS, 2006, ACCREDITATION QUALIT; Tiscione NB, 2017, J ANAL TOXICOL, V41, P313, DOI 10.1093/jat/bkx005; UNDOC, 2017, 4 UNDOC; UNODC, 2017, 2 UNODC; VANDAELE PGH, 1976, ARZNEIMITTELFORSCH, V26, P1521; Vardanyan RS, 2014, FUTURE MED CHEM, V6, P385, DOI 10.4155/fmc.13.215; Weltrowska G, 2010, J MED CHEM, V53, P2875, DOI 10.1021/jm9019068	20	5	5	2	10	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0146-4760	1945-2403		J ANAL TOXICOL	J. Anal. Toxicol.	JAN	2019	43	1					18	24		10.1093/jat/bky060			7	Chemistry, Analytical; Toxicology	Chemistry; Toxicology	HQ7DS	WOS:000462580500005	30215771				2020-06-30	J	Konapur, R; Searls, N; Babcock, CCK; Blough, E; Patel, I				Konapur, Rahul; Searls, Noah; Babcock, Charles C. K.; Blough, Eric; Patel, Isha			Combative Treatment for Carfentanil Epidemic	JOURNAL OF ADDICTIONS NURSING			English	Editorial Material									[Konapur, Rahul] Manipal Coll Pharmaceut Sci, Manipal, Karnataka, India; [Searls, Noah] Marshall Univ, Sch Pharm, Huntington, WV USA; [Babcock, Charles C. K.; Patel, Isha] Marshall Univ, Sch Pharm, Dept Pharm Practice Res & Adm, One John Marshall Dr, Huntington, WV 25755 USA; [Blough, Eric] Marshall Univ, Sch Pharm, Dept Pharmaceut Sci & Res, Huntington, WV USA	Patel, I (reprint author), Marshall Univ, Sch Pharm, Dept Pharm Practice Res & Adm, One John Marshall Dr, Huntington, WV 25755 USA.	pateli@marshall.edu					[Anonymous], 2016, CBC NEWS; [Anonymous], 2017, GUARDIAN; [Anonymous], 2014, VICE NEWS       0506; Centers for Disease Control and Prevention, 2015, CDC HLTH AL NETW INC; CNN, 2016, CNN; Strang J, 2012, NEW HEROIN ASSISTED; United States Drug Enforcement Administration, 2016, DEA ISS CARF WARN PO; WOLOZIN BL, 1982, J NEUROSCI, V2, P708	8	1	1	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1088-4602	1548-7148		J ADDICT NURS	J. Addict. Nurs.	JAN-MAR	2019	30	1					2	3		10.1097/JAN.0000000000000266			2	Substance Abuse; Nursing	Substance Abuse; Nursing	HP1QR	WOS:000461442100002	30829994				2020-06-30	J	Fornili, KS				Fornili, Katherine Smith			International Control Efforts to Curb the Global Production and Trafficking of Fentanyl and Other Synthetic Opioids	JOURNAL OF ADDICTIONS NURSING			English	Editorial Material						Fentanyl; Fentanyl Analogues; Fentanyl Precursors; Human Rights; International Drug Trafficking; Nursing Ethics; Opioids		The purpose of this Policy Watch column is to provide a brief overview of the global problems associated with the illicit production and trafficking of synthetic opioids as well as international efforts and policy approaches designed to curb them. An in-depth evaluation of drug control efforts of many different nations is important for a comprehensive analysis. However, because of the vast amount of information available, this column is limited to cooperative global control efforts, not efforts specific to any one nation. A great deal of information about production methods, clandestine laboratories, international trafficking methods, and online sales over the dark Web has been omitted. It is important to understand key issues regarding the illicit cultivation and distribution of plant-based opioids derived from natural compounds found in opium poppies (heroin, opium, morphine, codeine) or other drugs (cocaine, methamphetamines, etc.), but the scope of this column is limited to discussion about synthetic opioids including fentanyl, fentanyl analogues, and fentanyl precursor chemicals. Issues about human rights and ethical considerations for nurses and other addictions professionals are also discussed.	[Fornili, Katherine Smith] Univ Maryland, Sch Nursing Baltimore, Dept Family & Community Hlth, 655 W Lombard St,Suite 545 D, Baltimore, MD 21201 USA	Fornili, KS (reprint author), Univ Maryland, Sch Nursing Baltimore, Dept Family & Community Hlth, 655 W Lombard St,Suite 545 D, Baltimore, MD 21201 USA.	fornili@umaryland.edu					American Association of Colleges of Nursing, 2006, ESS DOCT ED ADV NURS; American Nurses Association, 2015, COD ETH NURS INT STA; American Nurses Association and the International Nurses Society on Addictions, 2013, ADD NURS SCOP STAND; Drug Enforcement Administration Strategic Intelligence Section, 2018, NAT DRUG THREAT ASS; Drug Enforcement Administration Strategic Intelligence Section, 2018, DEADCTDIB00318 US DE; Ehrenreich B., 2002, POLICY POLITICS NURS; Hedegaard H, 2018, NATL VITAL STAT REPO, V67; International Narcotics Control Board, 2017, PREC CHEM FREQ US IL; International Narcotics Control Board, 2017, REP INCB 2017; International Narcotics Control Board, 2018, PREC; National Institute on Drug Abuse, OP; United Nations Office on Drugs and Crime, 2018, GLOB SMART PROGR SE; United Nations Office on Drugs and Crime, 2017, WORLD DRUG REP 2 201; United Nations Office on Drugs and Crime, 2018, CND COMM NARC DRUGS; United Nations Office on Drugs and Crime, 2018, WORLD DRUG REP 3 201; United Nations Office on Drugs and Crime, 2017, GLOB SMART UPD FENT; United Nations Office on Drugs and Crime, 2018, MYANM HOSTS TALKS AS; United Nations Office on Drugs and Crime, 2016, OUTC 2016 UN GEN ASS; United States Mission to the United Nations, 2018, GLOB CALL ACT WORLD; US China Economic and Security Review Commission, 2017, FENT CHIN DEADL EXP; Walsh J., 2018, TRUMP HOST UN M DRUG	21	0	0	4	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1088-4602	1548-7148		J ADDICT NURS	J. Addict. Nurs.	JAN-MAR	2019	30	1					71	76		10.1097/JAN.0000000000000269			6	Substance Abuse; Nursing	Substance Abuse; Nursing	HP1QR	WOS:000461442100013	30830005				2020-06-30	J	Cabadas-Avion, R; Baluja, A; Ojea-Cendon, M; Leal-Ruiloba, MS; Vazquez-Lopez, S; Rey-Martinez, M; Magdalena-Lopez, P; Alvarez-Escudero, J				Cabadas-Avion, Rafael; Baluja, Aurora; Ojea-Cendon, Maria; Sonsoles Leal-Ruiloba, Maria; Vazquez-Lopez, Santiago; Rey-Martinez, Marcia; Magdalena-Lopez, Pilar; Alvarez-Escudero, Julian			Effectiveness and safety of gastrointestinal endoscopy during a specific sedation training program for non-anesthesiologists	REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS			English	Article						Endoscopy; Gastroenterology; Sedation; Training	CONSCIOUS SEDATION; MODERATE SEDATION; PROPOFOL SEDATION; RISK-FACTORS; COLONOSCOPY; GUIDELINES; QUALITY; GASTROENTEROLOGY; ANALGESIA; MIDAZOLAM	Introduction: sedation is a key component for the improvement of sedation quality. A correct administration requires appropriate training. We performed a study to compare sedation effectiveness, safety and patient satisfaction when administered by gastroenterologists, with and without specific training. Methods: a training program enrolled a group of gastroenterologists (trained group, n = 4) and their results were compared to those from a non-trained group (n = 3). ASA 1-3 patients who had undergone sedation by a gastroenterologist using midazolam and fentanyl were included over a period of 30 months. Safety was assessed in terms of the complication rate, effectiveness was assessed via the rate of completed endoscopic procedures and patient satisfaction was evaluated via a phone interview the day after the procedure. Results: a total of 3,475 patients were sedated by gastroenterologists during the study period. Significant differences were found that favored the trained group for completed procedures (5.6% vs 8.9%). A lower rate of excessive sedation (1.3% vs 8.61%), hypoxemia (0.72% vs 2.49%) and post-procedural pain (1.8% vs 4.3%) were also achieved. Patient satisfaction surpassed 99.5% and there were no significant differences between groups. Conclusions: our sedation training program improved the effectiveness and safety outcomes when compared to sedation administered by gastroenterologists without this specific training.	[Cabadas-Avion, Rafael; Ojea-Cendon, Maria; Sonsoles Leal-Ruiloba, Maria; Rey-Martinez, Marcia; Magdalena-Lopez, Pilar] Hosp POVISA, Dept Anesthesiol & Crit Care, C Salamanca 5, Vigo 36211, Spain; [Cabadas-Avion, Rafael; Rey-Martinez, Marcia; Magdalena-Lopez, Pilar] Univ Vigo, Escuela Univ Enfermeria Povisa, Vigo, Spain; [Baluja, Aurora; Alvarez-Escudero, Julian] Univ Santiago de Compostela, Dept Surg, Santiago De Compostela, A Coruna, Spain; [Baluja, Aurora; Alvarez-Escudero, Julian] Hosp Clin Univ, Dept Anesthesiol & Crit Care, Santiago De Compostela, A Coruna, Spain; [Vazquez-Lopez, Santiago] Hosp POVISA, Dept Gastroenterol & Hepatol, Vigo, Spain	Cabadas-Avion, R (reprint author), Hosp POVISA, Dept Anesthesiol & Crit Care, C Salamanca 5, Vigo 36211, Spain.	rcabadas@povisa.es	BALUJA, AURORA/R-6101-2019	BALUJA, AURORA/0000-0002-5204-0771; Alvarez, Julian/0000-0002-2518-0891			Agostoni M, 2011, GASTROINTEST ENDOSC, V74, P266, DOI 10.1016/j.gie.2011.04.028; Benjamini Y, 2001, ANN STAT, V29, P1165; Berzin TM, 2010, GASTROINTEST ENDOSC, V71, P597, DOI 10.1016/j.gie.2010.01.027; Casamassimo P, 2006, PEDIATRICS, V118, P2587, DOI 10.1542/peds.2006-2780; Cohen LB, 2007, GASTROENTEROLOGY, V133, P675, DOI 10.1053/j.gastro.2007.06.002; Kauling ALC, 2010, REV BRAS ANESTESIOL, V60, P577, DOI 10.1016/S0034-7094(10)70072-6; de Jonge V, 2012, GASTROINTEST ENDOSC, V75, P98, DOI 10.1016/j.gie.2011.06.032; Dumonceau JM, 2013, ENDOSCOPY, V45, P496, DOI 10.1055/s-0033-1344142; Ekkelenkamp VE, 2013, WORLD J GASTROENTERO, V19, P2355, DOI 10.3748/wjg.v19.i15.2355; Ghanouni A, 2016, ENDOSCOPY, V48, P232, DOI 10.1055/s-0042-100613; Godwin SA, 2005, ANN EMERG MED, V45, P177, DOI 10.1016/j.annemergmed.2004.11.002; Grendelmeier P, 2014, RESPIRATION, V88, P126, DOI 10.1159/000362797; Gross JB, 2002, ANESTHESIOLOGY, V96, P1004; Haynes AB, 2009, NEW ENGL J MED, V360, P491, DOI 10.1056/NEJMsa0810119; Ho Daniel E., 2011, J STAT SOFTW, V42, P1, DOI DOI 10.18637/JSS.V042.I08; Holme Oyvind, 2013, Tidsskr Nor Laegeforen, V133, P1074, DOI 10.4045/tidsskr.12.1467; Hung A, 2016, J CLIN GASTROENTEROL, V50, pE25, DOI 10.1097/MCG.0000000000000291; Jain R, 2010, GASTROINTEST ENDOSC, V72, P469, DOI 10.1016/j.gie.2010.02.017; Jover R, 2012, ENDOSCOPY, V44, P444, DOI 10.1055/s-0032-1306690; Kaminski MF, 2010, NEW ENGL J MED, V362, P1795, DOI 10.1056/NEJMoa0907667; Knape JTA, 2007, EUR J ANAESTH, V24, P563, DOI 10.1017/S0265021506002092; Kravochuck S, 2014, SURG ENDOSC, V28, P1588, DOI 10.1007/s00464-013-3355-z; Lee H, 2009, WORLD J GASTROENTERO, V15, P3783, DOI 10.3748/wjg.15.3783; Long YH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037614; McQuaid KR, 2008, GASTROINTEST ENDOSC, V67, P910, DOI 10.1016/j.gie.2007.12.046; Pambianco DJ, 2015, GASTROINTEST ENDOSC, V81, pAB192, DOI 10.1016/j.gie.2015.03.1946; Patel S, 2005, AM J GASTROENTEROL, V100, P2689, DOI 10.1111/j.1572-0241.2005.00320.x; Poincloux L, 2011, DIGEST LIVER DIS, V43, P553, DOI 10.1016/j.dld.2011.02.007; Porostocky P, 2011, CAN J GASTROENTEROL, V25, P255, DOI 10.1155/2011/783706; Qadeer MA, 2009, DIGEST DIS SCI, V54, P1035, DOI 10.1007/s10620-008-0452-2; Redondo-Cerezo E, 2012, EUR J GASTROEN HEPAT, V24, P506, DOI 10.1097/MEG.0b013e328350fcbd; Rex DK, 2005, GASTROENTEROLOGY, V129, P1384, DOI 10.1053/j.gastro.2005.08.014; Rex DK, 2009, GASTROENTEROLOGY, V137, P1229, DOI 10.1053/j.gastro.2009.06.042; Serrano-Atero M, 2002, REV SOC ESP DOLOR, V9, P94; Slagelse C, 2011, SCAND J GASTROENTERO, V46, P1503, DOI 10.3109/00365521.2011.619274; Storey JD, 2015, QVALUE Q VALUE ESTIM; Thomson A, 2010, J GASTROEN HEPATOL, V25, P469, DOI 10.1111/j.1440-1746.2009.06174.x; Valori R, 2007, BSG QUALITY SAFETY I; Vargo JJ, 2004, GASTROINTEST ENDOSC, DOI [10.1016/S0016-5107(04)00475-4, DOI 10.1016/S0016-5107(04)00475-4]; Vargo JJ, 2017, GASTROINTEST ENDOSC, V85, P101, DOI 10.1016/j.gie.2016.02.007; Voutilainen A, 2016, J ADV NURS, V72, P946, DOI 10.1111/jan.12875; Waring JP, 2003, GASTROINTEST ENDOSC, V58, P317, DOI 10.1067/S0016-5107(03)00001-4; Wehrmann T, 2008, SCAND J GASTROENTERO, V43, P368, DOI 10.1080/00365520701679181; Wickham H, 2009, USE R, P1, DOI 10.1007/978-0-387-98141-3_1	44	1	1	1	1	ARAN EDICIONES, S A	MADRID	CASTELLO, 128, 1O, 28006 MADRID, SPAIN	1130-0108	2340-4167		REV ESP ENFERM DIG	Rev. Esp. Enferm. Dig.		2019	111	3					199	207		10.17235/reed.2018.5713/2018			9	Gastroenterology & Hepatology	Gastroenterology & Hepatology	HN4KZ	WOS:000460154100006	30507244	DOAJ Gold			2020-06-30	J	Huang, YY; Suthananthan, AE; Hunt, V; Hruby, J; Koek, S; Rowcroft, A; Beh, H; Jayasundera, M				Huang, Yang Y.; Suthananthan, Arul E.; Hunt, Victoria; Hruby, Jan; Koek, Sharnice; Rowcroft, Alistair; Beh, Han; Jayasundera, Mohan			The role of intraperitoneal ropivacaine in laparoscopic appendicectomy: a prospective, double-blinded randomized control Australian study	ANZ JOURNAL OF SURGERY			English	Article						appendicectomy; intraperitoneal local anaesthetic; ropivacaine	ANALGESIA; SURGERY; INSTILLATION	BackgroundCurrently, intraoperative use of local anaesthetic is not routinely given in all laparoscopic appendicectomies. Although its use has been widely studied in laparoscopic hernia repairs, gynaecological laparoscopy and laparoscopic cholecystectomies, there are no published trials of the use of intraperitoneal local anaesthetic during laparoscopic appendicectomy in the Australasian setting. The aim of this study was to determine whether the use of intraperitoneal ropivacaine during laparoscopic appendicectomy will reduce the amount of post-operative opiate analgesia used, abdominal pain, post-operative nausea or vomiting, shoulder tip pain and length of hospital stay. MethodsA randomized double-blinded placebo versus control trial was conducted with patients with clinically diagnosed appendicitis undergoing laparoscopic appendicectomy. Primary outcomes measured were the number of times the patient-controlled analgesia (PCA) button was pressed post-operatively and the average and total amount of fentanyl from PCA consumed during the post-operative period from 0 to 6 h and from 6 to 16h. ResultsA total of 86 patients with 43 patients in the placebo normal saline group and 43 patients in the treatment ropivacaine group were included in the study. During the immediate post-operative period (0-6 h), there was a statistically significant reduction in the number of times the PCA button was pressed in the ropivacaine group compared to the normal saline group (16 versus 24 times, P=0.02). ConclusionIntraperitoneal ropivacaine has an analgesic effect for patients up to 6 h following emergency laparoscopic appendicectomy.	[Huang, Yang Y.; Suthananthan, Arul E.; Hunt, Victoria; Hruby, Jan; Koek, Sharnice; Rowcroft, Alistair; Beh, Han; Jayasundera, Mohan] Armadale Kelmscott Mem Hosp, Dept Gen Surg, Armadale, WA, Australia	Huang, YY (reprint author), Armadale Kelmscott Mem Hosp, Dept Gen Surg, 3056 Albany Highway, Mt Nasura, WA 6112, Australia.	yang.huang@health.wa.gov.au		Huang, Yang Yang/0000-0002-0035-7515			Boulind CE, 2013, BRIT J SURG, V100, P395, DOI 10.1002/bjs.8999; DiZerega GS, 2012, THE PERITONEUM, P378; Gurusamy KS, 2014, COCHRANE DB SYST REV, V3; Gurusamy KS, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007337.pub3; Hamill JK, 2017, J SURG RES, V212, P167, DOI 10.1016/j.jss.2017.01.022; Inugala RR, 2016, J EVOL MED DENT SCI-, V5, P4885, DOI 10.14260/jemds/2016/1111; Kahokehr A, 2011, ANZ J SURG, V81, P237, DOI 10.1111/j.1445-2197.2010.05573.x; Kang H, 2010, J INT MED RES, V38, P821, DOI 10.1177/147323001003800309; Koujalagi RS, 2015, J EVOL MED DENT SCI-, V4, P10301, DOI 10.14260/jemds/2015/1484; MacFater WS, 2018, WORLD J SURG, V42, P3112, DOI 10.1007/s00268-018-4623-9; Maestroni U, 2002, SURG ENDOSC, V16, P1336, DOI 10.1007/s00464-001-9181-8; Qureshi KZ, 2014, PAKISTAN ARMED FORCE, V64, P399; Thanapal MR, 2014, ANZ J SURG, V84, P47, DOI 10.1111/j.1445-2197.2012.06210.x; Vivek P, 2016, J EVOL MED DENT SCI, V5, P39	14	1	1	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1445-1433	1445-2197		ANZ J SURG	ANZ J. Surg.	JAN-FEB	2019	89	1-2					101	105		10.1111/ans.15049			5	Surgery	Surgery	HM7DR	WOS:000459638000041	30675985				2020-06-30	J	Peiper, NC; Clarke, SD; Vincent, LB; Ciccarone, D; Kral, AH; Zibbell, JE				Peiper, Nicholas C.; Clarke, Sarah Duhart; Vincent, Louise B.; Ciccarone, Dan; Kral, Alex H.; Zibbell, Jon E.			Fentanyl test strips as an opioid overdose prevention strategy: Findings from a syringe services program in the Southeastern United States	INTERNATIONAL JOURNAL OF DRUG POLICY			English	Article						Illicitly-manufactured fentanyl; Opioid overdose; Drug checking; Overdose prevention; Epidemiology	DRUG CHECKING; PSYCHOACTIVE SUBSTANCES; SYNTHETIC OPIOIDS; SELF-EFFICACY; INJECT DRUGS; DEATHS; REDUCTION; INCREASES; HEROIN; USERS	Background: In 2016, the number of overdose deaths involving illicitly-manufactured fentanyl (IMF) surpassed heroin and prescription opioid deaths in the United States for the first time, with IMF-involved overdose deaths increasing more than 500% across 10 states from 2013 to 2016. IMF is an extremely potent synthetic opioid that is regularly mixed with heroin and often sold to unwitting consumers. Community-based organizations have started to distribute fentanyl test strips (FTS) as a strategy to identify IMF in street purchased products. We investigated the association between FTS use and changes in drug use behavior and perceived overdose safety among a community-based sample of people who inject drugs (PWID) in the United States. Methods: Between September-October 2017, a total of 125 PWID completed an online survey about their most recent FTS use in Greensboro, North Carolina. Our first outcome of interest included whether PWID engaged in any of the following changes in drug use behavior after using FTS: used less than usual, administered tester shot, pushed syringe plunger slower than usual, and snorted instead of injected. Our second outcome of interest was whether PWID felt that FTS use made them feel better able to protect themselves from overdose. We conducted bivariate and multivariate analyses to determine the association between FTS use and these two outcomes. Results: Overall, 63% of the sample reported a positive FTS test result and 81% reported using FTS prior to consuming their drugs. For the outcomes, 43% reported a change in drug use behavior and 77% indicated increased perceived overdose safety by using FTS. In multivariable models adjusting for demographic and FTS correlates, PWID with a positive FTS test result had five times the odds of reporting changes in drug use behavior compared to those with a negative result. PWID who used the FTS after drug consumption were 70% less likely to report behavioral changes at subsequent drug consumption compared to those who used it before consumption. PWID who were not existing clients of the syringe services program had four times higher odds than existing clients to report increased overdose safety from using FTS. Conclusions: We found that using FTS and receiving a positive test result was associated with changes in drug use behavior and perceptions of overdose safety. FTS may represent an effective addition to current overdose prevention efforts when included with other evidence-based strategies to prevent opioid overdose and related harm.	[Peiper, Nicholas C.; Clarke, Sarah Duhart; Kral, Alex H.; Zibbell, Jon E.] RTI Int, Behav Hlth Res Div, Res Triangle Pk, NC USA; [Vincent, Louise B.] Piedmont Chapter, Urban Survivors Union, Greensboro, NC USA; [Ciccarone, Dan] Univ Calif San Francisco, Dept Family & Community Med, San Francisco, CA 94143 USA	Zibbell, JE (reprint author), RTI Int, Century Plaza 1,2987 Clairmont Rd,Suite 400, Atlanta, GA 30329 USA.	jzibbell@rti.org	; Ciccarone, Daniel/I-5404-2013	Duhart Clarke, Sarah/0000-0002-1544-9447; Ciccarone, Daniel/0000-0002-2355-5477	RTI's Strategic Investment Fund	As with any community-based field investigation, this study could not have happened without the support of numerous people and organizations. First and foremost, we extend a very special thanks to the study participants and program staff at the Piedmont Chapter of the Urban Survivors Union this study could not have happened without you. The authors also wish to thank Van Asher, Bill Matthews, Sharon Stancliff, and Eliza Wheeler for their formative role in developing earlier versions of the FTS measures used in this study. Dr. Gary Zarkin at RTI International provided administrative leadership throughout the course of the project. The research was supported by RTI's Strategic Investment Fund. Preliminary findings were presented at the 2018 National Rx Drug Abuse and Heroin Summit.	Armenian P, 2018, NEUROPHARMACOLOGY, V134, P121, DOI 10.1016/j.neuropharm.2017.10.016; Asher V., 2018, USING URINE DRUG TES; BANDURA A, 1990, EVAL PROGRAM PLANN, V13, P9, DOI 10.1016/0149-7189(90)90004-G; Barratt MJ, 2018, DRUG ALCOHOL REV, V37, P226, DOI 10.1111/dar.12576; Butterfield RJ, 2016, MED J AUSTRALIA, V204, P144, DOI 10.5694/mja15.01058; Case A, 2017, BROOKINGS PAP ECO AC, P397; Celentano DD, 2002, J URBAN HEALTH, V79, P245, DOI 10.1093/jurban/79.2.245; Ciccarone D, 2017, INT J DRUG POLICY, V46, P146, DOI 10.1016/j.drugpo.2017.06.004; Ciccarone D, 2017, INT J DRUG POLICY, V46, P107, DOI 10.1016/j.drugpo.2017.06.010; Cicero TJ, 2017, DRUG ALCOHOL DEPEN, V177, P101, DOI 10.1016/j.drugalcdep.2017.04.004; Dasgupta N, 2018, AM J PUBLIC HEALTH, V108, P182, DOI 10.2105/AJPH.2017.304187; Decorte T, 2001, EUR ADDICT RES, V7, P161, DOI 10.1159/000050737; Drug Enforcement Administration, 2017, 2017 NAT DRUG THREAT; Drug Enforcement Administration Diversion Control Division, 2017, NFLIS BRIEF FENT 200; Drug Enforcement Administration Office of Diversion Control, 2015, AC FENT N 1 PHEN 4 Y; Frank RG, 2017, NEW ENGL J MED, V376, P605, DOI 10.1056/NEJMp1615145; Galea S, 2002, PUBLIC HEALTH REP, V117, pS135; Grant S, 2000, NEUROPSYCHOLOGIA, V38, P1180, DOI 10.1016/S0028-3932(99)00158-X; Green TC, 2016, JAMA INTERN MED, V176, P1555, DOI 10.1001/jamainternmed.2016.4310; Greenland S, 2015, STAT MED, V34, P3133, DOI 10.1002/sim.6537; Harm Reduction Coalition, 2018, FENT TEST STRIP PIL; Harper L, 2017, HARM REDUCT J, V14, DOI 10.1186/s12954-017-0179-5; Health Canada, 2017, INF UPD HLTH CAN ADV; Hedegaard H., 2017, DRUG OVERDOSE DEATHS; Helander A, 2017, CLIN TOXICOL, V55, P589, DOI 10.1080/15563650.2017.1303141; HOSMER D. W., 2000, APPL LOGISTIC REGRES; Hungerbuehler I, 2011, HARM REDUCT J, V8, DOI 10.1186/1477-7517-8-16; Johns Hopkins University, 2018, FORECAST STUD SUMM R; Jones JL, 2012, SCIENCE, V338, P953, DOI 10.1126/science.1227489; Kennedy MC, 2018, DRUG ALCOHOL DEPEN, V185, P248, DOI 10.1016/j.drugalcdep.2017.12.026; Kerr T, 2017, HARM REDUCT J, V14, DOI 10.1186/s12954-017-0154-1; Kral AH, 2017, AM J PREV MED, V53, P919, DOI 10.1016/j.amepre.2017.06.010; Krieger MS, 2018, HARM REDUCT J, V15, DOI 10.1186/s12954-018-0213-2; Lambdin BH, 2018, INT J DRUG POLICY, V52, P52, DOI 10.1016/j.drugpo.2017.11.017; Lorvick J, 2006, SUBST USE MISUSE, V41, P865, DOI 10.1080/10826080600669041; Lysyshyn M, 2017, 25 HARM RED INT C; Marinetti LJ, 2014, J ANAL TOXICOL, V38, P592, DOI 10.1093/jat/bku086; Marshall BDL, 2017, INT J DRUG POLICY, V46, P130, DOI 10.1016/j.drugpo.2017.05.029; McClellan C, 2018, ADDICT BEHAV, V86, P90, DOI 10.1016/j.addbeh.2018.03.014; McGowan CR, 2018, INT J DRUG POLICY, V58, P31, DOI 10.1016/j.drugpo.2018.04.017; Mitchell K, 2017, HARM REDUCT J, V14, DOI 10.1186/s12954-017-0160-3; Mounteney J, 2016, ADDICTION, V111, P34, DOI 10.1111/add.13056; O'Donnell JK, 2017, MMWR-MORBID MORTAL W, V66, P1197, DOI 10.15585/mmwr.mm6643e1; O'Donnell JK, 2017, MMWR-MORBID MORTAL W, V66, P897, DOI 10.15585/mmwr.mm6634a2; Peterson AB, 2016, MMWR-MORBID MORTAL W, V65, P844, DOI 10.15585/mmwr.mm6533a3; Prekupec MP, 2017, J ADDICT MED, V11, P256, DOI 10.1097/ADM.0000000000000324; Riley ED, 2010, J URBAN HEALTH, V87, P534, DOI 10.1007/s11524-010-9468-y; Roux AVD, 2017, AM J PUBLIC HEALTH, V107, P1566, DOI [10.2105/ajph.2017.304041, 10.2105/AJPH.2017.304041]; Rudd RA, 2016, MMWR-MORBID MORTAL W, V64, P1378, DOI 10.15585/mmwr.mm6450a3; Saleemi S, 2017, J PSYCHOPHARMACOL, V31, P1056, DOI 10.1177/0269881117715596; Seth P, 2018, MMWR-MORBID MORTAL W, V67, P349, DOI 10.15585/mmwr.mm6712a1; Smith BD, 2013, J INFECT DIS, V208, P1934, DOI 10.1093/infdis/jit520; Somerville NJ, 2017, MMWR-MORBID MORTAL W, V66, P382, DOI 10.15585/mmwr.mm6614a2; Strang J, 2012, LANCET, V379, P71, DOI 10.1016/S0140-6736(11)61674-7; Tamburro L. P., 2016, J FORENSIC SCI MED, V2, P111, DOI [10.4103/2349-5014.184195, DOI 10.4103/2349-5014.184195]; Tomassoni Anthony J, 2017, MMWR Morb Mortal Wkly Rep, V66, P107, DOI 10.15585/mm6604a4; van den Boom W, 2014, JAIDS-J ACQ IMM DEF, V65, P375, DOI 10.1097/QAI.0000000000000051; Van Handel MM, 2016, JAIDS-J ACQ IMM DEF, V73, P323, DOI 10.1097/QAI.0000000000001098; Gine CV, 2017, INT J DRUG POLICY, V45, P46, DOI 10.1016/j.drugpo.2017.05.018; Volkow ND, 2000, CEREB CORTEX, V10, P318, DOI 10.1093/cercor/10.3.318; Walley AY, 2013, BMJ-BRIT MED J, V346, pf174, DOI DOI 10.1136/BMJ.F174; WEINSTEIN ND, 1989, PRIM PREV P, V13, P142; Zibbell JE, 2018, AM J PUBLIC HEALTH, V108, P175, DOI 10.2105/AJPH.2017.304132	63	34	34	7	12	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0955-3959	1873-4758		INT J DRUG POLICY	Int. J. Drug Policy	JAN	2019	63						122	128		10.1016/j.drugpo.2018.08.007			7	Substance Abuse	Substance Abuse	HL3CI	WOS:000458590000015	30292493	Other Gold	Y	N	2020-06-30	J	Cabadas-Avion, R; Leal-Ruiloba, MS; Vazquez-Lopez, S; Ojea-Cendon, M; Wi-Hijazi, I; Baluja-Gonzalez, MA; Alvarez-Escudero, J				Cabadas-Avion, Rafael; Sonsoles Leal-Ruiloba, Maria; Vazquez-Lopez, Santiago; Ojea-Cendon, Maria; Wi-Hijazi, Ismail; Aurora Baluja-Gonzalez, Maria; Alvarez-Escudero, Julian			A descriptive monitoring study of a non-anesthetist sedation quality program	REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS			English	Article						Sedation; Safety; Quality; Endoscopy	ADMINISTERED PROPOFOL SEDATION; GASTROINTESTINAL ENDOSCOPY; RISK-FACTORS; POSITION STATEMENT; EUROPEAN-SOCIETY; COLONOSCOPY; INDICATORS; EVENTS; COMPLICATIONS; GUIDELINES	Introduction: sedation substantially improves the quality of digestive endoscopy procedures but may result in severe complications. Methods: a joint commission-based multidisciplinary protocol was used to define a protocol for sedation by non-anesthesiologists. ASA 4 patients were excluded, as well as patients with a difficult airway, complex procedures and deep sedation. Quality based on the analysis of 9 indicators were monitored. Incomplete procedures were also monitored in order to assess efficacy. Results: patient safety was established based on a very low incidence of complications and a rate of respiratory events of 1.07. Furthermore, a low rate of hypotension and bradycardia was found, as well as a low rate of pain, either during or after endoscopy and an incidence of unexpected admissions lower than 0.5%. The quality indicators measured reflect the evolution of the results of the program. Conclusions: ongoing sedation program monitoring in endoscopy allows the control of different quality dimensions and the implementation of steps for process improvement.	[Cabadas-Avion, Rafael; Sonsoles Leal-Ruiloba, Maria; Ojea-Cendon, Maria; Wi-Hijazi, Ismail] Hosp Povisa, Dept Anesthesiol, C Salamanca 5, Vigo 36211, Pontevedra, Spain; [Vazquez-Lopez, Santiago] Hosp Povisa, Dept Gastroenterol, Vigo, Pontevedra, Spain; [Aurora Baluja-Gonzalez, Maria] Univ Santiago, Hosp Clin, Dept Anesthesiol, Santiago De Compostela, A Coruna, Spain; [Alvarez-Escudero, Julian] Univ Santiago, Fac Med, Hosp Clin, Dept Anesthesiol,Dept Surg, Santiago De Compostela, A Coruna, Spain	Cabadas-Avion, R (reprint author), Hosp Povisa, Dept Anesthesiol, C Salamanca 5, Vigo 36211, Pontevedra, Spain.	rcabadas@povisa.es	BALUJA, AURORA/R-6101-2019	BALUJA, AURORA/0000-0002-5204-0771; Alvarez, Julian/0000-0002-2518-0891			ALDRETE JA, 1995, J CLIN ANESTH, V7, P89, DOI 10.1016/0952-8180(94)00001-K; Cabadas R, 2015, CIR MAY AMB, V20, P79; Cabre LL, INDICADORES CALIDAD; Chun SY, 2012, GUT LIVER, V6, P464, DOI 10.5009/gnl.2012.6.4.464; Cote GA, 2010, CLIN GASTROENTEROL H, V8, P137, DOI 10.1016/j.cgh.2009.07.008; Deng XQ, 2015, J MED SYST, V39, DOI 10.1007/s10916-014-0169-z; Dumonceau JM, 2013, ENDOSCOPY, V45, P496, DOI 10.1055/s-0033-1344142; Ehrenfeld JM, 2011, J CLIN MONIT COMPUT, V25, P71, DOI 10.1007/s10877-010-9256-y; Ekkelenkamp VE, 2013, WORLD J GASTROENTERO, V19, P2355, DOI 10.3748/wjg.v19.i15.2355; Fatima H, 2008, AM J GASTROENTEROL, V103, P1649, DOI 10.1111/j.1572-0241.2008.01906.x; Fernandez-Urien I, 2017, REV ESP ENFERM DIG, V109, P33, DOI 10.17235/reed.2016.4705/2016; Gonzalez-Arevalo A, 2009, ANAESTHESIA, V64, P487, DOI 10.1111/j.1365-2044.2008.05852.x; Grant C, 2008, ANAESTH INTENS CARE, V36, P222, DOI 10.1177/0310057X0803600213; Green PHR, 2016, QUALITY METRICS PROC, P3; Hung A, 2016, J CLIN GASTROENTEROL, V50, pE25, DOI 10.1097/MCG.0000000000000291; Jensen JT, 2014, SCAND J GASTROENTERO, V49, P1014, DOI 10.3109/00365521.2014.896411; Johanson JF, 2000, GASTROINTEST ENDOSC, V52, P827, DOI 10.1016/S0016-5107(00)70218-5; Joint Commission, 2014, EST JC; Jover R, 2012, ENDOSCOPY, V44, P444, DOI 10.1055/s-0032-1306690; Khalid-de Bakker CA, 2011, NETH J MED, V69, P186; Knape JTA, 2007, EUR J ANAESTH, V24, P563, DOI 10.1017/S0265021506002092; Kravochuck S, 2014, SURG ENDOSC, V28, P1588, DOI 10.1007/s00464-013-3355-z; Long YH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037614; Lopez C, 2012, B ASOCIACION ESPANOL, V17, P77; Ma W T, 2007, Med J Malaysia, V62, P313; Estevez JM, 2012, REV ESP ANEST REANIM, V59, P3, DOI 10.1016/j.redar.2012.01.002; Ministerio de Sanidad y consumo, 2008, MAN UN CIR MAYOR AMB; Organizacion Mundial de la Salud, MAN APL LIST OMS VER; Pagano N, 2011, Diagn Ther Endosc, V2011, P542159, DOI 10.1155/2011/542159; Park WG, 2015, GASTROINTEST ENDOSC, V81, P17, DOI 10.1016/j.gie.2014.07.057; Qadeer MA, 2009, DIGEST DIS SCI, V54, P1035, DOI 10.1007/s10620-008-0452-2; Rembacken B, 2012, ENDOSCOPY, V44, P957, DOI 10.1055/s-0032-1325686; Rex DK, 2015, GASTROINTEST ENDOSC, V81, P31, DOI 10.1016/j.gie.2014.07.058; Rizk MK, 2015, GASTROINTEST ENDOSC, V81, P3, DOI 10.1016/j.gie.2014.07.055; Rutter MD, 2014, ENDOSCOPY, V46, P526, DOI 10.1055/s-0034-1365738; del Rio AS, 2010, MED CLIN-BARCELONA, V134, P49, DOI 10.1016/j.medcli.2009.07.047; Schroeder C, 2016, DIS COLON RECTUM, V59, P62; Sharma VK, 2007, GASTROINTEST ENDOSC, V66, P27, DOI 10.1016/j.gie.2006.12.040; Soria-Aledo V, 2012, CIR ESPAN, V90, P180, DOI 10.1016/j.ciresp.2011.09.007; Tang DM, 2012, J GASTROINTEST LIVER, V21; Tohda G, 2006, ENDOSCOPY, V38, P360, DOI 10.1055/s-2005-921192; Triantafyllou K, 2015, GASTROENT RES PRACT, DOI 10.1155/2015/195093; Uzman S, 2016, VIDEOSURGERY MINIINV, V11, P178, DOI 10.5114/wiitm.2016.61521; Vargo JJ, 2017, GASTROINTEST ENDOSC, V85, P101, DOI 10.1016/j.gie.2016.02.007; Verschoore T, 2016, ACTA GASTRO-ENT BELG, V79, P39	45	0	0	1	2	ARAN EDICIONES, S A	MADRID	CASTELLO, 128, 1O, 28006 MADRID, SPAIN	1130-0108	2340-4167		REV ESP ENFERM DIG	Rev. Esp. Enferm. Dig.		2019	111	1					55	61		10.17235/reed.2018.5763/2018			7	Gastroenterology & Hepatology	Gastroenterology & Hepatology	HK0FV	WOS:000457575100010	30424678	DOAJ Gold			2020-06-30	J	Mallette, JR; Casale, JF; Hays, PA				Mallette, Jennifer R.; Casale, John F.; Hays, Patrick A.			Characterization and differentiation of cyclopropylfentanyl from E-crotonylfentanyl, Z-crotonylfentanyl, and 3-butenylfentanyl	SCIENCE & JUSTICE			English	Article						Cyclopropylfentanyl; Crotonylfentanyl; Chromatography; Forensic chemistry; Spectrometry		Recently, a sample containing cyclopropylfentanyl was analyzed at this laboratory. Cyclopropylfentanyl began to appear in the United States' illicit drug markets in 2017. Unfortunately, cyclopropylfentanyl presents an analytical challenge due to its mass spectrum being almost identical to that of crotonylfentanyl. There are two possible isomers of crotonylfentanyl, Z- and E- crotonylfentanyl. In order to provide sufficient analytical data to distinguish the two isomers of crotonylfentanyl and cyclopropylfentanyl, crotonylfentanyl was synthesized and fully characterized. Each isomer was analyzed via nuclear magnetic resonance spectroscopy, gas chromatography mass spectrometry, and Fourier transform infrared spectroscopy. During the synthesis of crotonylfentanyl, an unknown compound was formed. The identification of this compound and the analytical characterization of the two isomers of crotonylfentanyl are presented. Through the comparison of these compounds, it was confirmed that cyclopropylfentanyl can be differentiated from crotonylfentanyl.	[Mallette, Jennifer R.; Casale, John F.; Hays, Patrick A.] US Drug Enforcement Adm, Special Testing & Res Lab, 22624 Dulles Summit Court, Dulles, VA 20166 USA	Mallette, JR (reprint author), US Drug Enforcement Adm, Special Testing & Res Lab, 22624 Dulles Summit Court, Dulles, VA 20166 USA.	Jennifer.R.Mallette@usdoj.gov					Armenian P, 2018, NEUROPHARMACOLOGY, V134, P121, DOI 10.1016/j.neuropharm.2017.10.016; Casale J. F., 2018, MICROGRAM J, V15, P1; Edison L, 2017, MMWR-MORBID MORTAL W, V66, P1119, DOI 10.15585/mmwr.mm6641a6; European Monitoring Centre for Drugs and Drug Adiction, 2017, EMCDDA EUR JOINT REP; Kanamori T, 2017, J FORENSIC SCI, V62, P1472, DOI 10.1111/1556-4029.13395; Mallette JR, 2018, FORENSIC CHEM, V8, P64, DOI 10.1016/j.forc.2018.02.001; Noble C, 2018, DRUG TEST ANAL, V10, P651, DOI 10.1002/dta.2263; Palaty J, 2018, CLIN BIOCHEM, V53, P164, DOI 10.1016/j.clinbiochem.2018.01.013; Schueler Harold E, 2017, Acad Forensic Pathol, V7, P36, DOI 10.23907/2017.004; Simons B., 2017, SOC FORENSIC TOX TOX, V41, P9; United Nations Office on Drugs and Crime (UNODC), GLOB SMART UPD; Vardanyan RS, 2014, FUTURE MED CHEM, V6, P385, DOI 10.4155/fmc.13.215	12	6	6	1	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1355-0306	1876-4452		SCI JUSTICE	Sci. Justice	JAN	2019	59	1					67	74		10.1016/j.scijus.2018.07.005			8	Medicine, Legal; Pathology	Legal Medicine; Pathology	HK1IH	WOS:000457658000008	30654970				2020-06-30	J	Bryant, B; Pittard, S; Jordan, NR; McMahon, CR				Bryant, B.; Pittard, S.; Jordan, N. R.; McMahon, C. R.			Chemical capture of wild swamp buffalo (Bubalus bubalis) in tropical northern Australia using thiafentanil, etorphine and azaperone combinations	AUSTRALIAN VETERINARY JOURNAL			English	Article						acidosis; anaesthesia; capnography; capture myopathy; oximetry; swamp buffalo	MANAGEMENT	Background Studying wild animals in situ is fundamental to collecting baseline information, but generally they need to be immobilised for examination, sampling, marking and/or equipping with tracking apparatus. Capturing wild animals is inherently risky and there is a need for immobilisation methods that are safe for both the animals and researchers. Methods A total of 16 free-ranging swamp buffalo (Bubalus bubalis) were chemically captured by dart for the application of satellite tracking collars in tropical northern Australia; 7 animals were anesthetised with a thiafentanil-etorphine-azaperone (TEA) combination and 9 animals with a thiafentanil-azaperone (TA) combination. Anaesthesia was reversed with intravenous naltrexone. Mean dosages of etorphine and thiafentanil for animals in the TEA group were 0.01 mg/kg of each drug and mean dosage of thiafentanil for animals in the TA group was 0.02 mg/kg. Total dose per animal of azaperone and naltrexone was 80 mg and 150 mg, respectively. Anaesthetic monitoring was by physical observation of physiological variables, pulse oximetry and capnography. Blood laboratory parameters including creatine kinase (CK), aspartate transaminase (AST), serum bicarbonate and anion gap were measured. Results All subject animals recovered well from anaesthesia despite the occurrence of subclinical acidosis in some patients. There was no significant difference between the treatment groups. Conversely, chase time had an adverse effect on body temperature, irrespective of the anaesthetic combination used. Conclusions Thiafentanil and azaperone, with or without etorphine, delivered rapid safe, effective, reversible field anaesthesia in healthy swamp buffalo.	[Bryant, B.; Jordan, N. R.] Taronga Western Plains Zoo, Dubbo, NSW, Australia; [Pittard, S.] Charles Darwin Univ, Res Inst Environm & Livelihoods, Darwin, NT, Australia; [Jordan, N. R.] Univ New South Wales, Australia Ctr Ecosyst Sci, Sch Biol Earth & Environm Sci, Sydney, NSW, Australia; [McMahon, C. R.] Sydney Inst Marine Sci, Mosman, NSW, Australia	Bryant, B (reprint author), Taronga Western Plains Zoo, Dubbo, NSW, Australia.	bbryant@zoo.nsw.gov.au	McMahon, Clive R/D-5713-2013	McMahon, Clive R/0000-0001-5241-8917; Jordan, Neil/0000-0002-0712-8301	Australian Research Council Linkage Project SchemeAustralian Research Council; Director of National Parks (Australia); Research Institute for the Environment and Livelihoods; Charles Darwin University	The Australian Research Council Linkage Project Scheme, Director of National Parks (Australia), the Research Institute for the Environment and Livelihoods and Charles Darwin University funded and supported this research. The findings and views expressed are those of the authors and do not necessarily represent the views of Parks Australia, the Director of National Parks or the Australian Government.	Arnemo Jon M., 2007, P103, DOI 10.1002/9780470376478.ch8; Australian Government . Department of Sustainability Environment Water Population and Communities., 2011, FER WAT BUFF BUB BUB; BAYLISS P, 1989, AUST WILDLIFE RES, V16, P651; Burroughs Richard, 2012, P53; CANFIELD PJ, 1984, AUST VET J, V61, P89, DOI 10.1111/j.1751-0813.1984.tb15525.x; CLERBAUX T, 1993, COMP BIOCHEM PHYS A, V106, P687, DOI 10.1016/0300-9629(93)90382-E; Curro Thomas G., 2007, P635, DOI 10.1002/9780470376478.ch57; FINLAYSON CM, 1996, [No title captured], P1; George JW, 1994, VET LAB MED CLIN PAT, P94; Haigh JC, 1978, CHEM IMMOBILISATION, P46; Hampton JO, 2016, WILDLIFE RES, V43, P429, DOI 10.1071/WR15230; Harthoorn A.M., 1973, P14; Harthoorn A.M., 1973, P51; HARTHOORN AM, 1965, RES VET SCI, V6, P290; Harthoorn AM, 1965, WILDLIFE MONOGR, V14, P1; Haskins S.C., 1996, LUMB JONES VET ANEST, P409; KNIGHTON AD, 1991, GEOLOGY, V19, P831, DOI 10.1130/0091-7613(1991)019<0831:TCEASI>2.3.CO;2; Lance William R., 2012, P589; Mcmahon CR, 2008, AUST VET J, V86, P235, DOI 10.1111/j.1751-0813.2008.00303.x; Nowak RM, 1991, WALKERS MAMMALS WORL, VII, P1334; Pienaar U de V, 1969, Acta Zool Pathol Antverp, V48, P163; Pienaar UV, 1973, CAPTURE CARE WILD AN, P35; Radostits OM, 2006, VET MED TXB DIS CATT, P626; Radostits OM, 2006, VET MED TXB DIS CATT, P3; Radunz B, 2006, VET MICROBIOL, V112, P283, DOI 10.1016/j.vetmic.2005.11.017; Robinson CJ, 2005, CONSERV BIOL, V19, P1385, DOI 10.1111/j.1523-1739.2005.00196.x; Schumacher Juergen, 2008, P455, DOI 10.1016/B978-141604047-7.50059-2; Soares FS, 2011, ASIAN AUSTRAL J ANIM, V24, P1587, DOI 10.5713/ajas.2011.11070	28	3	3	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0005-0423	1751-0813		AUST VET J	Aust. Vet. J.	JAN	2019	97	1-2					33	38		10.1111/avj.12782			6	Veterinary Sciences	Veterinary Sciences	HJ3IT	WOS:000457064400007	30693492	Bronze			2020-06-30	J	Barbosa, LD; Santos, JM; de Morais, DR; Nimtz, AV; Eberlin, MN; de Oliveira, MF; Costa, JL				Barbosa, Lilian de Melo; Santos, Jandyson Machado; de Morais, Damila Rodrigues; Nimtz, Alessandra Valerio; Eberlin, Marcos Nogueira; de Oliveira, Marcelo Firmino; Costa, Jose Luiz			Fast UHPLC-MS/MS method for analysis of furanylfentanyl in different seized blotter papers	DRUG TESTING AND ANALYSIS			English	Letter							PSYCHOACTIVE SUBSTANCE; SYNTHETIC OPIOIDS; IDENTIFICATION; FENTANYL; ACETYLFENTANYL; ACRYLFENTANYL; DRUG		[Barbosa, Lilian de Melo; Nimtz, Alessandra Valerio] Criminalist Inst, Tech Sci Police Superintendence, Campinas, SP, Brazil; [Barbosa, Lilian de Melo; de Oliveira, Marcelo Firmino] Univ Sao Paulo, Fac Filosofia Ciencias & Letras, Ribeirao Preto, SP, Brazil; [Santos, Jandyson Machado; de Morais, Damila Rodrigues; Eberlin, Marcos Nogueira] Univ Estadual Campinas, Inst Chem, ThoMSon Mass Spectrometry Lab, Campinas, SP, Brazil; [Santos, Jandyson Machado] Univ Fed Rural Pernambuco, Dept Chem, Recife, PE, Brazil; [Costa, Jose Luiz] Univ Estadual Campinas, Fac Pharmaceut Sci, BR-13083859 Campinas, SP, Brazil	Costa, JL (reprint author), Univ Estadual Campinas, Fac Pharmaceut Sci, BR-13083859 Campinas, SP, Brazil.	jose.jlc@fcf.unicamp.br	Santos, Jandyson Machado/H-5499-2015; de Oliveira, Marcelo F/F-8315-2012	Santos, Jandyson Machado/0000-0002-2099-6728; de Oliveira, Marcelo F/0000-0003-0858-2044; Barbosa, Lilian/0000-0002-3564-2770; Eberlin, Marcos Nogueira/0000-0003-4868-0618; Costa, Jose Luiz/0000-0001-9607-3391	Conselho Nacional de Desenvolvimento Cientifico e Tecnologico - CNPqNational Council for Scientific and Technological Development (CNPq) [400254/2017-4]; FundacAo de Amparo a Pesquisa do Estado de SAo Paulo - FAPESPFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2015/10650-8, 2018/00432-1]	The authors thank Conselho Nacional de Desenvolvimento Cientifico e Tecnologico - CNPq (process number 400254/2017-4) and FundacAo de Amparo a Pesquisa do Estado de SAo Paulo - FAPESP (process number 2015/10650-8 and 2018/00432-1) for fellowship and financial support.	[Anonymous], 1996, GUID IND Q2B VAL AN; Armenian P, 2018, NEUROPHARMACOLOGY, V134, P121, DOI 10.1016/j.neuropharm.2017.10.016; Breindahl T, 2017, DRUG TEST ANAL, V9, P415, DOI 10.1002/dta.2046; Drug Enforcement Administration (DEA), 2016, INT BRIEF COUNT PRES; Drug Enforcement AdministrationDepartment of Justice, 2016, FED REGISTER, V81, P229; EMCDDA, 2018, FENT SYNTH CANN DRIV; European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), 2017, RISK ASS REP NEW PSY; Goggin MM, 2017, J ANAL TOXICOL, V41, P367, DOI 10.1093/jat/bkx022; Guerrieri D, 2017, FORENSIC SCI INT, V277, pE21, DOI 10.1016/j.forsciint.2017.05.010; Guerrieri D, 2017, J ANAL TOXICOL, V41, P242, DOI 10.1093/jat/bkw129; Helander A, 2016, CLIN TOXICOL, V54, P324, DOI 10.3109/15563650.2016.1139715; Huang B-S, 1986, United States patent, Patent No. 4584303; KRAM TC, 1981, ANAL CHEM, V53, P1379, DOI 10.1021/ac00235a003; Lurie IS, 2012, FORENSIC SCI INT, V220, P191, DOI 10.1016/j.forsciint.2012.02.024; Mc Fadden K, 2006, J CHROMATOGR A, V1120, P54, DOI 10.1016/j.chroma.2006.01.071; Prekupec MP, 2017, J ADDICT MED, V11, P256, DOI 10.1097/ADM.0000000000000324; Rudd RA, 2016, MMWR-MORBID MORTAL W, V65, P1445, DOI 10.15585/mmwr.mm655051e1; Seither J, 2017, J ANAL TOXICOL, V41, P493, DOI 10.1093/jat/bkx049; Shoff EN, 2017, J ANAL TOXICOL, V41, P484, DOI 10.1093/jat/bkx041; Suzuki J, 2017, DRUG ALCOHOL DEPEN, V171, P107, DOI 10.1016/j.drugalcdep.2016.11.033; Swanson DM, 2017, J ANAL TOXICOL, V41, P498, DOI 10.1093/jat/bkx037; Ujvary I, 2017, FORENSIC TOXICOL, V35, P232, DOI 10.1007/s11419-017-0367-8; United Nations Office of Drugs and Crime (UNODC), 2009, GUID VAL AN METH CAL; United Nations Office on Drugs and Crime, 2017, RENT ITS AN 50 YEARS; United Nations Office on Drugs and Crime, 2018, MARCH 2018 UNODC 12; US Drug Enforcement Administration Diversion Control Division, 2017, NFLIS BRIEF FENT 200; Watanabe S, 2017, AAPS J, V19, P1102, DOI 10.1208/s12248-017-0070-z; Wood EF, 2017, INT J DRUG POLICY, V41, P132, DOI 10.1016/j.drugpo.2016.12.010; Wu F, 2017, J ANAL TOXICOL, V41, P289, DOI 10.1093/jat/bkx003	29	1	1	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1942-7603	1942-7611		DRUG TEST ANAL	Drug Test. Anal.	JAN	2019	11	1					178	183		10.1002/dta.2472			6	Biochemical Research Methods; Chemistry, Analytical; Pharmacology & Pharmacy	Biochemistry & Molecular Biology; Chemistry; Pharmacology & Pharmacy	HJ3IC	WOS:000457062700019	30054991				2020-06-30	J	Qin, YJ; Ni, LF; Shi, JW; Zhu, ZY; Shi, SJ; Lam, AL; Magiera, J; Sekar, S; Kuo, A; Smith, MT; Li, TY				Qin, Yajuan; Ni, Luofan; Shi, Jiawei; Zhu, Zhiying; Shi, Saijian; Lam, Ai-leen; Magiera, Julia; Sekar, Sunderajhan; Kuo, Andy; Smith, Maree T.; Li, Tingyou			Synthesis and Biological Evaluation of Fentanyl Analogues Modified at Phenyl Groups with Alkyls	ACS CHEMICAL NEUROSCIENCE			English	Article						Fentanyl; analgesics; opioid; beta-arrestin2	MU-OPIOID RECEPTOR; AGONIST/DELTA-ANTAGONIST; BIASED LIGAND; DISCOVERY; TRV130; TOLERANCE; MORPHINE; DEPENDENCE; SAFER; MOR	A series of fentanyl analogues modified at the phenyl group of the phenethyl with alkyl and/or hydroxyl and alkoxy, and the phenyl group in the anilido moiety replaced with benzyl or substituted benzyl, were synthesized. The in vitro opioid receptor functional activity of these compounds was evaluated by assessment of their ability to modulate forskolin-stimulated cAMP accumulation and by their ability to induce beta-arrestin2 recruitment. Compound 12 is a potent mu-opioid (MOP) receptor agonist, a potent kappa-opioid (KOP) receptor antagonist with weak beta-arrestin2 recruitment activity. Compounds 10 and 11 are potent MOP receptor agonists with weak delta-opioid (DOP) receptor antagonist activity and moderate KOP receptor antagonist activity as well as weak beta-arrestin2 recruitment activity at the MOP receptor. These compounds are promising leads for discovery of potent opioid analgesics with reduced side effects relative to clinically available strong opioid analgesics.	[Qin, Yajuan; Ni, Luofan; Shi, Jiawei; Zhu, Zhiying; Shi, Saijian; Li, Tingyou] Nanjing Med Univ, Sch Pharm, Nanjing 211166, Jiangsu, Peoples R China; [Lam, Ai-leen; Magiera, Julia; Sekar, Sunderajhan; Kuo, Andy; Smith, Maree T.] Univ Queensland, Fac Med, Sch Biomed Sci, Brisbane, Qld 4072, Australia; [Li, Tingyou] Nanjing Med Univ, Collaborat Innovat Ctr Cardiovasc Dis Translat Me, Key Lab Targeted Intervent Cardiovasc Dis, Nanjing 211166, Jiangsu, Peoples R China	Li, TY (reprint author), Nanjing Med Univ, Sch Pharm, Nanjing 211166, Jiangsu, Peoples R China.; Smith, MT (reprint author), Univ Queensland, Fac Med, Sch Biomed Sci, Brisbane, Qld 4072, Australia.; Li, TY (reprint author), Nanjing Med Univ, Collaborat Innovat Ctr Cardiovasc Dis Translat Me, Key Lab Targeted Intervent Cardiovasc Dis, Nanjing 211166, Jiangsu, Peoples R China.	maree.smith@uq.edu.au; l_tingyou@njmu.edu.cn	Smith, Maree T/I-4005-2015	Smith, Maree T/0000-0003-2281-3734	National Nature Science Foundation of China (NSFC)National Natural Science Foundation of China [81573280]; Jiangsu Province Funds for Young Scientists [BK20171048]; Smart Futures Research Industry Partnership Program	This work was supported in part by grants from the National Nature Science Foundation of China (NSFC No. 81573280) to T.L, and supported in part by grants to Y.Q from Jiangsu Province Funds for Young Scientists (No. BK20171048). Research done at The University of Queensland was supported by a Smart Futures Research Industry Partnership Program.	ABDELHAMID EE, 1991, J PHARMACOL EXP THER, V258, P299; Anand JP, 2018, BRIT J PHARMACOL, V175, P2013, DOI 10.1111/bph.14148; Andurkar SV, 2014, BIOORG MED CHEM LETT, V24, P644, DOI 10.1016/j.bmcl.2013.11.069; Bird MF, 2015, BRIT J ANAESTH, V114, P646, DOI 10.1093/bja/aeu454; Cai J, 2014, BIOORGAN MED CHEM, V22, P2208, DOI 10.1016/j.bmc.2014.02.015; Chen XT, 2013, J MED CHEM, V56, P8019, DOI 10.1021/jm4010829; DeWire SM, 2013, J PHARMACOL EXP THER, V344, P708, DOI 10.1124/jpet.112.201616; Eguchi M, 2004, MED RES REV, V24, P182, DOI 10.1002/med.10059; ESSAWI MYH, 1983, J MED CHEM, V26, P348, DOI 10.1021/jm00357a007; Fujita W, 2015, BRIT J PHARMACOL, V172, P375, DOI 10.1111/bph.12663; Gupta PK, 2013, MED CHEM RES, V22, P3888, DOI 10.1007/s00044-012-0390-6; Harland AA, 2016, J MED CHEM, V59, P4985, DOI 10.1021/acs.jmedchem.6b00308; Harland AA, 2015, J MED CHEM, V58, P8952, DOI 10.1021/acs.jmedchem.5b01270; Healy JR, 2013, ACS CHEM NEUROSCI, V4, P1256, DOI 10.1021/cn4000428; Kane BE, 2006, AAPS J, V8, pE126, DOI 10.1208/aapsj080115; Li T, 2007, J MED CHEM, V50, P2753, DOI 10.1021/jm061238m; LOBBEZOO MW, 1981, J MED CHEM, V24, P777, DOI 10.1021/jm00139a003; Madariaga-Mazon A, 2017, DRUG DISCOV TODAY, V22, P1719, DOI 10.1016/j.drudis.2017.07.002; Manglik A, 2016, NATURE, V537, P185, DOI 10.1038/nature19112; Monti L, 2016, J ENZYM INHIB MED CH, V31, P1638, DOI 10.3109/14756366.2016.1160902; Olson KM, 2017, YALE J BIOL MED, V90, P97; Portoghese PS, 2017, ACS CHEM NEUROSCI, V8, P426, DOI 10.1021/acschemneuro.7b00002; Schiller PW, 1999, J MED CHEM, V42, P3520, DOI 10.1021/jm980724+; Schmid CL, 2017, CELL, V171, P1165, DOI 10.1016/j.cell.2017.10.035; Singla N, 2017, J PAIN RES, V10, P2413, DOI 10.2147/JPR.S137952; Siuda ER, 2017, CURR OPIN PHARMACOL, V32, P77, DOI 10.1016/j.coph.2016.11.007; Soergel DG, 2014, PAIN, V155, P1829, DOI 10.1016/j.pain.2014.06.011; Spahn V, 2017, SCIENCE, V355, P966, DOI 10.1126/science.aai8636; Tachibana Y, 2006, J ORG CHEM, V71, P5093, DOI 10.1021/jo0601563; Vardanyan RS, 2014, FUTURE MED CHEM, V6, P385, DOI 10.4155/fmc.13.215; Viscusi ER, 2016, PAIN, V157, P264, DOI 10.1097/j.pain.0000000000000363; Vuckovic S, 2009, CURR MED CHEM, V16, P2468, DOI 10.2174/092986709788682074; Weltrowska G, 2014, BIOORGAN MED CHEM, V22, P4581, DOI 10.1016/j.bmc.2014.07.033; Weltrowska G, 2010, J MED CHEM, V53, P2875, DOI 10.1021/jm9019068; Yadav Shiv Kumar, 2014, Interdiscip Toxicol, V7, P93, DOI 10.2478/intox-2014-0013	35	1	1	3	16	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	1948-7193			ACS CHEM NEUROSCI	ACS Chem. Neurosci.	JAN	2019	10	1					201	208		10.1021/acschemneuro.8b00363			15	Biochemistry & Molecular Biology; Chemistry, Medicinal; Neurosciences	Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Neurosciences & Neurology	HI3LM	WOS:000456351300025	30179508				2020-06-30	J	Astrand, A; Toreskog, A; Watanabe, S; Kronstrand, R; Green, H; Vikingsson, S				Astrand, Anna; Toreskog, Amanda; Watanabe, Shimpei; Kronstrand, Robert; Green, Henrik; Vikingsson, Svante			Correlations between metabolism and structural elements of the alicyclic fentanyl analogs cyclopropyl fentanyl, cyclobutyl fentanyl, cyclopentyl fentanyl, cyclohexyl fentanyl and 2,2,3,3-tetramethylcyclopropyl fentanyl studied by human hepatocytes and LC-QTOF-MS	ARCHIVES OF TOXICOLOGY			English	Article						Fentanyl analogs; Metabolism; Human hepatocytes; LC-QTOF-MS	MASS; IDENTIFICATION; ACRYLFENTANYL; FURANYLFENTANYL; ACETYLFENTANYL; GAS	Recently, a number of fentanyl analogs have been implicated in overdose deaths in Europe and in the US. So far, little is known of the molecular behavior of the structurally related subgroup; the alicyclic fentanyls. In this study, reference standards of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and 2,2,3,3-tetramethylcyclopropyl fentanyl (TMCPF) at a final concentration of 5 mu M were incubated with cryopreserved human hepatocytes (1x10(6) cells/mL) for 0, 1, 3 and 5h. The metabolites formed were identified by liquid chromatography-quadrupole time-of-flight mass spectrometry analysis. The most abundant biotransformation found was N-dealkylation (formation of normetabolites) and oxidation of the alicyclic rings. As ring size increased, the significance of N-dealkylation decreased in favor of alicyclic ring oxidation. An example of this was cyclopropyl fentanyl, with a three-carbon ring, whose normetabolite covered 82% of the total metabolic peak area and no oxidation of the alicyclic ring was observed. In contrast, TMCPF, with a seven-carbon ring structure, rendered as much as 85% of its metabolites oxidized on the alicyclic ring. Other biotransformations found included oxidation of the piperidine ethyl moiety and/or the phenethyl substructure, glucuronidation as well as amide hydrolysis to form metabolites identical to despropionyl fentanyl. Taken together, this study provides a base for understanding the metabolism of a number of structurally related fentanyl analogs formed upon intake.	[Astrand, Anna; Kronstrand, Robert; Green, Henrik; Vikingsson, Svante] Linkoping Univ, Dept Med & Hlth Sci, Linkoping, Sweden; [Toreskog, Amanda; Watanabe, Shimpei; Kronstrand, Robert; Green, Henrik; Vikingsson, Svante] Natl Board Forens Med, Dept Forens Genet & Forens Toxicol, Linkoping, Sweden	Astrand, A (reprint author), Linkoping Univ, Dept Med & Hlth Sci, Linkoping, Sweden.	anna.astrand@liu.se		Vikingsson, Svante/0000-0001-5977-3049; Watanabe, Shimpei/0000-0001-5211-3283; Green, Henrik/0000-0002-8015-5728	Strategiomradet Forensiska Vetenskaper (Strategic Research Area Forensic Sciences) at Linkoping University; Eurostar project Psychomics	This study was supported by the Strategiomradet Forensiska Vetenskaper (Strategic Research Area Forensic Sciences) at Linkoping University and Eurostar project Psychomics.	[Anonymous], 2017, REP RISK ASS N 1 PHE; CASHMAN JR, 1992, CHEM RES TOXICOL, V5, P639, DOI 10.1021/tx00029a008; Drug Enforcement Administration Department of Justice., 2018, Fed Regist, V83, P469; Drug Enforcement Administration DoJ, 2018, FED REGISTER, V83, P4880; EMCDDA, 2017, REP RISK ASS N PHEN; European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), 2017, RISK ASS REP NEW PSY; European Monitoring Centre for Drugs Drug Addiction [ EMCDDA], 2018, EMCDDA EUR JOINT REP; GOROMARU T, 1984, ANESTHESIOLOGY, V61, P73, DOI 10.1097/00000542-198461010-00013; Grigoryev A, 2013, J ANAL TOXICOL, V37, P265, DOI 10.1093/jat/bkt028; Guerrieri D, 2017, FORENSIC SCI INT, V277, pE21, DOI 10.1016/j.forsciint.2017.05.010; Guerrieri D, 2017, J ANAL TOXICOL, V41, P242, DOI 10.1093/jat/bkw129; GULDBERG HC, 1975, PHARMACOL REV, V27, P135; Helander A, 2017, CLIN TOXICOL, V55, P589, DOI 10.1080/15563650.2017.1303141; Kanamori T, 2018, BIOL PHARM BULL, V41, P106, DOI 10.1248/bpb.b17-00709; Kotiaho T, 2000, J AM SOC MASS SPECTR, V11, P526, DOI 10.1016/S1044-0305(00)00116-1; Mahlke NS, 2014, INT J LEGAL MED, V128, P771, DOI 10.1007/s00414-014-1040-y; O'Brien PJ, 2005, CRIT REV TOXICOL, V35, P609, DOI 10.1080/10408440591002183; O'Donnell JK, 2017, MMWR-MORBID MORTAL W, V66, P1197, DOI 10.15585/mmwr.mm6643e1; Rang H.P., 2007, RANG DALES PHARM; Steuer AE, 2017, DRUG TEST ANAL, V9, P1085, DOI 10.1002/dta.2111; Watanabe S, 2017, AAPS J, V19, P1102, DOI 10.1208/s12248-017-0070-z; Wohlfarth A, 2013, CLIN CHEM, V59, P1638, DOI 10.1373/clinchem.2013.209965	22	9	9	1	2	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0340-5761	1432-0738		ARCH TOXICOL	Arch. Toxicol.	JAN	2019	93	1					95	106		10.1007/s00204-018-2330-9			12	Toxicology	Toxicology	HI3YW	WOS:000456388700008	30361799	Green Published, Other Gold			2020-06-30	J	Smolina, K; Crabtree, A; Chong, M; Zhao, B; Park, M; Mill, C; Schutz, CG				Smolina, Kate; Crabtree, Alexis; Chong, Mei; Zhao, Bin; Park, Mina; Mill, Christopher; Schutz, Christian G.			Patterns and history of prescription drug use among opioid-related drug overdose cases in British Columbia, Canada, 2015-2016	DRUG AND ALCOHOL DEPENDENCE			English	Article						Overdose; Opioids; Prescribing; Administrative data; Fentanyl; OAT	CHRONIC PAIN; NONFATAL OVERDOSE; UNITED-STATES; PRESCRIBING PATTERNS; RISK-FACTORS; DEATHS; HEROIN; TRENDS; ABUSE; EPIDEMIOLOGY	Background: British Columbia is the epicenter of the current fentanyl-related overdose crisis in Canada. Our study characterizes prescribing histories of people who had an opioid-related overdose compared to matched controls. Methods: We examined linked administrative data for individuals who overdosed between January 1, 2015 and November 30, 2016. Past prescriptions over five years were assessed for opioids for pain, opioid agonist therapy, benzodiazepines/z-drugs, antidepressants, antipsychotics, gabapentinoids, mood stabilizers and anti-epileptics, muscle relaxants, and other sedating medications. Prescribing history of 9964 cases was compared with that of 49,820 matched controls. Results: Overdose cases were more likely to be prescribed opioids for pain and to have used prescription opioids on a long-term basis in the previous five years compared to controls. However, at the time of overdose, 92% of men and 86% of women did not have an active opioid for pain prescription, and approximately half had not filled one in the past five years. Those who overdosed tended to have more prescriptions for psychotropic substances than controls. Fewer than 10% of cases had an active prescription for opioid agonist therapy and most were not on treatment in the past. Conclusions: Low prevalence of active prescriptions for opioids for pain at the time of overdose suggests that opioid prescribing plays a limited short-term impact in the current fentanyl-related crisis of overdoses. While liberal opioid prescribing practices may have contributed to the development of the current overdose crisis, regulation and enforcement of clinicians' prescribing practices will likely have limited impact in reducing overdoses.	[Smolina, Kate; Crabtree, Alexis; Chong, Mei; Zhao, Bin; Park, Mina] BC Ctr Dis Control, 655 W 12th Ave, Vancouver, BC V5Z 4R42, Canada; [Smolina, Kate; Crabtree, Alexis] Univ British Columbia, Sch Populat & Publ Hlth, 2206 East Mall, Vancouver, BC V6T 1Z3, Canada; [Mill, Christopher] Govt Canada, Publ Hlth Agcy Canada, 130 Colonnade Rd, Ottawa, ON K1A 0K9, Canada; [Schutz, Christian G.] Univ British Columbia, Dept Psychiat, Inst Mental Hlth, 2255 Wesbrook Mall, Vancouver, BC V6T 2A1, Canada; [Schutz, Christian G.] Burnaby Ctr Mental Hlth & Addict, 3405 Willingdon Ave, Burnaby, BC V5G 3H4, Canada	Smolina, K (reprint author), BC Ctr Dis Control, 2101-655 W 12th Ave, Vancouver, BC V5Z 4R4, Canada.	kate.smolina@bccdc.ca		Chong, Mei/0000-0002-6397-4385; Schuetz, Christian/0000-0002-5445-8290			Abouchedid R, 2018, J MED TOXICOL, V14, P134, DOI 10.1007/s13181-018-0659-3; [Anonymous], 2015, CLIN HDB PSYCHOTROPI; Arens AM, 2016, JAMA INTERN MED, V176, P1554, DOI 10.1001/jamainternmed.2016.4306; Bell JR, 2009, DRUG ALCOHOL DEPEN, V104, P73, DOI 10.1016/j.drugalcdep.2009.03.020; Bohnert ASB, 2011, JAMA-J AM MED ASSOC, V305, P1315, DOI 10.1001/jama.2011.370; Boscarino JA, 2016, SUBST ABUSE REHABIL, V7, P131, DOI 10.2147/SAR.S108302; Brady Joanne E, 2017, Inj Epidemiol, V4, P24, DOI 10.1186/s40621-017-0118-7; British Columbia Centre for Disease Control, 2018, CHRON DIS DASHB CAS; British Columbia Coroners Service, 2017, ILL DRUG OV DEATHS B; British Columbia Coroners Service, 2018, FENT DET ILL DRUG OV; Canadian Centre on Substance Abuse, 2009, SUBST AB CAN CONC DI; Chahua M, 2014, EUR ADDICT RES, V20, P1, DOI 10.1159/000346787; College of Physicians and Surgeons of British Columbia, 2016, PROF STAND GUID SAF; Daniulaityte R, 2006, J DRUG ISSUES, V36, P787, DOI 10.1177/002204260603600402; Dowell D, 2016, JAMA-J AM MED ASSOC, V315, P1624, DOI 10.1001/jama.2016.1464; European Monitoring Centre for Drugs and Drug Addiction, 2017, STAT B; Fischer B, 2004, CAN MED ASSOC J, V171, P235, DOI 10.1503/cmaj.1031416; Fischer B, 2018, PREV MED, V107, P109, DOI 10.1016/j.ypmed.2017.11.001; Gladstone EJ, 2015, MED CARE, V53, P954, DOI 10.1097/MLR.0000000000000431; Glanz JM, 2018, J GEN INTERN MED, V33, P1646, DOI 10.1007/s11606-017-4288-3; Gomes T, 2014, CMAJ OPEN, V2, P256; Gomes T, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002396; Government of British Columbia, 2016, PROV HLTH OFF DECL P; Groot E, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157512; Hakkinen M, 2014, FORENSIC SCI INT, V241, P1, DOI 10.1016/j.forsciint.2014.04.028; Hall AJ, 2008, JAMA-J AM MED ASSOC, V300, P2613, DOI 10.1001/jama.2008.802; Harocopos A, 2015, J DRUG ISSUES, V45, P385, DOI 10.1177/0022042615604345; Janjua NZ, 2018, INT J DRUG POLICY, V55, P31, DOI 10.1016/j.drugpo.2018.02.001; Johnson EM, 2013, J GEN INTERN MED, V28, P522, DOI 10.1007/s11606-012-2225-z; Kendall P., 2017, BC OPIOID SUBSTITUTI; Kerr T, 2007, DRUG ALCOHOL DEPEN, V87, P39, DOI 10.1016/j.drugalcdep.2006.07.009; Larochelle MR, 2018, ANN INTERN MED, V169, P137, DOI 10.7326/M17-3107; Larochelle MR, 2016, ANN INTERN MED, V164, P1, DOI 10.7326/M15-0038; Lyndon A, 2017, ADDICTION, V112, P1580, DOI 10.1111/add.13843; Madadi P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060600; Mars SG, 2014, INT J DRUG POLICY, V25, P257, DOI 10.1016/j.drugpo.2013.10.004; Martin J, 2018, BMJ-BRIT MED J, V361, DOI 10.1136/bmj.k2270; McLarnon M., 2017, PREVENTING PHARM OPI; Mui HZ, 2014, J DRUG ISSUES, V44, P236, DOI 10.1177/0022042613497935; Nadpara PA, 2018, PAIN MED, V19, P79, DOI 10.1093/pm/pnx038; Nielsen S, 2016, PHARMACOEPIDEM DR S, V25, P733, DOI 10.1002/pds.3945; Oliva EM, 2017, PSYCHOL SERV, V14, P34, DOI 10.1037/ser0000099; Otterstatter MC, 2018, HEALTH PROMOT CHRON, V38, P328, DOI 10.24095/hpcdp.38.9.04; Park TW, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h2698; Ramage-Morin Pamela L, 2010, Health Rep, V21, P53; Reitsma ML, 2012, PAIN RES MANAG, V17, P166, DOI 10.1155/2012/875924; Rudd RA, 2016, MMWR-MORBID MORTAL W, V65, P1445, DOI 10.15585/mmwr.mm655051e1; Rudd RA, 2016, MMWR-MORBID MORTAL W, V64, P1378, DOI 10.15585/mmwr.mm6450a3; Schopflocher D, 2011, PAIN RES MANAG, V16, P445, DOI 10.1155/2011/876306; Seth P, 2018, AM J PUBLIC HEALTH, V108, P500, DOI 10.2105/AJPH.2017.304265; Shah NG, 2008, ADDICTION, V103, P126, DOI 10.1111/j.1360-0443.2007.02054.x; Silva K, 2013, DRUG ALCOHOL DEPEN, V128, P104, DOI 10.1016/j.drugalcdep.2012.08.014; Slavova S, 2017, INT J DRUG POLICY, V46, P120, DOI 10.1016/j.drugpo.2017.05.051; Smolina K, 2016, CAN J PUBLIC HEALTH, V107, pE404, DOI [10.17269/cjph.107.5413, 10.17269/CJPH.107.5413]; Spies E. P. A., 2015, UNDETERMINED RISK FA; Sun EC, 2017, BMJ-BRIT MED J, V356, DOI 10.1136/bmj.j760; Tian TY, 2013, J AM MED INFORM ASSN, V20, pE275, DOI 10.1136/amiajnl-2013-001856; Tonelli M, 2015, BMC MED INFORM DECIS, V15, DOI 10.1186/s12911-015-0155-5; U.S. Food and drug administration (USFDA), 2016, FDA DRUG SAF COMM FD; Unick GJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054496; Vivolo-Kantor AM, 2018, MMWR-MORBID MORTAL W, V67, P279, DOI 10.15585/mmwr.mm6709e1; World Health Organisation, 2018, DEF GEN CONS; Zedler B, 2014, PAIN MED, V15, P1911, DOI 10.1111/pme.12480	63	7	7	3	7	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0376-8716	1879-0046		DRUG ALCOHOL DEPEN	Drug Alcohol Depend.	JAN 1	2019	194						151	158		10.1016/j.drugalcdep.2018.09.019			8	Substance Abuse; Psychiatry	Substance Abuse; Psychiatry	HI3NC	WOS:000456356100022	30439611				2020-06-30	J	Glick, JL; Christensen, T; Park, JN; McKenzie, M; Green, TC; Sherman, SG				Glick, Jennifer L.; Christensen, Tricia; Park, Ju Nyeong; McKenzie, Michelle; Green, Traci C.; Sherman, Susan G.			Stakeholder perspectives on implementing fentanyl drug checking: Results from a multi-site study	DRUG AND ALCOHOL DEPENDENCE			English	Article						Fentanyl; Drug checking; Implementation	PEOPLE; THREAT	Background: The opioid epidemic is one of the greatest public health crises of our times, driven increasingly by synthetic opioids such as fentanyl in the heroin supply. The implementation of drug checking in community settings has the potential to reduce the burden of fatal overdose, provide harm reduction education around safer drug consumption, and increase health access among people who use drugs (PWUD). To inform program development, we explored stakeholder opinions on drug checking technologies and implementation considerations. Methods: This study, from the larger FORECAST study, utilized semi-structured in-depth interviews (n = 32) with a range of stakeholders in Baltimore, Boston, and Providence, many of whom were service providers. Stakeholders represented various roles and levels in organization types including harm reduction, public health, peer groups, and advocates. Interviews were audio recorded and transcribed. Data were coded using a priori codes; the coded text was analyzed for key themes. Results: Stakeholders responded positively to drug checking technology, though they shared apprehensions regarding service implementation. Primary topics requiring consideration included: utility in fentanyl endemic areas, trust and rapport between providers and PWUD, legality and policy concerns. Additional considerations included: technology accuracy, cost, ease of distribution, and service delivery setting. Conclusions: Stakeholders overwhelmingly supported the concept of drug checking with the goals of providing needed risk reduction information and resources to PWUD and serving as a point for greater engagement in services. Programs need to be tailored to local circumstances. Law enforcement buy-in and policy change will be critical aspects of providing drug checking services.	[Glick, Jennifer L.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Mental Hlth, 624 N Broadway,Hampton House 749, Hampton, MD 749 USA; [Christensen, Tricia; Park, Ju Nyeong; Sherman, Susan G.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Behav & Soc, 624 N Broadway,Hampton House 163, Baltimore, MD USA; [McKenzie, Michelle] Miriam Hosp, 164 Summit Ave, Providence, RI 02906 USA; [Green, Traci C.] Brown Univ, Rhode Isl Hosp, Dept Emergency Med, Warren Alpert Med Sch, Providence, RI 02912 USA	Glick, JL (reprint author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Mental Hlth, 624 N Broadway,Hampton House 749, Hampton, MD 749 USA.	jglick5@jhu.edu			Bloomberg American Health Initiative; Drug Dependence Epidemiology Training Program, NIH/NIDA [T32DA007292]	This work was supported by the Bloomberg American Health Initiative and the Drug Dependence Epidemiology Training Program, NIH/NIDA (T32DA007292).	Amlani A, 2015, HARM REDUCT J, V12, DOI 10.1186/s12954-015-0088-4; Brunt T, 2017, DRUG CHECKING HARM R; BTNX Inc, 2018, RAP RESP FENT FYL TE; Ciccarone D, 2017, INT J DRUG POLICY, V46, P107, DOI 10.1016/j.drugpo.2017.06.010; Frank RG, 2017, NEW ENGL J MED, V376, P605, DOI 10.1056/NEJMp1615145; Harper L, 2017, HARM REDUCT J, V14, DOI 10.1186/s12954-017-0179-5; Higashikawa Y, 2008, FORENSIC TOXICOL, V26, P1, DOI 10.1007/s11419-007-0039-1; Hygiene M. D. o. H. a. M, 2017, DRUG ALC REL INT DEA; Krieger MS, 2018, HARM REDUCT J, V15, DOI 10.1186/s12954-018-0213-2; Macneil J, 2011, DRUG ALCOHOL REV, V30, P26, DOI 10.1111/j.1465-3362.2010.00188.x; Marshall K., 2018, FENTANYL TEST STRIP; Massachusetts Department of Public Health, 2018, DAT BRIEF OP REL OV; McGowan CR, 2018, INT J DRUG POLICY, V58, P31, DOI 10.1016/j.drugpo.2018.04.017; Rhode Island Department of Health, 2018, DRUG OV DEATHS; Sherman SG, 2018, FORECAST STUDY SUMMA; Treloar C, 2016, INT J DRUG POLICY, V27, P138, DOI 10.1016/j.drugpo.2015.08.018; Volpe DA, 2011, REGUL TOXICOL PHARM, V59, P385, DOI 10.1016/j.yrtph.2010.12.007	17	9	9	0	0	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0376-8716	1879-0046		DRUG ALCOHOL DEPEN	Drug Alcohol Depend.	JAN 1	2019	194						527	532		10.1016/j.drugalcdep.2018.10.017			6	Substance Abuse; Psychiatry	Substance Abuse; Psychiatry	HI3NC	WOS:000456356100073	30551090				2020-06-30	J	Chung, CP; Dupont, WD; Murray, KT; Hall, K; Stein, CM; Ray, WA				Chung, Cecilia P.; Dupont, William D.; Murray, Katherine T.; Hall, Kathi; Stein, C. Michael; Ray, Wayne A.			Comparative out-of-hospital mortality of long-acting opioids prescribed for non-cancer pain: A retrospective cohort study	PHARMACOEPIDEMIOLOGY AND DRUG SAFETY			English	Article						fentanyl; morphine; mortality; opioids; oxycodone; pharmacoepidemiology	PHARMACOKINETICS; PRESCRIPTIONS; MORPHINE; TRENDS; ANALGESICS; PREVENTION; OVERDOSE; THERAPY; DEATHS	Purpose Despite significant growth of opioid prescriptions, only limited data are available regarding the comparative safety of long-acting opioids for chronic non-cancer pain. Recent data suggest that transdermal fentanyl and oxycodone CR may have greater toxicity than morphine SR in patients with non-cancer pain. Thus, we compared the risk of out-of-hospital deaths in patients with non-cancer pain filling prescriptions for transdermal fentanyl or oxycodone CR with that for morphine SR. Methods We conducted a retrospective cohort study in 50 658 patients enrolled in Tennessee Medicaid who filled prescriptions for transdermal fentanyl (n = 8717), oxycodone CR (n = 14 118), or morphine SR (n = 27 823) between 1999 and 2011. We excluded individuals with cancer or other life-threatening diagnoses and used propensity scores to adjust for multiple potential confounders. The primary outcome was out-of-hospital mortality. Results During 44 385 person-years of follow-up, 689 patients died. The out-of-hospital mortality rate among all study subjects was 155/10 000 patient-years. Contrary to earlier data suggesting greater risk, mortality was not significantly different in patients filling prescriptions for transdermal fentanyl compared with morphine SR (adjusted HR = 0.96, 95% C.I.: 0.77-1.21); moreover, patients filling prescriptions for oxycodone CR had lower mortality risk compared with those filling prescriptions for morphine SR (adjusted HR = 0.79, 95% C.I. 0.66-0.95). Conclusion In the study population, long-acting opioids for non-cancer pain were associated with high out-of-hospital mortality rates. We found comparable out-of-hospital mortality risks associated with transdermal fentanyl and morphine SR. The risk of out-of-hospital death for oxycodone CR was lower than that for morphine SR.	[Chung, Cecilia P.; Murray, Katherine T.; Stein, C. Michael] Vanderbilt Univ, Med Ctr, Dept Med & Pharmacol, Nashville, TN USA; [Dupont, William D.] Vanderbilt Univ, Med Ctr, Dept Biostat, Nashville, TN USA; [Hall, Kathi; Ray, Wayne A.] Vanderbilt Univ, Med Ctr, Dept Hlth Policy, Nashville, TN USA	Chung, CP (reprint author), 1161 21 Ave South,T-3113 MCN, Nashville, TN 37232 USA.	c.chung@vanderbilt.edu			Rheumatology Research Foundation; National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS) [K23AR064768]; National Heart, Lung, and Blood InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [HL081707]	Rheumatology Research Foundation, Grant/Award Numbers: K-supplement award and R bridge; National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health, Grant/Award Number: K23AR064768; National Heart, Lung, and Blood Institute, Grant/Award Number: HL081707	Arbogast PG, 2011, AM J EPIDEMIOL, V174, P613, DOI 10.1093/aje/kwr143; Bedson J, 2016, PAIN, V157, P1525, DOI 10.1097/j.pain.0000000000000557; Beletsky L, 2012, JAMA-J AM MED ASSOC, V308, P1863, DOI 10.1001/jama.2012.14205; Berland D, 2012, AM FAM PHYSICIAN, V86, P252; Boudreau D, 2009, PHARMACOEPIDEM DR S, V18, P1166, DOI 10.1002/pds.1833; Centers for Disease Control and Prevention (CDC), 2011, MMWR Morb Mortal Wkly Rep, V60, P869; Chou R, 2015, ANN INTERN MED, V162, P276, DOI 10.7326/M14-2559; Dhalla IA, 2009, CAN MED ASSOC J, V181, P891, DOI 10.1503/cmaj.090784; Dunn KM, 2010, ANN INTERN MED, V152, P85, DOI 10.7326/0003-4819-152-2-201001190-00006; Ekholm O, 2014, PAIN, V155, P2486, DOI 10.1016/j.pain.2014.07.006; Gomes Tara, 2011, Open Med, V5, pe13; Grond S, 2000, CLIN PHARMACOKINET, V38, P59, DOI 10.2165/00003088-200038010-00004; Hartung DM, 2007, ANN PHARMACOTHER, V41, P921, DOI 10.1345/aph.1K066; Kirvela M, 1996, J CLIN ANESTH, V8, P13, DOI 10.1016/0952-8180(95)00092-5; Krebs EE, 2011, PAIN, V152, P1789, DOI 10.1016/j.pain.2011.03.023; Krinsky CS, 2011, AM J FOREN MED PATH, V32, P347, DOI 10.1097/PAF.0b013e31822ad269; Kuehn BM, 2007, JAMA-J AM MED ASSOC, V297, P249, DOI 10.1001/jama.297.3.249; Landen MG, 2003, AM J EPIDEMIOL, V157, P273, DOI 10.1093/aje/kwf196; Lotsch J, 2013, CLIN PHARMACOKINET, V52, P23, DOI 10.1007/s40262-012-0016-7; Morden NE, 2014, MED CARE, V52, P852, DOI 10.1097/MLR.0000000000000183; Okie S, 2010, NEW ENGL J MED, V363, P1981, DOI 10.1056/NEJMp1011512; OSBORNE R, 1986, BRIT MED J, V293, P1101, DOI 10.1136/bmj.293.6554.1101; Paulozzi Leonard J., 2011, Morbidity and Mortality Weekly Report, V60, P1487; Portenoy RK, 2002, J PAIN SYMPTOM MANAG, V23, P292, DOI 10.1016/S0885-3924(02)00382-2; Ray WA, 2003, NEW ENGL J MED, V349, P1592, DOI 10.1056/NEJMp038145; RAY WA, 1989, AM J EPIDEMIOL, V129, P837, DOI 10.1093/oxfordjournals.aje.a115198; Ray WA, 2016, JAMA-J AM MED ASSOC, V315, P2415, DOI 10.1001/jama.2016.7789; Rudd RA, 2016, MMWR-MORBID MORTAL W, V64, P1378, DOI 10.15585/mmwr.mm6450a3; Solomon DH, 2010, ARCH INTERN MED, V170, P1968, DOI 10.1001/archinternmed.2010.391; U.S. Department of Health and Human Services-Substance Abuse and Mental Health Services Administration, 2011, DRUG AB WARN NETW 20; Von Korff M, 2008, CLIN J PAIN, V24, P521, DOI 10.1097/AJP.0b013e318169d03b; Zin CS, 2014, EUR J PAIN, V18, P1343, DOI 10.1002/j.1532-2149.2014.496.x	32	1	1	1	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1053-8569	1099-1557		PHARMACOEPIDEM DR S	Pharmacoepidemiol. Drug Saf.	JAN	2019	28	1			SI		48	53		10.1002/pds.4619			6	Public, Environmental & Occupational Health; Pharmacology & Pharmacy	Public, Environmental & Occupational Health; Pharmacology & Pharmacy	HI2FQ	WOS:000456261000008	30003613	Green Accepted			2020-06-30	J	Cocoros, NM; Larochelle, MR; Popovic, J; Petrone, AB; Kornegay, C; Ju, J; Racoosin, JA				Cocoros, Noelle M.; Larochelle, Marc R.; Popovic, Jennifer; Petrone, Andrew B.; Kornegay, Cynthia; Ju, Jing; Racoosin, Judith A.			Assessment of prior opioid tolerance among new users of fentanyl transdermal system in FDA's Sentinel System	PHARMACOEPIDEMIOLOGY AND DRUG SAFETY			English	Article						analgesics; opioidfentanyl; pharmacoepidemiology; REMS		Purpose Fentanyl transdermal system (FTS) is intended only for patients with prior opioid tolerance. The purpose of this study is to identify the proportion of new FTS users who had evidence of prior opioid tolerance, by dosage strength, in FDA's Sentinel System. Methods We identified new FTS episodes (183-day washout) from 2009 through 2013. Members were <65 years and enrolled in medical and pharmacy coverage for 183 days prior to initial FTS dispensing (index). We assessed the proportion of users with prior tolerance stratified by dosage strength of FTS using four definitions of opioid tolerance: >= 30-mg oxycodone equivalents/day in each of 7 consecutive days immediately prior to index; >= 30-mg oxycodone equivalents/day for any 7 days in the 30 days prior to index (secondary); any dose in each of 7 days in the 7 consecutive days immediately prior to index (tertiary); and any dose for any 7 days in the 30 days prior to index (quaternary). Results Of 44 450 episodes of 25 mcg/hr FTS, 37% met the primary definition, and 77% met the quaternary definition. Of 3507 episodes of 100 mcg/hr FTS, 57% and 74% met the primary and quaternary definitions, respectively. Those aged 25 to 34 years had the highest proportion of episodes with prior tolerance; those aged 55 to 64 accounted for more of the episodes overall. Conclusions In Sentinel, many new users of FTS did not have evidence of prior opioid tolerance by the primary definition, ie, the product label definition, which is the minimum standard for the lowest FTS dose (12 mcg/hr), especially at the highest strength (100 mcg/hr). Validation of this metric is warranted, but our findings suggest the need for further prescriber education regarding appropriate prescribing of FTS.	[Cocoros, Noelle M.; Popovic, Jennifer; Petrone, Andrew B.] Harvard Med Sch, Dept Populat Med, 401 Pk Dr,Suite 401 East, Boston, MA 02215 USA; [Cocoros, Noelle M.; Popovic, Jennifer; Petrone, Andrew B.] Harvard Pilgrim Hlth Care Inst, 401 Pk Dr,Suite 401 East, Boston, MA 02215 USA; [Larochelle, Marc R.] Boston Univ, Sch Med, Dept Med, Gen Internal Med Sect, Boston, MA 02118 USA; [Larochelle, Marc R.] Boston Med Ctr, Boston, MA USA; [Kornegay, Cynthia; Ju, Jing; Racoosin, Judith A.] US FDA, Ctr Drug Evaluat & Res, Silver Spring, MD USA	Cocoros, NM (reprint author), Harvard Med Sch, Dept Populat Med, 401 Pk Dr,Suite 401 East, Boston, MA 02215 USA.; Cocoros, NM (reprint author), Harvard Pilgrim Hlth Care Inst, 401 Pk Dr,Suite 401 East, Boston, MA 02215 USA.	noelle_cocoros@harvardpilgrim.org		Cocoros, Noelle/0000-0001-7090-2761	FDAUnited States Department of Health & Human Services [HHSF223200910006I]	FDA, Grant/Award Number: HHSF223200910006I	[Anonymous], 2018, DURAGESIC PRODUCT LA; [Anonymous], OP MORPH EQ CONV FAC; FOLEY KM, 1985, NEW ENGL J MED, V313, P84, DOI 10.1056/NEJM198507113130205; Friesen KJ, 2016, CAN MED ASSOC J, V188, P648, DOI 10.1503/cmaj.150961; Larochelle Marc R, 2017, J Opioid Manag, V13, P315, DOI 10.5055/jom.2017.0400; Lucyk S, 2016, CAN MED ASSOC J, V188, P638, DOI 10.1503/cmaj.160291; Robb MA, 2012, PHARMACOEPIDEM DR S, V21, P9, DOI 10.1002/pds.2311; Salzman RT, 1999, J PAIN SYMPTOM MANAG, V18, P271, DOI 10.1016/S0885-3924(99)00079-2; U.S. Food and Drug Administration, RISK EV MIT STRAT RE; Willy ME, 2014, PAIN MED, V15, P1558, DOI 10.1111/pme.12459	10	0	0	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1053-8569	1099-1557		PHARMACOEPIDEM DR S	Pharmacoepidemiol. Drug Saf.	JAN	2019	28	1			SI		112	116		10.1002/pds.4677			5	Public, Environmental & Occupational Health; Pharmacology & Pharmacy	Public, Environmental & Occupational Health; Pharmacology & Pharmacy	HI2FQ	WOS:000456261000016	30379379				2020-06-30	J	Grimsrud, KN; Ivanova, X; Sherwin, CM; Palmieri, TL; Tran, NK				Grimsrud, Kristin N.; Ivanova, Xenia; Sherwin, Catherine M.; Palmieri, Tina L.; Tran, Nam K.			Identification of Cytochrome P450 Polymorphisms in Burn Patients and Impact on Fentanyl Pharmacokinetics: A Pilot Study	JOURNAL OF BURN CARE & RESEARCH			English	Article							INTERETHNIC DIFFERENCES; METABOLISM; POPULATION; PHARMACOGENOMICS; CYP2D6; DRUG	Pain management is critical for burn care. Unfortunately, interindividual variation in pharmacokinetics (PK) due to burn hypermetabolism and genetic polymorphisms can lead to treatment failures in this at-risk population. Analgesics may be affected by genetic polymorphisms affecting cytochrome P450 (CYP) drug metabolizing enzymes. Fentanyl is a common opiate primarily metabolized by CYP3A4 subtypes. Recent studies demonstrate CYP2D6 variants, affecting fentanyl PK. Functional CYP polymorphisms can significantly alter opiate levels resulting in inadequate analgesia or life-threatening toxicity. The goal of our study was to evaluate fentanyl PK and assess associations with CYP polymorphisms. We obtained samples from the previously banked blood of 13 patients (eight males and five females) with > 20% TBSA burns. Mean (SD) patient age was 41.7 (14.5) years, and mean burn size was 25.8 (15.3) % TBSA. Plasma fentanyl was quantified, and CYP genotyping was performed. Pharmacokinetic analysis was performed using Monolix software (Lixsoft, France) with a two-compartment population model best-representing fentanyl profiles. Three CYP slow-metabolizing genotypes were identified, which included CYP2D6*9, CYP2D6*29, and CYP3A4*1B. All three patients with variant polymorphisms had increased serum fentanyl concentrations due to impaired clearance. This pilot study supports the need for further research in this topic, and CYP genotyping of individual patients prior to receiving opiate analgesics to inform precision-guided decisions, improve therapeutic efficacy, and, most importantly, increase patient well-being and safety.	[Grimsrud, Kristin N.; Ivanova, Xenia; Tran, Nam K.] Univ Calif Davis, Sch Med, Dept Pathol & Lab Med, 1 Shields Ave, Davis, CA 95616 USA; [Sherwin, Catherine M.] Univ Utah, Sch Med, Dept Pediat, Div Clin Pharmacol, Salt Lake City, UT USA; [Palmieri, Tina L.] Univ Calif Davis, Sch Med, Dept Surg, Div Burn Surg, Davis, CA 95616 USA	Grimsrud, KN (reprint author), Univ Calif Davis, Sch Med, Dept Pathol & Lab Med, 1 Shields Ave, Davis, CA 95616 USA.	kngrimsrud@ucdavis.edu	Sherwin, Catherine Mary Turner/B-2888-2012	Sherwin, Catherine Mary Turner/0000-0002-0844-3207; Ivanova, Xenia/0000-0002-7447-0211; Tran, Nam/0000-0003-1565-0025	National Heart Lung and Blood Institute Emergency Medicine K12 [5K12HL108964-05]	We thank our Clinical Laboratory supporting this study. The project was supported in part by a National Heart Lung and Blood Institute Emergency Medicine K12 (no. 5K12HL108964-05) scholarship.	de Castro RJA, 2013, REV BRAS ANESTESIOL, V63, P149, DOI 10.1016/j.bjane.2012.02.003; Bernard S, 2006, ONCOLOGIST, V11, P126, DOI 10.1634/theoncologist.11-2-126; Dahabreh Issa, 2010, PLoS Curr, V2, DOI 10.1371/currents.RRN1176; Dumas EO, 2008, AAPS J, V10, P537, DOI 10.1208/s12248-008-9056-1; Elmallah Randa K, 2018, Surg Technol Int, V32, P306; Feierman DE, 1996, DRUG METAB DISPOS, V24, P932; Foster Adriana, 2007, Pain Pract, V7, P352, DOI 10.1111/j.1533-2500.2007.00153.x; Godwin Z, 2016, J BURN CARE RES, V37, pE10, DOI 10.1097/BCR.0000000000000298; Han TH, 2007, J CLIN PHARMACOL, V47, P674, DOI 10.1177/0091270007299756; Holmquist GL, 2009, PAIN MED, V10, pS20, DOI 10.1111/j.1526-4637.2009.00596.x; Jin M, 2005, J ANAL TOXICOL, V29, P590, DOI 10.1093/jat/29.7.590; Kaneda K, 2009, BURNS, V35, P790, DOI 10.1016/j.burns.2008.12.006; Kapur BM, 2014, CLIN BIOCHEM, V47, P1169, DOI 10.1016/j.clinbiochem.2014.05.065; Martin TL, 2006, J ANAL TOXICOL, V30, P603, DOI 10.1093/jat/30.8.603; Marwa KJ, 2014, MALARIA J, V13, DOI 10.1186/1475-2875-13-420; Morgan ET, 2009, CLIN PHARMACOL THER, V85, P434, DOI 10.1038/clpt.2008.302; National Hospital Ambulatory Medical Care Survey, 2011, EM DEP SUMM TABL; Prakash S, 2004, ANESTH ANALG, V99, P552, DOI 10.1213/01.ANE.0000125110.56886.90; Preissner SC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082562; Shi W., 2015, EUR J BIOMED RES, V1, P3; Singh MS, 2011, BREAST, V20, P111, DOI 10.1016/j.breast.2010.11.003; Steele AN, 2015, J BURN CARE RES, V36, pE194, DOI 10.1097/BCR.0000000000000120; Tannenbaum C, 2014, EXPERT REV CLIN PHAR, V7, P533, DOI 10.1586/17512433.2014.910111; Teh LK, 2012, DRUG METAB PHARMACOK, V27, P55, DOI 10.2133/dmpk.DMPK-11-RV-121; Topletz AR, 2013, DRUG METAB DISPOS, V41, P1651, DOI 10.1124/dmd.113.051094; van der Weide Jan, 2006, Clin Biochem Rev, V27, P17; Wennerholm A, 2001, PHARMACOGENETICS, V11, P417, DOI 10.1097/00008571-200107000-00005; Wu SB, 2015, GENET TEST MOL BIOMA, V19, P248, DOI 10.1089/gtmb.2014.0318; Zhou SF, 2009, DRUG METAB REV, V41, P89, DOI 10.1080/03602530902843483	29	2	2	0	1	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	1559-047X	1559-0488		J BURN CARE RES	J. Burn Care Res.	JAN-FEB	2019	40	1					91	96		10.1093/jbcr/iry053			6	Critical Care Medicine; Dermatology; Surgery	General & Internal Medicine; Dermatology; Surgery	HH9BB	WOS:000456027600012	30371861	Green Published			2020-06-30	J	Ding, SC; Ma, HZ; Wang, G; Yu, ZY; Li, KZ; Huang, AJ				Ding, Suchun; Ma, Hongzhong; Wang, Gao; Yu, Zhenyu; Li, Kezhong; Huang, Aijie			Effect of Remifentanil Combined Anesthesia on Cytokines and Oxidative Stress in Patients undergoing Laparoscopic Surgery for Colon Cancer	JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN			English	Article						Colon cancer; Laparoscopic surgery; Remifentanil; Fentanyl; Cytokines; Oxidative stress	PROPOFOL	Objective: To investigate the effect of remifentanil combined anesthesia on serum cytokines and oxidative stress indices in patients undergoing laparoscopic surgery for colon cancer. Study Design: Experimental study. Place and Duration of Study: Department of Anesthesiology, Yuhuangding Hospital Affiliated to Qingdao University, Yantai, China, from May 2016 to March 2018. Methodology: A total of 154 patients undergoing laparoscopic surgery for colon cancer were randomly divided into control group and observation group, with 77 cases in each group. Control group received fentanyl combined anesthesia, and observation group received remifentanil combined anesthesia. Levels of serum cytokines IL-8, IL-6, CRP, TNF-alpha and the levels of oxidative stress indices SOD, MDA, CAT, and GSH on the first day after operation were compared. Occurrence of adverse reactions during anesthesia recovery was observed and recorded in both groups. Results: On the first day after surgery, levels of serum cytokines IL-8, IL-6, CRP, TNF-alpha and MDA in the observation group were lower than those in the control group (all p<0.001); levels of serum SOD, GSH, and CAT in the observation group were higher than those in the control group (all p<0.001). The frequency of adverse reactions such as nausea and vomiting, chills, restlessness, cough, and tachycardia in the observation group was lower than that in the control group (p=0.029, 0.016, 0.009, 0.025, and 0.003, respectively). Conclusion: Compared with fentanyl combined anesthesia, the remifentanil combined anesthesia can significantly reduce serum levels of cytokines IL-8, IL-6, CRP, TNF-alpha and oxidative stress level, and is, therefore, more secure for patients undergoing laparoscopic surgery for colon cancer.	[Ding, Suchun; Ma, Hongzhong; Wang, Gao; Yu, Zhenyu; Li, Kezhong; Huang, Aijie] Qingdao Univ, Dept Anesthesiol, Yuhuangding Hosp, Yantai 264000, Peoples R China	Huang, AJ (reprint author), Qingdao Univ, Dept Anesthesiol, Yuhuangding Hosp, Yantai 264000, Peoples R China.	sangmi78814@163.com					Alirezaei M, 2016, J PHYSIOL SCI, V67, P1; Bajwa SJS, 2016, J MINIM ACCESS SURG, V12, P4, DOI 10.4103/0972-9941.169952; Bang YS, 2016, J ANESTH, V30, P935, DOI 10.1007/s00540-016-2249-3; Bhurgri H, 2017, JCPSP-J COLL PHYSICI, V27, P327, DOI 2629; Bonjer HJ, 2009, LANCET ONCOL, V10, P44, DOI 10.1016/S1470-2045(08)70310-3; Cappuccio Ellise, 2018, J Pediatr Pharmacol Ther, V23, P215, DOI 10.5863/1551-6776-23.3.215; Dang YJ, 2018, CAN J GASTROENTEROL, V2018, DOI 10.1155/2018/7940603; Ece I, 2017, ANN SURG TREAT RES, V92, P179, DOI 10.4174/astr.2017.92.4.179; Godos J, 2017, WORLD J GASTROENTERO, V23, P1909, DOI 10.3748/wjg.v23.i10.1909; Guthrie GJK, 2013, BRIT J CANCER, V109, P131, DOI 10.1038/bjc.2013.291; Kim HY, 2018, CLIN INTERV AGING, V13, P1053, DOI 10.2147/CIA.S166423; Liu XW, 2018, EXP THER MED, V16, P1079, DOI 10.3892/etm.2018.6286; Martinez-Perez A, 2017, SURG LAPARO ENDO PER, V27, P318, DOI 10.1097/SLE.0000000000000419; Palumbo P, 2017, G CHIR, V38, P273, DOI 10.11138/gchir/2017.38.6.273; Qi YY, 2016, ONCOL LETT, V11, P3361, DOI 10.3892/ol.2016.4394; Rocha RG, 2017, REV BRAS ANESTESIOL, V67, P500, DOI [10.1016/j.bjan.2017.04.024, 10.1016/j.bjane.2016.10.001]; Salem JF, 2018, SURG ONCOL CLIN N AM, V27, P303, DOI 10.1016/j.soc.2017.11.005; Shin Sooil, 2017, J Dent Anesth Pain Med, V17, P65, DOI 10.17245/jdapm.2017.17.1.65; Sighom JRN, 2017, FUTURE INTERNET, V9, DOI 10.3390/fi9030023; Vainer Noomi, 2018, Oncotarget, V9, P29820, DOI 10.18632/oncotarget.25661; Yiannakopoulou EC, 2013, SURG LAPARO ENDO PER, V23, P101, DOI 10.1097/SLE.0b013e3182827b33; Zheng XQ, 2017, MOL MED REP, V16, P5312, DOI 10.3892/mmr.2017.7305	22	1	2	0	1	COLL PHYSICIANS & SURGEONS PAKISTAN	KARACHI	SEVENTH CENTRAL ST, DEFENCE HOUSING AUTHORITY, KARACHI, 75500, PAKISTAN	1022-386X	1681-7168		JCPSP-J COLL PHYSICI	JCPSP-J. Coll. Physicians Surg.	JAN	2019	29	1					8	11		10.29271/jcpsp.2019.01.8			4	Medicine, General & Internal	General & Internal Medicine	HH0UJ	WOS:000455434800004	30630560	Bronze			2020-06-30	J	Kokubu, S; Eddinger, KA; Nguyen, TMD; Huerta-Esquivel, LL; Yamaguchi, S; Schiller, PW; Yaksh, TL				Kokubu, Shinichi; Eddinger, Kelly A.; Nguyen, Thi M-D; Huerta-Esquivel, Lena Libertad; Yamaguchi, Shigeki; Schiller, Peter W.; Yaksh, Tony L.			Characterization of the antinociceptive effects of intrathecal DALDA peptides following bolus intrathecal delivery	SCANDINAVIAN JOURNAL OF PAIN			English	Article						DMT-DALDA; Mu receptor; analgesia; cross-tolerance; tolerance	STRAUB TAIL REACTION; MU-OPIOID PEPTIDE; MORPHINE-TOLERANCE; CROSS-TOLERANCE; DEPENDENCE; PHARMACOLOGY; AGONISTS; RAT; DERMORPHIN; LIGAND	Background and aims: We systematically characterized the potency and side effect profile of a series of small opioid peptides with high affinity for the mu opioid receptor. Methods: Male Sprague Dawley rats were prepared with intrathecal (IT) catheters, assessed with hind paw thermal escape and evaluated for side effects including Straub tail, truncal rigidity, and pinnae and corneal reflexes. In these studies, DMT-DALDA (dDAL) (H-Dmt-D-ArgPhe-Lys-NH2 MW = 981), dDALc (H-Dmt-Cit-Phe-Lys-NH2 MW = 868), dDALcn (H-Dmt-D-Cit-Phe-Nle-NH2 MW = 739), TAPP (H-Tyr-D-Ala-Phe-Phe-NH2 MW = 659), dDAL-TICP ([Dmt1] DALDA-(CH2)(2)-NH-TICP[psi]; MW = 1519), and dDALTIPP (H-Dmt-D-Arg-Phe-Lys(Ne-TIPP)-NH2 were examined. In separate studies, the effects of approximately equiactive doses of IT DMT DALDA (10 pmol), morphine (30 nmol) and fentanyl (1 nmol) were examined on formalin-induced flinching at different pretreatment intervals (15 min -24 h). Results: (1) All agents resulted in a dose-dependent reversible effect upon motor function (Straub Tail > Truncal rigidity). (2) The ordering of analgesic activity (% MPE) at the highest dose lacking reliable motor signs after bolus delivery was: DMT-DALDA (80% +/- 6/3 pmol); dDALc (75% +/- 8/1 pmol); dDALcn (84% +/- 10/300 pmol); TAPP (56% +/- 12/10 nmol); dDAL-TICP (52% +/- 27/300 pmol). (3) All analgesic effects were reversed by systemic (IP) naloxone (1 mg/kg). Naltrindole (3 mg/kg, IP) had no significant effect upon the maximum usable peptide dose. (4) Tolerance and cross-tolerance development after 5 daily boluses of DMT-DALDA (3 pmol) and morphine (30 nmol) revealed that both agents displayed a progressive decline over 5 days. (5) Cross-tolerance assessed at day 5 revealed a reduction in response to morphine in DMT-DALDA treated animal but not DMT-DALDA in the morphine treated animal, indicating an asymmetric cross-tolerance. (6) IT DMT-DALDA, morphine and fentanyl resulted in significant reductions in phase 1 and phase 2 flinching. With a 15 min pretreatment all drugs resulted in comparable reductions in flinching. However, at 6 h, the reduction in flinching after DMT-DALDA and morphine were comparably reduced while fentanyl was not different from vehicle. All effects on flinching were lost by 24 h. Conclusions: These results emphasize the potent mu agonist properties of the DALDA peptidic structure series, their persistence similar to morphine and their propensity to produce tolerance. The asymmetric cross-tolerance between equiactive doses may reflect the relative intrinsic activity of morphine and DMT-DALDA.	[Kokubu, Shinichi; Eddinger, Kelly A.; Huerta-Esquivel, Lena Libertad; Yaksh, Tony L.] Univ Calif San Diego, Dept Anesthesiol, 9500 Gilman Dr, La Jolla, CA 92093 USA; [Kokubu, Shinichi; Yamaguchi, Shigeki] Dokkyo Med Univ, Dept Anesthesiol, Mibu, Tochigi, Japan; [Nguyen, Thi M-D; Schiller, Peter W.] Univ Montreal, Dept Pharmacol & Physiol, Montreal, PQ, Canada; [Huerta-Esquivel, Lena Libertad] Univ Strasbourg, Alsacia, France; [Huerta-Esquivel, Lena Libertad] Univ Autonoma Nuevo Lean, San Nicolas De Los Garza, NL, Mexico; [Schiller, Peter W.] Montreal Clin Res Inst, Montreal, PQ, Canada	Yaksh, TL (reprint author), Univ Calif San Diego, Dept Anesthesiol, 9500 Gilman Dr, La Jolla, CA 92093 USA.	tyaksh@ucsd.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [DA15353]	This work was supported completely by a NIH grant DA15353 (TY).	ABDELHAMID EE, 1991, J PHARMACOL EXP THER, V258, P299; ACETO MD, 1969, BRIT J PHARMACOL, V36, P225, DOI 10.1111/j.1476-5381.1969.tb09500.x; Allen JW, 2006, ANESTHESIOLOGY, V105, P590, DOI 10.1097/00000542-200609000-00025; BILBEY DLJ, 1960, BRIT J PHARM CHEMOTH, V15, P540, DOI 10.1111/j.1476-5381.1960.tb00277.x; Buerkle H, 1996, ANESTHESIOLOGY, V84, P926, DOI 10.1097/00000542-199604000-00021; CHAVKIN C, 1982, LIFE SCI, V31, P1687, DOI 10.1016/0024-3205(82)90186-2; Daniels DJ, 2005, P NATL ACAD SCI USA, V102, P19208, DOI 10.1073/pnas.0506627102; Ding JG, 2012, CHEM BIOL DRUG DES, V79, P186, DOI 10.1111/j.1747-0285.2011.01268.x; Dirig DM, 1997, J NEUROSCI METH, V76, P183, DOI 10.1016/S0165-0270(97)00097-6; FUNDYTUS ME, 1995, EUR J PHARMACOL, V286, P105, DOI 10.1016/0014-2999(95)00554-X; Hutchinson Mark R, 2007, ScientificWorldJournal, V7, P98; HYLDEN JLK, 1980, EUR J PHARMACOL, V67, P313, DOI 10.1016/0014-2999(80)90515-4; Kest B, 1996, BRAIN RES BULL, V39, P185, DOI 10.1016/0361-9230(95)02092-6; Kondo I, 2005, J NEUROSCI, V25, P3651, DOI 10.1523/JNEUROSCI.0252-05.2005; Kouchek M, 2013, J PHARMACOL EXP THER, V347, P258, DOI 10.1124/jpet.113.206573; Lansu K, 2017, NAT CHEM BIOL, V13, P529, DOI [10.1038/NCHEMBIO.2334, 10.1038/nchembio.2334]; Laurido C, 1996, INT J NEUROSCI, V87, P191, DOI 10.3109/00207459609070837; MALMBERG AB, 1992, J PHARMACOL EXP THER, V263, P264; MALMBERG AB, 1994, J NEUROSCI, V14, P4882; MJANGER E, 1991, J PHARMACOL EXP THER, V258, P544; NATH C, 1994, EUR J PHARMACOL, V263, P203, DOI 10.1016/0014-2999(94)90543-6; Negus SS, 2009, EUR J PHARMACOL, V602, P92, DOI 10.1016/j.ejphar.2008.11.004; Nielsen CK, 2000, J PHARMACOL EXP THER, V295, P91; Novoa A, 2012, J MED CHEM, V55, P9549, DOI 10.1021/jm3008079; Ro S, 1995, J Pept Sci, V1, P157, DOI 10.1002/psc.310010303; Rozenfeld Raphael, 2007, ScientificWorldJournal, V7, P64; Schiller PW, 2015, ACS CHEM NEUROSCI, V6, P1789, DOI 10.1021/acschemneuro.5b00228; Schiller PW, 2005, AAPS J, V7, pE560, DOI 10.1208/aapsj070356; Schiller PW, 2000, EUR J MED CHEM, V35, P895, DOI 10.1016/S0223-5234(00)01171-5; SCHMAUSS C, 1985, BRAIN RES, V337, P209, DOI 10.1016/0006-8993(85)90056-3; Schmidt-Rondon E, 2018, TOXICOL APPL PHARM, V338, P54, DOI 10.1016/j.taap.2017.10.017; Shimoyama M, 2001, J PHARMACOL EXP THER, V297, P364; Shimoyama M, 2009, PHARMACOLOGY, V83, P33, DOI 10.1159/000167878; SOSNOWSKI M, 1990, ANESTHESIOLOGY, V73, P1141, DOI 10.1097/00000542-199012000-00012; STEVENS CW, 1986, BRAIN RES, V385, P300, DOI 10.1016/0006-8993(86)91076-0; Straub W, 1911, DEUT MED WOCHENSCHR, V37, P1469, DOI 10.1055/s-0028-1130858; SULLIVAN AF, 1988, BRAIN RES, V461, P182, DOI 10.1016/0006-8993(88)90738-X; SUTTERS KA, 1990, BRAIN RES, V530, P290, DOI 10.1016/0006-8993(90)91297-T; Szeto HH, 2001, J PHARMACOL EXP THER, V298, P57; TUNG AS, 1982, BRAIN RES, V247, P75, DOI 10.1016/0006-8993(82)91029-0; Yaksh TL, 2001, J APPL PHYSIOL, V90, P2386; YAKSH TL, 1976, PHYSIOL BEHAV, V17, P1031, DOI 10.1016/0031-9384(76)90029-9; YAKSH TL, 1986, ANESTHESIOLOGY, V64, P54, DOI 10.1097/00000542-198601000-00009; YAKSH TL, 1978, CAN J PHYSIOL PHARM, V56, P754, DOI 10.1139/y78-120; Yaksh TL, 2017, CURR NEUROPHARMACOL, V15, P232, DOI 10.2174/1570159X14666160307145542; Yaksh TL, 2013, NEUROMODULATION, V16, P459, DOI 10.1111/j.1525-1403.2012.00534.x; Yaksh TL, 2013, ANESTHESIOLOGY, V118, P664, DOI 10.1097/ALN.0b013e31828351aa; Zarrindast MR, 2001, PHARMACOL BIOCHEM BE, V69, P419, DOI 10.1016/S0091-3057(01)00519-6; Zhao GM, 2003, J PHARMACOL EXP THER, V307, P947, DOI 10.1124/jpet.103.054775	49	3	3	0	5	WALTER DE GRUYTER GMBH	BERLIN	GENTHINER STRASSE 13, D-10785 BERLIN, GERMANY	1877-8860	1877-8879		SCAND J PAIN	Scand. J. Pain	JAN	2019	19	1					193	206		10.1515/sjpain-2018-0120			14	Clinical Neurology	Neurosciences & Neurology	HH2AJ	WOS:000455520700021	30367811				2020-06-30	J	Han, SJ; Lee, TH; Yang, JK; Cho, YS; Jung, Y; Chung, IK; Park, SH; Park, S; Kim, SJ				Han, Su Jung; Lee, Tae Hoon; Yang, Jae Kook; Cho, Young Sin; Jung, Yunho; Chung, Il-Kwun; Park, Sang-Heum; Park, Suyeon; Kim, Sun-Joo			Etomidate Sedation for Advanced Endoscopic Procedures	DIGESTIVE DISEASES AND SCIENCES			English	Article						Endoscopic sedation; Advanced endoscopic procedure; Propofol; Etomidate	ADMINISTERED PROPOFOL SEDATION; DOUBLE-BLIND; GASTROINTESTINAL ENDOSCOPY; RETROGRADE CHOLANGIOPANCREATOGRAPHY; ANESTHESIA; EFFICACY; INDUCTION; MYOCLONUS; SURGERY; SAFETY	Background and Study AimAlthough propofol is widely used for sedation for endoscopic procedures, concerns remain regarding cardiopulmonary adverse events. Etomidate has little effect on the cardiovascular and respiratory systems, but patient satisfaction analysis is lacking. We compared the efficacy and safety of balanced propofol and etomidate sedation during advanced endoscopic procedures.MethodsAs a randomized noninferiority trial, balanced endoscopic sedation was achieved using midazolam and fentanyl, and patients were randomly assigned to receive propofol (BPS) or etomidate (BES) as add-on drug. The main outcomes were sedation efficacy measured on a 10-point visual analog scale (VAS) and safety.ResultsIn total, 186 patients (94 in the BPS group and 92 in the BES group) were evaluated. BES did not show noninferiority in terms of overall patient satisfaction, with a difference in VAS score of -0.35 (97.5% confidence interval -1.03 to , p=0.03). Among endoscopists and nurses, BES showed noninferiority to BPS, with differences in VAS scores of 0.06 and 0.08, respectively. Incidence of cardiopulmonary adverse events was lower in the BES group (27.7 versus 14.1%, p=0.023). Hypoxia occurred in 5.3 and 1.1% of patients in the BPS and BES group (p=0.211). Myoclonus occurred in 12.1% (11/92) in the BES group. BES had lower risk of overall cardiopulmonary adverse events (odds ratio 0.401, p=0.018).ConclusionsBES was not noninferior to BPS in terms of patient satisfaction. However, BES showed better safety outcomes in terms of cardiopulmonary adverse events.	[Han, Su Jung; Lee, Tae Hoon; Yang, Jae Kook; Cho, Young Sin; Jung, Yunho; Chung, Il-Kwun; Park, Sang-Heum; Kim, Sun-Joo] Soonchunhyang Univ, Sch Med, Cheonan Hosp, Div Gastroenterol,Dept Internal Med,Digest Dis Ct, 31,Sooncheonhyang 6 Gil, Cheonan Si 31151, Chungcheongnam, South Korea; [Park, Suyeon] Soonchunhyang Univ, Sch Med, Dept Stat, Seoul, South Korea	Lee, TH (reprint author), Soonchunhyang Univ, Sch Med, Cheonan Hosp, Div Gastroenterol,Dept Internal Med,Digest Dis Ct, 31,Sooncheonhyang 6 Gil, Cheonan Si 31151, Chungcheongnam, South Korea.	thlee9@schmc.ac.kr			Soonchunhyang University Research Fund	This work was supported by the Soonchunhyang University Research Fund.	Baradari AG, 2017, ARCH MED SCI, V13, P1102, DOI [10.5114/aoms.016.63193, 10.5114/aoms.2016.63193]; Burtea DE, 2015, WORLD J GASTRO ENDOS, V7, P981, DOI 10.4253/wjge.v7.i10.981; Cote GA, 2010, CLIN GASTROENTEROL H, V8, P137, DOI 10.1016/j.cgh.2009.07.008; Dumonceau JM, 2015, ENDOSCOPY, V47, P1175, DOI 10.1055/s-0034-1393414; Falk J, 2004, ANN PHARMACOTHER, V38, P1272, DOI 10.1345/aph.1E008; Forman SA, 2011, ANESTHESIOLOGY, V114, P695, DOI 10.1097/ALN.0b013e3181ff72b5; Gouda B, 2017, SAUDI J GASTROENTERO, V23, P133, DOI 10.4103/sjg.SJG_501_16; Gross JB, 2002, ANESTHESIOLOGY, V87, P174; Han SJ, 2017, DIGEST ENDOSC, V29, P369, DOI 10.1111/den.12841; Huter L, 2007, ANESTH ANALG, V105, P1298, DOI 10.1213/01.ane.0000287248.25610.c0; Khan MA, 2016, DIGEST DIS SCI, V61, P684, DOI 10.1007/s10620-015-3933-0; Kim MG, 2017, GASTROINTEST ENDOSC, V86, P452, DOI 10.1016/j.gie.2017.02.033; Lee CK, 2011, GASTROINTEST ENDOSC, V73, P206, DOI 10.1016/j.gie.2010.09.035; Lee SJ, 2015, DIGEST ENDOSC, V27, P512, DOI 10.1111/den.12448; Lee TH, 2012, DIGEST DIS SCI, V57, P2113, DOI 10.1007/s10620-012-2234-0; Liu JF, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000007212; Lovett P, 2017, J PERIANESTH NURS, V32, P210, DOI 10.1016/j.jopan.2015.12.012; Meng QT, 2016, EXP THER MED, V12, P1515, DOI 10.3892/etm.2016.3475; Morel J, 2011, BRIT J ANAESTH, V107, P503, DOI 10.1093/bja/aer169; Park CH, 2018, GASTROINTEST ENDOSC, V87, P174, DOI 10.1016/j.gie.2017.05.050; Petrun AM, 2013, BRIT J ANAESTH, V110, P388, DOI 10.1093/bja/aes416; St Pierre M, 2000, EUR J ANAESTH, V17, P634, DOI 10.1046/j.1365-2346.2000.00747.x; Toklu S, 2009, EUR J ANAESTH, V26, P370, DOI 10.1097/EJA.0b013e328318c666; Triantafillidis JK, 2013, WORLD J GASTROENTERO, V19, P463, DOI 10.3748/wjg.v19.i4.463; van Oss G E, 1980, Acta Anaesthesiol Belg, V31, P39; Wang J, 2018, AM J THER, V25, pE517, DOI 10.1097/MJT.0000000000000404; Yates AM, 2013, AM J EMERG MED, V31, P852, DOI 10.1016/j.ajem.2013.02.042; Ye LM, 2017, SURG LAPARO ENDO PER, V27, P1, DOI 10.1097/SLE.0000000000000373; Yeung Janice K, 2002, CJEM, V4, P194; Yusoff IF, 2004, GASTROINTEST ENDOSC, V60, P356, DOI 10.1016/S0016-5107(04)01711-0; Zhou X, 2016, SURG ENDOSC, V30, P5108, DOI 10.1007/s00464-016-4861-6	31	1	1	0	3	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0163-2116	1573-2568		DIGEST DIS SCI	Dig. Dis. Sci.	JAN	2019	64	1					144	151		10.1007/s10620-018-5220-3			8	Gastroenterology & Hepatology	Gastroenterology & Hepatology	HG4GF	WOS:000454932700021	30054843				2020-06-30	J	Brockbals, L; Staeheli, SN; Gentile, S; Schlaepfer, M; Bissig, C; Bolliger, SA; Kraemer, T; Steuer, AE				Brockbals, Lana; Staeheli, Sandra N.; Gentile, Simon; Schlaepfer, Markus; Bissig, Christian; Bolliger, Stephan A.; Kraemer, Thomas; Steuer, Andrea E.			Fatal poisoning involving cyclopropylfentanyl - Investigation of time-dependent postmortem redistribution	FORENSIC SCIENCE INTERNATIONAL			English	Article						Cyclopropylfentanyl; Fentanyl analogue; Time-dependent postmortem redistribution; LC-MS/MS; Alternative matrices	ALTERNATIVE MATRICES; FENTANYL; BLOOD; METABOLITES; VALIDATION; LIVER	A growing number of fatal overdoses involving opioid drugs, in particular involving fentanyl and its analogues, pose an immense threat to public health. Postmortem casework of forensic toxicologists in such cases is challenging, as data on pharmacodynamic and pharmacokinetic properties as well as reference values for acute toxicities and data on potential postmortem redistribution (PMR) mechanisms often do not exist. A fatal case involving cyclopropylfentanyl was investigated at the Zurich Institute of Forensic Medicine and the Zurich Forensic Science Institute; an unknown powder found at the scene was reliably identified as cyclopropylfentanyl by gas chromatography-infrared spectroscopy (GC-IR). Femoral blood samples were collected at two time points after death; 11 h postmortem (t1) and during the medico-legal autopsy 29 h after death (t2). At the autopsy, additional samples from the heart blood, urine and gastric content were collected. Cyclopropylfentanyl was quantified using a validated liquid chromatography-tandem mass spectrometric (LC-MS/MS) method. Femoral blood concentration of cyclopropylfentanyl at autopsy was 19.8 ng/mL (t1 = 15.7 ng/mL; heart blood concentration at autopsy = 52.4 ng/mL). In the light of the current literature and under the exclusion that no other morphological findings could explain the cause of death, contribution of cyclopropylfentanyl to death was proposed (polydrug use). Significant postmortem concentration increases of cyclopropylfentanyl in femoral blood during 18 h after the first sampling were observed, thus indicating a relevant potential to undergo PMR. A central-to-peripheral blood concentration ratio of 2.6 supports this. Consequently, the current case suggests that postmortem cyclopropylfentanyl concentration should always be interpreted with care. (C) 2018 Elsevier B.V. All rights reserved.	[Brockbals, Lana; Staeheli, Sandra N.; Kraemer, Thomas; Steuer, Andrea E.] Univ Zurich, Dept Forens Pharmacol & Toxicol, Zurich Inst Forens Med, Winterthurerstr 190-52, CH-8057 Zurich, Switzerland; [Gentile, Simon; Bolliger, Stephan A.] Univ Zurich, Dept Forens Med & Imaging, Zurich Inst Forens Med, Zurich, Switzerland; [Schlaepfer, Markus; Bissig, Christian] Zurich Forens Sci Inst, Zurich, Switzerland	Steuer, AE (reprint author), Univ Zurich, Dept Forens Pharmacol & Toxicol, Zurich Inst Forens Med, Winterthurerstr 190-52, CH-8057 Zurich, Switzerland.	andrea.steuer@irm.uzh.ch		Brockbals, Lana/0000-0001-7310-2671; Kraemer, Thomas/0000-0002-3283-606X	Swiss National Science FoundationSwiss National Science Foundation (SNSF) [310030_165875]	The authors express their gratitude to Emma Louise Kessler, MD for her generous legacy that she donated to the Institute of Forensic Medicine at the University of Zurich, Switzerland for research purposes. The authors would like to thank the group from the Department of Forensic Medicine and Imaging, Zurich Institute of Forensic Medicine, for their assistance and the scientists from the Department of Forensic Pharmacology and Toxicology, Zurich Institute of Forensic Medicine, for helpful discussions. This work was supported by the Swiss National Science Foundation (Grant no. 310030_165875).	[Anonymous], 2017, LANCET, V390, P2016, DOI DOI 10.1016/S0140-6736(17)32129-3; Brockbals L, 2018, J ANAL TOXICOL, V42, P365, DOI 10.1093/jat/bky017; Ceelen L, 2012, AM J FOREN MED PATH, V33, P119, DOI 10.1097/PAF.0b013e3181fbbb49; Drug Enforcement Administration Department of Justice., 2018, Fed Regist, V83, P469; European Monitoring Centre for Drugs and Drug Addiction, 2018, RISK ASS REP NEW PSY; European Monitoring Centre for Drugs and Drug Addiction, 2018, FENT SYNTH CANN DRIV; European Monitoring Centre for Drugs Drug Addiction [ EMCDDA], 2018, EMCDDA EUR JOINT REP; European Project RESPONSE, 2017, CYCL FENT NPS REL CO; Fogarty MF, 2018, J ANAL TOXICOL, V42, P592, DOI 10.1093/jat/bky035; Han E, 2012, FORENSIC SCI INT, V219, P265, DOI 10.1016/j.forsciint.2012.01.016; HENDERSON GL, 1991, J FORENSIC SCI, V36, P422; Kennedy MC, 2010, INTERN MED J, V40, P183, DOI 10.1111/j.1445-5994.2009.02111.x; Krinsky CS, 2014, J FORENSIC SCI, V59, P1275, DOI 10.1111/1556-4029.12381; Launiainen T, 2014, DRUG TEST ANAL, V6, P308, DOI 10.1002/dta.1507; Luckenbill K, 2008, J ANAL TOXICOL, V32, P639, DOI 10.1093/jat/32.8.639; Maher S, 2018, DRUG TEST ANAL, V10, P1483, DOI 10.1002/dta.2417; Mallette JR, 2019, SCI JUSTICE, V59, P67, DOI 10.1016/j.scijus.2018.07.005; Matuszewski BK, 2003, ANAL CHEM, V75, P3019, DOI 10.1021/ac020361s; Maurer H.H., 2014, MAURER WISSENBACH WE; Olson KN, 2010, AM J CLIN PATHOL, V133, P447, DOI 10.1309/AJCP4X5VHFSOERFT; Palamalai V, 2013, CLIN BIOCHEM, V46, P598, DOI 10.1016/j.clinbiochem.2013.02.001; Palaty J, 2018, CLIN BIOCHEM, V53, P164, DOI 10.1016/j.clinbiochem.2018.01.013; Peters FT, 2007, FORENSIC SCI INT, V165, P216, DOI 10.1016/j.forsciint.2006.05.021; Scientific Working Group for the Analysis of Seized Drugs (SWGDRUG), 2017, SWGDRUG MON; Skopp G, 2010, FORENSIC SCI MED PAT, V6, P314, DOI 10.1007/s12024-010-9150-4; Staeheli SN, 2017, FORENSIC SCI INT, V279, P83, DOI 10.1016/j.forsciint.2017.08.007; Staeheli SN, 2017, INT J LEGAL MED, V131, P379, DOI 10.1007/s00414-016-1485-2; Staeheli SN, 2016, FORENSIC SCI INT, V266, P170, DOI 10.1016/j.forsciint.2016.05.034; Staeheli SN, 2015, ANAL BIOANAL CHEM, V407, P8681, DOI 10.1007/s00216-015-9023-5; Steuer AE, 2014, FORENSIC SCI INT, V244, P92, DOI 10.1016/j.forsciint.2014.08.022; United Nations Office for Drugs and Crime (UNODC), 2018, EARL WARN ADV NEW PS; United Nations Office on Drugs and Crime (UNODC), 2018, WORLD DRUG REP, P2018; UNODC, 2017, GLOB SMART UPD FENT	33	4	4	3	8	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0379-0738	1872-6283		FORENSIC SCI INT	Forensic Sci.Int.	JAN	2019	294						80	85		10.1016/j.forsciint.2018.11.007			6	Medicine, Legal	Legal Medicine	HG3GL	WOS:000454861200019	30497048	Green Accepted			2020-06-30	J	Peterson, BL; Schreiber, S; Fumo, N; Lerner, EB				Peterson, Brian L.; Schreiber, Sara; Fumo, Nicole; Lerner, E. Brooke			Opioid Deaths in Milwaukee County, Wisconsin 2013-2017: The Primacy of Heroin and Fentanyl	JOURNAL OF FORENSIC SCIENCES			English	Article						forensic science; opioids; heroin; fentanyl; toxicology; autopsy	SOLID-PHASE EXTRACTION; SYSTEMATIC TOXICOLOGICAL ANALYSIS; IMMUNALYSIS(R) MICROPLATE ELISA; NEUTRAL-DRUGS; WHOLE-BLOOD; POSTMORTEM; VALIDATION; ABUSE; METABOLITES; METHADONE	Heroin and fentanyl are the overwhelming and increasing cause of opioid deaths in Milwaukee County, Wisconsin. We reviewed all drug and opioid deaths from 2013 to 2017 to delineate the specific opioid drugs involved and changes in their incidence. From 2013 to 2017, 980 deaths were due to opioids, rising from 184 in 2013 to 337 in 2017. In 2017, opioid deaths exceeded combined non-natural deaths from homicide and suicide. Illicit heroin and fentanyl/analogs caused 84% of opioid deaths and 80% of drug deaths, with no increase in deaths due to oral prescription drugs such as oxycodone and hydrocodone. Any approach to decreasing this dramatic increase in opioid deaths should first focus on interdicting the supply and cheap availability of these illicit opioids. Fentanyl and its analogs represent the most deadly opioids and the greatest threat to human life in our population.	[Peterson, Brian L.; Schreiber, Sara] Milwaukee Cty Med Examiners Off, 933 West Highland Ave, Milwaukee, WI 53233 USA; [Peterson, Brian L.] Med Coll Wisconsin, Dept Pathol, Froedert Med Coll Lab Bldg FMCLB 239, Milwaukee, WI 53226 USA; [Fumo, Nicole] Med Coll Wisconsin, Comprehens Injury Ctr, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA; [Lerner, E. Brooke] Froedert Hosp, Dept Emergency Med, Med Coll Wisconsin, Pavil 1P,9200 W Wisconsin Ave, Milwaukee, WI 53226 USA	Peterson, BL (reprint author), Milwaukee Cty Med Examiners Off, 933 West Highland Ave, Milwaukee, WI 53233 USA.; Peterson, BL (reprint author), Med Coll Wisconsin, Dept Pathol, Froedert Med Coll Lab Bldg FMCLB 239, Milwaukee, WI 53226 USA.	brian.peterson@milwaukeecountywi.gov	Lerner, E. Brooke/AAM-9590-2020	Lerner, E. Brooke/0000-0003-0043-3757			Alexander Russell T, 2016, Acad Forensic Pathol, V6, P301, DOI 10.23907/2016.031; ANDERSON WH, 1987, J ANAL TOXICOL, V11, P198, DOI 10.1093/jat/11.5.198; Baselt RC, 2017, DISPOSITION TOXIC DR; BLAU K, 1993, [No title captured]; Burns G, 2016, CLIN TOXICOL, V54, P420, DOI 10.3109/15563650.2016.1157722; CHEN XH, 1992, J ANAL TOXICOL, V16, P351, DOI 10.1093/jat/16.6.351; CHEN XH, 1992, J FORENSIC SCI, V37, P61; CROUCH DJ, 1995, J ANAL TOXICOL, V19, P352, DOI 10.1093/jat/19.6.352; Darke S, 2016, ADDICTION, V111, P1607, DOI 10.1111/add.13429; Davis GG, 2013, ACAD FORENSIC PATHOL, V3, P77; Davis GG, 2014, J MED TOXICOL, V10, P100, DOI 10.1007/s13181-013-0323-x; Day J, 2003, J ANAL TOXICOL, V27, P513, DOI 10.1093/jat/27.7.513; Drug Enforcement Administration, 2017, DEADCTDIR04017; Drummer OH, 2004, FORENSIC SCI INT, V142, P101, DOI 10.1016/j.forsciint.2004.02.013; Drummer OH, 2013, INJURY PREV, V19, P284, DOI 10.1136/injuryprev-2012-040488; Ellis AD, 2016, FORENSIC SCI MED PAT, V12, P243, DOI 10.1007/s12024-016-9780-2; FOERSTER EH, 1979, J ANAL TOXICOL, V3, P87, DOI 10.1093/jat/3.3.87; Gilson T, 2014, ACAD FORENSIC PATHOL, V4, P109; Gilson Thomas P, 2017, Acad Forensic Pathol, V7, P41, DOI 10.23907/2017.005; Gladden RM, 2016, MMWR-MORBID MORTAL W, V65, P837, DOI 10.15585/mmwr.mm6533a2; Han EY, 2006, J ANAL TOXICOL, V30, P380, DOI 10.1093/jat/30.6.380; HANZLICK R, 2002, GUIDE MANNER DEATH C; Harrington W, 1975, METHODOLOGY ANAL TOX; Huestis MA, 2000, J ANAL TOXICOL, V24, P509, DOI 10.1093/jat/24.7.509; Karch SB, 2016, KARCHS PATHOLOGY DRU; Kemp P, 2002, J ANAL TOXICOL, V26, P504, DOI 10.1093/jat/26.7.504; Levine B, 2017, PRINCIPLES FORENSIC; Lillsunde P, 1996, FORENSIC SCI INT, V77, P191, DOI 10.1016/0379-0738(95)01862-X; Liu L, 2018, AM J CLIN PATHOL, V149, P105, DOI [10.1093/ajcp/aqx138, 10.1093/AJCP/AQX138]; Metushi IG, 2016, J ANAL TOXICOL, V40, P243, DOI 10.1093/jat/bkw009; Miller EI, 2006, J ANAL TOXICOL, V30, P115, DOI 10.1093/jat/30.2.115; Moffat AC, 2011, CLARKES ANAL DRUGS P; Mohr ALA, 2016, J ANAL TOXICOL, V40, P709, DOI 10.1093/jat/bkw086; Molina D. K., 2009, HDB FORENSIC TOXICOL; Moore PW, 2015, J FORENSIC SCI, V60, P243, DOI 10.1111/1556-4029.12559; Nieddu M, 2016, J ANAL TOXICOL, V40, P492, DOI 10.1093/jat/bkw060; O'Donnell JK, 2017, MMWR-MORBID MORTAL W, V66, P897, DOI 10.15585/mmwr.mm6634a2; Pearson Julia, 2015, Acad Forensic Pathol, V5, P676, DOI 10.23907/2015.072; Rohrig TP, 2015, J ANAL TOXICOL, V39, P137, DOI 10.1093/jat/bku139; Schumacher S, 2016, J IMMUNOL METHODS, V436, P34, DOI 10.1016/j.jim.2016.06.004; Skopp G, 2004, FORENSIC SCI INT, V142, P75, DOI 10.1016/j.forsciint.2004.02.012; Skov L, 2016, J ANAL TOXICOL, V40, P529, DOI 10.1093/jat/bkw059; Soriano T, 2001, J ANAL TOXICOL, V25, P137, DOI 10.1093/jat/25.2.137; Winklhofer S, 2014, EUR RADIOL, V24, P1276, DOI 10.1007/s00330-014-3128-7	44	3	3	1	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-1198	1556-4029		J FORENSIC SCI	J. Forensic Sci.	JAN	2019	64	1					144	148		10.1111/1556-4029.13808			5	Medicine, Legal	Legal Medicine	HG4HK	WOS:000454935900016	29684941	Bronze			2020-06-30	J	Avedschmidt, S; Schmidt, C; Isenschmid, D; Kesha, K; Moons, D; Gupta, A				Avedschmidt, Sarah; Schmidt, Carl; Isenschmid, Daniel; Kesha, Kilak; Moons, David; Gupta, Avneesh			Acetyl Fentanyl: Trends and Concentrations in Metro Detroit	JOURNAL OF FORENSIC SCIENCES			English	Article; Proceedings Paper	70th Annual Scientific Meeting of the American-Academy-of-Forensic-Sciences	FEB 17-24, 2018	Seattle, WA	Amer Acad Forens Sci		forensic science; forensic pathology; forensic toxicology; opioid abuse; acetyl fentanyl; fentanyl; overdose; synthetic opioids	OVERDOSE DEATHS	Acetyl fentanyl (N-[1-phenethylpiperidin-4-yl]-N-phenylacetamide) is a potent opioid analgesic with no medicinal uses. We report deaths between 2016 and 2017 at the Medical Examiner's Office in Detroit, MI where acetyl fentanyl was found in the decedent's blood and compare them to previously published deaths between 2015 and 2016. The recent cases (cohort B) had a mean acetyl fentanyl concentration of 0.9 ng/mL (range: 0.1-5.3 ng/mL) and an associated higher concentration of fentanyl along with multiple other drugs present. The older cases (cohort A) had higher concentrations of acetyl fentanyl (mean: 8.9 ng/mL; range: 0.28-37 ng/mL) with lower, yet still toxic, concentrations of fentanyl. We conclude that the cause of death in these recent cases was likely multiple drug toxicity with fentanyl and that the consistently observed lower peripheral blood concentrations of acetyl fentanyl are most likely an artifact in the manufacture of the consumed illicit fentanyl.	[Avedschmidt, Sarah; Schmidt, Carl; Moons, David; Gupta, Avneesh] Michigan Med Dept Pathol, Wayne Cty Med Examiners Off, 1300 E Warren Ave, Detroit, MI 48207 USA; [Isenschmid, Daniel] Natl Med Serv, 3701 Welsh Rd, Willow Grove, PA 19090 USA; [Kesha, Kilak] Auckland City Hosp, Dept Forens Pathol, POB 110031, Auckland 1148, New Zealand	Avedschmidt, S (reprint author), Michigan Med Dept Pathol, Wayne Cty Med Examiners Off, 1300 E Warren Ave, Detroit, MI 48207 USA.	becksar@umich.edu					[Anonymous], 2015, AC N 1 PHEN 4 YL N P; [Anonymous], OP; Centers for Disease Control and Prevention, UND EP; Cunningham SM, 2016, J FORENSIC SCI, V61, pS276, DOI 10.1111/1556-4029.12953; Drug Enforcement Administration Department of Justice, 2017, Fed Regist, V82, P26349; Drug Enforcement Administration Department of Justice, 2015, Fed Regist, V80, P42381; Dwyer JB, 2018, J FORENSIC SCI, V63, P195, DOI 10.1111/1556-4029.13517; Fort C, 2016, J ANAL TOXICOL, V40, P754, DOI 10.1093/jat/bkw068; HIBBS J, 1991, JAMA-J AM MED ASSOC, V265, P1011, DOI 10.1001/jama.265.8.1011; Isenschmid D, 2014, P WORLD FOR FEST 201; Lozier MJ, 2015, J MED TOXICOL, V11, P208, DOI 10.1007/s13181-015-0477-9; Martindale M., 2017, THE DETROIT NEWS; McIntyre IM, 2015, J ANAL TOXICOL, V39, P490, DOI 10.1093/jat/bkv043; O'Conner S, 2017, FENTANYL CHINAS DEAD; Poklis J, 2015, FORENSIC SCI INT, V257, P435, DOI 10.1016/j.forsciint.2015.10.021; Sofalvi S, 2017, J ANAL TOXICOL, V41, P473, DOI 10.1093/jat/bkx052; Stogner JM, 2014, ANN EMERG MED, V64, P637, DOI 10.1016/j.annemergmed.2014.07.017; Zhang X, 2015, P AM AC FOR SCI 67 A	18	4	4	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-1198	1556-4029		J FORENSIC SCI	J. Forensic Sci.	JAN	2019	64	1					149	153		10.1111/1556-4029.13840			5	Medicine, Legal	Legal Medicine	HG4HK	WOS:000454935900017	29940698	Bronze			2020-06-30	J	Terada, Y; Inoue, S; Konda, M; Egawad, J; Ueda, J; Kirita, T; Kawaguchi, M				Terada, Y.; Inoue, S.; Konda, M.; Egawad, J.; Ueda, J.; Kirita, T.; Kawaguchi, M.			Effects of deep sedation under mechanical ventilation on cognitive outcome in patients undergoing surgery for oral and maxillofacial cancer and microvascular reconstruction	MEDICINA INTENSIVA			English	Article						Sedation; Intensive care unit; Cognitive impairment; Cognitive test; Sedatives	INTENSIVE-CARE-UNIT; PROPOFOL NEUROTOXICITY; DYSFUNCTION; SURVIVORS; IMPACT	Objective: Cognitive impairment after intensive care unit (ICU) admission is becoming increasingly recognized. High-dose deep sedation has been suggested to play an important role in the development of cognitive impairment. However, the impact of heavy sedation as a single cause in the development of cognitive impairment in ICU patients remains unclear. In this study we investigated whether a three-day deep sedation protocol could reduce cognitive function in mechanically ventilated non-critical patients. Design: A prospective observational study was carried out. Patients: A total of 17 surgical patients were studied. Intervention: None. Variables of interest: Cognitive function before and after ICU admission. Results: Thirty-one patients requiring three days of sedation after microvascular reconstruction were initially enrolled in the study. Sedation in the ICU was maintained with propofol and dexmedetomidine combined with fentanyl. Cognitive function was assessed using a battery of 6 neuropsychological tests two days before surgery and three weeks after surgery. Finally, a total of 17 patients were included in the analysis. Cognitive impairment (defined as a decline of >20% from the pre-admission cognitive evaluation scores in at least two of 6 tests) was observed in 5 of the 17 patients (29%). However, there were no significant differences between the pre- and post-admission cognitive evaluations in 6 tests. Conclusions: Middle-term cognitive function can be impaired in some patients subjected to deep sedation during several days following maxillary-mandibular oral surgery with microvascular reconstruction. (C) 2018 Elsevier Espana, S.L.U. y SEMICYUC. All rights reserved.	[Terada, Y.; Inoue, S.; Konda, M.; Egawad, J.; Kawaguchi, M.] Nara Med Univ, Dept Anesthesiol, Kashihara, Nara, Japan; [Terada, Y.; Inoue, S.; Konda, M.; Egawad, J.; Kawaguchi, M.] Nara Med Univ, Div Intens Care, Kashihara, Nara, Japan; [Ueda, J.; Kirita, T.] Nara Med Univ, Dept Oral & Maxillofacial Surg, 840 Shijo Cho, Kashihara, Nara 6348522, Japan	Inoue, S (reprint author), Nara Med Univ, Dept Anesthesiol, Kashihara, Nara, Japan.; Inoue, S (reprint author), Nara Med Univ, Div Intens Care, Kashihara, Nara, Japan.	seninoue@naramed-u.ac.jp					AKL EA, 2012, BMJ, V344; Allak A, 2011, LARYNGOSCOPE, V121, P763, DOI 10.1002/lary.21397; Crosby G, 2011, ANESTH ANALG, V112, P999, DOI 10.1213/ANE.0b013e3182160431; Fernandez-Gonzalo S, 2018, MED INTENSIVA, V42, P114, DOI 10.1016/j.medin.2017.06.010; Grichnik KP, 1999, ANN THORAC SURG, V68, P1786, DOI 10.1016/S0003-4975(99)00992-3; Harvey MA, 2012, CRIT CARE MED, V40, P2506, DOI 10.1097/CCM.0b013e318258e943; Jackson JC, 2011, J TRAUMA, V71, P860, DOI 10.1097/TA.0b013e3182151961; Jevtovic-Todorovic V, 2005, NEUROBIOL AGING, V26, P947, DOI 10.1016/j.neurobiolaging.2004.07.009; Moller JT, 1998, LANCET, V351, P857, DOI 10.1016/S0140-6736(97)07382-0; MURKIN JM, 1995, ANN THORAC SURG, V59, P1289, DOI 10.1016/0003-4975(95)00106-U; Nelson BJ, 2000, CRIT CARE MED, V28, P3626, DOI 10.1097/00003246-200011000-00013; Newman S, 2007, ANESTHESIOLOGY, V106, P572, DOI 10.1097/00000542-200703000-00023; Nkenke E, 2009, HEAD NECK-J SCI SPEC, V31, P1461, DOI 10.1002/hed.21117; Ochroch EA, 2011, ANESTH ANALG, V112, P732, DOI 10.1213/ANE.0b013e318209d4e8; Pearn ML, 2012, ANESTHESIOLOGY, V116, P352, DOI 10.1097/ALN.0b013e318242a48c; Porhomayon J, 2016, LUNG, V194, P43, DOI 10.1007/s00408-015-9820-9; Porhomayon J, 2015, J CARDIOVASC THORAC, V7, P43, DOI 10.15171/jcvtr.2015.10; Rasmussen LS, 2001, ACTA ANAESTH SCAND, V45, P275, DOI 10.1034/j.1399-6576.2001.045003275.x; Reade MC, 2014, NEW ENGL J MED, V370, P444, DOI 10.1056/NEJMra1208705; Rundshagen I, 2014, DTSCH ARZTEBL INT, V111, DOI 10.3238/arztebl.2014.0119; Sebastiani A, 2016, CRIT CARE MED, V44, pE70, DOI 10.1097/CCM.0000000000001284; Sessler CN, 2002, AM J RESP CRIT CARE, V166, P1338, DOI 10.1164/rccm.2107138; Tanios MA, 2009, J CRIT CARE, V24, P66, DOI 10.1016/j.jcrc.2008.03.037; Wei Y, 2016, MOL MED REP, V14, P3413, DOI 10.3892/mmr.2016.5628; Wolters AE, 2013, INTENS CARE MED, V39, P376, DOI 10.1007/s00134-012-2784-9; Young C, 2005, BRIT J PHARMACOL, V146, P189, DOI 10.1038/sj.bjp.0706301	26	1	1	1	1	ELSEVIER ESPANA SLU	BARCELONA	AV JOSEP TARRADELLAS, 20-30, 1ERA PLANTA, BARCELONA, CP-08029, SPAIN	0210-5691	1578-6749		MED INTENSIVA	Med. Intensiv.	JAN-FEB	2019	43	1					3	9		10.1016/j.medin.2017.11.001			7	Critical Care Medicine	General & Internal Medicine	HG8NX	WOS:000455260400002	29258778				2020-06-30	J	Read, K; Khatun, M; Murphy, H				Read, Kate; Khatun, Mahmuda; Murphy, Helen			Comparison of transdermal fentanyl and oral tramadol for lateral thoracotomy in dogs: cardiovascular and behavioural data	VETERINARY ANAESTHESIA AND ANALGESIA			English	Article						analgesia; dog; fentanyl; telemetry; thoracotomy; tramadol	POSTOPERATIVE PAIN; PHARMACOKINETICS; BUPRENORPHINE; MORPHINE; OVARIOHYSTERECTOMY; GUIDELINES; ANALGESIA; SCALE	Objective To compare the analgesic efficacy and suitability of an existing oral tramadol-based protocol with a transdermal fentanyl-based protocol following lateral thoracotomy in dogs. Study design Prospective randomized clinical trial. Animals A group of 16 healthy laboratory beagle dogs. Methods Dogs were randomly allocated to one of two treatment groups: group F (intramuscular methadone 0.2 mg kg(-1) and transdermal fentanyl 2.6 mg kg(-1) both administered on discontinuation of anaesthesia, n = 8) or group T (intramuscular methadone 0.2 mg kg(-1) on discontinuation of anaesthesia and again 4 hours later, followed by oral tramadol 12 mg kg(-1) per 24 hours commencing 7 hours after discontinuation of anaesthesia, n = 8). Intercostal bupivacaine (0.5-1 mg kg(-1)) and subcutaneous carprofen (4 mg kg(-1)) were administered to all dogs at induction. Body weight (BW), presence of clinical signs, pain score, activity, heart rate (HR) and mean arterial pressure (MAP) were assessed for 72 hours postoperatively. Results No significant differences were observed in BW change, presence of clinical signs or gross locomotor activity between groups. Pain scores were low at all times for all dogs, and rescue analgesia was not required. Dogs in group T exhibited higher pedometric activity (p = 0.006), HR (p < 0.001) and MAP (p < 0.001) than those in group F, in particular on night 1 following surgery. Least squared mean (LSM) pedometric activity was 1.81 and 1.02 jerks minute(-1), LSM HR was 111.13 and 78.64 beats minute(-1) and LSM MAP was 111.62 and 105.24 mmHg, respectively, in groups T and F. Conclusions and clinical relevance Both regimes appear to provide adequate analgesia following lateral thoracotomy in dogs. Ease of administration of transdermal fentanyl compared to oral tramadol is advantageous. Reduced activity observed with the fentanyl regime was not associated with any adverse effects and may be desirable following some invasive surgeries. However, while transdermal fentanyl remains currently unavailable in the European Union, the oral tramadol-based regime provides an acceptable alternative.	[Read, Kate; Murphy, Helen] Envigo, Dept Vet Serv, Huntingdon, Cambs, England; [Khatun, Mahmuda] Envigo, Dept Stat & Data Management, Huntingdon, Cambs, England	Read, K (reprint author), Envigo, Dept Vet Serv, Woolley Rd, Alconbury PE28 4HS, Cambs, England.	Kate.Read@envigo.com					Conzemius MG, 1997, J AM VET MED ASSOC, V210, P1619; Davila D, 2013, JAVMA-J AM VET MED A, V243, P225, DOI 10.2460/javma.243.2.225; Epstein ME, 2015, J FELINE MED SURG, V17, P251, DOI 10.1177/1098612X15572062; European Medicines Agency, 2017, REC EMEA V C 002239; Firth AM, 1999, J AM VET MED ASSOC, V214, P651; Freise KJ, 2012, J VET PHARMACOL THER, V35, P21, DOI 10.1111/j.1365-2885.2012.01399.x; Freise KJ, 2012, J VET PHARMACOL THER, V35, P65, DOI 10.1111/j.1365-2885.2012.01407.x; Freise KJ, 2012, J VET PHARMACOL THER, V35, P27, DOI 10.1111/j.1365-2885.2012.01411.x; Gilroy BA, 1982, J VET CRIT CARE, V6, P1; Giorgi M, 2009, VET J, V180, P253, DOI 10.1016/j.tvjl.2007.12.011; Giudice E, 2017, J VET BEHAV, V19, P45, DOI 10.1016/j.jveb.2017.02.003; Hansen BD, 1997, APPL ANIM BEHAV SCI, V51, P101, DOI 10.1016/S0168-1591(96)01079-9; Holton LL, 1998, J SMALL ANIM PRACT, V39, P469, DOI 10.1111/j.1748-5827.1998.tb03681.x; Home Office, 2014, COD PRACT HOUS CAR A; International Council for Harmonisation, 2001, GUID IND S7A SAF PHA; Karrasch NM, 2015, CAN VET J, V56, P817; Kogel B, 2014, VET ANAESTH ANALG, V41, P297, DOI 10.1111/vaa.12140; KuKanich B, 2004, J VET PHARMACOL THER, V27, P239, DOI 10.1111/j.1365-2885.2004.00578.x; Kukanich B, 2012, J VET PHARMACOL THER, V35, P3, DOI 10.1111/j.1365-2885.2012.01416.x; Linton DD, 2012, J VET PHARMACOL THER, V35, P53, DOI 10.1111/j.1365-2885.2012.01408.x; Martinez SA, 2014, J VET PHARMACOL THER, V37, P394, DOI 10.1111/jvp.12096; Mastrocinque S, 2003, VET ANAESTH ANALG, V30, P220, DOI 10.1046/j.1467-2995.2003.00090.x; Mathews K, 2014, J SMALL ANIM PRACT, V55, pE10, DOI 10.1111/jsap.12200; Morgaz J, 2013, RES VET SCI, V95, P278, DOI 10.1016/j.rvsc.2013.03.003; Murrell J, 2014, IN PRACTICE, V36, P277, DOI 10.1136/inp.g3941; Pavlidou K, 2009, COMPENDIUM, V31, P432; Pekcan Z, 2010, VET ANAESTH ANALG, V37, P557, DOI 10.1111/j.1467-2995.2010.00571.x; RAFFA RB, 1992, J PHARMACOL EXP THER, V260, P275; Reid J, 2007, ANIM WELFARE, V16, P97; Savides MC, 2012, J VET PHARMACOL THER, V35, P35, DOI 10.1111/j.1365-2885.2012.01410.x; Tattersall Marshall Leslie, 2006, Journal of Pharmacological and Toxicological Methods, V53, P11, DOI 10.1016/j.vascn.2005.02.005; Walder B, 2001, EUR J ANAESTH, V18, P36, DOI 10.1046/j.1365-2346.2001.00772.x; Wegner K, 2008, J NEUROSCI METH, V168, P88, DOI 10.1016/j.jneumeth.2007.09.019; Yoon HY, 2015, J VET SCI, V16, P93, DOI [10.4142/jvs.2015.16.1.93, 10.4142/jvs.2015.16.1.87]	34	0	0	1	7	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1467-2987	1467-2995		VET ANAESTH ANALG	Vet. Anaesth. Analg.	JAN	2019	46	1					116	125		10.1016/j.vaa.2018.09.046			10	Veterinary Sciences	Veterinary Sciences	HF9CD	WOS:000454538300014	30527858				2020-06-30	J	Santos, C; Adam, A; Calello, D; Nelson, L				Santos, Cynthia; Adam, Adeeb; Calello, Diane; Nelson, Lewis			Safety of a Brief Emergency Department Observation Protocol for Patients With Presumed Fentanyl Overdose	ANNALS OF EMERGENCY MEDICINE			English	Letter							OPIOID OVERDOSE		[Santos, Cynthia; Calello, Diane; Nelson, Lewis] Rutgers New Jersey Med Sch, New Jersey Poison Informat & Educ Syst, Newark, NJ 07103 USA; [Adam, Adeeb] Newark Beth Israel Med Ctr, Newark, NJ USA	Santos, C (reprint author), Rutgers New Jersey Med Sch, New Jersey Poison Informat & Educ Syst, Newark, NJ 07103 USA.						Rudolph SS, 2011, RESUSCITATION, V82, P1414, DOI 10.1016/j.resuscitation.2011.06.027; Scheuermeyer FX, 2018, ANN EMERG MED, V72, P1, DOI 10.1016/j.annemergmed.2018.01.054; Weiner SG, 2017, ANN EMERG MED, V70, pS158, DOI 10.1016/j.annemergmed.2017.07.281; Willman MW, 2017, CLIN TOXICOL, V55, P81, DOI 10.1080/15563650.2016.1253846	4	2	2	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0196-0644	1097-6760		ANN EMERG MED	Ann. Emerg. Med.	JAN	2019	73	1					99	100		10.1016/j.annemergmed.2018.10.024			2	Emergency Medicine	Emergency Medicine	HE8NY	WOS:000453705100027	30577966	Bronze			2020-06-30	J	Scheuermeyer, FX; DeWitt, C; Purssell, R; Buxton, J				Scheuermeyer, Frank X.; DeWitt, Christoper; Purssell, Roy; Buxton, Jane			Safety of a Brief Emergency Department Observation Protocol for Patients With Presumed Fentanyl Overdose Reply	ANNALS OF EMERGENCY MEDICINE			English	Letter									[Scheuermeyer, Frank X.; DeWitt, Christoper] St Pauls Hosp, Dept Emergency Med, Vancouver, BC, Canada; [Scheuermeyer, Frank X.; DeWitt, Christoper; Purssell, Roy] Univ British Columbia, Vancouver, BC, Canada; [Scheuermeyer, Frank X.] St Pauls Hosp, Ctr Hlth Outcomes & Evaluat Sci, Vancouver, BC, Canada; [Purssell, Roy] Vancouver Gen Hosp, Dept Emergency Med, Vancouver, BC, Canada; [Buxton, Jane] Univ British Columbia, Sch Populat & Publ Hlth, Vancouver, BC, Canada; [Buxton, Jane] Ctr Dis Control, Vancouver, BC, Canada	Scheuermeyer, FX (reprint author), St Pauls Hosp, Dept Emergency Med, Vancouver, BC, Canada.; Scheuermeyer, FX (reprint author), Univ British Columbia, Vancouver, BC, Canada.; Scheuermeyer, FX (reprint author), St Pauls Hosp, Ctr Hlth Outcomes & Evaluat Sci, Vancouver, BC, Canada.						Boyer EW, 2012, NEW ENGL J MED, V367, P146, DOI 10.1056/NEJMra1202561; Coroner's Service of British Columbia, ILL DRUG OV DEATHS B; GLASS PSA, 1994, ANESTH ANALG, V78, P536; Palmer RB, 2010, CLIN TOXICOL, V48, P771, DOI 10.3109/15563650.2010.525514; Santos C, 2019, ANN EMERG MED, V73, P99, DOI 10.1016/j.annemergmed.2018.10.024; Vancouver Coastal Health, 86 DRUGS CHECK INS C	6	0	0	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0196-0644	1097-6760		ANN EMERG MED	Ann. Emerg. Med.	JAN	2019	73	1					100	101		10.1016/j.annemergmed.2018.10.023			3	Emergency Medicine	Emergency Medicine	HE8NY	WOS:000453705100028	30577957	Bronze			2020-06-30	J	Kommula, LK; Bansal, S; Rao, GSU				Kommula, Lakshman K.; Bansal, Sonia; Rao, Ganne S. Umamaheswara			Analgesia Nociception Index Monitoring During Supratentorial Craniotomy	JOURNAL OF NEUROSURGICAL ANESTHESIOLOGY			English	Article						analgesia; craniotomy; ANI monitor; spectral entropy; monitoring	POSTOPERATIVE PAIN; ANALGESIA/NOCICEPTION INDEX; PARAMETER; ANI	Background: Objective monitoring of pain during and after surgery has been elusive. Recently, Analgesia Nociception Index (ANI) monitor based on the high frequency component of heart rate variability has been launched into clinical practice. We monitored analgesia during craniotomy using ANI monitor and compared it with cardiovascular parameters and response entropy (RE) of entropy monitor. Materials and Methods: In 21 patients undergoing a craniotomy for a supratentorial lesion, we monitored ANI, heart rate (HR), mean arterial pressure (MAP), state entropy, and RE throughout the surgery. Also, ANI, hemodynamic variables and spectral entropy values were noted at the times of maximal stimulation, such as induction, intubation, head pin fixation, skin incision, craniotomy, durotomy, and skin closure. We also compared ANI with RE during administration of bolus doses of fentanyl. Results: There was an inverse correlation between ANI values and the hemodynamic changes. When the HR and MAP increased, ANI decreased suggesting a good correlation between hemodynamics and ANI values during the times of maximal stimulation. State entropy and RE did not change significantly in response to bolus doses of fentanyl administered during the course of surgery, while ANI increased significantly. Conclusion: In neurosurgical patients undergoing elective supratentorial craniotomy, ANI measures response to noxious stimuli with at least as much reliability as hemodynamic variables and changes in ANI parallel the changes in HR and MAP. ANI is superior to RE for measurement of response to noxious stimuli.	[Kommula, Lakshman K.] Apollo Hlth City, Hyderabad, India; [Bansal, Sonia; Rao, Ganne S. Umamaheswara] Natl Inst Mental Hlth & Neurosci NIMHANS, Dept Neuroanaesthesia & Neurocrit Care, Bengaluru 560029, Karnataka, India	Rao, GSU (reprint author), Natl Inst Mental Hlth & Neurosci NIMHANS, Dept Neuroanaesthesia & Neurocrit Care, Bengaluru 560029, Karnataka, India.	gsuma123@yahoo.com					Boselli E, 2016, J CLIN MONIT COMPUT, V30, P977, DOI 10.1007/s10877-015-9802-8; Boselli E, 2014, BRIT J ANAESTH, V112, P936, DOI 10.1093/bja/aeu116; Boselli E, 2013, BRIT J ANAESTH, V111, P453, DOI 10.1093/bja/aet110; Broucqsault-Dedrie C, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147720; Daccache G, 2017, ANAESTH CRIT CARE PA, V36, P229, DOI 10.1016/j.accpm.2016.08.006; Gall O, 2015, BRIT J ANAESTH, V115, P890, DOI 10.1093/bja/aev361; Gruenewald M, 2013, BRIT J ANAESTH, V110, P1024, DOI 10.1093/bja/aet019; Ilies C, 2010, BRIT J ANAESTH, V105, P533, DOI 10.1093/bja/aeq203; Jeanne M, 2012, J CLIN MONIT COMPUT, V26, P289, DOI 10.1007/s10877-012-9354-0; Jeanne M, 2009, IEEE ENG MED BIO, P1840, DOI 10.1109/IEMBS.2009.5332598; Jeanne M, 2014, CLIN J PAIN, V30, P1084, DOI 10.1097/AJP.0000000000000083; Le Guen M, 2012, INT J OBSTET ANESTH, V21, P146, DOI 10.1016/j.ijoa.2012.01.001; Ledowski T, 2005, ANESTH ANALG, V101, P1700, DOI 10.1213/01.ane.0000184041.32175.14; Ledowski T, 2014, ACTA ANAESTH SCAND, V58, P74, DOI 10.1111/aas.12216; Ledowski T, 2013, BRIT J ANAESTH, V111, P627, DOI 10.1093/bja/aet111; Ledowski T, 2009, ANAESTHESIA, V64, P727, DOI 10.1111/j.1365-2044.2008.05834.x; Roberts GC, 2005, EUR J ANAESTH, V22, P328, DOI 10.1017/S0265021505000554; Szental JA, 2015, BRIT J ANAESTH, V114, P640, DOI 10.1093/bja/aeu411; Takamatsu I, 2006, BRIT J ANAESTH, V96, P620, DOI 10.1093/bja/ael050	19	6	6	2	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0898-4921	1537-1921		J NEUROSURG ANESTH	J. Neurosurg. Anesthesiol.	JAN	2019	31	1					57	61		10.1097/ANA.0000000000000464			5	Anesthesiology; Clinical Neurology; Surgery	Anesthesiology; Neurosciences & Neurology; Surgery	HE7EG	WOS:000453590900010	28991059				2020-06-30	J	Wu, WT; Jia, ZY; Chen, Y; Chen, QF; Zu, QQ; Yang, ZQ; Liu, S; Shi, HB				Wu, Wen-Tao; Jia, Zhen-Yu; Chen, Yu; Chen, Qi-Feng; Zu, Qing-Quan; Yang, Zheng-Qiang; Liu, Sheng; Shi, Hai-Bin			The Safety and Efficacy of Oxycodone Versus Fentanyl in Percutaneous Microwave Ablation of a Liver Tumour Abutting the Capsule	CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY			English	Article						Microwave ablation; Pain; Anaesthesia; Oxycodone; Fentanyl	PATIENT-CONTROLLED ANALGESIA; OPIOID RECEPTOR AGONIST; VS. FENTANYL; PAIN; MORPHINE	PurposeThe present study compared the safety and efficacy of oxycodone with those of fentanyl under non-intubated general anaesthesia in percutaneous microwave ablation (MWA) of a liver tumour abutting the capsule.Materials and MethodsThirty-eight patients underwent MWA of liver cancers abutting the capsule. Patients received 0.1mg/kg oxycodone (O group) or 1g/kg fentanyl (F group) prior to the start of ablation. Both groups received continuous infusions of propofol for non-intubated general anaesthesia during ablation. The primary outcomes were the pain scores (11-point numeric rating scale, NRS) within 24h after MWA. Vital signs, body movement during ablation, and opioid side effects after ablation were recorded. The need for additional analgesics was recorded 24h after MWA.ResultsThe pain NRS scores were lower in the O group than in the F group at 0.5 (P=0.035), 3 (P=0.002), and 6h (P=0.001) after MWA, and fewer patients required additional analgesics in the O group (6 of 20 vs. 13 of 18, P=0.022) within 24h. The average 24-h dose of dezocine was 5.54.1mg in the F group and 2.1 +/- 3.3mg in the O group (P=0.008). A significant reduction in the respiratory rate (P=0.020) and more body movements were observed in the F group (P=0.027) during ablation with non-intubated general anaesthesia. No differences in post-operative nausea and vomiting (PONV) were observed between the two groups, but dizziness occurred significantly more often in the O group (P=0.033). No significant differences in other vital signs were observed before, during, and after the procedure.Conclusions Oxycodone provides better analgesia and reduces post-operative opioid consumption without significant respiratory or hemodynamic instability.	[Wu, Wen-Tao; Jia, Zhen-Yu; Chen, Qi-Feng; Zu, Qing-Quan; Yang, Zheng-Qiang; Liu, Sheng; Shi, Hai-Bin] Jiangsu Prov Hosp, Dept Radiol, Nanjing, Jiangsu, Peoples R China; [Wu, Wen-Tao; Jia, Zhen-Yu; Chen, Yu; Chen, Qi-Feng; Zu, Qing-Quan; Yang, Zheng-Qiang; Liu, Sheng; Shi, Hai-Bin] Nanjing Med Univ, Affiliated Hosp 1, 300 Guangzhou Rd, Nanjing 210029, Jiangsu, Peoples R China; [Chen, Yu] Jiangsu Prov Hosp, Dept Anesthesiol, 300 Guangzhou Rd, Nanjing 210029, Jiangsu, Peoples R China	Chen, Y (reprint author), Nanjing Med Univ, Affiliated Hosp 1, 300 Guangzhou Rd, Nanjing 210029, Jiangsu, Peoples R China.; Chen, Y (reprint author), Jiangsu Prov Hosp, Dept Anesthesiol, 300 Guangzhou Rd, Nanjing 210029, Jiangsu, Peoples R China.	chenyu201408@163.com					Andreano A, 2014, J VASC INTERV RADIOL, V25, P97, DOI 10.1016/j.jvir.2013.09.005; Arendt-Nielsen L, 2009, ANESTHESIOLOGY, V111, P616, DOI 10.1097/ALN.0b013e3181af6356; CERVERO F, 1994, PHYSIOL REV, V74, P95; Eisenach JC, 2003, PAIN, V101, P89, DOI 10.1016/S0304-3959(02)00259-2; Goldberg SN, 2005, RADIOLOGY, V235, P728, DOI 10.1148/radiol.2353042205; Haji A, 2001, JPN J PHARMACOL, V87, P333, DOI 10.1254/jjp.87.333; Hwang BY, 2014, INT J MED SCI, V11, P658, DOI 10.7150/ijms.8331; Kalso E, 2005, J PAIN SYMPTOM MANAG, V29, pS47, DOI 10.1016/j.jpainsymman.2005.01.010; Kim NS, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000006286; Koch S, 2008, ACTA ANAESTH SCAND, V52, P845, DOI 10.1111/j.1399-6576.2008.01643.x; Lee S, 2009, AM J ROENTGENOL, V192, P1064, DOI 10.2214/AJR.08.1350; Liang P, 2007, ONCOLOGY-BASEL, V72, P124, DOI 10.1159/000111718; Liang P, 2009, RADIOLOGY, V251, P933, DOI 10.1148/radiol.2513081740; Lubner MG, 2010, J VASC INTERV RADIOL, V21, pS192, DOI 10.1016/j.jvir.2010.04.007; Momeni M, 2006, DRUGS, V66, P2321, DOI 10.2165/00003495-200666180-00005; Pereira J, 2001, J PAIN SYMPTOM MANAG, V22, P672, DOI 10.1016/S0885-3924(01)00294-9; RAMSAY MAE, 1974, BRIT MED J, V2, P656, DOI 10.1136/bmj.2.5920.656; Silvasti M, 1998, ACTA ANAESTH SCAND, V42, P576, DOI 10.1111/j.1399-6576.1998.tb05169.x; Smart JA, 2000, BRIT J ANAESTH, V84, P735; Staahl C, 2007, SCAND J GASTROENTERO, V42, P383, DOI 10.1080/00365520601014414; Staahl C, 2006, PAIN, V123, P28, DOI 10.1016/j.pain.2006.02.006; Xie KJ, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000007376; Yates BJ, 1998, BRAIN RES BULL, V47, P395, DOI 10.1016/S0361-9230(98)00092-6; Zhang ZX, 2007, ANESTHESIOLOGY, V107, P288, DOI 10.1097/01.anes.0000270760.46821.67	24	0	0	0	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0174-1551	1432-086X		CARDIOVASC INTER RAD	Cardiovasc. Interv. Radiol.	JAN	2019	42	1					87	94		10.1007/s00270-018-1980-6			8	Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical Imaging	Cardiovascular System & Cardiology; Radiology, Nuclear Medicine & Medical Imaging	HD1GW	WOS:000452258700011	29740688				2020-06-30	J	Chenaf, C; Kabore, JL; Delorme, J; Pereira, B; Mulliez, A; Zenut, M; Delage, N; Ardid, D; Eschalier, A; Authier, N				Chenaf, C.; Kabore, J. -L.; Delorme, J.; Pereira, B.; Mulliez, A.; Zenut, M.; Delage, N.; Ardid, D.; Eschalier, A.; Authier, N.			Prescription opioid analgesic use in France: Trends and impact on morbidity-mortality	EUROPEAN JOURNAL OF PAIN			English	Article							CHRONIC NONCANCER PAIN; SHOPPING BEHAVIOR; UNITED-STATES; RETROSPECTIVE COHORT; NONMEDICAL USE; PUBLIC-HEALTH; ABUSE; EPIDEMIC; DOCTOR; MISUSE	Background While data from USA and Canada demonstrate an opioid overdose epidemic, very little nation-wide European studies have been published on this topical subject. Methods Using a nationally representative sample of the French Claims database (>700,000 patients), the exhaustive nationwide hospital discharge database, and national mortality registry, all patients dispensed at least one prescription opioid (PO) in 2004-2017 were identified, to describe trends in PO analgesic use, shopping behaviour, opioid-related hospitalizations and deaths. Annual prevalence of PO use and shopping behaviour (>= 1 day of overlapping prescriptions from >= 2 prescribers, dispensed by >= 3 pharmacies) was estimated. Results In 2004-2017, the annual prevalence of weak opioid use codeine, tramadol and opium rose by 150%, 123%, and 244%, respectively (p < 0.05). Strong opioid use increased from 0.54% to 1.1% (+104%, p < 0.05), significantly for oxycodone (+1950%). Strong opioid use in chronic noncancer pain rose by 88% (p < 0.05) and 1180% for oxycodone. Opioid shopping increased from 0.50% to 0.67% (+34%, p < 0.05), associated with higher mortality risk HR = 2.8 [95% confidence interval (CI): 1.2-6.4]. Opioid-related hospitalizations increased from 15 to 40 per 1,000,000 population (+167%, 2000-2017), and opioid-related deaths from 1.3 to 3.2 per 1,000,000 population (+146%, 2000-2015). Conclusions This study provided a first European approach to a nationwide estimation with complete access to several national registries. In 2004-2017 in France, PO use excluding dextropropoxyphene more than doubled. The increase in oxycodone and fentanyl use, and nontrivial increasing trend in opioid-related morbidity-mortality should prompt authorities to closely monitor PO consumption in order to prevent alarming increases in opioid-related morbidity-mortality. Significance In 2004-2017, prescription opioid use in France at least doubled and oxycodone use increased particularly, associated with a nontrivial increase in opioid-related morbidity-mortality. Although giving no indication for an 'opioid epidemic,' these findings call for proper monitoring of opioid use.	[Chenaf, C.; Kabore, J. -L.; Delorme, J.; Pereira, B.; Mulliez, A.; Zenut, M.; Delage, N.; Ardid, D.; Eschalier, A.; Authier, N.] Univ Clermont Auvergne, CHU Clermont Ferrand, Ctr Evaluat & Traitement Douleur,Ctr Addictovigil, Degat Rech Clin & Innovat,Inserm,Neurodol,Serv Ph, F-63001 Clermont Ferrand, France; [Chenaf, C.; Kabore, J. -L.; Delorme, J.; Pereira, B.; Mulliez, A.; Zenut, M.; Delage, N.; Ardid, D.; Eschalier, A.; Authier, N.] Univ Clermont Auvergne, CHU Clermont Ferrand, Ctr Evaluat & Traitement Douleur,Ctr Pharmacovigi, Degat Rech Clin & Innovat,Inserm,Neurodol,Serv Ph, F-63001 Clermont Ferrand, France; [Chenaf, C.; Delorme, J.; Zenut, M.; Delage, N.; Eschalier, A.; Authier, N.] Univ Clermont Auvergne, CHU Clermont Ferrand, French Monitoring Ctr Analges Drugs, OFMA, F-63001 Clermont Ferrand, France; [Chenaf, C.; Kabore, J. -L.; Delorme, J.; Zenut, M.; Delage, N.; Ardid, D.; Eschalier, A.; Authier, N.] Fac Med, Inst Analgesia, BP38, F-63001 Clermont Ferrand, France	Eschalier, A (reprint author), Univ Clermont Auvergne, CHU Clermont Ferrand, Ctr Evaluat & Traitement Douleur,Ctr Addictovigil, Degat Rech Clin & Innovat,Inserm,Neurodol,Serv Ph, F-63001 Clermont Ferrand, France.; Eschalier, A (reprint author), Univ Clermont Auvergne, CHU Clermont Ferrand, Ctr Evaluat & Traitement Douleur,Ctr Pharmacovigi, Degat Rech Clin & Innovat,Inserm,Neurodol,Serv Ph, F-63001 Clermont Ferrand, France.; Eschalier, A (reprint author), Univ Clermont Auvergne, CHU Clermont Ferrand, French Monitoring Ctr Analges Drugs, OFMA, F-63001 Clermont Ferrand, France.; Eschalier, A (reprint author), Fac Med, Inst Analgesia, BP38, F-63001 Clermont Ferrand, France.	alain.eschalier@uca.fr	ESCHALIER, Alain/L-9957-2015; ardid, denis/K-2234-2015		French National Agency for Medicines and Health Products Safety (ANSM: Agence Nationale de Securite du Medicament et des Produits de Sante) [20145013]	This study was a part of the POMA project (Prescription Opioids Misuse Assessment in chronic pain patients) and was funded by the French National Agency for Medicines and Health Products Safety (ANSM: Agence Nationale de Securite du Medicament et des Produits de Sante - Grant number 20145013). The financial sponsor of this work played no role in the design and conduct of the study, nor in the collection, management, analysis or interpretation of the data. The sponsor also had no role in either the preparation or review of the manuscript or the decision to submit the article for publication.	Afssaps, 2010, AG FRANC SEC SAN PRO; Atluri S., 2014, PAIN PHYSICIAN, V17, pE119; Berterame S, 2016, LANCET, V387, P1644, DOI 10.1016/S0140-6736(16)00161-6; Califf RM, 2016, NEW ENGL J MED, V374, P1480, DOI 10.1056/NEJMsr1601307; Cepeda MS, 2014, CLIN J PAIN, V30, P1051, DOI 10.1097/AJP.0000000000000067; Cepeda MS, 2013, J CLIN PHARMACOL, V53, P112, DOI 10.1177/0091270012436561; Cepeda MS, 2013, J PAIN, V14, P158, DOI 10.1016/j.jpain.2012.10.012; Cepeda MS, 2012, DRUG SAFETY, V35, P325, DOI 10.2165/11596600-000000000-00000; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Chenaf C, 2016, J PAIN, V17, P1291, DOI 10.1016/j.jpain.2016.08.010; Cheung CW, 2014, PAIN PHYSICIAN, V17, P401; Compton WM, 2016, NEW ENGL J MED, V374, P154, DOI 10.1056/NEJMra1508490; Dart RC, 2015, NEW ENGL J MED, V372, P241, DOI [10.1056/NEJMc1501822, 10.1056/NEJMsa1406143]; Dasgupta N, 2016, PAIN MED, V17, P85, DOI 10.1111/pme.12907; Delorme J, 2016, DRUG ALCOHOL DEPEN, V162, P99, DOI 10.1016/j.drugalcdep.2016.02.035; Dowell D, 2016, JAMA-J AM MED ASSOC, V315, P1624, DOI 10.1001/jama.2016.1464; Ekholm O, 2014, PAIN, V155, P2486, DOI 10.1016/j.pain.2014.07.006; EMEA, 2010, QUEST ANSW WITHDR MA; European Monitoring Centre for Drugs and Drug Addiction, 2018, EUR DRUG REP 2018 TR; Fischer B, 2015, PHARMACOEPIDEM DR S, V24, P1334, DOI 10.1002/pds.3901; Fischer B, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/1472-6963-14-90; Frenk SM, 2015, NCHS DATA BRIEF, V189, P1; Giraudon I, 2013, BRIT J CLIN PHARMACO, V76, P823, DOI 10.1111/bcp.12133; Gomes T, 2011, ARCH INTERN MED, V171, P686, DOI 10.1001/archinternmed.2011.117; Guy GP, 2017, MMWR-MORBID MORTAL W, V66, P697, DOI 10.15585/mmwr.mm6626a4; Hamunen K, 2009, EUR J PAIN, V13, P954, DOI 10.1016/j.ejpain.2008.11.006; Heilig M, 2018, ACTA ORTHOP, V89, P368, DOI 10.1080/17453674.2018.1465285; Helmerhorst GTT, 2017, BONE JOINT J, V99B, P856, DOI 10.1302/0301-620X.99B7.BJJ-2016-1350.R1; Hider-Mlynarz K, 2018, BRIT J CLIN PHARMACO, V84, P1324, DOI 10.1111/bcp.13564; Jani M, 2017, BMJ-BRIT MED J, V359, DOI 10.1136/bmj.j5514; Joranson DE, 2000, JAMA-J AM MED ASSOC, V283, P1710, DOI 10.1001/jama.283.13.1710; Karanges EA, 2016, BRIT J CLIN PHARMACO, V82, P255, DOI 10.1111/bcp.12937; Kissin I, 2013, J PAIN RES, V6, P513, DOI [10.2147/JPR.S47182, 10.2147/JPR.S47162]; Knotkova H, 2009, J PAIN SYMPTOM MANAG, V38, P426, DOI 10.1016/j.jpainsymman.2009.06.001; Kuehn BM, 2007, JAMA-J AM MED ASSOC, V297, P249, DOI 10.1001/jama.297.3.249; Levy B, 2015, AM J PREV MED, V49, P409, DOI 10.1016/j.amepre.2015.02.020; Manchikanti L, 2012, PAIN PHYSICIAN, V15, pES9; Manchikanti L, 2010, PAIN PHYSICIAN, V13, P401; Markotic F, 2018, EUR J PAIN, V22, P716, DOI 10.1002/ejp.1157; Marschall U, 2016, EUR J PAIN, V20, P767, DOI 10.1002/ejp.802; Martin-Latry K, 2010, PHARMACOEPIDEM DR S, V19, P256, DOI 10.1002/pds.1912; Maxwell JC, 2011, DRUG ALCOHOL REV, V30, P264, DOI 10.1111/j.1465-3362.2011.00291.x; McDonald DC, 2014, PHARMACOEPIDEM DR S, V23, P1258, DOI 10.1002/pds.3690; Moisset X, 2016, PRESSE MED, V45, P447, DOI 10.1016/j.lpm.2016.02.014; Moulis G, 2015, REV MED INTERNE, V36, P411, DOI 10.1016/j.revmed.2014.11.009; Noize P, 2009, PHARMACOEPIDEM DR S, V18, P310, DOI 10.1002/pds.1717; O'Brien T, 2017, EUR J PAIN, V21, P3, DOI 10.1002/ejp.970; Peirce GL, 2012, MED CARE, V50, P494, DOI 10.1097/MLR.0b013e31824ebd81; Pereira J, 2001, J PAIN SYMPTOM MANAG, V22, P672, DOI 10.1016/S0885-3924(01)00294-9; Pergolizzi JV, 2018, POSTGRAD MED, V130, P1, DOI 10.1080/00325481.2018.1407618; Pergolizzi JV, 2012, J PSYCHOSOM RES, V72, P443, DOI 10.1016/j.jpsychores.2012.02.009; Quan HD, 2005, MED CARE, V43, P1130, DOI 10.1097/01.mlr.0000182534.19832.83; Ray WA, 2016, JAMA-J AM MED ASSOC, V315, P2415, DOI 10.1001/jama.2016.7789; Rudd RA, 2016, MMWR-MORBID MORTAL W, V64, P1378, DOI 10.15585/mmwr.mm6450a3; Schnoll SH, 2018, CLIN PHARMACOL THER, V103, P963, DOI 10.1002/cpt.1033; Schubert I, 2013, DTSCH ARZTEBL INT, V110, P45, DOI 10.3238/arztebl.2013.0045; Tuppin P, 2010, REV EPIDEMIOL SANTE, V58, P286, DOI 10.1016/j.respe.2010.04.005; van Amsterdam Jan, 2015, Curr Drug Abuse Rev, V8, P3; VERGNESALLE P, 2012, DOULEURS, V13, P259; von Elm E, 2007, LANCET, V370, P1453, DOI 10.1016/S0140-6736(07)61602-X; Vorilhon C, 2015, EUR J CLIN PHARMACOL, V71, P251, DOI 10.1007/s00228-014-1794-7; Weisberg DF, 2014, INT J DRUG POLICY, V25, P1124, DOI 10.1016/j.drugpo.2014.07.009; WHO, 2016, COLL CTR DRUG STAT M; Winstock AR, 2014, INT J CLIN PRACT, V68, P1147, DOI 10.1111/ijcp.12429; Zee AV, 2009, AM J PUBLIC HEALTH, V99, P221, DOI 10.2105/AJPH.2007.131714; Zin CS, 2014, EUR J PAIN, V18, P1343, DOI 10.1002/j.1532-2149.2014.496.x	66	17	18	2	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1090-3801	1532-2149		EUR J PAIN	Eur. J. Pain	JAN	2019	23	1					124	134		10.1002/ejp.1291			11	Anesthesiology; Clinical Neurology; Neurosciences	Anesthesiology; Neurosciences & Neurology	HE3AG	WOS:000453222000013	30051548	Bronze			2020-06-30	J	Benitez-Rosario, MA; Rosa-Gonzalez, I; Gonzalez-Davila, E; Sanz, E				Angel Benitez-Rosario, Miguel; Rosa-Gonzalez, Inmaculada; Gonzalez-Davila, Enrique; Sanz, Emilio			Fentanyl treatment for end-of-life dyspnoea relief in advanced cancer patients	SUPPORTIVE CARE IN CANCER			English	Article						Fentanyl; Dyspnoea; Subcutaneous fentanyl; Endovenous fentanyl; Refractory dyspnoea; Palliative care	CHRONIC REFRACTORY BREATHLESSNESS; PILOT DOUBLE-BLIND; INTRAVENOUS FENTANYL; BUCCAL TABLET; OPIOIDS; MANAGEMENT; MORPHINE; CARE; PHARMACOVIGILANCE; CORTICOSTEROIDS	PurposeWe assessed the effects of subcutaneous-endovenous fentanyl on dyspnoea in a cohort of advanced cancer patients.MethodsWe performed a retrospective study in a cohort of advanced cancer patients with dyspnoea at rest who received subcutaneous or intravenous fentanyl. Patients with no shortness of breath at rest or at minimal exertion, no rescue doses per 24h, were deemed to be responders to fentanyl. The period of assessment was 6days from the beginning of fentanyl treatment.ResultsSeventy-two patients were evaluated: 65% males, 50% 75years, Palliative Performance Scale (PPS) median of 30%. Seventy-six percent of the patients were responders to fentanyl. Fentanyl efficacy was not statistically related to age, gender, cancer type, previous opioid treatment, steroid and midazolam doses and PPS. The median fentanyl dose in responders was 25mcg/h (interquartile range 12-70). It was significantly related to age (37 vs 12mcg/h, for 75 vs >75years, respectively; p=0.02). There was not a significant difference between fentanyl doses of responders and non-responder patients. Thirty-six, 23 and 15 patients had sustained improvements in dyspnoea over 48, 72 and 96h. Fentanyl had no significant toxicity. The length of inclusion in the study and exclusion were related to low performance status (hazard ratio 0.961; 95%CI 0.927-0.996; Cox-regression) but not to fentanyl doses (hazard ratio 0.875; 95%CI 0.620-1.234; Cox-regression).ConclusionOur preliminary data suggest that subcutaneous-endovenous fentanyl may be associated with dyspnoea relief in dying patients. Further research is needed to confirm these findings.	[Angel Benitez-Rosario, Miguel; Rosa-Gonzalez, Inmaculada] Hosp Univ NS La Candelaria, Palliat Care Unit, Crta Rosario 145, Tenerife 38010, SC, Spain; [Angel Benitez-Rosario, Miguel; Gonzalez-Davila, Enrique; Sanz, Emilio] Univ La Laguna, Sch Hlth Sci Med, Tenerife, Spain; [Gonzalez-Davila, Enrique] Univ La Laguna, Dept Stat, Tenerife, Spain; [Sanz, Emilio] Univ La Laguna, Dept Pharmacol, Tenerife, Spain	Benitez-Rosario, MA (reprint author), Hosp Univ NS La Candelaria, Palliat Care Unit, Crta Rosario 145, Tenerife 38010, SC, Spain.; Benitez-Rosario, MA (reprint author), Univ La Laguna, Sch Hlth Sci Med, Tenerife, Spain.	mabenros@gmail.com	Benitez-Rosario, Miguel-Angel/I-3824-2019	Benitez-Rosario, Miguel-Angel/0000-0001-7706-3171			Allard P, 1999, J PAIN SYMPTOM MANAG, V17, P256, DOI 10.1016/S0885-3924(98)00157-2; Barnes H, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011008.pub2; Benitez-Rosario MA, 2005, J PAIN SYMPTOM MANAG, V30, P395, DOI 10.1016/j.jpainsymman.2005.10.002; Currow DC, 2016, EUR RESPIR J, V47, P342, DOI 10.1183/13993003.00653-2015; Currow DC, 2013, PALLIATIVE MED, V27, P932, DOI 10.1177/0269216313493819; Currow DC, 2012, J PALLIAT MED, V15, P282, DOI 10.1089/jpm.2012.9605; Currow DC, 2010, J PAIN SYMPTOM MANAG, V39, P680, DOI 10.1016/j.jpainsymman.2009.09.017; Ekstrom M, 2015, CURR OPIN SUPPORT PA, V9, P238, DOI 10.1097/SPC.0000000000000147; Ekstrom M, 2018, THORAX, V73, P88, DOI 10.1136/thoraxjnl-2016-209868; Gauna AA, 2008, J PALLIAT MED, V11, P643, DOI 10.1089/jpm.2007.0161; Hardy J, 2016, SUPPORT CARE CANCER, V24, P3069, DOI 10.1007/s00520-016-3125-2; Hui D, 2017, J PAIN SYMPTOM MANAG, V54, P798, DOI 10.1016/j.jpainsymman.2017.08.001; Hui D, 2016, J PAIN SYMPTOM MANAG, V52, P459, DOI 10.1016/j.jpainsymman.2016.05.013; Hui D, 2016, J PAIN SYMPTOM MANAG, V52, P8, DOI 10.1016/j.jpainsymman.2015.10.023; Hui D, 2015, J PAIN SYMPTOM MANAG, V50, P488, DOI 10.1016/j.jpainsymman.2014.09.003; Hui D, 2014, J PAIN SYMPTOM MANAG, V47, P209, DOI 10.1016/j.jpainsymman.2013.03.017; Hui D, 2013, CANCER-AM CANCER SOC, V119, P1098, DOI 10.1002/cncr.27854; Jansen K, 2018, J PAIN SYMPTOM MANAG, V55, P508, DOI 10.1016/j.jpainsymman.2017.06.010; Johnson MJ, 2015, CURR OPIN SUPPORT PA, V9, P203, DOI 10.1097/SPC.0000000000000150; Johnson MJ, 2013, EUR RESPIR J, V42, P758, DOI 10.1183/09031936.00139812; Johnson MJ, 2012, J PAIN SYMPTOM MANAG, V43, P614, DOI 10.1016/j.jpainsymman.2011.04.024; Kehl KA, 2013, AM J HOSP PALLIAT ME, V30, P601, DOI 10.1177/1049909112468222; Kornick CA, 2003, CANCER, V97, P3121, DOI 10.1002/cncr.11457; Maeda T, 2016, J PAIN PALLIAT CARE, V30, P106, DOI 10.3109/15360288.2016.1167803; Mercadante S, 2016, PAIN, V157, P2657, DOI 10.1097/j.pain.0000000000000721; Mori M, 2017, SUPPORT CARE CANCER, V25, P1169, DOI 10.1007/s00520-016-3507-5; Navigante AH, 2006, J PAIN SYMPTOM MANAG, V31, P38, DOI 10.1016/j.jpainsymman.2005.06.009; Pang GS, 2016, AM J HOSP PALLIAT ME, V33, P222, DOI 10.1177/1049909114559769; Pereira J, 2001, J PAIN SYMPTOM MANAG, V22, P672, DOI 10.1016/S0885-3924(01)00294-9; Sanderson C, 2016, BMJ SUPPORT PALLIAT, V6, P323, DOI 10.1136/bmjspcare-2014-000825; Schug SA, 2017, DRUGS, V77, P747, DOI 10.1007/s40265-017-0727-z; Simon ST, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007354.pub3; Simon ST, 2016, J PAIN SYMPTOM MANAG, V52, P617, DOI 10.1016/j.jpainsymman.2016.05.023; Simon ST, 2013, J PAIN SYMPTOM MANAG, V46, P874, DOI 10.1016/j.jpainsymman.2013.02.019; Sitte Thomas, 2008, J Pain Symptom Manage, V36, pe3, DOI 10.1016/j.jpainsymman.2008.08.002; Smallwood N, 2015, INTERN MED J, V45, P898, DOI 10.1111/imj.12857; Takeyasu M, 2016, INTERNAL MED, V55, P725, DOI 10.2169/internalmedicine.55.5362	37	1	1	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0941-4355	1433-7339		SUPPORT CARE CANCER	Support. Care Cancer	JAN	2019	27	1					157	164		10.1007/s00520-018-4309-8			8	Oncology; Health Care Sciences & Services; Rehabilitation	Oncology; Health Care Sciences & Services; Rehabilitation	HD1LA	WOS:000452270300018	29915993				2020-06-30	J	Kinshella, MLW; Gauthier, T; Lysyshyn, M				Kinshella, Mai-Lei Woo; Gauthier, Tim; Lysyshyn, Mark			Rigidity, dyskinesia and other atypical overdose presentations observed at a supervised injection site, Vancouver, Canada	HARM REDUCTION JOURNAL			English	Article						Opioid overdose; Fentanyl; Atypical overdose presentations; Rigidity; Dyskinesia; Supervised consumption sites	CHEST-WALL RIGIDITY; INDUCED MUSCLE RIGIDITY; FENTANYL; ANISOCORIA; ANESTHESIA	ObjectiveIn midst of the overdose crisis, the clinical features of opioid overdoses seem to be changing. Understanding of the adverse effects of synthetic opioids such as fentanyl is currently limited to clinical settings. Insite, a supervised injection site in Vancouver, Canada, provides an opportunity to better understand illicit drug overdose presentations.MethodsA review of clinical records at Insite for October 2016 to April 2017 was undertaken to quantify atypical overdose presentations. Overdose reports were reviewed for the number of atypical opioid overdose presentations, temporal trends over the study period, concurrent symptoms, and interventions employed by staff.ResultsInsite staff responded to 1581 overdoses during the study period, including 497 (31.4%) that did not fit a typical presentation for opioid overdoses. Of these, 485 fit into five categories of atypical features: muscle rigidity, dyskinesia, slow or irregular heart rate, confusion, and anisocoria. Muscle rigidity was the most common atypical presentation, observed in 240 (15.2%) of the overdose cases, followed by dyskinesia, observed in 150 (9.2%). Slow or irregular heart rate was observed in 69 (4.4%) cases, confusion in 24 (1.5%), and anisocoria in 2 (0.1%) of overall overdose cases.DiscussionThe similarity of atypical overdose cases at Insite with anesthesiology case reports supports the understanding that the illicit drug supply is contaminated by fentanyl and other synthetic opioids. Atypical overdose presentations can affect clinical overdose response. The experience at Insite highlights the potential for supervised consumption sites to be innovative spaces for community learning and knowledge translation.	[Kinshella, Mai-Lei Woo; Gauthier, Tim; Lysyshyn, Mark] Vancouver Coastal Hlth, Vancouver, BC, Canada; [Lysyshyn, Mark] Univ British Columbia, Sch Populat & Publ Hlth, Vancouver, BC, Canada; [Lysyshyn, Mark] Off Med Hlth Officer, 5th Floor,132 West Esplanade, N Vancouver, BC, Canada	Lysyshyn, M (reprint author), Vancouver Coastal Hlth, Vancouver, BC, Canada.; Lysyshyn, M (reprint author), Univ British Columbia, Sch Populat & Publ Hlth, Vancouver, BC, Canada.	mark.lysyshyn@vch.ca		Lysyshyn, Mark/0000-0001-6684-2030	Vancouver Coastal Health	Vancouver Coastal Health.	Ahmad M, 2017, J BRONCHOL INTERN PU, V24, pE9, DOI 10.1097/LBR.0000000000000329; Akhlaghi M., 2016, J BAS RES MED SCI, V3, P1; [Anonymous], 2012, NALOXONE DRUG INFORM; [Anonymous], 2017, SUP CONS SERV OP GUI; BC Centre for Disease Control, 2018, BC PUBL HLTH OP OV E; BCCDC Clinical Prevention Services, 2016, DEC SUPP TOOL ADM NA; Burns G, 2016, CLIN TOXICOL, V54, P420, DOI 10.3109/15563650.2016.1157722; Buxton JA, 2018, CAN MED ASSOC J, V190, pE539, DOI 10.1503/cmaj.171468; Coruh B, 2013, CHEST, V143, P1145, DOI 10.1378/chest.12-2131; Deik Andres, 2012, Curr Drug Abuse Rev, V5, P243; Dewhirst E, 2012, PEDIATR EMERG CARE, V28, P465, DOI 10.1097/PEC.0b013e3182535a2a; Dimitriou Vassilios, 2014, Middle East Journal of Anesthesiology, V22, P619; Duran EZ, 2018, GLOBAL NEWS; Iselin-Chaves IA, 2009, ANAESTHESIA, V64, P1359, DOI 10.1111/j.1365-2044.2009.06068.x; Jarmoc M, 2010, J ORAL MAXIL SURG, V68, P898, DOI 10.1016/j.joms.2009.02.010; Jones AA, 2018, JAMA PSYCHIAT, V75, P298, DOI 10.1001/jamapsychiatry.2017.4432; Kounang N, 2017, CNN; Kuhn I, 1996, PAEDIATR ANAESTH, V6, P411, DOI 10.1046/j.1460-9592.1996.d01-4.x; Lai HC, 2013, J CLIN ANESTH, V25, P58, DOI 10.1016/j.jclinane.2012.06.007; Martinez L P, 1997, AANA J, V65, P150; Muller P, 2000, AM J PERINAT, V17, P23, DOI 10.1055/s-2000-7289; National Institute on Drug Abuse, IMP DRUGS NEUR; Phua CK, 2017, RESPIR MED CASE REP, V20, P205, DOI 10.1016/j.rmcr.2017.02.012; Rosenberg M, 1977, Anesth Prog, V24, P50; Stolbach A, 2018, ACUTE OPIOID INTOXIC; Toward the Heart, 2017, HEART FENTANYL INDUC; Vancouver Coastal Health, INS US STAT; Vaughn R L, 1981, Anesth Prog, V28, P50; Viscomi CM, 1997, OBSTET GYNECOL, V89, P822, DOI 10.1016/S0029-7844(97)81423-8; World Health Organization, 2014, INF SHEET OP OV	30	8	8	0	1	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1477-7517			HARM REDUCT J	Harm Reduct. J.	DEC 22	2018	15								64	10.1186/s12954-018-0271-5			7	Substance Abuse	Substance Abuse	HF5ES	WOS:000454256000001	30577844	DOAJ Gold, Green Published			2020-06-30	J	Bergh, MSS; Bogen, IL; Wilson, SR; Oiestad, AML				Bergh, Marianne Skov-Skov; Bogen, Inger Lise; Wilson, Steven Ray; Oiestad, Ase Marit Leere			Addressing the Fentanyl Analogue Epidemic by Multiplex UHPLC-MS/MS Analysis of Whole Blood	THERAPEUTIC DRUG MONITORING			English	Article						fentanyl analogues; naloxone; UHPLC-MS/MS; postmortem blood samples; structural isomer separation	LIQUID-CHROMATOGRAPHY; ACETYL FENTANYL; SYNTHETIC OPIOIDS; OVERDOSE DEATHS; HUMAN URINE; LC-MS/MS; POSTMORTEM; METABOLITES; DRUGS; BUTYRFENTANYL	Background: Fentanyl and fentanyl analogues (fentanyls) are very potent opioids posing a serious threat to the public health. Thousands of overdose deaths across the world are caused by fentanyls, and the numbers are increasing. Rapid mapping of current trends in opioid abuse is necessary to accelerate preventive measures. To ensure this, there is a need for sensitive targeted multiplex MS/MS methods to pinpoint drugs of abuse. We present a fully validated UHPLC-MS/MS method for the determination of 26 fentanyls, including several structural isomers, and the opioid antagonist naloxone in human whole blood. Methods: Blood samples were prepared by liquid-liquid extraction with ethyl acetate and heptane. The fentanyls were separated with UHPLC, using a Kinetex biphenyl column (2.1 x 100 mm, 1.7 mu m; Phenomenex, Verlose, Denmark) with an acidic mobile phase. Quantification was performed by MS/MS. The method was validated according to SWGTOX guidelines. Results: The developed method could successfully separate all 27 analytes, including 7 isomers, and was validated according to SWGTOX guidelines with very low limits of quantification (4-20 pg/mL). The applicability of the method was demonstrated by determination of fentanyls in postmortem blood samples from 2 cases. Conclusions: A selective, highly sensitive, and robust method for determination of a large panel of fentanyls and naloxone in blood was developed and validated. Naloxone was included to monitor use and efficacy of the opioid antidote in cases of fentanyl overdoses. The method demonstrated good ability to separate structural isomers, which is important to differentiate between the numerous available fentanyls with variable potency, toxicity, and legal status. The developed method can be used to identify fentanyls on the drug market to help combat the fentanyl crisis.	[Bergh, Marianne Skov-Skov; Bogen, Inger Lise; Oiestad, Ase Marit Leere] Oslo Univ Hosp, Div Lab Med, Dept Forens Sci, Oslo, Norway; [Bergh, Marianne Skov-Skov; Wilson, Steven Ray] Univ Oslo, Fac Math & Nat Sci, Dept Chem, Oslo, Norway; [Bogen, Inger Lise] Univ Oslo, Fac Med, Div Physiol, Oslo, Norway	Bergh, MSS (reprint author), Lovisenberggata 6, N-0456 Oslo, Norway.	Marianne.Skov-Skov.Bergh@ous-hf.no	Bergh, Marianne Skov-Skov/AAB-9563-2019	Oiestad, Ase Marit Leere/0000-0001-7909-5863; Bogen, Inger Lise/0000-0003-2877-0624			[Anonymous], 2013, J ANAL TOXICOL, V37, P452, DOI 10.1093/jat/bkt054; Anzillotti L, 2014, FORENSIC SCI INT, V243, P99, DOI 10.1016/j.forsciint.2014.05.005; Armenian P, 2018, NEUROPHARMACOLOGY, V134, P121, DOI 10.1016/j.neuropharm.2017.10.016; Backberg M, 2015, CLIN TOXICOL, V53, P609, DOI 10.3109/15563650.2015.1054505; Bazazi AR, 2010, J HEALTH CARE POOR U, V21, P1108, DOI 10.1353/hpu.2010.0935; Bork WR, 2012, TOXICHEM KRIMTECH, V79, P150; Breindahl T, 2017, DRUG TEST ANAL, V9, P415, DOI 10.1002/dta.2046; Clarke SFJ, 2005, EMERG MED J, V22, P612, DOI 10.1136/emj.2003.009613; Dowell D, 2017, JAMA-J AM MED ASSOC, V318, P2295, DOI 10.1001/jama.2017.15971; Eckart K, 2015, J CHROMATOGR B, V1001, P1, DOI 10.1016/j.jchromb.2015.06.028; European Monitoring Centre for Drugs and Drug Addiction, 2012, EMCDDA TRENDSP STUD; European Monitoring Centre for Drugs and Drug Addiction, 2016, EUR DRUG REP 2016 TR; Gergov M, 2009, FORENSIC SCI INT, V186, P36, DOI 10.1016/j.forsciint.2009.01.013; Goggin MM, 2018, J ANAL TOXICOL, V42, P384, DOI 10.1093/jat/bky013; Helander A, 2017, CLIN TOXICOL, V55, P589, DOI 10.1080/15563650.2017.1303141; Helander A, 2016, CLIN TOXICOL, V54, P324, DOI 10.3109/15563650.2016.1139715; Helland A, 2017, J ANAL TOXICOL, V41, P708, DOI 10.1093/jat/bkx050; HENDERSON GL, 1988, J FORENSIC SCI, V33, P569; Kenney SR, 2018, J SUBST ABUSE TREAT, V86, P65, DOI 10.1016/j.jsat.2018.01.005; Lozier MJ, 2015, J MED TOXICOL, V11, P208, DOI 10.1007/s13181-015-0477-9; Lurie IS, 2009, J CHROMATOGR A, V1216, P1515, DOI 10.1016/j.chroma.2008.12.097; Matuszewski BK, 2003, ANAL CHEM, V75, P3019, DOI 10.1021/ac020361s; McIntyre IM, 2016, J ANAL TOXICOL, V40, P162, DOI 10.1093/jat/bkv138; Mohr ALA, 2016, J ANAL TOXICOL, V40, P709, DOI 10.1093/jat/bkw086; Moody MT, 2018, DRUG TEST ANAL, V10, P1358, DOI 10.1002/dta.2393; Mounteney J, 2015, INT J DRUG POLICY, V26, P626, DOI 10.1016/j.drugpo.2015.04.003; Noble C, 2018, DRUG TEST ANAL, V10, P651, DOI 10.1002/dta.2263; O'Donnell JK, 2017, MMWR-MORBID MORTAL W, V66, P1197, DOI 10.15585/mmwr.mm6643e1; Odoardi S, 2014, FORENSIC SCI INT, V243, P61, DOI 10.1016/j.forsciint.2014.04.015; Poklis J, 2016, J ANAL TOXICOL, V40, P703, DOI 10.1093/jat/bkw048; Poklis J, 2015, FORENSIC SCI INT, V257, P435, DOI 10.1016/j.forsciint.2015.10.021; Shaner RL, 2014, J CHROMATOGR B, V962, P52, DOI 10.1016/j.jchromb.2014.05.025; Shanks KG, 2017, J ANAL TOXICOL, V41, P466, DOI 10.1093/jat/bkx042; Shoff EN, 2017, J ANAL TOXICOL, V41, P484, DOI 10.1093/jat/bkx041; Sofalvi S, 2017, J ANAL TOXICOL, V41, P473, DOI 10.1093/jat/bkx052; Staeheli SN, 2016, FORENSIC SCI INT, V266, P170, DOI 10.1016/j.forsciint.2016.05.034; Strayer KE, 2018, ACS OMEGA, V3, P514, DOI 10.1021/acsomega.7b01536; Sutter ME, 2017, ACAD EMERG MED, V24, P106, DOI 10.1111/acem.13034; Suzuki J, 2017, DRUG ALCOHOL DEPEN, V171, P107, DOI 10.1016/j.drugalcdep.2016.11.033; Taylor T., GETTING MOST PHENYL; United Nations Office on Drugs and Crime, GLOB SMART UPD, V17; Vardanyan RS, 2014, FUTURE MED CHEM, V6, P385, DOI 10.4155/fmc.13.215; Wang LQ, 2006, J ANAL TOXICOL, V30, P335, DOI 10.1093/jat/30.5.335; Yonemitsu K, 2016, FORENSIC SCI INT, V267, pE6, DOI 10.1016/j.forsciint.2016.08.025	44	6	6	2	10	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0163-4356	1536-3694		THER DRUG MONIT	Ther. Drug Monit.	DEC	2018	40	6					738	748		10.1097/FTD.0000000000000564			11	Medical Laboratory Technology; Pharmacology & Pharmacy; Toxicology	Medical Laboratory Technology; Pharmacology & Pharmacy; Toxicology	HK3VJ	WOS:000457846600010	30157097				2020-06-30	J	Jang, JS; Hwang, SM; Kwon, Y; Tark, H; Kim, YJ; Ryu, BY; Lee, JJ				Jang, Ji Su; Hwang, Sung Mi; Kwon, Youngsuk; Tark, Hyunjin; Kim, Young Joon; Ryu, Byoung Yoon; Lee, Jae Jun			Is the transdermal fentanyl patch an efficient way to achieve acute postoperative pain control? A randomized controlled trial	MEDICINE			English	Article						fentanyl concentration; postoperative pain; transdermal fentanyl patch	ANALGESIA; MANAGEMENT; PHARMACOKINETICS; ARTHROPLASTY; EFFICACY; SURGERY	Backgroupd: This study investigated the plasma fentanyl concentration and efficacy of transdermal fentanyl patch (TFP) (25 mu g/h) in the management of acute postoperative pain. Methods: Patients undergoing laparoscopic cholecystectomy were randomly allocated to 2 groups. The TFP group (n=30) received a single TFP 25 mu g/h to the anterior chest wall 14 h before operation. The IV group (n=30) received a placebo patch. After the operation, intravenous fentanyl infusion (25 mu g/h)was begun with loading dose 25 mu g in the IV group and only normal saline in the TFP group. Plasma fentanyl levels were measured at admission, 1, 6, 12, 24, and 48 h postoperatively. Pain severity and adverse effects were evaluated too. Results: The fentanyl level peaked 1 h after operation in the TFP group (3.27 +/- 0.34 ng/mL) and 24 h postoperatively in the IV group (2.9 +/- 0.42 ng/mL). Pain scores and the use of rescue analgesics were not significantly different between 2 groups. Respiratory depression was not happened in both groups. Conclusions: The TFP (25 mu g/h) affixed 14 h before surgery reached a higher constant concentration than the same dose setting of a constant IV infusion of fentanyl after surgery. Although the concentration of fentanyl was higher than those of previous researches, there was no respiratory depression. But, there was no advantage of reducing pain score and the use of rescue analgesics.	[Jang, Ji Su; Hwang, Sung Mi; Tark, Hyunjin; Kim, Young Joon; Lee, Jae Jun] Hallym Univ, Chuncheon Sacred Heart Hosp, Dept Anesthesiol & Pain Med, Chunchon, South Korea; [Kwon, Youngsuk] Kangwon Natl Univ, Coll Med, Dept Anesthesiol & Pain Med, Chunchon, South Korea; [Ryu, Byoung Yoon] Hallym Univ, Chuncheon Sacred Heart Hosp, Dept Gen Surg, Chunchon, South Korea	Hwang, SM (reprint author), Chuncheon Sacred Heart Hosp, Dept Anesthesiol & Pain Med, 77 Sakju Ro, Chuncheon Si 24253, Gangwon Do, South Korea.; Lee, JJ (reprint author), Chuncheon Sacred Heart Hosp, Dept Anesthesiol & Pain Med, 77 Sakju Ro, Chunchon 24253, South Korea.	h70sm@hallym.or.kr; iloveu59@hallym.or.kr		Kwon, Young Suk/0000-0001-7753-8464			CAPLAN RA, 1989, JAMA-J AM MED ASSOC, V261, P1036, DOI 10.1001/jama.261.7.1036; CARTWRIGHT P, 1983, ANESTH ANALG, V62, P966; Cepeda MS, 2003, CLIN PHARMACOL THER, V74, P102, DOI 10.1016/S0009-9236(03)00152-8; GOURLAY GK, 1989, PAIN, V37, P193, DOI 10.1016/0304-3959(89)90130-9; GOURLAY GK, 1990, PAIN, V40, P21, DOI 10.1016/0304-3959(90)91046-L; GOURLAY GK, 1988, ANESTH ANALG, V67, P329; GUPTA SK, 1992, J PAIN SYMPTOM MANAG, V7, pS17, DOI 10.1016/0885-3924(92)90049-N; HOLLEY FO, 1988, BRIT J ANAESTH, V60, P608, DOI 10.1093/bja/60.6.608; KILBRIDE M, 1994, DIS COLON RECTUM, V37, P1070, DOI 10.1007/BF02049805; Larsen RH, 2003, PHARMACOL TOXICOL, V93, P244, DOI 10.1046/j.1600-0773.2003.pto930508.x; Lebovits AH, 2001, PAIN MED, V2, P280, DOI 10.1046/j.1526-4637.2001.01051.x; LEHMANN K A, 1988, Acta Anaesthesiologica Belgica, V39, P11; LEHMANN KA, 1991, EUR J CLIN PHARMACOL, V41, P17, DOI 10.1007/BF00280100; Lehmann LJ, 1997, REGION ANESTH, V22, P24, DOI 10.1016/S1098-7339(06)80052-0; Macintyre PE, 2001, BRIT J ANAESTH, V87, P36, DOI 10.1093/bja/87.1.36; Merivirta R, 2015, J PAIN RES, V8, P39, DOI 10.2147/JPR.S69511; Merivirta R, 2013, ARTHROSCOPY, V29, P1129, DOI 10.1016/j.arthro.2013.04.018; Minville V, 2008, J CLIN ANESTH, V20, P280, DOI 10.1016/j.jclinane.2007.12.013; Nelson L, 2009, J MED TOXICOL, V5, P230, DOI 10.1007/BF03178274; Peng PWH, 1999, ANESTHESIOLOGY, V90, P576, DOI 10.1097/00000542-199902000-00034; REILLY CS, 1985, ANAESTHESIA, V40, P837, DOI 10.1111/j.1365-2044.1985.tb11043.x; Sathitkarnmanee T, 2014, J PAIN RES, V7, P449, DOI 10.2147/JPR.S66741; VANBASTELAERE M, 1995, J CLIN ANESTH, V7, P26, DOI 10.1016/0952-8180(94)00000-T; VARVEL JR, 1989, ANESTHESIOLOGY, V70, P928, DOI 10.1097/00000542-198906000-00008; Viscusi ER, 2004, JAMA-J AM MED ASSOC, V291, P1333, DOI 10.1001/jama.291.11.1333	25	0	0	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0025-7974	1536-5964		MEDICINE	Medicine (Baltimore)	DEC	2018	97	51							e13768	10.1097/MD.0000000000013768			6	Medicine, General & Internal	General & Internal Medicine	HI3GA	WOS:000456334600107	30572528	DOAJ Gold, Green Published			2020-06-30	J	Kim, MK; Ahn, SE; Shin, E; Park, SW; Choi, JH; Kang, HY				Kim, Mi Kyeong; Ahn, Sang Eun; Shin, Eunsil; Park, Sung Wook; Choi, Jeong-Hyun; Kang, Hee Yong			Comparison of analgesic efficacy of oxycodone and fentanyl after total hip replacement surgery A randomized controlled trial	MEDICINE			English	Article						fentanyl; oxycodone; postoperative pain; total hip replacement	PATIENT-CONTROLLED ANALGESIA; POSTOPERATIVE PAIN; VS. FENTANYL; MORPHINE	Background: Total hip replacement (THR) is often accompanied by severe postoperative pain. We aimed to study whether oxycodone can be an effective alternative for fentanyl in the management of early postoperative pain after total hip replacement. Methods: We conducted a randomized controlled trial on 46 patients scheduled to undergo THR. We followed a standard general anesthetic technique, with endotracheal intubation. Twenty minutes before the end of surgery, single bolus injection of fentanyl, 50 mu g (fentanyl group [group F], n=23) or oxycodone, 4 mg (oxycodone group [group O], n=23) was administered intravenously. Numeric rating scale (NRS) was used to assess pain in the post-anesthesia care unit (PACU). All patients had intravenous patient-controlled analgesia (PCA) with 10 mu g/kg of fentanyl for 48 hours. Intravenous boluses of 50 mu g were administered for breakthrough pain. The cumulative opioid dose administered at 6, 12, 24, and 48h after surgery were recorded. A P value of less than .05 was considered statistically significant. Results: The NRS of group O in the PACU was significantly lower (P<.05); fewer patients in group O required additional fentanyl boluses in the PACU (P<.05). The cumulative opioid requirement was significantly less in group O at 6, 12, 24, and 48hours after surgery. (P<.05) Conclusions: A single bolus injection of oxycodone is more effective than that of fentanyl in the acute phase of postoperative pain after THR. It may be used as an alternative drug for fentanyl in pain control after orthopedic surgery.	[Kim, Mi Kyeong; Ahn, Sang Eun; Shin, Eunsil; Park, Sung Wook; Choi, Jeong-Hyun; Kang, Hee Yong] Kyung Hee Univ, Dept Anesthesiol & Pain Med, Seoul, South Korea	Kang, HY (reprint author), Kyung Hee Univ Hosp, Dept Anesthesiol & Pain Med, 23 Kyungheedae Ro, Seoul 02447, South Korea.	hykang531@gmail.com	Choi, Jeong-Hyun/AAI-1864-2020	Choi, Jeong-Hyun/0000-0003-1995-1220			Ding Z, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000004943; Eisenach JC, 2003, PAIN, V101, P89, DOI 10.1016/S0304-3959(02)00259-2; ENNIS M, 1991, AGENTS ACTIONS, V33, P20, DOI 10.1007/BF01993116; Gallego AO, 2007, CLIN TRANSL ONCOL, V9, P298, DOI 10.1007/s12094-007-0057-9; Herrick IA, 1996, ANAESTHESIA, V51, P356, DOI 10.1111/j.1365-2044.1996.tb07748.x; Hwang BY, 2014, INT J MED SCI, V11, P658, DOI 10.7150/ijms.8331; Joshi Girish P, 2005, Anesthesiol Clin North Am, V23, P21, DOI 10.1016/j.atc.2004.11.013; Kalso E, 2005, J PAIN SYMPTOM MANAG, V29, pS47, DOI 10.1016/j.jpainsymman.2005.01.010; KALSO E, 1991, ACTA ANAESTH SCAND, V35, P642, DOI 10.1111/j.1399-6576.1991.tb03364.x; Kang H, 2015, J KOREAN ACAD NURS, V45, P641, DOI 10.4040/jkan.2015.45.5.641; Kim NS, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000006286; Kim NS, 2015, KOREAN J ANESTHESIOL, V68, P261, DOI 10.4097/kjae.2015.68.3.261; Koch S, 2008, ACTA ANAESTH SCAND, V52, P845, DOI 10.1111/j.1399-6576.2008.01643.x; LEOW KP, 1995, ANESTH ANALG, V80, P296, DOI 10.1097/00000539-199502000-00016; Lovich-Sapola J, 2015, SURG CLIN N AM, V95, P301, DOI 10.1016/j.suc.2014.10.002; Minville V, 2008, J CLIN ANESTH, V20, P280, DOI 10.1016/j.jclinane.2007.12.013; Russo A, 2017, J ANESTH, V31, P51, DOI 10.1007/s00540-016-2268-0; Shin S, 2014, YONSEI MED J, V55, P800, DOI 10.3349/ymj.2014.55.3.800; Wang N, 2015, PAK J MED SCI, V31, P300, DOI 10.12669/pjms.312.6686; Yu EHY, 2016, ANAESTHESIA, V71, P1347, DOI 10.1111/anae.13602	20	1	2	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0025-7974	1536-5964		MEDICINE	Medicine (Baltimore)	DEC	2018	97	49							e13385	10.1097/MD.0000000000013385			6	Medicine, General & Internal	General & Internal Medicine	HI3AM	WOS:000456318600046	30544411	DOAJ Gold, Green Published			2020-06-30	J	Cattano, D; Rigamonti, A				Cattano, Davide; Rigamonti, Andrea			Taking the pain by the horns: rams and measuring tape	MINERVA ANESTESIOLOGICA			English	Editorial Material							SCALP BLOCK; DEXMEDETOMIDINE; ANESTHESIA		[Cattano, Davide] UTHlth Houston, McGovern Med Sch, Houston, TX USA; [Rigamonti, Andrea] Univ Toronto, St Michaels Hosp, Dept Anesthesia & Crit Care, Toronto, ON, Canada	Cattano, D (reprint author), UTHlth Houston, Dept Anesthesiol, McGovern Med Sch, 6431 Fannin,MSB 5-020, Houston, TX 77030 USA.	Davide.Cattano@uth.tmc.edu					Boselli E, 2013, BRIT J ANAESTH, V111, P453, DOI 10.1093/bja/aet110; Enneking FK, 2000, ANESTH ANALG, V90, P1, DOI 10.1097/00000539-200001000-00001; Garavaglia MM, 2014, J NEUROSURG ANESTH, V26, P226, DOI 10.1097/ANA.0b013e3182a58aba; Gray AT, 2006, ANESTHESIOLOGY, V104, P368, DOI 10.1097/00000542-200602000-00024; Guilfoyle MR, 2013, ANESTH ANALG, V116, P1093, DOI 10.1213/ANE.0b013e3182863c22; McAuliffe N, 2018, CAN J ANESTH, V65, P1129, DOI 10.1007/s12630-018-1178-z; Piccioni F, 2008, MINERVA ANESTESIOL, V74, P393; Shipton EA, 2018, NEW ZEAL MED J, V131, P7; Theerth KA, 2018, MINERVA ANESTESIOL, V84, P1361, DOI 10.23736/S0375-9393.18.12837-9; Zheng L, 2017, MINERVA ANESTESIOL, V83, P1137, DOI 10.23736/S0375-9393.17.11881-X	10	0	0	0	0	EDIZIONI MINERVA MEDICA	TURIN	CORSO BRAMANTE 83-85 INT JOURNALS DEPT., 10126 TURIN, ITALY	0375-9393	1827-1596		MINERVA ANESTESIOL	Minerva Anestesiol.	DEC	2018	84	12					1334	1336		10.23736/S0375-9393.18.13248-2			3	Anesthesiology; Critical Care Medicine	Anesthesiology; General & Internal Medicine	HG8MA	WOS:000455254900003	30328336				2020-06-30	J	Theerth, KA; Sriganesh, K; Reddy, KM; Chakrabarti, D; Umamaheswara Rao, GS				Theerth, Kaushic A.; Sriganesh, Kamath; Reddy, K. Madhusudan; Chakrabarti, Dhritiman; Umamaheswara Rao, Ganne S.			Analgesia Nociception Index-guided intraoperative fentanyl consumption and postoperative analgesia in patients receiving scalp block versus incision-site infiltration for craniotomy	MINERVA ANESTESIOLOGICA			English	Article						Craniotomy; Pain; Analgesics, opioid	HEMODYNAMIC-RESPONSE; PAIN; BUPIVACAINE; ANESTHESIA	BACKGROUND: Scalp block or local anesthetic infiltration for craniotomy blunts hemodynamic response to noxious stimuli, reduces opioid requirement and decreases postoperative pain. Analgesia Nociception Index (ANI) provides objective information about the magnitude of pain (rated from 0 to 100 with 0 indicating extreme nociception and 100 indicating absence of nociception) and adequacy of infra-operative analgesia. This study compared intra-operative fentanyl consumption guided by ANI and postoperative pain in patients who receive scalp block with those who receive incisionsite local anesthetic infiltration tier craniotomy. METHODS: Sixty adult patients undergoing elective supra-tentorial tumor surgery were randomly allocated to receive scalp block or incision-site infiltration after induction of anesthesia. Throughout the intra-operative period, patients received fentanyl 0.5 mu g/kg/h and ANI was continuously monitored. Fentanyl 1 mu g/kg bolus was administered when ANI decreased to <50. Intraoperative fentanyl consumption was compared using unpaired t-test. Correlation between ANI and postoperative numerical rating scale (NRS) pain score was done using Spearman's rho. RESULTS: The fentanyl consumption (mu g/kg/h) was less with scalp block when compared to incision-site infiltration (median [interquartile range]; 1.04 [0.92-1.34] vs. 1.34 [1.18-1.59], P=0.001). Postoperative pain scores were similar [median (interquartile range); 1.5 (0-4) vs. 3 (0-4), P=0.840]. No correlation was observed between postoperative NRS Score and ANI (correlation coefficient = 0.072; P=0.617). CONCLUSIONS: ANI-guided analgesic administration during craniotomy demonstrated lower intra-operative fentanyl consumption in patients receiving scalp block as compared to incision-site local anesthetic infiltration. No correlation was seen between postoperative NRS and ANI.	[Theerth, Kaushic A.] Rajagiri Hosp, Dept Neuroanaesthesia & Neurocrit Care, Ernakulam, India; [Sriganesh, Kamath; Reddy, K. Madhusudan; Chakrabarti, Dhritiman; Umamaheswara Rao, Ganne S.] Natl Inst Mental Hlth & Neurosci, Dept Neuroanaesthesia & Neurocrit Care, Bengaluru 560029, Karnataka, India	Sriganesh, K (reprint author), Natl Inst Mental Hlth & Neurosci, Dept Neuroanaesthesia & Neurocrit Care, Bengaluru 560029, Karnataka, India.	drsri23@gmail.com					Akcil EF, 2017, CLIN NEUROL NEUROSUR, V154, P98, DOI 10.1016/j.clineuro.2017.01.018; Biswas BK, 2003, J NEUROSURG ANESTH, V15, P234, DOI 10.1097/00008506-200307000-00011; Bloomfield EL, 1998, ANESTH ANALG, V87, P579, DOI 10.1097/00000539-199809000-00015; Boselli E, 2016, J CLIN MONIT COMPUT, V30, P977, DOI 10.1007/s10877-015-9802-8; Boselli E, 2013, BRIT J ANAESTH, V111, P453, DOI 10.1093/bja/aet110; De Oliveira GS, 2011, ANESTHESIOLOGY, V115, P575, DOI 10.1097/ALN.0b013e31822a24c2; El-Dahab HA, 2009, EGYPT J ANAESTH, V25, P439; Guilfoyle MR, 2013, ANESTH ANALG, V116, P1093, DOI 10.1213/ANE.0b013e3182863c22; Jeanne M, 2009, AUTON NEUROSCI-BASIC, V147, P91, DOI 10.1016/j.autneu.2009.01.005; Kommula LK, 2017, J NEUROSURG ANESTHES; Le Gall L, 2017, ANAESTH CRIT CARE PA; Ledowski T, 2013, BRIT J ANAESTH, V111, P627, DOI 10.1093/bja/aet111; Osborn I, 2010, J NEUROSURG ANESTH, V22, P187, DOI 10.1097/ANA.0b013e3181d48846; Pinosky ML, 1996, ANESTH ANALG, V83, P1256, DOI 10.1097/00000539-199612000-00022; TEMPELHOFF R, 1990, CAN J ANAESTH, V37, P327, DOI 10.1007/BF03005584; Tuchinda L, 2010, ASIAN BIOMED, V4, P243, DOI 10.2478/abm-2010-0031; Upton HD, 2017, ANESTH ANALG, V125, P81, DOI 10.1213/ANE.0000000000001984; Vadivelu N, 2016, J PAIN RES, V9, P37, DOI 10.2147/JPR.S85782; vanVlymen JM, 1997, ANESTH ANALG, V84, P148, DOI 10.1097/00000539-199701000-00027; Zheng L, 2017, MINERVA ANESTESIOL, V83, P1137, DOI 10.23736/S0375-9393.17.11881-X	20	6	6	1	5	EDIZIONI MINERVA MEDICA	TURIN	CORSO BRAMANTE 83-85 INT JOURNALS DEPT., 10126 TURIN, ITALY	0375-9393	1827-1596		MINERVA ANESTESIOL	Minerva Anestesiol.	DEC	2018	84	12					1361	1368		10.23736/S0375-9393.18.12837-9			8	Anesthesiology; Critical Care Medicine	Anesthesiology; General & Internal Medicine	HG8MA	WOS:000455254900008	29991223				2020-06-30	J	Laing, MK; Tupper, KW; Fairbairn, N				Laing, Matthew K.; Tupper, Kenneth W.; Fairbairn, Nadia			Drug checking as a potential strategic overdose response in the fentanyl era	INTERNATIONAL JOURNAL OF DRUG POLICY			English	Article						Drug checking; Drug testing; Opioid overdose; Fentanyl; Synthetic opioids; Harm reduction; Overdose epidemic	PSYCHOACTIVE SUBSTANCES; OPIOID OVERDOSE; PILL; HEROIN	Adulteration of illicit drug supplies with synthetic opioids such as fentanyl has contributed to a dramatic rise in overdose morbidity and mortality in North America. One promising response to this crisis is the implementation of "drug checking" services. Drug checking encompasses a range of interventions used to assess the constituents of illicit drug samples, such as colour-spot testing, gas or liquid chromatography, and various methods of spectroscopy. Testing may be performed on-site at events or harm reduction service locales, performed independently by consumers, or sent to a centralized lab for analysis. This information may then serve to inform individual decision-making, enhance harm reduction efforts and strengthen public health surveillance and response strategies to prevent harms associated with illicit drug use. Historical examples of drug checking services that emerged with the 1990s synthetic "party drug" movement in Europe provide a theoretical and practical basis for the adaptation of these services for use in context of the current opioid overdose crisis. Potential harm reduction benefits of drug checking for synthetic opioid adulterants include individuals being more likely to use drugs more safely or to dispose of drugs found to contain harmful adulterants. Public health benefits of drug checking may also include negative feedback on the illicit drug supply with decreased availability or consumption of drugs from sources adulterated with synthetic opioids following public health warning campaigns. As part of the response to the current synthetic opioid epidemic in BC, pilot efforts are being undertaken in Vancouver to determine the feasibility and effectiveness of drug checking as an overdose response strategy. Models of drug checking service delivery and comparison of differing technologies, including unique challenges and potential solutions related to access to these services, legal obstacles, and sensitivity and specificity of testing technologies, are explored, alongside suggestions for future research and directions.	[Laing, Matthew K.; Fairbairn, Nadia] Univ British Columbia, Dept Med, Vancouver, BC, Canada; [Laing, Matthew K.; Tupper, Kenneth W.; Fairbairn, Nadia] British Columbia Ctr Subst Use, 1045 Howe St, Vancouver, BC V6Z 2A9, Canada; [Tupper, Kenneth W.] Univ British Columbia, Sch Populat & Publ Hlth, Vancouver, BC, Canada	Fairbairn, N (reprint author), Univ British Columbia, St Pauls Hosp, British Columbia Ctr Subst Use, 608-1081 Burrard St, Vancouver, BC V6Z 1Y6, Canada.	nadia.fairbaim@bccsu.ubc.ca			Michael Smith Foundation for Health Research/St. Paul's Foundation Scholar Award; Health Canada for a Substance Use and Addictions Program grant	The authors wish to thank Chiarine Hsu for her administrative assistance. We would also like to express our sincere thanks to the reviewers of our paper for their thoughtful suggestions. Dr. Nadia Fairbairn is supported by a Michael Smith Foundation for Health Research/St. Paul's Foundation Scholar Award. Dr. Kenneth Tupper wishes to acknowledge Health Canada for a Substance Use and Addictions Program grant to the BC Centre on Substance Use to implement and evaluate a drug checking pilot in British Columbia. Funding agencies had no role in the research, design, or writing of the manuscript, nor did they have a role in the decision to submit the paper for publication.	Adhopia Vik, 2017, CBC NEWS; Barker-Williams R., 2017, DRUG CONSUMPTION ROO; Barratt M. J., 2018, DRUG POLICY MODELLIN; Barratt MJ, 2016, ADDICTION, V111, P558, DOI 10.1111/add.13194; Bohannon J., 2005, SCIENTIST; British Columbia Centre for Disease Control, 2017, OP OV EM INF; British Columbia Coroners Service, 2018, ILL DRUG OV DEATHS B; British Columbia Ministry of Mental Health and Addictions, 2018, RESP BCS ILL DRUG OV; Brunt TM, 2017, DRUG TEST ANAL, V9, P188, DOI 10.1002/dta.1954; Brunt TM, 2011, DRUG TEST ANAL, V3, P621, DOI 10.1002/dta.323; Bryksa J., 2016, WINNIPEG FREE P 1026; Busardo FP, 2016, J ANAL TOXICOL, V40, P561, DOI 10.1093/jat/bkw051; Butterfield RJ, 2016, MED J AUSTRALIA, V204, P144, DOI 10.5694/mja15.01058; Camilleri AM, 2005, FORENSIC SCI INT, V151, P53, DOI 10.1016/j.forsciint.2004.07.004; Caul S., 2018, DRUG RELATED DEATHS; Crawford T., 2018, VANCOUVER SUN   0602; DanceSafe, 2018, DRUG CHECK; Daniulaityte R., 2017, OVERDOSE DEATHS RELA; Ellis E., 2015, VANCOUVER SUN   0708; Giraudon I, 2007, SUBST USE MISUSE, V42, P1567, DOI 10.1080/10826080701212428; Global Commission on Drug Policy, 2017, OP CRIS N AM POS PAP; Gomez M., 2015, ELECT FOREST SHUTS D; Harper L, 2017, HARM REDUCT J, V14, DOI 10.1186/s12954-017-0179-5; Hempstead K, 2014, HEALTH ECON, V23, P688, DOI 10.1002/hec.2937; Hungerbuehler I, 2011, HARM REDUCT J, V8, DOI 10.1186/1477-7517-8-16; ICaramouzian M., 2018, HARM REDUCT J, V15, P46, DOI [10.1186/s12954-018-0252-8, DOI 10.1186/S12954-018-0252-8]; Keijsers L, 2008, HEALTH RISK SOC, V10, P283, DOI 10.1080/13698570802160913; Kenyon SL, 2005, THER DRUG MONIT, V27, P793, DOI 10.1097/01.ftd.0000180227.04137.3c; Korf D., 2002, PILL TESTING ECSTASY; Kriener H., 2002, MONOGRAPH TURNING PO; Lupick T., 2018, GEORGIA STRAIGH 0510; Martins D, 2017, HUM PSYCHOPHARM CLIN, V32, DOI 10.1002/hup.2608; McElroy Justin, 2017, CBC NEWS; McGowan CR, 2018, INT J DRUG POLICY, V58, P31, DOI 10.1016/j.drugpo.2018.04.017; Measham F., 2017, 10 INT C NIGHTL SUBS; Mooney H., 2017, VANCOUVER SUN   0811; Ostermann KM, 2014, CLIN CHIM ACTA, V433, P254, DOI 10.1016/j.cca.2014.03.013; Pirona A, 2017, INT J DRUG POLICY, V40, P84, DOI 10.1016/j.drugpo.2016.10.004; POKLIS A, 1995, J TOXICOL-CLIN TOXIC, V33, P439, DOI 10.3109/15563659509013752; Quintana P, 2017, INT J DRUG POLICY, V40, P78, DOI 10.1016/j.drugpo.2016.10.006; Reynolds L, 2004, PAIN, V110, P182, DOI 10.1016/j.pain.2004.03.024; Rudd RA, 2016, AM J TRANSPLANT, V16, P1323, DOI 10.1111/ajt.13776; Sage C, 2015, HARM REDUCTION DRUG; Sage C, 2016, DRUG CHECKING MUSIC; Schroers A, 2002, J DRUG ISSUES, V32, P635, DOI 10.1177/002204260203200219; Seth P., 2018, OVERDOSE DEATHS INVO; Soukup-Baljak Y, 2015, INT J DRUG POLICY, V26, P1251, DOI 10.1016/j.drugpo.2015.06.006; Spruit IP, 2001, SUBST USE MISUSE, V36, P23, DOI 10.1081/JA-100000227; Stogner JM, 2014, ANN EMERG MED, V64, P637, DOI 10.1016/j.annemergmed.2014.07.017; Sutter ME, 2017, ACAD EMERG MED, V24, P106, DOI 10.1111/acem.13034; Trans European Drug Information (TEDI), 2011, FACTSH DRUG CHECK EU; Tupper K., 2017, VANCOUVER SUN   0811; Tupper KW, 2018, DRUG ALCOHOL DEPEN, V190, P242, DOI 10.1016/j.drugalcdep.2018.06.020; Gine CV, 2017, INT J DRUG POLICY, V45, P46, DOI 10.1016/j.drugpo.2017.05.018; Winstock AR, 2001, ADDICTION, V96, P1139, DOI 10.1046/j.1360-0443.2001.96811397.x; Woo A., 2016, GLOBE MAIL; Woo A, 2017, GLOBE MAIL; Yuzda L., 2018, GLOBAL NEWS     0523	58	9	9	5	14	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0955-3959	1873-4758		INT J DRUG POLICY	Int. J. Drug Policy	DEC	2018	62						59	66		10.1016/j.drugpo.2018.10.001			8	Substance Abuse	Substance Abuse	HF6UQ	WOS:000454374200008	30359874				2020-06-30	J	Yang, PF; Links, DJR; Petrovski, J				Yang, Phillip F.; Links, David J. R.; Petrovski, Johnny			Anesthetic Considerations for Ivor-Lewis Esophagectomy in a Patient With Hereditary Spastic Paraplegia: A Case Report	A & A PRACTICE			English	Article							STRUMPELL-LORRAIN DISEASE; PARAPARESIS; OUTCOMES; STATES	Hereditary spastic paraplegia (HSP), also known as familial spastic paraparesis or Strumpell-Lorrain disease, is a rare group of inherited disorders characterized by progressive spastic weakness in the lower limbs due to axonal degeneration of the corticospinal tracts. We describe the anesthetic management of a 52-year-old man with HSP who underwent an Ivor-Lewis esophagectomy for esophageal adenocarcinoma. This is the first report in the literature describing the anesthetic management of a patient with HSP successfully undergoing complex thoracoabdominal surgery. Key to the provision of postoperative analgesia was the intraoperative placement of catheters in the right thoracic paravertebral space and retro-rectus plane for continuous infusion of ropivacaine 0.2% for 3 days, as well as a fentanyl patient-controlled analgesia for 7 days.	[Yang, Phillip F.; Links, David J. R.] Prince Wales Hosp, Dept Surg, Sydney, NSW, Australia; [Yang, Phillip F.] Univ New South Wales, Sydney, NSW, Australia; [Petrovski, Johnny] Prince Wales Hosp, Dept Anaesthet, Sydney, NSW, Australia	Yang, PF (reprint author), Prince Wales Hosp, Dept Surg, Barker St, Randwick, NSW 2031, Australia.	p.yang@unsw.edu.au		Yang, Phillip/0000-0002-6610-1758			Franco-Hernandez JA, 2013, REV BRAS ANESTESIOL, V63, P113, DOI [10.1016/S0034-7094(13)70203-4, 10.1016/j.bjane.2012.05.002]; Connors RC, 2007, J AM COLL SURGEONS, V205, P735, DOI 10.1016/j.jamcollsurg.2007.07.001; Dallman M, 2010, INT STUD J NURSE ANE, V9, P28; Deruddre S, 2006, ANESTH ANALG, V102, P1910, DOI 10.1213/01.ANE.0000215148.29795.70; Fink JK, 2006, CURR NEUROL NEUROSCI, V6, P65, DOI 10.1007/s11910-996-0011-1; Fuchs HF, 2017, SURG ENDOSC, V31, P2491, DOI 10.1007/s00464-016-5251-9; Guinan EM, 2017, DIS ESOPHAGUS, V30, DOI 10.1111/dote.12514; Jellish WS, 2000, ANESTH ANALG, V91, P1250; Martyn JAJ, 2006, ANESTHESIOLOGY, V104, P158, DOI 10.1097/00000542-200601000-00022; Mc Monagle P, 2002, J NEUROL NEUROSUR PS, V72, P43, DOI 10.1136/jnnp.72.1.43; McIver T, 2007, INT J OBSTET ANESTH, V16, P190, DOI 10.1016/j.ijoa.2006.11.002; McTiernan C, 1999, CAN J ANAESTH, V46, P679, DOI 10.1007/BF03013958; Munasinghe A, 2015, ANN SURG, V262, P79, DOI 10.1097/SLA.0000000000000805; Ponsonnard S, 2017, EUR J ANAESTH, V34, P562, DOI 10.1097/EJA.0000000000000615; Sedel F, 2007, J INHERIT METAB DIS, V30, P855, DOI 10.1007/s10545-007-0745-1; Thomas I, 2006, INT J OBSTET ANESTH, V15, P254, DOI 10.1016/j.ijoa.2006.01.002	16	0	0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2325-7237			A A PRACT	A A Pract.	DEC 1	2018	11	11					296	298		10.1213/XAA.0000000000000811			3	Anesthesiology	Anesthesiology	HD6TD	WOS:000452679700002	29851689	Bronze			2020-06-30	J	Blachman-Forshay, J; Nolan, ML; McAteer, JM; Paone, D				Blachman-Forshay, Jaclyn; Nolan, Michelle L.; McAteer, Jonathan M.; Paone, Denise			Estimating the Risk of Exposure to Fentanyl in New York City: Testing Drug Residue in Used Syringes	AMERICAN JOURNAL OF PUBLIC HEALTH			English	Article							OVERDOSE DEATHS; INCREASES	Objectives. To estimate the risk of exposure to fentanyl among syringe exchange program (SEP) participants in New York City. Methods. We recruited a convenience sample from 11 SEPs in New York City between March and June 2017. Consenting participants (n = 434) received a labeled syringe for their next injection. We tested collected syringes with gas chromatography-mass spectrometry and liquid chromatography-quadrupole-time-of-flight mass spectrometry. Fentanyl or fentanyl analogs detected in quantities greater than 10% of the residue mass were reported. Results. The Final analysis included 271 syringes; 46 (17.0%) contained Fentanyl or a fentanyl analog. Fentanyl was the most frequently identified fentanyl compound, identified in 36 (13.3%) syringes. Furanyl-fentanyl was detected in 10 (3.7%) syringes, and 4-fluoroisobutyryl Fentanyl was detected in 5 (1.8%) syringes. Conclusions. The risk of exposure to fentanyl in syringes used by SEP participants was significantly lower significantly lower than the amount of fentanyls identified among overdose decedents in New York City. Further research is needed to understand how people who use drugs have adapted to fentanyl in the drug market. Understanding the risk of exposure to fentanyls is critical to development of targeted public health messaging.	[Blachman-Forshay, Jaclyn; Nolan, Michelle L.; McAteer, Jonathan M.; Paone, Denise] New York City Dept Hlth & Mental Hyg, Bur Alcohol & Drug Use Prevent Care & Treatment, Queens, NY USA	Paone, D (reprint author), NYC Dept Hlth & Mental Hyg, 42-09 28th St,19th Floor,CN-14, Queens, NY 11101 USA.	dpaone@health.nyc.gov		Nolan, Michelle/0000-0003-1951-4151	Office of the Assistant Secretary for Planning and Evaluation	Funding for this study was provided by the Office of the Assistant Secretary for Planning and Evaluation.	Drug Enforcement Administration (DEA) Department of Justice, 2008, Fed Regist, V73, P43355; Griswold MK, 2018, CLIN TOXICOL, V56, P37, DOI 10.1080/15563650.2017.1339889; Knopf A., 2016, ALCOHOLISM DRUG ABUS, V28, P1, DOI DOI 10.1002/adaw.30537; Lefrancois E, 2016, FORENSIC SCI INT, V266, P534, DOI 10.1016/j.forsciint.2016.07.021; Nefau T, 2015, INT J DRUG POLICY, V26, P412, DOI 10.1016/j.drugpo.2014.09.010; New York City Department of Health and Mental Hygiene, 2018, PROVISIONAL DATA REP; New York City Department of Health and Mental Hygiene, 2017, 2017 ADVISORY 10 PRE; Peterfi A, 2018, DRUG TEST ANAL, V10, P357, DOI 10.1002/dta.2217; Peterson AB, 2016, MMWR-MORBID MORTAL W, V65, P844, DOI 10.15585/mmwr.mm6533a3; Rudd RA, 2016, MMWR-MORBID MORTAL W, V64, P1378, DOI 10.15585/mmwr.mm6450a3; Somerville NJ, 2017, MMWR-MORBID MORTAL W, V66, P382, DOI 10.15585/mmwr.mm6614a2	11	3	3	0	3	AMER PUBLIC HEALTH ASSOC INC	WASHINGTON	800 I STREET, NW, WASHINGTON, DC 20001-3710 USA	0090-0036	1541-0048		AM J PUBLIC HEALTH	Am. J. Public Health	DEC	2018	108	12					1666	1668		10.2105/AJPH.2018.304694			3	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	GZ6RK	WOS:000449568900031	30359110				2020-06-30	J	Azar, P; Nikoo, M; Miles, I				Azar, Pouya; Nikoo, Mohammadali; Miles, Isabelle			Methadone to buprenorphine/naloxone induction without withdrawal utilizing transdermal fentanyl bridge in an inpatient setting-Azar method	AMERICAN JOURNAL ON ADDICTIONS			English	Article							MAINTENANCE TREATMENT; CONVERSION RATIOS; MORTALITY; PAIN	Background and Objectives Methods Although buprenorphine/naloxone is widely recognized as first-line therapy for opioid use disorder, the requirement for moderate withdrawal prior to initiation in efforts to avoid precipitated withdrawal can be a barrier to its initiation. We present a case utilizing transdermal fentanyl as a bridging treatment to eliminate withdrawal during the transition from methadone to buprenorphine/naloxone in a patient who had ongoing significant intravenous heroin use while on methadone. Results Discussion and Conclusions Patient was successfully transitioned from methadone to buprenorphine/naloxone without a period of withdrawal utilizing transdermal fentanyl as a bridge in an inpatient setting. Our experience indicates a transdermal depot of fentanyl allows for slow release and elimination while buprenorphine doses are introduced during an induction without presence of withdrawal, as quantified by serial clinical opiate withdrawal score. Scientific Significance This case report highlights ways to minimize barriers to induction of first-line opioid substitution therapy, buprenorphine/naloxone, by eliminating withdrawal during induction phase utilizing a fentanyl bridge within the limitations of a transdermal fentanyl bridge in an inpatient setting. (Am J Addict 2018;XX:1-4)	[Azar, Pouya] St Pauls Hosp, Vancouver, BC, Canada; [Azar, Pouya] Vancouver Gen Hosp, Vancouver, BC, Canada; [Azar, Pouya] Inner City Youth, Vancouver, BC, Canada; [Nikoo, Mohammadali] Univ British Columbia, Inst Mental Hlth, Addict & Concurrent Disorders Grp, Vancouver, BC, Canada; [Miles, Isabelle] Univ Ottawa, Ottawa, ON, Canada	Azar, P (reprint author), Vancouver Gen Hosp, DHCC, Floor 8-2775 Laurel St, Vancouver, BC V5Z 1M9, Canada.	pazar@providencehealth.bc.ca					American Society of Addiction Medicine, ASAM NAT PRACT GUID; [Anonymous], GUID CLIN MAN OP US; British Columbia Coroners Office, 2017, ILL DRUG OV DEATHS B; Clausen T, 2008, DRUG ALCOHOL DEPEN, V94, P151, DOI 10.1016/j.drugalcdep.2007.11.003; Daniulaityte R, 2015, AM J ADDICTION, V24, P403, DOI 10.1111/ajad.12213; Gowing L, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004145.pub3; Hess M, 2011, AM J ADDICTION, V20, P480, DOI 10.1111/j.1521-0391.2011.00159.x; Hser YI, 2016, ADDICTION, V111, P695, DOI 10.1111/add.13238; Kornfeld H, 2015, AM J THER, V22, P199, DOI 10.1097/MJT.0b013e31828bfb6e; Mattick RP, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002207.pub4; Mattick RP, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002209.pub2; Mercadante S, 2011, PALLIATIVE MED, V25, P504, DOI 10.1177/0269216311406577; Nolan S, 2015, DRUG ALCOHOL DEPEN, V156, P57, DOI 10.1016/j.drugalcdep.2015.08.037; Pollock AB, 2011, AM J HOSP PALLIAT ME, V28, P135, DOI 10.1177/1049909110373508; Spring B., 2007, VCH COMMUNITY PALLIA; Volpe DA, 2011, REGUL TOXICOL PHARM, V59, P385, DOI 10.1016/j.yrtph.2010.12.007; Weschules DJ, 2008, PAIN MED, V9, P595, DOI 10.1111/j.1526-4637.2008.00461.x; Wesson DR, 2003, J PSYCHOACTIVE DRUGS, V35, P253, DOI 10.1080/02791072.2003.10400007	18	4	4	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1055-0496	1521-0391		AM J ADDICTION	Am. J. Addict.	DEC	2018	27	8					601	604		10.1111/ajad.12809			4	Substance Abuse	Substance Abuse	HD0WJ	WOS:000452229700001	30387894				2020-06-30	J	Kessler, M; Mamach, M; Beutelmann, R; Bankstahl, JP; Bengel, FM; Klump, GM; Berding, G				Kessler, M.; Mamach, M.; Beutelmann, R.; Bankstahl, J. P.; Bengel, F. M.; Klump, G. M.; Berding, Georg			Activation in the auditory pathway of the gerbil studied with F-18-FDG PET: effects of anesthesia	BRAIN STRUCTURE & FUNCTION			English	Article						Positron emission tomography; Fluorodeoxyglucose; Anesthesia; Mongolian gerbil; Auditory system; Inferior colliculus	POSITRON-EMISSION-TOMOGRAPHY; MONGOLIAN GERBIL; MERIONES-UNGUICULATUS; INFERIOR COLLICULUS; FUNCTIONAL-ORGANIZATION; CORTEX ACTIVITY; BRAIN; SYSTEM; FREQUENCY; REPRESENTATION	Here, we present results from an F-18-fluorodeoxyglucose (F-18-FDG) positron emission tomography (PET) study in the Mongolian gerbil, a preferred animal model in auditory research. One major issue in preclinical nuclear imaging, as well as in most of the neurophysiological methods investigating auditory processing, is the need of anesthesia. We compared the usability of two types of anesthesia which are frequently employed in electrophysiology, ketamine/xylazine (KX), and fentanyl/midazolam/medetomidine (FMM), for valid measurements of auditory activation with F-18-FDG PET. Gerbils were placed in a sound-shielding box and injected with F-18-FDG. Two acoustic free-field conditions were used: (1) baseline (no stimulation, 25 dB background noise) and (2) 90 dB frequency-modulated tones (FM). After 40min of F-18-FDG uptake, a 30min acquisition was performed using a small animal PET/CT system. Blood glucose levels were measured after the uptake phase before scanning. Standardized uptake value ratios for relevant regions were determined after implementing image and volume of interest templates. Scans demonstrated a significantly higher uptake in the inferior colliculus with FM stimulation compared to baseline in awake subjects (+12%; p=0.02) and with FMM anesthesia (+13%; p=0.0012), but not with KX anesthesia. In non-auditory brain regions, no significant difference was detected. Blood glucose levels were significantly higher under KX compared to FMM anesthesia (17.29 +/- 0.42mmol/l vs. 14.30 +/- 1.91mmol/l; p=0.024). These results suggest that valid F-18-FDG PET measurements of auditory activation comparable to electrophysiology can be obtained from gerbils during opioid-based anesthesia due to its limited effects on interfering blood glucose levels.	[Kessler, M.; Mamach, M.; Bankstahl, J. P.; Bengel, F. M.; Berding, Georg] Hannover Med Sch, Dept Nucl Med, Carl Neuberg Str 1, D-30625 Hannover, Germany; [Kessler, M.; Mamach, M.; Beutelmann, R.; Klump, G. M.; Berding, Georg] Carl von Ossietzky Univ Oldenburg, Cluster Excellence Hearing4all, Oldenburg, Germany; [Mamach, M.] Hannover Med Sch, Dept Med Phys & Radiat Protect, Carl Neuberg Str 1, D-30625 Hannover, Germany; [Beutelmann, R.; Klump, G. M.] Carl von Ossietzky Univ Oldenburg, Sch Med & Hlth Sci, Dept Neurosci, Div Anim Physiol, Carl von Ossietzky Str 9-11, D-26129 Oldenburg, Germany; [Beutelmann, R.; Klump, G. M.] Carl von Ossietzky Univ Oldenburg, Sch Med & Hlth Sci, Dept Neurosci, Behav Grp, Carl von Ossietzky Str 9-11, D-26129 Oldenburg, Germany	Berding, G (reprint author), Hannover Med Sch, Dept Nucl Med, Carl Neuberg Str 1, D-30625 Hannover, Germany.; Berding, G (reprint author), Carl von Ossietzky Univ Oldenburg, Cluster Excellence Hearing4all, Oldenburg, Germany.	Berding.Georg@mh-hannover.de		Bengel, Frank/0000-0003-4529-7963	Deutsche ForschungsgemeinschaftGerman Research Foundation (DFG) [EXC 1077]	This work was supported by a grant from the Deutsche Forschungsgemeinschaft (EXC 1077). We wish to thank Silvia Eilert, Alexander Kanwischer, and Petra Felsch for their support during the PET scans. We thank Dr. Pablo Bascunana for his comments on a previous version of the manuscript.	Alan RP, 2010, STRUCTURAL ORG ASCEN; Astl J, 1996, AUDIOLOGY, V35, P335; Bauerle P, 2011, J NEUROSCI, V31, P9708, DOI 10.1523/JNEUROSCI.5814-10.2011; Belliveau LAC, 2014, J NEUROSCI, V34, P16796, DOI 10.1523/JNEUROSCI.2432-14.2014; Berding G, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128743; Berti V, 2014, PET CLIN, V9, P129, DOI 10.1016/j.cpet.2013.10.006; Bizley JK, 2009, J NEUROSCI, V29, P2064, DOI 10.1523/JNEUROSCI.4755-08.2009; Bonhomme V, 2011, CURR OPIN ANESTHESIO, V24, P474, DOI 10.1097/ACO.0b013e32834a12a1; Brown ET, 2005, VISUAL NEUROSCI, V22, P615, DOI 10.1017/S0952523805225105; Budinger E, 2000, EUR J NEUROSCI, V12, P2452, DOI 10.1046/j.1460-9568.2000.00143.x; Budinger E, 2000, EUR J NEUROSCI, V12, P2425, DOI 10.1046/j.1460-9568.2000.00142.x; Cant NB, 2008, NEUROSCIENCE, V154, P206, DOI 10.1016/j.neuroscience.2008.02.015; Cant NB, 2005, HEARING RES, V206, P12, DOI 10.1016/j.heares.2005.02.014; CATALANAHUMADA M, 1993, BRAIN RES, V623, P287, DOI 10.1016/0006-8993(93)91439-Y; Chatziioannou Arion F, 2005, Proc Am Thorac Soc, V2, P533, DOI 10.1513/pats.200508-079DS; CHEAL M, 1986, EXP AGING RES, V12, P3, DOI 10.1080/03610738608259430; Coez A, 2009, NEUROIMAGE, V47, P1792, DOI 10.1016/j.neuroimage.2009.05.053; Constantinescu CC, 2009, PHYS MED BIOL, V54, P2885, DOI 10.1088/0031-9155/54/9/020; Dunn JT, 2009, J CEREBR BLOOD F MET, V29, P1059, DOI 10.1038/jcbfm.2009.21; ELMOTAL SMA, 1985, ENDOCRINOLOGY, V116, P2337, DOI 10.1210/endo-116-6-2337; FINK BR, 1973, ANESTHESIOLOGY, V39, P199, DOI 10.1097/00000542-197308000-00011; Geven LI, 2014, NEUROSCIENCE, V256, P117, DOI 10.1016/j.neuroscience.2013.10.015; Giraud AL, 2000, BRAIN, V123, P1391, DOI 10.1093/brain/123.7.1391; Gleich O, 2002, HEARING RES, V164, P166, DOI 10.1016/S0378-5955(01)00430-0; Grana GD, 2017, J COMP NEUROL, V525, P2050, DOI 10.1002/cne.24155; Green K M J, 2011, Cochlear Implants Int, V12, P3, DOI 10.1179/146701010X486507; Grothe B, 2010, PHYSIOL REV, V90, P983, DOI 10.1152/physrev.00026.2009; Hamann I, 2002, HEARING RES, V171, P82, DOI 10.1016/S0378-5955(02)00454-9; Hromadka T, 2009, CURR OPIN NEUROBIOL, V19, P430, DOI 10.1016/j.conb.2009.07.009; Hsu WC, 2009, ACTA OTO-LARYNGOL, V129, P423, DOI 10.1080/00016480802593497; Huang SC, 2000, NUCL MED BIOL, V27, P643; Huet A, 2016, HEARING RES, V338, P32, DOI 10.1016/j.heares.2016.05.006; ISHIZU K, 1994, J NUCL MED, V35, P1104; Jang DP, 2012, NEUROREPORT, V23, P228, DOI 10.1097/WNR.0b013e32835022c7; Johnsrude IS, 2002, AUDIOL NEURO-OTOL, V7, P251, DOI 10.1159/000064446; Kilbourn MR, 2017, SEMIN NUCL MED, V47, P536, DOI 10.1053/j.semnuclmed.2017.05.005; Knoop BO, 2002, PHYS MED BIOL, V47, P1237, DOI 10.1088/0031-9155/47/8/302; Langguth B, 2006, ACTA OTO-LARYNGOL, V126, P84, DOI 10.1080/03655230600895317; Lee JS, 2003, J NUCL MED, V44, P1435; Lesica NA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001655; Lesica NA, 2008, J NEUROSCI, V28, P5412, DOI 10.1523/JNEUROSCI.0073-08.2008; Meyer AF, 2014, FRONT COMPUT NEUROSC, V8, P1, DOI 10.3389/fncom.2014.00165; Meyer AF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093062; MILLS JH, 1990, HEARING RES, V46, P201, DOI 10.1016/0378-5955(90)90002-7; Nelken I, 2004, CURR OPIN NEUROBIOL, V14, P474, DOI 10.1016/j.conb.2004.06.005; Ohl FW, 2000, J PHYSIOLOGY-PARIS, V94, P549, DOI 10.1016/S0928-4257(00)01091-3; Okuda T, 2013, ORL J OTO-RHINO-LARY, V75, P342, DOI 10.1159/000357474; Osmanski MS, 2015, BRAIN TOPOGR, V28, P365, DOI 10.1007/s10548-015-0428-4; Pachitariu M, 2015, J NEUROSCI, V35, P2058, DOI 10.1523/JNEUROSCI.3318-14.2015; Palmer AR, 2013, J PHYSIOL-LONDON, V591, P4003, DOI 10.1113/jphysiol.2013.255943; Palmer AR, 2000, J NEUROPHYSIOL, V84, P844; Radtke-Schuller S, 2016, BRAIN STRUCT FUNCT, V221, P1, DOI 10.1007/s00429-016-1259-0; RAUSCHECKER JP, 1995, SCIENCE, V268, P111, DOI 10.1126/science.7701330; Riemann B, 2008, Q J NUCL MED MOL IM, V52, P215; RYAN A, 1976, J ACOUST SOC AM, V59, P1222, DOI 10.1121/1.380961; RYAN AF, 1982, J COMP NEUROL, V207, P369, DOI 10.1002/cne.902070408; Saha JK, 2005, EXP BIOL MED, V230, P777, DOI 10.1177/153537020523001012; Sanes DH, 1998, J NEUROSCI, V18, P794; SCHEICH H, 1993, EUR J NEUROSCI, V5, P898, DOI 10.1111/j.1460-9568.1993.tb00941.x; SCHEICH H, 1995, BEHAV BRAIN RES, V66, P195, DOI 10.1016/0166-4328(94)00140-B; Schmidt KC, 2005, NUCL MED BIOL, V32, P719, DOI 10.1016/j.nucmedbio.2005.04.020; Schmiedt RA, 1996, J NEUROPHYSIOL, V76, P2799; SCHWENDER D, 1993, BRIT J ANAESTH, V71, P622, DOI 10.1093/bja/71.5.622; Shamma S, 2014, CURR OPIN NEUROBIOL, V25, P164, DOI 10.1016/j.conb.2014.01.011; SHARP FR, 1981, BRAIN RES, V230, P87, DOI 10.1016/0006-8993(81)90393-0; Siikanen J, 2015, AM J NUCL MED MOLEC, V5, P270; Sinnott Joan M., 2003, Ear and Hearing, V24, P30, DOI 10.1097/01.AUD.0000051747.58107.89; Toyama H, 2004, NUCL MED BIOL, V31, P251, DOI 10.1016/S0969-8051(03)00124-0; Tucci DL, 1999, LARYNGOSCOPE, V109, P1359, DOI 10.1097/00005537-199909000-00001; Walker KMM, 2011, J NEUROSCI, V31, P14565, DOI 10.1523/JNEUROSCI.2074-11.2011; WANG ZX, 1987, HEARING RES, V27, P145; Willmore BDB, 2009, CURR BIOL, V19, pR1123, DOI 10.1016/j.cub.2009.11.003; Yu X, 2005, NAT NEUROSCI, V8, P961, DOI 10.1038/nn1477	73	1	1	0	7	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	1863-2653	1863-2661		BRAIN STRUCT FUNCT	Brain Struct. Funct.	DEC	2018	223	9					4293	4305		10.1007/s00429-018-1743-9			13	Anatomy & Morphology; Neurosciences	Anatomy & Morphology; Neurosciences & Neurology	HB4XR	WOS:000451061700023	30203305				2020-06-30	J	Mema, SC; Sage, C; Xu, YH; Tupper, KW; Ziemianowicz, D; McCrae, K; Leigh, M; Munn, MB; Taylor, D; Corneil, T				Mema, Silvina C.; Sage, Chloe; Xu, Yuhui; Tupper, Kenneth W.; Ziemianowicz, Daniel; McCrae, Karen; Leigh, Mark; Munn, Matthew Brendan; Taylor, Deanne; Corneil, Trevor			Drug checking at an electronic dance music festival during the public health overdose emergency in British Columbia	CANADIAN JOURNAL OF PUBLIC HEALTH-REVUE CANADIENNE DE SANTE PUBLIQUE			English	Article						Electinnic music festival; Drug checking; Fentanyl		Setting Shambhala is a 5-day electronic dance music (EDM) festival held in rural British Columbia that annually hosts between 15,000 and 18,000 people on a 500-acre ranch. The AIDS Network Outreach & Support Society (ANKORS) has provided harm reduction services throughout the duration of the festival since 2003, including point-of-care drug checking, which allows real-time testing of illicit substances to assess their composition. Drug checking results are provided directly to clients and displayed in aggrogate on a screen for all attendees to see. Intervention In 2017, ANKORS added fentanyl checking to their repertoire of drug checking technologies for festivalgoers. Volunteers used a brief survey to collect information on what clients expected the samples to contain. Volunteers carried out drug checks and subsequently logged test results. ANKORS provided an amnesty bin at the tent for clients who chose to discard their substances. Outcomes Of the 2683 surveys, 2387 included data on both the client's belief and the actual test result. Clients were more likely to discard when the test result differed from their belief (5.16%) than when their belief was confirmed (0.69%). Discarding increased to 15.54% when the test could not clearly identify a substance and to 30.77% if the client did not have a prior belief of the substance. Of 1971 samples tested for fentanyl, 31 tested positive and 16.13% of clients discarded compared to 2.63% in the negative group. Implications Drug checking services appeal to festivalgoers who, when faced with uncertainty, may discard their substances. This innovative harm reduction service allows for a personalized risk discussion, potentially reaching others via word-of-mouth and early warning systems.	[Mema, Silvina C.; Xu, Yuhui; Taylor, Deanne; Corneil, Trevor] Interior Hlth Author, 505 Doyle Ave, Kelowna, BC V1Y 6V8, Canada; [Mema, Silvina C.; Tupper, Kenneth W.; Corneil, Trevor] Univ British Columbia, Sch Populat & Publ Hlth, Vancouver, BC, Canada; [Sage, Chloe; Ziemianowicz, Daniel; Leigh, Mark] AIDS Network Outreach & Support Soc ANKORS, Nelson, BC, Canada; [Tupper, Kenneth W.; McCrae, Karen] British Columbia Ctr Subst Use, Vancouver, BC, Canada; [Munn, Matthew Brendan] Univ British Columbia, Dept Emergency Med, Vancouver, BC, Canada; [Taylor, Deanne] Univ British Columbia, Fac Hlth & Social Dev, Vancouver, BC, Canada	Mema, SC (reprint author), Interior Hlth Author, 505 Doyle Ave, Kelowna, BC V1Y 6V8, Canada.; Mema, SC (reprint author), Univ British Columbia, Sch Populat & Publ Hlth, Vancouver, BC, Canada.	Silvina.Mema@interiorhealth.ca					[Anonymous], 2016, CBC NEWS; Chloe Sage, DRUG CHECKING MUSIC; Coroners Service, 2018, ILL DRUG OV DEATHS B; Kerr T, 2017, DRUG CHECKING HARM R; Krieger MS, 2018, HARM REDUCT J, V15, DOI 10.1186/s12954-018-0213-2; Mohr ALA, 2018, FORENSIC SCI INT, V282, P168, DOI 10.1016/j.forsciint.2017.11.017; Tupper KW, 2018, DRUG ALCOHOL DEPEN, V190, P242, DOI 10.1016/j.drugalcdep.2018.06.020	7	5	5	3	10	SPRINGER INTERNATIONAL PUBLISHING AG	CHAM	GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND	0008-4263	1920-7476		CAN J PUBLIC HEALTH	Can. J. Public Health-Rev. Can. Sante Publ.	DEC	2018	109	5-6					740	744		10.17269/s41997-018-0126-6			5	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	HD1IB	WOS:000452262200016	30251119	Green Published			2020-06-30	J	Zuin, M; Rigatelli, G; Roncon, L				Zuin, Marco; Rigatelli, Gianluca; Roncon, Loris			Use of Fentanyl During Percutaneous Coronary Interventions: Safety and Drawbacks	CARDIOVASCULAR DRUGS AND THERAPY			English	Review						Fentanyl; Coronary angiography; Percutaneous coronary intervention; Sedation	RADIAL ARTERY SPASM; MYOCARDIAL PROTECTION; PROCEDURAL SEDATION; TICAGRELOR ABSORPTION; INTRAVENOUS FENTANYL; PLATELET INHIBITION; MILD HYPOTHERMIA; FEMORAL APPROACH; CARDIAC-SURGERY; ANALGESIA	Over the last years, fentanyl, a potent synthetic receptor-stimulating opioid, has become one of the most used drugs for both procedural analgesia and sedation in patients undergoing coronary angiography (CA) and/or percutaneous coronary intervention (PCI). However, few studies have been performed to evaluate the efficacy and the impact of this drug in patients with coronary artery disease (CAD) treated with PCI. Most of the previous studies have investigated the self-reported discomfort pain, demonstrating that patients premedicated with fentanyl generally reported a lower pain/discomfort when compared to placebo, benzodiazepines, or local anesthesia at the site of the artery cannulation, without significant variation in the hemodynamic response. The biochemical properties of fentanyl have been used to prevent the radial arterial spasm, which represents one of the major causes of the access site cross-over during PCI, experienced when radial artery cannulation has failed and successful access can be obtained only switching to an alternative arterial route, as the ulnar or the femoral artery. However, some unresolved problems, as fentanyl-induced hypothermia and delayed absorption of P2Y(12) inhibitors required further investigations.	[Zuin, Marco] Univ Ferrara, Sect Internal & Cardiopulm Med, Ferrara, Italy; [Zuin, Marco; Roncon, Loris] Santa Maria Misericordia Hosp, Dept Cardiol, Viale Tre Martiri 140, I-45100 Rovigo, Italy; [Rigatelli, Gianluca] Santa Maria Misericordia Hosp, Dept Cardiovasc Diag & Endoluminal Intervent, Rovigo, Italy	Roncon, L (reprint author), Santa Maria Misericordia Hosp, Dept Cardiol, Viale Tre Martiri 140, I-45100 Rovigo, Italy.	lorisroncon@gmail.com					Abdel-Wahab M, 2008, J INTERV CARDIOL, V21, P232, DOI 10.1111/j.1540-8183.2008.00355.x; Aminian A, 2013, JACC-CARDIOVASC INTE, V6, P1214, DOI 10.1016/j.jcin.2013.04.026; Ang CK, 2007, INT J CARDIOL, V116, P321, DOI 10.1016/j.ijcard.2006.04.045; Baris S, 2001, CAN J CARDIOL, V17, P277; Barnett ML, 2017, NEW ENGL J MED, V376, P663, DOI 10.1056/NEJMsa1610524; Bauer T, 2015, CATHETER CARDIO INTE, V86, pS8, DOI 10.1002/ccd.25987; Benedict PE, 1999, CIRCULATION, V100, P357; Campelo-Parada F, 2018, J INVASIVE CARDIOL, V30, P262; COMETTAMORINI C, 1992, MOL PHARMACOL, V41, P185; Conway A, 2016, J PERIANESTH NURS, V31, P226, DOI 10.1016/j.jopan.2014.07.016; Conway A, 2015, J CARDIOTHOR VASC AN, V29, P1285, DOI 10.1053/j.jvca.2015.06.002; Coppola John, 2006, J Invasive Cardiol, V18, P155; da Luz VF, 2015, CLIN EXP PHARMACOL P, V42, P1098, DOI 10.1111/1440-1681.12456; Deftereos S, 2013, JACC-CARDIOVASC INTE, V6, P267, DOI 10.1016/j.jcin.2012.11.005; Empey PE, 2012, CRIT CARE MED, V40, P1221, DOI 10.1097/CCM.0b013e31823779f9; Fritz HG, 2005, ANESTH ANALG, V100, P996, DOI 10.1213/01.ANE.0000146517.17910.54; Fulton T R, 2000, Am J Crit Care, V9, P125; Giannopoulos G, 2016, CIRC-CARDIOVASC INTE, V9, DOI 10.1161/CIRCINTERVENTIONS.116.004229; Green SM, 2002, ANN EMERG MED, V39, P433, DOI 10.1067/mem.2002.122770; Gursoy S, 2006, EUR J ANAESTH, V23, P496, DOI 10.1017/S0265021506000172; Hetherington SL, 2009, HEART, V95, P1612, DOI 10.1136/hrt.2009.170233; Hobl EL, 2016, EUR J CLIN INVEST, V46, P7, DOI 10.1111/eci.12550; Ibrahim K, 2018, THROMB HAEMOSTASIS, V118, P1409, DOI 10.1055/s-0038-1666862; Ibrahim K, 2018, CONTEMP CLIN TRIALS, V64, P8, DOI 10.1016/j.cct.2017.11.011; Kato R, 2002, CAN J ANAESTH, V49, P777, DOI 10.1007/BF03017409; Kato R, 2000, BRIT J ANAESTH, V84, P608, DOI 10.1093/bja/84.5.608; Latsios G, 2017, J INTERV CARDIOL, V30, P382, DOI 10.1111/joic.12399; Lavi S, 2014, CAN J CARDIOL, V30, P627, DOI 10.1016/j.cjca.2014.03.034; Levine GN, 2011, J AM COLL CARDIOL, V58, pE44, DOI 10.1016/j.jacc.2011.08.007; McCarthy CP, 2016, AM HEART J, V176, P114, DOI 10.1016/j.ahj.2016.04.004; McEvoy JW, 2018, CIRCULATION, V137, P307, DOI 10.1161/CIRCULATIONAHA.117.031678; Murphy GS, 2009, ANESTH ANALG, V109, P311, DOI 10.1213/ane.0b013e3181a90adc; Myles PS, 2002, ANESTH ANALG, V95, P805, DOI 10.1097/00000539-200210000-00004; Peng PWH, 1999, ANESTHESIOLOGY, V90, P576, DOI 10.1097/00000542-199902000-00034; Rathore S, 2010, JACC-CARDIOVASC INTE, V3, P475, DOI 10.1016/j.jcin.2010.03.009; Shah R, 2018, EUR HEART J, V39, P642, DOI 10.1093/eurheartj/ehy016; Sivilotti MLA, 1998, ANN EMERG MED, V31, P313, DOI 10.1016/S0196-0644(98)70341-5; Stanley TH, 2014, J PAIN, V15, P1215, DOI 10.1016/j.jpain.2014.08.010; Sullivan Kristina R., 2010, CARDIAC INTENSIVE CA, P504; Tatli E, 2018, PERFUSION-UK, V33, P110, DOI 10.1177/0267659117727823; Tomai F, 1999, CIRCULATION, V100, P559, DOI 10.1161/01.CIR.100.5.559; Zakaria S, 2017, EUR HEART J ACUTE CA, V2048872617695231	42	1	1	1	8	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0920-3206	1573-7241		CARDIOVASC DRUG THER	Cardiovasc. Drugs Ther.	DEC	2018	32	6					625	632		10.1007/s10557-018-6835-5			8	Cardiac & Cardiovascular Systems; Pharmacology & Pharmacy	Cardiovascular System & Cardiology; Pharmacology & Pharmacy	HB7UW	WOS:000451287700011	30357518				2020-06-30	J	Mayer, S; Boyd, J; Collins, A; Kennedy, MC; Fairbairn, N; McNeil, R				Mayer, Samara; Boyd, Jade; Collins, Alexandra; Kennedy, Mary Clare; Fairbairn, Nadia; McNeil, Ryan			Characterizing fentanyl-related overdoses and implications for overdose response: Findings from a rapid ethnographic study in Vancouver, Canada	DRUG AND ALCOHOL DEPENDENCE			English	Article						Fentanyl; Overdose; Opioids; Qualitative; Ethnographic	CONTAMINATED HEROIN; EXPOSURE; PEOPLE; HEALTH; STATES; PERCEPTIONS; INCREASES; MORTALITY; RIGIDITY; NALOXONE	Background: North America is experiencing an opioid overdose epidemic, fuelled by the proliferation of fentanyl, related analogues, and fentanyl-adulterated opioids. British Columbia, Canada has similarly experienced a rapid increase in the proportion of opioid overdose deaths associated with fentanyl. This study builds off of research characterizing fentanyl exposure to further explore the presentation of fentanyl use and related overdoses among people who use drugs. Methods: From December 2016 to April 2017, rapid ethnographic fieldwork was conducted in Vancouver, Canada to examine the implementation of low-threshold overdose prevention sites, where people use drugs under the supervision of staff and peers trained to respond to overdose. Data collection included 185 h of ethnographic observation and in-depth interviews with 72 people who inject drugs, 44 of whom reported experiencing an overdose in the year prior to the interviews. Results: While most participants had experienced previous opioid-related overdose, they characterized how fentanyl was markedly distinct in terms of: potency, and rapid onset. Ethnographic observations and participant narratives highlighted how fentanyl use and related overdoses had implications for frontline response, including: rapid onset, multiple concurrent overdoses, body and chest rigidity, and the need to administer larger doses of naloxone. Conclusions: Participant narratives and observational data documented distinct symptoms for fentanyl-attributed overdoses compared to other opioid related overdose events, which had implications for response. Findings may serve to inform best practices in responding to fentanyl-related overdoses including; the provision of oxygen and effective doses of naloxone, and also considerations regarding overdose identification.	[Mayer, Samara; Boyd, Jade; Collins, Alexandra; Kennedy, Mary Clare; Fairbairn, Nadia; McNeil, Ryan] British Columbia Ctr Subst Use, Level 4,1045 Howe St, Vancouver, BC V6Z 2A9, Canada; [Boyd, Jade; Fairbairn, Nadia; McNeil, Ryan] Univ British Columbia, St Pauls Hosp, Dept Med, 608-1081 Burrard St, Vancouver, BC V6Z 1Y6, Canada; [Collins, Alexandra] Simon Fraser Univ, Fac Hlth Sci, 8888 Univ Dr, Burnaby, BC V5A 1S6, Canada; [Kennedy, Mary Clare] Univ British Columbia, Sch Populat & Publ Hlth, 2206 E Mall, Vancouver, BC V6T 1Z3, Canada	McNeil, R (reprint author), British Columbia Ctr Subst Use, Level 4,1045 Howe St, Vancouver, BC V6Z 2A9, Canada.	samara.mayer@bccsu.ubc.ca; jade.boyd@bccsu.ubc.ca; alex.collins@bccsu.ubc.ca; maryclare.kennedy@bccsu.ubc.ca; nadia.fairbairn@bccsu.ubc.ca; ryan.mcneil@bccsu.ubc.ca			Vanier Canada graduate scholarship; Social Sciences & Humanities Research Council; Michael Smith Foundation for Health Research (MSFHR) Scholar AwardMichael Smith Foundation for Health Research; MSFHR Scholar AwardMichael Smith Foundation for Health Research; Canadian Institutes of Health Research New Investigator AwardCanadian Institutes of Health Research (CIHR); United States National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01DA044181]	We would like to thank study participants for their contributions to this research. We also thank current and past staff and peer research assistants at the British Columbia Centre on Substance Use for their research and administrative assistance. AC is supported by a Vanier Canada graduate scholarship. MK is supported by a doctoral fellowship from the Social Sciences & Humanities Research Council. NF is supported by a Michael Smith Foundation for Health Research (MSFHR) Scholar Award. RM is supported by a MSFHR Scholar Award and Canadian Institutes of Health Research New Investigator Award. This study was funded by the United States National Institutes of Health (R01DA044181).	Amlani A, 2015, HARM REDUCT J, V12, DOI 10.1186/s12954-015-0088-4; Burns G, 2016, CLIN TOXICOL, V54, P420, DOI 10.3109/15563650.2016.1157722; Carroll JJ, 2017, INT J DRUG POLICY, V46, P136, DOI 10.1016/j.drugpo.2017.05.023; Ciccarone D, 2017, INT J DRUG POLICY, V46, P146, DOI 10.1016/j.drugpo.2017.06.004; Ciccarone D, 2017, INT J DRUG POLICY, V46, P107, DOI 10.1016/j.drugpo.2017.06.010; Dart RC, 2015, NEW ENGL J MED, V372, P241, DOI [10.1056/NEJMc1501822, 10.1056/NEJMsa1406143]; Fairbairn N, 2017, INT J DRUG POLICY, V46, P172, DOI 10.1016/j.drugpo.2017.06.005; Gladden RM, 2016, MMWR-MORBID MORTAL W, V65, P837, DOI 10.15585/mmwr.mm6533a2; Government of Canada, 2018, NAT REP APP OP REL D; Green TC, 2016, JAMA INTERN MED, V176, P1555, DOI 10.1001/jamainternmed.2016.4310; Handwerker P., 2001, QUICK ETHNOGRAPHY GU; Hayashi K, 2018, DRUG ALCOHOL DEPEN, V183, P1, DOI 10.1016/j.drugalcdep.2017.10.020; Hedegaard H, 2017, DRUG OVERDOSE DEATHS, P1999; Irvine MA, 2018, LANCET PUBLIC HEALTH, V3, pE218, DOI 10.1016/S2468-2667(18)30044-6; Johnson GA, 2017, SOC SCI MED, V189, P63, DOI 10.1016/j.socscimed.2017.07.029; Jones AA, 2018, JAMA PSYCHIAT, V75, P298, DOI 10.1001/jamapsychiatry.2017.4432; Kennedy MC, 2017, CURR HIV-AIDS REP, V14, P161, DOI 10.1007/s11904-017-0363-y; Kenney SR, 2018, J SUBST ABUSE TREAT, V86, P65, DOI 10.1016/j.jsat.2018.01.005; Lynn RR, 2018, THER ADV DRUG SAF, V9, P63, DOI 10.1177/2042098617744161; Macmadu A, 2017, ADDICT BEHAV, V68, P35, DOI 10.1016/j.addbeh.2017.01.014; Mars SG, 2018, J PSYCHOACTIVE DRUGS, V50, P167, DOI 10.1080/02791072.2017.1394508; Marshall BDL, 2011, LANCET, V377, P1429, DOI 10.1016/S0140-6736(10)62353-7; McNeil R, 2014, SOC SCI MED, V106, P151, DOI 10.1016/j.socscimed.2014.01.051; Miller JM, 2018, DRUG ALCOHOL REV, V37, P121, DOI 10.1111/dar.12502; O'Donnell JK, 2017, MMWR-MORBID MORTAL W, V66, P1197, DOI 10.15585/mmwr.mm6643e1; Quesada J, 2011, MED ANTHROPOL, V30, P339, DOI 10.1080/01459740.2011.576725; Rudd RA, 2016, AM J TRANSPLANT, V16, P1323, DOI 10.1111/ajt.13776; Schumann H, 2008, CLIN TOXICOL, V46, P501, DOI 10.1080/15563650701877374; Somerville NJ, 2017, MMWR-MORBID MORTAL W, V66, P382, DOI 10.15585/mmwr.mm6614a2; STREISAND JB, 1993, ANESTHESIOLOGY, V78, P629, DOI 10.1097/00000542-199304000-00003; Suzuki J, 2017, DRUG ALCOHOL DEPEN, V171, P107, DOI 10.1016/j.drugalcdep.2016.11.033; Tomassoni Anthony J, 2017, MMWR Morb Mortal Wkly Rep, V66, P107, DOI 10.15585/mm6604a4	32	13	13	0	3	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0376-8716	1879-0046		DRUG ALCOHOL DEPEN	Drug Alcohol Depend.	DEC 1	2018	193						69	74		10.1016/j.drugalcdep.2018.09.006			6	Substance Abuse; Psychiatry	Substance Abuse; Psychiatry	HD5NW	WOS:000452578200011	30343236	Green Accepted			2020-06-30	J	Christopher, PP; Anderson, B; Stein, MD				Christopher, Paul P.; Anderson, Bradley; Stein, Michael D.			Civil commitment experiences among opioid users	DRUG AND ALCOHOL DEPENDENCE			English	Article						Opioids; Civil; Commitment; Court; Involuntary	PROCEDURAL JUSTICE; OVERDOSE DEATHS; USE DISORDER; COERCION; COCAINE	Introduction: Civil commitment is an increasingly used policy intervention to combat the opioid epidemic. Yet little is known about persons who get committed and outcomes following commitment for opioid use. In the current cross-sectional study, we compared the characteristics of persons with and without a history of civil commitment, and the correlates of post-commitment abstinence. Methods: Between October 2017 and May 2018, we surveyed consecutive persons entering a brief, inpatient opioid detoxification (n = 292) regarding their lifetime experiences with civil commitment for opioid use. Results: Participants averaged 34.6 years of age, 27.1% were female, and 78.1% were White. Seventy-eight (26.7%) experienced civil commitment for opioid use at least once in their lifetime. Committed individuals had significantly higher rates of fentanyl, heroin, and injection drug use, drug overdoses, past incarceration, current criminal justice involvement, and past medication treatment for opioid use (p <.05). The average time to relapse following commitment was 72 days, although 33.8% relapsed on the same day of their release. Longer post-commitment abstinence was significantly associated with post -commitment medication treatment, higher perceived procedural justice (i.e., fairness) during the commitment hearing, positive attitude and higher motivation at the end of commitment, and improvement in attitude during commitment (p <.05). Conclusion: Opioid users who experience civil commitment constitute an especially high risk group. A positive commitment experience and post -commitment medication treatment are associated with longer post-commitment abstinence.	[Christopher, Paul P.] Brown Univ, Warren Alpert Med Sch, Dept Psychiat & Human Behav, Box G-BH, Providence, RI 02912 USA; [Anderson, Bradley] Butler Hosp, Gen Med Unit, Providence, RI 02906 USA; [Stein, Michael D.] Boston Univ, Sch Publ Hlth, Dept Hlth Law Policy & Management, Boston, MA 02215 USA	Christopher, PP (reprint author), Brown Univ, Warren Alpert Med Sch, Dept Psychiat & Human Behav, Box G-BH, Providence, RI 02912 USA.	paul_christopher@brown.edu			National Institute on Drug AbuseUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [RO1 DA034261, NCT01751789]	This study was funded by the National Institute on Drug Abuse (RO1 DA034261). Trial registered at clinicaltrials.gov; Clinical Trial #NCT01751789.	Ault A., 2017, MEDSCAPE; Cascardi M, 2000, BEHAV SCI LAW, V18, P731, DOI 10.1002/bsl.421; Cavaiola AA, 2016, SUBST ABUS, V37, P181, DOI 10.1080/08897077.2015.1029207; Centers for Disease Control, 2018, CDCHAN00413; Centers for Disease Control, 2017, NCHS FACT SHEET; Christopher PP, 2015, J AM ACAD PSYCHIATRY, V43, P313; Dowell D, 2017, JAMA-J AM MED ASSOC, V318, P2295, DOI 10.1001/jama.2017.15971; GOSTIN LO, 1991, MILBANK Q, V69, P561, DOI 10.2307/3350228; Harvard Institute of Politics, 2014, POLICY BRIEF; Israelsson M, 2011, EUR ADDICT RES, V17, P329, DOI 10.1159/000331003; Jain A, 2018, PSYCHIAT SERV, V69, P374, DOI 10.1176/appi.ps.201800066; Jones CM, 2017, AM J PUBLIC HEALTH, V107, P430, DOI 10.2105/AJPH.2016.303627; Klag S, 2005, SUBST USE MISUSE, V40, P1777, DOI 10.1080/10826080500260891; Larochelle MR, 2018, ANN INTERN MED, V169, P137, DOI 10.7326/M17-3107; Martins SS, 2017, JAMA PSYCHIAT, V74, P445, DOI 10.1001/jamapsychiatry.2017.0113; Massachusetts Department of Public Health, 2018, NUMB OP REL OV DEATH; Massachusetts Department of Public Health, 2017, ASS FAT NONF OP OV M; McKenna BG, 2000, AUST NZ J PSYCHIAT, V34, P671, DOI 10.1080/j.1440-1614.2000.00744.x; Olfson M, 2018, DRUG ALCOHOL DEPEN, V190, P112, DOI 10.1016/j.drugalcdep.2018.06.004; Poythress NG, 2002, INT J LAW PSYCHIAT, V25, P517, DOI 10.1016/S0160-2527(01)00110-8; Ruhm CJ, 2018, ADDICTION, V113, P1339, DOI 10.1111/add.14144; Saha TD, 2016, J CLIN PSYCHIAT, V77, P772, DOI 10.4088/JCP.15m10386; Seth P, 2018, MMWR-MORBID MORTAL W, V67, P349, DOI 10.15585/mmwr.mm6712a1; Substance Abuse and Mental Health Services Administration, 2017, HHS PUBL SMA, V52; Werb D, 2016, INT J DRUG POLICY, V28, P1, DOI 10.1016/j.drugpo.2015.12.005	25	4	4	0	4	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0376-8716	1879-0046		DRUG ALCOHOL DEPEN	Drug Alcohol Depend.	DEC 1	2018	193						137	141		10.1016/j.drugalcdep.2018.10.001			5	Substance Abuse; Psychiatry	Substance Abuse; Psychiatry	HD5NW	WOS:000452578200020	30384320	Green Accepted			2020-06-30	J	Soeyland, T; Garner, A; Vidler, S; Gutierrez, CH; Foster, A; Kitcher, J				Soeyland, Torgrim; Garner, Alan; Vidler, Sam; Gutierrez, Cristian Humberto; Foster, Arnold; Kitcher, Jane			Predrawn prehospital medications are microbiologically safe for up to 48 hours	EMERGENCY MEDICINE JOURNAL			English	Article							DOSING ERRORS; STERILITY; GROWTH	Background Prehospital medical teams are commonly required to administer a range of medications for urgent stabilisation and treatment. The safe preparation of medications during resuscitation requires attention, time and resources, and can be a source of medication error. In our two road and HEMS (Helicopter Emergency Medical Service) prehospital services, medication errors are mitigated by predrawing commonly used medications to set concentrations daily (Hunter Retrieval Service, HRS) or second-daily (CareFlight Sydney, CFS). However, there are no published data confirming that such practice is microbiologically safe. Methods A convenience sample of 299 predrawn medication syringes with syringe dwell times up to 48 hours were collected at the end of their operational deployment. Predrawn medication syringes collected for culture were ketamine, midazolam, fentanyl, thiopentone, rocuronium, suxamethonium, metaraminol and normal saline. The samples were incubated and cultured at a tertiary hospital pathology laboratory using best-practice methodology for non-tissue samples. The samples were collected from June 2017 to February 2018. Results The mean dwell times ranged from 30.7 hours (fentanyl at HRS) to 48.5 hours (rocuronium at CFS). None of the 299 cultured samples yielded significant micro-organisms. One sample of suxamethonium with a syringe dwell time of 34 hours grew Bacillus cereus but was likely a contaminant introduced during sample collection. Conclusion Predrawing of the eight studied medications for urgent prehospital procedures appears to be a microbiologically safe practice with syringe dwell times up to 48 hours.	[Soeyland, Torgrim] John Hunter Hosp, Hunter Retrieval Serv, New Lambton, NSW 2305, Australia; [Garner, Alan] CareFlight Ltd New South Wales, Operat, Wentworthville, NSW, Australia; [Vidler, Sam] Hunter New England Local Hlth Dist, Hunter Retrieval Serv, New Lambton, NSW, Australia; [Gutierrez, Cristian Humberto] John Hunter Hosp, Hunter New England Local Hlth Dist, New Lambton, NSW, Australia; [Foster, Arnold; Kitcher, Jane] Hunter New England Local Hlth Dist, New South Wales Hlth Pathol, Newcastle, NSW, Australia	Soeyland, T (reprint author), John Hunter Hosp, Hunter Retrieval Serv, New Lambton, NSW 2305, Australia.	Torgrim.Soeyland@health.nsw.gov.au	Garner, Alan/AAN-1513-2020	Garner, Alan/0000-0002-4010-9137			Abeysekera A, 2005, ANAESTHESIA, V60, P220, DOI 10.1111/j.1365-2044.2005.04123.x; Boulay D, 2010, INT J OBSTET ANESTH, V19, P349, DOI 10.1016/j.ijoa.2010.03.012; Driver RP, 1998, ANESTH ANALG, V86, P994, DOI 10.1097/00000539-199805000-00015; HIGHSMITH AK, 1982, J CLIN MICROBIOL, V15, P1024, DOI 10.1128/JCM.15.6.1024-1028.1982; Hoyle JD, 2012, PREHOSP EMERG CARE, V16, P59, DOI 10.3109/10903127.2011.614043; SOSIS MB, 1993, ANESTH ANALG, V77, P766; Stevens AD, 2015, RESUSCITATION, V96, P85, DOI 10.1016/j.resuscitation.2015.07.035; Stone JP, 2009, INT J OBSTET ANESTH, V18, P242, DOI 10.1016/j.ijoa.2009.01.013; Wagner DS, 2002, INT J OBSTET ANESTH, V11, P252, DOI 10.1054/ijoa.2002.0983	9	1	1	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1472-0205	1472-0213		EMERG MED J	Emerg. Med. J.	DEC	2018	35	12					743	745		10.1136/emermed-2018-207864			3	Emergency Medicine	Emergency Medicine	HD8ET	WOS:000452788300007	30343266				2020-06-30	J	Bechakra, M; Moerdijk, F; van Rosmalen, J; Koch, BCP; van der Rijt, CCD; Smitt, PAES; Jongen, JLM				Bechakra, Malik; Moerdijk, Floor; van Rosmalen, Joost; Koch, Birgit C. P.; van der Rijt, Carin C. D.; Smitt, Peter A. E. Sillevis; Jongen, Joost L. M.			Opioid responsiveness of nociceptive versus mixed pain in clinical cancer patients	EUROPEAN JOURNAL OF CANCER			English	Article						Cancer; Nociceptive pain; Neuropathic pain; Mixed pain; Opioid; Adjuvant analgesics	SPINAL-CORD COMPRESSION; NEUROPATHIC PAIN; MORPHINE; PREVALENCE; MECHANISMS; METHADONE; FENTANYL	Objective: To investigate whether clinical cancer patients with mixed nociceptive-neuropathic pain are less responsive to opioids than patients with nociceptive pain. Background: Pain is common in advanced cancer patients. Pain driven by neuropathic mechanisms is considered to be resistant to opioids. This hypothesis is mainly based on animal studies and single-dose opioid studies in humans but has not been confirmed in clinical practice. Methods: Data were prospectively collected from 240 clinical cancer pain patients using opioids. Multiple linear regression was used for assessing the associations between the logarithm of the morphine equivalent dose (MED) at three days after admission (T = 3d) relative to admission (T = 0d) (logRMED) and type of pain (nociceptive versus mixed pain), corrected for gender, age, primary cancer site and use of non-opioid and adjuvant analgesics. As secondary outcome measures, associations between logMED and logPFent (fentanyl plasma level) at T = 3d and type of pain were assessed. Results: Pain intensity between T = 0d and T = 3d was significantly and evenly reduced in patients with nociceptive pain (n = 173) and mixed pain (n = 67). Median (interquartile range) MED was 20 (10-52) and 20 (20-80) mg (T = 0d), 40 (10-67) and 40 (20-100) mg (T = 3d), median PFent (T = 3d) was 1.59 (0.58-3.19) and 1.38 (0.54-4.39) ng/ml, none of them significantly different, in patients with nociceptive and mixed pain, respectively. Neither logRMED, logMED (T = 3d), or logPFent (T = 3d) was significantly associated with type of pain, after correction for confounding factors. Conclusions: We conclude that, at least in clinical cancer patients, mixed pain is as responsive to opioids as nociceptive pain. (C) 2018 Elsevier Ltd. All rights reserved.	[Bechakra, Malik; Moerdijk, Floor; Smitt, Peter A. E. Sillevis; Jongen, Joost L. M.] Erasmus MC, Dept Neurol, Dr Molewaterpl 40, NL-3015 GD Rotterdam, Netherlands; [van Rosmalen, Joost] Erasmus MC, Dept Biostat, Wytemaweg 80, NL-3015 CN Rotterdam, Netherlands; [Koch, Birgit C. P.] Erasmus MC, Hosp Pharm, Dr Molewaterpl 40, NL-3015 GD Rotterdam, Netherlands; [van der Rijt, Carin C. D.] Erasmus MC, Dept Clin Oncol, Dr Molewaterpl 40, NL-3015 GD Rotterdam, Netherlands; [van der Rijt, Carin C. D.] Netherlands Comprehens Canc Org, Godebaldkwartier 419, NL-3511 DT Utrecht, Netherlands	Jongen, JLM (reprint author), Erasmus MC, Dept Neurol, Dr Molewaterpl 40, NL-3015 GD Rotterdam, Netherlands.	j.jongen@erasmusmc.nl			Erasmus MC Grant 2011	This study was funded by an Erasmus MC Grant 2011. The funding source had no role in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication.	[Anonymous], 2008, LAND RICHTL PIJN BIJ; ARNER S, 1988, PAIN, V33, P11, DOI 10.1016/0304-3959(88)90198-4; Bell RF, 2012, COCHRANE DB SYST REV, V11, DOI DOI 10.1002/14651858; Bennett MI, 2006, PAIN, V122, P289, DOI 10.1016/j.pain.2006.02.002; Bennett MI, 2012, PAIN, V153, P359, DOI 10.1016/j.pain.2011.10.028; Bruera E, 2004, J CLIN ONCOL, V22, P185, DOI 10.1200/JCO.2004.03.172; CHERNY NI, 1994, NEUROLOGY, V44, P857, DOI 10.1212/WNL.44.5.857; de Bruijn P, 2018, J PHARMACEUT BIOMED, V149, P475, DOI 10.1016/j.jpba.2017.11.035; Dellemijn P, 1999, PAIN, V80, P453, DOI 10.1016/S0304-3959(98)00256-5; Everdingen MHJVDBV, 2007, ANN ONCOL, V18, P1437, DOI 10.1093/annonc/mdm056; de Paredes MLG, 2011, ANN ONCOL, V22, P924, DOI 10.1093/annonc/mdq449; Gomez-Iturriaga A, 2015, BMC PALLIAT CARE, V14, DOI 10.1186/s12904-015-0045-8; Hadley G, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010270.pub2; Haumann J, 2016, EUR J CANCER, V65, P121, DOI 10.1016/j.ejca.2016.06.025; Jongen Joost L M, 2011, BMJ Support Palliat Care, V1, P322, DOI 10.1136/bmjspcare-2011-000087; Jongen JLM, 2013, J PAIN SYMPTOM MANAG, V46, P581, DOI 10.1016/j.jpainsymman.2012.10.230; Loblaw DA, 2003, CLIN ONCOL-UK, V15, P211, DOI 10.1016/S0936-6555(02)00400-4; Luger NM, 2002, PAIN, V99, P397, DOI 10.1016/S0304-3959(02)00102-1; Matic M, 2017, PHARMACOGENOMICS, V18, P1133, DOI 10.2217/pgs-2017-0060; Mercadante S, 2009, J PAIN, V10, P594, DOI 10.1016/j.jpain.2008.12.002; Oldenmenger WH, 2009, EUR J CANCER, V45, P1370, DOI 10.1016/j.ejca.2009.01.007; Patchell RA, 2005, LANCET, V366, P643, DOI 10.1016/S0140-6736(05)66954-1; Pereira J, 2001, J PAIN SYMPTOM MANAG, V22, P672, DOI 10.1016/S0885-3924(01)00294-9; PORTENOY RK, 1990, PAIN, V43, P273, DOI 10.1016/0304-3959(90)90025-9; PUKE MJC, 1993, ANESTH ANALG, V77, P104; Sittl R, 2006, PALLIATIVE MED, V20, pS25, DOI 10.1191/0269216306pm1125oa; Treede RD, 2008, NEUROLOGY, V70, P1630, DOI 10.1212/01.wnl.0000282763.29778.59	27	1	1	0	5	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0959-8049	1879-0852		EUR J CANCER	Eur. J. Cancer	DEC	2018	105						79	87		10.1016/j.ejca.2018.09.036			9	Oncology	Oncology	HB6XR	WOS:000451217700010	30439627				2020-06-30	J	Juri, T; Suehiro, K; Kimura, A; Mukai, A; Tanaka, K; Yamada, T; Mori, T; Nishikawa, K				Juri, Takashi; Suehiro, Koichi; Kimura, Aya; Mukai, Akira; Tanaka, Katsuaki; Yamada, Tokuhiro; Mori, Takashi; Nishikawa, Kiyonobu			Impact of non-invasive continuous blood pressure monitoring on maternal hypotension during cesarean delivery: a randomized-controlled study	JOURNAL OF ANESTHESIA			English	Article						ClearSight; Cesarean delivery; Hypotension; Spinal anesthesia	SPINAL-ANESTHESIA; ARTERIAL-PRESSURE; GENERAL-ANESTHESIA; CARDIAC-OUTPUT; SECTION; PREVENTION; MANAGEMENT; STABILITY; AGREEMENT; SURGERY	PurposeThis study aimed to investigate the efficacy of the ClearSight system (Edwards Lifesciences, Irvine, CA) for reducing the incidence of hypotension compared with the traditional oscillometric blood pressure monitoring in cesarean delivery under spinal anesthesia.MethodsForty patients undergoing cesarean delivery under spinal anesthesia were enrolled. The patients were randomly divided into two groups (Control and ClearSight groups). All patients received spinal anesthesia using 0.5% hyperbaric bupivacaine (11.5mg) and fentanyl (10 mu g). Blood pressure was managed with the same protocol using the ClearSight system (ClearSight group) and oscillometric blood pressure monitoring (Control group). Furthermore, we compared the accuracy of the ClearSight system with the traditional oscillometric monitoring for blood pressure measurement using Bland-Altman, four-quadrant plot, and polar plot analyses.ResultsThe incidence of hypotension was significantly lower in the ClearSight group from induction to delivery (45% vs. 0%, p<0.001) and to the end of surgery (50% vs. 20%, p=0.049). Intraoperative nausea occurred more frequently in the Control group (45% vs. 10%, p=0.012). The ClearSight system demonstrated acceptable accuracy with a bias of -4.311.7mmHg throughout the procedure. Four-quadrant analysis revealed an excellent trending ability of the ClearSight system with a concordance rate of approximately 95%. In the polar plot analysis, the angular bias and concordance rate were -13.5 degrees +/- 19.0 degrees and 76.9%, respectively.Conclusions The accuracy and trending ability of the ClearSight system for blood pressure measurement was clinically acceptable in cesarean delivery under spinal anesthesia, leading to reductions in maternal hypotension and nausea.	[Juri, Takashi; Suehiro, Koichi; Kimura, Aya; Mukai, Akira; Tanaka, Katsuaki; Yamada, Tokuhiro; Mori, Takashi; Nishikawa, Kiyonobu] Osaka City Univ, Grad Sch Med, Dept Anesthesiol, Abeno Ku, 1-5-7 Asahimachi, Osaka, Osaka 5458586, Japan	Suehiro, K (reprint author), Osaka City Univ, Grad Sch Med, Dept Anesthesiol, Abeno Ku, 1-5-7 Asahimachi, Osaka, Osaka 5458586, Japan.	suehirokoichi@yahoo.co.jp	Tanaka, Katsuaki/A-8864-2010	Tanaka, Katsuaki/0000-0002-4748-2022; Mukai, Akira/0000-0003-2809-9818			Akkermans J, 2009, HYPERTENS PREGNANCY, V28, P230, DOI 10.1080/10641950802601260; Auroy Y, 2002, ANESTHESIOLOGY, V97, P1274, DOI 10.1097/00000542-200211000-00034; Bartels K, 2016, ANESTH ANALG, V122, P1866, DOI 10.1213/ANE.0000000000001340; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; Butwick AJ, 2015, BRIT J ANAESTH, V114, P183, DOI 10.1093/bja/aeu267; Chen G, 2012, J CLIN MONIT COMPUT, V26, P133, DOI 10.1007/s10877-012-9344-2; Critchley LA, 2011, J CARDIOTHOR VASC AN, V25, P536, DOI 10.1053/j.jvca.2011.01.003; Hawkins JL, 2011, OBSTET GYNECOL, V117, P69, DOI 10.1097/AOG.0b013e31820093a9; Hirose N, 2016, J ANESTH, V30, P603, DOI 10.1007/s00540-016-2165-6; Ilies C, 2012, BRIT J ANAESTH, V109, P413, DOI 10.1093/bja/aes224; Kee WDN, 2006, CURR OPIN ANESTHESIO, V19, P238, DOI 10.1097/01.aco.0000192816.22989.ba; Kee WDN, 2000, ANESTH ANALG, V90, P1390, DOI 10.1097/00000539-200006000-00024; Kim SH, 2014, ANESTHESIOLOGY, V120, P1080, DOI 10.1097/ALN.0000000000000226; Kinsella SM, 2018, ANAESTHESIA, V73, P71, DOI 10.1111/anae.14080; Klohr S, 2010, ACTA ANAESTH SCAND, V54, P909, DOI 10.1111/j.1399-6576.2010.02239.x; LATSON TW, 1994, ANESTHESIOLOGY, V80, P326, DOI 10.1097/00000542-199402000-00013; Lin FQ, 2013, INT J MED SCI, V10, P355, DOI 10.7150/ijms.5294; Lonjaret L, 2014, INTEGR BLOOD PRESS C, V7, P49, DOI 10.2147/IBPC.S45292; Matsota P, 2015, J ANESTH, V29, P352, DOI 10.1007/s00540-014-1926-3; Meidert AS, 2017, EUR J ANAESTH, V34, P716, DOI 10.1097/EJA.0000000000000690; Mercier FJ, 2014, BRIT J ANAESTH, V113, P459, DOI 10.1093/bja/aeu103; Miyabe M, 1997, REGION ANESTH, V22, P239, DOI 10.1016/S1098-7339(06)80008-8; Myles PS, 2007, BRIT J ANAESTH, V99, P309, DOI 10.1093/bja/aem214; Okudaira Sayaka, 2005, Archives of Gynecology and Obstetrics, V271, P292, DOI 10.1007/s00404-003-0594-6; Qian XW, 2008, INT J OBSTET ANESTH, V17, P309, DOI 10.1016/j.ijoa.2008.01.018; Sng BL, 2015, ANAESTHESIA, V70, P691, DOI 10.1111/anae.13008; Suehiro K, 2015, ANAESTHESIA, V70, P150, DOI 10.1111/anae.12857; Suehiro K, 2015, J CLIN MONIT COMPUT, V29, P333, DOI 10.1007/s10877-014-9609-z; Tsuchiya M, 2012, MINERVA ANESTESIOL, V78, P1241; van Bogaert LJ, 1998, INT J GYNECOL OBSTET, V61, P233, DOI 10.1016/S0020-7292(98)00052-6	30	6	7	2	3	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	0913-8668	1438-8359		J ANESTH	J. Anesth.	DEC	2018	32	6					822	830		10.1007/s00540-018-2560-2			9	Anesthesiology	Anesthesiology	HC3CM	WOS:000451678600006	30267340				2020-06-30	J	Kim, D; Lim, HS; Kim, MJ; Jeong, W; Ko, S				Kim, Deokkyu; Lim, Hyung-Sun; Kim, Myung-Jong; Jeong, WooJoo; Ko, Seonghoon			High-dose intraoperative remifentanil infusion increases early postoperative analgesic consumption: a prospective, randomized, double-blind controlled study	JOURNAL OF ANESTHESIA			English	Article						Hyperalgesia; Postoperative pain; Remifentanil	OPIOID-INDUCED HYPERALGESIA; ACUTE TOLERANCE; RAPID DEVELOPMENT; PAIN; ALFENTANIL; MODEL	PurposeThe purpose of this study was to determine whether intraoperative infusion of remifentanil induces acute tolerance to opioids, and compare the postoperative pain and opioid consumption by the effect site concentrations of remifentanil.MethodsOne hundred and ninety-eight patients undergoing gastrectomy were randomly assigned to maintain target effect site concentrations of remifentanil at 0 (Group 1, n=39), 2 (Group 2, n=40), 4 (Group 3, n=39), 8 (Group 4, n=40), or 12ng/ml (Group 5, n=40) during operation. Postoperative pain intensities and fentanyl requirement were recorded at postoperative 2, 6, 24, and 48h.ResultsFentanyl requirement for postoperative 2h was significantly greater in Group 5 compared to Group 1 (376116 vs. 283 +/- 129 mu g, P=0.03). However, there were no differences in fentanyl requirements among the groups after postoperative 2h. Also, total fentanyl consumption for 48h was similar in all groups (Group 1; 3106 +/- 629, Group 2; 2970 +/- 705, Group 3; 3017 +/- 555, Group 4; 3151 +/- 606, and Group 5; 2984 +/- 443 mu g, P=0.717). Pain scores at rest and during deep breathing were comparable in all groups at the time of each examination.Conclusion Intraoperative infusion of remifentanil with 12ng/ml of effect site concentration in patients undergoing gastrectomy increases early postoperative fentanyl requirement. Acute opioid tolerance would be developed by higher concentration of remifentanil than dosage of common anesthetic practice.	[Kim, Deokkyu; Lim, Hyung-Sun; Kim, Myung-Jong; Jeong, WooJoo; Ko, Seonghoon] Chonbuk Natl Univ Hosp, Dept Anesthesiol & Pain Med, Geonji Ro 20, Jeonju 54907, South Korea; [Lim, Hyung-Sun; Ko, Seonghoon] Chonbuk Natl Univ, Sch Med, Res Inst Clin Med, Biomed Res Inst, Jeonju, South Korea	Ko, S (reprint author), Chonbuk Natl Univ Hosp, Dept Anesthesiol & Pain Med, Geonji Ro 20, Jeonju 54907, South Korea.; Ko, S (reprint author), Chonbuk Natl Univ, Sch Med, Res Inst Clin Med, Biomed Res Inst, Jeonju, South Korea.	shko@jbnu.ac.kr					Cabanero D, 2009, ANESTHESIOLOGY, V111, P1334, DOI 10.1097/ALN.0b013e3181bfab61; Chia YT, 1999, CAN J ANAESTH, V46, P872, DOI 10.1007/BF03012978; Chu LF, 2008, CLIN J PAIN, V24, P479, DOI 10.1097/AJP.0b013e31816b2f43; COLPAERT FC, 1978, EUR J PHARMACOL, V49, P335, DOI 10.1016/0014-2999(78)90114-0; Colvin LA, 2010, BRIT J ANAESTH, V104, P125, DOI 10.1093/bja/aep392; Cortinez LI, 2001, BRIT J ANAESTH, V87, P866, DOI 10.1093/bja/87.6.866; Crawford MW, 2006, ANESTH ANALG, V102, P1662, DOI 10.1213/01.ane.0000216036.95705.c2; De Baerdemaeker LEC, 2007, BRIT J ANAESTH, V99, P404, DOI 10.1093/bja/aem164; Gu XP, 2009, MOL PAIN, V5, DOI 10.1186/1744-8069-5-76; Guignard B, 2000, ANESTHESIOLOGY, V93, P409, DOI 10.1097/00000542-200008000-00019; Hansen EG, 2005, ACTA ANAESTH SCAND, V49, P1464, DOI 10.1111/j.1399-6576.2005.00861.x; Hayashida M, 2003, ANESTH ANALG, V97, P1347, DOI 10.1213/01.ANE.0000083370.80416.38; Ho ST, 1999, BRIT J ANAESTH, V82, P112; Ishida R, 2012, ANESTH ANALG, V114, P224, DOI 10.1213/ANE.0b013e318237f678; Joly V, 2005, ANESTHESIOLOGY, V103, P147, DOI 10.1097/00000542-200507000-00022; Kissin I, 1996, ANESTH ANALG, V83, P600, DOI 10.1097/00000539-199609000-00029; KISSIN I, 1991, ANESTHESIOLOGY, V74, P166, DOI 10.1097/00000542-199101000-00025; Lahtinen P, 2008, J CARDIOTHOR VASC AN, V22, P225, DOI 10.1053/j.jvca.2007.07.004; Lee LHY, 2005, ANESTHESIOLOGY, V102, P398, DOI 10.1097/00000542-200502000-00024; Minville V, 2010, BRIT J ANAESTH, V104, P231, DOI 10.1093/bja/aep363; Schraag S, 1999, ANESTH ANALG, V89, P753, DOI 10.1097/00000539-199909000-00042; Silverman SM, 2009, PAIN PHYSICIAN, V12, P679; Vinik HR, 1998, ANESTH ANALG, V86, P1307, DOI 10.1097/00000539-199806000-00033; Yeom JH, 2012, KOREAN J ANESTHESIOL, V63, P103, DOI 10.4097/kjae.2012.63.2.103	24	3	3	0	1	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	0913-8668	1438-8359		J ANESTH	J. Anesth.	DEC	2018	32	6					886	892		10.1007/s00540-018-2569-6			7	Anesthesiology	Anesthesiology	HC3CM	WOS:000451678600014	30374890				2020-06-30	J	Clements, W; Sneddon, D; Kavnoudias, H; Joseph, T; Goh, GS; Koukounaras, J; Snow, T				Clements, Warren; Sneddon, David; Kavnoudias, Helen; Joseph, Tim; Goh, Gerard S.; Koukounaras, Jim; Snow, Thomas			Randomized and controlled study comparing patient controlled and radiologist controlled intra-procedural conscious sedation, using midazolam and fentanyl, for patients undergoing insertion of a central venous line	JOURNAL OF MEDICAL IMAGING AND RADIATION ONCOLOGY			English	Article						analgesia; central line; interventional radiology; sedation	ANALGESIA	Introduction Interventional Radiology procedures can provoke anxiety and may be painful. Current practice, Radiologist Controlled Sedation (RCS), involves titrating aliquots of midazolam and fentanyl to patient response but underdosing and overdosing may occur. This study tests a new method of titrating sedation/analgesia during the procedure, Patient Controlled Sedation (PCS), in which a combination of fentanyl and midazolam are administered using a patient-controlled analgesia pump. This allows the patient to self-control their sedation/analgesia during the procedure. Methods We performed a randomised control trial comparing the effects of pain, sedation, amnesia and overall patient satisfaction between PCS and RCS, by enrolling forty patients undergoing insertion of a tunnelled central line. Results Our results showed that PCS was safe, with no adverse events. PCS was effective in providing sedation, amnesia and overall pain relief comparable to RCS. There was no significant difference in dose given to patients using PCS or RCS. There was a tendency for patients in the PCS group to begin sedation later than those in the RCS group, but both were equally sedated during the procedure. We show that patients in the PCS group were very satisfied with the procedure. Conclusions We show that PCS is non-inferior to RCS in terms of dosage given and degree of sedation. To the authors' knowledge, this is the first study to show intra-procedural PCS in an Interventional Radiology setting using midazolam and fentanyl as a randomised comparative trial. It has wide applicability in a procedural setting for very low cost and with minimal additional training required.	[Clements, Warren; Sneddon, David; Kavnoudias, Helen; Joseph, Tim; Goh, Gerard S.; Koukounaras, Jim] Alfred Hosp, Dept Radiol, Melbourne, Vic, Australia; [Clements, Warren; Kavnoudias, Helen; Goh, Gerard S.] Monash Univ, Dept Surg, Melbourne, Vic, Australia; [Snow, Thomas] Holy Spirit Northside Hosp, Queensland Diagnost Imaging, Brisbane, Qld, Australia	Clements, W (reprint author), Alfred Hlth, Dept Radiol, 55 Commercial Rd, Melbourne, Vic 3004, Australia.	w.clements@alfred.org.au	Clements, Warren/AAD-3610-2019	Clements, Warren/0000-0003-1859-5850; Goh, Gerard/0000-0002-1552-5470	Royal Australian and New Zealand College of Radiologists [2014/RANZCR/009]		[Anonymous], 2007, AC PAIN MAN TOOLK; Bulach R, 2005, BRIT J ANAESTH, V94, P300, DOI 10.1093/bja/aei040; Chung HY, 2011, TECH VASC INTERV RAD, V14, P186, DOI 10.1053/j.tvir.2011.05.005; Clements W, 2015, INT RAD SOC AUSTR AN; Gross JB, 2002, ANESTHESIOLOGY, V96, P1004; Haidar SH, 1996, J PHARMACEUT BIOMED, V14, P1727, DOI 10.1016/0731-7085(96)01831-6; MacIntyre PE, 2010, AUST NZ COLL ANAESTH, V181, P1; Martin ML, 2003, J VASC INTERV RADIOL, V14, P1119, DOI 10.1097/01.RVI.0000086536.86489.82; Mazanikov M, 2012, ENDOSCOPY, V44, P487, DOI 10.1055/s-0031-1291655; Moran TC, 2013, RADIOGRAPHICS, V33, pE47, DOI 10.1148/rg.332125012; Palumbo P, 2013, ANN ITAL CHIR, V84, P661; Stark PA, 2013, ANESTHESIOLOGY, V118, P1332, DOI 10.1097/ALN.0b013e318289b84b; Wakita Ryo, 2012, Anesth Prog, V59, P62, DOI 10.2344/11-11.1; Whizar-Lugo V, 2016, J ANESTH CRIT CARE O, V4	14	3	3	1	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1754-9477	1754-9485		J MED IMAG RADIAT ON	J. Med. Imag. Radiat. Oncol.	DEC	2018	62	6					781	788		10.1111/1754-9485.12817			8	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	HD1BF	WOS:000452243300006	30295410				2020-06-30	J	Zhang, Y; Qin, QR; Hui, LT				Zhang, Yang; Qin, Qing-Rong; Hui, Liang-Tu			Motor blocks and operative deliveries with ropivacaine and fentanyl for labor epidural analgesia: A meta-analysis	JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH			English	Article						analgesia; delivery; epidural; fentanyl; labor; ropivacaine	CESAREAN DELIVERY; 0.125-PERCENT BUPIVACAINE; 0.1-PERCENT ROPIVACAINE; CONTROLLED-TRIAL; PLUS FENTANYL; PROLONG LABOR; LEVOBUPIVACAINE; SUFENTANIL; INFUSIONS; INCREASE	Aim Aim of this study was to estimate the incidence of motor blocks, instrumental deliveries and cesarean deliveries with ropivacaine and fentanyl in epidural analgesia for labor and to identify factors affecting the outcomes. Methods Results Electronic databases were searched for original research papers by using appropriate medical subject heading terms and keywords. Effect sizes of individual studies were pooled under random effects model to obtain weighted overall effect size/s. Metaregression analyses were performed to evaluate the factors affecting motor block and cesarean delivery incidences. Thirty studies (2851 women; age 27.42 years [95% CI 26.56, 28.26]) were included. Concentrations of drugs (weighted average) were: 0.095% [0.08, 0.11] ropivacaine and 0.000215% [0.00018, 0.00025] fentanyl. Overall, incidences of motor blocks, instrumental deliveries and cesarean deliveries were 14.36% [13.47, 15.26]; 25.55% [22.38, 28.71] and 12.45% [11.17, 13.73], respectively. Maternal age was significantly positively associated with motor blocks as well as cesarean deliveries. Second stage of labor duration was also positively associated with motor block and instrumental delivery incidences. Cervical diameter at trial entry was significantly negatively associated with cesarean deliveries. Fentanyl concentration as well as total usage were associated negatively with instrumental delivery but positively with cesarean delivery incidence. Conclusion Epidural analgesia for labor with ropivacaine and fentanyl is associated with the incidence of approximately 14% motor blocks, 25% instrumental deliveries and 12% cesarean deliveries. Age, duration of the second stage of labor, cervical dilatation at initiation of neuraxial analgesia and dose of fentanyl may affect obstetric outcome.	[Zhang, Yang; Hui, Liang-Tu] Binzhou Peoples Hosp, Inpatient Dept 2, Binzhou, Peoples R China; [Qin, Qing-Rong] Binzhou Polytech Coll, Sch Nursing, Binzhou, Peoples R China	Qin, QR (reprint author), Binzhou Vocat Coll, Sch Nursing, 919,Huanghe 12 Rd, Binzhou 256603, Shandong, Peoples R China.	qrqin_med@126.com			Binzhou People's Hospital; Binzhou Vocational College	We acknowledge the support and input from Binzhou People's Hospital and Binzhou Vocational College.	Aneiros F, 2009, J CLIN ANESTH, V21, P94, DOI 10.1016/j.jclinane.2008.06.020; Asik I, 2002, EUR J ANAESTH, V19, P263; Atienzaar MC, 2008, INT J OBSTET ANESTH, V17, P106, DOI 10.1016/j.ijoa.2007.10.003; Atienzar MC, 2004, EUR J ANAESTH, V21, P770; Bakhamees Hassan, 2007, Middle East Journal of Anesthesiology, V19, P693; Bang EC, 2012, INT J OBSTET ANESTH, V21, P45, DOI 10.1016/j.ijoa.2011.10.002; Bawdane Kishori Dhaku, 2016, J Anaesthesiol Clin Pharmacol, V32, P38, DOI 10.4103/0970-9185.173350; Bernard JM, 2003, ANESTH ANALG, V97, P1800, DOI 10.1213/01.ANE.0000090149.42478.B5; Bolukbasi D, 2005, INT J OBSTET ANESTH, V14, P288, DOI 10.1016/j.ijoa.2005.04.007; Cambic CR, 2010, BR J ANAESTH S1, V105, pi50, DOI 10.1093/bja/aeq311; Campbell DC, 2000, ANESTH ANALG, V90, P1384, DOI 10.1097/00000539-200006000-00023; Casati A, 2001, Minerva Anestesiol, V67, P15; Chen SY, 2014, TAIWAN J OBSTET GYNE, V53, P8, DOI 10.1016/j.tjog.2012.01.039; Chhetty YK, 2013, J OBSTET ANAESTH CRI, V3, P16; DEWAN DM, 1994, ANESTHESIOLOGY, V80, P1189, DOI 10.1097/00000542-199406000-00004; Fan YX, 2011, UPSALA J MED SCI, V116, P252, DOI 10.3109/03009734.2011.601532; Fernandez-Guisasola J, 2001, ANESTH ANALG, V92, P1261, DOI 10.1097/00000539-200105000-00034; Fettes PDW, 2006, BRIT J ANAESTH, V97, P359, DOI 10.1093/bja/ael157; Finegold H, 2000, CAN J ANAESTH, V47, P740, DOI 10.1007/BF03019475; Gautier P, 1999, ANESTHESIOLOGY, V90, P772, DOI 10.1097/00000542-199903000-00020; Girard T, 2006, Acta Anaesthesiol Belg, V57, P45; Gomar C, 2000, EUR J ANAESTH, V17, P542, DOI 10.1046/j.1365-2346.2000.00733.x; Grant EN, 2015, BJOG-INT J OBSTET GY, V122, P288, DOI 10.1111/1471-0528.12966; Guo SB, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000000880; Halpern SH, 2003, ANESTHESIOLOGY, V98, P1431, DOI 10.1097/00000542-200306000-00020; Jung H, 2013, KOREAN J ANESTHESIOL, V65, P379, DOI 10.4097/kjae.2013.65.5.379; Lee BB, 2004, ANESTH ANALG, V98, P1145, DOI 10.1213/01.ANE.0000103264.71747.0F; Lee BB, 2002, REGION ANESTH PAIN M, V27, P31, DOI 10.1053/rapm.2002.27836; Leone Stefania, 2008, Acta Biomed, V79, P92; Lim Y, 2006, ANAESTHESIA, V61, P339, DOI 10.1111/j.1365-2044.2006.04535.x; Lim Y, 2008, ANESTH ANALG, V107, P1968, DOI 10.1213/ane.0b013e3181887ffb; Meister GC, 2000, ANESTH ANALG, V90, P632, DOI 10.1097/00000539-200003000-00024; MORTON SC, 1994, OBSTET GYNECOL, V83, P1045, DOI 10.1097/00006250-199406000-00029; Osterman Michelle J K, 2011, Natl Vital Stat Rep, V59, P1; Owen M D, 2000, Expert Opin Pharmacother, V1, P325, DOI 10.1517/14656566.1.2.325; Owen MD, 2002, ANESTH ANALG, V94, P179, DOI 10.1097/00000539-200201000-00034; Paddalwar S, 2013, INDIAN J PAIN, V27, P147; Palm S, 2001, ANAESTHESIA, V56, P526, DOI 10.1046/j.1365-2044.2001.02050.x; Patkar Chinmayi Surendra, 2015, J Anaesthesiol Clin Pharmacol, V31, P234, DOI 10.4103/0970-9185.155155; Pirbudak L, 2002, EUR J ANAESTH, V19, P271, DOI 10.1017/S0265021502000431; Purdie NL, 2004, ANAESTHESIA, V59, P133, DOI 10.1111/j.1365-2044.2004.03582.x; RAYBURN W, 1989, AM J OBSTET GYNECOL, V161, P202, DOI 10.1016/0002-9378(89)90266-4; Ruban P, 2000, ANAESTH INTENS CARE, V28, P517, DOI 10.1177/0310057X0002800505; Saito Miwako, 2005, J Anesth, V19, P208, DOI 10.1007/s00540-005-0316-2; Smedvig JP, 2001, ACTA ANAESTH SCAND, V45, P595, DOI 10.1034/j.1399-6576.2001.045005595.x; Sng BL, 2015, CURR OPIN ANESTHESIO, V28, P285, DOI 10.1097/ACO.0000000000000183; THORP JA, 1993, AM J OBSTET GYNECOL, V169, P851, DOI 10.1016/0002-9378(93)90015-B; Vallejo MC, 2007, J PAIN, V8, P970, DOI 10.1016/j.jpain.2007.07.002; van de Velde M, 2007, ANESTHESIOLOGY, V106, P149, DOI 10.1097/00000542-200701000-00024; Zhang J, 1999, AM J OBSTET GYNECOL, V180, P970, DOI 10.1016/S0002-9378(99)70669-1; Zhang J, 2001, AM J OBSTET GYNECOL, V185, P128, DOI 10.1067/mob.2001.113874	51	0	0	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1341-8076	1447-0756		J OBSTET GYNAECOL RE	J. Obstet. Gynaecol. Res.	DEC	2018	44	12					2156	2165		10.1111/jog.13772			10	Obstetrics & Gynecology	Obstetrics & Gynecology	HC5PE	WOS:000451854100004	30084116	Bronze			2020-06-30	J	Liu, R; Wang, J; Zhao, TT; Cao, J; Che, DL; Ma, PY; Zhang, YJ; Zhang, T; Wang, N				Liu, Rui; Wang, Jue; Zhao, Tingting; Cao, Jiao; Che, Delu; Ma, Pengyu; Zhang, Yongjing; Zhang, Tao; Wang, Nan			Relationship between MRGPRX2 and pethidine hydrochloride- or fentanyl citrate-induced LAD2 cell degranulation	JOURNAL OF PHARMACY AND PHARMACOLOGY			English	Article						degranulation; fentanyl; mast cells; MRGPRX2; pethidine	MAST-CELLS; DRUG HYPERSENSITIVITY; REVISED NOMENCLATURE; ALLERGIC REACTIONS; MORPHINE; PATIENT; CHROMATOGRAPHY; RECEPTORS; X2	Objectives Pethidine hydrochloride (PH) and fentanyl citrate (FC) are opioid receptor agonists commonly used to treat pain clinically. PH and FC have been reported to have a high potential for pseudoallergic effects, but the underlying mechanism has not been well studied. MRGPRX2 is a novel atypical opioid receptor that is mainly expressed in human mast cells and considered to mediate drug-induced pseudoallergic reactions. This study aimed to investigate the allergy effect of these two opioid receptor agonists and the possible association of MRGPRX2 with this response. Methods Key findings HEK293-MRGPRX2/CMC assay, molecular docking assay, calcium mobilization assay, the test of beta-hexosaminidase, histamine and cytokine release assay were performed in this article. PH but not FC induced LAD2 cell activation and degranulation dose-dependently. Histamine, tumour necrosis factor (TNF)-alpha, interleukin (IL)-8, monocyte chemotactic protein 1 (MCP-1) and macrophage inflammatory protein (MIP-1 beta) levels were upregulated by PH, but not FC. The PH-induced activation of mast cell was MRGPRX2-dependent. Conclusions PH but not FC activated mast cells, leading to degranulation mediated via MRGPRX2 receptors, which could be greatly significant in future clinical applications of opioid receptor drugs.	[Liu, Rui; Wang, Jue; Zhao, Tingting; Cao, Jiao; Che, Delu; Ma, Pengyu; Zhang, Yongjing; Zhang, Tao; Wang, Nan] Xi An Jiao Tong Univ, Sch Pharm, 76 Yanta West Rd, Xian 710061, Shaanxi, Peoples R China	Wang, N (reprint author), Xi An Jiao Tong Univ, Sch Pharm, 76 Yanta West Rd, Xian 710061, Shaanxi, Peoples R China.	wangnan2014@xjtu.edu.cn			National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81230079, 81227802, 81503321]; Fundamental Research Funds for the Central University [xjj2016125]; Shaanxi Administration of Traditional Chinese Medicine [15-ZY032]	This work was supported by the National Natural Science Foundation of China (Grant Number: 81230079, 81227802 and 81503321), the Fundamental Research Funds for the Central University (Grant Number: xjj2016125) and foundation from Shaanxi Administration of Traditional Chinese Medicine (Grant Number: 15-ZY032).	Boyce JA, 2006, J ALLERGY CLIN IMMUN, V117, P1415, DOI 10.1016/j.jaci.2006.04.003; Broide DH, 2010, ALLERGY ASTHMA PROC, V31, P370, DOI 10.2500/aap.2010.31.3388; Bulfone-Paus S, 2017, TRENDS IMMUNOL, V38, P657, DOI 10.1016/j.it.2017.01.008; CHANEY MA, 1995, CAN J ANAESTH, V42, P891, DOI 10.1007/BF03011037; deShazo RD, 1997, JAMA-J AM MED ASSOC, V278, P1895, DOI 10.1001/jama.278.22.1895; Du H, 2012, J CHROMATOGR B, V887, P67, DOI 10.1016/j.jchromb.2012.01.011; Finkelman BS, 2010, PHARMACOEPIDEM DR S, V19, pS114; Fujisawa D, 2014, J ALLERGY CLIN IMMUN, V134, P622, DOI 10.1016/j.jaci.2014.05.004; Galli SJ, 1999, CURR OPIN IMMUNOL, V11, P53, DOI 10.1016/S0952-7915(99)80010-7; GROSMAN N, 1981, AGENTS ACTIONS, V11, P196, DOI 10.1007/BF01967614; Johansson SGO, 2001, ALLERGY, V56, P813, DOI 10.1034/j.1398-9995.2001.t01-1-00001.x; Johansson SGO, 2004, J ALLERGY CLIN IMMUN, V113, P832, DOI 10.1016/j.jaci.2003.12.591; Kashem SW, 2011, EUR J PHARMACOL, V668, P299, DOI 10.1016/j.ejphar.2011.06.027; Lansu K, 2017, NAT CHEM BIOL, V13, P529, DOI [10.1038/NCHEMBIO.2334, 10.1038/nchembio.2334]; McNeil BD, 2015, NATURE, V519, P237, DOI 10.1038/nature14022; Meng XL, 2016, CURR PHARM DESIGN, V22, P6734, DOI 10.2174/1381612822666161003115103; Moaddel R, 2005, ANAL CHEM, V77, P895, DOI 10.1021/ac048826x; Pergolizzi Joseph, 2008, Pain Pract, V8, P287, DOI 10.1111/j.1533-2500.2008.00204.x; Pfaunmiller EL, 2013, ANAL BIOANAL CHEM, V405, P2133, DOI 10.1007/s00216-012-6568-4; Pichler WJ, 2016, INT ARCH ALLERGY IMM, V171, P166, DOI 10.1159/000453265; SCHLUMBERGER HD, 1983, ANN ALLERGY, V51, P317; Simons FER, 2009, J ALLERGY CLIN IMMUN, V124, P625, DOI 10.1016/j.jaci.2009.08.025; Subramanian H, 2016, J ALLERGY CLIN IMMUN, V138, P700, DOI 10.1016/j.jaci.2016.04.051; Tatemoto K, 2006, BIOCHEM BIOPH RES CO, V349, P1322, DOI 10.1016/j.bbrc.2006.08.177; Vassilatis DK, 2003, P NATL ACAD SCI USA, V100, P4903, DOI 10.1073/pnas.0230374100; Wahler RG, 2017, J PAIN PALLIAT CARE, V31, P38, DOI 10.1080/15360288.2017.1279499; Woodhouse A, 1999, PAIN, V80, P545, DOI 10.1016/S0304-3959(98)00247-4; Woodhouse A, 1996, PAIN, V64, P115, DOI 10.1016/0304-3959(95)00082-8	28	0	0	1	15	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3573	2042-7158		J PHARM PHARMACOL	J. Pharm. Pharmacol.	DEC	2018	70	12					1596	1605		10.1111/jphp.13009			10	Pharmacology & Pharmacy	Pharmacology & Pharmacy	GZ7TT	WOS:000449687300002	30256417				2020-06-30	J	Arenillas, M; de Segura, IAG				Arenillas, Mario; Gomez de Segura, Ignacio A.			Anaesthetic effects of alfaxalone administered intraperitoneally alone or combined with dexmedetomidine and fentanyl in the rat	LABORATORY ANIMALS			English	Article						alfaxalone; dexmedetomidine; fentanyl; intraperitoneal; anaesthesia; rat	MEDETOMIDINE; COMBINATION; PROPOFOL; PHARMACOKINETICS; CYCLODEXTRIN; BRADYCARDIA; REVERSAL	Alfaxalone is a neuroactive steroid used as a general anaesthetic in several species including dogs, cats, rabbits and ferrets. It has a wide margin of safety and a similar anaesthetic profile to propofol. To increase its aqueous solubility, a new formulation with cyclodextrins has been marketed recently. The objective of this study was to evaluate the anaesthetic effect of several doses of alfaxalone alone, considering differences between sexes, and alfaxalone combined with dexmedetomidine and fentanyl in the rat administered by the intraperitoneal route. A total of 40 Sprague Dawley rats, involved in three studies, were used. Firstly, 25, 35 and 45 mg kg(-1) of alfaxalone alone were tested. In a second study, alfaxalone (25 mg kg(-1), females; 75 mg kg(-1), males) was combined with dexmedetomidine (0.05 mg kg(-1)). Finally, alfaxalone (20 mg kg(-1), females; 60 mg kg(-1), males) was combined with dexmedetomidine (0.05 mg kg(-1)) and fentanyl (0.1 mg kg(-1)). Times of onset and duration of anaesthesia, and analgesia, deemed as losing of withdrawal pedal reflex, were recorded. Alfaxalone alone produced a 2 - to 3-fold longer time of anaesthesia in females, although surgical anaesthesia was not achieved in either sex. The addition of dexmedetomidine and fentanyl to alfaxalone produced a similar time of analgesia as well as increased time of anaesthesia in both sexes. In conclusion, alfaxalone produces light anaesthesia in rats, and males required a higher dose. The combination with other sedatives or analgesics, such as dexmedetomidine or fentanyl, allows a more prolonged anaesthesia with analgesic effects, potentially suitable for invasive procedures.	[Arenillas, Mario; Gomez de Segura, Ignacio A.] Univ Complutense Madrid, Dept Anim Med & Surg, Madrid, Spain	Arenillas, M (reprint author), Univ Complutense Madrid, Vet Clin Teaching Hosp, Vet Fac, Dept Anim Med & Surg,Anaesthesiol Serv, Avda Puerta Hierro S-N, Madrid 28040, Spain.	marioare@ucm.es	Gomez de Segura, Ignacio/E-4687-2010	Gomez de Segura, Ignacio/0000-0001-5436-5396; Arenillas, Mario/0000-0002-3315-7931			Alves HC, 2007, LAB ANIM-UK, V41, P329, DOI 10.1258/002367707781282767; Alves HC, 2009, LAB ANIM-UK, V43, P27, DOI 10.1258/la.2008.007036; Bol CJJG, 1999, J PHARMACOL EXP THER, V291, P153; Alves HN, 2010, J AM ASSOC LAB ANIM, V49, P454; CHILD KJ, 1971, BRIT J ANAESTH, V43, P2, DOI 10.1093/bja/43.1.2-a; Claassen V., 1994, TECHNIQUES BEHAV NEU, P46; ESTES KS, 1990, INT J PHARM, V65, P101, DOI 10.1016/0378-5173(90)90014-U; Fernandes FC, 2006, RESP PHYSIOL NEUROBI, V154, P342, DOI 10.1016/j.resp.2006.02.002; FINK G, 1982, NATURE, V298, P270, DOI 10.1038/298270a0; Giral M, 2014, LAB ANIM-UK, V48, P313, DOI 10.1177/0023677214539150; Grubb TL, 2013, J FELINE MED SURG, V15, P858, DOI 10.1177/1098612X13478265; Higuchi S, 2016, JPN J VET RES, V64, P131, DOI 10.14943/jjvr.64.2.131; HU C, 1992, LAB ANIM-UK, V26, P15, DOI 10.1258/002367792780809075; Lau C, 2013, J VET PHARMACOL THER, V36, P516, DOI 10.1111/jvp.12055; LAUBIE M, 1974, EUR J PHARMACOL, V28, P66, DOI 10.1016/0014-2999(74)90113-7; Huynh M, 2015, VET REC, V176, P255, DOI 10.1136/vr.102522; Muir W, 2008, VET ANAESTH ANALG, V35, P451, DOI 10.1111/j.1467-2995.2008.00406.x; Muir W, 2009, VET ANAESTH ANALG, V36, P42, DOI 10.1111/j.1467-2995.2008.00428.x; MUNSON ES, 1970, ANESTHESIOLOGY, V32, P507, DOI 10.1097/00000542-197006000-00007; Pinelas R, 2014, VET ANAESTH ANALG, V41, P378, DOI 10.1111/vaa.12121; REITAN JA, 1978, ANESTH ANALG, V57, P31; Rodrigo-Mocholi D, 2016, VET ANAESTH ANALG, V43, P291, DOI 10.1111/vaa.12304; SAVOLA JM, 1989, ACTA VET SCAND, P39; TURNER DM, 1989, J PHARMACOL EXP THER, V248, P960; VIRTANEN R, 1989, ACTA VET SCAND, P29; White KL, 2017, VET ANAESTH ANALG, V44, P865, DOI 10.1016/j.vaa.2017.01.001	26	6	7	1	5	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0023-6772	1758-1117		LAB ANIM-UK	Lab. Anim.	DEC	2018	52	6					588	598		10.1177/0023677218764214			11	Veterinary Sciences; Zoology	Veterinary Sciences; Zoology	HD1JZ	WOS:000452267600003	29580166				2020-06-30	J	Tassonyi, E; Asztalos, L; Szabo-Maak, Z; Nemes, R; Pongracz, A; Lengyel, S; Fulesdi, B				Tassonyi, Edoemer; Asztalos, Laszlo; Szabo-Maak, Zoltan; Nemes, Reka; Pongracz, Adrienn; Lengyel, Szabolcs; Fulesdi, Bela			Reversal of Deep Pipecuronium-Induced Neuromuscular Block With Moderate Versus Standard Dose of Sugammadex: A Randomized, Double-Blind, Noninferiority Trial	ANESTHESIA AND ANALGESIA			English	Article							VECURONIUM; ANESTHESIA; BROMIDE; PANCURONIUM; ROCURONIUM; EQUIVALENCE; ISOFLURANE	BACKGROUND: Certain surgical interventions may require a deep neuromuscular block (NMB). Reversal of such a block before tracheal extubation is challenging. Because anticholinesterases are ineffective in deep block, sugammadex 4 mg/kg has been recommended for the reversal of rocuronium- or vecuronium-induced deep NMB. However, this recommendation requires opening 2 vials of 200 mg sugammadex, which results in an increase in drug costs. Therefore, we sought a less expensive solution for the induction and reversal of deep NMB. Although the optimal dose of sugammadex for antagonism of deep block from pipecuronium has not been established, data pertaining to moderate block are available. Accordingly, we hypothesized that sugammadex 2 mg/kg would be a proper dose to reverse deep pipecuronium block, enabling us to avoid cost increases. In the present study, we compared sugammadex 2 mg/kg with the standard dose of 4 mg/kg for reversal of deep block from pipecuronium. METHODS: This single-center, randomized, double-blind, 2 parallel-arms, noninferiority study comprised 50 patients undergoing general anesthesia with propofol, sevoflurane, fentanyl, and pipecuronium. Neuromuscular monitoring was performed with acceleromyography (TOF-Watch SX). Noninferiority margin was specified beforehand as an increase in reversal time of no >10% (corresponding to 1 minute for the primary outcome). When the block spontaneously recovered to posttetanic count 1, the patients randomly received sugammadex 2 or 4 mg/kg, and the time from the injection to the train-of-four (TOF) ratio of 1.0 was measured. Primary outcome was the time to achieve the normalized TOF ratio of 0.9 in a particular patient. Residual or recurrent postoperative NMB was additional end point. RESULTS: Each patient recovered to the normalized TOF ratio of 0.9. In the 2 mg/kg group, reversal time was 1.73 1.03 minutes (95% confidence interval [CI], 1.33-2.13; n = 25), and in the 4 mg/kg group, reversal time was 1.42 +/- 0.63 minutes (mean +/- standard deviation) (95% CI, 1.17-1.67; n = 25). The mean difference in reversal times between the 2 groups was 0.31 minutes (95% CI, -0.18 to 0.8), and the upper limit of CI was below the noninferiority margin of 1 minute. Postoperative block did not occur. CONCLUSIONS: The effect of sugammadex 2 mg/kg was noninferior to that of 4 mg/kg in reversing posttetanic count-1 degree pipecuronium block. Sugammadex reversal of deep pipecuronium block appears to be effective.	[Tassonyi, Edoemer; Asztalos, Laszlo; Szabo-Maak, Zoltan; Nemes, Reka; Pongracz, Adrienn; Fulesdi, Bela] Univ Debrecen, Dept Anesthesiol & Intens Care, Fac Med, Debrecen, Hungary; [Lengyel, Szabolcs] Hungarian Acad Sci, Ctr Ecol Res, Dept Tisza Res, Danube Res Inst, Debrecen, Hungary	Fulesdi, B (reprint author), Univ Debrecen, Dept Anesthesiol & Intens Care, Nagyerdei Krt 98, H-4032 Debrecen, Hungary.	fulesdi@med.unideb.hu	Lengyel, Szabolcs/A-3483-2011	Lengyel, Szabolcs/0000-0002-7049-0100	Hungarian Brain Research Program [510, KTIA 13 NAP A II/5]	Supported by the Hungarian Brain Research Program Grant 510 No. KTIA 13 NAP A II/5 and by departmental sources.	Austin PC, 2009, STAT MED, V28, P3083, DOI 10.1002/sim.3697; AZAD SS, 1989, J CLIN PHARMACOL, V29, P657, DOI 10.1002/j.1552-4604.1989.tb03396.x; Berg H, 1997, ACTA ANAESTH SCAND, V41, P1095, DOI 10.1111/j.1399-6576.1997.tb04851.x; Biehl J W, 2001, AANA J, V69, P31; Bom A, 2002, ANGEW CHEM INT EDIT, V41, P266; BOROS M, 1980, ARZNEIMITTELFORSCH, V30-1, P389; Duvaldestin P, 2010, ANESTH ANALG, V110, P74, DOI 10.1213/ANE.0b013e3181c3be3c; Fuchs-Buder T, 2007, ACTA ANAESTH SCAND, V51, P789, DOI 10.1111/j.1399-6576.2007.01352.x; HARROPGRIFFITHS W, 1992, ANAESTHESIA, V47, P105, DOI 10.1111/j.1365-2044.1992.tb02003.x; Hristovska AM, 2017, COCHRANE DB SYST REV, V8, DOI DOI 10.1002/14651858; LARIJANI GE, 1989, ANESTH ANALG, V68, P734; Madsen MV, 2015, ACTA ANAESTH SCAND, V59, P1, DOI 10.1111/aas.12419; Mascha EJ, 2011, ANESTH ANALG, V112, P678, DOI 10.1213/ANE.0b013e318206f872; Piaggio G, 2006, JAMA-J AM MED ASSOC, V295, P1152, DOI 10.1001/jama.295.10.1152; PITTET JF, 1989, ANESTHESIOLOGY, V71, P210, DOI 10.1097/00000542-198908000-00008; Schoeffler P, 2000, ANN FR ANESTH, V19, p391S; Srivastava A, 2009, BRIT J ANAESTH, V103, P115, DOI 10.1093/bja/aep093; Suy K, 2007, ANESTHESIOLOGY, V106, P283, DOI 10.1097/00000542-200702000-00016; TASSONYI E, 1988, ANESTHESIOLOGY, V69, P793, DOI 10.1097/00000542-198811000-00032; Tassonyi E, 1986, HDB EXPT PHARM, V79, P599; Tassonyi E, 2015, ANESTH ANALG, V121, P373, DOI 10.1213/ANE.0000000000000766; TUBA Z, 1980, ARZNEIMITTEL-FORSCH, V30-1, P342	22	1	1	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	DEC	2018	127	6					1344	1350		10.1213/ANE.0000000000003719			7	Anesthesiology	Anesthesiology	HA6ZN	WOS:000450430400024	30169407				2020-06-30	J	Hollerbach, A; Fedick, PW; Cooks, RG				Hollerbach, Adam; Fedick, Patrick W.; Cooks, R. Graham			Ion Mobility-Mass Spectrometry Using a Dual-Gated 3D Printed Ion Mobility Spectrometer	ANALYTICAL CHEMISTRY			English	Article							PLASMA CHROMATOGRAPHY; MANIPULATIONS; POWER; FUNDAMENTALS; PERFORMANCE; SEPARATION; PATH; MS	Described herein is the development of a 3D-printed drift-tube ion mobility spectrometer (IMS) which operates in the open air and is capable of being coupled to any mass spectrometer. The IMS possesses one electrospray focusing electrode, 31 drift electrodes with 7 mm inner diameters, and 2 ion gates at opposite ends of the IMS, totaling 109 mm in length. The second ion gate was timed with respect to the first ion gate to transmit portions of the separating ion packets to the MS at specified time intervals. By scanning the second ion gate and acquiring mass spectra during each time interval, we reconstructed ion mobility chronograms using mass spectra. Resolving powers of up to 45 were acquired using tetraalkylammonium cations. Separation is also demonstrated for solutions of amphetamines, opioids (fentanyls/fentanils), and bradykinin and angiotensin II. The highest mobility resolving powers were obtained when the injection times of the first and second ion gates were 0.3 and 1.0 ms, respectively. Experiments were performed on both an ion trap and triple quadruple mass analyzer to showcase the adaptability of the plastic IMS. Insights were gained into how ions separate in the open air compared to vacuum conditions with pure gas.	[Hollerbach, Adam; Fedick, Patrick W.; Cooks, R. Graham] Purdue Univ, Chem Dept, 560 Oval Dr, W Lafayette, IN 47907 USA	Cooks, RG (reprint author), Purdue Univ, Chem Dept, 560 Oval Dr, W Lafayette, IN 47907 USA.	cooks@purdue.edu	Cooks, R Graham/G-1051-2015; Hollerbach, Adam/T-1408-2017	Cooks, R Graham/0000-0002-9581-9603; Fedick, Patrick/0000-0002-8199-9500; Hollerbach, Adam/0000-0003-2465-6031	United States Department of Energy, Office of Science, Office of Basic Energy Sciences, Separations and Analysis ProgramUnited States Department of Energy (DOE) [DE-FG02-06ER15807]; Department of Defense SMART scholarship	This material is based upon work supported by the United States Department of Energy, Office of Science, Office of Basic Energy Sciences, Separations and Analysis Program, under Award DE-FG02-06ER15807. P.W.F. would like to acknowledge support from the Department of Defense SMART scholarship. Chris Harrilal is acknowledged for allowing the use of a high voltage waveform generator. Erick Norwood is thanked for his electronics expertise.	Baether W., 2012, SENSORS J IEEE, V12, P1748; Baird Z, 2015, METHODS INSTRUMENTAT; Barmpounis K, 2016, AEROSOL SCI TECH, V50, DOI 10.1080/02786826.2015.1130216; Bohnhorst A, 2016, INT J ION MOBIL SPEC, V19, P167, DOI 10.1007/s12127-016-0202-7; BOWERS MT, 1993, SCIENCE, V260, P1446, DOI 10.1126/science.260.5113.1446; Bush MF, 2010, ANAL CHEM, V82, P9557, DOI 10.1021/ac1022953; COHEN MJ, 1970, J CHROMATOGR SCI, V8, P330, DOI 10.1093/chromsci/8.6.330; Cumeras R, 2015, ANALYST, V140, P1391, DOI 10.1039/c4an01101e; Cumeras R, 2015, ANALYST, V140, P1376, DOI 10.1039/c4an01100g; Davis EJ, 2009, ANAL CHEM, V81, P3270, DOI 10.1021/ac802431q; Deng LL, 2017, ANAL CHEM, V89, P4628, DOI 10.1021/acs.analchem.7b00185; Deng LL, 2016, CHEMISTRYSELECT, V1, P2396, DOI 10.1002/slct.201600460; Fedick PW, 2017, ANAL CHEM, V89, P10973, DOI 10.1021/acs.analchem.7b02798; Fernandez-Lima FA, 2011, REV SCI INSTRUM, V82, DOI 10.1063/1.3665933; Fernandez-Lima F, 2011, INT J ION MOBIL SPEC, V14, P93, DOI 10.1007/s12127-011-0067-8; Groessl M, 2015, ANALYST, V14, P6904, DOI 10.1039/c5an00838g; Gunzer F, 2010, ANAL CHEM, V82, P3756, DOI 10.1021/ac100166m; Hollerbach A, 2018, ANALYST, V143, P232, DOI 10.1039/c7an01278k; Hollerbach A, 2017, ANAL CHEM, V89, P5058, DOI 10.1021/acs.analchem.7b00469; Intra A. P. D. P, 2008, SONGKLANAKARIN J SCI, V30, P243; Kailemia MJ, 2014, J AM SOC MASS SPECTR, V25, P258, DOI 10.1007/s13361-013-0771-1; Kanu AB, 2008, J MASS SPECTROM, V43, P1, DOI 10.1002/jms.1383; Kaplan K, 2010, ANAL CHEM, V82, P9336, DOI 10.1021/ac1017259; KARASEK FW, 1976, J CHROMATOGR, V117, P327, DOI 10.1016/0021-9673(76)80009-X; KARASEK FW, 1974, ANAL CHEM, V46, pA710, DOI 10.1021/ac60344a053; Keelor JD, 2017, ANAL CHEM, V89, P11301, DOI 10.1021/acs.analchem.7b01866; Knutson E. O., 1975, Journal of Aerosol Science, V6, P443, DOI 10.1016/0021-8502(75)90060-9; Kwasnik M, 2007, ANAL CHEM, V79, P7782, DOI 10.1021/ac071226o; Kwasnik M, 2010, RAPID COMMUN MASS SP, V24, P1911, DOI 10.1002/rcm.4592; Lanucara F, 2014, NAT CHEM, V6, P281, DOI [10.1038/NCHEM.1889, 10.1038/nchem.1889]; Larriba C, 2014, J AM SOC MASS SPECTR, V25, P1332, DOI 10.1007/s13361-014-0885-0; Liu WJ, 2017, ANAL CHEM, V89, P2800, DOI 10.1021/acs.analchem.6b03727; Matz LM, 2002, J AM SOC MASS SPECTR, V13, P300, DOI 10.1016/S1044-0305(01)00366-X; Michelmann K, 2015, J AM SOC MASS SPECTR, V26, P14, DOI 10.1007/s13361-014-0999-4; Nahin M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-06448-w; Oberreit D, 2015, J CHEM PHYS, V143, DOI 10.1063/1.4930278; Purves RW, 1999, ANAL CHEM, V71, P2346, DOI 10.1021/ac981380y; Reinecke T., 2018, HARDWAREX, V4, DOI [10.1016/J.OHX.2018.E00030., DOI 10.1016/J.OHX.2018.E00030]; Rus J, 2010, INT J MASS SPECTROM, V298, P30, DOI 10.1016/j.ijms.2010.05.008; Sacristan E, 1998, IEEE T INSTRUM MEAS, V47, P769, DOI 10.1109/19.744345; Schneider BB, 2016, MASS SPECTROM REV, V35, P687, DOI 10.1002/mas.21453; Shvartsburg AA, 2008, ANAL CHEM, V80, P9689, DOI 10.1021/ac8016295; Sisco E, 2017, FORENSIC CHEM, V4, P108, DOI 10.1016/j.forc.2017.04.001; Spangler GE, 2010, ANAL CHEM, V82, P8052, DOI 10.1021/ac100240t; Tabrizchi M, 2010, ANAL CHEM, V82, P746, DOI 10.1021/ac902009c; Webb IK, 2016, J AM SOC MASS SPECTR, V27, P1285, DOI 10.1007/s13361-016-1397-x; Webb IK, 2014, ANAL CHEM, V86, P9169, DOI 10.1021/ac502055e	47	8	8	2	33	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	0003-2700	1520-6882		ANAL CHEM	Anal. Chem.	NOV 20	2018	90	22					13265	13272		10.1021/acs.analchem.8b02209			8	Chemistry, Analytical	Chemistry	HB7GS	WOS:000451246100021	30281279				2020-06-30	J	Yan, Q; Su, Y; Gao, L; Ding, N; Zhang, HY; E, W; Wang, Y; Feng, Y; An, HY				Yan, Qi; Su, Yi; Gao, Lan; Ding, Nan; Zhang, Hong-Ying; E, Wen; Wang, Yue; Feng, Yi; An, Hai-Yan			Impact of CYP3A4*1G Polymorphism on Fentanyl Analgesia Assessed by Analgesia Nociception Index in Chinese Patients Undergoing Hysteroscopy	CHINESE MEDICAL JOURNAL			English	Article						Analgesia; CYP3A4; Fentanyl; Genetic Polymorphism	POSTOPERATIVE PAIN; ANALGESIA/NOCICEPTION INDEX; VARIABILITY; PHARMACOKINETICS; CHILDREN; ALLELES	Background: The clinical efficacy of fentanyl for pain control differs greatly across individuals. The purpose of this study was to investigate the impact of CYP3A4*1G polymorphism including wild-type homozygote (CYP3A4*1/*1, GG), mutant heterozygote (CYP3A4*1/*1G, GA), and mutant homozygote (CYP3A4*1G/*1G, AA) on fentanyl analgesia in Chinese patients undergoing hysteroscopy by the assessment of analgesia nociception index (ANI). Methods: A total of 200 gynecologic patients scheduled for elective hysteroscopy under general anesthesia at Peking University People's Hospital from May to December in 2017 were enrolled in this study. Venous blood was withdrawn for genotyping of CYP3A4*1G before operation. Fentanyl 1 mg/kg was administered preoperatively followed by target-controlled infusion of propofol for induction and maintenance. Intraoperative analgesic efficacy of fentanyl was assessed by ANI monitoring at T0 (entering room), T1 (cervical dilation), T2 (start of cervical aspiration), and T3 (end of cervical aspiration) time points. The duration of propofol infusion and total dosage of propofol were recorded as well. Results: The patients were divided into three groups according to CYP3A4*1G polymorphism, including 143 in GG group, 47 in GA group, and 10 in AA group. There was no significant difference in clinical demographics among three groups. The frequency of CYP3A4*1G variant alleles accounted for 16.8% and the distribution of variant alleles was consistent with HardyuWeinberg equilibrium. Using a multilevel model, ANI values at T1 (63.81 19.61), T2 (63.63 17.82), and T3 (65.68 17.79) were significantly lower than that at T0 (77.16 12.93) in the study population (F = 23.50, P < 0.001), suggesting that higher levels of pain at T1, T2, and T3 than T0. Patients with GG genotype showed significantly lower ANI than those with GA or AA genotypes during hysteroscopy under the same dose of fentanyl. Conclusion: CYP3A4*1G polymorphism associated with the analgesic efficacy of intraoperative fentanyl in the patients undergoing hysteroscopy under general anesthesia.	[Yan, Qi; Gao, Lan; Feng, Yi; An, Hai-Yan] Peking Univ, Dept Anesthesiol, Peoples Hosp, Beijing 100044, Peoples R China; [Su, Yi] Jincheng Maternal & Child Hlth Care Hosp, Dept Anesthesiol, Jincheng 048000, Shanxi, Peoples R China; [Ding, Nan; Zhang, Hong-Ying; E, Wen] Peking Univ, Dept Pathol, Hlth Sci Ctr, Beijing 100191, Peoples R China; [Wang, Yue] Peking Univ, Dept Gynecol, Peoples Hosp, Beijing 100044, Peoples R China	An, HY (reprint author), Peking Univ, Dept Anesthesiol, Peoples Hosp, Beijing 100044, Peoples R China.	anhaiyan76@163.com			Peking University People's Hospital Research and Development Funds [RDC2013-10]	The study was supported by a grant from Peking University People's Hospital Research and Development Funds (No. RDC2013-10).	Armenian P, 2018, NEUROPHARMACOLOGY, V134, P121, DOI 10.1016/j.neuropharm.2017.10.016; Boselli E, 2014, BRIT J ANAESTH, V112, P715, DOI 10.1093/bja/aet407; Boselli E, 2013, BRIT J ANAESTH, V111, P453, DOI 10.1093/bja/aet110; Chen JZ, 2014, ANN TRANSL MED, V2, DOI 10.3978/j.issn.2305-5839.2013.03.02; Dong ZL, 2012, J CLIN PHARM THER, V37, P153, DOI 10.1111/j.1365-2710.2011.01268.x; Gall O, 2015, BRIT J ANAESTH, V115, P890, DOI 10.1093/bja/aev361; Garcia-Martin E, 2002, CLIN PHARMACOL THER, V71, P196, DOI 10.1067/mcp.2002.121371; Gulati S, 2014, ENVIRON TOXICOL PHAR, V37, P1186, DOI 10.1016/j.etap.2014.03.013; Haan S, 1999, J BIOL CHEM, V274, P1342, DOI 10.1074/jbc.274.3.1342; Jeanne M, 2012, J CLIN MONIT COMPUT, V26, P289, DOI 10.1007/s10877-012-9354-0; Kharasch ED, 2004, ANESTHESIOLOGY, V101, P729, DOI 10.1097/00000542-200409000-00022; Kuip EJM, 2017, BRIT J CLIN PHARMACO, V83, P294, DOI 10.1111/bcp.13129; Le Gall L, 2019, ANAESTH CRIT CARE PA, V38, P35, DOI 10.1016/j.accpm.2017.09.004; Le Guen M, 2012, INT J OBSTET ANESTH, V21, P146, DOI 10.1016/j.ijoa.2012.01.001; Li JW, 2018, SUPPORT CARE CANCER, V26, P2763, DOI 10.1007/s00520-018-4130-4; Liu SB, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00176; Nielsen LM, 2015, PAIN PRACT, V15, P580, DOI 10.1111/papr.12232; Ren ZY, 2015, PAIN PHYSICIAN, V18, P131; Rodriguez-Antona C, 2005, BIOCHEM BIOPH RES CO, V338, P299, DOI 10.1016/j.bbrc.2005.09.020; Werk AN, 2014, CLIN PHARMACOL THER, V96, P340, DOI 10.1038/clpt.2014.129; Yan Q, 2017, BRIT J ANAESTH, V118, P635, DOI 10.1093/bja/aex061; Yuan JJ, 2015, PHARMACOLOGY, V96, P55, DOI 10.1159/000433441; Yuan RM, 2011, CLIN CHIM ACTA, V412, P755, DOI 10.1016/j.cca.2010.12.038; Zhang HD, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000006013; Zhang JL, 2018, GENE, V661, P78, DOI 10.1016/j.gene.2018.03.081; Zhang W, 2010, EUR J CLIN PHARMACOL, V66, P61, DOI 10.1007/s00228-009-0726-4; Zhou SF, 2019, XENOBIOTICA, V49, P375, DOI 10.1080/00498254.2018.1447711; Ziesenitz VC, 2018, CLIN PHARMACOKINET, V57, P125, DOI 10.1007/s40262-017-0569-6	28	1	1	0	2	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0366-6999			CHINESE MED J-PEKING	Chin. Med. J.	NOV 20	2018	131	22					2693	+		10.4103/0366-6999.243934			7	Medicine, General & Internal	General & Internal Medicine	HA3AJ	WOS:000450120700007	30381583	DOAJ Gold, Green Published			2020-06-30	J	Liu, YF; Song, X; Sun, D; Wang, JB; Lan, YL; Yang, GC; Meng, FZ; Wang, Y; Cui, YF; Zhang, B; Li, XY; Liu, LX				Liu, Yufeng; Song, Xuan; Sun, Dan; Wang, Jiabei; Lan, Yaliang; Yang, Guangchao; Meng, Fanzheng; Wang, Yan; Cui, Yifeng; Zhang, Bo; Li, Xianying; Liu, Lianxin			Evaluation of Intravenous Parecoxib Infusion Pump of Patient-Controlled Analgesia Compared to Fentanyl for Postoperative Pain Management in Laparoscopic Liver Resection	MEDICAL SCIENCE MONITOR			English	Article						Analgesia; Anti-Inflammatory Agents, Non-Steroidal; Laparoscopy	GASTROINTESTINAL TOXICITY; EFFICACY; MORPHINE; CHOLECYSTECTOMY; SODIUM; PARACETAMOL; INJECTION	Background: As laparoscopic liver resection is becoming a commonly used method for hepatic surgery, postoperative pain management is emerging as one of the trickiest problems after surgery. The ideal method of pain management is controversial and the optimal strategy for postoperative pain management after surgery remains unclear. The present study evaluated the postoperative analgesic efficacy of parecoxib and fentanyl, and the benefit of a new intravenous parecoxib infusion pump with patient-controlled analgesia after laparoscopic liver resection. Material/Methods: This controlled, prospective, randomized, double-blind trial compared VAS scores among 3 groups of patients: a fentanyl group (FEN group) using a fentanyl citrate pump, an intravenous parecoxib group (IVPA group) receiving intravenous parecoxib, and a parecoxib pump group (PUPA group) receiving parecoxib sodium by analgesia pump. We enrolled 124 patients planned for laparoscopic liver resection. The primary outcome was VAS score at rest and with movement. Secondary outcomes were adverse effects (including nausea), sedation, pruritus, and quality of life. Result: For all time intervals, the VAS scores were significantly lower in the PUPA group. VAS scores at rest and with movement in the PUPA group were the lowest among the 3 groups, while the scores in the FEN group were the highest. More adverse effects were detected in the FEN group, and no significant differences in adverse effects were found between the intravenous group and the parecoxib pump group. Conclusions: Use of the intravenous infusion parecoxib pump for patient-controlled analgesia provides superior analgesic efficacy and fewer adverse effects for patients after laparoscopic liver resection.	[Liu, Yufeng; Song, Xuan; Sun, Dan; Wang, Jiabei; Lan, Yaliang; Yang, Guangchao; Meng, Fanzheng; Wang, Yan; Cui, Yifeng; Zhang, Bo; Li, Xianying; Liu, Lianxin] Harbin Med Univ, Affiliated Hosp 1, Dept Gen Surg, Lab Hepatosplen Surg,Minist Educ, Harbin, Heilongjiang, Peoples R China	Liu, LX (reprint author), Harbin Med Univ, Affiliated Hosp 1, Dept Gen Surg, Lab Hepatosplen Surg,Minist Educ, Harbin, Heilongjiang, Peoples R China.	liulianxin@ems.hrbmu.edu.cn			National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81772588, 81803001, 81773194]; First Affiliated Hospital Youth Innovating Talents Training Plan Fund for Regular Undergraduate Colleges [UNPYSCT-2017066]; Harbin Medical University Doctoral Research Innovation Fund [2018B003]; Heilongjiang Province Postdoctoral Science FoundationChina Postdoctoral Science Foundation [LBH-Z17135]; China Postdoctoral Science FoundationChina Postdoctoral Science Foundation [2018M631948]	This study was supported by the National Natural Science Foundation of China (81773194), the First Affiliated Hospital Youth Innovating Talents Training Plan Fund for Regular Undergraduate Colleges (UNPYSCT-2017066), the Harbin Medical University Doctoral Research Innovation Fund (2018B003), the Heilongjiang Province Postdoctoral Science Foundation (LBH-Z17135), the China Postdoctoral Science Foundation Funded Project (2018M631948), the National Natural Science Foundation of China (81803001), and the National Natural Science Foundation of China (81772588)	Abdulla S, 2012, PAIN RES TREAT, V2012, DOI 10.1155/2012/305821; Akaraviputh T, 2009, WORLD J GASTROENTERO, V15, P2005, DOI 10.3748/wjg.15.2005; Anastase DM, 2014, ANESTHESIOL RES PRAC, V2014, DOI 10.1155/2014/569319; Baratta Jaime L, 2014, J Surg Orthop Adv, V23, P22; Barton SF, 2002, ANESTHESIOLOGY, V97, P306, DOI 10.1097/00000542-200208000-00004; Benyamin R, 2008, PAIN PHYSICIAN, V11, pS105; Bisgaard T, 2006, ANESTHESIOLOGY, V104, P835, DOI 10.1097/00000542-200604000-00030; Bombardier C, 2000, NEW ENGL J MED, V343, P1520, DOI 10.1056/NEJM200011233432103; Busch CA, 2006, J BONE JOINT SURG AM, V88A, P959, DOI 10.2106/JBJS.E.00344; Cakan T, 2008, J NEUROSURG ANESTH, V20, P169, DOI 10.1097/ANA.0b013e3181705cfb; Chia YT, 1999, CAN J ANAESTH, V46, P872, DOI 10.1007/BF03012978; Clivatti J, 2010, REV BRAS ANESTESIOL, V60, P355; Dilmen OK, 2010, EUR J ANAESTH, V27, P428, DOI 10.1097/EJA.0b013e32833731a4; Fletcher D, 1997, CAN J ANAESTH, V44, P479, DOI 10.1007/BF03011934; Gan TJ, 2004, ACTA ANAESTH SCAND, V48, P1194, DOI 10.1111/j.1399-6576.2004.00495.x; Grass JA, 2005, ANESTH ANALG, V101, pS44, DOI 10.1213/01.ANE.0000177102.11682.20; Guignard B, 2000, ANESTHESIOLOGY, V93, P409, DOI 10.1097/00000542-200008000-00019; Kehlet H, 2006, LANCET, V367, P1618, DOI 10.1016/S0140-6736(06)68700-X; Leal PD, 2010, REV BRAS ANESTESIOL, V60, P639, DOI 10.1016/S0034-7094(10)70080-5; Lee M, 2011, PAIN PHYSICIAN, V14, P145; Li Y, 2018, SPINE, V43, pE98, DOI 10.1097/BRS.0000000000002245; Lloyd R, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004771.pub4; Malan TP, 2005, ANESTH ANALG, V100, P454, DOI 10.1213/01.ANE.0000143355.52418.CF; Momeni M, 2006, DRUGS, V66, P2321, DOI 10.2165/00003495-200666180-00005; Stanley TH, 2014, J PAIN, V15, P1215, DOI 10.1016/j.jpain.2014.08.010; Toygar P, 2008, AGRI, V20, P14; Warner TD, 1999, P NATL ACAD SCI USA, V96, P7563, DOI 10.1073/pnas.96.13.7563	27	1	1	0	4	INT SCIENTIFIC INFORMATION, INC	MELVILLE	150 BROADHOLLOW RD, STE 114, MELVILLE, NY 11747 USA	1643-3750			MED SCI MONITOR	Med. Sci. Monitor	NOV 15	2018	24						8224	8231		10.12659/MSM.913182			8	Medicine, Research & Experimental	Research & Experimental Medicine	HB4OP	WOS:000451033700003	30439866	Green Published			2020-06-30	J	Davies, T; Edwards, JC				Davies, Todd; Edwards, Joan C.			An Unusual Amnestic Syndrome Associated With Combined Fentanyl and Cocaine Use	ANNALS OF INTERNAL MEDICINE			English	Letter							ABUSE		[Davies, Todd] Marshall Univ, Joan C Edwards Sch Med, Huntington, WV 25755 USA	Davies, T (reprint author), Marshall Univ, Joan C Edwards Sch Med, Huntington, WV 25755 USA.						[Anonymous], 2015, NEURONTIN PACKAGE IN; Baird CRW, 2014, EUR ADDICT RES, V20, P115, DOI 10.1159/000355268; Duru UB, 2018, ANN INTERN MED, V168, P747, DOI 10.7326/L17-0575; Evoy KE, 2017, DRUGS, V77, P403, DOI 10.1007/s40265-017-0700-x; Mallick-Searle T, 2016, J MULTIDISCIP HEALTH, V9, DOI 10.2147/JMDH.S106340	5	0	0	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 6	2018	169	9					662	662		10.7326/L18-0410			1	Medicine, General & Internal	General & Internal Medicine	GZ4UP	WOS:000449399700019	30398630				2020-06-30	J	Haddad, A; Comanescu, MA; Green, O; Kubic, TA; Lombardi, JR				Haddad, Abed; Comanescu, Mircea A.; Green, Omar; Kubic, Thomas A.; Lombardi, John R.			Detection and Quantitation of Trace Fentanyl in Heroin by Surface-Enhanced Raman Spectroscopy	ANALYTICAL CHEMISTRY			English	Article							SENSITIVE DETECTION; QUALITY ASSURANCE; FILTER-PAPER; SILVER; SERS; COCAINE; SCATTERING; DRUGS; QUANTIFICATION; IDENTIFICATION	The identification of fentanyl, a main culprit in opioid overdose deaths, has become critical. Whereas Raman spectroscopy is an effective tool for detecting illicit drugs, the weak intensity of Raman scattering can make it difficult to distinguish trace materials. This shortcoming is addressed by surface-enhanced Raman spectroscopy (SERS), which produces strong signal enhancements when target compounds are near metal nanoparticles. This work examines the use of a paper-based substrate impregnated with silver nanoparticles for the detection of trace quantities of fentanyl alone and as an adulterant in heroin. In addition, intensity ratios of diagnostic peaks associated with each substance were fitted to a Langmuir isotherm calibration model and used for the quantitative analysis of fentanyl in heroin mixtures. Linearity was observed at <6% fentanyl, a significant finding that is consistent with concentrations found in drugs seized during law enforcement efforts. In addition, swabbing with these paper-based SERS substrates facilitated the recovery of fentanyl from surfaces, showing this to be applicable for crime scene investigations. However, assessment using the calibration model proved difficult for swabbed samples. Overall, this work demonstrates a potentially simple and sensitive technique for the forensic analysis and quantitation of fentanyl in trace amounts.	[Haddad, Abed] CUNY Grad Sch & Univ Ctr, PhD Program Chem, 365 Fifth Ave, New York, NY 10016 USA; [Haddad, Abed; Lombardi, John R.] CUNY City Coll, Dept Chem, 160 Convent Ave, New York, NY 10031 USA; [Comanescu, Mircea A.; Kubic, Thomas A.] CUNY John Jay Coll Criminal Justice, PhD Program Criminal Justice, Forens Sci Specializat, 524 West 59th St, New York, NY 10019 USA; [Green, Omar] Ionica Sci Inc, McGovern Ctr Venture Dev Life Sci, 413 Weill Hall,526 North Campus Dr, Ithaca, NY 14853 USA	Haddad, A (reprint author), CUNY Grad Sch & Univ Ctr, PhD Program Chem, 365 Fifth Ave, New York, NY 10016 USA.; Haddad, A (reprint author), CUNY City Coll, Dept Chem, 160 Convent Ave, New York, NY 10031 USA.	ahaddad@gradcenter.cuny.edu		Haddad, Abed/0000-0001-8710-0394	National Science FoundationNational Science Foundation (NSF) [HRD-1547830, CHE-1402750]; City University of New York PSC-CUNY Faculty Research Award Program [69079]	We thank the Museum of Modern Art, namely, Chris McGlinchey and Ana Martins, for instrumental access and research facilities. We thank the National Science Foundation (CHE-1402750) for partial funding of this project. This work was also partially supported by National Science Foundation grant number HRD-1547830 (IDEALS CREST). Further support came from the City University of New York PSC-CUNY Faculty Research Award Program, Grant No. 69079. The opinions, findings, and conclusions or recommendations expressed in this publication are those of the authors and do not necessarily reflect those of the National Science Foundation.	Asadi Z, 2017, J MOL STRUCT, V1128, P552, DOI 10.1016/j.molstruc.2016.09.027; B&W Tek Inc, 2017, US SURF ENH RAM SPEC; Behrman AD, 2008, J EMERG NURS, V34, P80, DOI 10.1016/j.jen.2007.10.001; Betz JF, 2014, PHYS CHEM CHEM PHYS, V16, P2224, DOI 10.1039/c3cp53560f; Bilankohi SM, 2015, ORIENT J CHEM, V31, P2259, DOI 10.13005/ojc/310452; Boyd S, 2013, J FORENSIC SCI, V58, P753, DOI 10.1111/1556-4029.12120; Brettell T. A, 2004, MODERN PRACTICE GAS, P883; Broseus J, 2015, FORENSIC SCI INT, V257, P307, DOI 10.1016/j.forsciint.2015.09.014; Caro C, 2008, J RAMAN SPECTROSC, V39, P1162, DOI 10.1002/jrs.1957; Chamuah N, 2017, J PHYS D APPL PHYS, V50, DOI 10.1088/1361-6463/aa8fef; Cobaugh DJ, 2014, AM J HEALTH-SYST PH, V71, P1539, DOI 10.2146/ajhp140157; Cole C, 2011, DRUG TEST ANAL, V3, P89, DOI 10.1002/dta.220; Comanescu MA, 2018, APPL SPECTROSC, V72, P60, DOI 10.1177/0003702817723339; Diagnostic anSERS Inc, 2017, APPL EX; Dies H, 2018, SENSOR ACTUAT B-CHEM, V257, P382, DOI 10.1016/j.snb.2017.10.181; Drug Enforcement Administration, 2015, DEA ISS NAT AL FENT; Farquharson Stuart, 2011, Pharmaceutics, V3, P425, DOI 10.3390/pharmaceutics3030425; Fedick PW, 2017, ANAL CHEM, V89, P10973, DOI 10.1021/acs.analchem.7b02798; Penido CAFD, 2017, J RAMAN SPECTROSC, V48, P1732, DOI 10.1002/jrs.5231; Penido CAFD, 2016, J RAMAN SPECTROSC, V47, P28, DOI 10.1002/jrs.4864; Fierro-Mercado PM, 2012, INT J SPECTROSC, DOI 10.1155/2012/716527; Hasi WLJ, 2015, APPL PHYS A-MATER, V118, P799, DOI 10.1007/s00339-014-8800-x; He S, 2017, RSC ADV, V7, P16264, DOI 10.1039/c6ra28450g; HORWITZ W, 1980, J ASSOC OFF ANA CHEM, V63, P1344; Huang ZF, 2017, J NANOMATER, V2017, DOI 10.1155/2017/4807064; Inscore F, 2011, APPL SPECTROSC, V65, P1004, DOI 10.1366/11-06310; Karpov SV, 2007, COLLOID J+, V69, P170, DOI 10.1134/S1061933X07020056; KIM M, 1987, J PHYS CHEM-US, V91, P126, DOI 10.1021/j100285a029; Lee CH, 2010, ACS APPL MATER INTER, V2, P3429, DOI 10.1021/am1009875; Lee M, 2018, ACS SENSORS, V3, P151, DOI 10.1021/acssensors.7b00782; LEE PC, 1982, J PHYS CHEM-US, V86, P3391, DOI 10.1021/j100214a025; Leonard J, 2017, J RAMAN SPECTROSC, V48, P1323, DOI 10.1002/jrs.5220; Maher R. C., 2012, RAMAN SPECTROSCOPY N, P215, DOI DOI 10.1007/978-3-642-20620-7_10; Marinetti LJ, 2014, J ANAL TOXICOL, V38, P592, DOI 10.1093/jat/bku086; MESLEY RJ, 1991, ANALYST, V116, P975, DOI 10.1039/an9911600975; Muehlethaler C, 2016, FORENSIC SCI INT, V268, P1, DOI 10.1016/j.forsciint.2016.09.005; Peters FT, 2011, CLIN BIOCHEM, V44, P54, DOI 10.1016/j.clinbiochem.2010.08.008; Sallum LF, 2014, SPECTROCHIM ACTA A, V133, P107, DOI 10.1016/j.saa.2014.04.198; Seth P, 2018, MMWR-MORBID MORTAL W, V67, P349, DOI 10.15585/mmwr.mm6712a1; Smith SL, 2008, SPECTROCHIM ACTA A, V71, P186, DOI 10.1016/j.saa.2007.12.002; Sun LL, 2011, J PHYS CHEM C, V115, P16295, DOI 10.1021/jp205545g; SWGDRUG, 2016, SWGDRUG REC VERS 7 1; UNODC, 2017, GLOB SMART UPD 2017, V17; Wu MM, 2018, SPECTROCHIM ACTA A, V196, P110, DOI 10.1016/j.saa.2018.02.014; Yu WW, 2013, ANALYST, V138, P1020, DOI 10.1039/c2an36116g; Zhang ZM, 2010, ANALYST, V135, P1138, DOI 10.1039/b922045c; Zhao JT, 2002, SPECTROSC SPECT ANAL, V22, P588	47	23	23	17	90	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	0003-2700	1520-6882		ANAL CHEM	Anal. Chem.	NOV 6	2018	90	21					12678	12685		10.1021/acs.analchem.8b02909			8	Chemistry, Analytical	Chemistry	GZ8FJ	WOS:000449722500049	30247896				2020-06-30	J	Duru, UB; Pawar, G; Barash, JA; Miller, LE; Thiruselvam, IK; Haut, MW				Duru, Uzoma B.; Pawar, Gauri; Barash, Jed A.; Miller, Liv E.; Thiruselvam, Indrani K.; Haut, Marc W.			An Unusual Amnestic Syndrome Associated With Combined Fentanyl and Cocaine Use RESPONSE	ANNALS OF INTERNAL MEDICINE			English	Letter							OVERDOSE		[Duru, Uzoma B.; Pawar, Gauri; Miller, Liv E.; Thiruselvam, Indrani K.; Haut, Marc W.] West Virginia Univ, Sch Med, Morgantown, WV 26506 USA; [Barash, Jed A.] Soldiers Home, Chelsea, MA USA	Duru, UB (reprint author), West Virginia Univ, Sch Med, Morgantown, WV 26506 USA.		Miller, Liv/AAM-2018-2020		NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [U54 GM104942]		Barash JA, 2018, NEW ENGL J MED, V378, P2247, DOI 10.1056/NEJMc1805681; Barash JA, 2018, NEUROCASE, V24, P124, DOI 10.1080/13554794.2018.1475572; Barash JA, 2018, NEW ENGL J MED, V378, P1157, DOI 10.1056/NEJMc1716355; Barash JA, 2017, MMWR-MORBID MORTAL W, V66, P76, DOI 10.15585/mmwr.mm6603a2; GOV. UK, 2017, GAB NEUR RISK SEV RE	5	2	2	1	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 6	2018	169	9					662	663		10.7326/L18-0411			2	Medicine, General & Internal	General & Internal Medicine	GZ4UP	WOS:000449399700020	30398631	Green Accepted			2020-06-30	J	Kwon, WJ; Bang, SU; Sun, WY				Kwon, Woo Jin; Bang, Seung Uk; Sun, Woo Young			Erector Spinae Plane Block for Effective Analgesia after Total Mastectomy with Sentinel or Axillary Lymph Node Dissection: a Report of Three Cases	JOURNAL OF KOREAN MEDICAL SCIENCE			English	Editorial Material									[Kwon, Woo Jin; Bang, Seung Uk] Catholic Univ Korea, Daejeon St Marys Hosp, Coll Med, Dept Anesthesiol & Pain Med, 64 Daeheung Ro, Daejeon 34943, South Korea; [Kwon, Woo Jin; Bang, Seung Uk] Catholic Univ Korea, Dept Anesthesiol & Pain Med, Coll Med, Seoul, South Korea; [Sun, Woo Young] Catholic Univ Korea, Daejeon St Marys Hosp, Dept Surg, Coll Med, Daejeon, South Korea; [Sun, Woo Young] Catholic Univ Korea, Dept Surg, Coll Med, Seoul, South Korea	Bang, SU (reprint author), Catholic Univ Korea, Daejeon St Marys Hosp, Coll Med, Dept Anesthesiol & Pain Med, 64 Daeheung Ro, Daejeon 34943, South Korea.	seungukb@naver.com	Bang, Seung Uk/O-7540-2019	Bang, Seung Uk/0000-0001-6609-7691; KWON, WOOJIN/0000-0001-6806-5677			Chae YJ, 2016, KOREAN J ANESTHESIOL, V69, P66, DOI 10.4097/kjae.2016.69.1.66; Chin KJ, 2017, REGION ANESTH PAIN M, V42, P372, DOI 10.1097/AAP.0000000000000581; Choe WJ, 2016, KOREAN J ANESTHESIOL, V69, P189, DOI 10.4097/kjae.2016.69.2.189; Forero M, 2016, REGION ANESTH PAIN M, V41, P621, DOI 10.1097/AAP.0000000000000451; Ramos J, 2018, CAN J ANESTH, V65, P852, DOI 10.1007/s12630-018-1097-z; Rawal N, 2012, REGION ANESTH PAIN M, V37, P310, DOI 10.1097/AAP.0b013e31825735c6; Scimia P, 2017, REGION ANESTH PAIN M, V42, P537, DOI 10.1097/AAP.0000000000000616; Woodworth GE, 2017, REGION ANESTH PAIN M, V42, P609, DOI 10.1097/AAP.0000000000000641; Yeung J. H., 2016, COCHRANE DB SYST REV, V2, DOI DOI 10.1002/14651858.CD009121.PUB2	9	6	6	1	1	KOREAN ACAD MEDICAL SCIENCES	SEOUL	302 75 DONG DU ICHON, DONG YONGSAN KU, SEOUL 140 031, SOUTH KOREA	1011-8934	1598-6357		J KOREAN MED SCI	J. Korean Med. Sci.	NOV 5	2018	33	45							UNSP e291	10.3346/jkms.2018.33.e291			3	Medicine, General & Internal	General & Internal Medicine	GZ6XU	WOS:000449616500006	31044575	DOAJ Gold, Green Published			2020-06-30	J	Rogers, E; Wright, C; King, P				Rogers, Edward; Wright, C.; King, P.			Fentanyl lozenge story part 2: from military procurement to package	JOURNAL OF THE ROYAL ARMY MEDICAL CORPS			English	Review						anaesthetics; pain management		This paper describes the selection of fentanyl as a replacement for morphine as the United Kingdom Ministry of Defence's first-line battlefield analgesic agent. It is a detailed review of the 6 year journey from selection to eventual roll-out in October 2017. It concentrates on the procurement and governance process of the deployment of fentanyl for individual issue and self-use. It highlights the significant differences in military and civilian legislation, the specialist environment we work in and the safety concerns surrounding controlled drugs in the austere environment. The lessons learnt can be applied to other organisations working in specialist environments that are looking to improve patient care through novel or off-license techniques that meet legislative resistance.	[Rogers, Edward; Wright, C.] Def Med Serv, Army Med Serv, London, England; [King, P.] British Army, Army Headquarters, Andover, England	Rogers, E (reprint author), Def Med Serv, London SL4 3DN, England.	edward.rogers@doctors.org.uk					Aldington D, 2014, J ROY ARMY MED CORPS, V160, P102, DOI 10.1136/jramc-2013-000227; Curtis KM, 2007, J TRAUMA, V63, P819, DOI 10.1097/01.ta.0000240979.31046.98; Davies C, 2013, BRIT J PAIN, V7, P122, DOI 10.1177/2049463713496226; Jackson D S, 2007, J R Army Med Corps, V153 Suppl 1, P50; Kotwal R. S., 2013, SAVING LIVES BATTLEF; Kotwal RS, 2004, ANN EMERG MED, V44, P121, DOI 10.1016/j.annemergmed.2004.03.025; legislationgovuk, HUM MED REG 2012; STREISAND JB, 1991, ANESTHESIOLOGY, V75, P223, DOI 10.1097/00000542-199108000-00009; Wedmore IS, 2012, J TRAUMA ACUTE CARE, V73, pS490, DOI 10.1097/TA.0b013e3182754674; Wyldbore M, 2013, BRIT J PAIN, V7, P74, DOI 10.1177/2049463713487515	10	1	1	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0035-8665	2052-0468		J ROY ARMY MED CORPS	J. R. Army Med. Corps	NOV	2018	164	6					458	462		10.1136/jramc-2017-000901			5	Medicine, General & Internal	General & Internal Medicine	HK3GV	WOS:000457802300015	29440467				2020-06-30	J	Bahr, MP; Williams, BA				Bahr, Marshall P.; Williams, Brian A.			Esmolol, Antinociception, and Its Potential Opioid-Sparing Role in Routine Anesthesia Care	REGIONAL ANESTHESIA AND PAIN MEDICINE			English	Article							BETA-ADRENERGIC-BLOCKADE; INTRAOPERATIVE ESMOLOL; INDUCED HYPERALGESIA; PAIN MANAGEMENT; DOUBLE-BLIND; FENTANYL; HIPPOCAMPAL; INJECTION; ANALGESIA; SURGERY	beta-Adrenergic blockade is an important mechanism for reducing morbidity and mortality in patients with hypertension and heart failure. Esmolol has been used widely for its chronotropic and antihypertensive effects. However, there has been recent inquiry regarding perioperative esmolol use and nociceptive modulation. Conventional postoperative analgesic treatment has relied primarily on opioids, which present their own adverse effects and pharmacoepidemiologic repercussions. Esmolol, to date, has not shown any direct analgesic or anesthetic properties; however, recent studies suggest that esmolol may have antinociceptive and postoperative opioid-sparing effects. In this Daring Discourse narrative, we describe the role of esmolol in current perioperative beta-blockade guidelines (related to noncardiac surgery), briefly describe studies supporting the antinociceptive effects of esmolol, propose mechanisms for esmolol antinociception, and forecast potential routine esmolol use intraoperatively (as part of a multimodal total intravenous anesthetic) and its effects on opioid sparing. The reading audience of regional anesthesiologists and acute pain medicine physicians is uniquely positioned to take a lead role in promulgating this care advance amid (i) the unwanted effects of the opioid epidemic and (ii) the uncertain notion of whether routine general anesthesia care (with fentanyl) may indirectly be contributing to the epidemic.	[Bahr, Marshall P.; Williams, Brian A.] Univ Pittsburgh, Dept Anesthesiol, Suite A-1305,Scaife Hall,3550 Terrace St, Pittsburgh, PA 15261 USA; [Williams, Brian A.] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA	Williams, BA (reprint author), Univ Pittsburgh, Dept Anesthesiol, Suite A-1305,Scaife Hall,3550 Terrace St, Pittsburgh, PA 15261 USA.	williamsba@anes.upmc.edu					Avram MJ, 2004, J PHARMACOL EXP THER, V311, P617, DOI 10.1124/jpet.104.070094; Boersma E, 2001, JAMA-J AM MED ASSOC, V285, P1865, DOI 10.1001/jama.285.14.1865; BOOZE RM, 1993, SYNAPSE, V13, P206, DOI 10.1002/syn.890130303; Cakirgoz MY, 2014, REV BRAS ANESTESIOL, V64, P425, DOI [10.1016/j.bjan.2013.09.008, 10.1016/j.bjane.2013.09.009]; Chia YY, 2004, BRIT J ANAESTH, V93, P799, DOI 10.1093/bja/aeh268; Collard V, 2007, ANESTH ANALG, V105, P1255, DOI 10.1213/01.ane.0000282822.07437.02; Davidson EM, 2001, CAN J ANAESTH, V48, P59, DOI 10.1007/BF03019816; Elvir-Lazo OL, 2010, CURR OPIN ANESTHESIO, V23, P697, DOI 10.1097/ACO.0b013e32833fad0a; Fleisher LA, 2015, J NUCL CARDIOL, V22, P162, DOI 10.1007/s12350-014-0025-z; Gelineau AM, 2018, ANESTH ANALG, V126, P1035, DOI 10.1213/ANE.0000000000002469; HAGELUKEN A, 1994, BIOCHEM PHARMACOL, V47, P1789, DOI 10.1016/0006-2952(94)90307-7; HAYASHI Y, 1995, ANESTHESIOLOGY, V83, P816, DOI 10.1097/00000542-199510000-00022; Kavak Akelma F, 2014, ANESTEZI DERGISI, V22, P25; Kharasch ED, 2016, ANESTHESIOLOGY, V124, P960, DOI 10.1097/ALN.0000000000001012; Kim Y, 2015, SURG INNOV, V22, P177, DOI 10.1177/1553350614532534; Lee MH, 2014, KOREAN J ANESTHESIOL, V66, P222, DOI 10.4097/kjae.2014.66.3.222; Lee SJ, 2010, KOREAN J ANESTHESIOL, V59, P179, DOI 10.4097/kjae.2010.59.3.179; London MJ, 2013, JAMA-J AM MED ASSOC, V309, P1704, DOI 10.1001/jama.2013.4135; Lopez-Alvarez S, 2012, CAN J ANESTH, V59, P442, DOI 10.1007/s12630-012-9684-x; Mauermann E, 2016, ANESTHESIOLOGY, V124, P453, DOI 10.1097/ALN.0000000000000976; Maurovich-Horvat P, 2015, J CARDIOVASC COMPUT, V9, P139, DOI 10.1016/j.jcct.2015.02.001; Menigaux C, 2002, BRIT J ANAESTH, V89, P857, DOI 10.1093/bja/aef275; Pranevicius M, 2009, ANESTH ANALG, V108, P1048, DOI 10.1213/ane.0b013e3181938f3f; Salman EA, 2013, AGRI, V25, P13, DOI 10.5505/agri.2013.29484; SARVEY JM, 1989, J NEUROSCI METH, V28, P109, DOI 10.1016/0165-0270(89)90016-2; Sinha R, 2004, ANN NY ACAD SCI, V1032, P254, DOI 10.1196/annals.1314.032; STANLEY TH, 1982, CAN ANAESTH SOC J, V29, P319, DOI 10.1007/BF03007519; SUM CY, 1983, CLIN PHARMACOL THER, V34, P427, DOI 10.1038/clpt.1983.193; Wasserman RA, 2015, REGION ANESTH PAIN M, V40, P687, DOI 10.1097/AAP.0000000000000315; Wiest DB, 2012, CLIN PHARMACOKINET, V51, P347, DOI 10.2165/11631590-000000000-00000; Wilson ES, 2004, ANAESTHESIA, V59, P122, DOI 10.1111/j.1365-2044.2004.03460.x; WOOD AJJ, 1983, CLIN PHARMACOKINET, V8, P253, DOI 10.2165/00003088-198308030-00004; Yasui Y, 2011, BMC ANESTHESIOL, V11, DOI 10.1186/1471-2253-11-15; Zaugg M, 1999, ANESTHESIOLOGY, V91, P1674, DOI 10.1097/00000542-199912000-00020	34	4	4	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1098-7339	1532-8651		REGION ANESTH PAIN M	Region. Anesth. Pain Med.	NOV	2018	43	8					815	818		10.1097/AAP.0000000000000873			4	Anesthesiology	Anesthesiology	HK4JT	WOS:000457895100003	30216240				2020-06-30	J	Krieger, MS; Goedel, WC; Buxton, JA; Lysyshyn, M; Bernstein, E; Sherman, SG; Rich, JD; Hadland, SE; Green, TC; Marshall, BDL				Krieger, Maxwell S.; Goedel, William C.; Buxton, Jane A.; Lysyshyn, Mark; Bernstein, Edward; Sherman, Susan G.; Rich, Josiah D.; Hadland, Scott E.; Green, Traci C.; Marshall, Brandon D. L.			Use of rapid fentanyl test strips among young adults who use drugs	INTERNATIONAL JOURNAL OF DRUG POLICY			English	Article						Overdose; Opioids; Fentanyl; Harm reduction; Uptake; Acceptability	OVERDOSE DEATHS; RHODE-ISLAND; PRESCRIPTION OPIOIDS; CONTAMINATED HEROIN; UNITED-STATES; EXPOSURE; RISK; ANALOGS; CANADA	Background: The overdose epidemic has been exacerbated by a dramatic increase in deaths involving illicitly manufactured fentanyl (IMF). Drug checking is a novel strategy to identify IMF in illicit drugs. We examined the uptake and acceptability of rapid fentanyl test strips among young adults. Methods: From May to September 2017, we recruited 93 young adults in Rhode Island who reported injecting drugs or using heroin, cocaine, or illicitly obtained prescription pills in the past 30 days. Participants were asked to test either their urine after drug use (post-consumption) or a drug sample prior to use (pre-consumption) using rapid fentanyl test strips. After a questionnaire and a brief training, participants received ten strips for their personal use and were asked to return for a one-month follow-up visit, which assessed the uptake and acceptability of the rapid strips tests and the behavioral outcomes associated with receipt of a positive test. Results: Of the 81 (87%) participants who returned for follow-up and who had complete data, the mean age was 27, 45 (56%) were male, and 37 (46%) were non-white. A total of 62 participants (77%) reported using at least one test strip. Of these, 31 (50%) received at least one positive result. A positive result was associated with older age, homelessness, heroin use, injection drug use, ever witnessing an overdose, and concern about overdose or drugs being laced with fentanyl (all p < 0.05). Receiving a positive result was significantly associated with reporting a positive change in overdose risk behavior between baseline and follow-up (p <= 0.01). Among all participants, 79 (98%) reported confidence in their ability to use the test strips and 77 (95%) wanted to use them in the future. Conclusions: Young adults reported high uptake and acceptability of fentanyl test strips to detect IMF in illicit drugs.	[Krieger, Maxwell S.; Goedel, William C.; Rich, Josiah D.; Green, Traci C.; Marshall, Brandon D. L.] Brown Univ, Sch Publ Hlth, Dept Epidemiol, Providence, RI 02912 USA; [Buxton, Jane A.; Lysyshyn, Mark] Univ British Columbia, Sch Populat & Publ Hlth, Vancouver, BC, Canada; [Buxton, Jane A.] British Columbia Ctr Dis Control, Vancouver, BC, Canada; [Lysyshyn, Mark] Vancouver Coastal Hlth, Vancouver, BC, Canada; [Bernstein, Edward; Hadland, Scott E.; Green, Traci C.] Boston Univ, Sch Med, Dept Emergency Med, Grayken Ctr Addict, Boston, MA 02118 USA; [Bernstein, Edward; Hadland, Scott E.; Green, Traci C.] Boston Med Ctr, Grayken Ctr Addict, Dept Pediat, Boston, MA USA; [Sherman, Susan G.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Behav & Soc, Baltimore, MD USA; [Rich, Josiah D.; Green, Traci C.] Brown Univ, Warren Alpert Med Sch, Dept Emergency Med, Providence, RI 02912 USA	Marshall, BDL (reprint author), Brown Univ, Sch Publ Hlth, 121 South Main St,Box G-S-121-2, Providence, RI 02912 USA.	brandon_marshall@brown.edu		Krieger, Maxwell/0000-0001-9975-1610; Goedel, William/0000-0002-2869-1048; Lysyshyn, Mark/0000-0001-6684-2030	Office of the Vice President of Research at Brown University	This project was supported by a research seed grant from the Office of the Vice President of Research at Brown University to Brandon D.L. Marshall, PhD. The funders had no role in study design, data analysis, or decision to publish. The views expressed in this manuscript do not reflect the opinions of the funder.	[Anonymous], 2015, NON TRADITIONAL REF; [Anonymous], 2018, POCKETLAB FENTANYL T; Armenian P, 2018, NEUROPHARMACOLOGY, V134, P121, DOI 10.1016/j.neuropharm.2017.10.016; Bebinger M, 2017, FENTANYL DEATHS RISE; Bloomberg School of Public Health, 2018, FENT OV RED CHECK AN; BTNX, 2018, RAP RESP FENT FYL TE; Burns G, 2016, CLIN TOXICOL, V54, P420, DOI 10.3109/15563650.2016.1157722; Carroll JJ, 2017, INT J DRUG POLICY, V46, P136, DOI 10.1016/j.drugpo.2017.05.023; Ciccarone D, 2017, INT J DRUG POLICY, V46, P146, DOI 10.1016/j.drugpo.2017.06.004; Ciccarone D, 2017, INT J DRUG POLICY, V46, P107, DOI 10.1016/j.drugpo.2017.06.010; Daniulaityte R, 2017, MMWR-MORBID MORTAL W, V66, P904, DOI 10.15585/mmwr.mm6634a3; Fischer B, 2015, PHARMACOEPIDEM DR S, V24, P1334, DOI 10.1002/pds.3901; Frank D, 2015, INT J DRUG POLICY, V26, P84, DOI 10.1016/j.drugpo.2014.07.013; Griswold MK, 2018, CLIN TOXICOL, V56, P37, DOI 10.1080/15563650.2017.1339889; Hayashi K, 2018, DRUG ALCOHOL DEPEN, V183, P1, DOI 10.1016/j.drugalcdep.2017.10.020; Jones CM, 2015, MMWR-MORBID MORTAL W, V64, P719; Krieger MS, 2018, HARM REDUCT J, V15, DOI 10.1186/s12954-018-0213-2; Lysyshyn M, 2017, HARM RED INT MONTR C; Macmadu A, 2017, ADDICT BEHAV, V68, P35, DOI 10.1016/j.addbeh.2017.01.014; Marshall B. D. L, 2018, SUBST USE MISUSE, P1; Marshall BDL, 2017, INT J DRUG POLICY, V46, P130, DOI 10.1016/j.drugpo.2017.05.029; McGowan CR, 2018, INT J DRUG POLICY, V58, P31, DOI 10.1016/j.drugpo.2018.04.017; McKesson, 2018, DRUGS AB TEST SINGL; Mercado-Crespo MC, 2014, MMWR-MORBID MORTAL W, V63, P531; Mounteney J, 2015, INT J DRUG POLICY, V26, P626, DOI 10.1016/j.drugpo.2015.04.003; O'Donnell JK, 2017, MMWR-MORBID MORTAL W, V66, P1197, DOI 10.15585/mmwr.mm6643e1; Raimondo G. G. M, 2015, OVERDOSE PREVENTION; Roxburgh A, 2013, DRUG ALCOHOL REV, V32, P269, DOI 10.1111/dar.12033; Rudd RA, 2016, MMWR-MORBID MORTAL W, V65, P1445, DOI 10.15585/mmwr.mm655051e1; Rudd RA, 2016, MMWR-MORBID MORTAL W, V64, P1378, DOI 10.15585/mmwr.mm6450a3; Seth P, 2018, MMWR-MORBID MORTAL W, V67, P349, DOI 10.15585/mmwr.mm6712a1; Somerville NJ, 2017, MMWR-MORBID MORTAL W, V66, P382, DOI 10.15585/mmwr.mm6614a2; Stewart B, 2017, DEMAND FENTANYL TEST; Tomassoni Anthony J, 2017, MMWR Morb Mortal Wkly Rep, V66, P107, DOI 10.15585/mm6604a4; Tupper KW, 2018, DRUG ALCOHOL DEPEN, V190, P242, DOI 10.1016/j.drugalcdep.2018.06.020; United States Department of Justice, 2015, DEA ISS NAT AL FENT; Yedinak JL, 2016, AM J ADDICTION, V25, P659, DOI 10.1111/ajad.12466	37	17	17	1	5	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0955-3959	1873-4758		INT J DRUG POLICY	Int. J. Drug Policy	NOV	2018	61						52	58		10.1016/j.drugpo.2018.09.009			7	Substance Abuse	Substance Abuse	HF6UT	WOS:000454374500008	30344005	Green Accepted			2020-06-30	J	Thaxton, L; Pitotti, J; Espey, E; Teal, S; Sheeder, J; Singh, RH				Thaxton, Lauren; Pitotti, Jennifer; Espey, Eve; Teal, Stephanie; Sheeder, Jeanelle; Singh, Rameet H.			Nitrous Oxide Compared With Intravenous Sedation for Second-Trimester Abortion A Randomized Controlled Trial	OBSTETRICS AND GYNECOLOGY			English	Article							1ST-TRIMESTER SURGICAL ABORTION; PAIN MANAGEMENT; DOUBLE-BLIND; OXIDE/OXYGEN; PREGNANCY	OBJECTIVE: To assess whether inhaled nitrous oxide is noninferior to intravenous (IV) sedation for pain control during outpatient surgical abortion between 12 and 16 weeks of gestation. METHODS: We enrolled women undergoing surgical abortion at 12-16 weeks of gestation into a multisite, double-blind clinical trial. Participants were randomized to sedation with nitrous oxide (70% nitrous/30% oxygen) or IV fentanyl (100 micrograms) and midazolam (2 mg). Paracervical block was administered to both groups. The primary outcome measure was immediate postabortion recall of maximum pain on a 100-mm visual analog scale. RESULTS: Between August 2016 and March 2017, we assessed 170 women for eligibility and enrolled 39, 19 in the nitrous group and 20 in the IV sedation group. Seven participants in the nitrous group (36.8%) required conversion to IV sedation for inadequate pain control. No participants in the IV sedation group required additional medication. The proportion of women requiring additional pain control in the nitrous group exceeded our predefined stopping rule. Intention-to-treat analysis demonstrated that immediate postabortion visual analog scale pain scores were lower by 20.1 mm (95% CI 1.6-38.6) in women randomized to IV sedation than in women randomized to nitrous. CONCLUSION: Intravenous sedation is a better choice than inhaled nitrous oxide for pain control in second-trimester abortion.	Univ New Mexico, Sch Med, Dept Obstet & Gynecol, Albuquerque, NM 87131 USA; Univ Colorado, Sch Med, Dept Obstet & Gynecol, Denver, CO USA	Thaxton, L (reprint author), Univ New Mexico Hosp, Dept Obstet & Gynecol, Mail Stop Code 10 5580, Albuquerque, NM 87131 USA.	lauren.thaxton@austin.utexas.edu	Sheeder, Jeanelle/D-4960-2013; Teal, Stephanie/A-3097-2019	Sheeder, Jeanelle/0000-0002-4463-3569; 	Society of Family Planning Research Fund; National Institutes of Health/National Center for Research Resources Colorado Clinical and Translational Science Institute [UL1 RR025780]	Supported by a grant from the Society of Family Planning Research Fund and by National Institutes of Health/National Center for Research Resources Colorado Clinical and Translational Science Institute Grant Number UL1 RR025780. The contents are the authors' sole responsibility and do not necessarily represent official National Institutes of Health views.	Agostini A, 2012, CONTRACEPTION, V86, P79, DOI 10.1016/j.contraception.2011.11.015; ALDRETE JA, 1970, ANESTH ANAL CURR RES, V49, P924; *AM SOC AN, CONT DEPTH SED DEF G; Clark MS, 2008, HDB NITROUS OXIDE OX, P235; Fassoulaki A, 2010, DIGESTION, V82, P80, DOI 10.1159/000285351; Gross JB, 2002, ANESTHESIOLOGY, V96, P1004; Guttmacher Institute, 2014, AB INC SERV AV US; Hahn Seokyung, 2012, Korean J Pediatr, V55, P403, DOI 10.3345/kjp.2012.55.11.403; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; JAMES MFM, 1982, ANAESTHESIA, V37, P285, DOI 10.1111/j.1365-2044.1982.tb01100.x; Jones RK, 2012, CONTRACEPTION, V85, P544, DOI 10.1016/j.contraception.2011.10.012; Kan ASY, 2006, HUM REPROD, V21, P2606, DOI 10.1093/humrep/del234; Likis FE, 2012, NITROUS OXIDE MANAGE; Malamed SF, 2010, SEDATION GUIDE PATIE, P608; McLemore MR, 2014, WOMEN HEALTH ISS, V24, P594, DOI 10.1016/j.whi.2014.07.001; Mentula M, 2014, CONTRACEPTION, V90, P609, DOI 10.1016/j.contraception.2014.06.031; O'Connell K, 2008, CONTRACEPTION, V78, P492, DOI 10.1016/j.contraception.2008.07.011; O'Sullivan I, 2003, EMERG MED J, V20, P214, DOI 10.1136/emj.20.3.214; Piaggio G, 2012, JAMA-J AM MED ASSOC, V308, P2594, DOI 10.1001/jama.2012.87802; Renner RM, 2012, OBSTET GYNECOL, V119, P1030, DOI 10.1097/AOG.0b013e318250b13e; Schneider EN, 2017, CONTRACEPTION, V95, P239, DOI 10.1016/j.contraception.2016.09.006; Singh RH, 2017, CONTRACEPTION, V96, P118, DOI 10.1016/j.contraception.2017.06.003; Stoelting RK, 2007, BASICS ANESTHESIA, P697	23	1	1	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0029-7844			OBSTET GYNECOL	Obstet. Gynecol.	NOV	2018	132	5					1192	1197		10.1097/AOG.0000000000002915			6	Obstetrics & Gynecology	Obstetrics & Gynecology	HF2CB	WOS:000454042600020	30303904				2020-06-30	J	Stone, AC; Carroll, JJ; Rich, JD; Green, TC				Stone, Andrew C.; Carroll, Jennifer J.; Rich, Josiah D.; Green, Traci C.			Methadone maintenance treatment among patients exposed to illicit fentanyl in Rhode Island: Safety, dose, retention, and relapse at 6 months	DRUG AND ALCOHOL DEPENDENCE			English	Article						Opioid use disorder; Methadone maintenance treatment; Illicitly manufactured fentanyl	OVERDOSE; ANALOGS; DEATHS; HEROIN; STATES; USERS; RISK	Introduction: Illicitly manufactured fentanyl (IMF) is a potent synthetic opioid that has been contributing to overdose deaths in the United States. This study examined intake toxicology and six-month treatment outcomes for patients newly admitted to a single methadone maintenance treatment program (MMTP) in Rhode Island with a high prevalence of illicit fentanyl. Methods: We conducted a retrospective chart review of patients admitted to a single MMTP between November 1st, 2016 and August 31st, 2017 followed for six months. Outcomes measured included: 1) retention in treatment at 6 months; 2) evidence of sustained abstinence; 3) relapse; 4) methadone dosage required to achieve sustained abstinence; and 5) the number of days required to achieve abstinence. Results: We observed 154 unique intake events (representing 147 patients). 80% (n = 123) tested positive for fentanyl at intake. During the six-month follow up period, 32% (n = 49) left treatment before six months, two individuals died within five weeks of discontinuation. No deaths were seen among those remaining in treatment. The majority (89%) who remained in treatment at six months achieved abstinence. No significant difference was seen for dose or time to achieve abstinence. Relapse was common (57%). Repeated exposure to fentanyl was seen frequently (71%) while in MMT before and after achieving abstinence. Conclusion: While there is concern that the potency of IMF may reduce the effectiveness of MAT, this study suggests that MMT is safe, abstinence achievable, and MMT is protective against death among fentanyl-exposed patients.	[Stone, Andrew C.] Discovery House Comprehens Treatment Ctr, 1625 Diamond Hill Rd, Woonsocket, RI 02895 USA; [Carroll, Jennifer J.; Green, Traci C.] Brown Univ, Warren Alpert Sch Med, Rhode Isl Hosp, Dept Emergency Med, 55 Claverick St, Providence, RI 02903 USA; [Rich, Josiah D.] Brown Univ, 164 Summit Ave, Providence, RI 02906 USA; [Rich, Josiah D.] Miriam Hosp, Ctr Prisoner Hlth & Human Rights, 164 Summit Ave, Providence, RI 02906 USA	Stone, AC (reprint author), Discovery House Comprehens Treatment Ctr, 1625 Diamond Hill Rd, Woonsocket, RI 02895 USA.	ACStoneMD@gmail.com			National Institute of General Medical Sciences of the National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [P20GM125507]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [K24DA0222112, T32DA013911, P30AI042853]	We wish to draw the attention of the Editor to the following facts, which may be considered as potential conflicts of interest, and to note significant financial contributions to this work: Dr. Stone was a full time contract employee and Medical Director at Discovery House CTC at the time of this study. He is also a paid member of the Scientific and Addiction Advisory Board at Dominion Diagnostics. Dr. Rich states that his work was supported, by the National Institute of General Medical Sciences of the National Institutes of Health (NIH) under Award Number P20GM125507 and in part by grants K24DA0222112, T32DA013911 and P30AI042853 from the NIH. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. Dr. Green and Dr. Carroll report no conflicts of interest.	Arfken CL, 2017, J SUBST ABUSE TREAT, V75, P17, DOI 10.1016/j.jsat.2017.01.004; Carroll JJ, 2017, INT J DRUG POLICY, V46, P136, DOI 10.1016/j.drugpo.2017.05.023; Ciccarone D, 2017, INT J DRUG POLICY, V46, P146, DOI 10.1016/j.drugpo.2017.06.004; Green TC, 2018, JAMA PSYCHIAT, V75, P405, DOI 10.1001/jamapsychiatry.2017.4614; Hill R, 2016, NEUROPSYCHOPHARMACOL, V41, P762, DOI 10.1038/npp.2015.201; Kenney SR, 2018, J SUBST ABUSE TREAT, V86, P65, DOI 10.1016/j.jsat.2018.01.005; Marshall BDL, 2017, AM J PUBLIC HEALTH, V107, P1760, DOI [10.2105/ajph.2017.304007, 10.2105/AJPH.2017.304007]; Mattick RP, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002209.pub2; Nielsen S, 2017, DRUG ALCOHOL REV, V36, P311, DOI 10.1111/dar.12418; Nielsen S, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011117.pub2; O'Donnell J, 2018, MMWR-MORBID MORTAL W, V67, P767, DOI 10.15585/mmwr.mm6727a4; O'Donnell JK, 2017, MMWR-MORBID MORTAL W, V66, P1197, DOI 10.15585/mmwr.mm6643e1; Parpouchi Milad, 2017, Addict Behav Rep, V6, P106, DOI 10.1016/j.abrep.2017.09.001; Rudd RA, 2016, MMWR-MORBID MORTAL W, V64, P1378, DOI 10.15585/mmwr.mm6450a3; Somerville NJ, 2017, MMWR-MORBID MORTAL W, V66, P382, DOI 10.15585/mmwr.mm6614a2; Sordo L, 2017, BMJ-BRIT MED J, V357, DOI 10.1136/bmj.j1550; Special Advisory Committee on the Epidemic of Opioid Overdoses, 2018, NAT REP APP OP REL D; U. S. Drug Enforcement Agency (DEA, 2018, 2017 NAT DRUG THREAT; Wakeman SE, 2017, J ADDICT MED, V11, P1, DOI 10.1097/ADM.0000000000000275	19	5	5	1	6	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0376-8716	1879-0046		DRUG ALCOHOL DEPEN	Drug Alcohol Depend.	NOV 1	2018	192						94	97		10.1016/j.drugalcdep.2018.07.019			4	Substance Abuse; Psychiatry	Substance Abuse; Psychiatry	GZ5GO	WOS:000449447400013	30243145				2020-06-30	J	Xie, DW; Shi, XY; Zhang, YX				Xie, Duowen; Shi, Xiaoyuan; Zhang, Yinxia			Effect of Combined Acupuncture Anesthesia on Surgical Dosage and Serum IL-4, IL-10 of Pneumonectomy Patients	JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN			English	Article						Combined acupuncture anesthesia; Pneumonectomy; Propofol; Fentanyl; Interleukin-4; Interleukin-10	CANCER; STIMULATION; FREQUENCY; IMMUNE; CELL	Objective: To analyse the effects of combined acupuncture anesthesia on surgical dosage and serum interleukin-4 (IL-4), interleukin-10 (IL-10) of pneumonectomy patients. Study Design: A randomised controlled trial (RCT). Place and Duration of Study: Lanzhou University Second Hospital, Lanzhou, China, from January 2016 to November 2017. Methodology: A total of 110 patients undergoing pneumonectomy were randomly divided into group A and group B, with 55 cases in each group. Group A was treated with combined 2Hz acupuncture anesthesia, while group B was treated with combined 2Hz/100Hz acupuncture anesthesia. The additional propofol, fentanyl dosage, and changes in heart rate and systolic blood pressure 5 min before and during extubation were compared between the two groups. The serum IL-4 and IL-10 levels were measured 10 minutes after skin incision and 24 hours after surgery using ELISA. Pain was rated by visual analogue scale (VAS) at 24 hours after surgery. Results: There was no statistically significant difference between group A and group B in the intraoperative additional propofol and fentanyl dosags (p=0.541 and 0.719, respectively). There is no statistical difference in heart rate and systolic blood pressure between group A and group B at 5 minutes before and during extubation (p=0.151, 0.660 and 0.734, 0.528, respectively). There is no statistical difference between group A and group B in serum IL-4 and IL-10 levels 10 minutes after surgical incision (p=0.916 and 0.841, respectively). However, serum IL-4 and IL-2 levels in group A are statistically lower than that of group B at 24 hours after surgery (all p<0.001). The VAS score at 24 hours after surgery in group A was 2.44 +/- 0.71 points, which was significantly lower than that of group B (3.82 +/- 0.77 points, p<0.001). Conclusion: Combined 2 Hz, 2 Hz/100 Hz acupuncture anesthesia need few anesthetic dosages of propofol and fentanyl to stabilise the patient's blood pressure and heart rate when intubated under general anesthesia; but combined 2 Hz acupuncture anesthesia can reduce IL-4 and IL-10 levels during surgery stress to a greater extent than the latter, and can effectively lower patients' serum IL-4, IL-10 expression after surgery.	[Xie, Duowen] Lanzhou Univ, Hosp 2, Dept Intens Care Unit, Lanzhou 730000, Gansu, Peoples R China; [Shi, Xiaoyuan] Lanzhou Univ, Hosp 2, Med Record, Lanzhou 730000, Gansu, Peoples R China; [Zhang, Yinxia] Northwest Minzu Univ Hosp, Dept Hlth, Lanzhou 730000, Gansu, Peoples R China	Zhang, YX (reprint author), Northwest Minzu Univ Hosp, Dept Hlth, Lanzhou 730000, Gansu, Peoples R China.	pu088u@163.com					Abeles G, 1999, DERMATOL SURG, V25, P559, DOI 10.1046/j.1524-4725.1999.98225.x; Agelink MW, 2003, FORTSCHR NEUROL PSYC, V71, P141, DOI 10.1055/s-2003-37756; Ding C, 2008, J CLIN ENDOCR METAB, V93, P1952, DOI 10.1210/jc.2007-2325; Fan Wen-Chao, 2012, Zhongguo Zhen Jiu, V32, P715; Fu Guo-qiang, 2011, Zhen Ci Yan Jiu, V36, P361; Glocker EO, 2009, NEW ENGL J MED, V361, P2033, DOI 10.1056/NEJMoa0907206; Gomes M, 2012, GENE, V504, P111, DOI 10.1016/j.gene.2012.05.008; Hamza MA, 1999, ANESTHESIOLOGY, V91, P1232, DOI 10.1097/00000542-199911000-00012; Kim SB, 2014, J ACUPUNCT MERIDIAN, V7, P122, DOI 10.1016/j.jams.2014.04.001; Liu LY, 2015, CHINESE J PHYSIOL, V58, P165, DOI 10.4077/CJP.2015.BAD290; Min Yihua, 2015, Zhongguo Zhen Jiu, V35, P367; Peng Li-chao, 2008, Zhongguo Zhen Jiu, V28, P910; Ramanathan M, 2008, AM J RHINOL, V22, P115, DOI 10.2500/ajr.2008.22.3136; Romita VV, 1997, BRAIN RES BULL, V42, P289, DOI 10.1016/S0361-9230(96)00264-X; Sharma A, 2007, AM J REPROD IMMUNOL, V58, P21, DOI 10.1111/j.1600-0897.2007.00486.x; Sharma S, 1999, J IMMUNOL, V163, P5020; Szechenyi I, 2015, MED ACUPUNCT, V27, P23, DOI 10.1089/acu.2014.1072; Vijayalakshmi I, 2014, Indian J Physiol Pharmacol, V58, P69; Wang NK, 2018, ONCOL LETT, V15, P189, DOI 10.3892/ol.2017.7262; Wang Y, 1993, Zhen Ci Yan Jiu, V18, P44; Yang Q G, 2001, Zhongguo Zhong Xi Yi Jie He Za Zhi, V21, P729	21	0	1	0	6	COLL PHYSICIANS & SURGEONS PAKISTAN	KARACHI	SEVENTH CENTRAL ST, DEFENCE HOUSING AUTHORITY, KARACHI, 75500, PAKISTAN	1022-386X	1681-7168		JCPSP-J COLL PHYSICI	JCPSP-J. Coll. Physicians Surg.	NOV	2018	28	11					817	820		10.29271/jcpsp.2018.11.817			4	Medicine, General & Internal	General & Internal Medicine	GZ6NX	WOS:000449556100002	30369370	Bronze			2020-06-30	J	Fogarty, MF; Papsun, DM; Logan, BK				Fogarty, Melissa F.; Papsun, Donna M.; Logan, Barry K.			Analysis of Fentanyl and 18 Novel Fentanyl Analogs and Metabolites by LC-MS-MS, and report of Fatalities Associated with Methoxyacetylfentanyl and Cyclopropylfentanyl	JOURNAL OF ANALYTICAL TOXICOLOGY			English	Article							OPIOIDS; DEATH	Methoxyacetylfentanyl and cyclopropylfentanyl are two of the newest illicit opioids that are infiltrating the heroin market. Methoxyacetylfentanyl and cyclopropylfentanyl were reported by the Drug Enforcement Administration (DEA) in their third quarter report of 2017 to have been chemically identified seven and five times, respectively, from drug evidence analyzed by the DEA's lab system; Q3 was the first time cyclopropylfentanyl was identified by the DEA's lab system, while methoxyacetylfentanyl was reported one time in Q2 2017. A method was developed using liquid chromatography tandem mass spectrometry for the quantitation of fentanyl, norfentanyl and 17 fentanyl analogs: furanylfentanyl, butyrylfentanyl, despropionylfentanyl (4-ANPP), methoxyacetylfentanyl, tetrahydrofuran fentanyl, fluoro-isobutyrylfentanyl, acrylfentanyl, para-fluorofentanyl, ortho-fluorofentanyl, carfentanil, beta-methylfentanyl, isobutyrylfentanyl, para-methylfentanyl, cyclopentylfentanyl, cyclopropylfentanyl, beta-hydroxyfentanyl and alpha-methylfentanyl. The calibration range for all compounds was 0.1-100 ng/mL. Blood samples from 42 postmortem cases involving cyclopropylfentanyl and methoxyacetylfentanyl from Florida, Illinois, Michigan and Tennessee were submitted for toxicological analysis. The mean and median concentration for the cases testing positive for cyclopropylfentanyl (n = 32) was 15.3 (+/- 11.9) ng/mL and 12.3 ng/mL, respectively, with a range of 1.4-43.3 ng/mL. The mean (+/- SD) and median concentrations for the 11 cases quantitatively confirmed (3 cases were below the limit of quantitation) for methoxyacetylfentanyl was 17.7 (+/- 11.4) ng/mL and 15.1 ng/mL respectively, with a range of 0.21-39.9 ng/mL. These novel illicit substances typically are outside the scope of routine drug testing by hospitals and toxicology laboratories or below the sensitivity levels for the detection of these substances in biological specimens. These compounds have not previously been studied in humans; therefore, it is significant to be able to associate the pharmacological effects derived from case reports to the quantitative values found in the postmortem specimens.	[Fogarty, Melissa F.; Logan, Barry K.] CFSRE, 2300 Stratford Ave, Willow Grove, PA 19090 USA; [Papsun, Donna M.; Logan, Barry K.] NMS Labs, Toxicol, 2300 Welsh Rd, Willow Grove, PA 19090 USA	Fogarty, MF (reprint author), CFSRE, 2300 Stratford Ave, Willow Grove, PA 19090 USA.	melissa.friscia@frfoundation.org					Armenian P, 2017, NEUROPHARMACOLOGY, P1; Baldwin C, 2017, NON TRADITIONAL REF; CHATURVEDI AK, 1990, J ANAL TOXICOL, V14, P385, DOI 10.1093/jat/14.6.385; Dolinak David, 2017, Acad Forensic Pathol, V7, P19, DOI 10.23907/2017.003; Drug Enforcement Administration, 2017, FED REGISTER, V82, P55333; Drug Enforcement Administration Department of Justice., 2018, Fed Regist, V83, P469; Drug Enforcement Administration Department of Justice, 2016, Fed Regist, V81, P79389; Drug Enforcement Administration Department of Justice, 2017, Fed Regist, V82, P32453; Drug Enforcement Administration Department of Justice, 2016, Fed Regist, V81, P85873; Edison L, 2017, MMWR MORBIDITY MORTA, P66; European Monitoring Centre for Drugs and Drug Addiction, 2017, NON TRADITIONAL REF; Fowler David R, 2017, Acad Forensic Pathol, V7, P2, DOI 10.23907/2017.001; GARRIOTT JC, 1984, J ANAL TOXICOL, V8, P288, DOI 10.1093/jat/8.6.288; Huang B.-S, 1986, N ARYL N 4 PIPERIDIN; Hull MJ, 2007, J FORENSIC SCI, V52, P1383, DOI 10.1111/j.1556-4029.2007.00564.x; Janssen P. A. J., 1965, 1 ARALKYL 4 N ARYL C; Jeffrey O, 2017, SAULT STAR       SEP; Lee D, 2016, J ANAL TOXICOL, V40, P588, DOI 10.1093/jat/bkw087; MATEJCZYK RJ, 1988, J ANAL TOXICOL, V12, P236, DOI 10.1093/jat/12.4.236; McClure FL, 2017, J ADDICT MED, V11, P420, DOI 10.1097/ADM.0000000000000354; Mohr ALA, 2016, J ANAL TOXICOL, V40, P709, DOI 10.1093/jat/bkw086; Office of Public Affiars Department of Justice, 2017, JUSTICE NEWS     NOV; Tharp AM, 2004, AM J FOREN MED PATH, V25, P178, DOI 10.1097/01.paf.0000127398.67081.11; United States Department of Justice Drug Enforcement Administration, 2017, 2017 NAT DRUG THREAT	24	28	29	5	34	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0146-4760	1945-2403		J ANAL TOXICOL	J. Anal. Toxicol.	NOV	2018	42	9					592	604		10.1093/jat/bky035			13	Chemistry, Analytical; Toxicology	Chemistry; Toxicology	HA6MZ	WOS:000450395000002	29750250				2020-06-30	J	D'Errico, S				D'Errico, Stefano			Commentary. Fentanyl-related death and the underreporting risk	JOURNAL OF FORENSIC AND LEGAL MEDICINE			English	Editorial Material						Fentanyl; Syntethic opioid; Forensic toxicology; Fake heroin	POSTMORTEM REDISTRIBUTION; ANALOGS; PATCH; SPECTROMETRY; NORFENTANYL; FATALITIES; EXPOSURE; OVERDOSE; HEROIN; BLOOD	Novel synthetic opioid overdose deaths have been rising largely worldwide as a result of fentanyl adulteration in the illegal drug supply. Interpretation of post mortem analytical results concerning fentanyl can be challenging in particular due to redistribution phenomena. Lacking of resources, infrastructures and expertise to perform forensic toxicological investigation when an unknown drug or complex mixture of drugs is suspected can affect failure in exactly reporting cause in drug related death. Public safety and public health entities are called working together to enhance the timeliness and accuracy of the analytical characterization and toxicology testing of novel synthetic opioids.	[D'Errico, Stefano] Azienda USL Toscana Nordovest, Dept Legal Med, Lucca, Italy	D'Errico, S (reprint author), Azienda USL Toscana Nordovest, Dept Legal Med, Lucca, Italy.	stefano.derrico@uslnordovest.toscana.it	D'ERRICO, Stefano/AAO-8500-2020	D'ERRICO, Stefano/0000-0003-3689-0001			Abdulahim D, 2018, MISUSE SYNTHETIC OPI; Armenian P, 2018, NEUROPHARMACOLOGY, V134, P121, DOI 10.1016/j.neuropharm.2017.10.016; Bakovic M, 2015, INT J LEGAL MED, V129, P1247, DOI 10.1007/s00414-015-1209-z; Barash JA, 2018, NEW ENGL J MED, V378, P1157, DOI 10.1056/NEJMc1716355; Brockbals L, 2018, J ANAL TOXICOL, V42, P365, DOI 10.1093/jat/bky017; CDC, 2018, RIS NUMB DEATHS INV; Centers for Disease Control (CDC), 2015, INCR FENT DRUG CONF; Chapman E, 2012, CHEST, V141, P1321, DOI 10.1378/chest.11-1462; Chatterton CN, 2018, FORENSIC SCI INT, V284, P146, DOI 10.1016/j.forsciint.2017.12.031; Ciccarone D, 2017, INT J DRUG POLICY, V46, P146, DOI 10.1016/j.drugpo.2017.06.004; Cummings OT, 2016, J ANAL TOXICOL, V40, P595, DOI 10.1093/jat/bkw067; Fischer B, 2018, PREV MED, V107, P109, DOI 10.1016/j.ypmed.2017.11.001; Fogarty MF, 2018, J ANAL TOXICOL, V42, P592, DOI 10.1093/jat/bky035; Gill JR, 2013, J MED TOXICOL, V9, P34, DOI 10.1007/s13181-012-0253-z; Green TC, 2016, JAMA INTERN MED, V176, P1555, DOI 10.1001/jamainternmed.2016.4310; Hikin L, 2018, FORENSIC SCI INT, V282, P179, DOI 10.1016/j.forsciint.2017.11.036; Kronstrand R, 1997, FORENSIC SCI INT, V88, P185, DOI 10.1016/S0379-0738(97)00068-6; Kuczynska K, 2018, FORENSIC SCI INT, V289, P207, DOI 10.1016/j.forsciint.2018.05.042; Lotsch J, 2013, CLIN PHARMACOKINET, V52, P23, DOI 10.1007/s40262-012-0016-7; Luckenbill K, 2008, J ANAL TOXICOL, V32, P639, DOI 10.1093/jat/32.8.639; McIntyre IM, 2014, INT J LEGAL MED, V128, P65, DOI 10.1007/s00414-013-0897-5; Morrow JB, 2019, J ANAL TOXICOL, V43, P1, DOI 10.1093/jat/bky049; Mounteney J, 2015, INT J DRUG POLICY, V26, P626, DOI 10.1016/j.drugpo.2015.04.003; O'Donnell JK, 2017, MMWR-MORBID MORTAL W, V66, P1197, DOI 10.15585/mmwr.mm6643e1; Olson KN, 2010, AM J CLIN PATHOL, V133, P447, DOI 10.1309/AJCP4X5VHFSOERFT; Park JN, 2018, HARM REDUCT J, V15, DOI 10.1186/s12954-018-0240-z; Peterson BL, 2019, J FORENSIC SCI, V64, P144, DOI 10.1111/1556-4029.13808; Pichini S, 2018, THER DRUG MONIT, V40, P38, DOI 10.1097/FTD.0000000000000465; POKLIS A, 1995, J TOXICOL-CLIN TOXIC, V33, P439, DOI 10.3109/15563659509013752; Poklis J, 2015, FORENSIC SCI INT, V257, P435, DOI 10.1016/j.forsciint.2015.10.021; Prosser JM, 2010, J MED TOXICOL, V6, P443, DOI 10.1007/s13181-010-0092-8; Quintana P, 2017, INT J DRUG POLICY, V40, P78, DOI 10.1016/j.drugpo.2016.10.006; Ruan XL, 2016, FORENSIC SCI MED PAT, V12, P363, DOI 10.1007/s12024-016-9789-6; Ruzycki S, 2016, J MED TOXICOL, V12, P185, DOI 10.1007/s13181-015-0509-5; Sisco E, 2017, FORENSIC CHEM, V4, P108, DOI 10.1016/j.forc.2017.04.001; Somerville NJ, 2017, MMWR-MORBID MORTAL W, V66, P382, DOI 10.15585/mmwr.mm6614a2; Stanley TH, 2014, J PAIN, V15, P1215, DOI 10.1016/j.jpain.2014.08.010; Suzuki J, 2017, DRUG ALCOHOL DEPEN, V171, P107, DOI 10.1016/j.drugalcdep.2016.11.033; Thompson JG, 2007, J FORENSIC SCI, V52, P978, DOI 10.1111/j.1556-4029.2007.00481.x; Tupper KW, 2018, DRUG ALCOHOL DEPEN, V190, P242, DOI 10.1016/j.drugalcdep.2018.06.020; U.S. Department of Homeland Security, 201802319 FR US DEP	41	6	6	1	9	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1752-928X	1532-2009		J FORENSIC LEG MED	J. Forensic Leg. Med.	NOV	2018	60						35	37		10.1016/j.jflm.2018.09.007			3	Medicine, Legal	Legal Medicine	GX4BQ	WOS:000447672300007	30265903				2020-06-30	J	Qi, H; Mariager, CO; Lindhardt, J; Nielsen, PM; Stodkilde-Jorgensen, H; Laustsen, C				Qi, Haiyun; Mariager, Christian Ostergaard; Lindhardt, Jakob; Nielsen, Per Mose; Stodkilde-Jorgensen, Hans; Laustsen, Christoffer			Effects of anesthesia on renal function and metabolism in rats assessed by hyperpolarized MRI	MAGNETIC RESONANCE IN MEDICINE			English	Article						anesthesia; hyperpolarization; metabolism; MRI	ACUTE KIDNEY INJURY; MAGNETIC-RESONANCE; IN-VIVO; ISOFLURANE ANESTHESIA; GLUCOSE-METABOLISM; REPERFUSION INJURY; PLASMA-GLUCOSE; HEMODYNAMICS; SEVOFLURANE; INSULIN	Purpose: Anesthesia is necessary for most animal studies requiring invasive procedures. It is well documented that various types of anesthesia modulate a wide variety of important metabolic and functional processes in the body, and as such, represent a potential limitation in the study design. In the present study, we aimed to investigate the renal functional and metabolic consequences of 3 typical rodent anesthetics used in preclinical MRI: sevoflurane, inaction, and a mixture of fentanyl, fluanisone, and midazolam (FFM). Methods: The renal effects of 3 different classes of anesthetics (inactin, servoflurane, and FFM) were investigated using functional and metabolic MRI. The renal glucose metabolism and hemodynamics was characterized with hyperpolarized [1-C-13] pyruvate MRI and by DCE imaging. Results: Rats receiving sevoflurane or FFM had blood glucose levels that were 1.3-fold to 1.4-fold higher than rats receiving inactin. A 2.9-fold and 4.8-fold increased C-13-lactate/C-13-pyruvate ratio was found in the FFM mixture anesthetized group compared with the sevoflurane and the inactin anesthetized groups. The FFM anesthesia resulted in a 50% lower renal plasma flow compared with the sevoflurane and the inactin anesthetized groups. Conclusion: This study demonstrates different renal metabolic and hemodynamic changes under 3 different anesthetics, using hyperpolarized MR in rats. Inactin and sevoflurane were found to affect the renal hemodynamic and metabolic status to a lesser degree than FFM. Sevoflurane anesthesia is particularly easy to induce and maintain during the whole anesthesia procedure, and as such, represents a good alternative to inaction, although it alters the blood glucose level.	[Qi, Haiyun; Mariager, Christian Ostergaard; Lindhardt, Jakob; Nielsen, Per Mose; Stodkilde-Jorgensen, Hans; Laustsen, Christoffer] Aarhus Univ, Dept Clin Med, MR Res Ctr, Palle Juul Jensens Blvd 99, DK-8200 Aarhus N, Denmark	Laustsen, C (reprint author), Aarhus Univ, Dept Clin Med, MR Res Ctr, Palle Juul Jensens Blvd 99, DK-8200 Aarhus N, Denmark.	cl@clin.au.dk	Laustsen, Christoffer/AAF-4522-2019	Laustsen, Christoffer/0000-0002-0317-2911; Stodkilde-Jorgensen, Hans/0000-0002-8649-4173			Ailiani AC, 2014, NEUROGASTROENT MOTIL, V26, P1477, DOI 10.1111/nmo.12410; Ardenkjaer-Larsen JH, 2011, NMR BIOMED, V24, P927, DOI 10.1002/nbm.1682; Baumann D, 2000, MAGN RESON IMAGING, V18, P587, DOI 10.1016/S0730-725X(00)00134-X; Bimpisidis Z, 2017, EXP NEUROL, V292, P113, DOI 10.1016/j.expneurol.2017.03.006; BRUNPASCAUD M, 1982, RESP PHYSIOL, V48, P45, DOI 10.1016/0034-5687(82)90049-4; Comment A, 2014, BIOCHEMISTRY-US, V53, P7333, DOI 10.1021/bi501225t; Fang F, 2012, NEUROSCI BULL, V28, P499, DOI 10.1007/s12264-012-1260-4; FLECKNELL PA, 1984, LAB ANIM, V18, P143, DOI 10.1258/002367784780891406; Gui LL, 2017, J MOL MED, V95, P369, DOI 10.1007/s00109-017-1521-9; GUMBLETON M, 1990, J PHARM PHARMACOL, V42, P693, DOI 10.1111/j.2042-7158.1990.tb06561.x; HOLSTEINRATHLOU NH, 1982, ACTA PHYSIOL SCAND, V114, P193, DOI 10.1111/j.1748-1716.1982.tb06972.x; HORBER FF, 1990, ANESTHESIOLOGY, V73, P82, DOI 10.1097/00000542-199007000-00013; Husby P, 1998, LAB ANIM, V32, P316, DOI 10.1258/002367798780559257; Iversen AB, 2015, ACTA ONCOL, V54, P1393, DOI 10.3109/0284186X.2015.1070964; JOHANSEN O, 1994, LAB ANIM, V28, P244, DOI 10.1258/002367794780681723; Josan S, 2013, MAGN RESON MED, V70, P1117, DOI 10.1002/mrm.24532; Kim SB, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147745; Kitamura T, 2009, ANESTH ANALG, V109, P1479, DOI 10.1213/ANE.0b013e3181b8554a; Laustsen C, 2017, AM J PHYSIOL-RENAL, V312, pF192, DOI 10.1152/ajprenal.00148.2016; Laustsen C, 2015, MAGN RESON MED, V74, P558, DOI 10.1002/mrm.25692; Laustsen C, 2013, DIABETES-METAB RES, V29, P125, DOI 10.1002/dmrr.2370; Lee HT, 2008, AM J PHYSIOL-RENAL, V295, pF128, DOI 10.1152/ajprenal.00577.2007; Lee HT, 2004, ANESTHESIOLOGY, V101, P1313; Lorenz JN, 2002, AM J PHYSIOL-REG I, V282, pR1565, DOI 10.1152/ajpregu.00759.2001; Lukasik VM, 2003, NMR BIOMED, V16, P459, DOI 10.1002/nbm.836; Mariager CO, 2017, TOMOGRAPHY, V3, P146, DOI 10.18383/j.tom.2017.00010; Nielsen PM, 2017, AM J PHYSIOL-RENAL, V312, pF465, DOI 10.1152/ajprenal.00561.2015; Nielsen PM, 2017, SCI REP-UK, V7, DOI 10.1038/srep40812; Paasonen J, 2016, EUR NEUROPSYCHOPHARM, V26, P518, DOI 10.1016/j.euroneuro.2015.12.034; Palm F, 2004, DIABETOLOGIA, V47, P1223, DOI 10.1007/s00125-004-1434-3; Petersen JS, 1996, PHYSIOL BEHAV, V60, P759; Qualls-Creekmore E, 2010, NEUROGASTROENT MOTIL, V22, P181, DOI 10.1111/j.1365-2982.2009.01393.x; Saho S, 1997, ANESTH ANALG, V84, P1359, DOI 10.1097/00000539-199706000-00034; Schroeder M, 2017, BIOSCIENCE REP, V37, DOI 10.1042/BSR20160186; Sharp PS, 2015, SCI REP-UK, V5, DOI 10.1038/srep12621; Sonnay S, 2017, J NEUROSCI RES, V95, P2297, DOI 10.1002/jnr.24032; Tanaka Tadashi, 2005, J Anesth, V19, P277, DOI 10.1007/s00540-005-0341-1; ter Horst EN, 2018, LAB ANIM-UK, V52, P271, DOI 10.1177/0023677217724485; Tremoleda JL, 2012, EJNMMI RES, V2, DOI 10.1186/2191-219X-2-44; Wang Zhu, 2010, Wei Sheng Yan Jiu, V39, P133; Wiesinger F, 2012, MAGN RESON MED, V68, P8, DOI 10.1002/mrm.23212; Zollner FG, 2015, Z MED PHYS, V25, P58, DOI 10.1016/j.zemedi.2014.01.002; Zuurbier CJ, 2002, AM J PHYSIOL-HEART C, V282, pH2099, DOI 10.1152/ajpheart.01002.2001; Zuurbier CJ, 2008, ANESTH ANALG, V106, P135, DOI 10.1213/01.ane.0000297299.91527.74	44	9	9	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0740-3194	1522-2594		MAGN RESON MED	Magn. Reson. Med.	NOV	2018	80	5					2073	2080		10.1002/mrm.27165			8	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	GY8JR	WOS:000448872700028	29520870				2020-06-30	J	Fomin, D; Baranauskaite, V; Usaviciene, E; Sumkovskaja, A; Laima, S; Jasulaitis, A; Minkuviene, ZN; Chmieliauskas, S; Stasiuniene, J				Fomin, Dmitrij; Baranauskaite, Vilma; Usaviciene, Emilija; Sumkovskaja, Alina; Laima, Sigitas; Jasulaitis, Algimantas; Minkuviene, Zita Nijole; Chmieliauskas, Sigitas; Stasiuniene, Jurgita			Human deaths from drug overdoses with carfentanyl involvement-new rising problem in forensic medicine A STROBE-compliant retrospective study	MEDICINE			English	Article						autopsy; carfentanyl; drugs; forensic science; opioids; overdose; toxicology	FENTANYL; ANALOGS	Carfentanyl, an ultra-potent synthetic opioid, is approved for use only in veterinary medicine as a tranquilizing agent. However, many cases of human poisoning with carfentanyl have recently appeared in the news with limited information given and scientific literature provides only 1 case of documented human exposure to carfentanyl. Fifteen cases of death from drug overdoses with carfentanyl involvement are being presented. Fifteen blood and urine samples have been taken for alcohol and drug testing. Headspace gas chromatography was used for alcohol detection. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) and liquid chromatography-time-of-flight mass spectrometry (LC/MS TOF) system was used for drug detection. Sixty-three cases of death from poisoning with drugs have been tested for carfentanyl in the State Forensic Medicine Service. Fifteen of them were positive for carfentanyl. The cases mentioned above show that carfentanyl exposure causes signs and symptoms similar to other opioid toxicity. Carfentanyl intoxication may even be fatal if appropriate treatment is not available. Therefore, nowadays it is very important to draw forensic medicine expert's attention to new substances in drug trade.	[Fomin, Dmitrij; Laima, Sigitas; Jasulaitis, Algimantas; Minkuviene, Zita Nijole; Chmieliauskas, Sigitas; Stasiuniene, Jurgita] Vilnius Univ, Fac Med, Inst Biomed Sci, Dept Pathol Forens Med & Pharmacol, MK Ciurlionio Str 21-27, Vilnius, Lithuania; [Fomin, Dmitrij; Baranauskaite, Vilma; Usaviciene, Emilija; Sumkovskaja, Alina; Laima, Sigitas; Minkuviene, Zita Nijole; Chmieliauskas, Sigitas] State Forens Med Serv, Vilnius, Lithuania	Chmieliauskas, S (reprint author), Vilnius Univ, Fac Med, Inst Biomed Sci, Dept Pathol Forens Med & Pharmacol, MK Ciurlionio Str 21-27, Vilnius, Lithuania.	sigitas.chmieliauskas@mf.vu.lt	Chmieliauskas, Sigitas/I-8900-2017	Chmieliauskas, Sigitas/0000-0001-9104-9835			Daniulaityte R, 2017, MMWR-MORBID MORTAL W, V66, P904, DOI 10.15585/mmwr.mm6634a3; Feasel MG, 2016, AAPS J, V18, P1489, DOI 10.1208/s12248-016-9963-5; George AV, 2010, AM J EMERG MED, V28, P530, DOI 10.1016/j.ajem.2010.03.003; Heard DJ, 1996, AM J VET RES, V57, P87; Kreeger TJ, 2002, HDB WILDLIFE CHEM IM, P125; MEERT TF, 1988, EUR J ANAESTH, V5, P313; O'Donnell JK, 2017, MMWR-MORBID MORTAL W, V66, P1197, DOI 10.15585/mmwr.mm6643e1; Riches JR, 2012, J ANAL TOXICOL, V36, P647, DOI 10.1093/jat/bks078; Stanley TH, 2008, ANESTH ANALG, V106, P451, DOI 10.1213/ane.0b013e3181605add; Swanson DM, 2017, J ANAL TOXICOL, V41, P498, DOI 10.1093/jat/bkx037; Thompson RG, 1987, OPIATE RECEPTOR BIND; VANBEVER WFM, 1976, ARZNEIMITTELFORSCH, V26, P1548	12	2	2	2	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0025-7974	1536-5964		MEDICINE	Medicine (Baltimore)	NOV	2018	97	48							e13449	10.1097/MD.0000000000013449			4	Medicine, General & Internal	General & Internal Medicine	HD4AE	WOS:000452467000085	30508965	DOAJ Gold, Green Published			2020-06-30	J	Carrozzo, MV; Alcorn, J; Ambros, B				Carrozzo, Maria Valentina; Alcorn, Jane; Ambros, Barbara			Effects of two fentanyl constant rate infusions on thermal thresholds and plasma fentanyl concentrations in awake cats	VETERINARY ANAESTHESIA AND ANALGESIA			English	Article						antinociception; cats; constant rate infusion; fentanyl; thermal threshold	INTRAVENOUS HYDROMORPHONE; PHARMACOKINETICS; BUPRENORPHINE; BUTORPHANOL; DOGS; ANALGESIA; MORPHINE	Objective To determine the pharmacokinetics and effects on thermal thresholds (TT) of two fentanyl constant rate infusions in awake cats. Study design A blinded, randomized crossover study. Animals A group of six healthy female cats, aged 3 +/- 1 years, weighing 4.1 +/- 0.7 kg. Methods Skin temperature (T-SKIN) and TT were evaluated using a wireless TT device. TSKIN, TT, sedation score (SS) and blood samples were collected before an intravenous loading dose (LD; over 5 seconds) and at specific time points during (360 minutes) and after infusion. Each cat was administered two treatments: fentanyl (LD 3 mu g kg(-1), infusion 3 mu g kg(-1) hour(-1); treatment F3) or fentanyl (LD 5 mu g kg(-1), infusion 5 mg kg(-1) hour(-1); treatment F5). SS between treatments was analyzed using a Kruskal-Wallis test. Statistical analysis of TT and T-SKIN was performed using analysis of variance with appropriate post hoc test (p < 0.05). Results T-SKIN did not vary over time for each treatment. SS did not differ between treatments. TTs were significantly higher than baseline at 15 minutes after LD for F3 and F5. TT was significantly increased at 30, 90, 120, 180 and 300 minutes in treatment F5 but not in F3. Plasma fentanyl concentrations decreased rapidly in both treatments over the first 30 minutes after infusion. The terminal half-life was 3.31 (2.93-4.41) hours for F3 and 3.67 (3.39-4.32) hours for F5 (median, range). Systemic clearance for treatments F3 and F5 was 1.95 (1.46-2.44) and 2.25 (1.98-2.47) L hour(-1) kg(-1) (median, range), respectively. Plasma concentrations <1.84 ng mL(-1) were not associated with a significant increase in TT. Conclusions and clinical relevance A fentanyl infusion rate of 5 mu g kg(-1) hour(-1) increased TT during the infusion period. Effects on TT were lost rapidly with cessation of the infusion.	[Carrozzo, Maria Valentina; Ambros, Barbara] Western Coll Vet Med, Dept Small Anim Clin Sci, 52 Campus Dr, Saskatoon, SK S7N 5B4, Canada; [Alcorn, Jane] Univ Saskatoon, Coll Pharm & Nutr, Saskatoon, SK, Canada	Carrozzo, MV (reprint author), Western Coll Vet Med, Dept Small Anim Clin Sci, 52 Campus Dr, Saskatoon, SK S7N 5B4, Canada.	mac991@mail.usask.ca			Companion Animal Health Fund, Western College of Veterinary Medicine, SK, Canada [411748]	This study was funded by the Companion Animal Health Fund (grant number 411748), Western College of Veterinary Medicine, SK, Canada. The authors thank Dr Billinsky, Government of Saskatchewan, for assistance with the plasma fentanyl analysis.	Ambros B, 2014, AM J VET RES, V75, P716, DOI 10.2460/ajvr.75.8.716; Dixon MJ, 2002, RES VET SCI, V72, P205, DOI 10.1053/rvsc.2001.0543; HARDY JD, 1953, J APPL PHYSIOL, V5, P725; Hedges AR, 2014, J VET PHARMACOL THER, V37, P252, DOI 10.1111/jvp.12084; Iizuka T, 2015, J VET MED SCI, V77, P615, DOI 10.1292/jvms.14-0549; Johnson JA, 2007, AM J VET RES, V68, P699, DOI 10.2460/ajvr.68.7.699; Kamata M, 2012, J VET MED SCI, V74, P231, DOI 10.1292/jvms.10-0565; Lascelles BDX, 2004, AM J VET RES, V65, P1085, DOI 10.2460/ajvr.2004.65.1085; Lee DD, 2000, AM J VET RES, V61, P672, DOI 10.2460/ajvr.2000.61.672; Martinez MN, 1998, J AM VET MED ASSOC, V213, P1122; Millette VM, 2008, VET ANAESTH ANALG, V35, P543, DOI 10.1111/j.1467-2995.2008.00419.x; NOLAN A, 1988, J VET PHARMACOL THER, V11, P94, DOI 10.1111/j.1365-2885.1988.tb00126.x; Peng PWH, 1999, ANESTHESIOLOGY, V90, P576, DOI 10.1097/00000542-199902000-00034; Robertson SA, 2005, J VET PHARMACOL THER, V28, P87, DOI 10.1111/j.1365-2885.2004.00628.x; Robertson SA, 2003, VET REC, V153, P462, DOI 10.1136/vr.153.15.462; Sano T, 2006, VET ANAESTH ANALG, V33, P266, DOI 10.1111/j.1467-2995.2005.00266.x; Smith JS, 2018, J VET PHARMACOL THER, V41, P555, DOI 10.1111/jvp.12501; SPINK RR, 1966, AM J VET RES, V27, P1041; Steagall PVM, 2013, VET ANAESTH ANALG, V40, P83, DOI 10.1111/j.1467-2995.2012.00779.x; Steagall PMV, 2006, J VET PHARMACOL THER, V29, P351; Wegner K, 2004, J VET PHARMACOL THER, V27, P329, DOI 10.1111/j.1365-2885.2004.00593.x; Wegner K, 2007, VET ANAESTH ANALG, V34, P132, DOI 10.1111/j.1467-2995.2006.00311.x	22	1	1	0	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1467-2987	1467-2995		VET ANAESTH ANALG	Vet. Anaesth. Analg.	NOV	2018	45	6					831	838		10.1016/j.vaa.2018.06.006			8	Veterinary Sciences	Veterinary Sciences	GY6AW	WOS:000448668700014	30145048				2020-06-30	J	Barratt, MJ; Latimer, J; Jauncey, M; Tay, E; Nielsen, S				Barratt, Monica J.; Latimer, Julie; Jauncey, Marianne; Tay, Emma; Nielsen, Suzanne			Urine drug screening for early detection of unwitting use of fentanyl and its analogues among people who inject heroin in Sydney, Australia	DRUG AND ALCOHOL REVIEW			English	Article						fentanyl; heroin; designer drugs; sentinel surveillance; immunoassay	BRITISH-COLUMBIA; OVERDOSE; INCREASES; OPIOIDS; DEATHS; CANADA	Introduction and Aims North America has witnessed a dramatic rise in fatal opioid overdoses due to the unwitting consumption of non-pharmaceutical fentanyl and its analogues. While some of the drivers of this crisis-including profitability and access to high-potency opioids through internet sources-also apply in Australia, to our knowledge, there have been no ongoing surveillance studies of local populations. Therefore, this pilot study aimed to detect unintentional fentanyl consumption among people who inject heroin through instant urine screening, and determine the feasibility and acceptability of voluntary urinalysis of clients at the Medically Supervised Injecting Centre, Kings Cross, Sydney. Design and Methods Results Brief surveys and urine drug screens were conducted with 67 participants in Wave 1 (October 2017) and 51 participants in Wave 2 (March 2018). Urine samples were tested with BTNX Rapid Response (TM) fentanyl urine strip test at a detection level of 20 ng/mL norfentanyl. These strips also cross-react to numerous fentanyl analogues. There were no cases where positive urine tests suggested unwitting fentanyl use detected in this study. Discussion and Conclusions These negative findings contrast sharply with similar Canadian studies. While no cases of fentanyl-laced heroin use have been detected so far, we have demonstrated that this surveillance design is low-cost, feasible and scalable approach to monitoring the considerable public-health threat of undetected fentanyl and its analogues in Australia. Further validation of cross-reactivity of test strips would strengthen this method.	[Barratt, Monica J.] UNSW Sydney, Natl Drug & Alcohol Res Ctr, Drug Policy Modelling Program, Sydney, NSW, Australia; [Barratt, Monica J.] Curtin Univ, Fac Hlth Sci, Natl Drug Res Inst, Perth, WA, Australia; [Barratt, Monica J.] Burnet Inst, Behav & Hlth Risks Program, Melbourne, Vic, Australia; [Latimer, Julie; Jauncey, Marianne] Uniting Med Supervised Injecting Ctr, Sydney, NSW, Australia; [Tay, Emma] St Vincents Hosp, Sydney, NSW, Australia; [Nielsen, Suzanne] Monash Addict Res Ctr, Melbourne, Vic, Australia; [Nielsen, Suzanne] UNSW Sydney, Natl Drug & Alcohol Res Ctr, Sydney, NSW, Australia	Nielsen, S (reprint author), Monash Univ, Monash Addict Res Ctr, Peninsula Campus,Bldg G 3rd Floor,McMahons Rd, Frankston, Vic 3199, Australia.	suzanne.nielsen@monash.edu	; Barratt, Monica/C-3078-2008	Tay, Emma/0000-0003-1947-0267; Barratt, Monica/0000-0002-1015-9379	National Health and Medical Research CouncilNational Health and Medical Research Council of Australia [APP1070140, APP1132433]; Australian Government under the Drug and Alcohol Program Fund	We thank all the MSIC clients who gave up their time to participate in this study. Thanks to Michael Gilbert for initial advice when setting up this study and Michala Kowalski for assistance with data entry. MB and SN are supported by fellowships from the National Health and Medical Research Council (APP1070140 & APP1132433). The National Drug and Alcohol Research Centre and the National Drug Research Institute are supported by funding from the Australian Government under the Drug and Alcohol Program Fund. We also acknowledge the contribution of the Victorian Operational Infrastructure Support Program received by the Burnet Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the funders listed. An earlier version of this paper was presented at the APSAD Scientific Alcohol and Drug Conference, 12-15 November 2017, Melbourne.	Amlani A, 2015, HARM REDUCT J, V12, DOI 10.1186/s12954-015-0088-4; BTNX Inc, 2016, RAP RESP FENT FYL TE; Burdon D., 2016, WARNING CANBERRAS DR; Ciccarone D, 2017, INT J DRUG POLICY, V46, P146, DOI 10.1016/j.drugpo.2017.06.004; Drummer OH., 2018, FORENSIC SCI RES, V1790, P1; Gladden RM, 2016, MMWR-MORBID MORTAL W, V65, P837, DOI 10.15585/mmwr.mm6533a2; Hayashi K, 2018, DRUG ALCOHOL DEPEN, V183, P1, DOI 10.1016/j.drugalcdep.2017.10.020; Johns Hopkins Bloomberg School of Public Health, 2018, FENT OV RED CHECK AN; Jones AA, 2018, JAMA PSYCHIAT, V75, P298, DOI 10.1001/jamapsychiatry.2017.4432; Kennedy MC, 2018, DRUG ALCOHOL DEPEN, V185, P248, DOI 10.1016/j.drugalcdep.2017.12.026; Latimer J, 2016, INT J DRUG POLICY, V37, P111, DOI 10.1016/j.drugpo.2016.08.004; McKeown HE, 2018, SCI JUSTICE, V58, P366, DOI 10.1016/j.scijus.2018.04.004; Mema SC, 2018, HARM REDUCT J, V15, DOI 10.1186/s12954-018-0224-z; Miranda C., 2017, RISE DARK WEB DRUGS; Peterson AB, 2016, MMWR-MORBID MORTAL W, V65, P844, DOI 10.15585/mmwr.mm6533a3; Prekupec MP, 2017, J ADDICT MED, V11, P256, DOI 10.1097/ADM.0000000000000324; Quintana P, 2017, INT J DRUG POLICY, V40, P78, DOI 10.1016/j.drugpo.2016.10.006; Rodda LN, 2017, J ANAL TOXICOL, V41, P318, DOI 10.1093/jat/bkx013; Sisco E, 2017, FORENSIC CHEM, V4, P108, DOI 10.1016/j.forc.2017.04.001; Suzuki J, 2017, DRUG ALCOHOL DEPEN, V171, P107, DOI 10.1016/j.drugalcdep.2016.11.033	20	7	7	1	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0959-5236	1465-3362		DRUG ALCOHOL REV	Drug Alcohol Rev.	NOV	2018	37	7					847	850		10.1111/dar.12864			4	Substance Abuse	Substance Abuse	GZ8BW	WOS:000449712400004	30289187				2020-06-30	J	Ukai, T; Ebihara, G; Watanabe, M				Ukai, Taku; Ebihara, Goro; Watanabe, Masahiko			Opioid administration via epidural catheter is a risk factor for postoperative nausea and vomiting in total hip arthroplasty: A retrospective study	JOURNAL OF ORTHOPAEDIC SCIENCE			English	Article							TOTAL-KNEE REPLACEMENT; BUPIVACAINE MIXTURES; SURGICAL ANALGESIA; FENTANYL; SURGERY; ROPIVACAINE; MANAGEMENT; MORPHINE; PATIENT; PAIN	Background: Postoperative nausea and vomiting (PONV) may lead to extended hospital stay due to severe discomfort and restriction of patient activity. We retrospectively studied PONV incidence following total hip arthroplasty (THA) to evaluate the effect of opioid administration via epidural catheter. Methods: Our study included 155 affected joints in 136 patients who underwent a first THA from 2011 to 2016. For postoperative analgesia, an epidural catheter was preoperatively placed and used for continuous analgesic delivery into the epidural space up to 2 days after surgery. We analyzed patient age, sex, body mass index (BMI), opioid use via epidural catheter, amount of opioid used intraoperatively, amount of opioid used immediately before the end of the operation, anesthesia duration, and amount of opioid used postoperatively. Results: PONV was reported for 51 affected joints. Opioid was infused via epidural catheter in 114 affected joints, but not in 41 affected joints. Logistic regression analysis for PONV occurrence revealed a significant difference according to sex (P < 0.05), BMI (P < 0.01), and opioid use via epidural catheter (P < 0.05). Correlation analysis evaluating the occurrence of PONV and BMI using the chi(2) test demonstrated a significantly higher incidence of PONV in the subgroup of patients with a BMI <= 20 kg/m(2) (P <0.01). Conclusions: These results indicate that without using opioid or other action should be considered when epidural catheter is used in female patients with a BMI <= 20 kg/m(2). (C) 2018 The Japanese Orthopaedic Association. Published by Elsevier B.V. All rights reserved.	[Ukai, Taku; Ebihara, Goro; Watanabe, Masahiko] Tokai Univ, Sch Med, Dept Orthopaed Surg, Surg Sci, 143 Shimokasuya, Isehara, Kanagawa 2591193, Japan	Ukai, T (reprint author), Tokai Univ, Sch Med, Dept Orthopaed Surg, Surg Sci, 143 Shimokasuya, Isehara, Kanagawa 2591193, Japan.	taku115@is.icc.u-tokai.ac.jp; goro_ebihara@yahoo.co.jp; masahiko@is.icc.u-tokai.ac.jp					Adam F, 2005, ANESTH ANALG, V100, P475, DOI 10.1213/01.ANE.0000142117.82241.DC; Apfel CC, 2012, BRIT J ANAESTH, V109, P742, DOI 10.1093/bja/aes276; Apfel CC, 1999, ANESTHESIOLOGY, V91, P693, DOI 10.1097/00000542-199909000-00022; Apfel CC, 2012, ANESTHESIOLOGY, V117, P475, DOI 10.1097/ALN.0b013e318267ef31; Borgeat A, 2003, ANESTHESIOLOGY, V98, P530, DOI 10.1097/00000542-200302000-00036; CHANEY MA, 1995, CAN J ANAESTH, V42, P891, DOI 10.1007/BF03011037; Curatolo M, 1998, ACTA ANAESTH SCAND, V42, P910, DOI 10.1111/j.1399-6576.1998.tb05349.x; Dorr LD, 2007, CLIN ORTHOP RELAT R, P7, DOI 10.1097/BLO.0b013e318149296c; Engel JM, 1998, ANAESTHESIST, V47, P565, DOI 10.1007/s001010050597; FISCHER RL, 1988, ANESTH ANALG, V67, P559; GAFFUD MP, 1986, ANESTHESIOLOGY, V65, P331; GAN TJ, 1995, ANESTH ANALG, V80, P81, DOI 10.1097/00000539-199501000-00014; Gan TJ, 2014, ANESTH ANALG, V118, P85, DOI 10.1213/ANE.0000000000000002; Gedney JA, 1998, ANAESTHESIA, V53, P1148, DOI 10.1046/j.1365-2044.1998.00636.x; HJORTSO NC, 1986, ANESTH ANALG, V65, P1033; KAUSTE A, 1986, EUR J ANAESTH, V3, P1; Khanna A, 2017, J CLIN ANESTH, V37, P7, DOI 10.1016/j.jclinane.2016.08.020; LANZ E, 1985, ANESTH ANALG, V64, P786; MAHONEY OM, 1990, CLIN ORTHOP RELAT R, P30, DOI 10.1097/00003086-199011000-00007; Mallory TH, 2002, J ARTHROPLASTY, V17, P129, DOI 10.1054/arth.2002.32460; Pitimana-Aree S, 2005, REGION ANESTH PAIN M, V30, P446, DOI 10.1016/j.rapm.2005.05.010; PRESTON PG, 1988, ANESTHESIOLOGY, V68, P938, DOI 10.1097/00000542-198806000-00019; Roberts GW, 2005, ANESTH ANALG, V101, P1343, DOI 10.1213/01.ANE.0000180204.64588.EC; RUCCI FS, 1985, BRIT J ANAESTH, V57, P275, DOI 10.1093/bja/57.3.275; WEINGARTEN SR, 1995, WESTERN J MED, V163, P26	25	1	1	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0949-2658	1436-2023		J ORTHOP SCI	J. Orthop. Sci.	NOV	2018	23	6					973	976		10.1016/j.jos.2018.06.011			4	Orthopedics	Orthopedics	GZ8CF	WOS:000449713300020	30431008				2020-06-30	J	Michenot, N; Rostaing, S; Baron, L; Faure, S; Jovenin, N; Hubault, P; Delorme, T; Collin, E; Filbet, M; Chvetzoff, G; Delorme, C; Minello, C; Magnet, M; Ammar, D; Krakowski, I; Poulain, P				Michenot, Nathalie; Rostaing, Sylvie; Baron, Laurent; Faure, Sebastien; Jovenin, Nicolas; Hubault, Philippe; Delorme, Thierry; Collin, Elisabeth; Filbet, Marilene; Chvetzoff, Gisele; Delorme, Claire; Minello, Christian; Magnet, Marc; Ammar, Didier; Krakowski, Ivan; Poulain, Philippe			Opioid switch and change of route of administration in cancer patients treated by morphine	BULLETIN DU CANCER			French	Review						Morphine; Oxycodone; Fentanyl; Hydromorphone; Methadone; Equianalgesic ratios	CONTROLLED-RELEASE OXYCODONE; EQUIANALGESIC DOSE RATIO; OPEN-LABEL TRIAL; TRANSDERMAL FENTANYL; METHADONE TITRATION; PALLIATIVE CARE; ORAL METHADONE; PAIN; CONVERSION; ROTATION	This paper reviewed the 2002 guidelines established by the National Federation of Cancer Centres. A group of experts nominated by the 3 French Societies involved in the treatment of cancer pain (AFSOS, SFAP, SFETD), established new guidelines ratios for morphine switching and/or changing of route of administration, in patients for whom either pain was not adequatly managed or adverse effects were unbearable. After a rapid reminder of the pharmacokinetics and metabolism properties of morphine, experts explained why the theory of opioid rotation (oxycodone, hydromorphone, fentanyl, methadone, tapentadol) using fixed equianalgesic ratios is not any more appropriate for a secure clinical practice. In the light of recent publications enhancing our knowledge on the efficacy of new drug switching ratios and for changing the route of administration of morphine, the group of experts recommended to use reconsidered switching ratios favoring security upon efficacy, to minimize overdosing and adverse effects. Consequently, after the new conversion ratio (using slow release opioids) was applied, a second titration should be done by means of normal release rescue formulations for breakthrough pain episodes. A smartphone App. OpioConvert (R) will be available for rapid and secure dose conversions.	[Michenot, Nathalie] Ctr Hosp Versailles, 177 Rue Versailles, F-78150 Le Chesnay, France; [Rostaing, Sylvie] Inst St Catherine, 250 Chem Baigne Pieds, F-84000 Avignon, France; [Baron, Laurent] Cabinet Med, 11 Bis,Chem Bourdalats, F-65140 Rabastens De Bigorre, France; [Faure, Sebastien] Univ Angers, UFR Sci Pharmaceut & Ingn Sante, 16 Blvd Daviers, F-49045 Angers, France; [Jovenin, Nicolas] Inst Jean Godinot, 1 Rue General Koenig, F-51100 Reims, France; [Hubault, Philippe] CHU Angers, EMASSP, 4 Rue Larrey, F-49100 Angers, France; [Delorme, Thierry] Ctr Paul Papin, Inst Cancerol Ouest, 15 Rue Andre Boquel, F-49055 Angers, France; [Collin, Elisabeth] CHU Avicenne, 125 Ave Stalingrad, F-93000 Bobigny, France; [Filbet, Marilene] CHU Lyon Sud, 165 Chem Grand Revoyet, F-69310 Pierre Benite, France; [Chvetzoff, Gisele] Ctr Leon Berard, DISSPO, 29 Prom Lea & Napoleon Bullukian, F-69008 Lyon, France; [Delorme, Claire] Ctr Hosp Bayeux, CETD, 13 Rue Nesmond, F-14400 Bayeux, France; [Minello, Christian] Ctr Reg Lutte Canc Georges Francois Leclerc, 1 Rue Pr Marion, F-21000 Dijon, France; [Magnet, Marc] HAD Soins & Sante, 325 Rue Maryse Bastie, F-69141 Rillieux La Pape, France; [Ammar, Didier] Ctr Reg Lutte Canc Paoli Calmettes, 232 Blvd St Marguerite, F-13009 Marseille, France; [Krakowski, Ivan] Inst Bergonie, DISSPO, 229 Cours Argonne, F-33000 Bordeaux, France; [Poulain, Philippe] USP, Polyclin Ormeau Ctr, 12 Chem Ormeau, F-65000 Tarbes, France	Poulain, P (reprint author), USP, Polyclin Ormeau Ctr, 12 Chem Ormeau, F-65000 Tarbes, France.	phpoulain@wanadoo.fr		Faure, Sebastien/0000-0001-7524-8295			Andersen G, 2003, J PAIN SYMPTOM MANAG, V25, P74, DOI 10.1016/S0885-3924(02)00531-6; Benitez-Rosario MA, 2009, J PAIN SYMPTOM MANAG, V37, P1061, DOI 10.1016/j.jpainsymman.2008.05.016; Auret K, 2006, THER DRUG MONIT, V28, P359, DOI 10.1097/01.ftd.0000211827.03726.e4; Bruera E, 1998, J CLIN ONCOL, V16, P3222, DOI 10.1200/JCO.1998.16.10.3222; de Wildt SN, 1999, CLIN PHARMACOKINET, V36, P439, DOI 10.2165/00003088-199936060-00005; DeConno F, 1996, J CLIN ONCOL, V14, P2836, DOI 10.1200/JCO.1996.14.10.2836; Donner B, 1996, PAIN, V64, P527, DOI 10.1016/0304-3959(95)00180-8; Ferrell B, 1996, DOULEURS AIGUES; Galvez R, 2013, ADV THER, V30, P229, DOI 10.1007/s12325-013-0015-6; Hagen NA, 1999, J PAIN SYMPTOM MANAG, V18, P369, DOI 10.1016/S0885-3924(99)00083-4; Heiskanen T, 1997, PAIN, V73, P37, DOI 10.1016/S0304-3959(97)00072-9; KALSO E, 1990, CLIN PHARMACOL THER, V47, P639, DOI 10.1038/clpt.1990.85; Kawano C, 2011, YAKUGAKU ZASSHI, V131, P463, DOI 10.1248/yakushi.131.463; Lasheen W, 2010, PALLIATIVE MED, V24, P9, DOI 10.1177/0269216309346595; Lauretti GR, 2003, BRIT J CANCER, V89, P2027, DOI 10.1038/sj.bjc.6601365; Lawlor P, 1997, PAIN, V72, P79, DOI 10.1016/S0304-3959(97)00018-3; Lawlor PG, 1998, CANCER, V82, P1167, DOI 10.1002/(SICI)1097-0142(19980315)82:6<1167::AID-CNCR23>3.3.CO;2-8; McNamara P, 2002, PALLIATIVE MED, V16, P425, DOI 10.1191/0269216302pm536oa; Mercadante S, 1999, J CLIN ONCOL, V17, P3307, DOI 10.1200/JCO.1999.17.10.3307; Mercadante S, 2003, SUPPORT CARE CANCER, V11, P326, DOI 10.1007/s00520-003-0440-1; Mercadante S, 2001, J CLIN ONCOL, V19, P2898, DOI 10.1200/JCO.2001.19.11.2898; Mercadante S, 2014, CURR MED RES OPIN, V30, P2063, DOI 10.1185/03007995.2014.934793; Mercadante S, 2013, CURR MED RES OPIN, V29, P661, DOI 10.1185/03007995.2013.791617; Mercadante S, 2013, J PAIN SYMPTOM MANAG, V45, P298, DOI 10.1016/j.jpainsymman.2012.02.025; Mercadante S, 2011, PALLIATIVE MED, V25, P504, DOI 10.1177/0269216311406577; Mercadante S, 2009, J PAIN SYMPTOM MANAG, V37, P632, DOI 10.1016/j.jpainsymman.2007.12.024; Moksnes K, 2011, EUR J CANCER, V47, P2463, DOI 10.1016/j.ejca.2011.06.047; Moriarty M, 1999, J CLIN RES, V2, P1; Morita T, 2005, J PAIN SYMPTOM MANAG, V30, P96, DOI 10.1016/j.jpainsymman.2004.12.010; Moryl N, 2002, PAIN, V96, P325, DOI 10.1016/S0304-3959(01)00465-1; Moryl Natalie, 2005, Palliat Support Care, V3, P311; Mystakidou K, 2003, INT J CANCER, V107, P486, DOI 10.1002/ijc.11416; Narabayashi M, 2008, JPN J CLIN ONCOL, V38, P296, DOI 10.1093/jjco/hyn010; Nelson KA, 1997, J PAIN SYMPTOM MANAG, V13, P262, DOI 10.1016/S0885-3924(96)00329-6; Poulain P, 2016, J PAIN SYMPTOM MANAG, V52, P626, DOI 10.1016/j.jpainsymman.2016.05.022; Riley J, 2006, SUPPORT CARE CANCER, V14, P56, DOI 10.1007/s00520-005-0843-2; Ripamonti C, 1998, J CLIN ONCOL, V16, P3216, DOI 10.1200/JCO.1998.16.10.3216; SAWE J, 1981, BRIT MED J, V282, P771, DOI 10.1136/bmj.282.6266.771; Scholes CF, 1999, EUR J CANCER CARE, V8, P26; Tse DMW, 2003, PALLIATIVE MED, V17, P206, DOI 10.1191/0269216303pm696oa; Tzschentke TM, 2007, J PHARMACOL EXP THER, V323, P265, DOI 10.1124/jpet.107.126052; Walker PW, 2008, J PALLIAT MED, V11, P1103, DOI 10.1089/jpm.2007.0285; Wirz S, 2006, CLIN J PAIN, V22, P770, DOI 10.1097/01.ajp.0000210925.33783.4d	43	1	1	1	7	JOHN LIBBEY EUROTEXT LTD	MONTROUGE	127 AVE DE LA REPUBLIQUE, 92120 MONTROUGE, FRANCE	0007-4551	1769-6917		B CANCER	Bull. Cancer	NOV	2018	105	11					1052	1073		10.1016/j.bulcan.2018.06.011			22	Oncology	Oncology	GZ7XY	WOS:000449701400009	30274680				2020-06-30	J	Martens, MJM; Janssen, DJA; Schols, JMGA; van den Beuken-van Everdingen, MHJ				Martens, Mark J. M.; Janssen, Daisy J. A.; Schols, Jos M. G. A.; van den Beuken-van Everdingen, Marieke H. J.			Opioid Prescribing Behavior in Long-Term Geriatric Care in the Netherlands	JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION			English	Article						Analgesics; opioid; aged; pain management; palliative care; nursing homes; surveys and questionnaires	OF-LIFE CARE; SYRINGE DRIVERS; UNITED-STATES; CANCER PAIN; MORPHINE; MORPHINE-3-GLUCURONIDE; PHARMACOKINETICS; METABOLITES; END; PREVALENCE	Objectives: Pain is a highly prevalent problem in older adults and dying patients. Opioids are the main analgesic for moderate to severe pain in these patients. Different properties of various opioids can make them more or less suitable for this specific population. We therefore aim to explore opioid prescribing behavior in a group of physicians specialized in long-term geriatric care and to identify factors that are taken into account when selecting a specific opioid for treatment of pain in older patients and patients in the dying phase. Design: A cross-sectional study using an online questionnaire. Setting and Participants: All members of the Dutch Association of Elderly Care Physicians and Social Geriatricians (Verenso) on the mailing list of the weekly digital newsletter were invited to participate between November and December 2017. Measures: Preferences in opioids for the treatment of pain in nondying and dying older patients were recorded, as were the factors that were considered for these preferences. Results: 142 members completed the questionnaire (9%). Opioids of first choice were oxycodone (61%) for nondying and morphine (90%) for dying older patients. The second choice in both cases was fentanyl (56% for nondying and 31% in dying older patients). Personal experience was the main consideration in opioid prescribing (74%-98%). In daily practice, recommendations in guidelines are only considered by 8% to 9% and renal function by 0% to 1% of the respondents. Conclusions/Implications: Oxycodone is the opioid of first choice for physicians in long-term geriatric care in the Netherlands when prescribing for nondying older patients. In contrast, morphine is preferred for dying patients. Fentanyl as a second choice is mainly reserved for situations of stable pain. Prescribers base their choices almost exclusively on personal experience and are barely influenced by guidelines. Further research should therefore focus on clinical relevance for, and implementation in, daily practice. (C) 2018 AMDA - The Society for Post-Acute and Long-Term Care Medicine.	[Martens, Mark J. M.; Janssen, Daisy J. A.; van den Beuken-van Everdingen, Marieke H. J.] Maastricht Univ, Med Ctr, Ctr Expertise Palliat Care, POB 5800, NL-6202 AZ Maastricht, Netherlands; [Martens, Mark J. M.; Schols, Jos M. G. A.] Envida, Maastricht, Netherlands; [Janssen, Daisy J. A.] Ctr Expertise Chron Organ Failure, CIRO, Horn, Netherlands; [Schols, Jos M. G. A.] Maastricht Univ, Dept Hlth Serv Res, Caphri, Maastricht, Netherlands; [Schols, Jos M. G. A.] Maastricht Univ, Dept Family Med, Maastricht, Netherlands	Martens, MJM (reprint author), Maastricht Univ, Med Ctr, Ctr Expertise Palliat Care, POB 5800, NL-6202 AZ Maastricht, Netherlands.	mark.martens@mumc.nl	Martens, Mark/T-6766-2018	Martens, Mark/0000-0002-8098-8543	Netherlands Organization for Health Research and Development (ZonMw)Netherlands Organization for Health Research and Development [844001314]; The Hague, The NetherlandsNetherlands Government; Envida, Maastricht, the Netherlands	This work was supported by funding from The Netherlands Organization for Health Research and Development (ZonMw), grant number 844001314, The Hague, The Netherlands, and Envida, Maastricht, the Netherlands.	Abdulla A, 2013, AGE AGEING, V42, pI1, DOI 10.1093/ageing/afs200; Ashby M, 1997, J PAIN SYMPTOM MANAG, V14, P157, DOI 10.1016/S0885-3924(97)00020-1; BARTLETT SE, 1994, LIFE SCI, V54, P687, DOI 10.1016/0024-3205(94)00552-4; Christrup LL, 1997, ACTA ANAESTH SCAND, V41, P116, DOI 10.1111/j.1399-6576.1997.tb04625.x; Conill C, 1997, J PAIN SYMPTOM MANAG, V14, P328, DOI 10.1016/S0885-3924(97)00263-7; Dowell D, 2016, JAMA-J AM MED ASSOC, V315, P1624, DOI 10.1001/jama.2016.1464; Engbers-Buijtenhuijs P, 2008, NED TIJDSCH KLIN CHE, V33, P48; Faura CC, 1998, PAIN, V74, P43, DOI 10.1016/S0304-3959(97)00142-5; Ferrell B, 2009, J AM GERIATR SOC, V57, P1331, DOI 10.1111/j.1532-5415.2009.02376.x; Fosse A, 2017, J AM MED DIR ASSOC, V18, P713, DOI 10.1016/j.jamda.2017.03.005; Foundation capacity: Institute for Medical and Dental Education, 2016, CAP PLAN 2016 SUBR 5; Franken LG, 2016, CLIN PHARMACOKINET, V55, P697, DOI 10.1007/s40262-015-0345-4; Gloth FM, 2011, J PAIN, V12, pS14, DOI 10.1016/j.jpain.2010.11.006; Herndon CM, 2001, J PAIN SYMPTOM MANAG, V22, P1027, DOI 10.1016/S0885-3924(01)00365-7; King S, 2011, PALLIATIVE MED, V25, P525, DOI 10.1177/0269216311406313; Kurita GP, 2015, ACTA ANAESTH SCAND, V59, P1049, DOI 10.1111/aas.12521; Lalovic B, 2006, CLIN PHARMACOL THER, V79, P461, DOI 10.1016/j.clpt.2006.01.009; Lewis SS, 2010, NEUROSCIENCE, V165, P569, DOI 10.1016/j.neuroscience.2009.10.011; Masman AD, 2016, J PALLIAT MED, V19, P822, DOI 10.1089/jpm.2015.0548; Masman AD, 2015, INT J CLIN PHARM-NET, V37, P767, DOI 10.1007/s11096-015-0094-3; MILNER PC, 1989, PUBLIC HEALTH, V103, P345, DOI 10.1016/S0033-3506(89)80004-6; National Collaborating Centre for Cancer (UK), 2012, OP PALL CAR SAF EFF; Nederlandse Vereniging voor Anesthesiologie, 2016, RICHTL DIAGN BEH PIJ; Netherlands Comprehensive Cancer Organization (IKNL), 2016, PALL PIJN LAND RICHT; Northern Health Authority, 2008, HOSP PALL CAR S GUID; O'Doherty CA, 2001, PALLIATIVE MED, V15, P149, DOI 10.1191/026921601666624292; OSBORNE R, 1993, CLIN PHARMACOL THER, V54, P158, DOI 10.1038/clpt.1993.127; Pain & Policy Study Group University of Winsconsin/WHO Collaborating Center, 2018, CUST CONS GRAPHS OP; Rurup Mette L, 2010, BMC Palliat Care, V9, P23, DOI 10.1186/1472-684X-9-23; Schols J M G A, 2004, J Am Med Dir Assoc, V5, P207, DOI 10.1097/01.JAM.0000123031.43619.60; Smith AK, 2010, ANN INTERN MED, V153, P563, DOI 10.7326/0003-4819-153-9-201011020-00005; Smith GD, 1998, J PHARMACOL EXP THER, V285, P1157; SMITH MT, 1990, LIFE SCI, V47, P579, DOI 10.1016/0024-3205(90)90619-3; Sverrisdottir E, 2015, EUR J PHARM SCI, V74, P45, DOI 10.1016/j.ejps.2015.03.020; Sykes N, 2003, LANCET ONCOL, V4, P312, DOI 10.1016/S1470-2045(03)01079-9; Toscani F, 2005, J PAIN SYMPTOM MANAG, V30, P33, DOI 10.1016/j.jpainsymman.2005.01.013; Watanabe S, 2008, J PALLIAT MED, V11, P570, DOI 10.1089/jpm.2007.0176	37	2	2	1	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1525-8610	1538-9375		J AM MED DIR ASSOC	J. Am. Med. Dir. Assoc.	NOV	2018	19	11					974	980		10.1016/j.jamda.2018.07.009			7	Geriatrics & Gerontology	Geriatrics & Gerontology	GY3CN	WOS:000448423900008	30170936				2020-06-30	J	Khatri, UG; Viner, K; Perrone, J				Khatri, Utsha G.; Viner, Kendra; Perrone, Jeanmarie			Lethal Fentanyl and Cocaine Intoxication	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter									[Khatri, Utsha G.] Hosp Univ Penn, 3400 Spruce St, Philadelphia, PA 19104 USA; [Viner, Kendra] Philadelphia Dept Publ Hlth, Philadelphia, PA USA; [Perrone, Jeanmarie] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA	Khatri, UG (reprint author), Hosp Univ Penn, 3400 Spruce St, Philadelphia, PA 19104 USA.						Klar SA, 2016, MMWR-MORBID MORTAL W, V65, P1015, DOI 10.15585/mmwr.mm6537a6	1	8	8	2	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 1	2018	379	18					1782	1782		10.1056/NEJMc1809521			1	Medicine, General & Internal	General & Internal Medicine	GY8OL	WOS:000448891600018	30380395				2020-06-30	J	Takahashi, J; Goto, T; Okamoto, H; Hagiwara, Y; Watase, H; Shiga, T; Hasegawa, K				Takahashi, Jin; Goto, Tadahiro; Okamoto, Hiroshi; Hagiwara, Yusuke; Watase, Hiroko; Shiga, Takashi; Hasegawa, Kohei		Japanese Emergency Med Network Inv	Association of fentanyl use in rapid sequence intubation with post-intubation hypotension	AMERICAN JOURNAL OF EMERGENCY MEDICINE			English	Article						Fentanyl; Adverse events; Post-intubation hypotension; Rapid sequence intubation; Emergency department	EMERGENCY AIRWAY MANAGEMENT; TRACHEAL INTUBATION; RISK-FACTORS; INDUCTION; JAPAN; HYPERTENSION; DEPARTMENTS; LIDOCAINE; PRESSURE; OUTCOMES	Background: The anesthesia literature has reported that pre-intubation fentanyl use is associated with post-intubation hypotension which is a risk factor of poor post-emergency department (ED) prognosis. However, little is known about the relations between fentanyl use for intubation and post-intubation hypotension in the ED. We aimed to determine whether pretreatment with fentanyl was associated with a higher risk of post-intubation hypotension in the ED. Methods: We conducted a secondary analysis of data of ED airway management collected from a multicenter prospective study of 14 Japanese EDs from February 2012 through November 2016. We included all adult non-cardiac-arrest patients who underwent rapid sequence intubation for medical indication. Patients were divided into fentanyl and non-fentanyl groups. The primary outcome was post-intubation hypotension (systolic blood pressure <= 90 mm Hg) in the ED. Results: Of 1263 eligible patients, 466 (37%) patients underwent pretreatment with fentanyl. The fentanyl group had a higher risk of post-intubation hypotension (17% vs. 6%; unadjusted OR, 1.73; 95%CI. 1.01-2.97; P - 0.048) compared to the non-fentanyl group. In the multivariable analysis adjusting for age, sex, weight, principal indication, sedatives, intubator's specialty, number of intubation attempts, and patient clustering within EDs, the fentanyl group had a higher risk of post-intubation hypotension (adjusted OR, 1.87: 95%CI, 1.05 3.34: P = 0.03) compared to the non-fentanyl group. In the sensitivity analysis using propensity score matching, this association remained significant (OR, 3.17; 95%CI, 1.96-5.14; P < 0.01). Conclusion: In this prospective multicenter study of ED airway management, pretreatment with fentanyl in rapid sequence intubation was associated with higher risks of post-intubation hypotension. (C) 2018 Elsevier Inc. All rights reserved.	[Takahashi, Jin; Shiga, Takashi] Tokyo Ray Urayasu Ichikawa Med Ctr, Dept Emergency & Crit Care Med, 3-4-32 Todaijima, Urayasu, Chiba 2790001, Japan; [Goto, Tadahiro; Hasegawa, Kohei] Massachusetts Gen Hosp, Dept Emergency Med, 125 Nashua St Boston,Suite 920, Boston, MA 02114 USA; [Okamoto, Hiroshi] St Lukes Int Univ, Ctr Clin Epidemiol, Chuo Ku, 3-6 Tsukiji, Tokyo 1040045, Japan; [Hagiwara, Yusuke] Tokyo Metropolitan Childrens Med Ctr, Dept Pediat Emergency & Crit Care Med, 2-8-29 Musashidai, Fuchu, Tokyo 1838561, Japan; [Watase, Hiroko] Univ Washington, Dept Radiol, 850 Republican St, Seattle, WA 98006 USA; [Shiga, Takashi] Int Univ Hlth & Welf, Dept Emergency Med, 1-4-3 Mita, Tokyo 1088329, Japan; [Hasegawa, Kohei] Harvard Med Sch, Boston, MA USA	Takahashi, J (reprint author), Tokyo Ray Urayasu Ichikawa Med Ctr, Dept Emergency & Crit Care Med, 3-4-32 Todaijima, Urayasu, Chiba 2790001, Japan.	jint@jadecom.jp	Hagiwara, Yusuke/L-1886-2019	Takahashi, Jin/0000-0001-5396-0054	St. Luke's Science Institute (Tokyo, Japan)	This work was supported by grants from St. Luke's Science Institute (Tokyo, Japan). The study sponsor has no involvement in the study deign, in the collection, analysis and interpretation of data, in the writing of the manuscript, and in the decision to submit the manuscript for publication.	Austin PC, 2011, MULTIVAR BEHAV RES, V46, P119, DOI 10.1080/00273171.2011.540480; BILLARD V, 1994, ANESTHESIOLOGY, V81, P1384, DOI 10.1097/00000542-199412000-00013; CORK RC, 1984, ANESTH ANALG, V63, P60; Fang J, 2013, MMWR-MORBID MORTAL W, V62, P237; FRANKLIN C, 1994, AM J EMERG MED, V12, P425, DOI 10.1016/0735-6757(94)90053-1; GABOR AJ, 1984, ELECTROEN CLIN NEURO, V57, P497, DOI 10.1016/0013-4694(84)90085-3; Goto T, 2016, WEST J EMERG MED, V17, P129, DOI 10.5811/westjem.2016.1.28685; Goto T, 2015, EMERG MED J, V32, P781, DOI 10.1136/emermed-2013-203473; Goto T, 2015, SCAND J TRAUMA RESUS, V23, DOI 10.1186/s13049-014-0085-8; Goto Y, 2017, RESUSCITATION, V114, P14, DOI 10.1016/j.resuscitation.2017.02.009; Goto Y, 2014, ACUTE MED SURG, V1, P214, DOI 10.1002/ams2.43; Green R, 2014, CAN J EMERG MED, V16, P69, DOI 10.2310/8000.2013.131004; Green RS, 2015, J CRIT CARE, V30, P1055, DOI 10.1016/j.jcrc.2015.06.007; Green RS, 2012, CAN J EMERG MED, V14, P74, DOI 10.2310/8000.2012.110548; Hagiwara Y, 2015, AM J EMERG MED, V33, P1492, DOI 10.1016/j.ajem.2015.06.038; Hasegawa K, 2013, INT J EMERG MED, V6, DOI 10.1186/1865-1380-6-12; Hasegawa K, 2012, ANN EMERG MED, V60, P749, DOI 10.1016/j.annemergmed.2012.04.005; Hasegawa K, 2012, RESUSCITATION, V83, P428, DOI 10.1016/j.resuscitation.2011.11.027; Hashemian AM, 2018, AM J EMERG MED, V36, P197, DOI 10.1016/j.ajem.2017.07.069; Heffner AC, 2012, J CRIT CARE, V27, DOI 10.1016/j.jcrc.2011.08.011; HELFMAN SM, 1991, ANESTH ANALG, V72, P482; Imamura T, 2013, AM J EMERG MED, V31, P190, DOI 10.1016/j.ajem.2012.07.008; KAUTTO UM, 1982, ACTA ANAESTH SCAND, V26, P217, DOI 10.1111/j.1399-6576.1982.tb01757.x; Lehman LWH, 2013, CRIT CARE MED, V41, P34, DOI 10.1097/CCM.0b013e318265ea46; Liu B, 2014, ARTERY RES, V8, P209, DOI 10.1016/j.artres.2014.07.001; Mort TC, 2004, ANESTH ANALG, V99, P607, DOI 10.1213/01.ANE.0000122825.04923.15; Nakao S, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2014-006623; Overbeck MC, 2016, EMERG MED CLIN N AM, V34, P97, DOI 10.1016/j.emc.2015.08.007; Reich DL, 2005, ANESTH ANALG, V101, P622, DOI 10.1213/01.ANE.0000175214.38450.91; Sagarin MJ, 2005, ANN EMERG MED, V46, P328, DOI 10.1016/j.annemergmed.2005.01.009; Sakles JC, 1998, ANN EMERG MED, V31, P325, DOI 10.1016/S0196-0644(98)70342-7; Schofer Joel M, 2006, Cal J Emerg Med, V7, P75; Smischney NJ, 2016, MED SCI MONITOR, V22, P346, DOI 10.12659/MSM.895919; Walls RM, 2011, J EMERG MED, V41, P347, DOI 10.1016/j.jemermed.2010.02.024	34	5	6	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0735-6757	1532-8171		AM J EMERG MED	Am. J. Emerg. Med.	NOV	2018	36	11					2044	2049		10.1016/j.ajem.2018.03.026			6	Emergency Medicine	Emergency Medicine	GW7MK	WOS:000447152300020	29653790				2020-06-30	J	Parham, MA; Pomerleau, AC; Peralta, G; Drenzek, CL; Edison, LS				Parham, M. Angela; Pomerleau, A. C.; Peralta, G.; Drenzek, C. L.; Edison, L. S.			Fentanyl-associated illness among substance users - Fulton County, Georgia, 2015	AMERICAN JOURNAL OF EMERGENCY MEDICINE			English	Letter							COOK COUNTY; DEATHS; ILLINOIS; EPIDEMIC		[Parham, M. Angela] CDC, Epidem Intelligence Serv, Div Sci Educ & Profess Dev, Ctr Dis Control & Prevent, Atlanta, GA 30333 USA; [Parham, M. Angela; Peralta, G.; Edison, L. S.] Georgia Dept Publ Hlth, Acute Dis Epidemiol Sect, Atlanta, GA USA; [Pomerleau, A. C.] Emory Univ, Sch Med, Dept Emergency Med, Atlanta, GA 30322 USA; [Peralta, G.] CDC, CSTE Appl Epidemiol Fellowship Program, Atlanta, GA 30333 USA; [Drenzek, C. L.] Georgia Dept Publ Hlth, Div Hlth Protect, Atlanta, GA USA; [Edison, L. S.] CDC, Off Publ Hlth Preparedness & Response, Atlanta, GA 30333 USA	Pomerleau, AC (reprint author), 50 Hurt Plaza,Suite 600, Atlanta, GA 30307 USA.	apomerleau@gmail.com		Pomerleau, Adam/0000-0001-6394-3709			Algren DA, 2013, J MED TOXICOL, V9, P106, DOI 10.1007/s13181-012-0285-4; Centers for Disease Control and Prevention, 2016, CDCHAN00395 CDCP; Denton JS, 2008, J FORENSIC SCI, V53, P452, DOI 10.1111/j.1556-4029.2008.00669.x; Immunalysis Corporation, 2016, FENT HOM ENZ IMM HEI; Jones T. S., 2008, Morbidity and Mortality Weekly Report, V57, P793; Mercado-Crespo MC, 2014, MMWR-MORBID MORTAL W, V63, P531; Schumann H, 2008, CLIN TOXICOL, V46, P501, DOI 10.1080/15563650701877374; Sutter ME, 2017, ACAD EMERG MED, V24, P106, DOI 10.1111/acem.13034	8	0	0	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0735-6757	1532-8171		AM J EMERG MED	Am. J. Emerg. Med.	NOV	2018	36	11					2115	2117		10.1016/j.ajem.2018.03.041			4	Emergency Medicine	Emergency Medicine	GW7MK	WOS:000447152300041	29625855				2020-06-30	J	Phalen, P; Ray, B; Watson, DP; Huynh, P; Greene, MS				Phalen, Peter; Ray, Bradley; Watson, Dennis P.; Huynh, Philip; Greene, Marion S.			Fentanyl related overdose in Indianapolis: Estimating trends using multilevel Bayesian models	ADDICTIVE BEHAVIORS			English	Article						Overdose; Fentanyl; Opioids; Race/ethnicity; Gender	UNITED-STATES; PRESCRIPTION OPIOIDS; HEROIN OVERDOSE; TRANSITIONS; PREVALENCE; MORTALITY; THREAT; PAIN	Introduction: The opioid epidemic has been largely attributed to changes in prescribing practices over the past 20 years. Although current overdose trends appear driven by the opioid fentanyl, heroin has remained the focus of overdose fatality assessments. We obtained full toxicology screens on lethal overdose cases in a major US city, allowing more accurate assessment of the time-course of fentanyl-related deaths. Methods: We used coroner data from Marion County, Indiana comprising 1583 overdose deaths recorded between January 1, 2010 and April 30, 2017. Bayesian multilevel models were fitted to predict likelihood of lethal fentanyl-related overdose using information about the victim's age, race, sex, zip code, and date of death. Results: Three hundred and seventy-seven (23.8%) overdose deaths contained fentanyl across the seven-year period. Rates rose exponentially over time, beginning well below 15% from 2010 through 2013 before rising to approximately 50% by 2017. At the beginning of the study period, rates of fentanyl overdose were lowest among Black persons but increased more rapidly, eventually surpassing Whites. Currently, White females are at particularly low risk of fentanyl overdose whereas Black females are at high risk. Rates were highest for younger and middle-aged groups. Over time, fentanyl was more likely detected without the presence of other opioids. Conclusions: Fentanyl has increasingly been detected in fatal overdose deaths in Marion County. Policy and program responses must focus on education for those at highest risk of fentanyl exposure and death. These responses should also be tailored to meet the unique needs of high-risk demographics.	[Phalen, Peter] Univ Maryland, Sch Med, Dept Psychiat, 655 W Baltimore St, Baltimore, MD 21201 USA; [Ray, Bradley] Indiana Univ Purdue Univ, Sch Publ & Environm Affairs, 801 W Michigan St, Indianapolis, IN 46202 USA; [Watson, Dennis P.; Huynh, Philip] Indiana Univ, Richard M Fairbanks Sch Publ Hlth, Dept Social & Behav Sci, 1050 Wishard Blvd, Indianapolis, IN 46202 USA; [Greene, Marion S.] Indiana Univ, Richard M Fairbanks Sch Publ Hlth, Dept Hlth Policy & Management, Ctr Hlth Policy, 1050 Wishard Blvd, Indianapolis, IN 46202 USA	Ray, B (reprint author), Indiana Univ Purdue Univ, Sch Publ & Environm Affairs, 801 W Michigan St, Indianapolis, IN 46202 USA.	bradray@iupui.edu	Ray, Bradley/C-1843-2017; Phalen, Peter/F-4782-2016	Ray, Bradley/0000-0003-3643-775X; Huynh, Philip/0000-0002-2361-8925; Phalen, Peter/0000-0002-4219-3475	Centers for Disease Control and PreventionUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [5NU17CE002721-02]	This publication was supported by the Grant Number, 5NU17CE002721-02, funded by the Centers for Disease Control and Prevention. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the Centers for Disease Control and Prevention or the Department of Health and Human Services.	Alpert A, 2017, NATL BUREAU EC RES W, V23031, DOI [10.3386/w23031, DOI 10.3386/W23031]; Amlani A, 2015, HARM REDUCT J, V12, DOI 10.1186/s12954-015-0088-4; Avella J, 2007, J ANAL TOXICOL, V31, P540, DOI 10.1093/jat/31.8.540; Banta-Green CJ, 2013, J URBAN HEALTH, V90, P1102, DOI 10.1007/s11524-013-9814-y; Carroll JJ, 2017, INT J DRUG POLICY, V46, P136, DOI 10.1016/j.drugpo.2017.05.023; Cerda M, 2015, J PEDIATR-US, V167, P605, DOI 10.1016/j.jpeds.2015.04.071; Chen I, 2005, J GEN INTERN MED, V20, P593, DOI 10.1007/s11606-005-0105-5; Cicero TJ, 2014, JAMA PSYCHIAT, V71, P821, DOI 10.1001/jamapsychiatry.2014.366; Dart RC, 2015, NEW ENGL J MED, V372, P241, DOI [10.1056/NEJMc1501822, 10.1056/NEJMsa1406143]; Epstein DH, 2014, DRUG ALCOHOL DEPEN, V134, P22, DOI [10.1016/j.drugalcdep.2013.09.007, 10.1016/j.d]; Fernandez W, 2006, J SUBST ABUSE TREAT, V31, P151, DOI 10.1016/j.jsat.2006.04.008; Frank RG, 2017, NEW ENGL J MED, V376, P605, DOI 10.1056/NEJMp1615145; Gelman A., 2007, DATA ANAL USING REGR, V1; Harruff RC, 2015, ACAD FORENSIC PATHOL, V5, P499, DOI DOI 10.23907/2015.055; Hempstead K, 2014, HEALTH ECON, V23, P688, DOI 10.1002/hec.2937; Macmadu A, 2017, ADDICT BEHAV, V68, P35, DOI 10.1016/j.addbeh.2017.01.014; Mars SG, 2014, INT J DRUG POLICY, V25, P257, DOI 10.1016/j.drugpo.2013.10.004; McCabe SE, 2005, ADDICT BEHAV, V30, P789, DOI 10.1016/j.addbeh.2004.08.024; Meghani SH, 2012, PAIN MED, V13, P150, DOI 10.1111/j.1526-4637.2011.01310.x; Mennis J, 2016, DRUG ALCOHOL DEPEN, V165, P288, DOI 10.1016/j.drugalcdep.2016.06.019; National Center for Injury Prevention and Control, 2016, OP OV SYNTH OP DAT; Ossiander EM, 2014, AM J EPIDEMIOL, V179, P884, DOI 10.1093/aje/kwt333; Paulozzi Leonard J., 2011, Morbidity and Mortality Weekly Report, V60, P1487; Ray B, 2017, J URBAN HEALTH, V94, P301, DOI 10.1007/s11524-016-0113-2; Rudd R.A., 2016, MMWR MORBIDITY MORTA; Rudd RA, 2014, MMWR-MORBID MORTAL W, V63, P849; Somerville NJ, 2017, MMWR-MORBID MORTAL W, V66, P382, DOI 10.15585/mmwr.mm6614a2; Warner Margaret, 2016, Natl Vital Stat Rep, V65, P1; Watanabe S, 2010, J MACH LEARN RES, V11, P3571; Wickramatilake S, 2017, PUBLIC HEALTH REP, V132, P171, DOI 10.1177/0033354916688206; Wysowski DK, 2007, DRUG SAFETY, V30, P533, DOI 10.2165/00002018-200730060-00007	31	11	11	0	12	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4603	1873-6327		ADDICT BEHAV	Addict. Behav.	NOV	2018	86				SI		4	10		10.1016/j.addbeh.2018.03.010			7	Psychology, Clinical; Substance Abuse	Psychology; Substance Abuse	GQ9DE	WOS:000442065300002	29631798				2020-06-30	J	Thepsoparn, M; Sereeyotin, J; Pannangpetch, P				Thepsoparn, Marvin; Sereeyotin, Jariya; Pannangpetch, Patt			Effects of Combined Lower Thoracic Epidural/General Anesthesia on Pain Control in Patients Undergoing Elective Lumbar Spine Surgery	SPINE			English	Article						general anesthesia; low thoracic epidural anesthesia; lumbar spine surgery; pain	GENERAL-ANESTHESIA; ANALGESIA; LAMINECTOMY; FUSION	Study Design. Randomized controlled trial. Objective. Our objective was to compare postoperative pain relief and operating field condition of single-shot, low-thoracic epidural anesthesia combined with general anesthesia versus general anesthesia alone. Summary of Background Data. Prior studies have suggested that continuous epidural analgesia provides better postoperative pain relief and less intraoperative blood loss, but with the risk of the epidural catheter contaminating the surgical field. Methods. A total of 22 patients scheduled for elective lumbar spine surgery were enrolled and randomly allocated into two groups. Group B (block) received a single-shot epidural block with 0.25% bupivacaine plus 4mg of morphine with a total volume of 10 mL before receiving general anesthesia with desflurane, and cisatracurium. Group G (general) received general anesthesia alone with desflurane, cisatracurium, and any systemic analgesia deemed appropriate by the attending anesthesiologist. Postoperative pain score, opioid consumption, intraoperative blood loss, surgical field rating score, and other side effects were recorded at the postanesthesia care unit (PACU) and at 24 hours postoperatively. Results. Both groups were comparable for age, sex, body mass index, and American Society of Anaesthesiologists physical status. Fentanyl consumption was significantly lower (P<0.05) for group B (block) at the PACU and 24 hours. Mean fentanyl consumption at PACU was 20 mu g for group B and 85 mu g for group G. At 24 hours mean fentanyl consumption was 80 mu g for group B and 386 mu g for group G. Pain measured with numerical rating scale, surgical field rating score, blood loss, and complications were similar in both groups. Conclusion. Single-shot low-thoracic epidural anesthesia combined with general anesthesia provides better pain control than general anesthesia alone.	[Thepsoparn, Marvin; Sereeyotin, Jariya] Chulalongkorn Univ, King Chulalongkorn Mem Hosp, Fac Med, Pain Management Res Unit,Dept Anesthesiol, Bangkok, Thailand; [Pannangpetch, Patt] Khon Kaen Univ, Dept Anesthesiol, Fac Med, Khon Kaen, Thailand	Thepsoparn, M (reprint author), King Chulalongkorn Mem Hosp, Dept Anesthesia, 1873 Rama 4 Rd, Bangkok 10330, Thailand.	marvin.thep@gmail.com					Attari MA, 2011, J RES MED SCI, V16, P524; BOURKE DL, 1992, J CLIN ANESTH, V4, P277, DOI 10.1016/0952-8180(92)90128-N; Cohen BE, 1997, SPINE, V22, P1892, DOI 10.1097/00007632-199708150-00016; Ezhevskaya AA, 2013, SPINE, V38, P1324, DOI 10.1097/BRS.0b013e318290ff26; Jellish WS, 1996, ANESTH ANALG, V83, P559, DOI 10.1097/00000539-199609000-00021; Jin FL, 2001, J CLIN ANESTH, V13, P524, DOI 10.1016/S0952-8180(01)00320-8; JOSHI GP, 1995, ANESTH ANALG, V80, P511, DOI 10.1097/00000539-199503000-00013; Khajavi Mohammad Reza, 2013, Surg Neurol Int, V4, P105, DOI 10.4103/2152-7806.116683; Kundra P, 1997, ANESTH ANALG, V85, P135, DOI 10.1097/00000539-199707000-00024; Papadopoulos Elias C, 2006, Spine J, V6, P561, DOI 10.1016/j.spinee.2005.12.002; Sekar C, 2004, Spine J, V4, P261; Urmey WF, 2000, TECH REG ANESTH PAIN, V4, P101; Yoshimoto H, 2005, SPINE, V30, P863, DOI 10.1097/01.brs.0000158879.26544.69	13	2	2	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0362-2436	1528-1159		SPINE	SPINE	OCT 15	2018	43	20					1381	1385		10.1097/BRS.0000000000002662			5	Clinical Neurology; Orthopedics	Neurosciences & Neurology; Orthopedics	HD0ED	WOS:000452179600011	29624542				2020-06-30	J	Magnani, C; Giannarelli, D; Calvieri, A; Dardeli, A; Eusepi, G; Restuccia, MR; Mastroianni, C; Casale, G				Magnani, Caterina; Giannarelli, Diana; Calvieri, Alice; Dardeli, Ana; Eusepi, Giovanni; Restuccia, Maria Rosa; Mastroianni, Chiara; Casale, Giuseppe			Breakthrough cancer pain tailored treatment: which factors influence the medication choice? An observational, prospective and cross-sectional study in patients with terminal cancer	POSTGRADUATE MEDICAL JOURNAL			English	Article						pain management; adult palliative care; breakthrough pain; cancer pain; fentanyl; oral morphine	FENTANYL BUCCAL TABLET; TRANSMUCOSAL FENTANYL; PALLIATIVE CARE; ORAL MUCOSITIS; PREVALENCE; RECOMMENDATIONS; ASSOCIATION; MANAGEMENT	Background Various options for the pharmacological treatment of breakthrough cancer pain (BTcP) are available. International guidelines on BTcP treatment are not univocal. A tailored treatment should be based on the assessment of different variables such as BTcP characteristics, oral mucositis, chronic rhinitis and a patient's ability to take medication. Objective The goal of this study is to assess the relationship between these variables and the medication treatment for BTcP in a sample of patients with terminal cancer. Methods A prospective, cross-sectional study was carried out among 1180 patients who were receiving palliative care programmes. Patients were recruited if they had a diagnosis of BTcP and had been prescribed rescue opioids. Variables that might influence the BTcP treatment were assessed. Results One hundred and forty-nine eligible patients were enrolled; 59.1% of patients received short-acting oral morphine (OM), 27.5% transmucosal immediate-release fentanyl (TIRF) and 13.4% parenteral morphine for BTcP treatment. Short-acting OM prescription was related to background pain treatment with OM <60 mg daily (p<0.0001) and to home-care setting of assistance (p=0.004). Continuous intravenous morphine infusion and the presence of a vascular access were the main factors related to intravenous morphine prescription for BTcP. TIRF use was mainly related to background opioid dosage and the patient's self-sufficiency in taking medication. Conclusion In clinical practice, the factors that most influenced the pharmacological treatment for BTcP were baseline opioid dosage, setting of assistance and self-ability to take medication. Further research is needed to improve the knowledge on tailored BTcP treatment.	[Magnani, Caterina] Antea Assoc, Res Dept, Palliat Care Unit, Rome, Italy; [Giannarelli, Diana] Ist Regina Elena, Dept Biostat, Rome, Italy; [Calvieri, Alice; Dardeli, Ana; Eusepi, Giovanni; Restuccia, Maria Rosa] Antea, Hosp Care Dept, Rome, Italy; [Mastroianni, Chiara] Antea Assoc, Dept Educ, Palliat Care Unit, Rome, Italy; [Casale, Giuseppe] Antea Assoc, Hlth & Sci Management, Palliat Care Unit, Rome, Italy	Magnani, C (reprint author), Antea, Res Dept, Palliat Care Unit, I-00135 Rome, Italy.	c.magnani@antea.net	Giannarelli, Diana/T-5507-2017	Giannarelli, Diana/0000-0002-6085-1195	Molteni Farmaceutici	This work was supported by an unconditional grant from Molteni Farmaceutici. Molteni had no role in the design or conduct of the study; in the collection, management, analysis or interpretation of the data; or in the preparation, review or approval of the manuscript. The content of this article is solely the responsibility of the authors. The authors report no other conflicts of interest.	Brunelli C, 2010, HEALTH QUAL LIFE OUT, V8, DOI 10.1186/1477-7525-8-42; Caraceni A, 2012, LANCET ONCOL, V13, pE58, DOI 10.1016/S1470-2045(12)70040-2; Cheng KKF, 2010, SUPPORT CARE CANCER, V18, P1477, DOI 10.1007/s00520-009-0771-7; Corli O, 2014, MINERVA ANESTESIOL, V80, P1123; Darwish M, 2007, CLIN DRUG INVEST, V27, P605, DOI 10.2165/00044011-200727090-00002; Davies A, 2013, J PAIN SYMPTOM MANAG, V46, P619, DOI 10.1016/j.jpainsymman.2012.12.009; Davies AN, 2009, EUR J PAIN, V13, P331, DOI 10.1016/j.ejpain.2008.06.014; Deandrea S, 2014, J PAIN SYMPTOM MANAG, V47, P57, DOI 10.1016/j.jpainsymman.2013.02.015; Fallon Marie, 2011, J Support Oncol, V9, P224, DOI 10.1016/j.suponc.2011.07.004; Finn Andrew L, 2011, J Pain Res, V4, P245, DOI 10.2147/JPR.S22641; Hjermstad MJ, 2016, BMJ SUPPORT PALLIAT, V6, P344, DOI 10.1136/bmjspcare-2015-000887; Jandhyala R, 2013, J PAIN SYMPTOM MANAG, V46, P573, DOI 10.1016/j.jpainsymman.2012.09.009; Lohre ET, 2016, J PAIN SYMPTOM MANAG, V51, P1013, DOI 10.1016/j.jpainsymman.2015.12.329; Magnani C, 2017, CLIN J PAIN, V33, P707, DOI 10.1097/AJP.0000000000000450; Mercadante S, 2007, BRIT J CANCER, V96, P1828, DOI 10.1038/sj.bjc.6603811; Mercadante S, 2017, ADV THER, V34, P120, DOI 10.1007/s12325-016-0440-4; Mercadante S, 2016, PAIN, V157, P2657, DOI 10.1097/j.pain.0000000000000721; Mercadante S, 2016, VALUE HEALTH, V19, P531, DOI 10.1016/j.jval.2016.03.002; Mercadante S, 2015, SUPPORT CARE CANCER, V23, P3249, DOI 10.1007/s00520-015-2720-y; Mercadante S, 2015, CLIN J PAIN, V31, P214, DOI 10.1097/AJP.0000000000000161; Mercadante S, 2012, CURR MED RES OPIN, V28, P963, DOI 10.1185/03007995.2012.683112; National Institute for Health and Care Excellence, 2012, PALL CAR AD STRONG O; Perelman M, 2013, INT J CLIN PHARM TH, V51, P349, DOI 10.5414/CP201825; PORTENOY RK, 1990, PAIN, V41, P273, DOI 10.1016/0304-3959(90)90004-W; Smith HS, 2013, J PAIN RES, V6, P189, DOI 10.2147/JPR.S40745; Sonis ST, 2004, CANCER-AM CANCER SOC, V100, P1995, DOI 10.1002/cncr.20162; Sonis Stephen T, 2012, ORAL MUCOSITIS; Walker G, 2003, PALLIATIVE MED, V17, P219, DOI 10.1191/0269216303pm755oa	28	1	1	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0032-5473	1469-0756		POSTGRAD MED J	Postgrad. Med. J.	OCT	2018	94	1116					566	570		10.1136/postgradmedj-2018-135659			5	Medicine, General & Internal	General & Internal Medicine	HF6FD	WOS:000454329500005	30317182				2020-06-30	J	Rangappa, S; Rangan, KK; Sudarshan, TS; Murthy, SN				Rangappa, Srinath; Rangan, Krishnaswamy K.; Sudarshan, Tirumalai S.; Murthy, S. Narasimha			Antiallodynic and Antihyperalgesic Activities of Fentanyl-Loaded Dermal Clay Dressings in Rat Model of Second-Degree Burn Injury	JOURNAL OF PHARMACEUTICAL SCIENCES			English	Article						hyperalgesia; allodynia; clay patch; second-degree burn; pain	MECHANICAL ALLODYNIA; PAIN; HYPERALGESIA; MANAGEMENT; SILVER	Second-degree burn injury is the most common type of burn injury, which usually takes 2-3 weeks for complete healing. However, such patients suffer with intense pain associated with development of hyperalgesia and allodynia. Here, we prepare a silver clay patch using montmorillonite clay, betaine, and silver nitrate. Later, the silver clay patches were loaded with fentanyl. Furthermore, the patches were fabricated into burn wound dressings. The dressings were first subjected to ex vivo skin penetration studies and were later evaluated for thermal hyperalgesia and mechanical allodynia using second-degree burn injury rodent model. Our results show that application of fentanyl-loaded dermal clay (FLDC) dressings for 3 h showed significant increase of paw withdrawal latency (p < 0.001) against hyperalgesia starting from 30 min after removal of patch to up to 6 h. Similarly, the FLDC dressings also potentiated the paw withdrawal threshold for up to 4 h after application (p < 0.001). From these studies, we can conclude that FLDC dressings are ideal topical formulations for better management of pain in seconddegree burns. (c) 2018 American Pharmacists Association (R). Published by Elsevier Inc. All rights reserved.	[Rangappa, Srinath; Murthy, S. Narasimha] Univ Mississippi, Dept Pharmaceut & Drug Delivery, University, MS 38677 USA; [Rangan, Krishnaswamy K.; Sudarshan, Tirumalai S.] Mat Modificat Inc, Fairfax, VA 22031 USA; [Murthy, S. Narasimha] Inst Drug Delivery & Biomed Res, Bangalore, Karnataka, India	Murthy, SN (reprint author), Univ Mississippi, Dept Pharmaceut & Drug Delivery, University, MS 38677 USA.; Murthy, SN (reprint author), Inst Drug Delivery & Biomed Res, Bangalore, Karnataka, India.	murthygroup@gmail.com			Small Business Innovation Research (SBIR) Program [W81XWH-16-C-0006]; United States Army Medical Research and Materiel Command Combat Casualty Care Research programU.S. Army Medical Research & Materiel Command (USAMRMC); United States Army Medical Research and Materiel Command Clinical and Rehabilitative Medicine Research program	This work was supported by the Small Business Innovation Research (SBIR) Program under the contract #W81XWH-16-C-0006 (2016) and the United States Army Medical Research and Materiel Command Combat Casualty Care Research and the Clinical and Rehabilitative Medicine Research programs. The opinions or assertions contained herein are the private views of the authors and are not to be construed as official or as reflecting the views of the Department of the Army or the Department of Defense. The authors would like to thank Dr. John L. Clifford, U.S. Army Institute of Surgical Research, Battlefield Pain Management Research Task Area, Fort Sam Houston, TX, USA, for helpful suggestions on animal studies and discussions.	Abram SE, 1990, PAIN SYMPATHETIC NER, P1; ATCHISON NE, 1991, PAIN, V47, P41, DOI 10.1016/0304-3959(91)90009-M; Avsar U, 2016, OSTOMY WOUND MANAG, V62, P26; BAUER AW, 1966, AM J CLIN PATHOL, V45, P493; Chang YW, 2010, J PAIN, V11, P1146, DOI 10.1016/j.jpain.2010.02.010; Chang YW, 2010, J PAIN, V11, P119, DOI 10.1016/j.jpain.2009.06.009; Clifford JL, 2017, BURNS, V43, P1709, DOI 10.1016/j.burns.2017.04.020; Fowler M, 2014, BURNS, V40, P759, DOI 10.1016/j.burns.2013.10.011; Friesen KJ, 2016, CAN MED ASSOC J, V188, P648, DOI 10.1503/cmaj.150961; Garnock-Jones KP, 2016, CLIN DRUG INVEST, V36, P413, DOI 10.1007/s40261-016-0394-y; Green DP, 2013, PAIN, V154, P2512, DOI 10.1016/j.pain.2013.07.040; Guggenbichler JP, 1999, INFECTION, V27, pS16, DOI 10.1007/BF02561612; Hendricks SB, 1940, J AM CHEM SOC, V62, P1457, DOI 10.1021/ja01863a037; Kofke WA, 1996, ANESTH ANALG, V83, P1298, DOI 10.1097/00000539-199612000-00029; Long TD, 2001, J BURN CARE REHABIL, V22, P118, DOI 10.1097/00004630-200103000-00006; Mao JR, 2002, PAIN, V100, P213, DOI 10.1016/S0304-3959(02)00422-0; MAO JR, 1995, PAIN, V62, P259, DOI 10.1016/0304-3959(95)00073-2; Martin TJ, 2001, J PHARMACOL EXP THER, V299, P811; Maurya A, 2014, J PHARM SCI-US, V103, P1497, DOI 10.1002/jps.23938; McCaffrey M, 1999, PAIN CLIN MANUAL, P712; Mukhopadhyay K., US Patent application, Patent No. [2014152481 A1, 2014152481]; Nozaki-Taguchi N, 1999, ANESTHESIOLOGY, V90, P225, DOI 10.1097/00000542-199901000-00029; OSGOOD PF, 1989, PEDIATR CLIN N AM, V36, P1001; Parsons D, 2005, WOUNDS, V17, P222; Patterson DR, 2001, BONICAS MANAGEMENT P, V780-787; Payne R., 1990, PAIN SYNDROMES NEURO, P107; RAJA SN, 1984, BRAIN, V107, P1179, DOI 10.1093/brain/107.4.1179; Rangappa S, 2017, J DRUG DELIV SCI TEC, V39, P450, DOI 10.1016/j.jddst.2017.03.026; Rangari VK, 2010, NANOTECHNOLOGY, V21, DOI 10.1088/0957-4484/21/9/095102; Sawynok J, 2003, PHARMACOL REV, V55, P1, DOI 10.1124/pr.55.1.1; Schafheutle EI, 2001, J ADV NURS, V33, P728, DOI 10.1046/j.1365-2648.2001.01714.x; Selvarajah D, 2014, DIABETES VASC DIS RE, V11, P218, DOI 10.1177/1479164114522135; STEIN C, 1989, J PHARMACOL EXP THER, V248, P1269; Summer GJ, 2007, BURNS, V33, P1021, DOI 10.1016/j.burns.2007.02.007; Susuki T., 1983, CLIN REP, V17, P3827; ZIMMERMANN M, 1983, PAIN, V16, P109, DOI 10.1016/0304-3959(83)90201-4	36	1	1	1	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0022-3549	1520-6017		J PHARM SCI-US	J. Pharm. Sci.	OCT	2018	107	10					2628	2634		10.1016/j.xphs.2018.06.005			7	Chemistry, Medicinal; Chemistry, Multidisciplinary; Pharmacology & Pharmacy	Pharmacology & Pharmacy; Chemistry	HF2CQ	WOS:000454044100012	29920252				2020-06-30	J	Shin, SH; Srivilai, J; Ibrahim, SA; Strasinger, C; Hammell, DC; Hassan, HE; Stinchcomb, AL				Shin, Soo Hyeon; Srivilai, Jukkarin; Ibrahim, Sarah A.; Strasinger, Caroline; Hammell, Dana C.; Hassan, Hazem E.; Stinchcomb, Audra L.			The Sensitivity of In Vitro Permeation Tests to Chemical Penetration Enhancer Concentration Changes in Fentanyl Transdermal Delivery Systems	AAPS PHARMSCITECH			English	Article						chemical penetration enhancer (CPE); transdermal delivery system (TDS); in vitro permeation test (IVPT); fentanyl	PERMEABILITY; MODEL; BIOEQUIVALENCE; ADHESIVES; RAT	Chemical penetration enhancers (CPEs) are frequently incorporated into transdermal delivery systems (TDSs) to improve drug delivery and to reduce the required drug load in formulations. However, the minimum detectable effect of formulation changes to CPE-containing TDSs using in vitro permeation tests (IVPT), a widely used method to characterize permeation of topically applied drug products, remains unclear. The objective of the current exploratory study was to investigate the sensitivity of IVPT in assessing permeation changes with CPE concentration modifications and subsequently the feasibility of IVPT's use for support of quality control related to relative CPE concentration variation in a given formulation. A series of drug-in-adhesive (DIA) fentanyl TDSs with different amounts of CPEs were prepared, and IVPT studies utilizing porcine and human skin were performed. Although IVPT could discern TDSs with different amounts of CPE by significant differences in flux profiles, maximum flux (J(max)) values, and total permeation amounts, the magnitudes of the CPE increment needed to see such significant differences were very high (43-300%) indicating that IVPT may have limitations in detecting small changes in CPE amounts in some TDSs. Possible reasons for such limitations include formulation polymer and/or other excipients, type of CPE, variability associated with IVPT, skin type used, and disrupted stratum corneum (SC) barrier effects caused by CPEs.	[Shin, Soo Hyeon; Hammell, Dana C.; Hassan, Hazem E.; Stinchcomb, Audra L.] Univ Maryland, Sch Pharm, Dept Pharmaceut Sci, Baltimore, MD 21201 USA; [Srivilai, Jukkarin] Univ Phayao, Sch Pharmaceut Sci, Dept Cosmet Sci, Phayao 56000, Thailand; [Ibrahim, Sarah A.; Strasinger, Caroline] US FDA, Ctr Drug Evaluat & Res, Off Pharmaceut Qual, Silver Spring, MD 20903 USA; [Hassan, Hazem E.] Helwan Univ, Fac Pharm, Dept Pharmaceut & Ind Pharm, Cairo, Egypt	Stinchcomb, AL (reprint author), Univ Maryland, Sch Pharm, Dept Pharmaceut Sci, Baltimore, MD 21201 USA.	astinchc@rx.umaryland.edu	张, 张鑫月/AAP-1001-2020	Shin, Soo Hyeon/0000-0001-5091-8870; Stinchcomb, Audra/0000-0001-7316-969X; Srivilai, Jukkarin/0000-0002-5524-2029	Food and Drug AdministrationUnited States Department of Health & Human Services [5U01FD004275-05, NIPTE-U01-MD-2016-003-001]	Funding for this project was made possible, in part, by the Food and Drug Administration through grant 5U01FD004275-05 (Subaward NIPTE-U01-MD-2016-003-001).	Akomeah FK, 2007, J PHARM SCI-US, V96, P824, DOI 10.1002/jps.20773; Banerjee S, 2014, INT J ADHES ADHES, V50, P70, DOI 10.1016/j.ijadhadh.2014.01.001; BARTEK MJ, 1972, J INVEST DERMATOL, V58, P114, DOI 10.1111/1523-1747.ep12538909; Caussin J, 2008, BBA-BIOMEMBRANES, V1778, P1472, DOI 10.1016/j.bbamem.2008.03.003; Dragicevic N., 2015, PERCUTANEOUS PENETRA, P11, DOI [10.1007/978-3-662-47039-8, DOI 10.1007/978-3-662-47039-8_2]; Eichner A, 2017, BBA-BIOMEMBRANES, V1859, P745, DOI 10.1016/j.bbamem.2017.01.029; Femenia-Fonta A, 2006, INT J PHARMACEUT, V323, P125, DOI 10.1016/j.ijpharm.2006.05.049; Jung EC, 2015, TOPICAL DRUG BIOAVAI, P21; Karande P, 2005, P NATL ACAD SCI USA, V102, P4688, DOI 10.1073/pnas.0501176102; Karande P, 2009, BBA-BIOMEMBRANES, V1788, P2362, DOI 10.1016/j.bbamem.2009.08.015; Lehman PA, 2014, PHARM RES-DORDR, V31, P3529, DOI 10.1007/s11095-014-1439-7; Lopes LB, 2015, THER DELIV, V6, P1053, DOI 10.4155/tde.15.61; Mehdizadeh Amir, 2006, Acta Pharmaceutica (Zagreb), V56, P219; Raney SG, 2015, CLIN PHARMACOKINET, V54, P1095, DOI 10.1007/s40262-015-0292-0; Shin SH, 2017, PHARM RES-DORDR, V34, P1817, DOI 10.1007/s11095-017-2189-0; U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research Center for Biologics Evaluation and Research Center for Veterinary Medicine, 2011, GUID IND PREP IDES I, P1; Williams AC, 2012, ADV DRUG DELIVER REV, V64, P128, DOI 10.1016/j.addr.2012.09.032	17	4	4	0	3	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1530-9932			AAPS PHARMSCITECH	AAPS PharmSciTech	OCT	2018	19	7					2778	2786		10.1208/s12249-018-1130-0			9	Pharmacology & Pharmacy	Pharmacology & Pharmacy	HD5RP	WOS:000452587900003	30084070				2020-06-30	J	Swaminathan, SK; Fisher, J; Kandimalla, KK				Swaminathan, Suresh Kumar; Fisher, James; Kandimalla, Karunya K.			Sensitive Determination of Fentanyl in Low-Volume Serum Samples by LC-MS/MS	AAPS PHARMSCITECH			English	Article						fentanyl; LC-MS; MS; validation; analytical method; human serum	PERFORMANCE LIQUID-CHROMATOGRAPHY; MASS-SPECTROMETRY; HUMAN PLASMA; WHOLE-BLOOD; NORFENTANYL; ASSAY; METABOLITES; VALIDATION; URINE; PHARMACOKINETICS	Fentanyl is a widely used drug in the management of pain. Present LC-MS/MS methods for analysis of fentanyl require a large volume of serum, but yet the sensitivity was at about 50pg/mL. Here, we report a modified liquid-liquid extraction method for the analysis of fentanyl in serum. The method is very sensitive with a LLOQ of 5pg/mL while using only 0.175mL of serum for analysis. The separation was performed on a Zorbax XDB-C18 column (4.6x50mm, 1.8m, 600bar) using a mobile phase of water: acetonitrile (70:30 v/v) with 0.1% formic acid that was pumped isocratically at a flow rate of 0.5mL per minute. The calibration curve was found to be linear over a range of 5-10,000pg/mL. The inter-day and intra-day accuracy and precision were tested using low (20pg/mL), medium (1000pg/mL), and high (5000pg/mL) quality control samples of fentanyl prepared in blank human serum and were within +/- 15% of the nominal value. Fentanyl was also found to be stable in various storage and sample preparation conditions, including short-term bench-top storage (for 5h), freeze-thaw cycling (three cycles), long-term frozen condition (4.5months at -70 degrees C), and post-preparative storage (for 48h).	[Swaminathan, Suresh Kumar; Kandimalla, Karunya K.] Univ Minnesota, Coll Pharm, Dept Pharmaceut, Minneapolis, MN 55455 USA; [Fisher, James] Univ Minnesota, Coll Pharm, Clin Pharmacol Analyt Serv CPAS Lab, Minneapolis, MN 55455 USA	Kandimalla, KK (reprint author), Univ Minnesota, Coll Pharm, Dept Pharmaceut, Minneapolis, MN 55455 USA.	kkandima@umn.edu					Bista SR, 2014, J CHROMATOGR B, V960, P27, DOI 10.1016/j.jchromb.2014.04.019; Clavijo CF, 2011, J SEP SCI, V34, P3568, DOI 10.1002/jssc.201100422; Coopman V, 2007, FORENSIC SCI INT, V169, P223, DOI 10.1016/j.forsciint.2006.03.018; Ghassabian S, 2012, J CHROMATOGR B, V903, P126, DOI 10.1016/j.jchromb.2012.07.005; Gu HD, 2014, ANAL CHEM, V86, P8959, DOI 10.1021/ac5018265; Huynh NH, 2005, J PHARMACEUT BIOMED, V37, P1095, DOI 10.1016/j.jpba.2004.09.024; Koch DE, 2004, J PHARMACEUT BIOMED, V34, P577, DOI 10.1016/S0731-7085(03)00652-6; Kumar K, 1996, J PHARMACEUT BIOMED, V14, P667, DOI 10.1016/0731-7085(95)01685-6; Mahlke NS, 2014, INT J LEGAL MED, V128, P771, DOI 10.1007/s00414-014-1040-y; Nelson L, 2009, J MED TOXICOL, V5, P230, DOI 10.1007/BF03178274; PHIPPS JA, 1983, J CHROMATOGR, V272, P392, DOI 10.1016/S0378-4347(00)86145-9; Portier EJG, 1999, J CHROMATOGR B, V723, P313, DOI 10.1016/S0378-4347(98)00518-0; RODBARD D, 1974, CLIN CHEM, V20, P1255; Sofalvi S, 2017, J ANAL TOXICOL, V41, P473, DOI 10.1093/jat/bkx052; Strayer KE, 2018, ACS OMEGA, V3, P514, DOI 10.1021/acsomega.7b01536; Thomasy SM, 2008, J ANAL TOXICOL, V32, P754, DOI 10.1093/jat/32.9.754; Tiscione NB, 2017, J ANAL TOXICOL, V41, P313, DOI 10.1093/jat/bkx005; Torben B., 2011, J BIOANAL BIOMED, V3, P103; Veldhorst-Janssen NML, 2010, CLIN THER, V32, P1427, DOI 10.1016/j.clinthera.2010.07.001; Verplaetse R, 2016, DRUG TEST ANAL, V8, P30, DOI 10.1002/dta.1927; Verplaetse R, 2010, J CHROMATOGR B, V878, P1987, DOI 10.1016/j.jchromb.2010.05.033; Wang BT, 2014, J ANAL TOXICOL, V38, P672, DOI 10.1093/jat/bku103; Weng ND, 2002, J PHARMACEUT BIOMED, V28, P1115, DOI 10.1016/S0731-7085(02)00002-X; Yu MM, 2017, BIOANALYSIS, V9, P1551, DOI 10.4155/bio-2017-0174	24	0	0	1	5	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1530-9932			AAPS PHARMSCITECH	AAPS PharmSciTech	OCT	2018	19	7					2812	2817		10.1208/s12249-018-1103-3			6	Pharmacology & Pharmacy	Pharmacology & Pharmacy	HD5RP	WOS:000452587900007	30191378				2020-06-30	J	Park, MH; Kim, JA; Ahn, HJ; Yang, MK; Son, HJ; Seong, BG				Park, M. H.; Kim, J. A.; Ahn, H. J.; Yang, M. K.; Son, H. J.; Seong, B. G.			A randomised trial of serratus anterior plane block for analgesia after thoracoscopic surgery	ANAESTHESIA			English	Article						nerve block: serratus anterior plane block; pain management: thoracoscopic surgery; ultrasonography: thorax	THORACIC EPIDURAL ANALGESIA; PAIN MANAGEMENT; THORACOTOMY; POSTTHORACOTOMY; LOBECTOMY; CANCER	We evaluated the effect of pre-operative serratus anterior plane block on postoperative pain and opioid consumption after thoracoscopic surgery. We randomly allocated 89 participants to block with 30 ml ropivacaine 0.375% (n = 44), or no block without placebo or sham procedure (n = 45). We analysed results from 42 participants in each group. Serratus anterior plane block reduced mean (SD) remifentanil dose during surgery, 0.12 (0.06) mg.h(-1) vs. 0.16 (0.06) mg.h(-1), p = 0.016, and reduced mean (SD) fentanyl consumption in the first 24 postoperative hours, 3.8 (1.9) g.kg(-1) vs. 5.7 (1.6) g.kg(-1), p = 0.000004. Block also reduced the worst median (IQR [range]) pain scores reported in the first 24 postoperative hours: 6 (5-7 [3-10]) vs. 7 (6-7 [3-10]), p = 0.027. Block decreased dissatisfaction with pain management, categorised as highly unsatisfactory', unsatisfactory', neutral', satisfactory' or highly satisfactory': 1/2/21/18/0 vs. 1/14/15/11/1, p = 0.0038. There were no differences in the rates of nausea, vomiting, dizziness or length of hospital stay. Serratus anterior plane block may be used to reduce pain and opioid use after thoracoscopic lung surgery.	[Park, M. H.; Kim, J. A.; Ahn, H. J.; Yang, M. K.; Seong, B. G.] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Anesthesiol & Pain Med, Seoul, South Korea; [Park, M. H.; Son, H. J.] Kangwon Natl Univ, Grad Sch Med, Dept Anesthesiol & Pain Med, Chunchon, South Korea	Kim, JA (reprint author), Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Anesthesiol & Pain Med, Seoul, South Korea.	Jieae.kim@samsung.com					Barbera C, 2017, J PAIN RES, V10, P73, DOI 10.2147/JPR.S121441; Blanco R, 2013, ANAESTHESIA, V68, P1107, DOI 10.1111/anae.12344; Borner C, 2009, J IMMUNOL, V183, P882, DOI 10.4049/jimmunol.0802763; Bottiger BA, 2014, SEMIN CARDIOTHORAC V, V18, P45, DOI 10.1177/1089253213514484; Chu GM, 2017, A A CASE REP, V8, P322, DOI 10.1213/XAA.0000000000000502; Corso RM, 2017, MINERVA ANESTESIOL, V83, P775, DOI 10.23736/S0375-9393.17.11807-9; Dolin SJ, 2005, BRIT J ANAESTH, V95, P584, DOI 10.1093/bja/aei227; Harris DJ, 2015, REGION ANESTH PAIN M, V40, P232, DOI 10.1097/AAP.0000000000000239; Joshi GP, 2008, ANESTH ANALG, V107, P1026, DOI 10.1213/01.ane.0000333274.63501.ff; Kamiyoshihara Mitsuhiro, 2010, Asian Cardiovasc Thorac Ann, V18, P464, DOI 10.1177/0218492310381817; Khalil AE, 2017, J CARDIOTHOR VASC AN, V31, P152, DOI 10.1053/j.jvca.2016.08.023; Kunhabdulla NP, 2014, PAIN PHYSICIAN, V17, pE553; Laursen LO, 2016, EUR J CARDIO-THORAC, V49, P870, DOI 10.1093/ejcts/ezv205; Madabushi R, 2015, PAIN PHYSICIAN, V18, pE421; Mayes J, 2016, ANAESTHESIA, V71, P1064, DOI 10.1111/anae.13549; MCQUAY HJ, 1992, BRIT J ANAESTH, V69, P1, DOI 10.1093/bja/69.1.1; Okmen K, 2017, J ANESTH, V31, P579, DOI 10.1007/s00540-017-2364-9; Piracha MM, 2017, REGION ANESTH PAIN M, V42, P259, DOI 10.1097/AAP.0000000000000555; Steinthorsdottir KJ, 2014, EUR J CARDIO-THORAC, V45, P959, DOI 10.1093/ejcts/ezt525; Stoving K, 2015, REGION ANESTH PAIN M, V40, P355, DOI 10.1097/AAP.0000000000000252; Tamura M, 2013, J CARDIOTHORAC SURG, V8, DOI 10.1186/1749-8090-8-153; Wildgaard K, 2012, EUR J CARDIO-THORAC, V41, P1072, DOI 10.1093/ejcts/ezr151; Zocca JA, 2017, PAIN PRACT, V17, P141, DOI 10.1111/papr.12482	23	15	16	2	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0003-2409	1365-2044		ANAESTHESIA	Anaesthesia	OCT	2018	73	10					1260	1264		10.1111/anae.14424			5	Anesthesiology	Anesthesiology	GT5HP	WOS:000444538000012	30120832	Bronze			2020-06-30	J	Flint, RB; Bahmany, S; van der Nagel, BCH; Koch, BCP				Flint, Robert B.; Bahmany, Soma; van der Nagel, Bart C. H.; Koch, Birgit C. P.			Simultaneous quantification of fentanyl, sufentanil, cefazolin, doxapram and keto-doxapram in plasma using liquid chromatography-tandem mass spectrometry	BIOMEDICAL CHROMATOGRAPHY			English	Article						cefazolin; doxapram; fentanyl; sufentanil; UPLC-MS/MS	BETA-LACTAM ANTIBIOTICS; LC-MS/MS; PRETERM INFANTS; HUMAN SERUM; METABOLITES; BLOOD; NORFENTANYL; URINE; ASSAY; PAIN	A simple and specific UPLC-MS/MS method was developed and validated for simultaneous quantification of fentanyl, sufentanil, cefazolin, doxapram and its active metabolite keto-doxapram. The internal standard was fentanyl-d5 for all analytes. Chromatographic separation was achieved with a reversed-phase Acquity UPLC HSS T3 column with a run-time of only 5.0 min per injected sample. Gradient elution was performed with a mobile phase consisting of ammonium acetate or formic acid in Milli-Q ultrapure water or in methanol with a total flow rate of 0.4 mL min(-1). A plasma volume of only 50 mu L was required to achieve adequate accuracy and precision. Calibration curves of all five analytes were linear. All analytes were stable for at least 48 h in the autosampler. The method was validated according to US Food and Drug Administration guidelines. This method allows quantification of fentanyl, sufentanil, cefazolin, doxapram and keto-doxapram, which is useful for research as well as therapeutic drug monitoring, if applicable. The strength of this method is the combination of a small sample volume, a short run-time, a deuterated internal standard, an easy sample preparation method and the ability to simultaneously quantify all analytes in one run.	[Flint, Robert B.; Bahmany, Soma; van der Nagel, Bart C. H.; Koch, Birgit C. P.] Erasmus Univ, Med Ctr, Dept Pharm, Rotterdam, Netherlands; [Flint, Robert B.] Erasmus Univ, Med Ctr Sophia, Dept Pediat, Div Neonatol, Rotterdam, Netherlands; [Flint, Robert B.] Dept Pharm, Nijmegen, Netherlands; [Flint, Robert B.] Radboud Inst Hlth Sci, Nijmegen, Netherlands	Flint, RB (reprint author), Erasmus Univ, Med Ctr, Dept Pharm, Rotterdam, Netherlands.	r.flint@erasmusmc.nl	Flint, Robert B/A-1862-2016	Flint, Robert B/0000-0002-3658-594X	Netherlands Organisation for Health Research and Development ZonMwNetherlands Organization for Health Research and Development [80-83600-98-10190]	Netherlands Organisation for Health Research and Development ZonMw, Grant/Award Number: Grant number: 80-83600-98-10190	ARANDA JV, 1988, J LIQ CHROMATOGR, V11, P2983, DOI 10.1080/01483918808076774; Barbe F, 1999, THER DRUG MONIT, V21, P547, DOI 10.1097/00007691-199910000-00011; Carlier M, 2012, INT J ANTIMICROB AG, V40, P416, DOI 10.1016/j.ijantimicag.2012.06.022; Chanques G, 2006, CRIT CARE MED, V34, P1691, DOI 10.1097/01.CCM.0000218416.62457.56; Clavijo CF, 2011, J SEP SCI, V34, P3568, DOI 10.1002/jssc.201100422; Coppini R, 2016, PHARMACOL RES, V108, P80, DOI 10.1016/j.phrs.2016.04.025; FDA Food and Drug Administration of the United States, 2003, GUID IND BIOAN METH; Flint R, 2017, ACTA PAEDIATR, V106, P733, DOI 10.1111/apa.13761; Flint RB, 2017, CURR PHARM DESIGN, V23, P5919, DOI 10.2174/1381612823666170918121556; HAYAKAWA F, 1986, J PEDIATR-US, V109, P138, DOI 10.1016/S0022-3476(86)80594-7; Hisada T, 2013, BIOL PHARM BULL, V36, P412, DOI 10.1248/bpb.b12-00825; Huttner A, 2015, J ANTIMICROB CHEMOTH, V70, P3178, DOI 10.1093/jac/dkv201; Kiriazopoulos E, 2017, DRUG TEST ANAL, V9, P1062, DOI 10.1002/dta.2104; LEGATT DF, 1986, J CHROMATOGR, V378, P478, DOI 10.1016/S0378-4347(00)80746-X; Lillico R, 2016, J CHROMATOGR B, V1031, P94, DOI 10.1016/j.jchromb.2016.07.032; Mahlke NS, 2014, INT J LEGAL MED, V128, P771, DOI 10.1007/s00414-014-1040-y; MATHER LE, 1983, CLIN PHARMACOKINET, V8, P422, DOI 10.2165/00003088-198308050-00004; Matuszewski BK, 2003, ANAL CHEM, V75, P3019, DOI 10.1021/ac020361s; McWhinney BC, 2010, J CHROMATOGR B, V878, P2039, DOI 10.1016/j.jchromb.2010.05.027; NICHOL H, 1980, J CHROMATOGR, V182, P191, DOI 10.1016/S0378-4347(00)81623-0; Nosseir NS, 2014, J CHROMATOGR B, V973, P133, DOI 10.1016/j.jchromb.2014.10.006; Pacifici GM, 2015, PEDIATR NEONATOL, V56, P143, DOI 10.1016/j.pedneo.2014.06.002; Palleschi L, 2003, J PHARMACEUT BIOMED, V32, P329, DOI 10.1016/S0731-7085(03)00110-9; Parker SL, 2016, BIOMED CHROMATOGR, V30, P872, DOI 10.1002/bmc.3622; Prins SA, 2013, INT J PEDIAT, DOI 10.1155/2013/251047; Fernandez MDR, 2013, THER DRUG MONIT, V35, P510, DOI 10.1097/FTD.0b013e31828e7e6b; ROBSON RH, 1977, J CHROMATOGR, V143, P527, DOI 10.1016/S0378-4347(00)81800-9; Saar E, 2010, J MASS SPECTROM, V45, P915, DOI 10.1002/jms.1783; Saari TI, 2012, J PHARMACEUT BIOMED, V66, P306, DOI 10.1016/j.jpba.2012.03.050; Suzuki Y, 2017, BIOANALYSIS, V9, P503, DOI 10.4155/bio-2016-0267; Touw DJ, 2005, THER DRUG MONIT, V27, P10, DOI 10.1097/00007691-200502000-00004; Van Eeckhaut A, 2009, J CHROMATOGR B, V877, P2198, DOI 10.1016/j.jchromb.2009.01.003	32	3	4	2	18	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0269-3879	1099-0801		BIOMED CHROMATOGR	Biomed. Chromatogr.	OCT	2018	32	10							e4290	10.1002/bmc.4290			8	Biochemical Research Methods; Biochemistry & Molecular Biology; Chemistry, Analytical; Pharmacology & Pharmacy	Biochemistry & Molecular Biology; Chemistry; Pharmacology & Pharmacy	GU3KH	WOS:000445175600007	29768657	Other Gold, Green Published			2020-06-30	J	Tuval, A; Las, L; Shilo-Benjamini, YS				Tuval, Avishag; Las, Liora; Shilo-Benjamini, Yael			Evaluation of injectable anaesthesia with five medetomidine-midazolam based combinations in Egyptian fruit bats (Rousettus aegyptiacus)	LABORATORY ANIMALS			English	Article						bats; Rousettus aegyptiacus; ketamine; medetomidine-midazolam; opioids	FOXES PTEROPUS-HYPOMELANUS; SHORT-TERM IMMOBILIZATION; WATER RESTRICTION; DOGS; BUTORPHANOL; MICE; ISOFLURANE; FENTANYL; REVERSAL; KETAMINE	Egyptian fruit bats are increasingly used as model animals in neuroscience research. Our aim was to characterize suitable injectable anaesthesia for this species, possibly replacing inhalant anaesthesia, thus minimizing occupational health hazards. Eight bats were randomly assigned by a crossover design for subcutaneously administered combinations of medetomidine-midazolam with: saline (MM-Sal), ketamine (MM-Ket), fentanyl (MM-Fen), morphine (MM-Mor), or butorphanol (MM-But). The anaesthetic depth and vital signs were monitored at baseline and every 10min until bats recovered. If after 180min the bats did not recover, atipamezole was administered. Mean induction times were 7-11.5min with all combinations. Twitching during induction was common. All combinations produced anaesthesia, with significantly decreased heart rate (from 400 to 200bpm) and respiratory rate (from 120-140 to 36-65rpm). Arrhythmia and irregular breathing patterns occurred. MM-Fen, MM-Mor, and MM-But depressed respiration significantly more than MM-Sal. Time to first movement with MM-Ket and MM-But lasted significantly longer than with MM-Sal. Recovery time was significantly shorter in the MM-Sal (88min) in comparison to all other treatments, and it was significantly longer in the MM-But (159min), with atipamezole administered to four of the eight bats. In conclusion, all five anaesthetic protocols are suitable for Egyptian fruit bats; MM-Ket produces long anaesthesia and minimal respiratory depression, but cannot be antagonized completely. MM-Fen, MM-Mor, and MM-But depress respiration, but are known to produce good analgesia, and can be fully antagonized. Administration of atipamezole following the use of MM-But in Egyptian fruit bats is recommended.	[Tuval, Avishag] Weizmann Inst Sci, Dept Vet Resources, IL-7610001 Rehovot, Israel; [Tuval, Avishag; Las, Liora] Weizmann Inst Sci, Dept Neurobiol, IL-7610001 Rehovot, Israel; [Shilo-Benjamini, Yael] Hebrew Univ Jerusalem, Koret Sch Vet Med, Jerusalem, Israel	Tuval, A (reprint author), Weizmann Inst Sci, Dept Vet Resources, IL-7610001 Rehovot, Israel.; Tuval, A (reprint author), Weizmann Inst Sci, Dept Neurobiol, IL-7610001 Rehovot, Israel.	avishag.tuval@weizmann.ac.il					Albrecht M, 2014, BMC VET RES, V10, DOI 10.1186/s12917-014-0198-3; *AM SOC AN, CONT DEPTH SED DEF G; Amman BR, 2015, J WILDLIFE DIS, V51, P774, DOI 10.7589/2015-02-044; Amman BR, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002877; ARAD Z, 1993, J COMP PHYSIOL B, V163, P401; Barrett J, 2009, BATS IN CAPTIVITY; Becker Daniel E, 2009, Anesth Prog, V56, P14, DOI 10.2344/0003-3006-56.1.14; Bertrand HGMJ, 2016, BMC VET RES, V12, DOI 10.1186/s12917-016-0721-9; Borges LPB, 2016, VET ANAESTH ANALG, V43, P549, DOI 10.1111/vaa.12339; Bruniges N, 2016, J FELINE MED SURG, V18, P860, DOI 10.1177/1098612X15598550; Canfran S, 2016, VET J, V210, P56, DOI 10.1016/j.tvjl.2016.01.015; Duke T, 2013, CAN VET J, V54, P276; Epstein JH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025361; Fahlman A, 2014, J WILDLIFE DIS, V50, P574, DOI 10.7589/2013-06-148; Fahlman A, 2012, J ZOO WILDLIFE MED, V43, P67, DOI 10.1638/2011-0064.1; Finkelstein A, 2015, NATURE, V517, P159, DOI 10.1038/nature14031; Flecknell P, 2009, LAB ANIMAL ANAESTHES; Fleischmann T, 2016, LAB ANIM-UK, V50, P264, DOI 10.1177/0023677216631458; Geva-Sagiv M, 2016, NAT NEUROSCI, V19, P952, DOI 10.1038/nn.4310; Geva-Sagiv M, 2015, NAT REV NEUROSCI, V16, P94, DOI 10.1038/nrn3888; Giachero M, 2015, HIPPOCAMPUS, V25, P545, DOI 10.1002/hipo.22409; Heard D, 2006, J WILDLIFE DIS, V42, P437, DOI 10.7589/0090-3558-42.2.437; Heard D, 2014, ZOO ANIMAL AND WILDLIFE IMMOBILIZATION AND ANESTHESIA, 2ND EDITION, P543; Henke J, 2005, VET ANAESTH ANALG, V32, P261, DOI 10.1111/j.1467-2995.2005.00242.x; Henke J, 2004, J VET MED A, V51, P259, DOI 10.1111/j.1439-0442.2004.00632.x; Hoffmann S, 2016, EUR J NEUROSCI, V44, P2685, DOI 10.1111/ejn.13394; Hoffmann S, 2013, J NEUROPHYSIOL, V110, P1257, DOI 10.1152/jn.00226.2013; HU C, 1992, LAB ANIM-UK, V26, P15, DOI 10.1258/002367792780809075; Huske C, 2016, BRAIN RES, V1642, P364, DOI 10.1016/j.brainres.2016.04.019; Itamoto K, 2000, J VET MED A, V47, P411, DOI 10.1046/j.1439-0442.2000.00302.x; Kageyama A, 2016, J VET MED SCI, V78, P1283, DOI 10.1292/jvms.16-0039; Kirihara Y, 2015, EXP ANIM TOKYO, V64, P39, DOI 10.1538/expanim.14-0039; KORINE C, 1993, J THERM BIOL, V18, P61, DOI 10.1016/0306-4565(93)90018-O; Korine C, 2016, IUCN RED LIST THREAT; Kraus TM, 2016, BMC MUSCULOSKEL DIS, V17, DOI 10.1186/s12891-016-0999-6; Lamont LA, 2014, ZOO ANIMAL AND WILDLIFE IMMOBILIZATION AND ANESTHESIA, 2ND EDITION, P5; Lane H. C, 1971, Revue Suisse de Zoologie, V78, P655; Lewis JCM, 2004, J ZOO WILDLIFE MED, V35, P303, DOI 10.1638/03-072; Mihova D, 2016, J COMP PHYSIOL A, V202, P517, DOI 10.1007/s00359-016-1098-8; Murphy KL, 2010, VET ANAESTH ANALG, V37, P222, DOI 10.1111/j.1467-2995.2009.00525.x; NOLL UG, 1979, COMP BIOCHEM PHYS A, V63, P79, DOI 10.1016/0300-9629(79)90631-5; Olkkola K. T., 2008, V182, P335, DOI 10.1007/978-3-540-74806-9_16; Prat Y, 2015, SCI ADV, V1, DOI 10.1126/sciadv.1500019; Rigby EL, 2012, VET REC, V170, DOI 10.1136/vr.100075; Sanday L, 2012, PROG NEURO-PSYCHOPH, V37, P1, DOI 10.1016/j.pnpbp.2012.01.013; Sarel A, 2017, SCIENCE, V355, P176, DOI 10.1126/science.aak9589; Schmitz S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0174423; Sinclair MD, 2003, CAN VET J, V44, P885; Sohayati AR, 2008, J ZOO WILDLIFE MED, V39, P674, DOI 10.1638/2006-0061.1; Todd TE, 2013, LAB ANIMAL, V42, P371, DOI 10.1038/laban.282; Tranquilli WJ, 2015, LUMB JONES VET ANEST, P1; VAHAVAHE T, 1989, ACTA VET SCAND, V30, P267; VAINIO O, 1989, J VET PHARMACOL THER, V12, P225, DOI 10.1111/j.1365-2885.1989.tb00664.x; Venturini Elisa, 2017, Neurosignals, V25, P26, DOI 10.1159/000480643; VERSTEGEN J, 1993, VET REC, V132, P353, DOI 10.1136/vr.132.14.353; Yartsev MM, 2011, NATURE, V479, P103, DOI 10.1038/nature10583	56	0	0	0	3	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0023-6772	1758-1117		LAB ANIM-UK	Lab. Anim.	OCT	2018	52	5					515	525		10.1177/0023677218756456			11	Veterinary Sciences; Zoology	Veterinary Sciences; Zoology	GU4VX	WOS:000445284200007	29448876				2020-06-30	J	Brimdyr, K; Cadwell, K				Brimdyr, Kajsa; Cadwell, Karin			A plausible causal relationship between the increased use of fentanyl as an obstetric analgesic and the current opioid epidemic in the US	MEDICAL HYPOTHESES			English	Article							PRENATAL ALCOHOL EXPOSURE; DEATHS; STATES; ADDICTION; ANALOGS; TRENDS	Drug poisoning deaths have more than doubled in the United States since 2000 with fentanyl and fentanyl analogues primarily responsible for the jump in opioid deaths. Robust data indicate a convincing correlation between the exposure of the fetus to other labor medications (morphine, pethidine hydrochloride, barbiturates, phenobarbitone, meperidine, and secobarbital) and the later addiction of young adults to the same category of drug. We present the hypothesis that this effect is also true of the opioid, fentanyl: there is a causal relationship between the increased popularity of fentanyl as a labor anesthetic in the United States since the 1980's and the current epidemic of fentanyl abuse.	[Brimdyr, Kajsa; Cadwell, Karin] Hlth Children Project Inc, 327 Quaker Meeting House Rd, East Sandwich, MA 02537 USA	Brimdyr, K (reprint author), Hlth Children Project Inc, 327 Quaker Meeting House Rd, East Sandwich, MA 02537 USA.	kajsa@centerforbreastfeeding.org		Brimdyr, Kajsa/0000-0003-3789-635X			[Anonymous], 2018, NATL VITAL STAT REPO, V67, P76; BADER AM, 1995, ANESTH ANALG, V81, P829, DOI 10.1097/00000539-199510000-00029; Baer JS, 1998, J STUD ALCOHOL, V59, P533, DOI 10.15288/jsa.1998.59.533; Baer JS, 2003, ARCH GEN PSYCHIAT, V60, P377, DOI 10.1001/archpsyc.60.4.377; Beauchamp GK, 2011, DIGESTION, V83, P1, DOI 10.1159/000323397; Blondel B, 2017, J GYNECOL OBSTET HUM, V46, P701, DOI 10.1016/j.jogoh.2017.09.002; Centers for Disease Control and Prevention, DRUG OV DEATH DAT; Chotro MG, 2007, NEUROSCI BIOBEHAV R, V31, P181, DOI 10.1016/j.neubiorev.2006.06.021; Collis R E, 1994, Int J Obstet Anesth, V3, P75, DOI 10.1016/0959-289X(94)90173-2; Curtin S. C., 2017, NATL CENT HLTH STAT, V282, P1; Daniulaityte R, 2017, MMWR-MORBID MORTAL W, V66, P904, DOI 10.15585/mmwr.mm6634a3; FRANCIS DM, 1981, ANAESTHESIA, V36, P69, DOI 10.1111/j.1365-2044.1981.tb08613.x; Gladden RM, 2016, MMWR-MORBID MORTAL W, V65, P837, DOI 10.15585/mmwr.mm6533a2; HENDERSON GL, 1991, J FORENSIC SCI, V36, P422; Hsu DJ, 2017, ADDICTION, V112, P1558, DOI 10.1111/add.13795; JACOBSON B, 1990, BRIT MED J, V301, P1067, DOI 10.1136/bmj.301.6760.1067; Jonaki Bose, 2016, HHS PUBLICATION; Jordan S, 2016, COCHRANE DB SYST REV; JUSTINS DM, 1982, BRIT J ANAESTH, V54, P409, DOI 10.1093/bja/54.4.409; Kane JM, 2018, PEDIATRICS, V141, DOI 10.1542/peds.2017-3335; Mennella JA, 2014, AM J CLIN NUTR, V99, p704S, DOI 10.3945/ajcn.113.067694; Moises ECD, 2005, EUR J CLIN PHARMACOL, V61, P517, DOI 10.1007/s00228-005-0967-9; NHS Digital, 2017, NHS DIGITAL; NIDA, 2014, LESS PREV RES; Nyberg K, 2000, EPIDEMIOLOGY, V11, P715, DOI 10.1097/00001648-200011000-00018; NYBERG K, 1992, BRIT J ADDICT, V87, P1669; O'Donnell JK, 2017, MMWR-MORBID MORTAL W, V66, P1197, DOI 10.15585/mmwr.mm6643e1; Ruhm CJ, 2017, AM J PREV MED, V53, P745, DOI 10.1016/j.amepre.2017.06.009; Stanley TH, 2014, J PAIN, V15, P1215, DOI 10.1016/j.jpain.2014.08.010; Sue Jordan, 2010, PHARM MIDWIVES EVIDE; The Council of Economic Advisors, 2017, UND COSTS OP CRIS; U. S. House of Representatives Committee on Energy and Commerce, HEAR ENT FENT NEXT W; United Nations Office on Drugs and Crime (UNODC), 2017, FENT ITS AN 50 YEARS, V17; Vivolo-Kantor AM, 2018, MMWR-MORBID MORTAL W, V67, P279, DOI 10.15585/mmwr.mm6709e1; Weden MM, 2012, AM J PUBLIC HEALTH, V102, P723, DOI 10.2105/AJPH.2011.300214	35	1	1	0	6	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	0306-9877	1532-2777		MED HYPOTHESES	Med. Hypotheses	OCT	2018	119						54	57		10.1016/j.mehy.2018.07.027			4	Medicine, Research & Experimental	Research & Experimental Medicine	GS6GS	WOS:000443787300013	30122491	Other Gold			2020-06-30	J	Kahl, JH; Gonyea, J; Humphrey, SM; Hime, GW; Boland, DM				Kahl, Joseph H.; Gonyea, Jennifer; Humphrey, Susan M.; Hime, George W.; Boland, Diane M.			Quantitative Analysis of Fentanyl and Six Fentanyl Analogs in Postmortem Specimens by UHPLC-MS-MS	JOURNAL OF ANALYTICAL TOXICOLOGY			English	Article; Proceedings Paper	Meeting of the Society-of-Forensic-Toxicologists (SOFT), International-Association-of-Forensic-Toxicologists (TIAFT)	JAN 07-11, 2018	Boca Raton, FL	Soc Forens Toxicol, Int Assoc Forens Toxicol			WHOLE-BLOOD; LC-MS/MS; DRUG; FATALITY; DEATHS	Since 2013, opioid-related deaths have increased in Miami-Dade County, FL due to fentanyl and fentanyl analogs in the local heroin supply. From 2014 to 2015, a near 600% increase in fentanyl and fentanyl analog-related deaths was observed, followed by another 200% increase in 2016. In addition to fentanyl, six fentanyl analogs were identified in this time period: beta-hydroxythiofentanyl, acetyl fentanyl, furanyl fentanyl, carfentanil, butyryl fentanyl and para-fluoroisobutyryl fentanyl. As a result, an analytical method to quantify these compounds in postmortem biological fluids and tissues using solid-phase extraction with analysis by ultra high-performance liquid chromatography-tandem mass spectrometry (UHPLC-MS-MS) was developed and validated. All analytes except carfentanil were linear from 1 to 50 ng/mL with a limit of detection (LOD) of 0.5 ng/mL; carfentanil was linear from 0.2 to 10 ng/mL with a LOD of 0.1 ng/mL. For all analytes, bias was within +/- 14%, intra- and inter-day precision were <= 5% and extraction efficiency was >87%. Dilution integrity was assessed at 1:1, 1:4 and 1:9 (v/v) ratios; percent error from target was <12% for all analytes. No exogenous interferences were observed. Analytes were stable in preserved whole blood stored at 4 degrees C for 9 months; extracted samples were stable in the refrigerated autosampler (15 degrees C) for up to 72 h. The ability to distinguish the isomer pairs isobutyryl/butyryl fentanyl and p-fluoroisobutyryl/p-fluorobutyryl fentanyl is achieved by this method. The method was applied to 312 cases in which fentanyl and/or fentanyl analogs were previously identified. Postmortem concentrations in blood ranged from <0.2 to 0.73 ng/mL for carfentanil and from 30.6 to 91.7 ng/mL for p-fluoroisobutyryl fentanyl in cases in which these analytes were listed as the sole cause of death.	[Kahl, Joseph H.; Gonyea, Jennifer; Humphrey, Susan M.; Hime, George W.; Boland, Diane M.] Miami Dade Med Examiner Dept, 1851 NW 10th Ave, Miami, FL 33136 USA	Kahl, JH (reprint author), Miami Dade Med Examiner Dept, 1851 NW 10th Ave, Miami, FL 33136 USA.	joe.kahl@miamidade.gov					Algren DA, 2013, J MED TOXICOL, V9, P106, DOI 10.1007/s13181-012-0285-4; [Anonymous], 2013, J ANAL TOXICOL, V37, P452, DOI 10.1093/jat/bkt054; [Anonymous], 2008, NAT FOR LAB INF SYST; [Anonymous], 2017, 4 FLUOR 4 FIBF CRIT; Araujo P, 2009, J CHROMATOGR B, V877, P2224, DOI 10.1016/j.jchromb.2008.09.030; Backberg M, 2015, CLIN TOXICOL, V53, P609, DOI 10.3109/15563650.2015.1054505; Centers for Disease Control and Prevention, NAT VIT STAT SYST MO; Cunningham SM, 2016, J FORENSIC SCI, V61, pS276, DOI 10.1111/1556-4029.12953; Dolan JW, 2009, LC GC N AM, V27, P534; Dussy FE, 2016, J ANAL TOXICOL, V40, P761, DOI 10.1093/jat/bkw096; Fort C, 2016, J ANAL TOXICOL, V40, P754, DOI 10.1093/jat/bkw068; Guerrieri D, 2017, J ANAL TOXICOL, V41, P242, DOI 10.1093/jat/bkw129; Helander A, 2016, CLIN TOXICOL, V54, P324, DOI 10.3109/15563650.2016.1139715; HENDERSON GL, 1991, J FORENSIC SCI, V36, P422; HIBBS J, 1991, JAMA-J AM MED ASSOC, V265, P1011, DOI 10.1001/jama.265.8.1011; Johnson H., 2012, MMWR-MORBID MORTAL W, V63, P569; Jones G. R., 2013, CLARKES ANAL FORENSI, P201; KRAM TC, 1981, ANAL CHEM, V53, P1379, DOI 10.1021/ac00235a003; Matuszewski BK, 2003, ANAL CHEM, V75, P3019, DOI 10.1021/ac020361s; McIntyre IM, 2015, J ANAL TOXICOL, V39, P490, DOI 10.1093/jat/bkv043; Mohr ALA, 2016, J ANAL TOXICOL, V40, P709, DOI 10.1093/jat/bkw086; Ojanpera I, 2008, INT J LEGAL MED, V122, P395, DOI 10.1007/s00414-008-0230-x; Papsun D, 2017, J ANAL TOXICOL, V41, P777, DOI 10.1093/jat/bkx068; Peters FT, 2007, FORENSIC SCI INT, V165, P216, DOI 10.1016/j.forsciint.2006.05.021; Poklis J, 2016, J ANAL TOXICOL, V40, P703, DOI 10.1093/jat/bkw048; Rudd RA, 2016, MMWR-MORBID MORTAL W, V65, P1445, DOI 10.15585/mmwr.mm655051e1; Shanks KG, 2017, J ANAL TOXICOL, V41, P466, DOI 10.1093/jat/bkx042; Shoff EN, 2017, J ANAL TOXICOL, V41, P484, DOI 10.1093/jat/bkx041; Sofalvi S, 2017, J ANAL TOXICOL, V41, P473, DOI 10.1093/jat/bkx052; Stanley TH, 2014, J PAIN, V15, P1215, DOI 10.1016/j.jpain.2014.08.010; Strayer KE, 2018, ACS OMEGA, V3, P514, DOI 10.1021/acsomega.7b01536; Swanson DM, 2017, J ANAL TOXICOL, V41, P498, DOI 10.1093/jat/bkx037; Tiscione NB, 2016, J ANAL TOXICOL, V40, P639, DOI 10.1093/jat/bkw063; Tuusov J, 2013, J FORENSIC LEG MED, V20, P51, DOI 10.1016/j.jflm.2012.04.023; US Drug Enforcement Administration, 2017, NAT FOR LAB INF SYST	35	5	5	2	10	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0146-4760	1945-2403		J ANAL TOXICOL	J. Anal. Toxicol.	OCT	2018	42	8			SI		570	580		10.1093/jat/bky054			11	Chemistry, Analytical; Toxicology	Chemistry; Toxicology	HA6MT	WOS:000450394400008	30371841	Bronze			2020-06-30	J	DeRienz, RT; Baker, DD; Kelly, NE; Mullins, AM; Barnett, RY; Hobbs, JM; Daniels, JA; Harshbarger, KE; Ortiz, AM				DeRienz, Rebecca T.; Baker, Daniel D.; Kelly, Nancy E.; Mullins, Amber M.; Barnett, Rachel Y.; Hobbs, Jennifer M.; Daniels, John A.; Harshbarger, Kent E.; Ortiz, Anahi M.			Child Fatalities Due to Heroin/Fentanyl Exposure: What the Case History Missed	JOURNAL OF ANALYTICAL TOXICOLOGY			English	Article; Proceedings Paper	68th Annual Scientific Meeting of the American-Academy-of-Forensic-Sciences (AAFS)	FEB 22-27, 2016	Las Vegas, NV	Amer Acad Forens Sci			HEROIN; FENTANYL; DIACETYLMORPHINE; DURAGESIC(R); MORPHINE; ABUSE	This case report presents three unrelated children found to have heroin and/or fentanyl in their systems after general unknown systematic toxicological analysis (STA). The first case involves an 11-month-old male found unresponsive at their residence. The scene response suggested a potentially unsafe sleeping condition or a sudden unexplained infant death. The second case is a 14-month-old female found unresponsive after eating soft candies, suggesting that a choking related death may have occurred. The third case is a 12-year-old male found unresponsive in bed and foaming from the mouth. Gum was removed from the child's airway, suggesting another choking related death. The STA included a 14-drug category enzyme linked immunosorbant assay (ELISA) screening in whole blood. Cases 1 and 3 were presumptively positive for fentanyl, while Case 2 was presumptively positive for opiates and fentanyl. Reflex confirmation was performed in blood, urine and gastric contents, by solid-phase extraction (SPE) for 12 opiates including morphine and 6-monoacetylmorphine (6MAM) by gas chromatography-mass spectrometry (GC-MS) and for fentanyl, norfentanyl, and novel analogs, by liquid chromatography tandem mass spectrometry (LC-MS-MS). High concentrations of fentanyl and 6MAM in the gastric contents of Case 1, along with the presence of diacetylmorphine, suggested probable enteral ingestion of heroin and fentanyl, separately or in a combined formulation. Interpretation of the toxicology results could not determine a probable route of exposure to heroin/fentanyl in Case 2, however, the cause of death was clearly related to this drug mixture. In Case 3, the presence of acetylfentanyl suggested an illicit fentanyl exposure. The intention of this case report is to demonstrate the need for a STA approach for all non-trauma postmortem cases regardless of case circumstances, age or suspicion of drug use.	[DeRienz, Rebecca T.; Baker, Daniel D.; Kelly, Nancy E.; Mullins, Amber M.; Barnett, Rachel Y.; Hobbs, Jennifer M.; Daniels, John A.; Harshbarger, Kent E.; Ortiz, Anahi M.] Franklin Cty Coroners Off, 520 King Ave, Columbus, OH 43201 USA	DeRienz, RT (reprint author), Franklin Cty Coroners Off, 520 King Ave, Columbus, OH 43201 USA.	rtderien@franklincountyohio.gov					Anderson DT, 2000, J ANAL TOXICOL, V24, P627, DOI 10.1093/jat/24.7.627; [Anonymous], ACIDIC NEUTRAL BASIC, P25; [Anonymous], 1999, GC ANAL COMMONLY ABU, P4; Duflou J, 2009, J FORENSIC SCI, V54, P1181, DOI 10.1111/j.1556-4029.2009.01123.x; Ferner RE, 2008, BRIT J CLIN PHARMACO, V66, P430, DOI 10.1111/j.1365-2125.2008.03231.x; Frick U, 2006, ADDICTION, V101, P1631, DOI 10.1111/j.1360-0443.2006.01569.x; Gyr E, 2000, INT J CLIN PHARM TH, V38, P486; Halbsguth U, 2008, BRIT J CLIN PHARMACO, V66, P781, DOI 10.1111/j.1365-2125.2008.03286.x; Hall D., 2014, EXTRACTION BASIC NEU; JOYNT BP, 1985, J ANAL TOXICOL, V9, P238, DOI 10.1093/jat/9.5.238; Kuhlman JJ, 2003, J ANAL TOXICOL, V27, P499, DOI 10.1093/jat/27.7.499; McIntyre I.M., 2012, J FORENSIC RES, V3, P157, DOI [DOI 10.4172/2157-7145.1000157, 10.4172/2157-7145.1000157]; Perger L, 2009, EUR J PHARM SCI, V36, P421, DOI 10.1016/j.ejps.2008.11.008; Rop PP, 1997, J ANAL TOXICOL, V21, P232, DOI 10.1093/jat/21.3.232; Teske J, 2007, INT J LEGAL MED, V121, P147, DOI 10.1007/s00414-006-0137-3; The International Association of Forensic Toxicologists (TIAFT), TIAFT B, VXXXI, P23; Woodall KL, 2008, J FORENSIC SCI, V53, P222, DOI 10.1111/j.1556-4029.2007.00597.x	17	2	2	0	4	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0146-4760	1945-2403		J ANAL TOXICOL	J. Anal. Toxicol.	OCT	2018	42	8			SI		581	585		10.1093/jat/bky052			5	Chemistry, Analytical; Toxicology	Chemistry; Toxicology	HA6MT	WOS:000450394400009	30371840	Bronze			2020-06-30	J	McKnight, C; Des Jarlais, DC				McKnight, C.; Des Jarlais, D. C.			Being "hooked up" during a sharp increase in the availability of illicitly manufactured fentanyl: Adaptations of drug using practices among people who use drugs (PWUD) in New York City	INTERNATIONAL JOURNAL OF DRUG POLICY			English	Article						Fentanyl; Heroin; Harm reduction; Overdose	SUPERVISED INJECTION SERVICES; CONTAMINATED HEROIN; OVERDOSE DEATHS; OPIOID OVERDOSE; UNITED-STATES; RHODE-ISLAND; EPIDEMIOLOGY; EXPOSURE; NALOXONE; ANALOGS	Illicitly manufactured fentanyl (IMF), a category of synthetic opioids 50-100 times more potent than morphine, is increasingly being added to heroin and other drugs in the United States (US). Persons who use drugs (PWUD) are frequently unaware of the presence of fentanyl in drugs. Use of heroin and other drugs containing fentanyl has been linked to sharp increases in opioid mortality. In New York City (NYC), opioid-related mortality increased from 8.2 per 100,000 residents in 2010 to 19.9 per 100,000 residents in 2016; and, in 2016, fentanyl accounted for 44% of NYC overdose deaths. Little is known about how PWUD are adapting to the increase in fentanyl and overdose mortality. This study explores PWUDs' adaptations to drug using practices due to fentanyl. In-depth qualitative interviews were conducted with 55 PWUD at three NYC syringe services programs (SSP) about perceptions of fentanyl, overdose experiences and adaptations of drug using practices. PWUD utilized test shots, a consistent drug dealer, fentanyl test strips, naloxone, getting high with or near others and reducing drug use to protect from overdose. Consistent application of these methods was often negated by structural level factors such as stigma, poverty and homelessness. To address these, multi-level overdose prevention approaches should be implemented in order to reduce the continuing increase in opioid mortality.	[McKnight, C.; Des Jarlais, D. C.] NYU, Coll Global Publ Hlth, 665 Broadway,8th Floor, New York, NY 10012 USA	McKnight, C (reprint author), NYU, Coll Global Publ Hlth, 665 Broadway,8th Floor, New York, NY 10012 USA.	courtney.mcknight@nyu.edu			Center for Drug Use and HIV Research (CDUHR) at the NYU School of Nursing; US NIH/NIDAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [5R01DA003574-34, P30 DA011041]	Funding for this study was provided through a Pilot Project Award from the Center for Drug Use and HIV Research (CDUHR) at the NYU School of Nursing. Funding for CDUHR is provided by US NIH/NIDA, Grant P30 DA011041. Support for Dr. Des Jarlais was provided by US NIH/NIDA, Grant 5R01DA003574-34. A special thanks to Janie Simmons for assistance with project development and to the three NYC SSP that served as recruitment sites. Finally, we are incredibly grateful for the individuals who participated in the study, particularly for their wisdom, generosity and patience.	Administration U. S. D. E.  & Division D. C, 2016, NELIS BRIEF FENT FEN; Carroll JJ, 2017, INT J DRUG POLICY, V46, P136, DOI 10.1016/j.drugpo.2017.05.023; CDC Health Action Network, 2016, INFL FENT LAC COUNTR; CDC Health Alert Network, 2015, INCR FENT DRUG CONF; Centers for Disease Control and Prevention, 2017, OP DAT AN DRUG OV CD; Ciccarone D, 2017, INT J DRUG POLICY, V46, P146, DOI 10.1016/j.drugpo.2017.06.004; Ciccarone D, 2017, INT J DRUG POLICY, V46, P107, DOI 10.1016/j.drugpo.2017.06.010; Daniulaityte R, 2017, MMWR-MORBID MORTAL W, V66, P904, DOI 10.15585/mmwr.mm6634a3; Darke S, 1999, DRUG ALCOHOL DEPEN, V54, P155, DOI 10.1016/S0376-8716(98)00159-8; Drug Enforcement Administration, 2016, COUNT PRESCR PILLS C; Drug Enforcement Administration, 2015, NAT FOR LAB INF SYST; Drug Enforcement Administration Special Testing and Research Laboratory, 2017, EM THREAT REP ANN; Drug Enforcement Administration Special Testing and Research Laboratory, 2018, 1 DRUG ENF ADM SPEC; Drug Enforcement Administration U.  & Control Division D, 2017, FENT FENT REL SUBST; European Monitoring Centre for Drugs and Drug Addiction, 2017, DRUG CONS ROOMS OV P; Fairbairn N, 2017, INT J DRUG POLICY, V46, P172, DOI 10.1016/j.drugpo.2017.06.005; Goodman J. David, 2018, NY TIMES; Guest G., 2012, APPL THEMATIC ANAL; Katz J., 2017, 1 COUNT FENTANYL DEA; Kennedy MC, 2018, DRUG ALCOHOL DEPEN, V185, P248, DOI 10.1016/j.drugalcdep.2017.12.026; Krieger MS, 2018, HARM REDUCT J, V15, DOI 10.1186/s12954-018-0213-2; Macmadu A, 2017, ADDICT BEHAV, V68, P35, DOI 10.1016/j.addbeh.2017.01.014; Mars SG, 2018, HARM REDUCT J, V15, DOI 10.1186/s12954-018-0232-z; Mars Sarah G, 2018, J Psychoactive Drugs, V50, P167, DOI 10.1080/02791072.2017.1394508; Marshall BDL, 2017, INT J DRUG POLICY, V46, P130, DOI 10.1016/j.drugpo.2017.05.029; McGowan CR, 2018, INT J DRUG POLICY, V58, P31, DOI 10.1016/j.drugpo.2018.04.017; New York City Department of Health and Mental Hygiene, 2017, NYCDHOMH HLTH ADV PR; O'Donnell JK, 2017, MMWR-MORBID MORTAL W, V66, P1197, DOI 10.15585/mmwr.mm6643e1; Paone D, 2016, INCREASE DRUG OVERDO; Paone D, 2016, UNINTENTIONAL DRUG P; Potier C, 2014, DRUG ALCOHOL DEPEN, V145, P48, DOI 10.1016/j.drugalcdep.2014.10.012; Prekupec MP, 2017, J ADDICT MED, V11, P256, DOI 10.1097/ADM.0000000000000324; Rudd R. A., 2016, MMWR-MORBID MORTAL W, V64, P50, DOI [10. 15585/mmwr. mm6450a3, DOI 10.15585/MMWR.MM6450A3]; Rudd RA, 2016, MMWR-MORBID MORTAL W, V65, P1445, DOI 10.15585/mmwr.mm655051e1; Sherman SG, 2018, FENTANYL OVERDOSE RE; Slavova S, 2017, INT J DRUG POLICY, V46, P120, DOI 10.1016/j.drugpo.2017.05.051; Spies E, 2016, UNDETERMINED RISK FA; Stogner JM, 2014, ANN EMERG MED, V64, P637, DOI 10.1016/j.annemergmed.2014.07.017; Sutter ME, 2017, ACAD EMERG MED, V24, P106, DOI 10.1111/acem.13034; Suzuki J, 2017, DRUG ALCOHOL DEPEN, V171, P107, DOI 10.1016/j.drugalcdep.2016.11.033; Tempalski B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064789; The City of New York Office of the Mayor, 2017, HEAL NYC PREV OV SAV; Tomassoni Anthony J, 2017, MMWR Morb Mortal Wkly Rep, V66, P107, DOI 10.15585/mm6604a4; United States Department of Justice Drug Enforcement Administration, 2017, 2017 NAT DRUG THREAT; Wheeler E, 2012, GUIDE DEV MANAGING O; Wheeler E, 2015, MMWR-MORBID MORTAL W, V64, P631	46	18	18	0	5	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0955-3959	1873-4758		INT J DRUG POLICY	Int. J. Drug Policy	OCT	2018	60						82	88		10.1016/j.drugpo.2018.08.004			7	Substance Abuse	Substance Abuse	HA0JK	WOS:000449894100012	30176422	Green Accepted			2020-06-30	J	Burns, SM; Cunningham, CW; Mercer, SL				Burns, S. Mallory; Cunningham, Christopher W.; Mercer, Susan L.			DARK Classics in Chemical Neuroscience: Fentanyl	ACS CHEMICAL NEUROSCIENCE			English	Review						Fentanyl; opioid; analgesic; pain; designer drug	MU-OPIOID RECEPTOR; INDUCED RESPIRATORY DEPRESSION; 4-ANILIDOPIPERIDINE ANALGESICS; PHARMACOLOGICAL-PROPERTIES; SYNTHETIC ANALGESICS; CONTINUOUS-INFUSION; OPIATE RECEPTORS; OVERDOSE DEATHS; DRUG OVERDOSE; UNITED-STATES	Fentanyl rose to prominence as an alternative analgesic to morphine nearly 50 years ago; today, fentanyl has re-emerged as a dangerous recreational substance. The increased potency and analgesic effect of fentanyl are advantageous in the treatment of pain but are also responsible for the rise in unintentional opioid overdose deaths. In response to this crisis, fentanyl, its analogues, and even precursors are under heightened regulatory scrutiny. Despite this controversial history, derivatization of fentanyl has resulted in numerous synthetic analogues that provide valuable insights into opioid receptor binding and signaling events. In this review, the impact of fentanyl on chemical neuroscience is shown through its synthesis and properties, manufacturing, metabolism, pharmacology, approved and off-label indications, adverse effects, and the responsibility it has in the opioid epidemic.	[Burns, S. Mallory; Mercer, Susan L.] Lipscomb Univ, Dept Pharmaceut Sci, Coll Pharm, Nashville, TN 37204 USA; [Cunningham, Christopher W.] Concordia Univ, Dept Pharmaceut Sci, Wisconsin Sch Pharm, Mequon, WI 53097 USA; [Mercer, Susan L.] Vanderbilt Univ, Dept Pharmacol, Med Ctr, Nashville, TN 37232 USA	Mercer, SL (reprint author), Lipscomb Univ, Dept Pharmaceut Sci, Coll Pharm, Nashville, TN 37204 USA.; Mercer, SL (reprint author), Vanderbilt Univ, Dept Pharmacol, Med Ctr, Nashville, TN 37232 USA.	susan.mercer@lipscomb.edu		Cunningham, Christopher/0000-0002-4468-2213	Lipscomb University College of Pharmacy and Health Sciences; Concordia University Wisconsin	S.M.B. and S.L.M. are supported by funding from the Lipscomb University College of Pharmacy and Health Sciences. C.W.C. is supported by departmental funds provided by Concordia University Wisconsin.	A J., 1978, PRZEML CHEM, V57, P131; AMIN HM, 1995, J PHARMACOL EXP THER, V274, P34; [Anonymous], 2018, DRUG REC FENT AN; [Anonymous], 2017, OP OV PRESCR DAT; [Anonymous], 2016, FENT BRIEF DESCR; [Anonymous], 2017, OP OV; [Anonymous], 2016, DEA REL 2016 DRUG TH; [Anonymous], 2016, HIGHL PRESCR INF DUR, P1; [Anonymous], 2016, BUT BUT CRIT REV REP, P1; [Anonymous], 2017, FENT BRIEF GUID 1 RE; [Anonymous], 2018, STAND NAM SUBST FENT; [Anonymous], 2017, DRUGS AB DEA RES GUI, P38; [Anonymous], 2011, HIGHL PRESCR INF FEN, P1; [Anonymous], 2018, US DRUG ENF ADM EM S; Aragon-Poce F, 2002, INT CONGR SER, V1242, P19, DOI 10.1016/S0531-5131(02)00600-3; Armenian P, 2018, NEUROPHARMACOLOGY, V134, P121, DOI 10.1016/j.neuropharm.2017.10.016; Benyamin R, 2008, PAIN PHYSICIAN, V11, pS105; Blakemore PR, 2002, CHEM COMMUN, P1159, DOI 10.1039/b111551k; Blau M., 2018, NEXT NALOXONE COMPAN; Bohn LM, 1999, SCIENCE, V286, P2495, DOI 10.1126/science.286.5449.2495; BORNE RF, 1984, J MED CHEM, V27, P1271, DOI 10.1021/jm00376a007; Bot G, 1998, J PHARMACOL EXP THER, V285, P1207; Brook Karolina, 2017, J Anesth Hist, V3, P50, DOI 10.1016/j.janh.2017.02.001; Bryson EO, 2008, ANESTHESIOLOGY, V109, P905, DOI 10.1097/ALN.0b013e3181895bc1; Cassel JA, 2005, EUR J PHARMACOL, V520, P29, DOI 10.1016/j.ejphar.2005.08.008; Casy A. F., 1986, OPIOID ANALGESICS CH, P287; CASY AF, 1969, J PHARM PHARMACOL, V21, P434, DOI 10.1111/j.2042-7158.1969.tb08284.x; Chen Q, 2016, J CLIN ANESTH, V28, P67, DOI 10.1016/j.jclinane.2015.08.010; Chou R, 2009, J PAIN, V10, P113, DOI 10.1016/j.jpain.2008.10.008; Ciccarone D, 2017, INT J DRUG POLICY, V46, P107, DOI 10.1016/j.drugpo.2017.06.010; Dahan A, 2010, ANESTHESIOLOGY, V112, P226, DOI 10.1097/ALN.0b013e3181c38c25; Davis MP, 2011, EXPERT REV NEUROTHER, V11, P1197, DOI [10.1586/ERN.11.63, 10.1586/ern.11.63]; Devereaux AL, 2018, ACS CHEM NEUROSCI, V9, P2395, DOI 10.1021/acschemneuro.8b00150; DiPiro JT, 2017, PHARMACOTHERAPY PATH; Dosen-Micovic L, 2006, BIOORGAN MED CHEM, V14, P2887, DOI 10.1016/j.bmc.2005.12.010; Dowell D, 2017, JAMA-J AM MED ASSOC, V318, P2295, DOI 10.1001/jama.2017.15971; Dowell D, 2016, MMWR RECOMM REP, V65, P1, DOI 10.15585/mmwr.rr6501e1; Drug Enforcement Administration, 2017, 2017 NAT DRUG THREAT; Fairbairn N, 2017, INT J DRUG POLICY, V46, P172, DOI 10.1016/j.drugpo.2017.06.005; Feierman DE, 1996, DRUG METAB DISPOS, V24, P932; FINNEY ZG, 1980, J MED CHEM, V23, P895, DOI 10.1021/jm00182a016; Giron R, 2002, LIFE SCI, V71, P1023, DOI 10.1016/S0024-3205(02)01798-8; Gladden RM, 2016, MMWR-MORBID MORTAL W, V65, P837, DOI 10.15585/mmwr.mm6533a2; GLASS PSA, 1995, J CLIN ANESTH, V7, P558, DOI 10.1016/0952-8180(95)00127-1; GOLDFRANK L, 1986, ANN EMERG MED, V15, P566, DOI 10.1016/S0196-0644(86)80994-5; Goodman L., 2011, GOODMAN GILLMANS PHA; Gota V, 2015, INDIAN J ANAESTH, V59, P767, DOI 10.4103/0019-5049.171555; Guan W., 2011, PRIM CARE COMPANION, V13, P1; Haeseler G, 2006, PAIN, V126, P234, DOI 10.1016/j.pain.2006.07.003; Henderson F, 2014, RESP PHYSIOL NEUROBI, V191, P95, DOI 10.1016/j.resp.2013.11.005; Henthorn TK, 1999, J PHARMACOL EXP THER, V289, P1084; Hoffman RS, 2015, GOLDFRANKS TOXICOLOG; Huang B. S., 1985, EUR PAT APPL, V1; Iula D. M., 2017, WHAT WE KNOW MET NEW; JAMES MK, 1991, J PHARMACOL EXP THER, V259, P712; Janssen P., 1964, US Patent US, Patent No. 3141823A; Janssen P. A. J., 1965, US Patent, Patent No. [US 3164600A, 3164600A]; Janssen P. A. J., 1964, French patent FR, Patent No. M2430; JANSSEN PAJ, 1960, J MED PHARMACEUT CH, V2, P271, DOI 10.1021/jm50010a003; JANSSEN PAJ, 1959, J MED PHARMACEUT CH, V1, P309, DOI 10.1021/jm50005a002; JANSSEN PAJ, 1959, J MED PHARMACEUT CH, V1, P105, DOI 10.1021/jm50002a008; JANSSEN PAJ, 1963, ARZNEIMITTEL-FORSCH, V13, P502; Jeal W, 1997, DRUGS, V53, P109, DOI 10.2165/00003495-199753010-00011; Katzung B., 2018, BASIC CLIN PHARM; Kintz P, 2005, FORENSIC SCI INT, V153, P81, DOI 10.1016/j.forsciint.2005.04.033; Krishnamurti C, 2016, INDIAN J ANAESTH, V60, P861, DOI 10.4103/0019-5049.193696; Labroo RB, 1997, DRUG METAB DISPOS, V25, P1072; LEMMENS HJM, 1995, CLIN PHARMACOKINET, V29, P231, DOI 10.2165/00003088-199529040-00003; Lipinski CA, 1997, ADV DRUG DELIVER REV, V23, P3, DOI 10.1016/S0169-409X(96)00423-1; Lynn RR, 2018, THER ADV DRUG SAF, V9, P63, DOI 10.1177/2042098617744161; Madariaga-Mazon A, 2017, DRUG DISCOV TODAY, V22, P1719, DOI 10.1016/j.drudis.2017.07.002; MAGUIRE P, 1992, EUR J PHARMACOL, V213, P219, DOI 10.1016/0014-2999(92)90685-W; Mansour A, 1997, J NEUROCHEM, V68, P344, DOI 10.1046/j.1471-4159.1997.68010344.x; MARYANOFF BE, 1982, J MED CHEM, V25, P913, DOI 10.1021/jm00350a006; MATHER LE, 1983, CLIN PHARMACOKINET, V8, P422, DOI 10.2165/00003088-198308050-00004; MCCLAIN DA, 1980, CLIN PHARMACOL THER, V28, P106, DOI 10.1038/clpt.1980.138; McFadyen I, 2002, PROGR MED CHEM, V40, P107, DOI 10.1016/S0079-6468(08)70083-3; MCGILLIARD KL, 1978, J PHARMACOL EXP THER, V207, P494; MONK JP, 1988, DRUGS, V36, P286, DOI 10.2165/00003495-198836030-00003; Mori T, 2017, MOL PAIN, V13, DOI 10.1177/1744806917740030; Paulozzi LJ, 2011, PAIN MED, V12, P747, DOI 10.1111/j.1526-4637.2011.01062.x; Peckham EM, 2006, J PHARMACOL EXP THER, V316, P1195, DOI 10.1124/jpet.105.094276; Peng PWH, 1999, ANESTHESIOLOGY, V90, P576, DOI 10.1097/00000542-199902000-00034; PERRINE DM, 1996, CHEM MIND ALTERING D; Pil J, 2001, BRIT J PHARMACOL, V134, P496, DOI 10.1038/sj.bjp.0704263; Pogozheva ID, 2005, AAPS J, V7; Pogozheva ID, 1998, BIOPHYS J, V75, P612, DOI 10.1016/S0006-3495(98)77552-6; POKLIS A, 1995, J TOXICOL-CLIN TOXIC, V33, P439, DOI 10.3109/15563659509013752; Raehal KM, 2005, J PHARMACOL EXP THER, V314, P1195, DOI 10.1124/jpet.105.087254; REDFERN N, 1983, BRIT MED J, V287, P751, DOI 10.1136/bmj.287.6394.751; Rickli A, 2018, BRIT J PHARMACOL, V175, P532, DOI 10.1111/bph.14105; RILEY TN, 1973, J PHARM SCI, V62, P983, DOI 10.1002/jps.2600620627; Rogers JS, 2016, J EMERG MED, V50, P433, DOI 10.1016/j.jemermed.2015.10.014; Rollins MD, 2014, ANESTHESIOLOGY, V121, P1037, DOI 10.1097/ALN.0000000000000384; ROSE PG, 1993, ANESTH ANALG, V77, P390, DOI 10.1213/00000539-199377020-00029; Rudd RA, 2016, MMWR-MORBID MORTAL W, V65, P1445, DOI 10.15585/mmwr.mm655051e1; Schmid CL, 2017, CELL, V171, P1165, DOI 10.1016/j.cell.2017.10.035; Selley DE, 1998, J PHARMACOL EXP THER, V285, P496; Stanley TH, 2008, ANESTH ANALG, V106, P451, DOI 10.1213/ane.0b013e3181605add; Stanley TH, 2014, J PAIN, V15, P1215, DOI 10.1016/j.jpain.2014.08.010; Strang J, 2016, DRUG ALCOHOL DEPEN, V163, P16, DOI 10.1016/j.drugalcdep.2016.02.042; Subramanian G, 2000, J MED CHEM, V43, P381, DOI 10.1021/jm9903702; Suh YG, 1998, ARCH PHARM RES, V21, P70, DOI 10.1007/BF03216756; Sutter ME, 2017, ACAD EMERG MED, V24, P106, DOI 10.1111/acem.13034; Suzuki J, 2017, DRUG ALCOHOL DEPEN, V171, P107, DOI 10.1016/j.drugalcdep.2016.11.033; Takahashi Masahiko, 2004, J Anesth, V18, P1, DOI 10.1007/s00540-003-0214-4; Tateishi T, 1996, ANESTH ANALG, V82, P167; Tharp AM, 2004, AM J FOREN MED PATH, V25, P178, DOI 10.1097/01.paf.0000127398.67081.11; Toll L, 1998, NIDA Res Monogr, V178, P440; Trang T, 2015, J NEUROSCI, V35, P13879, DOI 10.1523/JNEUROSCI.2711-15.2015; TRAYNOR JR, 1995, MOL PHARMACOL, V47, P848; UNDOC, 2017, GLOB SMART UPD FENT, V17; Valdez CA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108250; VANBEVER WFM, 1976, ARZNEIMITTELFORSCH, V26, P1548; VANDAELE PGH, 1976, ARZNEIMITTELFORSCH, V26, P1521; VANGESTEL S, 1986, DRUG DEVELOP RES, V8, P1, DOI 10.1002/ddr.430080103; Vardanyan RS, 2014, FUTURE MED CHEM, V6, P385, DOI 10.4155/fmc.13.215; VARTANYAN RS, 1989, KHIM FARM ZH+, V23, P573; Volpe DA, 2011, REGUL TOXICOL PHARM, V59, P385, DOI 10.1016/j.yrtph.2010.12.007; Walley AY, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f174; WARD CF, 1983, JAMA-J AM MED ASSOC, V250, P922, DOI 10.1001/jama.250.7.922; Watanabe S, 2017, AAPS J, V19, P1102, DOI 10.1208/s12248-017-0070-z; Whistler JL, 1998, P NATL ACAD SCI USA, V95, P9914, DOI 10.1073/pnas.95.17.9914; WRIGHT WB, 1961, J ORG CHEM, V26, P485, DOI 10.1021/jo01061a049; Wyman J. R., 1994, WARNING MISUSING FEN, P1; Yassen A, 2007, CLIN PHARMACOKINET, V46, P965, DOI 10.2165/00003088-200746110-00004; YEADON M, 1988, J PHARM PHARMACOL, V40, P736, DOI 10.1111/j.2042-7158.1988.tb07008.x; Zhang Y, 2005, ANESTHESIOLOGY, V102, P371, DOI 10.1097/00000542-200502000-00020; Zuckerman M, 2014, PREHOSP EMERG CARE, V18, P550, DOI 10.3109/10903127.2014.896961	129	10	10	2	20	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	1948-7193			ACS CHEM NEUROSCI	ACS Chem. Neurosci.	OCT	2018	9	10			SI		2428	2437		10.1021/acschemneuro.8b00174			19	Biochemistry & Molecular Biology; Chemistry, Medicinal; Neurosciences	Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Neurosciences & Neurology	GX7LS	WOS:000447954300013	29894151				2020-06-30	J	Fan, WX; Wang, HL; Zhang, Y; Loh, HH; Law, PY; Xu, C				Fan, Wenxiang; Wang, Helei; Zhang, Yue; Loh, Horace H.; Law, Ping-Yee; Xu, Chi			Morphine regulates adult neurogenesis and contextual memory extinction via the PKC epsilon/Prox1 pathway	NEUROPHARMACOLOGY			English	Article						Neural stem/progenitor cells; PKC epsilon; Prox1; Adult neurogenesis; Contextual memory; Hippocampus	CONDITIONED PLACE PREFERENCE; DEPENDENT ERK ACTIVATION; MORRIS WATER MAZE; KINASE-C-EPSILON; HIPPOCAMPAL NEUROGENESIS; COCAINE ADDICTION; DENTATE GYRUS; PROGENITOR CELLS; MICE; PHOSPHORYLATION	We have previously reported that the miR-181a/Prox1/Notch1 pathway mediates the effect of morphine on modulating lineage-specific differentiation of adult neural stem/progenitor cells (NSPCs) via a PKC epsilon-dependent pathway, whereas fentanyl shows no such effect. However, the role of the PKC epsilon/Prox1 pathway in mediating drug-associated contextual memory remains unknown. The current study investigated the effect of PKC epsilon/Prox1 on morphine-induced inhibition of adult neurogenesis and drug-associated contextual memory in mice, while the effect of fentanyl was tested simultaneously. By using BrdU labeling, we were able to examine the lineages of differentiated NSPCs in adult DG. PKC epsilon knockout blocked morphine's effects on inducing in vivo astrocyte-preferential differentiation of NSPCs, but did not alter NSPC lineages upon fentanyl treatment. Inhibited adult neurogenesis further resulted in prolonged extinction and enhanced reinstatement of morphine-induced CPP, as well as prolonged extinction of space reference memory indicated by the Morris water maze paradigm. However, after fentanyl administration, no significant changes were found between wild-type and PKC epsilon knockout mice, during either CPP or water maze tasks. When the lentivirus encoding Nestin-promoter-controlled Prox1 cDNA was injected into hippocampi of wildtype and PKC epsilon knockout adult mice to modulate PKC epsilon/Prox1 activity, similar effects were discovered in adult mice injected with lentivirus encoding Prox1, and more dramatic effects were found in PKC epsilon knockout mice with concurrent Prox1 overexpression. In conclusion, morphine mediates lineage-specific NSPC differentiation, inhibits adult neurogenesis and regulates contextual memory retention via the PKC epsilon/Prox1 pathway, which are implicated in the eventual context-associated relapse.	[Fan, Wenxiang; Wang, Helei; Xu, Chi] China Pharmaceut Univ, Sch Basic Med & Clin Pharm, State Key Lab Nat Med, 24 Tong Jia Xiang, Nanjing 210009, Jiangsu, Peoples R China; [Zhang, Yue; Loh, Horace H.; Law, Ping-Yee] Univ Minnesota, Sch Med, Dept Pharmacol, 6-120 Jackson Hall,321 Church St SE, Minneapolis, MN 55455 USA	Xu, C (reprint author), China Pharmaceut Univ, Sch Basic Med & Clin Pharm, 24 Tong Jia Xiang, Nanjing 210009, Jiangsu, Peoples R China.	xuchi@cpu.edu.cn	Xu, Chi/N-5249-2014	Xu, Chi/0000-0001-5470-7376	National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81701313]; NIDAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [DA031442-05]; National Science & Technology Major Project [2017ZX09101003-003-007]; Program for Changjiang Scholars and Innovative Research Team in [IRT1193]	This work was supported by the National Natural Science Foundation of China (81701313), NIDA Grant DA031442-05, the National Science & Technology Major Project (No. 2017ZX09101003-003-007) and Program for Changjiang Scholars and Innovative Research Team in University (IRT1193).	Abrous DN, 2005, PHYSIOL REV, V85, P523, DOI 10.1152/physrev.00055.2003; Aimone JB, 2014, PHYSIOL REV, V94, P991, DOI 10.1152/physrev.00004.2014; Marchese NA, 2016, PSYCHOPHARMACOLOGY, V233, P795, DOI 10.1007/s00213-015-4153-1; Apple DM, 2017, BRAIN RES, V1655, P270, DOI 10.1016/j.brainres.2016.01.023; Bilfinger TV, 1998, INT J CARDIOL, V64, pS61, DOI 10.1016/S0167-5273(98)00037-0; Boldrini M, 2018, CELL STEM CELL, V22, P589, DOI 10.1016/j.stem.2018.03.015; Bortolotto V, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00254; Bortolotto V, 2014, BIOMED RES INT, DOI 10.1155/2014/612798; Canales JJ, 2007, EUR ARCH PSY CLIN N, V257, P261, DOI 10.1007/s00406-007-0730-6; Castilla-Ortega E, 2017, BIOCHEM PHARMACOL, V141, P100, DOI 10.1016/j.bcp.2017.05.003; Castilla-Ortega E, 2016, NEUROSCI BIOBEHAV R, V66, P15, DOI 10.1016/j.neubiorev.2016.03.030; Castilla-Ortega E, 2016, ADDICT BIOL, V21, P575, DOI 10.1111/adb.12248; Chandrasekar V, 2009, MOL CELL NEUROSCI, V42, P350, DOI 10.1016/j.mcn.2009.08.009; Cunningham CL, 2006, BEHAV NEUROSCI, V120, P1115, DOI 10.1037/0735-7044.120.5.1115; Galichet C, 2008, DEVELOPMENT, V135, P2031, DOI 10.1242/dev.015115; Goncalves JT, 2016, CELL, V167, P897, DOI 10.1016/j.cell.2016.10.021; Goodman J, 2016, FRONT PSYCHIATRY, V7, DOI 10.3389/fpsyt.2016.00024; Guo SJ, 2016, ADDICT BIOL, V21, P547, DOI 10.1111/adb.12236; Kempermann G., 2015, COLD SPRING HARBOR P, V7; Kempermann G, 2018, CELL STEM CELL, V23, P25, DOI 10.1016/j.stem.2018.04.004; Khasar SG, 1999, NEURON, V24, P253, DOI 10.1016/S0896-6273(00)80837-5; Kibaly C, 2016, BIOL PSYCHIAT, V79, P906, DOI 10.1016/j.biopsych.2015.04.019; Kramar CP, 2014, NEUROPSYCHOPHARMACOL, V39, P1645, DOI 10.1038/npp.2014.11; Kutlu MG, 2016, LEARN MEMORY, V23, P515, DOI 10.1101/lm.042192.116; Lavado A, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000460; Li W, 2014, BIOL PSYCHIAT, V76, P775, DOI 10.1016/j.biopsych.2014.05.013; Maekawa M, 2005, GENES CELLS, V10, P1001, DOI 10.1111/j.1365-2443.2005.00893.x; Mendez IA, 2008, NEUROBIOL LEARN MEM, V89, P185, DOI 10.1016/j.nlm.2007.08.005; Nader Michael A, 2016, Prog Brain Res, V224, P3, DOI 10.1016/bs.pbr.2015.07.012; Noonan MA, 2010, J NEUROSCI, V30, P304, DOI 10.1523/JNEUROSCI.4256-09.2010; Schuster DJ, 2013, J NEUROSCI, V33, P13538, DOI 10.1523/JNEUROSCI.4013-12.2013; Seo S, 2007, EMBO J, V26, P5093, DOI 10.1038/sj.emboj.7601923; Shalev U, 2002, PHARMACOL REV, V54, P1, DOI 10.1124/pr.54.1.1; Sorrells SF, 2018, NATURE, V555, P377, DOI 10.1038/nature25975; Spalding KL, 2013, CELL, V153, P1219, DOI 10.1016/j.cell.2013.05.002; Steinmetz AB, 2016, NEUROBIOL LEARN MEM, V136, P228, DOI 10.1016/j.nlm.2016.11.002; Stergiopoulos A, 2015, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00454; Tramullas M, 2008, NEUROPHARMACOLOGY, V54, P640, DOI 10.1016/j.neuropharm.2007.11.018; Trezza V, 2010, TRENDS PHARMACOL SCI, V31, P463, DOI 10.1016/j.tips.2010.06.008; Vallejo R, 2011, PAIN PHYSICIAN, V14, pE343; van Praag H, 1999, NAT NEUROSCI, V2, P266; Vorhees CV, 2006, NAT PROTOC, V1, P848, DOI 10.1038/nprot.2006.116; Wang J, 2012, CELL STEM CELL, V11, P23, DOI 10.1016/j.stem.2012.03.016; Watanabe S, 2011, BEHAV PHARMACOL, V22, P203, DOI 10.1097/FBP.0b013e328345c815; Xu C, 2016, CELL MOL LIFE SCI, V73, P327, DOI 10.1007/s00018-015-2067-z; Xu C, 2015, STEM CELLS, V33, P2762, DOI 10.1002/stem.2055; Xu C, 2014, STEM CELLS, V32, P2961, DOI 10.1002/stem.1774; Yonelinas AP, 2013, BEHAV BRAIN RES, V254, P34, DOI 10.1016/j.bbr.2013.05.030; Zhang Y, 2017, NEUROPHARMACOLOGY, V126, P58, DOI 10.1016/j.neuropharm.2017.08.030; Zhang Y, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153628; Zheng H, 2008, MOL PHARMACOL, V73, P178, DOI 10.1124/mol.107.039842; Zheng H, 2013, NEUROPSYCHOPHARMACOL, V38, P770, DOI 10.1038/npp.2012.242; Zheng H, 2010, J BIOL CHEM, V285, P21994, DOI 10.1074/jbc.M110.112607; Zheng H, 2010, J NEUROSCI, V30, P8102, DOI 10.1523/JNEUROSCI.6069-09.2010; Zheng H, 2010, MOL PHARMACOL, V77, P102, DOI 10.1124/mol.109.060848	55	4	4	0	6	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3908	1873-7064		NEUROPHARMACOLOGY	Neuropharmacology	OCT	2018	141						126	138		10.1016/j.neuropharm.2018.08.031			13	Neurosciences; Pharmacology & Pharmacy	Neurosciences & Neurology; Pharmacology & Pharmacy	GX1NA	WOS:000447482800012	30170081	Green Accepted			2020-06-30	J	Moustafa, MA; Kandeel, AA				Moustafa, Moustafa Abdelaziz; Kandeel, Alaa A.			Randomized comparative study between two different techniques of intercostobrachial nerve block together with brachial plexus block during superficialization of arteriovenous fistula	JOURNAL OF ANESTHESIA			English	Article						Anesthesia, local; Arteriovenous fistula; Intercostobrachial nerve; Nerve block	SURGERY; ANATOMY	Background This study compared proximal and distal approaches of intercostobrachial nerve block (ICBNB) combined with infraclavicular brachial plexus block (ICBPB) during superficialization of arteriovenous fistula. Methods Seventy adult patients were randomized to receive ICBPB and 6 ml 0.25% bupivacaine at the level of the 3rd rib in the anterior axillary line between pectoralis minor and serratus anterior muscles (group P) or subcutaneously along the medial side of the upper arm (group D). The primary outcome was the achievement of complete sensory block. Secondary outcomes were onset of analgesia, volume of local anesthetic (LA) supplementation, fentanyl administration, success rate, and conversion to general anesthesia (GA). Results Complete sensory block in the medial side of the upper arm was achieved in 91% of patients in group P and 51% in group D. Failure rate of ICBNB was higher in group D (49%) than group P (14%). Conversion to GA was determined by the attending anesthesiologist in 26% of patients in group D and 0% in group P. LA supplementation was required in 5 patients in group P and 11 patients in group D, and the mean volume of LA was statistically higher in group D than group P (9.5 +/- 1.5, 7.5 +/- 2 ml, respectively). Onset of sensory block was faster in group P than group D (8.75 +/- 1.67 and 10 +/- 2.14 min, respectively). No differences were observed regarding fentanyl administration. Conclusion ICBNB proximal approach provides a high success rate with less amount of rescue analgesia compared to the distal approach.	[Moustafa, Moustafa Abdelaziz; Kandeel, Alaa A.] Alexandria Univ, Dept Anesthesia & Surg Intens Care, Fac Med, Antoniadis City Compound C2B7,Champollion St, Alexandria 21521, Egypt	Moustafa, MA (reprint author), Alexandria Univ, Dept Anesthesia & Surg Intens Care, Fac Med, Antoniadis City Compound C2B7,Champollion St, Alexandria 21521, Egypt.	moustafa.abdelaziz@alexmed.edu.eg	Moustafa, Moustafa/H-2110-2019	Moustafa, Moustafa/0000-0001-8689-5025			Desgagnes MC, 2009, ANESTH ANALG, V109, P668, DOI 10.1213/ane.0b013e3181aa308f; Hara K, 2012, ESRA ACAD, V6, P22047; Henry BM, 2017, CUREUS, V9, DOI 10.7759/cureus.1101; Loukas M, 2006, CLIN ANAT, V19, P106, DOI 10.1002/ca.20226; MACIVER MB, 1992, ANESTHESIOLOGY, V76, P617; Magazzeni P, 2018, REGION ANESTH PAIN M, V43, P832, DOI 10.1097/AAP.0000000000000823; Maria PS, 2017, J ANEST INTEN CARE M, V3, DOI 10.19080/JAICM.2017.03.555624; Neal J, 2010, TXB REGIONAL ANESTHE, P467; O'Rourke MGE, 1999, AUST NZ J SURG, V69, P860, DOI 10.1046/j.1440-1622.1999.01718.x; Purcell N, 2014, ANAESTHESIA, V69, P1294, DOI 10.1111/anae.12876; Roussel John, 2014, AANA J, V82, P121; Sandhu NS, 2002, BRIT J ANAESTH, V89, P254, DOI 10.1093/bja/aef186; Seidel R, 2017, BRIT J ANAESTH, V118, P472, DOI 10.1093/bja/aex009; Sidawy AN, 2002, J VASC SURG, V35, P603, DOI 10.1067/mva.2002.122025; Wijayasinghe N, 2016, PAIN PHYSICIAN, V19, pE309; Wisotzky EM, 2016, PM&R, V8, P273, DOI 10.1016/j.pmrj.2015.10.003	16	0	0	1	4	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	0913-8668	1438-8359		J ANESTH	J. Anesth.	OCT	2018	32	5					725	730		10.1007/s00540-018-2547-z			6	Anesthesiology	Anesthesiology	GW2IN	WOS:000446706900010	30167783				2020-06-30	J	Martin, EJ; Vaughan, CL; Atayee, R; Hirst, JM; O'Donnell, K; Edmonds, KP				Martin, Emily J.; Vaughan, Christina L.; Atayee, Rabia; Hirst, Jeremy M.; O'Donnell, Kaitlyn; Edmonds, Kyle P.			Hydromorphone-induced chorea as an atypical presentation of opioid neurotoxicity: A case report and review of the literature	PALLIATIVE MEDICINE			English	Review						Hydromorphone; chorea; analgesics; opioid; movement disorders; neurotoxicity syndromes; case report	MOVEMENTS; MORPHINE; DOPAMINE; BEHAVIOR; SYSTEM	Background: While opioid-induced myoclonus is well described, there are limited reports of opioid-induced chorea. Here we present the first case of chorea as a manifestation of opioid neurotoxicity due to hydromorphone. Case presentation: A 20-year-old woman presenting with fevers and cutaneous lesions was diagnosed with hemophagocytic lymphohistiocytosis secondary to primary cutaneous lymphoma. Surgical resection of a cutaneous lesion was complicated by severe postoperative pain requiring rapid opioid dose escalation. Seven days after hydromorphone was initiated, she developed positive myoclonus, hallucinations, delirium, and involuntary, flowing movements consistent with chorea. She had no personal or family history of nervous system disorders and was not taking any medications associated with drug-induced chorea. Case management: The remainder of her neurologic examination was unremarkable. Her renal function was normal and no etiology was found on neuroimaging or laboratory workup. Hydromorphone was discontinued and pain control was achieved with fentanyl. Case outcome: The patient's neurotoxic symptoms including chorea resolved within 72h of hydromorphone discontinuation. Conclusion: Further studies are needed to determine which patients have a unique sensitivity to opioids predisposing them to chorea. Clinicians should be aware that chorea may be a sign of such toxicity so that rapid corrective action can be taken.	[Martin, Emily J.; Hirst, Jeremy M.; O'Donnell, Kaitlyn; Edmonds, Kyle P.] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA; [Vaughan, Christina L.] Univ Colorado, Anschutz Med Campus, Denver, CO 80202 USA; [Atayee, Rabia] Univ Calif San Diego, Skaggs Sch Pharm & Pharmaceut Sci, La Jolla, CA 92093 USA	Martin, EJ (reprint author), Univ Calif San Diego, Moores Canc Ctr, Doris A Howell Palliat Med Serv, La Jolla, CA 92093 USA.	ejm006@ucsd.edu		Martin, Emily/0000-0003-1413-482X			Anagnostakis Y, 1992, Eur Neuropsychopharmacol, V2, P65, DOI 10.1016/0924-977X(92)90038-A; Bonnet U, 1998, PHARMACOPSYCHIATRY, V31, P143, DOI 10.1055/s-2007-979316; CARROLL BJ, 1972, BRIT J PHARMACOL, V46, P124, DOI 10.1111/j.1476-5381.1972.tb06855.x; Chokroverty S, 2015, SLEEP MED COMPREHENS, P237; Clark JD, 2001, CLIN J PAIN, V17, P375, DOI 10.1097/00002508-200112000-00013; Deiva K, 2012, NEUROLOGY, V78, P1150, DOI 10.1212/WNL.0b013e31824f800a; Gallagher M, 2017, MOVEMENT DISORD, V32; Gallagher R, 2007, CAN FAM PHYSICIAN, V53, P426; Grebosky J., 2005, AM FAM PHYS, V71; HENING WA, 2009, SLEEP DISORDERS MED, P397; Hoff AM, 2017, J PALLIAT MED, V20, P1042, DOI 10.1089/jpm.2016.0502; KAUFMAN DK, 1994, ANN NEUROL, V36, P625, DOI 10.1002/ana.410360411; KLEIN RB, 1975, PEDIATRICS, V55, P882; KOLLER WC, 1989, MOVEMENT DISORD, V4, P153, DOI 10.1002/mds.870040207; LUGARESI E, 1986, J NEUROL NEUROSUR PS, V49, P375, DOI 10.1136/jnnp.49.4.375; Lussier D, 2003, J PAIN SYMPTOM MANAG, V26, P688, DOI 10.1016/S0885-3924(03)00256-2; Mehta A, 2001, J NEUROSCI, V21, P4436, DOI 10.1523/JNEUROSCI.21-12-04436.2001; Micheli FE., 2014, CHOREA, P249; Neutel D, 2015, SLEEP MED, V16, P754, DOI 10.1016/j.sleep.2014.12.021; Okon TR, 2008, J PAIN SYMPTOM MANAG, V35, P327, DOI 10.1016/j.jpainsymman.2007.04.023; Pan J, 2017, TRANSL NEURODEGENER, V6, DOI 10.1186/s40035-017-0071-y; SANDYK R, 1985, LIFE SCI, V37, P1655, DOI 10.1016/0024-3205(85)90292-9; Sarhill N, 2001, Am J Hosp Palliat Care, V18, P51, DOI 10.1177/104990910101800113; Schwab LC, 2015, EXPERT REV NEUROTHER, V15, P445, DOI 10.1586/14737175.2015.1025383; Shneerson JM., 2009, SLEEP MED GUIDE SLEE, P194; Smith MT, 2000, CLIN EXP PHARMACOL P, V27, P524, DOI 10.1046/j.1440-1681.2000.03290.x; Vella-Brincat Jane, 2007, J Pain Palliat Care Pharmacother, V21, P15, DOI 10.1300/J354v21n01_05; WALKER JM, 1987, EUR J PHARMACOL, V134, P53, DOI 10.1016/0014-2999(87)90130-0; WASSERMAN S, 1980, ARCH NEUROL-CHICAGO, V37, P727, DOI 10.1001/archneur.1980.00500600075016	29	0	0	0	1	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0269-2163	1477-030X		PALLIATIVE MED	Palliat. Med.	OCT	2018	32	9					1529	1532		10.1177/0269216318786861			4	Health Care Sciences & Services; Public, Environmental & Occupational Health; Medicine, General & Internal	Health Care Sciences & Services; Public, Environmental & Occupational Health; General & Internal Medicine	GU9CL	WOS:000445642100011	30004301				2020-06-30	J	Aminiahidashti, H; Shafiee, S; Hosseininejad, SM; Firouzian, A; Barzegarnejad, A; Kiasari, AZ; Kerigh, BF; Bozorgi, F; Shafizad, M; Geraeeli, A				Aminiahidashti, Hamed; Shafiee, Sajad; Hosseininejad, Seyed Mohammad; Firouzian, Abulfazl; Barzegarnejad, Ayyub; Kiasari, Alieh Zamani; Kerigh, Behzad Feizzadeh; Bozorgi, Farzad; Shafizad, Misagh; Geraeeli, Ahmad			Propofol-fentanyl versus propofol-ketamine for procedural sedation and analgesia in patients with trauma	AMERICAN JOURNAL OF EMERGENCY MEDICINE			English	Article						Procedural sedation and analgesia; Emergency department; Propofol; Fentanyl; Ketamine	EMERGENCY-DEPARTMENT; DOUBLE-BLIND; CHILDREN; PAIN	Objective: Many procedures performed in emergency department are stressful and painful, and creating proper and timely analgesia and early and effective assessment are the challenges in this department. This study has been conducted in order to compare the efficacy of propofol and fentanyl combination with propofol and ketamine combination for procedural sedation and analgesia (PSA) in trauma patients in the emergency department. Method: This is a randomized prospective double-blind clinical trial conducted in the emergency department of Imam Khomeini Hospital, a tertiary academic trauma center in northern Iran. Patients with trauma presenting to the emergency department who needed PSA were included in study. Patients were divided into two groups of propofol fentanyl (PF) and propofol ketamine (PK). Pain score and sedation depth were set as primary outcome measures and were recorded. Results: Out of about 379 patients with trauma, who needed PSA, 253 met the criteria to be included in the study, 117 of which were excluded. The remaining 136 patients were randomly allocated to either PI' group (n = 70) or PK group (n = 66). Pain management after drug administration was significantly different between the groups and the analgesia caused by fentanyl was significantly higher than ketamine. The sedation score after 15 min of PSA in the group PP was significantly higher than the group PK. Conclusion: It seems that regarding PSA in the emergency department, PF caused better analgesia and deeper sedation and it is recommended to use PP for PSA in the emergency departments. (C) 2018 Elsevier Inc. All rights reserved.	[Aminiahidashti, Hamed; Hosseininejad, Seyed Mohammad] Mazandaran Univ Med Sci, Dept Emergency Med, Fac Med, Sari, Iran; [Shafiee, Sajad; Bozorgi, Farzad; Shafizad, Misagh] Mazandaran Univ Med Sci, Orthoped Res Ctr, Sari, Iran; [Firouzian, Abulfazl; Kiasari, Alieh Zamani] Mazandaran Univ Med Sci, Dept Anesthesiol, Fac Med, Sari, Iran; [Barzegarnejad, Ayyub; Kerigh, Behzad Feizzadeh] Mazandaran Univ Med Sci, Dept Urol, Fac Med, Sari, Iran; [Geraeeli, Ahmad] Mazandaran Univ Med Sci, Dept Emergency Med, Student Res Comm, Sari, Iran	Aminiahidashti, H (reprint author), Mazandaran Univ Med Sci, Dept Emergency Med, Fac Med, Sari, Iran.	h.aminiahidashti@mazums.ac.ir					Akin A, 2005, J CLIN ANESTH, V17, P187, DOI 10.1016/j.jclinane.2004.06.019; Bahrami Gorji F, 2016, ANESTH PAIN MED, V6; Barkan S, 2014, EMERG MED J, V31, P649, DOI 10.1136/emermed-2012-202189; Bawden J, 2011, AM J EMERG MED, V29, P1083, DOI 10.1016/j.ajem.2010.06.036; Bordo D, 2008, WEST J EMERG MED, V9, P86; Cevik E, 2013, AM J EMERG MED, V31, P108, DOI 10.1016/j.ajem.2012.06.012; Chiaretti A, 2010, EUR J CANCER CARE, V19, P212, DOI 10.1111/j.1365-2354.2008.01006.x; DAS-Taskforce 2015, 2015, Ger Med Sci, V13, pDoc19, DOI 10.3205/000223; Gaisl T, 2016, BMC PULM MED, V16, DOI 10.1186/s12890-016-0275-4; Godwin SA, 2005, ANN EMERG MED, V45, P177, DOI 10.1016/j.annemergmed.2004.11.002; Haytural C, 2015, BIOMED RES INT, DOI 10.1155/2015/465465; Kb N, 2014, J CLIN DIAGN RES, V8; Khutia SK, 2012, INDIAN J ANAESTH, V56, P145, DOI 10.4103/0019-5049.96313; Migita RT, 2006, ARCH PEDIAT ADOL MED, V160, P46, DOI 10.1001/archpedi.160.1.46; Pinto RF, 2013, CAN J RURAL MED, V18, P130; Singh Ranju, 2013, Saudi J Anaesth, V7, P24, DOI 10.4103/1658-354X.109801; Stolz D, 2009, EUR RESPIR J, V34, P1024, DOI 10.1183/09031936.00180808; Todd KH, 2007, J PAIN, V8, P460, DOI 10.1016/j.jpain.2006.12.005; Tosun Z, 2007, PEDIATR ANESTH, V17, P983, DOI 10.1111/j.1460-9592.2007.02206.x; Wakai A, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007399.pub2; Yan JW, 2015, ACAD EMERG MED, V22, P1003, DOI 10.1111/acem.12737	21	1	1	0	6	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0735-6757	1532-8171		AM J EMERG MED	Am. J. Emerg. Med.	OCT	2018	36	10					1766	1770		10.1016/j.ajem.2018.01.080			5	Emergency Medicine	Emergency Medicine	GU1FE	WOS:000445001600008	29397258				2020-06-30	J	Weber, F; Geerts, NJE; Roeleveld, HG; Warmenhoven, AT; Liebrand, CA				Weber, F.; Geerts, N. J. E.; Roeleveld, H. G.; Warmenhoven, A. T.; Liebrand, C. A.			The predictive value of the heart rate variability-derived Analgesia Nociception Index in children anaesthetized with sevoflurane: An observational pilot study	EUROPEAN JOURNAL OF PAIN			English	Article							REMIFENTANIL ANESTHESIA; BALANCE	BackgroundThe heart rate variability (HRV)-derived Analgesia Nociception Index (ANI) is a continuous noninvasive tool to assess the nociception/antinociception balance in unconscious patients. It has been shown to be superior to haemodynamic variables in detecting insufficient antinociception in children, while little is known about its predictive value. MethodsThe primary objective of this prospective observational pilot study in paediatric surgical patients under sevoflurane anaesthesia was to compare the predictive value of the ANI and heart rate to help decide to give additional opioids. The paediatric anaesthesiologist in charge was blinded to ANI values. ResultsIn patients with an ANI value <50 (indicating insufficient antinociception) at the moment of decision, ANI values dropped from 55 (indicating sufficient antinociception) to 35, starting 60s before decision. Within 120s after administration of fentanyl (1g/kg), ANI values returned to +/- 60. This phenomenon was only observed in the ANI values derived from HRV data averaged over 2min. Heart rate remained unchanged. In patients with ANI values 50 at the time of decision, opioid administration had no effect on ANI or heart rate. The same accounts for morphine for postoperative analgesia and fentanyl in case of intraoperative movement. ConclusionsThis study provides evidence of a better predictive value of the ANI in detecting insufficient antinociception in paediatric surgical patients than heart rate. The same accounts for depicting re-establishment of sufficient antinociception after opioid drug administration. SignificanceIn paediatric surgical patients anaesthetized with sevoflurane, the heart rate variability-derived Analgesia Nociception Index (ANI) appears to be a better predictor of insufficient antinociception than heart rate. The ANI also appears to depict re-establishment of sufficient antinociception better than heart rate.	[Weber, F.; Geerts, N. J. E.; Roeleveld, H. G.; Warmenhoven, A. T.; Liebrand, C. A.] Erasmus Univ, Med Ctr, Sophia Childrens Hosp, Paediat Anaesthesia Div,Dept Anaesthesia, Rotterdam, Netherlands	Weber, F (reprint author), Erasmus Univ, Med Ctr, Sophia Childrens Hosp, Paediat Anaesthesia Div,Dept Anaesthesia, Rotterdam, Netherlands.	f.weber@erasmusmc.nl					Bobkowski W, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00311; Boselli E, 2015, MINERVA ANESTESIOL, V81, P288; Daccache G, 2017, ANESTH ANALG, V125, P15, DOI 10.1213/ANE.0000000000002145; Gruenewald M, 2015, MINERVA ANESTESIOL, V81, P480; Gruenewald M, 2013, BRIT J ANAESTH, V110, P1024, DOI 10.1093/bja/aet019; Gruenewald M, 2013, BEST PRACT RES-CLIN, V27, P235, DOI 10.1016/j.bpa.2013.06.007; Jeanne M, 2012, J CLIN MONIT COMPUT, V26, P289, DOI 10.1007/s10877-012-9354-0; Jeanne M, 2009, IEEE ENG MED BIO, P1840, DOI 10.1109/IEMBS.2009.5332598; Jeanne M, 2014, CLIN J PAIN, V30, P1084, DOI 10.1097/AJP.0000000000000083; Migeon A, 2013, PEDIATR ANESTH, V23, P1160, DOI 10.1111/pan.12243; Sabourdin N, 2013, PEDIATR ANESTH, V23, P149, DOI 10.1111/pan.12071	11	5	5	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1090-3801	1532-2149		EUR J PAIN	Eur. J. Pain	OCT	2018	22	9					1597	1605		10.1002/ejp.1242			9	Anesthesiology; Clinical Neurology; Neurosciences	Anesthesiology; Neurosciences & Neurology	GT7CH	WOS:000444677400004	29754420	Other Gold, Green Published			2020-06-30	J	Nusrat, S; Madhoun, MF; Tierney, WM				Nusrat, Salman; Madhoun, Mohammed F.; Tierney, William M.			Use of diphenhydramine as an adjunctive sedative for colonoscopy in patients on chronic opioid therapy: a randomized controlled trial	GASTROINTESTINAL ENDOSCOPY			English	Article							GASTROINTESTINAL ENDOSCOPY; INCOMPLETE COLONOSCOPY; PROPOFOL SEDATION; TOLERANCE; SAFETY; PAIN	Background and Aims: Chronic opioid use increases tolerance to sedatives. Diphenhydramine is recommended for difficult-to-sedate patients during endoscopic procedures. We hypothesized that the addition of diphenhydramine to midazolam and fentanyl would improve objective and subjective measures of procedural sedation. Methods: This randomized, double-blind, placebo-controlled trial included patients on chronic opioids undergoing colonoscopy. Patients were randomized to receive 50 mg of diphenhydramine intravenously (n = 61) or placebo (n = 58), in addition to fentanyl and midazolam. Baseline characteristics, amount of fentanyl and midazolam, procedure times, and adverse events were recorded. Quality of sedation was assessed by the physician and nurse. Patients rated pain and amnesia on a 10-point scale. Results: There was no difference in amounts of fentanyl (125.4 +/- 56.2 mg vs 126.9 +/- 53.5 mg, P = .88) and midazolam (4.9 +/- 2.1 mg vs 5 +/- 1.9 mg, P = .79) used. The mean sedation scores from the physician (6.2 +/- 1.1 vs 5.3 +/- 1.2, P = .0002) and nurses (5.6 +/- 1.5 vs 5.1 +/- 1.4, P = .04) were statistically significant in favor of the diphenhydramine arm. Patient scores for pain (2.05 +/- 2.17 vs 3.09 +/- 3.95, P = .047) and amnesia (7.8 +/- 3.4 vs 6.5 +/- 3.8, P = .047) favored the group that received diphenhydramine. Qualitative assessment showed no significant difference between the groups. There was no difference in induction time (P = .86), procedure duration (P = .98), or recovery time (P = .16). Hypotensive episodes were more common in the placebo group (P = .027). Conclusions: In patients on chronic opioid therapy, administration of diphenhydramine does not allow for lower doses of procedural sedatives but improves quality of sedation without increasing the number of adverse events.	[Nusrat, Salman; Madhoun, Mohammed F.; Tierney, William M.] Univ Oklahoma, Hlth Sci Ctr, Dept Med, Sect Digest Dis, Oklahoma City, OK USA; [Nusrat, Salman; Madhoun, Mohammed F.; Tierney, William M.] Vet Affairs Med Ctr, Dept Med, Sect Digest Dis & Nutr, Oklahoma City, OK 73104 USA	Nusrat, S (reprint author), Univ Oklahoma, Hlth Sci Ctr, Div Digest Dis & Nutr, Neurogastroenterol & Motil Program, Andrews Acad Tower,Suite 7400, Oklahoma City, OK 73104 USA.; Nusrat, S (reprint author), Univ Oklahoma, Hlth Sci Ctr, Div Digest Dis & Nutr, Med, Andrews Acad Tower,Suite 7400, Oklahoma City, OK 73104 USA.	salman-nusrat@ouhsc.edu					Aboumarzouk OM, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008506.pub2; Aisenberg James, 2006, Gastrointest Endosc Clin N Am, V16, P695, DOI 10.1016/j.giec.2006.08.004; Aljebreen Abdulrahman Mohammed, 2004, Saudi J Gastroenterol, V10, P150; Baldo BA, 2012, ANAESTH INTENS CARE, V40, P216, DOI 10.1177/0310057X1204000204; BLYDEN GT, 1986, J CLIN PHARMACOL, V26, P529, DOI 10.1002/j.1552-4604.1986.tb02946.x; Bourque AL, 2012, GASTROENTEROL NURS, V35, P308, DOI 10.1097/SGA.0b013e3182603436; Brahmania M, 2012, CAN J GASTROENTEROL, V26, P589, DOI 10.1155/2012/353457; Cardin F, 2012, BMC SURG, V12, DOI 10.1186/1471-2482-12-S1-S9; Cardin F, 2010, BMC GASTROENTEROL, V10, DOI 10.1186/1471-230X-10-123; COOK PJ, 1984, BRIT MED J, V289, P351, DOI 10.1136/bmj.289.6441.351; Ennaifer Rym, 2015, Tunis Med, V93, P138; Fanti L, 2011, DIGEST LIVER DIS, V43, P726, DOI 10.1016/j.dld.2011.04.012; Ferreira AO, 2015, WORLD J GASTRO ENDOS, V7, P102, DOI 10.4253/wjge.v7.i2.102; Hirsh I, 2006, DIGEST DIS SCI, V51, P1946, DOI 10.1007/s10620-006-9413-9; KEEFFE EB, 1990, GASTROINTEST ENDOSC, V36, P541, DOI 10.1016/S0016-5107(90)71146-7; Lamanna Alicia, 2016, Gastroenterol Hepatol (N Y), V12, P547; Lichtenstein DR, 2008, GASTROINTEST ENDOSC, V68, P815, DOI 10.1016/j.gie.2008.09.029; Martindale F, 2014, GASTROENTEROL NURS, V37, P338, DOI 10.1097/SGA.0000000000000066; Nusrat S, 2015, DIGEST DIS SCI, V60, P1016, DOI 10.1007/s10620-015-3639-3; Pena LR, 2005, DIGEST DIS SCI, V50, P1860, DOI 10.1007/s10620-005-2952-7; Pezalla EJ, 2017, J PAIN RES, V10, DOI 10.2147/JPR.S129553; Rex DK, 2007, CLIN GASTROENTEROL H, V5, P879, DOI 10.1016/j.cgh.2007.03.015; Rudd RA, 2016, MMWR-MORBID MORTAL W, V64, P1378, DOI 10.15585/mmwr.mm6450a3; Sachar H, 2018, GASTROINTEST ENDOSC, V87, P1297, DOI 10.1016/j.gie.2017.01.028; Sathananthan D, 2017, ENDOSC INT OPEN, V5, pE110, DOI 10.1055/s-0042-121667; Tu RH, 2006, GASTROINTEST ENDOSC, V63, P87, DOI 10.1016/j.gie.2005.08.015; Turk HS, 2014, TURK J GASTROENTEROL, V25, P644, DOI 10.5152/tjg.2014.7014; Voiosu A, 2014, Rom J Intern Med, V52, P151	28	2	2	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0016-5107	1097-6779		GASTROINTEST ENDOSC	Gastrointest. Endosc.	OCT	2018	88	4					695	702		10.1016/j.gie.2018.04.2342			8	Gastroenterology & Hepatology	Gastroenterology & Hepatology	GT1QZ	WOS:000444249600017	29689257	Bronze			2020-06-30	J	Haidl, F; Rosseland, LA; Spigset, O; Dahl, V				Haidl, F.; Rosseland, L. A.; Spigset, O.; Dahl, V.			Effects of Adrenaline on maternal and fetal fentanyl absorption in epidural analgesia: A randomized trial	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article						adrenaline; epidural analgesia; fentanyl; labor	LABOR ANALGESIA; PLACENTAL-TRANSFER; DOUBLE-BLIND; BUPIVACAINE; EPINEPHRINE; ANESTHESIA; EFFICACY; INFUSION	BackgroundThe combination of low-dose local anesthesia and lipophilic opioids such as fentanyl is established as a standard solution for labor epidural analgesia. Fentanyl increases efficacy, but may have negative effects on the neonate in terms of reduced neonatal neurologic and adaptive capacity scores and breast feeding. We hypothesized that addition of adrenaline 2g/mL to a solution of bupivacaine 1mg/mL and fentanyl 2g/mL would reduce the systemic uptake of fentanyl, resulting in reduced serum fentanyl in the fetus at birth. MethodsForty-one nulliparous women requesting epidural analgesia were randomized to epidural analgesia with or without adrenaline. Blood samples were drawn from the mother with regular intervals, and at delivery. An umbilical vein blood sample (used as a proxy for fetal exposure) was drawn after clamping. ResultsThere were no significant differences between the groups in fentanyl concentrations in the umbilical vein and maternal serum at birth. There was a significantly lower mean area under the maternal serum-concentration curve for the first 2hours of treatment in the adrenaline group (mean difference 0.161nmolh/L [0.034; 0.289], P=.015), implying slower systemic uptake in the adrenaline group initially. There were no significant differences in treatment duration, motor block, Apgar scores, umbilical pH and base excess, or mode of delivery. ConclusionsThe addition of adrenaline to an epidural solution containing fentanyl lowered maternal systemic serum fentanyl concentration during the first 2hours, but did not lower serum fentanyl concentration in the umbilical vein and mother at delivery.	[Haidl, F.; Dahl, V.] Akershus Univ Hosp, Dept Anesthesia, Lorenskog, Norway; [Haidl, F.; Rosseland, L. A.; Dahl, V.] Univ Oslo, Inst Clin Med, Oslo, Norway; [Rosseland, L. A.] Oslo Univ Hosp, Div Emergencies & Crit Care, Dept Res & Dev, Oslo, Norway; [Spigset, O.] St Olavs Univ Hosp, Dept Clin Pharmacol, Trondheim, Norway; [Spigset, O.] Norwegian Univ Sci & Technol, Dept Clin & Mol Med, Trondheim, Norway	Haidl, F (reprint author), Akershus Univ Hosp, Dept Anesthesia, Lorenskog, Norway.	felix.haidl@ahus.no	; Rosseland, Leiv Arne/A-4761-2008	Haidl, Felix/0000-0001-7225-848X; Rosseland, Leiv Arne/0000-0002-6372-8117	Department of Anesthesia, Akershus University Hospital	Department of Anesthesia, Akershus University Hospital	ABBOUD TK, 1985, ANESTH ANALG, V64, P585; Beilin Y, 2005, ANESTHESIOLOGY, V103, P1211, DOI 10.1097/00000542-200512010-00016; BREEN TW, 1993, ANESTH ANALG, V77, P919; Brimdyr K, 2015, BIRTH-ISS PERINAT C, V42, P319, DOI 10.1111/birt.12186; Connelly NR, 2011, J CLIN ANESTH, V23, P265, DOI 10.1016/j.jclinane.2010.09.005; Desprats R, 1995, Int J Obstet Anesth, V4, P225, DOI 10.1016/0959-289X(95)82915-W; EISENACH JC, 1987, ANESTH ANALG, V66, P447, DOI 10.1213/00000539-198705000-00014; Fernando R, 1997, ANAESTHESIA, V52, P517, DOI 10.1111/j.1365-2044.1997.154-az0160.x; GRICE SC, 1990, ANESTHESIOLOGY, V72, P623, DOI 10.1097/00000542-199004000-00008; HAMZA J, 1992, PEDIATR RES, V32, P412, DOI 10.1203/00006450-199210000-00009; Leonard SA, 2002, INT J OBSTET ANESTH, V11, P180, DOI 10.1054/ijoa.2002.0948; LOFTUS JR, 1995, ANESTHESIOLOGY, V83, P300, DOI 10.1097/00000542-199508000-00010; MacArthur C, 2002, ANESTHESIOLOGY, V97, P1567; Mainland D, 1963, ELEMENTARY MED STAT; Moher D, 2010, BMJ-BRIT MED J, V340, DOI [10.1136/bmj.c869, 10.1016/j.jclinepi.2010.03.004]; Neal JM, 2003, REGION ANESTH PAIN M, V28, P124, DOI 10.1053/rapm.2003.50024; Niemi G, 1998, ACTA ANAESTH SCAND, V42, P897, DOI 10.1111/j.1399-6576.1998.tb05348.x; Okutomi T, 2000, REGION ANESTH PAIN M, V25, P529, DOI 10.1053/rapm.2000.7600; Pedersen AB, 2017, CLIN EPIDEMIOL, V9, P157, DOI 10.2147/CLEP.S129785; REYNOLDS F, 1973, BRIT J ANAESTH, V45, P1049, DOI 10.1093/bja/45.10.1049; Wang K, 2014, CAN J ANESTH, V61, P695, DOI 10.1007/s12630-014-0185-y	21	0	0	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-5172	1399-6576		ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	OCT	2018	62	9					1267	1273		10.1111/aas.13175			7	Anesthesiology	Anesthesiology	GS5CF	WOS:000443673500012	29943508	Other Gold, Green Published			2020-06-30	J	Taketa, Y; Irisawa, Y; Fujitani, T				Taketa, Yasuko; Irisawa, Yumi; Fujitani, Taro			Comparison of analgesic efficacy between two approaches of paravertebral block for thoracotomy: A randomised trial	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article						intercostal approach; paralaminar approach; paravertebral block; post-thoracotomy pain; ultrasound guide	PARALAMINAR INPLANE APPROACH; ULTRASOUND; PLACEMENT; SPREAD; UPDATE	BackgroundAlthough several approaches for ultrasound-guided thoracic paravertebral block have been introduced, little is known regarding the differences in analgesic efficacy. We conducted this prospective randomised trial to examine whether the type of approach for ultrasound-guided thoracic paravertebral block could affect analgesic quality in thoracotomy. MethodsPatients scheduled for video-assisted thoracotomy were randomly allocated into two groups by block technique: the intercostal approach (group IC) or the paralaminar approach (group PL). At the start and end of surgery, 20mL of 0.5% ropivacaine was injected, followed by a continuous infusion of 0.2% ropivacaine at 5mL h(-1). We also started intravenous fentanyl patient-controlled analgesia at 0.5g kg(-1)h(-1) and bolus dose of 15g. The main outcome was the number of rescue fentanyl use. We also evaluated postoperative pain scores and number of blocked dermatomes showing a reduced sensation. ResultsEnrolment was ceased because of implementation of a minimally invasive surgical method. Overall, 42 subjects completed the trial for analysis. The number of rescue fentanyl use in group PL was significantly less than that in group IC at 3, 6, 12 and 24hour postoperatively. The numerical rating scale (NRS) at rest in group PL was significantly lower at 1, 3, 6, and 12hour postoperatively. Patients in Group PL developed significantly wider sensory block level (median (IQR [range]); 4 (4-5 [2-7])) than those in Group IC (3 (3-3 [2-9])). ConclusionsWe suggested that paralaminar approach provided superior analgesia for thoracotomy rather than the intercostal approach.	[Taketa, Yasuko; Irisawa, Yumi; Fujitani, Taro] Ehime Prefectural Cent Hosp, Dept Anesthesiol & Crit Care, 83 Kasuga Machi, Matsuyama, Ehime 7900024, Japan	Taketa, Y (reprint author), Ehime Prefectural Cent Hosp, Dept Anesthesiol & Crit Care, 83 Kasuga Machi, Matsuyama, Ehime 7900024, Japan.	suko1231@yahoo.co.jp					Abrahams M, 2016, REGION ANESTH PAIN M, V41, P275, DOI 10.1097/AAP.0000000000000372; Baidya DK, 2014, INTERACT CARDIOV TH, V18, P626, DOI 10.1093/icvts/ivt551; Bendixen M, 2016, LANCET ONCOL, V17, P836, DOI 10.1016/S1470-2045(16)00173-X; Cowie B, 2010, ANESTH ANALG, V110, P1735, DOI 10.1213/ANE.0b013e3181dd58b0; Fibla JJ, 2009, EUR J CARDIO-THORAC, V36, P901, DOI 10.1016/j.ejcts.2009.05.041; Fujii T, 2017, Asian J Anesthesiol, V55, P24, DOI 10.1016/j.aja.2017.05.004; Fujii Tasuku, 2016, Acta Anaesthesiol Taiwan, V54, P101, DOI 10.1016/j.aat.2016.05.004; Joshi GP, 2008, ANESTH ANALG, V107, P1026, DOI 10.1213/01.ane.0000333274.63501.ff; Krediet AC, 2015, ANESTHESIOLOGY, V123, P459, DOI 10.1097/ALN.0000000000000747; Luyet C, 2011, BRIT J ANAESTH, V106, P246, DOI 10.1093/bja/aeq309; Okajima H, 2015, J ANESTH, V29, P373, DOI 10.1007/s00540-014-1947-y; Pintaric TS, 2011, REGION ANESTH PAIN M, V36, P256, DOI 10.1097/AAP.0b013e3182176f42; Shibata Y, 2009, ANESTH ANALG, V109, P996, DOI 10.1213/ane.0b013e3181af7e7b; Taketa Y, 2017, BRIT J ANAESTH, V119, P339, DOI 10.1093/bja/aex209; Taketa Y, 2017, J ANESTH, V31, P271, DOI 10.1007/s00540-016-2289-8; Taketa Y, 2015, REGION ANESTH PAIN M, V40, P390, DOI 10.1097/AAP.0000000000000259; Thavaneswaran P, 2010, ANESTH ANALG, V110, P1740, DOI 10.1213/ANE.0b013e3181da82c8; Thomas Collin, 2015, GRAYS ANATOMY ANATOM, P944; Uppal V, 2017, REGION ANESTH PAIN M, V42, P575, DOI 10.1097/AAP.0000000000000631; Wardhan R, 2015, CURR OPIN ANESTHESIO, V28, P588, DOI 10.1097/ACO.0000000000000235; Yeung J. H., 2016, COCHRANE DB SYST REV, V2, DOI DOI 10.1002/14651858.CD009121.PUB2; Yoshida T, 2014, ANAESTHESIA, V69, P231, DOI 10.1111/anae.12531; Yoshida T, 2016, J ANESTH, V30, P727, DOI 10.1007/s00540-016-2170-9	23	6	6	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-5172	1399-6576		ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	OCT	2018	62	9					1274	1279		10.1111/aas.13216			6	Anesthesiology	Anesthesiology	GS5CF	WOS:000443673500013	30047132				2020-06-30	J	Ebrahimi, R; Tan, WY				Ebrahimi, Ramin; Tan, Weiyi			Role of Music for Conscious Sedation During Invasive Cardiac Catheterization	AMERICAN JOURNAL OF CARDIOLOGY			English	Article							ANXIETY; THERAPY	Patients undergoing invasive cardiac catheterization (ICC) can experience anxiety and pain. A common practice in the United States is to administer benzodiazepines and opioids for conscious sedation to relieve these symptoms. Music may reduce anxiety and pain perception. We sought to evaluate the role of music in lieu of pharmacotherapy for conscious sedation during elective ICC. A retrospective data analysis was performed on patients who underwent ICC and received music therapy +/- intravenous sedation/analgesics based on patient's preference compared with control patients who were offered and received intravenous sedation/analgesics based on patient's preference. A total of 161 patients were analyzed, 49 in the music arm, and 112 in the control arm. Baseline characteristics were similar in the 2 groups except that the rate of drug addiction, back pain, post-traumatic stress disorder, and hearing loss were higher in the control group when compared with the music arm. 42 (86%) of the patients in the music group and 29 (26 %) of the control group received no sedation or analgesia in the periprocedural period. The average dose of midazolam (0.7 mg vs 0.1 mg, p < 0.0001) and fentanyl (39.5 mcg vs 3 mcg, p < 0.0001) was higher in the control than the music arm, respectively. 42 (86%) of patients receiving music therapy believed music was helpful in reducing their stress/anxiety levels. In conclusion, music may serve as adjunctive/alternative intervention to pharmacotherapy in relieving anxiety and stress for patients undergoing elective ICC. (C) 2018 Elsevier Inc. All rights reserved.	[Ebrahimi, Ramin; Tan, Weiyi] Vet Affairs Greater Los Angeles Healthcare Syst, Dept Med, Cardiol Sect, Los Angeles, CA 90073 USA; [Ebrahimi, Ramin; Tan, Weiyi] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA	Ebrahimi, R (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Dept Med, Cardiol Sect, Los Angeles, CA 90073 USA.; Ebrahimi, R (reprint author), Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA.	ebrahimi@ucla.edu					Bradt J, 2013, COCHRANE DB SYST REV, V6; Delewi R, 2017, INT J CARDIOL, V228, P926, DOI 10.1016/j.ijcard.2016.11.043; Forooghy M, 2015, NURS MIDWIFERY STUD, V4, DOI 10.17795/nmsjournal25800; Jimenez-Jimenez M, 2013, J VASC NURS, V31, P101, DOI 10.1016/j.jvn.2012.10.002; Ko CH, 2017, J CHIN MED ASSOC, V80, P154, DOI 10.1016/j.jcma.2016.08.010; Okada K, 2009, INT HEART J, V50, P95, DOI 10.1536/ihj.50.95; Weeks BP, 2011, EUR J CARDIOVASC NUR, V10, P88, DOI 10.1016/j.ejcnurse.2010.07.002; Zengin S, 2013, COMPLEMENT THER MED, V21, P689, DOI 10.1016/j.ctim.2013.08.017	8	0	1	0	9	EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC	BRIDGEWATER	685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA	0002-9149	1879-1913		AM J CARDIOL	Am. J. Cardiol.	SEP 15	2018	122	6					1095	1097		10.1016/j.amjcard.2018.05.039			3	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	GY8TT	WOS:000448907600028	30072130				2020-06-30	J	Karamouzian, M; Dohoo, C; Forsting, S; McNeil, R; Kerr, T; Lysyshyn, M				Karamouzian, Mohammad; Dohoo, Carolyn; Forsting, Sara; McNeil, Ryan; Kerr, Thomas; Lysyshyn, Mark			Evaluation of a fentanyl drug checking service for clients of a supervised injection facility, Vancouver, Canada	HARM REDUCTION JOURNAL			English	Article						Drug checking; Substance use; Injection drug use; Supervised injection facility; Canada	DEATHS INVOLVING FENTANYL; PUBLIC-HEALTH APPROACH; BRITISH-COLUMBIA; OVERDOSE DEATHS; MANAGEMENT; ADDICTION; EXPOSURE; PEOPLE; RISK	Background: British Columbia, Canada, is experiencing a public health emergency related to opioid overdoses driven by consumption of street drugs contaminated with illicitly manufactured fentanyl. This cross-sectional study evaluates a drug checking intervention for the clients of a supervised injection facility (SIF) in Vancouver. Methods: Insite is a facility offering supervised injection services in Vancouver's Downtown East Side, a community with high levels of injection drug use and associated harms, including overdose deaths. During July 7, 2016, to June 21, 2017, Insite clients were offered an opportunity to check their drugs for fentanyl using a test strip designed to test urine for fentanyl. Results of the drug check were recorded along with information including the substance checked, whether the client intended to dispose of the drug or reduce the dose and whether they experienced an overdose. Logistic regression models were constructed to assess the associations between drug checking results and dose reduction or drug disposal. Crude odds ratios (OR) and 95% confidence intervals (CI) were reported. Results: About 1% of the visits to Insite during the study resulted in a drug check. Out of 1411 drug checks conducted by clients, 1121 (79.8%) were positive for fentanyl. Although most tests were conducted post-consumption, following a positive pre-consumption drug check, 36.3% (n = 142) of participants reported planning to reduce their drug dose while only 11.4% (n = 50) planned to dispose of their drug. While the odds of intended dose reduction among those with a positive drug check was significantly higher than those with a negative result (OR = 9.36; 95% CI 4.25-20.65), no association was observed between drug check results and intended drug disposal (OR = 1.60; 95% CI 0.79-3.26). Among all participants, intended dose reduction was associated with significantly lower odds of overdose (OR = 0.41; 95% CI 0.18-0.89). Conclusions: Although only a small proportion of visits resulted in a drug check, a high proportion (similar to 80%) of the drugs checked were contaminated with fentanyl. Drug checking at harm reduction facilities such as SIFs might be a feasible intervention that could contribute to preventing overdoses in the context of the current overdose emergency.	[Karamouzian, Mohammad; McNeil, Ryan; Kerr, Thomas] St Pauls Hosp, British Columbia Ctr Excellence HIV AIDS, 608-1081 Burrard St, Vancouver, BC V6Z 1Y6, Canada; [Karamouzian, Mohammad; Lysyshyn, Mark] Univ British Columbia, Sch Populat & Publ Hlth, 5804 Fairview Ave, Vancouver, BC V6T 1Z3, Canada; [Karamouzian, Mohammad] Kerman Univ Med Sci, HIV STI Surveillance Res Ctr, Kerman 7616913555, Iran; [Karamouzian, Mohammad] Kerman Univ Med Sci, WHO Collaborating Ctr HIV Surveillance, Inst Futures Studies Hlth, Kerman 7616913555, Iran; [Dohoo, Carolyn] Publ Hlth Agcy Canada, Ottawa, ON K1A 0K9, Canada; [Forsting, Sara; Lysyshyn, Mark] Vancouver Coastal Hlth Author, Vancouver, BC V5Z 4C2, Canada; [McNeil, Ryan; Kerr, Thomas] Univ British Columbia, St Pauls Hosp, Dept Med, 608-1081 Burrard St, Vancouver, BC V6Z 1Y6, Canada	Lysyshyn, M (reprint author), Univ British Columbia, Sch Populat & Publ Hlth, 5804 Fairview Ave, Vancouver, BC V6T 1Z3, Canada.; Lysyshyn, M (reprint author), Vancouver Coastal Hlth Author, Vancouver, BC V5Z 4C2, Canada.	mark.lysyshyn@vch.ca	Karamouzian, Mohammad/C-9277-2018	Karamouzian, Mohammad/0000-0002-5631-4469; Lysyshyn, Mark/0000-0001-6684-2030	Vancouver Coastal Health; Vanier Canada Graduate Scholarship; Pierre Elliott Trudeau Doctoral Scholarship	This study was funded by Vancouver Coastal Health. Mohammad Karamouzian is supported by Vanier Canada Graduate and Pierre Elliott Trudeau Doctoral Scholarships.	Amlani A, 2015, HARM REDUCT J, V12, DOI 10.1186/s12954-015-0088-4; Armenian P, 2018, NEUROPHARMACOLOGY, V134, P121, DOI 10.1016/j.neuropharm.2017.10.016; BC Coroners Service, 2017, FENT DET ILL DRUG OV, P19; Boyd N, 2013, DRUG-EDUC PREV POLIC, V20, P234, DOI 10.3109/09687637.2012.755495; Brunt T, 2017, DRUG CHECKING HARM R; Brunt TM, 2017, DRUG TEST ANAL, V9, P188, DOI 10.1002/dta.1954; Harper L, 2017, HARM REDUCT J, V14, DOI 10.1186/s12954-017-0179-5; Hayashi K, 2018, DRUG ALCOHOL DEPEN, V183, P1, DOI 10.1016/j.drugalcdep.2017.10.020; Higgins JP, 2010, STAT METHODS GROUP C, P1; Hondebrink L, 2015, DRUG ALCOHOL DEPEN, V147, P109, DOI 10.1016/j.drugalcdep.2014.11.033; Hungerbuehler I, 2011, HARM REDUCT J, V8, DOI 10.1186/1477-7517-8-16; Jafari S, 2015, CAN J ADDICT, V6, P4; Jones JD, 2017, ADDICT BEHAV, V71, P104, DOI 10.1016/j.addbeh.2017.03.008; Karamouzian M, 2018, LANCET, V391, P201, DOI 10.1016/S0140-6736(18)30057-6; Kennedy MC, 2018, DRUG ALCOHOL DEPEN, V185, P248, DOI 10.1016/j.drugalcdep.2017.12.026; Kennedy MC, 2017, CURR HIV-AIDS REP, V14, P161, DOI 10.1007/s11904-017-0363-y; Kenney SR, 2018, J SUBST ABUSE TREAT, V86, P65, DOI 10.1016/j.jsat.2018.01.005; Klar SA, 2016, MMWR-MORBID MORTAL W, V65, P1015, DOI 10.15585/mmwr.mm6537a6; Kolodny A, 2015, ANNU REV PUBL HEALTH, V36, P559, DOI 10.1146/annurev-publhealth-031914-122957; Latimer J, 2016, INT J DRUG POLICY, V37, P111, DOI 10.1016/j.drugpo.2016.08.004; Lefrancois E, 2018, DRUG TEST ANAL, V10, P874, DOI 10.1002/dta.2335; O'Donnell JK, 2017, MMWR-MORBID MORTAL W, V66, P1197, DOI 10.15585/mmwr.mm6643e1; PAIX A, 1995, PAIN, V63, P263, DOI 10.1016/0304-3959(95)00084-6; Potier C, 2014, DRUG ALCOHOL DEPEN, V145, P48, DOI 10.1016/j.drugalcdep.2014.10.012; Sage C, 2016, HARM REDUCTION DRUG; Schroers A, 2002, J DRUG ISSUES, V32, P635, DOI 10.1177/002204260203200219; Sherman SG, 2018, FENTANYL OVERDOSE RE; Suzuki J, 2017, DRUG ALCOHOL DEPEN, V171, P107, DOI 10.1016/j.drugalcdep.2016.11.033; Toumbourou JW, 2007, LANCET, V369, P1391, DOI 10.1016/S0140-6736(07)60369-9; Vancouver Coastal Health, INS US STAT VANC; Winstock AR, 2001, ADDICTION, V96, P1139, DOI 10.1046/j.1360-0443.2001.96811397.x; Wood E, 2006, NEW ENGL J MED, V354, P2512, DOI 10.1056/NEJMc052939; Young MM, 2015, CAN J ADDICT, V6, P13	33	21	21	3	6	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1477-7517			HARM REDUCT J	Harm Reduct. J.	SEP 10	2018	15								46	10.1186/s12954-018-0252-8			8	Substance Abuse	Substance Abuse	GT1OP	WOS:000444241100001	30200991	DOAJ Gold, Green Published	Y	N	2020-06-30	J	Pieper, L; Wager, J; Zernikow, B				Pieper, Lucas; Wager, Julia; Zernikow, Boris			Intranasal fentanyl for respiratory distress in children and adolescents with life-limiting conditions	BMC PALLIATIVE CARE			English	Article						Dyspnea; Fentanyl; Intranasal application; Palliative; Pediatric	QUALITY-OF-LIFE; PALLIATIVE CARE; REFRACTORY BREATHLESSNESS; SYMPTOM CONTROL; HEART-DISEASE; MANAGEMENT; CANCER; END; DYSPNEA; MORPHINE	Background: Respiratory distress is one of the most common and frightening symptoms of children with life-limiting conditions. Because treatment of the underlying cause is frequently impossible or insufficient, in many children, symptomatic treatment is warranted. The purpose of this study was to describe the circumstances of the use of intranasal fentanyl in an acute attack of respiratory distress (AARD) in children receiving palliative care, as well as to describe outcomes and adverse events after its use. Methods: Children and adolescents treated in a pediatric palliative unit or attended by a specialized home care team between 2010 and 2016 were included in this study. A retrospective chart review was conducted of those who were treated with intranasal fentanyl for an AARD. Results: During the study period 16 children (0.5-18.6 years) with various life-limiting conditions were treated with intranasal fentanyl for AARD. In total, 70 AARDs were analyzed. In 74% of all AARDs, a single dose of intranasal fentanyl was used. Frequent causes for an AARD were excessive secretions and acute respiratory infection. The median starting dose of intranasal fentanyl was 1.5 mu g/kg body weight. Labored breathing (96%), tachypnea (79%) and related suffering (97%) improved after treatment. An adverse event occurred in one child. Conclusions: Intranasal fentanyl may be a safe and effective medication for the treatment of acute attacks of respiratory distress in children with life-limiting conditions. However, prospective studies with larger sample sizes and a control group are needed to validate these findings.	[Pieper, Lucas; Wager, Julia; Zernikow, Boris] Witten Herdecke Univ, Sch Med, Fac Hlth, Dept Childrens Pain Therapy & Paediat Palliat Car, Witten, Germany; [Wager, Julia; Zernikow, Boris] Childrens & Adolescents Hosp Datteln, Paediat Palliat Care Ctr, Dr Friedrich Steiner Str 5, D-45711 Datteln, Germany	Zernikow, B (reprint author), Witten Herdecke Univ, Sch Med, Fac Hlth, Dept Childrens Pain Therapy & Paediat Palliat Car, Witten, Germany.; Zernikow, B (reprint author), Childrens & Adolescents Hosp Datteln, Paediat Palliat Care Ctr, Dr Friedrich Steiner Str 5, D-45711 Datteln, Germany.	B.Zernikow@kinderklinik-datteln.de		Wager, Julia/0000-0003-4493-6356			Abernethy AP, 2003, BRIT MED J, V327, P523, DOI 10.1136/bmj.327.7414.523; Alt-Epping B, 2012, J PALLIAT MED, V15, P971, DOI 10.1089/jpm.2011.0434; Bausewein C, 2016, INTERNIST, V57, P978, DOI 10.1007/s00108-016-0122-y; Bausewein C, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005623.pub2; Bausewein C, 2014, CURR OPIN SUPPORT PA, V8, P208, DOI 10.1097/SPC.0000000000000071; Blume ED, 2014, PEDIATR CRIT CARE ME, V15, P336, DOI 10.1097/PCC.0000000000000072; Borland M, 2007, ANN EMERG MED, V49, P335, DOI 10.1016/j.annemergmed.2006.06.016; Borland Meredith L, 2002, Emerg Med (Fremantle), V14, P275, DOI 10.1046/j.1442-2026.2002.00344.x; Borland ML, 2008, EMERG MED AUSTRALAS, V20, P515, DOI 10.1111/j.1742-6723.2008.01138.x; Collins JJ, 2000, J PAIN SYMPTOM MANAG, V19, P363, DOI 10.1016/S0885-3924(00)00127-5; Craig F, 2015, CURR OPIN SUPPORT PA, V9, P217, DOI 10.1097/SPC.0000000000000154; Crellin D, 2010, EMERG MED AUSTRALAS, V22, P62, DOI 10.1111/j.1742-6723.2010.01257.x; Davis MP, 2011, EXPERT REV NEUROTHER, V11, P1197, DOI [10.1586/ERN.11.63, 10.1586/ern.11.63]; Drake R, 2003, J PAIN SYMPTOM MANAG, V26, P594, DOI 10.1016/S0885-3924(03)00202-1; Finkel JC, 2001, ANESTH ANALG, V92, P1164; Freye Enno, 2007, Pain Pract, V7, P324, DOI 10.1111/j.1533-2500.2007.00157.x; Galinkin JL, 2000, ANESTHESIOLOGY, V93, P1378, DOI 10.1097/00000542-200012000-00006; Garske D, 2016, Z PALLIATIVMEDIZIN, V17, P302, DOI DOI 10.1055/S-0042-111268; Gormley PK, 1999, INT J PEDIATR OTORHI, V51, P23, DOI 10.1016/S0165-5876(99)00252-9; Graff GR, 2004, RESPIRATION, V71, P646, DOI 10.1159/000081769; Grassin-Delyle S, 2012, PHARMACOL THERAPEUT, V134, P366, DOI 10.1016/j.pharmthera.2012.03.003; Harlos MS, 2013, J PAIN SYMPTOM MANAG, V46, P265, DOI 10.1016/j.jpainsymman.2012.07.009; Hechler T, 2008, KLIN PADIATR, V220, P166, DOI 10.1055/s-2008-1065347; Holdgate A, 2010, ACAD EMERG MED, V17, P214, DOI 10.1111/j.1553-2712.2009.00636.x; HUNT AM, 1990, DEV MED CHILD NEUROL, V32, P341; Jennings AL, 2002, THORAX, V57, P939, DOI 10.1136/thorax.57.11.939; Kamal AH, 2011, J PALLIAT MED, V14, P1167, DOI 10.1089/jpm.2011.0109; Lansing RW, 2009, RESP PHYSIOL NEUROBI, V167, P53, DOI 10.1016/j.resp.2008.07.012; Leach RM, 2010, OXFORD TXB PALLIATIV, P1231; Manjushree R, 2002, CAN J ANAESTH, V49, P190; MANNING HL, 1995, NEW ENGL J MED, V333, P1547, DOI 10.1056/NEJM199512073332307; Meek PM, 1999, AM J RESP CRIT CARE, V159, P321; Monnier P., 2003, European Archives of Oto-Rhino-Laryngology, V260, P295, DOI 10.1007/s00405-002-0465-y; Mudd S, 2011, J PEDIATR HEALTH CAR, V25, P316, DOI 10.1016/j.pedhc.2010.04.011; Murphy A, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009942.pub2; Nave R, 2013, DRUG DELIV, V20, P216, DOI 10.3109/10717544.2012.762435; Parshall MB, 2012, AM J RESP CRIT CARE, V185, P435, DOI 10.1164/rccm.201111-2042ST; Pieper L, 2018, J PALLIAT MED, V21, P552, DOI 10.1089/jpm.2017.0240; REUBEN DB, 1986, CHEST, V89, P234, DOI 10.1378/chest.89.2.234; Robinson WM, 2012, CHRON RESP DIS, V9, P251, DOI 10.1177/1479972312452439; Schindera C, 2014, AM J HOSP PALLIAT ME, V31, P548, DOI 10.1177/1049909113497419; Simon ST, 2013, J PAIN SYMPTOM MANAG, V46, P874, DOI 10.1016/j.jpainsymman.2013.02.019; Sitte T, 2009, WIEN MED WOCHENSCHR, V159, P566, DOI 10.1007/s10354-009-0724-2; Sitte Thomas, 2008, J Pain Symptom Manage, V36, pe3, DOI 10.1016/j.jpainsymman.2008.08.002; Solano JP, 2006, J PAIN SYMPTOM MANAG, V31, P58, DOI 10.1016/j.jpainsymman.2005.06.007; St-Laurent-Gagnon T, 1998, Paediatr Child Health, V3, P165; Theunissen JMJ, 2007, PEDIATR BLOOD CANCER, V49, P160, DOI 10.1002/pbc.21042; von Lutzau P, 2012, J PALLIAT CARE, V28, P274, DOI 10.1177/082585971202800406; Wolfe J, 2000, NEW ENGL J MED, V342, P326, DOI 10.1056/NEJM200002033420506; Wolfe J, 2008, J CLIN ONCOL, V26, P1717, DOI 10.1200/JCO.2007.14.0277; Younge P, 1999, EMERGEN MED, V11, P90	51	2	2	0	0	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1472-684X			BMC PALLIAT CARE	BMC Palliat. Care	SEP 10	2018	17								106	10.1186/s12904-018-0361-x			8	Health Care Sciences & Services; Health Policy & Services	Health Care Sciences & Services	GT0TI	WOS:000444160300001	30200942	DOAJ Gold, Green Published			2020-06-30	J	Chryssa, P; Georgia, T; Georgios, P; Athanassios, K; Constantinos, Z; Aristeidis, K; Faye, M; Dimitrios, K				Chryssa, Pourzitaki; Georgia, Tsaousi; Georgios, Papazisis; Athanassios, Kyrgidis; Constantinos, Zacharis; Aristeidis, Kritis; Faye, Malliou; Dimitrios, Kouvelas			Fentanyl and naloxone effects on glutamate and GABA release rates from anterior hypothalamus in freely moving rats	EUROPEAN JOURNAL OF PHARMACOLOGY			English	Article						Fentanyl; Naloxone; Hypothalamus; Tail pinch; Push pull superfusion; High performance liquid chromatography; GABA; Glutamate	AMINO-ACID NEUROTRANSMITTERS; ENDOGENOUS OPIATE PEPTIDES; NMDA RECEPTOR ANTAGONISTS; PARAVENTRICULAR NUCLEUS; NITRIC-OXIDE; ARGININE-VASOPRESSIN; KETAMINE-XYLAZINE; LOCUS-COERULEUS; ASCORBIC-ACID; SPINAL-CORD	Fentanyl, a mu-opioid receptor agonist, has been studied for its neuro/psycho-pharmacological effects since its first clinical use; however, its effect on the release rate of the Central Nervous System (CNS) neurotransmitters has not been yet elucidated. In the present study the influence of fentanyl on the release rates of glutamate and GABA is investigated. Specifically, we examined the effects of intravenous (10 mu g/kg) as well as intrahypothalamic (0.1 nmol/min) fentanyl administration on the release rates of GABA and glutamate in the superfusate of anterior hypothalamus, under tail pinch manipulation. The release rate of the neurotransmitters was monitored by the push-pull superfusion technique. To investigate the role of fentanyl the opioid antagonist, naloxone 0.1 mg/kg was administered intravenously, or 50 nmol/min intrahypothalamicaly. The amino acids were determined by High Performance Liquid Chromatography (HPLC) and fluorimetric detection after NBD-Cl derivatisation. After intravenous fentanyl administration a significant decrease of glutamate and increase of GABA release rates were observed. However during the pain manipulations, the release rate of glutamate was increased. Intravenous naloxone did not affect significantly the release rates of both amino acids, while intrahypothalamic antagonist administration reversed the alterations in both neurotransmitters release rates. Our results demonstrate that there is an opioid-glutamatergic transmission pathway, located in hypothalamus and that opioids can activate NMDA receptors, thus reducing the nociceptive threshold and the opioid analgesic effect.	[Chryssa, Pourzitaki; Georgios, Papazisis; Athanassios, Kyrgidis; Faye, Malliou; Dimitrios, Kouvelas] Aristotle Univ Thessaloniki, Sch Hlth Sci, Fac Med, Dept Clin Pharmacol, Univ Campus, Thessaloniki 54124, Greece; [Georgia, Tsaousi] Aristotle Univ Thessaloniki, Sch Hlth Sci, Fac Med, Clin Anesthesiol & Intens Care,AHEPA Univ Hosp, Univ Campus, Thessaloniki 54006, Greece; [Constantinos, Zacharis] Pharmathen SA, Analyt Dev Lab, R&D API Operat, Thessaloniki, Greece; [Aristeidis, Kritis] Aristotle Univ Thessaloniki, Sch Hlth Sci, Fac Med, Dept Expt Physiol, Thessaloniki, Greece	Chryssa, P (reprint author), Aristotle Univ Thessaloniki, Sch Hlth Sci, Fac Med, Dept Clin Pharmacol, Univ Campus, Thessaloniki 54124, Greece.	chpour@auth.gr		Zacharis, Constantinos/0000-0001-9362-8523; Kritis, Aristeidis/0000-0002-2067-8842; Malliou, Faye (Foteini)/0000-0001-9186-3466	Research Committee of Aristotle University of Thessaloniki, Greece [50120]; Foundation Tsagka-Despotidou in Athens, Greece [74/07]	This work was supported by the Research Committee of Aristotle University of Thessaloniki, Greece (Grant number 50120) and by the Foundation Tsagka-Despotidou in Athens, Greece (Grant number 74/07).	Albrecht M, 2014, BMC VET RES, V10, DOI 10.1186/s12917-014-0198-3; Andresen MC, 2013, FRONT NEUROSCI-SWITZ, V6, DOI 10.3389/fnins.2012.00191; Baechtold F, 2001, PFLUG ARCH EUR J PHY, V443, P155, DOI 10.1007/s004240100693; Bester H, 1997, J COMP NEUROL, V383, P439; Bhat GK, 1998, ENDOCRINOLOGY, V139, P955, DOI 10.1210/en.139.3.955; Bilsky EJ, 1996, PAIN, V68, P229, DOI 10.1016/S0304-3959(96)03185-5; Cao WH, 2005, AM J PHYSIOL-REG I, V288, pR723, DOI 10.1152/ajpregu.00669.2004; Denuelle M, 2007, HEADACHE, V47, P1418, DOI 10.1111/j.1526-4610.2007.00776.x; Desole MS, 1996, BRAIN RES, V723, P154, DOI 10.1016/0006-8993(96)00235-1; Dodelet-Devillers A, 2016, EXP ANIM TOKYO, V65, P383, DOI 10.1538/expanim.16-0026; ELIOTT K, 1994, PAIN, V59, P361, DOI 10.1016/0304-3959(94)90022-1; ELLIOTT K, 1994, PAIN, V56, P69, DOI 10.1016/0304-3959(94)90151-1; Enrico P, 1998, BRAIN RES, V797, P94, DOI 10.1016/S0006-8993(98)00371-0; Fundytus ME, 2001, CNS DRUGS, V15, P29, DOI 10.2165/00023210-200115010-00004; Gengo PJ, 2003, J PHARMACOL EXP THER, V307, P1227, DOI 10.1124/jpet.103.054429; Gonzalez P, 1997, EUR J PHARMACOL, V332, P257, DOI 10.1016/S0014-2999(97)01099-6; Hahnenkamp K, 2004, ANESTHESIOLOGY, V100, P1531, DOI 10.1097/00000542-200406000-00028; Iremonger KJ, 2009, J NEUROSCI, V29, P7349, DOI 10.1523/JNEUROSCI.0381-09.2009; Klinker CC, 2007, ANAL CHEM, V79, P8747, DOI 10.1021/ac071433o; KLUVER H, 1953, J NEUROPATH EXP NEUR, V12, P400; Kohsaka A, 1999, NEUROENDOCRINOLOGY, V69, P245, DOI 10.1159/000054425; Kosten TA, 2001, PROG NEURO-PSYCHOPH, V25, P1283, DOI 10.1016/S0278-5846(01)00180-4; Kouvelas D, 2006, NEUROSCI LETT, V393, P194, DOI 10.1016/j.neulet.2005.09.063; Le Greves P, 1998, EUR J PHARMACOL, V341, P161, DOI 10.1016/S0014-2999(97)01400-3; LIN YJ, 1973, CHEM PHARM BULL, V21, P2749; Liu QS, 1999, J NEUROPHYSIOL, V82, P3000; Malick A, 2000, J NEUROPHYSIOL, V84, P2078; MIELE M, 1994, NEUROSCIENCE, V62, P87, DOI 10.1016/0306-4522(94)90316-6; NOTO T, 1984, NEUROCHEM RES, V9, P1653, DOI 10.1007/BF00964598; Park J, 2015, PAIN, V156, P318, DOI 10.1097/01.j.pain.0000460312.79195.ed; Paxinos G., 1996, RAT BRAIN STEREOTAXI; Philippu A., 2017, VIVO NEUROPHARMACOLO; Popik P, 1999, POL J PHARMACOL, V51, P223; Popik P, 2000, N-S ARCH PHARMACOL, V361, P425, DOI 10.1007/s002109900205; Popik P, 2008, PSYCHOPHARMACOLOGY, V198, P421, DOI 10.1007/s00213-008-1158-z; Porro CA, 1998, J NEUROPHYSIOL, V80, P3312; Prast H, 1996, N-S ARCH PHARMACOL, V354, P731, DOI 10.1007/BF00166899; Singewald N, 1995, BRAIN RES, V704, P42, DOI 10.1016/0006-8993(95)01102-1; Slot LAB, 2002, PHARMACOL BIOCHEM BE, V72, P943, DOI 10.1016/S0091-3057(02)00760-8; Succu S, 2006, NEUROSCI LETT, V404, P1, DOI 10.1016/j.neulet.2006.05.007; Verborgh C, 1999, PAIN, V83, P17, DOI 10.1016/S0304-3959(99)00068-8; Wen ZH, 2004, BRAIN RES, V995, P253, DOI 10.1016/j.brainres.2003.10.008; Wu XM, 2014, BIOMED CHROMATOGR, V28, P459, DOI 10.1002/bmc.3062; Yang C, 2007, J SEP SCI, V30, P3154, DOI 10.1002/jssc.200700160; Yang J, 2006, BRAIN RES, V1069, P127, DOI 10.1016/j.brainres.2005.11.045; Yang J, 2006, NEUROSCI RES, V54, P49, DOI 10.1016/j.neures.2005.10.006; Yang J, 2008, INT J NEUROSCI, V118, P473, DOI 10.1080/00207450601123563; Yang J, 2009, PEPTIDES, V30, P740, DOI 10.1016/j.peptides.2009.01.004; YONEDA Y, 1977, BRAIN RES, V124, P373, DOI 10.1016/0006-8993(77)90896-4; Yoshida Y, 1999, NEUROSCIENCE, V92, P1357, DOI 10.1016/S0306-4522(99)00046-9	50	2	3	0	5	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0014-2999	1879-0712		EUR J PHARMACOL	Eur. J. Pharmacol.	SEP 5	2018	834						169	175		10.1016/j.ejphar.2018.07.029			7	Pharmacology & Pharmacy	Pharmacology & Pharmacy	GP6FZ	WOS:000440974700020	30030987				2020-06-30	J	Hernandez, M; Tribino, G; Bustamante, C				Hernandez, Marcela; Tribino, Gabriel; Bustamante, Carlos			Characterization of potential drug-drug interactions in patients hospitalized in the intensive care unit of a tertiary hospital in Bogota	BIOMEDICA			Spanish	Article						Drug interactions; critical care; drug prescriptions; incidence; risk factors; cohort studies	PREVALENCE; FREQUENCY; BRAZIL	Introduction: Drug-drug interactions occur more frequently in intensive care units than in other services. However, in Colombia, there are few studies on this problem in critically ill patients. Objectives: To characterize potential drug-drug interactions generated from prescriptions during hospitalization in an intensive care unit and to determine factors associated with their onset. Materials and methods: A retrospective cohort was assembled with patients hospitalized in an intensive care unit for a seven-month period. The daily prescription was assessed for potential drug-drug interactions using the Lexicomp (R) program. We calculated the incidence of interactions, classified them by type, severity, and level of documentation, and evaluated the factors associated with their onset using logistic regression. Results: The proportion of patients with at least one interaction was 84% while 87% had more than one interaction; the median was six interactions per patient. The most frequent was fentanyl and midazolam (23%). Moderate interactions were the most frequent by severity (77.6%) and by documentation (52.6%). The most common index and precipitating drugs were midazolam (12%) and fentanyl (10.6%), respectively. Age (OR=3.1) and the number of drugs (OR=11.8) were associated with the occurrence of interactions. Conclusions: Given their high frequency and potential negative impact, the systematic monitoring of prescriptions in intensive care units to detect interactions is important. Such monitoring contributes to the rational use of medicines and to improve the quality of care.	[Hernandez, Marcela; Tribino, Gabriel; Bustamante, Carlos] Univ La Sabana, Dept Farmacol Clin & Terapeut, Chia, Colombia	Hernandez, M (reprint author), Univ La Sabana, Dept Farmacol Clin & Terapeut, Chia, Colombia.	marcela.herlon@outlook.com					Almeida SM, 2007, EINSTEIN-SAO PAULO, V5, P347; Askari M, 2013, PHARMACOEPIDEM DR S, V22, P430, DOI 10.1002/pds.3415; Barrons R, 2004, AM J HEALTH-SYST PH, V61, P380, DOI 10.1093/ajhp/61.4.380; Becker ML, 2007, PHARMACOEPIDEM DR S, V16, P641, DOI 10.1002/pds.1351; Bergk V, 2004, CLIN PHARMACOL THER, V76, P85, DOI 10.1016/j.clpt.2004.02.009; Bucsa C, 2013, EUR J INTERN MED, V24, P27, DOI 10.1016/j.ejim.2012.09.011; Caribé R. A., 2013, Farm Hosp., V37, P383, DOI 10.7399/FH.2013.37.5.534; Cruciol-Souza JM, 2006, J PHARM PHARM SCI, V9, P427; Devlin JW, 2009, CRIT CARE CLIN, V25, P431, DOI 10.1016/j.ccc.2009.03.003; ELANJIAN S, 1993, AM J HOSP PHARM, V50, P2546, DOI 10.1093/ajhp/50.12.2546; de Carvalho REFL, 2013, ACTA PAUL ENFERM, V26, P150, DOI 10.1590/S0103-21002013000200008; Lima REF, 2009, REV LAT-AM ENFERM, V17, P222, DOI 10.1590/S0104-11692009000200013; Hammes Jean André, 2008, Rev. bras. ter. intensiva, V20, P349, DOI 10.1590/S0103-507X2008000400006; Hansten PD, 2003, PHARM WORLD SCI, V25, P94, DOI 10.1023/A:1024077018902; Kohn L., 2000, ERR IS HUMAN BUILDIN; Lopez JM, METABOLISMO FARMACOS; MCFARLAND H, [No title captured]; Mohamed Mahmoud Abd El Samia, 2013, ADV PHARMACOEPIDEMIO, V2, P144, DOI DOI 10.4172/2167-1052.1000144; Reis AMM, 2011, CLINICS, V66, P9, DOI 10.1590/S1807-59322011000100003; Pirmohamed M, 2004, BMJ-BRIT MED J, V329, P15, DOI 10.1136/bmj.329.7456.15; Plaza J, 2010, REV MED CHILE, V138, P452, DOI [10.4067/S0034-98872010000400009, /S0034-98872010000400009]; Pouyanne P, 2000, BRIT MED J, V320, P1036, DOI 10.1136/bmj.320.7241.1036; Riker RR, 2009, CRIT CARE CLIN, V25, P527, DOI 10.1016/j.ccc.2009.05.004; Rivkin A, 2011, J CRIT CARE, V26, DOI 10.1016/j.jcrc.2010.04.014; Rodrigues DA, 2008, DRUG DRUG INTERACTIO, P768; Schweickert WD, 2008, CRIT CARE, V12, DOI 10.1186/cc6151; Smithburger Pamela L, 2012, Int J Pharm Pract, V20, P402, DOI 10.1111/j.2042-7174.2012.00221.x	27	1	2	0	2	INST NACIONAL SALUD	BOGOTA D C	AVENIDA CALLE 26 NO 51-60, APARTADO AEREO 80334 Y 80080, BOGOTA D C, 00000, COLOMBIA	0120-4157			BIOMEDICA	Biomedica	SEP	2018	38	3					407	416		10.7705/biomedica.v38i4.3884			10	Tropical Medicine	Tropical Medicine	GZ5JD	WOS:000449454300014	30335246	DOAJ Gold			2020-06-30	J	Tupper, KW; McCrae, K; Garber, I; Lysyshyn, M; Wood, E				Tupper, Kenneth W.; McCrae, Karen; Garber, Ian; Lysyshyn, Mark; Wood, Evan			Initial results of a drug checking pilot program to detect fentanyl adulteration in a Canadian setting	DRUG AND ALCOHOL DEPENDENCE			English	Article						Drug checking; Fentanyl; Opioid; Overdose; Harm reduction; Public health	SERVICES	Background: Opioid overdose deaths in North America have been rising largely as a result of fentanyl adulteration in the illegal drug supply. Drug checking is an established harm reduction intervention in some European settings but has not been broadly implemented or evaluated in North America. We are evaluating a pilot program offering drug checking for people who use street drugs in Vancouver, British Columbia. Methods: Drug checking services were implemented at two locations in Vancouver between November 2017 and April 2018 using a Fourier transform infrared (FTIR) spectrometer and fentanyl immunoassay strips. We report on the findings generated by this technological combination during the study period. Results: During the study period, a total of 1714 samples were tested. Of 907 samples expected to be heroin, only 160 (17.6%) contained the expected substance, and 822 (90.6%) tested positive for fentanyl. Of 256 samples expected to be speed or crystal meth, 225 (87.9%) contained amphetamine or methamphetamine, and 15 (5.9%) tested positive for fentanyl. The FTIR also found unexpected and potentially dangerous substances and adulterants other than fentanyl. Conclusions: This pilot program has demonstrated the feasibility of drug checking for identifying individual drug samples containing unexpected or hazardous substances, including fentanyl. By identifying the range of adulterants and diluents and giving an estimate of their prevalence in different drug types, it has also provided information about the composition of the illicit drug supply in an urban North American setting.	[Tupper, Kenneth W.; McCrae, Karen; Garber, Ian; Wood, Evan] British Columbia Ctr Subst Use, 400-1045 Howe St, Vancouver, BC V6Z 2A9, Canada; [Tupper, Kenneth W.; Lysyshyn, Mark] Univ British Columbia, Sch Populat & Publ Hlth, 2206 E Mall, Vancouver, BC V6T 1Z3, Canada; [Lysyshyn, Mark] Vancouver Coastal Hlth Author, 5th Floor,132 West Esplanade, N Vancouver, BC V7M 1A2, Canada; [Wood, Evan] Univ British Columbia, Dept Med, 2775 Laurel St,10th Floor, Vancouver, BC V5Z 1M9, Canada	Tupper, KW (reprint author), British Columbia Ctr Subst Use, 400-1045 Howe St, Vancouver, BC V6Z 2A9, Canada.	kenneth.tupper@bccsu.ubc.ca		Lysyshyn, Mark/0000-0001-6684-2030	City of Vancouver; BC Ministry of Health; BC Ministry of Mental Health and Addictions; Health Canada; Vancouver Coastal Health; Canada Research Chairs program through a Tier 1 Canada Research Chair in Inner City MedicineCanada Research Chairs	This pilot program was supported by the City of Vancouver, the BC Ministry of Health, the BC Ministry of Mental Health and Addictions, Health Canada, and Vancouver Coastal Health. This research was undertaken, in part, thanks to funding from the Canada Research Chairs program through a Tier 1 Canada Research Chair in Inner City Medicine, which supports Dr. Evan Wood.	British Columbia Coroners Service, 2018, ILL DRUG OV DEATHS B; British Columbia Coroners Service, 2018, FENT DET ILL DRUG OV; Fischer B, 2018, PREV MED, V107, P109, DOI 10.1016/j.ypmed.2017.11.001; Frank RG, 2017, NEW ENGL J MED, V376, P605, DOI 10.1056/NEJMp1615145; Green TC, 2016, JAMA INTERN MED, V176, P1555, DOI 10.1001/jamainternmed.2016.4310; Kennedy MC, 2018, DRUG ALCOHOL DEPEN, V185, P248, DOI 10.1016/j.drugalcdep.2017.12.026; Kerr T, 2017, DRUG CHECKING HARM R; Lysyshyn M, 2017, HARM RED 2017 MONTR; McGowan CR, 2018, INT J DRUG POLICY, V58, P31, DOI 10.1016/j.drugpo.2018.04.017; O'Donnell JK, 2017, MMWR-MORBID MORTAL W, V66, P1197, DOI 10.15585/mmwr.mm6643e1; Quintana P, 2017, INT J DRUG POLICY, V40, P78, DOI 10.1016/j.drugpo.2016.10.006; Sherman SG, 2018, FORECAST STUDY SUMMA; Somerville NJ, 2017, MMWR-MORBID MORTAL W, V66, P382, DOI 10.15585/mmwr.mm6614a2; Special Advisory Committee on the Epidemic of Opioid Overdoses, 2018, NAT REP APP OP REL D; Gine CV, 2017, INT J DRUG POLICY, V45, P46, DOI 10.1016/j.drugpo.2017.05.018	15	42	41	3	9	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0376-8716	1879-0046		DRUG ALCOHOL DEPEN	Drug Alcohol Depend.	SEP 1	2018	190						242	245		10.1016/j.drugalcdep.2018.06.020			4	Substance Abuse; Psychiatry	Substance Abuse; Psychiatry	GU3IG	WOS:000445169200036	30064061				2020-06-30	J	Moody, MT; Diaz, S; Shah, P; Papsun, D; Logan, BK				Moody, Marykathryn Tynon; Diaz, Stephanie; Shah, Parul; Papsun, Donna; Logan, Barry K.			Analysis of fentanyl analogs and novel synthetic opioids in blood, serum/plasma, and urine in forensic casework	DRUG TESTING AND ANALYSIS			English	Article						Designer opioids; forensic toxicology; liquid chromatography-mass spectrometry	IDENTIFICATION; FLORIDA	In recent years an increasing number of novel opioids have appeared on the illicit drug market and have been linked to the growing opioid crisis in the United States. It is suspected that synthetic-opioid-related deaths are underestimated since many laboratories either use a screening method that is not specific and sensitive enough for these compounds or testing is not performed for fentanyl and its related analogs in general. We describe a method for the analysis of 19 of the most current novel opioid drugs quantitatively in whole blood and serum, and 17 analytes qualitatively in urine using solid phase extraction with liquid chromatography-tandem mass spectrometry (LC-MS/MS). The limit of detection was determined to be at a minimum 0.25 ng/mL for beta-hydroxythiofentanyl, 0.05 ng/mL for butyryl/isobutyrylfentanyl, AH-7921, 2-furanylfentanyl, 4-ANPP, and U-47700; 0.025 ng/mL for MT-45, paramethoxybutyrylfentanyl, 4-methylphenethyl acetyl fentanyl, U-50488, acrylfentanyl, valerylfentanyl, and carfentanil; and 0.0125 ng/ml. for para-fluorofentanyl, orthofluorofentanyl, para-fluorobutyrylfentanyl/FIBF, and alpha-methylfentanyl. The lower limit of quantitation was determined to be 0.1 ng/mL for all analytes except AH-7921, U-47700, U-50488 which were 0.05 ng/mL and beta-hydroxythiofentanyl which was 0.5 ng/mL. The method was validated successfully according to a Scientific Working Group in Forensic Toxicology (SWGTOX) compliant approach. This method was applied to the analysis of 2758 samples between October 2016 and September 2017. It was determined that 4-ANPP, furanylfentanyl, and carfentanil were the 3 most prevalent fentanyl related compounds detected: 56.1% of cases were positive for 4-ANPP, 44.5% were positive for furanylfentanyl, and 25.2% cases were positive for carfentanil.	[Moody, Marykathryn Tynon; Diaz, Stephanie; Shah, Parul; Papsun, Donna; Logan, Barry K.] NMS Labs, 3701 Welsh Rd, Willow Grove, PA 19090 USA	Moody, MT (reprint author), NMS Labs, 3701 Welsh Rd, Willow Grove, PA 19090 USA.	marykathryn.moody@nmslabs.com		Moody, Marykathryn/0000-0001-8923-6287			[Anonymous], 2013, J ANAL TOXICOL, V37, P452, DOI 10.1093/jat/bkt054; Centers for Disease Control and Prevention National Center for Health Statistics, PROV COUNTS DRUG OV; DEA, 2016, COUNT PRESCR PILLS C; Drug Enforcement Administration (DEA), DIV CONTR DIV CONTR; GOROMARU T, 1984, ANESTHESIOLOGY, V61, P73, DOI 10.1097/00000542-198461010-00013; Guerrieri D, 2017, J ANAL TOXICOL, V41, P242, DOI 10.1093/jat/bkw129; Hall TG, 2012, IDENTIFYING OVERCOMI; Helland A, 2017, J ANAL TOXICOL, V41, P708, DOI 10.1093/jat/bkx050; Lee D, 2016, J ANAL TOXICOL, V40, P588, DOI 10.1093/jat/bkw087; Logan BK, 2017, J ANAL TOXICOL, V41, P573, DOI 10.1093/jat/bkx031; McIntyre IM, 2016, J ANAL TOXICOL, V40, P162, DOI 10.1093/jat/bkv138; Mohr ALA, 2016, J ANAL TOXICOL, V40, P709, DOI 10.1093/jat/bkw086; National Forensic Laboratory Information System (NFLIS), NFLIS BRIEF FENT REL; National Forensic Laboratory Information System (NFLIS), ANN REP 2007 2016; National Institute on Drug Abuse, FENT; O'Donnell JK, 2017, MMWR-MORBID MORTAL W, V66, P1197, DOI 10.15585/mmwr.mm6643e1; Papsun Donna, 2017, Acad Forensic Pathol, V7, P477, DOI 10.23907/2017.040; Papsun D, 2016, J ANAL TOXICOL, V40, P313, DOI 10.1093/jat/bkw012; Peterson AB, 2016, MMWR-MORBID MORTAL W, V65, P844, DOI 10.15585/mmwr.mm6533a3; Prekupec MP, 2017, J ADDICT MED, V11, P256, DOI 10.1097/ADM.0000000000000324; Ruan XL, 2016, FORENSIC SCI MED PAT, V12, P363, DOI 10.1007/s12024-016-9789-6; SCHNEIDER E, 1986, N-S ARCH PHARMACOL, V334, P267, DOI 10.1007/BF00508781; Shanks KG, 2017, J ANAL TOXICOL, V41, P466, DOI 10.1093/jat/bkx042; Sofalvi S, 2017, J ANAL TOXICOL, V41, P473, DOI 10.1093/jat/bkx052; Stogner JM, 2014, ANN EMERG MED, V64, P637, DOI 10.1016/j.annemergmed.2014.07.017; Swanson DM, 2017, J ANAL TOXICOL, V41, P498, DOI 10.1093/jat/bkx037; United Nations Office on Drugs and Crime, FENT ITS AN 50 YEARS	27	17	17	10	37	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1942-7603	1942-7611		DRUG TEST ANAL	Drug Test. Anal.	SEP	2018	10	9					1358	1367		10.1002/dta.2393			10	Biochemical Research Methods; Chemistry, Analytical; Pharmacology & Pharmacy	Biochemistry & Molecular Biology; Chemistry; Pharmacology & Pharmacy	GU5MJ	WOS:000445329400002	29633785				2020-06-30	J	Mardal, M; Johansen, SS; Davidsen, AB; Telving, R; Jornil, JR; Dalsgaard, PW; Hasselstrom, JB; Oiestad, AM; Linnet, K; Andreasen, MF				Mardal, M.; Johansen, S. S.; Davidsen, A. B.; Telving, R.; Jornil, J. R.; Dalsgaard, P. W.; Hasselstrom, J. B.; Oiestad, A. M.; Linnet, K.; Andreasen, M. F.			Postmortem analysis of three methoxyacetylfentanyl-related deaths in Denmark and in vitro metabolite profiling in pooled human hepatocytes	FORENSIC SCIENCE INTERNATIONAL			English	Article						Fentanyl analogue; Methoxyacetylfentanyl; Metabolism; LC-HR-MS/MS; Hepatocytes; Postmortem	SYNTHETIC OPIOIDS; FENTANYL; OCFENTANIL; BLOOD; IDENTIFICATION; ACRYLFENTANYL; ANESTHESIA; FATALITY; SAMPLES; ANALOGS	Methoxyacetylfentanyl belongs to the group of fentanyl analogues and has been associated with several deaths in recent years. We present three case reports of deceased individuals that tested positive for methoxyacetylfentanyl consumption, as well as in vitro and in vivo metabolite profiles. Methoxyacetylfentanyl was quantified by ultra-high performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS) in femoral blood, as well as in urine and brain tissue when these were available. Metabolite profiling was performed by incubating methoxyacetylfentanyl with pooled human hepatocytes (pHH) in Leibovitz's L-15 medium supplemented with fetal bovine serum. Metabolites were identified in vivo and in vitro using UHPLC-high resolution (HR)-MS/MS. The measured methoxyacetylfentanyl concentration was 0.022-0.056 mg/kg (N = 3) in femoral blood, 0.12 mg/kg (N = 1) in urine, and 0.074 mg/kg (N = 1) in brain tissue homogenate. A total of 10 metabolites were identified. The observed metabolic pathways were: hydroxylation(s), N-dealkylation, O-demethylation, deamination, glucuronidation, and combinations thereof. Major analytical targets in vitro and across measured biological samples in vivo were methoxyacetylfentanyl, the O-demethyl- metabolite, and the deamide-metabolite. Intoxication with methoxyacetylfentanyl was judged as the cause of death or a major contributing factor in all three presented cases. (C) 2018 Elsevier B.V. All rights reserved.	[Mardal, M.; Johansen, S. S.; Davidsen, A. B.; Dalsgaard, P. W.; Linnet, K.] Univ Copenhagen, Sect Forens Chem, Dept Forens Med, Copenhagen, Denmark; [Telving, R.; Jornil, J. R.; Hasselstrom, J. B.; Andreasen, M. F.] Aarhus Univ, Sect Forens Chem, Dept Forens Med, Aarhus, Denmark; [Oiestad, A. M.] Oslo Univ Hosp, Sect Forens Toxicol Anal, Dept Forens Sci, Oslo, Norway	Mardal, M (reprint author), Univ Copenhagen, Sect Forens Chem, Dept Forens Med, Copenhagen, Denmark.	marie.mardal@sund.ku.dk		Davidsen, Anders Bork/0000-0003-0568-0861; Oiestad, Ase Marit Leere/0000-0001-7909-5863; Linnet, Kristian/0000-0001-6974-5535; Dalsgaard, Petur/0000-0002-8967-7477; Johansen, Sys Stybe/0000-0002-9555-5134; Hasselstrom, Jorgen Bo/0000-0002-5928-9238; Andreasen, Mette Findal/0000-0001-9702-1673; Mardal, Marie/0000-0002-3203-7305			ADAMS AP, 1978, BRIT MED J, V1, P278, DOI 10.1136/bmj.1.6108.278; Allibe N., 2017, DRUG TEST ANAL; Bergh M. S., 2018, THER DRUG MONIT; Butler DC, 2018, J ANAL TOXICOL, V42, pE6, DOI 10.1093/jat/bkx083; Coopman V, 2016, FORENSIC SCI INT, V266, P469, DOI 10.1016/j.forsciint.2016.07.005; Dussy FE, 2016, J ANAL TOXICOL, V40, P761, DOI 10.1093/jat/bkw096; Europol, 2018, EMCDDA EUR JOINT REP; Fabritius M, 2012, FORENSIC SCI INT, V223, P114, DOI 10.1016/j.forsciint.2012.08.013; FLETCHER JE, 1991, ANESTH ANALG, V73, P622; Fogarty MF, 2018, J ANAL TOXICOL, V42, P592, DOI 10.1093/jat/bky035; GOROMARU T, 1984, ANESTHESIOLOGY, V61, P73, DOI 10.1097/00000542-198461010-00013; Helander A, 2018, DRUG TEST ANAL, V10, P1297, DOI 10.1002/dta.2382; Marchei E, 2018, TRAC-TREND ANAL CHEM, V102, P1, DOI 10.1016/j.trac.2018.01.007; Matuszewski BK, 2003, ANAL CHEM, V75, P3019, DOI 10.1021/ac020361s; Nielsen MKK, 2018, DRUG TEST ANAL, V10, P1147, DOI 10.1002/dta.2359; Noble C, 2018, DRUG TEST ANAL, V10, P651, DOI 10.1002/dta.2263; Pichini S, 2018, THER DRUG MONIT, V40, P38, DOI 10.1097/FTD.0000000000000465; Skov L, 2015, J ANAL TOXICOL, V39, P557, DOI 10.1093/jat/bkv072; Sorensen L. K., 2013, ANAL METHODS, V5, P9; Telving R, 2016, FORENSIC SCI INT, V266, P453, DOI 10.1016/j.forsciint.2016.07.004; Watanabe S, 2017, AAPS J, V19, P1102, DOI 10.1208/s12248-017-0070-z	21	9	9	1	8	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0379-0738	1872-6283		FORENSIC SCI INT	Forensic Sci.Int.	SEP	2018	290						310	317		10.1016/j.forsciint.2018.07.020			8	Medicine, Legal	Legal Medicine	GS2EX	WOS:000443355600045	30107329				2020-06-30	J	Tiscione, NB; Alford, I				Tiscione, Nicholas B.; Alford, Ilene			Carfentanil in Impaired Driving Cases and the Importance of Drug Seizure Data	JOURNAL OF ANALYTICAL TOXICOLOGY			English	Article							SIMULTANEOUS FLAME-IONIZATION; HEADSPACE GAS-CHROMATOGRAPHY; MASS-SPECTROMETRY; WHOLE-BLOOD; PHARMACOKINETICS; NALTREXONE	Drug seizures containing carfentanil continue to increase in Palm Beach County, FL, USA despite international efforts to control the distribution of the drug. The analysis of drug seizures from the county in 2016 and 2017 demonstrated that carfentanil was the most commonly identified fentanyl analog and was most often detected in combination with heroin, fentanyl, furanyl fentanyl and/or other fentanyl analogs. Carfentanil is an ultra-potent opioid requiring a method with adequate sensitivity for detection in blood specimens from impairment cases. Previous research indicated that carfentanil could not be identified in biological specimens by routine drug testing protocols and that detection requires targeted analysis with greater sensitivity. Due to the prevalence of carfentanil in drug seizures, a sensitive targeted qualitative method by liquid chromatography tandem mass spectrometry in antemortem blood samples was evaluated, validated and implemented. The method included identification of carfentanil, acetyl fentanyl, beta-hydroxythiofentanyl, butyryl fentanyl, fentanyl, furanyl fentanyl, kavain, mitragynine, MT-45 and U-47700. In 2017 carfentanil was the second most frequently detected drug, after ethanol, in driving under the influence blood cases. Of all blood cases in which drug testing was performed (n = 145), carfentanil was detected in 38% followed by alprazolam (29%), fentanyl (27%), delta-9-tetrahydrocannabinol (24%) and morphine (23%). In toxicology cases carfentanil was rarely identified alone (only four cases) and was most commonly identified with other opioids (73% of cases), benzodiazepines (43%) and stimulants (29%). The high incidence of carfentanil-positive cases detected by this method underscores the importance of continually monitoring regional drug seizure trends, and evaluating the adequacy of toxicology testing panels based on these trends.	[Tiscione, Nicholas B.; Alford, Ilene] Palm Beach Cty Sheriffs Off, 3228 Gun Club Rd, W Palm Beach, FL 33406 USA	Tiscione, NB (reprint author), Palm Beach Cty Sheriffs Off, 3228 Gun Club Rd, W Palm Beach, FL 33406 USA.	TiscioneN@pbso.org			Palm Beach County Sheriff's Office	The authors would like to thank Dustin Tate Yeatman and Dr Cecelia Crouse for their helpful review of this manuscript and the Palm Beach County Sheriff's Office for supporting this work.	[Anonymous], 2013, J ANAL TOXICOL, V37, P452, DOI 10.1093/jat/bkt054; [Anonymous], 2017, CHINA ANNOUNCES SCHE; [Anonymous], 2018, PALM BEACH COUNTY FI; [Anonymous], 2016, DRUGS IDENTIFIED DEC; [Anonymous], 2016, CHINA FIRMS HAPPY SE; Berning A., 2015, 812118 DOT HS; Capozzi J., 2017, OPIOID OVERDOSE DEAT; Cole A, 2006, J ZOO WILDLIFE MED, V37, P318, DOI 10.1638/05-070.1; Feasel MG, 2016, AAPS J, V18, P1489, DOI 10.1208/s12248-016-9963-5; Frankel T. C., 2016, SURPRISING DISAPPEAR; George AV, 2010, AM J EMERG MED, V28, P530, DOI 10.1016/j.ajem.2010.03.003; Minkowski CP, 2012, ADDICT BIOL, V17, P149, DOI 10.1111/j.1369-1600.2010.00256.x; Mol HGJ, 2012, DRUG TEST ANAL, V4, P10, DOI 10.1002/dta.1364; Muller S, 2018, CLIN TOXICOL, V56, P151, DOI 10.1080/15563650.2017.1355464; Mutlow A, 2004, J ZOO WILDLIFE MED, V35, P489, DOI 10.1638/03-074; National Center for Statistics and Analysis, 2017, 812450 DOT HS NAT CT; Papsun D, 2017, J ANAL TOXICOL, V41, P777, DOI 10.1093/jat/bkx068; Seither J, 2017, J ANAL TOXICOL, V41, P493, DOI 10.1093/jat/bkx049; Shanks KG, 2017, J ANAL TOXICOL, V41, P466, DOI 10.1093/jat/bkx042; Shoff EN, 2017, J ANAL TOXICOL, V41, P484, DOI 10.1093/jat/bkx041; Sofalvi S, 2017, J ANAL TOXICOL, V41, P473, DOI 10.1093/jat/bkx052; Swanson DM, 2017, J ANAL TOXICOL, V41, P498, DOI 10.1093/jat/bkx037; Tiscione N.B., 2016, TOXTALK, V40, P14; Tiscione NB, 2017, J ANAL TOXICOL, V41, P530, DOI 10.1093/jat/bkx038; Tiscione NB, 2016, J ANAL TOXICOL, V40, P639, DOI 10.1093/jat/bkw063; Tiscione NB, 2013, J ANAL TOXICOL, V37, P573, DOI 10.1093/jat/bkt072; Tiscione NB, 2011, J ANAL TOXICOL, V35, P501, DOI 10.1093/anatox/35.7.501; Tynon M, 2017, DRUG TEST ANAL, V9, P924, DOI 10.1002/dta.2096	28	9	9	3	8	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0146-4760	1945-2403		J ANAL TOXICOL	J. Anal. Toxicol.	SEP	2018	42	7					476	484		10.1093/jat/bky026			9	Chemistry, Analytical; Toxicology	Chemistry; Toxicology	GS3SY	WOS:000443543400007	29659874	Bronze			2020-06-30	J	Fenster, DB; Dayan, PS; Babineau, J; Aponte-Patel, L; Tsze, DS				Fenster, Daniel B.; Dayan, Peter S.; Babineau, John; Aponte-Patel, Linda; Tsze, Daniel S.			Randomized Trial of Intranasal Fentanyl Versus Intravenous Morphine for Abscess Incision and Drainage	PEDIATRIC EMERGENCY CARE			English	Article						abscess; analgesia; incision and drainage; intranasal fentanyl; procedural pain	PEDIATRIC EMERGENCY-DEPARTMENT; MEASURING CHILDRENS DISTRESS; PROCEDURAL-SEDATION; KETAMINE SEDATION; LACERATION REPAIR; PAIN; KETAMINE/MIDAZOLAM; ANALGESIA; PATIENT; MIDAZOLAM	Objectives Abscess incision and drainage (I&D) are painful and distressing procedures in children. Intranasal (IN) fentanyl is an effective analgesic for reducing symptomatic pain associated with fractures and burns but has not been studied for reducing procedural pain during abscess I&D. Our objective was to compare the analgesic efficacy of IN fentanyl with intravenous (IV) morphine for abscess I&D in children. Methods We performed a randomized noninferiority trial in children aged 4 to 18 years undergoing abscess I&D in a pediatric emergency department. Patients received IN fentanyl (2 g/kg; maximum, 100 g) or IV morphine (0.1 mg/kg; maximum, 8 mg). The primary outcome, determined independently by blinded assessors, was the Observational Scale of Behavioral Distress-Revised (OSBD-R). The prestated margin of noninferiority () was 1.80. Secondary outcomes included self-reported pain, treatment failure, and patient and parental satisfaction. Results We enrolled 20 children (median age, 15.4 years), 10 in each group. The difference between total OSBD-R scores was -13.45 (95% confidence interval, -24.24 to -2.67), favoring IN fentanyl. There was less self-reported pain in patients who received IN fentanyl immediately after the procedure. Four patients (40%) receiving IV morphine had treatment failures and required moderate sedation or had the procedure terminated. More patients who received IN fentanyl were satisfied with the analgesic administered compared with those who received IV morphine. Conclusions In a small sample of children aged 4 to 18 years undergoing abscess I&D, IN fentanyl was noninferior, and potentially superior, to IV morphine for reducing procedural pain and distress.	[Fenster, Daniel B.; Dayan, Peter S.; Babineau, John; Aponte-Patel, Linda; Tsze, Daniel S.] Columbia Univ Coll Phys & Surg, Dept Pediat, New York, NY 10032 USA	Fenster, DB (reprint author), Div Pediat Emergency Med, 3959 Broadway,CHN 116, New York, NY 10032 USA.	dbf2114@cumc.columbia.edu		Tsze, Daniel/0000-0002-7567-8743			Bendall JC, 2011, PREHOSP EMERG CARE, V15, P158, DOI 10.3109/10903127.2010.541980; Borland M, 2007, ANN EMERG MED, V49, P335, DOI 10.1016/j.annemergmed.2006.06.016; Borland Meredith L, 2002, Emerg Med (Fremantle), V14, P275, DOI 10.1046/j.1442-2026.2002.00344.x; Cohen LL, 2008, J PEDIATR PSYCHOL, V33, P939, DOI 10.1093/jpepsy/jsm103; Cole J, 2009, EMERG MED AUSTRALAS, V21, P395, DOI 10.1111/j.1742-6723.2009.01216.x; Constantine E, 2014, PEDIATR EMERG CARE, V30, P474, DOI 10.1097/PEC.0000000000000164; Cummings EA, 1996, PAIN, V68, P25, DOI 10.1016/S0304-3959(96)03163-6; ELLIOTT CH, 1987, J PEDIATR PSYCHOL, V12, P543, DOI 10.1093/jpepsy/12.4.543; Enders CK, 2010, APPL MISSING DATA AN; Finn M, 2010, EMERG MED J, V27, P300, DOI 10.1136/emj.2008.070474; Gelman A, 2006, DATA ANAL USING REGR; Godambe SA, 2003, PEDIATRICS, V112, P116, DOI 10.1542/peds.112.1.116; Green SM, 2009, ANN EMERG MED, V54, P158, DOI 10.1016/j.annemergmed.2008.12.011; Hicks CL, 2001, PAIN, V93, P173, DOI 10.1016/S0304-3959(01)00314-1; Hippard HK, 2012, ANESTH ANALG, V115, P356, DOI 10.1213/ANE.0b013e31825afef3; JAY SM, 1984, J CONSULT CLIN PSYCH, V52, P1106, DOI 10.1037/0022-006X.52.6.1106; JAY SM, 1983, [No title captured], V2, P133, DOI DOI 10.1037/0278-6133.2.2.133; Kennedy RM, 1998, PEDIATRICS, V102, P956, DOI 10.1542/peds.102.4.956; Korownyk C, 2007, CAN FAM PHYSICIAN, V53, P1680; Lawrence LM, 1998, PEDIATR EMERG CARE, V14, P393, DOI 10.1097/00006565-199812000-00003; Lee-Jayaram JJ, 2010, PEDIATR EMERG CARE, V26, P408, DOI 10.1097/PEC.0b013e3181e057cd; Luhmann JD, 2001, ANN EMERG MED, V37, P20, DOI 10.1067/mem.2001.112003; Rickard C, 2007, AM J EMERG MED, V25, P911, DOI 10.1016/j.ajem.2007.02.027; Saunders M, 2010, ACAD EMERG MED, V17, P1155, DOI 10.1111/j.1553-2712.2010.00905.x; Singer AJ, 1999, ANN EMERG MED, V33, P652, DOI 10.1016/S0196-0644(99)70194-0; Stevenson MD, 2005, PEDIATR EMERG CARE, V21, P712, DOI 10.1097/01.pec.0000186423.84764.5a; Uspal NG, 2013, AM J EMERG MED, V31, P302, DOI 10.1016/j.ajem.2012.07.028; Wathen JE, 2000, ANN EMERG MED, V36, P579, DOI 10.1067/mem.2000.111131; Younge P, 1999, EMERGEN MED, V11, P90	29	2	2	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0749-5161	1535-1815		PEDIATR EMERG CARE	Pediatr. Emerg. Care	SEP	2018	34	9					607	612		10.1097/PEC.0000000000000810			6	Emergency Medicine; Pediatrics	Emergency Medicine; Pediatrics	GT5MN	WOS:000444553200009	27387971				2020-06-30	J	Haacker, L; Maliekel, M; Bardsley, CEH; Bergren, R; Meresh, E; Halaris, A				Haacker, Lindsay; Maliekel, MaryJo; Bardsley, Christina E. Hantsch; Bergren, Ryan; Meresh, Edwin; Halaris, Angelos			Serotonin Syndrome Following Septal Myectomy in Association With Fentanyl and Methylene Blue: A Case Report	PSYCHOSOMATICS			English	Article							OLANZAPINE; DIAGNOSIS; TOXICITY		[Haacker, Lindsay] Loyola Univ, Stritch Sch Med, 2160 S 1st Ave, Maywood, IL 60153 USA; [Maliekel, MaryJo] Loyola Univ Chicago, Stritch Sch Med, Maywood, IL 60153 USA; [Bardsley, Christina E. Hantsch] Loyola Univ, Med Ctr, Dept Emergency Med, 2160 S 1st Ave, Maywood, IL 60153 USA; [Bergren, Ryan; Meresh, Edwin; Halaris, Angelos] Loyola Univ, Med Ctr, Dept Psychiat, 2160 S 1st Ave, Maywood, IL 60153 USA	Halaris, A (reprint author), Loyola Univ Chicago, Stritch Sch Med, Fahey Ctr, 2160 S 1st Ave,Bldg 54 Rm 222, Maywood, IL 60153 USA.	ahalaris@lumc.edu			NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [T35 HL120835]		Ables AZ, 2010, AM FAM PHYSICIAN, V81, P1139; Ailawadhi S, 2007, J CLIN PHARM THER, V32, P199, DOI 10.1111/j.1365-2710.2007.00813.x; Boddy R, 2004, J TOXICOL-CLIN TOXIC, V42, P725; Boyer EW, 2005, NEW ENGL J MED, V352, P1112, DOI 10.1056/NEJMra041867; Dunkley EJC, 2003, QJM-INT J MED, V96, P635, DOI 10.1093/qjmed/hcg109; Dvir Y, 2008, GEN HOSP PSYCHIAT, V30, P284, DOI 10.1016/j.genhosppsych.2007.09.007; Francescangeli J, 2016, AM J CASE REP, V17, P347, DOI 10.12659/AJCR.897671; Gillman PK, 2010, PSYCHOSOMATICS, V51, P448, DOI 10.1176/appi.psy.51.5.448; Haslett CD, 2002, PSYCHIAT CLIN NEUROS, V56, P533, DOI 10.1046/j.1440-1819.2002.01050.x; Kapadia K, 2016, UROL CASE REP, V9, P15, DOI 10.1016/j.eucr.2016.07.012; Koury KM, 2015, PAIN PHYSICIAN, V18, pE27; Lonergan E, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005594.pub2; Ng BKW, 2010, PSYCHOSOMATICS, V51, P194, DOI 10.1176/appi.psy.51.3.194; Preskorn SH, 1997, CLIN PHARMACOKINET, V32, P1, DOI 10.2165/00003088-199700321-00003; Schumacher LED, 2017, J THORAC CARDIOV SUR, V154, pE39, DOI 10.1016/j.jtcvs.2017.05.053; Shanmugam Ganesh, 2008, Interact Cardiovasc Thorac Surg, V7, P656, DOI 10.1510/icvts.2007.173104; Smith PJ, 2016, AM J GERIAT PSYCHIAT, V24, P232, DOI 10.1016/j.jagp.2015.12.004; Verre M, 2008, MINERVA ANESTESIOL, V74, P41; Wang RZ, 2016, CLEV CLIN J MED, V83, P810, DOI 10.3949/ccjm.83a.15129	19	2	2	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0033-3182			PSYCHOSOMATICS	Psychosomatics	SEP-OCT	2018	59	5					512	516		10.1016/j.psym.2018.02.001			5	Psychiatry; Psychology	Psychiatry; Psychology	GY1YM	WOS:000448333400010	29571985				2020-06-30	J	Zhang, Q; Murawsky, M; LaCount, T; Kasting, GB; Li, SK				Zhang, Qian; Murawsky, Michael; LaCount, Tern; Kasting, Gerald B.; Li, S. Kevin			Transepidermal water loss and skin conductance as barrier integrity tests	TOXICOLOGY IN VITRO			English	Article						Skin; Skin integrity test; Skin permeation; Transepidermal water loss (TEWL); Skin electrical resistance	HUMAN EPIDERMAL MEMBRANE; LOW-FREQUENCY SONOPHORESIS; IN-VITRO PERMEATION; IONTOPHORETIC TRANSPORT; ELECTRICAL-RESISTANCE; DERMAL ABSORPTION; STRATUM-CORNEUM; DELIVERY; PERMEABILITY; OLIGONUCLEOTIDES	In vitro skin permeation studies are commonly used in the risk assessment of toxic compound skin exposure. The present study examined the utility of transepidermal water loss (TEWL) and electrical conductance as barrier integrity tests before skin permeation studies in vitro using a large number of skin samples and fentanyl. TEWL and conductance of the skin samples were measured before the permeation experiments in Franz diffusion cells in vitro with a vapometer and low voltage application, respectively. The data were analyzed based on the in vitro permeation results and in vivo skin absorption information from the transdermal fentanyl product labels. The results showed poor correlations between TEWL and electrical conductance for the skin samples. Weak correlations between fentanyl delivery rate (flux x area) and TEWL and skin conductance were observed. For comparison, TEWL and conductance were also examined after skin perturbation with a syringe needle, and both TEWL and conductance values of the skin samples increased after the perturbation. The data suggest that either TEWL of 10 g/m(2)/h or skin conductance of 0.07 mS/cm(2) can be used as exclusion criteria in skin integrity testing to remove skin samples with high permeabilities under the in vitro conditions studied.	[Zhang, Qian; Murawsky, Michael; LaCount, Tern; Kasting, Gerald B.; Li, S. Kevin] Univ Cincinnati, Coll Pharm, Div Pharmaceut Sci, Cincinnati, OH 45267 USA	Li, SK (reprint author), Univ Cincinnati, Coll Pharm, 231 Albert Sabin Way,MSB 3005, Cincinnati, OH 45267 USA.	kevin.li@uc.edu	Li, S. Kevin/AAF-4877-2019	Li, S. Kevin/0000-0001-8626-9630	U.S. Food and Drug Administration (FDA) [U01 FD004942]	The authors thank Drs. Sam G Raney, Priyanka Ghosh, and Jinsong Hao for helpful discussion. Funding for this project was made possible, in part, by the U.S. Food and Drug Administration (FDA) through a cooperative agreement (Research Award U01 FD004942). The views expressed in this paper do not reflect the official policies of the Department of Health and Human Services; nor does any mention of trade names, commercial practices, or organization imply endorsement by the United States Government.	[Anonymous], 2009, TEST 1 6 ABG DER EB, P1; Bassani AS, 2016, PAIN MED, V17, P230, DOI 10.1111/pme.12899; Chantasart D, 2007, J PHARM SCI-US, V96, P2310, DOI 10.1002/jps.20865; Chantasart Doungdaw, 2012, Pharmaceutics, V4, P71, DOI 10.3390/pharmaceutics4010071; Charoenputtakun P, 2015, INT J PHARMACEUT, V495, P318, DOI 10.1016/j.ijpharm.2015.08.094; Chilcott RP, 2002, J INVEST DERMATOL, V118, P871, DOI 10.1046/j.1523-1747.2002.01760.x; Davies DJ, 2004, TOXICOL IN VITRO, V18, P351, DOI 10.1016/j.tiv.2003.10.004; Elkeeb R, 2010, SKIN RES TECHNOL, V16, P9, DOI 10.1111/j.1600-0846.2009.00406.x; EPA, 2012, EPI SUIT EST PRGR IN; Fasano WJ, 2002, TOXICOL IN VITRO, V16, P731, DOI 10.1016/S0887-2333(02)00084-X; FDA, 2016, DRAFT GUID AC GUID I; Flynn G.L., 1990, PRINCIPLES ROUTE TO, P93; Franz TJ, 2009, SKIN PHARMACOL PHYS, V22, P276, DOI 10.1159/000235828; Frasch HF, 2014, J EXPO SCI ENV EPID, V24, P65, DOI 10.1038/jes.2013.23; GRUBAUER G, 1989, J LIPID RES, V30, P89; Guth K, 2015, TOXICOL IN VITRO, V29, P113, DOI 10.1016/j.tiv.2014.09.007; Heylings JR, 2001, TOXICOL IN VITRO, V15, P597, DOI 10.1016/S0887-2333(01)00069-8; Hui XY, 2012, SKIN RES TECHNOL, V18, P108, DOI 10.1111/j.1600-0846.2011.00541.x; Ibrahim S. B. M., 2009, THESIS; Ibrahim SA, 2009, J CONTROL RELEASE, V136, P117, DOI 10.1016/j.jconrel.2009.01.023; Kopecna M, 2017, PHARM RES-DORDR, V34, P2097, DOI 10.1007/s11095-017-2214-3; Lehman PA, 2014, PHARM RES-DORDR, V31, P3529, DOI 10.1007/s11095-014-1439-7; Li SK, 2013, SKIN PHARMACOL PHYS, V26, P243, DOI 10.1159/000351926; Li SK, 2001, J PHARM SCI, V90, P915, DOI 10.1002/jps.1043; Li SK, 1999, J PHARM SCI-US, V88, P419, DOI 10.1021/js980331y; Li SK, 1998, INT J PHARMACEUT, V170, P93, DOI 10.1016/S0378-5173(98)00139-2; Li X, 2016, J PHARM SCI-US, V105, P1141, DOI 10.1016/S0022-3549(15)00173-2; Myer K, 2013, SKIN RES TECHNOL, V19, P213, DOI 10.1111/srt.12011; Netzlaff F, 2006, EUR J PHARM BIOPHARM, V63, P44, DOI 10.1016/j.ejpb.2005.10.009; Nicoli S, 2006, INT J PHARMACEUT, V325, P2, DOI 10.1016/j.ijpharm.2006.06.010; Olivier JC, 2003, INT J PHARM, V252, P133, DOI 10.1016/S0378-5173(02)00637-3; Roy SD, 1996, J PHARM SCI, V85, P491, DOI 10.1021/js950415w; Saadatmand M, 2017, SKIN RES TECHNOL, V23, P500, DOI 10.1111/srt.12362; SCHEUPLE.RJ, 1966, BIOPHYS J, V6, P1, DOI 10.1016/S0006-3495(66)86636-5; Song Y, 2002, INT J PHARM, V232, P45, DOI 10.1016/S0378-5173(01)00910-3; Tang H, 2001, J PHARM SCI, V90, P545, DOI 10.1002/1520-6017(200105)90:5<545::AID-JPS1012>3.0.CO;2-H; Tezel A, 2004, PHARM RES-DORDR, V21, P2219, DOI 10.1007/s11095-004-7674-6; White EA, 2013, PHARM RES-DORDR, V30, P2036, DOI 10.1007/s11095-013-1052-1; Xu QF, 2009, INT J PHARMACEUT, V369, P105, DOI 10.1016/j.ijpharm.2008.11.001; Zhang Q., 2017, THESIS	40	2	2	3	18	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0887-2333			TOXICOL IN VITRO	Toxicol. Vitro	SEP	2018	51						129	135		10.1016/j.tiv.2018.04.009			7	Toxicology	Toxicology	GL3XT	WOS:000437079000014	29698667	Green Accepted			2020-06-30	J	Setlur, A; Friedland, H				Setlur, Anuradha; Friedland, Howard			Treatment of pain with intranasal fentanyl in pediatric patients in an acute care setting: a systematic review	PAIN MANAGEMENT			English	Review						acute; analgesia; emergency; fentanyl; intranasal; pain; pediatrics	EMERGENCY-DEPARTMENT; CHILDREN; MANAGEMENT; ANALGESIA; RELIEF; MORPHINE; TRIAL; KETAMINE; QUALITY; OPIOIDS	Aim: The primary objective of this review is to provide an updated, comprehensive overview on the efficacy of intranasal fentanyl (INF) for acute pain relief in the pediatric population. Methods: Utilizing the Preferred Reporting Instructions for Systematic Reviews and Meta-Analyses (PRISMA), we were able to screen articles based on key words to reach a final number of 10 studies. Results: All but one study showed that INF was efficacious for pain relief in this select pediatric population. Conclusion: It is evident that INF is efficacious for analgesia, but other agents should also be considered in this patient population. As a result, further research is needed to investigate the clinically efficacy of INF in an acute care setting for pediatric patients.	[Setlur, Anuradha; Friedland, Howard] St Josephs Med Ctr, Dept Pediat, Paterson, NJ 07503 USA	Setlur, A (reprint author), St Josephs Med Ctr, Dept Pediat, Paterson, NJ 07503 USA.	Anuradha.setlur1@gmail.com					Adelgais KM, 2017, J EMERG MED, V53, P607, DOI 10.1016/j.jemermed.2017.05.027; Bendall JC, 2011, PREHOSP EMERG CARE, V15, P158, DOI 10.3109/10903127.2010.541980; Berde CB, 2002, NEW ENGL J MED, V347, P1094, DOI 10.1056/NEJMra012626; Bias Methods Group (BMG), 2018, COCHRANE METHODS BIA; Borland M, 2007, ANN EMERG MED, V49, P335, DOI 10.1016/j.annemergmed.2006.06.016; Borland Meredith L, 2002, Emerg Med (Fremantle), V14, P275, DOI 10.1046/j.1442-2026.2002.00344.x; Borland ML, 2008, EMERG MED AUSTRALAS, V20, P515, DOI 10.1111/j.1742-6723.2008.01138.x; Cole J, 2009, EMERG MED AUSTRALAS, V21, P395, DOI 10.1111/j.1742-6723.2009.01216.x; Dale O, 2002, ACTA ANAESTH SCAND, V46, P759, DOI 10.1034/j.1399-6576.2002.460702.x; Fein DM, 2017, PEDIATR BLOOD CANCER, V64, DOI 10.1002/pbc.26332; Fenster DB, 2016, PEDIATR EMERG CARE, V34, P607; Fleischman RJ, 2010, PREHOSP EMERG CARE, V14, P167, DOI 10.3109/10903120903572301; Galinski M, 2011, AM J EMERG MED, V29, P1062, DOI 10.1016/j.ajem.2010.06.031; Graudins A, 2015, ANN EMERG MED, V65, P248, DOI 10.1016/j.annemergmed.2014.09.024; Harlos MS, 2013, J PAIN SYMPTOM MANAG, V46, P265, DOI 10.1016/j.jpainsymman.2012.07.009; Hennes Halim, 2005, Prehosp Emerg Care, V9, P32, DOI 10.1080/10903120590891705; KAMATH B, 1990, BRIT J ANAESTH, V64, P728, DOI 10.1093/bja/64.6.728; Karlsen APH, 2014, ANN EMERG MED, V63, P699, DOI 10.1016/j.annemergmed.2013.10.025; Kavanagh PL, 2015, PEDIATRICS, V136, pE1016, DOI 10.1542/peds.2014-3470; Kelly G, 2018, AM J EMERG MED, V36, P1305, DOI 10.1016/j.ajem.2017.11.015; Lim S, 2003, J PHARM PRACT RES, V33, p59e63; Mathias MD, 2015, PEDIATRICS, V135, P475, DOI 10.1542/peds.2014-2874; Maurice SC, 2002, EMERG MED J, V19, P4, DOI 10.1136/emj.19.1.4; Mudd S, 2011, J PEDIATR HEALTH CAR, V25, P316, DOI 10.1016/j.pedhc.2010.04.011; Murphy A, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009942.pub2; Murphy AP, 2017, EUR J EMERG MED, V24, P450, DOI 10.1097/MEJ.0000000000000389; Pai A, 2007, BJA EDUC, V7, P59, DOI 10.1093/bjaceaccp/mkm008; Panagiotou I, 2010, EXPERT REV ANTICANC, V10, P1009, DOI [10.1586/era.10.77, 10.1586/ERA.10.77]; Prommer E, 2011, PATIENT PREFER ADHER, V5, P157, DOI 10.2147/PPA.S7665; Reynolds SL, 2017, ACAD EMERG MED, V24, P1430, DOI 10.1111/acem.13313; Reynolds SL, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-012190; Saunders M, 2010, ACAD EMERG MED, V17, P1155, DOI 10.1111/j.1553-2712.2010.00905.x; SCHECHTER NL, 1989, PEDIATR CLIN N AM, V36, P781; Schoolman-Anderson K, 2018, AM J EMERG MED; Shelley Katherine, 2008, Current Drug Delivery, V5, P55; Toussaint S, 2000, CAN J ANAESTH, V47, P299, DOI 10.1007/BF03020941; Ugwoke MI, 2001, J PHARM PHARMACOL, V53, P3, DOI 10.1211/0022357011775145; Vyas TK, CURR DRUG DELIV, V2, P165; Younge P, 1999, EMERGEN MED, V11, P90; Zempsky WT, 2010, J EMERG MED, V39, P691, DOI 10.1016/j.jemermed.2009.06.003; Zempsky WT, 2004, PEDIATRICS, V114, P1348, DOI 10.1542/peds.2004-1752	41	0	0	2	3	FUTURE MEDICINE LTD	LONDON	UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3 1QB, ENGLAND	1758-1869	1758-1877		PAIN MANAG	Pain Manag.	SEP	2018	8	5					341	352		10.2217/pmt-2018-0016			12	Clinical Neurology	Neurosciences & Neurology	GZ0ER	WOS:000449034000006	30278812				2020-06-30	J	Tse, AHW; Ling, L; Lee, A; Joynt, GM				Tse, Andrew H. W.; Ling, Lowell; Lee, Anna; Joynt, Gavin M.			Altered Pharmacokinetics in Prolonged Infusions of Sedatives and Analgesics Among Adult Critically Ill Patients: A Systematic Review	CLINICAL THERAPEUTICS			English	Review						analgesics; critical care; pharmacokinetics; sedatives; systematic review	INTENSIVE-CARE PATIENTS; LONG-TERM SEDATION; ICU PATIENTS; POPULATION PHARMACOKINETICS; CLINICAL PHARMACOKINETICS; MIDAZOLAM INFUSION; PROTEIN-BINDING; BLOOD-FLOW; PROPOFOL; LORAZEPAM	Purpose: The pharmacokinetic (PK) parameters of many drugs are altered as a consequence of the pathophysiological changes associated with critical illness. The critically ill population presents challenges when titrating infusions of sedatives and analgesics to maintain optimal sedation and pain levels. This systematic review examined the PK data in critically ill adult patients with prolonged infusions (>24 hours) of commonly used sedatives and analgesics to highlight possible altered PK parameters compared with noncritically ill patients. Methods: A literature search of PK studies was performed by using MEDLINE (1946 December 2017) and EMBASE (1910 December 2017); we identified further studies by citation tracking (Web of Science) and checked references of retrieved studies and review articles. All studies were included that were published in English, Chinese, or German; conducted in critically ill adult patients receiving lorazepam, midazolam, propofol, dexmedetomidine, sufentanil, alfentanil, remifentanil, morphine, or fentanyl infusion for >= 24 hours; and reported PK parameters. When appropriate, we conducted a meta-analysis on volume of distribution at steady state (V-dss) (liters), clearance (Cl) (liters per hour), and elimination t(1/2) (hours) by using a DerSimonian-Laird random effects model to estimate the summary mean and 95% CIs. Results were compared with commonly reported PK ranges in 70-kg noncritically ill patients. Findings: Thirty-three randomized controlled trials and prospective cohort studies were identified involving 1803 adult critically ill patients with 35 drug treatment arms: fifteen midazolam (n = 906) studies, three dexmedetomidine (n = 561), nine propofol (n = 165), four lorazepam (n = 86), one morphine (n = 20), two remifentanil (n = 55), and one sufentanil (n = 10). Each study showed large variations in V-dss, Cl, and elimination t(1/2), within and between individual participants. High clinical and methodical heterogeneity between the dexmedetomidine studies prevented the direct comparison of PK parameters between critically ill and noncritically ill patients. Use of midazolam, propofol, and lorazepam in critically ill patients was associated with at least a 2- to 4-fold increase in V-dss compared with non critically ill patients; Cl decreased similar to 2-fold for midazolam and 10-fold for morphine. Critically ill patients receiving prolonged infusions of midazolam, propofol, remifentanil, and sufentanil had at least 2-fold longer elimination or terminal t(1/2) than noncritically ill patients. (C) 2018 Elsevier Inc. All rights reserved.	[Tse, Andrew H. W.; Ling, Lowell; Lee, Anna; Joynt, Gavin M.] Chinese Univ Hong Kong, Dept Anaesthesia & Intens Care, Shatin, Hong Kong, Peoples R China	Lee, A (reprint author), Chinese Univ Hong Kong, Dept Anaesthesia & Intens Care, Prince Wales Hosp, 4 F-L Main Clin Block & Trauma Ctr, Shatin, Hong Kong, Peoples R China.	annalee@cuhk.edu.hk	Lee, Anna/B-2773-2009; Tse, Andrew/AAH-2336-2019; Joynt, Gavin M/C-7606-2009	Lee, Anna/0000-0003-2864-0045; Tse, Andrew/0000-0002-3904-1745; Joynt, Gavin M/0000-0002-5823-3435; Ling, Lowell/0000-0001-6639-7344			Ahonen J, 1999, ACTA ANAESTH SCAND, V43, P509, DOI 10.1034/j.1399-6576.1999.430504.x; Al-Rifai Z, 2016, BJA EDUC, V16, P276, DOI 10.1093/bjaed/mkv074; ALBANESE J, 1990, ANESTHESIOLOGY, V73, P214, DOI 10.1097/00000542-199008000-00004; Albrecht S, 1999, ANAESTHESIST, V48, P794, DOI 10.1007/s001010050787; Aoyama T, 2016, J CLIN PHARM THER, V41, P392, DOI 10.1111/jcpt.12395; BAILIE GR, 1992, BRIT J ANAESTH, V68, P486, DOI 10.1093/bja/68.5.486; BALL M, 1985, LANCET, V1, P784; Barr J, 2001, ANESTHESIOLOGY, V95, P324, DOI 10.1097/00000542-200108000-00011; Barr J, 2001, ANESTHESIOLOGY, V95, P286, DOI 10.1097/00000542-200108000-00007; Bastani B, 1997, NEPHROL DIAL TRANSPL, V12, P2802, DOI 10.1093/ndt/12.12.2802; Bastiaans DET, 2013, INT J CLIN PHARM-NET, V35, P210, DOI 10.1007/s11096-012-9725-0; Beigmohammadi MT, 2013, IRAN J PHARM RES, V12, P483; Bienert A, 2010, J PHARMACOKINET PHAR, V37, P289, DOI 10.1007/s10928-010-9161-5; BION JF, 1986, INTENS CARE MED, V12, P359, DOI 10.1007/BF00292926; Bista SR, 2015, XENOBIOTICA, V45, P207, DOI 10.3109/00498254.2014.971093; Bolon M, 2003, J PHARM PHARMACOL, V55, P765, DOI 10.1211/002235703765951366; Bremer F, 2004, THER DRUG MONIT, V26, P643, DOI 10.1097/00007691-200412000-00010; Buckley PM, 1997, INTENS CARE MED, V23, P969, DOI 10.1007/s001340050440; Burke JF, 2015, BMJ-BRIT MED J, V351, DOI 10.1136/bmj.h5651; Chanques G, 2006, CRIT CARE MED, V34, P1691, DOI 10.1097/01.CCM.0000218416.62457.56; de Wit M, 2006, INT J CLIN PHARM TH, V44, P466; Driessen J J, 1991, Acta Anaesthesiol Belg, V42, P149; Egan TD, 1997, WESTERN J MED, V166, P202; Ethuin F, 2003, INTENS CARE MED, V29, P1916, DOI 10.1007/s00134-003-1920-y; Goncalves-Pereira J, 2011, CRIT CARE, V15, DOI 10.1186/cc10441; GREENBLATT DJ, 1979, CLIN PHARMACOL THER, V26, P103; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Hirata K, 2003, YAKUGAKU ZASSHI, V123, P811, DOI 10.1248/yakushi.123.811; Hozo Stela Pudar, 2005, BMC Med Res Methodol, V5, P13, DOI 10.1186/1471-2288-5-13; Iirola T, 2012, BRIT J ANAESTH, V108, P460, DOI 10.1093/bja/aer441; Iirola T, 2011, CRIT CARE, V15, DOI 10.1186/cc10518; Jackson DL, 2009, CRIT CARE, V13, DOI 10.1186/cc8212; Jamal JA, 1998, NEPHROL DIAL TRANSPL, V13, P1535, DOI 10.1093/ndt/13.6.1535; Knibbe CAJ, 2004, ACTA ANAESTH SCAND, V48, P302, DOI 10.1111/j.1399-6576.2004.0339.x; Knibbe CAJ, 2002, CLIN PHARMACOL THER, V72, P670, DOI 10.1067/mcp.2002.129500; KRAUS JW, 1978, CLIN PHARMACOL THER, V24, P411; Labroo RB, 1997, DRUG METAB DISPOS, V25, P1072; LANG TA, 1997, REPORT STAT MED ANNO; MALACRIDA R, 1992, CRIT CARE MED, V20, P1123, DOI 10.1097/00003246-199208000-00010; Mangoni AA, 2004, BRIT J CLIN PHARMACO, V57, P6, DOI 10.1046/j.1365-2125.2003.02007.x; MATHER LE, 1983, CLIN PHARMACOKINET, V8, P422, DOI 10.2165/00003088-198308050-00004; Matthews JNS, 1996, BRIT MED J, V313, P862; MICHALK S, 1988, INTENS CARE MED, V15, P37; Miller RD., 2015, MILLERS ANESTHESIA; Moher D, 2010, INT J SURG, V8, P336, DOI 10.1016/j.ijsu.2010.02.007; OLDENHOF H, 1988, CLIN PHARMACOL THER, V43, P263, DOI 10.1038/clpt.1988.31; Peeters MMM, 2008, CLIN PHARMACOL THER, V83, P443, DOI 10.1038/sj.clpt.6100309; Peeters MYM, 2010, CLIN PHARMACOKINET, V49, P269, DOI 10.2165/11319350-000000000-00000; Pitsiu M, 2004, BRIT J ANAESTH, V92, P493, DOI 10.1093/bja/aeh086; Roberts Jason A., 2009, Journal of Pharmacy Practice and Research, V39, P198; ROLAN PE, 1994, BRIT J CLIN PHARMACO, V37, P125, DOI 10.1111/j.1365-2125.1994.tb04251.x; SHAFER A, 1990, CRIT CARE MED, V18, P1039, DOI 10.1097/00003246-199009000-00024; Smith BS, 2012, CHEST, V141, P1327, DOI 10.1378/chest.11-1396; Smuszkiewicz P, 2016, BIOPHARM DRUG DISPOS, V37, P456, DOI 10.1002/bdd.2028; Swart EL, 1999, CRIT CARE MED, V27, P1461, DOI 10.1097/00003246-199908000-00009; Swart EL, 2004, BRIT J CLIN PHARMACO, V57, P135, DOI 10.1046/j.1365-2125.2003.01957.x; Tse AHW, 2017, PHARMACOL RES, V117, P156, DOI 10.1016/j.phrs.2016.12.028; Udy AA, 2014, CRIT CARE MED, V42, P520, DOI 10.1097/CCM.0000000000000029; Valitalo PA, 2013, CLIN DRUG INVEST, V33, P579, DOI 10.1007/s40261-013-0101-1; Wallis S, 2012, J CLIN TOXICOL S, V4; Walter SD, 2007, J CLIN EPIDEMIOL, V60, P849, DOI 10.1016/j.jclinepi.2006.11.003; Wilhelm W, 2008, CRIT CARE, V12, DOI 10.1186/cc6152; WYNNE HA, 1989, HEPATOLOGY, V9, P297, DOI 10.1002/hep.1840090222; Yang S, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-16358-6; Yap FHY, 2002, ANAESTH INTENS CARE, V30, P202, DOI 10.1177/0310057X0203000213; Zoli M, 1999, AGE AGEING, V28, P29, DOI 10.1093/ageing/28.1.29	66	2	3	2	10	ELSEVIER	BRIDGEWATER	685 ROUTE 202-206, BRIDGEWATER, NJ 08807 USA	0149-2918	1879-114X		CLIN THER	Clin. Ther.	SEP	2018	40	9					1598	1615		10.1016/j.clinthera.2018.07.021			18	Pharmacology & Pharmacy	Pharmacology & Pharmacy	GW1NP	WOS:000446646600018	30173953				2020-06-30	J	Biello, P; Bateman, SW; Kerr, CL				Biello, Patricia; Bateman, Shane W.; Kerr, Carolyn L.			Comparison of fentanyl and hydromorphone constant rate infusions for pain management in dogs in an intensive care unit	VETERINARY ANAESTHESIA AND ANALGESIA			English	Article						constant rate infusion; dog; fentanyl; hydromorphone; pain	INTRAVENOUS HYDROMORPHONE; MORPHINE-SULFATE; CONSCIOUS DOGS; HEALTHY DOGS; PHARMACOKINETICS; HYDROCHLORIDE; INJECTION; COMPATIBILITY; ACEPROMAZINE; OXYMORPHONE	Objective To compare the efficacy and quality of analgesia provided by constant rate infusions (CRIs) of hydromorphone and fentanyl in dogs in the intensive care unit (ICU). Study design Prospective, randomized, blinded, clinical trial. Animals A total of 29 client-owned dogs. Methods Dogs prescribed a m-opioid agonist infusion for postsurgical or medical pain were randomized to be administered either hydromorphone (0.025 or 0.05 mg kg(-1) bolus, followed by a 0.03 mg kg(-1) hour-1 infusion) or fentanyl (2.5 or 5 mg kg(-1) bolus, followed by a 3 mg kg(-1) hour(-1) infusion). The technical staff and clinicians were blinded as to which drug was administered. Pain scores, using the Colorado State University Canine Acute Pain Scale, sedation scores and nausea scores were assigned at regular intervals and compared between groups. Dose escalation and deescalation of the study drug were performed according to set protocols. Adverse clinical signs and all other medications administered were recorded and compared between groups. The study drug was discontinued if the animal remained painful despite dose escalations, or if adverse effects were noted. Results The pain scores were of low magnitude and were not significantly different between groups. The use of concurrent analgesia, sedation/anxiolytic medications and antacid/antiemetic medications was not different between groups. Sedation and nausea scores were not statistically different between groups. Conclusions and clinical relevance Hydromorphone and fentanyl CRIs appear to be equally effective for adequate pain relief in dogs, with no significant differences in adverse effects. Therefore, either drug may be chosen for control of postsurgical or medical pain in an ICU setting.	[Biello, Patricia; Bateman, Shane W.; Kerr, Carolyn L.] Univ Guelph, Ontario Vet Coll, Dept Clin Studies, Guelph, ON, Canada	Biello, P (reprint author), Ontario Vet Coll, Hlth Sci Ctr, Dept Clin Studies, 50 Stone Rd, Guelph, ON N1G 2W1, Canada.	pbiello@uoguelph.ca	Bateman, Shane/N-1687-2019	Bateman, Shane/0000-0002-0468-0256			American Animal Hospital Association, 2010, BOD COND SCOR SYST; ARNDT JO, 1984, ANESTHESIOLOGY, V61, P355, DOI 10.1097/00000542-198410000-00001; Becker WM, 2013, VET SURG, V42, P302, DOI 10.1111/j.1532-950X.2012.01080.x; Campbell VL, 2003, J AM VET MED ASSOC, V222, P330, DOI 10.2460/javma.2003.222.330; Epstein ME, 2015, HDB VET PAIN MANAGEM, P161, DOI DOI 10.1016/B978-0-323-08935-7.00009-0; Grimm KA, 2005, AM J VET RES, V66, P1222, DOI 10.2460/ajvr.2005.66.1222; Guedes AGP, 2008, J VET PHARMACOL THER, V31, P334, DOI 10.1111/j.1365-2885.2008.00966.x; Guedes AGP, 2007, J VET PHARMACOL THER, V30, P516, DOI 10.1111/j.1365-2885.2007.00911.x; Guedes AGP, 2012, CLIN BRIEF       MAR, V2012, P29; HANNA C, 1962, ANESTH ANALG, V41, P755; Hellyer PW, 2006, CANINE ACUTE PAIN SC; HILL HF, 1991, ANESTH ANALG, V72, P330; Hofmeister EH, 2006, J VET EMERG CRIT CAR, V16, P44, DOI 10.1111/j.1476-4431.2005.04022.x; Kenward H, 2015, VET J, V203, P36, DOI 10.1016/j.tvjl.2014.10.007; Kerr CL, 2016, BSAVA MANUAL CANINE, P124; KuKanich B, 2008, VET ANAESTH ANALG, V35, P256, DOI 10.1111/j.1467-2995.2007.00379.x; Lipkowski AW, 2004, PURE APPL CHEM, V76, P941, DOI 10.1351/pac200476050941; Lucas AN, 2001, J AM VET MED ASSOC, V218, P884, DOI 10.2460/javma.2001.218.884; MURPHY MR, 1982, ANESTHESIOLOGY, V57, P485, DOI 10.1097/00000542-198212000-00009; Pelligand L, 2016, BSAVA MANUAL CANINE, P113; Pettifer G, 2000, CAN VET J, V41, P135; Robinson R, 2013, VET ANAESTH ANALG, V40, P455, DOI 10.1111/vaa.12052; Sano T, 2006, VET ANAESTH ANALG, V33, P266, DOI 10.1111/j.1467-2995.2005.00266.x; Smith LJ, 2001, J AM VET MED ASSOC, V218, P1101, DOI 10.2460/javma.2001.218.1101; TRISSEL LA, 1994, AM J HOSP PHARM, V51, P2138, DOI 10.1093/ajhp/51.17.2138; Xu QYA, 1996, ANN PHARMACOTHER, V30, P756, DOI 10.1177/106002809603000709; YAKSH TL, 1986, ANESTHESIOLOGY, V64, P54, DOI 10.1097/00000542-198601000-00009; Young Adam, 2012, Anesthesiol Clin, V30, P91, DOI 10.1016/j.anclin.2011.12.002; Zacny JP, 1998, J PHARMACOL EXP THER, V286, P1197	29	1	1	0	4	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1467-2987	1467-2995		VET ANAESTH ANALG	Vet. Anaesth. Analg.	SEP	2018	45	5					673	683		10.1016/j.vaa.2018.05.005			11	Veterinary Sciences	Veterinary Sciences	GV8LW	WOS:000446394200011	30082181				2020-06-30	J	Lewis, P; Wright, C; Hooper, C				Lewis, Pip; Wright, C.; Hooper, C.			Opioid analgesia on the battlefield: a retrospective review of data from Operation HERRICK	JOURNAL OF THE ROYAL ARMY MEDICAL CORPS			English	Review						pain management; military; analgesia; opioids	POSTTRAUMATIC-STRESS-DISORDER; PAIN; MORPHINE; FENTANYL; AFGHANISTAN; EVACUATION; MANAGEMENT; CASUALTIES; INJURY; IRAQ	Background Acute pain secondary to trauma is commonly encountered on the battlefield. The use of morphine to manage pain during combat has been well established since the 19th century. Despite this, there is relatively little research on analgesia use in this environment. This study aims to review the use and complications of morphine and other opioids during Operation HERRICK. Methods A database search of the Joint Theatre Trauma Registry was completed looking for all incidences of morphine, fentanyl or naloxone use from February 2007 to September 2014. Microsoft Excel was used to analyse the results. Results Opioid analgesia was administered to 5801 casualties. Morphine was administered 6742 times to 3808 patients. Fentanyl was administered 9672 times to 4318 patients. Naloxone was used 18 times on 14 patients, giving a complication rate of 0.24%. Opioid doses prior to naloxone administration range from 0 to 72mg of morphine and from 0 to 100 mcg of fentanyl. Four casualties (two local civilians and two coalition forces) received naloxone despite no recorded opioids being administered. Opium abuse was prevalent among the local population in Afghanistan, and this could explain the rationale behind two local national casualties receiving naloxone without any documented opioids being given. Conclusion The use of opioids in a battlefield environment is extremely safe. Complication rates are similar to previously published data which is reassuring. The efficacy of different opioids was not covered by this study, and further analysis is required, particularly following the introduction of oral transmucosal fentanyl citrate and the availability of novel non-opioid analgesics.	[Lewis, Pip; Wright, C.] Imperial Coll Healthcare NHS Trust, Emergency Dept, London W2 1NY, England; [Lewis, Pip; Wright, C.] Royal Ctr Def Med, Acad Dept Mil Emergency Med, Birmingham, AL USA; [Hooper, C.] RNAS Culdrose, 1700 Naval Air Squadron, Helston, Cornwall, England	Lewis, P (reprint author), Imperial Coll Healthcare NHS Trust, Emergency Dept, London W2 1NY, England.	pip.lewis1@nhs.net					Aldington D, 2014, J ROY ARMY MED CORPS, V160, P102, DOI 10.1136/jramc-2013-000227; Beecher HK, 1944, J AMER MED ASSOC, V124, P1193, DOI 10.1001/jama.1944.62850170001007; Benov A, 2017, J TRAUMA ACUTE CARE, V83, pS150, DOI 10.1097/TA.0000000000001481; Boyer EW, 2012, NEW ENGL J MED, V367, P146, DOI 10.1056/NEJMra1202561; Buckenmaier CC, 2009, PAIN MED, V10, P1487, DOI 10.1111/j.1526-4637.2009.00731.x; Cross JD, 2011, J AM ACAD ORTHOP SUR, V19, pS1, DOI 10.5435/00124635-201102001-00002; Davey CMT, 2012, J ROY ARMY MED CORPS, V158, P190, DOI 10.1136/jramc-158-03-08; Galvagno SM, 2018, J TRAUMA ACUTE CARE, V84, P150, DOI 10.1097/TA.0000000000001715; Gaunt C, 2009, J R Army Med Corps, V155, P46; HOFFMAN RS, 1995, JAMA-J AM MED ASSOC, V274, P562, DOI 10.1001/jama.274.7.562; Holbrook TL, 2010, NEW ENGL J MED, V362, P110, DOI 10.1056/NEJMoa0903326; Islamic Republic of Afghanistan Ministry of Counter Narcotics, 2014, AFGH OP SURV; Islamic Republic of Afghanistan Ministry of Counter Narcotics, 2012, AFGH DRUG REP 2012; Nikolajsen L, 1997, PAIN, V72, P393, DOI 10.1016/S0304-3959(97)00061-4; Otis JD, 2003, J REHABIL RES DEV, V40, P397, DOI 10.1682/JRRD.2003.09.0397; Park C, 2010, J ROY ARMY MED CORPS, V156, pS295, DOI [10. 1136/jramc-156-04s-05, DOI 10.1136/JRAMC-156-04S-05]; Petz LN, 2015, MIL MED, V180, P14, DOI 10.7205/MILMED-D-14-00383; Rogers E, 2018, J ROY ARMY MED CORPS, V164, P458, DOI 10.1136/jramc-2017-000901; Shackelford SA, 2015, MIL MED, V180, P304, DOI 10.7205/MILMED-D-14-00257; Smith J E, 2009, J R Army Med Corps, V155, P44; Smith MD, 2012, J EMERG MED, V43, P69, DOI 10.1016/j.jemermed.2011.05.018; Wedmore IS, 2012, J TRAUMA ACUTE CARE, V73, pS490, DOI 10.1097/TA.0b013e3182754674	22	1	1	1	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0035-8665	2052-0468		J ROY ARMY MED CORPS	J. R. Army Med. Corps	SEP	2018	164	5					328	331		10.1136/jramc-2017-000897			4	Medicine, General & Internal	General & Internal Medicine	GV4RN	WOS:000446088000005	29626143	Bronze			2020-06-30	J	Nechuta, SJ; Tyndall, BD; Mukhopadhyay, S; McPheeters, ML				Nechuta, Sarah J.; Tyndall, Benjamin D.; Mukhopadhyay, Sutapa; McPheeters, Melissa L.			Sociodemographic factors, prescription history and opioid overdose deaths: a statewide analysis using linked PDMP and mortality data	DRUG AND ALCOHOL DEPENDENCE			English	Article						Drug overdose; Drug mortality; Prescription drugs; Fentanyl; Heroin; Benzodiazepines	NEW-YORK-CITY; DRUG OVERDOSE; MONITORING PROGRAM; FENTANYL OVERDOSES; PUBLIC-HEALTH; UNITED-STATES; CHRONIC PAIN; RISK; HEROIN; ANALGESICS	Background: Opioid overdose deaths have continued to rise in Tennessee (TN) with fentanyl emerging as a major contributor. Current data are needed to identify at-risk populations to guide prevention strategies. We conducted a large statewide observational study among TN adult decedents (2013-2016) to evaluate the association of sociodemographic factors and prescribing patterns with opioid overdose deaths. Methods: Among drug overdose decedents identified using death certificate data (n = 5483), we used logistic regression to estimate adjusted odds ratios and 95% confidence intervals for characteristics associated with prescription opioid (PO) (excluding fentanyl), fentanyl, and heroin alone overdoses. Among decedents linked to TN's Prescription Drug Monitoring Database using deterministic algorithms, we obtained prescription history in the year before death (n = 3971), which was evaluated by type of overdose using descriptive statistics. Results: Younger, non-White decedents had lower odds of PO overdose, while females and benzodiazepines as a contributing cause were associated with increased odds of PO overdose. Younger age, Non-Hispanic Black race/ ethnicity, greater than high school education, and cocaine/other stimulants as a contributing cause were associated with increased odds of fentanyl or heroin overdoses. Over 55% of PO, 39.2% of fentanyl, and 20.7% of heroin overdoses had an active opioid prescription at death. For PO, fentanyl, and heroin decedents, respectively, 46.0%, 30.5%, and 26.2% had an active prescription for benzodiazepines at death. Conclusions: Prescription opioid overdose deaths were associated with different sociodemographic profiles and prescribing history compared to fentanyl and heroin overdose deaths in TN. Data can guide prevention strategies to reduce opioid overdose mortality.	[Nechuta, Sarah J.; Tyndall, Benjamin D.; Mukhopadhyay, Sutapa] Tennessee Dept Hlth, Off Informat & Analyt, 665 Mainstream Dr, Nashville, TN 37243 USA; [Nechuta, Sarah J.] Vanderbilt Univ, Dept Med, Div Epidemiol, Med Ctr, 2525 West End Ave, Nashville, TN 37240 USA; [McPheeters, Melissa L.] Tennessee Dept Hlth, Off Informat & Analyt, Andrew Johnson Tower,7th Floor, Nashville, TN 37243 USA; [McPheeters, Melissa L.] Vanderbilt Univ, Med Ctr, Dept Hlth Policy, 2525 West End Ave,Suite 1200, Nashville, TN 37203 USA	Nechuta, SJ (reprint author), Tennessee Dept Hlth, Off Informat & Analyt, 665 Mainstream Dr, Nashville, TN 37243 USA.	sarah.nechuta@tn.gov	Nechuta, Sarah/AAG-4025-2020	Nechuta, Sarah/0000-0003-2773-6678	Centers for Disease Control and Prevention, Prescription Drug Overdose Prevention for States Program [5 NU17CE002731-02-00]	This work was supported by a grant from the Centers for Disease Control and Prevention, Prescription Drug Overdose Prevention for States Program (5 NU17CE002731-02-00). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Austin AE, 2017, DRUG ALCOHOL DEPEN, V181, P44, DOI 10.1016/j.drugalcdep.2017.09.014; Barocas JA, 2015, DRUG ALCOHOL DEPEN, V154, P283, DOI 10.1016/j.drugalcdep.2015.06.023; Brady Joanne E, 2017, Inj Epidemiol, V4, P24, DOI 10.1186/s40621-017-0118-7; Cerda M, 2013, DRUG ALCOHOL DEPEN, V132, P53, DOI 10.1016/j.drugalcdep.2012.12.027; Cochran G, 2016, INTEGR PHARM RES PRA, V5, P65, DOI 10.2147/IPRP.S99539; Coffin PO, 2016, ANN INTERN MED, V165, P245, DOI 10.7326/M15-2771; Dasgupta N, 2016, PAIN MED, V17, P85, DOI 10.1111/pme.12907; Dilokthornsakul P, 2016, J PAIN, V17, P436, DOI 10.1016/j.jpain.2015.12.006; Ellis AD, 2016, FORENSIC SCI MED PAT, V12, P243, DOI 10.1007/s12024-016-9780-2; Fairbairn N, 2017, INT J DRUG POLICY, V46, P172, DOI 10.1016/j.drugpo.2017.06.005; Garg RK, 2017, MED CARE, V55, P661, DOI 10.1097/MLR.0000000000000738; Golladay M., 2018, LESSONS LEARNED DEEP; Green TC, 2011, DRUG ALCOHOL DEPEN, V115, P221, DOI 10.1016/j.drugalcdep.2010.11.007; Hall AJ, 2008, JAMA-J AM MED ASSOC, V300, P2613, DOI 10.1001/jama.2008.802; Hartung DM, 2017, PHARMACOEPIDEM DR S, V26, P1053, DOI 10.1002/pds.4254; Jones CM, 2015, AM J PREV MED, V49, P493, DOI 10.1016/j.amepre.2015.03.040; Kandel DB, 2017, DRUG ALCOHOL DEPEN, V178, P501, DOI 10.1016/j.drugalcdep.2017.05.047; King NB, 2014, AM J PUBLIC HEALTH, V104, pE32, DOI 10.2105/AJPH.2014.301966; Kolodny A, 2015, ANNU REV PUBL HEALTH, V36, P559, DOI 10.1146/annurev-publhealth-031914-122957; Kresina TF, 2011, INT J ENV RES PUB HE, V8, P4102, DOI 10.3390/ijerph8104102; Lev R, 2016, AM J EMERG MED, V34, P510, DOI 10.1016/j.ajem.2015.12.023; Lev R, 2015, FORENSIC SCI INT, V257, P347, DOI 10.1016/j.forsciint.2015.09.021; McCoy AB, 2013, BMJ QUAL SAF, V22, P219, DOI 10.1136/bmjqs-2012-001419; Mercado MC, 2018, PAIN MED, V19, P511, DOI 10.1093/pm/pnx015; Mertz KJ, 2014, J FORENSIC SCI, V59, P1583, DOI 10.1111/1556-4029.12541; MOYER LA, 1989, AM J EPIDEMIOL, V130, P1024, DOI 10.1093/oxfordjournals.aje.a115403; Muhuri PK, 2013, CBHSQ DATA REV; National Center for Injury Prevention and Control, 2016, CTR DIS CONTR PREV C; Pardo B, 2017, ADDICTION, V112, P1773, DOI 10.1111/add.13741; Park TW, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h2698; Patrick SW, 2016, HEALTH AFFAIR, V35, P1324, DOI 10.1377/hlthaff.2015.1496; Paulozzi LJ, 2012, PAIN MED, V13, P87, DOI 10.1111/j.1526-4637.2011.01260.x; Paulozzi LJ, 2009, ADDICTION, V104, P1541, DOI 10.1111/j.1360-0443.2009.02650.x; Peterson AB, 2016, MMWR-MORBID MORTAL W, V65, P844, DOI 10.15585/mmwr.mm6533a3; Raffel K. E, 2018, PERM J, V22; Rockett IRH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135296; Rudd RA, 2016, MMWR-MORBID MORTAL W, V65, P1445, DOI 10.15585/mmwr.mm655051e1; Siegler A, 2014, INT J DRUG POLICY, V25, P569, DOI 10.1016/j.drugpo.2013.10.015; Slavova S, 2017, INT J DRUG POLICY, V46, P120, DOI 10.1016/j.drugpo.2017.05.051; Slavova S, 2017, PHARM MED, V31, P155, DOI 10.1007/s40290-017-0185-7; Slavova S, 2015, PUBLIC HEALTH REP, V130, P339, DOI 10.1177/003335491513000411; Smith-Warner SA, 2006, AM J EPIDEMIOL, V163, P1053, DOI 10.1093/aje/kwj127; Starrels JL, 2011, J GEN INTERN MED, V26, P958, DOI 10.1007/s11606-011-1648-2; Stone DM, 2017, AM J PUBLIC HEALTH, V107, P1233, DOI [10.2105/ajph.2017.303863, 10.2105/AJPH.2017.303863]; Straus MM, 2013, SUBST ABUSE REHABIL; Suffoletto B, 2018, J PAIN, V19, P430, DOI 10.1016/j.jpain.2017.11.010; Tennessee Department of Health, 2017, TENN CHRON PAIN GUID; Trinidad James P, 2016, Natl Vital Stat Rep, V65, P1; Volkow ND, 2016, NEW ENGL J MED, V374, P1253, DOI 10.1056/NEJMra1507771; Warner Margaret, 2016, Natl Vital Stat Rep, V65, P1; Weimer MB, 2011, J ADDICT MED, V5, P188, DOI 10.1097/ADM.0b013e318211c56a	51	13	13	4	17	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0376-8716	1879-0046		DRUG ALCOHOL DEPEN	Drug Alcohol Depend.	SEP 1	2018	190						62	71		10.1016/j.drugalcdep.2018.05.004			10	Substance Abuse; Psychiatry	Substance Abuse; Psychiatry	GU3IG	WOS:000445169200011	29981943				2020-06-30	J	Fogarty, MF; Papsun, DM; Logan, BK				Fogarty, Melissa F.; Papsun, Donna M.; Logan, Barry K.			Analysis of cis and trans 3-methylfentanyl by liquid chromatography-high resolution mass spectrometry and findings in forensic toxicology casework	DRUG TESTING AND ANALYSIS			English	Article						3-methylfentanyl; high resolution mass spectrometry; LC-QToF; toxicology	SYNTHETIC OPIOIDS; FENTANYL; DRUGS; EPIDEMIC; ANALOGS; BLOOD	3-methylfentanyl (3-MF), N-(3-methyl-1-phenethyl-4-piperidyl)-N-phenyl-propanamide, has reappeared on the US illicit drug market since its disappearance after a series of overdose deaths in 1988. 3-MF presents an analytical challenge, due to presence of cis and trans stereoisomers, each with different potencies, and ultimately very low concentrations in the blood after use. A method was developed using liquid chromatography-time-of-flight-mass spectrometry for the analysis of (+/-)-cis-3-MF and (+/-)-trans-3-MF in blood specimens after solid phase extraction. The linear dynamic range of this method was 0.1-10 ng/mL. Blood samples from 25 postmortem cases and 2 human performance case involving 3-MF were submitted for quantitative analysis. The mean and median concentration for the (+/-)-cis-3-MF were 0.84 ng/mL (+/- 0.81) and 0.67 ng/mL, respectively, range 0.14-3.43 ng/mL. The resulting (+/-)-trans-3-MF mean concentration was 0.46 ng/mL (+/- 0.38) and the median concentration was 0.37 ng/mL with a range of 0.11-1.90 ng/mL. The resulting (+/-)-cis-3-MF and (+/-)trans-3-MF concentrations were summed to give the total amount of 3-MF present in the case with the resulting average concentration at 1.28 ng/mL (+/- 1.16), median at 1.01 ng/mL and range 0.18-5.18. As the estimated dose of this compound is approximately 0.1 mg-0.5 mg with the resulting concentrations in the sub-nanogram range, it is necessary for forensic toxicology laboratories to obtain instruments sensitive enough to detect these substances in driving under the influence of drugs and postmortem cases. Quantitation of 3-MF with separation of (+/-)-cis and (+/-)-trans-3-MF provides additional detail for more specific toxicological interpretation.	[Fogarty, Melissa F.; Logan, Barry K.] Fredr Rieders Family Fdn, CFSRE, 2300 Stratford Ave, Willow Grove, PA 19090 USA; [Papsun, Donna M.; Logan, Barry K.] NMS Labs, Willow Grove, PA 19090 USA	Fogarty, MF (reprint author), Fredr Rieders Family Fdn, CFSRE, 2300 Stratford Ave, Willow Grove, PA 19090 USA.	melissa.friscia@frfoundation.org					[Anonymous], 2013, J ANAL TOXICOL, V37, P452, DOI 10.1093/jat/bkt054; [Anonymous], UND EP DRUG OV; [Anonymous], 1985, CHEM ENG NEWS ARCH, V63, P5, DOI [10. 1021/cen-v063n051. p005, DOI 10.1021/CEN-V063N051.P005]; AYRES WA, 1981, J PSYCHOACTIVE DRUGS, V13, P91, DOI 10.1080/02791072.1981.10471455; Cooreman S, 2010, J SEP SCI, V33, P2654, DOI 10.1002/jssc.201000330; Gergov M, 2009, FORENSIC SCI INT, V186, P36, DOI 10.1016/j.forsciint.2009.01.013; HENDERSON GL, 1988, J FORENSIC SCI, V33, P569; HIBBS J, 1991, JAMA-J AM MED ASSOC, V265, P1011, DOI 10.1001/jama.265.8.1011; Kanamori T, 2017, J FORENSIC SCI, V62, P1472, DOI 10.1111/1556-4029.13395; Marchei E, 2018, TRAC-TREND ANAL CHEM, V102, P1, DOI 10.1016/j.trac.2018.01.007; MARTIN M, 1991, ANN EMERG MED, V20, P158, DOI 10.1016/S0196-0644(05)81216-8; Mohr ALA, 2016, J ANAL TOXICOL, V40, P709, DOI 10.1093/jat/bkw086; O'Donnell JK, 2017, MMWR-MORBID MORTAL W, V66, P1197, DOI 10.15585/mmwr.mm6643e1; Ojanpera I, 2008, INT J LEGAL MED, V122, P395, DOI 10.1007/s00414-008-0230-x; Ojanpera I, 2006, AM J FOREN MED PATH, V27, P328, DOI 10.1097/01.paf.0000188097.78132.e5; Radke J, 2014, CLIN REV ALLERG IMMU, V46, P54, DOI 10.1007/s12016-013-8373-z; Sofalvi S, 2017, J ANAL TOXICOL, V41, P473, DOI 10.1093/jat/bkx052; VANBEVER WF, 1974, J MED CHEM, V17, P1047, DOI 10.1021/jm00256a003; Vardanyan RS, 2014, FUTURE MED CHEM, V6, P385, DOI 10.4155/fmc.13.215; XU H, 1991, NEUROPHARMACOLOGY, V30, P455, DOI 10.1016/0028-3908(91)90006-W	20	2	2	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1942-7603	1942-7611		DRUG TEST ANAL	Drug Test. Anal.	SEP	2018	10	9					1474	1482		10.1002/dta.2414			9	Biochemical Research Methods; Chemistry, Analytical; Pharmacology & Pharmacy	Biochemistry & Molecular Biology; Chemistry; Pharmacology & Pharmacy	GU5MJ	WOS:000445329400013	29801193				2020-06-30	J	Maher, S; Elliott, SP; George, S				Maher, Shane; Elliott, Simon P.; George, Steve			The analytical challenges of cyclopropylfentanyl and crotonylfentanyl: An approach for toxicological analysis	DRUG TESTING AND ANALYSIS			English	Article						Crotonylfentanyl; cyclopropylfentanyl; fentanils; NPS; post-mortem	FENTANYL; FATALITIES; SERIES	New psychoactive substances (NPS) are increasingly being seen in forensic casework globally and encompass a number of types of drugs including "designer opioids", especially fentanyl analogues, which are of particular concern due to their high potency and significant risk of toxicity. They are often sold as heroin or mixed with other illicit drugs and therefore users may be unaware they are taking such hazardous compounds. Two fentanyl analogues that have recently been detected are cyclopropylfentanyl and crotonylfentanyl. In order to accurately determine the prevalence of such compounds in clinical and forensic casework, including potential toxicity, they need to be correctly identified using definitive and defensible techniques. Cyclopropylfentanyl and crotonylfentanyl are structural isomers, and it has previously been highlighted that these 2 compounds are analytically difficult to specifically identify owing to their similarity in structure and chromatographic behaviour. To further investigate in an attempt to overcome this problem, analysis of certified reference material using high performance liquid chromatography with diode array UV detection (HPLC-DAD), liquid chromatography-tandem mass spectrometry (LC-MS/MS), and liquid chromatography-quadrupole time-of-flight-mass spectrometry (LC-QToF-MS) has been performed. Whilst the compounds were shown to have an identical mass-spectral fragmentation pattern, they had different UV spectra. This was coupled with a discernible difference in retention time with the HPLC conditions applied, allowing differentiation of the 2 compounds. Using this approach, cyclopropylfentanyl was positively identified and subsequently quantified in 4 fatalities with the exclusion of crotonylfentanyl.	[Maher, Shane; Elliott, Simon P.; George, Steve] Alere Forens, Malvern Hills Sci Pk,Geraldine Rd, Malvern WR14 3SZ, Worcs, England	Elliott, SP (reprint author), Alere Forens, Malvern Hills Sci Pk,Geraldine Rd, Malvern WR14 3SZ, Worcs, England.	simontox@yahoo.co.uk					Armenian P, 2018, NEUROPHARMACOLOGY, V134, P121, DOI 10.1016/j.neuropharm.2017.10.016; Elliott SP, 2018, J ANAL TOXICOL, V42, pE41, DOI 10.1093/jat/bkx109; Elliott Simon P, 2016, Drug Test Anal, V8, P875, DOI 10.1002/dta.1984; EMCDDA, EMCDDA EUR JOINT REP; EMCDDA, EUR DRUG REP 2017; Hikin L, 2018, FORENSIC SCI INT, V282, P179, DOI 10.1016/j.forsciint.2017.11.036; Palaty J, 2018, CLIN BIOCHEM, V53, P164, DOI 10.1016/j.clinbiochem.2018.01.013; Pichini S, 2018, THER DRUG MONIT, V40, P38, DOI 10.1097/FTD.0000000000000465; Pichini S, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00785; Simons B., 2017, SOC FORENSIC TOX TOX, V41, P9; Soh YNA, 2014, DRUG TEST ANAL, V6, P696, DOI 10.1002/dta.1576; United Nations Office on Drugs and Crime (UNODC), 2017, GLOB SMART UPD 17 FE; United Nations Office on Drugs and Crime (UNODC), EARL WARN ADV NEW PS; United Nations Office on Drugs and Crime (UNODC), WORLD DRUG REP 20 4	14	12	12	1	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1942-7603	1942-7611		DRUG TEST ANAL	Drug Test. Anal.	SEP	2018	10	9					1483	1487		10.1002/dta.2417			5	Biochemical Research Methods; Chemistry, Analytical; Pharmacology & Pharmacy	Biochemistry & Molecular Biology; Chemistry; Pharmacology & Pharmacy	GU5MJ	WOS:000445329400014	29803198				2020-06-30	J	McKeown, HE; Rook, TJ; Pearson, JR; Jones, OAH				McKeown, Hugh E.; Rook, Trevor J.; Pearson, James R.; Jones, Oliver A. H.			Is Australia ready for fentanyl?	SCIENCE & JUSTICE			English	Review							DEATHS; EPIDEMIC; ESTONIA; EUROPE; TRENDS; DRUGS		[McKeown, Hugh E.; Jones, Oliver A. H.] RMIT Univ, Sch Sci, Australian Ctr Res Separat Sci, GPO Box 2476, Melbourne, Vic 3001, Australia; [Rook, Trevor J.] RMIT Univ, Appl Chem & Environm Sci, Sch Sci, GPO Box 2476, Melbourne, Vic 3001, Australia; [Pearson, James R.] Forens Serv Dept, Off Chief Forens Scientist, Macleod, Vic 3085, Australia; [Pearson, James R.] La Trobe Univ, Coll Sci Hlth & Engn, Sch Mol Sci, Bundoora, Vic 3086, Australia	McKeown, HE (reprint author), RMIT Univ, Sch Sci, Australian Ctr Res Separat Sci, GPO Box 2476, Melbourne, Vic 3001, Australia.	s3630922@student.rmit.edu.au	Jones, Oliver A.H./B-9778-2008; Rook, Trevor J/G-7878-2011	Jones, Oliver A.H./0000-0002-4541-662X; Rook, Trevor/0000-0003-2973-1213			Abel-Ollo K., 2014, NATL REPORT EMCDDA R, P80; Armstrong C., 2017, THE COURIER MAIL; Australian Crime Intelligence Commission, 2016, ILL DRUG DAT REP 201; Boddiger D, 2006, LANCET, V368, P569, DOI 10.1016/S0140-6736(06)69181-2; Crouch Brad, 2016, THE ADVERTISER; Dickson L., 2016, TIMES COLONIST; Drug Enforcement Administration, 2016, OFF SAF AL CARF DANG; Drug Enforcement Administration, 2016, COUNT PRESCR PILLS C; Drug Enforcement Administration, 2016, NAT DRUG THREAT ASS, P2016; Drug Enforcement Administration, 2016, NAT HER THREAT ASS S; Drug Enforcement Administration, 2016, OFF SAF AL FENT REAL; Drug Enforcement Administration, 2015, NAT DRUG THREAT ASS, P2015; European Monitoring Centre of Drugs and Drug Addiction, 2012, TRENDSP STUD FENT EU; EUROPOL, 2007, AMPH TYP STIM EUR UN; Fodale V, 2008, EXPERT OPIN DRUG SAF, V7, P213, DOI [10.1517/14740338.7.3.213, 10.1517/14740338.7.3.213 ]; Gibson A., 2007, EXTENT DIVERSION FEN; Golunov Serghei, 2012, EU RUSSIAN BORDER SE; Griffiths P, 2012, ADDICTION, V107, P1539, DOI 10.1111/j.1360-0443.2012.03829.x; Gupta PK, 2005, J CHEM RES, P452; HENDERSON GL, 1988, J FORENSIC SCI, V33, P569; HENDERSON GL, 1991, J FORENSIC SCI, V36, P422; Henson E., 2016, THE ADVERTISER; Higginbotham A., 2007, FENTANYL ANATOMY MYS, P212; Jacobs Harrison, 2016, BUSINESS INSIDER; Jones T. S., 2008, Morbidity and Mortality Weekly Report, V57, P793; Lurie IS, 2012, FORENSIC SCI INT, V220, P191, DOI 10.1016/j.forsciint.2012.02.024; Mayer BP, 2016, ANAL CHEM, V88, P4303, DOI 10.1021/acs.analchem.5b04434; Metherell L., 2016, FENTANYL SPATE FATAL; Miller A, 2016, GLOBAL NEWS; Mord M., 2016, DAILY TELEGRAPH; Mounteney J, 2015, INT J DRUG POLICY, V26, P626, DOI 10.1016/j.drugpo.2015.04.003; National Coronial Information System, 2013, DEATHS REL FENT MISS; Ojanpera I, 2008, INT J LEGAL MED, V122, P395, DOI 10.1007/s00414-008-0230-x; Partridge RA, 2012, OXFORD AM HDB DISAST; Perl R. F., 2001, CRS REPORT C TALIBAN; Prichard J, 2014, SCI TOTAL ENVIRON, V472, P550, DOI 10.1016/j.scitotenv.2013.11.039; Riches JR, 2012, J ANAL TOXICOL, V36, P647, DOI 10.1093/jat/bks078; Rodda LN, 2017, J ANAL TOXICOL, V41, P318, DOI 10.1093/jat/bkx013; Roxburgh A, 2013, DRUG ALCOHOL REV, V32, P269, DOI 10.1111/dar.12033; Schumann H, 2008, CLIN TOXICOL, V46, P501, DOI 10.1080/15563650701877374; Stanley TH, 2014, J PAIN, V15, P1215, DOI 10.1016/j.jpain.2014.08.010; Sustkova M., 2015, INT J EMERG MENT HLT, V17, P694; The Canadian Centre on Substance Abuse and Addiction and the Canadian Community Epidemiology Network on Drug Use, 2015, DEATHS INV FENT CAN; Therapeutic Goods Administration, 2016, FIN DEC REAS DEC DEL; Tuusov J, 2013, J FORENSIC LEG MED, V20, P51, DOI 10.1016/j.jflm.2012.04.023; U.S. Department of Justice, 2006, FENT SIT REP; U.S. Department of Justice, 2008, FIN RUL CONTR CHEM P; U.S. Department of State, 2015, INT NARC CONTR STRAT, P2015; United Nations, 2016, PREC CHEM FREQ US IL; United Nations Office on Drugs and Crime, 2015, AFGH OP SURV 2015 EX; Valdez CA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108250	51	5	5	0	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1355-0306	1876-4452		SCI JUSTICE	Sci. Justice	SEP	2018	58	5					366	371		10.1016/j.scijus.2018.04.004			6	Medicine, Legal; Pathology	Legal Medicine; Pathology	GU3HB	WOS:000445166100008	30193662				2020-06-30	J	Harrop, E; Jamieson, L; Choy, TH; Ho, WHP; Wong, ICK				Harrop, Emily; Jamieson, Liz; Choy, Tsun Ho; Ho, Wing Hei Phoebe; Wong, Ian C. K.			Barriers to the use of buccal and intranasal fentanyl for breakthrough pain in paediatric palliative care: an exploratory survey	BMJ SUPPORTIVE & PALLIATIVE CARE			English	Letter									[Harrop, Emily] Helen & Douglas House Hosp, Oxford OX4 1RW, Oxon, England; [Jamieson, Liz; Wong, Ian C. K.] UCL, Sch Pharm, London, England; [Choy, Tsun Ho; Ho, Wing Hei Phoebe] Univ Hong Kong, Dept Pharmacol & Pharm, Li Ka Shing Fac Med, Hong Kong, Hong Kong, Peoples R China	Harrop, E (reprint author), Helen & Douglas House Hosp, Oxford OX4 1RW, Oxon, England.	emilyharrop@yahoo.com		Harrop, Emily/0000-0002-2480-2062; Wong, Ian Chi Kei/0000-0001-8242-0014			Beecham E, 2015, COCHRANE DB SYST REV, V3; Jandhyala R, 2013, J PAIN SYMPTOM MANAG, V46, P573, DOI 10.1016/j.jpainsymman.2012.09.009; Jassal SS, 2015, ASS PAEDIAT PALLIATI, P44; National Institute for Health and Care Excellence (NICE), END LIF CAR INF CHIL; Pediatric Formulary Committee, 2016, BRIT NAT FORM CHILDR	5	1	1	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	2045-435X	2045-4368		BMJ SUPPORT PALLIAT	BMJ Support. Palliat. Care	SEP	2018	8	3					355	+		10.1136/bmjspcare-2017-001413			2	Health Care Sciences & Services	Health Care Sciences & Services	GU1UQ	WOS:000445053100021	28801316				2020-06-30	J	Yoshida, M; Shimizu, Y; Yoshida, K; Mukai, A; Doi, M; Irifune, M				Yoshida, Mitsuhiro; Shimizu, Yoshitaka; Yoshida, Keita; Mukai, Akari; Doi, Mitsuru; Irifune, Masahiro			Effective Postoperative Analgesia Using Intravenous Flurbiprofen and Acetaminophen	JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY			English	Article							PARACETAMOL ACETAMINOPHEN; PAIN	Purpose: Management of postoperative pain is one of the most important components in postoperative care, because most patients have pain after dental surgery The aim of this study was to evaluate whether acetaminophen could be an alternative to fentanyl in combination with a nonsteroidal anti-inflammatory drug (NSAID) as an analgesic after dental surgery in cases in which narcotic drugs were contraindicated. Materials and Methods: Patients were 24- to 54-year-old men who underwent enucleation of a mandibular cyst under general anesthesia. The authors measured time from discontinuation of anesthetic administration until discharge from the operating room and postoperative pain during 4 hours after discharge. They compared these parameters between patients who were intravenously administered an NSAID such as flurbiprofen with fentanyl (NSAID/fentanyl group) and those administered an NSAID with acetaminophen (NSAID/acetaminophen group). Parametric data of time were analyzed using Student t test. Nonparametric data of the analgesic effect were analyzed using Mann-Whitney U test. Results: Time until discharge from the operating room after discontinuation of anesthetics in the NSAID/fentanyl group was significantly longer than that in the NSAID/acetaminophen group (P < .05). In contrast, there was no significant difference in analgesic effect between the NSAID/acetaminophen and NSAID/fentanyl groups (P > .05). Conclusion: Although recovery time in the operating room of the flurbiprofen and acetaminophen group was markedly shorter than that of the flurbiprofen and fentanyl group, the postoperative analgesic effects of the 2 drugs were equipotent. Therefore, acetaminophen can be an alternative to fentanyl in cases in which narcotic drugs are contraindicated. (C) 2018 American Association of Oral and Maxillofacial Surgeons	[Yoshida, Mitsuhiro; Yoshida, Keita] Hiroshima Univ Hosp, Dept Oral & Maxillofacial Surg & Oral Med, Sect Dent Anesthesiol, Hiroshima, Japan; [Shimizu, Yoshitaka; Mukai, Akari; Doi, Mitsuru; Irifune, Masahiro] Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Dept Dent Anesthesiol, Program Dent Sci, Hiroshima, Japan	Yoshida, M (reprint author), Hiroshima Univ Hosp, Dept Oral & Maxillofacial Surg & Oral Med, Sect Dent Anesthesiol, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348551, Japan.	mh-yoshida@hotmail.co.jp					ALDRETE JA, 1995, J CLIN ANESTH, V7, P89, DOI 10.1016/0952-8180(94)00001-K; Best AD, 2017, J ORAL MAXIL SURG, V75, P2063, DOI 10.1016/j.joms.2017.04.045; Cadence Pharmaceuticals Inc, 2010, OFIRMEV AC INJ; DOWNIE WW, 1978, ANN RHEUM DIS, V37, P378, DOI 10.1136/ard.37.4.378; Duggan ST, 2009, DRUGS, V69, P101, DOI 10.2165/00003495-200969010-00007; Joris J, 1996, Acta Anaesthesiol Belg, V47, P115; Kehlet H, 2006, LANCET, V367, P1618, DOI 10.1016/S0140-6736(06)68700-X; Kumpulainen E, 2007, PEDIATRICS, V119, P766, DOI 10.1542/peds.2006-3378; Ong Cliff K S, 2003, Anesth Prog, V50, P5; Polomano RC, 2017, AM J NURS, V117, P12; Smith HS, 2009, PAIN PHYSICIAN, V12, P269; Van Dyke T, 2004, CLIN THER, V26, P2003, DOI 10.1016/j.clinthera.2004.12.002; White PF, 2005, ANESTH ANALG, V101, pS5, DOI 10.1213/01.ANE.0000177099.28914.A7	13	0	0	0	9	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0278-2391	1531-5053		J ORAL MAXIL SURG	J. Oral Maxillofac. Surg.	SEP	2018	76	9					1869	1872		10.1016/j.joms.2018.03.031			4	Dentistry, Oral Surgery & Medicine	Dentistry, Oral Surgery & Medicine	GR6JS	WOS:000442756400015	29678487				2020-06-30	J	Schoolman-Anderson, K; Lane, RD; Schunk, JE; Mecham, N; Thomas, R; Adelgais, K				Schoolman-Anderson, Kristin; Lane, Roni D.; Schunk, Jeff E.; Mecham, Nancy; Thomas, Richard; Adelgais, Kathleen			Pediatric emergency department triage-based pain guideline utilizing intranasal fentanyl: Effect of implementation	AMERICAN JOURNAL OF EMERGENCY MEDICINE			English	Article; Proceedings Paper	Annual Meeting of the Pediatric-Academic-Societies	APR-MAY -, 2012	Boston, MA	Pediat Acad Soc		INF; Intranasal fentanyl; Time to analgesia; Pediatric; Clinical guideline	RANDOMIZED CONTROLLED-TRIAL; CROSSOVER TRIAL; INTRAVENOUS MORPHINE; ORAL MORPHINE; DOUBLE-BLIND; OPEN-LABEL; ANALGESIA; CHILDREN; MANAGEMENT; EFFICACY	Background: Pain management guidelines in the emergency department (ED) may reduce time to analgesia administration (TTA). Intranasal fentanyl (INF) is a safe and effective alternative to intravenous opiates. The effect of an ED pain management guideline providing standing orders for nurse-initiated administration of intranasal fentanyl (INF) is not known. The objective of this study was to determine the impact of a pediatric ED triage-based pain protocol utilizing intranasal fentanyl (INF) on time to analgesia administration (TTA) and patient and parent satisfaction. Methods: This was a prospective study of patients 3-17 years with an isolated orthopedic injury presenting to a pediatric ED before and after instituting a triage-based pain guideline allowing for administration of INF by triage nurses. Our primary outcome was median TTA and secondary outcomes included the proportion of patients who received INF for pain, had unnecessary IV placement, and patient and parent satisfaction. Results: We enrolled 132 patients; 72 pre-guideline, 60 post-guideline. Demographics were similar between groups. Median TTA was not different between groups (34.5min vs. 33min, p=. 7). Utilization of INF increased from 41% pre-guideline to 60% post-guideline (p=. 01) and unnecessary IV placement decreased from 24% to 0% (p=. 002). Patients and parents preferred the IN route for analgesia administration. Conclusion: A triage-based pain protocol utilizing INF did not reduce TTA, but did result in increased INF use, decreased unnecessary IV placement, and was preferred by patients and parents to IV medication. INF is a viable analgesia alternative for children with isolated extremity injuries. (C) 2018 Elsevier Inc. All rights reserved.	[Schoolman-Anderson, Kristin] Phoenix Childrens Hosp, Dept Pediat Emergency Med, Phoenix, AZ USA; [Lane, Roni D.; Schunk, Jeff E.] Univ Utah, Sch Med, Div Pediat Emergency Med, Salt Lake City, UT USA; [Mecham, Nancy; Thomas, Richard] Primary Childrens Med Ctr, Salt Lake City, UT USA; [Adelgais, Kathleen] Univ Colorado, Sch Med, Sect Emergency Med, Dept Pediat, Aurora, CO USA	Adelgais, K (reprint author), Univ Colorado, Sch Med, Sect Pediat Emergency Med, Dept Pediat, 13123 E 16th Ave,Mail Stop B251, Aurora, CO 80045 USA.	kathleen.adelgais@childrenscolorado.org					Adelgais KM, 2017, J EMERG MED, V53, P607, DOI 10.1016/j.jemermed.2017.05.027; [Anonymous], 2017, Ann Emerg Med, V70, P446, DOI 10.1016/j.annemergmed.2017.06.043; Borland M, 2007, ANN EMERG MED, V49, P335, DOI 10.1016/j.annemergmed.2006.06.016; Borland Meredith L, 2002, Emerg Med (Fremantle), V14, P275, DOI 10.1046/j.1442-2026.2002.00344.x; Borland ML, 2008, EMERG MED AUSTRALAS, V20, P515, DOI 10.1111/j.1742-6723.2008.01138.x; Borland ML, 2005, BURNS, V31, P831, DOI 10.1016/j.burns.2005.05.001; Boyd RJ, 2005, EMERG MED J, V22, P30, DOI 10.1136/emj.2002.003574; Brown JC, 2003, ANN EMERG MED, V42, P197, DOI 10.1067/mem.2003.275; Byczkowski TL, 2013, ANN EMERG MED, V62, P340, DOI 10.1016/j.annemergmed.2013.04.025; Cheng Xiang, 2008, Zhonghua Yi Xue Za Zhi, V88, P2898; Cimpello LB, 2004, PEDIATR EMERG CARE, V20, P228, DOI 10.1097/01.pec.0000121242.99242.e0; Cole J, 2009, EMERG MED AUSTRALAS, V21, P395, DOI 10.1111/j.1742-6723.2009.01216.x; Finn J, 2004, BURNS, V30, P262, DOI 10.1016/j.burns.2003.10.017; Fosnocht DE, 2007, AM J EMERG MED, V25, P791, DOI 10.1016/j.ajem.2006.12.020; Fosnocht DE, 2005, EMERG MED CLIN N AM, V23, P297, DOI 10.1016/j.emc.2004.12.003; Friedland LR, 1997, PEDIATR EMERG CARE, V13, P103, DOI 10.1097/00006565-199704000-00005; Fry Margaret, 2002, Emerg Med (Fremantle), V14, P249, DOI 10.1046/j.1442-2026.2002.00339.x; Hatherley C, 2016, AUSTRALAS EMERG NURS, V19, P26, DOI 10.1016/j.aenj.2015.11.001; Holdgate A, 2010, ACAD EMERG MED, V17, P214, DOI 10.1111/j.1553-2712.2009.00636.x; Kaplan CP, 2008, PEDIATR EMERG CARE, V24, P605, DOI 10.1097/PEC.0b013e3181850c1c; Kress HG, 2009, CLIN THER, V31, P1177, DOI 10.1016/j.clinthera.2009.05.022; Mercadante S, 2009, CURR MED RES OPIN, V25, P2805, DOI 10.1185/03007990903336135; Petrack EM, 1997, PEDIATRICS, V99, P711, DOI 10.1542/peds.99.5.711; Rickard C, 2007, AM J EMERG MED, V25, P911, DOI 10.1016/j.ajem.2007.02.027; Rupp T, 2004, ANN EMERG MED, V43, P494, DOI 10.1016/j.annemergmed.2003.11.019; Saunders M, 2010, ACAD EMERG MED, V17, P1155, DOI 10.1111/j.1553-2712.2010.00905.x; SELBST SM, 1990, ANN EMERG MED, V19, P1010, DOI 10.1016/S0196-0644(05)82565-X; Shavit I, 2004, ISR MED ASSOC J, V6, P350; Somers LJ, 2001, EMERG MED J, V18, P159, DOI 10.1136/emj.18.3.159; Van Woerden G, 2016, INT J EMERG MED, V9, DOI 10.1186/s12245-016-0102-y; Walco Gary A, 2008, Pediatrics, V122 Suppl 3, pS125, DOI 10.1542/peds.2008-1055d; WILSON JE, 1989, AM J EMERG MED, V7, P620, DOI 10.1016/0735-6757(89)90286-6; Zempsky WT, 2004, PEDIATRICS, V114, P1348, DOI 10.1542/peds.2004-1752	33	3	3	0	1	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0735-6757	1532-8171		AM J EMERG MED	Am. J. Emerg. Med.	SEP	2018	36	9					1603	1607		10.1016/j.ajem.2018.01.042			5	Emergency Medicine	Emergency Medicine	GQ2TH	WOS:000441510000015	29371045				2020-06-30	J	Kendall, MC				Kendall, Mark C.			Confounding biases in the association between fentanyl use and hypotension after rapid sequence intubation	AMERICAN JOURNAL OF EMERGENCY MEDICINE			English	Letter									[Kendall, Mark C.] Brown Univ, Rhode Isl Hosp, Dept Anesthesiol, Warren Alpert Med Sch, Providence, RI 02903 USA	Kendall, MC (reprint author), Brown Univ, Warren Alpert Med Sch, Dept Anesthesiol, 593 Eddy St, Providence, RI 02903 USA.	mark.kendall@lifespan.org					Jin JH, 2017, J CLIN ANESTH, V39, P120, DOI 10.1016/j.jclinane.2017.03.031; Kurahashi N, 2017, J CLIN ANESTH, V39, P15, DOI 10.1016/j.jclinane.2017.03.017; Pourmand A, 2017, AM J EMERG MED, V35, P1177, DOI 10.1016/j.ajem.2017.06.006; Tachibana N, 2017, J CLIN ANESTH, V39, P113, DOI 10.1016/j.jclinane.2016.10.026; Takahashi J, 2018, AM J EMERG MED, V36, P2044, DOI 10.1016/j.ajem.2018.03.026	5	0	0	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0735-6757	1532-8171		AM J EMERG MED	Am. J. Emerg. Med.	SEP	2018	36	9					1694	1695		10.1016/j.ajem.2018.07.017			3	Emergency Medicine	Emergency Medicine	GQ2TH	WOS:000441510000035	30001814				2020-06-30	J	Takahashi, J; Goto, T; Okamoto, H; Hagiwara, Y; Watase, H; Shiga, T; Hasegawa, K				Takahashi, Jin; Goto, Tadahiro; Okamoto, Hiroshi; Hagiwara, Yusuke; Watase, Hiroko; Shiga, Takashi; Hasegawa, Kohei			In reply: Confounding biases in the association between fentanyl use and hypotension after rapid sequence intubation	AMERICAN JOURNAL OF EMERGENCY MEDICINE			English	Letter							RISK-FACTORS		[Takahashi, Jin; Shiga, Takashi] Tokyo Bay Urayasu Ichikawa Med Ctr, Dept Emergency & Crit Care Med, 3-4-32 Todaijima, Chiba 2790001, Japan; [Goto, Tadahiro; Hasegawa, Kohei] Massachusetts Gen Hosp, Dept Emergency Med, 125 Nashua St Boston,Suite 920, Boston, MA 02114 USA; [Okamoto, Hiroshi] St Lukes Int Univ, Ctr Clin Epidemiol, Chuo Ku, 3-6 Tsukiji, Tokyo 1040045, Japan; [Hagiwara, Yusuke] Tokyo Metropolitan Childrens Med Ctr, Dept Pediat Emergency & Crit Care Med, 2-8-29 Musashidai, Fuchu, Tokyo 1838561, Japan; [Watase, Hiroko] Univ Washington, Dept Radiol, 850 Republican St, Seattle, WA 98006 USA; [Shiga, Takashi] Int Univ Hlth & Welf, Dept Emergency Med, Minato Ku, 1-4-3 Mita, Tokyo 1088329, Japan; [Hasegawa, Kohei] Harvard Med Sch, Boston, MA USA	Takahashi, J (reprint author), Tokyo Bay Urayasu Ichikawa Med Ctr, Dept Emergency & Crit Care Med, 3-4-32 Todaijima, Chiba 2790001, Japan.	tshsf007001@gmail.com	Hagiwara, Yusuke/L-1886-2019	Takahashi, Jin/0000-0001-5396-0054			Green RS, 2012, CAN J EMERG MED, V14, P74, DOI 10.2310/8000.2012.110548; Heffner AC, 2012, J CRIT CARE, V27, DOI 10.1016/j.jcrc.2011.08.011; Seamon MJ, 2010, J TRAUMA, V68, P1289, DOI 10.1097/TA.0b013e3181db05dc; Smischney NJ, 2016, MED SCI MONITOR, V22, P346, DOI 10.12659/MSM.895919; Takahashi J, 2018, ASS FENTANYL USE RAP, DOI [10.1016/j.ajem.2018.03.026, DOI 10.1016/J.AJEM.2018.03.026]	5	0	0	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0735-6757	1532-8171		AM J EMERG MED	Am. J. Emerg. Med.	SEP	2018	36	9					1695	1695		10.1016/j.ajem.2018.07.018			1	Emergency Medicine	Emergency Medicine	GQ2TH	WOS:000441510000036	30005839				2020-06-30	J	Rex, DK; Bhandari, R; Desta, T; DeMicco, MP; Schaeffer, C; Etzkorn, K; Barish, CF; Pruitt, R; Cash, BD; Quirk, D; Tiongco, F; Sullivan, S; Bernstein, D				Rex, Douglas K.; Bhandari, Raj; Desta, Taddese; DeMicco, Michael P.; Schaeffer, Cynthia; Etzkorn, Kyle; Barish, Charles F.; Pruitt, Ronald; Cash, Brooks D.; Quirk, Daniel; Tiongco, Felix; Sullivan, Shelby; Bernstein, David			A phase III study evaluating the efficacy and safety of remimazolam (CNS 7056) compared with placebo and midazolam in patients undergoing colonoscopy	GASTROINTESTINAL ENDOSCOPY			English	Article							OUTPATIENT COLONOSCOPY; SEDATION; PROPOFOL; ANESTHESIA; BENZODIAZEPINES; ENDOSCOPISTS	Background and Aims: Remimazolam is an ultrashort-acting benzodiazepine. Methods: We performed a randomized double-blind comparison of remimazolam to placebo for outpatient colonoscopy. This study design was a requirement of the U.S. Food and Drug Administration. An additional group was randomized to open-label midazolam administered according to its package insert instructions (the randomization ratio for remimazolam:placebo:midazolam was 30:6:10). Study medications were administered under the supervision of the endoscopist, without any involvement of an anesthesia specialist. Patients were given 50 to 75 mg of fentanyl before receiving study medications. Patients who failed to achieve adequate sedation in any arm were rescued with midazolam dosed at the investigator's discretion. The primary endpoint was a composite that required 3 criteria be met: completion of the colonoscopy, no need for rescue medication, and <= 5 doses of remimazolam or placebo in any 15-minute interval (<= 3 doses of midazolam in any 12-minute interval in the open-label midazolam arm). Results: There were 461 randomized patients in 12 U.S. sites. The primary endpoint was met for remimazolam, placebo, and midazolam in 91.3%, 1.7%, and 25.2% of patients, respectively (P < .0001 for remimazolam vs placebo). Patients administered remimazolam received less fentanyl, had faster recovery of neuropsychiatric function, were ready for discharge earlier, and felt back to normal sooner than patients with both placebo and midazolam. Hypotension was less frequent with remimazolam, and hypoxia occurred in 1% of patients with remimazolam or midazolam. There were no treatment-emergent serious adverse events. Conclusion: Remimazolam can be administered safely under the supervision of endoscopists for outpatient colonoscopy, and it allows faster recovery of neuropsychiatric function compared with placebo (midazolam rescue) and midazolam.	[Rex, Douglas K.] Indiana Univ Sch Med, Indianapolis, IN 46202 USA; [Bhandari, Raj] Delta Res Partners, Monroe, LA USA; [Desta, Taddese] Precis Res Inst, San Diego, CA USA; [DeMicco, Michael P.] Adv Clin Res Inst, Anaheim, CA USA; [Schaeffer, Cynthia] Precis Res Inst, Chula Vista, CA USA; [Etzkorn, Kyle] Borland Groover Clin, Jacksonville, FL USA; [Barish, Charles F.] Wake Res Associates, Raleigh, NC USA; [Pruitt, Ronald] Nashville Med Res Inst, Nashville, TN USA; [Cash, Brooks D.] Univ S Alabama, Mobile, AL USA; [Quirk, Daniel] Thomas Jefferson Med Coll, Philadelphia, PA USA; [Tiongco, Felix] Gastroenterol Associates Tidewater, Chesapeake, VA USA; [Sullivan, Shelby] Univ Colorado, Dept Med, Denver, CO USA; [Bernstein, David] Hofstra Northwell Sch Med, Hempstead, NY USA	Rex, DK (reprint author), Indiana Univ Hosp, 4100,550 North Univ Blvd, Indianapolis, IN 46202 USA.				PAION UK Limited	PAION UK Limited participated in the study design, funded the study, performed the statistical analyses, prepared data tables and figures, and reviewed the manuscript for content and accuracy. B. Cash and D. Bernstein are consultants and advisors for PAION. D. Quirk is a Senior Medical Director at Pfizer. All other authors disclosed no financial relationships relevant to this publication.	Bazett HC, 1920, HEART-J STUD CIRC, V7, P353; Borkett KM, 2015, ANESTH ANALG, V120, P771, DOI 10.1213/ANE.0000000000000548; BRICE DD, 1970, BRIT J ANAESTH, V42, P535, DOI 10.1093/bja/42.6.535; Cohen LB, 2006, AM J GASTROENTEROL, V101, P967, DOI 10.1111/j.1572-0241.2006.00500.x; Cooper GS, 2013, JAMA INTERN MED, V173, P551, DOI 10.1001/jamainternmed.2013.2908; Fridericia LS, 1920, ACTA MED SCAND, V53, P469, DOI [DOI 10.1111/J.0954-6820.1920.TB18266.X, 10.1111/j.0954-6820.1920.tb18266.x]; Inadomi JM, 2010, GASTROINTEST ENDOSC, V72, P580, DOI 10.1016/j.gie.2010.04.040; Kim TK, 2015, BRIT J ANAESTH, V115, P569, DOI 10.1093/bja/aev306; Olkkola K. T., 2008, V182, P335, DOI 10.1007/978-3-540-74806-9_16; Pambianco DJ, 2016, TECH GASTROINTEST EN, V18, P22, DOI 10.1016/j.tgie.2016.02.004; Pambianco DJ, 2016, GASTROINTEST ENDOSC, V83, P984, DOI 10.1016/j.gie.2015.08.062; Rex DK, 2009, GASTROENTEROLOGY, V137, P1229, DOI 10.1053/j.gastro.2009.06.042; Shapiro AM, 1999, CLIN NEUROPSYCHOL, V13, P348, DOI 10.1076/clin.13.3.348.1749; Sipe BW, 2002, GASTROINTEST ENDOSC, V55, P815, DOI 10.1067/mge.2002.124636; Ulmer BJ, 2003, CLIN GASTROENTEROL H, V1, P425, DOI 10.1016/S1542-3565(03)00226-X; VanNatta ME, 2006, AM J GASTROENTEROL, V101, P2209, DOI 10.1111/j.1572-0241.2006.00760.x; Vargo JJ, 2009, GASTROINTEST ENDOSC, V70, P1053, DOI 10.1016/j.gie.2009.07.020; Wernli KJ, 2016, GASTROENTEROLOGY, V150, P888, DOI 10.1053/j.gastro.2015.12.018	18	6	9	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0016-5107	1097-6779		GASTROINTEST ENDOSC	Gastrointest. Endosc.	SEP	2018	88	3					427	+		10.1016/j.gie.2018.04.2351			17	Gastroenterology & Hepatology	Gastroenterology & Hepatology	GQ3GJ	WOS:000441549400002	29723512	Bronze			2020-06-30	J	Reardon, S				Reardon, Sara			Model citizens	NATURE			English	News Item																Bobashev Georgiy, 2018, Social, Cultural, and Behavioral Modeling. 11th International Conference, SBP-BRiMS 2018. Proceedings: LNCS 10899, P274, DOI 10.1007/978-3-319-93372-6_31; Grefenstette JJ, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-940; Seth P, 2018, MMWR-MORBID MORTAL W, V67, P349, DOI 10.15585/mmwr.mm6712a1	3	1	1	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 16	2018	560	7718					295	297		10.1038/d41586-018-05939-8			3	Multidisciplinary Sciences	Science & Technology - Other Topics	GQ4VN	WOS:000441673400013	30108352	Bronze			2020-06-30	J	Bruera, E				Bruera, Eduardo			Parenteral Opioid Shortage - Treating Pain during the Opioid-Overdose Epidemic	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Bruera, Eduardo] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA	Bruera, E (reprint author), Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.						Dowell D, 2016, JAMA-J AM MED ASSOC, V315, P1624, DOI 10.1001/jama.2016.1464; Haider A, 2017, J ONCOL PRACT, V13, pE972, DOI 10.1200/JOP.2017.024901; Hollingsworth Hanna, 2018, J Opioid Manag, V14, P81, DOI 10.5055/jom.2018.0434; Parsons HA, 2008, J PALLIAT MED, V11, P1319, DOI 10.1089/jpm.2008.0155; Winstanley EL, 2018, DRUG ALCOHOL DEPEN, V188, P169, DOI 10.1016/j.drugalcdep.2018.03.036	5	11	11	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 16	2018	379	7					601	603		10.1056/NEJMp1807117			3	Medicine, General & Internal	General & Internal Medicine	GQ4QV	WOS:000441659100001	30020849	Bronze			2020-06-30	J	Kennedy, JH; Palaty, J; Gill, CG; Wiseman, JM				Kennedy, Joseph H.; Palaty, Jan; Gill, Chris G.; Wiseman, Justin M.			Rapid analysis of fentanyls and other novel psychoactive substances in substance use disorder patient urine using paper spray mass spectrometry	RAPID COMMUNICATIONS IN MASS SPECTROMETRY			English	Article							OVERDOSE DEATHS; UNITED-STATES; RHODE-ISLAND; IONIZATION; DRUGS; INCREASES; BLOOD; CARFENTANIL; ABUSE; PAIN	RationaleDrug overdose deaths due to fentanyls and other novel psychoactive substances (NPS) are on the rise. The higher potencies of fentanyl analogs compared with morphine require new technologies to identify and quantitate NPS. MethodsPaper spray tandem mass spectrometry (MS/MS) and high-resolution mass spectrometry were used to identify and measure fentanyl analogs as well as common drugs of abuse in urine samples from substance use disorder clinics. Ten-microliter urine samples were deposited directly on paper spray cartridges previously loaded with internal standards, dried, and analyzed with no other sample treatment. Quantitative results were obtained using MS/MS. Individual drugs were identified using high-resolution accurate mass spectrometry, and confirmed by data-dependent MS/MS. ResultsCalibration curves in urine were linear over a range of 0.5-50ng/mL with R-2 of 0.99 or better for eight representative fentanyl analogs. Cartridges preloaded with internal standards demonstrated satisfactory quantitative results compared with LC/MS. Direct identification and confirmation of fentanyl analogs and other common drugs of abuse in urine using high-resolution accurate mass and MS/MS fragmentation were demonstrated at low picogram levels. ConclusionsPaper spray mass spectrometry can reliably identify and quantitate fentanyl analogs and other drugs of abuse in urine. Using paper spray cartridges as collection devices reduces exposure and transportation risks associated with biological fluids. Cartridges preloaded with labeled internal standards can be effective for targeted screening of fentanyl analogs and other drugs of abuse.	[Kennedy, Joseph H.; Wiseman, Justin M.] Prosolia Inc, 6500 Technol Ctr Dr, Indianapolis, IN 46202 USA; [Palaty, Jan] LifeLabs Med Lab Serv, Burnaby, BC V5G 4V8, Canada; [Gill, Chris G.] Vancouver Isl Univ, AERL, Dept Chem, 900 Fifth St, Nanaimo, BC V9R 5S5, Canada; [Gill, Chris G.] Univ Victoria, Dept Chem, Victoria, BC V8P 5C2, Canada; [Gill, Chris G.] Simon Fraser Univ, Dept Chem, Burnaby, BC V5A 1S6, Canada; [Gill, Chris G.] Univ Washington, Dept Environm & Occupat Hlth Sci, Seattle, WA 98195 USA	Kennedy, JH (reprint author), Prosolia Inc, 6500 Technol Ctr Dr, Indianapolis, IN 46202 USA.; Gill, CG (reprint author), Vancouver Isl Univ, AERL, Dept Chem, 900 Fifth St, Nanaimo, BC V9R 5S5, Canada.	kennedy@prosolia.com; chris.gill@viu.ca		Wiseman, Justin/0000-0003-0080-7173	Natural Sciences and Engineering Research Council of CanadaNatural Sciences and Engineering Research Council of Canada [RGPIN-2016-05380]	Natural Sciences and Engineering Research Council of Canada, Grant/Award Number: RGPIN-2016-05380	Beck R, 2016, J ANAL TOXICOL, V40, P140, DOI 10.1093/jat/bkv128; Carroll JJ, 2017, INT J DRUG POLICY, V46, P136, DOI 10.1016/j.drugpo.2017.05.023; Carvalho TC, 2016, ANAL METHODS-UK, V8, P614, DOI 10.1039/c5ay01265a; Casale JF, 2017, FORENSIC CHEM, V3, P74, DOI 10.1016/j.forc.2017.02.003; Centers for Disease Control and Prevention (USA), OP DAT AN 2017; CHEATLE M, 2017, ANN BEHAV MED S1, V51, pS423; Dowell D, 2016, MMWR RECOMM REP, V65, P1, DOI 10.15585/mmwr.rr6501e1; Espy RD, 2014, ANAL CHEM, V86, P7712, DOI 10.1021/ac5016408; Espy RD, 2012, INT J MASS SPECTROM, V325, P167, DOI 10.1016/j.ijms.2012.06.017; Gladden RM, 2016, MMWR-MORBID MORTAL W, V65, P837, DOI 10.15585/mmwr.mm6533a2; Harper L, 2017, HARM REDUCT J, V14, DOI 10.1186/s12954-017-0179-5; Iula DM, 2017, OPIOID CRISIS PUBLIC; Jett R, 2017, ANAL METHODS-UK, V9, P5037, DOI 10.1039/c7ay01009e; Johns Hopkins Bloomberg School of Public Health, FENT OV RED CHECK AN; Kanowitz A, 2006, PREHOSP EMERG CARE, V10, P1, DOI 10.1080/10903120500373264; Kennedy J, 2016, CLIN MASS SPECTROM, V1, P3, DOI 10.1016/j.clinms.2016.08.003; Liu JJ, 2010, ANAL CHEM, V82, P2463, DOI 10.1021/ac902854g; Manicke NE, 2011, INT J MASS SPECTROM, V300, P123, DOI 10.1016/j.ijms.2010.06.037; Manicke NE, 2011, J AM SOC MASS SPECTR, V22, P1501, DOI 10.1007/s13361-011-0177-x; McKenna J, 2018, J ANAL TOXICOL, V42, P300, DOI 10.1093/jat/bky001; O'Donnell JK, 2017, MMWR-MORBID MORTAL W, V66, P1197, DOI 10.15585/mmwr.mm6643e1; Ogilvie L, 2013, MMWR-MORBID MORTAL W, V62, P703; Palaty J, 2018, CLIN BIOCHEM, V53, P164, DOI 10.1016/j.clinbiochem.2018.01.013; Peterson AB, 2016, MMWR-MORBID MORTAL W, V65, P844, DOI 10.15585/mmwr.mm6533a3; Rudd RA, 2016, MMWR-MORBID MORTAL W, V65, P1445, DOI 10.15585/mmwr.mm655051e1; Steiner RR, 2009, J FORENSIC SCI, V54, P617, DOI 10.1111/j.1556-4029.2009.01006.x; Su Y, 2013, ANALYST, V138, P4443, DOI 10.1039/c3an00934c; Teunissen SF, 2017, J AM SOC MASS SPECTR, V28, P2665, DOI 10.1007/s13361-017-1790-0; Thermo Fisher Scientific, 2015, THERMO FISHER SCI PR; Valdez CA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108250; Vandergrift GW, 2018, CLIN BIOCHEM, V54, P106, DOI 10.1016/j.clinbiochem.2018.02.005; Wang H, 2010, ANGEW CHEM INT EDIT, V49, P877, DOI 10.1002/anie.200906314; Wang LQ, 2006, J ANAL TOXICOL, V30, P335, DOI 10.1093/jat/30.5.335; Wiseman JM, 2014, LC GC N AM, P69	34	10	10	7	31	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0951-4198	1097-0231		RAPID COMMUN MASS SP	Rapid Commun. Mass Spectrom.	AUG 15	2018	32	15					1280	1286		10.1002/rcm.8164			7	Biochemical Research Methods; Chemistry, Analytical; Spectroscopy	Biochemistry & Molecular Biology; Chemistry; Spectroscopy	GM1PO	WOS:000437842100014	29757475				2020-06-30	J	Khan, SA; Ekeoduru, RA; Tariq, S				Khan, Sabina A.; Ekeoduru, Rhashedah A.; Tariq, Sarah			Traumatic Tracheobronchial Laceration Causing Complete Tracheal Resection: Challenges of Anesthetic Management	A & A PRACTICE			English	Article							BLUNT TRAUMA; RUPTURE	We report the case of a 9-year-old girl who sustained blunt trauma to the chest and presented for emergent repair of a complete tracheobronchial laceration. Tracheobronchial laceration is potentially life threatening. While conservative management has been described for simple tears, more complex injuries require surgical repair. We discuss the anesthetic challenges, airway management, and ventilation options for surgical repair in a child with a complex laceration involving the tracheobronchial tree.	[Khan, Sabina A.; Ekeoduru, Rhashedah A.; Tariq, Sarah] Univ Texas Hlth Sci Ctr Houston, Dept Anesthesiol, Houston, TX 77030 USA	Khan, SA (reprint author), Univ Texas Hlth Sci Ctr Houston, 6431 Fannin St,MSB 5-020, Houston, TX 77030 USA.	sabina.ali.khan@gmail.com					Ballouhey Q, 2013, EUR J TRAUMA EMERG S, V39, P167, DOI 10.1007/s00068-012-0248-0; Cheaito A, 2016, INT J SURG CASE REP, V27, P172, DOI 10.1016/j.ijscr.2016.08.014; Juvekar NM, 2013, ANN CARD ANAESTH, V16, P140, DOI 10.4103/0971-9784.109772; Rieley RD, 2004, TRAUMA; Sengupta S, 2008, ANN CARD ANAESTH, V11, P123, DOI 10.4103/0971-9784.41582; SYMBAS PN, 1992, ANN THORAC SURG, V54, P177, DOI 10.1016/0003-4975(92)91177-B; Wintermark M, 2001, EUR RADIOL, V11, P409, DOI 10.1007/s003300000581	7	1	1	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2325-7237			A A PRACT	A A Pract.	AUG 15	2018	11	4					109	111		10.1213/XAA.0000000000000756			3	Anesthesiology	Anesthesiology	GQ2UV	WOS:000441515200008	29634532				2020-06-30	J	Grasso, SC; Ko, JC; Weil, AB; Hess, JA; Paranjape, V; Payton, M				Grasso, Stefania C.; Ko, Jeff C.; Weil, Ann B.; Hess, Jennifer A.; Paranjape, Vaidehi; Payton, Mark			Effects of transdermal fentanyl solution application and subsequent naloxone hydrochloride administration on minimum alveolar concentration of isoflurane in dogs	JAVMA-JOURNAL OF THE AMERICAN VETERINARY MEDICAL ASSOCIATION			English	Article							HEALTHY LABORATORY BEAGLES; POSTOPERATIVE PAIN; INDUCED HYPOTENSION; ANESTHETIC POTENCY; ENFLURANE; PHARMACOKINETICS; SEVOFLURANE; HALOTHANE; REDUCTION; CARPROFEN	OBJECTIVE To assess the isoflurane-sparing effect of a transdermal formulation of fentanyl solution (TFS) and subsequent naloxone administration in dogs. DESIGN Experiment. ANIMALS 6 healthy mixed-breed dogs. PROCEDURES Minimum alveolar concentration (MAC) of isoflurane was determined in each dog with a tail clamp method (baseline). Two weeks later, dogs were treated with TFS (2.7 mg/kg [1.23 mg/lb]), and the MAC of isoflurane was determined 4 and 24 hours later. After the 4-hour MAC assessment, saline (0.9% NaCl) solution was immediately administered IV and MAC was reassessed. After the 24-hour MAC assessment, naloxone hydrochloride (0.02 mg/kg [0.01 mg/lb], IV) was immediately administered and MAC was reassessed. Heart rate, respiratory rate, arterial blood pressure, end-tidal partial pressure of CO2, and oxygen saturation as measured by pulse oximetry were recorded for each MAC assessment. RESULTS Mean +/- SD MAC of isoflurane at 4 and 24 hours after TFS application was 45.4 +/- 4.0% and 45.5 +/- 4.5% lower than at baseline, respectively. Following naloxone administration, only a minimal reduction in MAC was identified (mean percentage decrease from baseline of 13.1 +/- 2.2%, compared with 43.8 +/- 5.6% for saline solution). Mean heart rate was significantly higher after naloxone administration (113.2 +/- 22.2 beats/min) than after saline solution administration (76.7 +/- 20.0 beats/min). No significant differences in other variables were identified among treatments. CONCLUSIONS AND CLINICAL RELEVANCE The isoflurane-sparing effects of TFS in healthy dogs were consistent and sustained between 4 and 24 hours after application, and these effects should be taken into consideration when anesthetizing or reanesthetizing TFStreated dogs.	[Grasso, Stefania C.; Ko, Jeff C.; Weil, Ann B.; Hess, Jennifer A.; Paranjape, Vaidehi] Purdue Univ, Coll Vet Med, Dept Vet Clin Sci, W Lafayette, IN 47907 USA; [Payton, Mark] Oklahoma State Univ, Dept Stat, Coll Vet Med, Stillwater, OK 74078 USA; [Grasso, Stefania C.] Vet Ctr Anesthesia & Neurol, Unit 203,1155 Lola St, Ottawa, ON K1K 4C1, Canada; [Paranjape, Vaidehi] Univ Florida, Coll Vet Med, Dept Large Anim Clin Sci, Gainesville, FL 32608 USA	Ko, JC (reprint author), Purdue Univ, Coll Vet Med, Dept Vet Clin Sci, W Lafayette, IN 47907 USA.	jcko@purdue.edu	Hess, Jennifer/V-7859-2019	Hess, Jennifer/0000-0002-0479-0498			Aarnes TK, 2009, AM J VET RES, V70, P1345, DOI 10.2460/ajvr.70.11.1345; EGER EI, 1965, ANESTHESIOLOGY, V26, P756, DOI 10.1097/00000542-196511000-00010; FLACKE JW, 1983, ANESTH ANALG, V62, P305; Freise KJ, 2012, J VET PHARMACOL THER, V35, P21, DOI 10.1111/j.1365-2885.2012.01399.x; Freise KJ, 2012, J VET PHARMACOL THER, V35, P65, DOI 10.1111/j.1365-2885.2012.01407.x; Freise KJ, 2012, J VET PHARMACOL THER, V35, P45, DOI 10.1111/j.1365-2885.2012.01409.x; Freise KJ, 2012, J VET PHARMACOL THER, V35, P27, DOI 10.1111/j.1365-2885.2012.01411.x; Gilberto DB, 2003, CONTEMP TOP LAB ANIM, V42, P21; GOURLAY GK, 1988, ANESTH ANALG, V67, P329; Hofmeister EH, 2004, J AM ANIM HOSP ASSOC, V40, P468, DOI 10.5326/0400468; ILKIW JE, 1994, CAN J VET RES, V58, P248; KAZAMA T, 1988, ANESTHESIOLOGY, V68, P435, DOI 10.1097/00000542-198803000-00020; Ko JCH, 2000, J AM VET MED ASSOC, V217, P1025, DOI 10.2460/javma.2000.217.1025; Ko JCH, 2009, J AM ANIM HOSP ASSOC, V45, P19, DOI 10.5326/0450019; Kukanich B, 2015, LUMB JONES VET ANEST, P207; LAUBIE M, 1980, EUR J PHARMACOL, V67, P403, DOI 10.1016/0014-2999(80)90181-8; Linton DD, 2012, J VET PHARMACOL THER, V35, P53, DOI 10.1111/j.1365-2885.2012.01408.x; LIU WS, 1976, ANESTH ANALG, V55, P168; LOEB JM, 1984, J AUTONOM NERV SYST, V11, P91, DOI 10.1016/0165-1838(84)90010-9; Martinez SA, 2014, J VET PHARMACOL THER, V37, P394, DOI 10.1111/jvp.12096; MCEWAN AI, 1993, ANESTHESIOLOGY, V78, P864, DOI 10.1097/00000542-199305000-00009; MURPHY MR, 1982, ANESTHESIOLOGY, V57, P485, DOI 10.1097/00000542-198212000-00009; Mutoh T, 1997, AM J VET RES, V58, P885; SCHELLER MS, 1990, BRIT J ANAESTH, V65, P388, DOI 10.1093/bja/65.3.388; Simoes CR, 2016, VET ANAESTH ANALG, V43, P136, DOI 10.1111/vaa.12282; Steagall PVM, 2006, JAVMA-J AM VET MED A, V229, P522, DOI 10.2460/javma.229.4.522; STEFFEY EP, 1977, AM J VET RES, V38, P1833; STEFFEY EP, 1978, AM J VET RES, V39, P573; Valverde A, 2012, CAN J VET RES, V76, P99; Wilson D, 2006, JAVMA-J AM VET MED A, V228, P1042, DOI 10.2460/javma.228.7.1042	30	0	0	0	1	AMER VETERINARY MEDICAL ASSOC	SCHAUMBURG	1931 N MEACHAM RD SUITE 100, SCHAUMBURG, IL 60173-4360 USA	0003-1488	1943-569X		JAVMA-J AM VET MED A	JAVMA-J. Am. Vet. Med. Assoc.	AUG 15	2018	253	4					431	436		10.2460/javma.253.4.431			6	Veterinary Sciences	Veterinary Sciences	GO6NQ	WOS:000440164800020	30058966				2020-06-30	J	Weed, PF; Gerak, LR; France, CP				Weed, Peter F.; Gerak, Lisa R.; France, Charles P.			Ventilatory-depressant effects of opioids alone and in combination with cannabinoids in rhesus monkeys	EUROPEAN JOURNAL OF PHARMACOLOGY			English	Article						mu opioid receptor agonist; Cannabinoid receptor agonist; Rhesus monkey; Ventilation; Respiration; Drug-drug interactions	ANTINOCICEPTIVE TOLERANCE; RECEPTOR AGONISTS; UNITED-STATES; PAIN; MORPHINE; DELTA(9)-TETRAHYDROCANNABINOL; DELTA9-TETRAHYDROCANNABINOL; DISCRIMINATION; MECHANISMS; ABUSE	Pain is a serious health problem that is commonly treated with opioids, although the doses of opioids needed to treat pain are often similar to those that decrease respiration. Combining opioids with drugs that relieve pain through non-opioid mechanisms can decrease the doses of opioids needed for analgesia, resulting in an improved therapeutic window, but only if the doses of opioids that decrease respiration are not similarly decreased. Using small doses of opioids to treat pain has the potential to reduce the number of overdoses and deaths. This study investigated whether the cannabinoid receptor agonists Delta(9)-tetrahydrocannabinol (Delta(9)-THC) and CP 55,940 modify the ventilatory-depressant effects of morphine and fentanyl in three monkeys. Ventilatory parameters, including minute volume (V-E), were monitored with a head plethysmograph. When given alone, morphine (0.032 - 10 mg/kg) and fentanyl (0.00032 - 0.1 mg/kg) dose dependently decreased V-E. Doses of Delta(9)-THC (1 mg/ kg) and CP 55,940 (0.01 mg/kg) that enhance the potency of opioids to produce antinociception modestly decreased ventilation when given alone but did not significantly change morphine or fentanyl dose-effect curves. A larger dose of CP 55,940 (0.032 mg/kg) shifted the fentanyl dose-effect curve downward in two monkeys, without significantly changing the morphine dose-effect curve. In summary, cannabinoid receptor agonists, which increase the potency of opioids to produce antinociception, did not increase their potency to depress ventilation. Thus, the therapeutic window is greater for opioids when they are combined with cannabinoid receptor agonists, indicating a possible advantage for these drug mixtures in treating pain.	[Weed, Peter F.; Gerak, Lisa R.; France, Charles P.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, 7703 Floyd Curl Dr,Mail Code 7764, San Antonio, TX 78229 USA; [France, Charles P.] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA; [Weed, Peter F.; Gerak, Lisa R.; France, Charles P.] Univ Texas Hlth Sci Ctr San Antonio, Treatment & Training Ctr Excellence, Addict Res, San Antonio, TX 78229 USA	France, CP (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, 7703 Floyd Curl Dr,Mail Code 7764, San Antonio, TX 78229 USA.	france@uthscsa.edu			National Institutes of Health, National Institute on Drug AbuseUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [R01DA05018, T32DA031115]; Welch FoundationThe Welch Foundation [AQ-0039]	This work was supported by the National Institutes of Health, National Institute on Drug Abuse [Grants R01DA05018, T32DA031115] and by the Welch Foundation [Grant AQ-0039]. All funding sources had no involvement beyond financial support of this study. The content is solely the responsibility of the authors and does not represent the official views of the National Institutes of Health or the National Institute on Drug Abuse.	BORISON HL, 1977, PHARMACOL THER PT B, V3, P227, DOI 10.1016/0306-039X(77)90034-4; Cichewicz DL, 2003, J PHARMACOL EXP THER, V305, P812, DOI 10.1124/jpet.102.046870; Compton WM, 2006, DRUG ALCOHOL DEPEN, V81, P103, DOI 10.1016/j.drugalcdep.2005.05.009; Dunn KM, 2011, PAIN, V152, P66, DOI 10.1016/j.pain.2010.09.006; Fischer BD, 2010, NEUROPHARMACOLOGY, V58, P544, DOI 10.1016/j.neuropharm.2009.08.005; FRANCE CP, 1992, PSYCHOPHARMACOLOGY, V109, P291, DOI 10.1007/BF02245876; Gerak LR, 2016, J PHARMACOL EXP THER, V357, P357, DOI 10.1124/jpet.115.231381; Gerak LR, 2015, PSYCHOPHARMACOLOGY, V232, P3637, DOI 10.1007/s00213-015-4023-x; Gerak L. R., 1994, J PHARMACOL EXP THER, V297, P882; Gerak LR, 1998, PSYCHOPHARMACOLOGY, V137, P164, DOI 10.1007/s002130050606; Hosking RD, 2008, BRIT J ANAESTH, V101, P59, DOI 10.1093/bja/aen119; JENNETT S, 1968, BRIT J ANAESTH, V40, P746, DOI 10.1093/bja/40.10.746; JOHNSTONE RE, 1975, ANESTHESIOLOGY, V42, P674, DOI 10.1097/00000542-197506000-00009; KEATS AS, 1985, ANNU REV PHARMACOL, V25, P41, DOI 10.1146/annurev.pharmtox.25.1.41; Li JX, 2008, PSYCHOPHARMACOLOGY, V199, P199, DOI 10.1007/s00213-008-1157-0; Li JX, 2012, BEHAV PHARMACOL, V23, P754, DOI 10.1097/FBP.0b013e32835a3907; Maguire DR, 2014, J PHARMACOL EXP THER, V351, P383, DOI 10.1124/jpet.114.216648; Maguire DR, 2013, J PHARMACOL EXP THER, V345, P354, DOI 10.1124/jpet.113.204099; MALIT LA, 1975, ANESTHESIOLOGY, V42, P666, DOI 10.1097/00000542-197506000-00008; MATHEW RJ, 1992, J CEREBR BLOOD F MET, V12, P750, DOI 10.1038/jcbfm.1992.106; Naef M, 2003, PAIN, V105, P79, DOI 10.1016/S0304-3959(03)00163-5; Padley JR, 2003, BRIT J PHARMACOL, V140, P384, DOI 10.1038/sj.bjp.0705422; Paulozzi Leonard J., 2011, Morbidity and Mortality Weekly Report, V60, P1487; Pertwee RG, 2001, PROG NEUROBIOL, V63, P569, DOI 10.1016/S0301-0082(00)00031-9; Pfitzer T, 2004, BRIT J PHARMACOL, V142, P943, DOI 10.1038/sj.bjp.0705874; Rudd RA, 2016, MMWR-MORBID MORTAL W, V64, P1378, DOI 10.15585/mmwr.mm6450a3; Schmid K, 2003, N-S ARCH PHARMACOL, V368, P301, DOI 10.1007/s00210-003-0787-3; Smith PA, 2007, EUR J PHARMACOL, V571, P129, DOI 10.1016/j.ejphar.2007.06.001; Vivian JA, 1998, J PHARMACOL EXP THER, V286, P697; Volkow ND, 2016, NEW ENGL J MED, V374, P1253, DOI 10.1056/NEJMra1507771; Walker JM, 2005, HANDB EXP PHARMACOL, V168, P509; Ware MA, 2010, CAN MED ASSOC J, V182, pE694, DOI 10.1503/cmaj.091414; White JM, 1999, ADDICTION, V94, P961, DOI 10.1046/j.1360-0443.1999.9479612.x; ZWILLICH CW, 1978, AM REV RESPIR DIS, V118, P885	34	4	4	0	5	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0014-2999	1879-0712		EUR J PHARMACOL	Eur. J. Pharmacol.	AUG 15	2018	833						94	99		10.1016/j.ejphar.2018.05.041			6	Pharmacology & Pharmacy	Pharmacology & Pharmacy	GN8IX	WOS:000439404200012	29807027	Green Accepted			2020-06-30	J	Shinohara, A; Andoh, T; Saiki, I; Kuraishi, Y				Shinohara, Akira; Andoh, Tsugunobu; Saiki, Ikuo; Kuraishi, Yasushi			Analgesic effects of systemic fentanyl on cancer pain are mediated by not only central but also peripheral opioid receptors in mice	EUROPEAN JOURNAL OF PHARMACOLOGY			English	Article						Fentanyl; Cancer pain; Mu-opioid receptor; Naloxone; Melanoma	MECHANICAL ALLODYNIA; MORPHINE ANALGESIA; NERVE INJURY; TUMOR-GROWTH; MOUSE MODEL; MU; EXPRESSION; INFLAMMATION; INOCULATION; LOPERAMIDE	Fentanyl is an opioid commonly prescribed for cancer pain. Using melanoma-bearing mice, we investigated whether peripheral action would contribute to fentanyl analgesia in cancer pain. Intravenous injection of fentanyl inhibited mechanical nociception in healthy mice, which was markedly inhibited by the opioid antagonist naloxone, but not naloxone methiodide, a peripherally acing opioid antagonist. Melanoma-bearing mice showed mechanical allodynia and spontaneous licking, a pain-related behavior, which were suppressed by intravenous and local injections of fentanyl. Both naloxone and naloxone methiodide inhibited the analgesic effect of intravenous fentanyl to the same degree. Electrophysiological analysis showed that melanoma growth increased the spontaneous and mechanical stimuli-evoked activity of the tibial nerve, which were inhibited by intravenous fentanyl. There was a greater expression of mu- opioid receptors in skin with a melanoma mass than in the contralateral normal skin. In addition, we found mu-opioid receptors in cultured melanoma cells. There was no difference between the number of mu-opioid receptors in the dorsal root ganglia and spinal cord of the melanoma-bearing and contralateral skin side. These results suggest that the analgesic effect of systemic fentanyl is produced via central and peripheral mu- opioid receptors in cancer pain, and cancer cells are a key site of peripheral action.	[Shinohara, Akira] Natl Canc Ctr Hosp East, Dept Pharm, Kashiwa, Chiba 2778527, Japan; [Shinohara, Akira; Andoh, Tsugunobu; Kuraishi, Yasushi] Univ Toyama, Grad Sch Med & Pharmaceut Sci, Dept Appl Pharmacol, 2630 Sugitani, Toyama 9300194, Japan; [Saiki, Ikuo] Univ Toyama, Inst Nat Med, Dept Pathogen Biochem, Toyama 9300194, Japan	Andoh, T (reprint author), Univ Toyama, Grad Sch Med & Pharmaceut Sci, Dept Appl Pharmacol, 2630 Sugitani, Toyama 9300194, Japan.	andoht@pha.u-toyama.ac.jp			Wakan-yaku and Biotechnology program from Toyama Prefectural Government [H29]	This study was supported in part by the Wakan-yaku and Biotechnology program from Toyama Prefectural Government (H29) (to T.A.).	Andoh T, 2017, PHARMACOL REP, V69, P139, DOI 10.1016/j.pharep.2016.10.005; Baamonde A, 2005, N-S ARCH PHARMACOL, V372, P213, DOI 10.1007/s00210-005-0013-6; Dagenais C, 2004, BIOCHEM PHARMACOL, V67, P269, DOI 10.1016/j.bcp.2003.08.027; DeHaven-Hudkins D.L., 1994, J PHARMACOL EXP THER, V289, P494; Everdingen MHJVDBV, 2007, ANN ONCOL, V18, P1437, DOI 10.1093/annonc/mdm056; Fujita M, 2008, J PHARMACOL SCI, V106, P257, DOI 10.1254/jphs.FP0072051; Fujita M, 2010, EUR J PAIN, V14, P588, DOI 10.1016/j.ejpain.2009.10.010; Guan Y, 2008, PAIN, V138, P318, DOI 10.1016/j.pain.2008.01.004; Ji RR, 1995, J NEUROSCI, V15, P8156; Kalso E, 1997, PAIN, V71, P127, DOI 10.1016/S0304-3959(97)03344-7; Kalso E, 2002, PAIN, V98, P269, DOI 10.1016/S0304-3959(02)00019-2; Menendez L, 2005, PHARMACOL BIOCHEM BE, V81, P114, DOI 10.1016/j.pbb.2005.02.007; Mercadante S, 1999, CANCER, V86, P1856, DOI 10.1002/(SICI)1097-0142(19991101)86:9<1856::AID-CNCR30>3.0.CO;2-G; Mercadante S, 2016, CRIT REV ONCOL HEMAT, V99, P241, DOI 10.1016/j.critrevonc.2015.12.011; Nylund G, 2008, DIGEST DIS SCI, V53, P461, DOI 10.1007/s10620-007-9897-y; Ossipov MH, 2004, J NEUROBIOL, V61, P126, DOI 10.1002/neu.20091; Peters CM, 2004, NEUROSCIENCE, V126, P1043, DOI 10.1016/j.neuroscience.2004.04.027; POLLOCK RE, 1984, CANCER RES, V44, P3888; Reddy A, 2016, CANCER-AM CANCER SOC, V122, P149, DOI 10.1002/cncr.29688; Ripamonti CI, 2011, ANN ONCOL, V22, pvi69, DOI 10.1093/annonc/mdr390; Sabino MAC, 2002, CANCER RES, V62, P7343; Sasaki A, 2007, J PHARMACOL SCI, V104, P218, DOI 10.1254/jphs.FP0070294; Sasamura T, 2002, EUR J PHARMACOL, V441, P185, DOI 10.1016/S0014-2999(02)01450-4; Stein C, 1996, J CLIN INVEST, V98, P793, DOI 10.1172/JCI118852; Stein C, 2003, NAT MED, V9, P1003, DOI 10.1038/nm908; Truong W, 2003, ANN NEUROL, V53, P366, DOI 10.1002/ana.10465; Watterson G, 2004, ARCH DIS CHILD, V89, P679, DOI 10.1136/adc.2003.032003; Yamamoto J, 2008, NEUROSCIENCE, V151, P843, DOI 10.1016/j.neuroscience.2007.11.025; Zhang HW, 2003, J PHARMACOL SCI, V91, P167; Zollner C, 2003, MOL PHARMACOL, V64, P202, DOI 10.1124/mol.64.2.202	30	3	3	1	4	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0014-2999	1879-0712		EUR J PHARMACOL	Eur. J. Pharmacol.	AUG 15	2018	833						275	282		10.1016/j.ejphar.2018.06.008			8	Pharmacology & Pharmacy	Pharmacology & Pharmacy	GN8IX	WOS:000439404200033	29886241				2020-06-30	J	Doucette, ML; Shields, WC; Haring, RS; Frattaroli, S				Doucette, Mitchell L.; Shields, Wendy C.; Haring, R. Sterling; Frattaroli, Shannon			Storing and Disposing of Opioid Analgesics: What Does Our Medicine Tell Us?	ANNALS OF INTERNAL MEDICINE			English	Letter							MEDICATIONS; STORAGE		[Doucette, Mitchell L.; Shields, Wendy C.; Frattaroli, Shannon] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD 21205 USA; [Haring, R. Sterling] Vanderbilt Univ, Med Ctr, Nashville, TN USA	Doucette, ML (reprint author), Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD 21205 USA.	mdoucet3@jhmi.edu		Doucette, Mitchell/0000-0002-5558-2218			Alexander GCFS, 2017, OPIOID EPIDEMIC EVID; Bicket MC, 2017, JAMA SURG, V152, P1066, DOI 10.1001/jamasurg.2017.0831; Dart RC, 2015, NEW ENGL J MED, V372, P241, DOI [10.1056/NEJMc1501822, 10.1056/NEJMsa1406143]; Frattaroli S, 2017, CLIN PEDIATR, V56, P678, DOI 10.1177/0009922816668631; Kennedy-Hendricks A, 2016, JAMA INTERN MED, V176, P1027, DOI 10.1001/jamainternmed.2016.2543; McCauley JL, 2013, ADDICT BEHAV, V38, P2230, DOI 10.1016/j.addbeh.2013.01.019; U. S. National Library of Medicine, 2005, DAILYMED        0403; Watson KT, 2009, ANESTH ANALG, V108, P211, DOI 10.1213/ane.0b013e31818c1b27	8	1	1	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 7	2018	169	3					198	+		10.7326/M17-3381			2	Medicine, General & Internal	General & Internal Medicine	GQ0AJ	WOS:000441277700013	29710198				2020-06-30	J	Bitar, H; Zia, H; Bashir, M; Parava, P; Hanafi, M; Tierney, W; Madhoun, M				Bitar, Hussein; Zia, Hassaan; Bashir, Muhammad; Parava, Pratyusha; Hanafi, Muhammad; Tierney, William; Madhoun, Mohammad			Impact of fellowship training level on colonoscopy quality and efficiency metrics	GASTROINTESTINAL ENDOSCOPY			English	Article							ADENOMA DETECTION RATES; GASTROINTESTINAL ENDOSCOPY; COLORECTAL-CANCER; SCREENING COLONOSCOPY; SEDATION; RETROFLEXION; CURRICULUM; COLON; PARTICIPATION; INDICATORS	Background and Aims: Previous studies have described variable effects of fellow involvement on the adenoma detection rate (ADR), but few have stratified this effect by level of training. We aimed to evaluate the "fellow effect" on multiple procedural metrics including a newly defined adenoma management efficiency index, which may have a role in documenting colonoscopy proficiency for trainees. We also describe the impact of level of training on moderate sedation use. Methods: We performed a retrospective review of 2024 patients (mean age, 60.9 +/- 10 years; 94% men) who underwent outpatient colonoscopy between June 2012 and December 2014 at our Veterans Affairs Medical Center. Colonoscopies were divided into 5 groups. The first 2 groups were first-year fellows in the first 6 months and last 6 months of the training year. Second-and third-year fellows and attending-only procedures accounted for 1 group each. We collected data on doses of sedatives used, frequency of adjunctive agent use, procedural times, and location, size, and histology of polyps. We defined the adenoma management efficiency index as average time required per adenoma resected during withdrawal. Results: Of the colonoscopies performed, 1675 involved a fellow and 349 were performed by the attending alone. There was no difference in ADR between fellows according to level of training (P=.8) or between fellows compared with attending-only procedures (P=.67). Procedural times decreased consistently during training and declined further for attending-only procedures. This translated into improvement in the adenoma management efficiency index (fellow groups by ascending level of training: 23.5 minutes vs 18.3 minutes vs 13.7 minutes vs 13.4 minutes vs attending group 11.7 minutes; P<.001). There was no difference in the average doses of midazolam and fentanyl used among fellow groups (P=.16 and P=.1, respectively). Compared with attending-only procedures, fellow involvement was associated with higher doses of fentanyl and midazolam and more frequent use of diphenhydramine and glucagon (P<.0001, P=.0002, P<.0001, and P=.01, respectively). Conclusions: ADR was similar at different stages of fellowship training and comparable with the attending group. Efficiency of detecting and resecting polyps improved throughout training without reaching the attending level. Fellow involvement led to a greater use of moderate sedation, which may relate to a longer procedure duration and an evolving experience in endoscopic technique.	[Bitar, Hussein; Zia, Hassaan; Bashir, Muhammad; Parava, Pratyusha; Hanafi, Muhammad; Tierney, William; Madhoun, Mohammad] Univ Oklahoma, Hlth Sci Ctr, Sect Digest Dis & Nutr, Oklahoma City, OK USA; [Bitar, Hussein; Zia, Hassaan; Bashir, Muhammad; Parava, Pratyusha; Hanafi, Muhammad; Tierney, William; Madhoun, Mohammad] Vet Affairs Med Ctr, Sect Digest Dis & Nutr, Oklahoma City, OK 73104 USA	Bitar, H (reprint author), Univ Oklahoma, 800 SL Young Blvd Suite 7400, Oklahoma City, OK 73104 USA.	Hussein-Bitar@ouhsc.edu					Abdeljawad K, 2015, GASTROINTEST ENDOSC, V81, P517, DOI 10.1016/j.gie.2014.04.064; Adler A, 2012, CLIN GASTROENTEROL H, V10, P155, DOI 10.1016/j.cgh.2011.10.026; [Anonymous], 2017, ACGME PROGRAMREQUIRE; Atkin W, 2004, GASTROENTEROLOGY, V126, P1247, DOI 10.1053/j.gastro.2004.01.023; Barclay RL, 2006, NEW ENGL J MED, V355, P2533, DOI 10.1056/NEJMoa055498; Bond A, 2017, CLIN COLORECTAL CANC, V16, P44, DOI 10.1016/j.clcc.2016.07.006; Buchner AM, 2011, GASTROINTEST ENDOSC, V73, P1223, DOI 10.1016/j.gie.2011.01.060; Chandran S, 2015, GASTROINTEST ENDOSC, V81, P608, DOI 10.1016/j.gie.2014.08.039; Chen SC, 2007, AM J GASTROENTEROL, V102, P856, DOI 10.1111/j.1572-0241.2006.01054.x; Cohen LB, 2006, AM J GASTROENTEROL, V101, P967, DOI 10.1111/j.1572-0241.2006.00500.x; Corley DA, 2014, NEW ENGL J MED, V370, P1298, DOI 10.1056/NEJMoa1309086; Dellon ES, 2008, CLIN GASTROENTEROL H, V6, P1342, DOI 10.1016/j.cgh.2008.06.014; DeMaria Samuel Jr, 2008, Gastrointest Endosc Clin N Am, V18, P801, DOI 10.1016/j.giec.2008.06.010; Eckardt AJ, 2009, DIS COLON RECTUM, V52, P1337, DOI 10.1007/DCR.0b013e3181a80d8f; Gianotti RJ, 2016, DIGEST DIS SCI, V61, P2831, DOI 10.1007/s10620-016-4228-9; Hewett DG, 2011, GASTROINTEST ENDOSC, V74, P246, DOI 10.1016/j.gie.2011.04.005; Inadomi JM, 2010, GASTROINTEST ENDOSC, V72, P580, DOI 10.1016/j.gie.2010.04.040; Kahi CJ, 2011, CLIN GASTROENTEROL H, V9, P42, DOI 10.1016/j.cgh.2010.09.013; Kaminski MF, 2010, NEW ENGL J MED, V362, P1795, DOI 10.1056/NEJMoa0907667; Klochan C, 2012, AM J GASTROENTEROL, V107, pS26, DOI 10.14309/00000434-201210001-00060; Kushnir VM, 2015, AM J GASTROENTEROL, V110, P415, DOI 10.1038/ajg.2015.21; Manser CN, 2012, GASTROINTEST ENDOSC, V76, P110, DOI 10.1016/j.gie.2012.02.040; McCashland T, 2000, AM J GASTROENTEROL, V95, P3129; MULLER AD, 1995, ANN INTERN MED, V123, P904, DOI 10.7326/0003-4819-123-12-199512150-00002; Munroe CA, 2012, GASTROINTEST ENDOSC, V75, P561, DOI 10.1016/j.gie.2011.11.037; Pan J, 2016, AM J GASTROENTEROL, V111, P355, DOI 10.1038/ajg.2015.418; Peters SL, 2010, CLIN GASTROENTEROL H, V8, P439, DOI 10.1016/j.cgh.2010.01.013; Radaelli F, 2015, GUT; Rex DK, 2006, AM J GASTROENTEROL, V101, P873, DOI 10.1111/j.1572-0241.2006.00673.x; Rex DK, 2012, AM J GASTROENTEROL, V107, P1315, DOI 10.1038/ajg.2012.161; Rex DK, 2009, AM J GASTROENTEROL, V104, P739, DOI 10.1038/ajg.2009.104; Rogart JN, 2008, AM J GASTROENTEROL, V103, P2841, DOI 10.1111/j.1572-0241.2008.02085.x; Sedlack RE, 2012, GASTROINTEST ENDOSC, V76, P482, DOI 10.1016/j.gie.2012.04.438; Siegel RL, 2016, CA-CANCER J CLIN, V66, P7, DOI 10.3322/caac.21332; Spier BJ, 2010, GASTROINTEST ENDOSC, V71, P319, DOI 10.1016/j.gie.2009.05.012; Stanford SB, 2015, WORLD J GASTRO ENDOS, V7, P1279, DOI 10.4253/wjge.v7.i18.1279; Tamai N, 2013, EUR J GASTROEN HEPAT, V25, P575, DOI 10.1097/MEG.0b013e32835e33db; Triantafillidis JK, 2013, WORLD J GASTROENTERO, V19, P463, DOI 10.3748/wjg.v19.i4.463; Triantafyllou K, 2014, WORLD J GASTRO ENDOS, V6, P6, DOI 10.4253/wjge.v6.i1.6; Tu RH, 2006, GASTROINTEST ENDOSC, V63, P87, DOI 10.1016/j.gie.2005.08.015; Vargo JJ, 2012, GASTROINTEST ENDOSC, V76, pE1, DOI 10.1016/j.gie.2012.03.001	41	8	8	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0016-5107	1097-6779		GASTROINTEST ENDOSC	Gastrointest. Endosc.	AUG	2018	88	2					378	387		10.1016/j.gie.2018.04.2338			10	Gastroenterology & Hepatology	Gastroenterology & Hepatology	GN0XL	WOS:000438703600025	29679692				2020-06-30	J	McGowan, CR; Harris, M; Platt, L; Hope, V; Rhodes, T				McGowan, Catherine R.; Harris, Magdalena; Platt, Lucy; Hope, Vivian; Rhodes, Tim			Fentanyl self-testing outside supervised injection settings to prevent opioid overdose: Do we know enough to promote it?	INTERNATIONAL JOURNAL OF DRUG POLICY			English	Article						Fentanyl; Self-testing; Overdose; Test-strips; Forensic; Off-label	HARM REDUCTION; DRUG-USE; HEROIN; RISK; NALOXONE; SCIENCE; STATES	Since 2013, North America has experienced a sharp increase in unintentional fatal overdoses: fentanyl, and its analogues, are believed to be primarily responsible. Currently, the most practical means for people who use drugs (PWUD) to avoid or mitigate risk of fentanyl-related overdose is to use drugs in the presence of someone who is in possession of, and experienced using, naloxone. Self-test strips which detect fentanyl, and some of its analogues, have been developed for off-label use allowing PWUD to test their drugs prior to consumption. We review the evidence on the off-label sensitivity and specificity of fentanyl test strips, and query whether the accuracy of fentanyl test strips might be mediated according to situated practices of use. We draw attention to the weak research evidence informing the use of fentanyl self-testing strips.	[McGowan, Catherine R.; Harris, Magdalena; Platt, Lucy; Rhodes, Tim] London Sch Hyg & Trop Med, Fac Publ Hlth & Policy, 15-17 Tavistock Pl, London WC1H 9SH, England; [McGowan, Catherine R.] Save Children UK, Humanitarian Publ Hlth Tech Unit, London, England; [Hope, Vivian] Liverpool John Moores Univ, Publ Hlth Inst, Liverpool, Merseyside, England; [Rhodes, Tim] Univ New South Wales, Ctr Social Res Hlth, Sydney, NSW, Australia	McGowan, CR (reprint author), London Sch Hyg & Trop Med, Fac Publ Hlth & Policy, 15-17 Tavistock Pl, London WC1H 9SH, England.	Catherine.McGowan@lshtm.ac.uk		Platt, Lucy/0000-0002-0943-0045; Harris, Magdalena/0000-0001-8718-8226; McGowan, Catherine/0000-0001-6941-6539; Hope, Vivian/0000-0001-5712-5734	National Institute for Health ResearchNational Institute for Health Research (NIHR) [CDF-2016-09-014]	Magdalena Harris is funded by the National Institute for Health Research [CDF-2016-09-014]. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health.	[Anonymous], 2017, VANCOUVER SUN; [Anonymous], 2017, HARM RED PEOPL WHO U; [Anonymous], 2018, CBC NEWS; [Anonymous], 2018, BBC; Australian Injecting & Illicit Drug Users League, 2013, INJ FENT MIN RISKS; Bebinger M, 2018, FENTANYL DEATHS RISE; Bryant B, 2018, INSIDE ONE UK LAB TE; BTNX Inc, 2018, RAP RESP FENT FYL TE; Centers for Disease Control and Prevention, 2018, OP OV FENT; Centers for Disease Control and Prevention, 2015, TOD HER EP MOR PEOPL; Ciccarone D, 2017, INT J DRUG POLICY, V46, P146, DOI 10.1016/j.drugpo.2017.06.004; Ciccarone D, 2017, INT J DRUG POLICY, V46, P107, DOI 10.1016/j.drugpo.2017.06.010; Ciccarone D, 2015, INT J DRUG POLICY, V26, P1103, DOI 10.1016/j.drugpo.2015.04.009; Clark AK, 2014, J ADDICT MED, V8, P153, DOI 10.1097/ADM.0000000000000034; Compton WM, 2016, NEW ENGL J MED, V374, P154, DOI 10.1056/NEJMra1508490; Cressman Alex M, 2017, CMAJ Open, V5, pE779, DOI 10.9778/cmajo.20170123; DanceSafe, 2018, DANCESAFE NOW OFF FE; Daniulaityte R, 2017, MMWR-MORBID MORTAL W, V66, P904, DOI 10.15585/mmwr.mm6634a3; European Monitoring Centre for Drugs and Drug Addiction, 2001, INV ON SIT PILL TEST; Exchange Supplies, 2018, POCKETLAB FENT TEST; Fairbairn N, 2017, INT J DRUG POLICY, V46, P172, DOI 10.1016/j.drugpo.2017.06.005; Frank D, 2015, INT J DRUG POLICY, V26, P84, DOI 10.1016/j.drugpo.2014.07.013; Friedman SR, 2007, INT J DRUG POLICY, V18, P107, DOI 10.1016/j.drugpo.2006.11.006; Gladden RM, 2016, MMWR-MORBID MORTAL W, V65, P837, DOI 10.15585/mmwr.mm6533a2; Harris M, EXPT HELPS HEROIN US; Harris M, 2015, INT J DRUG POLICY, V26, P51, DOI 10.1016/j.drugpo.2014.09.009; Health Canada, 2018, INF UPD HLTH CAN IS; Human Rights Watch, 2017, 2 CHANC OV PREV NAL; International Programme on Chemical Safety (INCHEM), 2017, DIAM; Ireland N, 2017, FENTANYL TEST STRIPS; Johns Hopkins Bloomberg School of Public Health, 2018, FENT OV RED CHECK AN; Jozaghi E, 2017, CAN J PUBLIC HEALTH, V108, pE457, DOI [10.17269/cjph.108.6480, 10.17269/CJPH.108.6480]; Lysyshyn M, 2017, 25 HARM RED INT C; Marshall BDL, 2011, LANCET, V377, P1429, DOI 10.1016/S0140-6736(10)62353-7; Massey J, 2017, MMWR-MORBID MORTAL W, V66, P975, DOI 10.15585/mmwr.mm6637a3; McGowan C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077038; Messac L, 2013, SOC SCI MED, V99, P176, DOI 10.1016/j.socscimed.2013.04.009; Mounteney J, 2015, INT J DRUG POLICY, V26, P626, DOI 10.1016/j.drugpo.2015.04.003; Murray RA, 2003, PHARMACOTHERAPY, V23, P1238, DOI 10.1592/phco.23.12.1238.32704; National Center for Biotechnology Information, 2017, PUBCHEM COMP DAT; Neira-Leon M, 2011, INT J DRUG POLICY, V22, P16, DOI 10.1016/j.drugpo.2010.06.003; O'Brien M, 2017, TESTING FENTANYL AVO; O'Donnell J. K., 2017, MORBIDITY MORTALITY, V66; Preston A, 2018, SAFER INJECTING HDB; Quest DW, 2007, J ANAL TOXICOL, V31, P354, DOI 10.1093/jat/31.6.354; Rhodes T, 1999, LANCET, V354, P65, DOI 10.1016/S0140-6736(98)07612-0; Rhodes T, 2007, SOC SCI MED, V65, P572, DOI 10.1016/j.socscimed.2007.03.033; Rhodes T, 2016, INT J DRUG POLICY, V30, P17, DOI 10.1016/j.drugpo.2016.01.002; Rhodes T, 2009, INT J DRUG POLICY, V20, P193, DOI 10.1016/j.drugpo.2008.10.003; Schneider J, 2016, INTERN MED J, V46, P1249, DOI 10.1111/imj.13250; Seth P, 2018, MMWR-MORBID MORTAL W, V67, P349, DOI 10.15585/mmwr.mm6712a1; Shaheen PE, 2009, J PAIN SYMPTOM MANAG, V38, P409, DOI 10.1016/j.jpainsymman.2009.06.004; Socias ME, 2017, BMJ-BRIT MED J, V358, DOI 10.1136/bmj.j4355; Special Advisory Committee on the Epidemic of Opioid Overdoses, 2018, NON TRADITIONAL REF; Stewart B, 2017, CBC NEWS; Toward the Heart, 2018, HEART KNOW YOUR SOUR; United Nations Office on Drugs and Crime, 2018, COMM NARC DRUGS TAK; United Nations Office on Drugs and Crime, 2017, FENT ITS AN 50 YEARS, V17; United States Drug Enforcement Administration, 2016, NAT HER THREAT ASS S; United States Drug Enforcement Administration, 2017, 2017 NAT DRUG THREAT; Vancouver Coastal Health, 2018, 86 DRUGS CHECK INS C; Vancouver Coastal Health, 2018, FENT CHECK EXP MOR V; Winstock AR, 2001, ADDICTION, V96, P1139, DOI 10.1046/j.1360-0443.2001.96811397.x	63	20	20	0	8	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0955-3959	1873-4758		INT J DRUG POLICY	Int. J. Drug Policy	AUG	2018	58						31	36		10.1016/j.drugpo.2018.04.017			6	Substance Abuse	Substance Abuse	GR5XG	WOS:000442714600005	29758542	Green Accepted, Other Gold			2020-06-30	J	Smith, JS; Coetzee, JF; Fisher, IWG; Borts, DJ; Mochel, JP				Smith, J. S.; Coetzee, J. F.; Fisher, I. W. G.; Borts, D. J.; Mochel, J. P.			Pharmacokinetics of fentanyl citrate and norfentanyl in Holstein calves and effect of analytical performances on fentanyl parameter estimation	JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS			English	Article						calves; cattle; fentanyl; norfentanyl	TRANSDERMAL FENTANYL; PLASMA-CONCENTRATIONS; ANALGESIA; DOGS; QUANTIFICATION; EXTRACTION; CLEARANCE; SURGERY; HORSES; LAMBS	This study describes the pharmacokinetics of intravenously administered (i.v.) fentanyl citrate, and its primary metabolite norfentanyl in Holstein calves. Eight calves (58.6 +/- 2.2kg), aged 3-4weeks, were administered fentanyl citrate at a single dose of 5.0g/kg i.v. Blood samples were collected from 0 to 24hr. Plasma (nor)fentanyl concentrations were determined using liquid chromatography with mass spectrometry and a lower limit of quantification (LLOQ) of 0.03ng/ml. To explore the effect of analytical performance on fentanyl parameter estimation, the noncompartmental pharmacokinetic analysis was then repeated with a hypothetical LLOQ value of 0.05ng/ml. Terminal elimination half-life was estimated at 12.7 and 3.6hr for fentanyl and norfentanyl, respectively. For fentanyl, systemic clearance was estimated at 2.0Lhr(-1)kg(-1), volume of distribution at steady-state was 24.8L/kg and extraction ratio was 0.42. At a hypothetical LLOQ of 0.05ng/ml fentanyl half-life, volume of distribution at steady-state and clearance were, respectively, of 3.0hr, 8.8L/kg and 3.4Lkg(-1)hr(-1). Fentanyl citrate administered i.v. at 5.0g/kg can reach levels associated with analgesia in other species. Pharmacokinetic parameters should be interpreted with respect to LLOQ, as lower limits can influence estimated parameters, such as elimination half-life or systemic clearance and have significant impact on dosage regimen selection in clinical practice.	[Smith, J. S.; Fisher, I. W. G.; Borts, D. J.; Mochel, J. P.] Iowa State Univ, Vet Diagnost & Prod Anim Med, Ames, IA 50011 USA; [Coetzee, J. F.] Kansas State Univ, Coll Vet Med, Dept Anat & Physiol, Manhattan, KS 66506 USA	Smith, JS (reprint author), Iowa State Univ, Vet Diagnost & Prod Anim Med, Ames, IA 50011 USA.	jss303@iastate.edu	Smith, Joseph/AAH-5810-2019	Smith, Joseph/0000-0002-4288-2262; Coetzee, Johann/0000-0003-1802-3991; Mochel, Jonathan/0000-0002-0997-3111			Ahern BJ, 2010, AM J VET RES, V71, P1127, DOI 10.2460/ajvr.71.10.1127; ARNDT JO, 1984, ANESTHESIOLOGY, V61, P355, DOI 10.1097/00000542-198410000-00001; Carroll GL, 1999, AM J VET RES, V60, P986; Christou C, 2015, RES VET SCI, V100, P252, DOI 10.1016/j.rvsc.2015.04.006; Clavijo CF, 2011, J SEP SCI, V34, P3568, DOI 10.1002/jssc.201100422; Delaski KM, 2017, J AVIAN MED SURG, V31, P6, DOI 10.1647/2015-153; GAUNTLETT IS, 1988, ANESTHESIOLOGY, V69, P683, DOI 10.1097/00000542-198811000-00008; GREENBLATT DJ, 1985, ANNU REV MED, V36, P421; Hing JP, 2001, J PHARMACOKINET PHAR, V28, P465, DOI 10.1023/A:1012247131190; KAMERLING SG, 1985, GEN PHARMACOL, V16, P253, DOI 10.1016/0306-3623(85)90078-3; Koch DE, 2004, J PHARMACEUT BIOMED, V34, P577, DOI 10.1016/S0731-7085(03)00652-6; KUHLS E, 1995, J PHARMACOL EXP THER, V274, P115; LIN SN, 1981, J PHARM SCI, V70, P1276, DOI 10.1002/jps.2600701124; Livingston A, 2010, HANDB EXP PHARMACOL, V199, P159, DOI 10.1007/978-3-642-10324-7_7; Lovasz M, 2017, J VET PHARMACOL THER, V40, P663, DOI 10.1111/jvp.12403; Maxwell LK, 2003, EQUINE VET J, V35, P484, DOI 10.2746/042516403775600415; Mochel JP, 2013, J VET PHARMACOL THER, V36, P417, DOI 10.1111/jvp.12060; Mochel JP, 2015, PHARM RES-DORDR, V32, P1931, DOI 10.1007/s11095-014-1587-9; Peng PWH, 1999, ANESTHESIOLOGY, V90, P576, DOI 10.1097/00000542-199902000-00034; Robertson SA, 2005, J VET PHARMACOL THER, V28, P87, DOI 10.1111/j.1365-2885.2004.00628.x; Robinson TM, 1999, J AM ANIM HOSP ASSOC, V35, P95, DOI 10.5326/15473317-35-2-95; Ruan XL, 2016, CLIN TOXICOL, V54, P893, DOI 10.1080/15563650.2016.1199030; Toutain PL, 2004, J VET PHARMACOL THER, V27, P415, DOI 10.1111/j.1365-2885.2004.00605.x	23	4	4	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0140-7783	1365-2885		J VET PHARMACOL THER	J. Vet. Pharmacol. Ther.	AUG	2018	41	4					555	561		10.1111/jvp.12501			7	Pharmacology & Pharmacy; Veterinary Sciences	Pharmacology & Pharmacy; Veterinary Sciences	GL4OS	WOS:000437133600009	29603262				2020-06-30	J	Ibrahim, K; Shah, R; Goli, RR; Kickler, TS; Clarke, WA; Hasan, RK; Blumenthal, RS; Thiemann, DR; Resar, JR; Schulman, SP; McEvoy, JW				Ibrahim, Khalil; Shah, Rohan; Goli, Rakesh R.; Kickler, Thomas S.; Clarke, William A.; Hasan, Rani K.; Blumenthal, Roger S.; Thiemann, David R.; Resar, Jon R.; Schulman, Steven P.; McEvoy, John W.			Fentanyl Delays the Platelet Inhibition Effects of Oral Ticagrelor: Full Report of the PACIFY Randomized Clinical Trial	THROMBOSIS AND HAEMOSTASIS			English	Article						fentanyl; ticagrelor; platelet inhibition; percutaneous coronary intervention	PERCUTANEOUS CORONARY INTERVENTION; INTRAVENOUS FENTANYL; CONSCIOUS SEDATION; DOUBLE-BLIND; MORPHINE; ABSORPTION; CLOPIDOGREL; ANALGESIA; PRASUGREL; CANGRELOR	Morphine delays oral P2Y(12) platelet inhibitor absorption and is associated with adverse outcomes after myocardial infarction. Consequently, many physicians and first responders are now considering fentanyl as an alternative. We conducted a single-centre trial randomizing cardiac patients undergoing coronary angiography to intravenous fentanyl or not. All participants received local anaesthetic and intravenous midazolam. Those requiring percutaneous coronary intervention (PCI) with stenting received 180 mg oral ticagrelor intraprocedurally. The primary outcome was area under the ticagrelor plasma concentration-time curve (AUC(0-24) (hours)). The secondary outcomes were platelet function assessed at 2 hours after loading, measured by P2Y(12) reaction units (PRUs) and light transmission platelet aggregometry. Troponin-I was measured post-PCI using a high-sensitivity troponin-I assay (hs-TnI). All participants completed a survey of pain and anxiety. Of the 212 randomized, 70 patients required coronary stenting and were loaded with ticagrelor. Two participants in the no-fentanyl arm crossed over to receive fentanyl for pain. In as-treated analyses, ticagrelor concentrations were higher in the no-fentanyl arm (AUC(0-24) (hours) 70% larger, p = 0.03). Platelets were more inhibited by 2 hours in the no-fentanyl arm (71 vs. 113 by PRU, p = 0.03, and 25% vs. 41% for adenosine diphosphate response by platelet aggregation, p < 0.01). Mean hs-TnI was higher with fentanyl at 2 hours post-PCI (11.9 vs. 7.0 ng/L, p = 0.04) with a rate of enzymatic myocardial infarction of 11% for fentanyl and 0% for no-fentanyl (p = 0.08). No statistical differences in self-reported pain or anxiety were found. In conclusion, fentanyl administration can impair ticagrelor absorption and delay platelet inhibition, resulting in mild excess of myocardial damage. This newly described drug interaction should be recognized by physicians and suggests that the interaction between opioids and oral P2Y(12) platelet inhibitors is a drug class effect associated with all opioids.	[Ibrahim, Khalil; Hasan, Rani K.; Blumenthal, Roger S.; Thiemann, David R.; Resar, Jon R.; Schulman, Steven P.; McEvoy, John W.] Johns Hopkins Univ, Sch Med, Div Cardiol, 600 N Wolfe St,Blalock 524C, Baltimore, MD 21287 USA; [Shah, Rohan; Goli, Rakesh R.] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; [Kickler, Thomas S.; Clarke, William A.] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA; [Blumenthal, Roger S.; McEvoy, John W.] Johns Hopkins Univ, Sch Med, Ciccarone Ctr Prevent Heart Dis, Baltimore, MD USA	McEvoy, JW (reprint author), Johns Hopkins Univ, Sch Med, Div Cardiol, 600 N Wolfe St,Blalock 524C, Baltimore, MD 21287 USA.; McEvoy, JW (reprint author), Johns Hopkins Univ, Sch Med, Johns Hopkins Ciccarone Ctr Prevent Heart Dis, 600 N Wolfe St,Blalock 524C, Baltimore, MD 21287 USA.	jmcevoy1@jhmi.edu			Johns Hopkins Magic That Matters Research Grant	This study was supported by the Johns Hopkins Magic That Matters Research Grant.	Angiolillo DJ, 2016, J AM COLL CARDIOL, V67, P603, DOI 10.1016/j.jacc.2015.11.044; Angiolillo DJ, 2012, JAMA-J AM MED ASSOC, V307, P265, DOI 10.1001/jama.2011.2002; Baris S, 2001, CAN J CARDIOL, V17, P277; Bhatt DL, 2009, NEW ENGL J MED, V361, P2330, DOI 10.1056/NEJMoa0908629; Breet NJ, 2010, JAMA-J AM MED ASSOC, V303, P754, DOI 10.1001/jama.2010.181; Farag M, 2018, THROMB HAEMOSTASIS, V118, P601, DOI 10.1055/s-0038-1629896; Hobl EL, 2016, CLIN RES CARDIOL, V105, P349, DOI 10.1007/s00392-015-0927-z; Hobl EL, 2016, EUR J CLIN INVEST, V46, P7, DOI 10.1111/eci.12550; Hobl EL, 2014, J AM COLL CARDIOL, V63, P630, DOI 10.1016/j.jacc.2013.10.068; Ibrahim K, 2018, CONTEMP CLIN TRIALS, V64, P8, DOI 10.1016/j.cct.2017.11.011; Kennedy PT, 2000, RADIOLOGY, V216, P660, DOI 10.1148/radiology.216.3.r00se04660; Kolh P, 2014, EUR J CARDIO-THORAC, V46, P517, DOI [10.1093/ejcts/ezu366, 10.1093/eurheartj/ehu278]; Kubica J, 2016, EUR HEART J, V37, P245, DOI 10.1093/eurheartj/ehv547; Lavi S, 2014, CAN J CARDIOL, V30, P627, DOI 10.1016/j.cjca.2014.03.034; Li P, 2016, SCI REP-UK, V6, DOI 10.1038/srep31838; McCarthy CP, 2016, AM HEART J, V176, P114, DOI 10.1016/j.ahj.2016.04.004; McEvoy JW, 2018, CIRCULATION, V137, P307, DOI 10.1161/CIRCULATIONAHA.117.031678; Meine TJ, 2005, AM HEART J, V149, P1043, DOI 10.1016/j.ahj.2005.02.010; NIMMO WS, 1975, BRIT J CLIN PHARMACO, V2, P509, DOI 10.1111/j.1365-2125.1975.tb00568.x; Parodi G, 2015, J AM COLL CARDIOL, V65, P511, DOI 10.1016/j.jacc.2014.08.056; Price MJ, 2008, EUR HEART J, V29, P992, DOI 10.1093/eurheartj/ehn046; Rollini F, 2016, NAT REV CARDIOL, V13, P11, DOI 10.1038/nrcardio.2015.113; Shah R, 2018, EUR HEART J, V39, P642, DOI 10.1093/eurheartj/ehy016; Silvain J, 2016, THROMB HAEMOSTASIS, V116, P369, DOI 10.1160/TH15-12-0944; Teng RL, 2014, J DRUG ASSESS, V3, P43, DOI 10.3109/21556660.2014.946604; Thomas MR, 2016, THROMB HAEMOSTASIS, V116, P96, DOI 10.1160/TH16-02-0102	26	12	12	0	3	GEORG THIEME VERLAG KG	STUTTGART	RUDIGERSTR 14, D-70469 STUTTGART, GERMANY	0340-6245	2567-689X		THROMB HAEMOSTASIS	Thromb. Haemost.	AUG	2018	118	8					1409	1418		10.1055/s-0038-1666862			10	Hematology; Peripheral Vascular Disease	Hematology; Cardiovascular System & Cardiology	GO7EF	WOS:000440219100010	29972861	Other Gold, Green Published			2020-06-30	J	Zgheib, NK; Aouad, MT; Taha, SK; Nassar, AH; Masri, RF; Khoury, MY; Makki, MH; Siddik-Sayyid, SM				Zgheib, Nathalie K.; Aouad, Marie T.; Taha, Samar K.; Nassar, Anwar H.; Masri, Riwa F.; Khoury, Mira Y.; Makki, Maha H.; Siddik-Sayyid, Sahar M.			mu-opioid receptor genetic polymorphisms and duration of epidural fentanyl analgesia during early labor	MINERVA ANESTESIOLOGICA			English	Article						Analgesia, epidural; Fentanyl; Labor, obstetric; OPRM1 protein, human	SINGLE-NUCLEOTIDE POLYMORPHISM; MORPHINE CONSUMPTION; INTRATHECAL FENTANYL; A118G POLYMORPHISM; CLINICAL-RESPONSE; OPRM1 GENE; PAIN; ASSOCIATION; REQUIREMENTS; VARIANT	BACKGROUND: Epidural fentanyl is commonly used for initiation of early labor analgesia. The aim of this prospective study is to test the hypothesis that duration of epidural fentanyl analgesia differs in nulliparous women requesting epidural analgesia in early labor who are variant allele carriers of the OPR8A1 SNVs 118A>G rs1799971. IVS2+31G>A rs9479757, and IVS2+691G>C rs2075572. METHODS: Two hundred and twenty parturients who received epidural analgesia with fentanyl were included in the 118A>G analysis, and a 196 sub-cohort was included in the 1142+31G>A and IVS2+691G>C exploratory analysis. Peripheral blood DNA was genotyped using Taqman allele discrimination assays. RESULTS: One hundred and seventy-four subjects (79%; 95% CI: 74 84) were homozygous for the wild type OPRml 118A >G SNV (AA), and forty six subjects (21%; 95% CI: 16 26) were heterozygous AG (N.=40) or homozygous GG (N.=6) for the variant allele. The minor allele frequency (MAF) was hence 12%. The MAFs for the IVS2+31G>A and IVS2+6916>C SNVs in the sub-cohort of 196 participants were 5% and 59% respectively. There was no significant difference in duration of epidural fentanyl analgesia for the three SNVs (161+68 and 143+51 min for wild type and allele carriers of the 118A>G SNV respectively [P=0.08]). Similarly, no significant differences were shown with the visual analog scale scores, side effects, and satisfaction for each of the three SNVs. CONCLUSIONS: OPRM1 SNVs did not affect the duration of epidural fentanyl administered for early labor analgesia in nulliparous women. These results should be confirmed in patients receiving epidural opioids in other clinical settings.	[Zgheib, Nathalie K.] Amer Univ Beirut, Fac Med, Dept Pharmacol & Toxicol, Beirut, Lebanon; [Aouad, Marie T.; Taha, Samar K.; Masri, Riwa F.; Khoury, Mira Y.; Siddik-Sayyid, Sahar M.] Amer Univ Beirut, Med Ctr, Dept Anesthesiol, POB 11-0236, Beirut, Lebanon; [Nassar, Anwar H.] Amer Univ Beirut, Med Ctr, Dept Obstet & Gynecol, Beirut, Lebanon; [Makki, Maha H.] Amer Univ Beirut, Med Ctr, Clin Res Inst, Beirut, Lebanon	Siddik-Sayyid, SM (reprint author), Amer Univ Beirut, Med Ctr, Dept Anesthesiol, POB 11-0236, Beirut, Lebanon.	ss01@aub.edu.lb		, Nathalie/0000-0002-0571-768X	American University of Beirut Faculty of Medicine (AUBFM) Medical Practice Plan (MPP) grant	This study was funded by the American University of Beirut Faculty of Medicine (AUBFM) Medical Practice Plan (MPP) grant to Dr. Sahar M. Siddik-Sayyid.	Bond C, 1998, P NATL ACAD SCI USA, V95, P9608, DOI 10.1073/pnas.95.16.9608; Camorcia M, 2012, INT J OBSTET ANESTH, V21, P40, DOI 10.1016/j.ijoa.2011.10.001; Capogna G, 2003, ANESTH ANALG, V96, P1178, DOI 10.1213/01.ANE.0000054003.03645.CF; CARRIE LES, 1981, ANAESTHESIA, V36, P965, DOI 10.1111/j.1365-2044.1981.tb08658.x; Chou WY, 2006, ACTA ANAESTH SCAND, V50, P787, DOI 10.1111/j.1399-6576.2006.01058.x; Chou WY, 2006, ANESTHESIOLOGY, V105, P334, DOI 10.1097/00000542-200608000-00016; Connelly NR, 2003, ANESTH ANALG, V96, P1799, DOI 10.1213/01.ANE.0000061583.77068.0B; Connelly NR, 2001, ANESTH ANALG, V93, P1001, DOI 10.1097/00000539-200110000-00041; Fukuda Ken-ichi, 2010, Anesth Prog, V57, P145, DOI 10.2344/0003-3006-57.4.145; Gelernter J, 1999, MOL PSYCHIATR, V4, P476, DOI 10.1038/sj.mp.4000556; Ginosar Y, 2013, BRIT J ANAESTH, V111, P433, DOI 10.1093/bja/aet075; Hastie BA, 2012, PAIN, V153, P1610, DOI 10.1016/j.pain.2012.03.022; Hayashida M, 2008, PHARMACOGENOMICS, V9, P1605, DOI 10.2217/14622416.9.11.1605; Henker RA, 2013, BIOL RES NURS, V15, P309, DOI 10.1177/1099800411436171; Hernandez-Avila CA, 2003, AM J MED GENET B, V118B, P60, DOI 10.1002/ajmg.b.10054; Hernandez-Avila CA, 2007, PHARMACOGENET GENOM, V17, P1031, DOI 10.1097/FPC.0b013e3282f0b99c; Hoehe MR, 2000, HUM MOL GENET, V9, P2895, DOI 10.1093/hmg/9.19.2895; Huang P, 2012, BIOCHEM J, V441, P379, DOI 10.1042/BJ20111050; JUSTINS DM, 1982, BRIT J ANAESTH, V54, P409, DOI 10.1093/bja/54.4.409; Klepstad P, 2004, ACTA ANAESTH SCAND, V48, P1232, DOI 10.1111/j.1399-6576.2004.00517.x; Landau R, 2008, PAIN, V139, P5, DOI 10.1016/j.pain.2008.02.023; Landau R, 2010, BEST PRACT RES CL OB, V24, P277, DOI 10.1016/j.bpobgyn.2009.11.009; Lotsch J, 2006, PHARMACOGENOMICS J, V6, P200, DOI 10.1038/sj.tpj.6500362; Margas W, 2007, J NEUROPHYSIOL, V97, P1058, DOI 10.1152/jn.01007.2006; Ross JR, 2005, PHARMACOGENOMICS J, V5, P324, DOI 10.1038/sj.tpj.6500327; Sia AT, 2008, ANESTHESIOLOGY, V109, P520, DOI 10.1097/ALN.0b013e318182af21; Sia AT, 2013, J PAIN, V14, P1045, DOI 10.1016/j.jpain.2013.03.008; Song ZM, 2013, GENET TEST MOL BIOMA, V17, P743, DOI 10.1089/gtmb.2013.0282; Tan EC, 2009, MOL PAIN, V5, DOI 10.1186/1744-8069-5-32; Ummenhofer WC, 2000, ANESTHESIOLOGY, V92, P739, DOI 10.1097/00000542-200003000-00018; Walter C, 2009, PAIN, V146, P270, DOI 10.1016/j.pain.2009.07.013; Wong CA, 2012, INT J OBSTET ANESTH, V21, P105, DOI 10.1016/j.ijoa.2012.02.003; Wong CA, 2010, INT J OBSTET ANESTH, V19, P246, DOI 10.1016/j.ijoa.2009.09.005; Wu WD, 2009, MOL DIAGN THER, V13, P331, DOI 10.2165/11317320-000000000-00000; Xin LL, 2002, AAPS PHARMSCI, V4; Zahari Zalina, 2013, Current Pharmacogenomics & Personalized Medicine, V11, P59; Zhang W, 2011, MINERVA ANESTESIOL, V77, P33; Zhang W, 2010, ANAESTHESIA, V65, P130, DOI 10.1111/j.1365-2044.2009.06193.x; Zhang Y, 2005, J BIOL CHEM, V280, P32618, DOI 10.1074/jbc.M504942200	39	1	1	0	3	EDIZIONI MINERVA MEDICA	TURIN	CORSO BRAMANTE 83-85 INT JOURNALS DEPT., 10126 TURIN, ITALY	0375-9393	1827-1596		MINERVA ANESTESIOL	Minerva Anestesiol.	AUG	2018	84	8					946	954		10.23736/S0375-9393.18.12697-6			9	Anesthesiology; Critical Care Medicine	Anesthesiology; General & Internal Medicine	GU4VD	WOS:000445282100012	29756748				2020-06-30	J	Bullingham, A; Liang, S; Edmonds, E; Mathur, S; Sharma, S				Bullingham, A.; Liang, S.; Edmonds, E.; Mathur, S.; Sharma, S.			Continuous epidural infusion vs programmed intermittent epidural bolus for labour analgesia: a prospective, controlled, before-and-after cohort study of labour outcomes	BRITISH JOURNAL OF ANAESTHESIA			English	Article						anaesthesia obstetrical; analgesia; epidural; obstetric labour	EXTERNAL VALIDITY; CONTROLLED-TRIALS; FENTANYL	Background: Recent evidence that programmed intermittent epidural bolus (PIEB) improves maternal outcomes encouraged us to change our labour epidural analgesia protocols and investigate if we could achieve similar results in a clinical setting. Methods: We conducted a prospective, controlled, before-and-after cohort study. Outcomes after labour analgesia delivered by continuous epidural infusion (CEI) with ropivacaine 0.2% and fentanyl 2 mu g ml(-1) were compared with PIEB with patient controlled epidural analgesia (PIEB+PCEA) with ropivacaine 0.1% and fentanyl 2 mu g ml(-1). The primary outcome was lower limb motor block. Secondary outcomes were local anaesthetic and fentanyl dose, duration of the second stage of labour, mode of delivery, and maternal satisfaction. Outcomes were compared using univariate t-test, chi(2) test or Fisher's exact test. Significant differences in outcomes were further evaluated by multiple regression analysis. Results: A total of 397 women completed the study (CEI 188; PIEB+PCEA 209). The PIEB+PCEA group had significantly fewer patients with motor block [CEI 41/188 (21.8%) vs PCEA+PIEB 2/209 (1.0%), P<0.001], shorter second stage of labour for primiparous women [CEI 108.2 (61.2), mean (standard deviation), min vs PIEB+PCA 79.4 (55.1) min, P<0.001], and received less ropivacaine [CEI 72.5 (43.0) mg vs PIEB+PCEA 40.4 (23.8) mg, P<0.001]. There was no significant difference in mode of delivery, fentanyl dose, or maternal satisfaction. Conclusions: Benefits of PIEB+PCEA over CEI previously demonstrated in small randomised controlled trials were reproducible on a larger scale in a clinical setting.	[Bullingham, A.; Liang, S.; Edmonds, E.] Blacktown Hosp, Dept Anesthesia, Blacktown, NSW, Australia; [Mathur, S.; Sharma, S.] Westmead Hosp, Dept Anesthesia, Westmead, NSW, Australia	Bullingham, A (reprint author), Blacktown Hosp, Dept Anesthesia, Blacktown, NSW, Australia.	adbull55@gmail.com		Liang, Sophie/0000-0002-5409-1687	Smiths Medical	E.E. has received consultancy fees and travel expenses from Smiths Medical. The other authors declare that they have no conflicts of interest.	Alemayehu D, 2013, J EVAL CLIN PRACT, V19, P579, DOI 10.1111/j.1365-2753.2011.01802.x; Altman DG, 1999, BRIT MED J, V318, P1209; Black N, 1996, BRIT MED J, V312, P1215; Capogna G, 2011, ANESTH ANALG, V113, P826, DOI 10.1213/ANE.0b013e31822827b8; Carvalho B, 2016, ANESTH ANALG, V123, P965, DOI 10.1213/ANE.0000000000001407; Chua SMH, 2004, CAN J ANAESTH, V51, P581, DOI 10.1007/BF03018402; Dahlen HG, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2012-001723; George RB, 2013, ANESTH ANALG, V116, P133, DOI 10.1213/ANE.0b013e3182713b26; Guyatt G, 2008, USERS GUIDES MED LIT; Lee BB, 2002, REGION ANESTH PAIN M, V27, P31, DOI 10.1053/rapm.2002.27836; Lim Y, 2010, ANAESTH INTENS CARE, V38, P894, DOI 10.1177/0310057X1003800514; Mowat I, 2016, BRIT J ANAESTH, V116, P277, DOI 10.1093/bja/aev432; Nallamothu BK, 2008, CIRCULATION, V118, P1294, DOI 10.1161/CIRCULATIONAHA.107.703579; Rothwell PM, 2005, LANCET, V365, P82, DOI 10.1016/S0140-6736(04)17670-8; Sia AT, 2007, ANESTH ANALG, V104, P673, DOI 10.1213/01.ane.0000253236.89376.60; Steckler A, 2008, AM J PUBLIC HEALTH, V98, P9, DOI 10.2105/AJPH.2007.126847; Thornton JG, 2001, LANCET, V358, P2, DOI 10.1016/S0140-6736(00)05295-8; von Elm E, 2007, PLOS MED, V4, P1623, DOI 10.1371/journal.pmed.0040296	18	11	14	0	6	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0007-0912	1471-6771		BRIT J ANAESTH	Br. J. Anaesth.	AUG	2018	121	2					432	437		10.1016/j.bja.2018.03.038			6	Anesthesiology	Anesthesiology	GT5CE	WOS:000444522700015	30032882	Bronze			2020-06-30	J	Rauck, RL; Oh, DA; Singla, N; Koch, C; Parikh, N; Nalamachu, S; Yu, J; James, S				Rauck, Richard L.; Oh, D. Alexander; Singla, Neil; Koch, Christian; Parikh, Neha; Nalamachu, Srinivas; Yu, Jin; James, Steven			Pharmacokinetics of Fentanyl Sublingual Spray in Opioid-Na < ve Participants: Results of a Phase 1, Multiple Ascending Dose Study	CLINICAL DRUG INVESTIGATION			English	Article							CITRATE; SAFETY	Background and Objectives Fentanyl sublingual spray may be a viable alternative to intravenous (IV) opioids for the treatment of acute pain. As patients with acute pain may include those who have limited prior exposure to opioids, this phase 1, open-label, randomized, multiple ascending-dose study was conducted to assess the pharmacokinetics, pharmacodynamics, safety, and tolerability of multiple doses of fentanyl sublingual spray in opioid naive participants. This article primarily reports the pharmacokinetics results. Methods Study drugs were administered in four dosing cohorts: every 0.5, 1, 2, or 4 h for a maximum of three doses per cohort. Eight fasted individuals per cohort were randomized to either fentanyl sublingual spray (100, 200, or 400 mu g) or fentanyl citrate IV 50 mu g (6:2 ratio). Blood samples were collected pre-dose through 24 h post first dose. Results A total of 98 healthy adults were enrolled and 96 completed the study. Mean plasma fentanyl concentrations increased with increasing doses of fentanyl sublingual spray administered every 0.5-4 h. With multiple doses, systemic exposure increased relative to the first dose; shorter dosing intervals resulted in higher concentrations. Analysis of dose proportionality suggested that systemic exposure increased in a linear but slightly greater than dose-proportional manner. Accumulation between the first and last doses of fentanyl sublingual spray was more pronounced with shorter dosing intervals. Conclusion Dose-dependent fentanyl pharmacokinetics following multiple doses of fentanyl sublingual spray were well characterized in an opioid-naive population.	[Rauck, Richard L.] Carolinas Pain Inst, 145 Kimel Pk Dr,Ste 330, Winston Salem, NC 27103 USA; [Rauck, Richard L.] Ctr Clin Res, 145 Kimel Pk Dr,Ste 330, Winston Salem, NC 27103 USA; [Oh, D. Alexander; Parikh, Neha; Yu, Jin; James, Steven] Insys Dev Co Inc, Chandler, AZ USA; [Singla, Neil; Koch, Christian] Lotus Clin Res LLC, Pasadena, CA USA; [Nalamachu, Srinivas] Mid Amer PolyClin, Overland Pk, KS USA	Rauck, RL (reprint author), Carolinas Pain Inst, 145 Kimel Pk Dr,Ste 330, Winston Salem, NC 27103 USA.; Rauck, RL (reprint author), Ctr Clin Res, 145 Kimel Pk Dr,Ste 330, Winston Salem, NC 27103 USA.	RRauck@ccrpain.com			Insys Development Company, Inc., Chandler, AZ	Funding for this study and editorial support was provided by Insys Development Company, Inc., Chandler, AZ.	[Anonymous], 2017, DURAGESIC FENT TRANS; [Anonymous], 2014, SUBS FENT SUBL SPRAY; [Anonymous], 2012, SUBLIMAZE FENT CITR; Nelson L, 2009, J MED TOXICOL, V5, P230, DOI 10.1007/BF03178274; Parikh N, 2013, CLIN DRUG INVEST, V33, P391, DOI 10.1007/s40261-013-0079-8; Parikh N, 2013, CLIN THER, V35, P236, DOI 10.1016/j.clinthera.2013.02.017; Rauck R, 2017, CURR MED RES OPIN, V33, P1915, DOI 10.1080/03007995.2017.1352496; Rauck RL, 2017, CURR MED RES OPIN, V33, P1921, DOI 10.1080/03007995.2017.1371681; Smith BP, 2000, PHARMACEUT RES, V17, P1278, DOI 10.1023/A:1026451721686; STANLEY TH, 1992, J PAIN SYMPTOM MANAG, V7, pS3, DOI 10.1016/0885-3924(92)90047-L	10	2	2	0	1	ADIS INT LTD	NORTHCOTE	5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND	1173-2563	1179-1918		CLIN DRUG INVEST	Clin. Drug Invest.	AUG	2018	38	8					715	726		10.1007/s40261-018-0658-9			12	Pharmacology & Pharmacy	Pharmacology & Pharmacy	GO6NY	WOS:000440165800005	29909433	Green Published, Other Gold			2020-06-30	J	Santangelo, D; Page, CR; Danesi, H; Jones, JB; Joshi, N; Wilcox, SB; Sneeringer, P; Phipps, JB				Santangelo, Diane; Page, Christopher R.; Danesi, Hassan; Jones, James B.; Joshi, Nitin; Wilcox, Steve B.; Sneeringer, Peter; Phipps, J. Bradley			Human Factors Results for Fentanyl Iontophoretic Transdermal System (ITS) With Enhanced Controller for Postoperative Pain Management	JOURNAL OF PERIANESTHESIA NURSING			English	Article						human factors; fentanyl; iontophoretic transdermal system; usability; postoperative pain management	PATIENT-CONTROLLED ANALGESIA; PLACEBO-CONTROLLED TRIAL; MEDICATION ERRORS; MORPHINE; EFFICACY; SURGERY; EVENTS; SAFETY	Purpose: The purpose of this analysis was to conduct summative usability evaluations, including behavioral and subjective evaluations, for the fentanyl iontophoretic transdermal system (ITS). Design: Four usability studies were conducted in representative users. Methods: The first three studies were conducted with (1) health care professionals (HCPs; N = 31), (2) patients who received placebo fentanyl ITS (N = 30), and (3) healthy volunteers (N = 30), and focused on the understanding and use of fentanyl ITS. The fourth study included HCPs (N = 31) and healthy volunteers (N = 30), and focused on the effectiveness of formal training regarding the use of fentanyl ITS. Findings: Overall, user groups found the fentanyl ITS easy to use. There were no use errors that could potentially have safety implications. In the three early studies, there were some minor difficulties experienced; however, the introduction of a structured training reduced these difficulties. Conclusions: Patients, nurses, and pharmacists were able to use fentanyl ITS with ease.	[Santangelo, Diane; Page, Christopher R.] Stony Brook Med, New York, NY USA; [Danesi, Hassan; Jones, James B.; Joshi, Nitin; Phipps, J. Bradley] Med Co, 8 Sylvan Way, Parsippany, NJ 07054 USA; [Wilcox, Steve B.; Sneeringer, Peter] Design Sci Consulting Inc, Philadelphia, PA USA	Joshi, N (reprint author), Med Co, 8 Sylvan Way, Parsippany, NJ 07054 USA.	nitin.joshi@themedco.com			Medicines Company (Parsippany, NJ); Medicines Company	Study funding was provided by The Medicines Company (Parsippany, NJ). The analyses and writing of this manuscript were supported financially by The Medicines Company. Design Science Consulting was retained by The Medicines Company to perform the studies.	[Anonymous], 2002, Health Devices, V31, P342; Chelly JE, 2004, ANESTH ANALG, V98, P427, DOI 10.1213/01.ANE.0000093314.13848.7E; Grond S, 2007, BRIT J ANAESTH, V98, P806, DOI 10.1093/bja/aem102; Hankin CS, 2007, AM J HEALTH-SYST PH, V64, P1492, DOI 10.2146/ajhp060220; Harding G, 2007, J ADV NURS, V59, P530, DOI 10.1111/j.1365-2648.2007.04284.x; Hartrick CT, 2006, REGION ANESTH PAIN M, V31, P546, DOI 10.1016/j.rapm.2006.08.011; Hicks RW, 2008, AM J HEALTH-SYST PH, V65, P429, DOI 10.2146/ajhp070194; Lindley P, 2009, J ADV NURS, V65, P1370, DOI 10.1111/j.1365-2648.2009.04991.x; Minkowitz HS, 2007, PAIN MED, V8, P657, DOI 10.1111/j.1526-4637.2006.00257.x; Palmer PP, 2014, BEST PRACT RES-CLIN, V28, P81, DOI 10.1016/j.bpa.2013.12.001; Panchal SJ, 2007, ANESTH ANALG, V105, P1437, DOI 10.1213/01.ane.0000281442.36582.81; Schein JR, 2009, DRUG SAFETY, V32, P549, DOI 10.2165/00002018-200932070-00002; US Department of Health and Human Service Food and Drug Administration, 2011, DRAFT GUID IND FOOD; Viscusi ER, 2006, ANESTH ANALG, V102, P188, DOI 10.1213/01.ane.0000183649.58483.77; Viscusi ER, 2004, JAMA-J AM MED ASSOC, V291, P1333, DOI 10.1001/jama.291.11.1333	15	0	0	1	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1089-9472	1532-8473		J PERIANESTH NURS	J. PeriAnesthesia Nurs.	AUG	2018	33	4					537	550		10.1016/j.jopan.2016.03.014			14	Nursing	Nursing	GO9BQ	WOS:000440398700108	30077298	Other Gold			2020-06-30	J	Duerschmied, D; Bode, C				Duerschmied, Daniel; Bode, Christoph			Life-Saving Therapy versus Symptom Relief: Anti-Platelet Agents and Opioids in Coronary Intervention	THROMBOSIS AND HAEMOSTASIS			English	Article							ST-SEGMENT ELEVATION; TICAGRELOR; INHIBITION; MORPHINE		[Duerschmied, Daniel; Bode, Christoph] Univ Freiburg, Dept Cardiol & Angiol 1, Ctr Heart, Fac Med, Freiburg, Germany	Bode, C (reprint author), Univ Freiburg, Dept Cardiol & Angiol 1, Ctr Heart, Fac Med, Freiburg, Germany.	christoph.bode@universitaets-herzzentrum.de					Cohen MV, 2014, J CARDIOVASC PHARM T, V19, P179, DOI 10.1177/1074248413508465; Farag M, 2018, THROMB HAEMOSTASIS, V118, P601, DOI 10.1055/s-0038-1629896; Flierl U, 2017, THROMB HAEMOSTASIS, V117, P99, DOI 10.1160/TH16-07-0569; Hobl EL, 2014, J AM COLL CARDIOL, V63, P630, DOI 10.1016/j.jacc.2013.10.068; Ibanez B, 2018, EUR HEART J, V39, P119, DOI 10.1093/eurheartj/ehx393; Ibrahim K, 2018, THROMB HAEMOSTASIS, V118, P1409, DOI 10.1055/s-0038-1666862; Kubica J, 2016, EUR HEART J, V37, P245, DOI 10.1093/eurheartj/ehv547; McEvoy JW, 2018, CIRCULATION, V137, P307, DOI 10.1161/CIRCULATIONAHA.117.031678; Montalescot G, 2014, J AM COLL CARDIOL, V64, P2563, DOI 10.1016/j.jacc.2014.08.053; Montalescot G, 2014, NEW ENGL J MED, V371, P1016, DOI 10.1056/NEJMoa1407024; Niezgoda P, 2017, THROMB HAEMOSTASIS, V117, P718, DOI 10.1160/TH16-08-0670; Parodi G., 2014, CIRC-CARDIOVASC INTE, V8, P1, DOI DOI 10.1161/CIRCINTERVENTI0NS.114.001593; Silvain J, 2016, THROMB HAEMOSTASIS, V116, P369, DOI 10.1160/TH15-12-0944	13	2	2	0	0	GEORG THIEME VERLAG KG	STUTTGART	RUDIGERSTR 14, D-70469 STUTTGART, GERMANY	0340-6245	2567-689X		THROMB HAEMOSTASIS	Thromb. Haemost.	AUG	2018	118	8					1350	1351		10.1055/s-0038-1667173			2	Hematology; Peripheral Vascular Disease	Hematology; Cardiovascular System & Cardiology	GO7EF	WOS:000440219100004	30060255	Bronze			2020-06-30	J	Seki, H; Furumoto, K; Sato, M; Kagoya, A; Hashimoto, H; Sekiguchi, Y; Nakatsuka, I				Seki, Hiroyuki; Furumoto, Kyoko; Sato, Masato; Kagoya, Aya; Hashimoto, Hiroka; Sekiguchi, Yoshihiro; Nakatsuka, Itsuo			Effects of epidural anesthesia on postoperative nausea and vomiting in laparoscopic gynecological surgery: a randomized controlled trial	JOURNAL OF ANESTHESIA			English	Article						Postoperative nausea and vomiting; Laparoscopic surgery; Gynecological surgery; Epidural anesthesia	ABDOMINIS PLANE BLOCK; MAJOR COMPLICATIONS; COLORECTAL SURGERY; ANALGESIA; PAIN; DEXAMETHASONE; HYSTERECTOMY; METAANALYSIS; GUIDELINES; MANAGEMENT	Patients undergoing laparoscopic gynecological surgery are susceptible to postoperative nausea and vomiting (PONV). We hypothesized that a combination of epidural and general anesthesia to minimize intraoperative opioid administration would reduce the incidence of PONV following laparoscopic gynecological surgery. Women undergoing elective laparoscopic gynecological surgery were randomly assigned to receive general anesthesia alone (group G, n = 45) or general anesthesia with epidural anesthesia (group GE, n = 45). Patients in group G received fentanyl and remifentanil for intraoperative analgesia, and those in group GE received single-shot ropivacaine at the time of induction of anesthesia. The primary outcome was the incidence of PONV within 24 h of surgery. Secondary outcomes included the use of rescue metoclopramide within 24 h of surgery and the time to first incidence of PONV and first use of rescue metoclopramide. The incidence of PONV within 24 h of surgery was 60.0% in group G and 44.4% in group GE [relative risk (RR): 0.53, 95% confidence interval (CI): 0.23-1.23, p = 0.14]. There were no intergroup differences in the use of rescue metoclopramide (40.0% in group G, 24.4% in group GE, RR: 0.49, 95% CI 0.20-1.20, p = 0.11) and the time to first incidence of PONV and first use of rescue metoclopramide (p = 0.20 and 0.12, respectively). Minimizing intraoperative opioid administration by combining epidural and general anesthesia did not reduce the 24-h incidence of PONV or rescue metoclopramide use after laparoscopic gynecological surgery.	[Seki, Hiroyuki; Furumoto, Kyoko; Kagoya, Aya; Hashimoto, Hiroka; Sekiguchi, Yoshihiro; Nakatsuka, Itsuo] Tokyo Saiseikai Cent Hosp, Dept Anesthesiol, Minato Ku, 4-17 Mita 1 Chome, Tokyo 1080073, Japan; [Seki, Hiroyuki; Furumoto, Kyoko] Keio Univ, Dept Anesthesiol, Sch Med, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan; [Sato, Masato] Keiyu Hosp, Dept Anesthesiol, Yokohama, Kanagawa, Japan	Seki, H (reprint author), Tokyo Saiseikai Cent Hosp, Dept Anesthesiol, Minato Ku, 4-17 Mita 1 Chome, Tokyo 1080073, Japan.; Seki, H (reprint author), Keio Univ, Dept Anesthesiol, Sch Med, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.	hseki.a3@keio.jp		seki, hiroyuki/0000-0001-5311-5088			ALDRETE JA, 1970, ANESTH ANAL CURR RES, V49, P924; Apfel CC, 2012, BRIT J ANAESTH, V109, P742, DOI 10.1093/bja/aes276; Apfel CC, 1999, ANESTHESIOLOGY, V91, P693, DOI 10.1097/00000542-199909000-00022; Apfel CC, 2004, NEW ENGL J MED, V350, P2441, DOI 10.1056/NEJMoa032196; Apfel CC, 2002, BRIT J ANAESTH, V88, P659, DOI 10.1093/bja/88.5.659; Baeriswyl M, 2015, ANESTH ANALG, V121, P1640, DOI 10.1213/ANE.0000000000000967; Baldini G, 2009, ANESTHESIOLOGY, V110, P1139, DOI 10.1097/ALN.0b013e31819f7aea; Choi JB, 2016, INT J MED SCI, V13, P562, DOI 10.7150/ijms.15875; Cook TM, 2009, BRIT J ANAESTH, V102, P179, DOI 10.1093/bja/aen360; Ekstein P, 2006, ANN SURG, V243, P41, DOI 10.1097/01.sla.0000193806.81428.6f; Finucane BT, 2001, ANESTH ANALG, V92, P1276, DOI 10.1097/00000539-200105000-00038; Gan TJ, 2014, ANESTH ANALG, V118, P85, DOI 10.1213/ANE.0000000000000002; Gerbershagen HJ, 2013, ANESTHESIOLOGY, V118, P934, DOI 10.1097/ALN.0b013e31828866b3; Ghisi D, 2016, ANESTH ANALG, V123, P488, DOI 10.1213/ANE.0000000000001267; HONKAVAARA P, 1991, CAN J ANAESTH, V38, P876, DOI 10.1007/BF03036963; Hubner M, 2015, ANN SURG, V261, P648, DOI 10.1097/SLA.0000000000000838; Joshi GP, 2013, COLORECTAL DIS, V15, P146, DOI 10.1111/j.1463-1318.2012.03062.x; Kang XH, 2014, ACTA ANAESTH SCAND, V58, P858, DOI 10.1111/aas.12360; Korolija D, 2004, SURG ENDOSC, V18, P879, DOI 10.1007/s00464-003-9263-x; Lim H, 2016, KOREAN J ANESTHESIOL, V69, P51, DOI 10.4097/kjae.2016.69.1.51; Macario A, 1999, ANESTH ANALG, V89, P652, DOI 10.1097/00000539-199909000-00022; Pitkanen MT, 2013, ACTA ANAESTH SCAND, V57, P553, DOI 10.1111/aas.12064; Popping DM, 2014, ANN SURG, V259, P1056, DOI 10.1097/SLA.0000000000000237; Shirakami Gotaro, 2006, J Anesth, V20, P188, DOI 10.1007/s00540-006-0413-x; Smith I, 2008, EUR J ANAESTH, V25, P790, DOI 10.1017/S026502150800464X; Wang JJ, 2000, BRIT J ANAESTH, V84, P459; Yu NZ, 2014, BMC ANESTHESIOL, V14, DOI 10.1186/1471-2253-14-121; Yuksek M, 2003, J INT MED RES, V31, P481, DOI 10.1177/147323000303100603; Zhao X, 2014, INT J CLIN EXP MED, V7, P2966; Ziemann-Gimmel P, 2014, BRIT J ANAESTH, V112, P906, DOI 10.1093/bja/aet551	30	0	0	0	2	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	0913-8668	1438-8359		J ANESTH	J. Anesth.	AUG	2018	32	4					608	615		10.1007/s00540-018-2525-5			8	Anesthesiology	Anesthesiology	GO5ZF	WOS:000440112700018	29936600				2020-06-30	J	Trifa, M; Tumin, D; Whitaker, EE; Bhalla, T; Jayanthi, VR; Tobias, JD				Trifa, Mehdi; Tumin, Dmitry; Whitaker, Emmett E.; Bhalla, Tarun; Jayanthi, Venkata R.; Tobias, Joseph D.			Spinal anesthesia for surgery longer than 60 min in infants: experience from the first 2 years of a spinal anesthesia program	JOURNAL OF ANESTHESIA			English	Article						Spinal anesthesia; Children; Clonidine; Epinephrine	GENERAL-ANESTHESIA; REGIONAL ANESTHESIA; HERNIA REPAIR; CLONIDINE; BUPIVACAINE; PYLOROMYOTOMY	Spinal anesthesia (SA) is being increasingly used in infants to avoid the potential negative neurocognitive effects of general anesthesia (GA). However, SA has been reported to provide a relatively short duration of surgical anesthesia. We retrospectively reviewed SA cases for surgical procedures lasting more than 60 min in children up to 3 years old. All patients received bupivacaine 0.5% (1 mg/kg up to 7 mg) with clonidine 1 A mu g/kg +/- epinephrine. The primary outcome was success of SA without subsequent conversion to GA. Thirty-five patients met inclusion criteria (all males, age 7 +/- 5 months, weight 8 +/- 2 kg). Procedures included male genital, groin and multiple site surgeries. Average surgical duration was 71 +/- 12 min (range 60-111 min). SA was successful in 31 of 35 patients (89%; 95% confidence interval 78, 99%). The cause of failure was rarely due to the duration of surgery (1 of 4 patients). Six patients with successful SA required sedation with dexmedetomidine +/- fentanyl. Differences in procedure duration and patient characteristics were not statistically significant between successful and failed SA. SA is a highly successful technique and may offer an alternative to GA in children undergoing appropriate surgery expected to last as long as 60-100 min.	[Trifa, Mehdi; Tumin, Dmitry; Whitaker, Emmett E.; Bhalla, Tarun; Tobias, Joseph D.] Nationwide Childrens Hosp, Dept Anesthesiol Pain Med, 700 Childrens Dr, Columbus, OH 43205 USA; [Trifa, Mehdi] Univ Tunis El Manar, Fac Med, Tunis, Tunisia; [Whitaker, Emmett E.; Bhalla, Tarun; Tobias, Joseph D.] Ohio State Univ, Coll Med, Dept Anesthesiol, Pain Med, Columbus, OH 43210 USA; [Jayanthi, Venkata R.] Nationwide Childrens Hosp, Div Pediat Urol, Columbus, OH USA; [Jayanthi, Venkata R.] Ohio State Univ, Coll Med, Dept Urol, Columbus, OH 43210 USA	Trifa, M (reprint author), Nationwide Childrens Hosp, Dept Anesthesiol Pain Med, 700 Childrens Dr, Columbus, OH 43205 USA.; Trifa, M (reprint author), Univ Tunis El Manar, Fac Med, Tunis, Tunisia.	mehditrifa@gmail.com	Whitaker, Emmett/D-2820-2016	Whitaker, Emmett/0000-0002-1362-1653			ABAJIAN JC, 1984, ANESTH ANALG, V63, P359; Batra YK, 2010, PEDIATR ANESTH, V20, P625, DOI 10.1111/j.1460-9592.2010.03326.x; Batra YK, 2008, PEDIATR ANESTH, V18, P613, DOI 10.1111/j.1460-9592.2008.02613.x; Eisenach JC, 1996, ANESTHESIOLOGY, V85, P655, DOI 10.1097/00000542-199609000-00026; Frawley G, 2015, ANESTHESIOLOGY, V123, P55, DOI 10.1097/ALN.0000000000000708; Ing C, 2016, REGION ANESTH PAIN M, V41, P532, DOI 10.1097/AAP.0000000000000421; Kachko L, 2007, PEDIATR ANESTH, V17, P647, DOI 10.1111/j.1460-9592.2007.02194.x; Kachko L, 2012, PEDIATR ANESTH, V22, P647, DOI 10.1111/j.1460-9592.2011.03769.x; Kachko L, 2009, J PEDIATR SURG, V44, P1942, DOI 10.1016/j.jpedsurg.2009.03.038; Kokki H, 2012, PEDIATR ANESTH, V22, P56, DOI 10.1111/j.1460-9592.2011.03693.x; Lambertz A, 2014, PEDIATR SURG INT, V30, P1069, DOI 10.1007/s00383-014-3590-y; Lopez T, 2012, MINERVA ANESTESIOL, V78, P78, DOI 10.1111/j.1460-9592.2011.03769.x; Nelson LE, 2003, ANESTHESIOLOGY, V98, P428, DOI 10.1097/00000542-200302000-00024; Ratajczak-Enselme M, 2007, BRIT J ANAESTH, V99, P881, DOI 10.1093/bja/aem291; Rochette A, 2005, PEDIATR ANESTH, V15, P1072, DOI 10.1111/j.1460-9592.2005.01664.x; Rochette A, 2004, ANESTH ANALG, V98, P56, DOI 10.1213/01.ANE.0000093229.17729.6C; Tzong KYS, 2012, J NEUROSURG ANESTH, V24, P391, DOI 10.1097/ANA.0b013e31826a0345; Wang X, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085760; Whitaker EE, 2017, J PEDIATR UROL, V13, P396, DOI 10.1016/j.jpurol.2017.06.006; Williams RK, 2006, ANESTH ANALG, V102, P67, DOI 10.1213/01.ANE.0000159162.86033.21	20	4	4	0	0	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	0913-8668	1438-8359		J ANESTH	J. Anesth.	AUG	2018	32	4					637	640		10.1007/s00540-018-2517-5			4	Anesthesiology	Anesthesiology	GO5ZF	WOS:000440112700022	29808260				2020-06-30	J	Kuczynska, K; Grzonkowski, P; Kacprzak, L; Zawilska, JB				Kuczynska, Katarzyna; Grzonkowski, Piotr; Kacprzak, Lukasz; Zawilska, Jolanta B.			Abuse of fentanyl: An emerging problem to face	FORENSIC SCIENCE INTERNATIONAL			English	Review						Fentanyl; Synthetic opioids; Transdermal fentanyl patches; Abuse; Overdose; Naloxone	OVERDOSE DEATHS; ILLICIT FENTANYL; CONTAMINATED HEROIN; INTRAVENOUS MISUSE; TRANSDERMAL PATCH; YOUNG-ADULTS; LACED HEROIN; INJECT DRUGS; EXPOSURE; FATALITIES	Fentanyl is a potent synthetic opioid used as a narcotic analgesic supplement in general and regional anesthesia as well as in management of persistent, severe chronic pain. Alarming epidemiological and forensic medicine reports, accumulated mainly during the last two decades, point to a growing increase in illicit use of fentanyl, mainly in North America and Europe. Toxicological data indicates that fentanyl use is inextricably linked with polydrug use. There are two main sources of fentanyl on the "recreational" drug market. First, the most common, combines illicitly manufactured fentanyl from clandestine sources. The drug is often mixed up with heroin ("fake heroin") to increase its potency at a little cost, or included in cocaine products. It can also be mixed into and sold as oxycodone-, hydrocodone-or alprazolam-containing tablets. The other way to gain fentanyl is through the diversion of fentanyl-containing medicines, especially transdermal patches (FTPs). Fentanyl extracted from FTP can be administered intravenously, insufflated or inhaled after volatilization. The drug can also be delivered by oral or transmucosal application of the whole patch, or by rectal insertion. The most common overdose symptoms are coma, lethargy, respiratory depression and arrest. Although naloxone, an opioid receptor antagonist, is the standard drug for fentanyl overdose rescue, attempts to revive patients with naloxone could be unsuccessful, due to the rapid onset of fentanyl's action. As the fentanyl problem is constantly growing, there is an urgent need for new, effective harm-reduction strategies and technologies, as well as overdose maintenance. (c) 2018 Elsevier B.V. All rights reserved.	[Kuczynska, Katarzyna; Grzonkowski, Piotr; Kacprzak, Lukasz; Zawilska, Jolanta B.] Med Univ Lodz, Dept Pharmacodynam, Muszynskiego 1, PL-90151 Lodz, Poland	Zawilska, JB (reprint author), Med Univ Lodz, Dept Pharmacodynam, Muszynskiego 1, PL-90151 Lodz, Poland.	jolanta.zawilska@umed.lodz.pl		Zawilska, Jolanta/0000-0002-3696-2389	Medical University of Lodz, Poland [503/3-011-01/503-31-002]	Supported by the Medical University of Lodz, Poland (503/3-011-01/503-31-002).	Abdulahim D., 2018, BEHALF NEPTUNE GROUP; Algren DA, 2013, J MED TOXICOL, V9, P106, DOI 10.1007/s13181-012-0285-4; Anderson DT, 2000, J ANAL TOXICOL, V24, P627, DOI 10.1093/jat/24.7.627; [Anonymous], 2003, JANSSEN PHARM PRODUC; Arens AM, 2016, JAMA INTERN MED, V176, P1554, DOI 10.1001/jamainternmed.2016.4306; Arfken CL, 2017, J SUBST ABUSE TREAT, V75, P17, DOI 10.1016/j.jsat.2017.01.004; Barash JA, 2018, NEW ENGL J MED, V378, P1157, DOI 10.1056/NEJMc1716355; Bode AD, 2017, AM J EMERG MED, V35, P1364, DOI 10.1016/j.ajem.2017.02.043; Booth JV, 2002, ANESTH ANALG, V95, P1024, DOI 10.1213/01.ANE.0000026379.66419.DB; Canadian Community Epidemiology Network on Drug Use (CCENDU), 2015, CCENDY B; Carroll JJ, 2017, INT J DRUG POLICY, V46, P136, DOI 10.1016/j.drugpo.2017.05.023; Carson HJ, 2010, LEGAL MED, V12, P157, DOI 10.1016/j.legalmed.2010.03.001; Chapman E, 2012, CHEST, V141, P1321, DOI 10.1378/chest.11-1462; CHEN JC, 1993, LIFE SCI, V52, P389, DOI 10.1016/0024-3205(93)90152-S; Ciccarone D, 2017, INT J DRUG POLICY, V46, P146, DOI 10.1016/j.drugpo.2017.06.004; Ciccarone D, 2017, INT J DRUG POLICY, V46, P107, DOI 10.1016/j.drugpo.2017.06.010; Cicero TJ, 2007, DRUG ALCOHOL DEPEN, V91, P115, DOI 10.1016/j.drugalcdep.2007.05.008; Cicero TJ, 2017, DRUG ALCOHOL DEPEN, V177, P101, DOI 10.1016/j.drugalcdep.2017.04.004; Coon TP, 2005, ANN EMERG MED, V46, P473, DOI 10.1016/j.annemergmed.2005.06.450; D'Orazio JL, 2012, J EMERG MED, V42, P543, DOI 10.1016/j.jemermed.2011.03.011; Daniulaityte R, 2017, MMWR-MORBID MORTAL W, V66, P904, DOI 10.15585/mmwr.mm6634a3; Darke S, 2016, ADDICTION, V111, P1607, DOI 10.1111/add.13429; Darke S, 2011, ADDICTION, V106, P1035, DOI 10.1111/j.1360-0443.2011.03395.x; DEA, 2016, COUNT PRESCR PILLS C; Drug Enforcement Administration (DEA), 2016, DEA WARN POL PUBL FE; Edinboro LE, 1997, J FORENSIC SCI, V42, P741; European Monitoring Centre for Drugs and Drug Addiction, 2012, REP EMCDDA EXP M 9 1, DOI [10.2810/75056, DOI 10.2810/75056]; Fairbairn N, 2017, INT J DRUG POLICY, V46, P172, DOI 10.1016/j.drugpo.2017.06.005; Fischer B, 2018, PREV MED, V107, P109, DOI 10.1016/j.ypmed.2017.11.001; Frank RG, 2017, NEW ENGL J MED, V376, P605, DOI 10.1056/NEJMp1615145; Geddes L, 2018, DRUG ALCOHOL REV, V37, pS314, DOI 10.1111/dar.12668; Giorgetti A, 2017, HUM PSYCHOPHARM CLIN, V32, DOI 10.1002/hup.2605; Green TC, 2016, JAMA INTERN MED, V176, P1555, DOI 10.1001/jamainternmed.2016.4310; Griswold MK, 2018, CLIN TOXICOL, V56, P37, DOI 10.1080/15563650.2017.1339889; Hayashi K, 2018, DRUG ALCOHOL DEPEN, V183, P1, DOI 10.1016/j.drugalcdep.2017.10.020; HENDERSON GL, 1991, J FORENSIC SCI, V36, P422; Hikin L, 2018, FORENSIC SCI INT, V282, P179, DOI 10.1016/j.forsciint.2017.11.036; Hull MJ, 2007, J FORENSIC SCI, V52, P1383, DOI 10.1111/j.1556-4029.2007.00564.x; Joranson DE, 2000, JAMA-J AM MED ASSOC, V283, P1710, DOI 10.1001/jama.283.13.1710; Jumbelic MI, 2010, AM J FOREN MED PATH, V31, P18, DOI 10.1097/PAF.0b013e31818738b8; Kenney SR, 2018, J SUBST ABUSE TREAT, V86, P65, DOI 10.1016/j.jsat.2018.01.005; Kimergard A, 2018, DRUG TEST ANAL, V10, P917, DOI 10.1002/dta.2397; Kintz P, 2005, FORENSIC SCI INT, V153, P81, DOI 10.1016/j.forsciint.2005.04.033; Krause D, 2017, SUBST USE MISUSE, V52, P639, DOI 10.1080/10826084.2016.1246571; Krieger MS, 2018, HARM REDUCT J, V15, DOI 10.1186/s12954-018-0213-2; Krinsky CS, 2011, AM J FOREN MED PATH, V32, P347, DOI 10.1097/PAF.0b013e31822ad269; Kronstrand R, 1997, FORENSIC SCI INT, V88, P185, DOI 10.1016/S0379-0738(97)00068-6; Kuhlman JJ, 2003, J ANAL TOXICOL, V27, P499, DOI 10.1093/jat/27.7.499; Latimer J, 2016, INT J DRUG POLICY, V37, P111, DOI 10.1016/j.drugpo.2016.08.004; Lee D, 2016, J ANAL TOXICOL, V40, P588, DOI 10.1093/jat/bkw087; Liappas IA, 2004, J PSYCHOPHARMACOL, V18, P277, DOI 10.1177/0269881104042634; Lilleng PK, 2004, J FORENSIC SCI, V49, P1364; Macmadu A, 2017, ADDICT BEHAV, V68, P35, DOI 10.1016/j.addbeh.2017.01.014; Marinetti LJ, 2014, J ANAL TOXICOL, V38, P592, DOI 10.1093/jat/bku086; MARQUARDT KA, 1994, J TOXICOL-CLIN TOXIC, V32, P75, DOI 10.3109/15563659409000433; MARQUARDT KA, 1995, ANN PHARMACOTHER, V29, P969, DOI 10.1177/106002809502901001; MARTIN M, 1991, ANN EMERG MED, V20, P158, DOI 10.1016/S0196-0644(05)81216-8; Martin TL, 2006, J ANAL TOXICOL, V30, P603, DOI 10.1093/jat/30.8.603; Massachusetts Department of Public Health, 2017, DAT BRIEF OP REL OV; Mercado MC, 2018, PAIN MED, V19, P511, DOI 10.1093/pm/pnx015; Mounteney J, 2015, INT J DRUG POLICY, V26, P626, DOI 10.1016/j.drugpo.2015.04.003; Mrvos R, 2012, J EMERG MED, V42, P549, DOI 10.1016/j.jemermed.2011.05.017; National Coronial Information System, 2013, NCIS FACT SHEET; Nelson L, 2009, J MED TOXICOL, V5, P230, DOI 10.1007/BF03178274; Peterson AB, 2016, MMWR-MORBID MORTAL W, V65, P844, DOI 10.15585/mmwr.mm6533a3; Pichini S, 2018, THER DRUG MONIT, V40, P38, DOI 10.1097/FTD.0000000000000465; Prosser JM, 2010, J MED TOXICOL, V6, P443, DOI 10.1007/s13181-010-0092-8; Raffa RB, 2018, J CLIN PHARM THER, V43, P154, DOI 10.1111/jcpt.12640; Ray B, 2017, J URBAN HEALTH, V94, P301, DOI 10.1007/s11524-016-0113-2; Reeves MD, 2002, MED J AUSTRALIA, V177, P552, DOI 10.5694/j.1326-5377.2002.tb04951.x; Rodda LN, 2017, J ANAL TOXICOL, V41, P318, DOI 10.1093/jat/bkx013; Roxburgh A, 2017, DRUG ALCOHOL DEPEN, V179, P291, DOI 10.1016/j.drugalcdep.2017.07.018; Ruzycki S, 2016, J MED TOXICOL, V12, P185, DOI 10.1007/s13181-015-0509-5; Schauer CKMW, 2015, BASIC CLIN PHARMACOL, V117, P358, DOI 10.1111/bcpt.12412; Scheuermeyer FX, 2018, ANN EMERG MED, V72, P1, DOI 10.1016/j.annemergmed.2018.01.054; Schumann H, 2008, CLIN TOXICOL, V46, P501, DOI 10.1080/15563650701877374; Sinicina I, 2017, DRUG ALCOHOL DEPEN, V180, P286, DOI 10.1016/j.drugalcdep.2017.08.021; Slavova S, 2017, INT J DRUG POLICY, V46, P120, DOI 10.1016/j.drugpo.2017.05.051; SMIALEK JE, 1994, J FORENSIC SCI, V39, P159; Somerville NJ, 2017, MMWR-MORBID MORTAL W, V66, P382, DOI 10.15585/mmwr.mm6614a2; Sommerfeld-Klatta K., 2018, 35 C FOR TOX SZCZEC, P41; Stanley TH, 2014, J PAIN, V15, P1215, DOI 10.1016/j.jpain.2014.08.010; Sutter ME, 2017, ACAD EMERG MED, V24, P106, DOI 10.1111/acem.13034; Suzuki J, 2017, DRUG ALCOHOL DEPEN, V171, P107, DOI 10.1016/j.drugalcdep.2016.11.033; Tharp AM, 2004, AM J FOREN MED PATH, V25, P178, DOI 10.1097/01.paf.0000127398.67081.11; Thompson JG, 2007, J FORENSIC SCI, V52, P978, DOI 10.1111/j.1556-4029.2007.00481.x; Tomassoni Anthony J, 2017, MMWR Morb Mortal Wkly Rep, V66, P107, DOI 10.15585/mm6604a4; Turock MK, 2009, AM J EMERG MED, V27, P237, DOI 10.1016/j.ajem.2008.09.043; Tuusov J, 2013, J FORENSIC LEG MED, V20, P51, DOI 10.1016/j.jflm.2012.04.023; Uuskula A, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-2604-6; Warner Margaret, 2016, Natl Vital Stat Rep, V65, P1; Woodall KL, 2008, J FORENSIC SCI, V53, P222, DOI 10.1111/j.1556-4029.2007.00597.x; Zawilska JB, 2017, FRONT PSYCHIATRY, V8, DOI 10.3389/fpsyt.2017.00110	93	26	27	4	31	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0379-0738	1872-6283		FORENSIC SCI INT	Forensic Sci.Int.	AUG	2018	289						207	214		10.1016/j.forsciint.2018.05.042			8	Medicine, Legal	Legal Medicine	GM9RG	WOS:000438589000031	29902699				2020-06-30	J	Davis, MP; McPherson, ML; Mehta, Z; Behm, B; Fernandez, C				Davis, Mellar P.; McPherson, Mary Lynn; Mehta, Zankhana; Behm, Bertrand; Fernandez, Carlos			What Parenteral Opioids to Use in Face of Shortages of Morphine, Hydromorphone, and Fentanyl	AMERICAN JOURNAL OF HOSPICE & PALLIATIVE MEDICINE			English	Article						opioid; pain; nalbuphine; buprenorphine; analgesia	CHRONIC PAIN PATIENTS; TRANSDERMAL BUPRENORPHINE; SUBLINGUAL BUPRENORPHINE; NALBUPHINE HYDROCHLORIDE; RESPIRATORY DEPRESSION; HEALTHY-VOLUNTEERS; P-GLYCOPROTEIN; INTRAVENOUS NALBUPHINE; SUBSTITUTION THERAPY; WITHDRAWAL SYNDROME	Parenteral potent opioid availability is becoming an issue in acute pain management. Two opioids, nalbuphine and buprenorphine, are available which can be substituted for hydromorphone, fentanyl, and morphine. There are advantages and disadvantages in using these 2 opioids which are discussed, and potential dosing strategies are outlined.	[Davis, Mellar P.; Mehta, Zankhana; Behm, Bertrand; Fernandez, Carlos] Geisinger Med Ctr, Dept Palliat Care, 100 N Acad Ave, Danville, PA 17822 USA; [McPherson, Mary Lynn] Univ Maryland, Sch Pharm, Adv Postgrad Educ Palliat Care, Dept Pharm Practice & Sci, Baltimore, MD 21201 USA	Davis, MP (reprint author), Geisinger Med Ctr, Dept Palliat Care, 100 N Acad Ave, Danville, PA 17822 USA.	mdavis2@geisinger.edu					AITKENHEAD AR, 1988, BRIT J CLIN PHARMACO, V25, P264, DOI 10.1111/j.1365-2125.1988.tb03300.x; Alhaddad H, 2012, CRIT CARE MED, V40, P3215, DOI 10.1097/CCM.0b013e318265680a; Anderson TA, 2017, ANESTHESIOLOGY, V126, P1180, DOI 10.1097/ALN.0000000000001633; Andresen T, 2011, BRIT J PHARMACOL, V164, P934, DOI 10.1111/j.1476-5381.2010.01180.x; BEAVER WT, 1978, J PHARMACOL EXP THER, V204, P487; BEAVER WT, 1981, CLIN PHARMACOL THER, V29, P174, DOI 10.1038/clpt.1981.28; Bliesener N, 2005, J CLIN ENDOCR METAB, V90, P203, DOI 10.1210/jc.2004-0929; Brown SM, 2012, J PHARMACOL EXP THER, V343, P53, DOI 10.1124/jpet.112.193433; Brown SM, 2011, ANESTHESIOLOGY, V115, P1251, DOI 10.1097/ALN.0b013e318238fea0; Cowan A, 2007, J ADDICT MED, V1, P68, DOI 10.1097/ADM.0b013e31806c9202; CUSCHIERI RJ, 1984, BRIT J ANAESTH, V56, P855, DOI 10.1093/bja/56.8.855; Dahan A, 2006, BRIT J ANAESTH, V96, P627, DOI 10.1093/bja/ael051; Daitch D, 2014, PAIN MED, V15, P2087, DOI 10.1111/pme.12520; Daitch J, 2012, PAIN PHYSICIAN, V15, pES59; Deseva B, 1993, Khirurgiia (Sofiia), V46, P18; DESOUZA EB, 1988, J PHARMACOL EXP THER, V244, P391; ELLIOTT H W, 1970, Journal of Medicine (Westbury), V1, P74; Franchi S, 2007, BRAIN BEHAV IMMUN, V21, P767, DOI 10.1016/j.bbi.2007.01.001; FREYE E, 1985, Acta Anaesthesiologica Belgica, V36, P365; Freye Enno, 2007, Pain Pract, V7, P123, DOI 10.1111/j.1533-2500.2007.00119.x; Galligan James J, 2014, Am J Gastroenterol Suppl, V2, P17, DOI 10.1038/ajgsup.2014.5; Grinnell SG, 2016, SYNAPSE, V70, P395, DOI 10.1002/syn.21914; Grinnell SG, 2014, J PHARMACOL EXP THER, V350, P710, DOI 10.1124/jpet.114.213199; Hawi A, 2015, BMC NEPHROL, V16, DOI 10.1186/s12882-015-0043-3; Heit HA, 2008, CLIN J PAIN, V24, P93, DOI 10.1097/AJP.0b013e31815ca2b4; Horvat CM, 2017, PEDIATR RES, V82, P29, DOI 10.1038/pr.2017.103; Huxtable CA, 2013, EUR J ANAESTH, V30, P717, DOI 10.1097/EJA.0b013e32836394fe; Jang S, 2006, ARCH PHARM RES, V29, P677, DOI 10.1007/BF02968252; Jannuzzi RG, 2016, CLIN J PAIN, V32, P87, DOI 10.1097/AJP.0000000000000211; JASINSKI DR, 1978, ARCH GEN PSYCHIAT, V35, P501; JASINSKI DR, 1972, CLIN PHARMACOL THER, V13, P78; Johnson RE, 2005, J PAIN SYMPTOM MANAG, V29, P297, DOI 10.1016/j.jpainsymman.2004.07.005; Kogel B, 2005, EUR J PAIN, V9, P599, DOI 10.1016/j.ejpain.2005.02.002; Koppert W, 2005, PAIN, V118, P15, DOI 10.1016/j.pain.2005.06.030; Kornfeld H, 2015, AM J THER, V22, P199, DOI 10.1097/MJT.0b013e31828bfb6e; Krenn H, 2001, EUR J PAIN-LONDON, V5, P219, DOI 10.1053/eujp.2001.0238; Kress HG, 2009, EUR J PAIN, V13, P219, DOI 10.1016/j.ejpain.2008.04.011; LAKE CL, 1984, ACTA ANAESTH SCAND, V28, P305, DOI 10.1111/j.1399-6576.1984.tb02066.x; LAKE CL, 1982, ANESTHESIOLOGY, V57, P498, DOI 10.1097/00000542-198212000-00012; Latasch L, 1989, Acta Anaesthesiol Belg, V40, P35; LATASCH L, 1984, ANESTH ANALG, V63, P814; LAUBY V, 1994, THERAPIE, V49, P143; LO MW, 1984, RES COMMUN CHEM PATH, V43, P159; LO MW, 1987, J CLIN PHARMACOL, V27, P866, DOI 10.1002/j.1552-4604.1987.tb05581.x; LO MW, 1987, EUR J CLIN PHARMACOL, V33, P297, DOI 10.1007/BF00637566; Macintyre PE, 2017, ANAESTH INTENS CARE, V45, P143, DOI 10.1177/0310057X1704500202; Macintyre PE, 2013, ANAESTH INTENS CARE, V41, P222, DOI 10.1177/0310057X1304100212; Majumdar S, 2011, P NATL ACAD SCI USA, V108, P19778, DOI 10.1073/pnas.1115231108; Malinovsky JM, 2002, J CLIN ANESTH, V14, P535, DOI 10.1016/S0952-8180(02)00425-7; Martucci C, 2004, PAIN, V110, P385, DOI 10.1016/j.pain.2004.04.020; McPherson J, 2010, MOL PHARMACOL, V78, P756, DOI 10.1124/mol.110.066613; Mercadante S, 2009, CLIN THER, V31, P2134, DOI 10.1016/j.clinthera.2009.10.013; Mercadante S, 2009, SUPPORT CARE CANCER, V17, P715, DOI 10.1007/s00520-008-0546-6; Mercer SL, 2011, CURR TOP MED CHEM, V11, P1157; Parker RK, 1997, ANESTH ANALG, V84, P757, DOI 10.1097/00000539-199704000-00011; PAUSAWASDI S, 1984, J MED ASSOC THAILAND, V67, P329; Pergolizzi Joseph, 2008, Pain Pract, V8, P287, DOI 10.1111/j.1533-2500.2008.00204.x; PICK CG, 1992, J PHARMACOL EXP THER, V262, P1044; Raehal KM, 2005, J PHARMACOL EXP THER, V313, P1150, DOI 10.1124/jpet.104.082966; RAWAL N, 1990, ACTA ANAESTH SCAND, V34, P197, DOI 10.1111/j.1399-6576.1990.tb03069.x; ROTH A, 1988, AM J CARDIOL, V62, P551, DOI 10.1016/0002-9149(88)90653-4; Schmidt W K, 1986, NIDA Res Monogr, V67, P145; SEITZ W, 1986, ANAESTHESIST, V35, P108; SHOOK JE, 1987, J PHARMACOL EXP THER, V243, P492; Sittl R, 2005, CLIN THER, V27, P225, DOI 10.1016/j.clinthera.2005.02.012; Sittl R, 2006, CLIN THER, V28, P1144, DOI 10.1016/j.clinthera.2006.08.002; Sloan Paul, 2012, J Support Oncol, V10, P220, DOI 10.1016/j.suponc.2012.06.002; Teter K A, 1990, Orthop Nurs, V9, P51, DOI 10.1097/00006416-199007000-00009; Traynor JR, 1999, J PHARMACOL EXP THER, V291, P1093; TRAYNOR JR, 1995, MOL PHARMACOL, V47, P848; Wala EP, 2011, EUR J PHARMACOL, V651, P89, DOI 10.1016/j.ejphar.2010.10.083; Wang HJ, 2014, PHARM RES-DORDR, V31, P1676, DOI 10.1007/s11095-013-1272-4; Webster L, 2016, PAIN MED, V17, P899, DOI 10.1093/pm/pnv110; Weiner Michelle, 2012, J Opioid Manag, V8, P414, DOI 10.5055/jom.2012.0141; Wines JD, 1999, AM J ADDICTION, V8, P161; Woollard M, 2004, EMERG MED J, V21, P362, DOI 10.1136/emj.2004.014324; Xu J, 2011, MOL PAIN, V7, DOI 10.1186/1744-8069-7-9; Yeh YC, 2008, BRIT J ANAESTH, V101, P542, DOI 10.1093/bja/aen213; Yeh YC, 2009, J FORMOS MED ASSOC, V108, P548, DOI 10.1016/S0929-6646(09)60372-7; Yeo AKS, 2006, ANN ACAD MED SINGAP, V35, P487; Yu YK, 1997, J BIOL CHEM, V272, P28869, DOI 10.1074/jbc.272.46.28869; Zacny JP, 1997, J PHARMACOL EXP THER, V280, P1159; Zaki PA, 2000, J PHARMACOL EXP THER, V292, P1127; Zeng Z, 2015, SCI REP-UK, V5, DOI 10.1038/srep10927	84	4	4	2	6	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1049-9091	1938-2715		AM J HOSP PALLIAT ME	Am. J. Hosp. Palliat. Med.	AUG	2018	35	8					1118	1122		10.1177/1049909118771374			5	Health Care Sciences & Services	Health Care Sciences & Services	GM9GE	WOS:000438553600013	29649890				2020-06-30	J	O'Donnell, J; Gladden, RM; Mattson, CL; Kariisa, M				O'Donnell, Julie; Gladden, R. Matthew; Mattson, Christine L.; Kariisa, Mbabazi			Overdose Deaths with Carfentanil and Other Fentanyl Analogs Detected-10 States, July 2016-June 2017	MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT			English	Article									[O'Donnell, Julie; Gladden, R. Matthew; Mattson, Christine L.; Kariisa, Mbabazi] CDC, Div Unintent Injury Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30329 USA	O'Donnell, J (reprint author), CDC, Div Unintent Injury Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30329 USA.	irh8@cdc.gov					CDC, 2016, INFL FENT LAC COUNT; CDC, 2018, RIS NUMB DEATHS INV; Centers for Disease Control (CDC), 2015, INCR FENT DRUG CONF; Florida Department of Law Enforcement, 2017, FLOR MED EX COMM 201; Fogarty MF, 2018, J ANAL TOXICOL, V42, P592, DOI 10.1093/jat/bky035; O'Donnell JK, 2017, MMWR-MORBID MORTAL W, V66, P1197, DOI 10.15585/mmwr.mm6643e1; Suzuki J, 2017, DRUG ALCOHOL DEPEN, V171, P107, DOI 10.1016/j.drugalcdep.2016.11.033	7	30	30	0	4	CENTERS  DISEASE CONTROL	ATLANTA	1600 CLIFTON RD, ATLANTA, GA 30333 USA	0149-2195	1545-861X		MMWR-MORBID MORTAL W	MMWR-Morb. Mortal. Wkly. Rep.	JUL 13	2018	67	27					767	768		10.15585/mmwr.mm6727a4			2	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	GN1FX	WOS:000438734000004	30001560	Green Published, Bronze			2020-06-30	J	Asakura, A; Mihara, T; Goto, T				Asakura, Ayako; Mihara, Takahiro; Goto, Takahisa			Does fentanyl or remifentanil provide better postoperative recovery after laparoscopic surgery? a randomized controlled trial	BMC ANESTHESIOLOGY			English	Article						Quality of recovery; Postoperative recovery; Opioids	SF-36 HEALTH SURVEY; CARDIAC-SURGERY; QUALITY; ANESTHESIA; DEXMEDETOMIDINE; VALIDATION; VALIDITY; SCALE	Background: Fentanyl and remifentanil are widely used opioids in surgery, but it has not been evaluated whether the choice of opioids during surgery affects the patients' postoperative quality of recovery. Accordingly, we aim to compare postoperative recovery of fentanyl-based anesthesia with remifentanil-based anesthesia after laparoscopic surgery using the QoR 40 questionnaire (QoR-40). Methods: The study was prospective, randomized, patient and investigator-blinded, controlled, clinical trial. Seventy patients undergoing laparoscopic or retroperitoneoscopic renal or ureteral surgery were recruited and randomized to either fentanyl or remifentanil based anesthesia groups. The primary outcome was the global QoR-40 at 24 h after surgery. Results: The global median (interquartile range) QoR-40 score was 160 (138-177) in the fentanyl group (n = 32) and 140 (127-166) in the remifentanil group (n = 31). Physical comfort and physical independence, the two out of the five dimensions of the QoR-40, demonstrated significantly high scores in the fentanyl group (P = 0.047 and P = 0. 032, respectively). Conclusion: Although the global QoR is higher in the fentanyl group by 20 points compared with remifentanil group, no significant differences revealed between the groups. Further studies with large numbers of subjects of the same gender are needed.	[Asakura, Ayako; Mihara, Takahiro; Goto, Takahisa] Yokohama City Univ, Dept Anesthesiol & Crit Care Med, Grad Sch Med, Kanazawa Ku, 3-9 Fukuura, Yokohama, Kanagawa, Japan	Asakura, A (reprint author), Yokohama City Univ, Dept Anesthesiol & Crit Care Med, Grad Sch Med, Kanazawa Ku, 3-9 Fukuura, Yokohama, Kanagawa, Japan.	aauaaao@gmail.com	Mihara, Takahiro/AAH-8487-2020	Mihara, Takahiro/0000-0003-0613-511X	Japan Society for the Promotion of Science (JSPS), Tokyo, JapanMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science [24791611]	This work was supported by Grants-in-Aid for Scientific Research (KAKENHI) from Japan Society for the Promotion of Science (JSPS), Tokyo, Japan. Grants Number 24791611 to Ayako Asakura.	Bekker A, 2013, J NEUROSURG ANESTH, V25, P16, DOI 10.1097/ANA.0b013e31826318af; Bowyer AJ, 2016, ANAESTHESIA, V71, P72, DOI 10.1111/anae.13312; Buchanan FF, 2011, BRIT J ANAESTH, V106, P832, DOI 10.1093/bja/aer094; De Oliveira GS, 2011, BRIT J ANAESTH, V107, P362, DOI 10.1093/bja/aer156; De Oliveira GS, 2012, ANESTH ANALG, V115, P262, DOI 10.1213/ANE.0b013e318257a380; EGAN TD, 1993, ANESTHESIOLOGY, V79, P881, DOI 10.1097/00000542-199311000-00004; Fukuhara S, 1998, J CLIN EPIDEMIOL, V51, P1037, DOI 10.1016/S0895-4356(98)00095-X; Fukuhara S, 1998, J CLIN EPIDEMIOL, V51, P1045, DOI 10.1016/S0895-4356(98)00096-1; Fukuhara S, 2004, MANUAL SF 36V2 JAPAN; Ge DJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep21514; Le V, 2016, PAIN MED, V17, P1163, DOI 10.1093/pm/pnv113; Lee WK, 2015, BRIT J ANAESTH, V114, P663, DOI 10.1093/bja/aeu405; Mihara T, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162961; Murphy GS, 2011, ANESTHESIOLOGY, V114, P882, DOI 10.1097/ALN.0b013e3181ec642e; Murphy GS, 2009, ANESTH ANALG, V109, P311, DOI 10.1213/ane.0b013e3181a90adc; Myles PS, 2016, ANESTHESIOLOGY, V125, P39, DOI 10.1097/ALN.0000000000001158; Myles PS, 2001, ANESTHESIOLOGY, V95, P862, DOI 10.1097/00000542-200110000-00013; Myles PS, 2000, BRIT J ANAESTH, V84, P11; Paddison JS, 2011, J SURG RES, V167, pE85, DOI 10.1016/j.jss.2010.12.043; Royse CF, 2010, ANESTHESIOLOGY, V113, P892, DOI 10.1097/ALN.0b013e3181d960a9; Tanaka Y, 2011, J ANESTH, V25, P509, DOI 10.1007/s00540-011-1151-2; Watanabe K, 2014, J ANESTH, V28, P334, DOI 10.1007/s00540-013-1738-x; Wong J, 2009, ANESTHESIOLOGY, V110, P596, DOI 10.1097/ALN.0b013e318197a16d	23	0	0	0	2	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1471-2253			BMC ANESTHESIOL	BMC Anesthesiol.	JUL 11	2018	18								81	10.1186/s12871-018-0547-z			7	Anesthesiology	Anesthesiology	GM7YE	WOS:000438413500001	29996760	DOAJ Gold, Green Published			2020-06-30	J	Kikkert, WJ; Delewi, R; Claessen, BEPM				Kikkert, Wouter J.; Delewi, Ronak; Claessen, Bimmer E. P. M.			Letter by Kikkert et al Regarding Article, "Effect of Intravenous Fentanyl on Ticagrelor Absorption and Platelet Inhibition Among Patients Undergoing Percutaneous Coronary Intervention: The PACIFY Randomized Clinical Trial (Platelet Aggregation With Ticagrelor Inhibition and Fentanyl)"	CIRCULATION			English	Letter									[Kikkert, Wouter J.; Delewi, Ronak; Claessen, Bimmer E. P. M.] Univ Amsterdam, Acad Med Ctr, Dept Cardiol, Ctr Heart, Amsterdam, Netherlands	Kikkert, WJ (reprint author), Univ Amsterdam, Acad Med Ctr, Dept Cardiol, Ctr Heart, Amsterdam, Netherlands.		Claessen, Bimmer E. P. M./K-3870-2018	Claessen, Bimmer E. P. M./0000-0002-1703-7921			Kubica J, 2016, EUR HEART J, V37, P245, DOI 10.1093/eurheartj/ehv547; McEvoy JW, 2018, CIRCULATION, V137, P307, DOI 10.1161/CIRCULATIONAHA.117.031678	2	0	0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0009-7322	1524-4539		CIRCULATION	Circulation	JUL 10	2018	138	2					214	215		10.1161/CIRCULATIONAHA.117.032464			2	Cardiac & Cardiovascular Systems; Peripheral Vascular Disease	Cardiovascular System & Cardiology	GM1SW	WOS:000437853000016	29986966				2020-06-30	J	Ibrahim, K; Shah, R; McEvoy, JW				Ibrahim, Khalil; Shah, Rohan; McEvoy, John W.			Response by Ibrahim et al to Letter Regarding Article, "Effect of Intravenous Fentanyl on Ticagrelor Absorption and Platelet Inhibition Among Patients Undergoing Percutaneous Coronary Intervention: The PACIFY Randomized Clinical Trial (Platelet Aggregation With Ticagrelor Inhibition and Fentanyl)"	CIRCULATION			English	Letter									[Ibrahim, Khalil; Shah, Rohan; McEvoy, John W.] Johns Hopkins Univ, Sch Med, Dept Med, Div Cardiol, Baltimore, MD 21205 USA	Ibrahim, K (reprint author), Johns Hopkins Univ, Sch Med, Dept Med, Div Cardiol, Baltimore, MD 21205 USA.						Ibrahim K, 2018, THROMB HAEMOSTASIS, V118, P1409, DOI 10.1055/s-0038-1666862; Ibrahim K, 2018, CONTEMP CLIN TRIALS, V64, P8, DOI 10.1016/j.cct.2017.11.011; McCarthy CP, 2016, AM HEART J, V176, P114, DOI 10.1016/j.ahj.2016.04.004; McEvoy JW, 2018, CIRCULATION, V137, P307, DOI 10.1161/CIRCULATIONAHA.117.031678; Shah R, 2018, EUR HEART J, V39, P642, DOI 10.1093/eurheartj/ehy016	5	0	0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0009-7322	1524-4539		CIRCULATION	Circulation	JUL 10	2018	138	2					216	217		10.1161/CIRCULATIONAHA.118.034741			2	Cardiac & Cardiovascular Systems; Peripheral Vascular Disease	Cardiovascular System & Cardiology	GM1SW	WOS:000437853000017	29986967				2020-06-30	J	Park, JN; Weir, BW; Allen, ST; Chaulk, P; Sherman, SG				Park, Ju Nyeong; Weir, Brian W.; Allen, Sean T.; Chaulk, Patrick; Sherman, Susan G.			Fentanyl-contaminated drugs and non-fatal overdose among people who inject drugs in Baltimore, MD	HARM REDUCTION JOURNAL			English	Article						Opioids; Heroin; Overdose; Substance use; Epidemiology	ILLICIT OPIOID USERS; BRITISH-COLUMBIA; HEROIN OVERDOSE; UNITED-STATES; RISK; DEATHS; CANADA; CITY; ASSOCIATION; EXPOSURE	Background: The opioid crisis remains a major public health issue in the US and beyond. Despite rapid rises in fentanyl-related mortality nationally, little is known about the role of fentanyl in the occurrence of non-fatal overdose among people who use drugs. We examined the prevalence of non-fatal overdose and perceived fentanyl exposure among syringe services program (SSP) clients and modeled the correlates of non-fatal overdose. Methods: Data were drawn from a cross-sectional survey of 203 SSP clients in Baltimore, MD recruited in 2016. Logistic regression models were used to identify the correlates of experiencing non-fatal overdose in the past 12 months. Results: The majority (65%) was male, 52% were black, 41% were white, and 37% were homeless. Almost all (97%) used heroin, 64% injected heroin with cocaine (i.e., speedball), and many used other types of drugs. Half (53%) perceived fentanyl presence in their drugs either half, most or all of the time. Lifetime and past 12 month prevalence of non-fatal overdose were 58 and 31%, respectively. Independent correlates of non-fatal overdose in the past 12 months were perceiving fentanyl in drugs more than half the time (aOR = 2.79; 95% CI = 1.00-4.68), speedball injection (aOR = 2.80, 95% CI = 1.26-6.23), non-prescription buprenorphine use (aOR = 6.37; 95% CI = 2.86-14.17), and homelessness (aOR = 3.07; 95% CI = 1.28-7.39). Conclusions: These data demonstrate that SSP clients are at high-risk of overdose, some of which is likely attributable to fentanyl exposure. Addressing the rising fentanyl epidemic will require comprehensive and innovative strategies that attend to drug use patterns and structural factors such as homelessness.	[Park, Ju Nyeong; Weir, Brian W.; Allen, Sean T.; Sherman, Susan G.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Behav & Soc, Ju Nyeong Pk,624 N Broadway,HH163, Baltimore, MD 21205 USA; [Park, Ju Nyeong; Sherman, Susan G.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, 615 N Wolfe St, Baltimore, MD 21205 USA; [Chaulk, Patrick] Baltimore City Dept Hlth, 1001 E Fayette St, Baltimore, MD 21201 USA; [Chaulk, Patrick] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, 624 N Broadway, Baltimore, MD 21205 USA; [Chaulk, Patrick] Johns Hopkins Univ, Sch Med, Div Infect Dis, Baltimore, MD 21205 USA	Park, JN (reprint author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Behav & Soc, Ju Nyeong Pk,624 N Broadway,HH163, Baltimore, MD 21205 USA.; Park, JN (reprint author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, 615 N Wolfe St, Baltimore, MD 21205 USA.	ju.park@jhu.edu		Weir, Brian/0000-0003-1634-218X; Park, Ju Nyeong/0000-0001-6490-9887	amfAR; Johns Hopkins University Center for AIDS Research, an NIH - NIH [P30AI094189]; Johns Hopkins University Center for AIDS Research, an NIH - NIAID [P30AI094189]; Johns Hopkins University Center for AIDS Research, an NIH - NCI [P30AI094189]; Johns Hopkins University Center for AIDS Research, an NIH - NICHD [P30AI094189]; Johns Hopkins University Center for AIDS Research, an NIH - NHLBI [P30AI094189]; Johns Hopkins University Center for AIDS Research, an NIH - NIDA [P30AI094189]; Johns Hopkins University Center for AIDS Research, an NIH - NIMH [P30AI094189]; Johns Hopkins University Center for AIDS Research, an NIH - NIA [P30AI094189]; Johns Hopkins University Center for AIDS Research, an NIH - FIC [P30AI094189]; Johns Hopkins University Center for AIDS Research, an NIH - NIGMS [P30AI094189]; Johns Hopkins University Center for AIDS Research, an NIH - NIDDK [P30AI094189]; Johns Hopkins University Center for AIDS Research, an NIH - OAR [P30AI094189]	This research was funded in part by amfAR and a 2015-2016 developmental grant from the Johns Hopkins University Center for AIDS Research, an NIH funded program (P30AI094189), which is supported by the following NIH Co-Funding and Participating Institutes and Centers: NIAID, NCI, NICHD, NHLBI, NIDA, NIMH, NIA, FIC, NIGMS, NIDDK, and OAR. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.	Amlani A, 2015, HARM REDUCT J, V12, DOI 10.1186/s12954-015-0088-4; Beletsky L, 2015, AM J PUBLIC HEALTH, V105, P1872, DOI 10.2105/AJPH.2015.302681; Bohnert ASB, 2011, DRUG ALCOHOL DEPEN, V113, P62, DOI 10.1016/j.drugalcdep.2010.07.008; Britton PC, 2010, DRUG ALCOHOL DEPEN, V107, P51, DOI 10.1016/j.drugalcdep.2009.09.005; Carroll JJ, 2017, INT J DRUG POLICY, V46, P136, DOI 10.1016/j.drugpo.2017.05.023; Caudarella A, 2016, DRUG ALCOHOL DEPEN, V162, P51, DOI 10.1016/j.drugalcdep.2016.02.024; Coffin PO, 2003, ADDICTION, V98, P739, DOI 10.1046/j.1360-0443.2003.00376.x; Darke S, 2005, DRUG ALCOHOL REV, V24, P425, DOI 10.1080/09595230500286005; Drug Enforcement Administration, 2016, COUNT PRESCR PILLS C; Escudero DJ, 2016, ADDICT BEHAV, V60, P8, DOI 10.1016/j.addbeh.2016.03.029; Fischer B, 2004, CAN MED ASSOC J, V171, P235, DOI 10.1503/cmaj.1031416; Green TC, 2016, JAMA INTERN MED, V176, P1555, DOI 10.1001/jamainternmed.2016.4310; Higashikawa Y, 2008, FORENSIC TOXICOL, V26, P1, DOI 10.1007/s11419-007-0039-1; Hungerbuehler I, 2011, HARM REDUCT J, V8, DOI 10.1186/1477-7517-8-16; Hunter K, 2018, INT J DRUG POLICY, V57, P25, DOI 10.1016/j.drugpo.2018.03.026; Jafari S, 2015, CAN J ADDICT, V6, P4; Kerr T, 2007, DRUG ALCOHOL DEPEN, V87, P39, DOI 10.1016/j.drugalcdep.2006.07.009; Klar SA, 2016, MMWR-MORBID MORTAL W, V65, P1015, DOI 10.15585/mmwr.mm6537a6; Kolodny A, 2015, ANNU REV PUBL HEALTH, V36, P559, DOI 10.1146/annurev-publhealth-031914-122957; Kourounis G, 2016, DRUG ALCOHOL DEPEN, V161, P1, DOI 10.1016/j.drugalcdep.2015.12.021; Linton SL, 2013, DRUG ALCOHOL DEPEN, V132, P457, DOI 10.1016/j.drugalcdep.2013.03.009; Maryland Department of Health and Mental Hygiene, 2014, DRUG ALC REL INT DEA; Peterson JA, 2010, INT J DRUG POLICY, V21, P36, DOI 10.1016/j.drugpo.2008.07.004; Potier C, 2014, DRUG ALCOHOL DEPEN, V145, P48, DOI 10.1016/j.drugalcdep.2014.10.012; Rudd RA, 2016, MMWR-MORBID MORTAL W, V65, P1445, DOI 10.15585/mmwr.mm655051e1; Sherman S., 2017, SAFE DRUG CONSUMPTIO; Sherman SG, 2007, DRUG ALCOHOL DEPEN, V88, P182, DOI 10.1016/j.drugalcdep.2006.10.006; Sutter ME, 2017, ACAD EMERG MED, V24, P106, DOI 10.1111/acem.13034; Tobin KE, 2009, INT J DRUG POLICY, V20, P131, DOI 10.1016/j.drugpo.2008.03.002; Turner L, 2015, AM J ADDICTION, V24, P24, DOI 10.1111/ajad.12174; Volpe DA, 2011, REGUL TOXICOL PHARM, V59, P385, DOI 10.1016/j.yrtph.2010.12.007; Warner-Smith M, 2001, ADDICTION, V96, P1113, DOI 10.1046/j.1360-0443.2001.96811135.x	32	23	22	1	6	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1477-7517			HARM REDUCT J	Harm Reduct. J.	JUL 5	2018	15								34	10.1186/s12954-018-0240-z			8	Substance Abuse	Substance Abuse	GM2NP	WOS:000437924400001	29976195	DOAJ Gold, Green Published	Y	N	2020-06-30	J	Hochberg, U; Perez, J				Hochberg, Uri; Perez, Jordi			Retrograde Intrathecal Drug Delivery: A Report of Three Cases for the Management of Cancer-Related Sacropelvic Pain	JOURNAL OF PAIN & PALLIATIVE CARE PHARMACOTHERAPY			English	Article						cancer pain; retrograde; intrathecal; drug delivery	BUPIVACAINE; ANALGESIA; CATHETER; THERAPY; TERM	We report three cases of sacral and pelvic pain resistant to oral medications successfully managed with intraspinal drug delivery through a catheter placed at the intrathecal sacral space to deliver low doses of bupivacaine and fentanyl with local effects.	[Hochberg, Uri] McGill Univ, Cedars Canc Ctr, Canc Pain Clin, Montreal, PQ, Canada; [Perez, Jordi] McGill Univ, Canc Pain Program, Montreal, PQ, Canada	Perez, J (reprint author), Cedars Canc Ctr, Canc Ctr, Canc Pain Program, Room D02-7442,1001 Boul Decarie, Montreal, PQ H4A 3J1, Canada.	Jordi.perez@muhc.mcgill.ca			Louise and Alan Edwards Foundation	The authors wish to thank the Louise and Alan Edwards Foundation for their generous and unconditional support to the MUHC Cancer Pain Program.	Bernards Christopher M, 2002, Best Pract Res Clin Anaesthesiol, V16, P489, DOI 10.1053/bean.2002.0255; Brejt N, 2013, CANCER IMAGING, V13, P591, DOI 10.1102/1470-7330.2013.0052; Brogan SE, 2013, PAIN MED, V14, P478, DOI 10.1111/pme.12060; Bruel BM, 2016, PAIN MED, V17, P2404, DOI 10.1093/pm/pnw060; D'Angelo R, 1998, ANESTHESIOLOGY, V88, P1519, DOI 10.1097/00000542-199806000-00016; Deer TR, 2011, PAIN PHYSICIAN, V14, pE283; Gupta R, 2016, INDIAN J PALLIAT CAR, V22, P180, DOI 10.4103/0973-1075.179604; Kirksey MA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137312; Kurita GP, 2015, ACTA ANAESTH SCAND, V59, P1103, DOI 10.1111/aas.12485; McRoberts WP, 2016, PAIN PHYSICIAN, V19, pE1087; Miguel R, 2000, Cancer Control, V7, P149; NITESCU P, 1991, CLIN J PAIN, V7, P143, DOI 10.1097/00002508-199106000-00011; Perez J, 2016, PAIN RES MANAG, V2016, DOI 10.1155/2016/2157950; Smith TJ, 2002, J CLIN ONCOL, V20, P4040, DOI 10.1200/JCO.2002.02.118; Virlos I, 2010, BRIT J SURG, V97, P1401, DOI 10.1002/bjs.7127	15	0	0	0	0	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1536-0288	1536-0539		J PAIN PALLIAT CARE	J. Pain Palliat. Care Pharmacother.	JUL 3	2018	32	2-3					149	154		10.1080/15360288.2018.1491927			6	Anesthesiology; Pharmacology & Pharmacy	Anesthesiology; Pharmacology & Pharmacy	HY0TN	WOS:000467825900014	30589369				2020-06-30	J	Friesgaard, KD; Riddervold, IS; Kirkegaard, H; Christensen, EF; Nikolajsen, L				Friesgaard, Kristian D.; Riddervold, Ingunn S.; Kirkegaard, Hans; Christensen, Erika F.; Nikolajsen, Lone			Acute pain in the prehospital setting: a register-based study of 41.241 patients	SCANDINAVIAN JOURNAL OF TRAUMA RESUSCITATION & EMERGENCY MEDICINE			English	Article						Acute pain; Prehospital; Causes of acute pain	INTERNATIONAL EMS SYSTEMS; HOSPITAL OUTCOMES RESEARCH; TRAUMA PATIENTS; MANAGEMENT; ANALGESIA; SERVICES; CARE; EPIDEMIOLOGY; CHALLENGES; GUIDELINE	Background: Acute pain is a frequent symptom, but little is known about the frequency and causes of acute pain in the prehospital population. The objectives of this study were to investigate the frequency of moderate to severe pain among prehospital patients and the underlying causes according to primary hospital diagnose codes. Methods: This was a register-based study on 41.241 patients transported by ambulance. Information on moderate to severe pain [Numeric Rating Scale (NRS, 0 10) > 3 or moderate pain or higher on 4-point likert scale] was extracted from a national electronic prehospital patient record. Patient information was merged with primary hospital diagnose codes based on the 10th version of the International Classification of Diseases (ICD-10) to investigate underlying causes of pain. Results: 11.430 patients (27.7%) reported moderate to severe pain during ambulance transport. As a measure of opioid demanding acute pain, 3.275 of 41.241 patients (7.9%) were treated with intravenous fentanyl. Underlying causes of pain were heterogenic according to ICD 10 chapters with injuries being the largest group of patients with moderate to severe pain (XIX: 42.8% of 8.041 patients), followed by non-specific diagnoses (XVIII: 28.5% of 7.101 patients and XXI: 31.6% of 5.148 patients), diseases of the circulatory system (IX: 22.1% of 4.812 patients) and other (20.3% of 16.139 miscellaneous patients). Discussion: Due to the high frequency of moderate to severe pain affecting a wide range of patients, more attention on acute pain is necessary. Whether ambulance personnel have sufficient options for treating various pain conditions might be a subject of future evaluation. Non specific diagnoses accounted for surprisingly many patients with moderate to severe pain, of which many were treated with intravenous fentanyl. This may be substance of further investigation. Conclusions: Moderate to severe pain is a highly frequent and probably underestimated symptom among patients transported by ambulance. Underlying causes of pain are heterogenic as described by primary hospital diagnose codes. More focus on the treatment of acute pain is needed.	[Friesgaard, Kristian D.; Riddervold, Ingunn S.; Kirkegaard, Hans] Cent Denmark Reg, Res Dept, Prehosp Emergency Med Serv, Aarhus, Denmark; [Friesgaard, Kristian D.] Reg Hosp Horsens, Dept Anesthesiol, Horsens, Denmark; [Christensen, Erika F.] Aalborg Univ, Ctr Prehosp & Emergency Res, Dept Clin Med, Aalborg, Denmark; [Christensen, Erika F.] Aalborg Univ Hosp, Dept Anesthesiol & Intens Care, Emergency Clin, Aalborg, Denmark; [Christensen, Erika F.] North Denmark Reg, Prehosp Emergency Med Serv, Aalborg, Denmark; [Nikolajsen, Lone] Aarhus Univ Hosp, Dept Anesthesiol, Aarhus, Denmark	Friesgaard, KD (reprint author), Cent Denmark Reg, Res Dept, Prehosp Emergency Med Serv, Aarhus, Denmark.; Friesgaard, KD (reprint author), Reg Hosp Horsens, Dept Anesthesiol, Horsens, Denmark.	k.friesgaard@me.com		Christensen, Erika F./0000-0003-3673-9694; Nikolajsen, Lone/0000-0002-2705-7088	Health Research Fund of Central Denmark Region	The Health Research Fund of Central Denmark Region funded this project.	Adnet F, 2004, RESUSCITATION, V63, P7, DOI 10.1016/j.resuscitation.2004.04.001; Albrecht E, 2013, BRIT J ANAESTH, V110, P96, DOI 10.1093/bja/aes355; Alonso-Serra Hector M, 2003, Prehosp Emerg Care, V7, P482; Andersen MS, 2013, SCAND J TRAUMA RESUS, V21, DOI 10.1186/1757-7241-21-53; Botker MT, 2017, ANN EMERG MED, V70, P366, DOI 10.1016/j.annemergmed.2016.12.017; Botker MT, 2016, SCAND J TRAUMA RESUS, V24, DOI 10.1186/s13049-016-0204-9; Breivik H, 2008, BRIT J ANAESTH, V101, P17, DOI 10.1093/bja/aen103; Carr DB, 1999, LANCET, V353, P2051, DOI 10.1016/S0140-6736(99)03313-9; Chou R, 2016, J PAIN, V17, P131, DOI 10.1016/j.jpain.2015.12.008; Christensen EF, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-014508; Christensen EF, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-011558; Cousins MJ, 2011, PAIN, V152, P2673, DOI 10.1016/j.pain.2011.09.012; Eidenbenz D, 2016, ANAESTHESIA, V71, P779, DOI 10.1111/anae.13462; Fassbender K, 2017, LANCET NEUROL, V16, P227, DOI 10.1016/S1474-4422(17)30008-X; Galinski M, 2010, PREHOSP EMERG CARE, V14, P334, DOI 10.3109/10903121003760218; Garrison HG, 2002, ANN EMERG MED, V40, P81, DOI 10.1067/mem.2002.124758; Gausche-Hill M, 2014, PREHOSP EMERG CARE, V18, P25, DOI 10.3109/10903127.2013.844873; Gomes E, 2004, RESUSCITATION, V62, P257, DOI 10.1016/j.resuscitation.2004.04.013; Haley KB, 2016, PREHOSP EMERG CARE, V20, P752, DOI 10.1080/10903127.2016.1182599; Han B, 2017, ANN INTERN MED, V167, P293, DOI 10.7326/M17-0865; Hewes HA, 2018, PREHOSP EMERG CARE, V22, P189, DOI 10.1080/10903127.2017.1367444; Hojfeldt SG, 2014, ACTA ANAESTH SCAND, V58, P1025, DOI 10.1111/aas.12347; Jennings PA, 2009, EMERG MED J, V26, P552, DOI 10.1136/emj.2008.062539; Jennings PA, 2011, EMERG MED J, V28, P530, DOI 10.1136/emj.2010.098954; Jones Georgina E, 2003, Accid Emerg Nurs, V11, P166, DOI 10.1016/S0965-2302(02)00219-9; Kruger AJ, 2013, ACTA ANAESTH SCAND, V57, P1175, DOI 10.1111/aas.12181; Kudenchuk PJ, 2016, NEW ENGL J MED, V374, P1711, DOI 10.1056/NEJMoa1514204; Langhelle A, 2004, RESUSCITATION, V61, P9, DOI 10.1016/j.resuscitation.2003.12.008; Luiz T, 2015, ANAESTHESIST, V64, P927, DOI 10.1007/s00101-015-0089-4; Maio RF, 2002, ANN EMERG MED, V40, P172, DOI 10.1067/mem.2002.124756; Maio RF, 1999, ANN EMERG MED, V33, P423, DOI 10.1016/S0196-0644(99)70307-0; Marinangeli F, 2009, PAIN PRACT, V9, P282, DOI 10.1111/j.1533-2500.2009.00277.x; McLean Samuel A, 2002, Prehosp Emerg Care, V6, P402, DOI 10.1080/10903120290938021; McManus JG, 2005, EMERG MED CLIN N AM, V23, P415, DOI 10.1016/j.emc.2004.12.009; Middleton PM, 2010, PREHOSP EMERG CARE, V14, P439, DOI 10.3109/10903127.2010.497896; Mikkelsen S, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-014383; Moller TP, 2017, SCAND J TRAUMA RESUS, V25, DOI 10.1186/s13049-017-0366-0; Moller TP, 2015, SCAND J TRAUMA RESUS, V23, DOI 10.1186/s13049-015-0169-0; Mounteney J, 2015, INT J DRUG POLICY, V26, P626, DOI 10.1016/j.drugpo.2015.04.003; Papaspyrou E, 2004, RESUSCITATION, V63, P255, DOI 10.1016/j.resuscitation.2004.06.009; Perkins GD, 2015, LANCET, V385, P947, DOI 10.1016/S0140-6736(14)61886-9; Pickering A, 2015, J TRAUMA ACUTE CARE, V78, P164, DOI 10.1097/TA.0000000000000483; Platts-Mills TF, 2013, J PAIN, V14, P966, DOI 10.1016/j.jpain.2013.03.014; Platts-Mills TF, 2012, ANN EMERG MED, V60, P199, DOI 10.1016/j.annemergmed.2011.09.014; Roessler M, 2006, RESUSCITATION, V68, P45, DOI 10.1016/j.resuscitation.2005.08.004; Saver JL, 2015, NEW ENGL J MED, V372, P528, DOI 10.1056/NEJMoa1408827; Schmidt M, 2015, CLIN EPIDEMIOL, V7, P449, DOI 10.2147/CLEP.S91125; Schmidt M, 2014, EUR J EPIDEMIOL, V29, P541, DOI 10.1007/s10654-014-9930-3; Spaite DW, 2001, ANN EMERG MED, V37, P657, DOI 10.1067/mem.2001.115215; Spilman SK, 2016, INJURY, V47, P2018, DOI 10.1016/j.injury.2016.03.012; Steg PG, 2013, NEW ENGL J MED, V369, P2207, DOI 10.1056/NEJMoa1311096; Studnek JR, 2013, PREHOSP EMERG CARE, V17, P386, DOI 10.3109/10903127.2013.764948; Sundararajan V, 2004, J CLIN EPIDEMIOL, V57, P1288, DOI 10.1016/j.jclinepi.2004.03.012; Walsh B, 2013, PREHOSP EMERG CARE, V17, P78, DOI 10.3109/10903127.2012.717167; Young MF, 2013, J EMERG MED, V45, P46, DOI 10.1016/j.jemermed.2012.07.088	55	5	5	0	1	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1757-7241			SCAND J TRAUMA RESUS	Scand. J. Trauma Resusc. Emerg. Med.	JUL 3	2018	26								53	10.1186/s13049-018-0521-2			10	Emergency Medicine	Emergency Medicine	GL8GT	WOS:000437456000001	29970130	DOAJ Gold, Green Published			2020-06-30	J	Tan, WL; Li, S; Liu, XC; Gao, X; Huang, WQ; Guo, JY; Wang, ZX				Tan, Wulin; Li, Si; Liu, Xiaochen; Gao, Xiang; Huang, Wenqi; Guo, Junying; Wang, Zhongxing			Prophylactic Intravenous Lidocaine at Different Doses for Fentanyl-Induced Cough (FIC): A Meta-Analysis	SCIENTIFIC REPORTS			English	Article							DOUBLE-BLIND; TRACHEAL INTUBATION; INJECTION; PAIN; PROPOFOL; PREVENTION; SALBUTAMOL; INFUSIONS; EPHEDRINE; TRIAL	To evaluate whether different doses of intravenous lidocaine are effective at preventing fentanyl-induced cough (FIC), we searched PubMed, Scopus, Cochrane Library, EMBASE and Web of Science, according to predefined criteria, for all articles published until June 2017. A meta-analysis and subgroup analysis were performed by combining the reported incidence of FIC. The odds ratio (OR) was used as a summary statistic. Eleven articles were included, with 965 patients in the lidocaine group and 745 patients in the control group. A pooled analysis indicated that the overall incidence of FIC was significantly different between the lidocaine group and the control group (OR, 0.27; 95% confidence interval (CI), 0.21-0.35; P < 0.05), as well as between the adult and paediatric subgroups. Sensitivity analysis showed that the results were stable. Subgroup analyses showed that compared to a placebo, both low (0.5-1.0 mg/kg) and high doses of lidocaine (1.5-2.0 mg/kg) were effective at reducing FIC incidence. There was no significant difference between low or high doses of lidocaine. Fentanyl doses added no significant heterogeneity as shown by meta-regression. The findings of this meta-analysis indicate that prophylactic intravenous lidocaine is effective at preventing FIC in both adults and children.	[Tan, Wulin; Huang, Wenqi; Guo, Junying; Wang, Zhongxing] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Anaesthesiol, Guangzhou, Guangdong, Peoples R China; [Li, Si] Sun Yat Sen Univ, Affiliated Hosp 6, Guangzhou, Guangdong, Peoples R China; [Liu, Xiaochen] Sun Yat Sen Univ, Zhongshan Sch Med, Guangzhou, Guangdong, Peoples R China; [Gao, Xiang] Sun Yat Sen Univ, Dept Pharm, Affiliated Hosp 1, Guangzhou, Guangdong, Peoples R China	Wang, ZX (reprint author), Sun Yat Sen Univ, Affiliated Hosp 1, Dept Anaesthesiol, Guangzhou, Guangdong, Peoples R China.	doctorwzx@126.com			Natural Scientific Foundation of Guangdong Province [2016A030313255]; Foundation of Sun Yat-sen University [16ykpy36]	This study was supported by The Natural Scientific Foundation of Guangdong Province (2016A030313255) and the Foundation of Sun Yat-sen University for Young Teachers (16ykpy36). Both grants were awarded to Zhongxing Wang. The authors also thank American Journal Experts for polishing the language of the manuscript.	Agarwal A, 2003, CAN J ANAESTH, V50, P297, DOI 10.1007/BF03017801; Aldrete JA, 2010, ACTA ANAESTH SCAND, V54, P442, DOI 10.1111/j.1399-6576.2009.02174.x; Arslan Z, 2016, REV BRAS ANESTESIOL, V66, P383, DOI [10.1016/j.bjane.2014.11.018, 10.1016/j.bjan.2015.10.005]; BOHRER H, 1990, ANAESTHESIA, V45, P18, DOI 10.1111/j.1365-2044.1990.tb14496.x; DEMCZUK RJ, 1984, ANESTHESIOLOGY, V60, P69, DOI 10.1097/00000542-198401000-00016; El Baissari Mabelle C. Tannous, 2014, Middle East Journal of Anesthesiology, V22, P449; Euasobhon P, 2016, COCHRANE DB SYST REV, V2, pD7874; Gecaj-Gashi Agreta, 2013, Cough, V9, P20, DOI 10.1186/1745-9974-9-20; Gibbons K, 2016, PEDIATR BLOOD CANCER, V63, P1168, DOI 10.1002/pbc.25870; Guler G, 2010, CURR THER RES CLIN E, V71, P289, DOI 10.1016/j.curtheres.2010.10.004; Han Chao, 2007, Fudan Xuebao (Yixueban), V34, P135; Han JI, 2010, J CLIN ANESTH, V22, P3, DOI 10.1016/j.jclinane.2009.01.019; Hassani Valiallah, 2013, Anesth Pain Med, V2, P115, DOI 10.5812/aapm.6442; Kim DH, 2014, KOREAN J ANESTHESIOL, V67, P171, DOI 10.4097/kjae.2014.67.3.171; Kim JE, 2014, J ANESTH, V28, P257, DOI 10.1007/s00540-013-1695-4; Kindler CH, 1996, J CLIN ANESTH, V8, P491, DOI 10.1016/0952-8180(96)00109-2; Lee Keon Young, 2012, Journal of korean biological nursing science, V14, P275, DOI 10.7586/jkbns.2012.14.4.275; Li SY, 2016, J CLIN ANESTH, V34, P440, DOI 10.1016/j.jclinane.2016.05.034; Lim KJ, 2013, KOREAN J ANESTHESIOL, V65, P251, DOI 10.4097/kjae.2013.65.3.251; Lin CS, 2004, CAN J ANAESTH, V51, P654, DOI 10.1007/BF03018421; Lui PW, 1996, CAN J ANAESTH, V43, P1216; Mendonca FT, 2017, REV BRAS ANESTESIOL, V67, P50, DOI [10.1016/j.bjane.2015.08.004, 10.1016/j.bjan.2016.02.001]; Mooney JJ, 2014, PAIN MED, V15, P820, DOI 10.1111/pme.12333; Oshima T, 2006, CAN J ANAESTH, V53, P753, DOI 10.1007/BF03022790; Ozmen O, 2016, PAK J MED SCI, V32, P715, DOI 10.12669/pjms.323.9496; Pandey CK, 2005, CAN J ANAESTH, V52, P172, DOI 10.1007/BF03027724; Pandey CK, 2004, ANESTH ANALG, V99, P1696, DOI 10.1213/01.ANE.0000136967.82197.82; Shrestha S K, 2012, Kathmandu Univ Med J (KUMJ), V10, P16; Soltani M.S, 2016, ANESTH PAIN MED, V6; Sun L, 2014, J ANESTH, V28, P325, DOI 10.1007/s00540-013-1732-3; Tweed WA, 2001, ANESTH ANALG, V92, P1442; Uvelin A, 2009, ACTA ANAESTH SCAND, V53, P1228, DOI 10.1111/j.1399-6576.2009.02041.x; Viechtbauer W., 2010, J STAT SOFTWARE, V36, pi03, DOI 10.18637/jss.v036.i03; Walker BJ, 2011, REGION ANESTH PAIN M, V36, P41, DOI 10.1097/AAP.0b013e31820306da; [张瑞冬 ZHANG Ruidong], 2007, [上海医学, Shanghai medical journal], V30, P185; [张兆平 ZHANG Zhao-ping], 2009, [临床麻醉学杂志, The Journal of Clinical Anesthestology], V25, P35	36	1	1	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	JUL 2	2018	8								9946	10.1038/s41598-018-27457-3			8	Multidisciplinary Sciences	Science & Technology - Other Topics	GL2MG	WOS:000436955000001	29967371	DOAJ Gold, Green Published			2020-06-30	J	Chen, WL; Jin, N; Lin, YY; Villani, V; Shimizu, A; Zhao, X; Lu, FN; Li, C; Chen, KG; Lin, Z; Qi, ZQ				Chen, Weili; Jin, Ning; Lin, Yingying; Villani, Vincenzo; Shimizu, Akira; Zhao, Xia; Lu, FangNa; Li, Cheng; Chen, KeGong; Lin, Zhi; Qi, Zhongquan			Immunomodulatory Effects of Fentanyl or Dexmedetomidine Hydrochloride Infusion After Allogeneic Heart Transplantation in Mice	REGIONAL ANESTHESIA AND PAIN MEDICINE			English	Article							MYCOPHENOLATE-MOFETIL; KIDNEY-TRANSPLANTATION; IMMUNE-RESPONSES; TACROLIMUS; MODULATION; REJECTION; MORPHINE; MOUSE; PAIN	Background and Objectives Postoperatively, transplant recipients receive immunosuppressants, as well as sedatives and analgesics. The immunomodulatory effects of these other agents during the induction period following transplantation remain unclear. We aimed to determine whether the agents dexmedetomidine hydrochloride (Dex) and fentanyl (Fen) have immunomodulatory effects during the induction period following heart transplantation (HTx). Methods Fifty mice were used for antinociception tests after administration of Dex and Fen, and T cells from 3 naive animals were used for in vitro lymphocyte transformation test (study 1). Fifty-four B6 mice received HTx from BALB/c mice and were treated with Dex, Fen, or neither (study 2). Thirty-six recipients were used for graft survival data and were humanely killed at the time of cessation of heart graft contraction. The remaining 18 were humanely killed at either postoperative day (POD) 4 or 6 for histologic examination of graft survival, as well as in vitro analysis. Results Based on the results of study 1, daily intraperitoneal administration of Dex at 30 g/kg or Fen at 0.25 mg/kg was determined to be the optimal dose to induce analgesia without oversedation following HTx. Graft survivals in both Dex- or Fen-treated animals were statistically prolonged compared with control (P < 0.01). Graft survival of Fen-treated recipients was increased up to 15 days, and graft survival of Dex-treated animals was also increased up to 10 days, whereas control mice rejected heart grafts by POD 7. Mixed lymphocyte reaction responses on POD 4 showed statistically lower responses in Dex-treated recipients and Fen-treated recipients when compared with controls (P < 0.01). Cytokine profiles of splenocytes showed markedly fewer interferon -positive splenocytes in Fen-treated recipients on POD 4. Conclusions These data suggest that both Dex and Fen have immunomodulatory properties in the induction period following transplantation.	[Chen, Weili; Zhao, Xia; Chen, KeGong; Lin, Zhi] Xiamen Univ, Xiamen Cardiovasc Hosp, Xiamen 361004, Fujian, Peoples R China; [Chen, Weili; Jin, Ning; Lin, Yingying; Lu, FangNa; Li, Cheng; Qi, Zhongquan] Fujian Key Lab Organ & Tissue Regenerat, Xiamen, Peoples R China; [Chen, Weili; Jin, Ning; Lin, Yingying; Lu, FangNa; Li, Cheng; Qi, Zhongquan] Xiamen Univ, Organ Transplantat Inst, Xiamen, Fujian, Peoples R China; [Jin, Ning] Shanxi Med Univ, Shanxi Key Lab Birth Defects & Cell Regenerat, Taiyuan, Shanxi, Peoples R China; [Villani, Vincenzo] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA; [Shimizu, Akira] Nippon Med Sch, Grad Sch Med, Dept Analyt Human Pathol, Tokyo, Japan	Chen, WL (reprint author), Xiamen Univ, Xiamen Cardiovasc Hosp, Xiamen 361004, Fujian, Peoples R China.	forever_vicky1999@hotmail.com		Villani, Vincenzo/0000-0002-6078-9766; Qi, Zhongquan/0000-0002-7210-4955	Youth Foundation of Health Department of Fujian Province, China [2013-2-108]; Natural Science Fund of Fujian Province, China [2014D015, 2016JO414]; joint research project of health and education of Fujian Province [WKJ2016-2-20]	This research was supported by the Youth Foundation of Health Department of Fujian Province, China (2013-2-108, to Z.L.); Natural Science Fund of Fujian Province, China (2014D015, to Z.L.); Natural Science Fund of Fujian Province, China (2016JO414, to Z.Q.); and the joint research project of health and education of Fujian Province (WKJ2016-2-20, to Z.Q.).	Al-Hashimi M, 2013, BRIT J ANAESTH, V111, P80, DOI 10.1093/bja/aet153; Buggy DJ, 2015, BRIT J ANAESTH, V114, P2, DOI 10.1093/bja/aeu262; Eisenstein TK, 1998, J NEUROIMMUNOL, V83, P36, DOI 10.1016/S0165-5728(97)00219-1; Halloran PF, 2010, AM J TRANSPLANT, V10, P1126, DOI 10.1111/j.1600-6143.2010.03053.x; Hiramitsu T, 2016, INT IMMUNOPHARMACOL, V39, P192, DOI 10.1016/j.intimp.2016.07.019; Klintmalm GB, 2014, AM J TRANSPLANT, V14, P1817, DOI 10.1111/ajt.12810; Lai YC, 2009, J SURG RES, V154, P212, DOI 10.1016/j.jss.2008.07.010; Lee SH, 2016, CLIN NEPHROL, V86, P319, DOI 10.5414/CN108945; Mantz J, 2011, EUR J ANAESTH, V28, P3, DOI 10.1097/EJA.0b013e32833e266d; Martucci C, 2004, PAIN, V110, P385, DOI 10.1016/j.pain.2004.04.020; Molina-Martinez LM, 2014, BRAIN BEHAV IMMUN, V42, P60, DOI 10.1016/j.bbi.2014.06.011; Plein LM, 2017, BR J PHARM; Priyanka HP, 2013, INT IMMUNOPHARMACOL, V17, P774, DOI 10.1016/j.intimp.2013.08.020; Qazi Y, 2017, AM J TRANSPLANT, V17, P1358, DOI 10.1111/ajt.14090; Rostaing L, 2016, AM J KIDNEY DIS, V67, P648, DOI 10.1053/j.ajkd.2015.10.024; Sacerdote P, 2000, ANESTH ANALG, V90, P1411, DOI 10.1097/00000539-200006000-00028; Tham SM, 2005, BRIT J PHARMACOL, V144, P875, DOI 10.1038/sj.bjp.0706045; van Gelder T, 2014, AM J TRANSPLANT, V14, P1221, DOI 10.1111/ajt.12682; Wang M, 2016, INT J CLIN PHARM TH, V54, P433, DOI 10.5414/CP202499; Weber RJ, 2006, AM J IMMUNOL, V2, P35; YAMADA K, 1995, J IMMUNOL, V155, P5249; YASUURA K, 1991, TRANSPLANTATION, V51, P896, DOI 10.1097/00007890-199104000-00031; YOUSEM SA, 1990, J HEART TRANSPLANT, V9, P593	23	0	0	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1098-7339	1532-8651		REGION ANESTH PAIN M	Region. Anesth. Pain Med.	JUL	2018	43	5					509	515		10.1097/AAP.0000000000000747			7	Anesthesiology	Anesthesiology	HK3TG	WOS:000457840300009	29509567				2020-06-30	J	Xiang, LS; Klemcke, HG; Wienandt, NA; Ryan, KL; Hinojosa-Laborde, C				Xiang, Lusha; Klemcke, Harold G.; Wienandt, Nathan A.; Ryan, Kathy L.; Hinojosa-Laborde, Carmen			A novel rat model of extremity trauma for prehospital pain management research	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article; Proceedings Paper	Military Health Sciences System Research Symposium	AUG 26-30, 2017	Kissimmee, FL			Trauma model; pain model; opioids; ketamine; prehospital care	FEMUR FRACTURE MODEL; INJURY; KETAMINE; HYPERALGESIA; ALLODYNIA; BLOCKADE; OUTCOMES; ANXIETY	BACKGROUND: Painmanagement is important in prehospital care of patients with extremity trauma (ET). The goal of this study was to establish a rat model of ET for prehospital pain research and validate it using pain behaviors and analgesics. METHODS: Rats were anesthetized using isoflurane, and ET was induced in one hindlimb via clamping retrofemoral tissues for 30 seconds, followed by closed fibula fracture. Rats regained consciousness after ET. Pain responses in the injured hindlimb to thermal hyperalgesia (paw withdrawal latency [PWL]), mechanical allodynia (paw withdrawal pressure [PWP]), and weight bearing (WB) were determined before and 90 minutes after ET. Morphine (2 mg/kg), fentanyl (10 mu g/kg), sufentanil (1 mu g/kg), ketamine (5 mg/kg), or vehicle (saline) were then administered via intravenous (i.v.) injection, followed by PWL, PWP, and WB assessments at 10 minutes, 40 minutes, 80 minutes, and 120 minutes after analgesia. RESULTS: After ET, PWL, PWP, and WB were significantly decreased by 61 +/- 4%, 64 +/- 8%, and 65 +/- 4%, respectively, compared with pre-ET values. These pain behaviors were maintained for 3 hours to 4 hours. Compared with the saline group, opioid analgesics significantly increased PWL for at least 80 minutes, with sufentanil exhibiting the highest analgesic effect. An increase in PWL was only observed at 10 minutes after ketamine. The PWP was transiently increased with opioid analgesics for 10 minutes to 40 minutes, but was not changed with ketamine. Weight bearing was improved with opioid analgesics for at least 2 hours, but only for up to 80 minutes with ketamine. CONCLUSION: Our ET model includes long bone fracture and soft tissue injury, but no fixation surgery, mimicking prehospital ET. Our model produces acute, steady, and reproducible trauma-related pain behaviors, and is clinically relevant regarding the pain behaviors and established responses to common analgesics. This model of acute pain due to ET is ideal for prehospital pain management research. (Copyright (C) 2018 Wolters Kluwer Health, Inc. All rights reserved.)	[Xiang, Lusha; Klemcke, Harold G.; Wienandt, Nathan A.; Ryan, Kathy L.; Hinojosa-Laborde, Carmen] US Army Inst Surg Res, Tact Combat Casualty Care Res, Jbsa Ft Sam Houston, TX 78234 USA	Hinojosa-Laborde, C (reprint author), US Army Inst Surg Res, 3698 Chambers Pass, Jbsa Ft Sam Houston, TX 78234 USA.	carmen.hinojosa-laborde.civ@mail.mil			US Army Clinical and Rehabilitative Medicine Research Program, Joint Program Committee 8, Applied Pain Research Award	This study was funded by the US Army Clinical and Rehabilitative Medicine Research Program, Joint Program Committee 8, Applied Pain Research Award.	Bellamy RF, 1995, TXB MILITARY MED ANE, V4, P1; Bennett GJ, 2012, J PAIN, V13, P921, DOI 10.1016/j.jpain.2012.05.008; Brown CVR, 2016, AM SURGEON, V82, P1055; Butler Frank K, 2014, J Spec Oper Med, V14, P13; Champion HR, 2003, J TRAUMA, V54, pS13, DOI 10.1097/01.TA.0000057151.02906.27; Cohen L, 2015, ANN EMERG MED, V65, P43, DOI 10.1016/j.annemergmed.2014.06.018; Feinberg SD, 2000, GERIATRICS, V55, P44; Fowler M, 2014, BURNS, V40, P759, DOI 10.1016/j.burns.2013.10.011; Frampton JE, 2016, DRUGS, V76, P719, DOI 10.1007/s40265-016-0571-6; Freeman KT, 2008, ANESTHESIOLOGY, V108, P473, DOI 10.1097/ALN.0b013e3181649351; HEMMINGSEN C, 1991, ACTA ANAESTH SCAND, V35, P755, DOI 10.1111/j.1399-6576.1991.tb03385.x; Ivanhoe CB, 2004, J HEAD TRAUMA REHAB, V19, P29, DOI 10.1097/00001199-200401000-00004; LAMOTTE RH, 1991, J NEUROPHYSIOL, V66, P190; Losvik OK, 2015, SCAND J TRAUMA RESUS, V23, DOI 10.1186/s13049-015-0176-1; Majuta LA, 2015, PAIN, V156, P157, DOI 10.1016/j.pain.0000000000000017; Manigrasso MB, 2004, J ORTHOP TRAUMA, V18, P687, DOI 10.1097/00005131-200411000-00006; Mehta Vivek, 2009, Rev Pain, V3, P10, DOI 10.1177/204946370900300204; Miller M, 2016, ANN EMERG MED, V68, P181, DOI 10.1016/j.annemergmed.2016.03.041; Minville V, 2008, ANESTHESIOLOGY, V108, P467, DOI 10.1097/ALN.0b013e3181649333; Molina PE, 2004, SHOCK, V21, P526, DOI 10.1097/01.shk.0000126904.67614.21; Nozaki-Taguchi N, 2002, ANESTHESIOLOGY, V96, P617, DOI 10.1097/00000542-200203000-00018; Pamplin JC, 2017, J SPEC OPER MED, V17, P106; Parikh Beena, 2011, J Anaesthesiol Clin Pharmacol, V27, P485, DOI 10.4103/0970-9185.86592; Ploghaus A, 2001, J NEUROSCI, V21, P9896, DOI 10.1523/JNEUROSCI.21-24-09896.2001; Rhudy JL, 2000, PAIN, V84, P65, DOI 10.1016/S0304-3959(99)00183-9; Sessler CN, 2002, AM J RESP CRIT CARE, V166, P1338, DOI 10.1164/rccm.2107138; Toroyan T, 2013, INJURY PREV, V19, P150, DOI 10.1136/injuryprev-2013-040775; Xiang LS, 2014, AM J PHYSIOL-HEART C, V307, pH621, DOI 10.1152/ajpheart.00208.2014; Xiang LS, 2014, AM J PHYSIOL-HEART C, V306, pH684, DOI 10.1152/ajpheart.00868.2013; Xu J, 2011, CURR OPIN ANESTHESIO, V24, P508, DOI 10.1097/ACO.0b013e32834a50d8; Yaksh TL, 2010, IARS	31	1	1	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	JUL	2018	85			2			S49	S56		10.1097/TA.0000000000001833			8	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	HB9BD	WOS:000451385500009	29443860				2020-06-30	J	Paul, M; Bougouin, W; Dumas, F; Geri, G; Champigneulle, B; Guillemet, L; Salem, OB; Legriel, S; Chiche, JD; Charpentier, J; Mira, JP; Sandroni, C; Cariou, A				Paul, Marine; Bougouin, Wulfran; Dumas, Florence; Geri, Guillaume; Champigneulle, Benoit; Guillemet, Lucie; Salem, Omar Ben Hadj; Legriel, Stephane; Chiche, Jean-Daniel; Charpentier, Julien; Mira, Jean-Paul; Sandroni, Claudio; Cariou, Alain			Comparison of two sedation regimens during targeted temperature management after cardiac arrest	RESUSCITATION			English	Article						Cardiac arrest; Sedation; Prognosis; Therapeutic hypothermia	EUROPEAN RESUSCITATION COUNCIL; INTENSIVE-CARE MEDICINE; LONG-TERM SEDATION; THERAPEUTIC HYPOTHERMIA; RANDOMIZED-TRIAL; ICU PATIENTS; PROPOFOL; PROGNOSTICATION; PROGNOSIS; MIDAZOLAM	Purpose: Although guidelines on post-resuscitation care recommend the use of short-acting agents for sedation during targeted temperature management (TTM) after cardiac arrest (CA), the potential advantages of this strategy have not been clinically demonstrated. Methods: We compared two sedation regimens (propofol-remifentanil, period P2, vs midazolam-fentanyl, period P1) among comatose TTM-treated CA survivors. Management protocol, apart from sedation and neuromuscular blockers use, did not change between the two periods. Baseline severity was assessed with Cardiac-ArrestHospital- Prognosis (CAHP) score. Time to awakening was measured starting from discontinuation of sedation at the end of rewarming. Awakening was defined as delayed when it occurred after more than 48 h. Results: 460 patients (134 in P2, 326 in P1) were included. CAHP score did not significantly differ between P2 and P1 (P = 0.93). Sixty percent of patients awoke in both periods (81/134 vs. 194/326, P = 0.85). Median time to awakening was 2.5 (IQR 1-9) hours in P2 vs. 17 (IQR 7-60) hours in P1. Awakening was delayed in 6% of patients in P2 vs. 29% in P1 (p < 0.001). After adjustment, P2 was associated with significantly lower odds of delayed awakening (OR 0.08, 95% CI 0.03-0.2; P < 0.001). Patients in P2 had significantly more ventilator-free days (25 vs. 24 days; P = 0.007), and lower catecholamine-free days within day 28. Survival and favorable neurologic outcome at discharge did not differ across periods. Conclusions: During TTM following resuscitation from CA, sedation with propofol-remifentanil was associated with significantly earlier awakening and more ventilator-free days as compared with midazolam-fentanyl.	[Paul, Marine; Bougouin, Wulfran; Dumas, Florence; Champigneulle, Benoit; Chiche, Jean-Daniel; Mira, Jean-Paul; Cariou, Alain] Univ Paris 05, Sorbonne Paris Cite, UFR Med, Paris, France; [Paul, Marine; Geri, Guillaume; Guillemet, Lucie; Salem, Omar Ben Hadj; Chiche, Jean-Daniel; Charpentier, Julien; Mira, Jean-Paul; Cariou, Alain] Cochin Hosp, AP HP, Med ICU, Paris, France; [Bougouin, Wulfran; Dumas, Florence; Geri, Guillaume; Legriel, Stephane; Cariou, Alain] Paris Sudden Death Expertise Ctr, Paris, France; [Bougouin, Wulfran; Dumas, Florence; Geri, Guillaume; Cariou, Alain] INSERM, Paris Cardiovasc Res Ctr, U970, Paris, France; [Dumas, Florence] Cochin Hotel Dieu Hosp, APHP, Emergency Dept, Paris, France; [Champigneulle, Benoit] Georges Pompidou European Hosp, APHP, Surg & Trauma Intens Care Unit, Paris, France; [Legriel, Stephane] Mignot Hosp, ICU, Le Chesnay, France; [Sandroni, Claudio] Catholic Univ, Dept Anaesthesiol & Intens Care, Sch Med, Rome, Italy	Cariou, A (reprint author), Cochin Hosp, Med ICU, 27 Rue Faubourg St Jacques, F-75014 Paris, France.	alain.cariou@cch.aphp.fr	Sandroni, Claudio/A-7320-2019; Legriel, Stephane/J-1307-2017; Chiche, Jean-Daniel/P-5220-2017; Geri, Guillaume/L-7872-2018	Sandroni, Claudio/0000-0002-8878-2611; Legriel, Stephane/0000-0003-4782-6734; Chiche, Jean-Daniel/0000-0002-6433-6254; Geri, Guillaume/0000-0002-7691-6635			Anderson KB, 2016, THER HYPOTHERMIA TEM, V6, P169, DOI 10.1089/ther.2016.0003; Andresen JM, 2014, CRIT CARE MED, V42, P2244, DOI 10.1097/CCM.0000000000000522; Badjatia N, 2008, STROKE, V39, P3242, DOI 10.1161/STROKEAHA.108.523654; Bjelland TW, 2012, INTENS CARE MED, V38, P959, DOI 10.1007/s00134-012-2540-1; Bougouin W, 2014, INTENS CARE MED, V40, P846, DOI 10.1007/s00134-014-3252-5; Boulila C, 2016, CRIT CARE NURSE, V36, P33, DOI 10.4037/ccn2016387; Chamorro C, 2010, ANESTH ANALG, V110, P1328, DOI 10.1213/ANE.0b013e3181d8cacf; Champigneulle B, 2016, RESUSCITATION, V103, P60, DOI 10.1016/j.resuscitation.2016.03.021; Deye N, 2016, ANN INTENSIVE CARE, V6, DOI 10.1186/s13613-015-0104-6; Deye N, 2015, CIRCULATION, V132, P182, DOI 10.1161/CIRCULATIONAHA.114.012805; Dragancea I, 2013, RESUSCITATION, V84, P337, DOI 10.1016/j.resuscitation.2012.09.015; Ely EW, 2003, JAMA-J AM MED ASSOC, V289, P2983, DOI 10.1001/jama.289.22.2983; Geri G, 2015, INTENSIVE CARE MED; Gold B, 2014, RESUSCITATION, V85, P211, DOI 10.1016/j.resuscitation.2013.10.030; Graham JW, 2009, ANNU REV PSYCHOL, V60, P549, DOI 10.1146/annurev.psych.58.110405.085530; Hall RI, 2001, CHEST, V119, P1151, DOI 10.1378/chest.119.4.1151; Ho KM, 2008, INTENS CARE MED, V34, P1969, DOI 10.1007/s00134-008-1186-5; JENNETT B, 1975, LANCET, V1, P480; Kamps MJA, 2013, INTENS CARE MED, V39, P1671, DOI 10.1007/s00134-013-3004-y; Kirwan CJ, 2012, INTENS CARE MED, V38, P76, DOI 10.1007/s00134-011-2360-8; Laver S, 2004, INTENS CARE MED, V30, P2126, DOI 10.1007/s00134-004-2425-z; Lemiale V, 2013, INTENS CARE MED, V39, P1972, DOI 10.1007/s00134-013-3043-4; Levey AS, 1999, ANN INTERN MED, V130, P461, DOI 10.7326/0003-4819-130-6-199903160-00002; Maupain C, 2016, EUR HEART J, V37, P3222, DOI 10.1093/eurheartj/ehv556; Muellejans B, 2006, CRIT CARE, V10, DOI 10.1186/cc4939; Nolan JP, 2015, INTENS CARE MED, V41, P2039, DOI 10.1007/s00134-015-4051-3; Orban JC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045284; Paul M, 2016, INTENSIVE CARE M APR; Perkins GD, 2014, RESUSCITATION; Rozendaal F, 2009, INTENS CARE MED, V35, P291, DOI 10.1007/s00134-008-1328-9; Samaniego EA, 2011, NEUROCRIT CARE, V15, P113, DOI 10.1007/s12028-010-9412-8; Sandroni C, 2016, INTENS CARE MED, V42, P104, DOI 10.1007/s00134-015-4082-9; Sandroni C, 2014, INTENS CARE MED, V40, P1816, DOI 10.1007/s00134-014-3470-x; Weinbroum AA, 1997, INTENS CARE MED, V23, P1258, DOI 10.1007/s001340050495	34	19	19	0	3	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0300-9572			RESUSCITATION	Resuscitation	JUL	2018	128						204	210		10.1016/j.resuscitation.2018.03.025			7	Critical Care Medicine; Emergency Medicine	General & Internal Medicine; Emergency Medicine	GK7TH	WOS:000436411800040	29555261				2020-06-30	J	Yi, MS; Kang, H; Kim, MK; Choi, GJ; Park, YH; Baek, CW; Jung, YH; Woo, YC				Yi, Myung Sub; Kang, Hyun; Kim, Min Kyoung; Choi, Geun-Joo; Park, Yong-Hee; Baek, Chong Wha; Jung, Yong Hun; Woo, Young Cheol			Relationship between the incidence and risk factors of postoperative nausea and vomiting in patients with intravenous patient-controlled analgesia	ASIAN JOURNAL OF SURGERY			English	Article						analgesia; antiemetics; patient-controlled analgesia; postoperative nausea and vomiting	NITROUS-OXIDE; ANESTHESIA; SEVOFLURANE; DESFLURANE; SURGERY; TRIAL; ISOFLURANE; INTUBATION; RECOVERY; DESIGN	Objective: This study aims to evaluate retrospectively the electronic medical records of surgical patients who received intravenous patient-controlled analgesia, to identify potential relationships between the incidence and risk factors of postoperative nausea and vomiting (PONV). Methods: Records of 6773 adult patients who received fentanyl-based intravenous patient-controlled analgesia after surgery at Chung-Ang University Hospital between January 1, 2010 and December 31, 2015 were reviewed. Multiple logistic regressions were used to identify risk factors for PONV. Results: Of 6773 patients, 1216 (18.0%) were recorded to have PONV. In multiple logistic regression analysis, female gender, nonsmoking status, history of motion sickness or PONV, use of desflurane and nitrous oxide, and preintubation use of opioid analgesia were independent risk factors for PONV. Conclusions: Despite the use of antiemetic prophylaxis, 18.0% of patients with intravenous patient-controlled analgesia had PONV. Use of desflurane and nitrous oxide, in addition to risk factors included in the Apfel score (female gender, nonsmoking status, history of PONV or motion sickness, and use of postoperative opioids) were identified as independent risk factors. As the incidence of PONV was 2.8%, 6.0%, 11.7%, 15.2%, 21.1%, 50.0%, and 100% for patients who had 0, 1, 2, 3, 4, 5, and all these risk factors, respectively, risk-adapted, multimodal, or combination therapy should be applied for patients receiving general anesthesia. (C) 2017 Asian Surgical Association and Taiwan Robotic Surgical Association. Publishing services by Elsevier B.V.	[Yi, Myung Sub; Kang, Hyun; Kim, Min Kyoung; Choi, Geun-Joo; Park, Yong-Hee; Baek, Chong Wha; Jung, Yong Hun; Woo, Young Cheol] Chung Ang Univ, Coll Med, Dept Anesthesiol & Pain Med, 224-1 Heukseok Ro, Seoul 156755, South Korea	Kang, H (reprint author), Chung Ang Univ, Coll Med, Dept Anesthesiol & Pain Med, 224-1 Heukseok Ro, Seoul 156755, South Korea.	roman00@naver.com	Kang, Hyun/AAE-7872-2020	Kang, Hyun/0000-0003-2844-5880			Ahn E, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0168509; Apfel CC, 2012, BRIT J ANAESTH, V109, P742, DOI 10.1093/bja/aes276; Apfel CC, 2005, ANAESTHESIST, V54, P201, DOI 10.1007/s00101-005-0803-8; Apfel CC, 1999, ANESTHESIOLOGY, V91, P693, DOI 10.1097/00000542-199909000-00022; Apfel CC, 2004, ANAESTHESIA, V59, P1078, DOI 10.1111/j.1365-2044.2004.03875.x; Apfel CC, 2002, BRIT J ANAESTH, V88, P659, DOI 10.1093/bja/88.5.659; Apfel CC, 2015, MILLERS ANESTHESIA, P2947; Apfel Christian C, 2003, Int Anesthesiol Clin, V41, P13, DOI 10.1097/00004311-200341040-00004; Breitinger HGA, 2001, BIOCHEMISTRY-US, V40, P8419, DOI 10.1021/bi0106890; Choi JB, 2014, YONSEI MED J, V55, P1430, DOI [10.3349/ymj.2014.55.5.1430, 10.3349/YMJ.2014.55.5.1430]; DAVIS I, 1979, ANAESTHESIA, V34, P147, DOI 10.1111/j.1365-2044.1979.tb06269.x; Fernandez-Guisasola J, 2010, ANAESTHESIA, V65, P379, DOI 10.1111/j.1365-2044.2010.06249.x; FORBES AM, 1970, BRIT J ANAESTH, V42, P618, DOI 10.1093/bja/42.7.618; Hwang BY, 2014, INT J MED SCI, V11, P658, DOI 10.7150/ijms.8331; Karlsen KL, 2000, ACTA ANAESTH SCAND, V44, P489; Kim MK, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000005135; Koivuranta M, 1997, ANAESTHESIA, V52, P443, DOI 10.1111/j.1365-2044.1997.117-az0113.x; Lesin M, 2016, THER CLIN RISK MANAG, V12, P93, DOI 10.2147/TCRM.S97024; Macario A, 1999, ANESTH ANALG, V89, P652, DOI 10.1097/00000539-199909000-00022; Macario A, 2005, AM J HEALTH-SYST PH, V62, P63, DOI 10.1093/ajhp/62.1.63; MURAKAWA M, 1994, ANESTH ANALG, V78, P376, DOI 10.1213/00000539-199402000-00030; Myles PS, 2016, ANESTHESIOLOGY, V124, P1032, DOI 10.1097/ALN.0000000000001057; Ohashi Y, 2003, ANESTHESIOLOGY, V99, P947, DOI 10.1097/00000542-200310000-00030; Orhan-Sungur M, 2005, CURR OPIN ANESTHESIO, V18, P620, DOI 10.1097/01.aco.0000188417.00011.78; Peyton PJ, 2014, ANESTHESIOLOGY, V120, P1137, DOI 10.1097/ALN.0000000000000122; SHRIBMAN AJ, 1987, BRIT J ANAESTH, V59, P295, DOI 10.1093/bja/59.3.295; Sun R, 2015, COCHRANE DB SYST REV, V11; Sweeney BP, 2002, BRIT J ANAESTH, V89, P810, DOI 10.1093/bja/aef269; von Elm E, 2008, J CLIN EPIDEMIOL, V61, P344, DOI 10.1016/j.jclinepi.2007.11.008; Wallenborn J, 2007, J CLIN ANESTH, V19, P180, DOI 10.1016/j.jclinane.2006.09.004	30	5	7	1	2	ELSEVIER SINGAPORE PTE LTD	SINGAPORE	3 KILLINEY ROAD 08-01, WINSLAND HOUSE 1, SINGAPORE, 239519, SINGAPORE	1015-9584	0219-3108		ASIAN J SURG	Asian J. Surg.	JUL	2018	41	4					301	306		10.1016/j.asjsur.2017.01.005			6	Surgery	Surgery	GV8MR	WOS:000446397200002	28372932	DOAJ Gold			2020-06-30	J	Oberoi-Jassal, R; Portman, D; Smith, J; Rajasekhara, S; Desai, VV; Donovan, KA; Chang, YD				Oberoi-Jassal, Ritika; Portman, Diane; Smith, Joshua; Rajasekhara, Sahana; Desai, Vijay V.; Donovan, Kristine A.; Chang, Young D.			Burning Mouth Pain: A Case Report	JOURNAL OF ONCOLOGY PRACTICE			English	Editorial Material									[Oberoi-Jassal, Ritika; Portman, Diane; Smith, Joshua; Rajasekhara, Sahana; Desai, Vijay V.; Donovan, Kristine A.; Chang, Young D.] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA	Oberoi-Jassal, R (reprint author), 12902 Magnolia Dr, Tampa, FL 33612 USA.	ritika.oberoi-jassal@moffitt.org					Grushka M, 1998, ORAL SURG ORAL MED O, V86, P557, DOI 10.1016/S1079-2104(98)90345-6; McMillan R, 2016, COCHRANE DB SYST REV, V11, DOI DOI 10.1111/ODI.12402; Moghadam-Kia S, 2017, CLIN DERMATOL, V35, P453, DOI [10.1016/j.clindermatol.2017.06.006, 10.1016/j.clindermato1.2017.06.006]; Nasri-Heir Cibele, 2015, J Indian Prosthodont Soc, V15, P300, DOI 10.4103/0972-4052.171823; The International Headache Society, INT CLASS HEAD DIS	5	0	0	0	0	AMER SOC CLINICAL ONCOLOGY	ALEXANDRIA	2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA	1554-7477	1935-469X		J ONCOL PRACT	J. Oncol. Pract.	JUL 1	2018	14	7					447	+		10.1200/JOP.17.00080			3	Oncology	Oncology	GU9MJ	WOS:000445670000016	29589986				2020-06-30	J	Williamson, AJ; Soares, JHN; Henao-Guerrero, N; Council-Troche, RM; Pavlisko, ND				Williamson, Allan J.; Soares, Joao H. N.; Henao-Guerrero, Natalia; Council-Troche, Roberto McAlister; Pavlisko, Noah D.			Cardiovascular and respiratory effects of two doses of fentanyl in the presence or absence of bradycardia in isoflurane-anesthetized dogs	VETERINARY ANAESTHESIA AND ANALGESIA			English	Article						bradycardia; cardiovascular; dogs; fentanyl; isoflurane; respiratory	MINIMUM ALVEOLAR CONCENTRATION; BLOOD; ENFLURANE; REMIFENTANIL; ANESTHESIA; ATROPINE; POTENCY	Objective To compare the cardiopulmonary effects of low and high doses of fentanyl before and after the correction of bradycardia in isofluraneanesthetized dogs. Study design Prospective, randomized crossover trial. Animals Eight healthy male Beagle dogs weighing 11.1 +/- 1.3 kg [mean +/- standard deviation (SD)] and aged approximately 1 year. Methods The dogs were anesthetized with isoflurane [1.3 x minimum alveolar concentration (MAC)] on two occasions and fentanyl was administered intravenously; either low-dose fentanyl, loading dose (33 mu g kg(-1)) and infusion (0.2 mg kg(-1) minute(-1)) or a high-dose, loading dose (102 mg kg(-1)) and infusion (0.8 mg kg(-1) minute(-1)). Cardiopulmonary variables were measured at three time points in equipotent isoflurane concentrations (1.3 MAC): before fentanyl administration (ISO), during fentanyl-induced bradycardia (ISO-F) and after administration of glycopyrrolate normalized heart rate (ISO-F-NHR). Data are mean +/- SD. Results Heart rate and cardiac index (CI) decreased and systemic vascular resistance index (SVRI) increased at ISO-F in both treatments. Bradycardia and vasoconstriction at ISO-F were greater in high than in low-dose fentanyl (42 +/- 7 versus 57 +/- 15 beats minute(-1) and 3457 +/- 1108 versus 2528 +/- 968 dyne second cm(-5) m(-2)), respectively. Oxygen delivery index (DO2I) decreased only during high-dose fentanyl. CI and DO2I were higher in both treatments at ISO-F-NHR than at ISO-F; however, they were higher only during the high-dose fentanyl than at ISO. SVRI was higher at ISO-F than at ISO and ISO-F-NHR in both treatments, and was higher at ISO-F in the high than in the low-dose treatment. Conclusions and clinical relevance An overall improvement in cardiovascular function of dogs anesthetized with equipotent isoflurane doses (1.3 MAC) was observed after the treatment of brady-cardia only with the high-dose fentanyl.	[Williamson, Allan J.; Soares, Joao H. N.; Henao-Guerrero, Natalia; Pavlisko, Noah D.] Virginia Tech, Virginiae Maryland Coll Vet Med, Dept Small Anim Clin Sci, MC 0442,235 Duck Pond Dr, Blacksburg, VA 24061 USA; [Council-Troche, Roberto McAlister] Virginia Tech, Virginiae Maryland Coll Vet Med, Dept Biomed Sci & Pathobiol, Lab Toxicol, Blacksburg, VA USA	Soares, JHN (reprint author), Virginia Tech, Virginiae Maryland Coll Vet Med, Dept Small Anim Clin Sci, MC 0442,235 Duck Pond Dr, Blacksburg, VA 24061 USA.	jhsoares@vt.edu	Soares, Joao/AAD-7928-2019		Veterinary Memorial Fund of the Virginia-Maryland College of Veterinary Medicine, Virginia Tech [033-4-44167]	The authors thank Betsy Midkiff for valuable technical assistance and John H Rossmeisl Jr, Geraldine Magnin-Bissel and Scott Were for assistance in manuscript preparation and consultation services, Virginia-Maryland College of Veterinary Medicine, Virginia Tech. This work was supported by the Veterinary Memorial Fund (no. 033-4-44167) of the Virginia-Maryland College of Veterinary Medicine, Virginia Tech.	Bednarski RM, 2015, VET ANAESTH ANALG, P817, DOI 10.1002/9781119421375; Bjorkman S, 2000, J PHARM PHARMACOL, V52, P1065, DOI 10.1211/0022357001774985; BLOOR BC, 1992, J PHARMACOL EXP THER, V263, P690; Coopman V, 2007, FORENSIC SCI INT, V169, P223, DOI 10.1016/j.forsciint.2006.03.018; Francis RCE, 2008, LAB ANIM-UK, V42, P338, DOI 10.1258/la.2007.007048; Garofalo NA, 2012, VET J, V194, P398, DOI 10.1016/j.tvjl.2012.03.019; Griffioen KJS, 2004, BRAIN RES, V1007, P109, DOI 10.1016/j.brainres.2004.02.010; Hall JE, 2011, TXB MED PHYSL, P157; Haskins S, 2005, COMPARATIVE MED, V55, P156; HYSING ES, 1992, ANESTHESIOLOGY, V76, P979, DOI 10.1097/00000542-199206000-00018; ILKIW JE, 1994, CAN J VET RES, V58, P248; Ilkiw JE, 1999, CLIN TECH SMALL AN P, V14, P27, DOI 10.1016/S1096-2867(99)80024-3; KLIDE AM, 1976, AM J VET RES, V37, P127; Mama KR, 2015, LUMB JONES VET ANEST, P483; MIKAMI T, 1968, ANGIOLOGICA, V5, P281; Monteiro ER, 2010, AM J VET RES, V71, P1133, DOI 10.2460/ajvr.71.10.1133; Monteiro ER, 2010, AM J VET RES, V71, P150, DOI 10.2460/ajvr.71.2.150; MURPHY MR, 1983, ANESTHESIOLOGY, V59, P537, DOI 10.1097/00000542-198312000-00009; MURPHY MR, 1982, ANESTHESIOLOGY, V57, P485, DOI 10.1097/00000542-198212000-00009; REMINGTON JW, 1958, CIRC RES, V6, P146, DOI 10.1161/01.RES.6.2.146; Romano M, 2016, VET ANAESTH ANALG, V43, P44, DOI 10.1111/vaa.12275; Simoes CR, 2016, VET ANAESTH ANALG, V43, P136, DOI 10.1111/vaa.12282; STEFFEY EP, 1977, AM J VET RES, V38, P1833; WALKER BR, 1989, AM J PHYSIOL, V257, pH415; WEISKOPF RB, 1987, J PHARMACOL EXP THER, V242, P970; Williamson AJ, 2017, VET ANAESTH ANALG, V44, P738, DOI 10.1016/j.vaa.2017.02.002	26	4	4	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1467-2987	1467-2995		VET ANAESTH ANALG	Vet. Anaesth. Analg.	JUL	2018	45	4					423	431		10.1016/j.vaa.2018.03.001			9	Veterinary Sciences	Veterinary Sciences	GT4ZM	WOS:000444515500004	29716836				2020-06-30	J	Goya, S; Wada, T; Shimada, K; Hirao, D; Tanaka, R				Goya, Seijirow; Wada, Tomoki; Shimada, Kazumi; Hirao, Daiki; Tanaka, Ryou			Dose-dependent effects of isoflurane and dobutamine on cardiovascular function in dogs with experimental mitral regurgitation	VETERINARY ANAESTHESIA AND ANALGESIA			English	Article						anaesthesia; canine; cardiovascular; dobutamine	LEFT ATRIAL PRESSURE; VALVE REGURGITATION; HEART-FAILURE; CONDUCTANCE CATHETER; INDUCED BRADYCARDIA; CONSCIOUS DOGS; CARDIAC-OUTPUT; LEFT-VENTRICLE; VOLUME RATIO; BEAGLE DOG	Objective To investigate the dose-dependent effects of isoflurane and dobutamine on haemodynamics in dogs with experimentally induced mitral valve insufficiency (MI). Study design Experimental, doseeresponse study. Animals Six healthy Beagle dogs. Methods Dogs with surgically induced MI were anaesthetized once. First, anaesthesia was maintained at an end-tidal isoflurane concentration (FE ISO) 1.0% (ISO1.0) for 20 minutes. Then, dobutamine was infused successively at 2, 4, 8 and 12 mg kg(-1) minute(-1) (DOB2-12) for 10 minutes at each dose rate. Measurements were recorded at each stage. Dobutamine was discontinued and FE'Iso was increased to 1.5% (ISO1.5) for 20 minutes. Dobutamine was administered similarly to ISO1.0, and cardiovascular variables were recorded. The same sequence was repeated for FE'Iso 2.0% (ISO2.0). Aortic pressure (AoP) and left atrial pressure (LAP) were recorded by radiotelemetry. The combination method of the pressureevolume loop analysis and transoesophageal echocardiography was used to measure cardiovascular variables: end-systolic elastance (Ees), effective arterial elastance (Ea), Ea/Ees, forward stroke volume (FSV), heart rate (HR), and cardiac output (CO). Results High isoflurane concentration resulted in reduced Ees and increased Ea/ Ees, which indicated low arterial pressure. High-dose dobutamine administration resulted in increased Ees and FSV at all isoflurane concentrations. In ISO1.5 and ISO2.0, HR was lower at DOB4 than baseline (BL) but increased at DOB12 compared with DOB4. CO increased at >= DOB8 compared with BL. In ISO1.5 and ISO2.0, systolic and mean AoP increased at >= DOB4 and >= DOB8, respectively. LAP did not change under all conditions. Conclusions and clinical relevance The dose-dependent hypotensive effect of isoflurane in MI dogs was mainly derived from the decrease in contractility. Dobutamine increased AoP without increasing LAP by increasing the contractility attenuated by isoflurane. Our findings may improve the cardiovascular management of dogs with MI undergoing general anaesthesia with isoflurane.	[Goya, Seijirow; Wada, Tomoki; Shimada, Kazumi; Hirao, Daiki; Tanaka, Ryou] Tokyo Univ Agr & Technol, Fac Vet Med, Dept Vet Surg, Tokyo, Japan	Tanaka, R (reprint author), Tokyo Univ Agr & Technol, Fac Vet Med, Dept Vet Surg, 5-3-8 Saiwai Cho, Fuchu, Tokyo 1838509, Japan.	ryo@vet.ne.jp	Tanaka, Ryo S/C-8376-2013; Tanaka, Ryou/M-3078-2019	Tanaka, Ryo S/0000-0001-9948-6490; Tanaka, Ryou/0000-0001-9948-6490; Shimada, Kazumi/0000-0002-2514-695X			Abbott JA, 2008, MANUAL CANINE FELINE, P110; Atkins C, 2009, J VET INTERN MED, V23, P1142, DOI 10.1111/j.1939-1676.2009.0392.x; BAAN J, 1984, CIRCULATION, V70, P812, DOI 10.1161/01.CIR.70.5.812; BOBAN M, 1992, ANESTHESIOLOGY, V76, P775, DOI 10.1097/00000542-199205000-00016; Chantler PD, 2008, J APPL PHYSIOL, V105, P1342, DOI 10.1152/japplphysiol.90600.2008; CRIPPA L, 1992, LAB ANIM, V26, P190, DOI 10.1258/002367792780740512; Dart AM, 2001, J AM COLL CARDIOL, V37, P975, DOI 10.1016/S0735-1097(01)01108-1; DETOMBE PP, 1993, AM J PHYSIOL, V264, pH1817; Diez-Prieto I, 2010, J AM ASSOC LAB ANIM, V49, P31; Dunser MW, 2009, INTENS CARE MED, V35, P1225, DOI 10.1007/s00134-009-1427-2; Feldman MD, 1996, CIRCULATION, V93, P474, DOI 10.1161/01.CIR.93.3.474; Goya S, 2017, J VET MED SCI, V79, DOI 10.1292/jvms.16-0323; GUYTON AC, 1955, AM J PHYSIOL, V180, P463; Hansson K, 2002, VET RADIOL ULTRASOUN, V43, P568, DOI 10.1111/j.1740-8261.2002.tb01051.x; Hettrick DA, 1996, ANESTHESIOLOGY, V85, P403, DOI 10.1097/00000542-199608000-00023; Hofmeister EH, 2005, VET ANAESTH ANALG, V32, P107, DOI 10.1111/j.1467-2995.2004.00151.x; Ishikawa T, 2010, J VET INTERN MED, V24, P342, DOI 10.1111/j.1939-1676.2009.0455.x; Ishikawa T, 2009, J VET INTERN MED, V23, P824, DOI 10.1111/j.1939-1676.2009.0322.x; KAMEYAMA T, 1991, J AM COLL CARDIOL, V17, P199, DOI 10.1016/0735-1097(91)90728-R; Kittleson MD, 1998, SMALL ANIMAL CARDIOVASCULAR MEDICINE, P136; Kraetschmer S, 2008, J SMALL ANIM PRACT, V49, P240, DOI 10.1111/j.1748-5827.2007.00531.x; LITTLE WC, 1988, CIRCULATION, V78, P736, DOI 10.1161/01.CIR.78.3.736; NOZAWA T, 1988, CIRCULATION, V77, P1116, DOI 10.1161/01.CIR.77.5.1116; Rosati M, 2007, AM J VET RES, V68, P483, DOI 10.2460/ajvr.68.5.483; RUSY BF, 1987, ANESTHESIOLOGY, V67, P745; Scarabelli S., 2016, Companion Animal, V21, P337, DOI 10.12968/coan.2016.21.6.337; Schwartzenberg S, 2012, J AM COLL CARDIOL, V59, P442, DOI 10.1016/j.jacc.2011.09.062; Seifen E, 1987, J Cardiothorac Anesth, V1, P543, DOI 10.1016/0888-6296(87)90041-X; Seki H, 1996, Am J Physiol, V270, pH1279; Steendijk P, 2001, AM J PHYSIOL-HEART C, V281, pH755; SUGA H, 1973, CIRC RES, V32, P314, DOI 10.1161/01.RES.32.3.314; SUNAGAWA K, 1983, AM J PHYSIOL, V245, pH773; Suzuki S, 2011, J VET INTERN MED, V25, P1328, DOI 10.1111/j.1939-1676.2011.00800.x; Suzuki S, 2011, J VET INTERN MED, V25, P244, DOI 10.1111/j.1939-1676.2010.0672.x; SWANSON CR, 1988, ANESTHESIOLOGY, V68, P764, DOI 10.1097/00000542-198805000-00015; Tobata D, 2004, J VET MED SCI, V66, P1097, DOI 10.1292/jvms.66.1097; Tsompanidou PP, 2013, J SMALL ANIM PRACT, V54, P672, DOI 10.1111/jsap.12121; VATNER SF, 1974, J CLIN INVEST, V53, P1265, DOI 10.1172/JCI107673	38	1	1	0	4	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1467-2987	1467-2995		VET ANAESTH ANALG	Vet. Anaesth. Analg.	JUL	2018	45	4					432	442		10.1016/j.vaa.2018.03.010			11	Veterinary Sciences	Veterinary Sciences	GT4ZM	WOS:000444515500005	29887228				2020-06-30	J	Barros, DSB; Evans, AL; Arnemo, JM; Stenbacka, F; Ericsson, G				Barros, Daniela S. B.; Evans, Alina L.; Arnemo, Jon M.; Stenbacka, Fredrik; Ericsson, Goran			Effective thiafentanil immobilization and physiological responses of free-ranging moose (Alces alces) in northern Sweden	VETERINARY ANAESTHESIA AND ANALGESIA			English	Article						acid-base status; Alces alces; arterial blood gases; immobilization; thiafentanil	IMPALA AEPYCEROS-MELAMPUS; CHEMICAL IMMOBILIZATION; RESPIRATORY DEPRESSION; CARFENTANIL-XYLAZINE; SHIRAS MOOSE; ETORPHINE; HYPOXEMIA; MEDETOMIDINE; ANESTHESIA; TARANDUS	Objective To evaluate clinical and physiological responses in moose to thiafentanil administration for immobilization. Study design Cross-sectional clinical study. Animals Eleven (six males and five females) free-ranging adult moose (Alces alces). Methods Each moose was darted from a helicopter with 7.5 mg thiafentanil during March 2014 in northern Sweden. Physiological evaluation included vital signs and blood gases. Arterial blood was collected after induction and again after 10 minutes of intranasal oxygen administration and analyzed immediately with an i-STAT analyzer. A total of 10 mg naltrexone per milligram of thiafentanil was administered to all animals for reversal. Data were analyzed using descriptive statistics. Results All moose were sufficiently immobilized with a single dart injection. Induction occurred within 3 minutes in 10 of 11 moose. One individual became recumbent while crossing a river and naltrexone was immediately administered. Animals maintained sternal recumbency with their head raised and vital signs were stable. Nine of 10 moose were hypoxemic before oxygen administration, with seven becoming markedly hypoxemic [partial pressure of arterial oxygen (PaO2) between 40 and 59 mmHg (5.3-7.9 kPa)]. The PaO2 increased significantly between samples, but six moose remained hypoxemic despite therapy. Hypercapnia was seen in all moose, with eight having marked hypercapnia [partial pressure of arterial carbon dioxide (PaCO2) > 60 mmHg (> 8.0 kPa)]. All moose were acidemic, with nine showing marked acidemia (pH < 7.20). The pH increased significantly with time and lactate decreased. Recoveries were rapid and uneventful, and all moose were living 6 months after capture. Conclusions Thiafentanil provided rapid and sufficient immobilization of moose and its effects were rapidly reversed with naltrexone. As with other opioids, moose showed hypoxemia and varying degrees of respiratory and metabolic acidosis. Arterial oxygenation of moose improved following intranasal oxygen, but hypoxemia was not fully resolved despite therapy.	[Barros, Daniela S. B.; Evans, Alina L.; Arnemo, Jon M.] Inland Norway Univ Appl Sci, Dept Forestry & Wildlife Management, Campus Evenstad, NO-2480 Koppang, Norway; [Arnemo, Jon M.; Stenbacka, Fredrik; Ericsson, Goran] Swedish Univ Agr Sci, Dept Wildlife Fish & Environm Studies, Umea, Sweden	Barros, DSB (reprint author), Inland Norway Univ Appl Sci, Dept Forestry & Wildlife Management, Campus Evenstad, NO-2480 Koppang, Norway.	danielabraz@campus.ul.pt	Evans, Alina/AAH-8881-2019		Swedish University of Agricultural Sciences; Swedish EPA; Swedish Association of Hunting and Wildlife Management; program Beyond Moose	The Swedish University of Agricultural Sciences, the Swedish EPA and the program Beyond Moose and the Swedish Association of Hunting and Wildlife Management supported this project. The i-STAT analyzer and cartridges for the arterial blood-gas evaluation were provided by the Inland Norway University of Applied Sciences. Oliver Devineau from the Inland Norway University of Applied Sciences advised on the statistical analysis.	Arnemo JM, 2014, ZOO ANIMAL AND WILDLIFE IMMOBILIZATION AND ANESTHESIA, 2ND EDITION, P139; Burroughs Richard, 2012, P53; Buss P, 2012, CHEM PHYS RESTRAINT, P30; Cooper DV, 2005, J S AFR VET ASSOC, V76, P18; Ericsson G, 2001, ECOSCIENCE, V8, P157, DOI 10.1080/11956860.2001.11682641; Evans AL, 2013, J WILDLIFE DIS, V49, P1037, DOI 10.7589/2013-03-049; Evans AL, 2012, ACTA VET SCAND, V54, DOI 10.1186/1751-0147-54-77; Fahlman A, 2014, ZOO ANIMAL AND WILDLIFE IMMOBILIZATION AND ANESTHESIA, 2ND EDITION, P69; FRANZMANN A W, 1984, Journal of Wildlife Diseases, V20, P333; Haga HA, 2009, VET ANAESTH ANALG, V36, P555, DOI 10.1111/j.1467-2995.2009.00498.x; HAIGH JC, 1990, J ZOO WILDLIFE MED, V21, P391; Heard DJ, 1996, AM J VET RES, V57, P87; Howard LL, 2004, J ZOO WILDLIFE MED, V35, P312, DOI 10.1638/03-090; Jackson PGG, 2002, CLIN EXAMINATION FAR, V150, P303, DOI [10.1002/9780470752425.app3, DOI 10.1002/9780470752425.APP3]; Kreeger Terry J., 2005, Alces, V41, P121; Kreeger TJ, 2000, WILDLIFE SOC B, V28, P751; Kreeger TJ, 2012, HDB WILDLIFE CHEM IM, P33; Lamont LA, 2014, ZOO ANIMAL AND WILDLIFE IMMOBILIZATION AND ANESTHESIA, 2ND EDITION, P5; Lance William R., 2012, P589; Lian M, 2017, J WILDLIFE DIS, V53, P356, DOI 10.7589/2016-04-085; Lian M, 2016, J WILDLIFE DIS, V52, P327, DOI 10.7589/2015-04-101; Lian M, 2014, ACTA VET SCAND, V56, DOI 10.1186/s13028-014-0051-5; LLOYD MH, 1973, CLIN SCI MOL MED, V45, P543, DOI 10.1042/cs0450543; McCrimmon DR, 2003, AM J PHYSIOL-REG I, V285, pR1274, DOI 10.1152/ajpregu.00428.2003; McDonell WN, 2015, VET ANAESTH ANALG, P513; McJames Scott W., 1994, Alces, V30, P21; Meyer LCR, 2008, J S AFR VET ASSOC, V79, P121; Meyer LCR, 2008, J WILDLIFE DIS, V44, P404, DOI 10.7589/0090-3558-44.2.404; Meyer LCR, 2010, J WILDLIFE DIS, V46, P514, DOI 10.7589/0090-3558-46.2.514; Meyer LCR, 2015, BMC VET RES, V11, DOI 10.1186/s12917-015-0337-5; Pattinson KTS, 2008, BRIT J ANAESTH, V100, P747, DOI 10.1093/bja/aen094; R-Core-Team, 2012, LANG ENV STAT COMP; Rostal MK, 2012, J WILDLIFE DIS, V48, P548, DOI 10.7589/0090-3558-48.3.548; SEAL US, 1985, J WILDLIFE DIS, V21, P48, DOI 10.7589/0090-3558-21.1.48; TASHKIN DP, 1972, AM J PHYSIOL, V223, P968	35	3	3	1	6	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1467-2987	1467-2995		VET ANAESTH ANALG	Vet. Anaesth. Analg.	JUL	2018	45	4					502	509		10.1016/j.vaa.2018.02.008			8	Veterinary Sciences	Veterinary Sciences	GT4ZM	WOS:000444515500013	29891211				2020-06-30	J	Smith, JS; Mochel, JP; Borts, DJ; Lewis, KA; Coetzee, JF				Smith, Joe S.; Mochel, Jonathan P.; Borts, David J.; Lewis, Kerrie A.; Coetzee, Johann F.			Adverse reactions to fentanyl transdermal patches in calves: a preliminary clinical and pharmacokinetic study	VETERINARY ANAESTHESIA AND ANALGESIA			English	Article						adverse event; calf; fentanyl; fentanyl transdermal patch	GOATS; INFUSION; HORSES	Objective To describe adverse reactions and measure plasma fentanyl concentrations in calves following administration of a fentanyl transdermal patch (FTP). Study design Prospective, experimental clinical study. Animals Six female Holstein calves and one male Angus calf. Four calves were healthy experimental animals and three calves were clinical patients. Methods Plasma fentanyl concentrations were measured in blood collected from a jugular vein. FTP 2 mu g kg(-1) hour(-1) and 1 mu g kg(-1) hour(-1) was applied to four and three calves, respectively. Heart rate, respiratory rate, temperature and ataxia were recorded at the same times as blood collection (0, 2, 4, 6, 12, 24, 36, 48, 60, 72, 84 and 96 hours). Substance P concentrations were determined via radioimmunoassay for two calves. Results After the FTP (2 mu g kg(-1) hour(-1)) application, two calves developed tachycardia, hyperthermia, excitement and ataxia within 6 hours; no adverse effect was observed in the other two calves. The three calves administered FTP (1 mu g kg(-1) hour(-1)) exhibited tachycardia and excitement, and the FTP were removed at 4 hours. Naloxone was administered to two calves before the adverse clinical signs ceased, while adverse events in the other three calves resolved within 2 hours of FTP removal. Variables returned to previous baseline values by 2-4 hours after FTP removal. Maximum plasma fentanyl concentrations were variable among calves (0.726-6.923 ng mL(-1)). Substance P concentrations measured in two calves were not consistently depressed during FTP application. Fentanyl concentrations at 4 and 6 hours were significantly associated with the appearance of adverse effects. Conclusions and clinical relevance FTP (1-2 mu g kg(-1) hour(-1)) administered to calves may result in adverse behavioral and cardiovascular effects. Patch removal and treatment with an opioid antagonist may resolve these adverse effects. Additional research is needed to determine optimal FTP dosing for cattle.	[Smith, Joe S.; Mochel, Jonathan P.; Borts, David J.] Iowa State Univ, Vet Diagnost & Prod Anim Med, Coll Vet Med, Ames, IA USA; [Lewis, Kerrie A.] Univ Saskatchewan, Dept Small Anim Clin Sci, Western Coll Vet Med, Saskatoon, SK, Canada; [Coetzee, Johann F.] Kansas State Univ, Coll Vet Med, Anat & Physiol, Manhattan, KS 66506 USA	Smith, JS (reprint author), 2462 Lloyd Vet Med, Ames, IA 50011 USA.	jss303@iastate.edu	Smith, Joseph/AAH-5810-2019	Smith, Joseph/0000-0002-4288-2262; Mochel, Jonathan/0000-0002-0997-3111; Coetzee, Johann/0000-0003-1802-3991			Carroll GL, 1999, AM J VET RES, V60, P986; Christou C, 2015, RES VET SCI, V100, P252, DOI 10.1016/j.rvsc.2015.04.006; Clutton RE, 2010, VET CLIN N AM-EQUINE, V26, P493, DOI 10.1016/j.cveq.2010.07.002; Dzikiti BT, 2016, VET ANAESTH ANALG, V43, P316, DOI 10.1111/vaa.12300; Dzikiti TB, 2011, VET REC, V168, DOI 10.1136/vr.d999; Gorden PJ, 2016, J DAIRY SCI, V99, P8314, DOI 10.3168/jds.2016-10959; Marchionatti E, 2015, VET ANAESTH ANALG, V42, P229, DOI 10.1111/vaa.12228; MUIR WW, 1981, VET CLIN N AM-LARGE, V3, P17; Smith G, 2013, VET CLIN N AM-FOOD A, V29, P29, DOI 10.1016/j.cvfa.2012.11.003; Smith JS, 2018, J VET PHARMACOL THER, V41, P555, DOI 10.1111/jvp.12501; Wetmore LA, 2016, AM J VET RES, V77, P827, DOI 10.2460/ajvr.77.8.828	11	0	0	1	4	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1467-2987	1467-2995		VET ANAESTH ANALG	Vet. Anaesth. Analg.	JUL	2018	45	4					575	580		10.1016/j.vaa.2018.02.009			6	Veterinary Sciences	Veterinary Sciences	GT4ZM	WOS:000444515500021	29880278				2020-06-30	J	Yamaguchi, T; Shimakawa, Y; Mitsumizo, S; Fukui, A; Kawano, Y; Otsubo, T; Takahashi, Y; Hirota, K; Tsuchiya, T; Eshima, K				Yamaguchi, Takanori; Shimakawa, Yusuke; Mitsumizo, Shinji; Fukui, Akira; Kawano, Yuki; Otsubo, Toyokazu; Takahashi, Yuya; Hirota, Kei; Tsuchiya, Takeshi; Eshima, Kenichi			Feasibility of total intravenous anesthesia by cardiologists with the support of anesthesiologists during catheter ablation of atrial fibrillation	JOURNAL OF CARDIOLOGY			English	Article						Atrial fibrillation; Catheter ablation; General anesthesia; Pulmonary vein isolation; Total intravenous anesthesia	CONSECUTIVE PATIENTS; DEEP SEDATION; ADENOSINE; AIRWAY; VENTILATION; CONDUCTION; FORCE; RISK; ASIA	Background: The optimal methodology for sedation and anesthesia during atrial fibrillation (AF) ablation has not been well established. We assessed the feasibility of total intravenous anesthesia (TIVA) by cardiologists with support from anesthesiologists during AF ablation and quality of pulmonary vein isolation (PVI) and single procedure success rate at 12 months. Methods: TIVA was performed by cardiologists using IV propofol and fentanyl under controlled ventilation via i-gel (TM) without neuromuscular blocking drugs in 160 consecutive patients (80 non paroxysmal) with no anticipated difficult airway or other severe diseases. Anesthesiologists were requested to be on standby during the procedure. The incidence of anesthesia-associated complications and ablation-associated complications were assessed. To evaluate the quality of PVI, the prevalence of acute adenosine triphosphate (ATP)-provoked PV reconnections and late PV reconnections among those requiring a redo procedure was analyzed. Results: TIVA was successfully completed in 152 patients (95%). In five (3%), we requested help from anesthesiologists, and in three (2%), TIVA was abandoned. No major anesthesia-associated complications were observed. Ablation-associated complications were observed in seven patients (4%). ATP provocation test was performed in 141 patients, and no acute PV reconnections were observed in 134 (95%). Success rates at 12 months were 85% of patients off antiarrhythmic drugs. Twenty-one of 24 patients with recurrence underwent a redo session, and 18 (86%) had no PV reconnections. Conclusions: TIVA by cardiologists with support from anesthesiologists during AF ablation may be feasible. The success rate at 12 months was high, and prevalence of acute and late PV reconnection was very low. (C) 2018 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.	[Yamaguchi, Takanori; Kawano, Yuki; Eshima, Kenichi] Saga Ken Med Ctr Koseikan, Dept Cardiol, Nakabaru 400, Kase, Saga 8408571, Japan; [Shimakawa, Yusuke] Saga Ken Med Ctr Koseikan, Dept Anesthesiol, Kase, Saga, Japan; [Mitsumizo, Shinji] Saga Ken Med Ctr Koseikan, Dept Intens Care Unit, Kase, Saga, Japan; [Fukui, Akira; Otsubo, Toyokazu; Takahashi, Yuya; Hirota, Kei; Tsuchiya, Takeshi] EP Expert Doctors Team Tsuchiya, Kumamoto, Japan	Yamaguchi, T (reprint author), Saga Ken Med Ctr Koseikan, Dept Cardiol, Nakabaru 400, Kase, Saga 8408571, Japan.	takano-yamaguchi@nifty.com					Amaya F, 2015, J ANESTH, V29, P175, DOI 10.1007/s00540-014-1918-3; Bamgbade OA, 2008, EUR J ANAESTH, V25, P865, DOI 10.1017/S0265021508004511; Calkins H, 2012, HEART RHYTHM, V9, P632, DOI 10.1016/j.hrthm.2011.12.016; Chikata A, 2017, HEART VESSELS, V32, P997, DOI 10.1007/s00380-017-0961-z; de Waroux JBL, 2015, EUROPACE, V17, P877, DOI 10.1093/europace/euu329; Di Biase L, 2011, HEART RHYTHM, V8, P368, DOI 10.1016/j.hrthm.2010.10.043; Di Biase L, 2009, CIRC-ARRHYTHMIA ELEC, V2, P108, DOI 10.1161/CIRCEP.108.815266; Efremidis M, 2016, J CARDIOVASC ELECTR, V27, P1288, DOI 10.1111/jce.13059; Gatward JJ, 2008, ANAESTHESIA, V63, P1124, DOI 10.1111/j.1365-2044.2008.05561.x; Gavel G, 2014, BJA EDUC, V14, P47, DOI 10.1093/bjaceaccp/mkt031; Gross JB, 2002, ANESTHESIOLOGY, V96, P1004; Haissaguerre M, 1998, NEW ENGL J MED, V339, P659, DOI 10.1056/NEJM199809033391003; Ichihara N, 2015, CIRC J, V79, P346, DOI 10.1253/circj.CJ-14-1106; Inoue K, 2014, CIRC J, V78, P1112, DOI 10.1253/circj.CJ-13-1179; Kottkamp H, 2011, J CARDIOVASC ELECTR, V22, P1339, DOI 10.1111/j.1540-8167.2011.02120.x; Kuwahara T, 2012, EUROPACE, V14, P204, DOI 10.1093/europace/eur314; Miyazaki S, 2012, J CARDIOVASC ELECTR, V23, P256, DOI 10.1111/j.1540-8167.2011.02195.x; Nery Pablo B, 2016, JACC Clin Electrophysiol, V2, P474, DOI 10.1016/j.jacep.2016.02.003; OLSSON GL, 1984, ACTA ANAESTH SCAND, V28, P567, DOI 10.1111/j.1399-6576.1984.tb02121.x; Park SK, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000004598; Perel A, 2011, EUR J ANAESTH, V28, P580, DOI 10.1097/EJA.0b013e328348a977; Piccini JP, 2009, CIRC-ARRHYTHMIA ELEC, V2, P626, DOI 10.1161/CIRCEP.109.856633; Piorkowski C, 2011, CIRC-ARRHYTHMIA ELEC, V4, P157, DOI 10.1161/CIRCEP.110.957761; Saito T, 2015, ANAESTHESIA, V70, P1079, DOI 10.1111/anae.13153; Salukhe TV, 2012, EUROPACE, V14, P325, DOI 10.1093/europace/eur328; Wutzler A, 2012, PACE, V35, P38, DOI 10.1111/j.1540-8159.2011.03260.x; Yamaguchi T, 2016, J CARDIOVASC ELECTR, V27, P1055, DOI 10.1111/jce.13019; Yamaguchi T, 2014, EUROPACE, V16, P511, DOI 10.1093/europace/eut265	28	4	4	0	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0914-5087	1876-4738		J CARDIOL	J. Cardiol.	JUL-AUG	2018	72	1-2					19	25		10.1016/j.jjcc.2017.12.008			7	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	GQ9CI	WOS:000442063100003	29338895	Bronze			2020-06-30	J	Yen, TY; Chiou, JF; Chiang, WY; Su, WH; Huang, MY; Hu, MH; Wu, SC; Lai, YL				Yen, Tsung-Yu; Chiou, Jeng-Fong; Chiang, Wei-Yong; Su, Wen-Hao; Huang, Ming-Yuan; Hu, Ming-Hung; Wu, Shen-Chi; Lai, Yuen-Liang			Proportional dose of rapid-onset opioid in breakthrough cancer pain management: An open-label, multicenter study	MEDICINE			English	Article						breakthrough cancer pain; fentanyl buccal soluble film; palliative care; proportional dose	FENTANYL BUCCAL TABLET; SOLUBLE FILM; TRANSMUCOSAL FENTANYL; TOLERANT PATIENTS; HEALTHY-SUBJECTS; MORPHINE; PHARMACOKINETICS; RECOMMENDATIONS; PREVALENCE; TITRATION	Background:The management of breakthrough pain (BTP) in cancer patients is a challenge. It is clinically useful to evaluate the effectiveness of rapid-onset opioid at a starting dose in proportional to the background opioid regimen. This open-label, multicenter, noncomparative study aimed to assess the efficacy and safety of proportional doses of fentanyl buccal soluble film (FBSF) in patients with breakthrough cancer pain.Methods:Thirty patients aged 20 to 70, experiencing 1 to 3 BTP per day, receiving regimens equivalent to 60 to 360mg/day of oral morphine or 25 to 150g/h of transdermal fentanyl 1 week, were prospectively recruited. FBSF was administered proportionally based on their current opioid regimen for baseline pain. The percentage of patients requiring dose titration was evaluated. For each BTP episode, changes in pain intensity at 30 minutes (PID30) after dosing, patient's satisfaction, the percentage of episodes requiring rescue medication, and adverse events (AEs) were recorded.Results:The percentage of patients who required dose titration was 21.4% (6/28) and 12.0% (3/25) in the full analysis set and per-protocol populations, respectively. The average PID30 was 3.9, and a pain score 3 was achieved in 95.1% of the events. Eight out of 367 (2.2%) BTP episodes needed rescue medication. The majority of subjects (75.8%) rated their experience of pain management as good to excellent. A total of 6 drug-related AEs were reported by 3 (10.7%) patients in the safety population.Conclusions:FBSF dose in proportional to the regimen of opioid for baseline pain management is efficacious and well tolerated for the treatment of cancer patients with BTP.	[Yen, Tsung-Yu; Lai, Yuen-Liang] Taipei Med Univ, Dept Radiat Oncol, Taipei, Taiwan; [Yen, Tsung-Yu; Su, Wen-Hao; Huang, Ming-Yuan; Lai, Yuen-Liang] Taipei Med Univ, MacKay Mem Hosp, Hosp & Palliat Care Ctr, Taipei, Taiwan; [Chiou, Jeng-Fong] Taipei Med Univ, Coll Med, Sch Med, Dept Radiol, Taipei, Taiwan; [Chiou, Jeng-Fong] Taipei Med Univ Hosp, Dept Radiat Oncol, Taipei, Taiwan; [Chiou, Jeng-Fong] Taipei Med Univ, Taipei Canc Ctr, Taipei, Taiwan; [Chiou, Jeng-Fong; Wu, Shen-Chi] Taipei Med Univ Hosp, Canc Ctr, Taipei, Taiwan; [Chiang, Wei-Yong] Fu Jen Catholic Univ, Dept Palliat Med, New Taipei, Taiwan; [Hu, Ming-Hung] Fu Jen Catholic Univ, Cardinal Tien Hosp, Dept Med, Div Hematol & Oncol, New Taipei, Taiwan; [Hu, Ming-Hung] Fu Jen Catholic Univ, Sch Med, New Taipei, Taiwan; [Wu, Shen-Chi] Dept Hosp & Palliat Care, Taipei, Taiwan; [Lai, Yuen-Liang] MacKay Med Coll, New Taipei, Taiwan	Wu, SC (reprint author), Taipei Med Univ Hosp, Dept Hosp & Palliat Care, 252 Wuxing St, Taipei 11031, Taiwan.; Lai, YL (reprint author), MacKay Mem Hosp, Hosp & Palliat Care Ctr, 45 Minsheng Rd, New Taipei 25160, Taiwan.	sc.wu0724@msa.hinet.net; YuenLiangLai1201@gmail.com					[Anonymous], 2010, MED LETT DRUGS THER, V52, P30; [Anonymous], 2016, ONSOLIS PACK INS; Chang Andrew, 2015, J Pain Palliat Care Pharmacother, V29, P247, DOI 10.3109/15360288.2015.1063560; Coluzzi PH, 2001, PAIN, V91, P123, DOI 10.1016/S0304-3959(00)00427-9; Davies A, 2011, CLIN DRUG INVEST, V31, P317, DOI 10.2165/11533540-000000000-00000; Davies AN, 2009, EUR J PAIN, V13, P331, DOI 10.1016/j.ejpain.2008.06.014; Fine PG, 2010, J PAIN SYMPTOM MANAG, V40, P747, DOI 10.1016/j.jpainsymman.2010.02.009; Fine PG, 2010, PAIN MED, V11, P1024, DOI 10.1111/j.1526-4637.2010.00891.x; Finn AL, 2012, CLIN DRUG INVEST, V32, P63, DOI 10.2165/11594670-000000000-00000; Finn Andrew L, 2011, J Pain Res, V4, P245, DOI 10.2147/JPR.S22641; Garnock-Jones KP, 2016, CLIN DRUG INVEST, V36, P413, DOI 10.1007/s40261-016-0394-y; Hagen NA, 2007, J PALLIAT MED, V10, P47, DOI 10.1089/jpm.2006.0151; Hanks GW, 2001, BRIT J CANCER, V84, P587, DOI 10.1054/bjoc.2001.1680; Kosugi T, 2014, J PAIN SYMPTOM MANAG, V47, P990, DOI 10.1016/j.jpainsymman.2013.07.006; McDonald James, 2013, R I Med J (2013), V96, P38; Mercadante S, 2007, BRIT J CANCER, V96, P1828, DOI 10.1038/sj.bjc.6603811; Mercadante S, 2015, CURR OPIN ANESTHESIO, V28, P559, DOI 10.1097/ACO.0000000000000224; Mercadante S, 2013, SUPPORT CARE CANCER, V21, P2335, DOI 10.1007/s00520-013-1799-2; Mercadante S, 2012, CURR MED RES OPIN, V28, P963, DOI 10.1185/03007995.2012.683112; PORTENOY RK, 1990, PAIN, V41, P273, DOI 10.1016/0304-3959(90)90004-W; Portenoy RK, 2006, CLIN J PAIN, V22, P805, DOI 10.1097/01.ajp.0000210932.27945.4a; Taylor D, 2014, J PAIN SYMPTOM MANAG, V47, P1001, DOI 10.1016/j.jpainsymman.2013.07.012	22	1	2	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0025-7974	1536-5964		MEDICINE	Medicine (Baltimore)	JUL	2018	97	30							e11593	10.1097/MD.0000000000011593			6	Medicine, General & Internal	General & Internal Medicine	GR0ZU	WOS:000442255900044	30045291	DOAJ Gold, Green Published			2020-06-30	J	Yu, CC; Yuan, M; Yang, HY; Zhuang, XM; Li, H				Yu, Chenchen; Yuan, Mei; Yang, Haiying; Zhuang, Xiaomei; Li, Hua			P-Glycoprotein on Blood-Brain Barrier Plays a Vital Role in Fentanyl Brain Exposure and Respiratory Toxicity in Rats	TOXICOLOGICAL SCIENCES			English	Article						fentanyl; P-glycoprotein (P-gp); blood-brain barrier; brain exposure; respiratory depression	GENDER-DIFFERENCES; PHARMACOKINETICS; TRANSPORTER; GENE; IDENTIFICATION; PENETRATION; DISPOSITION; LOPERAMIDE; TARIQUIDAR; MORPHINE	Fentanyl is a rapid-acting, short duration opioid analgesic agent. In recent years, increased prescription and illicit use of fentanyl drugs have led to major safety concerns and a growing death toll. However, the causes of fentanyl-induced fatal adverse effects have not been thoroughly researched. This study investigated P-glycoprotein (P-gp) modulated blood-brain barrier penetration of fentanyl and its resulting toxicity in vitro and in vivo. ATPase assays were performed together with bi-directional transport assays using Caco-2 cells in the presence and absence of tariquidar, a P-gp inhibitor, to confirm the P-gp substrate property of fentanyl. In vivo determinations of brain pharmacokinetic profile, duration of loss of righting reflex, and respiratory function were further conducted following intravenous administration of low and high doses of fentanyl with and without tariquidar in rats. Fentanyl significantly increased the ATPase activity of P-gp membrane. The efflux ratio of fentanyl on Caco-2 cells was > 2, which was remarkably reduced when co-incubated with tariquidar. Using concomitant tariquidar with fentanyl (40 mu g/kg) in rats, the unbound brain-to-plasma concentration ratio in rats increased 2.9-fold. The duration of loss of righting reflex was significantly extended, and fentanyl-induced respiratory depression was aggravated. At high fentanyl doses (80 mu g/kg), inhibition of P-gp resulted in severe respiratory toxicity in the rats and even death. Collectively, these results gave strong evidence that P-gp plays a vital role in fentanyl blood-brain barrier penetration and the resulting toxicity. Fentanyl requires close monitoring in clinic when administered concomitantly with P-gp inhibitors.	[Yu, Chenchen; Yuan, Mei; Yang, Haiying; Zhuang, Xiaomei; Li, Hua] Beijing Inst Pharmacol & Toxicol, State Key Lab Toxicol & Med Countermeasures, Beijing 100850, Peoples R China	Li, H (reprint author), Beijing Inst Pharmacol & Toxicol, State Key Lab Toxicol & Med Countermeasures, Beijing 100850, Peoples R China.	amms_hli@126.com			Chinese National Science & Technology Major Special Project on Major New Drug Innovation [2008ZXJ09006001, 2015ZX09J15104]	This work was supported by Chinese National Science & Technology Major Special Project on Major New Drug Innovation (grant number 2008ZXJ09006001 and 2015ZX09J15104).	[Anonymous], 2008, FENT DAT; Bankstahl JP, 2008, J NUCL MED, V49, P1328, DOI 10.2967/jnumed.108.051235; Bauer F, 2010, BIOORGAN MED CHEM, V18, P5489, DOI 10.1016/j.bmc.2010.06.057; Bauer M, 2013, PHARMACOLOGY, V91, P12, DOI 10.1159/000343243; Bebawy M, 2009, CURR DRUG METAB, V10, P322, DOI 10.2174/138920009788498996; Boyer EW, 2012, NEW ENGL J MED, V367, P146, DOI 10.1056/NEJMra1202561; Burns G, 2016, CLIN TOXICOL, V54, P420, DOI 10.3109/15563650.2016.1157722; Chen L, 2018, J ETHNOPHARMACOL, V212, P74, DOI 10.1016/j.jep.2017.10.014; Coulbault L, 2006, CLIN PHARMACOL THER, V79, P316, DOI 10.1016/j.clpt.2006.01.007; Dagenais C, 2004, BIOCHEM PHARMACOL, V67, P269, DOI 10.1016/j.bcp.2003.08.027; Dagenais C, 2001, PHARMACEUT RES, V18, P957, DOI 10.1023/A:1010984110732; Di L, 2013, J MED CHEM, V56, P2, DOI 10.1021/jm301297f; Drug Enforcement Administration, 2015, DEA ISS NAT AL FENT; Ebert B, 2005, CARCINOGENESIS, V26, P1754, DOI 10.1093/carcin/bgi139; Elkiweri IA, 2009, ANESTH ANALG, V108, P149, DOI 10.1213/ane.0b013e31818e0bd1; Ferguson LM, 2006, BRIT J ANAESTH, V96, P384, DOI 10.1093/bja/ael011; Fodale V, 2008, EXPERT OPIN DRUG SAF, V7, P213, DOI [10.1517/14740338.7.3.213, 10.1517/14740338.7.3.213 ]; *FOOD DRUG ADM, 2001, GUID IND BIOAN METH; Friden M, 2010, J CEREBR BLOOD F MET, V30, P150, DOI 10.1038/jcbfm.2009.200; Gardner ER, 2009, J EXP CLIN CANC RES, V28, DOI 10.1186/1756-9966-28-99; Gharavi R, 2015, PHARM RES-DORDR, V32, P2477, DOI 10.1007/s11095-015-1711-5; Giacomini KM, 2010, NAT REV DRUG DISCOV, V9, P215, DOI 10.1038/nrd3028; Guidance for Industry, 2012, GUID IND DRUG INT ST; Hamabe W, 2006, PHARMACOL BIOCHEM BE, V85, P629, DOI 10.1016/j.pbb.2006.10.018; Kalvass JC, 2002, BIOPHARM DRUG DISPOS, V23, P327, DOI 10.1002/bdd.325; Kannan P, 2009, CLIN PHARMACOL THER, V86, P368, DOI 10.1038/clpt.2009.138; Kharasch ED, 2004, J CLIN PHARMACOL, V44, P224, DOI 10.1177/0091270003262075; Kong LL, 2016, FRONT PHARMACOL, V7, DOI 10.3389/fphar.2016.00242; Kornick CA, 2003, DRUG SAFETY, V26, P951, DOI 10.2165/00002018-200326130-00004; Latimer J, 2016, INT J DRUG POLICY, V37, P111, DOI 10.1016/j.drugpo.2016.08.004; Levin Tomer T, 2010, Gen Hosp Psychiatry, V32, DOI 10.1016/j.genhosppsych.2010.08.003; Linnet K, 2008, EUR NEUROPSYCHOPHARM, V18, P157, DOI 10.1016/j.euroneuro.2007.06.003; Lo Vecchio F., 2011, AM J EMERG MED, V29; Lotsch J, 2013, CLIN PHARMACOKINET, V52, P23, DOI 10.1007/s40262-012-0016-7; Martin TL, 2006, J ANAL TOXICOL, V30, P603, DOI 10.1093/jat/30.8.603; Morris ME, 2003, PHARMACOL REV, V55, P229, DOI 10.1124/pr.55.2.1; Oga EF, 2012, J ETHNOPHARMACOL, V144, P612, DOI 10.1016/j.jep.2012.10.001; Park HJ, 2007, CLIN PHARMACOL THER, V81, P539, DOI 10.1038/sj.clpt.6100046; Ramsey B., 2017, ONLINE J PUBLIC HLTH, V9, pe127; ROY SD, 1988, PHARMACEUT RES, V5, P580, DOI 10.1023/A:1015994030251; Saari TI, 2008, EUR J CLIN PHARMACOL, V64, P25, DOI 10.1007/s00228-007-0398-x; Sadeque AJM, 2000, CLIN PHARMACOL THER, V68, P231, DOI 10.1067/mcp.2000.109156; Serghini I, 2015, PAN AFR MED J, V20, DOI 10.11604/pamj.2015.20.21.5886; Smart JA, 2000, BRIT J ANAESTH, V84, P735; Sporer KA, 1999, ANN INTERN MED, V130, P584, DOI 10.7326/0003-4819-130-7-199904060-00019; Suzuki J, 2017, DRUG ALCOHOL DEPEN, V171, P107, DOI 10.1016/j.drugalcdep.2016.11.033; Tanaka N, 2014, THER DRUG MONIT, V36, P345, DOI 10.1097/FTD.0000000000000029; Tang K, 2002, PHARMACOGENETICS, V12, P437, DOI 10.1097/00008571-200208000-00004; Twycross R, 2012, J PAIN SYMPTOM MANAG, V44, P131, DOI 10.1016/j.jpainsymman.2012.05.001; Wandel C, 2002, ANESTHESIOLOGY, V96, P913, DOI 10.1097/00000542-200204000-00019; Yamazaki M, 2001, J PHARMACOL EXP THER, V296, P723; Yassen A, 2008, PHARM RES, V25, P183, DOI 10.1007/s11095-007-9440-z; Yong Z, 2014, EUR J PHARMACOL, V738, P153, DOI 10.1016/j.ejphar.2014.05.044; Zamek-Gliszczynski MJ, 2012, DRUG METAB DISPOS, V40, P1825, DOI 10.1124/dmd.112.046508; Zhuang XM, 2013, DRUG METAB DISPOS, V41, P2158, DOI 10.1124/dmd.113.054056; Ziesenitz VC, 2015, J CLIN PHARMACOL, V55, P708, DOI 10.1002/jcph.469	56	3	3	0	3	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	1096-6080	1096-0929		TOXICOL SCI	Toxicol. Sci.	JUL	2018	164	1					353	362		10.1093/toxsci/kfy093			10	Toxicology	Toxicology	GO1NM	WOS:000439719200030	29669042	Bronze			2020-06-30	J	Baumgartner, L; Townsend, N; Winkelman, K; MacLaren, R				Baumgartner, Laura; Townsend, Nicole; Winkelman, Katie; MacLaren, Robert			The Efficacy and Safety of an RN-Driven Ketamine Protocol for Adjunctive Analgesia During Burn Wound Care	AMERICAN JOURNAL OF NURSING			English	Article						analgesia; burn wound care; critical care; ketamine; RN-driven protocol; pain	PAIN MANAGEMENT; DRESSING CHANGES; SECONDARY HYPERALGESIA; POSTTRAUMATIC-STRESS; HEAT STIMULI; INJURY; DEXMEDETOMIDINE; EXPERIENCE; SEDATION; PATIENT	Objective: Traditional analgesic regimens often fail to control the severe pain patients experience during burn wound care, and the drugs are frequently administered at doses that can cause oversedation and respiratory depression. Ketamine may be an ideal agent for adjunctive analgesia in such patients because of its unique mechanism of action and lack of association with respiratory depression. This study evaluated the efficacy and safety of a critical care RN-driven protocol for IV ketamine administration during burn wound care. Methods: This retrospective cohort study examined all adult burn patients who received ketamine as part of a critical care RN-driven ketamine protocol for burn wound care from September 2011 through September 2013. Efficacy outcomes were opioid and benzodiazepine requirements (expressed as fentanyl and midazolam equivalents, respectively) four hours after ketamine administration compared with four hours before such administration. Safety parameters assessed were neurologic, hemodynamic, and respiratory effects. Results: Twenty-seven patients received 56 ketamine doses as part of this protocol; the mean (SD) dose was 0.75 (0.35) mg/kg. Twenty patients (74%) were male and seven (26%) were female; mean age was 39 years. The average percentage of total body surface area burned was 23.4%. With the protocol, opioid and benzodiazepine requirements were reduced by 29% and 20%, respectively. One patient experienced an episode of oversedation after concomitant administration of ketamine and fentanyl. No patients experienced neurologic or hemodynamic complications following ketamine administration. Conclusions: The administration of ketamine during burn wound care using a critical care RN-driven protocol was associated with reduced opioid and benzodiazepine requirements and few adverse effects. Prospective studies are needed to investigate additional patient outcomes and the independent administration of ketamine by critical care RNs.	[Baumgartner, Laura] Touro Univ Calif, Coll Pharm, Vallejo, CA 94592 USA; [Townsend, Nicole] Univ Colorado Hosp, Dept Surg, Aurora, CO USA; [Winkelman, Katie] Univ Colorado Hosp, Burn Ctr, Aurora, CO USA; [MacLaren, Robert] Univ Colorado, Skaggs Sch Pharm & Pharmaceut Sci, Dept Clin Pharm, Aurora, CO USA	Baumgartner, L (reprint author), Touro Univ Calif, Coll Pharm, Vallejo, CA 94592 USA.	baum0304@gmail.com					Ali Z, 1996, PAIN, V68, P401, DOI 10.1016/S0304-3959(96)03199-5; American College of Emergency Physicians Emergency Medicine Practice Committee, 2017, SUBD KET AN POL RES; [Anonymous], 2017, KET KET HYDR INJ CII; Bredmose PP, 2009, EMERG MED J, V26, P62, DOI 10.1136/emj.2007.052753; Canpolat DG, 2012, J BURN CARE RES, V33, P718, DOI 10.1097/BCR.0b013e3182504316; Gunduz Murat, 2011, J Anaesthesiol Clin Pharmacol, V27, P220, DOI 10.4103/0970-9185.81823; Hocking G, 2003, ANESTH ANALG, V97, P1730, DOI 10.1213/01.ANE.0000086618.28845.9B; Kundra P, 2013, BURNS, V39, P1150, DOI 10.1016/j.burns.2013.02.012; Laycock H, 2013, EUR J PHARMACOL, V716, P169, DOI 10.1016/j.ejphar.2013.01.071; Lexicomp, LEX DRUGS KET WOLT K; Li YX, 2012, BURNS, V38, P180, DOI 10.1016/j.burns.2011.09.006; McGuinness SK, 2011, PAIN MED, V12, P1551, DOI 10.1111/j.1526-4637.2011.01220.x; McKibben JBA, 2008, J BURN CARE RES, V29, P22, DOI 10.1097/BCR.0b013e31815f59c4; Mion G, 2013, CNS NEUROSCI THER, V19, P370, DOI 10.1111/cns.12099; Patterson DR, 2004, BURNS, V30, pA10, DOI 10.1016/j.burns.2004.08.004; Pedersen JL, 1998, PAIN, V76, P377, DOI 10.1016/S0304-3959(98)00070-0; Persson J, 2013, CNS NEUROSCI THER, V19, P396, DOI 10.1111/cns.12111; Petrenko AB, 2003, ANESTH ANALG, V97, P1108, DOI 10.1213/01.ANE.0000081061.12235.55; Richards JR, 2013, AM J EMERG MED, V31, P390, DOI 10.1016/j.ajem.2012.07.027; Richardson P, 2009, BURNS, V35, P921, DOI 10.1016/j.burns.2009.03.003; Sessler CN, 2002, AM J RESP CRIT CARE, V166, P1338, DOI 10.1164/rccm.2107138; Sih K, 2011, ANN PHARMACOTHER, V45, P1525, DOI 10.1345/aph.1Q370; Subramaniam K, 2004, ANESTH ANALG, V99, P482, DOI 10.1213/01.ANE.0000118109.12855.07; Summer GJ, 2007, J PAIN, V8, P533, DOI 10.1016/j.jpain.2007.02.426; Taal LA, 1997, BURNS, V23, P545, DOI 10.1016/S0305-4179(97)00788-2; Visser E, 2006, BIOMED PHARMACOTHER, V60, P341, DOI 10.1016/j.biopha.2006.06.021; Weinberg K, 2000, J BURN CARE REHABIL, V21, P157, DOI 10.1097/00004630-200021020-00013; Zor F, 2010, BURNS, V36, P501, DOI 10.1016/j.burns.2009.08.007	28	0	0	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0002-936X	1538-7488		AM J NURS	Am. J. Nurs.	JUL	2018	118	7					26	31		10.1097/01.NAJ.0000541433.66712.61			6	Nursing	Nursing	GL0VR	WOS:000436811100020	29905575				2020-06-30	J	Brockbals, L; Staeheli, SN; Gascho, D; Ebert, LC; Kraemer, T; Steuer, AE				Brockbals, Lana; Staeheli, Sandra N.; Gascho, Dominic; Ebert, Lars C.; Kraemer, Thomas; Steuer, Andrea E.			Time-Dependent Postmortem Redistribution of Opioids in Blood and Alternative Matrices	JOURNAL OF ANALYTICAL TOXICOLOGY			English	Article							PERIPHERAL-BLOOD; TISSUE CONCENTRATIONS; METABOLITE EDDP; METHADONE; FENTANYL; MORPHINE; LIVER; DRUG; ENANTIOMERS; DIAZEPAM	Forensic postmortem case interpretation can be challenging, in particular due to postmortem redistribution (PMR) phenomena. Recent studies have shown that computed tomography (CT)-guided collection of biopsy samples using a robotic arm (virtobot) provides a valuable tool for systematic studies on time-dependent PMR. Utilizing this strategy, several cases involving opioid use such as methadone, fentanyl, tramadol, codeine, oxycodone and hydrocodone were evaluated for time-dependent concentration changes and potential redistribution mechanisms. Upon admission to the institute (t1), blood (femoral and right ventricle heart blood) and tissue biopsy samples (lung, kidney, liver, spleen, thigh muscle and adipose tissue) were collected utilizing CT-guided biopsy. Approximately 24 h later (t2; mean 28 +/- 15 h), during the autopsy, samples from the same body regions were collected manually and in addition brain tissue, gastric content, urine and left ventricle heart blood. Analysis was conducted with liquid chromatography tandem mass spectrometry. Significant time-dependent methadone concentration increases in femoral blood (pB) indicate the occurrence of PMR, however, ultimately not relevant for forensic interpretation. The main metabolite of methadone, 2-ethylidene-1,5dimethyl- 3,3-diphenylpyrrolidine (EDDP), showed a less significant trend for PMR. Redistribution by passive diffusion along the muscle-to-pB concentration gradient seems likely for methadone, but not for EDDP. Results for fentanyl suggest extensive PMR. Other opioids such as tramadol, codeine, hydrocodone and oxycodone showed no consistent trend for significant PMR. Overall, CT-guided biopsy sampling proved to be a valuable tool for the investigation of PMR mechanisms.	[Brockbals, Lana; Staeheli, Sandra N.; Kraemer, Thomas; Steuer, Andrea E.] Univ Zurich, Zurich Inst Forens Med, Dept Forens Pharmacol & Toxicol, Winterthurerstr 190-52, CH-8057 Zurich, Switzerland; [Gascho, Dominic; Ebert, Lars C.] Univ Zurich, Zurich Inst Forens Med, Dept Forens Med & Imaging, Winterthurerstr 190-52, CH-8057 Zurich, Switzerland	Steuer, AE (reprint author), Univ Zurich, Zurich Inst Forens Med, Dept Forens Pharmacol & Toxicol, Winterthurerstr 190-52, CH-8057 Zurich, Switzerland.	andrea.steuer@irm.uzh.ch	Kraemer, Thomas/R-8407-2018; Gascho, Dominic/Y-4933-2019	Kraemer, Thomas/0000-0002-3283-606X; Gascho, Dominic/0000-0001-9004-4362; Brockbals, Lana/0000-0001-7310-2671; Steuer, Andrea Eva/0000-0001-8983-2353; Ebert, Lars Christian/0000-0002-8215-7006	Swiss National Science FoundationSwiss National Science Foundation (SNSF) [310030_165875]	This work was supported by the Swiss National Science Foundation (Grant no. 310030_165875).	[Anonymous], 2017, LANCET, V390, P2016, DOI 10.1016/S0140-6736(17)32808-8; Baselt RC, 2008, DISPOSITION TOXIC DR; Brinkmann B, 2004, HDB GERICHTLICHE MED; Caplehorn JRM, 2002, DRUG ALCOHOL REV, V21, P329, DOI 10.1080/0959523021000023171; Ceelen L, 2012, AM J FOREN MED PATH, V33, P119, DOI 10.1097/PAF.0b013e3181fbbb49; Costa I, 2013, J ANAL TOXICOL, V37, P670, DOI 10.1093/jat/bkt084; Danhof M, 2007, ANNU REV PHARMACOL, V47, P357, DOI 10.1146/annurev.pharmtox.47.120505.105154; Ebert LC, 2014, FORENSIC SCI MED PAT, V10, P179, DOI 10.1007/s12024-013-9520-9; Gerostamoulos D, 2012, FORENSIC SCI MED PAT, V8, P373, DOI 10.1007/s12024-012-9341-2; Han E, 2012, FORENSIC SCI INT, V219, P265, DOI 10.1016/j.forsciint.2012.01.016; Holm KMD, 2015, J FORENSIC SCI, V60, P95, DOI 10.1111/1556-4029.12627; Jantos R, 2013, FORENSIC SCI INT, V226, P254, DOI 10.1016/j.forsciint.2013.01.038; Kennedy MC, 2010, INTERN MED J, V40, P183, DOI 10.1111/j.1445-5994.2009.02111.x; Krinsky CS, 2014, J FORENSIC SCI, V59, P1275, DOI 10.1111/1556-4029.12381; Lemaire E, 2017, J FORENSIC SCI, V62, P1559, DOI 10.1111/1556-4029.13404; Lemaire E, 2016, J FORENSIC SCI, V61, P1596, DOI 10.1111/1556-4029.13213; Lemaire E, 2016, J FORENSIC SCI, V61, P1017, DOI 10.1111/1556-4029.13061; Levine B, 1997, FORENSIC SCI INT, V86, P43, DOI 10.1016/S0379-0738(97)02111-7; Luckenbill K, 2008, J ANAL TOXICOL, V32, P639, DOI 10.1093/jat/32.8.639; McIntyre IM, 2014, FORENSIC SCI MED PAT, V10, P91, DOI 10.1007/s12024-013-9503-x; Olson KN, 2010, AM J CLIN PATHOL, V133, P447, DOI 10.1309/AJCP4X5VHFSOERFT; Palamalai V, 2013, CLIN BIOCHEM, V46, P598, DOI 10.1016/j.clinbiochem.2013.02.001; Pelissier-Alicot AL, 2003, J ANAL TOXICOL, V27, P533, DOI 10.1093/jat/27.8.533; Rudd RA, 2016, MMWR-MORBID MORTAL W, V65, P1445, DOI 10.15585/mmwr.mm655051e1; Saitman A, 2015, FORENSIC SCI INT, V247, P36, DOI 10.1016/j.forsciint.2014.11.031; Skopp G, 2010, FORENSIC SCI MED PAT, V6, P314, DOI 10.1007/s12024-010-9150-4; Staeheli SN, 2017, INT J LEGAL MED, V131, P379, DOI 10.1007/s00414-016-1485-2; Staeheli SN, 2016, ANAL BIOANAL CHEM, V408, P1249, DOI 10.1007/s00216-015-9234-9; Staeheli SN, 2015, ANAL BIOANAL CHEM, V407, P8681, DOI 10.1007/s00216-015-9023-5; Stuart B, 2013, ENCY FORENSIC SCI, P11; Tolliver SS, 2010, J ANAL TOXICOL, V34, P491, DOI 10.1093/jat/34.8.491; Volkow ND, 2017, NEW ENGL J MED, V377, P391, DOI 10.1056/NEJMsr1706626	32	11	11	0	10	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0146-4760	1945-2403		J ANAL TOXICOL	J. Anal. Toxicol.	JUL	2018	42	6					365	374		10.1093/jat/bky017			10	Chemistry, Analytical; Toxicology	Chemistry; Toxicology	GN5YW	WOS:000439146400003	29579266	Bronze			2020-06-30	J	Doran, KM; Raja, AS; Samuels, EA				Doran, Kelly M.; Raja, Ali S.; Samuels, Elizabeth A.			Opioid Overdose Protocols in the Emergency Department: Are We Asking the Right Questions?	ANNALS OF EMERGENCY MEDICINE			English	Editorial Material							PRACTICE GUIDELINE; PROJECT ASSERT; PRIMARY-CARE; INTERVENTION; ADDICTION; DEPENDENCE; OUTCOMES; TRIAL; RULE		[Doran, Kelly M.] NYU, Sch Med, Dept Emergency Med, New York, NY 10003 USA; [Doran, Kelly M.] NYU, Sch Med, Dept Populat Hlth, New York, NY 10003 USA; [Raja, Ali S.] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA; [Raja, Ali S.] Harvard Med Sch, Boston, MA USA; [Samuels, Elizabeth A.] Yale Sch Med, Natl Clinician Scholars Program, New Haven, CT USA; [Samuels, Elizabeth A.] Yale Sch Med, Dept Emergency Med, New Haven, CT USA	Doran, KM (reprint author), NYU, Sch Med, Dept Emergency Med, New York, NY 10003 USA.; Doran, KM (reprint author), NYU, Sch Med, Dept Populat Hlth, New York, NY 10003 USA.	kelly.doran@nyumc.org	Raja, Ali S./AAE-5103-2019; Samuels, Elizabeth/E-6302-2018; Samuels, Elizabeth/AAC-9987-2020	Samuels, Elizabeth/0000-0003-2414-110X; Samuels, Elizabeth/0000-0003-2414-110X; Doran, Kelly/0000-0001-8961-3724	National Institutes of Health/National Institute on Drug AbuseUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [K23DA039179]; United Hospital Fund; Doris Duke Charitable Trust-NYU Langone Medical Center	By Annals policy, all authors are required to disclose any and all commercial, financial, and other relationships in any way related to the subject of this article as per ICMJE conflict of interest guidelines (see www.icmje.org). The authors have stated that no such relationships exist. Dr. Doran reports receiving grant support from National Institutes of Health/National Institute on Drug Abuse (K23DA039179), the United Hospital Fund, and the Doris Duke Charitable Trust-NYU Langone Medical Center.	Addiction Policy Forum, ANCHORED RHOD ISL; American College of Emergency Physicians, ACEP WITN TEST C OP; American Society of Addiction Medicine, ADV ACC ADD MED IMPL; Bebinger M., MGH BECOMES 1 MASS E; Bernstein E, 1997, ANN EMERG MED, V30, P181, DOI 10.1016/S0196-0644(97)70140-9; Bruneau J, 2018, CAN MED ASSOC J, V190, pE247, DOI 10.1503/cmaj.170958; Caudarella A, 2016, DRUG ALCOHOL DEPEN, V162, P51, DOI 10.1016/j.drugalcdep.2016.02.024; D'Onofrio G, 2017, J GEN INTERN MED, V32, P660, DOI 10.1007/s11606-017-3993-2; D'Onofrio G, 2015, JAMA-J AM MED ASSOC, V313, P1636, DOI 10.1001/jama.2015.3474; D'Onofrio G, 2010, ACAD EMERG MED, V17, P903, DOI 10.1111/j.1553-2712.2010.00824.x; Houry DE, 2018, ANN EMERG MED, V71, P688, DOI 10.1016/j.annemergmed.2018.01.052; Kampman K, 2015, J ADDICT MED, V9, P358, DOI 10.1097/ADM.0000000000000166; Kline JA, 2008, J THROMB HAEMOST, V6, P772, DOI 10.1111/j.1538-7836.2008.02944.x; Lynch MJ, 2018, ANN EMERG MED, V71, P676, DOI 10.1016/j.annemergmed.2018.01.051; Mahler SA, 2015, CIRC-CARDIOVASC QUAL, V8, P195, DOI 10.1161/CIRCOUTCOMES.114.001384; Marshall JR, 2019, SUBST ABUS, V40, P80, DOI 10.1080/08897077.2018.1442899; Martin A, 2018, ACAD EMERG MED, V25, P601, DOI 10.1111/acem.13367; Quinn J, 2006, ANN EMERG MED, V47, P448, DOI 10.1016/j.annemergmed.2005.11.019; Raja AS, N ENGL J MED; Rhode Island Department of Health; Department of Behavioral Healthcare and Hospitals Developmental Disabilities, LEV CAR RHOD ISL EM; Rubin R, 2018, JAMA-J AM MED ASSOC, V319, P2158, DOI 10.1001/jama.2018.4648; Scheuermeyer FX, 2018, ANN EMERG MED, V72; Strang J, 2003, BRIT MED J, V326, P959, DOI 10.1136/bmj.326.7396.959; Vivolo-Kantor AM, 2018, MMWR-MORBID MORTAL W, V67, P279, DOI 10.15585/mmwr.mm6709e1; Volkow ND, 2016, NEW ENGL J MED, V374, P363, DOI 10.1056/NEJMra1511480; Weiner SG, 2017, ANN EMERG MED, V70, pS158, DOI 10.1016/j.annemergmed.2017.07.281	26	3	3	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0196-0644			ANN EMERG MED	Ann. Emerg. Med.	JUL	2018	72	1					12	15		10.1016/j.annemergmed.2018.05.024			4	Emergency Medicine	Emergency Medicine	GN0LX	WOS:000438661000005	29929652				2020-06-30	J	Arnautovic, T; Sommese, K; Mullan, PC; Frazier, SB; Vazifedan, T; Ramirez, DE				Arnautovic, Tamara; Sommese, Kathryn; Mullan, Paul C.; Frazier, Steven Barron; Vazifedan, Turaj; Ramirez, Dana Erikson			Evaluating the Implementation Barriers of an Intranasal Fentanyl Pain Pathway for Pediatric Long-Bone Fractures	PEDIATRIC EMERGENCY CARE			English	Article						intranasal; fentanyl; pain; morphine; physician	CLINICAL-PRACTICE GUIDELINES; EMERGENCY-DEPARTMENT; MANAGEMENT; CHILDREN; PHYSICIANS; PROFESSIONALS; IMPROVEMENT; KNOWLEDGE; ATTITUDES; MEDICINE	Objectives This study aimed to assess physician comfort, knowledge, and implementation barriers regarding the use of intranasal fentanyl (INF) for pain management in patients with long-bone fractures in a pediatric emergency department (ED) with an INF pain pathway. Methods A retrospective chart review was conducted of patients, 3 to 21 years old, in our ED with an International Classification of Diseases-9th Revision code for a long-bone fracture from September 1, 2013, to August 31, 2015. Patients were divided into 4 groups: (1) received INF on the pathway appropriately; (2) missed opportunities to receive INF, defined as either INF was ordered and then subsequently canceled (for pain ratings, 6/10), or INF was ordered, cancelled, and intravenous (IV) morphine given, or INF was not ordered and a peripheral IV line was placed to give IV morphine as first-line medication; (3) peripheral IV established upon ED arrival; (4) no pain medication required. Additionally, a survey regarding practice habits for pain management was completed to evaluate physician barriers to utilization of the pathway. Results A total of 1374 patients met the inclusion criteria. Missed opportunities were identified 41% of the time. Neither younger patient age nor more years of physician experience in the ED were associated with increased rates of missed opportunities. The survey (95% response rate) revealed greater comfort with and preference for IV morphine over INF. Conclusions The high rate of missed opportunities, despite the implementation of an INF pain pathway, indicates the need for further exploration of the barriers to utilization of the INF pain pathway.	[Arnautovic, Tamara] Brown Univ, Dept Pediat, Hasbro Childrens Hosp, Alpert Med Sch, Providence, RI 02912 USA; [Sommese, Kathryn] Eastern Virginia Med Sch, Dept Pediat, Norfolk, VA 23501 USA; [Mullan, Paul C.; Vazifedan, Turaj; Ramirez, Dana Erikson] Childrens Hosp Kings Daughters, Dept Pediat, Div Emergency Med, Norfolk, VA USA; [Frazier, Steven Barron] Monroe Carell Jr Childrens Hosp Vanderbilt, Dept Pediat, Nashville, TN USA	Mullan, PC (reprint author), 601 Childrens Lane, Norfolk, VA 23507 USA.	mullan20@gmail.com		Vazifedan, Turaj/0000-0002-8319-7499			Agresti A., 2013, CATEGORICAL DATA ANA; Alexander J, 2003, ANN EMERG MED, V41, P617, DOI 10.1067/mem.2003.138; Balas E A, 2000, Yearb Med Inform, P65; Bawa Monika, 2015, J Pain Palliat Care Pharmacother, V29, P353, DOI 10.3109/15360288.2015.1082010; Borland M, 2007, ANN EMERG MED, V49, P335, DOI 10.1016/j.annemergmed.2006.06.016; Borland ML, 2008, EMERG MED AUSTRALAS, V20, P515, DOI 10.1111/j.1742-6723.2008.01138.x; Broome ME, 1996, J PAIN SYMPTOM MANAG, V11, P312, DOI 10.1016/0885-3924(95)00205-7; Cabana MD, 1999, JAMA-J AM MED ASSOC, V282, P1458, DOI 10.1001/jama.282.15.1458; Carey R.G., 2003, IMPROVING HEALTHCARE; Christakis DA, 1998, PEDIATRICS, V101, P825, DOI 10.1542/peds.101.5.825; Cohen LL, 2008, J PEDIATR PSYCHOL, V33, P939, DOI 10.1093/jpepsy/jsm103; Cummings EA, 1996, PAIN, V68, P25, DOI 10.1016/S0304-3959(96)03163-6; de Freitas GRM, 2014, PAIN MED, V15, P807, DOI 10.1111/pme.12332; Duarte JG, 2017, INT J MED INFORM, V102, P80, DOI 10.1016/j.ijmedinf.2017.03.007; Evans-Lacko S, 2010, BMC HEALTH SERV RES, V10, DOI 10.1186/1472-6963-10-182; Fosnocht DE, 2005, EMERG MED CLIN N AM, V23, P297, DOI 10.1016/j.emc.2004.12.003; Friedrichsdorf Stefan J, 2015, Hosp Pediatr, V5, P18, DOI 10.1542/hpeds.2014-0084; Gupta DM, 2017, IMPLEMENT SCI, V12, DOI 10.1186/s13012-017-0555-2; Hagan JF, 2001, PEDIATRICS, V108, P793; HODDINOTT SN, 1986, CAN FAM PHYSICIAN, V32, P2366; Holdgate A, 2010, ACAD EMERG MED, V17, P214, DOI 10.1111/j.1553-2712.2009.00636.x; Huskamp HA, 2013, PSYCHIAT SERV, V64, P324, DOI 10.1176/appi.ps.201200186; Iyer SB, 2011, PEDIATRICS, V127, pE219, DOI 10.1542/peds.2010-0632; Jackson L, 1997, CAN FAM PHYSICIAN, V43, P649; Kircher J, 2014, CAN J EMERG MED, V16, P449, DOI 10.2310/8000.2013.131211; Mansfield C D, 1995, Qual Health Care, V4, P250, DOI 10.1136/qshc.4.4.250; Mazer-Amirshahi M, 2014, PEDIATR EMERG CARE, V30, P230, DOI 10.1097/PEC.0000000000000102; Minitab 17 Statistical Software, 2010, MIN 17 STAT SOFTW; Murphy A, 2014, COCHRANE DB SYST REV, V10, P1; Muslin IS, 2014, HEALTH CARE MANAG, V33, P165, DOI 10.1097/HCM.0000000000000011; Petrack EM, 1997, PEDIATRICS, V99, P711, DOI 10.1542/peds.99.5.711; Probst BD, 2005, PEDIATR EMERG CARE, V21, P298, DOI 10.1097/01.pec.0000159074.85808.14; Ruest S, 2016, CURR OPIN PEDIATR, V28, P298, DOI 10.1097/MOP.0000000000000347; Saroyan JM, 2008, J PAIN SYMPTOM MANAG, V36, P628, DOI 10.1016/j.jpainsymman.2007.12.006; Saunders M, 2010, ACAD EMERG MED, V17, P1155, DOI 10.1111/j.1553-2712.2010.00905.x; Schacherer NM, 2015, PEDIATR EMERG CARE, V31, P560, DOI 10.1097/PEC.0000000000000435; Schaefer JA, 2015, AM J EMERG MED, V33, P1805, DOI 10.1016/j.ajem.2015.08.050; Shomaker Kyrie, 2015, Hosp Pediatr, V5, P363, DOI 10.1542/hpeds.2014-0195; Trottier ED, 2015, PAED CHILD HEALT-CAN, V20, P239, DOI 10.1093/pch/20.5.239; Tsze DS, 2016, PEDIAT EMERG CARE; von Baeyer CL, 2007, PAIN, V127, P140, DOI 10.1016/j.pain.2006.08.014; Wensing M, 2010, CAN MED ASSOC J, V182, pE85, DOI 10.1503/cmaj.081233; Wylie MC, 2014, AM J MED, V127, DOI 10.1016/j.amjmed.2014.06.011	43	0	0	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0749-5161	1535-1815		PEDIATR EMERG CARE	Pediatr. Emerg. Care	JUL	2018	34	7					473	478		10.1097/PEC.0000000000001375			6	Emergency Medicine; Pediatrics	Emergency Medicine; Pediatrics	GM9ED	WOS:000438545200012	29200140				2020-06-30	J	Kelly, G; Anders, JF; Stewart, RW; Strouse, JJ				Kelly, GeoffreyS.; Anders, Jennifer F.; Stewart, Rosalyn W.; Strouse, John J.			Intranasal fentanyl improves time to analgesic delivery in sickle cell paincrises	AMERICAN JOURNAL OF EMERGENCY MEDICINE			English	Letter							PEDIATRIC EMERGENCY-DEPARTMENT; DISEASE; MANAGEMENT; EPISODES; PAIN		[Kelly, GeoffreyS.; Anders, Jennifer F.] Johns Hopkins Univ, Sch Med, Pediat, Baltimore, MD 21218 USA; [Stewart, Rosalyn W.] Johns Hopkins Univ, Sch Med, Pediat, Internal Med, Baltimore, MD USA; [Strouse, John J.] Duke Univ, Sch Med, Durham, NC USA	Kelly, G (reprint author), Johns Hopkins Univ, Sch Med, Pediat, Baltimore, MD 21218 USA.	gskelly2@gmail.com	Strouse, J/A-2690-2008	Strouse, J/0000-0003-0341-1457			[Anonymous], 2014, EXP PAN REP; BAINBRIDGE R, 1985, J PEDIATR-US, V106, P881, DOI 10.1016/S0022-3476(85)80230-4; Cacciotti C, 2017, CLIN PEDIATR, V56, P1109, DOI 10.1177/0009922816674521; Hassell KL, 2010, AM J PREV MED, V38, pS512, DOI 10.1016/j.amepre.2009.12.022; Haywood C, 2013, AM J EMERG MED, V31, P651, DOI 10.1016/j.ajem.2012.11.005; Holdgate A, 2010, ACAD EMERG MED, V17, P214, DOI 10.1111/j.1553-2712.2009.00636.x; Kavanagh PL, 2015, PEDIATRICS, V136, pE1016, DOI 10.1542/peds.2014-3470; Lin SM, 2016, PEDIATR EMERG CARE, V32, P14, DOI 10.1097/PEC.0000000000000369; Murphy A, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009942.pub2; PLATT OS, 1991, NEW ENGL J MED, V325, P11, DOI 10.1056/NEJM199107043250103; Tanabe P, 2007, ACAD EMERG MED, V14, P419, DOI 10.1197/j.aem.2006.11.033; Yusuf HR, 2010, AM J PREV MED, V38, pS536, DOI 10.1016/j.amepre.2010.01.001	12	3	3	1	1	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0735-6757	1532-8171		AM J EMERG MED	Am. J. Emerg. Med.	JUL	2018	36	7					1305	1307		10.1016/j.ajem.2017.11.015			4	Emergency Medicine	Emergency Medicine	GL0EC	WOS:000436636000039	29128141				2020-06-30	J	Clemensen, J; Rasmussen, LV; Abelson, KSP				Clemensen, Johanne; Rasmussen, Lena, V; Abelson, Klas S. P.			Transdermal Fentanyl Solution Provides Long-term Analgesia in the Hind-paw Incisional Model of Postoperative Pain in Male Rats	IN VIVO			English	Article						Laboratory rats; pain; analgesia; transdermal; fentanyl	VOLUNTARILY-INGESTED BUPRENORPHINE; SUSTAINED-RELEASE BUPRENORPHINE; PLASMA-CORTICOSTERONE; RATTUS-NORVEGICUS; BODY-WEIGHT; MICE; MELOXICAM; WATER; DOGS; GEL	Background: A recently developed transdermal fentanyl solution was hypothesized to be effective for non-invasive postoperative analgesia in rats. Materials and Methods: Thirty-nine male Sprague-Dawley rats were treated once with 0.1, 0.33 or 1.0 mg/kg transdermal fentanyl solution at the skin of the scruff 1 h prior to subjected to hind-paw surgery, and compared to non-treated animals. All rats were tested for nociceptive response in the electronic von Frey (EVF) test between 1 and 72 h postoperatively, and assessed daily with regards to facial expression, body weight changes and welfare score. Results: Fentanyl treatment at all doses significantly reduced nociceptive response in the EVF test throughout the 72 h of experimentation, reduced facial expressions on all days postoperatively, slightly reduced the body weight and improved postoperative welfare parameters. Conclusion: The present study indicates that transdermal fentanyl solution seems to be an effective, non-invasive and long-lasting analgesic regimen in male rats.	[Clemensen, Johanne; Rasmussen, Lena, V; Abelson, Klas S. P.] Univ Copenhagen, Fac Hlth & Med Sci, Dept Expt Med, Copenhagen, Denmark	Abelson, KSP (reprint author), Univ Copenhagen, Dept Expt Med, Blegdamsvej 3B, DK-2200 Copenhagen N, Denmark.	klasab@sund.ku.dk		Abelson, Klas/0000-0002-4986-7882	Copenhagen Center for Applied Animal Research (CALAR)	This study was performed with support from the Copenhagen Center for Applied Animal Research (CALAR). The Authors also wish to thank Trine Marie Glahder and Helle Porsdal for technical assistance, and Dr. Carsten Grondahl for introducing us to the transdermal fentanyl solution in the first place.	Abelson KSP, 2012, LAB ANIM-UK, V46, P349, DOI 10.1258/la.2012.012028; Abelson KSP, 2011, HDB LAB ANIMAL SCI, VII, P123; Brennan MP, 2009, LAB ANIMAL, V38, P87, DOI 10.1038/laban0309-87; Brennan TJ, 1996, PAIN, V64, P493, DOI 10.1016/0304-3959(95)01441-1; Chum HH, 2014, J AM ASSOC LAB ANIM, V53, P193; DOBROMYLSKYJ P, 2000, PAIN MANAGEMENT ANIM, P81; European Medicines Agency, 2011, REC FENT ANN 1 SUMM; Flecknell PA, 1999, LAB ANIM, V33, P169, DOI 10.1258/002367799780578381; Foley PL, 2011, J AM ASSOC LAB ANIM, V50, P198; Goldkuhl R, 2008, EUR SURG RES, V41, P272, DOI 10.1159/000142372; Goldkuhl R, 2010, EUR SURG RES, V44, P117, DOI 10.1159/000264962; Goldkuhl R, 2010, LAB ANIM-UK, V44, P337, DOI 10.1258/la.2010.009115; Goldkuhl R, 2010, IN VIVO, V24, P131; Hampshire VA, 2001, LAB ANIM-UK, V35, P223, DOI 10.1258/0023677011911660; Hestehave S, 2017, LAB ANIM-UK, V51, P264, DOI 10.1177/0023677216668553; Hovard AMB, 2015, LAB ANIM-UK, V49, P40, DOI 10.1177/0023677214551108; Institute for Laboratory Animal Research, 2011, I LAB ANIMAL RES GUI; Jessen L, 2007, LAB ANIM-UK, V41, P185, DOI 10.1258/002367707780378131; Kalliokoski O, 2010, IN VIVO, V24, P641; Linton DD, 2012, J VET PHARMACOL THER, V35, P53, DOI 10.1111/j.1365-2885.2012.01408.x; Mahler M, 2014, LAB ANIM-UK, V48, P178, DOI 10.1177/0023677213516312; Martinez SA, 2014, J VET PHARMACOL THER, V37, P394, DOI 10.1111/jvp.12096; Molina-Cimadevila MJ, 2014, LAB ANIM-UK, V48, P216, DOI 10.1177/0023677214532454; Moller KA, 1998, J NEUROSCI METH, V84, P41, DOI 10.1016/S0165-0270(98)00083-1; Morton DB, 2011, HDB LAB ANIMAL SCI, P535; Seymour TL, 2016, J AM ASSOC LAB ANIM, V55, P300; Sotocinal SG, 2011, MOL PAIN, V7, DOI 10.1186/1744-8069-7-55; WOODMAN DD, 1997, LAB ANIMAL ENDOCRINO, P253	28	2	2	0	4	INT INST ANTICANCER RESEARCH	ATHENS	EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22, ATHENS 19014, GREECE	0258-851X	1791-7549		IN VIVO	In Vivo	JUL-AUG	2018	32	4					713	719		10.21873/invivo.11299			7	Medicine, Research & Experimental	Research & Experimental Medicine	GK5RJ	WOS:000436233800002	29936450	Bronze, Green Published			2020-06-30	J	Kuberan, A; Jain, K; Bagga, R; Makkar, JK				Kuberan, A.; Jain, K.; Bagga, R.; Makkar, J. K.			The effect of spinal hyperbaric bupivacaine-fentanyl or hyperbaric bupivacaine on uterine tone and fetal heart rate in labouring women: a randomised controlled study	ANAESTHESIA			English	Article						combined spinal-epidural; fentanyl; fetal heart rate; obstetric analgesia; uterine contractions; uterine tone	EPIDURAL ANALGESIA; RATE ABNORMALITIES; INTRATHECAL OPIOIDS; CONTROLLED-TRIAL; DOUBLE-BLIND; BASAL TONE; BRADYCARDIA; SUFENTANIL; ELEVATION; PAIN	The mechanism for fetal heart rate abnormalities following spinal opioids remains controversial. We evaluated uterine tone, using an intra-uterine pressure catheter, and fetal heart rate abnormalities in 30 women in spontaneous labour with cervical dilation of 3-5 cm having combined spinal-epidural analgesia. Women were randomly assigned to receive a spinal with 2.0 mg hyperbaric bupivacaine plus 15 g fentanyl, or 2.5 mg hyperbaric bupivacaine. The primary outcome measure was an increase > 10 mmHg in baseline uterine tone in the 30-min period following spinal injection. Only three (20%) women who had a bupivacaine-fentanyl spinal showed a > 10 mmHg increase in baseline tone vs. none who had bupivacaine (p = 0.63). The mean (SD) baseline uterine tone after the spinal injection was 13.3 (7.0) mmHg in the bupivacaine-fentanyl group and 7.7 (2.5) mmHg in the bupivacaine group (p = 0.01). Seven (47%) in the bupivacaine-fentanyl group showed new onset fetal heart rate changes during the 30-min period after the spinal, compared with two (13%) in the bupivacaine group (p = 0.04); however, these were transient and responded to intra-uterine resuscitation. Pain scores, sensory and motor block as well as neonatal outcomes were comparable between the groups. We found that raised baseline uterine tone was not more frequent when using bupivacaine-fentanyl rather than bupivacaine in the spinal component of combined spinal-epidural, although absolute values of baseline tone were higher, and fetal heart rate changes more frequent, in the former group.	[Kuberan, A.; Jain, K.; Makkar, J. K.] Postgrad Inst Med Educ & Res, Dept Anaesthesia & Intens Care, Chandigarh, India; [Bagga, R.] Postgrad Inst Med Educ & Res, Dept Obstet & Gynecol, Chandigarh, India	Jain, K (reprint author), Postgrad Inst Med Educ & Res, Dept Anaesthesia & Intens Care, Chandigarh, India.	kajalteji@gmail.com	Bagga, Rashmi/Y-1680-2019	Bagga, Rashmi/0000-0003-2693-2343			Abrao KC, 2009, OBSTET GYNECOL, V113, P41, DOI 10.1097/AOG.0b013e31818f5eb6; BREEN TW, 1993, ANESTH ANALG, V77, P919; Camorcia M, 2005, ANESTHESIOLOGY, V102, P646, DOI 10.1097/00000542-200503000-00025; Carvalho B, 2007, J CLIN ANESTH, V19, P476, DOI 10.1016/j.jclinane.2007.01.009; CLARKE VT, 1994, ANESTHESIOLOGY, V81, P1083, DOI 10.1097/00000542-199410000-00041; COLLIS RE, 1995, LANCET, V345, P1413, DOI 10.1016/S0140-6736(95)92602-X; Côrtes Carlos Alberto de Figueiredo, 2007, Rev. Bras. Anestesiol., V57, P39, DOI 10.1590/S0034-70942007000100005; Eberle RL, 1998, AM J OBSTET GYNECOL, V179, P150, DOI 10.1016/S0002-9378(98)70266-2; Gaiser RR, 2005, INT J OBSTET ANESTH, V14, P208, DOI 10.1016/j.ijoa.2004.12.010; Hattler J, 2016, ANESTH ANALG, V123, P955, DOI 10.1213/ANE.0000000000001412; Kartawiadi SL, 1996, REGION ANESTH, V21, P191; Landau R, 2009, OBSTET GYNECOL, V113, P1374, DOI 10.1097/AOG.0b013e3181a8909d; Loubert C, 2011, ANAESTHESIA, V66, P191, DOI 10.1111/j.1365-2044.2010.06616.x; Mardirosoff C, 2002, BJOG-INT J OBSTET GY, V109, P274, DOI 10.1016/S1470-0328(02)01380-0; Nageotte MP, 1997, NEW ENGL J MED, V337, P1715, DOI 10.1056/NEJM199712113372402; National Institute for Health and Care Excellence, 2007, INTR CAR CAR HLTH WO; Nicolet J, 2008, EUR J ANAESTH, V25, P721, DOI 10.1017/S0265021508004183; Nielsen PE, 1996, ANESTH ANALG, V83, P742, DOI 10.1097/00000539-199610000-00014; Norris MC, 2000, INT J OBSTET ANESTH, V9, P264, DOI 10.1054/ijoa.2000.0746; Palmer CM, 1999, ANESTH ANALG, V88, P577, DOI 10.1097/00000539-199903000-00021; Patel NP, 2014, ANAESTHESIA, V69, P458, DOI 10.1111/anae.12602; Rofaeel A, 2007, CAN J ANAESTH, V54, P15, DOI 10.1007/BF03021894; Segal S, 1998, ANESTH ANALG, V87, P864, DOI 10.1097/00000539-199810000-00022; STACEY RGW, 1993, BRIT J ANAESTH, V71, P499, DOI 10.1093/bja/71.4.499; Stocks GM, 2001, ANESTHESIOLOGY, V94, P593, DOI 10.1097/00000542-200104000-00011; Swini KA, 2014, ANAESTHESIA, V69, P1290, DOI 10.1111/anae.12833; Van de Velde M, 2004, ANESTH ANALG, V98, P1153, DOI 10.1213/01.ANE.0000101980.34587.66; Van de Velde M, 2000, ANESTHESIOLOGY, V92, P869, DOI 10.1097/00000542-200003000-00033; Van de Velde M, 2001, REGION ANESTH PAIN M, V26, P257, DOI 10.1053/rapm.2001.22258	29	2	2	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0003-2409	1365-2044		ANAESTHESIA	Anaesthesia	JUL	2018	73	7					832	838		10.1111/anae.14278			7	Anesthesiology	Anesthesiology	GJ0MF	WOS:000434947800007	29582422	Bronze			2020-06-30	J	Zhang, JL; Zhang, L; Zhao, X; Shen, SL; Luo, XP; Zhang, YL				Zhang, Jingliang; Zhang, Li; Zhao, Xia; Shen, Sheliang; Luo, Xiaopan; Zhang, Yunlong			Association between MDR1/CYP3A4/OPRM1 gene polymorphisms and the post-caesarean fentanyl analgesic effect on Chinese women	GENE			English	Article						Single-nucleotide polymorphism; Fentanyl; Pharmacology; Post-operative analgesia	CONVERTING ENZYME-INHIBITORS; ACUTE KIDNEY INJURY; CESAREAN-SECTION; CANCER-PATIENTS; PHARMACOKINETICS; SURGERY; PAIN; CYP3A4	Objective: Our study aimed to evaluate the association between the multidrug resistance 1 (MDR1)/cytochrome P450 3A4 (CYP3A4)/mu-opioid receptor (OPRM1) gene polymorphisms and the post-caesarean analgesic effect of fentanyl on Chinese women. Methods: We recruited 240 patients who received lower segment caesarean section surgeries. Sanger sequencing was used to analyze the MDR(1)1236C > T/CYP3A4*1G/OPRM(1)A118G polymorphisms. We evaluated post-operative fentanyl consumption and the effect of intravenous analgesia in patients with different genotypes. Results: 1. Subjects with the TT genotype at the 1236C > T polymorphism in the MORI gene consumed significantly more fentanyl than that consumed by subjects with the CC and CT genotypes in the first post-operative 24 h and 48 h (P < 0.05), and the MAP/HR/Cor/Ang-1 levels gradually increased immediately after surgery and in the first post-operative 24 h. 2. Subjects with the CYP3A4*1G/*1G genotype needed less fentanyl to achieve pain control than that needed by subjects carrying the CYP3A4*1/*1 and CYP3A4*1/*1G genotypes in the first post-operative 24 h and 48 h (P < 0.05), and the MAP/HR/Cor/Ang-1 levels gradually decreased immediately after surgery and in the first post-operative 24 h. 3. Subjects with the GG genotype at the A118G polymorphism in the OPRM1 gene consumed significantly more fentanyl than that consumed by subjects with the AA and AG genotypes in the first post-operative 24 h and 48 h (P < 0.05), and the MAP/HR/Cor/Ang-1 levels gradually increased immediately after surgery and in the first post-operative 24 h. 4. There were no significant differences in the adverse reactions to fentanyl in patients with different genotypes (P > 0.05). Conclusion: These results indicated that the MDR1/CYP3A4/OPRM1 gene polymorphisms influenced the fentanyl consumption and the physiological effects of intravenous analgesia in the Chinese women who received lower segment caesarean section surgeries. Moreover, the present study provides an important foundation and theoretical evidence for the gene-directed rationalization and individualization of medication before caesarean section surgeries.	[Zhang, Jingliang; Zhang, Li; Zhao, Xia] Yidu Cent Hosp Weifang, Dept Pain Clin, Qingzhou, Shandong, Peoples R China; [Shen, Sheliang; Luo, Xiaopan; Zhang, Yunlong] Zhejiang Prov Peoples Hosp, Hangzhou Med Coll, Peoples Hosp, Dept Anesthesiol, Hangzhou, Zhejiang, Peoples R China	Zhang, YL (reprint author), Zhejiang Prov Peoples Hosp, Hangzhou Med Coll, Peoples Hosp, Dept Anesthesiol, Hangzhou, Zhejiang, Peoples R China.	zhangyunlong@hmc.edu.cn			Health Bureau of Zhejiang Province [2017209464, 2018257012]	This project was supported by the funding from Health Bureau of Zhejiang Province (2017209464) and (2018257012).	Barratt DT, 2014, PHARMACOGENET GENOM, V24, P185, DOI 10.1097/FPC.0000000000000032; Benedetto U, 2008, ANN THORAC SURG, V86, P1160, DOI 10.1016/j.athoracsur.2008.06.018; Blanco F, 2016, PAIN PRACT, V16, P842, DOI 10.1111/papr.12343; Chen M, 2016, ANESTH ANALG, V123, P541, DOI 10.1213/01.ane.0000492815.84565.fd; Coca SG, 2013, NEPHROL DIAL TRANSPL, V28, P2787, DOI 10.1093/ndt/gft405; Cohen S, 2002, ANESTH ANALG, V94, P674, DOI 10.1097/00000539-200203000-00036; Duarte LD, 2009, EUR J CLIN PHARMACOL, V65, P803, DOI 10.1007/s00228-009-0645-4; Ebneshahidi A, 2008, J ALTERN COMPLEM MED, V14, P827, DOI 10.1089/acm.2007.0752; Elens L, 2013, PHARMACOGENOMICS, V14, P47, DOI [10.2217/PGS.12.187, 10.2217/pgs.12.187]; Elkiweri IA, 2009, ANESTH ANALG, V108, P149, DOI 10.1213/ane.0b013e31818e0bd1; Feng XL, 2012, B WORLD HEALTH ORGAN, V90, P30, DOI 10.2471/BLT.11.090399; Guo S., 2007, B WORLD HEALTH ORGAN, V85, P733; Huang Y., 2017, ENVIRON PLANN B, P1, DOI DOI 10.1109/TSMC.2017.2745419; Huang Y, 2017, INT J CLIN PHARM TH, V55, P109, DOI 10.5414/CP202559; Jie H.U., 2014, EFFECT MDR1 GENE POL, P19; Kimchi-Sarfaty C, 2007, SCIENCE, V315, P525, DOI 10.1126/science.1135308; Kozinszky Z., 2015, ACTA OBSTET GYNECOL, V81, P313; Kuip EJM, 2017, BRIT J CLIN PHARMACO, V83, P294, DOI 10.1111/bcp.13129; Li H, 2015, INT J CLIN EXP MED, V8, P14123; Lotsch J, 2002, ANESTHESIOLOGY, V97, P814; MATHER LE, 1983, CLIN PHARMACOKINET, V8, P422, DOI 10.2165/00003088-198308050-00004; Mendonca C, 2003, ANAESTHESIA, V58, P428, DOI 10.1046/j.1365-2044.2003.03090.x; Mi J, 2014, LANCET, V383, P1463, DOI 10.1016/S0140-6736(14)60716-9; Ray R, 2011, P NATL ACAD SCI USA, V108, P9268, DOI 10.1073/pnas.1018699108; Suzuki H, 2015, JA CLIN REP, V1, DOI 10.1186/s40981-015-0005-6; Yuan JJ, 2016, BMC MED GENET, V17, DOI 10.1186/s12881-016-0348-5; Zhang W, 2011, MINERVA ANESTESIOL, V77, P33; Zhang W, 2011, EUR J ANAESTH, V28, P245, DOI 10.1097/EJA.0b013e3283438b39; Zhang W, 2010, EUR J CLIN PHARMACOL, V66, P61, DOI 10.1007/s00228-009-0726-4	29	5	5	0	5	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0378-1119	1879-0038		GENE	Gene	JUN 30	2018	661						78	84		10.1016/j.gene.2018.03.081			7	Genetics & Heredity	Genetics & Heredity	GG2GH	WOS:000432507700009	29601950				2020-06-30	J	Joutsa, J; Karlsson, HK; Majuri, J; Nuutila, P; Helin, S; Kaasinen, V; Nummenmaa, L				Joutsa, Juho; Karlsson, Henry K.; Majuri, Joonas; Nuutila, Pirjo; Helin, Semi; Kaasinen, Valtteri; Nummenmaa, Lauri			Binge eating disorder and morbid obesity are associated with lowered mu-opioid receptor availability in the brain	PSYCHIATRY RESEARCH-NEUROIMAGING			English	Article						[C-11]carfentanil; Addiction; PET; MOR; Eating disorders	POSITRON-EMISSION-TOMOGRAPHY; DOPAMINE RELEASE; TEST-RETEST; IN-VIVO; BINDING; PET; CARFENTANIL; MECHANISMS; ADDICTION; BEHAVIOR	Both morbid obesity and binge eating disorder (BED) have previously been linked with aberrant brain opioid function. Behaviorally these two conditions are however different suggesting also differences in neurotransmitter function. Here we directly compared mu-opioid receptor (MOR) availability between morbidly obese and BED subjects. Seven BED and nineteen morbidly obese (non-BED) patients, and thirty matched control subjects underwent positron emission tomography (PET) with MOR-specific ligand [C-11]carfentanil. Both subjects with morbid obesity and BED had widespread reduction in [C-11]carfentanil binding compared to control subjects. However, there was no significant difference in brain MOR binding between subjects with morbid obesity and BED. Thus, our results indicate that there is common brain opioid abnormally in behaviorally different eating disorders involving obesity.	[Joutsa, Juho] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Boston, MA 02114 USA; [Joutsa, Juho] Harvard Med Sch, Boston, MA USA; [Joutsa, Juho] Beth Israel Deaconess Med Ctr, Berenson Allen Ctr Noninvas Brain Stimulat, Boston, MA 02215 USA; [Joutsa, Juho; Majuri, Joonas; Kaasinen, Valtteri] Univ Turku, Dept Neurol, Turku, Finland; [Joutsa, Juho; Karlsson, Henry K.; Majuri, Joonas; Nuutila, Pirjo; Helin, Semi; Kaasinen, Valtteri; Nummenmaa, Lauri] Univ Turku, Turku PET Ctr, Turku, Finland; [Nuutila, Pirjo] Turku Univ Hosp, Dept Endocrinol, Turku, Finland; [Joutsa, Juho; Kaasinen, Valtteri] Turku Univ Hosp, Div Clin Neurosci, Turku, Finland; [Nummenmaa, Lauri] Univ Turku, Dept Psychol, Turku, Finland	Joutsa, J (reprint author), MGH HST MIT Athinoula A Martinos Ctr Biomed Imagi, 149 13th St,Room 2301, Boston, MA 02129 USA.	jjoutsa@mgh.harvard.edu	Kaasinen, Valtteri/O-2086-2016; Nummenmaa, Lauri/G-6910-2012	Kaasinen, Valtteri/0000-0002-3446-7093; Nummenmaa, Lauri/0000-0002-2497-9757	Academy of FinlandAcademy of Finland [304385, 256836, 295580]; Finnish Medical Foundation; Finnish Alcohol Research Foundation; Turku University Hospital	The staff of Turku PET Centre is gratefully acknowledged for their invaluable practical assistance. The study was funded by the Academy of Finland (grants #304385, #256836, #295580), the Finnish Medical Foundation, the Finnish Alcohol Research Foundation and the Turku University Hospital (EVO grants).	Ashburner J, 2005, NEUROIMAGE, V26, P839, DOI 10.1016/j.neuroimage.2005.02.018; Ashburner J, 2007, NEUROIMAGE, V38, P95, DOI 10.1016/j.neuroimage.2007.07.007; Baek K, 2017, PSYCHOL MED, V47, P585, DOI 10.1017/S0033291716002646; Bencherif B, 2005, J NUCL MED, V46, P1349; Bettinardi V, 2011, MED PHYS, V38, P5394, DOI 10.1118/1.3635220; Boileau I, 2014, MOL PSYCHIATR, V19, P1305, DOI 10.1038/mp.2013.163; Burghardt PR, 2015, J CLIN ENDOCR METAB, V100, P3193, DOI 10.1210/jc.2015-1783; Clark L, 2012, NEUROIMAGE, V63, P40, DOI 10.1016/j.neuroimage.2012.06.067; Gorelick DA, 2005, BIOL PSYCHIAT, V57, P1573, DOI 10.1016/j.biopsych.2005.02.026; Gunn RN, 1997, NEUROIMAGE, V6, P279, DOI 10.1006/nimg.1997.0303; Haltia LT, 2007, SYNAPSE, V61, P748, DOI 10.1002/syn.20418; Heinz A, 2005, ARCH GEN PSYCHIAT, V62, P57, DOI 10.1001/archpsyc.62.1.57; Hermann D, 2017, NEUROPSYCHOPHARMACOL, V42, P606, DOI 10.1038/npp.2016.145; Hirvonen J, 2009, EUR J NUCL MED MOL I, V36, P275, DOI 10.1007/s00259-008-0935-6; Joutsa J, 2012, NEUROIMAGE, V60, P1992, DOI 10.1016/j.neuroimage.2012.02.006; Karjalainen T, 2016, SOC COGN AFFECT NEUR, V11, P1310, DOI 10.1093/scan/nsw044; Karlsson HK, 2015, J NEUROSCI, V35, P3959, DOI 10.1523/JNEUROSCI.4744-14.2015; Karlsson HK, 2015, MOL PSYCHIAT; Kessler RM, 2016, NEUROSCI BIOBEHAV R, V63, P223, DOI 10.1016/j.neubiorev.2016.01.013; Kessler RC, 2013, BIOL PSYCHIAT, V73, P904, DOI 10.1016/j.biopsych.2012.11.020; Kuikka JT, 2001, PSYCHOPHARMACOLOGY, V155, P310, DOI 10.1007/s002130100716; Linnet J, 2010, ACTA PSYCHIAT SCAND, V122, P326, DOI 10.1111/j.1600-0447.2010.01591.x; Majuri J., 2017, EUR NEUROPSYCHOPHARM; Majuri J, 2017, NEUROPSYCHOPHARMACOL, V42, P1169, DOI 10.1038/npp.2016.265; Mick I, 2016, NEUROPSYCHOPHARMACOL, V41, P1742, DOI 10.1038/npp.2015.340; Nogueiras R, 2012, OBESITY FACTS, V5, P196, DOI 10.1159/000338163; Palpacuer C, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001924; Pecina S, 2010, PHARMACOL BIOCHEM BE, V97, P34, DOI 10.1016/j.pbb.2010.05.016; Potenza MN, 2014, ADDICT BEHAV, V39, P1, DOI 10.1016/j.addbeh.2013.09.004; Schulte EM, 2015, CURR PSYCHIAT REP, V17, DOI 10.1007/s11920-015-0563-3; Steele KE, 2010, OBES SURG, V20, P369, DOI 10.1007/s11695-009-0015-4; Tuulari JJ, 2017, J NEUROSCI, V37, P8284, DOI 10.1523/JNEUROSCI.0976-17.2017; Val-Laillet D, 2015, NEUROIMAGE-CLIN, V8, P1, DOI 10.1016/j.nicl.2015.03.016; van Velden FHP, 2009, J NUCL MED, V50, P693, DOI 10.2967/jnumed.108.058628; Volkow ND, 2011, P NATL ACAD SCI USA, V108, P15037, DOI 10.1073/pnas.1010654108; Wang GJ, 2001, LANCET, V357, P354, DOI 10.1016/S0140-6736(00)03643-6; Yanovski S., 1999, DIAGNOSIS PREVALENCE; Ziauddeen H, 2012, NAT REV NEUROSCI, V13, P279, DOI 10.1038/nrn3212	38	6	6	1	7	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0925-4927	1872-7506		PSYCHIAT RES-NEUROIM	Psychiatry Res. Neuroimaging	JUN 30	2018	276						41	45		10.1016/j.pscychresns.2018.03.006			5	Clinical Neurology; Neuroimaging; Psychiatry	Neurosciences & Neurology; Psychiatry	GG7VW	WOS:000432907500006	29655552				2020-06-30	J	Park, SK; Yoo, S; Kim, WH; Lim, YJ; Bahk, JH; Kim, JT				Park, Sun-Kyung; Yoo, Seokha; Kim, Won Ho; Lim, Young-Jin; Bahk, Jae-Hyon; Kim, Jin-Tae			Association of nefopam use with postoperative nausea and vomiting in gynecological patients receiving prophylactic ramosetron: A retrospective study	PLOS ONE			English	Article							CONTROLLED OPIOID ANALGESIA; DOUBLE-BLIND; SAFETY; PAIN; EFFICACY; MORPHINE; SURGERY; INVOLVEMENT; MANAGEMENT; KETOROLAC	Background Postoperative nausea and vomiting (PONV) is a common adverse effect of opioid-based intravenous patient-controlled analgesia (IV PCA). Nefopam has been considered as a good candidate for inclusion in multimodal analgesia because of its opioid sparing effect, but it can be emetic. This study aims to examine whether the use of nefopam combined with fentanyl in IV PCA was associated with the higher incidence of PONV in patients receiving prophylactic ramosetron after gynecological surgery. Methods Data from 296 patients who underwent gynecological surgery were retrospectively reviewed. The patients received IV PCA containing either fentanyl 1500 mu g and ketorolac 90 mg (Group K) or fentanyl 1500 mu g and nefopam 80 mg (Group N). All patients in both groups received 0.3 mg of ramosetron at the end of surgery. The primary outcome measure was the incidence of PONV during the 3-day postoperative period. Results No difference was observed in the incidence of PONV during the 3-day postoperative period between the two groups. However, the incidence of nausea on postoperative day 2 was significantly higher in Group N (10.3%) than in Group K (2.8%) (P = 0.016). Multivariable logistic regression analysis showed that the use of nefopam was not associated with a higher incidence of PONV (adjusted odds ratio, 1.616; 95% confidence interval, 0.952-2.743, P = 0.076). There were no differences in postoperative pain scores between the two groups. Conclusion The combined use of nefopam with fentanyl in IV PCA was not associated with the higher incidence of PONV compared with the use of ketorolac and fentanyl combination in patients who received ramosetron as PONV prophylactic agent. However, prospective trials are required for a confirmative conclusion.	[Park, Sun-Kyung; Yoo, Seokha; Kim, Won Ho; Lim, Young-Jin; Bahk, Jae-Hyon; Kim, Jin-Tae] Seoul Natl Univ Hosp, Dept Anesthesiol & Pain Med, Seoul, South Korea	Kim, JT (reprint author), Seoul Natl Univ Hosp, Dept Anesthesiol & Pain Med, Seoul, South Korea.	jintae73@gmail.com	Yoo, Seokha/H-1638-2018; KIM, JIN TAE/D-5734-2012; Kim, Won Ho/S-8671-2019; Kim, Jin-Tae/T-7983-2019	Yoo, Seokha/0000-0003-4679-6027; KIM, JIN TAE/0000-0002-3738-0081; Kim, Won Ho/0000-0003-1748-1296; Kim, Jin-Tae/0000-0002-3738-0081; Bahk, Jae-Hyon/0000-0002-3082-5244			Bang YS, 2016, J ANESTH, V30, P935, DOI 10.1007/s00540-016-2249-3; BEAVER WT, 1977, J CLIN PHARMACOL, V17, P579, DOI 10.1177/009127007701701005; Choi YS, 2008, SPINE, V33, pE602, DOI 10.1097/BRS.0b013e31817c6bde; CONCATO J, 1993, ANN INTERN MED, V118, P201, DOI 10.7326/0003-4819-118-3-199302010-00009; Du Manoir B, 2003, BRIT J ANAESTH, V91, P836, DOI 10.1093/bja/aeg264; ESPOSITO E, 1986, EUR J PHARMACOL, V128, P157, DOI 10.1016/0014-2999(86)90762-4; Evans MS, 2008, BRIT J ANAESTH, V101, P610, DOI 10.1093/bja/aen267; Gan TJ, 2014, ANESTH ANALG, V118, P85, DOI 10.1213/ANE.0000000000000002; Girard P, 2016, CLIN EXP PHARMACOL P, V43, P3, DOI 10.1111/1440-1681.12506; HEEL RC, 1980, DRUGS, V19, P249, DOI 10.2165/00003495-198019040-00001; Hudcova J, 2006, COCHRANE DB SYST REV, DOI 10.1002/146518583.CD003348.pub2; HUNSKAAR S, 1987, EUR J PHARMACOL, V138, P77, DOI 10.1016/0014-2999(87)90339-6; Hwang Boo-Young, 2015, Int J Med Sci, V12, P644, DOI 10.7150/ijms.11828; Jin HS, 2016, J INT MED RES, V44, P844, DOI 10.1177/0300060516650783; Kapfer B, 2005, ANESTH ANALG, V100, P169, DOI 10.1213/01.ANE.0000138037.19757.ED; KEHLET H, 1993, ANESTH ANALG, V77, P1048; Kim K, 2014, J INT MED RES, V42, P684, DOI 10.1177/0300060514525351; Lu Kai-zhi, 2013, Int J Med Sci, V10, P1790, DOI 10.7150/ijms.5386; Mimoz O, 2001, ANAESTHESIA, V56, P520, DOI 10.1046/j.1365-2044.2001.01980.x; Moon JY, 2016, KOREAN J PAIN, V29, P110, DOI 10.3344/kjp.2016.29.2.110; Muchatuta Neil A, 2009, Ther Clin Risk Manag, V5, P21; Oh CS, 2015, CURR MED RES OPIN, V31, P1599, DOI 10.1185/03007995.2015.1058251; OHARA DA, 1987, CLIN PHARMACOL THER, V41, P556, DOI 10.1038/clpt.1987.71; Peng PWH, 1999, ANESTHESIOLOGY, V90, P576, DOI 10.1097/00000542-199902000-00034; PHILLIPS G, 1979, BRIT J ANAESTH, V51, P961, DOI 10.1093/bja/51.10.961; Rabasseda X, 2002, DRUGS TODAY, V38, P75, DOI 10.1358/dot.2002.38.2.820104; Son JS, 2017, KOREAN J ANESTHESIOL, V70, P612, DOI 10.4097/kjae.2017.70.6.612; SUNSHINE A, 1975, CLIN PHARMACOL THER, V18, P530; Walder B, 2001, ACTA ANAESTH SCAND, V45, P795, DOI 10.1034/j.1399-6576.2001.045007795.x	29	2	3	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 28	2018	13	6							e0199930	10.1371/journal.pone.0199930			11	Multidisciplinary Sciences	Science & Technology - Other Topics	GL0GK	WOS:000436645400097	29953514	DOAJ Gold, Green Published			2020-06-30	J	Eschenfeldt, PC; Kartoun, U; Heberle, CR; Kong, CY; Nishioka, NS; Ng, K; Kamarthi, S; Hur, C				Eschenfeldt, Patrick C.; Kartoun, Uri; Heberle, Curtis R.; Kong, Chung Yin; Nishioka, Norman S.; Ng, Kenney; Kamarthi, Sagar; Hur, Chin			Analysis of factors associated with extended recovery time after colonoscopy	PLOS ONE			English	Article							PATIENT; MODELS; CLASSIFICATION; PREDICTION; REGRESSION; PROPOFOL; FENTANYL	Background & aims A common limiting factor in the throughput of gastrointestinal endoscopy units is the availability of space for patients to recover post-procedure. This study sought to identify predictors of abnormally long recovery time after colonoscopy performed with procedural sedation. In clinical research, this type of study would be performed using only one regression modeling approach. A goal of this study was to apply various "machine learning" techniques to see if better prediction could be achieved. Methods Procedural data for 31,442 colonoscopies performed on 29,905 adult patients at Massachusetts General Hospital from 2011 to 2015 were analyzed to identify potential predictors of long recovery times. These data included the identities of hospital personnel, and the initial statistical analysis focused on the impact of these personnel on recovery time via multivariate logistic regression. Secondary analyses included more information on patient vitals both to identify secondary predictors and to predict long recoveries using more complex techniques. Results In univariate analysis, the endoscopist, procedure room nurse, recovery room nurse, and surgical technician all showed a statistically significant relationship to long recovery times, with p-value below 0.0001 in all cases. In the multivariate logistic regression, the most significant predictor of a long recovery time was the identity of the recovery room nurse, with the endoscopist also showing a statistically significant relationship with a weaker effect. Complex techniques led to a negligible improvement over simple techniques in prediction of long recovery periods. Conclusion The hospital personnel involved in performing a colonoscopy show a strong association with the likelihood of a patient spending an abnormally long time recovering from the procedure, with the most pronounced effect for the nurse in the recovery room. The application of more advanced approaches to improve prediction in this clinical data set only yielded modest improvements.	[Eschenfeldt, Patrick C.; Heberle, Curtis R.; Kong, Chung Yin; Hur, Chin] Massachusetts Gen Hosp, Inst Technol Assessment, Boston, MA 02114 USA; [Eschenfeldt, Patrick C.; Heberle, Curtis R.; Nishioka, Norman S.; Hur, Chin] Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA; [Eschenfeldt, Patrick C.; Kong, Chung Yin; Nishioka, Norman S.; Hur, Chin] Harvard Med Sch, Boston, MA 02115 USA; [Kartoun, Uri; Ng, Kenney] IBM Res, Ctr Computat Hlth, Cambridge, MA USA; [Kamarthi, Sagar] Northeastern Univ, Coll Engn, Boston, MA 02115 USA	Hur, C (reprint author), Massachusetts Gen Hosp, Inst Technol Assessment, Boston, MA 02114 USA.; Hur, C (reprint author), Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA.; Hur, C (reprint author), Harvard Med Sch, Boston, MA 02115 USA.	chur@mgh.harvard.edu	Jovani, Manol/AAF-5333-2020				Austin PC, 2013, J CLIN EPIDEMIOL, V66, P398, DOI 10.1016/j.jclinepi.2012.11.008; Beam AL, 2017, SCI REP-UK, V7, DOI 10.1038/srep42282; BURNS LR, 1991, MED CARE, V29, P251, DOI 10.1097/00005650-199103000-00007; Churpek MM, 2016, CRIT CARE MED, V44, P368, DOI 10.1097/CCM.0000000000001571; Dreiseitl S, 2002, J BIOMED INFORM, V35, P352, DOI 10.1016/S1532-0464(03)00034-0; Ehrenfeld JM, JOINT COMM J QUAL IM, V38, P73, DOI [10.1016/31553-7250(12)38010-0, DOI 10.1016/31553-7250(12)38010-0]; Friedman J, 2010, J STAT SOFTW, V33, P1, DOI 10.18637/jss.v033.i01; Ho WM, 2012, BMC GASTROENTEROL, V12, DOI 10.1186/1471-230X-12-164; Hothorn T, 2006, J COMPUT GRAPH STAT, V15, P651, DOI 10.1198/106186006X133933; Jonas DE, 2007, AM J GASTROENTEROL, V102, P2401, DOI 10.1111/j.1572-0241.2007.01387.x; Kuhn M, 2008, J STAT SOFTW, V28, P1, DOI 10.18637/jss.v028.i05; Lazaraki G, 2007, SURG ENDOSC, V21, P1631, DOI 10.1007/s00464-007-9215-y; Liaw A., 2002, R NEWS, V2, P18, DOI DOI 10.1177/154405910408300516; Lin CC, 2010, INJURY, V41, P869, DOI 10.1016/j.injury.2010.04.023; Meyer David, 2017, E1071 MISC FUNCTIONS; R Core Team, 2017, R LANG ENV STAT COMP; Ripley B., 2016, TREE CLASSIFICATION; Sipe BW, 2002, GASTROINTEST ENDOSC, V55, P815, DOI 10.1067/mge.2002.124636; Tambuyzer T, 2017, J CLIN MONIT COMPUT, V31, P407, DOI 10.1007/s10877-016-9870-4; Therneau T, 2017, RPART RECURSIVE PART; Tsugawa Y, 2017, BMJ-BRIT MED J, V357, DOI 10.1136/bmj.j1797; Veelo DP, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172806; Venables W. N., 2002, MODERN APPL STAT S; Wanderer JP, 2013, ANESTHESIOLOGY, V119, P516, DOI 10.1097/ALN.0b013e31829ce8fd; Wanderer JP, 2013, ANESTH ANALG, V117, P494, DOI 10.1213/ANE.0b013e318294fb64; Wu JL, 2010, MED CARE, V48, pS106, DOI 10.1097/MLR.0b013e3181de9e17; Zou H, 2006, J AM STAT ASSOC, V101, P1418, DOI 10.1198/016214506000000735	27	1	1	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 21	2018	13	6							e0199246	10.1371/journal.pone.0199246			16	Multidisciplinary Sciences	Science & Technology - Other Topics	GK0LV	WOS:000435802500062	29927978	DOAJ Gold, Green Published			2020-06-30	J	Broxterman, RM; Hureau, TJ; Layec, G; Morgan, DE; Bledsoe, AD; Jessop, JE; Amann, M; Richardson, RS				Broxterman, Ryan M.; Hureau, Thomas J.; Layec, Gwenael; Morgan, David E.; Bledsoe, Amber D.; Jessop, Jacob E.; Amann, Markus; Richardson, Russell S.			Influence of group III/IV muscle afferents on small muscle mass exercise performance: a bioenergetics perspective	JOURNAL OF PHYSIOLOGY-LONDON			English	Article						magnetic resonance spectroscopy; intrathecal fentanyl; muscle metabolism	HUMAN SKELETAL-MUSCLE; MAGNETIC-RESONANCE-SPECTROSCOPY; POWER-DURATION RELATIONSHIP; PROMOTE CENTRAL FATIGUE; BLOOD-FLOW OCCLUSION; IN-VIVO; METABOLIC-RESPONSES; ALL-OUT; VOLUNTARY CONTRACTIONS; ENDURANCE EXERCISE	The direct influence of group III/IV muscle afferents on exercise performance remains equivocal. Therefore, all-out intermittent isometric single-leg knee-extensor exercise and phosphorous magnetic resonance spectroscopy (P-31-MRS) were utilized to provide a high time resolution assessment of exercise performance and skeletal muscle bioenergetics in control conditions (CTRL) and with the attenuation of group III/IV muscle afferent feedback via lumbar intrathecal fentanyl (FENT). In both conditions, seven recreationally active men performed 60 maximal voluntary quadriceps contractions (MVC; 3s contraction, 2s relaxation), while knee-extensor force and P-31-MRS were assessed during each MVC. The cumulative integrated force was significantly greater (8 +/- 6%) in FENT than CTRL for the first minute of the all-out protocol, but was not significantly different for the second to fifth minutes. Total ATP production was significantly greater (16 +/- 21%) in FENT than CTRL throughout the all-out exercise protocol, due to a significantly greater anaerobic ATP production (11 +/- 13%) in FENT than CTRL with no significant difference in oxidative ATP production. The ATP cost of contraction was not significantly different between FENT and CTRL for the first minute of the all-out protocol, but was significantly greater (29 +/- 34%) in FENT than in CTRL for the second to fifth minutes. These findings reveal that group III/IV muscle afferents directly limit exercise performance during small muscle mass exercise, but, due to their critical role in maintaining skeletal muscle contractile efficiency, with time, the benefit from muscle afferent attenuation is negated.	[Broxterman, Ryan M.; Hureau, Thomas J.; Amann, Markus; Richardson, Russell S.] Geriatr Res Educ & Clin Ctr, Salt Lake City, UT USA; [Broxterman, Ryan M.; Hureau, Thomas J.; Layec, Gwenael; Amann, Markus; Richardson, Russell S.] Univ Utah, Dept Internal Med, Salt Lake City, UT 84112 USA; [Layec, Gwenael; Amann, Markus; Richardson, Russell S.] Univ Utah, Ctr Aging, Salt Lake City, UT USA; [Morgan, David E.; Bledsoe, Amber D.; Jessop, Jacob E.; Amann, Markus] Univ Utah, Dept Anesthesiol, Salt Lake City, UT USA; [Amann, Markus; Richardson, Russell S.] Univ Utah, Dept Nutr & Integrat Physiol, Salt Lake City, UT USA	Broxterman, RM (reprint author), VA Med Ctr, 500 Foothill Dr,GRECC 182, Salt Lake City, UT USA.	ryan.broxterman@utah.edu	Broxterman, Ryan/AAH-9569-2020; Hureau, Thomas J/I-2711-2019	Amann, Markus/0000-0002-4012-8880	NIH Heart, Lung, and Blood InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [HL-103786, HL-116579, HL-091830, K99HL125756]; Veterans Affairs Rehabilitation Research and Development Merit [E6910-R, E1697-R]; Spire [E1572-P, E1433-P]; Senior Research Career Scientist awards [E9275-L]; Flight Attendant Medical Research Institute [YFEL141011]	This study was supported by NIH Heart, Lung, and Blood Institute grants (HL-103786, HL-116579, HL-091830 and K99HL125756), Veterans Affairs Rehabilitation Research and Development Merit (E6910-R and E1697-R), Spire (E1572-P and E1433-P), Senior Research Career Scientist (E9275-L) awards, and the Flight Attendant Medical Research Institute (YFEL141011).	Amann M, 2008, J APPL PHYSIOL, V104, P861, DOI 10.1152/japplphysiol.01008.2007; Amann M, 2013, J APPL PHYSIOL, V115, P355, DOI 10.1152/japplphysiol.00049.2013; Amann M, 2011, J PHYSIOL-LONDON, V589, P5299, DOI 10.1113/jphysiol.2011.213769; Amann M, 2011, J PHYSIOL-LONDON, V589, P3855, DOI 10.1113/jphysiol.2011.209353; Amann M, 2009, J PHYSIOL-LONDON, V587, P271, DOI 10.1113/jphysiol.2008.163303; Bawa P, 2009, J NEUROPHYSIOL, V102, P2265, DOI 10.1152/jn.00278.2009; BIGLANDRITCHIE BR, 1986, J PHYSIOL-LONDON, V379, P451, DOI 10.1113/jphysiol.1986.sp016263; Blain GM, 2016, J PHYSIOL-LONDON, V594, P5303, DOI 10.1113/JP272283; Borg G, 1998, BORGS PERCEIVED EXER; Broxterman RM, 2015, J PHYSIOL-LONDON, V593, P4043, DOI 10.1113/JP270424; Broxterman RM, 2015, J APPL PHYSIOL, V118, P880, DOI 10.1152/japplphysiol.00875.2014; Broxterman RM, 2014, RESP PHYSIOL NEUROBI, V192, P102, DOI 10.1016/j.resp.2013.11.010; Broxterman RM, 2017, MED SCI SPORT EXER, V49, P2404, DOI 10.1249/MSS.0000000000001391; Broxterman RM, 2017, J APPL PHYSIOL, V122, P1208, DOI 10.1152/japplphysiol.01093.2016; Burnley M, 2010, EXP PHYSIOL, V95, P798, DOI 10.1113/expphysiol.2010.052688; Burnley M, 2009, J APPL PHYSIOL, V106, P975, DOI 10.1152/japplphysiol.91474.2008; Chidnok W, 2013, J APPL PHYSIOL, V115, P243, DOI 10.1152/japplphysiol.00334.2013; Chilibeck PD, 1998, EUR J APPL PHYSIOL O, V78, P460, DOI 10.1007/s004210050446; Conley KE, 1997, AM J PHYSIOL-CELL PH, V273, pC306; Conley KE, 1998, J PHYSIOL-LONDON, V511, P935, DOI 10.1111/j.1469-7793.1998.935bg.x; Copp SW, 2010, J PHYSIOL-LONDON, V588, P5077, DOI 10.1113/jphysiol.2010.198382; Dekerle J, 2012, EUR J APPL PHYSIOL, V112, P327, DOI 10.1007/s00421-011-1979-z; Enoka RM, 2008, J PHYSIOL-LONDON, V586, P11, DOI 10.1113/jphysiol.2007.139477; GARLAND SJ, 1990, J PHYSIOL-LONDON, V429, P17, DOI 10.1113/jphysiol.1990.sp018241; GOLDING EM, 1995, J EXP BIOL, V198, P1775; Grant GJ, 1996, J CLIN ANESTH, V8, P99, DOI 10.1016/0952-8180(95)00174-3; HARRIS RC, 1974, SCAND J CLIN LAB INV, V33, P109; Haseler LJ, 1999, J APPL PHYSIOL, V86, P2013; Haseler LJ, 2007, AM J PHYSIOL-REG I, V293, pR2046, DOI 10.1152/ajpregu.00039.2007; HAYWARD L, 1991, J NEUROPHYSIOL, V65, P360; Hill AV, 1923, Q J MED, V16, P135, DOI 10.1093/qjmed/os-16.62.135; Hill AV, 1925, NATURE, V116, P544, DOI 10.1038/116544a0; Hilty L, 2011, EXP PHYSIOL, V96, P505, DOI 10.1113/expphysiol.2010.056226; HOCHACHKA PW, 1983, SCIENCE, V219, P1391, DOI 10.1126/science.6298937; Hogan MC, 1999, J APPL PHYSIOL, V86, P1367; Hureau TJ, 2016, J PHYSIOL-LONDON, V594, P7165, DOI 10.1113/JP273333; JENESON JAL, 1995, AM J PHYSIOL-CELL PH, V268, pC1474; Jeneson JAL, 1996, J BIOL CHEM, V271, P27995, DOI 10.1074/jbc.271.45.27995; Jones AM, 2008, AM J PHYSIOL-REG I, V294, pR585, DOI 10.1152/ajpregu.00731.2007; Kemp GJ, 1997, EUR J APPL PHYSIOL O, V76, P462, DOI 10.1007/s004210050276; KEMP GJ, 1994, MAGN RESON QUART, V10, P43; KEMP GJ, 1993, NMR BIOMED, V6, P73, DOI 10.1002/nbm.1940060112; Kemp GJ, 2001, J PHYSIOL-LONDON, V535, P901, DOI 10.1111/j.1469-7793.2001.00901.x; Kennedy DS, 2013, J PHYSIOL-LONDON, V591, P3591, DOI 10.1113/jphysiol.2012.248559; Kushmerick MJ, 1997, AM J PHYSIOL-CELL PH, V272, pC1739; Lanza IR, 2006, J PHYSIOL-LONDON, V577, P353, DOI 10.1113/jphysiol.2006.114249; Layec G, 2008, MAGN RESON MATER PHY, V21, P227, DOI 10.1007/s10334-008-0117-3; Layec G, 2013, J APPL PHYSIOL, V115, P803, DOI 10.1152/japplphysiol.00257.2013; LESFUR Y, 2010, MAGMA, V23, P23; Lind AR, 1979, J PHYSL, V288, P526; MARSH GD, 1991, J APPL PHYSIOL, V71, P1076; Martin PG, 2008, J PHYSIOL-LONDON, V586, P1277, DOI 10.1113/jphysiol.2007.140426; MCCARTNEY N, 1983, J APPL PHYSIOL, V55, P218; MONOD H, 1965, ERGONOMICS, V8, P329, DOI 10.1080/00140136508930810; MORITANI T, 1981, ERGONOMICS, V24, P339, DOI 10.1080/00140138108924856; POOLE DC, 1988, ERGONOMICS, V31, P1265, DOI 10.1080/00140138808966766; Rossi A, 2003, CLIN NEUROPHYSIOL, V114, P279, DOI 10.1016/S1388-2457(02)00334-6; SARGEANT AJ, 1981, J APPL PHYSIOL, V51, P1175; Sidhu SK, 2017, CLIN NEUROPHYSIOL, V128, P44, DOI 10.1016/j.clinph.2016.10.008; Sidhu SK, 2015, AM J PHYSIOL-HEART C, V309, pH1479, DOI 10.1152/ajpheart.00433.2015; Sidhu SK, 2014, J PHYSIOL-LONDON, V592, P5011, DOI 10.1113/jphysiol.2014.275438; Standl TG, 2001, ANESTHESIOLOGY, V94, P230, DOI 10.1097/00000542-200102000-00011; Trenell MI, 2006, MUSCLE NERVE, V33, P524, DOI 10.1002/mus.20484; Vanhamme L, 1997, J MAGN RESON, V129, P35, DOI 10.1006/jmre.1997.1244; Vanhatalo A, 2016, J PHYSIOL-LONDON, V594, P4407, DOI 10.1113/JP271879; Vanhatalo A, 2011, AM J PHYSIOL-REG I, V300, pR700, DOI 10.1152/ajpregu.00761.2010; Vanhatalo A, 2010, EXP PHYSIOL, V95, P528, DOI 10.1113/expphysiol.2009.050500; Wigmore DM, 2006, EUR J APPL PHYSIOL, V96, P370, DOI 10.1007/s00421-005-0037-0; Wigmore DM, 2004, J APPL PHYSIOL, V97, P2385, DOI 10.1152/japplphysiol.01390.2003; Wilson LB, 1997, BRAIN RES REV, V23, P196, DOI 10.1016/S0165-0173(96)00019-7	70	10	10	2	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3751	1469-7793		J PHYSIOL-LONDON	J. Physiol.-London	JUN 15	2018	596	12					2301	2314		10.1113/JP275817			14	Neurosciences; Physiology	Neurosciences & Neurology; Physiology	GJ4AG	WOS:000435286000008	29644702	Bronze, Green Published			2020-06-30	J	Liang, XN; Yong, Z; Su, RB				Liang, Xiaonan; Yong, Zheng; Su, Ruibin			Inhibition of protein kinase A and GIRK channel reverses fentanyl-induced respiratory depression	NEUROSCIENCE LETTERS			English	Article						cAMP; Protein kinase A; Respiratory network; Fentanyl; GIRK	PRE-BOTZINGER COMPLEX; RHYTHM; EPAC; MODULATION; OPIOIDS; ROLES	Opioid-induced respiratory depression is a major obstacle to improving the clinical management of moderate to severe chronic pain. Opioids inhibit neuronal activity via various pathways, including calcium channels, adenylyl cyclase, and potassium channels. Currently, the underlying molecular pathway of opioid-induced respiratory depression is only partially understood. This study aimed to investigate the mechanisms of opioid-induced respiratory depression in vivo by examining the effects of different pharmacological agents on fentanyl-induced respiratory depression. Respiratory parameters were detected using whole body plethysmography in conscious rats. We show that pre-treatment with the protein kinase A (PKA) inhibitor H89 reversed the fentanyl-related effects on respiratory rate, inspiratory time, and expiratory time. Pre-treatment with the G protein-gated inwardly rectifying potassium (GIRK) channel blocker Tertiapin-Q dose-dependently reversed the fentanyl-related effects on respiratory rate and inspiratory time. A phosphodiesterase 4 (PDE4) inhibitor and cyclic adenosine monophosphate (cAMP) analogs did not affect fentanyl-induced respiratory depression. These findings suggest that PKA and GIRK may be involved in fentanyl-induced respiratory depression and could represent useful therapeutic targets for the treatment of fentanyl-induced ventilatory depression.	[Liang, Xiaonan; Yong, Zheng; Su, Ruibin] Beijing Inst Pharmacol & Toxicol, State Key Lab Toxicol & Med Countermeasures, Beijing Key Lab Neuropsychopharmacol, 27 Taiping Rd, Beijing 100850, Peoples R China	Yong, Z; Su, RB (reprint author), Beijing Inst Pharmacol & Toxicol, State Key Lab Toxicol & Med Countermeasures, Beijing Key Lab Neuropsychopharmacol, 27 Taiping Rd, Beijing 100850, Peoples R China.	yongzhabc@126.com; ruibinsu@126.com			Technology Major Project of China [2015ZX09501003]	This study was supported by the Technology Major Project of China (2015ZX09501003).	Al-Hasani R, 2011, ANESTHESIOLOGY, V115, P1363, DOI 10.1097/ALN.0b013e318238bba6; Bacallao K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082354; Burke PGR, 2013, EUR J NEUROSCI, V38, P2260, DOI 10.1111/ejn.12230; Dahan Albert, 2007, J Pain Palliat Care Pharmacother, V21, P63, DOI 10.1300/J354v21n01_15; Dahan A, 2010, ANESTHESIOLOGY, V112, P226, DOI 10.1097/ALN.0b013e3181c38c25; Efetova M, 2013, J CELL SCI, V126, P778, DOI 10.1242/jcs.114140; Fala Loretta, 2015, Am Health Drug Benefits, V8, pS51; Feldman JL, 2013, ANNU REV PHYSIOL, V75, P423, DOI 10.1146/annurev-physiol-040510-130049; Feldman JL, 2006, NAT REV NEUROSCI, V7, P232, DOI 10.1038/nrn1871; Gloerich M, 2010, ANNU REV PHARMACOL, V50, P355, DOI 10.1146/annurev.pharmtox.010909.105714; Grandoch M, 2010, BRIT J PHARMACOL, V159, P265, DOI 10.1111/j.1476-5381.2009.00458.x; Kimura S, 2014, EUR J PHARMACOL, V725, P87, DOI 10.1016/j.ejphar.2013.08.007; Kuo A, 2015, BRIT J PHARMACOL, V172, P532, DOI 10.1111/bph.12696; Lalley PM, 2008, RESP PHYSIOL NEUROBI, V164, P160, DOI 10.1016/j.resp.2008.02.004; Lalley PM, 1997, J NEUROPHYSIOL, V77, P1119; Lalley PM, 2004, RESP PHYSIOL NEUROBI, V139, P247, DOI 10.1016/j.resp.2003.10.007; Luscher C, 2010, NAT REV NEUROSCI, V11, P301, DOI 10.1038/nrn2834; Manglik A, 2016, NATURE, V537, P185, DOI 10.1038/nature19112; Manzke T, 2003, SCIENCE, V301, P226, DOI 10.1126/science.1084674; Manzke T, 2009, PHILOS T R SOC B, V364, P2589, DOI 10.1098/rstb.2009.0068; Montandon G, 2016, ANESTHESIOLOGY, V124, P641, DOI 10.1097/ALN.0000000000000984; Montandon G, 2011, J NEUROSCI, V31, P1292, DOI 10.1523/JNEUROSCI.4611-10.2011; Pattinson KTS, 2008, BRIT J ANAESTH, V100, P747, DOI 10.1093/bja/aen094; Ren J, 2009, ANESTHESIOLOGY, V110, P1364, DOI 10.1097/ALN.0b013e31819faa2a; Richter DW, 2000, NEUROSCIENTIST, V6, P181, DOI 10.1177/107385840000600309; Ruangkittisakul A, 2010, RESP PHYSIOL NEUROBI, V172, P94, DOI 10.1016/j.resp.2010.04.025; Schmid CL, 2017, CELL, V171, P1165, DOI 10.1016/j.cell.2017.10.035; SMITH JC, 1991, SCIENCE, V254, P726, DOI 10.1126/science.1683005; Smith JC, 2013, TRENDS NEUROSCI, V36, P152, DOI 10.1016/j.tins.2012.11.004; Solomon IC, 1999, J NEUROPHYSIOL, V81, P1150; Stanley TH, 2014, J PAIN, V15, P1215, DOI 10.1016/j.jpain.2014.08.010; Swarm RA, 2001, CURR PROB SURG, V38, P845, DOI 10.1067/msg.20011.118495; van der Schier Rutger, 2014, F1000Prime Rep, V6, P79, DOI 10.12703/P6-79; Zollner C., 2006, OPIOIDS HANDB EXP PH, V59, P31	34	2	2	0	13	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	JUN 11	2018	677						14	18		10.1016/j.neulet.2018.04.029			5	Neurosciences	Neurosciences & Neurology	GK5MW	WOS:000436220200003	29679681				2020-06-30	J	Kuip, EJM; Oldenmenger, WH; Thijs-Visser, MF; de Bruijn, P; Oosten, AW; Oomen-de Hoop, E; Koolen, SLW; Van der Rijt, CCD; Mathijssen, RHJ				Kuip, Evelien J. M.; Oldenmenger, Wendy H.; Thijs-Visser, Martine F.; de Bruijn, Peter; Oosten, Astrid W.; Oomen-de Hoop, Esther; Koolen, Stijn L. W.; Van der Rijt, Carin C. D.; Mathijssen, Ron H. J.			Effects of smoking and body mass index on the exposure of fentanyl in patients with cancer	PLOS ONE			English	Article							TRANSDERMAL FENTANYL; PHARMACOKINETIC INTERACTION; PAIN; VARIABILITY; ANALGESIA; EFFICACY; MORPHINE; OPIOIDS; FOCUS	The transdermal fentanyl patch is widely used to treat cancer-related pain despite its wide inter-and intrapatient variability in pharmacokinetics. The aim of this study was to investigate whether smoking and body size (i.e. body mass index) influence fentanyl exposure in patients with cancer. These are factors that typically change during treatment and disease trajectories. We performed an explorative cohort study in patients with cancer using transdermal fentanyl patches (Durogesic (R)), by taking a blood sample for pharmacokinetic analysis one day after applying a patch in patients with a stable fentanyl dose. A total of 88 patients were evaluable. Although no statistically significant difference was found, the plasma concentrations of non-smokers was 28% (95% CI [-14%; +89-%]) higher than those of smokers normalizing for a dose of 25 mu g/min. Patients with a low BMI (<20 kg/m2) had almost similar (10% (95% CI [-39%; +97%]) higher) plasma concentrations compared to patients with a high BMI (>25 kg/m2). A wider variation in fentanyl plasma concentrations was found in this study than anticipated. Due to this variation, studies in larger patient cohorts are needed to further investigate the effect of smoking on plasma concentration of fentanyl and thereby clarify the clinical significance of our findings.	[Kuip, Evelien J. M.; Oldenmenger, Wendy H.; Thijs-Visser, Martine F.; de Bruijn, Peter; Oosten, Astrid W.; Oomen-de Hoop, Esther; Koolen, Stijn L. W.; Van der Rijt, Carin C. D.; Mathijssen, Ron H. J.] Erasmus MC Canc Inst, Dept Med Oncol, Rotterdam, Netherlands; [Kuip, Evelien J. M.] Radboud Univ Nijmegen, Med Ctr, Dept Med Oncol, Nijmegen, Netherlands; [Kuip, Evelien J. M.] Radboud Univ Nijmegen, Med Ctr, Dept Anesthesiol Pain & Palliat Care, Nijmegen, Netherlands; [Van der Rijt, Carin C. D.] Netherlands Comprehens Canc Org, Utrecht, Netherlands	Kuip, EJM (reprint author), Erasmus MC Canc Inst, Dept Med Oncol, Rotterdam, Netherlands.; Kuip, EJM (reprint author), Radboud Univ Nijmegen, Med Ctr, Dept Med Oncol, Nijmegen, Netherlands.; Kuip, EJM (reprint author), Radboud Univ Nijmegen, Med Ctr, Dept Anesthesiol Pain & Palliat Care, Nijmegen, Netherlands.	Evelien.Kuip@radboudumc.nl			Nuts/Ohra Foundation [1104-0203]	No sources of funding were used in the preparation of this manuscript. This study was financially supported by Nuts/Ohra Foundation grant 1104-0203. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Blume-Peytavi U, 2016, GERONTOLOGIST, V56, pS230, DOI 10.1093/geront/gnw003; Boston Collaborative Drug Surveillance Program Boston University Medical Center, 1973, N Engl J Med, V288, P277; Caraceni A, 1999, PAIN, V82, P263, DOI 10.1016/S0304-3959(99)00073-1; Clark AJ, 2004, CURR MED RES OPIN, V20, P1419, DOI 10.1185/030079904X2114; Davis MP, 2011, EXPERT REV NEUROTHER, V11, P1197, DOI [10.1586/ERN.11.63, 10.1586/ern.11.63]; de Graan AJM, 2012, CLIN CANCER RES, V18, P4425, DOI 10.1158/1078-0432.CCR-12-0728; Desai HD, 2001, CNS DRUGS, V15, P469, DOI 10.2165/00023210-200115060-00005; Grond S, 1997, PAIN, V69, P191, DOI 10.1016/S0304-3959(96)03254-X; Grond S, 2000, CLIN PHARMACOKINET, V38, P59, DOI 10.2165/00003088-200038010-00004; Hamilton M, 2006, CLIN CANCER RES, V12, P2166, DOI 10.1158/1078-0432.CCR-05-2235; Heiskanen T, 2009, PAIN, V144, P218, DOI 10.1016/j.pain.2009.04.012; HOLLEY FO, 1988, BRIT J ANAESTH, V60, P608, DOI 10.1093/bja/60.6.608; Jeal W, 1997, DRUGS, V53, P109, DOI 10.2165/00003495-199753010-00011; Kharasch ED, 2004, ANESTHESIOLOGY, V101, P729, DOI 10.1097/00000542-200409000-00022; Kokubun Hideya, 2012, J Pain Palliat Care Pharmacother, V26, P98, DOI 10.3109/15360288.2012.679725; Kuip EJM, 2017, BRIT J CLIN PHARMACO, V83, P294, DOI 10.1111/bcp.13129; Lahmann C, 2001, LANCET, V357, P935, DOI 10.1016/S0140-6736(00)04220-3; Lewis LD, 2012, CLIN CANCER RES, V18, P4219, DOI 10.1158/1078-0432.CCR-12-1713; Martires KJ, 2009, ARCH DERMATOL, V145, P1375, DOI 10.1001/archdermatol.2009.303; Nomura M, 2013, CLIN J PAIN, V29, P487, DOI 10.1097/AJP.0b013e318266f6a5; Oosten AW, 2015, J PAIN, V16, P935, DOI 10.1016/j.jpain.2015.05.006; Simon Steven M, 2014, J Opioid Manag, V10, P207, DOI 10.5055/jom.2014.0209; Solassol I, 2005, ONCOL REP, V14, P1029; Tassinari D, 2008, J PALLIAT MED, V11, P492, DOI 10.1089/jpm.2007.0200; van der Bol JM, 2007, J CLIN ONCOL, V25, P2719, DOI 10.1200/JCO.2006.09.6115; Wrighton SA, 1996, J PHARMACOKINET BIOP, V24, P461, DOI 10.1007/BF02353474; ZECH DFJ, 1992, PAIN, V50, P293, DOI 10.1016/0304-3959(92)90034-9; Zevin S, 1999, CLIN PHARMACOKINET, V36, P425, DOI 10.2165/00003088-199936060-00004; Ziesenitz VC, 2015, J CLIN PHARMACOL, V55, P708, DOI 10.1002/jcph.469	29	0	0	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 8	2018	13	6							e0198289	10.1371/journal.pone.0198289			10	Multidisciplinary Sciences	Science & Technology - Other Topics	GI7ZT	WOS:000434728100015	29883454	DOAJ Gold, Green Published			2020-06-30	J	Rahimzadeh, P; Faiz, SHR; Imani, F; Derakhshan, P; Amniati, S				Rahimzadeh, Poupak; Faiz, Seyed Hamid Reza; Imani, Farnad; Derakhshan, Pooya; Amniati, Saeed			Comparative addition of dexmedetomidine and fentanyl to intrathecal bupivacaine in orthopedic procedure in lower limbs	BMC ANESTHESIOLOGY			English	Article						Lower limb surgery; Dexmedetomidine; Fentanyl; Intrathecal; Pain management	SPINAL-ANESTHESIA; MU-G; CLONIDINE; BLOCK	Background: Spinal block is a common procedure for lower limbs surgery. Fentanyl, a synthetic opioid and dexmedetomidine, a selective a2 agonist have been used as adjuvants in spinal anesthesia to prolong intraoperative and postoperative analgesia. The aim of current study is to compare the efficacy of dexmedetomidine and fentanyl added to intrathecal bupivacaine in orthopedic procedures in lower limbs. Methods: In this randomized clinical trial, 90 patients undergoing elective lower limb surgeries were randomly allocated to three groups. Via intrathecal approach, the patients received 2.5 ml hyperbaric bupivacaine 0.5% plus 5 micrograms dexmedetomidine (BD group), 25 micrograms fentanyl (BF group) or 0.5 ml normal saline (BN group), respectively. Time to reach the complete motor block, the highest sensory level, regression from block, analgesic request and duration of the drug effect, hemodynamic changes and side effects were compared between the groups. Results: There was no significant difference between the groups regrading time to reach complete motor block, but time to reach the highest sensory level was shorter in group BD than group BF (6.28 +/- 1.75 vs. 7.17 +/- 1.45, p = 0.03). Group BD had significantly lower mean of NRS 6 h after operation (1.90 +/- 0.84 vs. 6.16 +/- 1.44 vs. 6.30 +/- 1.17, p < 0.001) and longer duration to regress to Bromage 0 (331.60 +/- 73.96 vs. 185.56 +/- 35.87 vs. 147.03 +/- 33.05 min, p < 0.001), to analgesic request (496.63 +/- 70.19 vs. 296.33 +/- 44.83 vs. 221.83 +/- 22.26 min, p < 0.001), to regress two sensory levels (149.00 +/- 23.17 vs. 88.90 +/- 12.85 vs. 69.33 +/- 6.67 min, p < 0.001) and to regress to S1 (560.53 +/- 81.86 vs. 329.83 +/- 44.10 vs. 241.83 +/- 22.26 min, p < 0.001). Serial changes in SBP (p = 0.006), DBP (p = 0.03) and HR (p = 0.002) in group BF were significantly higher than the other two groups. The three groups had comparable side effects. Conclusions: Using dexmedetomidine as an adjuvant to bupivacaine for spinal anesthesia in lower limb surgeries has longer duration of sensory and motor block and longer postoperative analgesia.	[Rahimzadeh, Poupak; Imani, Farnad] Iran Univ Med Sci, Pain Res Ctr, Tehran, Iran; [Faiz, Seyed Hamid Reza] Iran Univ Med Sci, Rasoul E Akram Clin Res Dev Ctr, Tehran, Iran; [Derakhshan, Pooya; Amniati, Saeed] Iran Univ Med Sci, Rasoul E Akram Med Complex, Tehran, Iran	Faiz, SHR (reprint author), Iran Univ Med Sci, Rasoul E Akram Clin Res Dev Ctr, Tehran, Iran.	hrfaiz@hotmail.com	faiz, seyed hamid reza/P-2089-2018; Imani, Farnad/D-9810-2016; rahimzadeh, poupak/P-2904-2018	faiz, seyed hamid reza/0000-0001-7925-0878; Imani, Farnad/0000-0003-0814-0772; rahimzadeh, poupak/0000-0002-9042-3925			Al-Ghanem SM, 2009, AM J APPL SCI, V6, P882, DOI DOI 10.3844/AJASSP.2009.882.887; Al-Mustafa MM, 2009, SAUDI MED J, V30, P365; Bekker A, 2008, ANESTH ANALG, V107, P1340, DOI 10.1213/ane.0b013e3181804298; Boussofara M, 2006, REGION ANESTH PAIN M, V31, P501, DOI 10.1016/j.rapm.2006.05.013; Elia N, 2008, REGION ANESTH PAIN M, V33, P159, DOI 10.1016/j.rapm.2007.10.008; Faiz SHR, 2012, J RES MED SCI, V17, P918; Farooq N, 2017, RANDOMIZED STUDY ANE, V11, P730; Gupta M, 2016, PAIN PHYSICIAN, V19, pE411; Gupta Rajni, 2011, J Anaesthesiol Clin Pharmacol, V27, P339, DOI 10.4103/0970-9185.83678; Ibrahim F A, 2009, BENHA M J, V26, P207; Kanazi GE, 2006, ACTA ANAESTH SCAND, V50, P222, DOI 10.1111/j.1399-6576.2006.00919.x; Khan Aamir Laique, 2015, Anesth Essays Res, V9, P139, DOI 10.4103/0259-1162.156284; Liu SS, 2001, ANESTHESIOLOGY, V94, P888, DOI 10.1097/00000542-200105000-00030; Machin D., 2011, SAMPLE SIZE TABLES C; Mahendru Vidhi, 2013, J Anaesthesiol Clin Pharmacol, V29, P496, DOI 10.4103/0970-9185.119151; Mohamed Taznim, 2017, Anesth Essays Res, V11, P681, DOI 10.4103/aer.AER_243_16; Niu XY, 2013, CNS NEUROSCI THER, V19, P897, DOI 10.1111/cns.12172; Panzer O, 2009, CRIT CARE CLIN, V25, P451, DOI 10.1016/j.ccc.2009.04.004; POST C, 1987, ANESTH ANALG, V66, P317; Ravipati Prabhavathi, 2017, Anesth Essays Res, V11, P621, DOI 10.4103/0259-1162.206857; Saadalla Ayman Eskander T, 2017, Anesth Essays Res, V11, P554, DOI 10.4103/aer.AER_210_16; Shah A, 2013, INT J BASIC CLIN PHA, V2, P26; Sudheesh K, 2011, INDIAN J ANAESTH, V55, P323, DOI 10.4103/0019-5049.84824; Yektas A, 2014, PAIN RES MANAG, V19, P75, DOI 10.1155/2014/956825	24	5	5	0	1	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1471-2253			BMC ANESTHESIOL	BMC Anesthesiol.	JUN 6	2018	18								62	10.1186/s12871-018-0531-7			7	Anesthesiology	Anesthesiology	GI3YM	WOS:000434308000001	29875020	DOAJ Gold, Green Published			2020-06-30	J	Hwang, CS; Smith, LC; Natori, Y; Ellis, B; Zhou, B; Janda, KD				Hwang, Candy S.; Smith, Lauren C.; Natori, Yoshihiro; Ellis, Beverly; Zhou, Bin; Janda, Kim D.			Efficacious Vaccine against Heroin Contaminated with Fentanyl	ACS CHEMICAL NEUROSCIENCE			English	Article						Overdose; heroin; fentanyl; vaccine; hapten	OPIOIDS; BRAIN; OVERDOSE; MORPHINE; BLOOD	The sharp increase in overdose deaths involving illicit opioid use has been declared a national crisis in the United States. This growing number of overdose deaths can in part be attributed to the increased frequency of fentanyl contamination in the United States heroin supply. To combat this growing trend, we designed a vaccine containing a mixture of heroin and fentanyl hapten-conjugates as a proof-of-concept immunotherapy targeting a combination of these drugs. Rodents immunized with the admixture vaccine showed drug retention in serum and reduced distribution in the brain after administration of an intravenous bolus of heroin coadministered with fentanyl (10% w/w). Moreover, the admixture vaccine performed as well as or better than individual immunoconjugate vaccines in antinociception behavioral models and recognized six other fentanyl analogues with nanomolar affinity. Taken together, these data highlight the potential of an admixture vaccine against heroin contaminated with fentanyl.	[Janda, Kim D.] Scripps Res Inst, Skaggs Inst Chem Biol, Dept Chem, La Jolla, CA 92037 USA; Scripps Res Inst, Skaggs Inst Chem Biol, Dept Immunol, La Jolla, CA 92037 USA; Scripps Res Inst, Skaggs Inst Chem Biol, Dept Microbial Sci, La Jolla, CA 92037 USA	Janda, KD (reprint author), Scripps Res Inst, Skaggs Inst Chem Biol, Dept Chem, La Jolla, CA 92037 USA.	kdjanda@scripps.edu		Smith, Lauren/0000-0002-4290-3262; Hwang, Candy/0000-0003-2826-4078	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [UH3DA041146, F32AI126628]	This work was supported by National Institutes of Health Grants UH3DA041146 (K.D.J.) and F32AI126628 (C.S.H.).	Arens AM, 2016, JAMA INTERN MED, V176, P1554, DOI 10.1001/jamainternmed.2016.4306; Binswanger IA, 2012, ADDICT SCI CLIN PRAC, V7, DOI 10.1186/1940-0640-7-3; Boom M, 2012, CURR PHARM DESIGN, V18, P5994, DOI 10.2174/138161212803582469; Bremer PT, 2017, J AM CHEM SOC, V139, P8601, DOI 10.1021/jacs.7b03334; Bremer PT, 2016, ANGEW CHEM INT EDIT, V55, P3772, DOI 10.1002/anie.201511654; Bremer PT, 2014, MOL PHARMACEUT, V11, P1075, DOI 10.1021/mp400631w; CDC National Center for Injury Prevention and Control, 2017, PRESCR BEH SURV SYST; Diehl KH, 2001, J APPL TOXICOL, V21, P15, DOI 10.1002/jat.727; Gooyit M, 2017, ACS CHEM NEUROSCI, V8, P468, DOI 10.1021/acschemneuro.6b00389; Hull MJ, 2007, J FORENSIC SCI, V52, P1383, DOI 10.1111/j.1556-4029.2007.00564.x; Jalah R, 2015, BIOCONJUGATE CHEM, V26, P1041, DOI 10.1021/acs.bioconjchem.5b00085; Kalvass JC, 2007, J PHARMACOL EXP THER, V323, P346, DOI 10.1124/jpet.107.119560; Karinen R, 2009, J ANAL TOXICOL, V33, P345, DOI 10.1093/jat/33.7.345; Kimishima A, 2017, ACS CHEM BIOL, V12, P36, DOI 10.1021/acschembio.6b00977; Kimishima A, 2016, MOL PHARMACEUT, V13, P3884, DOI 10.1021/acs.molpharmaceut.6b00682; Kurokawa T, 2002, EUR J BIOCHEM, V269, P5459, DOI 10.1046/j.1432-1033.2002.03244.x; Macmadu A, 2017, ADDICT BEHAV, V68, P35, DOI 10.1016/j.addbeh.2017.01.014; Pauthner M, 2017, IMMUNITY, V46, P1073, DOI 10.1016/j.immuni.2017.05.007; Peckham EM, 2006, J PHARMACOL EXP THER, V316, P1195, DOI 10.1124/jpet.105.094276; Pravetoni M, 2012, VACCINE, V30, P4617, DOI 10.1016/j.vaccine.2012.04.101; Raleigh MD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115696; Schlosburg JE, 2013, P NATL ACAD SCI USA, V110, P9036, DOI 10.1073/pnas.1219159110; Solis E, 2017, ENEURO, V4, DOI 10.1523/ENEURO.0323-17.2017; Stogner JM, 2014, ANN EMERG MED, V64, P637, DOI 10.1016/j.annemergmed.2014.07.017; United States Drug Enforcement Administration, 2016, DEADCTDIR03116; Yardeni T, 2011, LAB ANIMAL, V40, P155, DOI 10.1038/laban0511-155	26	15	15	0	17	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	1948-7193			ACS CHEM NEUROSCI	ACS Chem. Neurosci.	JUN	2018	9	6					1269	1275		10.1021/acschemneuro.8b00079			13	Biochemistry & Molecular Biology; Chemistry, Medicinal; Neurosciences	Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Neurosciences & Neurology	GK5JQ	WOS:000436211800009	29558798	Green Accepted			2020-06-30	J	Ponte, C; Lepelley, M; Boucherie, Q; Mallaret, M; Mestre, ML; Pradel, V; Micallef, J				Ponte, Camille; Lepelley, Marion; Boucherie, Quentin; Mallaret, Michel; Mestre, Maryse Lapeyre; Pradel, Vincent; Micallef, Joelle			Doctor shopping of opioid analgesics relative to benzodiazepines: A pharmacoepidemiological study among 11.7 million inhabitants in the French countries	DRUG AND ALCOHOL DEPENDENCE			English	Article						Doctor shopping; Prescription opioid analgesics; Opioids abuse; Prescription drug database; Benzodiazepines; Addictovigilance	HIGH DOSAGE BUPRENORPHINE; PRESCRIPTION DRUG-ABUSE; MORPHINE-SULFATE ABUSE; RELEASE ORAL MORPHINE; POSTMARKETING SURVEILLANCE; MAINTENANCE TREATMENT; CONTROLLED SUBSTANCES; UNITED-STATES; CHRONIC PAIN; DATABASE	Background: The abuse of prescription opioids and its subsequent consequences is an important public concern particularly in the USA. The literature on opioid analgesic abuse is scarce. Objective: We assess the extent and risk of opioid analgesics abuse relative to benzodiazepines (BD)) using the doctor shopping method, taken into account the pharmacological characteristics (dosage, route of administration, extended or immediate release). Methods: We used SNIIRAM database covering 11.7 million inhabitants. All individuals with at least one reimbursement for non-injectable opioid analgesic or BZD in 2013 were included. Opioids for mild to moderate pain and for moderately severe to severe pain were studied. The Doctor Shopping Quantity (DSQ) is the quantity obtained by overlapping prescriptions from several prescribers. The Doctor Shopping Indicator (DSI) is the DSQ divided by the total dispensed quantity. Results: The strong opioid analgesics have the highest DSI (2.79%) versus 2.06% for BZD hypnotics. Flunitrazepam ranked first according to its DSI (13.2%), followed by morphine (4%), and zolpidem (2.2%). The three-strong opioids having the highest DSI were morphine, oxycodone and fentanyl (respectively 4%, 1.7% and 1.5%). The highest DSI was observed for the highest dosages of morphine (DSI = 8.4% for 200 mg) and oxycodone (DSI = 2.8% for 80 mg). The highest DSI for fentanyl was described with nasal and transmucosal forms (4.1% and 3.3% respectively). The highest DSI for morphine was described for extended-release (4.1%). Conclusion: There is a need to reinforce surveillance systems to track opioid misuse and to increase awareness of healthcare professionals.	[Ponte, Camille; Mestre, Maryse Lapeyre] Univ Paul Sabatier Toulouse III, CIC 1436, Ctr Evaluat & Informat Pharmacodependance Addicto, Serv Pharmacol Med & Clin,Inserm,UMR 1027, Toulouse, France; [Lepelley, Marion; Mallaret, Michel] Ctr Hosp Univ Grenoble, Ctr Evaluat & Informat Pharmacodependance Addicto, F-38043 Grenoble, France; [Boucherie, Quentin; Micallef, Joelle] Aix Marseille Univ, Ctr Evaluat & Informat Pharmacodependance Addicto, Serv Pharmacol Clin, Inst Neurosci Syst UMR INSEAM 1106, Marseille, France; [Pradel, Vincent] Hop St Marguerite, Ctr Evaluat & Informat Pharmacodependance Addicto, Ctr Associe, Lab Sante Publ,Fac Med,EA 3279, Marseille, France	Micallef, J (reprint author), Hop La Timone, CEIP Addictovigilance, Serv Pharmacol Clin, 254 Rue St Pierre, F-13005 Marseille, France.	joelle.micallef@ap-hm.fr	Lapeyre-Mestre, Maryse/C-8710-2012	Lapeyre-Mestre, Maryse/0000-0002-5494-5873			Aknouche F, 2015, TOXICOL ANAL CLIN, V27, P52, DOI 10.1016/j.toxac.2015.01.003; Atluri S, 2014, PAIN PHYSICIAN, V17, pE119; Baumblatt JAG, 2014, JAMA INTERN MED, V174, P796, DOI 10.1001/jamainternmed.2013.12711; Berterame S, 2016, LANCET, V387, P1644, DOI 10.1016/S0140-6736(16)00161-6; Boeuf O, 2007, DRUG SAFETY, V30, P265, DOI 10.2165/00002018-200730030-00007; Casati A, 2012, EUR ADDICT RES, V18, P228, DOI 10.1159/000337028; Cepeda MS, 2012, DRUG SAFETY, V35, P325, DOI 10.2165/11596600-000000000-00000; Chilcoat HD, 2016, DRUG ALCOHOL DEPEN, V165, P221, DOI 10.1016/j.drugalcdep.2016.06.009; Cicero TJ, 2016, PAIN, V157, P1232, DOI 10.1097/j.pain.0000000000000511; Dart RC, 2015, NEW ENGL J MED, V372, P241, DOI [10.1056/NEJMc1501822, 10.1056/NEJMsa1406143]; Dart RC, 2009, DRUG ALCOHOL DEPEN, V105, pS26, DOI 10.1016/j.drugalcdep.2009.08.011; Dhalla IA, 2009, CAN MED ASSOC J, V181, P891, DOI 10.1503/cmaj.090784; Djezzar S, 2009, INT J LEGAL MED, V123, P213, DOI 10.1007/s00414-008-0291-x; Ferri M, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009879.pub2; Frauger E, 2017, THERAPIE, V72, P491, DOI 10.1016/j.therap.2017.01.010; Frauger E, 2016, EUR ADDICT RES, V22, P119, DOI 10.1159/000439273; Frauger E, 2013, FUND CLIN PHARMACOL, V27, P672, DOI 10.1111/fcp.12024; Frauger E, 2011, FUND CLIN PHARMACOL, V25, P633, DOI 10.1111/j.1472-8206.2010.00882.x; Giraudon I, 2013, BRIT J CLIN PHARMACO, V76, P823, DOI 10.1111/bcp.12133; Griffiths P, 2012, ADDICTION, V107, P254, DOI 10.1111/j.1360-0443.2011.03369.x; Hall AJ, 2008, JAMA-J AM MED ASSOC, V300, P2613, DOI 10.1001/jama.2008.802; Hauser Winfried, 2017, Pain Rep, V2, pe599, DOI 10.1097/PR9.0000000000000599; Hernandez SH, 2010, CLIN PHARMACOL THER, V88, P307, DOI 10.1038/clpt.2010.154; INCB (International Narcotics Control Board), 2015, REP INT NARC CONR BO; International Narcotics Control Board (INCB), 2008, REP INT NARC CONTR B; Jegu J, 2011, BRIT J CLIN PHARMACO, V71, P832, DOI 10.1111/j.1365-2125.2011.03923.x; Jones JD, 2012, DRUG ALCOHOL DEPEN, V125, P8, DOI 10.1016/j.drugalcdep.2012.07.004; Jouanjus E, 2015, THERAPIE, V70, P123, DOI 10.2515/therapie/2015011; Kotecha MK, 2013, ANAESTHESIA, V68, P1210, DOI 10.1111/anae.12450; Lu TH, 2015, SLEEP, V38, P1039, DOI 10.5665/sleep.4806; Martyres RF, 2004, MED J AUSTRALIA, V180, P211, DOI 10.5694/j.1326-5377.2004.tb05887.x; McDonald DC, 2014, PHARMACOEPIDEM DR S, V23, P1258, DOI 10.1002/pds.3690; McDonald DC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069241; Micallef J., 2018, FUNDAM CLIN PHARM, V34; Micallef J, 2016, NEUROPATHOLOGY DRUG, V2, P1101; Micallef J, 2015, THERAPIE, V70, P197, DOI 10.2515/therapie/2015013; Moore N, 2015, JAMA PSYCHIAT, V72, P110, DOI 10.1001/jamapsychiatry.2014.2190; Moulis G, 2015, REV MED INTERNE, V36, P411, DOI 10.1016/j.revmed.2014.11.009; Nordmann S, 2013, PAIN PHYSICIAN, V16, P89; Ojanpera I, 2016, INT J LEGAL MED, V130, P1209, DOI 10.1007/s00414-016-1358-8; Okumura Y, 2016, DRUG ALCOHOL DEPEN, V158, P118, DOI 10.1016/j.drugalcdep.2015.11.010; Olfson M, 2015, JAMA PSYCHIAT, V72, P136, DOI 10.1001/jamapsychiatry.2014.1763; Palmaro A., 2017, CLIN THER S, V37, pe4; Palmaro A, 2016, FUND CLIN PHARMACOL, V30, P616, DOI 10.1111/fcp.12214; Patorno E, 2017, BMJ-BRIT MED J, V358, DOI 10.1136/bmj.j2941; Pauly V, 2012, DRUG ALCOHOL DEPEN, V126, P13, DOI 10.1016/j.drugalcdep.2012.03.009; Pauly V, 2011, THERAPIE, V66, P369, DOI 10.2515/therapie/2011037; Peirce GL, 2012, MED CARE, V50, P494, DOI 10.1097/MLR.0b013e31824ebd81; Peyriere H, 2016, FUND CLIN PHARMACOL, V30, P466, DOI 10.1111/fcp.12210; Peyriere H, 2013, EUR ADDICT RES, V19, P235, DOI 10.1159/000346179; Pradel V, 2004, PHARMACOEPIDEM DR S, V13, P473, DOI 10.1002/pds.892; Pradel V, 2010, CNS DRUGS, V24, P611, DOI 10.2165/11531570-000000000-00000; Pradel V, 2009, PHARMACOEPIDEM DR S, V18, P36, DOI 10.1002/pds.1681; Rouby F, 2012, FUND CLIN PHARMACOL, V26, P286, DOI 10.1111/j.1472-8206.2010.00906.x; Schifano F, 2016, EXPERT REV CLIN PHAR, V9, P867, DOI 10.1080/17512433.2016.1178571; Simeone R, 2017, SUBST ABUS-RES TREAT, V11, DOI 10.1177/1178221817696077; Thirion X, 2002, DRUG ALCOHOL DEPEN, V65, P197, DOI 10.1016/S0376-8716(01)00161-2; van Amsterdam Jan, 2015, Curr Drug Abuse Rev, V8, P3; Victorri-Vigneau C, 2014, J ADDICT DIS, V33, P15, DOI 10.1080/10550887.2014.882725; Volkow ND, 2016, NEW ENGL J MED, V374, P1253, DOI 10.1056/NEJMra1507771; Vowles KE, 2015, PAIN, V156, P569, DOI 10.1097/01.j.pain.0000460357.01998.f1; Weisberg D, 2013, ANAESTHESIA, V68, P1215, DOI 10.1111/anae.12503; WHO (World Health Organization), 2018, DDD DEF PRINC DDD AS; Wilsey BL, 2010, DRUG ALCOHOL DEPEN, V112, P99, DOI 10.1016/j.drugalcdep.2010.05.007; World Health Organization, 2013, GUID ATC CLASS DDD A	65	9	9	2	3	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0376-8716	1879-0046		DRUG ALCOHOL DEPEN	Drug Alcohol Depend.	JUN 1	2018	187						88	94		10.1016/j.drugalcdep.2018.01.036			7	Substance Abuse; Psychiatry	Substance Abuse; Psychiatry	GL1RR	WOS:000436885700014	29649695				2020-06-30	J	Belzak, L; Halverson, J				Belzak, Lisa; Halverson, Jessica			The opioid crisis in Canada: a national perspective	HEALTH PROMOTION AND CHRONIC DISEASE PREVENTION IN CANADA-RESEARCH POLICY AND PRACTICE			English	Article						opioid; overdose; crisis; harms; deaths; fentanyl; Canada		Introduction: This review provides a national summary of what is currently known about the Canadian opioid crisis with respect to opioid-related deaths and harms and potential risk factors as of December 2017. Methods: We reviewed all public-facing opioid-related surveillance or epidemiological reports published by provincial and territorial ministries of health and chief coroners' or medical examiners' offices. In addition, we reviewed publications from federal partners and reports and articles published prior to December 2017. We synthesized the evidence by comparing provincial and territorial opioid-related mortality and morbidity rates with the national rates to look for regional trends. Results: The opioid crisis has affected every region of the country, although some jurisdictions have been impacted more than others. As of 2016, apparent opioid-related deaths and hospitalization rates were highest in the western provinces of British Columbia and Alberta and in both Yukon and the Northwest Territories. Nationally, most apparent opioid-related deaths occurred among males; individuals between 30 and 39 years of age accounted for the greatest proportion. Current evidence suggests regional age and sex differences with respect to health outcomes, especially when synthetic opioids are involved. However, differences between data collection methods and reporting requirements may impact the interpretation and comparability of reported data. Conclusion: This report identifies gaps in evidence and areas for further investigation to improve our understanding of the national opioid crisis. The Public Health Agency of Canada will continue to work closely with the provinces, territories and national partners to further refine and standardize national data collection, conduct special studies and expand information-sharing to improve the evidence needed to inform public health action and prevent opioid-related deaths and harms.	[Belzak, Lisa; Halverson, Jessica] Publ Hlth Agcy Canada, Ottawa, ON, Canada	Belzak, L (reprint author), Publ Hlth Agcy Canada, Ctr Surveillance & Appl Res, 785 Carling Ave, Ottawa, ON K1A 0K9, Canada.	lisa.belzak@canada.ca					Alberta Health, 2017, OP SUBST MIS ALB REP; Alberta Health and the Alberta First Nations Information Governance Centre, 2017, OP SUBST MIS 1 NAT P; Archambault A, 2017, SPEC ADV COMM  UNPUB; Archambault B, 2017, E COMMUNICATION; BC Centre for Disease Control, 2017, HIST TAK HOM NAL BRI; Bell R., 2017, LITTLE PILLS BIG TRO; British Columbia Coroners Service, 2017, STAT REP BC FAT ILL; British Columbia Coroners Service, 2017, STAT REP BC FAT FENT; British Columbia Observatory Population and Public Health (BCOPPH) and BC Centre for Disease Control (BCCDC), 2017, BC PUBL HLTH OP OV E; Canadian Centre on Substance Abuse (CCSA), 2015, CCENDU B DEATHS INV; Canadian Centre on Substance Abuse (CCSA) and Canadian Community Epidemiology Network on Drug Use (CCENDU), 2017, CCENDU B CALL 911 DR; Canadian Institute for Health Information (CIHI), 2017, OP REL HARMS CAN CHA; Correctional Service Canada, 2016, ANN REP DEATHS CUST; First Nations Health Authority, 2017, OV DAT 1 NAT BC PREL; Fischer B, 2009, CAN MED ASSOC J, V181, P881, DOI 10.1503/cmaj.091791; Government of Canada, 2015, CAN TOB ALC DRUGS SU; Government of Canada, 2017, GOV CAN ACT OP 2016; Government of New Brunswick, 2016, APP DEATHS REL OP OV; Health Canada, 2017, UNPUB; Health Canada, DRUG AN SERV SUMM RE; Institut national de sante publique du Quebec (INSPQ), 2017, DEC ATTR INT OP QUEB; International Narcotics Control Board (INCB), 2014, REP INT NARC CONTR B; Laroche J., 2017, PRESCRIPTIONS OPIOID; Manitoba Health, 2017, SURV OP MIS OV MAN J; Nunavut Department of Health, 2016, FENT KUGL; Pain & Policy Studies Group University of Wisconsin/ WHO Collaborating Center, 2015, CAN OP CONS MORPH EQ; Public Health Agency of Canada, 2017, UNPUB; Public Health Agency of Canada, 2017, OP OV SURV TAS UNPUB; Public Health Agency of Canada, 2017, WHAT CAN CHIRPP TELL; Public Health Ontario, OP REL MORB MORT ONT; Southwick Reid, 2015, CALGARY HERALD; Special Advisory Committee on the Epidemic of Opioid Overdoses, 2017, NAT REP APP OP REL D; Statistics Canada, 2018, DAILY	33	39	39	2	16	PUBLIC HEALTH AGENCY CANADA	OTTAWA	130 COLONNADE RD, ADDRESS LOCATOR 6501G, OTTAWA, ONTARIO K1A 0K9, CANADA	2368-738X			HEALTH PROMOT CHRON	Health Promot. Chronic Dis. Prev. Can.-Res. Policy Pract.	JUN	2018	38	6			SI		224	233		10.24095/hpcdp.38.6.02			10	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	GJ6ZN	WOS:000435533700002	29911818	DOAJ Gold, Green Published	Y	Y	2020-06-30	J	Bozat-Emre, S; Marshall, SG; Zhong, CL; Reimer, J				Bozat-Emre, Songul; Marshall, Shelley G.; Zhong, Colin; Reimer, Joss			Lessons learned from launching the Manitoba Take-Home Naloxone Program	HEALTH PROMOTION AND CHRONIC DISEASE PREVENTION IN CANADA-RESEARCH POLICY AND PRACTICE			English	Article						naloxone distribution; opioid; overdose response		The Government of Manitoba launched the provincial Take-Home Naloxone Program in January 2017. By the end of September 2017, there were over 60 sites operating in Manitoba. These sites distributed 765 kits to people at risk of opioid overdose, and 93 of these kits were replacement kits used in overdose events. Most of these events occurred among males (60.2%) and in a private residence (72.0%). Fentanyl and carfentanil were the most common substances reported during overdose events. Take-Home Naloxone Program data provide important information about the unique context of the opioid crisis in Manitoba.	[Bozat-Emre, Songul; Zhong, Colin; Reimer, Joss] Manitoba Hlth Seniors & Act Living, Winnipeg, MB, Canada; [Bozat-Emre, Songul; Reimer, Joss] Univ Manitoba, Fac Hlth Sci, Max Rady Coll Med, Winnipeg, MB, Canada; [Marshall, Shelley G.; Reimer, Joss] Winnipeg Reg Hlth Author, Winnipeg, MB, Canada; [Zhong, Colin] Univ Manitoba, Fac Sci, Dept Stat, Winnipeg, MB, Canada	Bozat-Emre, S (reprint author), 4012-300 Carlton St, Winnipeg, MB R3B 2K6, Canada.	sbozatemre@gmail.com					BC Centre for Disease Control, 2012, BCS TAK HOM NAL PROG; Clark AK, 2014, J ADDICT MED, V8, P153, DOI 10.1097/ADM.0000000000000034; First Nations Information Governance Centre, 1 NAT PRINC OCAPR; Government of Manitoba, 2017, SURV OP MIS OV MAN A; Health Canada, NOT PRESCR DRUG LIST; Raffa RB, 2018, J CLIN PHARM THER, V43, P154, DOI 10.1111/jcpt.12640	6	3	3	0	0	PUBLIC HEALTH AGENCY CANADA	OTTAWA	130 COLONNADE RD, ADDRESS LOCATOR 6501G, OTTAWA, ONTARIO K1A 0K9, CANADA	2368-738X			HEALTH PROMOT CHRON	Health Promot. Chronic Dis. Prev. Can.-Res. Policy Pract.	JUN	2018	38	6			SI		252	255		10.24095/hpcdp.38.6.06			4	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	GJ6ZN	WOS:000435533700006	29911822	DOAJ Gold, Green Published			2020-06-30	J	Guan, Q; Khuu, W; Martins, D; Tadrous, M; Chiu, M; Do, MT; Gomes, T				Guan, Qi; Khuu, Wayne; Martins, Diana; Tadrous, Mina; Chiu, Maria; Do, Minh T.; Gomes, Tara			Evaluating the early impacts of delisting high-strength opioids on patterns of prescribing in Ontario	HEALTH PROMOTION AND CHRONIC DISEASE PREVENTION IN CANADA-RESEARCH POLICY AND PRACTICE			English	Article						fentanyl; morphine; hydromorphone; opioids; policy change; delisting; Ontario; palliative care	THERAPY; PAIN	Introduction: Ontario delisted high-strength fentanyl, hydromorphone and morphine from the public drug formulary for non-palliative care prescribers on 31 January, 2017. Our aim is to assess the early impact of this policy on prescribing patterns and to examine whether this impact varied by prescriber type, opioid type and opioid strength. Methods: We conducted a population-based, cross-sectional study on palliative and non-palliative care patients dispensed fentanyl, hydromorphone or morphine through the Ontario public drug program between 1 January, 2014, and 31 July, 2017. For each month during the study period, we reported the total number of high-strength opioid recipients stratified by prescriber type, and the total volume of each drug dispensed, stratified by strength. We used interventional autoregressive integrated moving average (ARIMA) models to assess the policy's impact on prescribing patterns. Results: We observed a 98% decrease in the total number of publicly funded recipients of high-strength opioids between December 2016 and July 2017 (5930 to 133 recipients) for all prescribers. The policy led to a significant decline in the total volume of all three opioids dispensed: hydromorphone from 20 374 621 to 16 952 097 mg (p < .01); morphine from 40 644 190 to 33 555 480 mg (p < .03); and fentanyl from 9 604 913 to 5 842 405 mcg/h (p < .01). For both fentanyl and hydromorphone, this reduction generally corresponded to an increase in the number of low-strength opioids dispensed. Conclusion: Delisting high-strength opioids substantially reduced the number of high-strength opioid recipients and reduced the overall volume of long-acting opioids dispensed in Ontario through the public drug program. Future studies should examine its impact on patient outcomes.	[Guan, Qi; Chiu, Maria; Gomes, Tara] Univ Toronto, Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada; [Khuu, Wayne; Martins, Diana; Tadrous, Mina; Chiu, Maria; Gomes, Tara] Inst Clin Evaluat Sci, Toronto, ON, Canada; [Tadrous, Mina; Gomes, Tara] St Michaels Hosp, Li Ka Shing Knowledge Inst, Toronto, ON, Canada; [Tadrous, Mina; Gomes, Tara] Univ Toronto, Leslie Dan Fac Pharm, Toronto, ON, Canada; [Do, Minh T.] Publ Hlth Agcy Canada, Ottawa, ON, Canada; [Do, Minh T.] Carleton Univ, Dept Hlth Sci, Ottawa, ON, Canada; [Do, Minh T.] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada	Gomes, T (reprint author), St Michaels Hosp, 30 Bond St, Toronto, ON M5B 1W8, Canada.	gomest@smh.ca	Guan, Qi/D-6506-2018	Guan, Qi/0000-0002-6479-0510			Blake H, 2015, BRIT J PAIN, V9, P225, DOI 10.1177/2049463715579284; Bohnert ASB, 2011, JAMA-J AM MED ASSOC, V306, P380, DOI 10.1001/jama.2011.1039; Busse JW, 2017, CAN MED ASSOC J, V189, pE659, DOI 10.1503/cmaj.170363; Butler J, 2017, CITIZEN PETITION; Clark DJ, 2017, ANESTH ANALG, V125, P1667, DOI 10.1213/ANE.0000000000002388; Els C, 2017, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD012299.pub2.13, DOI 10.1002/14651858.CD012299.PUB2.13]; Gomes T, 2013, JAMA INTERN MED, V173, P196, DOI 10.1001/2013.jamainternmed.733; Gomes T, 2011, ARCH INTERN MED, V171, P686, DOI 10.1001/archinternmed.2011.117; Levy Adrian R, 2003, Can J Clin Pharmacol, V10, P67; Makary MA, 2017, BMJ-BRIT MED J, V359, DOI 10.1136/bmj.j4792; Ministry of Health and Long- Term Care, 2017, REM REG DEL HIGH STR; Ministry of Health and Long-Term Care, 2017, TAK ACT PREV OP ADD; Ontario Medical Association, 2017, CHANG PALL CAR FAC A; Ontario Medical Association, 2017, PALL CAR FAC ACC FRE; Ontario Public Drug Programs Ministry of Health and Long-Term Care, 2016, NOT EX OFF CHANG ONT; Spooner L, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167479; Toth AR, 2017, PAIN MED, V18, P1706, DOI 10.1093/pm/pnw231; Tran T, 2017, J CLIN PHARM THER, V42, P567, DOI 10.1111/jcpt.12540; Von Korff M, 2011, ANN INTERN MED, V155, P325, DOI 10.7326/0003-4819-155-5-201109060-00011; Wright AP, 2016, JAMA INTERN MED, V176, P7, DOI 10.1001/jamainternmed.2015.5946	20	6	6	0	0	PUBLIC HEALTH AGENCY CANADA	OTTAWA	130 COLONNADE RD, ADDRESS LOCATOR 6501G, OTTAWA, ONTARIO K1A 0K9, CANADA	2368-738X			HEALTH PROMOT CHRON	Health Promot. Chronic Dis. Prev. Can.-Res. Policy Pract.	JUN	2018	38	6			SI		256	262		10.24095/hpcdp.38.6.07			7	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	GJ6ZN	WOS:000435533700007	29911823	DOAJ Gold, Green Published			2020-06-30	J	Lieberman, JA; Feiner, J; Rollins, M; Lyon, R				Lieberman, Jeremy A.; Feiner, John; Rollins, Mark; Lyon, Russ			Changes in transcranial motor evoked potentials during hemorrhage are associated with increased serum propofol concentrations	JOURNAL OF CLINICAL MONITORING AND COMPUTING			English	Article						Transcranial motor evoked potentials; Spinal nerve root monitoring; Propofol; Hemorrhage; Cardiac output; Blood pressure	IDIOPATHIC SCOLIOSIS SURGERY; SPINAL-CORD-INJURY; WAKE-UP TEST; ELECTRICAL-STIMULATION; HYPOTENSION; INFUSIONS; KYPHOSIS; SIGNALS; SWINE; SHOCK	Transcranial motor evoked potentials (TcMEPs) monitor the integrity of the spinal cord during spine surgery. Propofol-based anesthesia is favored in order to enhance TcMEP quality. During intraoperative hemorrhage, TcMEP amplitudes may be reduced. The serum concentration of propofol may increase during hemorrhage. No study has determined whether changes in TcMEPs due to hemorrhage are related to changes in propofol blood levels. We monitored TcMEPs, mean arterial pressure (MAP), and cardiac output (CO) and hemoglobin in pigs (n = 6) undergoing controlled progressive hemorrhage during a standardized anesthetic with infusions of propofol, ketamine, and fentanyl. We recorded TcMEPs from the rectus femoris (RF) and tibialis anterior (TA) muscles bilaterally. A pulmonary artery catheter was placed to measure CO. Progressive hemorrhage of 10% blood volume increments was done until TcMEP amplitude decreased by > 60% from baseline. Serum propofol levels were also measured following removal of each 10% blood volume increment. TcMEP responses were elicited every 3 min using constant stimulation parameters. We removed between 20 and 50% of total blood volume in order to achieve the > 60% reduction in TcMEP amplitude. MAP and CO decreased significantly from baseline. At maximum hemorrhage, TcMEP amplitude decreased in the RF and TA by an average of 73 and 62% respectively from baseline (P < 0.01). Serum propofol levels varied greatly among animals at baseline (range 410-1720 ng/mL) and increased in each animal during hemorrhage. The mean propofol concentration rose from 1190 +/- 530 to 2483 +/- 968 ng/mL (P < 0.01). The increased propofol concentration correlated with decreased CO. Multivariate analysis using hierarchical linear models indicated that the decline of TcMEP amplitude was primarily associated with rising propofol concentrations, but was also independently affected by reduced CO. We believe that the decrease in blood volume and CO during hemorrhage increased the serum concentration of propofol by reducing the volume of distribution and/or rate of hepatic metabolism of the drug. Despite wide acceptance of propofol as the preferred anesthetic when using TcMEPs, intravenous anesthetics are vulnerable to altered pharmacokinetics during conditions of hemorrhage and could contribute to false-positive TcMEP changes.	[Lieberman, Jeremy A.; Feiner, John; Rollins, Mark] UCSF, Dept Anesthesia & Perioperat Care, San Francisco, CA 94143 USA; [Lyon, Russ] UCSF, Div Operating Rooms, San Francisco, CA USA; [Lieberman, Jeremy A.] Univ Calif San Francisco, Dept Anesthesia & Perioperat Care, Div Spine Anesthesia, 4th Floor,East TowerRoom MUE 413, San Francisco, CA 94143 USA	Lieberman, JA (reprint author), UCSF, Dept Anesthesia & Perioperat Care, San Francisco, CA 94143 USA.; Lieberman, JA (reprint author), Univ Calif San Francisco, Dept Anesthesia & Perioperat Care, Div Spine Anesthesia, 4th Floor,East TowerRoom MUE 413, San Francisco, CA 94143 USA.	lieberman@anesthesia.ucsf.edu			UCSF Department of Anesthesia & Perioperative Care; California Neuromonitoring Services, San Francisco, California	This study was funded by the UCSF Department of Anesthesia & Perioperative Care and an unrestricted educational grant from California Neuromonitoring Services, San Francisco, California.	Baars JH, 2006, ACTA ANAESTH SCAND, V50, P193, DOI 10.1111/j.1399-6576.2006.00923.x; Balvin Mark J, 2010, Am J Electroneurodiagnostic Technol, V50, P219; BENDAVID B, 1987, SPINE, V12, P536, DOI 10.1097/00007632-198707000-00005; Cheh G, 2008, SPINE, V33, P1093, DOI 10.1097/BRS.0b013e31816f5f73; Chen BL, 2015, J SPINAL DISORD TECH, V28, P335, DOI 10.1097/BSD.0b013e3182aa736d; De Paepe P, 2000, ANESTHESIOLOGY, V93, P1482, DOI 10.1097/00000542-200012000-00021; Deletis V, 2008, CLIN NEUROPHYSIOL, V119, P248, DOI 10.1016/j.clinph.2007.09.135; DIPIRO JT, 1992, CRIT CARE MED, V20, P810, DOI 10.1097/00003246-199206000-00019; Fehlings MG, 2010, SPINE, V35, pS37, DOI 10.1097/BRS.0b013e3181d8338e; Hoymork SC, 2003, BRIT J ANAESTH, V91, P773, DOI 10.1093/bja/aeg258; Johnson KB, 2003, ANESTHESIOLOGY, V99, P409, DOI 10.1097/00000542-200308000-00023; Kakinohana M, 2002, ANESTH ANALG, V94, P1586, DOI 10.1097/00000539-200206000-00040; Kamysek S, 2011, ANAL BIOANAL CHEM, V401, P2093, DOI 10.1007/s00216-011-5099-8; Kazama T, 2002, ANESTHESIOLOGY, V97, P1156, DOI 10.1097/00000542-200211000-00020; Kelleher MO, 2008, J NEUROSURG-SPINE, V8, P215, DOI 10.3171/SPI/2008/8/3/215; Kurita T, 2002, ANESTHESIOLOGY, V96, P1498, DOI 10.1097/00000542-200206000-00033; Lieberman JA, 2008, SPINE, V33, pE414, DOI 10.1097/BRS.0b013e318175c292; Lieberman JA, 2013, ANESTHESIOLOGY, V119, P1109, DOI 10.1097/ALN.0b013e31829d4a92; Lyon R, 2004, J NEUROSURG ANESTH, V16, P167, DOI 10.1097/00008506-200404000-00012; Lyon R, 2010, J CLIN MONIT COMPUT, V24, P441, DOI 10.1007/s10877-010-9269-6; Lyon R, 2009, J CLIN MONIT COMPUT, V23, P403, DOI 10.1007/s10877-009-9205-9; MacDonald DB, 2003, SPINE, V28, P194, DOI 10.1097/00007632-200301150-00018; Malhotra NR, 2010, SPINE, V35, P2167, DOI 10.1097/BRS.0b013e3181f6f0d0; McGaughran L, 2006, J Clin Monit Comput, V20, P109; Minahan RE, 2001, CLIN NEUROPHYSIOL, V112, P1442, DOI 10.1016/S1388-2457(01)00567-3; Miyoshi S, 2006, ANESTH ANALG, V103, P1339, DOI 10.1213/01.ane.0000242326.01745.13; Mok JM, 2008, SPINE, V33, pE465, DOI 10.1097/BRS.0b013e318178e67f; Nathan N, 2003, BRIT J ANAESTH, V91, P493, DOI 10.1093/bja/aeg211; Noonan KJ, 2002, SPINE, V27, P825, DOI 10.1097/00007632-200204150-00009; Othman Z, 2004, SPINE, V29, pE258, DOI 10.1097/01.BRS.0000127193.89438.B7; Padberg AM, 1998, SPINE, V23, P1392, DOI 10.1097/00007632-199806150-00018; Pechstein U, 1998, EVOKED POTENTIAL, V108, P175, DOI 10.1016/S0168-5597(97)00086-5; Pelosi L, 2002, CLIN NEUROPHYSIOL, V113, P1082, DOI 10.1016/S1388-2457(02)00027-5; Pelosi L, 2001, CLIN NEUROPHYSIOL, V112, P1076, DOI 10.1016/S1388-2457(01)00529-6; Raudenbush SS, 2002, HIERARCHICAL LINEAR; Schwartz DM, 2007, J BONE JOINT SURG AM, V89A, P2440, DOI 10.2106/Jl3JS.F01476; Sloan TB, 1998, J CLIN NEUROPHYSIOL, V15, P217, DOI 10.1097/00004691-199805000-00005; Takita A, 2007, ANESTHESIOLOGY, V106, P659, DOI 10.1097/01.anes.0000264745.63275.59; Tamkus A, 2013, SPINE J, V13, P1484; van Dongen EP, 2000, ACTA ANAESTH SCAND, V44, P799, DOI 10.1034/j.1399-6576.2000.440705.x; Woodforth IJ, 1999, ANESTH ANALG, V89, P1182, DOI 10.1213/00000539-199911000-00018; Zhou HH, 2000, ANESTHESIOLOGY, V93, P32, DOI 10.1097/00000542-200007000-00010	42	4	4	0	2	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	1387-1307	1573-2614		J CLIN MONIT COMPUT	J. Clin. Monitor. Comp.	JUN	2018	32	3					541	548		10.1007/s10877-017-0057-4			8	Anesthesiology	Anesthesiology	GF3TE	WOS:000431877900022	28856576				2020-06-30	J	ter Horst, EN; Krijnen, PAJ; Flecknell, P; Meyer, KW; Kramer, K; van der Laan, AM; Piek, JJ; Niessen, HWM				ter Horst, Ellis N.; Krijnen, Paul A. J.; Flecknell, Paul; Meyer, Klaas W.; Kramer, Klaas; van der Laan, Anja M.; Piek, Jan J.; Niessen, Hans W. M.			Sufentanil-medetomidine anaesthesia compared with fentanyl/fluanisone-midazolam is associated with fewer ventricular arrhythmias and death during experimental myocardial infarction in rats and limits infarct size following reperfusion	LABORATORY ANIMALS			English	Article						ischaemia; anaesthesia; arrhythmias; sufentanil; medetomidine	DELTA-OPIOID RECEPTOR; ISCHEMIA-REPERFUSION; EXPERIMENTAL UNITS; RABBIT COLONIES; INJURY; HEART; CARDIOPROTECTION; METAANALYSIS; BUTORPHANOL; FENTANYL	To improve infarct healing following myocardial infarction in humans, therapeutic interventions can be applied during the inflammatory response. Animal models are widely used to study this process. However, induction of MI in rodents is associated with high mortality due to ventricular fibrillation (VF) during coronary artery ligation. The anaesthetic agent used during the procedure appears to influence the frequency of this complication. In this retrospective study, the effect on ventricular arrhythmia incidence during ligation and infarct size following invivo reperfusion of two anaesthetic regimens, sufentanil-medetomidine (SM) and fentanyl/fluanisone-midazolam (FFM) was evaluated in rats. Anaesthetics were administered subcutaneously using fentanyl/fluanisone (0.5mL/kg) with midazolam (5mg/kg) (FFM group, n=48) or sufentanil (0.05mg/kg) with medetomidine (0.15mg/kg) (SM group, n=47). The coronary artery was ligated for 40min to induce MI. Heart rate and ventricular arrhythmias were recorded during ligation, and infarct size was measured via histochemistry after three days of reperfusion. In the SM group, heart rate and VF incidence were lower throughout the experiment compared with the FFM group (6% versus 30%) (P<0.01). Fatal VF did not occur in the SM group whereas this occurred in 25% of the animals in the FFM group. Additionally, after three days of reperfusion, the infarcted area following SM anaesthesia was less than half as large as that following FFM anaesthesia (8.56.4% versus 20.75.6%) (P<0.01). Therefore, to minimize the possibility of complications related to VF and acute death arising during ligation, SM anaesthesia is recommended for experimental MI in rats.	[ter Horst, Ellis N.; van der Laan, Anja M.; Piek, Jan J.] Acad Med Ctr, Dept Cardiol, Amsterdam, Netherlands; [ter Horst, Ellis N.] Netherlands Heart Inst, Utrecht, Netherlands; [ter Horst, Ellis N.; Krijnen, Paul A. J.; Niessen, Hans W. M.] Vrije Univ Amsterdam Med Ctr, Inst Cardiovasc Res ICaR VU, Amsterdam, Netherlands; [ter Horst, Ellis N.; Krijnen, Paul A. J.; Niessen, Hans W. M.] Vrije Univ Amsterdam Med Ctr, Dept Pathol, Amsterdam, Netherlands; [Flecknell, Paul] Newcastle Univ, Comparat Biol Ctr, Newcastle Upon Tyne, Tyne & Wear, England; [Meyer, Klaas W.; Kramer, Klaas] Vrije Univ Amsterdam, Amsterdam Anim Res Ctr, Amsterdam, Netherlands; [Niessen, Hans W. M.] Vrije Univ Amsterdam, Dept Cardiac Surg, Amsterdam, Netherlands	ter Horst, EN (reprint author), Vrije Univ Amsterdam, Dept Pathol, VU Univ Med Ctr, Boelelaan 1117, NL-1018 HV Amsterdam, Netherlands.	e.terhorst@vumc.nl	Tan, Weihong/A-5412-2008	Tan, Weihong/0000-0002-8066-1524; Krijnen, Paul/0000-0002-5399-5617; Flecknell, Paul/0000-0002-1075-1129; Niessen, Hans/0000-0001-9404-9822	Netherlands Heart Institute [140.01]	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Ellis ter Horst was funded by The Netherlands Heart Institute (project 140.01). This research received no specific grant from any funding agency in the public or commercial sectors.	ANDREWS TC, 1991, CIRCULATION, V84, P236; Bell SP, 2000, J AM COLL CARDIOL, V36, P2296, DOI 10.1016/S0735-1097(00)01011-1; BOAS RA, 1985, BRIT J ANAESTH, V57, P192, DOI 10.1093/bja/57.2.192; Cale R, 2011, REV PORT CARDIOL, V30, P199; Cray C, 2009, COMPARATIVE MED, V59, P517; Crystal E, 2002, CIRCULATION, V106, P75, DOI 10.1161/01.CIR.0000021113.44111.3E; Flecknell P, 2015, LAB ANIMAL ANAESTHES; FLECKNELL PA, 1984, LAB ANIM, V18, P143, DOI 10.1258/002367784780891406; Frangogiannis NG, 2006, CURR MED CHEM, V13, P1877, DOI 10.2174/092986706777585086; Hedenqvist P, 2000, LAB ANIM-UK, V34, P244, DOI 10.1258/002367700780384762; HU C, 1992, LAB ANIM-UK, V26, P15, DOI 10.1258/002367792780809075; Ibanez B, 2013, CIRCULATION, V128, P1495, DOI 10.1161/CIRCULATIONAHA.113.003653; Jang YG, 2008, ANESTHESIOLOGY, V108, P243, DOI 10.1097/01.anes.0000299437.93898.4a; Koplan BA, 2009, MAYO CLIN PROC, V84, P289, DOI 10.1016/S0025-6196(11)61149-X; Lemoine S, 2011, ACTA ANAESTH SCAND, V55, P758, DOI 10.1111/j.1399-6576.2011.02456.x; London MJ, 2008, BEST PRACT RES-CLIN, V22, P95, DOI 10.1016/j.bpa.2007.09.008; Mahler M, 2014, LAB ANIM-UK, V48, P178, DOI 10.1177/0023677213516312; Maekawa Y, 2002, J AM COLL CARDIOL, V39, P241, DOI 10.1016/S0735-1097(01)01721-1; Miki T, 1998, MOL CELL BIOCHEM, V186, P3, DOI 10.1023/A:1006856124501; MURRY CE, 1986, CIRCULATION, V74, P1124, DOI 10.1161/01.CIR.74.5.1124; Nahrendorf M, 2010, CIRCULATION, V121, P2437, DOI 10.1161/CIRCULATIONAHA.109.916346; Nicklas W, 2002, LAB ANIM-UK, V36, P20, DOI 10.1258/0023677021911740; Nowbar AN, 2014, INT J CARDIOL, V174, P293, DOI 10.1016/j.ijcard.2014.04.096; SAVOLA JM, 1991, EUR J PHARMACOL, V195, P193, DOI 10.1016/0014-2999(91)90535-X; Schultz JE, 1998, CIRCULATION, V97, P1282, DOI 10.1161/01.CIR.97.13.1282; SCHULTZ JEJ, 1995, AM J PHYSIOL-HEART C, V268, pH2157, DOI 10.1152/ajpheart.1995.268.5.H2157; Schultz JJ, 1997, J MOL CELL CARDIOL, V29, P2187, DOI 10.1006/jmcc.1997.0454; Shekarforoush S, 2016, LAB ANIM-UK, V50, P179, DOI 10.1177/0023677215597136; Sinclair MD, 2003, CAN VET J, V44, P885; van der Laan AM, 2012, HEART, V98, P1384, DOI 10.1136/heartjnl-2012-301623; van der Laan AM, 2012, AM HEART J, V163, P57, DOI 10.1016/j.ahj.2011.09.002; van Dijk A, 2010, EUR J CLIN INVEST, V40, P893, DOI 10.1111/j.1365-2362.2010.02345.x; van Dijk A, 2009, APOPTOSIS, V14, P753, DOI 10.1007/s10495-009-0350-x; VIRTANEN R, 1989, ACTA VET SCAND, P29; WALKER MJA, 1988, CARDIOVASC RES, V22, P447, DOI 10.1093/cvr/22.7.447; Wang GY, 2001, AM J PHYSIOL-HEART C, V280, pH384; Wijeysundera DN, 2003, AM J MED, V114, P742, DOI 10.1016/S0002-9343(03)00165-7; Wong GTC, 2010, ACTA ANAESTH SCAND, V54, P510, DOI 10.1111/j.1399-6576.2009.02145.x; Wu QL, 2012, J SURG RES, V178, P563, DOI 10.1016/j.jss.2012.05.081; Wu Y, 2014, INTERACT CARDIOV TH, V18, P308, DOI 10.1093/icvts/ivt516; Wu Y, 2012, INT IMMUNOPHARMACOL, V13, P341, DOI 10.1016/j.intimp.2012.04.009; Zhao ZQ, 2003, AM J PHYSIOL-HEART C, V285, pH579, DOI 10.1152/ajpheart.01064.2002	42	3	3	0	5	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0023-6772	1758-1117		LAB ANIM-UK	Lab. Anim.	JUN	2018	52	3					271	279		10.1177/0023677217724485			9	Veterinary Sciences; Zoology	Veterinary Sciences; Zoology	GG5CW	WOS:000432713900005	28776458	Green Published, Other Gold			2020-06-30	J	Altiparmak, B; Celebi, N; Canbay, O; Toker, MK; Kilicarslan, B; Aypar, U				Altiparmak, Basak; Celebi, Nalan; Canbay, Ozgur; Toker, Melike K.; Kilicarslan, Banu; Aypar, Ulku			Effect of magnesium sulfate on anesthesia depth, awareness incidence, and postoperative pain scores in obstetric patients A double-blind randomized controlled trial	SAUDI MEDICAL JOURNAL			English	Article							POSTTRAUMATIC-STRESS-DISORDER; INTRAOPERATIVE AWARENESS; GENERAL-ANESTHESIA; RECALL; INFUSION	Objectives: To assess the effects of magnesium on the depth of anesthesia and to determine the effects of magnesium on incidence of awareness and postoperative pain after caesarean section. Methods: The study was designed as a double-blind, controlled, randomized study and conducted in Hacettepe University Hospital, Ankara, Turkey between January 2015 and March 2016. A total of 100 pregnant healthy women who were between 17 and 41 years old, ASA II, and scheduled for an elective cesarean section with general anesthesia were included in the study. After induction, sevoflurane was used for maintenance in Group S and desflurane in Group D (control groups). At Group S-M and Group D-M (study groups), magnesium infusion was started with sevoflurane and desflurane anesthesia respectively. Minimum alveolar concentration of sevoflurane and desflurane were kept constant. Bispectral index scores (BIS), fentanyl consumption and postoperative visual analogue scale (VAS) values were recorded. All of the patients had been followed-up for awareness until the postoperative first year. Results: Demographic variables of the patients were similar. BIS values were significantly higher in control groups throughout the operation (p<0.001). No significant difference was detected for intraoperative fentanyl consumption and awareness incidence. VAS values were significantly lower in study groups (p<0.05). Conclusion: Magnesium infusion provided significantly lower intraoperative BIS values and lower postoperative VAS scores. We believe that magnesium can be useful as an adjuvant to general anesthesia.	[Altiparmak, Basak; Toker, Melike K.] Mugla Sitki Kocman Univ Training & Res Hosp, Dept Anesthesiol & Reanimat, Mugla, Turkey; [Celebi, Nalan; Canbay, Ozgur; Kilicarslan, Banu; Aypar, Ulku] Hacettepe Univ, Dept Anesthesiol & Reanimat, Ankara, Turkey	Altiparmak, B (reprint author), Mugla Sitki Kocman Univ Training & Res Hosp, Dept Anesthesiol & Reanimat, Mugla, Turkey.	basak_ugurlu@yahoo.com	Toker, Melike/AAF-5969-2020; toker, melike/AAG-4329-2020				Amer MM, 2015, BMC ANESTHESIOL, V15, DOI 10.1186/s12871-015-0108-7; Barbosa FT, 2010, REV BRAS ANESTESIOL, V60, P104, DOI 10.1590/S0034-70942010000100013; BRICE DD, 1970, BRIT J ANAESTH, V42, P535, DOI 10.1093/bja/42.6.535; Bruhn J, 2006, BRIT J ANAESTH, V97, P85, DOI 10.1093/bja/ael120; Campagna JA, 2003, NEW ENGL J MED, V348, P2110, DOI 10.1056/NEJMra021261; Campbell J, 2009, BRIT J HOSP MED, V70, P605, DOI 10.12968/hmed.2009.70.10.44637; Dean C, 2013, INT J OBSTET ANESTH, V22, P52, DOI 10.1016/j.ijoa.2012.10.003; Do SH, 2013, KOREAN J ANESTHESIOL, V65, P4, DOI 10.4097/kjae.2013.65.1.4; Elhakim M, 2010, ACTA ANAESTH SCAND, V54, P703, DOI 10.1111/j.1399-6576.2009.02199.x; Frassanito L, 2015, MINERVA ANESTESIOL, V81, P1184; Fujimori Juichi, 2017, eNeurologicalSci, V9, P3, DOI 10.1016/j.ensci.2017.09.001; Ghoneim MM, 2000, ANESTHESIOLOGY, V92, P597, DOI 10.1097/00000542-200002000-00043; Ghoneim MM, 2009, ANESTH ANALG, V108, P527, DOI 10.1213/ane.0b013e318193c634; Gupta SD, 2011, SAUDI J ANAESTH, V5, P55, DOI 10.4103/1658-354X.76512; Jellish WS, 2005, OTOLARYNG HEAD NECK, V133, P269, DOI 10.1016/j.otohns.2005.04.011; Kino Atsunari, 2011, Masui, V60, P241; Kuo PJ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0186337; Kutlesic MS, 2017, J ANESTH, V31, P127, DOI 10.1007/s00540-016-2257-3; Lee DH, 2009, BRIT J ANAESTH, V103, P861, DOI 10.1093/bja/aep265; Leslie K, 2010, ANESTH ANALG, V110, P823, DOI 10.1213/ANE.0b013e3181b8b6ca; Mashour GA, 2013, ANESTH ANALG, V116, P889, DOI 10.1213/ANE.0b013e318281e9ad; Mashour GA, 2010, ANESTH ANALG, V110, P668, DOI 10.1213/ANE.0b013e3181c35926; MIRANDA HF, 1992, EUR J PHARMACOL, V217, P137, DOI 10.1016/0014-2999(92)90833-P; Mireskandari Seyed Mohamad, 2015, J Family Reprod Health, V9, P29; MOERMAN N, 1993, ANESTHESIOLOGY, V79, P454, DOI 10.1097/00000542-199309000-00007; Paech MJ, 2008, INT J OBSTET ANESTH, V17, P298, DOI 10.1016/j.ijoa.2008.01.016; Russell IF, 2016, ANAESTHESIA, V71, P590, DOI 10.1111/anae.13470; Samarkandi Abdul-Hamid, 2006, Middle East Journal of Anesthesiology, V18, P769; Sebel PS, 2004, ANESTH ANALG, V99, P833, DOI 10.1213/01.ANE.0000130261.90896.6C; Walker EMK, 2016, BRIT J ANAESTH, V117, P758, DOI 10.1093/bja/aew381; Yadav Monu, 2016, J Anaesthesiol Clin Pharmacol, V32, P168, DOI 10.4103/0970-9185.173367	31	1	1	1	1	SAUDI MED J	RIYADH	ARMED FORCES HOSPITAL, PO BOX 7897,, RIYADH 11159, SAUDI ARABIA	0379-5284			SAUDI MED J	Saudi Med. J.	JUN	2018	39	6					579	585		10.15537/smj.2018.6.22376			7	Medicine, General & Internal	General & Internal Medicine	HD4PH	WOS:000452509400005	29915852	DOAJ Gold, Green Published			2020-06-30	J	Matsota, PK; Drachtidi, KH; Batistaki, CZ; Karakosta, AV; Koukopoulou, IC; Koursoumi, EI; Kostopanagiotou, GG				Matsota, Paraskevi K.; Drachtidi, Kalliopi H.; Batistaki, Chrysanthi Z.; Karakosta, Agathi, V; Koukopoulou, Ioanna C.; Koursoumi, Eugenia, I; Kostopanagiotou, Georgia G.			Patient-controlled epidural analgesia with and without basal infusion using ropivacaine 0.15% and fentanyl 2 gamma/mL for labor analgesia: a prospective comparative randomized trial	MINERVA ANESTESIOLOGICA			English	Article						Epidural analgesia; Patient; controlled analgesia; Labor pain; Ropivacaine; Fentanyl	BACKGROUND INFUSION; DELIVERY; BUPIVACAINE; PCEA; LEVOBUPIVACAINE; METAANALYSIS; SUFENTANIL; MODE	BACKGROUND: Patient-controlled epidural analgesia (PCEA) is a common practice for labor pain relief. This study aimed to compare two different settings of a PCEA device using the same solution to obtain labor analgesia. METHODS: Fifty-two parturients were randomly allocated to receive ropivacaine 0.15% and fentanyl 2 gamma/mL via a PCEA device either as a background infusion of 5 mL/h plus 5 mL demand bolus doses with 10-minute lockout (group B/D, N.=26) or as only demand bolus doses of 5 mL with 10-minute lockout (group D, N.=26). The primary outcome was the total volume of local anesthetic administrated during labor, secondary outcomes included the analgesic efficacy and the effects on maternal and neonatal outcomes. RESULTS: No statistical difference was observed between the groups concerning demographic characteristics, duration of first and second stages of labor, administration of oxytocin and ephedrine, rescue doses, instrumental delivery, Brom-age Scale, maternal side effects and satisfaction, neonatal Apgar scores and pH. The total volume of local anesthetic was greater in group B/D compared to group D (P=0.015). A statistically significant difference was detected in VAS scores only at the end of the second stage (P=0.036) and at 60 minutes from the test dose administration (P=0.022) and with group D exhibited higher pain scores than group B/D. The incidence of breakthrough pain (VAS>4) was higher in group D compared with group B/D (P=0.035). CONCLUSIONS: The addition of background infusion plus PCEA demand bolus doses increased local anesthetic consumption and reduced breakthrough pain without affecting maternal satisfaction and neonatal outcomes.	[Matsota, Paraskevi K.; Drachtidi, Kalliopi H.; Batistaki, Chrysanthi Z.; Koukopoulou, Ioanna C.; Koursoumi, Eugenia, I; Kostopanagiotou, Georgia G.] Univ Athens, Dept Anesthesiol 2, Sch Med, Attikon Univ Hosp, Athens, Greece; [Karakosta, Agathi, V] NHS, Thriassio Gen Hosp, Athens, Greece	Matsota, PK (reprint author), 2nd Dept Anesthesiol, Rimini 1, Athens 12462, Greece.	matsota@yahoo.gr	Matsota, Paraskevi/AAD-8073-2019; Karakosta, Agathi/AAE-1570-2020	Matsota, Paraskevi/0000-0003-0971-4483; 			Antonakou A, 2016, OBSTET GYNECOL INT, V2016, DOI 10.1155/2016/5740534; Beilin Y, 2007, ANESTH ANALG, V105, P756, DOI 10.1213/01.ane.0000278131.73472.f4; Boselli E, 2004, ANESTHESIOLOGY, V100, P968, DOI 10.1097/00000542-200404000-00030; Bremerich DH, 2005, INT J OBSTET ANESTH, V14, P114, DOI 10.1016/j.ijoa.2004.12.005; Brogly N, 2011, MINERVA ANESTESIOL, V77, P1149; Chen SY, 2014, TAIWAN J OBSTET GYNE, V53, P8, DOI 10.1016/j.tjog.2012.01.039; Craig MG, 2015, ANESTHESIOLOGY, V122, P172, DOI 10.1097/ALN.0000000000000454; Dewandre PY, 2006, ACTA ANAESTH BELG, V57, P395; Eriksson SL, 2003, ACTA ANAESTH SCAND, V47, P1085, DOI 10.1034/j.1399-6576.2003.00207.x; FERRANTE FM, 1994, ANESTH ANALG, V79, P80; GAMBLING DR, 1988, CAN J ANAESTH, V35, P249, DOI 10.1007/BF03010618; Genc M, 2015, J OBSTET GYNAECOL, V35, P672, DOI 10.3109/01443615.2014.991299; Halpern SH, 2003, ANESTHESIOLOGY, V98, P1431, DOI 10.1097/00000542-200306000-00020; Halpern S, 2005, CURR OPIN ANESTHESIO, V18, P247, DOI 10.1097/01.aco.0000169229.75938.c8; Halpern SH, 2009, ANESTH ANALG, V108, P921, DOI 10.1213/ane.0b013e3181951a7f; Hawkins JL, 2010, NEW ENGL J MED, V362, P1503, DOI 10.1056/NEJMct0909254; Heesen M, 2015, ANESTH ANALG, V121, P149, DOI 10.1213/ANE.0000000000000743; IRESTEDT L, 1984, ACTA OBSTET GYN SCAN, P111; Kangas-Saarela T, 1994, Int J Obstet Anesth, V3, P67, DOI 10.1016/0959-289X(94)90172-4; Leone Stefania, 2008, Acta Biomed, V79, P92; Lim Y, 2008, ANESTH ANALG, V107, P1968, DOI 10.1213/ane.0b013e3181887ffb; MELZACK R, 1981, CAN MED ASSOC J, V125, P357; Petry J, 2000, Acta Anaesthesiol Belg, V51, P163; Sia AT, 2013, ANAESTHESIA, V68, P267, DOI 10.1111/anae.12093; Sultan P, 2013, CAN J ANESTH, V60, P840, DOI 10.1007/s12630-013-9981-z; Vallejo MC, 2007, J PAIN, V8, P970, DOI 10.1016/j.jpain.2007.07.002; Van de Velde M, 2009, REV ESP ANEST REANIM, V56, P546, DOI 10.1016/S0034-9356(09)70457-8; van der Vyver M, 2002, BRIT J ANAESTH, V89, P459, DOI 10.1093/bja/aef217; Wassen MMLH, 2015, BJOG-INT J OBSTET GY, V122, P344, DOI 10.1111/1471-0528.12854	29	2	2	0	2	EDIZIONI MINERVA MEDICA	TURIN	CORSO BRAMANTE 83-85 INT JOURNALS DEPT., 10126 TURIN, ITALY	0375-9393	1827-1596		MINERVA ANESTESIOL	Minerva Anestesiol.	JUN	2018	84	6					667	674		10.23736/S0375-9393.18.12070-0			8	Anesthesiology; Critical Care Medicine	Anesthesiology; General & Internal Medicine	GU4SW	WOS:000445275800007	29338142				2020-06-30	J	Rothberg, RL; Stith, K				Rothberg, Rachel L.; Stith, Kate			Fentanyl: A Whole New World?	JOURNAL OF LAW MEDICINE & ETHICS			English	Article								This article seeks to document the latest danger in the opioid crisis: fentanyl and related synthetic opioids. Fifty times more potent than pure heroin, cheaper to manufacture in laboratories worldwide, and easily distributed by mail and couriers, fentanyl is flooding the illicit opioid markets throughout the country.	[Rothberg, Rachel L.] Yale Law Sch, New Haven, CT 06511 USA; [Stith, Kate] Yale Law Sch, Law, New Haven, CT USA	Rothberg, RL (reprint author), Yale Law Sch, New Haven, CT 06511 USA.						[Anonymous], 2016, CHICAGO TRIBUNE; [Anonymous], 1993, NEWSWEEK; [Anonymous], 2017, NEW HAVEN REGISTER; Areddy J. T., 2017, WALL STREET J; Binder G, 2017, NOTRE DAME LAW REV, V92, P1141; Boyle B. D., 2017, COMMUNICATION; Brico E., 2018, POLITICO; DEA, 2016, DEA SCHED DEADL SYNT; DEA, 2016, DEA TARG FENT REAL T; DEA, DRUGS AB DEA RES GUI, P40; DEA, 2017, FENT BRIEF GUID 1 RE, P10; DEA, DRUG INF FENT FAQS; Department of Justice Office of Public Affairs, 2017, DEP JUST ANN SIGN TO; Department of Justice Office of Public Affairs, 2018, ATT GEN SESS APPL CH; Department of Justice Office of Public Affairs [DOJ OPA], 2017, JUST DEP ANN 1 EV IN; Dodds P., 2016, GLOBAL NEWS     1008; Drug Enforcement Administration [DEA], 2016, FENT; Drug Policy Alliance, 2017, OV DEATH IS NOT MURD, P17; Esposito L., 2016, US NEWS; Fry E., 2017, VALLEY INDEPEND 0928; Jiang S, 2017, CNN; McLaughlin K., 2017, SCIENCE; O'Connor S., 2017, US CHINA EC SECURITY; O'Donnell JK, 2017, MMWR-MORBID MORTAL W, V66, P1197, DOI 10.15585/mmwr.mm6643e1; Office of the Chief Medical Examiner [OCME], 2018, CONN ACC DRUG INT DE; Popper Nathaniel, 2017, NY TIMES; Rath A., 2017, NPR; Rondinone N., 2018, HARTFORD COURANT; Rosenberg C., 2017, COMMUNICATION; Rosenstein J., 2017, REM ENF ACT STOP DEA; Siemaszko Corky, 2017, NBC NEWS; Spector Robert M., 2017, COMMUNICATION; Spegele B, 2016, WALL STREET J; Spegele B., 2017, WALL STREET J; Stanley TH, 2014, J PAIN, V15, P1215, DOI 10.1016/j.jpain.2014.08.010; Torralva K., 2017, ORLANDO SENTINEL; United States Sentencing Commission [USSC], 2017, PUBL HEAR FENT FENT, P3; US Attorney's Office for the District of Connecticut [USAOCT], 2013, MASS JOINT LAW ENF O; USAO CT, 2018, ESS MAN ADM US DARK; USAO CT, 2017, W HARTF MAN ADM IMP; USAO- CT, 2016, DEA TASK FORC TAK FE; USAO- CT, 2017, DEA TASK FORC INV DI; USSC, 2018, PROP AM SENT GUID 16; USSC, 2018, SYNH DRUGS DAT BRIEF; USSC, 2017, PUBL HEAR FENT FENT, P1; Whalen J., 2017, WALL STREET J	46	7	7	0	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1073-1105	1748-720X		J LAW MED ETHICS	J. Law Med. Ethics	JUN	2018	46	2			SI		314	324		10.1177/1073110518782937			11	Ethics; Law; Medical Ethics; Medicine, Legal	Social Sciences - Other Topics; Government & Law; Medical Ethics; Legal Medicine	GO0OB	WOS:000439630000012	30147007				2020-06-30	J	Hochstetler, JL; Thompson, AJ; Ball, NM; Evans, MC; Frame, SC; Haney, AL; Little, AK; O'Donnell, JL; Rickett, BM; Mack, EH				Hochstetler, Jessica L.; Thompson, A. Jill; Ball, Natalie M.; Evans, Melissa C.; Frame, Shaun C.; Haney, A. Lauren; Little, Amelia K.; O'Donnell, Jaime L.; Rickett, Bryna M.; Mack, Elizabeth H.			Practice Change From Intermittent Medication Boluses to Bolusing From a Continuous Infusion in Pediatric Critical Care: A Quality Improvement Project	PEDIATRIC CRITICAL CARE MEDICINE			English	Article						infusion pumps; pediatrics; quality improvement; safety; utilization	ERRORS; UNIT; METAANALYSIS; PUMPS; ICU	Objectives: To determine whether implementing a guideline to bolus medications from continuous infusions in PICUs affects nursing satisfaction, patient safety, central line entries, medication utilization, or cost. Design: This is a pre- and postimplementation quality improvement study. Setting: An 11-bed ICU and 14-bed cardiac ICU in a university-affiliated children's hospital. Patients: Patients less than 18 years old admitted to the PICU or pediatric cardiac ICU receiving a continuous infusion of dexmedetomidine, midazolam, fentanyl, morphine, vecuronium, or cisatracurium from May 2015 to May 2016, excluding November 2015 (washout period), were eligible for inclusion. Interventions: Change in practice from administering bolus doses from an automated dispensing machine to administering bolus medications from continuous infusion in PICUs. Measurements and Main Results: Timing studies were conducted pre- and post implementation in 29 and 26 occurrences, respectively. The median time from the decision to give a bolus until it began infusing decreased by 169 seconds (p < 0.01). Nursing satisfaction increased from 19.3% pre- to 100% post implementation. Safety was assessed via barcode scanning compliance, which decreased by 1.4% for patients and 1% for medications, and smart pump limit overrides. The percentage of infusion pump bolus overrides increased as expected, with the majority (99%) of these exceeding soft maximum limits by less than two-fold. Central line entries were unaffected post implementation. To assess medication utilization, a total of 50 patients in each intervention group were selected for retrospective chart review. Daily fentanyl boluses increased from one to three (p = 0.021). However, midazolam infusion dose and fentanyl infusion duration decreased (p = 0.026 and p = 0.005, respectively). Medication utilization was otherwise unchanged post implementation (p > 0.05). Annualized cost avoidance was $124,160. Conclusions: Implementation of bolus medications from continuous infusion in PICUs significantly decreased time to begin a bolus dose and increased nursing satisfaction. The practice change also improved medication utilization without negatively impacting patient safety.	[Hochstetler, Jessica L.] Texas Childrens Hosp, Dept Pharm, Houston, TX 77030 USA; [Thompson, A. Jill; Haney, A. Lauren] Med Univ South Carolina, Dept Pharm Serv, Charleston, SC 29425 USA; [Ball, Natalie M.; Frame, Shaun C.; Little, Amelia K.; O'Donnell, Jaime L.; Rickett, Bryna M.] Med Univ South Carolina, Charleston, SC USA; [Evans, Melissa C.; Mack, Elizabeth H.] Med Univ South Carolina, Div Pediat Crit Care Med, Charleston, SC USA	Thompson, AJ (reprint author), Med Univ South Carolina, Dept Pharm Serv, Charleston, SC 29425 USA.	thompsam@musc.edu					Affolter JT, 2016, PEDIATR CRIT CARE ME, V17, P591, DOI 10.1097/PCC.0000000000000736; Bork S, 2013, CRIT CARE MED, V41, DOI 10.1097/01.ccm.0000440178.94598.7f; Carefusion, 2016, CAREFUSION ALARIS SY; Fields Marianne, 2005, Nurs Adm Q, V29, P78; Hicks Rodney W, 2006, J Pediatr Nurs, V21, P290, DOI 10.1016/j.pedn.2006.02.002; Hicks RW, 2006, J INFUS MURS, V29, P20, DOI 10.1097/00129804-200601000-00005; Kane-Gill SL, 2017, CRIT CARE MED, V45, pE877, DOI 10.1097/CCM.0000000000002533; Kastrup M, 2012, DRUG SAFETY, V35, P563, DOI 10.2165/11597350-000000000-00000; Latif A, 2013, CRIT CARE MED, V41, P389, DOI 10.1097/CCM.0b013e318274156a; Liu Q, 2016, J MED INTERNET RES, V18, DOI 10.2196/jmir.4807; Lobaugh LMY, 2017, ANESTH ANALG, V125, P936, DOI 10.1213/ANE.0000000000002279; Manrique-Rodriguez S, 2016, MED INTENSIVA, V40, P411, DOI 10.1016/j.medin.2016.01.011; Manrique-Rodriguez S, 2014, INT J MED INFORM, V83, P99, DOI 10.1016/j.ijmedinf.2013.10.011; Manrique-Rodriguez S, 2013, AM J HEALTH-SYST PH, V70, P1897, DOI 10.2146/ajhp120767; Manrique-Rodriguez S, 2012, ARTIF INTELL MED, V54, P155, DOI 10.1016/j.artmed.2011.12.001; Shin S, 2015, NURS EDUC TODAY, V35, P176, DOI 10.1016/j.nedt.2014.09.009	16	1	1	1	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1529-7535	1947-3893		PEDIATR CRIT CARE ME	Pediatr. Crit. Care Med.	JUN	2018	19	6					572	577		10.1097/PCC.0000000000001549			6	Critical Care Medicine; Pediatrics	General & Internal Medicine; Pediatrics	GJ4YQ	WOS:000435388800017	29652752				2020-06-30	J	Uddayasankar, U; Lee, C; Oleschuk, C; Eschun, G; Ariano, RE				Uddayasankar, Uvaraj; Lee, Colin; Oleschuk, Curtis; Eschun, Gregg; Ariano, Robert E.			The Pharmacokinetics and Pharmacodynamics of Carfentanil After Recreational Exposure: A Case Report	PHARMACOTHERAPY			English	Article						carfentanil; narcotic screening; pharmacokinetics; toxic exposure; drug of abuse	FENTANYL; CASUALTIES; ANALOGS; MOSCOW	Carfentanil and related fentanyl analogs have been linked to a number of overdose deaths from drug users in several cities across North America. Diagnosis of carfentanil exposure requires a very high index of clinical suspicion, especially because available laboratory narcotic screens do not detect this agent. We describe a 34-year-old man admitted with depressed level of consciousness and in respiratory failure after recreational exposure to a white powder later inferred to contain carfentanil. Urine and whole blood samples were obtained for conventional preliminary drug screen immunoassays for unknown exposures, in addition to utilizing a high-pressure liquid chromatography-tandem mass spectrometry assay for quantification of carfentanil and its metabolite. The patient was intubated and required mechanically assisted ventilation for 31 hours until he was able to breathe safely on his own. Pharmacokinetic modeling of three timed blood samples identified the elimination half-life as 5.7 hours for carfentanil and 11.8 hours for the norcarfentanil metabolite. Awakening and breathing spontaneously corresponded to an interpolated blood carfentanil concentration of 0.52 ng/ml. This is the first pharmacokinetic and pharmacodynamic case report on the recreational use of carfentanil. Critical care clinicians should anticipate long periods of ventilatory support in the care of patients exposed to carfentanil.	[Uddayasankar, Uvaraj] Univ Manitoba, Fac Med, Winnipeg, MB, Canada; [Lee, Colin; Oleschuk, Curtis] Diagnost Serv Manitoba, Winnipeg, MB, Canada; [Eschun, Gregg] Univ Manitoba, Pulm Med & Crit Care, Winnipeg, MB, Canada; [Ariano, Robert E.] St Boniface Gen Hosp, Dept Pharm, 409 Tache Ave, Winnipeg, MB R2H 2A6, Canada; [Ariano, Robert E.] Univ Manitoba, Coll Pharm, Winnipeg, MB, Canada	Ariano, RE (reprint author), St Boniface Gen Hosp, Dept Pharm, 409 Tache Ave, Winnipeg, MB R2H 2A6, Canada.	rariano@sbgh.mb.ca					Angst MS, 2009, PAIN, V142, P17, DOI 10.1016/j.pain.2008.11.001; [Anonymous], 2013, J ANAL TOXICOL, V37, P452, DOI 10.1093/jat/bkt054; Cole JB, 2017, AM J EMERG MED, V35, P1743, DOI 10.1016/j.ajem.2017.08.045; D'Argenio DZ, 2009, ADAPT 5 USER GUIDE P, P9; Daniulaityte R, 2017, MMWR-MORBID MORTAL W, V66, P904, DOI 10.15585/mmwr.mm6634a3; Feasel MG, 2016, AAPS J, V18, P1489, DOI 10.1208/s12248-016-9963-5; George AV, 2010, AM J EMERG MED, V28, P530, DOI 10.1016/j.ajem.2010.03.003; Lust EB, 2011, J EMERG MED, V40, P198, DOI 10.1016/j.jemermed.2009.09.026; Minkowski CP, 2012, ADDICT BIOL, V17, P149, DOI 10.1111/j.1369-1600.2010.00256.x; Muller S, 2017, CLIN TOXICOL, V31, P1; O'Donnell JK, 2017, MMWR-MORBID MORTAL W, V66, P1197, DOI 10.15585/mmwr.mm6643e1; Riches JR, 2012, J ANAL TOXICOL, V36, P647, DOI 10.1093/jat/bks078; Suzuki J, 2017, DRUG ALCOHOL DEPEN, V171, P107, DOI 10.1016/j.drugalcdep.2016.11.033; Swanson DM, 2017, J ANAL TOXICOL, V41, P498, DOI 10.1093/jat/bkx037; Wax PM, 2003, ANN EMERG MED, V41, P700, DOI 10.1067/mem.2003.148; Wolters Kluwer Clinical Drug Information Inc, 2018, LEX DRUGS VERS 2 7 5; Zawilska JB, 2017, FRONT PSYCHIATRY, V8, DOI 10.3389/fpsyt.2017.00110	17	12	12	1	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0277-0008	1875-9114		PHARMACOTHERAPY	Pharmacotherapy	JUN	2018	38	6					E41	E45		10.1002/phar.2117			5	Pharmacology & Pharmacy	Pharmacology & Pharmacy	GK2HZ	WOS:000435950100001	29679387				2020-06-30	J	Kwon, HM; Kim, SH; Park, SU; Rhim, JH; Park, HS; Kim, WJ; Nam, GB				Kwon, Hye-Mee; Kim, Sung-Hoon; Park, Se-Ung; Rhim, Jin-Ho; Park, Hee-Sun; Kim, Wook-Jong; Nam, Gi-Byoung			Propofol for implantable cardioverter defibrillator implantation in patients with Brugada syndrome	PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY			English	Article						arrhythmias; Brugada syndrome; implantable cardioverter defibrillator; propofol sedation	ST SEGMENT ELEVATION; INFUSION SYNDROME; CHILDREN; DEATH	AimsAvoiding propofol in patients with Brugada syndrome has been suggested because of the theoretical risk of provoking ventricular arrhythmias, although propofol may be selected for conscious sedation during electrophysiological procedures in catheterization laboratories. This study aimed to document periprocedural electrocardiographic changes and adverse events in patients with Brugada syndrome undergoing implantable cardioverter defibrillator (ICD) implantation using propofol sedation. MethodsWe reviewed the clinical data of 53 consecutive patients who underwent ICD implantation during 1998-2011. Sedation was achieved by combining propofol with either midazolam or fentanyl, and a bolus propofol dose (0.5-1mg/kg) was administered to induce deep sedation. Periprocedural events, including arrhythmias, defibrillations, and hyperthermia episodes, were evaluated, and electrocardiogram (ECG) variables were measured. The need for emergency anesthetic support/intubation and incidence of perioperative complications or mortality were analyzed. ResultsProcedure time and cumulative propofol dose for each patient was 125.2 (42.8) min and 204.6 (212.7) mg, respectively. During deep sedation, blood pressure, heart rate, and oxygen saturation were significantly decreased (P<0.001) such that eight (15.1%) patients required manual ventilation and one (1.9%) needed atropine injection. No significant ECG changes were observed. Only two (3.7%) patients showed newly developed ST elevation in the anterior precordial lead, whereas three (5.6%) had isolated premature ventricular contractions. ConclusionICD implantation without significant ECG changes or adverse outcomes is feasible under propofol sedation in patients with Brugada syndrome. However, because of significant hemodynamic changes and respiratory compromise, close monitoring and meticulous propofol dose titration is warranted.	[Kwon, Hye-Mee; Kim, Sung-Hoon; Park, Se-Ung; Rhim, Jin-Ho; Park, Hee-Sun; Kim, Wook-Jong] Univ Ulsan, Dept Anesthesiol & Pain Med, Asan Med Ctr, Coll Med, 88 Olymp Ro 43 Gil, Seoul 05505, South Korea; [Nam, Gi-Byoung] Univ Ulsan, Dept Internal Med Cardiol, Asan Med Ctr, Coll Med, 88 Olymp Ro 43 Gil, Seoul 05505, South Korea	Kim, SH (reprint author), Univ Ulsan, Dept Anesthesiol & Pain Med, Asan Med Ctr, Coll Med, 88 Olymp Ro 43 Gil, Seoul 05505, South Korea.; Nam, GB (reprint author), Univ Ulsan, Dept Internal Med Cardiol, Asan Med Ctr, Coll Med, 88 Olymp Ro 43 Gil, Seoul 05505, South Korea.	shkimans@amc.seoul.kr; gbnam@amc.seoul.kr		Kim, Wook-jong/0000-0001-9178-3044	Asan Institute for Life Sciences, Asan Medical Center, Seoul, Korea [2017-7013]; Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Science, ICT & Future Planning [2016M3A9E8941259]	This study was supported by a grant (2017-7013) from Asan Institute for Life Sciences, Asan Medical Center, Seoul, Korea. This study was also supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT & Future Planning (Grant Number 2016M3A9E8941259).	Bramall J, 2011, INT J OBSTET ANESTH, V20, P181, DOI 10.1016/j.ijoa.2010.10.006; Bray RJ, 1998, PAEDIATR ANAESTH, V8, P491; BRUGADA P, 1992, J AM COLL CARDIOL, V20, P1391, DOI 10.1016/0735-1097(92)90253-J; Chen QY, 1998, NATURE, V392, P293; Flamee P, 2013, PACE, V36, P1516, DOI 10.1111/pace.12246; Junttila MJ, 2008, CIRCULATION, V117, P1890, DOI 10.1161/CIRCULATIONAHA.107.746495; Kloesel B, 2011, CAN J ANESTH, V58, P824, DOI 10.1007/s12630-011-9546-y; Letsas KP, 2013, PACE, V36, P1570, DOI 10.1111/pace.12234; Lippi G, 2012, ADV CLIN CHEM, V56, P197, DOI 10.1016/B978-0-12-394317-0.00009-1; Miyazaki T, 1996, J AM COLL CARDIOL, V27, P1061, DOI 10.1016/0735-1097(95)00613-3; PARKE TJ, 1992, BRIT MED J, V305, P613, DOI 10.1136/bmj.305.6854.613; Phillips N, 2003, ANESTH ANALG, V97, P264, DOI 10.1213/01.ANE.0000067410.32384.3A; Pires LA, 1996, CARDIOLOGY, V87, P319, DOI 10.1159/000177113; Postema PG, 2009, HEART RHYTHM, V6, P1335, DOI 10.1016/j.hrthm.2009.07.002; Richter S, 2012, Herzschrittmacherther Elektrophysiol, V23, P56, DOI 10.1007/s00399-011-0156-8; Robinson JDC, 2008, PACE, V31, P1070, DOI 10.1111/j.1540-8159.2008.01138.x; Sakabe M, 2002, ANESTHESIOLOGY, V97, P265, DOI 10.1097/00000542-200207000-00035; Vernooy K, 2006, HEART RHYTHM, V3, P131, DOI 10.1016/j.hrthm.2005.11.005; Wilde AAM, 2002, CIRCULATION, V106, P2514, DOI 10.1161/01.CIR.0000034169.45752.4A; Yap YG, 2009, EUROPACE, V11, P989, DOI 10.1093/europace/eup114	20	0	0	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0147-8389	1540-8159		PACE	PACE-Pacing Clin. Electrophysiol.	JUN	2018	41	6					656	660		10.1111/pace.13342			5	Cardiac & Cardiovascular Systems; Engineering, Biomedical	Cardiovascular System & Cardiology; Engineering	GK0MJ	WOS:000435804000013	29626346				2020-06-30	J	Madras, BK				Madras, Bertha K.			The President's Commission on Combating Drug Addiction and the Opioid Crisis: Origins and Recommendations	CLINICAL PHARMACOLOGY & THERAPEUTICS			English	Editorial Material								The United States has the ignominious distinction of leading the world in opioid prescribing, 1 and in opioid-related overdose deaths. The Centers for Disease Control (CDC) estimates that over 40,000 people died of an opioid-related overdose, with fentanyl-related deaths exceeding those of heroin or prescription opioids. 2 Opioid overdoses are now the leading cause of unintentional deaths in the US and of declining lifespan expectancies. 3 With a worsening crisis, agencies of the US government and others produced an array of reports on the opioid crisis. Yet the death rate escalated further from 2010 to the present.	[Madras, Bertha K.] Harvard Med Sch, Dept Psychiat, Div Alcohol, Belmont, MA 02478 USA; [Madras, Bertha K.] Harvard Med Sch, Dept Psychiat, Div Drug Abuse, Belmont, MA 02478 USA; [Madras, Bertha K.] Harvard Med Sch, Dept Psychiat, Div Basic Neurosci Res, Belmont, MA 02478 USA	Madras, BK (reprint author), Harvard Med Sch, Dept Psychiat, Div Alcohol, Belmont, MA 02478 USA.; Madras, BK (reprint author), Harvard Med Sch, Dept Psychiat, Div Drug Abuse, Belmont, MA 02478 USA.; Madras, BK (reprint author), Harvard Med Sch, Dept Psychiat, Div Basic Neurosci Res, Belmont, MA 02478 USA.	bertha_madras@hms.harvard.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; NIH-NIDAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [DA042178]	National Institutes of Health; NIH-NIDA DA042178.	[Anonymous], 2017, PRESIDENTS COMMISSIO; Centers for Disease Control, 2017, PROV COUNTS DRUG OV; Dowell D, 2017, JAMA-J AM MED ASSOC, V318, P1065, DOI 10.1001/jama.2017.9308; Humphreys K., 2017, AVOIDING GLOBALIZATI, V390, P427; Madras BK, 2017, JAMA PSYCHIAT, V74, P441, DOI 10.1001/jamapsychiatry.2017.0163	5	11	12	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0009-9236	1532-6535		CLIN PHARMACOL THER	Clin. Pharmacol. Ther.	JUN	2018	103	6			SI		943	945		10.1002/cpt.1050			3	Pharmacology & Pharmacy	Pharmacology & Pharmacy	GJ0QS	WOS:000434959800014	29570781				2020-06-30	J	Kimergard, A; Dunne, J; Bogen, A; Hindersson, P; Breindahl, T				Kimergard, Andreas; Dunne, Jacklyn; Bogen, Anette; Hindersson, Peter; Breindahl, Torben			Characteristics of opioid-maintained clients smoking fentanyl patches: The importance of confirmatory drug analysis illustrated by a case series and mini-review	DRUG TESTING AND ANALYSIS			English	Review						Addiction treatment; confirmatory drug analysis; smoking; transdermal fentanyl patches; tampering	CHROMATOGRAPHY-MASS-SPECTROMETRY; TRANSDERMAL PATCHES; PUBLIC-HEALTH; MAINTENANCE TREATMENT; PAIN; IMMUNOASSAY; MEDICATION; ABUSE; NORFENTANYL; PYROLYSIS	The increase in opioid prescribing in many European countries over the last decade has raised concerns about associated diversion, overdose, and mortality. Fentanyl is one of these synthetic opioids that is typically prescribed as a transdermal patch for pain that requires continuous pain relief and has been the focus of investigation due to reports of overdose and death. We report a case series of 14 drug addiction treatment entrants, who entered treatment in a service located in the region of Southern Denmark from August 2015 to December 2015 for smoking fentanyl patches. Clients presented with difficulties breathing and pains in the lungs. The clients had a history of past opioid use, including heroin. Relapses resulted in treatment disengagement. Immunoassays for fentanyl were used in the service. In some cases, false negative results occurred. Clients' urine samples were subsequently analysed in a collaborating laboratory. Seven clients tested positive for fentanyl. One client was positive for both fentanyl and heroin. Analyses were also positive for other opioids and metabolites in 6 clients, predominantly codeine and oxycodone. Results from confirmatory analysis contributed to clearer insights into clients' drug histories, which facilitated personalised care plans consisting of opioid agonist therapy informed by confirmed drug use. In Denmark, prescription levels of fentanyl are high, which has been accompanied by observations of diversion and smoking in a smaller population. In addition to revision of inappropriate prescribing to reduce diversion, we recommend increased reliance upon confirmatory drug analysis in the addiction treatment sector in Denmark.	[Kimergard, Andreas; Dunne, Jacklyn] Kings Coll London, Natl Addict Ctr, Inst Psychiat Psychol & Neurosci, London, England; [Bogen, Anette] Drug Rehabil Ctr, Fredericia, Denmark; [Hindersson, Peter; Breindahl, Torben] Aalborg Univ, North Denmark Reg Hosp, Dept Clin Biochem, Hjorring, Denmark	Breindahl, T (reprint author), North Denmark Reg Hosp, Dept Clin Biochem, Bispensgade 37, DK-9800 Hjorring, Denmark.	torben.breindahl@rn.dk	Breindahl, Torben/I-8767-2016	Kimergard, Andreas/0000-0002-2080-9865; Dunne, Jacklyn/0000-0001-5095-5858; Breindahl, Torben/0000-0001-8166-1983	Guy's and St Thomas' Charity; Marie Pedersen and Jensine Heiberg Foundation; NIHR Collaboration for Leadership in Applied Health Research and Care South London	Guy's and St Thomas' Charity; Marie Pedersen and Jensine Heiberg Foundation; The NIHR Collaboration for Leadership in Applied Health Research and Care South London	Andreasen J, 2005, FORBRUGET SMERTEPLAS; [Anonymous], 2017, WHO MOD LIST ESS MED; Arnet I, 2016, J PAIN RES, V9, P993, DOI 10.2147/JPR.S116091; Bell S, 2015, DRUG TEST ANAL, V7, P445, DOI 10.1002/dta.1794; Breindahl T, 1999, J CHROMATOGR B, V732, P155, DOI 10.1016/S0378-4347(99)00276-5; Breindahl T, 2017, RETNINGSLINJER UPFOR; Breindahl T, 2018, UGESKRIFT LAEGER, P180; Breindahl T, 2017, DRUG TEST ANAL, V9, P415, DOI 10.1002/dta.2046; Cai B, 2015, INT J PHARMACEUT, V488, P102, DOI 10.1016/j.ijpharm.2015.04.061; Casati A, 2012, EUR ADDICT RES, V18, P228, DOI 10.1159/000337028; Chapman E, 2012, CHEST, V141, P1321, DOI 10.1378/chest.11-1462; Chaudhry A, 2018, CAN PHARM J, V151, P12, DOI 10.1177/1715163517743993; Clauw D, 2017, PAIN, V158, P2283, DOI 10.1097/j.pain.0000000000001060; Cone EJ, 2006, DRUG ALCOHOL DEPEN, V83, pS31, DOI 10.1016/j.drugalcdep.2005.11.027; Cummings OT, 2016, J ANAL TOXICOL, V40, P595, DOI 10.1093/jat/bkw067; Dale Eric, 2009, BMJ Case Rep, V2009, DOI 10.1136/bcr.01.2009.1454; Danish Health Authority, 2017, VEJL LAEG BEH OP PAT; Danish Health Authority, 2016, NARK DANM; Danish Health Authority, 2017, KORTL OP DANM; Danish Medicines Agency, 2017, INT BIV; Darling SS, 2014, FENTANYLTE UGESKR LA, V176; Dzieciol M, 2000, J APPL POLYM SCI, V77, P1894, DOI 10.1002/1097-4628(20000829)77:9<1894::AID-APP5>3.0.CO;2-Y; EMCDDA, 2012, FENT EUR EMCDDA TREN; EMCDDA, 2017, ACR REP RISK ASS N 1; EMCDDA, 2016, STRAT PREV DIV OP SU; EMCDDA, 2017, FUR REP RISK ASS PHE; European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), 2017, DENM COUNTR DRUG REP; European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), 2017, RISK ASS REP NEW PSY; Evans-Brown M, 2017, ADDICTION, V112, P36, DOI 10.1111/add.13528; Firestone M, 2009, INT J DRUG POLICY, V20, P90, DOI 10.1016/j.drugpo.2008.02.016; Frank RG, 2017, NEW ENGL J MED, V376, P605, DOI 10.1056/NEJMp1615145; Fredericia Kommune, 2018, ALK STOFB; Gagajewski A, 2002, CLIN CHEM, V48, P205; Hazell L, 2006, DRUG SAFETY, V29, P385, DOI 10.2165/00002018-200629050-00003; Health Canada, 2017, INF UPD HLTH CAN IS; Heikman PK, 2017, BMC PSYCHIATRY, V17, DOI 10.1186/s12888-017-1415-y; Helland A, 2017, J ANAL TOXICOL, V41, P708, DOI 10.1093/jat/bkx050; Jacobsen R, 2009, PAIN MED, V10, P1442, DOI 10.1111/j.1526-4637.2009.00724.x; Jarlbaek Lene, 2010, Ugeskr Laeger, V172, P3173; Juurlink DN, 2017, CAN MED ASSOC J, V189, pE1222, DOI 10.1503/cmaj.170628; Kimergard A, 2016, ADDICTION, V111, P1701, DOI 10.1111/add.13436; Kong TY, 2017, ARCH PHARM RES, V40, P180, DOI 10.1007/s12272-016-0862-1; Krause D, 2017, SUBST USE MISUSE, V52, P639, DOI 10.1080/10826084.2016.1246571; Larance B, 2011, DRUG ALCOHOL REV, V30, P236, DOI 10.1111/j.1465-3362.2010.00283.x; Larsen HL, 2011, IRRATIONELT DRUG STA, V3; Leece P, 2015, CAN MED ASSOC J, V187, P717, DOI 10.1503/cmaj.150329; Lichtman AH, 1996, J PHARMACOL EXP THER, V279, P69; Lu NT, 2001, AM J DRUG ALCOHOL AB, V27, P399, DOI 10.1081/ADA-100104509; MARQUARDT KA, 1994, J TOXICOL-CLIN TOXIC, V32, P75, DOI 10.3109/15563659409000433; MARQUARDT KA, 1995, ANN PHARMACOTHER, V29, P969, DOI 10.1177/106002809502901001; Maurer HH, 2016, ARCH TOXICOL, V90, P2161, DOI 10.1007/s00204-016-1764-1; Meng Y, 1997, NIDA Res Monogr, V173, P201; Meyer MR, 2016, ANAL CHIM ACTA, V927, P13, DOI 10.1016/j.aca.2016.04.046; Nishikawa RK, 2009, J ANAL TOXICOL, V33, P418, DOI 10.1093/jat/33.8.418; Oechsler Stephanie, 2009, Archiv fuer Kriminologie, V224, P26; Poklis A, 2004, J ANAL TOXICOL, V28, P422, DOI 10.1093/jat/28.6.422; Quintana P, 2017, INT J DRUG POLICY, V40, P78, DOI 10.1016/j.drugpo.2016.10.006; Reisfield GM, 2009, BIOANALYSIS, V1, P937, DOI 10.4155/BIO.09.81; Rosenzweig Mary, 2006, Ugeskr Laeger, V168, P1975; Saitman A, 2014, J ANAL TOXICOL, V38, P387, DOI 10.1093/jat/bku075; Shastay Ann, 2017, Home Healthc Now, V35, P398, DOI 10.1097/NHH.0000000000000563; Simonsen KW, 2015, FORENSIC SCI INT, V248, P172, DOI 10.1016/j.forsciint.2015.01.003; Snyder ML, 2017, PAIN PHYSICIAN, V20, pSE1; Socialtilsyn Syd, 2017, TILS; Sovova K, 2008, MOL PHYS, V106, P1205, DOI 10.1080/00268970802077876; Stannard C, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f5108; The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), 2016, EUR DRUG REP TRENDS; Ujvary I, 2017, FORENSIC TOXICOL, V35, P232, DOI 10.1007/s11419-017-0367-8; van Amsterdam J, 2015, REGUL TOXICOL PHARM, V73, P999, DOI 10.1016/j.yrtph.2015.09.014; Wang BT, 2014, J ANAL TOXICOL, V38, P672, DOI 10.1093/jat/bku103; Wang X, 2018, FORENSIC SCI INT, V285, pE1, DOI 10.1016/j.forsciint.2018.01.021; Warner Margaret, 2016, Natl Vital Stat Rep, V65, P1; Worley J, 2015, J AM PSYCHIAT NURSES, V21, P309, DOI 10.1177/1078390315612262; Yadav SK, 2014, CELL MOL BIOL, V60, P1	74	4	4	1	12	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1942-7603	1942-7611		DRUG TEST ANAL	Drug Test. Anal.	JUN	2018	10	6					917	926		10.1002/dta.2397			10	Biochemical Research Methods; Chemistry, Analytical; Pharmacology & Pharmacy	Biochemistry & Molecular Biology; Chemistry; Pharmacology & Pharmacy	GJ3YM	WOS:000435270300001	29675893				2020-06-30	J	Guitart, J; Vargas, MI; De Sanctis, V; Folch, J; Salazar, R; Fuentes, J; Coma, J; Ferreras, J; Moya, J; Tomas, A; Estivill, P; Rodelas, F; Jimenez, AJ; Sanz, A				Guitart, Jordi; Isabel Vargas, Maria; De Sanctis, Vicente; Folch, Jordi; Salazar, Rafael; Fuentes, Jose; Coma, Joan; Ferreras, Julia; Moya, Jordi; Tomas, Albert; Estivill, Pere; Rodelas, Francisco; Javier Jimenez, Antonio; Sanz, Almudena			Efficacy and Safety of Sublingual Fentanyl Tablets in Breakthrough Cancer Pain Management According to Cancer Stage and Background Opioid Medication	DRUGS IN R&D			English	Article							FORM HEALTH SURVEY; QUALITY-OF-LIFE; HOSPITAL ANXIETY; DEPRESSION SCALE; ASSOCIATION; POPULATION; PREVALENCE	Objective Our objective was to assess the effect of sublingual fentanyl tablets (SFTs) on pain relief, quality of life, and adverse effects in patients with cancer pain, according to cancer stage and background opioid regimen. Methods Subgroup analyses from a recently completed study were performed according to cancer stage (locally advanced cancer [LAC] vs. metastatic cancer) and most frequent background opioid medication (fentanyl vs. oxycodone/naloxone). The efficacy and safety of SFTs were evaluated, recording pain intensity (PI), onset of pain relief, and adverse events (AEs). Health status was assessed with the Short Form 12, version 2 (SF-12v2) questionnaire and the Hospital Anxiety and Depression Scale (anxiety subscale [HADS-A] and depression subscale [HADS-D]). Results In total, 54 (67.5%) patients had LAC and 26 (32.5%) had metastatic cancer. The oxycodone/naloxone group included 39 patients (48.1%) and the fentanyl group 29 (35.8%). In all subgroups, pain relief was achieved within 5 min in an increasing number of individuals over time; at the end of the study, PI values decreased (PI-end: 44.4% for LAC vs. 57.9% for metastatic cancer; 44.4% for fentanyl vs. 38.6% for oxycodone/naloxone). HADS and mental component summary (MCS) SF-12v2 scores significantly improved in the LAC group (HADS-A 9.44-8.04; HADS-D 10.46-8.15; MCS 44.69-45.94) and in the fentanyl group (HADS-A 10.05-8.33; HADS-D 11.95-8.76; MCS 44.38-47.19). AEs were reported in few patients and were mostly mild. Conclusions Exploratory subgroup analyses show the efficacy and safety of SFTs for the treatment of breakthrough pain in patients with cancer, regardless of their cancer stage and background opioid medication.	[Guitart, Jordi; Folch, Jordi] Hosp Plato, Dept Anesthesiol, C Plato 21, Barcelona 08006, Spain; [Isabel Vargas, Maria; Estivill, Pere] Parc Sanitari St Joan de Deu, Dept Anesthesiol, Barcelona, Spain; [De Sanctis, Vicente] Hosp Univ Sagrat Cor, Dept Anesthesiol, Pain Unit, Barcelona, Spain; [Salazar, Rafael; Rodelas, Francisco] Hosp Comarcal Inca, Dept Anesthesiol, Palma De Mallorca, Spain; [Fuentes, Jose] Pius Hosp Valls, Dept Anesthesiol, Tarragona, Spain; [Coma, Joan] Hosp Gen Hosp, Dept Anesthesiol, Barcelona, Spain; [Ferreras, Julia] Hosp Residencia St Camil, Dept Anesthesiol, Pain Unit, Barcelona, Spain; [Moya, Jordi] Hosp Mateu Orfila, Dept Anesthesiol, Pain Unit, Menorca, Spain; [Tomas, Albert] Fundacio Hosp St Bernabe, Dept Anesthesiol, Pain Unit, Barcelona, Spain; [Javier Jimenez, Antonio; Sanz, Almudena] Kyowa Kirin Farmaceut SLU, Madrid, Spain	Guitart, J (reprint author), Hosp Plato, Dept Anesthesiol, C Plato 21, Barcelona 08006, Spain.	jordi.guitart@hospitalplato.com			Kyowa Kirin Farmaceutica SLU	This work was supported by Kyowa Kirin Farmaceutica SLU. The authors received research funding from Kyowa Kirin Farmaceutica SLU for this study.	Brown LF, 2010, PSYCHO-ONCOLOGY, V19, P734, DOI 10.1002/pon.1627; Caraceni A, 2004, PALLIATIVE MED, V18, P177, DOI 10.1191/0269216304pm890oa; Chwieduk CM, 2010, DRUGS, V70, P2281, DOI 10.2165/11200910-000000000-00000; Davies AN, 2009, EUR J PAIN, V13, P331, DOI 10.1016/j.ejpain.2008.06.014; Guitart J, 2015, CLIN DRUG INVEST, V35, P815, DOI 10.1007/s40261-015-0344-0; Herrero MJ, 2003, GEN HOSP PSYCHIAT, V25, P277, DOI 10.1016/S0163-8343(03)00043-4; Jandhyala R, 2013, J PAIN SYMPTOM MANAG, V46, P573, DOI 10.1016/j.jpainsymman.2012.09.009; Lennernas B, 2010, PALLIATIVE MED, V24, P286, DOI 10.1177/0269216309356138; Mishra S, 2009, INDIAN J PALLIAT CAR, V15, P14, DOI 10.4103/0973-1075.53506; Nalamachu S, 2011, CURR MED RES OPIN, V27, P519, DOI 10.1185/03007995.2010.545380; Nersesyan H., 2007, J THERAPEUTICS CLIN, V3, P381, DOI DOI 10.1073/PNAS.0705759104; Pautex S, 2014, DRUG AGING, V31, P405, DOI 10.1007/s40266-014-0181-5; PORTENOY RK, 1990, PAIN, V41, P273, DOI 10.1016/0304-3959(90)90004-W; Rauck RL, 2009, CURR MED RES OPIN, V25, P2877, DOI 10.1185/03007990903368310; Schmidt S, 2012, MED CLIN-BARCELONA, V139, P613, DOI 10.1016/j.medcli.2011.10.024; Uberall MA, 2011, CURR MED RES OPIN, V27, P1385, DOI 10.1185/03007995.2011.583231; Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650-199603000-00003; Zeppetella G, 2011, CLIN ONCOL-UK, V23, P393, DOI 10.1016/j.clon.2010.12.002; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	19	2	3	1	4	SPRINGER INTERNATIONAL PUBLISHING AG	CHAM	GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND	1174-5886	1179-6901		DRUGS R&D	Drugs R&D	JUN	2018	18	2					119	128		10.1007/s40268-018-0231-2			10	Pharmacology & Pharmacy	Pharmacology & Pharmacy	GJ2IG	WOS:000435093100003	29572732	DOAJ Gold, Green Published			2020-06-30	J	Braaten, KP; Urman, RD; Maurer, R; Fortin, J; Goldberg, AB				Braaten, Kari P.; Urman, Richard D.; Maurer, Rie; Fortin, Jennifer; Goldberg, Alisa B.			A randomized comparison of intravenous sedation using a dosing algorithm compared to standard care during first-trimester surgical abortion	CONTRACEPTION			English	Article						Intravenous sedation; Algorithm; Surgical abortion; Pain control; Midazolam; Fentanyl	ACUTE PAIN; FEDERATION MEMBERS; UNITED-STATES; INTENSITY; OBESITY; VALIDATION; TRIAL	Objective: The objective was to compare the safety and efficacy of an algorithm for abortion intravenous sedation dosing (AAID) to standard dosing during first-trimester surgical abortion. Study design: This was a randomized, single-blinded, controlled trial in which women undergoing first-trimester surgical abortion received fentanyl and midazolam dosed per either an algorithm or clinic standard. Patient-level factors including weight, airway risk, anxiety, and drug and alcohol use determined MID doses. The primary outcome was pain with suction curettage measured immediately on a 21-point verbal numerical rating scale ranging from 0 to 100. Secondary outcomes included pain with cervical dilation and postprocedure, intraoperative pain as recalled postprocedure, need for additional doses of medication, oxygen saturation<93%, sedation level, adverse events, side effects and patient satisfaction. Results: We enrolled 196 women and randomized 98 to the AAID and 98 to standard care. Baseline factors were similar between groups. Median intraoperative pain scores did not differ between groups when measured immediately (47.5 vs. 50, p=.81) or on recall (30 in both arms, p=.68). There were no significant differences in other secondary outcomes. Women with a body mass index (BMI) 30-35 trended toward improved pain control with the algorithm (60 vs. 27.5, p=.07). Conclusions: Intravenous sedation determined by an algorithm did not produce differences in pain scores in a setting with highly experienced providers. (C) 2018 Elsevier Inc. All rights reserved.	[Braaten, Kari P.; Goldberg, Alisa B.] Planned Parenthood League Massachusetts, 1055 Commonwealth Ave, Boston, MA 02215 USA; [Braaten, Kari P.; Fortin, Jennifer; Goldberg, Alisa B.] Brigham & Womens Hosp, Dept Obstet Gynecol & Reprod Biol, 1620 Tremont St, Boston, MA 02120 USA; [Urman, Richard D.] Brigham & Womens Hosp, Dept Anesthesiol Perioperat & Pain Med, 75 Francis St, Boston, MA 02115 USA; [Maurer, Rie] Brigham & Womens Hosp, Dept Med, Ctr Clin Invest, 221 Longwood Ave, Boston, MA 02115 USA	Braaten, KP (reprint author), Planned Parenthood League Massachusetts, 1055 Commonwealth Ave, Boston, MA 02215 USA.; Braaten, KP (reprint author), Brigham & Womens Hosp, Dept Obstet Gynecol & Reprod Biol, 1620 Tremont St, Boston, MA 02120 USA.	kpbraaten@partners.org	Urman, Richard/AAH-7758-2019	Urman, Richard/0000-0002-0516-5977	Society of Family Planning Research Fund [SFPRF7-6]	Society of Family Planning Research Fund SFPRF7-6.	Allen RH, 2009, OBSTET GYNECOL, V113, P276, DOI 10.1097/AOG.0b013e3181938758; American Society of Anesthesiologists, 2014, CONT DEPTH SED DEF G; Bijur PE, 2003, ACAD EMERG MED, V10, P390, DOI 10.1111/j.1553-2712.2003.tb01355.x; Braaten KP, 2014, CONTRACEPTION, V89, P116, DOI 10.1016/j.contraception.2013.10.009; Cepeda MS, 2003, PAIN, V105, P151, DOI 10.1016/S0304-3959(03)00176-3; Farrar JT, 2001, PAIN, V94, P149, DOI 10.1016/S0304-3959(01)00349-9; Farrar JT, 2003, J PAIN SYMPTOM MANAG, V25, P406, DOI 10.1016/S0885-3924(03)00162-3; Gokhale P, 2016, ANESTH ANALG, V122, P1957, DOI 10.1213/ANE.0000000000001335; GREENBLATT DJ, 1984, ANESTHESIOLOGY, V61, P27, DOI 10.1097/00000542-198461010-00006; Hanley MJ, 2010, CLIN PHARMACOKINET, V49, P71, DOI 10.2165/11318100-000000000-00000; JENSEN MP, 1986, PAIN, V27, P117, DOI 10.1016/0304-3959(86)90228-9; Joshi GP, 2013, ANESTH ANALG, V117, P1082, DOI 10.1213/ANE.0b013e3182a823f4; Karamnov S, 2017, J PATIENT SAF, V13, P111, DOI 10.1097/PTS.0000000000000135; Lichtenberg ES, 2001, CONTRACEPTION, V64, P345, DOI 10.1016/S0010-7824(01)00279-7; Maranets I, 1999, ANESTH ANALG, V89, P1346, DOI 10.1097/00000539-199912000-00003; O'Connell K, 2009, CONTRACEPTION, V79, P385, DOI 10.1016/j.contraception.2008.11.005; Ogden CL, 2014, JAMA-J AM MED ASSOC, V311, P806, DOI 10.1001/jama.2014.732; Rawling MJ, 2001, AM J OBSTET GYNECOL, V185, P103, DOI 10.1067/mob.2001.115860; Renner RM, 2009, COCHRANE DB SYST REV, V2; Rudd RA, 2016, MMWR-MORBID MORTAL W, V65, P1445, DOI 10.15585/mmwr.mm655051e1; Williamson A, 2005, J CLIN NURS, V14, P798, DOI 10.1111/j.1365-2702.2005.01121.x; Wong CYG, 2002, HUM REPROD, V17, P1222, DOI 10.1093/humrep/17.5.1222	22	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0010-7824	1879-0518		CONTRACEPTION	Contraception	JUN	2018	97	6					490	496		10.1016/j.contraception.2018.01.013			7	Obstetrics & Gynecology	Obstetrics & Gynecology	GI1AK	WOS:000434101400004	29409833				2020-06-30	J	Srinivas, NR				Srinivas, Nuggehally R.			Lack of Translatable Proinflammatory Cytokines in Cerebrospinal Fluid in Rats With Increased Hyperalgesia With or Without Fentanyl Treatment	ANESTHESIA AND ANALGESIA			English	Letter							SURGERY		[Srinivas, Nuggehally R.] Zydus Res Ctr, Ahmadabad, Gujarat, India	Srinivas, NR (reprint author), Zydus Res Ctr, Ahmadabad, Gujarat, India.	nuggehally.srinivas@zyduscadila.com					Chang L, 2018, ANESTH ANALG, V126, P289, DOI 10.1213/ANE.0000000000002601; Coughlin JM, 2016, TRANSL PSYCHIAT, V6, DOI 10.1038/tp.2016.40; Yeager MP, 1999, REGION ANESTH PAIN M, V24, P557, DOI 10.1016/S1098-7339(99)90049-4	3	0	0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	JUN	2018	126	6					2150	2150		10.1213/ANE.0000000000002895			1	Anesthesiology	Anesthesiology	GG3GS	WOS:000432580900058	29517569				2020-06-30	